<SEC-DOCUMENT>0000939767-22-000026.txt : 20220218
<SEC-HEADER>0000939767-22-000026.hdr.sgml : 20220218
<ACCEPTANCE-DATETIME>20220218170522
ACCESSION NUMBER:		0000939767-22-000026
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		98
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220218
DATE AS OF CHANGE:		20220218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		22653755

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>exel-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:15eb203a-3ec7-40cd-9655-d78f522bbe80,g:fdc51e9e-f0fc-4164-a9b2-d81298576ebe,d:b1dc779af6a3491c9aef59246f08fe04--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:exel="http://www.exelixis.com/20211231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF80L2ZyYWc6OTc0Mzc2NmQzZjdiNDJhN2FlOWYwMWZhMjU0NTNhMTIvdGFibGU6NDVjNjRkMjU0OGMzNDNlM2E3Y2JhNDA3OWI1YmFlNDMvdGFibGVyYW5nZTo0NWM2NGQyNTQ4YzM0M2UzYTdjYmE0MDc5YjViYWU0M18yLTEtMS0xLTI1NzM5_878e1b87-4310-4548-b062-0d2011688c54">false</ix:nonNumeric><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF80L2ZyYWc6OTc0Mzc2NmQzZjdiNDJhN2FlOWYwMWZhMjU0NTNhMTIvdGFibGU6NDVjNjRkMjU0OGMzNDNlM2E3Y2JhNDA3OWI1YmFlNDMvdGFibGVyYW5nZTo0NWM2NGQyNTQ4YzM0M2UzYTdjYmE0MDc5YjViYWU0M180LTEtMS0xLTI1NzM5_840bc647-7fc5-4951-883e-2c50eb9786a4">2021</ix:nonNumeric><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF80L2ZyYWc6OTc0Mzc2NmQzZjdiNDJhN2FlOWYwMWZhMjU0NTNhMTIvdGFibGU6NDVjNjRkMjU0OGMzNDNlM2E3Y2JhNDA3OWI1YmFlNDMvdGFibGVyYW5nZTo0NWM2NGQyNTQ4YzM0M2UzYTdjYmE0MDc5YjViYWU0M181LTEtMS0xLTI1NzM5_8d33ec1a-02d8-4aba-a968-464758c9f24a">FY</ix:nonNumeric><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF80L2ZyYWc6OTc0Mzc2NmQzZjdiNDJhN2FlOWYwMWZhMjU0NTNhMTIvdGFibGU6NDVjNjRkMjU0OGMzNDNlM2E3Y2JhNDA3OWI1YmFlNDMvdGFibGVyYW5nZTo0NWM2NGQyNTQ4YzM0M2UzYTdjYmE0MDc5YjViYWU0M182LTEtMS0xLTI1NzM5_71562e9a-0eb9-47b8-ad01-126a08b6fd83">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_7a0e4465-a6b5-4b02-b58f-7014879a369f">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_dc2f3847-52aa-4192-8d7c-2b18b469e239">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_5d4462a3-e4ad-42c2-8f32-f51e009f8ca0">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_ae5d588d-a5da-417a-8318-ddd0d907793d">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79749347e30142e593fb3dd2087883ee_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i42b7e9e44a8149b69bfbe9366605fc00_I20220207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i048f2416fccc4e10b7965efb1a171533_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i890a097ba13b4d2aa44ba45c617df112_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81474236dfb14ff1ac531c41f5c16947_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief6bfa79af1c49bbac2074ef89ab2c4b_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31f5b5f30b734b15b1054bfb509ae021_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23f991a8511f4c6bb78932ffbb88e05a_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69ce00236de4479e9a6c6986301e7731_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5185d285db34c6d9e4c918f1420364c_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8016a7106ab5473891bf09f72524f38e_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35edcd5425bb4e4f8597665dcf1e7e5b_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d4436bfbe6489187e15748fba98eba_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aefcca4ad074b29b6a51fd6d458319c_D20201003-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-03</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9805c5e25eb64ed985d666f4c24de9ba_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d64ce6b48d24a04a0c93e22acd3904f_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i867ed8b4453c4a1a9044dab4bd539d50_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8210e6b19c34f939af1ed9a98c8914a_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i396cffc473714e59a1c966a366a443e2_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5a94021373d4840b95f6959bc4accd9_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff7c60d6d3b24087a7d0758be8cb1f5c_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9883712cd8e1413e8d0219e4ed8aad8d_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic73ea98630ee4a65b62bf4da8d1c3f41_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e8c40dbf5a94938b3a235b6331b0204_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99338e5e4fa243d89959abbe305c1ddc_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6020ec58ca0b4ac4b002e4acc9448876_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i012b294c4e2c4931a14f4be10ec2fe36_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d03c75ce0024c01a62fcd27957b4f04_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d4126cc2fa94615bd40a5daa4ef585e_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2944e77d8c04388810195fe26496810_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ccde781cd17461fb3e9f797e81654e9_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f7ff0b5436e42b3a597987061001835_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ce529a2e2894a0e92ed4a60ed0b95f9_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a546fb4a49e431a956a77f1680095df_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4109c1b12d9d4433bb8db86bc3cae091_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id655252138f44944870c02853be75c73_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ce7ca557f444499972aa47b8a85d655_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd55184171ad45c8be33cab3d4171b5f_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84b17fef833a40479881088e5855fc81_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac855e1b2d284da3adfcc70d50d6b045_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5ff5eb1df65416581656de05ef86494_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dcdcda3fc10404397110c8f9aaa5353_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebee7996e33a4d07b3a22638e4c253b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib427a6bae515457884e12ccece2b4122_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>exel:product</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>exel:country</xbrli:measure></xbrli:unit><xbrli:context id="i02820d73f6c54d589b048d50797c40a6_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exel:segment</xbrli:measure></xbrli:unit><xbrli:context id="i2ca33a540eff4370b1fd9baefd112b43_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="derivative_instrument"><xbrli:measure>exel:derivative_instrument</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ib1b9becbae9d413a818538229404c8e0_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6362d549434c4a3ebfb9ed76266ced8a_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0ce7596693de4c309e4046ee44e221d0_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4442ea86bfb449ca9e6184c51952a1e9_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad06c636df9d4082a61cd0476a607cb2_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0431c045c7b749419b8cb122e47b2fd8_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4d4c8762b46415b8ba90c8fc8e8bd01_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e8b773d3cd2476b9a6f98f0ec19f343_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5511677067b74ebb913d887f52a2848c_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10a667976104461cb71d5603b4d4af97_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9af17feaeb349989438dbf0d666ce00_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2da812635cea4a9b9116e4146e6cdea4_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17406e0670124dc6aa021883b5f49f2e_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia06ec631ab45435d9aa467e475199d25_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f3560ad4cbe4f5fa9e33117ca1cc45b_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a39ad000947444189cd4862efda588c_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie886e01e3e2442248812abddb9a3357c_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i802f06ff953349dcbd6e18868ae5c8ff_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a10a7f26ddf4e71ae1239be47deed9d_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e023361e8434930804854afbfdfd16d_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82d9fb00ead242beaea5c7ba0738621a_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23f80ed12dd445599bf289f8b30b88c0_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0937e3d1b0e1474a8b6f5365e91705d4_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55441d6740314dfba8168bd2502b1101_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i259af2d579ef48a689f2076724ddc735_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i594dc7db46f143248c87766268ac1585_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a26379cbf1740a7a0004b7311e38cc3_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b64a741d8eb4bc7bbac3a5db68a20bf_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib21e644bf9d94035b284ae2d64be8538_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica4c1bf73b7a497ea0f0cf3ee3121416_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fa15b9421324d2a8abcc78e7bf8af23_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i829c8635dc1a41a8867b90164ddc5c42_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a81f07947fc466f9ec4626bef20395b_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadbe770de5cb48ad8f72003a3c009cde_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b058fe448f6453eb17990c3983c40ce_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e8a704120c54d7d9733625903a75c0a_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb7ad7b5987c4c759bd3da195cccdda9_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc15983150c43b49a8bcd610f1d7622_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5510c7d658a0420fa7c4fd22f06b733d_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d553018b3f4e6ea41bdee893c4681c_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb41f135273846d2a5abf0e5b9d0f811_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56b939a4e3604e77961f68608050b413_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdceca8137604720b9dfc7e6e415d661_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i985f069de23b4373be549c007d2be40a_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c022e03b6b47659fb5320a00e0aff4_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64d8b101cb28463dbafce9a36192a9ec_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c4a22039764f45bfeb541853e2006b_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49d04f48075d4d9e9f242c365cff4b71_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2625931db6f641d1b8631cee45c5421e_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3cfec9cb4d04224a58db1a0560d4779_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f60afd811e645cc996074e0cd13ebbc_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2cf41534cf94f309749ad6b44872d98_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic57cbc70ed644ce9845fcfed669b497f_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0df0a5ea74244280ad89970ab96c16ea_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3769502a95e4f3684d2ef761cae6724_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief35aa55eff1427188342697996d37a8_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d6813dbf9b54533b3a13aa017eea398_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib163363f39ee47a1982ba34ffc40df1c_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4afda954bcde4a2d8442e84ea5f75854_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08840e0ec9404f91bb1ed1e90793003e_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i397c48f49ccd409781be83e43c34403b_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fd2c26c82744565a4a050d7c6936320_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4bf39a5ebec49a9b8c7c07b6ba5968f_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3093413adbae48879b92be020f6b4f95_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i759ddcce81f44cffa575713b1c443bd0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4de04499606844f9a42cd833027456e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7706be95a9254624abab7ee85d40a352_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d251f0fc574727b702a0a5caffb000_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf154a58f6564ff1becceb69660b10e2_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b9226f40009479393c872a6348134a4_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63e4041671b44fd599695a551a6412e2_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief888e56632141638b8427491992f9d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="id33282d755fe4cb187a33fa5ce4b49b5_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bf5c222f64a420686d2836dfecb6b8a_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b9b091c2fe54910a111a558a4e92d80_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i648d323ea30a42229de3c89c4cb186d1_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25f4e281d6f4588b0be1be89c974405_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib32003bccc214ae19d1adc2aa36ec6bc_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if22970cfc6004d70bfd9ff40c42079f6_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34b71d32c3af4d2c99a249ce89216823_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf4b8b36a8a1401ba536bf1da7af7544_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38b1163356184b27816cbad77cdf95c1_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1538f2b66fd943739c868b40f8b82675_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i942a6148cba44afbb7ce565e8f31caa4_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d7a173be1fe468581278e8058aaa8ce_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c4c0bb7d7c4d5ca6fcc41491abf1d5_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c892d9cb5bb4832a7807f3de3873c13_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de05268deff4e19bf1b0d6402584ef5_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia18f9c05acb24284aaefe29c49159029_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d5c9f1076cb460cb26ed364b3298866_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80cf15e8b90b415da4f4ddf22cf5de86_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7549b7123a984430b1eeb8ed0453f49d_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bbf116ba95d4f99b046b08cf6886f20_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88285abefe55431da86d133798712f97_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfa84e1a7dfa4fe394d99b30db90a03d_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i323181841f1447e19487c305609f6987_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c3ac03ee7454b6cac8c397afd4482c4_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40846f2291b646d0925baa2444ab430c_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f0fc047c9c4e42b491251f2246216c_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b8f7772fdd4b28b6761a4c19816e52_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ae90a8873dd4429b24fbecb4ac765cc_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5410770ddf84f099461a42667531965_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c1a218589024464b368812dcad02030_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i719737a56e4940dbaa44028a2131e87c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17469019aafd4e60b3681951461b5e32_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248a08fc00de455a8ba90662b6913cf3_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i845d978e80a94a059981545b4eaedc37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b021f45a0fa49c89d6035c19eaadbb3_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:CollaborativeAgreementWithGamaMabsPharmaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80195f3436714ec884ca333c40f2ee26_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:CollaborativeAgreementWithGamaMabsPharmaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia542815387ba453f9fd900fe25937400_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i839b859fbed548e38efc5fce9e64593a_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5a2784ff7d840bb982a4bc7823f075a_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad9dc6f5753a41ed9d96d235cc5108ba_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05641e68bc9f435c9afd7cdec45e36aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ff13830445e478385149192df956f88_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23bea1dd75274b42a74758ecc6636623_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2a61bcc4c3649f59f6a080941f4f893_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic64b739b318847c59da0eae266f9d1f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a311ca42562471db4f27e25d6d36db3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602bcc576371462380cb7add7c08ac3a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba29b67627794a5d9e0a76791c683b2e_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59895032150e486295f216709b152e49_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8be401936c61402c92d2967c8b58ca3b_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee1391eefb1148f5911a99610fca2132_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2243e5b1033e41bfa89446b83583a6e5_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>exel:investment</xbrli:measure></xbrli:unit><xbrli:context id="i9d6624d1a18a4542beeee361e4b2e980_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0e000d5830443279e6e124a4a3d90d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ed69927364241c79f4eb66d77b1b1b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0119576597c942bdb66a97f6e76ccf98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41e5087e044b46b29140a50002f1b602_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icda5e1974a7947e9b26e6b6e44e0d15d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2a433ba7c0841bc8a3e6d4e20f17f7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00dab545a5c24f8dbd1d9cc27963df2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5653f5a5eb54376bc10cfab4779dffe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f237af0ca95413b867a2e778f5fca0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa6e56eab91648cb8e0e757751bd275b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f12d2d69a4a4b56b51d7aaed03de152_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7258799b1a84728ace446b81f5e78f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2f80e9affa24a878bb82bc127dda141_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ccf77987385492998beaa7a87e03520_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d31a47bdaf94ea5ae092cf7132fada9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1abd401dbcc74a548779de9fef26b749_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia52a40c4b843407a840ac64aba523a6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93fadded2a81419dbf152f6fb044f9b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf16f215bd6842bd888163d7cadeea0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc382618cb454f7599202e9cac5b81e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea02ce752e444b2a83abe7a10a418b16_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf02d3488e39407e8c46e5743eff50d5_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i795179da2aab43418fa6db779e91263a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57679c13f2684cdd9f8cd6fd98ab8756_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id320ab8c9604499fbad568b50ccc1165_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b54dd876a1f4562af4c3afa7aa2048a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfbde743d8914198ab03af7fe8139476_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i427be21f708a40d28d6462416ac218ee_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b0e966652f44398a8c2e0a70b2baef5_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia54c8642ecfb409e951b6239615168c9_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1463aefcf3c149bbb077c0d3005c9401_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45ebd9c173484d88a6e494342999d3be_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b7e323ee87c4f05bfdbb7c4c7e201cd_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b3c6f3004bc4c89bcf1c9c12bd459ea_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c51f12115f14ed1b61d2747c01ae661_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib769eff617c64124810ebe511d945893_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3268bbdfa0414552b47fa9a338981cb9_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1eb5b5c04cc43349b70b9321ebc782f_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic984d9c89f24479a89d0d07b78b1cdaa_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfd60ccd881041a5ac4297dc0b25b292_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7389a754974512a4e774e51ae8a974_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd92c80358ee496096d3c673a7de6191_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i746a14780d0147c7824e0bef77b916db_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd7d2bd3e3e490fa8ce9475ab03c7f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0471012a562a4c27b88456f2732a0744_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3886df95730147449641343484c7d238_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide48db818a80458abbca38f5ab70bdd1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f085c7986f04f109f77b9011f31264d_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b4047a98c284e9286babc06d5858821_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c9cdc8841b46d8adc324d34793217d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a99337c2ce04dcfa30ad4ccee42117a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6230988b2ca747a8b89fd3cae1298175_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i178f5c4c23ca48a38655383d6e5977f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id73f4cd7fcee499eaf78ce808bb71d03_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i248ba0f7c8cb4181ad74bb080d0aeca1_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i935b27fac1984932861fb968e47b9877_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec14dcaa36142b2a22ec45b2e3e2493_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73ca698aa2a74a4e937a5a3b1de87b32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1089920ccded4380b0fbc39e750f1eb7_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b96bd3389d2490a8a78bc00fddfe7ce_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife6c6471ca35413da83fd2469f9c00a1_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38d5186b034a4d0999fca6ecb2ec9ece_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbb974755c29460293662406b5c181e4_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f33a19a84a140d380dc777b506fc9ba_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifecb0e7726f341c6ba6992570d045296_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i810b03546f7b400baf8f30d8a400ff09_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf28ef3d9ddd45609325a52b344679e7_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a39cce3d904d388c3adad8a7bfed10_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7abafca0ed6e40f88895c38bb6b81247_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff13c02dcfbe458cb3a8363106ef81dd_D20200520-20200520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-20</xbrli:startDate><xbrli:endDate>2020-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940612d122c84082acb652dba5991c69_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34532b015c584cba952c0caa678ee2fd_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib08f62d50d8d4c1793cae2caa25a90ec_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6d6926fdea445e7a6ebdc4a3ba1f78b_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b29032b66954a8db9da85d19b1be6a2_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie93bf1a0871644278ca4b892fe456191_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c17b70c74043af9b0e2017ab4409e8_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d0c6bc2e80b4232ae06f54a57a62638_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib29b3c5e0f37409da408786f8267b076_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74355fce090d4783894ca8f36c2a26dd_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c4744c0eeaa4ef89dc73f7f709e54b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fa59b8b15c4457ea85611acce275f22_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0c146506a74415eb481d9e61dae42b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i838b498a0efd4d9d9f799adee2661362_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ad4423cf59549fa83e3e98aa40b0aba_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74e6a3ef845a4a2c9ac7e354707c8e1f_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieac0ed4a145142fcaad1faa3308fe4da_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesClinicalTrialResultsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18d80baf7ec441d59bd2914f26cc7048_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1182bc4873c402f9d17b55ecb40b430_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesClinicalTrialResultsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6856ab9da0245a0b58e4a5a9d78c7c1_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesAchievedBeforeDecember312020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e812dfe05ab46da90f8b209737fba1e_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesAchievedBeforeDecember312021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96ebe2ef748948f0a75ba0527c466487_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f94a8c90d4404fbf57c14383810126_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:A2018PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad0a49c0e2794ae58f9a3ccbe473b7fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1cca4ef6d104b9db13688910f87a10c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf4e68b211e4463fb19f878a36d3a54a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:StatusAxis">exel:NotProbableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i420a84572c824730897fc79711ca81fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if84d627e667d48f29f5af7ff692d0370_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b39280de5b64a109031af851502c539_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13ee6cf1e5c848d2b6f0a4bd3a76af26_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i345c9b326f5c4c488b5009d48f08f45f_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i045cc234fe6d42e29ebae3f4719abd7e_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b2c55942a54b85b0a416b604b6a2b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i70af130f4dae44efb4c5edbc61ae24bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLease2021AmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09d02a3201ea4cd9abf78408a6c51ddc_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="renewal_options"><xbrli:measure>exel:renewal_options</xbrli:measure></xbrli:unit><xbrli:context id="ia7f4ccf1863646c7ad5275dd80a4cbd4_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib15b9dd84185469e883fb78ad72ac110_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseApril2019AmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3b3d07f431b4ca096bce3b9f83ca347_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseDecember2020AmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1ee46f49349499882d7dd859933eb48_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerSqft"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2e77e8a209894b9ea42d468fd28563b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7054208b42f440b38822d84184f73e38_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib1dc779af6a3491c9aef59246f08fe04_1"></div><div style="min-height:36pt;width:100%"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:199.50pt"><tr><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">FORM </span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6YmFkYzVjYWRiMDU3NDI2ZDk3M2IwMzVlNzg0NTAzYmEvdGFibGVyYW5nZTpiYWRjNWNhZGIwNTc0MjZkOTczYjAzNWU3ODQ1MDNiYV8wLTEtMS0xLTI1NzM5_8ccc0a83-a238-48f8-9ac2-6ab60da473bf">10-K</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTY5_6365c179-7f8e-45fa-aa8d-cda21d54ddfa">&#9746;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18xOTQ_e9899c78-0497-4b45-abfc-1c743211bfc1"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18xOTQ_7527d47e-9ae2-420b-92b2-8aec6d3c5590">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTcz_2c56a141-8348-4d2b-9e19-f28d5e92f236">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the transition period from               to                     </span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zODU_916897d9-5290-4eb4-9099-f5dc941bf21f">000-30235</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:204.00pt"><tr><td style="width:1.0pt"></td><td style="width:202.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:47pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="exel-20211231_g1.jpg" alt="exel-20211231_g1.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"/></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6OTljZjdlMjI4MzBhNGQwODlhMGQ2Y2IzNzg2ZWUwMWUvdGFibGVyYW5nZTo5OWNmN2UyMjgzMGE0ZDA4OWEwZDZjYjM3ODZlZTAxZV8xLTAtMS0xLTI1NzM5_c8aea761-f3ca-48e4-abc9-f9758105014c">EXELIXIS, INC.</ix:nonNumeric></span></td></tr><tr style="height:11pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6MWJhYWQyZWNjYzNlNDdiYmEwNDY3MjQyYThhNjQ3MjIvdGFibGVyYW5nZToxYmFhZDJlY2NjM2U0N2JiYTA0NjcyNDJhOGE2NDcyMl8wLTAtMS0xLTI1NzM5_c8e2014a-4ed2-4c16-9b61-71d8b08d86d4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6MWJhYWQyZWNjYzNlNDdiYmEwNDY3MjQyYThhNjQ3MjIvdGFibGVyYW5nZToxYmFhZDJlY2NjM2U0N2JiYTA0NjcyNDJhOGE2NDcyMl8wLTEtMS0xLTI1NzM5_26b23738-db9d-44a3-8c44-afd8d05b844b">04-3257395</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTU_9b2d0a0c-bcff-430e-909c-cbe344295904">1851 Harbor Bay Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTk_76aae436-447f-4868-a10d-be68b6dce7b2">Alameda,</ix:nonNumeric> <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM180MDI_cc1b2cb2-25b3-47c8-8a22-4a5d89fc8d45">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM180MDU_0a91ce8e-ca0b-43b3-9c79-5b2f9a3446f2">94502</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM180MTA_69110b24-b0e8-4a3e-8ea2-7bdc17d51600">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM180MTQ_3e17aba7-7721-49e2-bb45-93001e0666ee">837-7000</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:38.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6MjNkMTc1NTA1NmZhNDBiMTllYWNjODY4ODdjMjMzZWEvdGFibGVyYW5nZToyM2QxNzU1MDU2ZmE0MGIxOWVhY2M4Njg4N2MyMzNlYV8xLTAtMS0xLTI1NzM5_6d7aafdc-f08f-446b-b5fb-ed45e7853fd2">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6MjNkMTc1NTA1NmZhNDBiMTllYWNjODY4ODdjMjMzZWEvdGFibGVyYW5nZToyM2QxNzU1MDU2ZmE0MGIxOWVhY2M4Njg4N2MyMzNlYV8xLTEtMS0xLTI1NzM5_342e7bd3-9f00-4d8a-9d20-94eaedffb2ef">EXEL</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6MjNkMTc1NTA1NmZhNDBiMTllYWNjODY4ODdjMjMzZWEvdGFibGVyYW5nZToyM2QxNzU1MDU2ZmE0MGIxOWVhY2M4Njg4N2MyMzNlYV8xLTItMS0xLTI1NzM5_bca6e70d-66f0-4db2-aeb6-1eee3c712086">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;<ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTY0_3042264f-7615-4744-b478-d11750063828">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTcw_b6625946-5f41-45e9-a72b-be8be3d464fe">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTY1_da9d2bdc-b0af-4b72-bbae-c7987bc29cdd">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTcx_cb6a9cab-083e-460e-8bfc-09903b031c69">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6YWI5NWU5ZGNlNzdmNDkwMTk0YTAwZjYzNjhiYmUxOGMvdGFibGVyYW5nZTphYjk1ZTlkY2U3N2Y0OTAxOTRhMDBmNjM2OGJiZTE4Y18wLTAtMS0xLTI1NzM5_784265cc-bd73-47b5-98f2-37d7f35fea44">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6YWI5NWU5ZGNlNzdmNDkwMTk0YTAwZjYzNjhiYmUxOGMvdGFibGVyYW5nZTphYjk1ZTlkY2U3N2Y0OTAxOTRhMDBmNjM2OGJiZTE4Y18xLTQtMS0xLTI1NzM5_dca6f3e6-ac10-41ec-b3bc-4e5c770e4792">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6YWI5NWU5ZGNlNzdmNDkwMTk0YTAwZjYzNjhiYmUxOGMvdGFibGVyYW5nZTphYjk1ZTlkY2U3N2Y0OTAxOTRhMDBmNjM2OGJiZTE4Y18yLTQtMS0xLTI1NzM5_83f2edd8-9731-49ed-9fd8-2de03205e698">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTY2_d43a6770-45c4-43e1-81fb-5a78f2516c26">&#9746;</ix:nonNumeric></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTY3_da1271e4-a851-45aa-a09a-139514c3c4b8">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter: $<ix:nonFraction unitRef="usd" contextRef="i79749347e30142e593fb3dd2087883ee_I20210702" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18yOTk5_a17fce87-e2cd-4229-8093-46ef98dd22bf">5,680,065,864</ix:nonFraction>. Excludes shares of the registrant&#8217;s common stock held by persons who were directors and/or executive officers of the registrant at&#160;July&#160;2, 2021&#160;on the basis that such persons may be deemed to have been affiliates of the registrant at such date. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Number shares of the registrant&#8217;s common stock outstanding as of February&#160;7, 2022:  <ix:nonFraction unitRef="shares" contextRef="i42b7e9e44a8149b69bfbe9366605fc00_I20220207" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zNTkz_0130330a-90bf-415b-a2c0-b855508c9ce8">319,448,174</ix:nonFraction></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTcy_4b78e0cf-fff1-4ef7-ad2d-07b66d0c5c21" escape="true">Certain portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than April 30, 2022, in connection with the registrant&#8217;s 2022 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K.</ix:nonNumeric></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_10">PART&#160;I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_16">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_19">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_22">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_25">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_28">61</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_31">PART&#160;II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_34">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_37">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_37">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_40">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_55">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_55">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_58">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_58">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_124">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_124">122</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_127">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_127">122</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_130">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_130">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_130">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_130">124</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_133">PART&#160;III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_136">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_136">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_139">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_139">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_142">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_142">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_145">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_145">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_148">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_148">125</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_151">PART IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_154">Exhibits</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_154"> and</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_154"> Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_154">126</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_157">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_157">130</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_160">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_160">131</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of the statements under the captions &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business&#8221; and elsewhere in this Annual Report on Form&#160;10-K are forward-looking statements. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed under the heading &#8220;Item&#160;1A. Risk&#160;Factors&#8221; as well as those discussed elsewhere in this Annual Report on Form 10-K. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our securities involves a high degree of risk. Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found under the heading &#8220;Item 1A. Risk Factors&#8221; below.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications and the continued clinical development, regulatory approval, clinical acceptance and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Pricing for pharmaceutical products, both in the U.S. and in foreign countries, has come under increasing attention and scrutiny by federal, state and foreign national governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">The entrance of generic competitors and legislative and regulatory action designed to reduce the barriers to the development, approval and adoption of generic drugs in the U.S. could limit the revenue we derive from our products, most notably CABOMETYX, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">We are subject to healthcare laws, regulations and enforcement, as well as laws and regulations relating to privacy, data collection and processing of personal data; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">The regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, uncertain and subject to change, and may not result in regulatory approvals for additional cabozantinib indications or for our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">We may be unable to expand our discovery and development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates, grow more quickly than the revenues we generate.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks. For example, we rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and we are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S. In addition, our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Data breaches, cyber attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BASIS OF PRESENTATION</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2021, which was a 52-week year, ended December 31, 2021, fiscal year 2020, which was a 52-week fiscal year, ended on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the fiscal years ended January 1, 2021 and January 3, 2020 are indicated as being as of and for the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_13"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 61 other countries as: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA, for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important drug in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo). For additional information about these products, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Other Collaborations.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The year 2021 was our fifth year of profitability. Our total revenues grew by approximately 45% as a result of markedly increased sales of our cabozantinib products by our commercial organization in the U.S. and increased royalties and milestones earned pursuant to collaboration agreements with our ex-U.S. partners. Our plan is to utilize our operating cash flows and cash and investments to expand the cabozantinib franchise by potentially adding new indications in areas of unmet medical need. We will also leverage our operating cash flows to continue advancing our diverse small molecule and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biotherapeutics programs, exploring multiple modalities and mechanisms of action to discover new oncology drugs. So far, these drug discovery and preclinical activities have resulted in four clinical-stage compounds: XL092, a next-generation oral tyrosine kinase inhibitor (TKI); XB002, an antibody drug conjugate (ADC) that targets tissue factor (TF); XL102, a potent, selective and orally bioavailable covalent inhibitor of c</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">yclin-dependent kinase 7 (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDK7); and XL114, a n</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ovel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 (CBM) complex</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exelixis Marketed Products: CABOMETYX and COMETRIQ</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed below, CABOMETYX and COMETRIQ have been approved to treat patients with various forms of cancer by the FDA for the U.S. market, the European Commission (EC) for the European Union (EU) markets and the Japanese Ministry of Health, Labour and Welfare (MHLW), as well as by comparable regulatory authorities across other markets worldwide.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approval Date</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regimen</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Major Markets</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="15" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX&#174;<br/>(cabozantinib)</span></td><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Renal Cell Carcinoma (RCC) </span></td></tr><tr style="height:51pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patients with advanced RCC who have received prior anti-angiogenic therapy</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 25, 2016</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:42pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Advanced RCC in adults following prior VEGF-targeted therapy</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 9, 2016</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with advanced RCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 19, 2017</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:56pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-line treatment of adults with intermediate- or poor-risk advanced RCC</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 17, 2018</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr><tr style="height:38pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with curatively unresectable or metastatic RCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2020</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line treatment of patients with advanced RCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 22, 2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination with OPDIVO&#174; (nivolumab)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line treatment for patients with advanced RCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination with OPDIVO</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with unresectable or metastatic RCC</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 25, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination with OPDIVO</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td></tr><tr style="height:15pt"><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hepatocellular Carcinoma (HCC)</span></td></tr><tr style="height:38pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HCC in adults who have previously been treated with sorafenib</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2018</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr><tr style="height:39pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with HCC who have been previously treated with sorafenib</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 14, 2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:53pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with unresectable HCC that has progressed after cancer chemotherapy</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 27, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td></tr><tr style="height:20pt"><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Differentiated Thyroid Cancer (DTC)</span></td></tr><tr style="height:132pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adult and pediatric patients 12 years of age and older with locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy and who are RAI-refractory or ineligible</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 17, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ&#174;<br/>(cabozantinib)</span></td><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medullary Thyroid Cancer (MTC)</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with progressive, metastatic MTC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 29, 2012</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:65pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adult patients with progressive, unresectable locally advanced or metastatic MTC</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2014</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 2020 and 2019, our U.S. commercial organization generated $1,077.3 million, $741.6 million and $760.0 million, respectively, in net product revenues from sales of CABOMETYX and COMETRIQ. Outside the U.S., we rely on collaboration partners for the commercialization of CABOMETYX and COMETRIQ; Ipsen Pharma SAS (Ipsen) is responsible for all territories outside of the U.S. and Japan, and Takeda Pharmaceutical Company Limited (Takeda) is responsible for the Japanese market. In 2021, 2020 and 2019, we earned $105.2 million, $78.4 million and $62.4 million, respectively, of royalties on net sales of cabozantinib products outside of the U.S. For additional information on the terms of our collaboration agreements with Ipsen and Takeda, see &#8220;&#8212;Collaborations and  Business Development Activities&#8212;Cabozantinib Commercial Collaborations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Renal Cell Carcinoma - CABOMETYX is a Leading TKI Treatment Option for Patients with Advanced RCC</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CABOMETYX has become a standard of care for the treatment of patients suffering from advanced RCC, and a growing number of these patients have been or will be treated with CABOMETYX. Kidney cancer is among the top ten most commonly diagnosed forms of cancer among both men and women in the U.S. Estimates suggest that approximately 33,000 patients in the U.S. and over 71,000 worldwide will require systemic treatment for kidney cancer in 2022, with over 15,000 patients in need of a first-line treatment in the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since CABOMETYX was first approved, we have deployed our promotional and medical affairs teams to educate physicians about CABOMETYX, and we believe that the product&#8217;s success is attributable to the strength of the clinical data reflected in its FDA-approved labeling for advanced RCC. The CABOMETYX label incorporates the results of the METEOR, CABOSUN and CheckMate -9ER clinical trials. In July 2015, we announced positive results of METEOR, a phase 3 pivotal trial comparing CABOMETYX to everolimus in patients with advanced RCC who have experienced disease progression following treatment with at least one prior VEGF receptor inhibitor. These results formed the basis for the FDA&#8217;s approval in April 2016, following which CABOMETYX became the first and only single-agent therapy approved in the U.S. for previously treated advanced RCC to demonstrate statistically significant and clinically meaningful improvements in three key efficacy parameters in a global pivotal trial: overall survival (OS); progression-free survival (PFS); and objective response rate (ORR). Subsequently, in October 2016, we announced positive results from CABOSUN, a randomized, open-label, active-controlled phase 2 trial conducted by the Alliance for Clinical Trials in Oncology, comparing cabozantinib with sunitinib in patients with previously untreated advanced RCC with intermediate- or poor-risk disease. These results formed the basis for the FDA&#8217;s approval in December 2017 of CABOMETYX for previously untreated patients with advanced RCC, and for this patient population, CABOMETYX is the only approved single-agent therapy to demonstrate improved PFS compared with sunitinib, a first-generation TKI that was the previous standard of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CABOMETYX has also demonstrated positive clinical results in combination with immune checkpoint inhibitors (ICIs), most notably in CheckMate -9ER, an open-label, randomized, multinational phase 3 pivotal trial evaluating OPDIVO, an ICI developed by BMS, in combination with CABOMETYX versus sunitinib in patients with previously untreated, advanced or metastatic RCC. Results from CheckMate -9ER demonstrated that the combination of CABOMETYX and OPDIVO doubled PFS and ORR and reduced the risk of disease progression or death by 40% compared with sunitinib, and formed the basis for the FDA&#8217;s approval of the combination in January 2021 as a first-line treatment of patients with advanced RCC. The National Comprehensive Cancer Network (NCCN),</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the nation&#8217;s foremost non-profit alliance of leading cancer centers,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has included the combination of CABOMETYX with OPDIVO in its Clinical Practice Guidelines for Kidney Cancer as a Category 1 option for the first-line treatment of patients with clear cell RCC. The NCCN also lists single-agent CABOMETYX as a category 1 preferred regimen in subsequent treatments for patients with clear cell RCC, and as a preferred systemic therapy regimen for non-clear cell RCC, supporting CABOMETYX&#8217;s position in the RCC treatment landscape.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In markets outside the U.S. in 2021, we continued to work closely with our collaboration partner Ipsen in support of its regulatory strategy and commercialization efforts for CABOMETYX as a treatment for advanced RCC, both as a single </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agent and in combination with OPDIVO, as well as in preparation for submission of applications for approvals of CABOMETYX in combination with other therapies, and similarly with our collaboration partner Takeda with respect to the Japanese market. As a result of the approvals of CABOMETYX and/or the combination of CABOMETYX with OPDIVO for RCC indications in 61 countries outside of the U.S., including the Member States of the EU, Japan, the U.K., Canada, Brazil, Taiwan, South Korea and Australia, CABOMETYX has continued to grow markedly outside the U.S. both in sales revenue and the number of RCC patients benefiting from its clinical effect. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hepatocellular Carcinoma - CABOMETYX Offers an Important Alternative for Patients with Previously Treated HCC</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to published studies, liver cancer is a leading cause of cancer death worldwide, accounting for more than 800,000 deaths and 900,000 new cases each year. Although HCC is the most common form of liver cancer, making up about three-fourths of the more than 41,000 cases of liver cancer estimated to be diagnosed in the U.S. during 2022, this patient population has long been underserved. Prior to 2017, there was only one approved systemic therapy for the treatment of HCC. Since that time, multiple new therapies were approved in the U.S. for HCC, both for previously untreated patients and for patients previously treated with sorafenib. Given the introduction of new and demonstrably more effective therapies, including ICI combination therapies, we believe the second- and later-line market for HCC therapies has the potential to grow significantly in coming years, as these new treatment options are expected to improve longer-term outcomes, thereby resulting in a greater number of patients receiving multiple lines of therapy. With the approval of CABOMETYX in January 2019 for HCC patients previously treated with sorafenib, we expect to continue to play a key role in the treatment landscape for these patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s approval of CABOMETYX&#8217;s HCC indication was based on our phase 3 pivotal study, CELESTIAL. The CELESTIAL study met its primary endpoint, demonstrating that cabozantinib significantly improved OS, as compared to placebo. The NCCN has included CABOMETYX in its Clinical Practice Guidelines for Hepatobiliary Cancers as a Category 1 option for the treatment of patients with HCC (Child-Pugh Class A only) who have been previously treated with sorafenib, providing further support for CABOMETYX as an important treatment option for eligible HCC patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., the EC&#8217;s approval of CABOMETYX provided physicians in the EU with a second approved therapy for the second-line treatment of this aggressive and difficult-to-treat cancer, and approvals from Health Canada and the Japanese MHLW brought a much-needed therapy to HCC patients in those countries. In addition to the Member States of the EU, Japan, the U.K. and Canada, CABOMETYX is also approved for previously treated HCC indications in Brazil, Taiwan, South Korea, Australia and Hong Kong, among other countries.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Differentiated Thyroid Cancer - a New Opportunity for CABOMETYX to Help an Underserved Patient Population </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Published studies indicate that approximately 44,000 new cases of thyroid cancer will be diagnosed in the U.S. in 2022. Differentiated thyroid tumors, which make up about 90% of all thyroid cancers, are typically treated with surgery followed by ablation of the remaining thyroid with radioiodine (RAI). Approximately 5% to 15% of differentiated thyroid tumors are resistant to RAI treatment. With limited treatment options, these patients have a life expectancy of only three to six years from the time metastatic lesions are detected. New treatment options are therefore urgently needed.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced that COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib in patients with RAI-refractory DTC who have progressed after up to two prior VEGF receptor-targeted therapies, met its co-primary endpoint of demonstrating significant improvement in PFS as compared with placebo. These results formed the basis for the FDA&#8217;s approval in September 2021 of CABOMETYX f</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy and who are RAI-refractory or ineligible. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced the commercial launch of CABOMETYX in this patient group upon the FDA&#8217;s approval, and we have seen a strong uptake in prescriptions for CABOMETYX in previously treated DTC during the months that followed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., our collaboration partner Ipsen </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">submitted a variation application to the European Medicines Agency (EMA) seeking approval of CABOMETYX as a treatment for patients with previously treated, RAI-refractory DTC, with the EMA validating the variation application and beginning its centralized review process in August 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medullary Thyroid Cancer - COMETRIQ, the First Commercial Approval of Cabozantinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates suggest that there will be approximately 940 MTC cases diagnosed in the U.S. in 2022, and COMETRIQ has served as an important treatment option for these patients since January 2013. The FDA&#8217;s approval of COMETRIQ for progressive, metastatic MTC was based on our phase 3 trial, EXAM. The EXAM trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful prolongation in PFS for cabozantinib, as compared to placebo. In connection with the approval of COMETRIQ for the treatment of progressive, metastatic MTC, we were subject to post-marketing requirements, including a requirement to conduct the EXAMINER clinical study, comparing a lower 60mg dose of cabozantinib with the labeled dose of 140 mg. Although EXAMINER did not meet the prespecified statistical noninferiority criterion for PFS (per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1. as assessed by independent review) in the cabozantinib 60 mg arm compared with the 140 mg arm, it provided another rich data set of cabozantinib experience in MTC. In the meantime, we will continue to market COMETRIQ c</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">apsules for MTC patients at the labeled dose of 140 mg.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exelixis Development Programs</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have extensive expertise in the clinical development of oncology products, which we leverage when exploring additional clinical uses of cabozantinib in combination with other therapies and advancing that effort to new regulatory approvals. Those activities comprise the broad cabozantinib development program described below. In addition, we also apply that expertise to advancing our company&#8217;s next generation of cancer treatments: new, innovative therapies that have the potential to help future cancer patients recover stronger and live longer. Accordingly, we are initiating clinical studies for our small molecule drug candidates&#8212;XL092, XL102 and XL114&#8212;as well as for our first biotherapeutics product candidate, XB002, and these activities are described under &#8220;&#8212;Other Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cabozantinib and other development programs is provided below.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Development Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cabozantinib inhibits the activity of tyrosine kinases, including MET, AXL, VEGF receptors, and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance and maintenance of the tumor microenvironment. Objective tumor responses have been observed in patients treated with cabozantinib in multiple individual tumor types investigated in phase 1, 2 and 3 clinical trials to date, reflecting the medicine&#8217;s broad clinical potential. We continue to evaluate cabozantinib, both as a single agent and in combination with ICIs, in a broad development program comprising over 100 ongoing or planned clinical trials across multiple tumor types. We, along with our collaboration partners, sponsor some of those trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator sponsored trial (IST) program. In addition to co-funding select trials with us, our collaboration partners Ipsen and Takeda also conduct trials in their respective territories through similar independently-sponsored programs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following two tables summarize select cabozantinib clinical development activities, one describing studies that evaluate the potential of cabozantinib as a single-agent, and the other describing studies that evaluate the potential of cabozantinib in combination with other therapies, including ICIs:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CLINICAL DEVELOPMENT PROGRAM FOR CABOZANTINIB, SINGLE-AGENT</span></td></tr><tr><td colspan="3" style="background-color:#40aeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#40aeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status Update</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thyroid Cancer</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Progressive, metastatic medullary thyroid cancer</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in U.S. and EU (EXAM)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second-line differentiated thyroid cancer (DTC) after prior VEGF receptor-targeted therapy</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in U.S. (COSMIC-311)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Renal Cell Carcinoma (RCC)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in U.S., EU and Japan (METEOR and CABOSUN)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First- or second-line papillary RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Randomized phase 2&#8224; (PAPMET/SWOG S1500)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic variant histology RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* (CABOSUN II)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Locally advanced non-metastatic clear cell RCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clear cell or non-clear cell metastatic RCC</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hepatocellular Carcinoma (HCC)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second- and later-line HCC after prior sorafenib</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in U.S., EU and Japan (CELESTIAL)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced HCC with Child-Pugh class B cirrhosis after first-line therapy</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Small Cell Lung Cancer (NSCLC)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molecular alterations in RET, ROS1, MET, AXL, or NTRK1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Trials </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-risk prostate cancer</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* (SPARC)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic castration-resistant prostate cancer (mCRPC) with genomic alterations</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic urothelial carcinoma (UC)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* (ATLANTIS)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced or metastatic UC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224;</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorectal cancer (CRC)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-grade uterine sarcomas</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#167;</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pancreatic neuroendocrine tumors and carcinoid tumors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* and Phase 3&#8224; (CABINET)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic adrenocortical carcinoma</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic pheochromocytomas and paragangliomas</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plexiform neurofibromas (pediatric and adult cohorts)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroendocrine neoplasms</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soft-tissue sarcomas</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224;</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refractory germ cell tumors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-risk pediatric solid tumors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* (CaboMain)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pediatric refractory sarcoma, Wilms tumor and other rare tumors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-grade pediatric glioma</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Trial conducted through our IST program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8224; &#160;&#160;&#160;&#160;Trial conducted through collaboration with NCI-CTEP.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#167; &#160;&#160;&#160;&#160;Trial sponsored by the European Organization for Research and Treatment of Cancer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CLINICAL DEVELOPMENT PROGRAM FOR CABOZANTINIB, IN COMBINATION WITH OTHER THERAPIES</span></td></tr><tr><td colspan="3" style="background-color:#40aeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#40aeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Combination Regimen</span></td><td colspan="3" style="background-color:#40aeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status Update</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Genitourinary Cancers</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line advanced RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in U.S., EU and Japan (CheckMate -9ER)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line advanced or metastatic RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 pivotal trial (COSMIC-313)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">mCRPC that progressed during or following treatment with one novel hormonal therapy (NHT)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ atezolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 pivotal trial (CONTACT-02)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced RCC that progressed during or following treatment with an immune checkpoint inhibitor (ICI)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ atezolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 pivotal trial (CONTACT-03)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line metastatic RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab vs. nivolumab after 4 cycles of nivolumab + ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3&#8224; randomized (PDIGREE)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced or metastatic non-clear cell RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced RCC with bone metastasis</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ radium-223 dichloride</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224; (RadiCaL)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cisplatin-Ineligible advanced UC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ pembrolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* (PemCab)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neoadjuvant muscle-invasive UC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ atezolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* (ABATE)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genitourinary tumors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab &#177; ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1b&#8224;</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genitourinary tumors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224; (ICONIC)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced non-clear cell RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab after cytoreductive surgery</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* (Cyto-KIK)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ avelumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1b*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Locally advanced or metastatic UC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ enfortumab vedotin</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic hormone-sensitive prostate cancer</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ abiraterone + nivolumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1* (CABIOS)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic RCC</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab &#177; CBM 588</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1*</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gastrointestinal Cancers</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line advanced HCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ atezolizumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 pivotal trial (COSMIC-312), including a single-agent cabozantinib arm</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First- and later-line advanced HCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab &#177; ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1/2 (CheckMate 040)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neoadjuvant locally advanced HCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#177; nivolumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1b*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HCC who are not candidates for curative intent treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab + transarterial chemoembolization</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced HCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ pembrolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refractory metastatic microsatellite stable CRC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+nivolumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic, refractory pancreatic cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ atezolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic pancreatic adenocarcinoma</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+pembrolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic colorectal adenocarcinoma</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+trifluridine/tipiracil</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1*</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thyroid Cancers</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced DTC</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224;</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lung Cancers</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic NSCLC previously treated with an ICI and platinum-containing chemotherapy</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ atezolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 pivotal trial (CONTACT-01)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously treated non-squamous NSCLC</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Randomized phase 2&#8224;</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gynecologic Cancers</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced or metastatic endometrial cancer</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224;</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroendocrine Tumors (NET) and Carcinoid</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced carcinoid tumors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poorly differentiated neuroendocrine carcinomas</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224;</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Head and Neck Cancers</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recurrent, metastatic squamous cell carcinoma</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ cetuximab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recurrent, metastatic squamous cell carcinoma</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ pembrolizumab</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Melanoma</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unresectable, advanced melanoma</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced, metastatic melanoma</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ pembrolizumab</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sarcoma</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ temozolomide</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sarcomas of the extremities</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ radiation therapy</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic soft tissue sarcomas</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ PD-1 + CTLA-4 inhibition</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angiosarcoma pre-treated with taxane</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224;</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Trials in Multiple Tumor Types</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced solid tumors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ atezolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1b (COSMIC-012) with 20 cabozantinib and atezolizumab expansion cohorts, including mCRPC, RCC, UC, HCC, colorectal adenocarcinoma, DTC, NSCLC, endometrial cancer, ovarian cancer, breast cancer, gastric or gastroesophageal junction adenocarcinoma and head and neck cancer, and two single-agent cabozantinib exploratory cohorts (NSCLC and mCRPC), and one single-agent atezolizumab exploratory cohort (mCRPC)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced CRC, HCC, gastric, gastroesophageal or esophageal adenocarcinoma</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ durvalumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1* (CAMILLA)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or recurrent gastric or gastro-esophageal adenocarcinoma</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ pembrolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced non-squamous NSCLC, UC and advanced malignant mesothelioma</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ pemetrexed</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiple solid tumor types and HIV</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1&#8224;</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced solid tumors</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ pamiparib</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1*</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pediatric multiple tumor types</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ retinoic acid</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1*</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Trial conducted through our IST program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8224; &#160;&#160;&#160;&#160;Trial conducted through collaboration with NCI-CTEP.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#167; &#160;&#160;&#160;&#160;Trial sponsored by the European Organization for Research and Treatment of Cancer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trials Conducted Under our Clinical Collaboration Agreements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to invest significantly in the exploration of additional clinical uses of cabozantinib in combination with other therapies. In particular, given that clinical observations from clinical trials evaluating cabozantinib in combination with ICIs have shown promising activity across a diverse range of tumors, and that patients have been able to tolerate these drug combinations, we are focused on the potential of cabozantinib in combination with ICIs in additional late-stage or other potentially label-enabling trials. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Combination Studies with BMS</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a clinical collaboration agreement with BMS for the purpose of conducting clinical studies combining cabozantinib with BMS&#8217; PD-1 ICI, nivolumab, both with or without BMS&#8217; CTLA-4 ICI, ipilimumab. Based on the data from CheckMate -9ER, the first clinical trial conducted under this collaboration, the FDA approved CABOMETYX in combination with OPDIVO on January 22, 2021 as a first-line treatment of patients with advanced RCC. We continue to evaluate these combinations in COSMIC-313, a phase 3 pivotal trial in previously untreated advanced RCC. Pursuant to our agreements with BMS, each party is responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each trial is determined on a trial-by-trial basis. For additional information on the terms of the clinical trial collaboration agreement, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Cabozantinib Development Collaborations&#8212;BMS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RCC - COSMIC-313. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we initiated COSMIC-313, a multicenter, randomized, double-blinded, controlled phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. Patients were randomized 1:1 to the experimental arm of the triplet combination of cabozantinib, nivolumab and ipilimumab or to the control arm of nivolumab and ipilimumab in combination with matched placebo. The primary endpoint for the trial is PFS, and secondary endpoints include OS and ORR. Based on long-term follow-up results for CheckMate 214, in which the combination of nivolumab and ipilimumab showed a longer median OS compared to original assumptions, we expanded the enrollment target for COSMIC-313 to provide additional power to assess the secondary endpoint of OS for COSMIC-313. We completed the expanded enrollment of 855 patients in March 2021 and expect to report top-line results of the event-driven analyses from the trial in the first half of 2022. We are sponsoring COSMIC-313, and BMS is providing nivolumab and ipilimumab for the study free of charge.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Combination Studies with Roche</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diversifying our exploration of cabozantinib combinations with ICIs, in February 2017, we entered into a master clinical supply agreement with F. Hoffmann-La Roche Ltd. (Roche) for the purpose of evaluating cabozantinib and Roche&#8217;s anti-PD-L1 ICI, atezolizumab, in locally advanced or metastatic solid tumors. As part of the clinical supply agreement, we are evaluating this combination in a phase 1b trial in locally advanced or metastatic tumors, COSMIC-021, and a phase 3 pivotal trial in previously untreated advanced HCC. Informed by the data generated from COSMIC-021, we also entered into a joint clinical research agreement with Roche in December 2019, pursuant to which we are evaluating this combination in three late-stage clinical trials: the first, CONTACT-01, focuses on patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with an ICI and platinum-containing chemotherapy; the second, CONTACT-02, focuses on patients with metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with one novel hormonal therapy (NHT); and the third, CONTACT-03, focuses on patients with inoperable, locally advanced or metastatic RCC who have progressed during or following treatment with an ICI as the immediate preceding therapy. For additional information on the terms of the joint clinical research agreement, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Cabozantinib Development Collaborations&#8212;Roche</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Locally Advanced or Metastatic Solid Tumors - COSMIC-021</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors. We are the trial sponsor of COSMIC-021, and Roche is providing atezolizumab free of charge. The study is divided into two parts: a dose-escalation phase, which was completed in 2018; and an expansion cohort phase, which is ongoing. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment in the expansion phase of this study includes 20 combination therapy tumor expansion cohorts in NSCLC, mCRPC, RCC and various other tumor types. Encouraging efficacy and safety data has emerged from the trial and has been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting the initiation of COSMIC-312, CONTACT-01, CONTACT-02 and CONTACT-03. Moreover, certain cohorts have been expanded, including a cohort of patients with mCRPC who have been previously treated with enzalutamide and/or abiraterone acetate and experienced radiographic disease progression in soft tissue (Cohort 6) and a cohort of patients with NSCLC who have been previously treated with an ICI. Data from Cohort 6, announced in May 2021 and presented at the European Society for Medical Oncology (ESMO) 2021 Congress in September 2021, resulted in an investigator assessed ORR per RECIST v. 1.1 of 23% and a blinded independent radiology committee (BIRC) assessed ORR per RECIST v. 1.1 of 15%. Other more detailed results from Cohort 6 were also presented at the ESMO 2021 Congress, including investigator assessed PFS per RECIST v. 1.1 of 5.5 months and BIRC assessed PFS per RECIST v. 1.1 of 5.7 months. While these results show promise, following discussions with the FDA, we will not pursue a regulatory submission for the combination regimen based </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">solely on the Cohort 6 results; however, we will continue to evaluate the combination regimen in patients with previously treated mCRPC in the CONTACT-02 phase 3 pivotal trial. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HCC - COSMIC-312. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. The trial also includes a third arm evaluating cabozantinib monotherapy in this first-line setting in order to address the contribution of components for the combination therapy. We are sponsoring COSMIC-312, and Ipsen is co-funding the trial. Ipsen will have access to the results to support potential future regulatory submissions outside of the U.S. and Japan. Roche is providing atezolizumab free of charge. In August 2020, we announced the completion of patient enrollment in COSMIC-312, providing the requisite patient population to conduct the event-driven analyses of the trial&#8217;s two primary endpoints of PFS and OS. Separately, patient enrollment remains open in mainland China in order to enroll a sufficient number of patients to enable local registration, if supported by the clinical data. Patients are being randomized to one of three arms: cabozantinib (40 mg) in combination with atezolizumab; sorafenib; or cabozantinib monotherapy (60 mg). </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June and November 2021, we announced results from COSMIC-312, which were presented at the ESMO Asia Virtual Oncology Week in November 2021. The trial met one of the primary endpoints, demonstrating significant improvement in BIRC assessed PFS at the planned primary analysis, reducing the risk of disease progression or death by 37% compared with sorafenib (hazard ration [HR]: 0.63; 99% confidence interval [CI]: 0.44-0.91; P=0.0012; pre-specified critical P-value of 0.01). Median PFS was 6.8 months for cabozantinib in combination with atezolizumab versus 4.2 months for sorafenib. The interim OS analysis performed at the same time did not reach statistical significance (HR: 0.90; 96% CI: 0.69-1.18; P=0.438). Median OS was 15.4 months for cabozantinib in combination with atezolizumab versus 15.5 months for sorafenib. The trial is continuing as planned to the final analysis of OS, anticipated during the first quarter of 2022, and we intend to submit an sNDA to the FDA for the combination regimen if supported by the final OS analysis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NSCLC - CONTACT-01. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lung cancer is the second most common type of cancer in the U.S., with more than 236,000 new cases expected to be diagnosed in 2022. The disease is the leading cause of cancer-related mortality in both men and women, causing 25% of all cancer-related deaths. The majority (84%) of lung cancer cases are NSCLC, which mainly comprise adenocarcinoma, squamous cell carcinoma and large cell carcinoma. The five-year survival rate for patients with NSCLC is 25%, but that rate falls to just 7% for those with advanced or metastatic disease. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the urgent need for treatment options for patients with NSCLC and based on positive early-stage results from COSMIC-021, in June 2020, we and Roche initiated CONTACT-01, a global, multicenter, randomized, open-label phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus docetaxel in patients with metastatic NSCLC who have been previously treated with an ICI and platinum-containing chemotherapy. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients are randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab or to the control arm of docetaxel. The primary endpoint for the trial is OS, and secondary endpoints include PFS, ORR and DOR, in each case per RECIST v. 1.1.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2021, we announced the completion of enrollment of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">366 patients at 117 sites globally. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on current event rates, we anticipate announcing results of the interim OS analysis in the second half of 2022. CONTACT-01 is sponsored by Roche and co-funded by us. In addition, both Ipsen and Takeda have opted into and are co-funding the trial, and both companies will have access to the results to support potential future regulatory submissions in their respective territories outside of the U.S. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">mCRPC - CONTACT-02. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Cancer Society</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in 2022, approximately 268,500 new cases of prostate cancer will be diagnosed, and 34,500 people will die from the disease. Prostate cancer that has spread beyond the prostate and does not respond to androgen-suppression therapies&#8212;a common treatment for prostate cancer&#8212;is known as mCRPC. Researchers estimate that in 2020, 43,000 men were diagnosed with mCRPC, which has a median survival of less than two years. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to this significant unmet need and based on positive early-stage results from Cohort 6 of COSMIC-021, in June 2020, we and Roche initiated CONTACT-02, a global, multicenter, randomized, open-label phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab in patients with mCRPC who have been previously treated with one NHT. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he trial aims to enroll approximately 580 patients at approximately 280 sites globally, and we expect to complete enrollment in the second half of 2022. Patients are being randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab or to the control arm of a second NHT (either abiraterone and prednisone or enzalutamide). The two primary endpoints for the trial are PFS per RECIST v. 1.1 as assessed by BIRC and OS, and secondary endpoints include ORR, prostate-specific antigen response rate and DOR. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONTACT-02 is sponsored by us and co-funded by Roche. In addition, both Ipsen and Takeda have opted into and are co-funding the trial, and both companies will have access to the results to support potential future regulatory submissions in their respective territories outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RCC - CONTACT-03. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taking into account the rapidly evolving treatment landscape for RCC and based on positive early-stage results from COSMIC-021, in July 2020, we and Roche initiated CONTACT-03, a global, multicenter, randomized, open-label phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus cabozantinib alone in </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients with inoperable, locally advanced or metastatic RCC who progressed </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during or following treatment with an ICI as the immediate preceding therapy</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients are randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab or to the control arm of cabozantinib alone. The two primary endpoints for the trial are PFS per RECIST v. 1.1 as assessed by BIRC and OS, and secondary endpoints include PFS, ORR and DOR as assessed by the investigators. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONTACT-03 is sponsored by Roche and co-funded by us. In addition, both Ipsen and Takeda have the right to opt in and co-fund the trial and if doing so, they will have access to the results to support potential future regulatory submissions in their respective territories outside of the U.S. In January 2022, we announced the completion of enrollment of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">523 patients at 168 sites globally.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on current event rates, we anticipate announcing results of PFS and the first interim OS analysis in the second half of 2022.  We intend to use the data from CONTACT-03 to further study the therapeutic potential of cabozantinib in this patient population, both as a single agent and in combination with ICIs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Trials Evaluating Cabozantinib in Combination with other Therapies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RCC - CANTATA</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In January 2021 Calithera Biosciences, Inc. (Calithera) announced that the CANTATA trial did not meet its primary endpoint of improving PFS per independent review for Calithera&#8217;s teleaglenastat (also known as CB-839) plus cabozantinib as compared with cabozantinib alone in previously treated advanced or metastatic RCC. The HR was 0.94 (p=0.65), and median PFS was 9.2 months among patients treated with telaglenastat and cabozantinib as compared to 9.3 months for patients treated with cabozantinib and placebo. We provided cabozantinib for the trial through a material supply agreement with Calithera.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trials Conducted through our CRADA with NCI-CTEP and our IST Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2011, we entered into a CRADA with NCI-CTEP for the clinical development of cabozantinib. The CRADA and our IST program have enabled further expansion of the cabozantinib development program with less burden on our internal development resources. This CRADA reflects a major commitment by NCI-CTEP to support the broad exploration of cabozantinib&#8217;s potential in a wide variety of cancers, each representing a substantial unmet medical need. Through this mechanism, NCI-CTEP provides funding for as many as 20 active clinical trials of cabozantinib each year for a five-year period. We and NCI-CTEP have extended the term of the CRADA through October 2026, provided that both parties maintain the right to terminate the CRADA for any reason upon sixty days&#8217; notice, for an uncured material breach upon thirty days&#8217; notice and immediately for safety concerns. Investigational New Drug (IND) applications for trials under the CRADA are held by NCI-CTEP. NCI-CTEP also retains rights to any inventions made in whole or in part by NCI-CTEP investigators.&#160;However, for inventions that claim the use and/or the composition of cabozantinib, we have an automatic option to elect a worldwide, non-exclusive license to cabozantinib inventions for commercial purposes, with the right to sublicense to affiliates or collaborators working on our behalf, as well as an additional, separate option to negotiate an exclusive license to cabozantinib inventions.&#160;Further, before any trial proposed under the CRADA may commence, the protocol is subject to our review and approval, and the satisfaction of certain other conditions. As reflected by the results from completed trials and given the numerous ongoing and planned clinical trials, we believe our CRADA with NCI-CTEP has and will enable us to continue to expand the cabozantinib development program broadly in a cost-efficient manner. A summary of key trials under this collaboration is provided below.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advanced Genitourinary Tumors</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDIGREE is a phase 3 trial led by The Alliance that is enrolling 1,046 intermediate- or poor-risk advanced RCC patients who have a clear cell component in their tumors. All patients are initially treated with up to 4 cycles of induction ipilimumab combined with nivolumab. Subsequently, patients are treated based on their response to the induction therapy. Patients achieving a complete response (CR) continue on maintenance nivolumab, while patients with progressive disease (PD) are switched to cabozantinib monotherapy. Patients who neither achieve a CR nor develop PD during induction are randomized 1:1 to either maintenance nivolumab or nivolumab in combination with cabozantinib 40 mg daily. The primary endpoint is OS, while PFS, CR rate, ORR and safety are among the secondary endpoints.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, positive initial results were announced from PAPMET (also known as SWOG S1500), a randomized phase 2 trial conducted by the Southwest Oncology Group evaluating cabozantinib versus sunitinib in patients with metastatic papillary RCC. PAPMET met its primary endpoint, demonstrating a statistically significant and clinically meaningful prolongation of PFS, with a median PFS of 9.0 months for cabozantinib (95% CI: 6-12) versus 5.6 months for sunitinib (95% CI: 3-7) (</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HR: 0.60; 95% CI: 0.37-0.97; P=0.019)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Detailed results from PAPMET were presented at the virtual American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in February 2021 and published in </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RADICAL is a randomized phase 2 trial being conducted by The Alliance that plans to enroll up to 210 patients with advanced RCC. All patients must have at least 2 sites of bone metastases and may have received up to 2 prior lines of systemic therapy. Patients are randomized 1:1 to be treated with cabozantinib in combination with radium-223 dichloride or cabozantinib as a single agent. The primary endpoint is symptomatic skeletal event-free survival, while secondary endpoints include PFS, OS, ORR and safety.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neuroendocrine Tumors</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Alliance is leading the CABINET study that treats patients with well- or moderately-differentiated neuroendocrine tumors (NETs). CABINET includes 2 separate randomized studies, one for patients with pancreatic NETs and the other for patients with carcinoid tumors. The planned enrollment for the pancreatic NET study is 185 patients and for the carcinoid study is 210 patients. Both studies randomize previously treated patients 2:1 to cabozantinib 60 mg daily or placebo. The primary endpoint for both studies is PFS per Response Evaluation Criteria in Solid Tumors 1.1 as determined by a blinded IRRC. </span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Cancer Indications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, there are 66 ongoing and 26 planned externally sponsored trials evaluating the therapeutic potential of cabozantinib, including those administered through our CRADA with NCI-CTEP and our IST program.&#160;Like our CRADA with NCI-CTEP, our IST program helps us to continue to evaluate cabozantinib across a broad range of tumor types.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These externally sponsored trials include signal seeking studies of single-agent cabozantinib, novel combinations, and randomized trials.&#160;The monotherapy trials are focused on solid tumors including genitourinary neoplasms, gastrointestinal malignancies, lung cancer and a variety of less common tumor types.&#160;The combination studies include trials combining cabozantinib with several different ICIs, as well as studies adding cabozantinib to various other anti-cancer therapies, including monoclonal antibodies (mAbs), chemotherapeutic agents, small molecules which target specific cellular pathways, or radiation.&#160;In addition to the various trials described above, our CRADA includes an ongoing randomized phase 2 study in NSCLC, also in combination with an ICI.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A complete listing of all ongoing cabozantinib trials can be found at </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.ClinicalTrials.gov</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have advanced several other product candidates into clinical trials during recent years, including both small molecules and biotherapeutics that we have discovered or in-licensed and believe may have the potential to benefit patients with a variety of cancers. The following table summarizes our current and planned clinical development activities outside of the cabozantinib franchise:</span></div><div style="margin-top:9pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CLINICAL DEVELOPMENT PROGRAM FOR PIPELINE</span></div></td></tr><tr><td colspan="3" style="background-color:#40aeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product</span></div></td><td colspan="3" style="background-color:#40aeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Mechanism of Action</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#40aeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Setting</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#40aeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Status Update</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XL092</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next-generation tyrosine kinase inhibitor (TKI) targeting MET/VEGFR/AXL/MER</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced or metastatic solid tumors</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Phase 1b trials evaluating single-agent and immune checkpoint inhibitor (ICI)</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">combination regimens ongoing </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">In combination with atezolizumab and with avelumab (STELLAR-001)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">In combination with nivolumab, with nivolumab and ipilimumab and with nivolumab and bempegaldesleukin (STELLAR-002)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Potential to initiate late-stage trials in 2022 (including STELLAR-303) </span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XB002</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Next-generation tissue factor (TF)-targeting antibody-drug conjugate (ADC)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Advanced solid tumors</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1 trial evaluating single-agent ongoing <br/></span><span style="font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential to add combination regimens with ICIs and other targeted therapies in 2022</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XL102</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Potent, selective, orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Advanced or metastatic solid tumors</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Phase 1 trial evaluating single-agent</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and combination regimens ongoing</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.02pt">In combination with fulvestrant, with abiraterone and prednisone and potentially with other anti-cancer regimens</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XL114</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CARD11-BCL10-MALT1 (CBM) complex inhibitor</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Non-Hodgkin&#8217;s lymphoma (NHL)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1 trial evaluating single-agent planned for first half of 2022</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XL092 Development Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first compound discovered at Exelixis to enter the clinic following our re-initiation of drug discovery activities in 2017 was XL092, a next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer&#8217;s growth and spread. In designing XL092, we sought to build upon our experience with cabozantinib, retaining a similar target profile while improving key characteristics, including the pharmacokinetic half-life. We are evaluating XL092 in a growing clinical development program across various tumor types.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advanced Solid Tumors - STELLAR-001. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the FDA&#8217;s acceptance of our IND for XL092, in February 2019, we initiated STELLAR-001, a multicenter phase 1b clinical trial evaluating the pharmacokinetics, safety, tolerability and preliminary anti-tumor activity of XL092. STELLAR-001 is divided into dose-escalation and expansion phases. In October 2020, we presented data </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at the 32nd EORTC-NCI-AACR (ENA) Symposium that suggest XL092 has a desirable therapeutic profile. We believe it pairs the potential for significant anti-tumor activity with a much shorter clinical pharmacokinetic half-life than cabozantinib, and also presents the potential for synergistic effects in combination with ICIs. In consideration of these data, we amended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the phase 1 study protocol in October 2020 to include dose-escalation and expansion cohorts for XL092 in combination with atezolizumab, and again in March 2021 to include dose-escalation and expansion cohorts for XL092 in combination avelumab, an ICI developed by Merck KGaA, Darmstadt, Germany (Merck KGaA) and Pfizer Inc. (Pfizer). We are continuing to enroll patients into the dose-escalation cohorts of the combination part of the trial, and we expect that</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> once recommended doses are established for single-agent XL092, XL092 in combination with atezolizumab and XL092 in combination with avelumab, the trial will begin to enroll expansion cohorts for patients with clear cell and non-clear cell RCC, colorectal cancer (CRC), hormone-receptor positive breast cancer mCRPC and urothelial carcinoma (UC)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary efficacy endpoints for the expansion phase may include ORR per RECIST v. 1.1 and PFS per RECIST v. 1.1.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advanced Solid Tumors - STELLAR-002. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we initiated STELLAR-002, a multicenter phase 1 clinical trial evaluating the safety, tolerability and efficacy of XL092 in combination with either nivolumab, nivolumab and ipilimumab, or </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nivolumab and bempegaldesleukin, an investigational CD122-preferential IL-2&#8211;pathway agonist developed by Nektar Therapeutics (Nektar)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. STELLAR-002 is divided into dose-escalation and expansion phases. The dose-escalation phase of the trial is enrolling patients with advanced solid tumors and will determine the recommended dose in patients for each of the XL092 combination regimens. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the dose-escalation results, STELLAR-002 may enroll expansion cohorts for patients with clear cell and non-clear cell RCC, mCRPC and UC. The primary efficacy endpoint of the expansion phase will be ORR, except for the cohort of patients with mCRPC, for which the primary efficacy endpoint will be duration of radiographic PFS. To better understand the individual contribution of the therapies, treatment arms in the expansion cohorts may include XL092 as a single agent in addition to the ICI combination regimens.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to clinical updates for XL092 expected in 2022, we plan to initiate the first global phase 3 pivotal trial for the compound in the first half of the year, and other pivotal trials may follow throughout the year. This first planned trial, STELLAR-303, will evaluate XL092 in combination with atezolizumab versus regorafenib in patients with metastatic microsatellite stable CRC who have progressed after or are intolerant to the current standard of care. Preclinical data and emerging results from STELLAR-001 for XL092, both alone and in combination with ICIs, reinforce our belief in the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">opportunity for XL092, which pairs a target profile similar to cabozantinib with a potentially significantly improved safety profile. The decision to initiate STELLAR-303 is also supported by data from a CRC cohort of COSMIC-021, our phase 1b study evaluating cabozantinib in combination with atezolizumab, and from CAMILLA, a phase 1 IST evaluating cabozantinib in combination with durvalumab or with durvalumab and tremelimumab. Results from both of these trials were presented at the ASCO Gastrointestinal Cancers Symposium in January 2022. We intend to develop XL092 in novel combination regimens in a broad array of future potential indications where cabozantinib has demonstrated RECIST v. 1.1 anti-tumor activity.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XB002 Development Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XB002 (formerly ICON-2) is our lead TF-targeting ADC program, which we in-licensed from Iconic, Inc. (Iconic). XB002 is an ADC composed of human mAb against TF that is conjugated to a cytotoxic agent. TF is highly expressed on tumor cells and in the tumor microenvironment, and TF overexpression, while not oncogenic itself, facilitates angiogenesis, metastasis and other processes important to tumor development and progression. After binding to TF on tumor cells, XB002 is internalized, and the cytotoxic agent is released, resulting in targeted tumor cell death. XB002 is a rationally designed next-generation ADC that leverages proprietary linker-payload technology. Based on promising preclinical data</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we exercised our exclusive option to license XB002 in December 2020, resulting in our assuming responsibility for all subsequent clinical development of XB002. For additional information on our business development activities with Iconic, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations, In-licensing Arrangements and Other Business Development Activities&#8212;Iconic.&#8221; </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the FDA&#8217;s acceptance of our IND for XB002, in June 2021, we initiated a multicenter phase 1, open-label clinical trial</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">designed to evaluate its</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety, tolerability, pharmacokinetics and preliminary anti-tumor activity in patients with advanced solid tumors. The trial is divided into dose-escalation and cohort-expansion phases. The dose-escalation phase of the trial is enrolling patients with advanced solid tumors, with the primary objective of determining the maximum tolerated dose or recommended dose levels for intravenous infusion of XB002 as a single agent. Assuming positive data from the initial phase of the trial, the cohort-expansion phase is designed to further explore the selected dose of XB002 in individual tumor cohorts, which may include forms of NSCLC, cervical cancer, ovarian cancer, UC, squamous cell head and neck cancers, pancreatic cancer, esophageal cancer, mCRPC, triple negative breast cancer and hormone-receptor positive breast cancer, and will evaluate ORR per RECIST v. 1.1 as a primary endpoint as well as XB002&#8217;s safety, tolerability and pharmacokinetic profile. We expect to provide clinical updates from the ongoing phase 1 study of XB002 during 2022. We also intend to initiate additional dose-escalation and expansion cohorts to evaluate the potential of XB002 in combination with ICIs and other targeted therapies across a wide range of tumor types, including indications other than those currently addressed by commercially available TF-targeted therapies. Since initiating the XB002 phase 1 trial, we amended our exclusive option and license agreement with Iconic in December 2021 to acquire broad rights to use the anti-TF antibody used in XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics. </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our business development activities with Iconic, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations, In-licensing Arrangements and Other Business Development Activities&#8212;Iconic.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XL102 Development Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XL102 (formerly AUR102) is the lead compound under our research collaboration with Aurigene Discovery Technologies Limited (Aurigene). It is a potent, selective and orally bioavailable covalent inhibitor of CDK7, which is an important regulator of the cellular transcriptional and cell cycle machinery. Based on encouraging</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preclinical data for XL102, which we and Aurigene presented at the 32</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ENA Symposium in October 2020, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we exercised our exclusive option to license XL102 in December 2020, resulting in our assuming responsibility for all subsequent clinical development of XL102. For additional information on our collaboration with Aurigene, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations, In-licensing Arrangements and Other Business Development Activities&#8212;Aurigene.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the FDA&#8217;s acceptance of our IND for XL102, in January 2021, we initiated a multicenter phase 1, open-label clinical trial</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">designed to evaluate its</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety, tolerability, pharmacokinetics and preliminary anti-tumor activity, both as a single agent and in combination with other anti-cancer therapies, in up to 298 patients with inoperable, locally advanced or metastatic solid tumors. The trial is divided into dose-escalation and cohort-expansion phases. The dose-escalation phase of the trial is enrolling patients with advanced solid tumors, with the primary objective of determining the maximum tolerated dose or recommended dose levels for daily oral administration of XL102 as a single agent, as well as in combination with fulvestrant for patients with hormone-receptor positive breast cancer and with abiraterone and prednisone for patients with mCRPC. Combinations with other agents may also be evaluated. Assuming positive data from the initial phase of the trial, the cohort-expansion phase is designed to further explore the selected dose of XL102 as a </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">single agent and in combination regimens in individual tumor cohorts, including ovarian cancer, triple-negative breast cancer, hormone-receptor positive breast cancer and mCRPC, and will evaluate ORR per RECIST v. 1.1, as well as XL102&#8217;s safety, tolerability and pharmacokinetic profile. We expect to provide clinical updates from the ongoing phase 1 study of XL102 during 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XL114 Development Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XL114 (formerly AUR104) is </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a novel anti-cancer compound that inhibits activation of the CBM complex, a key component of signaling downstream of B- and T-cell receptors, which promotes B- and T-cell lymphoma survival and proliferation. Constitutive activation of B- or T-cell receptor signaling is a common feature of B-cell and T-cell lymphomas, and therefore we believe CBM is an attractive target for the development of new anti-cancer therapies with the potential to treat lymphoid malignancies. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notably, the CBM complex is downstream of BTK, inhibitors of which are approved therapies for certain B-cell lymphomas. Inhibitors of CBM complex activation may therefore provide options for patients who develop resistance to BTK inhibitors</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Association of Cancer Research</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Annual Meeting in April 2021, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurigene</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented preclinical data (Abstract 1266) demonstrating that XL114 exhibited potent anti-proliferative activity in a large panel of cancer cell lines ranging from hematological cancers to solid tumors with excellent selectivity over normal cells. We exercised our exclusive option to in-license XL114 in October 2021,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization of XL114. For additional information on our collaboration with Aurigene, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations, In-licensing Arrangements and Other Business Development Activities &#8212;Aurigene.&#8221; </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA accepted our IND application for XL114 in October 2021, and we plan to initiate a phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of the compound as a monotherapy in patients with non-Hodgkin&#8217;s lymphoma (NHL) in the first half of 2022. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial will be divided into dose-escalation and cohort-expansion phases and will aim to enroll approximately 144 patients with advanced NHL. The dose-escalation phase of the trial will determine the </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maximum tolerated dose or recommended dose levels for daily oral administration of XL114 as a monotherapy. Assuming positive data from the initial phase of the trial, the cohort-expansion phase</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will enroll subjects in cohorts with diffuse large cell B-cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, and mantle cell lymphoma, and will evaluate </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORR based on lymphoma-specific response criteria.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expansion of the Exelixis Pipeline</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working to expand our oncology product pipeline through drug discovery efforts, which encompass our diverse small molecule and biotherapeutics programs exploring multiple modalities and mechanisms of action. This approach provides a high degree of flexibility with respect to target selection and allows us to prioritize those targets that we believe have the greatest chance of yielding impactful therapeutics. As part of our strategy, our drug discovery activities include research collaborations, in-licensing arrangements and other strategic transactions that serve to increase our discovery bandwidth and allow us to access a wide range of technology platforms. We also opened a new laboratory building on our Alameda campus in 2021, effectively tripling our available lab space and significantly enhancing the capacity and capability of our small molecule discovery efforts. As of the date of this Annual Report, we are currently advancing more than 10 discovery programs and expect to progress up to five new development candidates into preclinical development during 2022. In addition, we will continue to engage in business development initiatives with the goal of acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Small Molecule Programs</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our small molecule discovery programs are supported by a robust and expanding infrastructure, including a library of 4.6 million compounds. We have extensive experience in the identification and optimization of drug candidates against multiple target classes for oncology, inflammation and metabolic diseases.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 1994, our drug discovery group has advanced 25 compounds to the IND stage, either independently or with collaboration partners, and today we deploy our drug discovery expertise in medicinal chemistry, tumor biology and pharmacology to advance small molecule drug candidates toward and through preclinical development. These efforts are led by our experienced scientists, including some of the same scientists that led the efforts to discover cabozantinib, cobimetinib and esaxerenone, each of which are now commercially distributed drug products. In pursuit of new drug discoveries, we concentrate our in-house work on the most demanding and time-sensitive aspects of lead optimization and use contract research organizations to support more routine activities, thereby minimizing our footprint </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">while still maintaining an agile, competitive approach. We also augment our small molecule discovery activities through research collaborations and in-licensing arrangements with other companies engaged in small molecule discovery, including:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">STORM Therapeutics LTD (STORM), which is focused on the discovery and development of inhibitors of novel RNA modifying enzymes, including ADAR1;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Aurigene, which is focused on the discovery and development of novel small molecules as therapies for cancer; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">StemSynergy</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutics, Inc. (StemSynergy), which is focused on the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting Casein Kinase 1 alpha (CK1&#945;) and the Notch pathway.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on these research collaborations and in-licensing arrangements related to our small molecule programs, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations, In-licensing Arrangements and Other Business Development Activities.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amongst our small molecule programs, furthest along are XL092, which was discovered at Exelixis, and XL102 and XL114, which were discovered at Aurigene. XL092 and XL102 entered the clinic in 2019 and 2021, respectively, and we plan to initiate a phase 1 clinical trial for XL114 in the first half of 2022. For additional information on these clinical trial programs, see &#8220;&#8212;Exelixis Development Programs&#8212;Other Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; In addition, we continue to make progress on multiple, additional lead optimization programs for inhibitors of a variety of targets that we believe play significant roles in tumor growth, and we anticipate that some of these other programs could reach development candidate status in 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biotherapeutics Programs</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also focusing our drug discovery activities on discovering and advancing various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, ADCs and other innovative treatments. The great potential of these classes has been evidenced by the multiple regulatory approvals for the commercial sale of ADCs in the past several years. To facilitate the growth of these programs, we have established multiple research collaborations and in-licensing arrangements and entered into other strategic transactions that provide us with access to antibodies and binders, which are the starting point for use with additional technology platforms that we employ to generate next-generation ADCs or multispecific antibodies. Our current research collaborations and in-licensing arrangements for biotherapeutics programs include: </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">WuXi Biologics Ireland Limited, a wholly owned subsidiary of WuXi Biologics (Cayman) Inc. (individually and collectively referred to as WuXi Bio), which is focused on leveraging WuXi Bio&#8217;s panel of mAbs for the development of ADC, bispecific and certain other novel tumor-targeting biotherapeutics applications;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Adagene Inc. (Adagene), which is focused on using Adagene&#8217;s SAFEbodyTM technology to develop novel masked ADCs or other innovative biotherapeutics with potential for improved therapeutic index;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc. (individually and collectively referred to as Catalent), which is focused on the discovery and development of multiple ADCs using Catalent&#8217;s proprietary SMARTag&#174; site-specific bioconjugation technology;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">N</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BE-Therapeutics AG (NBE), which is focused on the discovery and development of multiple ADCs by leveraging NBE&#8217;s unique expertise and proprietary platforms in ADC discovery, including NBE&#8217;s SMAC-Technology&#8482; (a site-specific conjugation technology) and novel payloads;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Iconic, which is focused on the advancement of a next-generation TF-targeting ADC program in solid tumors; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Invenra, Inc. (Invenra), which is focused on the discovery and development of novel binders and multispecific antibodies for the treatment of cancer.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have already made significant progress under these arrangements and believe we will continue to do so in 2022 and future years. For example, based on promising preclinical data for XB002, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we exercised our exclusive option to license XB002 in December 2020. Following the FDA&#8217;s acceptance of our IND for XB002 in April 2021, we initiated a phase 1 clinical trial in June 2021.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> For additional information on XB002, see &#8220;&#8212;Exelixis Development Programs&#8212;Other Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;XB002 Development Program.&#8221; Also, as a direct result of these arrangements, we designated XB010, our first ADC advanced internally, as a development candidate in late 2021. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XB010, which targets the tumor antigen 5T4, incorporates antibodies sourced from Invenra and was constructed using Catalent&#8217;s SMARTag site-specific bioconjugation platform.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, in May 2021, we </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">executed an asset purchase agreement with GamaMabs Pharma SA (GamaMabs), under which we will, upon the closing of the asset purchase and subject to certain conditions, acquire all rights, title and interest in GamaMabs&#8217; antibody program directed at anti-M&#252;llerian hormone receptor 2 (AMHR2), a novel oncology target with relevance in multiple forms of cancer. And most recently, in January 2022, we</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> announced an amendment to our May 2019 exclusive option and license agreement with Iconic to acquire broad rights to use the anti-TF antibody used in XB002 for any application, including conjugated to other payloads. For additional information on these specific research collaborations, in-licensing arrangements and other strategic transactions related to our biotherapeutics programs, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations, In-licensing Arrangements and Other Business Development Activities.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations and Business Development Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading biopharmaceutical companies for the commercialization and further development of the cabozantinib franchise. Additionally, we have made considerable progress under our existing research collaborations and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. We expect to enter into additional, external collaborative relationships around assets and technologies that complement our drug discovery and clinical development efforts. Consistent with our business strategy prior to the commercialization of our first product, COMETRIQ, we also entered into other collaborations with leading pharmaceutical companies including Genentech and Daiichi Sankyo for other compounds and programs in our portfolio. Under each of our collaborations, we are entitled to receive milestones and royalties or, in the case of cobimetinib, royalties from sales outside the U.S. and a share of profits (or losses) from commercialization in the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ipsen Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Under the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended on three occasions, including in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of $210.0 million in 2016. As of December&#160;31, 2021, we achieved aggregate milestone payments of $462.5 million related to regulatory and commercial progress by Ipsen since the inception of the collaboration agreement, including a milestone payment during 2021 of $12.5 million upon Ipsen&#8217;s submission of a variation application to the EMA for CABOMETYX as a treatment for patients with previously treated, RAI-refractory DTC. In addition, we recorded in license revenues a $100.0 million milestone from Ipsen in connection with the achievement of $400.0 million of net sales of cabozantinib in the related Ipsen license territory over four consecutive quarters, and we expect to receive the milestone payment in the first quarter of 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also eligible to receive future development and regulatory milestone payments from Ipsen, totaling an aggregate of $46.5 million upon additional approvals of cabozantinib in future indications and/or jurisdictions, as well as contingent payments of up to $350.0 million and CAD$26.5 million associated with future sales milestones. We will further receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. We were initially entitled to receive a tiered royalty of 2% to 12% on the initial $150.0 million of net sales; this amount was reached in the second quarter of 2018. During the year ended December&#160;31, 2021 and going forward, we are entitled to receive a tiered royalty of 22% to 26% on annual net sales, with separate tiers for Canada; these 22% to 26% royalty tiers reset each calendar year. As of December 31, 2021, we have earned royalties of $272.1 million on net sales of cabozantinib by Ipsen since the inception of the collaboration agreement. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on total net sales of any product containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Accordingly, and </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consistent with our historical agreement with GSK, we are required to pay a 3% royalty to Royalty Pharma on total net sales of any product incorporating cabozantinib, including net sales by Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for 35% of such costs, provided Ipsen chooses to opt into such trials. In accordance with the collaboration agreement, Ipsen has opted into and is co-funding certain clinical trials, including: CheckMate -9ER, COSMIC-021, COSMIC-311, COSMIC-312, CONTACT-01 and CONTACT-02. With respect to</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ipsen&#8217;s decision in the second quarter of 2021 to opt into and co-fund COSMIC-311 development costs, Ipsen is now responsible for 35% of the global development costs of COSMIC-311 and is obligated to reimburse us for these costs, as well as an additional payment calculated as a percentage of COSMIC-311 development costs, triggered by the timing of the exercise of its option.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Relatedly, we entered into a supply agreement with Ipsen to supply finished and labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a pharmacovigilance agreement, which defines each partner&#8217;s responsibilities for safety reporting. The pharmacovigilance agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from territories outside of the U.S. and Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (1) the expiration of patent claims related to cabozantinib, (2) the expiration of regulatory exclusivity covering cabozantinib or (3) ten years after the first commercial sale of cabozantinib, other than COMETRIQ. The supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the FDA or EMA orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended on three occasions to, among other things, modify the amount of reimbursements we receive for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive, as well as modify certain cost sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02. Under the collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of $50.0 million from Takeda in 2017. As of December&#160;31, 2021, we have also achieved regulatory and development milestones in the aggregate of $127.0 million related to regulatory and commercial progress by Takeda since the inception of the collaboration agreement, including milestone payments during 2021 of (1) $20.0 million upon Takeda&#8217;s first commercial sale in Japan of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable or metastatic RCC and (2) $15.0 million in connection with the initiations of CONTACT-01 and CONTACT-02. We are eligible </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to receive additional regulatory and development milestone payments, without limit, for additional potential future indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are further eligible to receive commercial milestones, including milestone payments earned for the first commercial sale of a product, of up to&#160;$119.0 million. We also receive royalties on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;15%&#160;to&#160;24%&#160;on the initial $300.0 million of net sales, and following this initial $300.0 million of net sales, we are then entitled to receive a tiered royalty of 20%&#160;to&#160;30%&#160;on annual net sales thereafter; these 20% to 30% royalty tiers reset each calendar year. As of December 31, 2021, we have earned royalties of $10.2&#160;million on net sales of cabozantinib by Takeda since the inception of the collaboration agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our historical agreement with GSK, we are required to pay a 3% royalty to Royalty Pharma on total net sales of any product incorporating cabozantinib, including net sales by Takeda. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for CONTACT-01 and CONTACT-02, Takeda is responsible for 20% of the costs associated with the cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and 100% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. In accordance with the collaboration agreement, Takeda has opted into and is co-funding CheckMate -9ER, certain cohorts of COSMIC-021, CONTACT-01 and CONTACT-02.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Relatedly, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#8217;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (1) two years after first generic entry with respect to such product in Japan or (2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first six years of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Development Collaborations </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BMS</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s ICIs, nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab as a treatment option for RCC in the COSMIC-313 trial. For a description of the COSMIC-313 trial, see &#8220;&#8212;Exelixis Development Programs&#8212;Cabozantinib Development Program&#8212;Trials Conducted Under our Clinical Collaboration Agreements&#8212;Combination Studies with BMS.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement with BMS, which was subsequently amended on three occasions, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial is conducted under a combination IND application, unless otherwise required by a regulatory authority. Each party is responsible for supplying finished drug product for the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable clinical trial, and responsibility for the payment of costs for each such trial will be determined on a trial-by-trial basis. Following the FDA&#8217;s approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, we and BMS commenced the commercial launch of the combination and have agreed to pursue commercialization and marketing efforts independently.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Under this agreement with Roche, in June 2017, we initiated COSMIC-021 and in December 2018, we initiated COSMIC-312. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge. For descriptions of the COSMIC-021 and COSMIC-312 trials, see &#8220;&#8212;Exelixis Development Programs&#8212;Cabozantinib Development Program&#8212;Trials Conducted Under our Clinical Collaboration Agreements&#8212;Combination Studies with Roche.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building upon encouraging clinical activity observed in COSMIC-021, in December 2019 we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, including in the CONTACT-01, CONTACT-02 and CONTACT-03 studies. If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond these three ongoing phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#8217;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#8217; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XL092 Clinical Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to diversify our exploration of the therapeutic potential of XL092, we have also entered into multiple supply agreements to evaluate XL092 in various combination trials, including with Roche&#8217;s atezolizumab, Merck KGaA and Pfizer&#8217;s avelumab, BMS&#8217; nivolumab and ipilimumab and Nektar&#8217;s bempegaldesleukin.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These supply agreements will facilitate the efficient exploration of the safety and efficacy of XL092 in combinations with a variety of established cancer therapies as we continue to build a broad development program for XL092. For descriptions of our ongoing clinical trials evaluating XL092 in combination with other therapies, see &#8220;&#8212;Exelixis Development Programs&#8212;Other Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;XL092 Development Program.&#8221; </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Collaborations, In-licensing Arrangements and Other Business Development Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">STORM</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we entered into an exclusive collaboration and license agreement with STORM to discover and advance novel drug candidates intended for the treatment of cancer. Our collaboration focuses initially on the RNA modifying enzyme ADAR1, building on early work by STORM applying its proprietary RNA epigenetic platform, as well as exploring an additional undisclosed target. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, we</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> made an upfront payment in exchange for exclusive licenses to these two discovery programs. STORM is responsible for discovery and generation of lead candidates for both target programs, and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we will assume responsibility for IND-enabling studies and all subsequent clinical development, manufacturing and commercialization activities.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">STORM is eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales. We have also committed to contribute research funding to STORM for discovery and preclinical development work for each program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GamaMabs</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into an asset purchase agreement with GamaMabs to acquire all rights, title and interest in GamaMabs&#8217; AMHR2 antibody program. Under the agreement, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> made an upfront payment in exchange for an initial technology transfer of certain materials and documents, additional payments for subsequent technology transfers and will make a final payment upon the closing of the transaction</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result of the transaction,</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we will own or control 100% of GamaMabs&#8217; AMHR2 antibody program, including all assets pertaining to GamaMabs&#8217; mAb drug product murlentamab (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GM</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-102). GamaMabs is eligible for potential development and regulatory milestone payments.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WuXi Bio</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we entered into an exclusive license agreement with WuXi Bio to support the continued expansion of our oncology </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biotherapeutics</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pipeline </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by leveraging WuXi Bio&#8217;s panel of mAbs for the development of ADC, bispecific and certain other novel tumor-targeting biotherapeutics applications</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, we</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> made an upfront payment in exchange for an exclusive license to a panel of mAbs directed to a preclinically validated target discovered using WuXi Bio&#8217;s integrated technology platforms. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will assume responsibility for all subsequent clinical development, manufacturing and commercialization activities under the agreement.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WuXi Bio is eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adagene</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we entered into a collaboration and license agreement with Adagene to utilize Adagene&#8217;s SAFEbody technology platform to generate masked versions of mAbs from our growing preclinical </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pipeline for the development of ADCs or other innovative biotherapeutics against Exelixis-nominated targets. Under the agreement, we made an upfront payment in exchange for an exclusive, worldwide license to develop and commercialize any potential ADC products generated by Adagene with respect to an initial target, as well as a second target we may nominate during the collaboration term. For each target that we nominate, we would then assume responsibility for all subsequent clinical development, manufacturing and commercialization for that program.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adagene is eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales .</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Catalent</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration and license agreement with Catalent to develop multiple ADCs using Catalent&#8217;s proprietary SMARTag site-specific bioconjugation technology. Under the agreement, we made an upfront payment in exchange for an exclusive option to license up to four targets using Catalent&#8217;s ADC platform over a three-year period. In addition, we have the right to extend the target selection term to five years and nominate up to two additional targets for an additional payment. For each option we decide to exercise, we will be required to pay an exercise fee, and we would then assume responsibility for all subsequent clinical development, manufacturing and commercialization for that program. Catalent would then become eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales. We have also committed to contribute research funding to Catalent for discovery and preclinical development work.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NBE</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration and license agreement with NBE to discover and develop multiple ADCs for oncology applications by leveraging NBE&#8217;s unique expertise and proprietary platforms in ADC discovery, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including NBE&#8217;s SMAC-Technology and novel payloads. Under the Agreement, we made an upfront payment in exchange for exclusive options to nominate four targets using NBE&#8217;s ADC platform over a two-year period. In addition, within the first 18 months of the agreement term, we also have the right to extend the target selection term to three years for an additional payment. For each option we decide to exercise, we will be required to pay an exercise fee, and we would then assume responsibility for all subsequent clinical development, manufacturing and commercialization connected with any resulting program. NBE would then become eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales. We have also committed to contribute research funding to NBE for discovery and preclinical development work.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aurigene</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we entered into an exclusive collaboration, option and license agreement with Aurigene to in-license as many as six oncology target programs to discover and develop small molecules as therapies for cancer, and in April 2021, we expanded the collaboration to include three additional early discovery programs for a total of nine programs. Under the agreement, we made upfront payments in exchange for exclusive options to license eight of the nine programs to date, and we will pay an additional upfront payment upon the nomination of the ninth program. Based on encouraging preclinical data for XL102, the lead Aurigene program targeting CDK7, we exercised our exclusive option to license XL102 in December 2020, resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization of XL102 and payment of an exercise fee to Aurigene. We also submitted an IND for XL102 in November 2020, and following the FDA&#8217;s acceptance of the IND in December 2020, we initiated a phase 1 clinical trial of XL102 in January 2021 designed to evaluate its pharmacokinetics, safety, tolerability and preliminary efficacy, both as a single agent and in combination with other anticancer therapies. For additional information on XL102, see &#8220;&#8212;Exelixis Development Programs&#8212;Other Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;XL102 Development Program.&#8221; </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we exercised our exclusive option to in-license XL114, Aurigene&#8217;s novel CBM inhibitor, in October 2021,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization of XL114 and payment of an option exercise fee to Aurigene</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Following the FDA&#8217;s acceptance of our IND application for the small molecule in October 2021, we plan to initiate a phase 1 clinical trial evaluating XL114 as a monotherapy in patients with NHL in the first half of 2022. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on XL114, see &#8220;&#8212;Exelixis Development Programs&#8212;Other Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;XL114 Development Program.&#8221; With respect to each of XL102 and XL114, Aurigene is eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond XL102 and XL114, we are continuing to work with Aurigene to advance the other small molecule programs through preclinical development. For each additional option we decide to exercise, we will be required to pay an exercise fee, and we would then assume responsibility for all subsequent clinical development, manufacturing and commercialization for that program. Aurigene would then become eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales. We are also responsible for research funding for the discovery and preclinical development work on these programs. Under the agreement, Aurigene retains limited development and commercial rights for India and Russia.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Iconic</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into an exclusive option and license agreement with Iconic to advance an innovative next-generation ADC program for cancer, leveraging Iconic&#8217;s expertise in targeting TF in solid tumors. Under the original May 2019 agreement, we gained an exclusive option to license XB002, Iconic&#8217;s lead TF ADC program, in exchange for an upfront payment to Iconic and a commitment for preclinical development funding. Based on encouraging preclinical data, we exercised our exclusive option to license XB002 in December 2020, resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization for XB002 and payment of an option exercise fee to Iconic. Following the FDA&#8217;s acceptance of our IND for XB002 in April 2021, we initiated a phase 1 clinical trial of XB002 in June 2021 designed to evaluate its pharmacokinetics, safety, tolerability and preliminary efficacy as a monotherapy in patients with advanced solid tumors. For additional information on XLB002, see &#8220;&#8212;Exelixis Development Programs&#8212;Other Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;XB002 Development Program.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we announced an amendment to our agreement with Iconic, which we entered into in December 2021, to acquire broad rights to use the anti-TF antibody used in XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics. Under the amended agreement, we made a final payment to Iconic and will not </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owe Iconic any further payments, but we will continue to be responsible for milestone payments and royalties owed to other companies pursuant to prior agreements between Iconic and those companies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invenra</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into a collaboration and license agreement with Invenra to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead IND-enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities. The collaboration agreement provides that we will receive an exclusive, worldwide license to one preclinical, multispecific antibody asset, and that we will pursue multiple additional discovery projects across three different programs during the term of the collaboration. In October 2019, we expanded our collaboration to include the development of novel binders against six additional targets, which we can use to generate multispecific antibodies based on Invenra&#8217;s B-Body</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform, or with other platforms and formats at our option. We amended the agreement again in March 2020 and January 2021 to enable the use of target binders in non-Invenra platform-based modalities, such as ADC platforms, and to enable the development of biparatropic antibodies, respectively. Then in August 2021, we further expanded our collaboration to include an additional 20 targets</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biotherapeutics</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> discovery and development, for which we agreed to pay Invenra exclusivity payments and research program funding over a three-year period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration, Invenra is eligible for project initiation fees and potential development, regulatory and commercial milestone payments, as well as tiered royalties on net sales of any approved products. We also have the right to exercise options with respect to certain of Invenra&#8217;s other research programs in exchange for an option exercise payment, and Invenra is eligible for milestone payments and royalties for any products that arise from these optioned research programs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">StemSynergy</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we entered into an exclusive collaboration and license agreement with StemSynergy for the discovery and development of novel oncology compounds targeting CK1&#945;, a component of the Wnt signaling pathway implicated in key oncogenic processes, including in colorectal cancers. One such compound, EXEL-4329, reached development candidate status in 2021. In May 2021, we amended the agreement to provide for an additional research platform to explore inhibitors of the Notch pathway, a major developmental pathway that regulates cancer stem cells in Notch-driven cancers, such as certain types of T-cell lymphomas and esophageal adenocarcinomas. Under the agreement, we paid StemSynergy upfront payments in each of 2018 and 2021, and StemSynergy is eligible for additional research and development funding on an as needed basis. StemSynergy is also eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales. We will be solely responsible for the commercialization of products that arise from the collaboration.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the commercialization of our first product, COMETRIQ, our primary business strategy was focused on the development and out-license of compounds to pharmaceutical and biotechnology companies under collaboration agreements that allowed us to retain economic participation in compounds and support additional development of our proprietary products.&#160;Our collaboration agreements with Genentech and Daiichi Sankyo described below are representative of this historical strategy. We have since evolved and are now a fully-integrated biopharmaceutical company focused on driving the expansion and depth of our product offerings through the continued development of the cabozantinib franchise and drug discovery efforts, including research collaborations, in-licensing arrangements and other strategic transactions that align with our oncology drug development, regulatory and commercialization expertise, all to improve care and outcomes for people with cancer around the world. While the historical collaboration agreements described below have the potential to provide future revenue, and while we have already received some collaboration revenues from these arrangements, we do not expect to receive significant revenues from these historical collaboration agreements unless and until our partnered compounds generate substantial sales in the territories and indications where they are approved. If these events occur, then the milestone payments, royalties or other rights and benefits under our historical collaboration agreements could become substantial.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genentech - Cobimetinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the further development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Cobimetinib is a reversible inhibitor of MEK, a kinase that is a </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component of the RAS/RAF/MEK/ERK pathway. Under the collaboration agreement, Genentech received an exclusive worldwide revenue-bearing license to cobimetinib and is responsible for all future clinical development of the compound. On&#160;November&#160;10, 2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in Switzerland, the EU, Canada, Australia, Brazil and multiple additional countries for use in the same indication. On July 30, 2020, the FDA approved COTELLIC, in combination with Genentech&#8217;s ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of BRAF V600 mutation-positive advanced melanoma in previously untreated patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#8217;s commercialization in the U.S. In addition to our profit share in the U.S., we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. During 2021, we earned royalties of $4.1 million on net sales of COTELLIC outside the U.S. and a $8.1 million profit on the profit and loss sharing of U.S. actual sales which are recorded in collaboration services revenues. Since the inception of the collaboration agreement, we have also received aggregate upfront and milestone payments of $50.0 million and are not eligible for any additional milestone payments.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its established commercialization of COTELLIC, Genentech continues to progress the clinical development, regulatory status and commercial potential of cobimetinib. Cobimetinib is being evaluated in a broad development program consisting of multiple clinical trials by Genentech or through Genentech&#8217;s IST program. Should these trials yield supporting data and Genentech obtain regulatory approvals based on such supporting data, we believe that cobimetinib may provide us with an additional source of revenue in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Daiichi Sankyo - Esaxerenone</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo for the discovery, development and commercialization of novel therapies targeted against the MR, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic diseases. Under the collaboration agreement, we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds and we do not have rights to reacquire such compounds.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Japanese MHLW first approved esaxerenone under the brand name MINNEBRO, as a treatment essential hypertension in Japan</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2021, we have received an aggreg</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ate of $65.5 million in deve</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lopment, regulatory and commercialization milestone payments related to MINNEBRO over the life of the collaboration agreement and are eligible to receive additional commercialization milestone payments of up to $90.0 million. We are also entitled to re</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ceive low double-digit royalties on sales of MINNEBRO. As of December 31, 2021, we have earned royalties of $5.3&#160;million on net sales of MINNEBRO by Daiichi Sankyo since the approval of MINNEBRO in January 2019. Pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of 0.5% to Ligand on net sales of MINNEBRO.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Daiichi Sankyo has further advanced the development program for esaxerenone, and in November 2019, Daiichi Sankyo announced positive results from a phase 3 pivotal trial evaluating esaxerenone as a treatment option for patients in Japan with diabetic nephropathy. Should Daiichi Sankyo obtain regulatory approval based on these results, and taking into account the approval of MINNEBRO by the MHLW for the treatment of hypertension and Daiichi Sankyo&#8217;s subsequent commercial sales of MINNEBRO, we believe that esaxerenone may provide an additional source of revenue in the future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Product Supply</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing or distribution facilities for chemistry, manufacturing and control (CMC) development activities, preclinical, clinical or commercial production and distribution for our current products. Instead, we rely on various third-party contract manufacturing organizations to conduct these operations on our behalf. As our operations continue to grow in these areas, we continue to expand our supply chain through secondary third-party contract manufacturers, distributors and suppliers. Specifically, we entered into agreements with secondary contract manufacturing organizations to produce additional commercial supplies of CABOMETYX tablets and cabozantinib drug substance, which bolsters our commercial supply chain and serves to mitigate the risk of supply chain interruptions or other failures. For our portfolio of small molecules and biotherapeutics, we continue to expand our network through well-established and reputable global third-party contract manufacturers for our CMC development and manufacturing that have good </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory standing, suitable manufacturing capacities and capabilities. These third parties must comply with applicable regulatory requirements, including the FDA&#8217;s Current Good Manufacturing Practice (GMP), the EC&#8217;s Guidelines on Good Distribution Practice (GDP), as well as other stringent regulatory requirements enforced by the FDA or foreign regulatory agencies, as applicable, and are subject to routine inspections by such regulatory agencies. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the Drug Supply Chain Security Act (DSCSA).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor and evaluate the performance of our third-party contract manufacturers on an ongoing basis for compliance with these requirements and to affirm their continuing capabilities to meet both our commercial and clinical needs. We also have contracted with a third-party logistics provider, with multiple distribution locations, to provide shipping and warehousing services for our commercial supply of both CABOMETYX and COMETRIQ in the U.S. We employ highly skilled personnel with both technical and manufacturing experience to diligently manage the activities at our third-party contract manufacturers and other supply chain partners, and our quality department audits them on a periodic basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We source raw materials that are used to manufacture our drug substance from multiple third-party suppliers in Asia, Europe and North America. We stock sufficient quantities of these materials and provide them to our third-party drug substance contract manufacturers so they can manufacture adequate drug substance quantities per our requirements, for both clinical and commercial purposes. We then store drug substance at third-party facilities and provide appropriate amounts to our third-party drug product contract manufacturers, who then manufacture, package and label our specified quantities of finished goods for COMETRIQ and CABOMETYX, respectively. In addition, we rely on our third-party contract manufacturers to source materials such as excipients, components and reagents, which are required to manufacture our drug substance and finished drug product.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to having expanded our supply chain to include secondary contract manufacturing organizations, we have established and continue to maintain sufficient safety stock inventories for our drug substance and drug products, and we store these quantities in multiple locations. The quantities that we store are based on our business needs and take into account scenarios for market demand, production lead times, potential supply interruptions and shelf life for our drug substance and drug products. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our response to the COVID-19 pandemic has included more frequent engagement with our vendors to maintain the consistency and effectiveness of our third-party contract manufacturers and other supply chain partners, we have not experienced significant production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more detailed discussion of the impact of the COVID-19 pandemic and our risk mitigation efforts, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;COVID-19 Update&#8221; in Part II, Item 7 of this Annual Report on Form 10-K. We believe that our current manufacturing network has the appropriate capacity to produce sufficient commercial quantities of CABOMETYX to support the currently approved RCC, HCC and DTC indications, as well as potential additional indications if trials evaluating CABOMETYX in those indications prove to be successful and gain regulatory approval in the future. Our manufacturing footprint also enables us to fulfill our supply obligations for CABOMETYX and COMETRIQ to our collaboration partners for global development and commercial purposes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing and Sales</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a fully integrated commercial team consisting of sales, marketing, market access, and commercial operations functions. Our sales team promotes CABOMETYX and COMETRIQ in the U.S. We market our products in the U.S. and concentrate our efforts on oncologists, oncology nurses, pharmacists and other healthcare professionals. In addition to using customary in-person pharmaceutical company practices, we also utilize digital marketing technologies to expand our engagement opportunities with customers.&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial products, CABOMETYX and COMETRIQ, are sold initially through wholesale distribution and specialty pharmacy channels and then, if applicable, resold to hospitals and other organizations that provide CABOMETYX and COMETRIQ to end-user patients. To facilitate our commercial activities in the U.S., we also employ various third parties, such as advertising agencies, market research firms and vendors providing other sales-support related services as needed, including digital marketing and other non-personal promotion. We believe that our commercial team and distribution practices are sufficient to facilitate our marketing efforts in reaching our target audience and our delivery of our products to patients in a timely and compliant fashion.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on Ipsen and Takeda for ongoing and further commercialization and distribution of CABOMETYX in territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs or similar programs with the effect of introducing earlier patient access to CABOMETYX, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and we also rely on Ipsen for these same activities with respect to the commercialization and distribution of COMETRIQ outside of the U.S. For COTELLIC, we rely on Genentech, as our collaboration partner, for all current and future commercialization and marketing activities, with the exception of the limited co-promotion activities highlighted above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help ensure that all eligible patients in the U.S. have appropriate access to CABOMETYX and COMETRIQ, we have established a comprehensive reimbursement and patient support program called Exelixis Access Services (EASE). Through EASE, we provide co-pay assistance to qualified, commercially insured patients to help minimize out-of-pocket costs and provide free drug to uninsured or under-insured patients who meet certain clinical and financial criteria. In addition, EASE provides comprehensive reimbursement support services, such as prior authorization support, benefits investigation and, if needed, appeals support. Beyond financial assistance, patients who participate in EASE also receive treatment coordination through a dedicated case manager, as well as clinical outreach and support from a network of oncology nurses or other healthcare professionals who help many of these patients better understand how to take their medication and mitigate side effects.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, Health and Safety</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes involve the controlled use of certain hazardous materials and chemicals. In the U.S., at the federal, state and local levels, and in other foreign countries, we are subject to environmental, health and workplace safety laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous materials. While we have incurred, and may continue to incur, expenditures to maintain compliance with these laws and regulations, we do not expect the cost of complying with these laws and regulations to be material.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laboratory Safety Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the focus of our business in discovering and developing drug products, many of our employees work in our on-site laboratory facilities. All new laboratory staff are trained on chemical hygiene, the use of personal protective equipment, and certain other relevant laboratory safety topics, such as working with blood-borne pathogens, and current staff are retrained regularly. We also extend these trainings to facilities staff and others who support our work in the labs. In an effort to maintain a safe environment for all staff, we regularly perform thorough safety inspections of our laboratories, and continuously update our procedures based on the observations made during these inspections. Additionally, we conduct periodic industrial hygiene monitoring to ensure lab staff working with certain known hazardous chemicals do not exceed regulated exposure limits, and we regularly test and certify fume hoods, biosafety cabinets and other individual pieces of equipment on which employees rely to maintain a safe work environment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Workplace Safety Measures in Response to COVID-19</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor the latest guidance issued by health authorities and have instituted several policies and procedures to protect against the spread of COVID-19 among our workforce. Since the third quarter of 2021, we have implemented a vaccination mandate and maintain several enhanced safety and social distancing protocols at our headquarters. In addition, we also offer on-site, rapid PCR COVID-19 testing, and utilize a mobile device app and web interface, which enable our team members to perform daily symptom tracking and schedule on-site tests at the Exelixis headquarters, and which also provide contact tracing and educational resources for any team member who may have tested positive.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other policies and procedures currently include frequent disinfection of common areas by our operations staff and investments in re-engineering workspace safety, such as providing ample supplies of hand sanitizer, sanitizing wipes and facemasks for use by our staff, and adjusting our ventilation systems in an effort to minimize risks of airborne transmission. Although the COVID-19 pandemic has presented several new challenges for us, to date, we have only experienced a modest impact on our productivity without significant interruptions in our general business operations. For a more detailed discussion of the impact of the COVID-19 pandemic and our risk mitigation efforts, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;COVID-19 Update&#8221; in Part II, Item 7 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate, among other things, research and development activities and the testing, marketing approval, manufacture, quality control, safety, effectiveness, labeling, storage, distribution, post-marketing safety reporting, export, import, record keeping, advertising and promotion of our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before product candidates may be marketed in the U.S. generally involves the following:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">nonclinical laboratory and animal tests, some of which must be conducted in accordance with Good Laboratory Practices (GLP);</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">submission of an IND, which contains results of nonclinical studies (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, laboratory evaluations of the chemistry, formulation, stability and toxicity of the product candidate), together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, and must become effective before human clinical trials may begin;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">approval by an independent institutional review board or ethics committee at each clinical trial site before each trial may be initiated;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">adequate and well-controlled human clinical trials conducted in accordance with the protocol, IND and Good Clinical Practice (GCP) to establish the safety and efficacy of the investigational drug candidate for its proposed intended use;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">for drug products, submission of a New Drug Application (NDA) to the FDA for commercial marketing, or generally of an sNDA, for approval of a new indication if the product is already approved for another indication;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">for biotherapeutic products, submission of a Biologics License Application (BLA) to the FDA for commercial marketing, or generally a supplemental Biologics License Application (sBLA) for approval of a new indication if the product is already approved for another indication;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">pre-approval inspection of manufacturing facilities and selected clinical investigators, clinical trial sites and/or Exelixis as the clinical trial sponsor for their compliance with GMP and GCP, respectively;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">payment of user fees for FDA review of an NDA or BLA unless a fee waiver applies;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">agreement with the FDA on the final labeling for the product;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">if the FDA convenes an advisory committee, satisfactory completion of the advisory committee review; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">FDA approval of the NDA or sNDA, or BLA or sBLA.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Phase 1 studies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which involve the initial introduction of a new drug product candidate into humans, are initially conducted in a limited number of subjects to test the product candidate for safety, tolerability, absorption, metabolism, distribution and excretion in healthy humans or patients. In rare cases, a Phase 1 study that is designed to assess effectiveness may serve as the basis for FDA marketing approval of a drug or for a label expansion. For instance, at FDA&#8217;s discretion, a product may receive approval based on a Phase 1b study if effectiveness results from the study are extremely compelling, approval of the drug would address a significant unmet patient need, and the drug is being approved through the accelerated approval pathway.&#160;As discussed below, Accelerated Approval generally requires a post-approval study to confirm clinical benefit.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Phase 2 studies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are conducted with groups of patients afflicted with a specified disease in order to provide enough data to evaluate the preliminary efficacy, optimal dosage, and common short-term side effect and risks associated with the drug. Multiple phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive phase 3 clinical trials. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Phase 3 studies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are conducted to gather the additional information about effectiveness and safety across a higher number of patients and evaluate the overall benefit-risk relationship of the product candidate following earlier phase evaluations, which will have provided preliminary evidence suggesting an effective dosage range </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and acceptable safety profile for the product candidate. Phase 3 trials are also intended to provide an adequate basis for physician labeling of the product if it is approved.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called post-marketing or &#8220;phase 4&#8221; studies may be deemed a condition to be satisfied after a drug receives approval. Failure to satisfy such post-marketing commitments can result in FDA enforcement action, up to and including withdrawal of NDA approval. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Review and Approval</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For approval of a new drug or changes to the labeling of an approved drug, including new indications, the results of product development, preclinical studies and clinical trials are submitted to the FDA as part of an NDA, or as part of an sNDA. The submission of an NDA requires payment of a substantial user fee to the FDA. The FDA may convene an advisory committee to provide clinical insight on NDA review questions, although the FDA is not required to follow the recommendations of an advisory committee. The FDA may initially issue a Refuse to File letter for an incomplete NDA or sNDA, or it may deny approval of an NDA or sNDA by way of a Complete Response letter if the applicable regulatory criteria are not satisfied, or alternatively require additional clinical and/or nonclinical data and/or an additional phase 3 pivotal clinical trial. Once issued, the FDA may withdraw product approval if ongoing regulatory standards are not met or if safety problems occur after the product reaches the market. Satisfaction of FDA development and approval requirements or similar requirements of state, local and foreign regulatory agencies typically takes several years, and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including obtaining prior FDA approval of certain changes to the approved NDA, record-keeping requirements, and reporting of adverse experiences with, and interruptions in the manufacture of, the drug. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies. Thus, we and our third-party contract manufacturing organizations are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMP, which impose certain manufacturing requirements (including procedural and documentation requirements) upon us and our third-party contract manufacturing organizations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Orphan Drug Act of 1983, as amended, provides incentives for the development of drugs and biotherapeutic products for rare diseases or conditions that affect fewer than 200,000 people in the U.S. (or for which there is no reasonable expectation that the cost of developing and making available the drug in the U.S. for such disease or condition will be recovered from sales of the drug in the U.S.). Certain of the incentives turn on the drug first being designated as an orphan drug. To be eligible for designation as an orphan drug (Orphan Drug Designation), the drug must have the potential to treat such rare disease or condition as described above. In addition, the FDA must not have previously approved a drug considered the &#8220;same drug,&#8221; as defined in the FDA&#8217;s orphan drug regulations, for the same orphan-designated indication or the sponsor of the subsequent drug must provide a plausible hypothesis of clinical superiority over the previously approved same drug. Upon receipt of Orphan Drug Designation, the sponsor is eligible for tax credits of up to 25% for qualified clinical trial expenses and waiver of the Prescription Drug User Fee Act application fee. In addition, upon marketing approval, an orphan-designated drug could be eligible for seven years of market exclusivity if no drug considered the same drug was previously approved for the same orphan condition (or if the subsequent drug is demonstrated to be clinically superior to any such previously approved same drug). Such orphan drug exclusivity, if awarded, would only block the approval of any drug considered the same drug for the same orphan indication. Moreover, a subsequent same drug could break an approved drug&#8217;s orphan exclusivity through a demonstration of clinical superiority over the previously approved drug.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expedited FDA Approval Pathways</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has various programs that are intended to expedite or simplify the process for developing and reviewing promising drugs, or to provide for the approval of a drug on the basis of a surrogate endpoint. Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. Examples of such programs included Fast Track designation, breakthrough therapy designation, priority review and accelerated approval, and the eligibility criteria of and benefits for each program vary: </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Fast Track is a process designed to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening diseases or conditions that demonstrate the potential to fill unmet medical needs, by providing, among other things, eligibility for accelerated approval if relevant criteria are met, and rolling review, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which allows submission of individually completed sections of an NDA or for FDA review before the entire submission is completed. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Breakthrough therapy designation is a process designed to expedite the development and review of drugs that are intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review, and rolling review.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Priority review is designed to shorten the review period for drugs that treat serious conditions and that, if approved, would offer significant advances in safety or effectiveness or would provide a treatment where no adequate therapy exists. Under priority review, the FDA aims to take action on the application within six months as compared to a standard review time of 10 months. Sponsors may also obtain a priority review voucher upon approval of an NDA for certain qualifying diseases and conditions that can be applied to a subsequent NDA submission</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Accelerated approval provides for an earlier approval for a new drug that is intended to treat a serious or life-threatening disease or condition and that provides a meaningful advantage over available therapies and demonstrates an effect on a surrogate endpoint, or an intermediate clinical endpoint, which is considered reasonably likely to predict clinical benefit. As a condition of approval, the FDA requires that a sponsor of a product candidate receiving accelerated approval perform post-marketing clinical trials or provide data on established clinical endpoints from the same trial to confirm the clinical benefit as predicted by the surrogate marker trial. The failure to conduct such trials, or confirm the clinically meaningful outcome in such trials, may result in withdrawal of the approval of the drug or the indication approved under accelerated approval.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to oncology products, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the FDA may review applications under the Real-Time Oncology Review (RTOR) pilot program established by the FDA&#8217;s Oncology Center of Excellence. The RTOR pilot program, which allows an applicant to pre-submit components of the application to allow the FDA to review clinical data before the complete filing is submitted, aims to explore a more efficient review process to ensure that safe and effective treatments are available to patients as early as possible, while maintaining and improving review quality. Drugs considered for review under the RTOR pilot program must be likely to demonstrate substantial improvements over available therapy, which may include drugs previously granted breakthrough therapy designation for the same or other indications, and must have straight-forward study designs and endpoints that can be easily interpreted.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abbreviated FDA Approval Pathways and Generic Products</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Drug Price Competition and Patent Term Restoration Act of 1984 (The Hatch-Waxman Act) established two abbreviated approval pathways for drug products in which potential competitors may rely upon the FDA&#8217;s prior approval of the same or similar drug product.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Abbreviated New Drug Application (ANDA).</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> An ANDA may be approved by the FDA if the applicant demonstrates that the proposed generic product is the same as the approved drug, which is referred to as the Reference Listed Drug (RLD).&#160;Generally, an ANDA must contain data and information showing that the proposed generic product and RLD (1)&#160;have the same active ingredient, in the same strength and dosage form, to be delivered via the same route of administration, (2)&#160;are intended for the same uses, and (3)&#160;are bioequivalent.&#160;This is instead of independently demonstrating the proposed product&#8217;s safety and effectiveness through clinical development. Conducting bioequivalence testing is generally less time consuming and costly than conducting a full set of clinical trials in humans. In this regard, the FDA has published draft guidance containing product-specific bioequivalence recommendations for drug products containing cabozantinib, the active pharmaceutical ingredient in CABOMETYX and COMETRIQ, as it does for many FDA-approved drug products.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">505(b)(2)&#160;NDAs.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;A 505(b)(2) NDA is an application for which one or more of the investigations relied upon by the applicant for approval were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. Under Section 505(b)(2) NDA of the Federal Food, Drug, and Cosmetic Act (FDCA), an applicant may rely, in part, on the FDA&#8217;s previous approval of a similar product, or published literature, in support of its application. If the 505(b)(2) applicant establishes that reliance on the FDA&#8217;s prior findings of safety and efficacy for an approved product is </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scientifically appropriate, it may eliminate the need to conduct certain preclinical or clinical studies. The FDA may require additional studies or measurements, including comparability studies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike a full NDA for which the sponsor has conducted or obtained a right of reference to all the data essential to approval, the filing of an ANDA or a 505(b)(2) NDA may be delayed due to patent or exclusivity protections covering an approved product. The Hatch-Waxman Act provides (a) up to five years of exclusivity for the first approval of a new chemical entity (NCE) exclusivity and (b) three years of exclusivity for approval of an NDA or sNDA for a product that is not an NCE but rather where the application contains new clinical studies conducted or sponsored by the sponsor and considered essential to the approval of the NDA or sNDA (three-year &#8220;changes&#8221; exclusivity). NCE exclusivity runs from the time of approval of the NDA and bars FDA from accepting for review of any ANDA or 505(b)(2) NDA for a drug containing the same active moiety for five years (or for four years if the application contains a Paragraph IV certification that a reference product patent is invalid or not infringed by the ANDA/505(b)(2) NDA product). The three-year &#8220;changes&#8221; exclusivity generally bars the FDA from approving any ANDA or 505(b)(2) NDA application that relies on the information supporting the approval of the drug or the change to the drug for which the information was submitted and the exclusivity granted.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both Congress and the FDA are considering, and have enacted, various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Ensuring Innovation Act, enacted in April 2021, amended the FDA&#8217;s statutory authority for granting NCE exclusivity to reflect the agency&#8217;s existing regulations and longstanding interpretation that award NCE exclusivity based on a drug&#8217;s active moiety, as opposed to its active ingredient, which is intended to limit the applicability of NCE exclusivity, thereby potentially facilitating generic competition. The FDA has also released, and continues to implement, a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; healthcare costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs. In addition, the Further Consolidated Appropriations Act, 2020, which incorporated the framework from the Creating and Restoring Equal Access To Equivalent Samples (CREATES) legislation, purports to promote competition in the market for drugs and biotherapeutic products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biotherapeutic products, including by allowing ANDA, 505(b)(2) NDA or biosimilar developers to obtain access to branded drug and biotherapeutic product samples.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book Listing.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;An NDA sponsor must identify to the FDA patents that claim the drug substance or drug product or approved method of using the drug. When the drug is approved, those patents are among the information about the product that is listed in the FDA publication, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is referred to as the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any applicant who files an ANDA or a 505(b)(2) NDA must certify, for each patent listed in the Orange Book for the RLD that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA, (2) such patent has expired, (3) the listed patent will expire on a particular date and approval is sought after patent expiration, or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. An ANDA or 505(b)(2) NDA applicant may also submit a statement that it intends to carve-out from the labeling of its product an RLD&#8217;s use that is protected by exclusivity or a method of use patent. The fourth certification described above is known as a Paragraph IV certification. A notice of the Paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the reference NDA holder. The reference NDA holder and patent owners may initiate a patent infringement lawsuit in response to the Paragraph IV notice. Filing such a lawsuit within 45 days of the receipt of the Paragraph IV certification notice prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA or 505(b)(2) NDA applicant. The ANDA or 505(b)(2) NDA also will not receive final approval until any applicable non-patent exclusivity listed in the Orange Book for the RLD has expired. We intend to defend vigorously any patents for our approved products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Approval Outside of the United States </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the U.S., we are subject to regulations of other countries governing clinical trials and the manufacturing, commercial sales and distribution of our products outside of the U.S. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the EU, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The way clinical trials are conducted in the EU has undergone a major change with the application of Regulation (EU) 536/2014, repealing the existing Directive 2001/20/EC. This new regulation harmonizes the assessment and supervision processes for clinical trials throughout the EU, via an EU portal and database, which the EMA will maintain in collaboration with the Member States and the EC. Following the EC&#8217;s confirmation of full functionality of the Clinical Trials Information System (CTIS) through an independent audit, which was published in the Official Journal of the European Union in August 2021, Regulation (EU) 536/2014 became applicable concurrent with the CTIS &#8220;go-live&#8221; date on January 31, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under EU regulatory systems, a company may submit a marketing authorization application (MAA) either under centralized or decentralized procedure. Under the centralized procedure, MAAs are submitted to the EMA for scientific review by the Committee for Medicinal Products for Human Use (CHMP) so that an opinion is issued on product approvability. The opinion is considered by the EC which is responsible for granting the centralized marketing authorization in the form of a binding EC decision. If the application is approved, the EC grants a single marketing authorization that is valid for all EU Member States as well as Iceland, Liechtenstein and Norway, collectively the European Economic Area. The decentralized and mutual recognition procedures, as well as national authorization procedure are available for products for which the centralized procedure is not compulsory. The mutual recognition procedure provides for the EU Member States selected by the applicant to mutually recognize a national marketing authorization that has already been granted by the competent authority of another Member State, referred to as the Reference Member State (RMS). The decentralized procedure is used when the product in question has yet to be granted a marketing authorization in any Member State. Under this procedure the applicant can select the Member State that will act as the RMS. In both the mutual recognition and decentralized procedures, the RMS reviews the application and submits its assessment of the application to the Member States where marketing authorizations are being sought, referred to as Concerned Member States. Within 90 days of receiving the application and assessment report, each Concerned Member State must decide whether to recognize the RMS assessment or reject it on the basis of potential serious risk to public health. If the disputed points cannot be resolved, the matter is eventually referred to the Coordination Group on Mutual Recognition and Decentralised Procedures in the first instance to reach an agreement and failing to reach such an agreement, a referral to the EMA and the CHMP for arbitration that will result in an opinion to form the basis of a decision to be issued by the EC binding on all Member States. If the application is successful during the decentralized or mutual recognition procedure, national marketing authorizations will be granted by the competent authorities in each of the Member States chosen by the applicant.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditional marketing authorizations may be granted in the centralized procedure for a limited number of medicinal products for human use referenced in EU law applicable to conditional marketing authorizations where the clinical dataset is not comprehensive, if (1) the risk-benefit balance of the product is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3) unmet medical needs will be fulfilled and (4) the benefit to public health of the immediate availability on the market of the medicinal product outweighs the risk inherent in the fact that additional data are still required.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the U.S., we may apply for designation of a product as an orphan drug for the treatment of a specific indication in the EU before the application for marketing authorization is made. In the EU, orphan designation is available for products in development which are either: (a) intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the EU; or (b) intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition affecting a larger number of persons but when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the medicinal product. Additionally, the sponsor of an application for designation of a product as an orphan drug in the EU must establish that there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition or even if such treatment exists, the product will be of significant benefit to those affected by that condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drugs in the EU enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant for a similar medicinal product can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product. The period of market exclusivity may be reduced to six years if at the end of the fifth year it is established that the criteria for orphan designation are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare and Privacy Regulation </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, also govern our business. If we fail to comply with those laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected. The laws that may affect our ability to operate </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include, but are not limited to: the federal Anti-Kickback Statute (AKS), which prohibits, among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce or reward for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as Medicare and Medicaid; the FDCA and its implementing regulations, which prohibit, among other things, the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded; and federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent. Additionally, we are subject to state law equivalents of each of the above federal laws, which may be broader in scope and apply regardless of whether the payer is a governmental healthcare program, and many of which differ from each other in significant ways and may not have the same effect, further complicate compliance efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information. For example, the California Consumer Privacy Act of 2018, as amended (CCPA), went into operation on January 1, 2020 and broadly defines personal information, affords California residents expanded privacy rights and protections and provides for civil penalties for violations and a private right of action related to certain data security breaches. These protections will be expanded by the California Privacy Rights Act (CPRA), which was approved by California voters in November 2020 and will be operational in most key respects on January 1, 2023. Similar legislative proposals have passed or are being advanced in other states, and Congress is considering additional federal privacy legislation. In addition, most healthcare professionals and facilities who may prescribe our products and from whom we may obtain patient health information, are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology and Clinical Health Act (HIPAA). Although we are not considered to be a covered entity or business associate under HIPAA with respect to our clinical and commercial activities, we could be subject to penalties if we use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including laws in all 50 states requiring security breach notification in some circumstances. The CCPA, CPRA, HIPAA and these other laws could create liability for us or increase our cost of doing business. International laws, such as the EU General Data Protection Regulation 2016/679 (GDPR), could also apply to our operations. Failure to provide adequate privacy protections and maintain compliance with applicable privacy laws could jeopardize business transactions across borders and result in significant penalties.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Patient Protection and Affordable Care Act of 2010, as amended (PPACA) created a federal requirement under the federal Open Payments program, that requires certain manufacturers to track and report to the Centers for Medicare &amp; Medicaid Services annually certain payments and other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistance and nurse practitioners) and teaching hospitals, as well as ownership interests held by such physicians and their immediate family during the previous calendar year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our products are covered in the U.S. by the Medicaid programs, we have various obligations, including government price reporting and rebate requirements, which generally require us to pay substantial rebates or offer our drugs at substantial discounts to certain purchasers (including &#8220;covered entities&#8221; purchasing under the 340B Drug Discount Program (the 340B Program)). We are also required to discount our products to authorized users of the Federal Supply Schedule of the General Services Administration, under which additional laws and requirements apply. These programs require submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas and regulatory guidance, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations, and the guidance governing such calculations is not always clear. Compliance with such requirements can require significant investment in personnel, systems and resources. Failure to properly calculate prices, or to offer required discounts or rebates could subject us to substantial penalties.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our approved products and any future products of ours will depend, in part, on the extent to which their costs will be covered by third-party payers, such as government health programs, commercial insurance and managed healthcare organizations. Each third-party payer may have its own policy regarding what products it will cover, the conditions under which it will cover such products, and how much it will pay for such products. Third-party payers may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. Moreover, a third-party payer&#8217;s decision to provide coverage for a drug product </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">does not guarantee what reimbursement rate, if any, will be approved. Patients may be less likely to use our products if coverage is not provided and reimbursement may not cover a significant portion of the cost of our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and other potentially significant markets for our products, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products and therapies, which may result in lower average selling prices. In some cases, for example, third-party payers try to encourage the use of less expensive generic products through their prescription benefits coverage and reimbursement and co-pay policies. Further, the increased emphasis on managed healthcare in the U.S. and on country-specific and national pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing coverage and/or reimbursement controls and measures, could have a material adverse impact on our net product revenues and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and some foreign countries are considering proposals or have enacted legislative and regulatory changes to the healthcare system that could affect our ability to sell our products profitably. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been increasing legislative and enforcement interest in the U.S. with respect to drug pricing practices. In particular, there have been several recent U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying the prices that Medicare reimburses for physician-administered drugs to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits; implement additional data collection and transparency reporting regarding drug pricing, rebates, fees and other remuneration provided by drug manufacturers; enable the government to negotiate prices under Medicare; revise rules associated with the calculation of average manufacturer price and best price under Medicaid; eliminate the AKS discount safe harbor protection for manufacturer rebate arrangements with Medicare Part D plan sponsors; create new AKS safe harbors applicable to certain point-of-sale discounts to patients and fixed fee administrative fee payment arrangements with pharmacy benefit managers; and revise the rebate methodology under the Medicaid Drug Rebate Program. For instance, President Biden issued an executive order in July 2021 supporting legislation to enact some of these drug pricing reforms, and in response, the U.S. Department of Health and Human Services (HHS) released a Comprehensive Plan for Addressing High Drug Prices in September 2021 with specific legislative and administrative policies that Congress could enact to help improve affordability of and access to prescription drugs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biotherapeutic product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. pharmaceutical industry has already been significantly impacted by major legislative initiatives and related political contests. For instance, efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA, some of which have been successful, create considerable uncertainties for all businesses involved in healthcare, including our own. In addition, there are pending federal and state-level legislative proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact on the healthcare industry. It is also possible that additional governmental actions will be taken in response to the ongoing COVID-19 pandemic, and that such actions would have a significant impact on these public health insurance programs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these developments and trends, third-party payers are increasingly attempting to contain healthcare costs by limiting coverage and the level of reimbursement of new drugs. These entities could refuse, limit or condition </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">coverage for our products, such as by using tiered reimbursement or pressing for new forms of contracting, including, for example, the movement by insurers towards &#8220;value-based&#8221; contracting, any of which could adversely affect product sales. Due to general uncertainty in the current regulatory and healthcare policy environment, and specifically regarding positions that the Biden Administration may take with respect to these issues, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, the proposed pricing for a drug must be approved before its cost may be funded within the respective national healthcare system. The requirements governing drug pricing vary widely from country to country. For example, EU Member States may restrict the range of medicinal products for which their national healthcare systems provide reimbursement and may control the prices of medicinal products for human use. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profits the medicinal product generates for the company placing it on the market. Pricing and reimbursement negotiations with governmental authorities or payers in EU Member States can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. To obtain reimbursement and/or pricing approval in some countries, drug manufacturers and collaboration partners may also be required to conduct a study or otherwise provide data that seeks to establish the cost effectiveness of a new drug compared with other available established therapies. Other cost-control initiatives are similarly focused on affordability and accessibility, such as the Regulation on Health Technology Assessment (HTA) adopted in December 2021 and other upcoming legislative and policy changes aimed at increasing cooperation between EU Member States, and once enacted may further impact the price and reimbursement status of many medicinal products. There can be no assurance that any country that has price controls, reimbursement limitations or other requirements for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products on cost-effectiveness grounds. Historically, products launched in EU Member States and other non-U.S. jurisdictions do not follow the price structures of the U.S., and they generally tend to be priced significantly lower.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many companies focused on the development of small molecules, antibodies and other treatments for cancer. Our competitors and potential competitors include major pharmaceutical and biotechnology companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research activities similar to ours. Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition for Cabozantinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our ability to successfully compete will depend on, among other things:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">efficacy, safety and reliability of cabozantinib, both alone and in combination with other therapies;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">timing and scope of regulatory approval;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the speed at which we develop cabozantinib for the treatment of additional tumor types beyond its approved indications;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to complete clinical development and obtain regulatory approvals for cabozantinib, both alone and in combination with other therapies;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to manufacture and sell commercial quantities of cabozantinib product to the market;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to successfully commercialize cabozantinib, both as a single agent and as part of any combination therapy regimen, and secure coverage and adequate reimbursement in approved indications;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">product acceptance by physicians and other health care providers;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the level of our collaboration partners&#8217; investments in the resources necessary to successfully commercialize cabozantinib, or any combination therapy regimen that includes cabozantinib, in&#160;territories where they are approved;&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">skills of our employees and our ability to recruit and retain skilled employees;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">protection of our intellectual property, including our ability to enforce our intellectual property rights against potential generic competition; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the availability of substantial capital resources to fund development and commercialization activities.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the quality and breadth of activity observed with cabozantinib, the skill of our employees and our ability to recruit and retain skilled employees, our patent portfolio and our capabilities for research and drug development are competitive strengths. However, many large pharmaceutical and biotechnology companies have significantly larger intellectual property estates than we do, more substantial capital resources than we have, and greater capabilities and experience than we do in preclinical and clinical development, sales, marketing, manufacturing and regulatory affairs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. While we have had success in adapting our development strategy for the cabozantinib franchise to address the competitive landscape, including through evaluation of therapies that combine ICIs with other targeted agents, it is uncertain whether current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in HCC, NSCLC and mCRPC, will lead to regulatory approvals, or whether physicians will prescribe regimens containing cabozantinib instead of competing product combinations in approved indications. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the principal competition for cabozantinib in the indications for which it is approved or for which it has been or is currently being evaluated in potentially label-enabling trials, both as a single agent and in combination with other therapies. The information below does not include all competitor products, but rather those approved products that have or we believe may capture significant market share within their respective indications, or with respect to therapies still in development, those that are likely to overlap with patient populations that are or may be treated with cabozantinib or a combination therapy regimen that includes cabozantinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition in Approved Cabozantinib Indications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CABOMETYX - RCC:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe the principal competition for CABOMETYX in advanced RCC includes: the combination of Merck &amp; Co.&#8217;s pembrolizumab and Pfizer&#8217;s axitinib; the combination of BMS&#8217;s ipilimumab and nivolumab; and the combination of Merck &amp; Co.&#8217;s pembrolizumab and Eisai&#8217;s lenvatinib. Additionally, there are a variety of therapies being developed for advanced RCC, including: the combination of Peloton Therapeutics&#8217; (a wholly owned subsidiary of Merck &amp; Co.) belzutifan (also known as MK-6482) and Eisai&#8217;s lenvatinib; the combination of Merck &amp; Co.&#8217;s pembrolizumab, Eisai&#8217;s lenvatinib and Peloton Therapeutics&#8217; belzutifan; the combination of Merck &amp; Co.&#8217;s pembrolizumab and quavonlimab and Eisai&#8217;s lenvatinib; and the combination of BMS&#8217; nivolumab and Nektar&#8217;s bempegaldesleukin.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The competitive landscape for RCC is evolving rapidly, especially given the entrance and increased adoption of ICI and ICI-TKI combination therapies into the RCC treatment landscape, particularly in the first-line setting. This has led to changing trends in prescribing and sequencing of certain drugs and combinations across different lines of therapy. It is difficult to predict how these changes will affect sales of CABOMETYX during 2022 and going forward.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CABOMETYX - HCC: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the principal competition for CABOMETYX in previously treated HCC includes: Bayer&#8217;s regorafenib; and Eisai&#8217;s lenvatinib. Additionally, there are a variety of therapies being developed for previously treated HCC, including the combination of Roche&#8217;s atezolizumab and either Eisai&#8217;s Lenvatinib or Bayer&#8217;s and Onyx&#8217;s sorafenib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competitive landscape for HCC has significantly changed with the increased adoption of ICI combination therapies in the first-line setting, which may lead to an increase in prescribing and sequencing of TKIs in subsequent lines of therapy. It is difficult to predict how these changes will affect sales of CABOMETYX during 2022 and going forward.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CABOMETYX - DTC: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the principal competition for CABOMETYX in its previously treated DTC indication includes two treatments that are also approved for previously untreated DTC: Bayer&#8217;s and Onyx&#8217;s sorafenib; and Eisai&#8217;s lenvatinib. In addition, we believe there is also competition for CABOMETYX from therapies approved to treat patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are RAI-refractory (if RAI is appropriate), including: Blueprint Medicine&#8217;s and Roche&#8217;s pralsetinib; and Loxo Oncology&#8217;s (a wholly owned subsidiary of Eli Lilly) selpercatinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the approvals of RET inhibitors to treat certain DTC patients, there has been little change in the competitive landscape for RAI-refractory DTC treatments during recent years. Due the limited number of ongoing late-stage clinical trials in this DTC indication, we do not except additional competitors to emerge during 2022. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COMETRIQ - MTC:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that the principal competing anti-cancer therapy to COMETRIQ in progressive, metastatic MTC is Genzyme&#8217;s vandetanib, which has been approved by the FDA and the EC for the treatment of symptomatic or progressive MTC in patients with unresectable, locally advanced, or metastatic disease, as well as other therapies that have been recently approved to treat patients with advanced or metastatic RET-mutant MTC who require systemic therapy, including: Blueprint Medicine&#8217;s and Roche&#8217;s pralsetinib; and Loxo Oncology&#8217;s selpercatinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the recent approvals of RET inhibitors to treat certain MTC patients, there has been little change in the treatment landscape for progressive, metastatic MTC during recent years, and due to the limited number of ongoing late-stage clinical trials in this indication, we do not expect many additional competitors to emerge in 2022. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition in Potential Cabozantinib Indications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cabozantinib in combination with ICI - HCC: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COSMIC-312, the phase 3 pivotal trial evaluating the combination of cabozantinib and atezolizumab in patients with previously untreated HCC, is continuing as planned to final analysis of OS, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we intend to submit an sNDA to the FDA for the combination regimen if supported by the final OS analysis</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Should the combination of cabozantinib and atezolizumab be approved for the treatment of patients with previously untreated advanced HCC, we believe its principal competition may include: the combination of Merck &amp; Co.&#8217;s pembrolizumab and Eisai&#8217;s lenvatinib; the combination of Roche&#8217;s bevacizumab and atezolizumab; </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the combination of AstraZeneca&#8217;s durvalumab and tremelimumab</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cabozantinib in combination with ICI &#8211; NSCLC:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are evaluating the combination of cabozantinib and atezolizumab in CONTACT-01, a phase 3 pivotal trial evaluating the combination of cabozantinib and atezolizumab in patients with metastatic NSCLC who have been previously treated with an ICI and platinum-containing chemotherapy. Should the combination of cabozantinib and atezolizumab be approved for the treatment of patients with NSCLC, we believe its principal competition may include: Sanofi&#8217;s docetaxel; the combination of Sanofi&#8217;s docetaxel and Eli Lilly&#8217;s ramucirumab; the combination of BMS&#8217; nivolumab and Mirati&#8217;s sitravatinib; the combination of Merck &amp; Co.&#8217;s pembrolizumab and Eisai&#8217;s lenvatinib; Daiichi Sankyo&#8217;s DS-1062; and generic versions of docetaxel.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cabozantinib in combination with ICI &#8211; mCRPC:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are evaluating the combination of cabozantinib and atezolizumab in CONTACT-02, a phase 3 pivotal trial evaluating the combination of cabozantinib and atezolizumab in patients with mCRPC who have been previously treated with one NHT. Should the combination of cabozantinib and atezolizumab be approved for the treatment of patients with mCRPC, we believe its principal competition may include: Janssen Biotech&#8217;s (a wholly owned subsidiary of Johnson &amp; Johnson) abiraterone; Astellas Pharma&#8217;s and Pfizer&#8217;s enzalutamide; Sanofi&#8217;s docetaxel; the combination of Merck &amp; Co.&#8217;s pembrolizumab and Sanofi&#8217;s docetaxel; the combination of Merck &amp; Co.&#8217;s pembrolizumab and Astellas Pharma&#8217;s and Pfizer&#8217;s enzalutamide; the combination of BMS&#8217; nivolumab and Sanofi&#8217;s docetaxel; Veru Pharma&#8217;s sabizabulin; and generic versions of abiraterone and docetaxel. In addition, we believe there may be competition for the combination of cabozantinib and atezolizumab in mCRPC from therapies in late-stage development focused on the subset of mCRPC patients who are prostate-specific membrane antigen positive, including: </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis&#8217; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">177</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lu-PSMA-617;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> POINT Biopharma&#8217;s </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">177</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lu-PNT2002; Telix International&#8217;s </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">177</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lu-DOTA-rosopatamab; and Curium US LLC&#8217;s </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">177</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lu-PSMA-I&amp;T.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition for Cobimetinib and Esaxerenone</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is competition for both cobimetinib and esaxerenone in the specific indications and territories where they are approved, and there are regular new entrants and developments in all aspects of these markets. However, given the relatively lesser degree of adoption of these therapies within the broader markets in which they compete and their minimal contribution to our total revenues as out-licensed products, we do not believe changes in the competitive landscape in these indications will have a material impact on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek patent protection in the U.S., EU and selected other foreign jurisdictions to cover our drug candidates and related technologies. Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country. We have numerous patents and pending patent applications that relate to methods of screening drug targets, compounds that modulate drug targets, as well as methods of making and using such compounds.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While many patent applications have been filed relating to the drug candidates that we have developed, the majority of these are not yet issued or allowed. To our knowledge, we own all global patents associated with cabozantinib and cobimetinib, and we either own or have in-licensed all global patents for our other drug candidates, as further described below.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cabozantinib is covered by more than 15 issued patents in the U.S., building from U.S. Pat. No.&#160;7,579,473, for the composition of matter of cabozantinib (the &#8216;473 Patent) and pharmaceutical compositions thereof. This composition of matter patent would expire in September 2024, but we have been granted a patent term extension to extend the term to August 2026. The following table describes the US patents that cover our marketed cabozantinib products, and which are listed in the Orange Book. Except as otherwise noted, the stated expiration dates include any patent term extensions already granted. In addition to the composition of matter patent referenced above, the table includes patents directed to, among other things, particular salts, polymorphs, formulations, or use of the compound in the treatment of specified diseases or conditions. We continue to pursue additional patents and patent term extensions in the U.S. and other territories covering various aspects of our cabozantinib products that may, if issued, extend exclusivity beyond the expiration of the patents listed in the table.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:12.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent No.</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">General Subject Matter</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Expiration</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="10" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579,473</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,497,284</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,877,776</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,724,342</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulations of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,034,873&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,039,757</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,091,439&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,091,440&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulations of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098,015&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,141,413&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579,473</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,877,776</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,717,720</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulations of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,091,439&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,091,440&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulations of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098,015&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the importance of our intellectual property portfolio to our business operations, we intend to vigorously enforce our rights and defend against challenges that have arisen or may arise with respect to patents and patent applications required for the commercialization of medicines containing cabozantinib. For example, in September 2019, we received a Paragraph IV notice letter regarding an ANDA submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets, which MSN then amended with additional Paragraph IV certifications in May 2020 to include the &#8216;473 Patent and U.S. Patent No. 8,497,284. In response, we filed patent infringement lawsuits against MSN in the United States District Court for the District of Delaware (the Delaware District Court) in October 2019 and May 2020, which were later consolidated and include infringement claims related to the &#8216;473 Patent and U.S. Patent No. 8,497,284. In addition, in May 2021, we received Paragraph IV certification notice letters regarding an ANDA submitted to the FDA by Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva), requesting approval to market a generic version of CABOMETYX tablets. In response, we filed a patent infringement lawsuit against Teva, along with Teva Pharmaceutical Industries Limited (Teva Parent), in the Delaware District Court in June 2021. We cannot predict the outcome of these lawsuits or provide assurance that these lawsuits will prevent the introduction of a generic version of CABOMETYX for any particular length of time, or at all. For a more detailed discussion of these litigation matters, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, cabozantinib is protected by issued patents covering the composition of matter and methods of use. The issued patent would expire in September 2024, but we have applied for and either have obtained, or expect to obtain Supplementary Protection Certificates in the EU to extend the term to 2029. In addition to the composition of matter patent, the table below includes certain later-expiring patents directed to the commercial product, including, particular salts, polymorphs, formulations, or use of the compound in the treatment of specified diseases or conditions. </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:12.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent No.</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">General Subject Matter</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Expiration</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX </span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2213661</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter and methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2387563</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib and methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ </span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2213661</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter and methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2387563</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib and methods of treatment</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2021, in a final decision before the Technical Board of Appeal, the Opposition Division of the European Patent Office upheld the validity of EP patent 2387563, directed to crystalline forms of cabozantinib malate, pharmaceutical compositions and certain uses thereof. This ruling favors continuing exclusivity of our cabozantinib patent portfolio in the EU through the expiration date of EP patent 2387563 in 2030.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, in Japan, cabozantinib is protected by issued patents covering the composition of matter, and salts thereof, as well as pharmaceutical compositions and related methods of use, and Takeda has applied for patent term extension in Japan to extend the term to 2029. Foreign counterparts of the issued U.S. and European composition of matter patents have been issued in Australia and Canada and are anticipated to expire in 2024. We have other filed patent applications and issued patents in the U.S. and other selected countries covering certain synthetic methods, salts, polymorphs, formulations, prodrugs, metabolites and combinations of cabozantinib that, if issued, are anticipated to expire as late as 2037. Outside the U.S. and Japan, cabozantinib is licensed to Ipsen, and in Japan, cabozantinib is licensed to Takeda, each in accordance with the respective collaboration agreements. A discussion of risks and uncertainties that may affect our patent position and other proprietary rights is set forth in &#8220;Risk Factors,&#8221; contained in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Drug Candidates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have issued patents and pending patent applications, and will continue to file new patent applications, in the U.S., the EU and other selected countries covering our other drug candidates in clinical and/or preclinical development, including XL092, XB002, XL102 and XL114.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained licenses from various parties that give us rights to technologies that we deem to be necessary or desirable for our research and development. These licenses (both exclusive and non-exclusive) may require us to pay royalties as well as upfront and milestone payments.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We require our scientific personnel to maintain laboratory notebooks and other research records in accordance with our policies, which are designed to strengthen and support our intellectual property protection. In addition to our patented intellectual property, we also rely on trade secrets and other proprietary information, especially when we do not believe that&#160;patent</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protection is appropriate or can be obtained. We also require all of our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive proprietary information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all proprietary information developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Furthermore, our agreements with employees and, in most circumstances, our agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors expressly provide that all inventions, concepts, developments, copyrights, trademarks or other intellectual property developed by an employee during the employment period, or developed by a service provider during the service period or utilizing our proprietary drugs or information, shall be our exclusive property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Employees and Commitment to Diversity, Equity and Inclusion</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had 954 full-time equivalent employees, representing a 23% increase in our employee workforce as compared to December 31, 2020. Of these employees, 509 are members of our various research and development teams and 445 are members of our various commercial and general and administrative teams. Of these employees, 149 hold Ph.D. degrees, 19 hold M.D. (or foreign equivalent) degrees, 30 hold PharmD degrees and 88 hold other professional degrees such as a J.D. or M.B.A. None of our employees are represented by a labor union, and we consider our employee relations to be good.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the past five years, our employee turnover has remained consistently below average for the U.S. life sciences industry generally. Given our expanding operations and need to further grow our headcount to support our business, we continually assess employee turnover, recruitment initiatives, compensation and benefits programs, safety in performing critical laboratory work, diversity and other matters relevant to human capital management, and we review results with our Board of Directors on a periodic basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an equal opportunity employer and maintain policies that prohibit unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital and veteran status. We are proud to employ a diverse workforce that, as of December 31, 2021, was 55% non-white and 53% women. In addition, as of December 31, 2021, 50% of our positions that manage other employees directly were held by non-whites and 47% were held by women, and after giving effect to the hiring of our new Chief Medical Officer in January 2022, women made up 33% of our senior leadership team. We strive to build and nurture a culture where all employees feel empowered to be their authentic selves. We respect and appreciate each employee&#8217;s unique perspective and experiences, and value their contributions to our mission. It is important that we celebrate, encourage and support similarities and differences to drive innovation for the benefit of our employees, patients and community.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Culture, Compensation and Benefits</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Exelixis, we value being exceptional in what we do and how we lead, excelling for patients by going the extra mile to care for them and exceeding together as a business and contributor to the scientific community. We strive to live these values every day across the company, integrating them into everything from our interview, hiring and onboarding processes, to our performance evaluation, rewards and promotion programs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide generous compensation packages designed to attract and retain high-quality employees, and all of our employees are eligible for cash bonuses and grants of equity awards. We regularly evaluate our compensation programs with an independent compensation consultant and utilize industry benchmarking in an effort to ensure they are competitive compared to similar biotechnology and biopharmaceutical companies with which we compete for talent, as well as fair and equitable across our workforce with respect to gender, race and other personal characteristics. In addition, we are proud to provide a variety of programs and services to help employees meet and balance their needs at work, at home and in life, including an attractive mix of healthcare, insurance and other benefit plans. We deliver a benefits program that is designed to keep our employees and their families healthy, which includes not only medical, dental and vision benefits, but also dependent care, mental health and other wellness benefits. For a discussion of workplace safety measures we have taken, including as a result of the COVID-19 pandemic, see &#8220;&#8212;Environmental, Health and Safety.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond compensation and benefits, we also value career development for all employees, and we offer a tuition reimbursement program, as well as professional development courses ranging from technical training, competency-based workshops and leadership development programs facilitated by external partners who are experts in their respective fields. Direct managers also take an active role in identifying individualized development plans to assist their employees in realizing their full potential and creating opportunities for promotions and added responsibilities that enhance the engagement and retention of our workforce.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in November 1994 as Exelixis Pharmaceuticals, Inc. and changed our name to Exelixis, Inc. in February 2000. Our principal executive offices are located at 1851 Harbor Bay Parkway, Alameda, California 94502. Our telephone number is (650) 837-7000. We maintain a site on the worldwide web at www.exelixis.com; however, information found on our website is not incorporated by reference into this report.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available free of charge on or through our website our Securities and Exchange Commission (SEC) filings, including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a site on the worldwide web that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov.</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_16"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to the risks discussed elsewhere in this report, the following are important factors that make an investment in our securities speculative or risky, and that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business and the value of your investment in our company could be harmed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Products</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications and the continued clinical development, regulatory approval, clinical acceptance and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib has been or is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. In this regard, part of our strategy is to pursue additional indications for CABOMETYX and increase the number of cancer patients who could potentially benefit from this medicine. However, we cannot be certain that the clinical trials we and our collaboration partners are conducting will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. If revenue from CABOMETYX decreases or remains flat, or if we are unable to expand the number of labeled indications for which CABOMETYX is approved, or if we or our collaboration partners fail to achieve anticipated product royalties and collaboration milestones, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow revenues from sales of CABOMETYX depends upon the degree of market acceptance among physicians, patients, healthcare payers, and the medical community.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase or maintain revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, foreign and U.S. government healthcare payers such as Medicare and Medicaid, commercial healthcare plans and the medical community. Market acceptance for CABOMETYX could be impacted by numerous factors, including the effectiveness and safety profile, or the perceived effectiveness and safety profile, of CABOMETYX compared to competing products, the strength of CABOMETYX sales and marketing efforts and changes in pricing and reimbursement for CABOMETYX. If CABOMETYX does not continue to be prescribed broadly for the treatment of patients in its approved indications, our product revenues could flatten or decrease, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our competitors may develop products and technologies that impair the relative value of our marketed products and any future product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is competitive and characterized by constant technological change and diverse offerings of products, particularly in the area of oncology therapies. Many of our competitors have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage. Further, our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitors may be more effective at in-licensing and developing new commercial products that could render our products, and those of our collaboration partners, obsolete and noncompetitive. We face, and will continue to face, intense competition from biopharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing scientific and clinical research activities similar to ours.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. While we have had success in adapting our development strategy for the cabozantinib franchise to address the competitive landscape, including through evaluation of therapies that combine ICIs with other targeted agents, it is uncertain whether current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in HCC, NSCLC and mCRPC, will lead to regulatory approvals, or whether physicians will prescribe regimens containing cabozantinib instead of competing product combinations in approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain or increase our sales, marketing, market access and product distribution capabilities for our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with maintaining and continuously improving our commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and precommercial-stage, oncology-focused biopharmaceutical companies seeking to build out and maintain their commercial organizations, as well as larger biopharmaceutical organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly scale the size and experience of our commercialization teams to market and sell CABOMETYX successfully in an expanded number of indications. If we are unable to maintain or scale our commercial function appropriately, or should we have to revert back to primarily telephonic and virtual interactions in lieu of in-person meetings with healthcare professionals for an extended period of time as a result of the COVID-19 pandemic, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including foreign and U.S. governmental payers, such as Medicare and Medicaid, and private health insurers. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and may limit reimbursement for newly approved products and indications. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. Accordingly, market acceptance of CABOMETYX and COMETRIQ is dependent on the extent to which coverage and reimbursement is available from third-party payers. These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of contracting. If third-party payers do not provide coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current healthcare laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governments in the U.S. are considering legislative and regulatory proposals to change the U.S. healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Similarly, among policy makers and payers, there is significant interest in promoting such changes with the stated goals of containing healthcare costs, improving quality and expanding patient access. The life sciences industry and specifically the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market for the sale, insurance coverage and distribution of pharmaceuticals has been a particular focus of these efforts and would likely be significantly affected by any major legislative or regulatory initiatives.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA, some of which have been successful, create considerable uncertainties for all businesses involved in healthcare, including our own. Although such efforts have not significantly impacted our business to date, it is possible that the PPACA will be subject to additional judicial or legislative challenges in the future, which may have a material adverse impact on our business, financial condition and results of operations, and we cannot predict how future healthcare reform measures of the Biden Administration and federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are pending federal and state-level legislative proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact on the healthcare industry. It is also possible that additional governmental actions will be taken in response to the ongoing COVID-19 pandemic, and that such actions would have a significant impact on these public health insurance programs. While we cannot predict how future legislation (or enacted legislation that has yet to be implemented) will affect our business, such proposals could have the potential to impact access to and sales of our products. Furthermore, the expansion of the 340B Program has increased the number of purchasers who are eligible for significant discounts on branded drugs, including our marketed products. Because we participate in the 340B Program to sell a portion of our marketed products, changes in the administration of the program could have a material adverse impact on our revenues, including the implementation of the program&#8217;s Administrative Dispute Resolution Process, which is in part intended to resolve claims by covered entities that manufacturers have overcharged them for covered outpatient drugs, and for which the Office of Management and Budget initiated review of a new proposed rule titled &#8220;340B Drug Pricing Program; Administrative Dispute Resolution&#8221; in November 2021. Due to general uncertainty in the current regulatory and healthcare policy environment, and specifically regarding positions that the Biden Administration may take with respect to these issues, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures. If enacted, we and any third parties we may engage may be unable to adapt to any changes implemented as a result of such measures, and we may have difficulties in sustaining profitability or otherwise experience a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. This may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continue to be U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying the prices that Medicare reimburses for physician-administered drugs to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits; implement additional data collection and transparency reporting regarding drug pricing, rebates, fees and other remuneration provided by drug manufacturers; enable the government to negotiate prices under Medicare; revise rules associated with the calculation of average manufacturer price and best price under Medicaid; eliminate the AKS discount safe harbor protection for manufacturer rebate arrangements with Medicare Part D plan sponsors; create new AKS safe harbors applicable to certain point-of-sale discounts to patients and fixed fee administrative fee payment arrangements with pharmacy benefit managers; and revise the rebate methodology under the Medicaid Drug Rebate Program. For instance, President Biden issued an executive order in July 2021 supporting legislation to enact some of these drug pricing reforms, and in response, HHS released a Comprehensive Plan for Addressing High Drug Prices in September 2021 with specific legislative and administrative policies that Congress could enact to help improve affordability of and access to prescription drugs. While we cannot know the final form or timing of any such legislative, regulatory and/or administrative measures, some of the pending and enacted legislative proposals or executive rulemaking if implemented without successful legal challenges, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biotherapeutic product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the National Medicaid Pooling Initiative. In particular, the obligation to provide notices of price increases to purchasers under laws such as California&#8217;s SB-17 may influence customer ordering patterns for CABOMETYX and COMETRIQ, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. Furthermore, adoption of these drug pricing transparency regulations, and our associated compliance obligations, may increase our general and administrative costs and/or diminish our revenues. Implementation of these federal and/or state cost-containment measures or other healthcare reforms may limit our ability to generate product revenue or commercialize our products, and in the case of drug pricing transparency regulations, may result in fluctuations in our results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products, resulting in a decrease in revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., including major markets in the EU and Japan, the pricing and reimbursement of prescription pharmaceuticals is generally subject to governmental control. In these countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partners Ipsen and Takeda may also be required to conduct a study or otherwise provide data that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, cost-control initiatives, increasingly based on affordability and accessibility, as well as post-marketing assessments of the added value of CABOMETYX and COMETRIQ as compared to existing treatments, could influence the prices paid for and net revenues we realize from CABOMETYX and COMETRIQ, or the indications for which we are able to obtain reimbursement, which would result in lower license revenues to us. Upcoming legislative and policy changes in the EU are aimed at increasing cooperation between the EU Member States. Such initiatives, particularly the HTA adopted in December 2021, may further impact the price and reimbursement status of CABOMETYX and COMETRIQ in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The entrance of generic competitors and legislative and regulatory action designed to reduce barriers to the development, approval and adoption of generic drugs in the U.S. could limit the revenue we derive from our products, most notably CABOMETYX, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDCA, the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve an NDA under section 505(b)(2) of the FDCA that relies in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug, where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. Both the ANDA and 505(b)(2) NDA processes are discussed in more detail above in &#8220;Item 1. Business&#8212;Government Regulation&#8212;FDA Review and Approval&#8212;Abbreviated FDA Approval Pathways and Generic Products&#8221; in this Annual Report on Form 10-K. In either case, if an ANDA or 505(b)(2) NDA applicant submits an application referencing one of our marketed products prior to the expiry of one or more our Orange Book-listed patents for the applicable product, we may litigate with the potential generic competitor to protect our patent rights, which would result in substantial costs, divert the attention of management, and could have an adverse impact on our stock price. For example, MSN and Teva have separately submitted ANDAs to the FDA requesting approval to market their respective generic versions of CABOMETYX tablets, and we have subsequently filed patent lawsuits against both companies. For a more detailed discussion of these litigation matters, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K. It is possible that MSN, Teva or other companies, following FDA approval of an ANDA or 505(b)(2) NDA, could introduce generic or otherwise competitor versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and we expect that generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. Therefore, regardless of the regulatory approach, the introduction of a generic version of cabozantinib would likely decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. There are also equivalent procedures in the EU permitting authorization of generic versions and biosimilars of medicinal products authorized in the EU once related data and market exclusivity periods have expired.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government has also taken numerous legislative and regulatory actions to expedite the development and approval of generic drugs and biosimilars. Both Congress and the FDA are considering, and have enacted, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Ensuring Innovation Act, enacted in April 2021, amended the FDA&#8217;s statutory authority for granting NCE exclusivity to reflect the agency&#8217;s existing regulations and longstanding interpretation that award NCE exclusivity based on a drug&#8217;s active moiety, as opposed to its active ingredient, which is intended to limit the applicability of NCE exclusivity, thereby potentially facilitating generic competition. The FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; healthcare costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs. In addition, the Further Consolidated Appropriations Act, 2020, which incorporated the framework from the CREATES legislation, purports to promote competition in the market for drugs and biotherapeutic products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biotherapeutic products, including by allowing ANDA, 505(b)(2) NDA or biosimilar developers to obtain access to branded drug and biotherapeutic product samples. While the full impact of these provisions is unclear at this time, its provisions do have the potential to facilitate the development and future approval of generic versions of our products, introducing generic competition that could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Healthcare Regulatory and Other Legal Compliance Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal and state healthcare laws and regulations, which laws and regulations are enforced by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper business conduct or inaccurate reporting, we could be subject to enforcement of the following, including, without limitation:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the federal AKS;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the FDCA and its implementing regulations;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">federal civil and criminal false claims laws, including the civil False Claims Act, and the Civil Monetary Penalties Law;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">HIPAA and its implementing regulations, as amended; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">state law equivalents of each of the above federal laws;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the Open Payments program of the PPACA;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">state and local laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">state and federal pharmaceutical price and price reporting laws and regulations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, medical professionals employed by national healthcare programs) and its foreign equivalents, as well as federal and state consumer protection and unfair competition laws.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These federal and state healthcare laws and regulations govern drug marketing practices, including off-label promotion. If our operations are found, or even alleged, to be in violation of the laws described above or other governmental regulations that apply to us, we, or our officers or employees, may be subject to significant penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, imprisonment, reputational harm, additional reporting requirements and oversight, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Furthermore, responding to any such allegation and/or defending against any such enforcement actions can be time-consuming and would require significant financial and personnel resources. Therefore, if any state or the federal government initiates an enforcement action against us, our business may be impaired, and even if we are ultimately successful in our defense, litigating these actions could result in substantial costs and divert the attention of management.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer patient assistance programs and donations to patient assistance foundations created by charitable organizations could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of Congressional interest and enhanced government scrutiny. The HHS Office of Inspector General established guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations that provide co-pay assistance to Medicare patients, provided that manufacturers meet certain specified compliance requirements. In the event we make such donations but are found not to have complied with these guidelines and other laws or regulations respecting the operation of these programs, we could be subject to significant damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. We also rely on a third-party hub provider and exercise oversight to monitor patient assistance program activities. Hub providers are generally hired by manufacturers to assist patients with insurance coverage, financial assistance and treatment support after the patients receive a prescription from their healthcare professional. For manufacturers of specialty pharmaceuticals (including our marketed products), the ability to have a single point of contact for their therapies helps ensure efficient medication distribution to patients. Accordingly, our hub activities are also subject to scrutiny and may create risk for us if not conducted appropriately. A variety of entities, including independent charitable foundations and pharmaceutical manufacturers, but not including our company, have received subpoenas from the U.S. Department of Justice and other enforcement authorities seeking information related to their patient assistance programs and support. Should we or our hub providers receive a subpoena or other process, regardless of whether we are ultimately found to have complied with the regulations governing patient assistance programs, this type of government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative and regulatory landscape for privacy and data protection continues to evolve in the U.S. and other jurisdictions around the world. For example, the CCPA went into operation in 2020 and affords California residents expanded privacy rights and protections, including civil penalties for violations and statutory damages under a private right of action for data security breaches. These protections will be expanded by the CPRA, which will be operational in most key respects on January 1, 2023. Similar legislative proposals have passed or are being advanced in other states, and Congress is also considering additional federal privacy legislation. In addition, most healthcare professionals and facilities are subject to privacy and security requirements under HIPAA with respect to our clinical and commercial activities. Although we are not considered to be a covered entity or business associate under HIPAA, we could be subject to penalties if we use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, in the EU, the GDPR regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also places restrictions on transfers of such data to countries outside of the EU, including the U.S. Should we fail to provide adequate privacy or data security protections or maintain compliance with these laws and regulations, including the CCPA, CPRA and GDPR, we could be subject to sanctions or other penalties, litigation, an increase in our cost of doing business and questions concerning the validity of our data processing activities, including clinical trials.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Growth of Our Product Portfolio and Research and Development</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval of a product candidate or of an approved product for a new indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and late-stage or other potentially label-enabling clinical trials may fail to confirm the results observed in early-stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events, during or as a result of clinical investigations, that could delay or prevent commercialization of cabozantinib in new indications or of new product candidates, and in some cases, as described in the risk factor titled, &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; the COVID-19 pandemic has already increased and may further increase the potential for such events to occur. These events may include:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">lack of acceptable efficacy or a tolerable safety profile;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our inability to identify and maintain a sufficient number of trial sites; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">lower-than-anticipated patient registration or enrollment in our clinical testing; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">additional complexities posed by clinical trials evaluating cabozantinib or our other product candidates in combination with other therapies, including extended timelines to provide for collaboration on clinical development planning, the failure by our collaboration partners to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">reduced staffing or shortages in laboratory supplies and other resources necessary to complete the trials; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials or delays, variations, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are further delays in or termination of the clinical testing of cabozantinib or our other product candidates due to any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our collaboration partners to fund a significant portion of our clinical development programs. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for financing the further development of the cabozantinib franchise or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to pursue the further development of the cabozantinib franchise or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions in accordance with our stated timelines or at all. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or otherwise may not result in an approvable product. The duration and the cost of clinical trials vary significantly as a result of factors relating to the clinical trial, including, among others: the characteristics of the product candidate under investigation; the number of patients who ultimately participate in the clinical trial; the duration of patient follow-up; the number of clinical sites included in the trials; and the length of time required to enroll eligible patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, uncertain and subject to change, and may not result in regulatory approvals for additional cabozantinib indications or for our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities associated with the research, development and commercialization of the cabozantinib franchise and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S., as well as by comparable regulatory authorities in other territories. The processes of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive and often takes many years, if approval is obtained at all, and they can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a marketing authorization application to the EMA or any application or submission to comparable regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, we may encounter delays or rejections based upon changes in policy, which could cause delays in the approval or rejection of an application for cabozantinib or for our other product candidates. For example, the FDA launched Project Optimus in 2021 as an initiative to reform the dose optimization and dose selection paradigm in oncology drug development, which was driven by the FDA&#8217;s concerns that the current paradigm for dose selection may result in doses and schedules of molecularly targeted therapies that are inadequately characterized before initiating pivotal trials. Through collaboration with the biopharmaceutical industry, academia and other stakeholders, the FDA&#8217;s goal for this initiative is to advance an oncology dose-finding and dose optimization paradigm that emphasizes dose selections that maximize efficacy as well as safety and tolerability. In support of this initiative, FDA may request sponsors of oncology product candidates to conduct dose optimization studies pre- or post-approval. Recently, in part due to questions raised by the process underlying the approval of the Alzheimer&#8217;s disease drug Aduhelm</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government authorities and other stakeholders have been scrutinizing the accelerated approval pathway, with some stakeholders advocating for reforms. Even prior to the Aduhelm approval, FDA has held Oncologic Drugs Advisory Committee meetings to discuss accelerated approvals for which confirmatory trials have not verified clinical benefit. Such scrutiny, among other factors, has resulted in voluntary withdrawals of certain products and indications approved on an accelerated basis.  Moreover, spurred by the Aduhelm controversy, the HHS Office of Inspector General has initiated an assessment of how the FDA implements the accelerated approval pathway.  At this time, it is not clear what impact, if any, these developments may have on the statutory accelerated approval pathway or our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more new indications, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, and/or production of the product and could impose requirements for post-marketing studies, including additional research and clinical trials, all of which may result in significant expense and limit our and our collaboration partners&#8217; ability to commercialize cabozantinib in one or more new indications. Failure to complete post-marketing requirements of the FDA in connection with a specific approval in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or ultimately restrict the commercialization of cabozantinib in that indication. Regulatory agencies could also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Further, current or any future laws or executive orders governing FDA or foreign regulatory approval processes that may be enacted or executed could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to expand our discovery and development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we have invested in substantial technical, financial and human resources toward drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. Notwithstanding this investment, many programs that initially show promise will ultimately fail to yield product candidates for multiple reasons. For example, product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apart from our drug discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates and technologies. However, the in-licensing and acquisition of product candidates and technologies is a highly competitive area, and many other companies are pursuing the same or similar product candidates and technologies to those that we may consider attractive. In particular, larger companies with more capital resources and more extensive clinical development and commercialization capabilities may have a competitive advantage over us. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may also be unable to in-license or acquire additional product candidates and technologies on acceptable terms that would allow us to realize an appropriate return on our investment. Even if we succeed in our efforts to obtain rights to suitable product candidates and technologies, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products and technologies will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target company, or retain key personnel of the acquired business. Furthermore, we could assume unknown or contingent liabilities or otherwise incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our financial condition and results of operations. If our drug discovery efforts, including research collaborations, in-licensing arrangements and other business development activities, do not result in suitable product candidates, our business and prospects for growth could suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Financial Matters and Capital Requirements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we reported net income of $231.1 million and $111.8 million for the years ended December&#160;31, 2021 and 2020, respectively, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; our achievement of development, regulatory and commercial milestones, if any, under our collaboration agreements; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements; other collaboration revenues; and the level of our expenses, including those associated with our extensive drug discovery, clinical development and business development activities, both for the cabozantinib franchise and our earlier-stage product candidates, as well as our general business expansion plans. Our expected future expenses in particular may also be increased by inflationary pressures, whether resulting from the effects of the COVID-19 pandemic or otherwise, which could increase the costs of outside services, labor, raw materials and finished drug product. We expect to continue to spend substantial amounts to fund the continued development of the cabozantinib franchise for additional indications and the commercialization of our approved products. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including research collaborations, in-licensing arrangements and other strategic transactions that align with our oncology drug development, regulatory and commercial expertise, which efforts could involve substantial costs. To offset these costs in the future, we will need to generate substantial revenues. If these costs exceed our current expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If additional capital is not available to us when we need it, we may be unable to expand our product offerings and maintain business growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of the cabozantinib franchise and our earlier-stage product candidates, and increasing drug discovery activities, as well as through the execution of business development transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing economic conditions and financial, business and other factors beyond our control. We do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be unable to expand our product offerings and maintain business growth, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and we are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon the regulatory, commercial, medical affairs, market access and other expertise and resources of our collaboration partners, Ipsen and Takeda, for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaboration partners dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaboration partners depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. Further, the operations of our collaboration partners, and ultimately their sales of CABOMETYX in their respective territories outside of the U.S., could be adversely affected by the degree and effectiveness of their respective corporate responses to the COVID-19 pandemic, as well as by the imposition of governmental price or other controls, political and economic instability, trade restrictions or barriers and changes in tariffs, escalating global trade and political tensions, or other factors. If our collaboration partners are unable or unwilling to invest the resources necessary to commercialize CABOMETYX successfully in the EU, Japan and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established clinical and commercial collaborations with leading biopharmaceutical companies for the development and commercialization of our products, and our dependence on these collaboration partners subjects us to a number of risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our collaboration partners&#8217; decision to terminate our collaboration, or their failure to comply with the terms of our collaboration agreements and related ancillary agreements, either intentionally or as a result of negligence or other insufficient performance;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our inability to control the amount and timing of resources that our collaboration partners devote to the development or commercialization of our products;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the possibility that our collaboration partners may stop or delay clinical trials, fail to supply us on a timely basis with product required for a combination trial, or deliver product that fails to meet appropriate quality and regulatory standards;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">disputes that may arise between us and our collaboration partners that result in the delay or termination of the development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the possibility that our collaboration partners may experience financial difficulties that prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our collaboration partners&#8217; inability to obtain regulatory approvals in a timely manner, or at all; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our collaboration partners&#8217; failure to comply with legal and regulatory requirements relevant to the authorization, marketing, distribution and supply of our marketed products in the territories outside the U.S. where they are approved; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our collaboration partners&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations, and our product development efforts and prospects for growth could be delayed or disrupted, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our early-stage product pipeline, we have augmented our drug discovery activities with multiple research collaborations and in-licensing arrangements with other companies. Our dependence on our relationships with these research and in-licensing partners subjects us to numerous risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our research and in-licensing partners&#8217; decision to terminate our relationship, or their failure to comply with the terms of our agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">disputes that may arise between us and our research and in-licensing partners that result in the delay or termination of research activities with respect to any in-licensed assets or supporting technology platforms;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the possibility that our research and in-licensing partners may experience financial difficulties that prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our research and in-licensing partners&#8217; failure to properly maintain or defend their intellectual property rights or their use of third-party intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our license to develop these assets or utilize technology platforms;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">laws, regulations or practices imposed by countries outside the U.S. that could impact or inhibit scientific research or the development of healthcare products by foreign competitors or otherwise disadvantage healthcare products made by foreign competitors, as well as general political or economic instability in those countries, any of which could complicate, interfere with or impede our relationships with our ex-U.S. research, development and in-licensing partners; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our research and in-licensing partners&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations related to GMP and GLP.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not be able to expand our product pipeline or otherwise realize a return on the resources we will have invested to develop these early-stage assets, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government, third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical trial or data security protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib beyond currently approved indications or obtain regulatory approval for our other product candidates. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to help advance our drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We lack our own manufacturing and distribution capabilities necessary for us to produce materials required for certain preclinical activities and to produce and distribute our products for clinical development or for commercial sale, and our reliance on third parties for these services subjects us to various risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing or distribution facilities for CMC development activities, preclinical, clinical or commercial production and distribution for our current products and new product candidates. Instead, we rely on various third-party contract manufacturing organizations to conduct these operations on our behalf. As our operations continue to grow in these areas, we continue to expand our supply chain through secondary third-party contract manufacturers, distributors and suppliers. To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to fulfill compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our preclinical, clinical development and commercial needs and applicable regulatory requirements, including as a result of the COVID-19 pandemic. Although we have not yet experienced significant production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers, distributors and suppliers could experience operational delays due to facility closures and other hardships as a result of the COVID-19 pandemic or otherwise, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our commercial or clinical products or product candidates. If our third-party contract manufacturers, distributors and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our manufacturing, distribution and supply arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude meeting commercial or clinical product supply requirements for us or our partners, which could delay product development and future commercialization efforts and have a material adverse impact on our business, financial condition and results of operations. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the DSCSA. If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party scientific advisors and contractors we rely on to assist with our drug discovery efforts do not perform as expected, the expansion of our product pipeline may be delayed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with scientific advisors at academic and other institutions, as well as third-party contractors in various locations throughout the world, that assist us in our research and development efforts, including in drug discovery and preclinical development strategy. These third parties are not our employees and may have other commitments or contractual obligations that limit their availability to us. Although these third-party scientific advisors and contractors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as scientific advisors and contractors or otherwise limit our access to these experts, or that the scientific advisors themselves may now be more reluctant to work with industry partners. Even if these scientific advisors and contractors with whom we have engaged intend to meet their contractual obligations, their ability to perform services may be impacted by increased demand for such services from other companies or by other external factors, such as reduced capacity to perform services, as we experienced in the early stages of the COVID-19 pandemic. If we experience additional delays in the receipt of services, lose work performed by these scientific advisors and contractors or are unable to engage them in the first place, our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Information Technology and Intellectual Property</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data breaches, cyber-attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and our third-party service providers, such as contract research organizations, collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our collaboration partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cybersecurity efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber-attack. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber-attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt critical business operations, expend key information technology resources and divert the attention of management. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the aggregate impact of cyber-attacks on our operations and financial condition has not been material to date, we and our third-party service providers have frequently been the target of threats of this nature and expect them to continue. Any future data breach and/or unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information or sensitive business information of our collaboration partners, which may lead to significant liability for us. A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others and result in harm to our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents including the GDPR, subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cybersecurity systems (including the recruitment and retention of experienced information technology professionals, who are in high demand) at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our third-party service providers may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. For example, we received Paragraph IV certification notice letters from MSN and Teva concerning the respective ANDAs that each had filed with the FDA seeking approval to market their respective generic versions of CABOMETYX tablets. Should MSN, Teva or any other third parties receive FDA approval of an ANDA or a 505(b)(2) NDA with respect to cabozantinib, it is possible that such company or companies could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and the resulting generic competition could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. They may also be negatively impacted by the decisions of foreign courts, which could limit the protection contemplated by the original regulatory approval and our ability to thwart the development of competing products that might otherwise have been determined to infringe our intellectual property rights. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in the EU, have compulsory licensing laws based on related EU rules, under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We also rely on trade secret protection for some of our confidential and proprietary information, and we are taking security measures to protect our proprietary information and trade secrets, particularly in light of recent instances of data loss and misappropriation of intellectual property in the biopharmaceutical industry. However, these measures may not provide adequate protection, and while we seek to protect our proprietary information by entering into confidentiality agreements with employees, partners and consultants, as well as maintain cybersecurity protocols within our information technology infrastructure, we cannot provide assurance that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense. In addition, we may be subject to claims that our employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that they used or sought to use patent inventions belonging to their former employers. Furthermore, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs and divert the attention of management and key technical personnel in defending ourselves against any such claims or enforcing our own patents. In the event of any third party&#8217;s successful claim of patent infringement or misappropriation of trade secrets, we may lose valuable intellectual property rights or personnel, which could impede or prevent the achievement of our product development goals, or we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations, Managing Our Growth and Employee Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the COVID-19 pandemic has had a modest impact on our business operations, in particular with respect to our clinical trial, drug discovery and commercial activities. For example, to varying degrees and at different rates across our clinical trials, we experienced declines in screening and enrollment activity during the early days of the COVID-19 pandemic, as well as delays in new site activations and restrictions on the access to treatment sites that is necessary to monitor clinical study progress and administration. As the COVID-19 pandemic continues to have a significant presence in various parts of the world, particularly with the emergence of the Delta, Omicron and other SARS-CoV-2 variants, the impact on our clinical development operations could continue or grow more severe. We anticipate that a further prolonged, or more severe, global public health crisis could limit our ability to identify and work with clinical investigators at clinical trial sites globally to enroll, initiate and maintain treatment per protocol of patients for our ongoing clinical trials. Disruptions to medical and administrative operations at clinical trial sites, including staffing and materials shortages and the implementation of crisis management initiatives, have and may continue to reduce personnel and other resources necessary to conduct our clinical trials, which could further delay some of our clinical trial plans or may require certain trials to be temporarily suspended. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, quarantines and travel restrictions have impeded and may continue to impede patient movement or interrupt healthcare services, which we anticipate over time, could also delay, interfere with and potentially negatively impact clinical trial execution, and ultimately results, particularly with respect to clinical trials evaluating our or our collaboration partners&#8217; product candidates that must be administered via intravenous infusion. In addition, increased costs connected with our efforts to mitigate the adverse impacts resulting from the COVID-19 pandemic on our clinical trials could cause the expenses we incur in conducting those clinical trials to increase considerably. Depending upon the duration and severity of the COVID-19 pandemic, we could also experience delays in planning and conducting new clinical trials of the investigative product candidates entering and advancing through our development pipeline, which could increase the operating expenses associated with these trials and adversely affect their timelines for completion and ultimately our ability to obtain regulatory approvals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both drug discovery work in our laboratories and outsourced drug discovery activities have fully resumed following temporary suspensions during the early days of the COVID-19 pandemic; however, we may be unable to maximize the potential of these programs due to the imposition of increased safety protocols, and should the effects of the COVID-19 pandemic become more severe, we may have to again scale back or suspend activities in the future. We are also reliant on laboratory materials manufactured and distributed from areas impacted by both the COVID-19 pandemic and other natural disasters, for which supply has become limited. If we are unable to obtain the requisite materials to conduct our planned drug discovery activities, we may be required to redirect the focus of, or even suspend, such activities. Should the COVID-19 pandemic be further prolonged or grow in severity, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines, which could have a material adverse impact on our prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that our commercial business has, to date, only experienced a modest impact related to the COVID-19 pandemic, it remains possible that over a longer period, changes to our standard sales and marketing practices, including any shifts from in-person back to primarily telephonic and virtual interactions with healthcare professionals, could negatively impact the flow of important information regarding our medicines, which along with obstacles to patient access to healthcare professionals, could diminish sales of our marketed products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although as of the date of this Annual Report on Form 10-K, we continue to maintain sufficient safety stock inventories for our drug substance and drug products and have not experienced significant production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers and suppliers could experience operational delays due to facility closures and other hardships as a result of the COVID-19 pandemic, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our commercial or clinical products or product candidates. These delays or disruptions could be further exacerbated if the COVID-19 pandemic begins to impact essential distribution systems, which could substantially increase delivery times and costs, or otherwise adversely affect our ability to provide our products to customers and clinical trial sites and generate product revenues. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of broad economic shifts during and as a consequence of efforts to address unemployment and other negative economic effects of the COVID-19 pandemic, we may experience reductions in the net price of our products. For example, there may be a substantial shift from private health insurance coverage to government insurance coverage, or additional downward pressure on the prices government purchasers will pay for our products due to significant increases in government debt incurred in connection with relief efforts, as well as significant increases in demand for our patient assistance and/or free drug program or other impacts that may not be foreseeable, all or any of which would adversely affect our product revenues.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect the COVID-19 pandemic to continue to have varying degrees of adverse impact on our business operations and, potentially in the future, our financial results, the extent of such adverse impact will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time. Such developments include, but are not limited to: continued spread of the Delta and Omicron variants in the U.S. and other countries and the potential emergence of other SARS-CoV-2 variants that may prove especially contagious or virulent, the ultimate duration of the pandemic and resulting disruptions to normal business and personal activities in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease, including the rate at which vaccinations are made available and are administered, the percentage of the population that becomes fully vaccinated and the effectiveness of the vaccines against Delta, Omicron or other SARS-CoV-2 variants. These continuing or future effects could materially and adversely affect our business, financial condition, results of operations and growth prospects, and exacerbate the other risks and uncertainties described elsewhere in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations, in particular as we continue to expand the cabozantinib franchise into new indications and grow our pipeline of product candidates. This growth places significant demands on our management and resources, and our current and planned personnel and operating practices may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, facilities, operational and financial systems, and procedures and controls, as well as expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We continue to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, including as a result of the COVID-19 pandemic or otherwise, or we are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial, scientific and pharmaceutical operations personnel will be critical to support activities related to advancing the development program for the cabozantinib franchise and our other product candidates, successfully executing upon our commercialization plan for the cabozantinib franchise and our proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials, and our operations can produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge, or any resultant injury from these materials, and we may face liability under applicable laws for any injury or contamination that results from our use or the use by our collaboration partners or other third parties of these materials. Such liability may exceed our insurance coverage and our total assets, and in addition, we may be required to indemnify our collaboration partners against all damages and other liabilities arising out of our development activities or products produced in connection with our collaborations with them. Moreover, our continued compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be held liable if any product we or our collaboration partners develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. We maintain limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib. However, our insurance may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and may in the future be highly volatile.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been highly volatile, and it may remain highly volatile or fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the announcement of FDA or other regulatory approval or non-approval, or delays in the FDA or other regulatory review process with respect to cabozantinib, our collaboration partners&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the commercial performance of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products, including royalties paid under our collaboration and license agreements;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">adverse or inconclusive results or announcements related to our or our collaboration partners&#8217; clinical trials or delays in those clinical trials;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the timing of achievement of our clinical, regulatory, partnering, commercial and other milestones for the cabozantinib franchise or any of our other programs or product candidates;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to make future investments in the expansion of our pipeline through drug discovery, including future research collaborations, in-licensing arrangements and other strategic transactions;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to obtain the materials and services, including an adequate product supply for any approved drug product, from our third-party vendors or do so at acceptable prices;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the announcement of new products or clinical trial data by our competitors;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the announcement of regulatory applications, such as MSN&#8217;s and Teva&#8217;s respective ANDAs, seeking approval of generic versions of our marketed products;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">changes in our relationships with our collaboration partners, including the termination or modification of our agreements, or other events or conflicts that may affect our collaboration partners&#8217; timing and willingness to develop, or if approved, commercialize our products and product candidates out-licensed to them;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the announcement of an in-licensed product candidate or strategic acquisition;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">changes in earnings estimates or recommendations by securities analysts, or financial guidance from our management team, and any failure to achieve the operating results projected by securities analysts or by our management team;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the entry into new financing arrangements;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">developments in the biopharmaceutical industry;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">additions and departures of key personnel or board members;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the disposition of any of our technologies or compounds; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors could have material adverse impact on the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Likewise, as a result of significant changes in U.S. or global political and economic conditions, policies governing foreign trade and healthcare spending and delivery, or future potential U.S. federal government shutdowns, the financial markets could continue to experience significant volatility that could also continue to negatively impact the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been initiated. A securities class action suit against us could result in substantial costs and divert the attention of management, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">a prohibition on actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">advance notice requirements for director nominations and stockholder proposals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_19"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_22"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters is located in Alameda, California, where&#160;we lease a total of 254,690 square feet of space. We took possession of an additional 25,749 square feet of space in 2021. The lease expires in October 2031. We have two five-year options to extend the lease. In October 2019, we entered into a build-to-suit lease agreement (the Build-to-Suit Lease) for approximately 220,000 square feet of additional office facilities adjacent to our current corporate headquarters. The term of the Build-to-Suit Lease is for a period of 242 months, which will begin on the substantial completion of the building and tenant improvements by the lessor. We currently anticipate that the term will begin in the first quarter of 2022. We believe these leased facilities are sufficient to accommodate our current and near-term needs.</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_25"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against the &#8217;473 Patent (composition of matter) or U.S. Patent No. 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: the &#8216;473 Patent and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the Delaware </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">District Court for patent infringement against MSN asserting infringement of the &#8216;473 Patent and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of the &#8216;473 Patent and U.S. Patent No. 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to the &#8216;473 Patent and U.S. Patent No. 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of the &#8216;473 Patent and U.S. Patent No. 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of the &#8216;473 Patent, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. A bench trial has been scheduled for May 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of four previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patent Nos. 11,091,439 (salt and polymorphic forms) 11,091,440 (formulations) and 11,098,015 (methods of treatment). We have 45 days from the receipt of the January 11, 2022 notice to file a patent infringement claim against MSN relating to the newly challenged patents.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with Teva Parent, asserting infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On February 8, 2022, the parties filed a stipulation to stay all proceedings, which was granted by the Delaware District Court on February 9, 2022. The stipulation and order were filed under seal.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_28"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_34"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has traded on the Nasdaq Global Select Market under the symbol &#8220;EXEL&#8221; since April 11, 2000.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;7, 2022, there were 347 holders of record of our common stock. The number of record holders is based upon the actual number of holders registered on our books at such date and does not include holders of shares in &#8220;street names&#8221; or persons, partnerships, associations, corporations or other entities identified in security position listings maintained by depository trust companies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have not paid dividends on our common stock. We currently intend to retain all future earnings, if any, for use in our business and currently do not plan to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our Board of Directors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no unregistered sales of equity securities by us during the year ended December&#160;31, 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Repurchases of Equity Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no repurchases&#160;of our common stock during the year ended December&#160;31, 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This performance graph shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of ours under the Securities Act of 1933, as amended.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares, for the five-year period ended December&#160;31, 2021, the cumulative total return for our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The graph assumes that $100 was invested on December&#160;31, 2016 in each of our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index and assumes reinvestment of any dividends. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</span></div><div style="margin-top:9pt;text-indent:36pt"><img src="exel-20211231_g2.jpg" alt="exel-20211231_g2.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2016</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Composite Total Return</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Biotechnology Total Return</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="ib1dc779af6a3491c9aef59246f08fe04_37"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Reserved</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_40"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of the statements under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; are forward-looking statements. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Item&#160;1A. Risk&#160;Factors&#8221; as well as those discussed elsewhere in this Annual Report on Form 10-K. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the FDA and in 61 other countries as: CABOMETYX tablets approved for advanced RCC, both alone and in combination with OPDIVO, for previously treated HCC and, currently by the FDA, for previously treated, RAI-refractory DTC; and COMETRIQ capsules approved for progressive MTC. For these types of cancer, cabozantinib has become or is becoming an important drug in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC, an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech; and MINNEBRO, an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo. For additional information about these products, see &#8220;Business&#8212;Collaborations and Business Development Activities&#8212;Other Collaborations&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan is to utilize our operating cash flows and cash and investments to expand the cabozantinib franchise by potentially adding new indications in areas of unmet medical need. We will also leverage our operating cash flows to continue advancing our diverse small molecule and biotherapeutics programs, exploring multiple modalities and mechanisms of action to discover new oncology drugs. So far, these drug discovery and preclinical activities have resulted in four clinical-stage compounds: XL092, a next-generation oral TKI; XB002, a TF-targeting ADC; XL102, a potent, selective and orally bioavailable covalent inhibitor of CDK7; and XL114, a n</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ovel anti-cancer compound that inhibits the CBM complex</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Franchise</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2021, the FDA approved CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC. This regulatory milestone expands upon the FDA&#8217;s prior approvals of CABOMETYX as a monotherapy for previously treated patients with advanced RCC in April 2016 and for previously untreated patients with advanced RCC in December 2017. Additionally, in January 2019, the FDA approved CABOMETYX for the treatment of patients with HCC who have been previously treated with sorafenib, and most recently, on September 17, 2021, the FDA approved CABOMETYX for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy and who are RAI-refractory or ineligible.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen and Takeda. We granted to Ipsen the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda the rights to develop and commercialize cabozantinib in Japan. Both Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of the cabozantinib franchise in other potential indications, and we continue to work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the EU, the U.K. and Canada, as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib. In addition, in March 2021, Ipsen and BMS received regulatory approval from the EC for CABOMETYX in combination with OPDIVO as a first-line treatment for patients with advanced RCC, and both Ipsen and BMS plan to submit applications to approve the combination in other territories beyond the EU. Ipsen also submitted a variation application to the EMA to approve CABOMETYX as a treatment for patients with previously treated, RAI-refractory DTC, with the EMA validating the variation and beginning its centralized review process in August 2021. With respect to the Japanese market, Takeda received Manufacturing and Marketing Approvals in 2020 from the Japanese MHLW of CABOMETYX as a treatment of patients with curatively unresectable or metastatic RCC and as a treatment of patients with unresectable HCC who progressed after cancer chemotherapy. Most recently, in August 2021, Takeda and Ono Pharmaceutical Co., Ltd. (Ono), BMS&#8217; development and commercialization partner in Japan, received Manufacturing and Marketing Approval from the Japanese MHLW of CABOMETYX in combination with OPDIVO as a treatment for unresectable or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our collaboration partners for rest-of-world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could potentially benefit from this medicine. We continue to evaluate cabozantinib, both as a single agent and in combination with ICIs, in a broad development program comprising over 100 ongoing or planned clinical trials across multiple tumor types. We, along with our collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our CRADA with NCI-CTEP or our IST program. Informed by the available data from these clinical trials, we advanced the development program for the cabozantinib franchise with potentially label-enabling trials, including COSMIC-311, and positive results from COSMIC-311 served as the basis for the FDA&#8217;s September 2021 DTC approval for CABOMETYX.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building on preclinical and clinical observations that cabozantinib in combination with ICIs may promote a more immune-permissive tumor environment, we initiated numerous pivotal studies to further explore these combination regimens. The first of these studies to deliver results was CheckMate -9ER, and positive results from CheckMate -9ER served as the basis for the FDA&#8217;s, EC&#8217;s and MHLW&#8217;s approvals of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC in January 2021, March 2021 and August 2021, respectively. We are also collaborating with BMS on COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. Enrollment for COSMIC-313 was completed in March 2021, and we expect to report top-line results of the event-driven analyses from the trial in the first half of 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our exploration of combinations with ICIs, we also initiated multiple trials evaluating cabozantinib in combination with Roche&#8217;s ICI, atezolizumab. COSMIC-021 is a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with a wide variety of locally advanced or metastatic solid tumors. Based on encouraging efficacy and safety data that has emerged from the trial, certain cohorts have been expanded, including Cohort 6 evaluating patients with mCRPC who have been previously treated with enzalutamide and/or abiraterone acetate and experienced radiographic disease progression in soft tissue and another cohort evaluating patients with NSCLC who have been previously treated with an ICI. We announced data from Cohort 6 in May 2021 and presented more detailed results from Cohort 6 at the ESMO 2021 Congress in September 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although, following our discussions with the FDA, we will not pursue a regulatory submission for the combination regimen in mCRPC based solely on the Cohort 6 results, data from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting the initiation of COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC, and three phase 3 pivotal trials in collaboration with Roche, CONTACT-01, CONTACT-02 and CONTACT-03, evaluating the combination of cabozantinib with atezolizumab in patients with metastatic NSCLC, mCRPC and advanced RCC, respectively. CONTACT-01 and CONTACT-03 are sponsored by Roche and co-funded by us; CONTACT-02 is sponsored by us and co-funded by Roche. In June 2021, we announced results from COSMIC-312. The trial met one of the primary endpoints, demonstrating significant improvement in BIRC assessed PFS at the planned primary analysis, reducing the risk of disease progression or death by 37% compared with sorafenib. The interim analysis for the second primary endpoint of OS, performed at the same time as the primary analysis for PFS, did not reach statistical significance. The trial is continuing as planned to the final analysis of OS, anticipated during the first quarter of 2022, and we intend to submit an sNDA to the FDA for the combination regimen if supported by the final OS analysis.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our cabozantinib clinical trials, see &#8220;Business&#8212;Exelixis Development Programs&#8212;Cabozantinib Development Program&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our small molecule discovery programs are supported by a robust and expanding infrastructure, including a library of 4.6 million compounds. We have extensive experience in the identification and optimization of drug candidates against multiple target classes for oncology, inflammation and metabolic diseases. The first compound to enter the clinic following our re-initiation of drug discovery activities in 2017 was XL092, a next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer&#8217;s growth and spread. In designing XL092, we sought to build upon our experience with cabozantinib, retaining a similar target profile while improving key characteristics, including the pharmacokinetic half-life. To date, we have initiated two large phase 1b clinical trials studying XL092: STELLAR-001 and STELLAR-002. STELLAR-001 is a phase 1b clinical trial evaluating XL092, both as a monotherapy and in combination with either atezolizumab or Merck KGaA&#8217;s and Pfizer&#8217;s avelumab. We are continuing to enroll patients into the dose-escalation cohorts of the combination part of the trial, and we expect that once recommended doses are established for single-agent XL092, XL092 in combination with atezolizumab and XL092 in combination with avelumab, the trial will begin to enroll expansion cohorts for patients with clear cell and non-clear cell RCC, CRC, hormone-receptor positive breast cancer, mCRPC and UC. STELLAR-002 is a phase 1b clinical trial evaluating XL092 in combination with either nivolumab, nivolumab and ipilimumab, or nivolumab and Nektar&#8217;s bempegaldesleukin. We are enrolling patients with advanced solid tumors in dose-escalation cohorts, and depending on the dose-escalation results, STELLAR-002 may enroll expansion cohorts for patients with clear cell and non-clear cell RCC, mCRPC and UC. To better understand the individual contribution of the therapies, treatment arms in the expansion cohorts may include XL092 as a single-agent in addition to the ICI combination regimens. In addition to clinical updates for XL092 expected in 2022, we plan to initiate the first global phase 3 pivotal trial for the compound in the first half of the year, and other pivotal trials may follow throughout the year. This first planned trial, STELLAR-303, will evaluate XL092 in combination with atezolizumab versus regorafenib in patients with metastatic microsatellite stable CRC who have progressed after or are intolerant to the current standard of care. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also augment our small molecule discovery activities through research collaborations and in-licensing arrangements with other companies. The most advanced compounds to emerge from these arrangements are XL102 , the lead program targeting CDK7 under our collaboration with Aurigene, and XL114, Aurigene&#8217;s novel anti-cancer compound that inhibits the CBM complex. Based on encouraging preclinical data, we have exercised our exclusive options to license each of XL102 and XL114 from Aurigene and initiated a phase 1 clinical trial evaluating XL102 in January 2021; we plan to initiate a phase 1 clinical trial for XL114 in the first half of 2022. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond small molecules, we have also launched rigorous efforts to discover and advance various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, ADCs and other innovative treatments. ADCs in particular present a unique opportunity for new cancer treatments, given their capabilities to deliver anti-cancer payload drugs to targets with increased precision while minimizing impact on healthy tissues, and have been validated by the multiple regulatory approvals for the commercial sale of ADCs in the past several years. To facilitate the growth of these programs, we have established multiple research collaborations and in-licensing arrangements and entered into other strategic transactions that provide us with access to antibodies or other binders, which are the starting point for use with additional technology platforms that we employ to generate next-generation ADCs or multispecific antibodies. We have already made significant progress under these arrangements and believe we will continue to do so in 2022 and future years. For example, based on promising preclinical data for XB002, Iconic&#8217;s lead TF-targeting ADC program, we exercised our exclusive option to license XB002 in December 2020 and initiated a phase 1 clinical trial in June 2021. We have expanded our access to antibodies through arrangements with WuXi Bio, focused on leveraging WuXi Bio&#8217;s panel of mAbs against an undisclosed target for the development of ADC, bispecific and certain other novel tumor-targeting biotherapeutics, and through the execution of an asset purchase agreement with GamaMabs, under which we will, upon the closing of the asset purchase and subject to certain conditions, acquire all rights, title and interest in GamaMabs&#8217; antibody program directed at AMHR2. These antibodies, as well as those originating from our collaboration with Invenra, which was expanded in August 2021 to include an additional 20 oncology targets, provide starting points for the construction of ADCs through our collaborations with NBE and Catalent, utilizing their site-specific conjugation technologies and payloads. In addition, our collaboration with Adagene, focused on using Adagene&#8217;s SAFEbody technology to develop novel masked ADCs or other innovative biotherapeutics, provides potential for developing ADCs or other biotherapeutics with improved therapeutic index. As a direct result of these arrangements, we designated XB010, our first ADC advanced internally, as a development candidate in late 2021. XB010, which targets the tumor antigen 5T4, incorporates antibodies sourced from Invenra and was constructed using and Catalent&#8217;s SMARTag site-specific bioconjugation platform.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on these early-stage trials of our small molecule and biotherapeutic product candidates, see &#8220;Business&#8212;Exelixis Development Programs&#8212;Other Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8221; in Part I, Item 1 of this Annual Report on Form 10-K. For additional information on our specific research collaborations, in-licensing arrangements and other strategic transactions related to our small molecule and biotherapeutics programs, see &#8220;Business&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations, In-licensing Arrangements and Other Business Development Activities&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, we are currently advancing more than 10 discovery programs and expect to progress up to five new development candidates into preclinical development during 2022. In addition, we will continue to engage in business development initiatives with the goal of acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report on Form 10-K, the COVID-19 pandemic continues to have a modest impact on our business operations, in particular with respect to our clinical trial and commercial activities. We have and continue to undertake considerable efforts to mitigate the various problems presented by this crisis, including as described below:</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Clinical Trials.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> To varying degrees and at different rates across our global clinical trials, we experienced declines in screening and enrollment activity during the early days of the COVID-19 pandemic, as well as delays in new site activations and restrictions on the access to treatment sites that is necessary to monitor clinical study progress and administration. However, we and our collaboration partners, including principal investigators and personnel at clinical trial sites, have been successful overall in preventing material delays to our ongoing and planned clinical trials due to the COVID-19 pandemic. We have done this through ongoing assessment of the COVID-19 pandemic&#8217;s impact, which has included staffing and materials shortages and other operational disruptions at clinical trial sites, and wherever possible, we take proactive steps in compliance with guidance issued by the FDA, EMA and other regulatory agencies to support the safety of our patients and their access to treatment, as well as to maintain the high quality of our clinical trials. We recognize, however, that we may have to make further operational adjustments to our ongoing and planned clinical trials and that patient enrollment, and new clinical trial site initiations may again be slowed due to recurring COVID-19 outbreaks and potential reintroduction of certain restrictions intended to mitigate the spread of COVID-19.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Discovery and Preclinical Development</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have fully resumed drug discovery in our laboratories following a temporary suspension of these activities while we observed the shelter in place orders issued by the State of California and Alameda County. While this temporary suspension combined with interruptions in the portion of drug discovery work outsourced to third-party contractors in regions first impacted by COVID-19 caused us to experience modest delays in the advancement of certain of our early-stage programs, we continued to substantially progress our product pipeline despite the COVID-19 pandemic, including the submission of INDs for XB002, XL102 and XL114.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Despite the challenges posed by the COVID-19 pandemic, including requiring us to temporarily shift to telephonic and virtual interactions with healthcare professionals, we believe our commercial business was only modestly impacted. Our field employees have now partially resumed their in-person promotional activities while supplementing these activities with telephonic and virtual interactions and we believe they are well-positioned to execute on our commercial objectives.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply Chain.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have not experienced significant production delays or seen any significant impairment to our supply chain as a result of the COVID-19 pandemic. In addition, we continue to maintain sufficient safety stock inventories for our commercial drug substance and drug products. We continue to work closely with our third-party contract manufacturers, distributors, suppliers, comparator drug sourcing vendors and collaboration partners to safeguard both the timely production and delivery of our products.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Business Operations. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken numerous precautions, some temporary and others still in place, to help mitigate the risk of transmission of the virus in the workplace, including: initially reducing the number of our employees working on-site at our Alameda headquarters; implementing a vaccination mandate and maintaining enhanced safety and social distancing protocols for those employees who have returned to working on-site, as well as initiating an on-site COVID-19 testing program and limiting certain non-essential business travel for our employees. While most of our employees worked remotely during much of 2020 and early 2021, our Alameda-based workforce has largely returned to working on-site at our headquarters consistent with the policies in place </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior to the COVID-19 pandemic. As of the date of this Annual Report on Form 10-K, the COVID-19 pandemic has only had a modest impact on our productivity and has not caused significant interruptions in our general business operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of workplace safety measures we have taken as a result of the COVID-19 pandemic, see &#8220;Business&#8212;Environmental, Health and Safety&#8212;Workplace Safety Measures in Response to COVID-19&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The circumstances and public health requirements surrounding the COVID-19 pandemic continue to be subject to rapid change, and we will continue to monitor new developments that could pose additional risks for us, including the spread of the Delta and Omicron variants in the U.S. and other countries and the potential emergence of other SARS-CoV-2 variants that may prove especially contagious or virulent. Despite our mitigation efforts, we may experience delays or an inability to execute on our clinical and preclinical development plans, reduced revenues or other adverse impacts to our business, which are described in more detail in &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K. We recognize that this pandemic will continue to present unique challenges for us throughout 2022, and potentially into 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our business, see &#8220;Business&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Business Updates and Financial Highlights</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we continued to execute on our business objectives, generating significant revenues from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for 2021 and subsequent to year-end include:</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Updates </span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2021, the FDA approved the combination of CABOMETYX and OPDIVO as a first-line treatment of patients with advanced RCC, and we commenced the commercial launch of the combination upon such approval. </span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2021, we announced the initiation of a phase 1 clinical trial evaluating XL102, both as a single agent and in combination with other anti-cancer therapies in patients with inoperable, locally advanced or metastatic solid tumors.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2021, we announced a collaboration and license agreement with Adagene to utilize Adagene&#8217;s SAFEbody technology platform to generate masked versions of mAbs from our growing preclinical pipeline for the development of ADCs or other innovative biotherapeutics.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2021, cabozantinib was the subject of multiple data presentations in forms of RCC and other genitourinary cancers at the virtual 2021 ASCO Genitourinary Cancers Symposium.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2021, we announced an exclusive license agreement with WuXi Bio for a panel of mAbs, which were discovered based on WuXi Bio&#8217;s integrated technology platforms for the development of ADC, bispecific and certain other novel tumor-targeting biotherapeutic applications.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2021, we announced a clinical trial collaboration and supply agreement with Merck KGaA and Pfizer to evaluate XL092 in combination with avelumab in patients with locally advanced or metastatic UC as part of the ongoing STELLAR-001 phase 1b dose escalation study.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2021, we announced the completion of enrollment for COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. We expect to report top-line results of the event-driven analyses from the trial in the first half of 2022.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2021 and April 2021, Ipsen and BMS, respectively, received regulatory approval from the EC for CABOMETYX in combination with OPDIVO as a first-line treatment for patients with advanced RCC.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In April 2021, we announced the FDA&#8217;s acceptance of the IND for XB002 and initiated a phase 1 trial evaluating the ADC in patients with advanced solid tumors in June 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In May 2021, we announced an asset purchase agreement with GamaMabs to acquire GamaMabs&#8217; antibody program directed at AMHR2.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2021, cabozantinib was the subject of multiple data presentations in forms of RCC and DTC at the  2021 ASCO Annual Meeting.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2021, we filed a patent lawsuit against Teva, following receipt of two Paragraph IV certification notice letters from Teva informing us that it had filed an ANDA with the FDA requesting approval to market a generic version of CABOMETYX tablets. For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2021, we announced results from the phase 3 COSMIC-312 trial, in which the combination of cabozantinib and atezolizumab met one of the primary endpoints, demonstrating significant improvement in PFS versus sorafenib in patients with previously untreated advanced HCC at the planned primary analysis. The interim OS analysis performed at the same time as the primary analysis for PFS did not demonstrate a statistically significant benefit for the combination. Detailed results from COSMIC-312 were later presented at the ESMO Asia Virtual Oncology Week in November 2021. The trial is continuing as planned to the final analysis of OS, anticipated during the first quarter of 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we intend to submit an sNDA to the FDA for the combination regimen if supported by the final OS analysis</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In August 2021, we announced the expansion of our discovery and licensing collaboration with Invenra to include an additional 20 oncology targets for multispecific antibody, ADC and other biotherapeutics candidate discovery and development.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In August 2021, Takeda and Ono received regulatory approval from the Japanese MHLW to manufacture and market CABOMETYX in combination with OPDIVO as a treatment for unresectable or metastatic RCC. </span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In September 2021, the FDA approved CABOMETYX for the treatment of adult and pediatric patients 12 and older with locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy and who are RAI-refractory or ineligible, and we commenced the commercial launch of CABOMETYX in this indication upon such approval. </span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In September 2021, cabozantinib was the subject of multiple data presentations in previously untreated advanced RCC, previously treated RAI-refractory DTC and mCRPC at the ESMO 2021 Congress. </span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In October 2021, we announced an exclusive collaboration and license agreement with STORM to discover and develop inhibitors of novel RNA modifying enzymes, including ADAR1. </span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In October 2021, we and Aurigene announced that we exercised our exclusive option for XL114, Aurigene&#8217;s novel anti-cancer compound that inhibits the CBM complex, resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization of XL114. Following the FDA&#8217;s acceptance of the IND for XL114 in October 2021, we plan to initiate a phase 1 clinical trial evaluating XL114 as a monotherapy in patients with NHL in the first half of 2022</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In November 2021, we announced the completion of enrollment for CONTACT-01, a phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus docetaxel in patients with metastatic NSCLC who have been previously treated with an ICI and platinum-containing chemotherapy. Based on current event rates, we anticipate announcing results of the interim OS analysis in the second half of 2022.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In December 2021, we announced the initiation of STELLAR-002, a phase 1b clinical trial evaluating XL092 in combination with either nivolumab, nivolumab and ipilimumab, or </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nivolumab and bempegaldesleukin</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with advanced solid tumors. Previously in June 2021, we announced a clinical trial collaboration and supply agreement with BMS pursuant to which BMS is providing nivolumab, ipilimumab and bempegaldesleukin for use in the trial. </span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In December 2021, we appointed Jacqueline Wright to our Board of Directors. Ms. Wright currently serves as Corporate Vice President &amp; Chief Digital Officer, U.S. Business at Microsoft Corporation.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, we appointed Vicki L. Goodman, M.D., as Executive Vice President, Product Development &amp; Medical Affairs, and Chief Medical Officer. Dr. Goodman had previously served as Vice President, Clinical Research and Therapeutic Area Head, Late Stage Oncology at Merck &amp; Co.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, we announced the completion of enrollment for CONTACT-03, a phase 3 pivotal trial evaluating the efficacy and safety of cabozantinib in combination with atezolizumab versus cabozantinib alone in patients with locally advanced or metastatic RCC who progressed during or following treatment with an ICI as the immediate preceding therapy. Based on current event rates, we anticipate announcing results of PFS and the first interim OS analysis in the second half of 2022.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, we announced an amendment to our exclusive option and license agreement with Iconic to acquire broad rights to use the anti-TF antibody incorporated into XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2022, we presented encouraging data from two early-stage studies evaluating cabozantinib in combination with ICIs in patients with previously treated CRC at the 2022 ASCO Gastrointestinal Cancers Symposium: cohort 16 from COSMIC-021, evaluating cabozantinib in combination with atezolizumab in patients with metastatic CRC who were previously treated with fluoropyrimidine-containing chemotherapy; and cohort 2 from CAMILLA, the phase 2 IST evaluating cabozantinib in combination with durvalumab in patients with advanced mismatch repair proficient/micro satellite stable CRC patients who were chemotherapy-refractory.</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2022, cabozantinib will be the subject of multiple data presentations in forms of RCC and other genitourinary cancers at the 2022 ASCO Genitourinary Cancers Symposium.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Financial Highlights</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Net product revenues for 2021 were $1,077.3 million, compared to $741.6 million for 2020.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Total revenues for 2021 were $1,435.0 million, compared to $987.5 million for 2020.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Research and development expenses for 2021 were $693.7 million, compared to $547.9 million for 2020.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Selling, general and administrative expenses for 2021 were $401.7 million, compared to $293.4 million for 2020.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Provision for income taxes for 2021 was $63.1 million, compared to $19.1 million for 2020.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Net income for 2021 was $231.1 million, or $0.73 per share, basic and $0.72 per share, diluted, compared to $111.8 million, or $0.36 per share, basic and $0.35 per share diluted, for 2020.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Cash and investments increased to $1.9 billion at December&#160;31, 2021, compared to $1.5&#160;billion at December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Results of Operations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outlook, Challenges and Risks</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to face a number of challenges and risks that may impact our ability to execute on our 2022 business objectives, and some of these risks to our business have been or may be exacerbated by the COVID-19 pandemic. In particular, for the foreseeable future, we expect our ability to generate sufficient cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib has been or is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. However, we cannot be certain that the clinical trials we and our collaboration partners are conducting will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. In addition, CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. However, as is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets, because of growing concerns over healthcare cost containment and corresponding policy initiatives and activities aimed at expanding access to, and restricting the prices of, pharmaceuticals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achievement of our 2022 business objectives will also depend on our ability to maintain a competitive position with respect to the shifting landscape of therapeutic strategy for the treatment of cancer, which we may not be able to do. While we have had success in adapting our development strategy for the cabozantinib franchise and other product candidates to address the competitive landscape, including through evaluation of therapies that combine ICIs with other targeted agents, it is uncertain whether current and future clinical trials will lead to regulatory approvals, or whether physicians will prescribe regimens containing our products instead of competing product combinations in approved indications. Moreover, the complexities of this development strategy have required and are likely to continue to require collaboration with some of our competitors. In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic versions of CABOMETYX tablets that are the subject of ANDAs submitted to the FDA by MSN and Teva, and the approval of either MSN&#8217;s or Teva&#8217;s ANDA could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with drug discovery operations, all of which may be increased as a result of the COVID-19 pandemic. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these challenges and risks are specific to our business, and others are common to companies in the biopharmaceutical industry with development and commercial operations. As described under &#8220;&#8212;COVID-19 Update&#8221; above, these risks have been or may be exacerbated by the COVID-19 pandemic. For a more detailed discussion of challenges and risks we face, including those relating to the COVID-19 pandemic, see &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_43"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31st. Fiscal 2021, which was a</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">52-week fiscal year, ended December 31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended January&#160;1, 2021. For convenience, references in this report as of and for the fiscal year ended January&#160;1, 2021 are indicated as being as of and for the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This discussion and analysis generally addresses 2021 and 2020 items and year-over-year comparisons between 2021 and 2020. Discussions of 2019 items and year-over-year comparisons between 2020 and 2019 that are not included in this Annual Report on Form 10-K can be found in &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, submitted to the U.S. Securities and Exchange Commission (SEC) on February&#160;10, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.292%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.046%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenues, discounts and allowances, and net product revenues were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962,591&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net product revenues for the year ended December&#160;31, 2021, as compared to 2020, was related to a 42% increase in the number of CABOMETYX units sold that was primarily driven by the strong uptake for the combination therapy of CABOMETYX and OPDIVO following approval by the FDA in January 2021, and to a lesser extent a 3% increase in the average net selling price of CABOMETYX.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our fiscal 2022 net product revenues will increase over fiscal 2021, primarily as a result of the growth in the number of units sold following the FDA&#8217;s approval of CABOMETYX in combination with OPDIVO as a first line treatment of patients with advanced RCC, in part due to the longer duration of therapy for this combination, as well as an increase in selling price reflecting the continued evolution of the metastatic RCC, HCC and DTC treatment landscapes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize product revenues net of discounts and allowances that are described in &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; to our &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this Annual Report on Form 10-K. Discounts and allowances as a percentage of gross revenue have increased over time as the number of patients participating in government programs has increased and as the discounts given and rebates paid to government payers have also increased. The increase in discounts and allowances for the year ended December&#160;31, 2021, as compared to 2020, was primarily the result of an increase in Public Health Service hospital utilization and the dollar amount of the related chargebacks, and to a lesser extent, an increase in Medicaid utilization and the dollar amount of the related Medicaid rebates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our discounts and allowances as a percentage of gross revenues may increase during fiscal 2022, for similar reasons noted above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues include: (a) the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the related period that the milestone would be achieved and a significant reversal of revenues would not occur in future periods; (b) royalty revenues and (c) the profit on the U.S. commercialization of COTELLIC from Genentech.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaborations and Business Development Activities&#8212;Cabozantinib Commercial Collaborations&#8212;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K for a discussion on the allocation of transaction price which impacts the proportion of milestone revenues allocated to license revenues and collaboration services revenues.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues, which are allocated between license revenues and collaboration services revenues, were $133.8 million for the year ended December&#160;31, 2021, as compared to $86.5 million for 2020.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt"> Milestone revenues for the year ended December&#160;31, 2021 included: (1) $100.0 million related to a commercial sales milestone from Ipsen upon their achievement of $400.0 million of net sales of cabozantinib in the related Ipsen license territory over four consecutive quarters, (2) $11.9 million related to a $12.5 million regulatory milestone Ipsen achieved upon submission of a variation application to the EMA for CABOMETYX as a treatment for patients with previously treated, RAI-refractory DTC and (3) $18.9 million in connection with a $20.0 million milestone achieved following Takeda&#8217;s first commercial sale in Japan of CABOMETYX in combination with OPDIVO for the treatment of patients with curatively unresectable or metastatic RCC; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Milestone revenues for the year ended December&#160;31, 2020 included: (1) $25.7 million in connection with a $31.0 million milestone achieved upon Takeda&#8217;s first commercial sale of CABOMETYX for the treatment of patients with curatively unresectable or metastatic RCC in Japan; (2) $19.0 million in connection with a $20.0 million development milestone from Ipsen for the initiation of a phase 3 pivotal trial; (3) $9.3 million in connection with a $10.0 million milestone for Takeda&#8217;s and Ono&#8217;s submission of a supplemental application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable, advanced or metastatic RCC; (4) $14.0 million in connection with a $15.0 million milestone achieved upon Takeda&#8217;s first commercial sale of CABOMETYX for the treatment of patients with advanced HCC; and (5) $14.0 million in connection with $15.0 million in milestones from Takeda for the initiation of two phase 3 pivotal clinical trials that were deemed probable of being achieved in 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainties surrounding the timing and achievement of development, regulatory and commercial milestones, it is difficult to predict the timing of future milestones revenues; consequently, milestones may vary significantly from period to period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenues increased primarily as a result of an increase in Ipsen&#8217;s net sales of cabozantinib outside of the U.S. and Japan. Ipsen royalty revenues were $97.2 million for the year ended December&#160;31, 2021, as compared to $76.2 million for 2020. Ipsen&#8217;s net sales of cabozantinib have continued to grow since their first commercial sale of the product in the fourth quarter of 2016, as a result of increased demand of CABOMETYX, due to regulatory approval in new territories, including the more recent regulatory approval in the EU for the combination therapy of CABOMETYX and OPDIVO received in March 2021. Royalty revenues for the year ended December&#160;31, 2021 also included $7.9 million, as compared to $2.3 million for 2020, related to Takeda&#8217;s net sales of CABOMETYX, which have continued to grow since their first commercial sale of product in Japan in 2020. Additionally, Takeda royalty revenues have increased due to the August 2021 regulatory approval in Japan for the combination therapy of CABOMETYX and OPDIVO. As of December&#160;31, 2021, CABOMETYX is approved and commercially available in 61 countries outside of the U.S.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of profits on the U.S. commercialization of COTELLIC under our collaboration agreement with Genentech was $8.1 million for the year ended December&#160;31, 2021, as compared to $6.3 million for 2020. We also earned royalty revenues on ex-U.S. net sales of COTELLIC by Genentech of $4.1 million for the year ended December&#160;31, 2021, as compared to $5.1 million for 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our license revenues may decrease in fiscal 2022, as compared to fiscal 2021, as a result of the anticipated achievement of fewer milestones in 2022, partially offset by an increase in royalty revenues related to an increase in product sales by Ipsen and Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Services Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, and product supply revenues, which are net of product supply costs and the royalties we pay to Royalty Pharma on sales by Ipsen and Takeda of products containing cabozantinib. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development cost reimbursements were $116.8 million for the year ended December&#160;31, 2021, as compared to $76.3 million for 2020. The increase in development cost reimbursement was primarily attributable to Ipsen&#8217;s decision to opt in and co-fund COSMIC-311 development costs in the second quarter of 2021. Ipsen is now responsible for 35% of the global development costs of COSMIC-311 and is obligated to reimburse us for these costs, as well as an additional payment calculated as a percentage of COSMIC-311 development costs, triggered by the timing of the exercise of its option. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, collaboration services revenues for the year ended December&#160;31, 2021, includes a cumulative catch-up of $43.2 million recognized in the second quarter of 2021 for Ipsen&#8217;s share of global development costs incurred since the beginning of the study. The increase in development cost reimbursements for the year ended December&#160;31, 2021 was partially offset by a decrease in total spending for the COSMIC-312 and COSMIC-021 studies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues were reduced by $14.3 million with respect to the 3% royalty we are required to pay on the net sales by Ipsen and Takeda of any product incorporating cabozantinib for the year ended December&#160;31, 2021, as compared to $10.6 million for 2020. As royalty generating sales of cabozantinib by Ipsen and Takeda have increased as described above, our royalty payments have also increased.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our collaboration services revenues may decrease in fiscal 2022, as compared to fiscal 2021, primarily as a result of decreased development cost reimbursements related to Ipsen&#8217;s opt in and co-funding of COSMIC-311 and the related cumulative catch-up in development cost reimbursements recognized in fiscal 2021 for which no similar event is projected to occur in 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of goods sold and our gross margins were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists of a 3% royalty payable on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring, excess and obsolete inventory, and other third-party logistics costs. The increase in cost of goods sold for the year ended December&#160;31, 2021, as compared to 2020, was the result of increases in royalty payments as a result of increased U.S. CABOMETYX sales and certain other period costs. We project our fiscal 2022 gross margin to remain consistent with fiscal 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track fully burdened research and development expenses on a project-by-project basis. We group our research and development expenses into three categories: (1) development; (2) drug discovery; and (3) other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies, including in-licensed technologies, to enable the rapid discovery, optimization and extensive characterization of lead compounds and biotherapeutics such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses and other collaboration costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and outside services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other development costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,493&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other drug discovery</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total drug discovery</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,690&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,716&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License and other collaboration costs presented in total development includes upfront license fees and development milestone payments associated with programs currently in clinical development stage while license and other collaboration costs presented in total drug discovery includes upfront license fees, development milestone payments, program initiation fees, and research funding commitments associated with programs in preclinical development stage.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Primarily includes personnel expenses, consulting and outside services and laboratory supplies, if not separately presented.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the allocation of general corporate costs to research and development services, and development cost reimbursements in connection with our collaboration arrangement with Roche executed in December 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expenses for the year ended December 31, 2021, as compared to 2020, was primarily related to increases in license and other collaboration costs, personnel expenses, stock-based compensation and other research and development costs, partially offset by a decrease in clinical trial costs. Drug discovery related license and other collaboration costs increased primarily due to increases in upfront license fees, including, in connection with our recent amended agreement with Iconic in the fourth quarter of 2021 for rights to additional compounds, and other increases in program initiation fees, development milestones, and research funding commitments related to business development activities. Development related license and other collaboration costs increased primarily due to our recent amended agreement with Iconic to buyout future contingent milestone payments and a development milestone we deemed probable of achievement under certain of our in-licensing collaboration arrangements. Personnel expenses increased primarily due to an increase in headcount to support our expanding discovery and development organization. Stock-based compensation expense increased primarily due to an increase related to service-based RSUs associated with higher headcount. Other research and development costs increased primarily related to technology services and related investments in support of digital transformation initiatives and an increase in allocated corporate costs, which were </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by development cost reimbursements in connection with our collaboration arrangement with Roche. Clinical trial costs decreased primarily due to lower costs associated with the COSMIC-312 and COSMIC-021 studies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. These factors include enrollment in clinical trials for our drug candidates, preliminary data and final results from clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:103%">We are focusing a significant amount of our development efforts on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we project that a substantial portion of our research and development expenses will relate to the continuing clinical development program of cabozantinib, which includes over 100 ongoing or planned clinical trials across multiple indications. Notable ongoing company-sponsored studies resulting from this program include: COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge and CONTACT-02 for which Roche is sharing the development costs and providing atezolizumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working to expand our oncology product pipeline through drug discovery efforts, which encompass our diverse small molecule and biotherapeutics programs exploring multiple modalities and mechanisms of action. In this regard, we conduct drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. In addition, we will continue to engage in business development initiatives with the goal of acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our research and development expenses may increase in fiscal 2022 as compared to fiscal 2021, driven by our ongoing clinical evaluation of cabozantinib, the initiation of new clinical trials and expansion of ongoing clinical trials evaluating other product candidates in our pipeline, including ongoing and planned early-stage trials evaluating XL092, XB002, XL102 and XL114, and anticipated business development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time required for clinical development of a particular product candidate and our&#160;development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product candidate, our decisions to develop a product candidate&#160;for additional indications and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet&#160;know for how many of those indications we will ultimately pursue regulatory approval. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue. Even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of, or total costs associated with the development of cabozantinib or any of our other research and development projects. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of this Annual Report on Form&#160;10-K.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Excludes stock-based compensation allocated to selling, general and administrative expenses. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel expenses, stock-based compensation, marketing costs and certain other administrative costs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in selling, general and administrative expenses for the year ended December&#160;31, 2021, as compared to 2020, was primarily related to increases in personnel expenses, marketing costs, legal costs, corporate giving and technology services. Personnel expenses increased primarily due to an increase in administrative headcount to support our commercial and research and development organizations. Marketing costs increased primarily to support the launch of the combination therapy of CABOMETYX and OPDIVO for the treatment of advanced RCC following approval by the FDA in January 2021. The increase in technology services relates to our digital transformation initiatives.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our selling, general and administrative expenses may increase in fiscal 2022, as compared to fiscal 2021 in support of our continued commercial investment in CABOMETYX and the growth in the broader organization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating Income</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income was as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in non-operating income for the year ended December&#160;31, 2021, as compared to 2020, was primarily the result of lower interest income due to lower interest rates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes and the effective tax rates were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in provision for income taxes for the year ended December&#160;31, 2021, as compared to 2020, was primarily due to the increase in pre-tax income. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Th</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e effective tax rate for the year ended December&#160;31, 2021 differed from the U.S. federal statutory rate of 21% primarily due to non-deductible executive compensation, partially offset by excess tax benefits related to the exercise of certain stock options during the period and the generation of federal tax credits. The effective tax rate for the year ended December&#160;31, 2020 differed from the U.S. federal statutory ra</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">te of 21% primarily due to </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">excess tax benefits related to the exercise of certain stock options and federal tax credits, offset by non-deductible executive compensation during the period. We project that our effective tax rate will be between 20% and 22% in 2022.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_46"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had $1.9 billion in cash and investments, compared to $1.5 billion as of December&#160;31, 2020. We anticipate that the aggregate of our current cash and cash equivalents, short-term and long-term investments available for operations, net product revenues and collaboration revenues will enable us to maintain our short-term operations and execute our long-term plans.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary cash requirements for operating activities, which we project will increase in 2022 as compared to 2021, are for employee related expenditures; costs related to our development programs including payments to third party contract research organizations that conduct and manage global clinical trials; drug discovery programs, including payments made to collaboration partners for in-licensing arrangements for upfront and option exercise fees, research and development funding, and development, regulatory and commercial milestones; royalties paid on our net product sales; and cost of inventory and our leased facilities. Our primary source of operating cash is cash collections from customers related to net product sales which we project will increase in 2022 compared to 2021 and cash collections from our commercial collaboration arrangements with Ipsen, Takeda and others related to royalties earned, the achievement of certain development, regulatory and commercial milestones as well as cash payments to us for cost reimbursements under certain of our development programs. The timing of cash generated from commercial collaborations and required for in-licensing collaborations related to upfront payments, initiation fees, milestone payments and cost reimbursements may vary from period to period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have cash requirements related to capital expenditures to support the planned growth of our business including investments in laboratory facilities and equipment. We project that we may continue to spend significant amounts of cash to fund the continued development and commercialization of cabozantinib. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including additional research collaborations, in-licensing arrangements and other strategic transactions that align with our oncology drug development, and regulatory and commercial expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity. Furthermore, even though we believe we have sufficient funds for our current and future operating plans, we may choose to incur debt or raise additional funds through the issuance of equity based on market conditions or strategic considerations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of $16.7 million and $1.6 million as of December&#160;31, 2021 and 2020, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a standby letter of credit as guarantee of our obligation to fund our portion of the tenant improvements related to our build-to-suit lease at our corporate campus. The letter of credit is secured by our short-term investments, which are recorded as restricted cash equivalents and presented in other long-term assets in our Consolidated Balance Sheets and will be reduced as we fund our portion of the tenant improvements. As of December&#160;31, 2021, restricted cash equivalents included $15.2 million of short-term investments as collateral under our standby letter of credit for our portion of the tenant improvements.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash equivalents and investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working capital</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase in working capital as of December&#160;31, 2021, as compared to December&#160;31, 2020, was primarily due to an increase in net product revenues and collaboration revenues, including a $100.0 million milestone from Ipsen, and proceeds received from issuing common stock under our employee equity incentive plans. These increases were partially offset by the reclassification of certain investments from short-term to other long-term assets related to the standby letter of credit noted above, cash used for capital expenditures incurred in connection with expanding our laboratory facilities and acquiring related equipment, cash paid for tax withholding on equity awards, and a net increase in </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating liabilities, including a $55.0 million collaboration liability related to the Iconic amended agreement. In the future, our working capital may be impacted by some or all of these factors, the amounts and timing of which are variable.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, cash equivalents, restricted cash equivalent and investments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents primarily consist of cash deposits held at major banks, commercial paper and other securities with original maturities 90 days or less. Restricted cash equivalents and investments relate to our letter of credit agreements and are invested in short-term marketable securities. For additional information regarding our cash, cash equivalents, restricted cash equivalents and investments, see &#8220;Note 4. Cash and Investments,&#8221; in our &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K. The increase in cash, cash equivalents, restricted cash equivalent and investments at December&#160;31, 2021, as compared to December&#160;31, 2020, was primarily due to cash inflows generated by our operations, including collections of amounts due from customers, partially offset by operating cash payments for employee related expenditures, our development and discovery programs, and capital expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow activities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary source of operating cash flows is cash collections from customers related to our net product sales and cash collections from our commercial collaboration arrangements. Our primary uses of cash from operating activities are for employee related costs, costs related to our development and discovery programs, cash payments for inventory, royalties paid on our net product sales, and our leased facilities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities is derived by adjusting our net income for non-cash operating items such as deferred taxes, stock-based compensation, depreciation, non-cash lease expense, and changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities increased for the year ended December&#160;31, 2021, as compared to 2020, primarily due to an increase in cash received on sales of our products, an increase in cash received from our commercial collaboration arrangements and net favorable changes in operating assets and liabilities, partially offset by an increase in cash paid for operating expenses.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in cash flows from investing activities primarily relates to the timing of marketable securities investment activity and capital expenditures. Our capital expenditures primarily consist of investments to expand our operations and acquire assets that further our research and development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities decreased for the year ended December 31, 2021 as compared to 2020 primarily due to a net increase in cash proceeds from maturities and sales of investments, net of investment purchases partially offset by an increase in capital expenditures. In 2021, capital expenditures primarily consisted of investments in leasehold improvements and equipment related to an expansion of laboratory facilities at our corporate campus and technology infrastructure investments to support our digital transformation initiatives.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in cash flows from financing activities primarily relate to proceeds from employee stock programs and taxes paid related to net share settlement of equity awards.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities decreased for the year ended December&#160;31, 2021, as compared to 2020 primarily as a result of lower withholding taxes remitted to the government related to net share settlements of equity awards and to a lesser extent a decrease in proceeds received from the issuance of common stock under our equity incentive and stock purchase plans.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_49"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we anticipate the aggregate of our cash, cash equivalents and short-term investments and cash generated from operations to be sufficient to fund our contractual obligations, as well as cash requirements to support our ongoing operations and capital expenditures. Our contractual obligations as of December 31, 2021 primarily consist of:</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating leases:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have certain lease agreements related to our corporate campus facilities, under which we are obligated to make minimum lease payments. As of December 31, 2021, we had $11.4 million of minimum lease payments due in one year and $289.1 million due over the remaining lease term. We entered into the build-to-suit lease agreement in October 2019, the term of the lease is for a period of 242 months, which is expected to begin in the first quarter of 2022. The amounts presented herein include the estimated lease commitment payments at the estimated commencement of the lease, subject to adjustment dependent upon the actual total development costs of the premises.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase obligations:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Purchase obligations include firm purchase commitments related to manufacturing of inventory, software services and other facilities and equipment. As of December 31, 2021, we had $40.0 million total purchase obligations due within one year and $10.6 million due after one year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have committed to make certain contingent payments for potential future milestones, research funding commitments and royalties to certain collaboration partners as part of our agreements with those parties. We do not expect these contingent payments to have a significant impact on our liquidity in the near term. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes 3 and 11 of &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K include additional information regarding our contractual obligations and contingencies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we did not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions; and the amounts of deferred tax assets and liabilities including the related valuation allowance. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock-based compensation and income taxes reflect the more significant estimates and assumptions used in the preparation of our Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete description of our significant accounting policies, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Revenues and Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues when our customers obtain control of promised goods or services, in an amount that reflects the consideration to which we are entitled to in exchange for those goods or services. We calculate gross product revenues based on the price that we charge to the specialty pharmacies and distributors in the U.S. We estimate our domestic net product revenues by deducting from our gross product revenues: (a)&#160;trade allowances, such as discounts for prompt payment; (b)&#160;estimated government rebates and chargebacks; (c) certain other fees paid to specialty pharmacies, distributors and commercial payors; and (d) returns.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initially record estimates for these deductions at the time we recognize the related gross product revenue. We base our estimates for the expected utilization on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates as well as third-party market research data. We update our estimates every quarter to reflect actual claims and other current information. Actual rebates and chargebacks claimed for prior periods have varied from our estimates by less than 1% of the amount deducted from gross product revenues for the years ended December 31, 2021 and 2020. Our current estimates may differ significantly from actual results.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements with third parties, under which we license certain rights to our intellectual property, and account for the arrangements as either license revenue or collaboration services revenue when the counterparty is a customer. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. We use key assumptions to determine the standalone selling price, which may include forecast revenues and costs, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. At the end of each subsequent reporting period, we re-evaluate the probability of earning of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. For arrangements that may include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sale occurs or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Development milestone adjustments are recorded on a cumulative catch-up basis, which would affect collaboration services revenues in the period of adjustment. In addition, in recording revenues for our research and development services performance obligations, we use projected development cost estimates to determine the amount of revenue to record as we satisfy this performance obligation. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial and Collaboration Accruals</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We execute all of our clinical trials with support from contract research organizations and other vendors and we accrue costs for clinical trial activities performed by these third parties based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the activities to be performed for each patient, the number of active clinical sites and the duration for which the patients will be enrolled in the trial. Certain of our in-licensing collaboration arrangements includes contingent </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considerations in the form of development, regulatory and commercial milestones payments. We recognize the contingent considerations when they are deemed probable of achievement which requires judgment as to the probability and timing of the achievement of the underlying milestones. We monitor patient enrollment levels and assess the related research and development activities progress, including the probability of achieving milestones payments associated to the respective terms and conditions of our in-licensing and collaboration arrangements to the extent possible through internal reviews and estimates of the operational progress of our discovery and early-stage clinical development programs, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us, which may allow us to make a more accurate estimate in future periods. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense requires us to estimate the fair value of stock options, performance-based restricted stock units (PSUs) and PSUs subject to market conditions, and the estimated the number of shares subject to PSUs that will ultimately vest. To determine the fair value, we use models that require a number of complex and subjective assumptions including our stock price volatility, employee exercise patterns and risk-free interest rates. The value of a stock option is derived from its potential for appreciation. The more volatile the stock, the more valuable the option becomes because of the greater possibility of significant changes in stock price. Because there is a market for options on our common stock, we consider implied volatility as well as our historical volatility when developing an estimate of expected volatility. The expected option term also has a significant effect on the value of the option. The longer the term, the more time the option holder has to allow the stock price to increase without a cash investment and thus, the more valuable the option. Further, lengthier option terms provide more opportunity to take advantage of market highs. However, empirical data show that employees typically do not wait until the end of the contractual term of a nontransferable option to exercise. Accordingly, we are required to estimate the expected term of the option for input to an option-pricing model. Monte Carlo simulation models are used to determine grant date fair value of awards with market conditions. The assumptions used in calculating the fair value of stock options and PSUs represent management&#8217;s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize stock-based compensation for PSUs over the requisite service period only for awards which we estimate will ultimately vest, which requires judgment as to the probability and timing of the achievement of the underlying performance goals. Significant factors we consider in making those judgments include forecasts of our product revenues and those of our collaboration partners, estimates regarding the operational progress of late-stage clinical development programs and discovery pipeline expansion performance targets. To the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised and as such, can materially affect our stock-based compensation expense in the current period and in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute our income tax provision or benefit under the asset and liability method. Significant estimates are required in determining our income tax provision or benefit. We base some of these estimates on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that we deem a reversal of any portion of our valuation allowance against our deferred tax assets to be appropriate, we recognize a tax benefit against our income tax provision in the period of such reversal. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this Annual Report on Form 10-K.</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_55"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to cash flow and earnings fluctuations as a result of certain market risks. These market risks primarily relate to credit risk, changes in interest rates and foreign exchange rates. Our investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. None of these market risk-sensitive instruments are held for trading purposes. We do not have derivative financial instruments in our investment portfolio.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our cash in a variety of financial instruments, principally securities issued by the U.S. government and its agencies, investment-grade corporate bonds and commercial paper, and money market funds. These investments are denominated in U.S. Dollars. All of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. Substantially all of our investment portfolio consists of marketable securities with active secondary or resale markets to help ensure portfolio liquidity, and we have implemented guidelines limiting the term-to-maturity of our investment instruments. Due to the conservative and short-term nature of these instruments, we do not believe that we have a material exposure to interest rate risk. If market interest rates were to increase or decrease by one percentage point, the fair value of our investment portfolio would increase or decrease by an immaterial amount.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Exchange Rate Risk </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in the exchange rates of the U.S. dollar and foreign currencies may have the effect of increasing or decreasing our revenues and expenses. Royalty revenues and sales-based milestones we receive from our collaboration agreements with Ipsen, Takeda and Genentech are a percentage of the net sales made by those collaboration partners from sales made in countries outside the U.S. and are denominated in currencies in which the product is sold, which is predominantly the Euro or Japanese Yen. Research and development expenses include clinical trial services performed by third-party contract research organizations and other vendors located outside the U.S. that may bill us in currencies where their services are provided, which is predominantly the Euro. If the U.S. dollar strengthens against a foreign currency, then our royalty revenues will decrease for the same number of units sold in that foreign currency and the date we achieve certain sales-based milestones may also be delayed. Similarly, if the U.S. dollar weakens against a foreign currency, then our research and development expenses would increase. However, we believe that we are not subject to material risks arising from changes in foreign exchange rates and that a hypothetical 10% increase or decrease in foreign exchange rates would not have a material adverse impact on our financial condition, results of operations or cash flows.</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_58"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_61">Report of Independent Registered Public Accounting Firm (PCAOB ID:</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF81OC9mcmFnOmZmMWIyYmFlZWU5ZDRiNjg5NDFmYjI1NzZhZTc3ZmIyL3RhYmxlOjZhOWQyNDdhNWZlMDQ4NmJhYjU3MTAzNmZkODg0N2RmL3RhYmxlcmFuZ2U6NmE5ZDI0N2E1ZmUwNDg2YmFiNTcxMDM2ZmQ4ODQ3ZGZfMS0wLTEtMS00MjcwNy90ZXh0cmVnaW9uOjljZWFhODQ1Yzg0YjRiODY4YzcyNTQwYjMyNmFmOTJmXzYwNDczMTM5NTI5ODM_9e593fa1-5c1a-4d4b-9c71-32a259653196">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_61">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_64">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_67">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_67">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_70">Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_70">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_73">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_73">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_76">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_76">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_79">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_79">90</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_61"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Exelixis, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Exelixis, Inc. (the Company) as of December 31, 2021 and January 1, 2021, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three fiscal years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8220;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and January 1, 2021, and the results of its operations and its cash flows for each of the three fiscal years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 18, 2022 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Critical Audit Matter</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue recognition - product sales and accounts receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company&#8217;s gross product revenues were $1,452.9 million. As discussed in Note 1 of the financial statements, the Company sells its products principally to specialty distributors and specialty pharmacy providers, or collectively, Customers. These Customers subsequently resell the products to health care providers and patients. Revenues from product sales are recognized when control is transferred to the Customer.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s product sales was challenging, specifically related to the effort required to audit Customer sales activity to assess whether incentives resulted in orders in excess of demand and whether any such transactions meet the criteria for revenue recognition. This involved judgmentally assessing factors including market demand, Customer ordering patterns, Customer inventory levels, contractual terms and incentives offered.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#24282d;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls designed to monitor and review inventory levels in the channel and sales under Customer incentive programs. This includes testing relevant controls over the information systems that are important to the initiation, recording and billing of revenue transactions as well as controls over the completeness and accuracy of the data used.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span><br/></span></div><div><span style="color:#212529;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures over the Company&#8217;s product sales included, among others, examination of inventory channel reports for unusual trends or transactions as well as performing analytical procedures to detect and investigate anomalies within the data. Procedures included those to detect sales of short dated product near year end as well as testing the completeness and accuracy of the underlying data. We also examined the terms and conditions of any new or amended contracts with Customers and its impact on the Company&#8217;s returns reserve. We also confirmed the terms and conditions of contracts directly with a selection of Customers, including whether there are side agreements and terms not formally included in the contract that may impact the Company&#8217;s returns reserve. In addition, we obtained written representations from members of the commercial function and the market access group regarding changes to Customer incentives and the completeness of the terms and conditions reported to the legal and accounting departments.</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82MS9mcmFnOjliZmE1YTQwMGFlYzQ1ZTlhOGNkMDI1NzMxYzNjYTQ5L3RleHRyZWdpb246OWJmYTVhNDAwYWVjNDVlOWE4Y2QwMjU3MzFjM2NhNDlfNjA0NzMxMzk3MDUzOA_2aad73da-c51c-4b78-9fa8-ec47121dc3cf">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2002.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82MS9mcmFnOjliZmE1YTQwMGFlYzQ1ZTlhOGNkMDI1NzMxYzNjYTQ5L3RleHRyZWdpb246OWJmYTVhNDAwYWVjNDVlOWE4Y2QwMjU3MzFjM2NhNDlfNjA0NzMxMzk3MDUzOQ_88e64418-1427-4647-b1a8-0480caa75909">Redwood City, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;18, 2022</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_64"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNi0xLTEtMS0yNTczOQ_1dfb53d8-3993-4513-a9e3-4fcf0bd6b409">647,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNi0zLTEtMS0yNTczOQ_56cb6928-3e6f-4dbc-8a16-e74ff4be9f4e">319,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNy0xLTEtMS0yNTczOQ_2cb0a842-e8c1-4249-9422-4a885e546ee3">819,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNy0zLTEtMS0yNTczOQ_b5b9816d-f6ea-4902-a729-3beef9aa1b1b">887,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfOC0xLTEtMS0yNTczOQ_8881ac8d-3f07-46eb-87bb-030c294b6b99">282,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfOC0zLTEtMS0yNTczOQ_6cbd578b-1a00-4e1d-b284-940c5aab3765">160,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfOS0xLTEtMS0yNTczOQ_4ab3dfc0-c71a-47b2-83ed-eb4108f1857b">27,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfOS0zLTEtMS0yNTczOQ_c0ce2a77-4bf6-4658-b06e-d74f595121cf">20,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTEtMS0xLTEtMjU3Mzk_049806b5-bc96-4a1a-8e61-2f829cf7d6ba">57,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTEtMy0xLTEtMjU3Mzk_fe4030af-2a68-44ff-815f-ce1a3f8e0195">57,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTItMS0xLTEtMjU3Mzk_258c906a-7938-46be-b944-bfa2371b8911">1,834,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTItMy0xLTEtMjU3Mzk_45dd5956-94fc-4ac7-acbf-faa644f12134">1,445,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTMtMS0xLTEtMjU3Mzk_125d4740-b928-4e3a-b87e-f190bb297ab0">371,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTMtMy0xLTEtMjU3Mzk_7bb537cd-72b8-4640-a1ea-610cfc4d182a">330,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTQtMS0xLTEtMjU3Mzk_69c1c3ae-ffe3-41a8-9407-fc6af030431e">104,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTQtMy0xLTEtMjU3Mzk_e247d190-0cd3-4416-9fde-8e34158fd8ab">67,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTUtMS0xLTEtMjU3Mzk_93bf3888-6355-4e62-a1c2-74f950efdb6a">111,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTUtMy0xLTEtMjU3Mzk_8792d4cd-3ab8-4dc6-86f4-d9a5d726e7c8">156,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTYtMS0xLTEtMjU3Mzk_3e55b267-62c1-40e6-b4d2-637e0df88dd4">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTYtMy0xLTEtMjU3Mzk_3c876e0d-d326-449a-a784-2c07856e9e07">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTctMS0xLTEtMjU3Mzk_de6fd91d-0a2a-4475-b1c6-e0cea6c6967b">131,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTctMy0xLTEtMjU3Mzk_f5905f39-44de-4358-be57-1d12663051a2">73,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTgtMS0xLTEtMjU3Mzk_a3cb295c-fa24-483d-a57c-4fd01d660289">2,616,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTgtMy0xLTEtMjU3Mzk_8dcde3ec-e84c-4664-bf2c-cb4773ce3de6">2,137,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjEtMS0xLTEtMjU3Mzk_d16c3150-a4f2-4c8b-b952-cd0d0055b578">24,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjEtMy0xLTEtMjU3Mzk_d05ceee6-954d-4c81-ae89-efc46a6c704c">23,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjItMS0xLTEtMjU3Mzk_d4c426fa-0880-4c70-b92f-fd1caa3cd71c">61,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjItMy0xLTEtMjU3Mzk_810eb5a9-7211-4f72-89da-556ec6312146">51,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="exel:AccruedClinicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjMtMS0xLTEtMjU3Mzk_aa558a47-f9b5-463b-b0fd-a00444ae2e5a">77,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="exel:AccruedClinicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjMtMy0xLTEtMjU3Mzk_216c558a-7894-41d7-a331-1c77ba062ca6">52,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates and fees due to customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjQtMS0xLTEtMjU3Mzk_ef61b14a-6a43-4b74-9e05-ceaa9a819ce5">33,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjQtMy0xLTEtMjU3Mzk_0de1a269-2349-4e1d-9a66-dacd39d22c7a">20,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="exel:AccruedCollaborationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjUtMS0xLTEtMjU3Mzk_e7f15412-5e2e-429c-823e-6ad4105292c6">86,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="exel:AccruedCollaborationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjUtMy0xLTEtMjU3Mzk_65f1f7cf-1b9f-4e7d-bbd2-74a72ebfef54">12,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjctMS0xLTEtMjU3Mzk_4416b5f7-8cbb-451d-b46a-2c9ca0a52819">53,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjctMy0xLTEtMjU3Mzk_7160b599-261a-4f06-8325-b0ea4659bef6">44,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjgtMS0xLTEtMjU3Mzk_09f89234-c30c-4af6-be69-abe172101a9f">337,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjgtMy0xLTEtMjU3Mzk_4f319852-379a-427b-a07b-098b45113cc3">204,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjktMS0xLTEtMjU3Mzk_fad9e3a3-cf35-4e25-901a-e49628584313">8,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjktMy0xLTEtMjU3Mzk_f6f13c8b-36b3-4091-8097-9021916f9fcf">3,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzAtMS0xLTEtMjU3Mzk_56941edc-7112-4fb8-9d63-ab635d5aa88b">51,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzAtMy0xLTEtMjU3Mzk_bb3f2269-4f8d-4d79-b2b2-20163d13fc23">49,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzEtMS0xLTEtMjU3Mzk_cb64106d-fe2e-4dc3-b22c-242941141a45">8,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzEtMy0xLTEtMjU3Mzk_17df630a-ae4f-43b0-a542-0ef15524124d">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzItMS0xLTEtMjU3Mzk_14c361ee-a0a8-4ce6-839d-ec7df26911e7">405,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzItMy0xLTEtMjU3Mzk_5eb3a4f1-dffc-46a2-b0f4-8e4931e7974c">258,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzMtMS0xLTEtMjU3Mzk_efa2ca68-7bb5-4cab-afbd-efeb6b5650d2"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzMtMy0xLTEtMjU3Mzk_48c4b64f-9b97-4282-92d8-18af70e59e19"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpmYzBmZmIwMmMyZDE0MmYyODkzOWVmMWY5MDExYzFhNF8yMQ_08b579ad-9015-4037-a464-055b01ebf271"><ix:nonFraction unitRef="usdPerShare" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpmYzBmZmIwMmMyZDE0MmYyODkzOWVmMWY5MDExYzFhNF8yMQ_e93a6e82-b8b1-409a-a1df-53b45dad86de">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpmYzBmZmIwMmMyZDE0MmYyODkzOWVmMWY5MDExYzFhNF8zNQ_29218d86-a733-494c-bf3c-8a023a802947"><ix:nonFraction unitRef="shares" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpmYzBmZmIwMmMyZDE0MmYyODkzOWVmMWY5MDExYzFhNF8zNQ_9c92b8ac-df28-487f-821a-ea3ce64d19ba">10,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpmYzBmZmIwMmMyZDE0MmYyODkzOWVmMWY5MDExYzFhNF82MA_c6d7a1a6-2ef1-4578-9616-4ad0ec8f11bd"><ix:nonFraction unitRef="shares" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpmYzBmZmIwMmMyZDE0MmYyODkzOWVmMWY5MDExYzFhNF82MA_f5f2d8d3-4ffc-447e-a3cf-f98dc6b404ab">no</ix:nonFraction></ix:nonFraction> shares issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMS0xLTEtMjU3Mzk_e153c552-76af-4781-85ee-3d73ed867621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMy0xLTEtMjU3Mzk_f7794b8b-0938-483f-a0ce-5e2b6f66ecd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF8xOA_64542db4-fd54-4713-b9d7-a15f655fb9c8"><ix:nonFraction unitRef="usdPerShare" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF8xOA_cbf7d80f-3ecb-46f7-bc8c-18daed58641c">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF8zMg_019c8a59-0089-4be0-95c3-b37126c7a49b"><ix:nonFraction unitRef="shares" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF8zMg_e8e3fa62-dc34-42d8-a30a-45061a41776c">400,000</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF83OA_27dce633-5aef-4982-8db9-db9fb1a0786f"><ix:nonFraction unitRef="shares" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF83OA_9eeee5a2-d8f4-4806-a912-e61ef8a81756">318,842</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF84NQ_4090fa26-1a66-4754-bcec-e34039cf9c17"><ix:nonFraction unitRef="shares" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF84NQ_a9cc6cb3-0680-4c55-b9cd-e24b2367432d">311,627</ix:nonFraction></ix:nonFraction> at December&#160;31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMS0xLTEtMjU3Mzk_57649489-6c87-4324-b1ec-efa04a7cda22">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMy0xLTEtMjU3Mzk_73554caa-a047-4d5a-af6c-178eb2c4816f">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzctMS0xLTEtMjU3Mzk_92f129cf-cb58-460f-9459-41176070f37c">2,427,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzctMy0xLTEtMjU3Mzk_943a1845-9bd6-46d7-aaea-5a0062ce84b2">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzgtMS0xLTEtMjU3Mzk_ab88a867-11b1-4c3b-b7b8-b421e6df28e0">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzgtMy0xLTEtMjU3Mzk_04f4e833-c932-4e2e-8c5d-8504719f532d">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzktMS0xLTEtMjU3Mzk_780f986b-f883-45e3-84b6-e0b76ab50691">216,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzktMy0xLTEtMjU3Mzk_afdf665d-e7a3-4437-a82a-7881e52aae2a">447,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNDAtMS0xLTEtMjU3Mzk_c06bcb8f-1e76-4e66-9b4c-ed741a106403">2,210,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNDAtMy0xLTEtMjU3Mzk_ff646de9-8e7e-45f1-bcef-c710f84a0133">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNDEtMS0xLTEtMjU3Mzk_8f614ffc-5731-4304-9ee4-1d8eaa769455">2,616,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNDEtMy0xLTEtMjU3Mzk_c88782b0-7f89-4b8f-93c1-341109d1081c">2,137,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i890a097ba13b4d2aa44ba45c617df112_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMy01LTEtMS0yNTczOQ_089ee80f-a944-41cd-ae48-f04fd5b135eb">1,077,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81474236dfb14ff1ac531c41f5c16947_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMy03LTEtMS0yNTczOQ_45797d43-e52d-454c-9dbe-40b3eed8e716">741,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6bfa79af1c49bbac2074ef89ab2c4b_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMy05LTEtMS0yNTczOQ_ca0e978a-609c-446c-b3f1-9f7b9b6f9fc6">759,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f5b5f30b734b15b1054bfb509ae021_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNC01LTEtMS0yNTczOQ_a76a7ad9-62ed-4342-a3e6-ed13690fa5f8">249,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23f991a8511f4c6bb78932ffbb88e05a_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNC03LTEtMS0yNTczOQ_e0093d0a-6d8d-4890-8d9b-863d8b7cd29d">167,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ce00236de4479e9a6c6986301e7731_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNC05LTEtMS0yNTczOQ_d06f031e-7998-479e-863b-885cab836319">165,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5185d285db34c6d9e4c918f1420364c_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNS01LTEtMS0yNTczOQ_381474ae-b46d-4839-b26e-91c442c7be4b">107,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8016a7106ab5473891bf09f72524f38e_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNS03LTEtMS0yNTczOQ_9d0e04ca-f94a-4585-95bf-803e3da9ff1c">78,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35edcd5425bb4e4f8597665dcf1e7e5b_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNS05LTEtMS0yNTczOQ_28a56a09-3347-4845-9365-585fdf44720b">41,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNi01LTEtMS0yNTczOQ_3214d4bd-db52-4442-a55f-819bb52b0d9a">1,434,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNi03LTEtMS0yNTczOQ_d2f6e443-5e77-4278-951d-c452e8ec367f">987,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNi05LTEtMS0yNTczOQ_c0d6a82c-37b3-4abd-abef-c1ba5eb1a105">967,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfOC01LTEtMS0yNTczOQ_46888da1-3667-4ad8-9bc9-ee7b23f9ea12">52,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfOC03LTEtMS0yNTczOQ_bc8cd585-50c0-4663-a826-abde17847895">36,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfOC05LTEtMS0yNTczOQ_af6e88a7-6933-4523-ae86-65e8ff21e6c7">33,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfOS01LTEtMS0yNTczOQ_29e98532-387a-4ef0-af83-933be973275d">693,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfOS03LTEtMS0yNTczOQ_a7efbbb0-1869-4b0c-a9bc-c2c6de9d7aa7">547,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfOS05LTEtMS0yNTczOQ_b062dc90-a7ab-4403-9f7e-b4b322637a75">336,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTAtNS0xLTEtMjU3Mzk_b55e7558-8115-4911-ada4-80ab7d69025f">401,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTAtNy0xLTEtMjU3Mzk_5f1dbd9c-cd6d-47e3-ac36-08f4dc3b7bc3">293,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTAtOS0xLTEtMjU3Mzk_67535ccf-1353-4129-a187-acd3cc2c689e">228,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTEtNS0xLTEtMjU3Mzk_03fabc03-6408-4512-987e-1dc953e10c4a">1,148,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTEtNy0xLTEtMjU3Mzk_9beaae9a-c642-4b6f-8cf0-52554ee6cea1">877,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTEtOS0xLTEtMjU3Mzk_93a9a18e-e9ef-4b76-9e7d-8f4009121259">598,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTItNS0xLTEtMjU3Mzk_e511c699-086b-43f4-ba6b-0cc9bcdad3ac">286,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTItNy0xLTEtMjU3Mzk_ffb2aa1d-5947-4104-9679-4f8e27a73b2c">110,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTItOS0xLTEtMjU3Mzk_3246c2ea-dd29-42fa-877b-b502de534fb0">369,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTMtNS0xLTEtMjU3Mzk_fbc84dc2-8d9e-4b1c-a3e7-687313108c9d">7,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTMtNy0xLTEtMjU3Mzk_0cda92d0-5035-43d0-bae3-30bac54e0be7">19,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTMtOS0xLTEtMjU3Mzk_94b65be8-1678-4092-8c7e-5af3b8cd320d">27,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTQtNS0xLTEtMjU3Mzk_c9188f1a-a226-4213-a211-35eefebe21a0">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTQtNy0xLTEtMjU3Mzk_435b1e72-4d9b-4e09-9b17-7729721189ed">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTQtOS0xLTEtMjU3Mzk_b840c816-ba2b-49a2-b1fd-a26035e66a9a">680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTUtNS0xLTEtMjU3Mzk_540d90ad-80dd-4eb8-9745-f72ff5c2d11a">294,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTUtNy0xLTEtMjU3Mzk_50425cda-d572-47e5-8b75-c90ddc54c6a8">130,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTUtOS0xLTEtMjU3Mzk_99b78927-1930-4602-b403-8cea995d5b47">398,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTYtNS0xLTEtMjU3Mzk_8c10b8ab-8e4f-4627-b24d-81ecaac0db34">63,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTYtNy0xLTEtMjU3Mzk_bd55152b-cfa4-4f4f-89b0-de43f09085c9">19,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTYtOS0xLTEtMjU3Mzk_00aab2be-6f54-4810-b99f-c08b0cd47dba">77,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d4436bfbe6489187e15748fba98eba_D20210102-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTctNS0xLTEtMjU3Mzk_a4a0e49b-538b-4769-b3b0-0a000826d2d8">231,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTctNy0xLTEtMjU3Mzk_8de384b5-b560-4513-8421-2ea9f5137b05">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTctOS0xLTEtMjU3Mzk_bc76ab92-7f7e-4c2e-90b3-592155118fc0">321,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTktNS0xLTEtMjU3Mzk_d0412897-a7a9-418b-ba1d-386e5c427995">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTktNy0xLTEtMjU3Mzk_17cb74be-19a8-408b-9aa9-1777d90d4f3d">0.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTktOS0xLTEtMjU3Mzk_3ef80348-21aa-44cd-ae45-1f3f7622a84a">1.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjAtNS0xLTEtMjU3Mzk_c137cefc-10d3-4f81-b90e-008ea0bcc9e2">0.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjAtNy0xLTEtMjU3Mzk_2bcdf78e-5712-4513-a37f-463e77663f96">0.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjAtOS0xLTEtMjU3Mzk_96fe491a-ecd6-4aa7-8be4-4584925d4d52">1.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjItNS0xLTEtMjU3Mzk_990c6d4e-41a0-40a9-9d5e-c73d6ccb9a7e">314,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjItNy0xLTEtMjU3Mzk_02b76316-39b2-4876-99df-4550bd25a008">308,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjItOS0xLTEtMjU3Mzk_ff47dd4e-b9d8-41fd-87c0-f315a2fb6270">302,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjMtNS0xLTEtMjU3Mzk_aef297bc-1597-4d3f-94bd-a22bd69182d0">322,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjMtNy0xLTEtMjU3Mzk_349d63f5-0ad2-431c-849c-c7d646aaf297">318,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjMtOS0xLTEtMjU3Mzk_239622e7-c18b-4fb3-82ea-4f174f5375bc">315,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_70"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d4436bfbe6489187e15748fba98eba_D20210102-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfMi01LTEtMS0yNTczOQ_a4a0e49b-538b-4769-b3b0-0a000826d2d8">231,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfMi03LTEtMS0yNTczOQ_8de384b5-b560-4513-8421-2ea9f5137b05">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfMi05LTEtMS0yNTczOQ_bc76ab92-7f7e-4c2e-90b3-592155118fc0">321,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNC0wLTEtMS0yNTczOS90ZXh0cmVnaW9uOjNmODE5ZmJiMDk5MDQ4MWM4N2M5MDEwMDU1NzNmZDc4Xzk1_ace109e8-cfdb-41d4-9b65-bb4e97e1bb31">1,481</ix:nonFraction>, $(<ix:nonFraction unitRef="usd" contextRef="i6aefcca4ad074b29b6a51fd6d458319c_D20201003-20210101" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNC0wLTEtMS0yNTczOS90ZXh0cmVnaW9uOjNmODE5ZmJiMDk5MDQ4MWM4N2M5MDEwMDU1NzNmZDc4Xzk5_0e36ccfa-fb39-4b79-acff-95d6ed603b66">394</ix:nonFraction>), and $(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNC0wLTEtMS0yNTczOS90ZXh0cmVnaW9uOjNmODE5ZmJiMDk5MDQ4MWM4N2M5MDEwMDU1NzNmZDc4XzEwNw_e6ff9858-e8a3-4fde-9ae0-efcbc685bcfd">1,049</ix:nonFraction>), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNC01LTEtMS0yNTczOQ_c9f6adea-0999-4076-99b7-bd5b99c50f02">5,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNC03LTEtMS0yNTczOQ_312b3d6d-3f88-4086-b5ed-e39b967d7030">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNC05LTEtMS0yNTczOQ_ac39bacc-ae49-4798-b694-ecaf6a6f1bad">3,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNi01LTEtMS0yNTczOQ_3db2bda0-ae2a-42d2-9964-cf09b42ab380">225,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNi03LTEtMS0yNTczOQ_ad935a7a-3cc6-45f9-b584-e3e5ab538124">113,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNi05LTEtMS0yNTczOQ_ed6cb400-ef4e-425b-8a07-96b4f65dda1d">324,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_73"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.678%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9805c5e25eb64ed985d666f4c24de9ba_I20181228" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzAtMS0xLTEtMjU3Mzk_27f667f0-03e4-401d-a7f5-5f5dab26ab65">299,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9805c5e25eb64ed985d666f4c24de9ba_I20181228" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzAtMy0xLTEtMjU3Mzk_464158c5-6fe7-484f-9682-8795796618cc">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d64ce6b48d24a04a0c93e22acd3904f_I20181228" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzAtNS0xLTEtMjU3Mzk_fd5e5996-af9a-4144-bc61-8a316b71a298">2,168,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i867ed8b4453c4a1a9044dab4bd539d50_I20181228" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzAtNy0xLTEtMjU3Mzk_8b2ade16-c9d0-449f-869a-732b6ae24046">701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8210e6b19c34f939af1ed9a98c8914a_I20181228" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzAtOS0xLTEtMjU3Mzk_eabe5a67-19bf-4c0f-8031-26150b9f581a">880,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i396cffc473714e59a1c966a366a443e2_I20181228" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzAtMTEtMS0xLTI1NzM5_cf68ef65-18b0-42bd-b144-81586e70fbb8">1,287,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a94021373d4840b95f6959bc4accd9_D20181229-20200103" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzEtOS0xLTEtMjU3Mzk_f13f2b9c-f09e-4669-b108-d2e48ba62af3">321,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzEtMTEtMS0xLTI1NzM5_0f223680-3b87-4b21-abe9-ed2503862980">321,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7c60d6d3b24087a7d0758be8cb1f5c_D20181229-20200103" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzItNy0xLTEtMjU3Mzk_4d592821-d9a7-43fc-b696-fa12e1608a69">3,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzItMTEtMS0xLTI1NzM5_af8a8967-5ebd-44b9-91d4-09f0d2d47b53">3,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9883712cd8e1413e8d0219e4ed8aad8d_D20181229-20200103" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzMtMS0xLTEtMjU3Mzk_5461889a-a5fc-4d06-bea8-5f70f30fdc8e">4,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9883712cd8e1413e8d0219e4ed8aad8d_D20181229-20200103" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzMtMy0xLTEtMjU3Mzk_e6d7b96a-4e63-41da-b00e-6dcc7d886c1e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73ea98630ee4a65b62bf4da8d1c3f41_D20181229-20200103" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzMtNS0xLTEtMjU3Mzk_db005461-6f7d-4c16-9860-a2222927f161">27,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzMtMTEtMS0xLTI1NzM5_2ccad43e-b201-43cf-a095-310a55bbf755">27,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic73ea98630ee4a65b62bf4da8d1c3f41_D20181229-20200103" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzQtNS0xLTEtMjU3Mzk_2449ab2e-a385-4daa-aa41-cb1d061b9204">9,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzQtMTEtMS0xLTI1NzM5_d2b0f386-7a8a-4a34-9e07-6f1062067f61">9,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73ea98630ee4a65b62bf4da8d1c3f41_D20181229-20200103" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzUtNS0xLTEtMjU3Mzk_e33e4a94-4a25-4351-90fd-17d9b079bfc0">56,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzUtMTEtMS0xLTI1NzM5_73369e16-08cc-407a-97b0-7c67f06cfd58">56,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e8c40dbf5a94938b3a235b6331b0204_I20200103" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtMS0xLTEtMjU3Mzk_b73bd6d9-4356-4038-8c35-d078f7148f5e">304,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8c40dbf5a94938b3a235b6331b0204_I20200103" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtMy0xLTEtMjU3Mzk_71ac8517-afa5-4682-a457-e955319fccbe">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99338e5e4fa243d89959abbe305c1ddc_I20200103" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtNS0xLTEtMjU3Mzk_30da5d05-8319-4243-bc46-5ee11806b72b">2,241,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6020ec58ca0b4ac4b002e4acc9448876_I20200103" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtNy0xLTEtMjU3Mzk_376c4c19-ce7a-4924-bfeb-f84f3d948a57">3,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i012b294c4e2c4931a14f4be10ec2fe36_I20200103" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtOS0xLTEtMjU3Mzk_c3bde12a-8aff-4635-825e-2502378c8693">559,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d03c75ce0024c01a62fcd27957b4f04_I20200103" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtMTEtMS0xLTI1NzM5_1552c64a-4810-4830-a773-bf9c22450a00">1,685,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d4126cc2fa94615bd40a5daa4ef585e_D20200104-20210101" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzctOS0xLTEtMjU3Mzk_2e9f2daa-7e6e-4daa-9ae4-8e4b350b11d0">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzctMTEtMS0xLTI1NzM5_a156dc7c-0236-4670-8718-f19d64fcc43d">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2944e77d8c04388810195fe26496810_D20200104-20210101" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzgtNy0xLTEtMjU3Mzk_9c1a9856-e7ad-40f0-ad8e-e4cb7b93f875">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzgtMTEtMS0xLTI1NzM5_dcd596b9-f668-48f8-8bf0-2acffd152722">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ccde781cd17461fb3e9f797e81654e9_D20200104-20210101" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzktMS0xLTEtMjU3Mzk_53703487-6004-484c-8d54-c43b1a1a8e25">6,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ccde781cd17461fb3e9f797e81654e9_D20200104-20210101" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzktMy0xLTEtMjU3Mzk_ddfcc248-a843-44b4-829a-2eb7314b4dd8">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f7ff0b5436e42b3a597987061001835_D20200104-20210101" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzktNS0xLTEtMjU3Mzk_5a528ed7-b5ff-4b57-9de5-4fa6dc52a941">24,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzktMTEtMS0xLTI1NzM5_992402b5-32d2-4f5c-b2ff-2c6e2c75c146">24,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f7ff0b5436e42b3a597987061001835_D20200104-20210101" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtNS0xLTEtMjU3Mzk_8aa871d9-dc56-4e07-9d9a-1bf8a4d0ff77">50,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtMTEtMS0xLTI1NzM5_5b4b4453-8cae-4cdb-8f73-70e5026eb7fd">50,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f7ff0b5436e42b3a597987061001835_D20200104-20210101" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDEtNS0xLTEtMjU3Mzk_b787f5ed-c864-42bd-a373-69144ca3ced3">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDEtMTEtMS0xLTI1NzM5_79e53d11-e210-432e-8039-b2e819e77373">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ce529a2e2894a0e92ed4a60ed0b95f9_I20210101" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDItMS0xLTEtMjU3Mzk_6a74b238-f8a1-4acb-b5cd-830213ce205b">311,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce529a2e2894a0e92ed4a60ed0b95f9_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDItMy0xLTEtMjU3Mzk_fac44488-c7a7-49d3-9277-304c97f2d2a8">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a546fb4a49e431a956a77f1680095df_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDItNS0xLTEtMjU3Mzk_b76b0a24-82f5-4fee-a475-8ca76df86d33">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4109c1b12d9d4433bb8db86bc3cae091_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDItNy0xLTEtMjU3Mzk_bcbafec4-899b-4eff-93f6-98568deee11c">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id655252138f44944870c02853be75c73_I20210101" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDItOS0xLTEtMjU3Mzk_527ebb72-7b47-47a0-a21e-7a5bb4301270">447,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDItMTEtMS0xLTI1NzM5_98f1aec9-5cd8-459e-9e45-db8bbbfb5d52">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzUtMTEtMS0xLTMxODIy_96d472c4-4e24-489c-971b-83255af6f8c5">231,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ce7ca557f444499972aa47b8a85d655_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtNy0xLTEtMzE4MDg_e72a7c0c-d309-46ea-a4a6-4fc86682134a">5,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtMTEtMS0xLTMxODIy_7c853193-b300-45ca-942e-ecaa336b95dd">5,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd55184171ad45c8be33cab3d4171b5f_D20210102-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzctMS0xLTEtMzE3Nzc_b81d0a5a-8e6b-40ee-bd07-f78754e6eae0">7,215</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd55184171ad45c8be33cab3d4171b5f_D20210102-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzctMy0xLTEtMzE3ODU_01f700ba-bc2b-4640-a2fe-ec28d4dd04f8">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b17fef833a40479881088e5855fc81_D20210102-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzctNS0xLTEtMzE3OTI_c32a5cfb-472d-4039-ab06-e560ac48017a">24,360</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzctMTEtMS0xLTMxODIy_67921937-865f-4c1b-acdd-9fd8c6178fe1">24,367</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84b17fef833a40479881088e5855fc81_D20210102-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzgtNS0xLTEtMzE3OTI_a7605029-dba1-4976-be39-58a988835ca4">39,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzgtMTEtMS0xLTMxODIy_298fe3e8-3049-45b2-9191-895665c5f72a">39,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b17fef833a40479881088e5855fc81_D20210102-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzktNS0xLTEtMzE3OTI_1d046f2f-c1bb-477a-bfc8-047760d49846">120,448</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzktMTEtMS0xLTMxODIy_77766f7b-0154-472c-be4f-e0280b8432e0">120,448</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac855e1b2d284da3adfcc70d50d6b045_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtMS0xLTEtMzIzMjQ_f85ce704-9157-402b-90c8-7006dd82f05a">318,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac855e1b2d284da3adfcc70d50d6b045_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtMy0xLTEtMzIzMjQ_01cbc102-9496-4659-9a55-36d9668bbfbb">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ff5eb1df65416581656de05ef86494_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtNS0xLTEtMzE3OTI_acef0950-a57e-4e8a-9663-43fb290d39ee">2,427,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dcdcda3fc10404397110c8f9aaa5353_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtNy0xLTEtMzIzMjQ_df5872a6-f362-4792-8ddb-6493b09914b2">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebee7996e33a4d07b3a22638e4c253b2_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtOS0xLTEtMzIzMjQ_8a150c22-16d1-4b94-971b-c777519ceea1">216,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtMTEtMS0xLTMyMzI0_2b008141-10e4-4066-976a-9f0229e4380c">2,210,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_76"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d4436bfbe6489187e15748fba98eba_D20210102-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMi0xLTEtMS0yNTczOQ_a4a0e49b-538b-4769-b3b0-0a000826d2d8">231,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMi0zLTEtMS0yNTczOQ_8de384b5-b560-4513-8421-2ea9f5137b05">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMi01LTEtMS0yNTczOQ_bc76ab92-7f7e-4c2e-90b3-592155118fc0">321,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNC0xLTEtMS0yNTczOQ_91012b16-0d60-4bdd-9463-4c5850d75a4e">13,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNC0zLTEtMS0yNTczOQ_a99bf2de-b133-4cb5-8418-671f5a519942">9,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNC01LTEtMS0yNTczOQ_8329191e-c9b1-4568-be37-c309f98e2f02">8,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNS0xLTEtMS0yNTczOQ_27e28292-5bf3-49f0-a775-a09e83e51be7">119,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNS0zLTEtMS0yNTczOQ_b3e4ff72-ee1d-42fe-b845-4ab5b9437e28">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNS01LTEtMS0yNTczOQ_590e7b92-b03d-48da-87c0-b34898164b03">56,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNi0xLTEtMS0yNTczOQ_8f176fc3-f7d2-4d0e-a5f9-6e902d030454">5,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNi0zLTEtMS0yNTczOQ_71b9cf29-2b4f-431d-bb98-8848b081e06a">4,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNi01LTEtMS0yNTczOQ_260e84a1-5ff3-467a-848f-9e449edad55e">2,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNy0xLTEtMS0yNTczOQ_9d3db304-469d-4106-8448-767ea798d215">46,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNy0zLTEtMS0yNTczOQ_14e655ae-64f2-4518-a55f-bed399839923">15,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNy01LTEtMS0yNTczOQ_06188e56-0f18-4b7b-82ff-01b3608a3845">71,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfOC0xLTEtMS0yNTczOQ_03aa28fa-a078-45dc-aa01-795ba24e2e86">23,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfOC0zLTEtMS0yNTczOQ_afdde090-fa23-4817-9e93-4ae7386ca341">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfOC01LTEtMS0yNTczOQ_09319e31-44ae-4a28-8dfd-cbcd7755e4a0">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTAtMS0xLTEtMjU3Mzk_eb739c39-c210-4b16-815f-788717d1f3c6">122,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTAtMy0xLTEtMjU3Mzk_bf946926-3e44-4431-84be-b85dd732131f">42,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTAtNS0xLTEtMjU3Mzk_0194ae3c-bf74-46b1-a1d6-68d001c690fc">43,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTEtMS0xLTEtMjU3Mzk_89aef772-d6b8-4cf0-bf09-0fb07f1d795c">13,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTEtMy0xLTEtMjU3Mzk_b5ace612-3172-4dac-b455-3062199f8fc2">21,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTEtNS0xLTEtMjU3Mzk_6a8d28c0-6bef-44e9-9e48-6e2fea3d226d">5,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTMtMS0xLTEtMjU3Mzk_ea5fc9dc-f4da-4d78-98f4-e646905e90cf">39,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTMtMy0xLTEtMjU3Mzk_f3c619bd-f52c-4f33-a715-a7adad495466">25,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTMtNS0xLTEtMjU3Mzk_b7674318-3e38-45dd-b721-89e3b6220ad3">5,723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTUtMS0xLTEtMjU3Mzk_f12662d0-37e9-46f6-95b5-969cc16bbdae">11,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTUtMy0xLTEtMjU3Mzk_3adb487b-ff3d-4f37-abc9-696d5a56dc98">1,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTUtNS0xLTEtMjU3Mzk_5b32a0ec-e46d-4d9c-90eb-ad88b910a819">9,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTYtMS0xLTEtNDUzMjM_ed651d24-fece-4b8b-a33c-572ec0ba5c1f">70,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTYtMy0xLTEtNDUzMzA_aa187cd3-f112-4b2b-8642-48eba1e8835d">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTYtNS0xLTEtNDUzMzc_1c345b1b-f3ce-4a7f-aa59-b7db9accd05e">4,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTYtMS0xLTEtMjU3Mzk_2c9a1db6-d5d6-4bfa-91bc-9c8107043a7e">55,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTYtMy0xLTEtMjU3Mzk_d77d51e9-3581-44be-b1e2-f5469d6906e9">50,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTYtNS0xLTEtMjU3Mzk_a98ed54e-072a-411b-87b1-8b22cd1b65b1">39,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTctMS0xLTEtMjU3Mzk_e06e405b-39c2-4da7-8397-2f5d063e76f1">400,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTctMy0xLTEtMjU3Mzk_36df1c26-89c4-4f39-8458-9e74bc21c2ac">208,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTctNS0xLTEtMjU3Mzk_85387ceb-341f-4a0c-8794-abefacca8799">526,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTktMS0xLTEtMjU3Mzk_0755a419-1c83-48a0-ae1d-3583c39c2431">64,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTktMy0xLTEtMjU3Mzk_984fb9d6-0506-400e-9f51-1adebead0d54">30,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTktNS0xLTEtMjU3Mzk_cb4f755a-350f-40f4-88a4-70f92135d06d">12,834</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjEtMS0xLTEtMjU3Mzk_67276339-9fca-4dc8-bfe9-a1c8df463535">1,357,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjEtMy0xLTEtMjU3Mzk_d0ba90ba-9087-45d2-b0f3-c9d54a78962d">1,070,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjEtNS0xLTEtMjU3Mzk_fa23c800-8a8c-4b6d-9628-45efb517c2a4">1,182,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjItMS0xLTEtMjU3Mzk_9ee06343-d935-438f-b94f-26bc8619308a">1,378,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjItMy0xLTEtMjU3Mzk_fab8da98-6f33-4ac8-89f9-e68ff0f78b39">969,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjItNS0xLTEtMjU3Mzk_a4aa3b36-85ea-4644-a869-fbd7a96b9750">608,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjMtMS0xLTEtMjU3Mzk_5facec09-c04e-4a1d-bfa8-9e1c6fc4bd13">42,884</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjMtMy0xLTEtMjU3Mzk_6a770d88-71e6-4cc9-940c-99ec10a9bc25">131,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjMtNS0xLTEtMjU3Mzk_e854a0f0-7670-40e7-b7a8-6622942ac03a">587,247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjUtMS0xLTEtMjU3Mzk_ede224be-be5b-4fc5-a62c-30bdefd3f6e1">24,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjUtMy0xLTEtMjU3Mzk_312b44e4-a366-4e52-aab0-80c028564bd3">24,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjUtNS0xLTEtMjU3Mzk_760361e5-f46a-4106-81ee-1f20db8b3f2f">22,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjYtMS0xLTEtMjU3Mzk_4de96e3d-c467-489f-9a9f-ad1007838f6a">39,108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjYtMy0xLTEtMjU3Mzk_63679ff1-77cc-4276-868a-c0963efd6d2d">50,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjYtNS0xLTEtMjU3Mzk_000c516c-20e3-416d-894a-3a677c666749">9,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjctMS0xLTEtMjU3Mzk_6238bde9-8167-43cb-825c-9828a4ec8b71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjctMy0xLTEtMjU3Mzk_4cd67300-f75d-418e-9fb4-b3cfc475455d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjctNS0xLTEtMjU3Mzk_85dab201-e0c0-4310-bf3a-40e5c9fb6361">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjgtMS0xLTEtMjU3Mzk_16c18c99-6920-4424-ace7-669846ad6212">14,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjgtMy0xLTEtMjU3Mzk_375e51ca-248f-43c6-ba6f-9f79d3bd76ca">25,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjgtNS0xLTEtMjU3Mzk_11722aee-e9d5-4fb5-a758-6814beac2d38">12,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjktMS0xLTEtMjU3Mzk_d089a5c3-0f1b-4fc8-bdcd-87e5835f23b5">343,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjktMy0xLTEtMjU3Mzk_a41c5a75-907b-44c2-a1f4-de0b8dd01d27">52,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjktNS0xLTEtMjU3Mzk_110cc771-3a22-4016-9ed0-50fb0ec7ba27">47,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzAtMS0xLTEtMjU3Mzk_a9ce197f-43ee-4036-8de0-110d3af5a137">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d03c75ce0024c01a62fcd27957b4f04_I20200103" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzAtMy0xLTEtMjU3Mzk_bccfb82c-797d-494c-af9a-335f3a86313c">268,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i396cffc473714e59a1c966a366a443e2_I20181228" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzAtNS0xLTEtMjU3Mzk_c3c1a330-92a2-4468-a167-848ba9becc56">315,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzEtMS0xLTEtMjU3Mzk_abb0e486-5e3f-4fd6-bdb4-78ac0489b934">663,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzEtMy0xLTEtMjU3Mzk_278adff1-c8fc-4a8c-b48d-5f9cd85ee790">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d03c75ce0024c01a62fcd27957b4f04_I20200103" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzEtNS0xLTEtMjU3Mzk_348814f5-a507-46f2-9154-2cd6275024c2">268,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzQtMS0xLTEtMjU3Mzk_c5835151-520b-42dc-ad91-af8305d7d8d0">12,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzQtMy0xLTEtMjU3Mzk_91eff752-fdff-4da5-8a1d-52ab1777f4a8">4,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzQtNS0xLTEtMjU3Mzk_221648f7-6bf1-4b10-805f-f5e691de9a30">7,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzYtMS0xLTEtMjU3Mzk_08aa28ec-b87d-46dc-a68f-e5358cd72ed2">4,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzYtMy0xLTEtMjU3Mzk_5a385480-ecee-4d2d-84cc-6ac6665a0d29">4,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzYtNS0xLTEtMjU3Mzk_d71af29b-4e5c-47fa-b3d6-dd48f5ce5cee">29,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred in asset acquisition</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:LiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzgtMS0xLTEtMzc0NjU_7c1366f3-2cb6-4add-a84c-f7dc02ab6c5e">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:LiabilitiesAssumed1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzgtMy0xLTEtMzc0Njc_1e3e049d-ab46-447a-860b-87876b11de08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:LiabilitiesAssumed1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzgtNS0xLTEtMzc0Njk_d90810b9-38f6-4282-81a9-356c8d9058f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred for purchases of property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzgtMS0xLTEtMjU3Mzk_9d826623-8190-498b-97f2-0ee8de9b4fc0">2,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzgtMy0xLTEtMjU3Mzk_d1a015ef-e4b7-471c-9f2f-e8296a49f25b">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzgtNS0xLTEtMjU3Mzk_6344471e-c2bd-440b-b621-2cf9739f3762">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred for unsettled investment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="exel:InvestmentsPurchasesIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzktMS0xLTEtMjU3Mzk_fc5570d6-78d3-4ed2-98a6-b3793090c493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="exel:InvestmentsPurchasesIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzktMy0xLTEtMjU3Mzk_4cf1f3e1-9a5e-483c-88e8-09d6edfb1e1e">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="exel:InvestmentsPurchasesIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzktNS0xLTEtMjU3Mzk_560cfe42-0aad-49cf-9b58-d72340417a9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable for unsettled investment sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="exel:AccountsReceivableForUnsettledInvestmentSales" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNDAtMS0xLTEtMjU3Mzk_e481fc58-4147-4fb8-8280-5deb77f46120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="exel:AccountsReceivableForUnsettledInvestmentSales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNDAtMy0xLTEtMjU3Mzk_4396cdeb-31a4-490b-85d2-19734a5b2af5">6,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="exel:AccountsReceivableForUnsettledInvestmentSales" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNDAtNS0xLTEtMjU3Mzk_db550d98-5dab-42e7-a5d9-ca39a4511e58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_79"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_82"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwOTQ_b0a3a511-6fe9-4c33-8e6f-63d11326d167" continuedAt="i92774118fa774ae8b639cc5c24b210f0" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i92774118fa774ae8b639cc5c24b210f0" continuedAt="i58759079d4d24371b37ff14f72cef653"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.</span></div><div><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, <ix:nonFraction unitRef="product" contextRef="ib427a6bae515457884e12ccece2b4122_D20210102-20211231" decimals="INF" name="exel:NumberofProductsinCommercialMarket" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfOTM0NTg0ODkwNzk2Ng_2354357b-4353-42bf-8a76-e48d1613f24d">four</ix:nonFraction> products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in <ix:nonFraction unitRef="country" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="INF" name="exel:NumberOfCountriesWithDrugApprovalExcludingTheUS" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDM5ODA0NjU4Nzg2Nw_3acdec0d-dc4a-4344-9337-323b5ac5fc45">61</ix:nonFraction> other countries as: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA, for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important drug in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other <ix:nonFraction unitRef="product" contextRef="i02820d73f6c54d589b048d50797c40a6_D20210102-20211231" decimals="INF" name="exel:NumberofProductsinCommercialMarket" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfOTM0NTg0ODkwNzk3NA_91e118d9-2a1b-4521-aa2f-88abac5fa3c4">two</ix:nonFraction> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo). </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan is to utilize our operating cash flows and cash and investments to expand the cabozantinib franchise by potentially adding new indications in areas of unmet medical need. We will also leverage our operating cash flows to continue advancing our diverse small molecule and biotherapeutics programs, exploring multiple modalities and mechanisms of action to discover new oncology drugs. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwODY_28a44bf3-e057-440f-b8ec-7d92a6ea275a" escape="true">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:FiscalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxMDI_bb5629bb-023a-4ef0-be8a-6f7897d8bbc3" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021, fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January&#160;3, 2020. For convenience, references in this report as of and for the fiscal years ended January&#160;1, 2021 and January&#160;3, 2020 are indicated as being as of and for the years ended December&#160;31, 2020 and 2019, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reclassifications to our prior years&#8217; Consolidated Financial Statements to conform to the current year&#8217;s presentation. These reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders&#8217; equity.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwOTg_a0b60fdb-bb59-4519-8681-540b7b553b3d" escape="true">We operate in <ix:nonFraction unitRef="segment" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMzY0NA_f802fc8f-5085-4215-b721-e3a89be935f1">one</ix:nonFraction> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i58759079d4d24371b37ff14f72cef653" continuedAt="ie21696da8362459ba733d590904b752a"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxNjc_c9b7dc7d-4986-467d-b1f8-a31487f406a6" escape="true">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwOTU_a9279812-7950-41d2-a12a-73fbbe92df7e" continuedAt="i9173e94864204b15941eeab84af52067" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted the Accounting Standards Board&#8217;s (FASB) Accounting Standards Update (ASU) 2019-12</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740)-Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, Income Taxes and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Consolidated Financial Statements.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwMzU_b7eafb5c-08cd-42d5-85f6-b46b1232dbab" escape="true">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNjA0NzMxNDAyOTQ1Nw_5d30ca3e-4ed3-45b2-adcd-4b66b2b853bf" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly, we assess each of our investments in available-for-sale debt securities whose fair value is below its cost basis to determine if the investment&#8217;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded as a reduction of other comprehensive income (loss), net of applicable taxes. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwNjM_df78b44e-799f-4bd5-96ef-4cf333616f6f" continuedAt="i69e48bd3245f474b9c585dfa1c979f99" escape="true">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that </ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="ie21696da8362459ba733d590904b752a" continuedAt="i0f00f5749c694c23a65559fc218244c3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i69e48bd3245f474b9c585dfa1c979f99">market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</ix:continuation></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfOTM0NTg0ODg5NDY3MQ_5b375de1-e03a-4538-9b2e-26ed0ce066c7" escape="true">In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchange rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro.</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had <ix:nonFraction unitRef="derivative_instrument" contextRef="i2ca33a540eff4370b1fd9baefd112b43_I20211231" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjE5OTAyMzMwMzUyNQ_9255cee1-fd71-4982-ba75-508d90dbcc92">one</ix:nonFraction> forward contract outstanding to sell &#8364;<ix:nonFraction unitRef="eur" contextRef="i2ca33a540eff4370b1fd9baefd112b43_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjE5OTAyMzMwMzU2OA_a3959ac4-d05b-458b-815d-eec26bf397f4">9.8</ix:nonFraction>&#160;million. The forward contract with a maturity of <ix:nonNumeric contextRef="ib1b9becbae9d413a818538229404c8e0_D20210102-20211231" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfOTM0NTg0ODg5NDcwNw_ac328d56-26c5-4cf0-bfee-c893a022464a">three months</ix:nonNumeric> is recorded at fair value and is included in prepaid expenses and other current assets in the Consolidated Balance Sheets. The unrealized loss on the forward contract is not material as of December&#160;31, 2021. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the year ended December&#160;31, 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="ib1b9becbae9d413a818538229404c8e0_D20210102-20211231" decimals="-5" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjE5OTAyMzMwMzk4Mg_3fd84b7f-e769-4f3c-aa7f-a5edd10a3274">0.8</ix:nonFraction>&#160;million of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfOTM0NTg0ODg5NDY3Mw_157a6abb-4ad0-4838-854b-912283263dad" escape="true">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the accompanying Consolidated Statements of Income.</ix:nonNumeric> Net foreign currency gains or losses were immaterial for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwODI_4ddf94c3-7e5d-4dda-b9fa-57745f1d6e04" escape="true">Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current economic conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. We write off trade receivables and related allowances for credit losses when it becomes probable we will not collect the amount receivable. Write-offs for the years ended December 31, 2021 and 2020 have been insignificant.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxNTI_5dae78cc-f890-4e74-a531-0aa650d0a0fc" escape="true">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxMjc_2227e592-92b9-48fe-8336-a136403a1ecb" escape="true">We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to <ix:nonNumeric contextRef="i6362d549434c4a3ebfb9ed76266ced8a_D20210102-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMTQ1MTI_6528f80f-fe31-4deb-9f2d-c2a3e9564da2">15</ix:nonNumeric> years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented.</ix:nonNumeric> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxMjg_f764c444-20c2-45e7-8a17-b5bf8cb1ffb3" continuedAt="ia8ace6c01d584d52b29ce573b764071c" escape="true">We recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes </ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i0f00f5749c694c23a65559fc218244c3" continuedAt="i89fb10e226f149da8a6a45487ab57869"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia8ace6c01d584d52b29ce573b764071c">in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in <ix:nonFraction unitRef="segment" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMTYxMDA_f802fc8f-5085-4215-b721-e3a89be935f1">one</ix:nonFraction> business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level.</ix:continuation> We did <ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMTYyNTc_3d8dfc74-019f-43b1-bf3b-df35f655cae9"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMTYyNTc_6a315e70-063a-4770-bf41-3ca1af4c4f47"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMTYyNTc_c8fc913d-4616-4d6b-b6db-b97d0546b953">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognize any impairment charges in any of the periods presented.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwMzc_fba7f1dc-a88b-4906-bd2c-21e6126afb90" escape="true">The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxNzg_4df8dee2-f8a7-4b96-ab62-c065a96fa127" continuedAt="i4a3d1658a80f496589717f45dd94c0b5" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenues under the guidance of ASU Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i89fb10e226f149da8a6a45487ab57869" continuedAt="id9556360830d42ceb7718c2cf5c80a92"><ix:continuation id="i4a3d1658a80f496589717f45dd94c0b5" continuedAt="ie446ed282e4b41ddaa4bb018434f477a"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts for Prompt Payment:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Customers in the U.S. receive a discount of <ix:nonFraction unitRef="number" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="2" name="exel:SalesRevenuePercentDiscountForPromptPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjEzMTI_aede4932-0be7-41da-8ed7-6f1779657b03">2</ix:nonFraction>% for prompt payment. We expect our Customers will earn <ix:nonFraction unitRef="number" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="INF" name="exel:SalesRevenueDiscountExpectedtobeEarnedPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjEzNjk_2bffda3a-5d57-4c89-91e6-0abf500ef567">100</ix:nonFraction>% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our Customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund <ix:nonFraction unitRef="number" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="2" name="exel:MedicarePartDFundingMandate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjI4MTY_8fa20206-a272-46d9-a130-7a43ee5d3feb">70</ix:nonFraction>% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to Customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Customer Credits: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="id9556360830d42ceb7718c2cf5c80a92" continuedAt="iddd0db72df4f4456b86280c43a33dbb3"><ix:continuation id="ie446ed282e4b41ddaa4bb018434f477a" continuedAt="i45151b0da9b743c7b2276957b9eebfe8"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Up-front License Fees: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory and Development Milestone Payments: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Cost Reimbursements:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation, which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Arrangements: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Sales-based Milestone Payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a <ix:nonFraction unitRef="number" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMzA3NDY_be10e243-5402-4393-8922-bf4c0436cdb1">3</ix:nonFraction>% royalty we are required to pay on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. </span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i45151b0da9b743c7b2276957b9eebfe8">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs.</ix:continuation> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="iddd0db72df4f4456b86280c43a33dbb3" continuedAt="i6408920431d84afeb6009924114a8a22"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxNjE_5cb7dcb4-5c5d-4211-b321-0cff653c4c46" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwNTg_8c8d1521-9d86-4240-b5a0-bfa81bf067e8" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-02</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842) for short-term leases.</span></ix:nonNumeric></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expenses were $<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMzQzODg_0ab083a6-8187-404e-98b5-17d5d8ff36d3">31.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjE5OTAyMzI5NTg1Ng_cf2168b2-fc89-48a5-96cd-83b26b5f8c05">25.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjE5OTAyMzI5NTgzMw_45ebd3b4-0551-405b-85e4-69dd183f07ff">17.9</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxODA_2bdd96a7-5788-4474-a99a-a29d2547abc3" escape="true">We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwNDg_1bc43e81-1918-4dca-8b40-822b3e3322c8" continuedAt="i05415a8098b94017b8405ef4a112031a" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock&#160;Compensation</span></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i05415a8098b94017b8405ef4a112031a">,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatility when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis.</ix:continuation> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i6408920431d84afeb6009924114a8a22"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwNjc_83ac73e1-e953-47fb-94a5-b2b000567024" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for income taxes in the period of such reversal. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div></ix:nonNumeric><ix:continuation id="i9173e94864204b15941eeab84af52067"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our Consolidated Financial Statements.</span></div></ix:continuation></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfNDE5NA_682ea583-75bf-462e-9e9e-1ec05e9316b9" continuedAt="i62a000f8ec4d4b08b0117990313bd422" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i62a000f8ec4d4b08b0117990313bd422" continuedAt="ic49ce543f56146beb2f811157f5b5fc6"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfNDIwMA_458fa646-f550-4696-bada-9a8950de91ec" continuedAt="i849f4c77481f47e3a19e034f3e39e3b2" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce7596693de4c309e4046ee44e221d0_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMy01LTEtMS0yNTczOQ_dd3905c4-b182-427b-84ec-e7998060ce6f">1,452,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4442ea86bfb449ca9e6184c51952a1e9_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMy03LTEtMS0yNTczOQ_f01af313-5657-40c0-8cb0-7a1c5d6a0fac">962,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad06c636df9d4082a61cd0476a607cb2_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMy05LTEtMS0yNTczOQ_87f9538d-6721-4c29-80a2-d021224a01a1">957,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0431c045c7b749419b8cb122e47b2fd8_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNC01LTEtMS0yNTczOQ_dd7b5f62-bce9-49f8-9ef0-97b780522fec">375,657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4d4c8762b46415b8ba90c8fc8e8bd01_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNC03LTEtMS0yNTczOQ_a58f9fa2-d60f-4899-a663-14afb0d93151">221,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e8b773d3cd2476b9a6f98f0ec19f343_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNC05LTEtMS0yNTczOQ_f528421b-8184-4f8a-9f95-6bedc57128d8">197,671</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i890a097ba13b4d2aa44ba45c617df112_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNS01LTEtMS0yNTczOQ_089ee80f-a944-41cd-ae48-f04fd5b135eb">1,077,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81474236dfb14ff1ac531c41f5c16947_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNS03LTEtMS0yNTczOQ_45797d43-e52d-454c-9dbe-40b3eed8e716">741,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6bfa79af1c49bbac2074ef89ab2c4b_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNS05LTEtMS0yNTczOQ_ca0e978a-609c-446c-b3f1-9f7b9b6f9fc6">759,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f5b5f30b734b15b1054bfb509ae021_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNy01LTEtMS0yNTczOQ_a76a7ad9-62ed-4342-a3e6-ed13690fa5f8">249,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23f991a8511f4c6bb78932ffbb88e05a_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNy03LTEtMS0yNTczOQ_e0093d0a-6d8d-4890-8d9b-863d8b7cd29d">167,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ce00236de4479e9a6c6986301e7731_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNy05LTEtMS0yNTczOQ_d06f031e-7998-479e-863b-885cab836319">165,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5185d285db34c6d9e4c918f1420364c_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfOC01LTEtMS0yNTczOQ_381474ae-b46d-4839-b26e-91c442c7be4b">107,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8016a7106ab5473891bf09f72524f38e_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfOC03LTEtMS0yNTczOQ_9d0e04ca-f94a-4585-95bf-803e3da9ff1c">78,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35edcd5425bb4e4f8597665dcf1e7e5b_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfOC05LTEtMS0yNTczOQ_28a56a09-3347-4845-9365-585fdf44720b">41,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5511677067b74ebb913d887f52a2848c_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMTAtNS0xLTEtMjU3Mzk_0b61a127-94c0-421f-9499-508aee48ede2">357,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10a667976104461cb71d5603b4d4af97_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMTAtNy0xLTEtMjU3Mzk_e35d1bea-c905-482e-8523-e2529f3c1bf7">245,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9af17feaeb349989438dbf0d666ce00_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMTAtOS0xLTEtMjU3Mzk_7405fd64-7c73-4205-a1a2-a3c631c532d5">207,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMTEtNS0xLTEtMjU3Mzk_3214d4bd-db52-4442-a55f-819bb52b0d9a">1,434,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMTEtNy0xLTEtMjU3Mzk_d2f6e443-5e77-4278-951d-c452e8ec367f">987,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMTEtOS0xLTEtMjU3Mzk_ef9a96b7-d84c-48c6-8597-e376ff2323cc">967,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on total net sales of any product containing cabozantinib for non-U.S. markets </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="ic49ce543f56146beb2f811157f5b5fc6" continuedAt="i00885c3f7baa49c283994c2e90fdcd4b"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. </span></div><ix:continuation id="i849f4c77481f47e3a19e034f3e39e3b2"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da812635cea4a9b9116e4146e6cdea4_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfMi01LTEtMS0yNTczOQ_f93f5746-dd5e-4b86-8682-1f6d42da6a72">1,054,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17406e0670124dc6aa021883b5f49f2e_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfMi03LTEtMS0yNTczOQ_d5ee8937-7e86-4b21-aaec-769f3577a709">718,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia06ec631ab45435d9aa467e475199d25_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfMi05LTEtMS0yNTczOQ_802a0c65-d95b-4509-b5b2-e582e16ff6d3">733,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f3560ad4cbe4f5fa9e33117ca1cc45b_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfMy01LTEtMS0yNTczOQ_129bb0d4-ab84-40b3-b4f5-d95c642c2b24">23,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a39ad000947444189cd4862efda588c_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfMy03LTEtMS0yNTczOQ_bd3c82ea-81a9-46ad-aea2-2e8d3dc3ebfd">22,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie886e01e3e2442248812abddb9a3357c_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfMy05LTEtMS0yNTczOQ_b08832dd-f67a-444c-8290-5d32f1bc8406">26,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i890a097ba13b4d2aa44ba45c617df112_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfNC01LTEtMS0yNTczOQ_563a0f44-1917-414f-bc71-b259d2f30690">1,077,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81474236dfb14ff1ac531c41f5c16947_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfNC03LTEtMS0yNTczOQ_dac231fc-d174-4684-9cae-d09d4420027b">741,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6bfa79af1c49bbac2074ef89ab2c4b_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfNC05LTEtMS0yNTczOQ_6812d777-a44a-4b6a-9973-886d7b58f184">759,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfNDIwMQ_f7aa61e8-2cf0-4778-b7ec-331f14ab60a0" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i802f06ff953349dcbd6e18868ae5c8ff_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfMi0xLTEtMS0yNTczOQ_31c75f12-5ffb-43dc-844f-f5b834622327">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a10a7f26ddf4e71ae1239be47deed9d_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfMi0zLTEtMS0yNTczOQ_bf1c123a-05f2-4ac1-93d0-c0211e81c97a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e023361e8434930804854afbfdfd16d_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfMi01LTEtMS0yNTczOQ_8544c863-1c10-4e34-9d06-93e7cdb0a3c7">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82d9fb00ead242beaea5c7ba0738621a_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfMy0xLTEtMS0yNTczOQ_e496b01f-f7a6-4610-8681-3bbeef8a08c8">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23f80ed12dd445599bf289f8b30b88c0_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfMy0zLTEtMS0yNTczOQ_0f989277-5600-4488-9e4a-31070f3d5b2e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0937e3d1b0e1474a8b6f5365e91705d4_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfMy01LTEtMS0yNTczOQ_ae98de8f-9413-419f-a34b-8b6a1d2b45a1">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55441d6740314dfba8168bd2502b1101_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNC0xLTEtMS0yNTczOQ_0476584f-4a95-4e8c-a218-46f82f246730">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i259af2d579ef48a689f2076724ddc735_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNC0zLTEtMS0yNTczOQ_07e4a93b-627a-4e9f-b634-eec3c6fa1fce">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i594dc7db46f143248c87766268ac1585_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNC01LTEtMS0yNTczOQ_12a500c3-03f9-4e2c-8fe1-6a411fd92831">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a26379cbf1740a7a0004b7311e38cc3_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNS0xLTEtMS00MTc1MA_ae3e5369-f058-4330-8302-2dd1dad6832b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b64a741d8eb4bc7bbac3a5db68a20bf_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNS0zLTEtMS00MTc1MA_0deb5798-0c7e-47f9-88df-5d509822a386">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib21e644bf9d94035b284ae2d64be8538_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNS01LTEtMS00MTc1MA_29821df6-bf70-4591-b9e6-56bf8368e269">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica4c1bf73b7a497ea0f0cf3ee3121416_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNS0xLTEtMS0yNTczOQ_fc1b1e31-592a-486e-a84d-993f37d1741d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fa15b9421324d2a8abcc78e7bf8af23_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNS0zLTEtMS0yNTczOQ_c126edf4-2dda-45b8-9fc3-7d9e4a8a1ce9">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i829c8635dc1a41a8867b90164ddc5c42_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNS01LTEtMS0yNTczOQ_29eb2ed3-8805-446b-be1f-31ecf2209f05">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a81f07947fc466f9ec4626bef20395b_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfMy0xLTEtMS0zMjQ1NQ_c5340b95-e11d-4a8b-95aa-eca730c9bf4d">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iadbe770de5cb48ad8f72003a3c009cde_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfMy0zLTEtMS0zMjQ1NQ_876f3390-5f6e-4a13-8252-436ffe23d6db">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b058fe448f6453eb17990c3983c40ce_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfNC0xLTEtMS0zMjQ1NQ_a43a2e62-6c28-4d4a-830a-76999643e655">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e8a704120c54d7d9733625903a75c0a_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfNC0zLTEtMS0zMjQ1NQ_24a43235-8541-4ec0-a4eb-78f4dd5eb8ea">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb7ad7b5987c4c759bd3da195cccdda9_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfNi0xLTEtMS0zMjQ1NQ_5a652560-2c68-416c-9af8-c628830dd235">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bc15983150c43b49a8bcd610f1d7622_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfNi0zLTEtMS0zMjQ1NQ_356d6530-a4d3-425a-9323-85eaa05561de">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5510c7d658a0420fa7c4fd22f06b733d_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfOS0xLTEtMS00MTc2OQ_5915003f-aa14-4d20-bf16-3cf504f22def">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1d553018b3f4e6ea41bdee893c4681c_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfOS0zLTEtMS00MTc2OQ_97af8ebf-f6df-478d-a163-d27089cbe67f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb41f135273846d2a5abf0e5b9d0f811_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfMTAtMS0xLTEtNDE3NzU_b34dde6c-d988-4974-bddc-dc7c324ce227">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56b939a4e3604e77961f68608050b413_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfMTAtMy0xLTEtNDE3NzU_9883cebc-c659-4457-b602-0ea559e91394">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfNDE4OQ_9c6eb15b-6004-48f3-842c-e221cf3d6efc" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdceca8137604720b9dfc7e6e415d661_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfMi01LTEtMS0yNTczOQ_b28e0de5-efee-4e70-96c5-78f922118256">1,089,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i985f069de23b4373be549c007d2be40a_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfMi03LTEtMS0yNTczOQ_cd1d3c59-c1a7-43e6-8a0d-4f5189fb036f">752,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4c022e03b6b47659fb5320a00e0aff4_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfMi05LTEtMS0yNTczOQ_8b10bd5f-dc5a-40e5-8368-3ef08bdc4a99">770,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64d8b101cb28463dbafce9a36192a9ec_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfMy01LTEtMS0yNTczOQ_d5409cc4-7d04-4110-bfcb-4521549e9cd5">302,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c4a22039764f45bfeb541853e2006b_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfMy03LTEtMS0yNTczOQ_a9ea0cc1-a6e0-4952-ba90-1ba05ccaee53">151,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49d04f48075d4d9e9f242c365cff4b71_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfMy05LTEtMS0yNTczOQ_064d2c92-dfc9-4a96-9940-6078519e67ba">152,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2625931db6f641d1b8631cee45c5421e_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfNC01LTEtMS0yNTczOQ_25a64611-7d02-4ebd-a134-8d807fe84377">43,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3cfec9cb4d04224a58db1a0560d4779_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfNC03LTEtMS0yNTczOQ_ea71a971-2c1f-42e2-9f8b-92f8c558281a">83,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f60afd811e645cc996074e0cd13ebbc_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfNC05LTEtMS0yNTczOQ_96a77890-a4f4-4121-99a1-32ee3aa2ad0f">44,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfNS01LTEtMS0yNTczOQ_ba27ca9c-cbb3-46d9-a1d7-dd40a10addca">1,434,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfNS03LTEtMS0yNTczOQ_fdcb3b06-c9cb-4e0c-84be-bad62c53f0d5">987,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfNS05LTEtMS0yNTczOQ_cb4c7dec-8fa0-4c60-bbed-a7af5f5d0014">967,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i00885c3f7baa49c283994c2e90fdcd4b" continuedAt="i2967ea0c260f4d259a36746eee10066e"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfNDE5MA_a06f3eeb-f8e4-41f6-b460-f0953e5901c8" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2cf41534cf94f309749ad6b44872d98_I20200103" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMS0xLTEtMS0yNTczOQ_8cda6f4a-04c3-4c35-82a4-327a236e6dcc">7,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic57cbc70ed644ce9845fcfed669b497f_I20200103" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMS0zLTEtMS0yNTczOQ_0bf81d6a-73af-41c8-bcff-97dc31c1819d">3,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0df0a5ea74244280ad89970ab96c16ea_I20200103" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMS01LTEtMS0yNTczOQ_11b338b1-3d34-4163-8267-846bb0847d6f">15,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d03c75ce0024c01a62fcd27957b4f04_I20200103" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMS03LTEtMS0yNTczOQ_007350c7-a43f-4da3-a1a8-a65388eefb9b">26,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3769502a95e4f3684d2ef761cae6724_D20200104-20210101" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMy0xLTEtMS0yNTczOQ_eb375826-ad11-4810-b91d-887b1342b7aa">146,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief35aa55eff1427188342697996d37a8_D20200104-20210101" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMy0zLTEtMS0yNTczOQ_757ed7fb-44b4-4d81-b745-18e1e31edd8c">16,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6813dbf9b54533b3a13aa017eea398_D20200104-20210101" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMy01LTEtMS0yNTczOQ_88b71eb6-a231-43a8-87fa-3725711ce673">58,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMy03LTEtMS0yNTczOQ_b16763d3-f0b4-4cf5-a904-64f52f899569">220,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3769502a95e4f3684d2ef761cae6724_D20200104-20210101" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNC0xLTEtMS0yNTczOQ_a104c8ff-abfb-42c9-8ae6-6567cdcac9ba">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief35aa55eff1427188342697996d37a8_D20200104-20210101" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNC0zLTEtMS0yNTczOQ_1816f2f2-4897-4152-ba4f-f639b5ed78a9">352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6813dbf9b54533b3a13aa017eea398_D20200104-20210101" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNC01LTEtMS0yNTczOQ_17a1b369-48e6-4f25-a4a1-6e283b42e73b">612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNC03LTEtMS0yNTczOQ_9f436ddf-b5d6-4cf1-9dd2-01c96d35d569">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3769502a95e4f3684d2ef761cae6724_D20200104-20210101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNS0xLTEtMS0yNTczOQ_ba98845e-6eef-4578-b016-80ec078dfb2d">144,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief35aa55eff1427188342697996d37a8_D20200104-20210101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNS0zLTEtMS0yNTczOQ_d524a1a7-b468-4010-a5e4-53b1ad90f7f2">16,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d6813dbf9b54533b3a13aa017eea398_D20200104-20210101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNS01LTEtMS0yNTczOQ_a3fad96b-18d1-4d59-956e-c25d479d92a6">56,479</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNS03LTEtMS0yNTczOQ_adbdad9e-1c7f-4a2f-a955-55b2fc19a013">216,738</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib163363f39ee47a1982ba34ffc40df1c_I20210101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNi0xLTEtMS0yNTczOQ_d8952650-df2d-4f49-a937-74a72b9c70d0">9,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4afda954bcde4a2d8442e84ea5f75854_I20210101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNi0zLTEtMS0yNTczOQ_ce3d8e55-3667-4b99-91ce-0870413cc0ab">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08840e0ec9404f91bb1ed1e90793003e_I20210101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNi01LTEtMS0yNTczOQ_882d3af2-f7fe-4367-bf36-726dc6678a69">17,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNi03LTEtMS0yNTczOQ_96209a2b-16b9-4b18-af78-02ba704a154b">30,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i397c48f49ccd409781be83e43c34403b_D20210102-20211231" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOC0xLTEtMS0yNTczOQ_2a249ee7-ae25-4f2f-aa08-3060df1908be">243,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd2c26c82744565a4a050d7c6936320_D20210102-20211231" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOC0zLTEtMS0yNTczOQ_080ef138-ae83-4424-b62c-76649543b55a">30,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bf39a5ebec49a9b8c7c07b6ba5968f_D20210102-20211231" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOC01LTEtMS0yNTczOQ_445da589-e5a5-492a-940b-dddc7b642712">100,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOC03LTEtMS0yNTczOQ_6633008a-8f91-4478-bda4-c8554350c186">374,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i397c48f49ccd409781be83e43c34403b_D20210102-20211231" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOS0xLTEtMS0yNTczOQ_2063d1ba-a27a-42ae-81fc-d6783e47637f">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fd2c26c82744565a4a050d7c6936320_D20210102-20211231" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOS0zLTEtMS0yNTczOQ_57705240-d062-4592-a9b5-a7ca353f7412">111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bf39a5ebec49a9b8c7c07b6ba5968f_D20210102-20211231" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOS01LTEtMS0yNTczOQ_5f07217a-cbde-40af-8a1c-acab85cb8f50">1,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOS03LTEtMS0yNTczOQ_31e8f387-f66e-472b-9935-abdd61cc0a94">1,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i397c48f49ccd409781be83e43c34403b_D20210102-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTAtMS0xLTEtMjU3Mzk_3cf58799-39d5-4311-b4b9-bca50631379e">238,283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fd2c26c82744565a4a050d7c6936320_D20210102-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTAtMy0xLTEtMjU3Mzk_c8ebca88-ed14-48a3-946c-8beed679c45b">25,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4bf39a5ebec49a9b8c7c07b6ba5968f_D20210102-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTAtNS0xLTEtMjU3Mzk_0c209b4f-ee2e-4e6d-9f94-0d4c53d6d792">94,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTAtNy0xLTEtMjU3Mzk_fd463a2d-8462-4bcf-af36-f1cb75c9f64e">357,868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3093413adbae48879b92be020f6b4f95_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTEtMS0xLTEtMjU3Mzk_e795381b-061b-4b02-b370-8e1eaaaa8bc9">14,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i759ddcce81f44cffa575713b1c443bd0_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTEtMy0xLTEtMjU3Mzk_f45f3a24-ad03-4a2b-bfa7-93e7890a7da6">8,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de04499606844f9a42cd833027456e2_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTEtNS0xLTEtMjU3Mzk_ab5a902f-e532-4319-a95b-97f78cb7439d">24,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTEtNy0xLTEtMjU3Mzk_b582cd15-5aa8-49f9-9d69-eabc67db0397">48,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Contract assets as of December&#160;31, 2021 are primarily related to contract assets from Ipsen Pharma SAS (Ipsen) and c</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ontract liabilities as of </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfNDE5MQ_40beb6d0-f808-40da-aa99-f27622828759" continuedAt="ia4b2487cee3945edbd5be6551f0044c9" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfMi0xLTEtMS0yNTczOQ_6f0f0aab-6b98-4585-9b5a-c0121bf68510">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfMi0zLTEtMS0yNTczOQ_e081fd4e-eae9-4262-9ce3-a4b97adbec13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfNS0xLTEtMS0yNTczOQ_3021528c-8e79-40b2-811c-86c36d0c1ed8">7,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfNS0zLTEtMS0yNTczOQ_8c11ea6b-ed51-4593-a087-3064abf83b69">1,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfNi0xLTEtMS0yNTczOQ_ca131d4e-05ca-4266-aeb0-9352a2227368">8,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfNi0zLTEtMS0yNTczOQ_d3a12f0b-22d9-497c-b79d-2281e944bb51">3,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfNy0xLTEtMS0yNTczOQ_d066e0b3-9496-42ea-97ec-9442c18b0a60">16,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfNy0zLTEtMS0yNTczOQ_21686083-358b-4956-8aee-4ea6da590ab8">5,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Presented in other long-term assets in the accompanying Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets.</span></div></ix:nonNumeric><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ia4b2487cee3945edbd5be6551f0044c9">(3)&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.</ix:continuation> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="i2967ea0c260f4d259a36746eee10066e"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020 and 2019, we recognized $<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzMwOA_daae3495-e660-43d4-aae3-c80f64771952">8.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzMxMg_7e08d216-04b4-4e33-b047-a6202eee833a">9.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzMxOQ_5fa24314-b2d6-4d76-a84f-da489a50b632">6.5</ix:nonFraction> million, respectively, in revenues that were included in the beginning deferred revenues balance for those years. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2021, 2020 and 2019, we recognized $<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzQ3OQ_7033d39d-cef5-4ada-a50d-eeb41b84f675">148.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzQ4Mw_60197d4e-3fe7-45a4-a9b6-9538eee16c12">169.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzQ5MA_02383aac-3c6d-40c6-b44e-03cf8b21c9c0">161.2</ix:nonFraction> million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to milestone and royalty payments allocated to our license performance obligations for our collaborations with Ipsen Pharma SAS (Ipsen), Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzc4Mg_8cb3f766-db17-4d50-9db6-45bd2f9e9170">87.5</ix:nonFraction> million of the combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements&#8212; Cabozantinib Collaborations &#8212;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; for additional information about the expected timing to satisfy these performance obligations.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMzg1NTI_ab8b01dc-ee38-4de5-a938-69409ab487cf" continuedAt="icd8602d87a4b474085d9852fc9858add" escape="true">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="icd8602d87a4b474085d9852fc9858add" continuedAt="i5c991b67794649dda77bfbc4fb7d8d71"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading biopharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have made considerable progress under our existing research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading biopharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, to receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. See &#8220;Note 2. Revenues&#8221; for additional information on revenues recognized under our collaboration agreements during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, Ipsen opted into and is now co-funding the development costs for COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with RAI-refractory DTC who have progressed after up to two VEGF receptor-targeted therapies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ipsen </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s now obligated to reimburse us for their share of COSMIC-311 global development costs, as well as an additional payment calculated as a percentage of such costs, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">triggered by the timing of the exercise of its option. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the decision to opt in and co-fund the development costs for COSMIC-311 represented a contract modification for additional distinct services at their standalone selling price and therefore was treated as a separate contract under Topic 606. Accordingly, collaboration services revenues for the year ended December&#160;31, 2021, includes a cumulative catch-up of $<ix:nonFraction unitRef="usd" contextRef="i7706be95a9254624abab7ee85d40a352_D20210102-20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNDM5ODA0NjYwMzAyNw_81d33703-1625-424e-a804-cdd4c9e96bc9">43.2</ix:nonFraction>&#160;million for Ipsen&#8217;s share of global development costs incurred since the beginning of the study and through the opt-in date.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (1) the expiration of patent claims related to cabozantinib, (2) the expiration of regulatory exclusivity covering cabozantinib or (3) <ix:nonNumeric contextRef="i17d251f0fc574727b702a0a5caffb000_D20210102-20211231" name="exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjI1Ng_1dc8ba26-9853-465e-86fd-3656cc5cb616">ten years</ix:nonNumeric> after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i5c991b67794649dda77bfbc4fb7d8d71" continuedAt="i1d68e611f018493b9a510c82d20e3426"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the FDA or European Medicines Agency (EMA) orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration under the Collaboration</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, we received aggregate upfront payments of $<ix:nonFraction unitRef="usd" contextRef="icf154a58f6564ff1becceb69660b10e2_D20160101-20161231" decimals="-5" name="exel:UpfrontPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNDA1MA_2a77414c-7386-4481-b54b-4a241807840a">210.0</ix:nonFraction> million from Ipsen in 2016. As of December&#160;31, 2021, we have achieved aggregate milestones of $<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-5" name="exel:MilestonePaymentsEarnedToDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNDEyNA_110d251b-b945-4267-9deb-60f00269c015">462.5</ix:nonFraction> million related to regulatory, development and sales-based threshold by Ipsen since the inception of the collaboration agreement, including $<ix:nonFraction unitRef="usd" contextRef="i17d251f0fc574727b702a0a5caffb000_D20210102-20211231" decimals="-5" name="exel:MilestonePaymentsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNDI1OQ_84212d65-2513-41bf-88a0-814a5accf04f">112.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6b9226f40009479393c872a6348134a4_D20200104-20210101" decimals="-5" name="exel:MilestonePaymentsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNDI2Mw_c69ee499-e791-4524-a55e-fc4936d34d36">20.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i63e4041671b44fd599695a551a6412e2_D20181229-20200103" decimals="-5" name="exel:MilestonePaymentsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NDQwMw_2d1ae6a5-b2f4-44e9-ac5e-26240c4dc6ac">55.0</ix:nonFraction> million in milestones achieved during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ief888e56632141638b8427491992f9d0_I20211231" decimals="-5" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNDQ4MA_036b1387-6264-43b7-998a-030bef089eb3">46.5</ix:nonFraction> million, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $<ix:nonFraction unitRef="usd" contextRef="ief888e56632141638b8427491992f9d0_I20211231" decimals="-5" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NDQxMQ_05779994-adf0-4b56-90d4-9b548fd514e5">350.0</ix:nonFraction> million and CAD$<ix:nonFraction unitRef="cad" contextRef="ief888e56632141638b8427491992f9d0_I20211231" decimals="-5" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NDQyMQ_d921d854-6eca-4158-b615-949117f55320">26.5</ix:nonFraction> million. We excluded these milestones from the transaction price as of December&#160;31, 2021 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will adjust the constraint applied to the variable consideration at each reporting period as uncertain events are resolved or other changes in circumstances occur. As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="ief888e56632141638b8427491992f9d0_I20211231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNTA5MQ_35146024-96ca-4258-9954-e558cdde784a">44.2</ix:nonFraction> million of the transaction price allocated to our research and development services performance obligation had not been satisfied. See &#8220;&#8212;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221;, below, for additional information related to the revenue recognition for this collaboration.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receive royalty revenues on the net sales of cabozantinib by Ipsen outside of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he U.S. and Japan. During the year ended December&#160;31, 2021 and going forward, we are entitled to receive a tiered royalty of <ix:nonFraction unitRef="number" contextRef="id33282d755fe4cb187a33fa5ce4b49b5_D20210102-20211231" decimals="INF" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNTYxMA_f489aa67-f4e0-4d13-a62a-f12c774a173d">22</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i4bf5c222f64a420686d2836dfecb6b8a_D20210102-20211231" decimals="INF" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNTYxNg_956ba169-aceb-4944-bf82-49614a52433d">26</ix:nonFraction>% on annual net sales, with separate tiers for Canada; these royalty tiers reset each calendar year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay a <ix:nonFraction unitRef="number" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNjAwNw_be10e243-5402-4393-8922-bf4c0436cdb1">3</ix:nonFraction>% royalty on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for <ix:nonFraction unitRef="number" contextRef="i17d251f0fc574727b702a0a5caffb000_D20210102-20211231" decimals="2" name="exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNjM5Mg_eff1a6c6-b3e1-46c7-b655-e0a7de617ff3">35</ix:nonFraction>% of such costs, provided Ipsen chooses to opt into such trials. Ipsen has opted into and is co-funding certain clinical trials, including: CheckMate -9ER, COSMIC-021, COSMIC-311, COSMIC-312, CONTACT-01 and CONTACT-02.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Relatedly, we entered into a supply agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product is supplied at our cost, as defined in the agreement.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i1d68e611f018493b9a510c82d20e3426" continuedAt="i8a50a6f95cd04b318ebd2269d9466f75"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from the Collaboration </span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMzg1NzY_2c4ef8c6-241b-4439-a98b-6904b24e36fa" continuedAt="i2aede1a36fee423bb2fdfffcebe34fd0" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9b091c2fe54910a111a558a4e92d80_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfMi01LTEtMS0yNTczOQ_1bfd73bb-de74-45d3-8aa2-ad12179cebb9">207,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i648d323ea30a42229de3c89c4cb186d1_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfMi03LTEtMS0yNTczOQ_706dad96-e620-4798-9e7b-9c85e8783fe6">93,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25f4e281d6f4588b0be1be89c974405_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfMi05LTEtMS0yNTczOQ_cd8ace9b-51f7-49e4-a7c5-a44de2a48d6e">117,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7706be95a9254624abab7ee85d40a352_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfMy01LTEtMS0yNTczOQ_34b652d2-4755-48a4-847d-6385f52c7729">94,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32003bccc214ae19d1adc2aa36ec6bc_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfMy03LTEtMS0yNTczOQ_9471515c-0795-4520-9bc3-65ded36f8992">58,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if22970cfc6004d70bfd9ff40c42079f6_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfMy05LTEtMS0yNTczOQ_a93c9613-b6f9-4e77-9a7b-a213e0e7b5a2">35,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d251f0fc574727b702a0a5caffb000_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfNC01LTEtMS0yNTczOQ_46a7d01d-00a6-4bd2-b74c-99c3278067e5">302,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b9226f40009479393c872a6348134a4_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfNC03LTEtMS0yNTczOQ_ad488190-c279-4606-b7de-e1f355381515">151,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e4041671b44fd599695a551a6412e2_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfNC05LTEtMS0yNTczOQ_2842d041-8e0f-4cdc-af61-901a9e35fb36">152,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues for the year ended December&#160;31, 2021 included $<ix:nonFraction unitRef="usd" contextRef="ief888e56632141638b8427491992f9d0_I20211231" decimals="-5" name="exel:RevenueFromContractWithCustomerCommercialSalesMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUwOTg0OQ_8b9a9d94-3a31-465a-810e-67e9c7e9b82b">100.0</ix:nonFraction> million related to a commercial sales milestone from Ipsen upon their achievement of $<ix:nonFraction unitRef="usd" contextRef="ief888e56632141638b8427491992f9d0_I20211231" decimals="-5" name="exel:RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUwOTg1Ng_708c507e-6d29-449b-a4f1-918d2354e4ac">400.0</ix:nonFraction> million of net sales of cabozantinib in the related Ipsen license territory over four consecutive quarters and a $<ix:nonFraction unitRef="usd" contextRef="ief888e56632141638b8427491992f9d0_I20211231" decimals="-5" name="exel:RevenueFromContractWithCustomerRegulatoryMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NjQwMw_e161a1ff-e361-410e-bf7d-a493e7904b98">12.5</ix:nonFraction> million regulatory milestone achieved upon submission of a variation application to the EMA for CABOMETYX as a treatment for patients with previously treated RAI-refractory DTC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018, May 2019 and September 2020, to, among other things, modify the amount of reimbursements we receive, for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive, as well as modify certain cost-sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02. We determined the amendment in September 2020 represented a contract modification that was treated as a termination of an existing contract and the creation of a new contract under Topic 606. As a result, we allocated the remaining transaction price to the performance obligations identified in the contract. The two remaining performance obligations are the research and development services associated with committed studies and the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. In allocating the transaction price for the modified contract we estimated the standalone selling price for the performance obligations. We utilized development costs incurred for these obligations in process and the projections of costs through the term of the arrangement. Revenue is recognized when, or as, we satisfy our performance obligations by transferring the promised services to Takeda. Revenue is being recognized using the cost proportional performance method, based on costs incurred to perform the research and development services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda is responsible for a portion of the costs associated with the cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and <ix:nonFraction unitRef="number" contextRef="i34b71d32c3af4d2c99a249ce89216823_D20210102-20211231" decimals="INF" name="exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTE1Mw_32104c94-2254-4d97-966d-464d376bf42d">100</ix:nonFraction>% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Takeda has opted into and is co-funding CheckMate -9ER, certain cohorts of COSMIC-021, CONTACT-01 and CONTACT-02. Under the collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (1) <ix:nonNumeric contextRef="i34b71d32c3af4d2c99a249ce89216823_D20210102-20211231" name="exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTAwMTE_e0185446-7d9d-45ff-95cf-5dd00095c145">two years</ix:nonNumeric> after first generic entry with respect to such product in Japan or (2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first <ix:nonNumeric contextRef="idf4b8b36a8a1401ba536bf1da7af7544_D20210102-20211231" name="exel:PeriodOfSpecificSalesVolumeThreshold" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTA1NzA_2f8c737d-e1d5-4a27-b269-1842cbb7fefb">six years</ix:nonNumeric> of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i8a50a6f95cd04b318ebd2269d9466f75" continuedAt="if8b584a56a4f4e7185df40ebf649d074"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration under the Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i38b1163356184b27816cbad77cdf95c1_D20170101-20171231" decimals="-5" name="exel:UpfrontPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTEzOTU_ba87c100-80fb-4272-819f-7e03653757af">50.0</ix:nonFraction> million from Takeda in 2017. As of December&#160;31, 2021, we have also achieved regulatory and development milestones in the aggregate of $<ix:nonFraction unitRef="usd" contextRef="i1538f2b66fd943739c868b40f8b82675_I20211231" decimals="-5" name="exel:MilestonePaymentsEarnedToDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTE1MDk_a8cf5406-1c4a-49f0-a99f-8163474c111f">127.0</ix:nonFraction> million since the inception of the collaboration agreement, including $<ix:nonFraction unitRef="usd" contextRef="idf4b8b36a8a1401ba536bf1da7af7544_D20210102-20211231" decimals="-5" name="exel:MilestonePaymentsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTE1NzQ_83c2f2c2-601b-43ac-bd1b-5047f569656c">35.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i942a6148cba44afbb7ce565e8f31caa4_D20200104-20210101" decimals="-5" name="exel:MilestonePaymentsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTE1Nzg_a5d20a02-89c4-4591-8184-6a1812ac9c2a">66.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3d7a173be1fe468581278e8058aaa8ce_D20181229-20200103" decimals="-5" name="exel:MilestonePaymentsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NDQ0OQ_f1e84ccd-0168-4daa-b273-92b557e0b43d">16.0</ix:nonFraction> million in milestones achieved during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, as amended in 2020, we are eligible to receive additional regulatory and development milestone payments, without contractual limit, for additional potential future indications. We are further eligible to receive commercial milestones, including milestone payments earned for the first commercial sale of a product, of up to $<ix:nonFraction unitRef="usd" contextRef="i1538f2b66fd943739c868b40f8b82675_I20211231" decimals="-5" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTIyNDY_f6318d70-da7a-4a6e-8656-81714c59bc48">119.0</ix:nonFraction> million. We excluded these milestones from the transaction price as of December&#160;31, 2021 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will adjust the constraint applied to the variable consideration at each reporting period as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also receive royalty revenues on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of <ix:nonFraction unitRef="number" contextRef="ic3c4c0bb7d7c4d5ca6fcc41491abf1d5_D20210102-20211231" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTI4NDA_130eaf6e-66fa-4ad0-afd0-acffe1aceb85">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6c892d9cb5bb4832a7807f3de3873c13_D20210102-20211231" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTI4NDY_d46cc5de-0477-4606-a2aa-316c2bdb89c7">24</ix:nonFraction>% on the initial $<ix:nonFraction unitRef="usd" contextRef="i7de05268deff4e19bf1b0d6402584ef5_D20210102-20211231" decimals="-5" name="exel:RoyaltyTier" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTI4NjQ_b9c15334-c153-45f0-b7ad-77c3cda897a1">300.0</ix:nonFraction>&#160;million of net sales, and following this initial $<ix:nonFraction unitRef="usd" contextRef="i7de05268deff4e19bf1b0d6402584ef5_D20210102-20211231" decimals="-5" name="exel:RoyaltyTier" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTI5MDg_77094316-e2f2-4667-94f5-c432dfdb9484">300.0</ix:nonFraction>&#160;million of net sales, we are then entitled to receive a tiered royalty of <ix:nonFraction unitRef="number" contextRef="ia18f9c05acb24284aaefe29c49159029_D20210102-20211231" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTI5Nzc_11759e8a-8459-4811-bb44-e06dad689684">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i9d5c9f1076cb460cb26ed364b3298866_D20210102-20211231" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTI5ODM_ca04499a-1392-42be-a726-c4ba2bdbc791">30</ix:nonFraction>% on annual net sales thereafter; these <ix:nonFraction unitRef="number" contextRef="ia18f9c05acb24284aaefe29c49159029_D20210102-20211231" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTMwMjQ_1455ea66-a5cb-4780-83b1-e9bf106ad58e">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i9d5c9f1076cb460cb26ed364b3298866_D20210102-20211231" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTMwMzA_31673828-4d04-40b5-a317-afb6e5b57952">30</ix:nonFraction>% royalty tiers reset each calendar year. Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay a <ix:nonFraction unitRef="number" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTMzNjI_be10e243-5402-4393-8922-bf4c0436cdb1">3</ix:nonFraction>% royalty on all net sales of any product incorporating cabozantinib, including net sales by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Additionally, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#8217;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from the Collaboration</span></div><ix:continuation id="i2aede1a36fee423bb2fdfffcebe34fd0"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80cf15e8b90b415da4f4ddf22cf5de86_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfMi01LTEtMS0yNTczOQ_f6c07c3a-e819-46cc-9796-831ed9d331d7">26,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7549b7123a984430b1eeb8ed0453f49d_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfMi03LTEtMS0yNTczOQ_a6b20100-802c-4899-89b7-cadd39fc928a">61,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bbf116ba95d4f99b046b08cf6886f20_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfMi05LTEtMS0yNTczOQ_d642c015-e4fa-4ba4-9a5a-12ac83adae54">18,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88285abefe55431da86d133798712f97_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfMy01LTEtMS0yNTczOQ_cd223be8-b81a-4e25-85e6-0d2be5b71971">13,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa84e1a7dfa4fe394d99b30db90a03d_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfMy03LTEtMS0yNTczOQ_65f5cf5f-5f93-4fc6-a362-c18bf882e77a">20,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i323181841f1447e19487c305609f6987_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfMy05LTEtMS0yNTczOQ_bb5f79cc-1d0b-4193-9c9a-2cad2abf8f15">6,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf4b8b36a8a1401ba536bf1da7af7544_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfNC01LTEtMS0yNTczOQ_0554db00-c98f-486a-bdec-8371ab4a8045">39,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i942a6148cba44afbb7ce565e8f31caa4_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfNC03LTEtMS0yNTczOQ_6c2fc843-013b-4614-80e8-5a277ef42bf9">81,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d7a173be1fe468581278e8058aaa8ce_D20181229-20200103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfNC05LTEtMS0yNTczOQ_da127449-4380-40d1-b9dd-77241b29ba82">24,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues for the year ended December&#160;31, 2021 included $<ix:nonFraction unitRef="usd" contextRef="idf4b8b36a8a1401ba536bf1da7af7544_D20210102-20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NjY5Nw_ad5af46f-7612-43d8-a077-8467d8bdfc3e">18.9</ix:nonFraction>&#160;million recognized in connection with a $<ix:nonFraction unitRef="usd" contextRef="i1538f2b66fd943739c868b40f8b82675_I20211231" decimals="-5" name="exel:RevenueFromContractWithCustomerCommercialSalesMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NjcwNg_4fa19c6a-3884-408a-befe-e543e8ef661b">20.0</ix:nonFraction>&#160;million milestone we achieved upon Takeda&#8217;s first commercial sale in Japan of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable, advanced or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i1538f2b66fd943739c868b40f8b82675_I20211231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTQ2NDU_14900b7c-d960-4062-b8a8-ac89fef3f26e">43.3</ix:nonFraction>&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified two performance obligations for the Ipsen collaboration agreement: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib; and (2) research and development services, </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="if8b584a56a4f4e7185df40ebf649d074" continuedAt="i14ee07cf1acb4187825b0c77a675a777"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified two remaining performance obligations for the Takeda collaboration agreement due to the amendment in September 2020: (1) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements) and (2) the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. As part of the original contract, we had a performance obligation associated with the exclusive license for the commercialization and further development of cabozantinib, which was transferred in 2017.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have allocated the transaction price for each of these collaborations to the identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and costs. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of the transaction price allocated to our license performance obligation is recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union for the Ipsen Collaboration and Japan for the Takeda Collaboration, both of which are early 2030. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust the constraint applied to the variable consideration for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the years ended December&#160;31, 2021, 2020 and 2019, the transaction price of the Ipsen and Takeda collaboration agreements increased as a result of the achievement of various milestones, and the reimbursements of research and development services related to committed and opt-in studies. We further updated the transaction price based upon the actual research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of December&#160;31, 2021, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Development Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BMS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab as a treatment option for RCC in the COSMIC-313 trial. Under the collaboration agreement with BMS, we may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement with BMS, as subsequently amended effective March 2019, May 2019 and November 2019, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial is conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party is responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each such trial will be determined on a trial-by-trial basis. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i14ee07cf1acb4187825b0c77a675a777" continuedAt="i85f6284c622e43e88a18416f55d77dcd"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">F. Hoffmann-La Roche Ltd. (Roche) Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Under this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, and in December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, including in the phase 3 pivotal clinical trials in advanced non-small cell lung cancer (CONTACT-01), metastatic castration-resistant prostate cancer (CONTACT-02) and RCC (CONTACT-03). If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond these phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, a supplement to the joint clinical research agreement was signed amongst us, Roche and Takeda due to Takeda opting into fund the combined therapy trial of CONTACT-01 sponsored by Roche. Chugai was added as an affiliate of Roche.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All parties including Chugai conduct combined therapy trials in Japan upon the terms of the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#8217;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#8217; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply of their drug for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the contract is within the scope of Topic 808 as it involves joint operating activities where both parties have active participation in the arrangement and are exposed to significant risks and rewards. Payments between us and Roche under this arrangement are not subject to other accounting literature. Payments due to Roche for our share of clinical trial costs incurred by Roche will be recorded as research and development expense and payments due from Roche for their share of clinical trial costs incurred by us will be recorded as a reduction of research and development expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i85f6284c622e43e88a18416f55d77dcd" continuedAt="idea3ad0207414335a507aa01608959e6"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK and Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GSK, that required us to pay a <ix:nonFraction unitRef="number" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5ODMzNg_be10e243-5402-4393-8922-bf4c0436cdb1">3</ix:nonFraction>% royalty to GSK on the total worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. As disclosed in Note 2, we received notification that, effective January 1, 2021, Royalty Pharma acquired from GSK all rights, title and interest in royalties on total net sales of any product containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalty revenues earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalty revenues were $<ix:nonFraction unitRef="usd" contextRef="i8c3ac03ee7454b6cac8c397afd4482c4_D20210102-20211231" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjYyOTE_887ea585-d8f2-48b4-9cac-3f9e1fc69218">46.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i40846f2291b646d0925baa2444ab430c_D20200104-20210101" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjYyOTU_fc8f3dac-f31f-40b1-b5cc-e20c188825a5">32.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id1f0fc047c9c4e42b491251f2246216c_D20181229-20200103" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjYzMDI_39d7eee5-283b-445f-88a4-5881ce0c1fb5">31.3</ix:nonFraction> million during the years ended December&#160;31, 2021, 2020 and 2019, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have out-licensed to Genentech under a worldwide collaboration agreement, the development and commercialization of cobimetinib, under the brand name COTELLIC. The terms of the collaboration agreement require that we share in the profits and losses received or incurred in connection with the commercialization of COTELLIC in the U.S. In addition to our profit share in the U.S., we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020, and 2019, we recognized $<ix:nonFraction unitRef="usd" contextRef="i52b8f7772fdd4b28b6761a4c19816e52_D20210102-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUxNDIwNQ_0157a15e-e8b5-407c-a329-b8c6200369a8">12.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2ae90a8873dd4429b24fbecb4ac765cc_D20200104-20210101" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUxNDE2OQ_edb8e951-b223-4f1e-b8df-1df11c9aa825">11.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ib5410770ddf84f099461a42667531965_D20181229-20200103" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUxNDE4OA_eb248088-e1cb-4857-8af0-5ea4995bcd89">10.3</ix:nonFraction> million, in revenues from profits and losses on U.S commercialization and royalties on ex-U.S. sales under the collaboration agreement with Genentech and are included within license revenues on our Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. In January 2019, the Japanese Ministry of Health, Labour and Welfare approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have achieved milestones of $<ix:nonFraction unitRef="usd" contextRef="i7c1a218589024464b368812dcad02030_D20181229-20200103" decimals="-5" name="exel:CollaborativeArrangementAchievedMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzMyMTU0OA_e30a3398-aa65-4c30-abfd-365a2727b20e">20.0</ix:nonFraction>&#160;million for the year ended December&#160;31, 2019 for the first commercial sale of MINNEBRO and are eligible to receive additional sales-based milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i719737a56e4940dbaa44028a2131e87c_I20211231" decimals="INF" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMzAzOTg_3ed4007f-473f-42f0-a7f5-7cf1ae955d61">90.0</ix:nonFraction> million under this collaboration agreement. In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue under the collaboration agreement with Daiichi Sankyo w</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as $<ix:nonFraction unitRef="usd" contextRef="i17469019aafd4e60b3681951461b5e32_D20210102-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzMyMTY5OA_0f45fe3e-e122-48bc-8079-b315c5a6a5a4">3.8</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i248a08fc00de455a8ba90662b6913cf3_D20200104-20210101" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzMyMTY4Mg_44406912-8ea7-4433-a096-aa4dee20c405">1.3</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $<ix:nonFraction unitRef="usd" contextRef="i7c1a218589024464b368812dcad02030_D20181229-20200103" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzMyMTcwOA_af45bced-0553-4ff6-bb27-bfb59cd95025">20.1</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into collaborative arrangements with other pharmaceutical or biotechnology companies to develop and commercialize drug candidates or intellectual property. Our research collaborations and in-licensing arrangements are intended to enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, development, regulatory, commercial milestone payments and royalty payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then assume the responsibilities for all subsequent clinical development, manufacturing and commercialization. In conjunction with each of these collaborative in-licensing arrangements, we were subject to upfront payments and will make payments for potential future development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i845d978e80a94a059981545b4eaedc37_I20211231" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUyODk2OA_dce34e8e-90ad-4b26-9ace-81e0aee596a0">254.3</ix:nonFraction>&#160;million, regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i845d978e80a94a059981545b4eaedc37_I20211231" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUyODk5MA_5d367b47-8a74-4f87-ab3e-3f4cd2c3eade">426.5</ix:nonFraction>&#160;million and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i845d978e80a94a059981545b4eaedc37_I20211231" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUyOTAxMQ_fda5f99c-8c6f-48ef-a82c-c3d5903f751e">1,911.5</ix:nonFraction>&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales. In conjunction with an asset purchase agreement, we made payments of $<ix:nonFraction unitRef="usd" contextRef="i2b021f45a0fa49c89d6035c19eaadbb3_D20210501-20210531" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTM0NTg0ODk2NTEwMw_ce3bd48e-9a9b-4a7c-bd76-9e953cdb0766">10.0</ix:nonFraction>&#160;million for the initial technology transfer, and subject to certain conditions, will make a $<ix:nonFraction unitRef="usd" contextRef="i80195f3436714ec884ca333c40f2ee26_I20210531" decimals="-5" name="exel:AssetAcquisitionPaymentUponClosingOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTM0NTg0ODk2NTExOA_7fd8dbdb-46c2-43b8-a382-871c72541ba5">4.0</ix:nonFraction>&#160;million payment upon the completion of the technology transfer of certain materials and documents specified in the asset purchase agreement. We will also make payments for potential future development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i80195f3436714ec884ca333c40f2ee26_I20210531" decimals="-5" name="exel:AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTM0NTg0ODk2NTEzMg_f8c467c6-28bc-4afd-a8a8-7bc42f14911f">42.0</ix:nonFraction>&#160;million and regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i80195f3436714ec884ca333c40f2ee26_I20210531" decimals="-5" name="exel:AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTM0NTg0ODk2NTE0Nw_3a89be01-efb3-4a9d-b842-acde54f567a7">22.5</ix:nonFraction>&#160;million, per product.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="idea3ad0207414335a507aa01608959e6"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we amended our collaboration agreement with Iconic to acquire broad rights to use the anti-TF antibody used in XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics. Under the amended agreement, we agreed to pay a final one-time payment to Iconic of $<ix:nonFraction unitRef="usd" contextRef="ia542815387ba453f9fd900fe25937400_D20211201-20211231" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsFinalPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTM0NTg0ODkyNjU0OQ_b846acd1-2430-46ef-b7fb-e3a65a5c17d7">55.0</ix:nonFraction>&#160;million and will not owe any further payments, but we will continue to be responsible for milestone payments and royalties owed to other companies pursuant to prior agreements between Iconic and those companies. Upon signing the amendment, we recognized $<ix:nonFraction unitRef="usd" contextRef="ia542815387ba453f9fd900fe25937400_D20211201-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTM0NTg0ODkyNjU2NA_56c166ca-b02f-4b3b-9902-73b399a2f5b4">55.0</ix:nonFraction>&#160;million in research and development expense, which amount was payable as of December 31, 2021 and presented in accrued collaboration liabilities in our Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020, and 2019, we recognized </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i839b859fbed548e38efc5fce9e64593a_D20210102-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUyOTA1OA_4a9064c1-e54c-4054-9b20-cc9a519d9555">176.1</ix:nonFraction>&#160;million,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ib5a2784ff7d840bb982a4bc7823f075a_D20200104-20210101" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUyOTA2MQ_5ed9a110-c976-4b58-b27e-b5f739d1246a">96.4</ix:nonFraction>&#160;million and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="iad9dc6f5753a41ed9d96d235cc5108ba_D20181229-20200103" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUyOTA2NA_23c89de0-cfa6-42f9-8c3c-0609844a8a1d">47.7</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, relating to upfront license payments, research and development funding, development milestones, option fees and other fees within research and development expenses on the Consolidated Statements of Income.</span></div></ix:continuation><div id="ib1dc779af6a3491c9aef59246f08fe04_91"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjI2NA_b55c9f48-cd0b-483f-84cb-eb2e6b021ac1" continuedAt="iaa80bf932d22498aa40ac5a50223fa49" escape="true">CASH AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="iaa80bf932d22498aa40ac5a50223fa49" continuedAt="i36265dde7d7d4c3da7764fc5f7b20065"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents</span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjI1NA_c55eb145-dc84-4c3a-b4c9-a1acdcc0935b" escape="true"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjI2NQ_0e558e71-bd49-40e8-ad72-96d0342961bf" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjYwNDEzMDZmZGE5ZjQyNjQ5ZjUwM2Q1MGVlOTQwM2UwL3RhYmxlcmFuZ2U6NjA0MTMwNmZkYTlmNDI2NDlmNTAzZDUwZWU5NDAzZTBfMi0xLTEtMS0yNTczOQ_1dfb53d8-3993-4513-a9e3-4fcf0bd6b409">647,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjYwNDEzMDZmZGE5ZjQyNjQ5ZjUwM2Q1MGVlOTQwM2UwL3RhYmxlcmFuZ2U6NjA0MTMwNmZkYTlmNDI2NDlmNTAzZDUwZWU5NDAzZTBfMi0zLTEtMS0yNTczOQ_56cb6928-3e6f-4dbc-8a16-e74ff4be9f4e">319,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjYwNDEzMDZmZGE5ZjQyNjQ5ZjUwM2Q1MGVlOTQwM2UwL3RhYmxlcmFuZ2U6NjA0MTMwNmZkYTlmNDI2NDlmNTAzZDUwZWU5NDAzZTBfNC0xLTEtMS0yNTczOQ_35eb06ba-6baa-4051-906d-c54444bf92b4">16,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjYwNDEzMDZmZGE5ZjQyNjQ5ZjUwM2Q1MGVlOTQwM2UwL3RhYmxlcmFuZ2U6NjA0MTMwNmZkYTlmNDI2NDlmNTAzZDUwZWU5NDAzZTBfNC0zLTEtMS0yNTczOQ_2f007c27-94a1-4b54-9222-392ae79e999d">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjYwNDEzMDZmZGE5ZjQyNjQ5ZjUwM2Q1MGVlOTQwM2UwL3RhYmxlcmFuZ2U6NjA0MTMwNmZkYTlmNDI2NDlmNTAzZDUwZWU5NDAzZTBfNS0xLTEtMS0yNTczOQ_fd388c80-a10f-49ba-a4b3-c60734104b9d">663,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjYwNDEzMDZmZGE5ZjQyNjQ5ZjUwM2Q1MGVlOTQwM2UwL3RhYmxlcmFuZ2U6NjA0MTMwNmZkYTlmNDI2NDlmNTAzZDUwZWU5NDAzZTBfNS0zLTEtMS0yNTczOQ_03306313-354a-4f47-9835-5262fa016aba">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of December&#160;31, 2021, restricted cash equivalents included $<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-5" name="us-gaap:RestrictedCashEquivalentsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMTY0OTI2NzQ0NDA3NA_fb7af98d-924a-4b74-997a-6822f3e39066">15.2</ix:nonFraction> million of short-term investments, which is collateral under our January 2021 standby letter of credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investment</span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjI3Mw_3b872c3a-d7dc-4e40-8fbe-f1437b3c0034" continuedAt="i57a08c4d85d7418fabb8dce41c77d644" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05641e68bc9f435c9afd7cdec45e36aa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMy0xLTEtMS0yNTczOQ_801142b0-935b-44ea-adc3-0966e28c1283">945,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05641e68bc9f435c9afd7cdec45e36aa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMy0zLTEtMS0yNTczOQ_abb812ed-b5dd-4dbf-8be2-ed0884749da0">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05641e68bc9f435c9afd7cdec45e36aa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMy01LTEtMS0yNTczOQ_c5c88b1b-ab20-43bf-8e8c-d5a21829dbf9">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05641e68bc9f435c9afd7cdec45e36aa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMy03LTEtMS0yNTczOQ_2ac6f97b-4ec2-45bf-b3b3-7276948dbe12">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff13830445e478385149192df956f88_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNC0xLTEtMS0yNTczOQ_e5d21e5f-33cc-4ad8-aab9-c987cd9d97a9">541,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff13830445e478385149192df956f88_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNC0zLTEtMS0yNTczOQ_5d344eed-dc5e-4d4d-a82e-5cc2516eb296">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ff13830445e478385149192df956f88_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNC01LTEtMS0yNTczOQ_c392538b-d9b8-4075-8129-e89abf29234b">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff13830445e478385149192df956f88_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNC03LTEtMS0yNTczOQ_e86e36f6-e0d4-46c7-8518-268319693fcc">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNS0xLTEtMS0yNTczOQ_2fd98055-8a58-4e9c-b258-20b60be415e8">33,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNS0zLTEtMS0yNTczOQ_5ccb3dc2-04df-4680-95e6-ceb47089e43a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNS01LTEtMS0yNTczOQ_5cd5418c-6adb-428c-9161-884452b643c0">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNS03LTEtMS0yNTczOQ_aaeea0bc-be76-40ff-a395-1ccb7b542b60">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bea1dd75274b42a74758ecc6636623_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNi0xLTEtMS0yNTczOQ_50b4c5f3-9626-47d4-b3e1-4d7d46933f90">12,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bea1dd75274b42a74758ecc6636623_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNi0zLTEtMS0yNTczOQ_310fe16c-5432-4800-a7b0-a83a49d82c4b">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23bea1dd75274b42a74758ecc6636623_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNi01LTEtMS0yNTczOQ_7cb95608-c818-4f8e-9271-684c6b5a7b26">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bea1dd75274b42a74758ecc6636623_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNi03LTEtMS0yNTczOQ_eb566ba9-92f9-4749-9e21-6f511752de38">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNy0xLTEtMS0yNTczOQ_9c8a523b-6f4e-4482-9efd-b92880360ff3">1,534,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNy0zLTEtMS0yNTczOQ_0493851b-51c5-4b8f-a66d-9e10ba828ed2">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNy01LTEtMS0yNTczOQ_f270e733-2986-491d-8f10-1bc0015a1ac7">1,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNy03LTEtMS0yNTczOQ_da77f391-9687-44b2-9d29-6828cad70771">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a61bcc4c3649f59f6a080941f4f893_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOC0xLTEtMS0yNTczOQ_19df3ce2-7283-457e-afe4-dc6b4f3bef4e">135,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a61bcc4c3649f59f6a080941f4f893_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOC0zLTEtMS0yNTczOQ_433f0e02-97de-4a60-944f-53440f1fed8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a61bcc4c3649f59f6a080941f4f893_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOC01LTEtMS0yNTczOQ_bd162880-ce1d-43bd-a866-c06323ccf485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a61bcc4c3649f59f6a080941f4f893_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOC03LTEtMS0yNTczOQ_d421a32c-52c9-495e-967e-8eb91084df74">135,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64b739b318847c59da0eae266f9d1f3_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOS0xLTEtMS0yNTczOQ_0bf224e2-d668-4ca9-af82-9a344ae01570">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64b739b318847c59da0eae266f9d1f3_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOS0zLTEtMS0yNTczOQ_62eacf0e-d08e-4cd7-8591-f4a40ec68adc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64b739b318847c59da0eae266f9d1f3_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOS01LTEtMS0yNTczOQ_5db4a0f6-d918-4af3-a227-14dd4c3ba4c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64b739b318847c59da0eae266f9d1f3_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOS03LTEtMS0yNTczOQ_41750981-cb63-47f8-af86-3445ae164ea6">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a311ca42562471db4f27e25d6d36db3_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTAtMS0xLTEtMjU3Mzk_cb0351cd-3077-490a-b9b7-4e06e42484a6">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a311ca42562471db4f27e25d6d36db3_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTAtMy0xLTEtMjU3Mzk_f9de7242-ad2f-4470-95c2-1ce90b71bba3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a311ca42562471db4f27e25d6d36db3_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTAtNS0xLTEtMjU3Mzk_21b80362-3447-4d26-a57c-0cd921307a3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a311ca42562471db4f27e25d6d36db3_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTAtNy0xLTEtMjU3Mzk_5a35f522-bc33-4a9a-bf3f-491a300c9b2d">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTEtMS0xLTEtMjU3Mzk_934abce3-29a8-4eac-8380-005c13ef7960">1,855,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTEtMy0xLTEtMjU3Mzk_3e5ce290-13ec-4665-950b-d1fa4a66f757">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTEtNS0xLTEtMjU3Mzk_037f9b22-03dc-4180-a4fc-b7dac70bf1c5">1,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTEtNy0xLTEtMjU3Mzk_154cf489-2816-4e4c-8113-aad7de4d7bb0">1,854,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i36265dde7d7d4c3da7764fc5f7b20065" continuedAt="i9da32229fccf4890bbaaaa4cc51768b2"><div style="margin-top:9pt;text-align:center"><ix:continuation id="i57a08c4d85d7418fabb8dce41c77d644"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602bcc576371462380cb7add7c08ac3a_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMy0xLTEtMS0yNTczOQ_f5e83414-7070-4996-9b1d-64d49d66b7d6">569,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602bcc576371462380cb7add7c08ac3a_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMy0zLTEtMS0yNTczOQ_2a39a544-459b-48e3-bc10-17e77534b18d">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602bcc576371462380cb7add7c08ac3a_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMy01LTEtMS0yNTczOQ_88a032cc-5449-4c20-9046-b00cf0fb6d23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602bcc576371462380cb7add7c08ac3a_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMy03LTEtMS0yNTczOQ_18b59206-1090-4ee1-8948-3359b694eeea">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNC0xLTEtMS0yNTczOQ_89aaa9e6-7a77-4f57-9453-d9a4cdcc3ef0">543,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNC0zLTEtMS0yNTczOQ_c4dbae42-52bd-4ff7-a202-a46d75dc22fc">5,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNC01LTEtMS0yNTczOQ_a728d4c8-ddf5-49c6-9745-cc93d98aada5">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNC03LTEtMS0yNTczOQ_c46a9a15-1d11-4574-9d9e-4e34cab34a9d">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba29b67627794a5d9e0a76791c683b2e_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS0xLTEtMS0yODgyMw_80b62a8b-ad75-4f06-aed5-2c3a2d95b2c8">208,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba29b67627794a5d9e0a76791c683b2e_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS0zLTEtMS0yODgyOA_f9de3a2f-b6b2-4ae1-9128-b71ad9da083b">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba29b67627794a5d9e0a76791c683b2e_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS01LTEtMS0yODgzMA_0305aa8e-f4c7-498f-98d5-f64210af976e">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba29b67627794a5d9e0a76791c683b2e_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS03LTEtMS0zNzQ0NA_d29004d3-da3b-4a3c-9c2d-6a5c272d0ae5">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59895032150e486295f216709b152e49_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS0xLTEtMS0yNTczOQ_1cc839f1-eb98-49b8-97c3-634041eb5e0b">28,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59895032150e486295f216709b152e49_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS0zLTEtMS0yNTczOQ_0055c7ae-bfcb-412a-9001-f01a3ea4e2b2">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59895032150e486295f216709b152e49_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS01LTEtMS0yNTczOQ_69362d3e-72ec-494c-957f-7bd22e88daa6">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59895032150e486295f216709b152e49_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS03LTEtMS0yNTczOQ_548f33a3-4cda-4e17-867f-708a3cd33696">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNi0xLTEtMS0yNTczOQ_99f6bb5b-e8f1-4595-bc70-36e083474555">1,349,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNi0zLTEtMS0yNTczOQ_d015db6c-5adf-4998-96bb-68bcf3720f11">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNi01LTEtMS0yNTczOQ_1cfc59c5-140c-4417-bc68-41e288ab2a95">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNi03LTEtMS0yNTczOQ_c7ece3ad-00f8-46e4-ac62-75b03963f7b5">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8be401936c61402c92d2967c8b58ca3b_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNy0xLTEtMS0yNTczOQ_e7bc631f-bb22-4483-8584-d59fdf8f7dad">82,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8be401936c61402c92d2967c8b58ca3b_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNy0zLTEtMS0yNTczOQ_8b85de3d-5892-40e0-9f59-a90f64546250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8be401936c61402c92d2967c8b58ca3b_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNy01LTEtMS0yNTczOQ_92439379-1afc-4dcc-a263-61387c15c999">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8be401936c61402c92d2967c8b58ca3b_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNy03LTEtMS0yNTczOQ_f27a8792-0f51-4d0d-991f-5015f46ca045">82,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1391eefb1148f5911a99610fca2132_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOC0xLTEtMS0yNTczOQ_f2bcdfc1-7c21-4779-a776-331553a04f84">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1391eefb1148f5911a99610fca2132_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOC0zLTEtMS0yNTczOQ_f61523cc-a891-4ce3-bef5-818ac8d4ccfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1391eefb1148f5911a99610fca2132_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOC01LTEtMS0yNTczOQ_3a346472-560d-445e-8d34-70aca3b504d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1391eefb1148f5911a99610fca2132_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOC03LTEtMS0yNTczOQ_fb2ebd49-6a98-4f55-80b8-ccbd01a26e1e">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2243e5b1033e41bfa89446b83583a6e5_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOS0xLTEtMS0yNTczOQ_09fcaa36-58bd-4ca5-810f-c9528d9662da">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2243e5b1033e41bfa89446b83583a6e5_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOS0zLTEtMS0yNTczOQ_55f4cb0a-d71a-4ed7-8124-b9ae59b1f78d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2243e5b1033e41bfa89446b83583a6e5_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOS01LTEtMS0yNTczOQ_9d172530-1cbc-454b-adc8-c383419a4374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2243e5b1033e41bfa89446b83583a6e5_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOS03LTEtMS0yNTczOQ_0a6c1274-f98c-4edf-bf96-1b4762619356">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMTAtMS0xLTEtMjU3Mzk_511c9a9b-f013-4020-9f5e-190a83bd52e3">1,532,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMTAtMy0xLTEtMjU3Mzk_1a5554fe-e4fa-45e4-8509-4d6a4cd4151a">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMTAtNS0xLTEtMjU3Mzk_b537a872-e6d6-4047-8374-78a8d43624d3">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMTAtNy0xLTEtMjU3Mzk_3d559598-0083-43e0-bcaf-a7d9e87557d8">1,538,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfNzcy_5cc3720c-6fe7-42f4-84da-c2af49db6bca">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfNzc5_f38c699e-f763-485e-81ed-cdaf7e55e2a8">4.5</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively, and is included in prepaid and other current assets in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjI2OA_812f488c-58a4-4123-be2a-1686903bbdfd" continuedAt="if1144597c10b4cc59f53bf7e86dc48ec" escape="true">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="if1144597c10b4cc59f53bf7e86dc48ec"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff13830445e478385149192df956f88_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfMy0xLTEtMS0yNTczOQ_f4ab5e43-4566-49a0-81d2-4bbc7da34b7f">385,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ff13830445e478385149192df956f88_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfMy0zLTEtMS0yNTczOQ_243724af-9943-428c-bc93-af78e09f80dd">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05641e68bc9f435c9afd7cdec45e36aa_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNC0xLTEtMS0zOTQ3Mg_22d4b1c5-d339-4e51-8126-075522e9887e">43,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05641e68bc9f435c9afd7cdec45e36aa_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNC0zLTEtMS0zOTQ3Mg_e8901ba2-7f89-46d7-8fa1-98e02c2c5c08">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNC0xLTEtMS0yNTczOQ_c3363991-4f61-4e80-af63-40da475ff5a0">18,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNC0zLTEtMS0yNTczOQ_97a7c9e7-5454-4e73-8731-4f349e5ed0d9">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bea1dd75274b42a74758ecc6636623_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNS0xLTEtMS0yNTczOQ_04b4997e-2702-4687-8f0d-cf9e9a950b38">7,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23bea1dd75274b42a74758ecc6636623_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNS0zLTEtMS0yNTczOQ_47dcf772-d3d6-4534-a658-a4bd88a7cc94">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNi0xLTEtMS0yNTczOQ_1e686174-fab5-4155-8362-e525ff17ab80">454,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNi0zLTEtMS0yNTczOQ_a2771157-dc74-4b3e-bf86-6e85fa4f386f">1,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfMy0xLTEtMS0yNTczOQ_455f7881-6719-4f7e-a0cd-cd4faf025a4f">28,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfMy0zLTEtMS0yNTczOQ_b7ea8ad9-826e-4f3f-82fe-9cacb42c70a0">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba29b67627794a5d9e0a76791c683b2e_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfNC0xLTEtMS0yNTczOQ_f57bb86b-acf7-44f3-88b3-399ef2e9a458">21,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba29b67627794a5d9e0a76791c683b2e_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfNC0zLTEtMS0yNTczOQ_d1447609-113c-4af3-9800-1fe6d600d2f8">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59895032150e486295f216709b152e49_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfNS0xLTEtMS0yODg2Ng_fef4fb51-21e7-4d31-ad15-4c4cc141069d">5,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59895032150e486295f216709b152e49_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfNS0zLTEtMS0yODg3NA_7a0cbcd0-d29d-4656-a149-5f8f48686604">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfNi0xLTEtMS0yNTczOQ_986e3a6b-016f-421f-ad8a-dc23f7583fe9">56,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfNi0zLTEtMS0yNTczOQ_5a6a4211-17da-4996-93c9-22a618d17545">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities presented have been in an unrealized loss position for less than 12 months. There were <ix:nonFraction unitRef="investment" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMTUxMw_89e3861a-2c13-4552-b92c-7184e52775e6">133</ix:nonFraction> and <ix:nonFraction unitRef="investment" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMTUyMA_cf23f732-b273-4b36-addf-08b189940f94">14</ix:nonFraction> debt securities in an unrealized loss position as of December&#160;31, 2021 and 2020, respectively. During the years ended December&#160;31, 2021 and 2020, we did <ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjE5OTAyMzI1Nzg4Ng_020b9f73-a6b3-487b-b17a-416b2f24345e"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjE5OTAyMzI1Nzg4Ng_cacfafd7-0f99-4e0c-847f-dd511fe95eeb">not</ix:nonFraction></ix:nonFraction> record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i9da32229fccf4890bbaaaa4cc51768b2"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjI1MA_79e451ff-8368-42bb-b7e7-fce96471a742" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOmE2YjA0Zjk3YWE1YzRjZDE4ZDU2OGYxOThmZjYwYmFiL3RhYmxlcmFuZ2U6YTZiMDRmOTdhYTVjNGNkMThkNTY4ZjE5OGZmNjBiYWJfMi0xLTEtMS0yNTczOQ_39fc381b-8980-4cd6-9da5-f853a8a7fdf5">1,168,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOmE2YjA0Zjk3YWE1YzRjZDE4ZDU2OGYxOThmZjYwYmFiL3RhYmxlcmFuZ2U6YTZiMDRmOTdhYTVjNGNkMThkNTY4ZjE5OGZmNjBiYWJfMi0zLTEtMS0yNTczOQ_9d6a7319-0db2-4f53-9328-ce0be1573c59">1,034,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOmE2YjA0Zjk3YWE1YzRjZDE4ZDU2OGYxOThmZjYwYmFiL3RhYmxlcmFuZ2U6YTZiMDRmOTdhYTVjNGNkMThkNTY4ZjE5OGZmNjBiYWJfMy0xLTEtMS0yNTczOQ_49a8511f-cc2a-488d-85ae-519ee1a6681b">365,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOmE2YjA0Zjk3YWE1YzRjZDE4ZDU2OGYxOThmZjYwYmFiL3RhYmxlcmFuZ2U6YTZiMDRmOTdhYTVjNGNkMThkNTY4ZjE5OGZmNjBiYWJfMy0zLTEtMS0yNTczOQ_021dbf4e-2d3d-4dbe-a098-c2ba9c7310a2">321,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOmE2YjA0Zjk3YWE1YzRjZDE4ZDU2OGYxOThmZjYwYmFiL3RhYmxlcmFuZ2U6YTZiMDRmOTdhYTVjNGNkMThkNTY4ZjE5OGZmNjBiYWJfNC0xLTEtMS0yNTczOQ_395a3cfe-4546-4ede-981a-04a91f3f95c7">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOmE2YjA0Zjk3YWE1YzRjZDE4ZDU2OGYxOThmZjYwYmFiL3RhYmxlcmFuZ2U6YTZiMDRmOTdhYTVjNGNkMThkNTY4ZjE5OGZmNjBiYWJfNC0zLTEtMS0yNTczOQ_ce9af42c-ec12-42f0-9216-6f97dafd5ee0">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib1dc779af6a3491c9aef59246f08fe04_94"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RleHRyZWdpb246NTQwMWIzYTY3MTNkNDU0MzlhMmNhM2IwYWIxNjg5NDJfMTU0NQ_c84d7673-fcd4-4065-8b2c-9ae087af32d7" continuedAt="i0275ac86a5ec41dd897c2ed7654998c7" escape="true">FAIR VALUE MEASUREMENTS </ix:nonNumeric></span></div><ix:continuation id="i0275ac86a5ec41dd897c2ed7654998c7" continuedAt="i3974f235429f4d32b8d38a8568f07767"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RleHRyZWdpb246NTQwMWIzYTY3MTNkNDU0MzlhMmNhM2IwYWIxNjg5NDJfMTU0MA_32a7bf84-a62f-414b-be07-4854c8e5f8f6" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6624d1a18a4542beeee361e4b2e980_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfMi0xLTEtMS0yNTczOQ_e1e805af-afaf-423d-8662-7f612aa40ca5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e000d5830443279e6e124a4a3d90d7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfMi0zLTEtMS0yNTczOQ_18ef9b8c-1d91-4ed2-a9c0-a3286996d8a2">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ed69927364241c79f4eb66d77b1b1b4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfMi01LTEtMS0yNTczOQ_a8dd5fcb-0b4d-465a-a0f0-e1be33004b4a">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0119576597c942bdb66a97f6e76ccf98_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfMy0xLTEtMS0yNTczOQ_4cba3750-19d4-41ef-aefc-37dd0edd9381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41e5087e044b46b29140a50002f1b602_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfMy0zLTEtMS0yNTczOQ_be7b1704-6593-448e-ac49-0d1130cad733">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda5e1974a7947e9b26e6b6e44e0d15d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfMy01LTEtMS0yNTczOQ_5d4b1029-dd2d-4f5c-b0d1-d41196d6f6ca">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2a433ba7c0841bc8a3e6d4e20f17f7e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNC0xLTEtMS0yNTczOQ_69870659-fd9d-46c2-bd48-d349986c6a16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00dab545a5c24f8dbd1d9cc27963df2a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNC0zLTEtMS0yNTczOQ_d2ac6283-a7a6-4943-b32d-01cfeb9505bd">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5653f5a5eb54376bc10cfab4779dffe_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNC01LTEtMS0yNTczOQ_977e487d-1283-49ed-9753-819c8ab13939">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f237af0ca95413b867a2e778f5fca0b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNS0xLTEtMS0yNTczOQ_23b44f80-a53a-4fcc-a13b-c856a03c884b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa6e56eab91648cb8e0e757751bd275b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNS0zLTEtMS0yNTczOQ_650702ce-4d25-47e5-953d-c1a502e3bb67">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f12d2d69a4a4b56b51d7aaed03de152_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNS01LTEtMS0yNTczOQ_7e8d8dd5-fd75-49f2-856a-f499a266605d">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7258799b1a84728ace446b81f5e78f4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNi0xLTEtMS0yNTczOQ_c85bd46a-a58a-4e08-81da-9ee2828c3b4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f80e9affa24a878bb82bc127dda141_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNi0zLTEtMS0yNTczOQ_effcf39f-a13c-4860-9313-4298f82a3423">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ccf77987385492998beaa7a87e03520_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNi01LTEtMS0yNTczOQ_348658cb-a9e4-4f86-8362-ee6a7a83a4ef">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d31a47bdaf94ea5ae092cf7132fada9_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNy0xLTEtMS0yNTczOQ_822627d2-131c-48e4-8606-40855372a951">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1abd401dbcc74a548779de9fef26b749_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNy0zLTEtMS0yNTczOQ_9b724d6b-b756-411b-8297-9016437631b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia52a40c4b843407a840ac64aba523a6b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNy01LTEtMS0yNTczOQ_6178cf0d-cb97-471e-88b2-639dda945760">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93fadded2a81419dbf152f6fb044f9b5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfOC0xLTEtMS0yNTczOQ_10a4d650-13ad-46c4-9f9b-50f957b7e3ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf16f215bd6842bd888163d7cadeea0d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfOC0zLTEtMS0yNTczOQ_17a3a390-16a4-45a2-8d48-a75f2d43efc7">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc382618cb454f7599202e9cac5b81e5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfOC01LTEtMS0yNTczOQ_4f0b14f0-c087-483e-be29-2d0d3c5082e7">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7258799b1a84728ace446b81f5e78f4_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfOS0xLTEtMS0yNTczOQ_4beadd9e-56bf-4b0b-893d-ee2db7f90531">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f80e9affa24a878bb82bc127dda141_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfOS0zLTEtMS0yNTczOQ_e4f897de-9553-45f9-a8f4-3d4012d9b98a">1,652,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ccf77987385492998beaa7a87e03520_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfOS01LTEtMS0yNTczOQ_e2dd0b26-7e87-427f-8eb6-1c6f37840d60">1,719,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea02ce752e444b2a83abe7a10a418b16_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfMi0xLTEtMS0yNTczOQ_33d9140a-8109-4ee9-9a8d-d70a57ec623e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf02d3488e39407e8c46e5743eff50d5_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfMi0zLTEtMS0yNTczOQ_b3002fd9-19a9-46f4-8d7e-fd5e0fbdd147">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795179da2aab43418fa6db779e91263a_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfMi01LTEtMS0yNTczOQ_150f991c-a56b-4625-b674-8329d2bdff4a">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57679c13f2684cdd9f8cd6fd98ab8756_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfMy0xLTEtMS0yNTczOQ_6a560182-8509-4c4b-939b-9f339717da2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id320ab8c9604499fbad568b50ccc1165_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfMy0zLTEtMS0yNTczOQ_6a2b702e-788a-4c8f-87da-0247358ab658">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b54dd876a1f4562af4c3afa7aa2048a_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfMy01LTEtMS0yNTczOQ_2a3f5847-fa74-43eb-9780-7a01e73a9418">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbde743d8914198ab03af7fe8139476_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNC0xLTEtMS0yNTczOQ_040831f2-0da7-4d37-9b14-394d5c73a6d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i427be21f708a40d28d6462416ac218ee_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNC0zLTEtMS0yNTczOQ_c4d92fb1-a4d6-4be7-9d60-89960a575697">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b0e966652f44398a8c2e0a70b2baef5_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNC01LTEtMS0yNTczOQ_d28a0456-786a-4f5a-834f-471b9e1ed69f">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54c8642ecfb409e951b6239615168c9_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNS0xLTEtMS0zMTMyMQ_48ad5779-8f0e-42a2-994a-de3b081e2e62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1463aefcf3c149bbb077c0d3005c9401_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNS0zLTEtMS0zMTMyNA_a5bc9cdf-e8d9-4d95-ae18-78b4b444b31b">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ebd9c173484d88a6e494342999d3be_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNS01LTEtMS0zNzQ0Mg_8eb1f288-7b01-41fd-addf-0846f1240c78">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7e323ee87c4f05bfdbb7c4c7e201cd_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNS0xLTEtMS0yNTczOQ_48ff4e9d-b801-47a2-b027-0cd7831981dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3c6f3004bc4c89bcf1c9c12bd459ea_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNS0zLTEtMS0yNTczOQ_f4664582-9205-42d0-9ac3-0828a2d807d5">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c51f12115f14ed1b61d2747c01ae661_I20210101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNS01LTEtMS0yNTczOQ_c6994359-c346-421b-8626-3945a22f9b3b">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib769eff617c64124810ebe511d945893_I20210101" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNi0xLTEtMS0yNTczOQ_028634e0-c7ca-4b65-8b88-a14ab64730c0">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3268bbdfa0414552b47fa9a338981cb9_I20210101" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNi0zLTEtMS0yNTczOQ_b6f20bc8-4a3e-4256-ae1e-4834358e9e89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1eb5b5c04cc43349b70b9321ebc782f_I20210101" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNi01LTEtMS0yNTczOQ_c50d108a-82f8-416a-8e96-2274ba3c0374">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic984d9c89f24479a89d0d07b78b1cdaa_I20210101" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNy0xLTEtMS0yNTczOQ_01217f36-b80e-485d-bb66-19e24f03c429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd60ccd881041a5ac4297dc0b25b292_I20210101" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNy0zLTEtMS0yNTczOQ_94ed5638-6c91-4f59-a520-5e033fc7a0c0">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d7389a754974512a4e774e51ae8a974_I20210101" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNy01LTEtMS0yNTczOQ_6cde899d-df35-4e55-aeca-33b8a4676821">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7e323ee87c4f05bfdbb7c4c7e201cd_I20210101" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfOC0xLTEtMS0yNTczOQ_7c6349bf-4465-4426-a19a-e2265e121f6f">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3c6f3004bc4c89bcf1c9c12bd459ea_I20210101" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfOC0zLTEtMS0yNTczOQ_8bb354c2-da67-4fb6-a570-0c36679e3863">1,415,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c51f12115f14ed1b61d2747c01ae661_I20210101" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfOC01LTEtMS0yNTczOQ_03c5b0bd-3a34-48f6-94fb-382d0cd3ad25">1,456,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3974f235429f4d32b8d38a8568f07767">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</ix:continuation> </span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_97"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RleHRyZWdpb246NTU2N2FhNmRkNjJmNDc4N2I0NWEwYmVkZTljYWFlYzJfMjAy_02e1aa11-9619-4d39-b721-65b2533e7168" continuedAt="i44dc340a95a44f7a9c2eab39026756d3" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="i44dc340a95a44f7a9c2eab39026756d3"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RleHRyZWdpb246NTU2N2FhNmRkNjJmNDc4N2I0NWEwYmVkZTljYWFlYzJfMjA4_b650412d-dc14-4dd8-be86-3e1ceca42c36" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfMi0xLTEtMS0yNTczOQ_eb24006f-5ea4-441c-86c6-5bfbe9d48dab">8,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfMi0zLTEtMS0yNTczOQ_8c6e5b00-af80-4766-91fe-16ce0c1c54b0">7,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfMy0xLTEtMS0yNTczOQ_3bc15b33-b627-466e-9803-092dd4cc48bc">27,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfMy0zLTEtMS0yNTczOQ_b7d13b49-bbb5-4f95-b496-87de8553ded8">20,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfNC0xLTEtMS0yNTczOQ_14840674-44b4-49fb-a9fc-b39a06c09351">12,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfNC0zLTEtMS0yNTczOQ_12ba293a-ef37-4177-9b25-18bc57970ebd">7,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfNS0xLTEtMS0yNTczOQ_aa9fd968-f4c2-47a8-860e-aab08ee3f920">49,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfNS0zLTEtMS0yNTczOQ_fdddc330-0601-4a53-bcf1-72fd353e4d11">35,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd92c80358ee496096d3c673a7de6191_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfOC0xLTEtMS0yNTczOQ_6134d3fa-2272-4920-94ad-d2c01528246c">27,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746a14780d0147c7824e0bef77b916db_I20210101" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfOC0zLTEtMS0yNTczOQ_9372b7b4-2a7a-456c-a9e2-b13b266f64b2">20,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd7d2bd3e3e490fa8ce9475ab03c7f9_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfOS0xLTEtMS0yNTczOQ_b26c2214-85ba-4616-9aea-ff67ea97f2fb">22,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0471012a562a4c27b88456f2732a0744_I20210101" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfOS0zLTEtMS0yNTczOQ_dbfe681d-82e6-4a44-9c41-8fab83e196c6">14,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfMTAtMS0xLTEtMjU3Mzk_169bff4d-4fb4-4545-b89a-9df082612672">49,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfMTAtMy0xLTEtMjU3Mzk_8beb0c5d-cba4-472c-9c19-8d1da426526b">35,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib1dc779af6a3491c9aef59246f08fe04_100"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90ZXh0cmVnaW9uOmYyOTY0MzI2ZTIzZDQ4NmVhODYwMDMwODE1ODdhOTc3XzE5OQ_a909225c-3c24-471e-b13f-d0213aeb8939" continuedAt="i6ed57f504829480888c3ad727a2026bc" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i6ed57f504829480888c3ad727a2026bc"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90ZXh0cmVnaW9uOmYyOTY0MzI2ZTIzZDQ4NmVhODYwMDMwODE1ODdhOTc3XzIwMw_d3bc5a85-07c7-4bf5-9f63-d9a5758fca33" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up to <ix:nonNumeric contextRef="i3886df95730147449641343484c7d238_D20210102-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzItMS0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpkZTJhMjMyNGMyZDE0NDQ5YTMxZWY3ZjU2OTAzMDZlMl8xMA_b7c87905-ae9d-4c5d-b44c-73c35f3bd8ea">15</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide48db818a80458abbca38f5ab70bdd1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzItMy0xLTEtMjU3Mzk_3188889c-80b4-4b5c-aa68-add61757e17b">73,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f085c7986f04f109f77b9011f31264d_I20210101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzItNS0xLTEtMjU3Mzk_613e7d61-548a-4cf3-bae6-3f9c6ae7f4e3">40,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8b4047a98c284e9286babc06d5858821_D20210102-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzMtMS0xLTEtMjU3Mzk_0df44cc7-ea71-442b-988a-ea8c7620b1e3">3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c9cdc8841b46d8adc324d34793217d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzMtMy0xLTEtMjU3Mzk_981446c0-727a-451d-8817-6caf3b7a3e04">14,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99337c2ce04dcfa30ad4ccee42117a_I20210101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzMtNS0xLTEtMjU3Mzk_069d106b-0ac8-4521-ab00-009c272238aa">18,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6230988b2ca747a8b89fd3cae1298175_D20210102-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzUtMS0xLTEtMjU3Mzk_58c021ee-94db-404f-b53f-0b27d2e8ccda">7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178f5c4c23ca48a38655383d6e5977f8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzUtMy0xLTEtMjU3Mzk_d7198d29-16d8-4157-ab7f-1de73e329540">15,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73f4cd7fcee499eaf78ce808bb71d03_I20210101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzUtNS0xLTEtMjU3Mzk_e3b3a903-8cd3-4fb9-add3-5521d5c9d67e">14,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i248ba0f7c8cb4181ad74bb080d0aeca1_D20210102-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzYtMS0xLTEtMjU3Mzk_e3bc4468-4b7a-4ae2-810c-31b1fea568e9">5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i935b27fac1984932861fb968e47b9877_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzYtMy0xLTEtMjU3Mzk_4c5693e6-458e-436b-87ae-4b0705296bf7">23,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ec14dcaa36142b2a22ec45b2e3e2493_I20210101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzYtNS0xLTEtMjU3Mzk_6a9752a0-fd14-485e-861a-18e60bb0ae4c">11,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73ca698aa2a74a4e937a5a3b1de87b32_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzctMy0xLTEtMjU3Mzk_ce23bb1f-03af-44cb-b213-356982a2a9d9">16,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1089920ccded4380b0fbc39e750f1eb7_I20210101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzctNS0xLTEtMjU3Mzk_19963210-dcfa-4208-87c0-03210e6a04cc">16,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzgtMy0xLTEtMjU3Mzk_e53f4a33-d7e5-49f2-8776-e01594d7629c">144,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzgtNS0xLTEtMjU3Mzk_86ecb5ca-deaf-4264-893f-1c3535030172">102,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzktMy0xLTEtMjU3Mzk_7c0fce51-06c2-4d26-a10b-832818c21b8b">40,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzktNS0xLTEtMjU3Mzk_c4a6d502-4153-40fa-9a4d-8cd29d428478">34,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzEwLTMtMS0xLTI1NzM5_4c05067f-b1bc-44bf-98d4-7a70fde10650">104,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzEwLTUtMS0xLTI1NzM5_12c16409-2f8b-4ee8-94a2-5efcd5073507">67,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90ZXh0cmVnaW9uOmYyOTY0MzI2ZTIzZDQ4NmVhODYwMDMwODE1ODdhOTc3XzEyOQ_4ce54c97-b335-448c-8d15-a460deec8e76">13.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90ZXh0cmVnaW9uOmYyOTY0MzI2ZTIzZDQ4NmVhODYwMDMwODE1ODdhOTc3XzEzMw_887ea35d-0a49-4b96-8423-1cf27d5032c7">9.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90ZXh0cmVnaW9uOmYyOTY0MzI2ZTIzZDQ4NmVhODYwMDMwODE1ODdhOTc3XzE0MA_711c6f68-bfdb-4234-8320-47c397574005">8.3</ix:nonFraction> million during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_106"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNjY_bf15f99d-87fa-4366-8fbd-581e462d1ac0" continuedAt="i5a4981e1ec5b47128cb10ac12286fef5" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i5a4981e1ec5b47128cb10ac12286fef5" continuedAt="i2e50e4f97ea64c4082cfcef068839430"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans and ESPP</span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNjQ_5e5b4fa9-5e8f-45fc-8b47-a071a083408e" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b96bd3389d2490a8a78bc00fddfe7ce_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzItMS0xLTEtMjU3Mzk_4681a601-ec2c-49ad-94c8-fc54c2fe73ff">46,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6c6471ca35413da83fd2469f9c00a1_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzItMy0xLTEtMjU3Mzk_69628424-388d-45d5-9ffb-cf9652a48cc9">37,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d5186b034a4d0999fca6ecb2ec9ece_D20181229-20200103" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzItNS0xLTEtMjU3Mzk_e86141a9-6e28-4883-b115-e1f01d540aad">19,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb974755c29460293662406b5c181e4_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzMtMS0xLTEtMjU3Mzk_b3c0e547-a616-4072-8ed5-d1fb49b00b5d">73,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f33a19a84a140d380dc777b506fc9ba_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzMtMy0xLTEtMjU3Mzk_7d3a3a0f-987d-4d54-9b6e-b120a9a0a137">67,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecb0e7726f341c6ba6992570d045296_D20181229-20200103" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzMtNS0xLTEtMjU3Mzk_4a923a24-7900-4d2d-9ee8-45075e6e221e">37,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzQtMS0xLTEtMjU3Mzk_f1d30119-b803-43e2-9306-071c9038a1fd">119,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzQtMy0xLTEtMjU3Mzk_e637f339-8706-428f-93f1-00ee0152fb73">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzQtNS0xLTEtMjU3Mzk_560af215-8279-4cb1-97b7-50475cb44d52">56,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzItMS0xLTEtMjU3Mzk_5184b696-2a63-4242-90a5-fdc261c9773f">19,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzItMy0xLTEtMjU3Mzk_00c4e59a-a49a-448a-8897-6efc6477c3a0">19,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzItNS0xLTEtMjU3Mzk_73d1932f-32b3-4602-8910-ca7757269222">23,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzMtMS0xLTEtMjU3Mzk_7524f015-73de-464e-9f9c-50806e14f4b1">53,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i810b03546f7b400baf8f30d8a400ff09_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzMtMy0xLTEtMjU3Mzk_1885e278-f3ce-4ce5-9526-e5ba3e8e8e3f">35,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf28ef3d9ddd45609325a52b344679e7_D20181229-20200103" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzMtNS0xLTEtMjU3Mzk_5c6a8d4f-1b04-49f6-9dc7-7f33d3392330">26,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzQtMS0xLTEtMjU3Mzk_3c58e678-e1fa-42b4-b83d-a528dae06b93">43,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a39cce3d904d388c3adad8a7bfed10_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzQtMy0xLTEtMjU3Mzk_03eed95e-bde7-4a63-a5d0-a88903596f66">47,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7abafca0ed6e40f88895c38bb6b81247_D20181229-20200103" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzQtNS0xLTEtMjU3Mzk_d7496e1b-74b6-4648-a0db-94660055a8b5">4,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzUtMS0xLTEtMjU3Mzk_d0fcbdf5-b1fc-4ac3-b3d9-8dad2d4acf6d">3,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzUtMy0xLTEtMjU3Mzk_95a8a2ad-3ce4-4b8b-8171-857cf814638d">2,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzUtNS0xLTEtMjU3Mzk_fc5a1668-00a2-40f8-a610-ed1159df6073">2,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzYtMS0xLTEtMjU3Mzk_91ec8503-2d7f-4628-a75d-5ee7176929a5">119,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzYtMy0xLTEtMjU3Mzk_c53b3bc3-10b7-4246-9ceb-e08457525e56">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzYtNS0xLTEtMjU3Mzk_f5bb0736-1bc7-479f-87b6-46267503ab79">56,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several equity incentive plans under which we granted stock options and RSUs, including PSUs, to employees and directors. At December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzM0MA_d2a81c37-05d3-4efb-9a32-39bdd004cc2f">11,004,584</ix:nonFraction> shares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by <ix:nonFraction unitRef="shares" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzUwMQ_23fcf4b9-91d1-45e8-b8ea-891653f56ffb">1</ix:nonFraction> share for each share issued pursuant to a stock option award and <ix:nonFraction unitRef="shares" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzU2OQ_b4249c02-cd04-4100-be2b-f92acf4c31a7">1.5</ix:nonFraction> shares for full value awards granted in the form of RSUs or PSUs. On May 20, 2020, at our 2020 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of the 2017 Plan. The amendment and restatement increased the share reserve under the 2017 Plan by <ix:nonFraction unitRef="shares" contextRef="iff13c02dcfbe458cb3a8363106ef81dd_D20200520-20200520" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzg1NA_8e5dc5fd-1552-4957-8720-faf9a7758229">21,000,000</ix:nonFraction> shares, subject to adjustment for certain changes in our capitalization, which became effective immediately upon stockholder approval. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors delegated responsibility for administration of our equity incentive plans to the Compensation Committee of our Board of Directors, including the authority to determine the term, exercise price and vesting requirements of each grant. Stock options granted to our employees and directors generally have a <ix:nonNumeric contextRef="i940612d122c84082acb652dba5991c69_D20210102-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNjU_537a763e-ec17-4765-a277-4419522ee8b9">four-year</ix:nonNumeric> vesting term and a <ix:nonNumeric contextRef="i34532b015c584cba952c0caa678ee2fd_D20210102-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNDM_66c47682-db95-49e8-983f-525bbd603d52">one-year</ix:nonNumeric> vesting term, respectively, an exercise price equal to the fair market value on the date of grant, and a <ix:nonNumeric contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNDg_8610ffa9-8917-410c-8f24-1fa95a0bfe1e">seven-year</ix:nonNumeric> life from the date of grant. RSUs granted to our employees and directors generally have a <ix:nonNumeric contextRef="ib08f62d50d8d4c1793cae2caa25a90ec_D20210102-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxMzI_ba597d37-d7e2-4a41-8601-af5f38e07127">four-year</ix:nonNumeric> vesting term and a <ix:nonNumeric contextRef="id6d6926fdea445e7a6ebdc4a3ba1f78b_D20210102-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxMzA_73a41860-74c5-46ed-803e-7a006fa558d4">one-year</ix:nonNumeric> vesting term, respectively. PSUs granted pursuant to our equity incentive plans vest upon specified service conditions and the achievement of a performance target or market condition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Change in Control and Severance Benefit Plan for certain executive officers. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#8217;s employment is terminated without cause during a period commencing <ix:nonNumeric contextRef="i1b29032b66954a8db9da85d19b1be6a2_D20210102-20211231" name="exel:ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzYwNDczMTM5NzA2MDM_9ad16dd3-01f1-4359-97a8-5b87526cd4be">one month</ix:nonNumeric> before and ending <ix:nonNumeric contextRef="i6362d549434c4a3ebfb9ed76266ced8a_D20210102-20211231" name="exel:ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzYwNDczMTM5NzA2MTg_23f45ebd-4301-4206-85af-e5477b593775">thirteen months</ix:nonNumeric> following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all their outstanding equity awards accelerated and the exercise period for their stock options extended to no more than one year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of <ix:nonFraction unitRef="number" contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI1ODI_42170df1-87ff-4bfa-8d84-71878dfd16c4">85</ix:nonFraction>% of the closing price at the beginning of the offering period or <ix:nonFraction unitRef="number" contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI2NDk_92edfd19-be99-4851-81b8-4bcbb25421e2">85</ix:nonFraction>% of the closing price at the end of each <ix:nonNumeric contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231" name="exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNzY_f03b04f2-0cd4-45f1-b9d9-367552c577ae">six-month</ix:nonNumeric> purchase period. As of December&#160;31, 2021, we had </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie93bf1a0871644278ca4b892fe456191_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI3MzU_15cce0d6-af59-4b82-a2fe-9f6a0e9e84df">3,168,354</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares available for issuance under our ESPP. Pursuant to the ESPP, we issued <ix:nonFraction unitRef="shares" contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI4MTY_d5ac8bfe-717f-4ce1-ac05-d0cc2cd020fb">536,226</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI4MjA_522bc071-73e7-4a7b-8cc7-8c6eb23d6e8b">534,419</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI4Mjc_46014ca1-d0f0-46fc-bf2c-022c8c95c070">483,009</ix:nonFraction> shares of common stock at an average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie93bf1a0871644278ca4b892fe456191_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI4ODY_3b83dba8-f0e3-4873-b8c8-a09974d8a226">17.76</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i85c17b70c74043af9b0e2017ab4409e8_I20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI4OTA_f867450d-f5cf-4c56-befa-a146f1dc3814">14.55</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i1d0c6bc2e80b4232ae06f54a57a62638_I20200103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI4OTc_e76cf039-0393-4c8d-ba05-6c701cc8a2b1">12.60</ix:nonFraction> during the years ended December&#160;31, 2021, 2020 and 2019, respectively. Cash received </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from purchases under the ESPP for the years ended December 31, 2021, 2020 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $<ix:nonFraction unitRef="usd" contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231" decimals="-5" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzMwNDc_086b3b07-f613-4b02-8d40-799d1761287e">9.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101" decimals="-5" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzMwNTE_6f907b92-1122-4ac3-96be-38bcc8096585">7.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103" decimals="-5" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzMwNTg_58c74c9e-9459-4593-a321-eb8f0e0eeb35">6.1</ix:nonFraction> million, respectively. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i2e50e4f97ea64c4082cfcef068839430" continuedAt="ia410903eafcf4a86b9b45b15872a27a5"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used a Black-Scholes Merton option pricing model to value stock options and ESPP purchases. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEyNjQ0MzgzNzM0ODY1_f4a02110-390f-4ddf-a0f7-02c1c48fe78a" continuedAt="iaa822214c7f242a095c0134995da59a8" escape="true">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="iaa822214c7f242a095c0134995da59a8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTphYjNhNTk3MDljNzg0MjdmOWI5YTg3NWIwNjdkMGNlMC90YWJsZXJhbmdlOmFiM2E1OTcwOWM3ODQyN2Y5YjlhODc1YjA2N2QwY2UwXzItMS0xLTEtMzkwOTA_8de5165e-1801-4c2f-8d7e-db440523a506">9.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTphYjNhNTk3MDljNzg0MjdmOWI5YTg3NWIwNjdkMGNlMC90YWJsZXJhbmdlOmFiM2E1OTcwOWM3ODQyN2Y5YjlhODc1YjA2N2QwY2UwXzItMy0xLTEtMzkwOTA_fbbaa0bd-95c3-438e-9429-735cb15293b2">9.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTphYjNhNTk3MDljNzg0MjdmOWI5YTg3NWIwNjdkMGNlMC90YWJsZXJhbmdlOmFiM2E1OTcwOWM3ODQyN2Y5YjlhODc1YjA2N2QwY2UwXzItNS0xLTEtMzkwOTA_8d368206-1d01-4d6c-9362-83ba5737c5ff">8.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTphYjNhNTk3MDljNzg0MjdmOWI5YTg3NWIwNjdkMGNlMC90YWJsZXJhbmdlOmFiM2E1OTcwOWM3ODQyN2Y5YjlhODc1YjA2N2QwY2UwXzMtMS0xLTEtMzkwOTA_a98d0805-1ca5-45ec-8933-801731b9d09f">6.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTphYjNhNTk3MDljNzg0MjdmOWI5YTg3NWIwNjdkMGNlMC90YWJsZXJhbmdlOmFiM2E1OTcwOWM3ODQyN2Y5YjlhODc1YjA2N2QwY2UwXzMtMy0xLTEtMzkwOTA_0d9b5d68-cf5b-47ce-92af-299c187d2d45">6.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTphYjNhNTk3MDljNzg0MjdmOWI5YTg3NWIwNjdkMGNlMC90YWJsZXJhbmdlOmFiM2E1OTcwOWM3ODQyN2Y5YjlhODc1YjA2N2QwY2UwXzMtNS0xLTEtMzkwOTA_50f3bda2-4152-4e44-8f2f-f7fdb298ae37">4.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxMTk_6c26d1d3-6077-4b03-a387-5d64de756dc4" escape="true"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNTA_53ead616-6578-4805-bda8-6f4dcad0cab4" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzMtMS0xLTEtMjU3Mzk_267ce474-52c0-42fa-85ab-41d87b128817">0.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzMtMy0xLTEtMjU3Mzk_53ad4b9e-fd70-42b6-93b9-7ce2c8502f7b">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzMtNS0xLTEtMjU3Mzk_17e8fb79-8f43-4fd3-ba59-99748e193ec6">1.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzQtMS0xLTEtMjU3Mzk_3db70f18-3e08-4319-bc6c-cc2675258cc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzQtMy0xLTEtMjU3Mzk_2306ad0b-cfd4-4d1c-80ac-a1dd95874daf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzQtNS0xLTEtMjU3Mzk_61a284a7-20dd-4522-9d2b-4e93ec7f6be4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzUtMS0xLTEtMjU3Mzk_0e8dd21a-e02c-450c-b635-f699901ea078">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzUtMy0xLTEtMjU3Mzk_d0a73ba7-6c3d-47e4-8caf-c0c6a93b6ecc">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzUtNS0xLTEtMjU3Mzk_46b86dea-2edb-443b-a21a-1fb24d9424b9">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzYtMS0xLTEtMjU3Mzk_c0d0d93e-d717-4113-afdc-a8c87393654e">4.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzYtMy0xLTEtMjU3Mzk_935dab74-6a01-4145-b691-d8f5e5262061">4.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzYtNS0xLTEtMjU3Mzk_2eaecd8d-c359-4ca4-b905-27e862d83ff1">4.3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzgtMS0xLTEtMjU3Mzk_2c5ef23f-135c-4c6f-80c5-0f0a631bdc55">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzgtMy0xLTEtMjU3Mzk_d5c292ed-05e3-43c4-9ab7-a05e83456c18">0.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzgtNS0xLTEtMjU3Mzk_ad8da521-5bd7-424c-ab26-c56eacc08896">2.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzktMS0xLTEtMjU3Mzk_7246493d-2e41-4554-aade-8c7a4f597895">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzktMy0xLTEtMjU3Mzk_6251e86e-4d8d-4fbc-b153-317c569855d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzktNS0xLTEtMjU3Mzk_eef16548-4cdb-4f1c-96a0-7e864965acc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzEwLTEtMS0xLTI1NzM5_6533d633-ec69-4298-990f-b9a946400160">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzEwLTMtMS0xLTI1NzM5_42cca744-8749-458d-8e57-bd92a4e11b1d">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzEwLTUtMS0xLTI1NzM5_36d9655a-1973-4c6e-bb5a-d7e453f27c14">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzExLTEtMS0xLTI1NzM5_2808fe17-6d84-464a-83b5-3523500615f8">6</ix:nonNumeric> months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzExLTMtMS0xLTI1NzM5_68b5970d-c959-42f7-b324-543c7d504df7">6</ix:nonNumeric> months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzExLTUtMS0xLTI1NzM5_6e5675dd-1fb1-4479-aedc-bef57ef709a2">6</ix:nonNumeric> months</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered both implied and historical volatility in developing our estimate of expected volatility. The assumption for the expected life of stock options is based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs, including PSUs, was based on the closing price of the underlying common stock on the date of grant. </span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxMjE_b85d2b85-26a4-456f-820f-2b2d7d18ecbb" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for stock options during the year ended December&#160;31, 2021 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzEtMS0xLTEtMjU3Mzk_24f322f0-d777-4eaf-bfdd-78ce900931f1">16,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzEtMy0xLTEtMjU3Mzk_ced73734-4d4b-4cd7-989c-373702aa01ba">12.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzItMS0xLTEtMjU3Mzk_1106d7d1-02eb-4d72-8e83-a47cc4ee2f55">2,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzItMy0xLTEtMjU3Mzk_536baf00-8650-41f7-8a07-a8e257ef2cdc">21.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzMtMS0xLTEtMjU3Mzk_c3547dba-bfe0-4b86-b562-f81b322176cd">4,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzMtMy0xLTEtMjU3Mzk_bff857bc-c1ef-41b6-b119-2a152df92739">4.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzQtMS0xLTEtMjU3Mzk_c6a4cd3b-9bed-4fb3-8433-51559909d480">545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzQtMy0xLTEtMjU3Mzk_57c1c286-9027-41a2-a896-5d3a88f99dcd">21.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzUtMS0xLTEtMjU3Mzk_e4f1c69f-c3df-4172-916e-0f4f18da0740">13,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzUtMy0xLTEtMjU3Mzk_a1e38f60-70ab-4852-8233-674ada7edcdd">16.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzUtNS0xLTEtMjU3Mzk_d51307c4-d965-4592-878b-41cfada89b2d">3.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzUtNy0xLTEtMjU3Mzk_74ed5260-034f-4875-90b9-9d5dada8f25a">48,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercisable at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzYtMS0xLTEtMjU3Mzk_5c068ce9-aae3-4c8a-9930-f98e499f0a64">9,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzYtMy0xLTEtMjU3Mzk_39a201d8-e0cc-4bc0-ab07-29d94880752d">15.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzYtNS0xLTEtMjU3Mzk_8dfe60df-1432-453a-bc61-819b54fa60bc">2.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzYtNy0xLTEtMjU3Mzk_c4eb1a99-a2f9-4172-9a0d-52e2e46a6f67">48,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="ib29b3c5e0f37409da408786f8267b076_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQyMzM_d6506f25-d4e7-4e31-bea9-057500d940f3">27.8</ix:nonFraction> million of unrecognized compensation expense related to our unvested stock options. The compensation expense for the unvested stock options will be recognized over a weighted-average period of <ix:nonNumeric contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ0Mzc_06a17866-3194-401c-9a10-91d83f7a63c3">2.7</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="ia410903eafcf4a86b9b45b15872a27a5" continuedAt="i0837d30a0e3340fc8d2a85844e4a9f9e"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal 2021 and the exercise prices, multiplied by the number of in-the-money stock options) that would have been received by the stock option holders had all stock option holders exercised their stock options on December&#160;31, 2021. The total intrinsic value of stock options exercised during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ5NDc4MDIzMzcyNzE_757730f2-6600-4593-866d-356459bd7c48">76.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ5NDc4MDIzMzcyNzc_ba3daa24-2c50-47c8-a879-c0fe3921110a">106.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ5NDc4MDIzMzcyODU_9424ed8d-482a-416a-a198-cd8bd9fa5824">54.1</ix:nonFraction> million, respectively. Cash received from stock option exercises during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ5NDc4MDIzMzczOTE_41849f92-6a12-4e9f-8706-3d8f4139ef11">14.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ5NDc4MDIzMzczOTc_8bf4c320-2e74-4d01-bc07-df5fa1474fc6">26.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ5NDc4MDIzMzc0MDU_0852b81d-ca3e-41b3-8c6d-e2d4cd234d76">16.4</ix:nonFraction> million, respectively.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxMjI_d8434ac3-dfb0-4df2-a7d2-479012c6fb0b" continuedAt="i7a05fdabce7048cdb95c56650a8d6677" escape="true">Activity for RSUs during the year ended December&#160;31, 2021 was as follows (in thousands, except per share amounts):</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i7a05fdabce7048cdb95c56650a8d6677" continuedAt="ic3b760ea5f0441e999724982733ee3c8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74355fce090d4783894ca8f36c2a26dd_I20210101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzEtMS0xLTEtMjU3Mzk_d1f61ffd-3317-4cf7-a2d8-bf6c508de8a1">5,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i74355fce090d4783894ca8f36c2a26dd_I20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzEtMy0xLTEtMjU3Mzk_da164b5d-9ebd-49e7-9349-6c6e3081c276">21.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzItMS0xLTEtMjU3Mzk_c08d0350-b047-45b2-ad1c-201482c810a6">4,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzItMy0xLTEtMjU3Mzk_d776183c-0839-4754-b895-c64fa9720585">21.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231" decimals="-3" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzMtMS0xLTEtMjU3Mzk_3fd4c021-8640-4de7-942c-23cd741af6af">2,020</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231" decimals="2" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzMtMy0xLTEtMjU3Mzk_01d1ad91-fb96-405e-96bc-cec9b31261c4">22.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzQtMS0xLTEtMjU3Mzk_ffdc17ce-dbfb-46a4-b458-9f8d38cc8c74">750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzQtMy0xLTEtMjU3Mzk_9361343d-d771-4877-809d-c5c6a2c71428">21.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c4744c0eeaa4ef89dc73f7f709e54b9_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzUtMS0xLTEtMjU3Mzk_017d7ce0-47da-42cf-9b2f-ae7a398011d3">6,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c4744c0eeaa4ef89dc73f7f709e54b9_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzUtMy0xLTEtMjU3Mzk_8449757d-61e6-45ca-8c95-dafc989a1b9b">21.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzUtNS0xLTEtMjU3Mzk_4145e987-6b69-4031-b6aa-acf10d6d9910">1.7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c4744c0eeaa4ef89dc73f7f709e54b9_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzUtNy0xLTEtMjU3Mzk_d1e2aa7f-ce23-44ea-886c-802148132633">124,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i4c4744c0eeaa4ef89dc73f7f709e54b9_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzYxMjQ_47b6ca1d-d859-4491-afb6-1ce23a72b990">123.6</ix:nonFraction> million of unrecognized compensation expense related to our unvested RSUs which will be recognized over a weighted-average period of <ix:nonNumeric contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzYyNTI_43185869-728f-4534-be8a-d158130e6621">2.9</ix:nonNumeric> years.</span></div><ix:continuation id="ic3b760ea5f0441e999724982733ee3c8"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for PSUs, during the year ended December&#160;31, 2021 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fa59b8b15c4457ea85611acce275f22_I20210101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzEtMS0xLTEtMjU3Mzk_6141777f-7050-4334-94a9-52c55939e15d">7,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6fa59b8b15c4457ea85611acce275f22_I20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzEtMy0xLTEtMjU3Mzk_015bf64a-3ca2-49b9-9d7d-bdad9b786880">21.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzItMS0xLTEtMjU3Mzk_a3bd8bf1-2a5c-4f98-a8c4-b61c868aa10c">2,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzItMy0xLTEtMjU3Mzk_fb09a280-4016-45f2-904b-8618a98c41f1">24.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231" decimals="-3" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzMtMS0xLTEtMjU3Mzk_70813ead-d19e-4974-87c5-a1e1f2fefb62">2,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231" decimals="2" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzMtMy0xLTEtMjU3Mzk_05d238ed-7e5a-4601-8047-1a78d95d64d7">19.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzQtMS0xLTEtMjU3Mzk_9c8851c5-dd7f-4802-a6cf-b7044baf4d20">736</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzQtMy0xLTEtMjU3Mzk_e5e03752-5082-47f1-b828-0dc31ab88cc1">22.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0c146506a74415eb481d9e61dae42b4_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzUtMS0xLTEtMjU3Mzk_701e2bf5-4b9a-44c7-8ee5-df1c4bb3b49b">6,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if0c146506a74415eb481d9e61dae42b4_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzUtMy0xLTEtMjU3Mzk_ddc34466-218c-4fd5-b244-41f533936769">23.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzUtNS0xLTEtMjU3Mzk_763869ca-e6e5-4695-ac95-4b853ee0ac95">3.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c146506a74415eb481d9e61dae42b4_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzUtNy0xLTEtMjU3Mzk_7908a649-b21d-4aac-836b-16ef9b8aea53">98,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, in connection with our long-term incentive compensation program, we awarded certain employees <ix:nonFraction unitRef="shares" contextRef="i838b498a0efd4d9d9f799adee2661362_D20210301-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzk4OTU2MDQ2NjI1MzM_0d005f36-7a81-4759-90cf-b4b6c665b979">1,027,650</ix:nonFraction> (the 2021 target amount) PSUs, subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to <ix:nonFraction unitRef="number" contextRef="i838b498a0efd4d9d9f799adee2661362_D20210301-20210331" decimals="INF" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzk4OTU2MDQ2NjI1NDQ_058f7d47-8a71-45df-92f2-2308b327e4db">200</ix:nonFraction>% of the 2021 target amount, or up to <ix:nonFraction unitRef="shares" contextRef="i838b498a0efd4d9d9f799adee2661362_D20210301-20210331" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzMxMzM2MDgxNDA5MjQx_c9341423-30bc-4e64-89a6-3a6fc7bba822">2,055,300</ix:nonFraction> total shares, depending on the level of achievement of the performance condition related to certain net product revenues and a total shareholder return (TSR) market condition. The TSR market condition is based on our relative TSR percentile rank compared to companies in the Nasdaq Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. <ix:nonFraction unitRef="number" contextRef="i1ad4423cf59549fa83e3e98aa40b0aba_D20210301-20210331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzk4OTU2MDQ2NjI1NDk_3d8a02e3-34f3-4372-901b-748f5b55f4e9">Fifty</ix:nonFraction> percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately <ix:nonNumeric contextRef="i74e6a3ef845a4a2c9ac7e354707c8e1f_D20210301-20210331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkzNDU4NDg4NDg2OTQ_22729623-adef-448b-963f-2a8d3ce576f5">one year</ix:nonNumeric> later subject to an employee&#8217;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023. The performance condition for a threshold of net product revenues relative to the 2021 PSUs was deemed probable of achievement in the fourth quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEwOTk1MTE2MjkwMjg0_463ffc31-ece0-44db-8ea6-b13560c877ab" continuedAt="i883f5d08ade44facafa65eaeb60a4b61" escape="true">A Monte Carlo simulation model was used to determine the grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEwOTk1MTE2MjkwMjc3_57b233b6-17e9-4bba-a3d1-b9c1223f3ffd">24.54</ix:nonFraction> for the 2021 PSUs based on the following assumptions:</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i0837d30a0e3340fc8d2a85844e4a9f9e" continuedAt="if87f9cb89d994ba293c4f1c9b61515be"><div style="margin-top:9pt;text-align:center"><ix:continuation id="i883f5d08ade44facafa65eaeb60a4b61"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="if0c146506a74415eb481d9e61dae42b4_I20211231" decimals="2" name="us-gaap:SharePrice" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpjZmU3MzMwNTY5Zjk0NGE1YjlhNmVhMzgzNzI3OWUxZC90YWJsZXJhbmdlOmNmZTczMzA1NjlmOTQ0YTViOWE2ZWEzODM3Mjc5ZTFkXzAtMS0xLTEtMzc1MTk_a81469b8-ccc6-4b5e-b30d-8f02f0f5fffb">21.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpjZmU3MzMwNTY5Zjk0NGE1YjlhNmVhMzgzNzI3OWUxZC90YWJsZXJhbmdlOmNmZTczMzA1NjlmOTQ0YTViOWE2ZWEzODM3Mjc5ZTFkXzEtMS0xLTEtMzc1MjE_d78e04e3-050b-42ae-8b4e-4821952b9082">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpjZmU3MzMwNTY5Zjk0NGE1YjlhNmVhMzgzNzI3OWUxZC90YWJsZXJhbmdlOmNmZTczMzA1NjlmOTQ0YTViOWE2ZWEzODM3Mjc5ZTFkXzItMS0xLTEtMzc1MjM_a6eca7d8-d349-4dc9-a83a-f360954140f4">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpjZmU3MzMwNTY5Zjk0NGE1YjlhNmVhMzgzNzI3OWUxZC90YWJsZXJhbmdlOmNmZTczMzA1NjlmOTQ0YTViOWE2ZWEzODM3Mjc5ZTFkXzMtMS0xLTEtMzc1MjU_30fb5dd5-d74f-422f-89be-76548558d837">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, in connection with our long-term incentive compensation program, we awarded <ix:nonFraction unitRef="shares" contextRef="ieac0ed4a145142fcaad1faa3308fe4da_D20200104-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEwOTk1MTE2MzgyMzY_42e476ea-3e4f-4e33-8c00-19fe5ba3ad9f">2,327,840</ix:nonFraction> PSUs (the 2020 target amount) that will vest upon the achievement of performance targets related to clinical trial positive top-line results and product approvals by the FDA (the 2020 PSUs). Pursuant to the terms of the 2020 PSUs, employees may earn up to <ix:nonFraction unitRef="number" contextRef="i76a39cce3d904d388c3adad8a7bfed10_D20200104-20210101" decimals="INF" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzY3MDk_7d16be56-e7f9-48e6-9cc4-a474bb74ab3d">200</ix:nonFraction>% of the 2020 target amount, or <ix:nonFraction unitRef="shares" contextRef="i76a39cce3d904d388c3adad8a7bfed10_D20200104-20210101" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEwOTk1MTE2MzgyNDM_5fcb6f03-ddd8-4387-9dba-443817024e30">4,655,680</ix:nonFraction> total shares, depending on the volume and timing of achievement of the performance targets. The 2020 PSUs will be forfeited if the performance targets are not met by December 31, 2024. The performance condition for threshold achievement of a product approval by the FDA relative to the 2020 PSUs occurred in the third quarter of 2021 representing <ix:nonFraction unitRef="number" contextRef="i18d80baf7ec441d59bd2914f26cc7048_D20210703-20211001" decimals="2" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzMxMzM2MDgxNDA5MjUy_00796f34-efcb-490c-92c4-52b612ccdab3">25</ix:nonFraction>% of the 2020 target amount.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December&#160;31, 2019, in connection with our long-term incentive compensation program, we awarded <ix:nonFraction unitRef="shares" contextRef="ia1182bc4873c402f9d17b55ecb40b430_D20181229-20200103" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQzOTgwNDY1Mjg1OTk_d8f8fc9e-7038-4e0c-8a5a-8eefc2621150">1,926,605</ix:nonFraction> PSUs (the 2019 target amount) that vest upon the achievement of performance targets related to product approvals by the FDA (the 2019 PSUs). Pursuant to the terms of the 2019 PSUs, employees may earn up to <ix:nonFraction unitRef="number" contextRef="i7abafca0ed6e40f88895c38bb6b81247_D20181229-20200103" decimals="INF" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzcyNjk_26705ac2-8f1d-49d0-bd83-06c4eee8c75f">200</ix:nonFraction>% of the 2019 target amount, or <ix:nonFraction unitRef="shares" contextRef="i7abafca0ed6e40f88895c38bb6b81247_D20181229-20200103" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEwOTk1MTE2MzgyNTg_f8771d9f-9846-4afc-8f05-99d9b9f547f5">3,853,210</ix:nonFraction> total shares, depending on the volume and timing of achievement of the performance targets. The performance condition for early achievement of the 2019 PSUs occurred during 2020 representing <ix:nonFraction unitRef="number" contextRef="if6856ab9da0245a0b58e4a5a9d78c7c1_D20200104-20210101" decimals="INF" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzc1MzU_58361aef-98e5-4329-a358-30d91e7be41a">150</ix:nonFraction>% of the 2019 target amount. The performance condition for earning the remaining <ix:nonFraction unitRef="number" contextRef="i7e812dfe05ab46da90f8b209737fba1e_D20210102-20211231" decimals="INF" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzc2MDk_28e97fdc-bf8c-4b48-bdc8-84d153f81f64">50</ix:nonFraction>% of the 2019 target amount occurred in early 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2018, we awarded <ix:nonFraction unitRef="shares" contextRef="i96ebe2ef748948f0a75ba0527c466487_D20180101-20181228" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEwOTk1MTE2Mzg0MTM_fff9e8aa-ddbc-48d7-b59f-dceb37905f78">693,131</ix:nonFraction> PSUs that vest upon the achievement of certain product revenue, late-stage clinical development programs and discovery pipeline expansion performance targets (the 2018 PSUs). The performance targets for <ix:nonFraction unitRef="shares" contextRef="i58f94a8c90d4404fbf57c14383810126_D20200104-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzIxOTkwMjMyNzEwMzI_fc85db1f-f1b3-475f-b437-f4d4913301ec">167,726</ix:nonFraction> remaining 2018 PSUs were achieved in 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognition for PSUs commences when it is determined that attainment of the performance target is probable. Of the aggregate outstanding PSUs, <ix:nonFraction unitRef="shares" contextRef="iad0a49c0e2794ae58f9a3ccbe473b7fe_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzIxOTkwMjMyNjQ3ODQ_3d7ecfac-3802-46e2-9eaf-78d9044fdc1d">4,853,112</ix:nonFraction> relate to awards for which we achieved the performance target. As of December&#160;31, 2021, the remaining unrecognized compensation expense for the PSUs achieved or deemed probable of achievement related to the PSUs was $<ix:nonFraction unitRef="usd" contextRef="id1cca4ef6d104b9db13688910f87a10c_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzg0NTY_f35bf111-dcb2-4e33-b6ed-3c8b915fe436">12.1</ix:nonFraction> million, which will be recognized over a weighted-average period of <ix:nonNumeric contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzg1MTk_736eae15-6157-4e9f-a32c-98b7b8b62754">3.0</ix:nonNumeric> years. The total unrecognized compensation expense for the PSUs for which we have not yet determined that attainment of the performance target is probable was $<ix:nonFraction unitRef="usd" contextRef="icf4e68b211e4463fb19f878a36d3a54a_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzg2NzU_e083f4c7-7775-4391-8c3d-8fb5b2149b36">121.6</ix:nonFraction> million as of December&#160;31, 2021.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exelixis, Inc. 401(k) Plan (the 401(k) Plan)</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if87f9cb89d994ba293c4f1c9b61515be">We sponsor the 401(k) Plan under which we have historically made matching contributions to our employees&#8217; 401(k) accounts in the form of our common stock. Beginning in 2020, our matching contributions are in the form of cash. We recorded compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzg5OTU_5b02cccb-0316-4fd2-a3e1-33bd1e305d91">9.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzg5OTk_bc73e6c6-ae29-4754-8909-9eb833b1c9ed">6.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkwMDY_c4219260-d888-493a-b4a5-181773578d84">4.6</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively, for matching contributions to our employees 401(k) accounts.</ix:continuation> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_109"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzQ3MDg_904b6d2e-5b86-4f3b-90fc-10c5f312ee4e" continuedAt="i9a05dcfa3b86479c89cc4fd6a7117cbe" escape="true">PROVISION FOR INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i9a05dcfa3b86479c89cc4fd6a7117cbe" continuedAt="iddbc0981724f4ae9897246884b1ecc2e"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzQ3MDM_21402c46-3993-452b-86bc-99773e519514" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income before income taxes is derived solely from within the U.S. Our provision for income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzMtMS0xLTEtMjU3Mzk_173e3bda-88dc-4924-b0b8-2cee0d8c2cbf">11,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzMtMy0xLTEtMjU3Mzk_e31b9c67-060b-4b94-aebf-af42327fee6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzMtNS0xLTEtMjU3Mzk_a7d53d10-7651-40a2-97ae-9c081ceba855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzQtMS0xLTEtMjU3Mzk_13a97c56-bc23-4e3e-9396-5462a594220a">5,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzQtMy0xLTEtMjU3Mzk_f33615bf-30c4-407a-bfcb-811cca7863ab">3,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzQtNS0xLTEtMjU3Mzk_e3c4af76-f7a9-4f15-99d5-0cdb10e6c6ff">6,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzUtMS0xLTEtMjU3Mzk_69809c97-94b3-4dd1-bc39-0cfb42cd6032">16,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzUtMy0xLTEtMjU3Mzk_55c01b20-863f-43b6-97b0-adc519d6fd7a">3,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzUtNS0xLTEtMjU3Mzk_5dcf5275-13f2-4809-9c2d-663e20fab323">6,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzctMS0xLTEtMjU3Mzk_2beb7f9f-877e-412c-8cb9-d2889d094fb4">46,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzctMy0xLTEtMjU3Mzk_b1b33849-ffd9-4d11-9a3e-f7895d7e83f9">14,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzctNS0xLTEtMjU3Mzk_415d1999-dbd6-4adb-b8dd-9d7493a7578f">71,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzgtMS0xLTEtMjU3Mzk_7173114e-6d70-4d4a-9069-32793a1b60b8">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzgtMy0xLTEtMjU3Mzk_1ac6479e-1bdf-487f-aed1-59e43cbb39b1">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzgtNS0xLTEtMjU3Mzk_3e76f0d3-5c2c-4e52-96fe-5d24c537397f">578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzktMS0xLTEtMjU3Mzk_2c9328e3-82ac-4ade-8f94-0188bd5d41a2">46,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzktMy0xLTEtMjU3Mzk_99b574d2-212a-4cfc-95d7-017978fdbd67">15,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzktNS0xLTEtMjU3Mzk_ffbdb562-4875-4178-aa3e-ce6f4c34e0ff">71,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzEwLTEtMS0xLTI1NzM5_e77c8404-d728-4c84-969c-47836b3a1947">63,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzEwLTMtMS0xLTI1NzM5_ad197e0a-8bc6-425e-ad1b-b0a4885bc963">19,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzEwLTUtMS0xLTI1NzM5_d257f71b-a6a2-42f1-810a-f42ee6b57b80">77,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the years ended December&#160;31, 2021, 2020, and 2019 primarily relates to the utilization of federal tax attributes and state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our historical net operating losses were sufficient to fully offset any federal taxable income for the years ended December 31, 2020 and 2019 but were not sufficient to fully offset federal taxable income for the year ended December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzQ2ODc_b9e3ce94-2ad3-476f-8d6f-a3ec87cfe494" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2021, 2020 and 2019, respectively, to our provision for income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal income tax provision at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzItMS0xLTEtMjU3Mzk_e26e27cb-d84a-4565-b467-86e0bbb678d1">61,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzItMy0xLTEtMjU3Mzk_633179db-0300-4d17-a8eb-f891906388a3">27,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzItNS0xLTEtMjU3Mzk_b076d806-3091-487c-9a7b-dbe0cbeb821e">83,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax (benefit) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzMtMS0xLTEtMjU3Mzk_5e6b6334-3406-4a27-a71b-33ce54fbe4dd">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzMtMy0xLTEtMjU3Mzk_5d3e15ac-a0fc-4ca9-bc9a-1c56da9b2a35">2,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzMtNS0xLTEtMjU3Mzk_035a2f65-8229-4ce9-a2c2-19e465c9d7f8">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzQtMS0xLTEtMjU3Mzk_bc70cc98-abfd-4948-9395-2cd24c8d7aba">2,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzQtMy0xLTEtMjU3Mzk_fdb05746-5c3c-40a9-9d87-4bbdfbcae5ac">5,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzQtNS0xLTEtMjU3Mzk_131ac572-4f69-477b-8622-4a41b6e3aabe">3,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzUtMS0xLTEtMjU3Mzk_dce2b892-8430-498e-b89a-8aa8d4b098ef">6,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzUtMy0xLTEtMjU3Mzk_85435b8a-c19d-4b14-8cea-9259931da9a1">11,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzUtNS0xLTEtMjU3Mzk_646b5792-a646-438f-b274-4c70f809234d">8,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzYtMS0xLTEtMjU3Mzk_21c47cef-4ee2-4aeb-8fd3-a96dc5c01c18">11,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzYtMy0xLTEtMjU3Mzk_c31d9e13-aac9-4738-941a-807a389367d5">20,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzYtNS0xLTEtMjU3Mzk_d328041c-bda5-4ed8-83cc-746e78752958">9,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzctMS0xLTEtMjU3Mzk_413f5490-64c5-4f09-97bf-8d223fe39d5f">11,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzctMy0xLTEtMjU3Mzk_ff2f3d8e-613c-4bd4-8ebb-f5b04af8d066">18,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzctNS0xLTEtMjU3Mzk_2e8a3807-360e-4961-9bd0-4397f5fcc93f">4,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzgtMS0xLTEtMjU3Mzk_a08a1dcc-b2f3-4997-818e-89617136ec7c">2,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzgtMy0xLTEtMjU3Mzk_ecc706b1-b4dc-409b-ab82-8cd0dc4d9b6d">2,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzgtNS0xLTEtMjU3Mzk_6beb0647-e979-4b8a-9694-565faa55ce9b">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzktMS0xLTEtMjU3Mzk_61e983b7-c891-45eb-8dcb-18f34213b640">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzktMy0xLTEtMjU3Mzk_d76a6f0b-80a7-4d36-ab3c-459451ec2a25">562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzktNS0xLTEtMjU3Mzk_7f96afcd-f895-48dd-a8fb-2b967ad45cce">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzEwLTEtMS0xLTI1NzM5_b6b21ea5-12e1-403e-aada-b0f69015468e">63,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzEwLTMtMS0xLTI1NzM5_16145e79-4c28-415a-affa-5f5e79ab41b3">19,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzEwLTUtMS0xLTI1NzM5_9c6a85c7-0f7e-4ae2-97c3-dee875474fd4">77,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="iddbc0981724f4ae9897246884b1ecc2e" continuedAt="i279c20ee7f2d49d7893c1599f0a0e753"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzQ2OTk_e92c3276-ae83-476b-a855-64046a47b4e7" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzMtMS0xLTEtMjU3Mzk_75036b15-ec57-43cf-b493-de578c5fe206">17,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzMtMy0xLTEtMjU3Mzk_0eddf34b-45c4-4356-b139-11494f25ec1f">37,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzQtMS0xLTEtMjU3Mzk_034aed2e-c143-4769-8ed2-2e3e4c0ff701">101,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzQtMy0xLTEtMjU3Mzk_089d2136-fc97-48b0-afc6-2ebb947bf09d">126,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzUtMS0xLTEtMjU3Mzk_febcc0c0-a2d0-4edc-86b3-9d802f576a57">7,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzUtMy0xLTEtMjU3Mzk_04072062-6338-4852-b69d-b807af94dc75">18,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzYtMS0xLTEtMjU3Mzk_8c7265db-51ae-44b9-8fad-a91a82b53c77">23,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzYtMy0xLTEtMjU3Mzk_e5c682bd-c6c1-4c55-a78a-a462b3d082b9">19,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="exel:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzctMS0xLTEtMjU3Mzk_cca9c06b-4628-4a26-b5b8-54cd1799a655">12,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="exel:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzctMy0xLTEtMjU3Mzk_0bdd156a-3701-4549-a595-fc81e939ada8">11,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves not currently deductible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzgtMS0xLTEtMjU3Mzk_1f1f6f98-ce07-48dc-bca2-0f4d045f218b">19,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzgtMy0xLTEtMjU3Mzk_67fcf444-3e23-47f3-8ff3-dd975297b1cf">12,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzktMS0xLTEtMjU3Mzk_0b0d2698-0644-4fa6-b909-f72459c5c1c5">8,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzktMy0xLTEtMjU3Mzk_2950c7c6-338c-4831-86b2-4ff152ea0c2c">7,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzEwLTEtMS0xLTI1NzM5_7fed7fed-b11a-4682-b2f6-6a0e3db807be">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzEwLTMtMS0xLTI1NzM5_dc0f13a5-8bd3-458e-9e91-20f775dd2da6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzExLTEtMS0xLTI1NzM5_6ee3bf51-9faa-4473-9843-80761b559ce8">191,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzExLTMtMS0xLTI1NzM5_2c1d370a-8b2f-41d2-b788-2c9637bf345f">234,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzEyLTEtMS0xLTI1NzM5_5422e5b9-d47b-4f5f-8c89-f515a844ff94">70,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzEyLTMtMS0xLTI1NzM5_def5c630-308f-4e9e-87de-affab0c5b4a1">67,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzEzLTEtMS0xLTI1NzM5_61f0e040-9a50-4117-8831-db284fc6da7b">121,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzEzLTMtMS0xLTI1NzM5_94f64b7b-8167-4f91-90fd-a3750f741935">166,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE1LTEtMS0xLTI1NzM5_926d6136-4287-4ee1-9033-9458ce9bd184">9,907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE1LTMtMS0xLTI1NzM5_28c7017c-1717-4a89-a5cc-89074266bfdc">9,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE2LTEtMS0xLTI1NzM5_fd7a1c1a-d6bb-4968-935a-781b52754538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE2LTMtMS0xLTI1NzM5_6d1ba847-2fa3-4b36-8363-a8e49a0e5d51">657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE3LTEtMS0xLTI1NzM5_cf811a8b-dc1d-4327-bc2e-e265d22051e2">9,907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE3LTMtMS0xLTI1NzM5_849df4de-e6af-4640-af15-eef8d25092b5">10,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE4LTEtMS0xLTI1NzM5_98bbd16b-0545-40c5-a5e7-0fa2cb35ca1e">111,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE4LTMtMS0xLTI1NzM5_8982027f-e461-44e0-b204-2855ce62713d">156,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 740: Income Taxes (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December&#160;31, 2021, based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position as of December&#160;31, 2021 and forecasts of future operating results, as well as considering the utilization of net operating losses and tax credits prior to their expiration, management determined that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets are realizable. As of December&#160;31, 2021 and 2020, we continue to carry a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzI0ODE_395164de-60e8-45fe-9c1e-bd81524479d1">70.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzI0ODg_1c7462fb-bda0-40d6-a2cf-2e58085856f5">67.2</ix:nonFraction> million, respectively, against our California state deferred tax assets. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzI1ODY_62ead1ee-2993-49da-9236-db3d74501b9f">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzI1OTM_75113d47-43c5-43b3-8a88-f37c17176b1f">5.5</ix:nonFraction> million during the years ended December 31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, we had federal business tax credits of approximately $<ix:nonFraction unitRef="usd" contextRef="i420a84572c824730897fc79711ca81fe_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzE2NDkyNjc0NTEyMjM_ecadc0c8-b7e7-49ba-9fcf-c48a81c5bc11">101.0</ix:nonFraction> million which expire in the years 2025 through 2041. We also had state net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="if84d627e667d48f29f5af7ff692d0370_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzE2NDkyNjc0NTEzNTc_e4a29ece-da63-4317-8111-3868c85595ce">426.0</ix:nonFraction> million, which expire in the years 2022 through 2036, California research and development tax credits of approximately $<ix:nonFraction unitRef="usd" contextRef="i8b39280de5b64a109031af851502c539_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzMwMjQ_3f5c73ee-d135-40a1-9fcf-8f1aa10bcb53">45.0</ix:nonFraction> million, which do not expire, and California Competes Tax Credits of approximately $<ix:nonFraction unitRef="usd" contextRef="i8b39280de5b64a109031af851502c539_I20211231" decimals="-5" name="exel:TaxCreditCarryforwardAmountWithExpirationPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzMwOTE_c7254881-7cc7-478c-b0f8-9ba1494de37c">2.0</ix:nonFraction> million, which expire in 2026.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 analysis through December&#160;31, 2021, and concluded that an ownership change, as defined under Section 382, had not occurred. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i279c20ee7f2d49d7893c1599f0a0e753" continuedAt="icfd2bea020a24b30ba4c9350a760603c"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzQ2OTQ_03af2b89-1ae4-49af-bdac-0b71a6ff37a3" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzItMS0xLTEtMjU3Mzk_e8cfe093-115a-4f3c-b930-56954a53c395">80,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d03c75ce0024c01a62fcd27957b4f04_I20200103" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzItMy0xLTEtMjU3Mzk_03160533-1bc5-4ae0-b02a-aed877c28a3b">79,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i396cffc473714e59a1c966a366a443e2_I20181228" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzItNS0xLTEtMjU3Mzk_ec25aa6a-dcb1-4727-855d-036edcd4b700">76,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to prior year provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzMtMS0xLTEtMjU3Mzk_9a2dc768-71db-4f29-a8cb-4d8b580297d8">728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzMtMy0xLTEtMjU3Mzk_b7ed7b32-7068-4a14-96e5-438d73f12201">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzMtNS0xLTEtMjU3Mzk_3257ae65-9d27-4141-bf79-4ef1a1855ce7">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to current year provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzQtMS0xLTEtMjU3Mzk_bae2f2fe-6916-472c-876a-2f5c95eef12f">2,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzQtMy0xLTEtMjU3Mzk_5eec1d32-c078-4251-b4f2-7c38c858557f">3,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzQtNS0xLTEtMjU3Mzk_30c897c2-9a5a-4f82-b7fd-d1812fcf067c">2,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on the lapse of the applicable statutes of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzUtMS0xLTEtMjU3Mzk_c010d732-15e8-4be3-bcd2-95d3c0e228c2">301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzUtMy0xLTEtMjU3Mzk_02d2c597-f1ea-4ddc-a31c-1bc1fc88833e">2,033</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzUtNS0xLTEtMjU3Mzk_1a750d71-76a9-47bf-aaa0-05525060e5d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzYtMS0xLTEtMjU3Mzk_dad5a72f-f460-44f1-9a21-dafcd20985a7">83,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzYtMy0xLTEtMjU3Mzk_f8842de1-ca51-4d7b-a2a9-eeba21064b7d">80,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d03c75ce0024c01a62fcd27957b4f04_I20200103" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzYtNS0xLTEtMjU3Mzk_7b57dc3d-3a7c-4b50-811b-84ce721c41c9">79,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate that the amount of unrecognized tax benefits existing as of December&#160;31, 2021 will significantly change over the next 12 months. As of December&#160;31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzM5MDI_9b08bb47-0077-4781-babc-540a2e13303b">83.6</ix:nonFraction> million in unrecognized tax benefits, of which $<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzE2NDkyNjc0NTE4OTE_576043d6-0275-475f-b0bb-a273ac29a719">52.6</ix:nonFraction> million would reduce our provision for income taxes and the effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Income as a component of income taxes. </span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icfd2bea020a24b30ba4c9350a760603c">We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 2001 through 2021 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.</ix:continuation> </span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_112"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90ZXh0cmVnaW9uOjg0OWNjMjY1OWUzOTQ5NjRiYmRhYTcwYjI1NGIwZjIyXzgzNA_82dc7508-93fd-4e6c-8b23-472752eba188" continuedAt="ia37057abbf8140b483d6b16cab027a9e" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ia37057abbf8140b483d6b16cab027a9e"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90ZXh0cmVnaW9uOjg0OWNjMjY1OWUzOTQ5NjRiYmRhYTcwYjI1NGIwZjIyXzgzMA_c2936f21-74b7-48e9-8400-99f6a0163045" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d4436bfbe6489187e15748fba98eba_D20210102-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzMtNS0xLTEtMjU3Mzk_a4a0e49b-538b-4769-b3b0-0a000826d2d8">231,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzMtNy0xLTEtMjU3Mzk_8de384b5-b560-4513-8421-2ea9f5137b05">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzMtOS0xLTEtMjU3Mzk_bc76ab92-7f7e-4c2e-90b3-592155118fc0">321,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzYtNS0xLTEtMjU3Mzk_990c6d4e-41a0-40a9-9d5e-c73d6ccb9a7e">314,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzYtNy0xLTEtMjU3Mzk_02b76316-39b2-4876-99df-4550bd25a008">308,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzYtOS0xLTEtMjU3Mzk_ff47dd4e-b9d8-41fd-87c0-f315a2fb6270">302,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzctNS0xLTEtMjU3Mzk_2e047825-8911-4491-ba3b-456d79f5f541">7,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzctNy0xLTEtMjU3Mzk_923d8b8b-1462-4c91-83be-9cc94f2a98c8">9,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzctOS0xLTEtMjU3Mzk_5271fe29-afc6-4cc9-ba8e-71313f89c5f7">12,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzgtNS0xLTEtMjU3Mzk_7b0f2823-8a19-4caa-8ce4-ede2d5e74a78">322,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzgtNy0xLTEtMjU3Mzk_cbba7e85-8ef4-45d2-8ee4-fe645921e55d">318,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzgtOS0xLTEtMjU3Mzk_ce175e41-5be8-4387-8b13-db0cec65ba3a">315,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzEwLTUtMS0xLTI1NzM5_d0412897-a7a9-418b-ba1d-386e5c427995">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzEwLTctMS0xLTI1NzM5_17cb74be-19a8-408b-9aa9-1777d90d4f3d">0.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzEwLTktMS0xLTI1NzM5_3ef80348-21aa-44cd-ae45-1f3f7622a84a">1.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzExLTUtMS0xLTI1NzM5_c137cefc-10d3-4f81-b90e-008ea0bcc9e2">0.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzExLTctMS0xLTI1NzM5_2bcdf78e-5712-4513-a37f-463e77663f96">0.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzExLTktMS0xLTI1NzM5_96fe491a-ecd6-4aa7-8be4-4584925d4d52">1.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, unvested RSUs and PSUs and ESPP contributions. Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. See &#8220;Note 8. Employee Benefit Plans&#8221; for a further description of our equity awards. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90ZXh0cmVnaW9uOjg0OWNjMjY1OWUzOTQ5NjRiYmRhYTcwYjI1NGIwZjIyXzgxOA_0a1495bc-89a9-428f-946a-62964258b542" continuedAt="ic3cccbb703cf4fdbab4c0020bc74f277" escape="true">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="ic3cccbb703cf4fdbab4c0020bc74f277"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13ee6cf1e5c848d2b6f0a4bd3a76af26_D20210102-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo2NmQ2YWNhMzMxZmE0NzM1OGVhMGM2ZjkxYjA2NWU0OS90YWJsZXJhbmdlOjY2ZDZhY2EzMzFmYTQ3MzU4ZWEwYzZmOTFiMDY1ZTQ5XzItNS0xLTEtMjU3Mzk_dc97d33f-e0da-42d9-a8b9-d23feb5a8bbe">14,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i345c9b326f5c4c488b5009d48f08f45f_D20200104-20210101" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo2NmQ2YWNhMzMxZmE0NzM1OGVhMGM2ZjkxYjA2NWU0OS90YWJsZXJhbmdlOjY2ZDZhY2EzMzFmYTQ3MzU4ZWEwYzZmOTFiMDY1ZTQ5XzItNy0xLTEtMjU3Mzk_952f0bde-dc9b-4a1c-a7d5-efd82338b809">10,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i045cc234fe6d42e29ebae3f4719abd7e_D20181229-20200103" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo2NmQ2YWNhMzMxZmE0NzM1OGVhMGM2ZjkxYjA2NWU0OS90YWJsZXJhbmdlOjY2ZDZhY2EzMzFmYTQ3MzU4ZWEwYzZmOTFiMDY1ZTQ5XzItOS0xLTEtMjU3Mzk_e0dcb058-62a0-4cf2-8a88-1c4f142273ba">9,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="ib1dc779af6a3491c9aef59246f08fe04_115"></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkwNDE_3e2507bf-0cf7-48f3-9b3d-09e2ae77116f" continuedAt="i796bb26ce4654e81b485772c0a1a0147" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i796bb26ce4654e81b485772c0a1a0147" continuedAt="i55798428beff4251a1dba5b6a0bfc089"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Headquarters Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located in Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018, April 2019, August 2019, January 2020 and December 2020, resulting in, among other things, an increase to the amount of space leased and changes to the lease term. Our right-of-use asset, lease liability and the related lease costs reflect the <ix:nonFraction unitRef="sqft" contextRef="ia8b2c55942a54b85b0a416b604b6a2b5_I20211231" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzQ5NDc4MDIzNTg5ODk_c88af4b2-ac08-41bf-88ad-96396b6ce6f6">254,690</ix:nonFraction> square feet of space we have taken possession of as of December 31, 2021 (the Current Premises) under the amended Lease, including <ix:nonFraction unitRef="sqft" contextRef="i70af130f4dae44efb4c5edbc61ae24bc_I20211231" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzMxMzM2MDgxNDM5NTM1_c6ce4674-330f-4df6-a76e-c0dd38cae610">25,749</ix:nonFraction> square feet of space we took possession of in 2021. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Lease continues through October 31, 2031 (the Lease Term). We have <ix:nonFraction unitRef="renewal_options" contextRef="i09d02a3201ea4cd9abf78408a6c51ddc_D20210102-20211231" decimals="INF" name="exel:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkxNQ_f957ccb9-4ac5-4b90-8268-b7eb91fdecbe">two</ix:nonFraction> <ix:nonNumeric contextRef="ia8b2c55942a54b85b0a416b604b6a2b5_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkwMzg_d62ec43e-abc7-4784-bf4c-d455df9c373d">five-year</ix:nonNumeric> options to extend the Lease; these optional periods have not been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made certain tenant improvements on the Initial Premises, for which we received $<ix:nonFraction unitRef="usd" contextRef="ia7f4ccf1863646c7ad5275dd80a4cbd4_I20190131" decimals="-5" name="exel:TenantLeaseImprovementsAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzEyNjI_217cfd58-83d6-499b-b82f-9aa031a2cdad">8.2</ix:nonFraction> million in reimbursements in January 2019. During 2020, we also made certain tenant improvements for which we have received $<ix:nonFraction unitRef="usd" contextRef="ib15b9dd84185469e883fb78ad72ac110_I20211231" decimals="-5" name="exel:TenantLeaseImprovementsAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2Xzk4OTU2MDQ2ODQ5ODE_7f20659e-ccd7-428b-9c0c-075db83b2bd5">1.7</ix:nonFraction>&#160;million in reimbursements in 2021 related to the additional space we obtained under the April 2019 amendment. We were also provided an allowance of up to $<ix:nonFraction unitRef="usd" contextRef="ia3b3d07f431b4ca096bce3b9f83ca347_I20211231" decimals="-5" name="exel:TenantLeaseImprovementsAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzIxOTkwMjMyNjQ2MTE_c8ec33d8-9bfa-4228-bc46-c014c976b6bb">1.4</ix:nonFraction> million in 2021 for certain planned tenant improvements to the additional space obtained under the December 2020 amendment. </span></div><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="exel:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkwNTE_69bf3b4e-871e-4b25-ac22-227dc1315073" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_7a0e4465-a6b5-4b02-b58f-7014879a369f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_dc2f3847-52aa-4192-8d7c-2b18b469e239">Right-of-use assets included in other long-term assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMS0xLTEtMjU3Mzk_ccd9d4b0-2b05-4583-b6fe-7c52cde9d843">45,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMy0xLTEtMjU3Mzk_c5cca64d-1062-4967-b0f6-b2cec75ab456">43,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_5d4462a3-e4ad-42c2-8f32-f51e009f8ca0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_ae5d588d-a5da-417a-8318-ddd0d907793d">Current portion included in other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMS0xLTEtMjU3Mzk_9eb860e7-cfd0-4237-b86a-7b29552ab7ed">5,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMy0xLTEtMjU3Mzk_36271583-8c85-4c00-a096-2876a256b08e">3,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzYtMS0xLTEtMjU3Mzk_ed5cac00-d484-4771-a568-18ecba1a31d7">51,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzYtMy0xLTEtMjU3Mzk_7837c2e2-65a4-48da-9db2-d432aad095fa">49,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzctMS0xLTEtMjU3Mzk_9a5c588e-f803-4519-aaf2-4d23b417e74a">56,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzctMy0xLTEtMjU3Mzk_1a03f2a9-100e-44ab-8134-49c2ec9912ba">52,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkwNDk_a9409f2a-45cf-43de-b749-e38ec1f01e43" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzItNS0xLTEtMjU3Mzk_271ed6f4-dc65-42f8-985e-e5958fbb11b1">5,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzItNy0xLTEtMjU3Mzk_93573153-583a-416f-af0f-35c650aa106a">4,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzItOS0xLTEtMjU3Mzk_2930490d-d382-4f21-b8bb-93e4aee779ee">2,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzMtNS0xLTEtMjU3Mzk_5a0da772-878a-4913-a0c8-04a024571ad3">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzMtNy0xLTEtMjU3Mzk_f1943849-f7fc-47a8-84a7-939e074d266d">2,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzMtOS0xLTEtMjU3Mzk_12b1a84a-0dfe-4251-a1c4-0c5cc7add315">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzUtNS0xLTEtMjU3Mzk_949e76a0-3433-4dde-ba43-496bdaee4665">8,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzUtNy0xLTEtMjU3Mzk_4b249734-cf5e-4aba-b977-9d4262e0c564">7,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzUtOS0xLTEtMjU3Mzk_57612d3b-df11-41ff-9efd-f16d66c53902">3,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities for the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzE5NzA_b83ccdc0-7f33-4932-9c20-4ea1f1e3ca1f">5.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzgyNDYzMzcyNTYxMjk_885b7a23-6551-4adb-8a6e-2a9bb3b7f613">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzgyNDYzMzcyNTYxMzk_e74c05e9-5cc1-4084-a452-a07295954d1f">2.9</ix:nonFraction>&#160;million, respectively, and was included in net cash provided by operating activities in our Consolidated Statements of Cash Flows.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i55798428beff4251a1dba5b6a0bfc089" continuedAt="i073f78f49ae440a8be451b93f3a62c00"><ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkwNTA_ffc3261c-d1a0-4986-89c2-125f3ca5d538" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.186%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzEtMi0xLTEtMjU3Mzk_14cf74ed-9406-4c26-99d0-04e01404a114">5,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzItMi0xLTEtMjU3Mzk_2de9a818-bbcb-40b0-bb2c-ce6ae71821e8">5,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzMtMi0xLTEtMjU3Mzk_b3f85c94-f6b2-49c3-beaa-8f5b76efa099">6,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzQtMi0xLTEtMjU3Mzk_7de7937b-4f85-4a97-8fba-e675d223bf56">6,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzUtMi0xLTEtMjU3Mzk_9662aa75-864e-491c-aed1-70d4bfdb5eec">6,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzYtMi0xLTEtMjU3Mzk_d9cec6a5-7799-4061-a4b8-66c25a290c4b">35,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzctMi0xLTEtMjU3Mzk_dcedd2cd-c5bd-4a0a-8f26-dec6b3bd057b">66,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzktMi0xLTEtMjU3Mzk_b8c5c61a-829b-4fc0-ab14-3566f59abc2a">9,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future tenant improvement reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzEwLTItMS0xLTI1NzM5_e163305e-a08d-4b08-8430-eccb14e356ca">426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzExLTItMS0xLTI1NzM5_96145ddd-d2ef-4a6c-a5bb-1bab4e14f751">56,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the weighted average discount rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzIyNzM_846d51cf-ac51-4c4f-89ff-47b3bdd18336">3.1</ix:nonFraction>% and the weighted average remaining lease term was <ix:nonNumeric contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzIzMjU_133d7649-3d1a-4a62-b834-c5416519bbec">9.8</ix:nonNumeric> years. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Build-to-Suit Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we entered into a build-to-suit Lease Agreement (the Build-to-Suit Lease) for approximately <ix:nonFraction unitRef="sqft" contextRef="id1ee46f49349499882d7dd859933eb48_I20191031" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzI0NTk_08b31d5f-253d-4942-af2e-7058539a8887">220,000</ix:nonFraction> square feet of office space located in Alameda, California (the New Premises), adjacent to the Current Premises.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Build-to-Suit Lease is for a period of <ix:nonNumeric contextRef="id1ee46f49349499882d7dd859933eb48_I20191031" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzI2MzA_19868f12-398c-487e-90b1-ca7146ef6355">242</ix:nonNumeric> months (the Term), which will begin upon the substantial completion of the building and tenant improvements by the lessor. We currently anticipate that the Term will begin in the first quarter of 2022 (which date will be the Lease Commencement Date). The monthly base rent under the Build-to-Suit Lease will equal a percentage of the total development costs incurred in connection with the development of the New Premises (excluding the cost of the tenant improvements in excess of the allowance provided by the lessor and any development costs we pay) and is currently estimated to be about $<ix:nonFraction unitRef="usd" contextRef="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031" decimals="-5" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzMxOTE_5f09c697-1938-4bb9-a7a7-6b06bede1dad">0.7</ix:nonFraction> million, subject to an annual increase of <ix:nonFraction unitRef="number" contextRef="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031" decimals="INF" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzMyMjg_7fddd606-8380-4e5c-ae43-a9a825be0784">3</ix:nonFraction>% during the Term. We will also be responsible for paying operating expenses related to the New Premises. The rent payments will begin <ix:nonNumeric contextRef="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031" name="exel:LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzMzNjQ_238f328b-9476-4800-85df-ef5137cab52f">sixty days</ix:nonNumeric> following commencement of the Term. We have been provided a tenant improvement allowance for the New Premises of approximately $<ix:nonFraction unitRef="usd" contextRef="id1ee46f49349499882d7dd859933eb48_I20191031" decimals="-5" name="exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzM0OTQ_d41cb13d-bddd-4d90-8e8b-69b1f0122a42">16.5</ix:nonFraction> million. To the extent that the total development costs of the New Premises exceeds $<ix:nonFraction unitRef="usdPerSqft" contextRef="id1ee46f49349499882d7dd859933eb48_I20191031" decimals="INF" name="exel:AreaOfRealEstatePropertyAvailableToLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzM1NzM_3a0803ad-4323-4f2f-b261-599c688c0868">525</ix:nonFraction> per square foot, we will also pay <ix:nonFraction unitRef="number" contextRef="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031" decimals="2" name="exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzM2MTA_eddbdb9d-5cb6-43b0-8ff0-101c964798a3">50</ix:nonFraction>% of such excess costs prior to the commencement of the Term, and we are required to secure such amount by providing a letter of credit or depositing such amounts in an account with the lessor&#8217;s lender.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Build-to-Suit Lease includes <ix:nonFraction unitRef="renewal_options" contextRef="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031" decimals="INF" name="exel:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzM4NDc_4d07c997-4001-4b96-894a-ba49608ef7ea">two</ix:nonFraction> <ix:nonNumeric contextRef="id1ee46f49349499882d7dd859933eb48_I20191031" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkwNTM_512b72e6-0557-4ca6-a38c-61634a92e437">five-year</ix:nonNumeric> options to extend the term of the Build-to-Suit Lease, exercisable under certain conditions and at a market rate determined in accordance with the Build-to-Suit Lease. We have a one-time option to terminate the Build-to-Suit Lease without cause after the <ix:nonNumeric contextRef="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031" name="exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzQxMTM_c0e989b7-3dd2-4089-9e6a-b5f32be63050">180</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month of the Term, exercisable under certain conditions as described in the Build-to-Suit Lease and subject to a termination payment calculated in accordance with the Build-to-Suit Lease. In addition, we have a right of first offer to purchase the New Premises, subject to certain procedures and exclusions set forth in the Build-to-Suit Lease. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that, under the guidance provided in Topic 842, we do not have control of the New Premises during the construction period. Therefore, we will not record a right-of-use asset or lease liability for the Build-to-Suit Lease until the Lease Commencement Date. We will evaluate the classification of the Build-to-Suit Lease as an operating lease or financing lease at the Lease Commencement Date. We determined the cost of tenant improvements during the construction period are lessor assets and considered a prepayment of lease under Topic 842. The costs incurred as of December&#160;31, 2021 of $<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-5" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzE2NDkyNjc0NTA3MzQ_2958b243-1de0-4579-a9af-48c0f71d68b4">36.8</ix:nonFraction> million are recorded as other long-term assets in the Consolidated Balance Sheets.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i073f78f49ae440a8be451b93f3a62c00" continuedAt="i14eade72847d4fdf875e9e445da748de"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of $<ix:nonFraction unitRef="usd" contextRef="i2e77e8a209894b9ea42d468fd28563b8_I20211231" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzQzOTgwNDY1NDYxODE_e29bf672-f4d5-4d99-9c0c-7a668c7203c7">16.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7054208b42f440b38822d84184f73e38_I20210101" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzQ5NDc4MDIzNTc4OTI_aa26e2bc-e833-448b-bb21-d7375c129ffc">1.6</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a standby letter of credit as guarantee of our obligation to fund our portion of the tenant improvements related to our build-to-suit lease at our corporate campus. The letter of credit is secured by our short-term investments, which are recorded as restricted cash equivalents and presented in Other long-term assets in our Consolidated Balance Sheets and is reduced as we fund our portion of the tenant improvements. As of December&#160;31, 2021, restricted cash equivalents included $<ix:nonFraction unitRef="usd" contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231" decimals="-5" name="us-gaap:RestrictedCashEquivalentsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzE2NDkyNjc0NzU5MjQ_fb7af98d-924a-4b74-997a-6822f3e39066">15.2</ix:nonFraction> million of short-term investments as collateral under our standby letter of credit for our portion of the tenant improvements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473 (composition of matter) or U.S. Patent No. 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patent Nos. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent Nos. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent Nos. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patent Nos. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patent Nos. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patent Nos. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. A bench trial has been scheduled for May 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of four previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patent Nos. 11,091,439 (salt and polymorphic forms) 11,091,440 (formulations) and 11,098,015 (methods of treatment). We have 45 days from receipt of the January 11, 2022 notice to file a patent infringement claim against MSN relating to the newly challenged patents.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><ix:continuation id="i14eade72847d4fdf875e9e445da748de"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with Teva Pharmaceutical Industries Limited (Teva Parent), asserting infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On February 8, 2022, the parties filed a stipulation to stay all proceedings, which was granted by the Delaware District Court on February 9, 2022. The stipulation and order were filed under seal.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_124"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_127"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the evaluation of our disclosure controls and procedures (as defined under Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) required by Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended, our Chief Executive Officer and our Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the Effectiveness of Controls.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f). Our internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S.&#160;generally accepted accounting principles.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of our 2021 fiscal year, management conducted an assessment of the effectiveness of our internal control over financial reporting based on the framework established in the original </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8211; Integrated Framework</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO). Based on this assessment, management has determined that our internal control over financial reporting as of December&#160;31, 2021 was effective. There were no material weaknesses in internal control over financial reporting identified by management.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The independent registered public accounting firm Ernst&#160;&amp; Young LLP has issued an audit report on our internal control over financial reporting, which is included on the following page.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Exelixis, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control </span><span style="color:#333333;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Over</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Exelixis, Inc.&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Exelixis, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and January 1, 2021 and, the related consolidated statements of income, comprehensive income, stockholders&#8216; equity and cash flows for each of the three fiscal years in the period ended December 31, 2021, and the related notes and our report dated February 18, 2022 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redwood City, California</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;18, 2022</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_130"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between February 15, 2022 and February 16, 2022, we entered into new indemnification agreements with each of our directors and executive officers, the form of which is attached as Exhibit 10.1 to this Form 10-K. Pursuant to the indemnification agreement, we are required to indemnify the director or executive officer for all direct and indirect costs, including attorney&#8217;s fees, witness fees, and other out of pocket costs of whatever nature, incurred by the director or executive officer in any action or proceeding, whether actual, pending or threatened, subject to certain limitations, to which any of these people may be made a party by reason of the fact that he or she is or was a director or an executive officer of Exelixis or is or was serving or at any time serves at our request as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_133"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_136"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item relating to our directors and nominees, including information with respect to our audit committee, audit committee financial experts and procedures by which stockholders may recommend nominees to our Board of Directors, is incorporated by reference to the section entitled &#8220;Proposal&#160;1&#160;&#8211; Election of Directors&#8221; appearing in our Proxy Statement for our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after December&#160;31, 2021, which we refer to as our 2022 Proxy Statement. The information required by this item regarding our executive officers is incorporated by reference to the section entitled &#8220;Information about our Executive Officers&#8221; appearing in our 2022 Proxy Statement. The information, if any, required by this item regarding compliance with Section&#160;16(a) of the Securities Exchange Act of 1934, as amended, is incorporated by reference to the section entitled &#8220;Delinquent Section 16(a) Reports&#8221; appearing in our 2022 Proxy Statement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Corporate Code of Conduct that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. The Corporate Code of Conduct is posted on our website at www.exelixis.com under the caption &#8220;Investors &amp; Media&#8212;Corporate Governance&#8212;Corporate Governance Documents and information.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to satisfy the disclosure requirement under Item&#160;5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Corporate Code of Conduct by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of the Nasdaq Stock Market, by filing a Current Report on Form 8-K with the SEC, disclosing such information.</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_139"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the sections entitled &#8220;Compensation of Executive Officers,&#8221; &#8220;Compensation of Directors,&#8221; &#8220;Compensation Committee Interlocks and Insider Participation&#8221; and &#8220;Compensation Committee Report&#8221; appearing in our 2022 Proxy Statement.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_142"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item relating to security ownership of certain beneficial owners and management is incorporated by reference to the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; appearing in our 2022 Proxy Statement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information about our common stock that may be issued upon the exercise of stock options and other rights under all of our existing equity compensation plans as of December&#160;31, 2021, which consists of our 2000 Employee Stock Purchase Plan (the ESPP), our 2014 Equity Incentive Plan (the 2014 Plan), our 2016 Inducement Award Plan (the 2016 Plan) and our 2017 Equity Incentive Plan (the 2017 Plan):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:52.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">securities to&#160;be issued upon exercise of outstanding&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options, warrants and rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise&#160;price of outstanding&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options, warrants&#160;and&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by stockholders</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,658,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,172,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by stockholders</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,809,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,172,938&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Equity plans approved by our shareholders include the 2014 Plan, the 2017 Plan and the ESPP. As of December&#160;31, 2021, a total of 3,168,354 shares of our common stock remained available for issuance under the ESPP, and up to a maximum of 534,037 shares of our common stock may be purchased in the current purchase period. The shares issuable pursuant to our ESPP are not included in the number of shares to be issued pursuant to rights outstanding or and the weighted-average exercise&#160;price of such rights as of December&#160;31, 2021, as those numbers are not known.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The weighted-average exercise price takes into account the shares subject to outstanding restricted stock units (RSUs), including such awards with performance conditions, which have no exercise price. The weighted-average exercise price, excluding such outstanding RSUs, is $16.76.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Represents shares of our common stock issuable pursuant to the 2016 Plan. As of December&#160;31, 2021, no shares of our common stock remained available for additional grants under the 2016 Plan. In November 2016, the Board adopted the 2016 Plan pursuant to which we reserved 1,500,000 shares of our common stock for issuance under the 2016 Plan. The only persons eligible to receive grants of Awards under the 2016 Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 - that is, generally, a person not previously an employee or director of Exelixis, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Exelixis. An &#8220;Award&#8221; is any right to receive Exelixis common stock pursuant to the 2016 Plan, consisting of non-statutory stock options, stock appreciation rights, RSUs, or any other stock award.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_145"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the sections entitled &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Proposal 1 &#8211; Election of Directors&#8221; appearing in our 2022 Proxy Statement.</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_148"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the section entitled &#8220;Proposal 2&#160;&#8211; Ratification of Selection of Independent Registered Public Accounting Firm&#8221; appearing in our 2022 Proxy Statement. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_151"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ib1dc779af6a3491c9aef59246f08fe04_154"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.15pt">The following documents are being filed as part of this report:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;The following financial statements and the Report of Independent Registered Public Accounting Firm are included in Part II, Item&#160;8:</span></div><div style="margin-top:5pt;padding-left:54pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.285%"><tr><td style="width:1.0%"></td><td style="width:83.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_61">Report of Independent Registered Public Accounting Firm</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_61"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_61">(PCAOB ID:</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonNumeric contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xNTQvZnJhZzoyNDgxMDA5NTdhNjk0YWYyYWZiNTE1YWNiODkzNjI4YS90YWJsZTowNjI1NjBlMmUzYTM0NjMwODUyNjZjNWIwYzUxZmJhNy90YWJsZXJhbmdlOjA2MjU2MGUyZTNhMzQ2MzA4NTI2NmM1YjBjNTFmYmE3XzEtMC0xLTEtNDc2MzkvdGV4dHJlZ2lvbjo1NzM1YWUxNjUwMjg0OTY0YjljMGE5OGJiNjUyMTA1ZV80Mzk4MDQ2NTExMTc1_9e593fa1-5c1a-4d4b-9c71-32a259653196">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_61">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_64">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_67">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_67">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_70">Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_70">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_73">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_73">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_76">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_76">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_79">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_79">90</a></span></div></td></tr></table></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;All financial statement schedules are omitted because the information is inapplicable or presented in the Notes to Consolidated Financial Statements.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The following Exhibits are filed as part of this report.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex31.htm">Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/5/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000024/exhibit31amendedandres.htm">Amended and Restated Bylaws of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/3/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001947/0001012870-00-001947.txt">Specimen Common Stock Certificate.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-96335</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/5/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit42.htm">Description of the Common Stock of Exelixis, Inc. Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit101.htm">Form of Indemn</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit101.htm">ification</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit101.htm"> Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000170/def14a-20160413xproxy.htm">Exelixis, Inc. 2000 Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 14A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/13/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit101.htm">Exelixis, Inc. 2014 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit102.htm">Form of Stock Option Agreement under the Exelixis, Inc. 2014 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit104.htm">Form of Stock Option Agreement (Non-Employee Director) under the Exelixis, Inc. 2014 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit105.htm">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2014 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit102.htm">Exelixis, Inc. 2016 Inducement Award Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000278/exel201611218-kexhibit102.htm">Form of Stock Option Agreement under the 2016 Inducement Award Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/22/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000278/exel201611218-kexhibit102.htm">Form of Restricted Stock Unit Agreement under the 2016 Inducement Award Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/22/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit103.htm">Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000939767/000162828021001852/exel20201231exhibit1011.htm">Form of Stock Option Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">00-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/11/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1022.htm">Form of Stock Option Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit105.htm">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit106.htm">Form of Restricted Stock Unit Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000068/exel20200331exhibit104.htm">Non-Employee Director Equity Compensation Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/5/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000110465904022709/a04-8650_1ex10d43.htm">Offer Letter Agreement, dated February 3, 2000, between Exelixis, Inc. and Michael Morrissey, Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/5/2004</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976715000102/exel20150930exhibit105.htm">Offer Letter Agreement, dated June 30, 2015, between Exelixis, Inc. and Christopher Senner</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/10/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit1018.htm">Offer Letter Agreement, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit1018.htm">December 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit1018.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit1018.htm">21</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit1018.htm">, between Exelixis, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit1018.htm">Vicki L. Goodman</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit1018.htm">,&#160;M.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000018/exel20140331exhibit104.htm">Offer Letter Agreement, dated February 10, 2014, between Exelixis, Inc. and Jeffrey J. Hessekiel.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/1/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000149/exel20151231exhibit1024.htm">Offer Letter Agreement, dated August 11, 2000, between Exelixis, Inc. and Peter Lamb.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/29/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1026.htm">Offer Letter Agreement, dated August 19, 2010, between Exelixis, Inc. and Patrick J. Haley</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000013/exel20180212exhibit101.htm">Annual Cash Bonus Compensation Plan for Executives</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000035/exel20191231exhibit1029.htm">Cash Compensation Information for Non-Employee Directors.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000069/exel20180331exhibit105.htm">Exelixis, Inc. Change in Control and Severance Benefit Plan, as amended and restated.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/2/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000109/exel20190331exhibit104.htm">Policy for Recoupment of Variable Compensation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/1/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000137/exel20170630exhibit101.htm">Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1039.htm">First Amendment dated October 16, 2017, to Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000136/exel20180630exhibit102.htm">Second Amendment dated June 13, 2018, to Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/1/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000090/exel20190401exhibit101.htm">Third Amendment dated April 1, 2019, to Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/5/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000190/exel20190930exhibit102.htm">Fourth Amendment dated August 30, 2019, to Lease Agreement dated May 2, 2017, between Hillwood Enterprises, L.P. (as successor in interest to Ascentris 105, LLC) and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/30/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000035/exel20191231exhibit1037.htm">Fifth Amendment dated January 16, 2020, to Lease Agreement dated May 2, 2017, between Waterfront EDP, LLC (as successor in interest to Hillwood Enterprises, L.P.) and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000939767/000162828021001852/exel20201231exhibit1032.htm">Sixth Amendment dated December 11, 2020, to Lease Agreement dated May 2, 2017, between SCG Harbor Bay Parkway Phase I, LLC (as successor in interest to Waterfront EDP, LLC) and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/10/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000190/exel20190930exhibit103.htm">Lease Agreement dated October 25, 2019, between Ernst Development Partners, Inc. and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/30/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000035/exel20191231exhibit1039.htm">First Amendment dated January 16, 2020, to Lease Agreement dated May 2, 2017, between Alameda BTS EDP, LLC (as successor in interest to Ernst Development Partners, Inc.) and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000045/exhibit101ipsencollaborati.htm">Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000045/exhibit102firstamendmentto.htm">First Amendment dated December 20, 2016, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000045/exhibit103secondamendmentt.htm">Second Amendment dated September 14, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000045/exhibit104thirdamendmentto.htm">Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000045/exhibit105ipsensupplyagree.htm">Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000045/exhibit106firstamendmentto.htm">First Amendment dated October 26, 2017, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000157/exel20190630exhibit102.htm">Second Amendment dated May 17, 2019, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit1042.htm">Third A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit1042.htm">mendment dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit1042.htm">December 10, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit1042.htm">, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000126/exel2017033110-qaexhibit101.htm">Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/14/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000136/exel20180630exhibit101.htm">First Amendment dated March 22, 2018, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/1/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000157/exel20190630exhibit103.htm">Second Amendment dated May 7, 2019, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000150/exel20200930exhibit101.htm">Third Amendment dated September 3, 2020, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/5/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976720000035/exel20191231exhibit1062.htm">Joint Clinical Research Agreement dated December 18, 2019, by and between Exelixis, Inc. and F. Hoffmann-La Roche Ltd</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit211.htm">Subsidiaries of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_160">Power of Attorney (contained on signature page)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit311.htm">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit312.htm">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20211231exhibit321.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formatted as Inline XBRL and contained in Exhibit 101.</span></td></tr></table></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment granted for certain portions of this exhibit.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted as being immaterial and would be competitively harmful if publicly disclosed.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies this Annual Report on Form 10-K, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Annual Report on Form 10-K), irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div id="ib1dc779af6a3491c9aef59246f08fe04_157"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;None provided.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><div id="ib1dc779af6a3491c9aef59246f08fe04_160"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</span></div><div style="margin-top:5pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/    M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ICHAEL </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">M. M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ORRISSEY        </span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that each person whose signature appears below constitutes and appoints </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MICHAEL M. MORRISSEY</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHRISTOPHER J. SENNER </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> JEFFREY J. HESSEKIEL </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signatures</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORRISSEY</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, President and</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Chief&#160;Executive&#160;Officer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;(Principal&#160;Executive&#160;Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/    C</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">HRISTOPHER</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">J. S</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ENNER</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Chief&#160;Financial&#160;Officer </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;(Principal&#160;Financial and</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounting&#160;Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/    S</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">TELIOS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> P</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">APADOPOULOS </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">       </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stelios Papadopoulos, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/    C</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">HARLES </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">C</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">OHEN        </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charles Cohen, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/    C</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ARL </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">B. F</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ELDBAUM        </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carl B. Feldbaum, Esq.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ARIA </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">C. F</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">REIRE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maria C. Freire, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib1dc779af6a3491c9aef59246f08fe04_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signatures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    A</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LAN</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. G</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARBER </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Alan M. Garber, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    V</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">INCENT</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> T. M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARCHESI</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vincent T. Marchesi, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    G</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EORGE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> P</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSTE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">George Poste, DVM, Ph.D., FRS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    J</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ULIE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. S</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MITH</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Julie A. Smith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    L</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ANCE </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">W</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ILLSEY </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lance Willsey, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    J</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACQUELINE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RIGHT</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jacqueline Wright</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    J</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACK</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L. W</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">YSZOMIERSKI</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jack L. Wyszomierski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>exel20211231exhibit42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i90788561a5c045d5ab010c552d823469_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:24pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.2</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF THE COMMON STOCK OF EXELIXIS, INC. <br>REGISTERED PURSUANT TO SECTION 12 OF THE<br>SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Capital Stock</font></div><div style="margin-top:12pt;text-indent:17.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The authorized capital stock of Exelixis, Inc. (Exelixis, we, our or us) consists of 400,000,000 shares of common stock, $0.001 par value, and 10,000,000 shares of preferred stock, $0.001 par value. A description of material terms and provisions of the common stock, and our restated certificate of incorporation (certificate incorporation) and amended and restated bylaws (bylaws) affecting the rights of holders of our common stock is set forth below. The description is intended as a summary and is qualified in its entirety by reference to our certificate of incorporation and bylaws. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Common stock </font></div><div style="margin-top:6pt;text-indent:17.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Dividend rights</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-indent:17.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Voting rights</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each holder of common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Our certificate of incorporation does not provide for the right of stockholders to cumulate votes for the election of directors. Our certificate of incorporation provides that all directors are elected at each annual meeting of our stockholders for one-year terms. </font></div><div style="margin-top:12pt;text-indent:17.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">No preemptive or similar rights</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of any series of our preferred stock that we may designate and issue in the future. </font></div><div style="margin-top:12pt;text-indent:17.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Right to receive liquidation distributions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Upon our dissolution, liquidation or winding-up, the assets legally available for distribution to holders of our common stock are distributable ratably among the holders of our common stock, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding shares of our preferred stock. </font></div><div style="margin-top:12pt;text-indent:17.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The rights of the holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares of any preferred stock that we may designate and issue in the future. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Anti-takeover effects of provisions of our certificate of incorporation and bylaws and Delaware law</font></div><div style="margin-top:6pt;text-indent:17.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Certificate of incorporation and bylaws. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The holders of our common stock do not have cumulative voting rights in the election of directors. Because holders of our common stock do not have cumulative voting rights, stockholders holding a majority of the shares of common stock outstanding are able to elect all of the directors to be elected at each annual meeting of our stockholders. Our board of directors is able to elect a director to fill a vacancy created by the expansion of the board of directors or due to the resignation or departure of an existing board member. Our certificate of incorporation and bylaws also provide that all stockholder actions must be effected at a duly called meeting of stockholders and not by a consent in writing, and our bylaws require the consent of stockholders holding at least 25% of our outstanding common stock in order for stockholders to call a special meeting of stockholders&#59; otherwise, only the chairman of the board of directors, the president or the board of directors (pursuant to a resolution adopted by a majority of the total number of authorized directors) may call a special meeting of stockholders. In addition, our bylaws include a requirement for the advance notice of nominations for election to the board of directors or for proposing matters that can be acted upon at a stockholders&#8217; meeting. Our certificate of incorporation provides for the ability of the board of directors to issue, without stockholder approval, up to 10,000,000 shares of preferred stock with terms set by the board of directors, which rights could be senior to those of our common stock. Our certificate of incorporation and bylaws also provides that approval of at least 66 2&#47;3% of the shares entitled to vote at an election of directors will be required to adopt, amend or repeal our bylaws, or repeal the provisions of our certificate of incorporation regarding the election of directors and the inability of stockholders to take action by written consent in lieu of a meeting. </font></div><div style="margin-top:12pt;text-indent:17.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The foregoing provisions make it difficult for holders of our common stock to replace our board of directors. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of our company. </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt 0 3.77pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Section 203 of the Delaware General Corporation Law </font></div><div style="margin-top:6pt;text-indent:17.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are subject to the provisions of Section 203 of the Delaware General Corporation Law regulating corporate takeovers. This section prevents some Delaware corporations from engaging, under some circumstances, in a business combination, which includes a merger or sale of at least 10% of the corporation&#8217;s assets with any interested stockholder, meaning a stockholder who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of the corporation&#8217;s outstanding voting stock, unless&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.877%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the transaction is approved by the board of directors prior to the time that the interested stockholder became an interested stockholder&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">upon consummation of the transaction which resulted in the stockholder&#8217;s becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced&#59; or</font></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.877%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">at or subsequent to such time that the stockholder became an interested stockholder the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders by at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</font></td></tr></table></div><div style="margin-top:12pt;text-indent:17.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate or incorporation or bylaws resulting from a stockholders&#8217; amendment approved by a majority of the outstanding voting shares. We have not &#8220;opted out&#8221; of these provisions and do not plan to do so. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forum Selection Bylaw</font></div><div style="margin-top:12pt;text-indent:17.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, another court as specified in our bylaws) and any appellate court therefrom shall, to the fullest extent permitted by law, be the sole and exclusive forum for the following claims or causes of action under Delaware statutory or common law&#58; (A) any derivative claim or cause of action brought on behalf of Exelixis&#59; (B) any claim or cause of action for breach of a fiduciary duty owed by any current or former director, officer or other employee of Exelixis, to Exelixis or our stockholders&#59; (C) any claim or cause of action against Exelixis or any current or former director, officer or other employee of Exelixis, arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or bylaws&#59; (D) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws&#59; (E) any claim or cause of action as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware&#59; and (F) any claim or cause of action against Exelixis or any current or former director, officer or other employee of Exelixis governed by the internal-affairs doctrine or otherwise related to our internal affairs. Any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of Exelixis is deemed to have notice of and consented to the forum selection provisions of the bylaws. This provision does not apply to actions arising under the Securities Act of 1933, as amended (the &#8220;33 Act&#8221;), or the Securities Exchange Act of 1934, as amended, or any claim for which the federal courts have exclusive jurisdiction.</font></div><div style="margin-top:12pt;text-indent:17.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the &#8217;33 Act.</font></div><div style="margin-top:12pt;text-indent:17.25pt"><font><br></font></div><div style="margin-top:24pt;text-align:center"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt 0 3.77pt"></td></tr></table></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>exel20211231exhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6c108de0226d49efa6e41ded88c8e5b4_1"></div><div style="min-height:84.24pt;width:100%"><div style="margin-top:24pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.24pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXELIXIS, INC.<br><br>INDEMNIFICATION AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.24pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Indemnification Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (this &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is dated as of _________________, 20__ and is between Exelixis, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and ______________ (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Indemnitee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recitals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Indemnitee&#8217;s service to the Company substantially benefits the Company, and given the nature of such services, the general protections provided to Indemnitee by applicable law and the Company&#8217;s governing documents may be insufficient.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In order to induce Indemnitee to continue to provide services to the Company, it is reasonable, prudent and necessary for the Company to provide adequate protection through insurance and indemnification against risk of claims and actions against Indemnitee and contractually obligate itself to indemnify, and to advance Expenses (as defined below) on behalf of, Indemnitee as permitted by applicable law.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Agreement is a supplement to and in furtherance of the indemnification provided in the Company&#8217;s bylaws, and any resolutions adopted pursuant thereto, and this Agreement shall not be deemed a substitute therefor, nor shall this Agreement be deemed to limit, diminish or abrogate any rights of Indemnitee thereunder.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties agree as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt">Definitions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.73pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Beneficial Owner</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given to such term in Rule 13d-3 under the Securities Exchange Act of 1934, as amended&#59; provided, however, that &#8220;Beneficial Owner&#8221; shall exclude any Person otherwise becoming a Beneficial Owner solely by reason of (i) the stockholders of the Company approving a merger of the Company with another Person, or entering into tender or support agreements relating thereto, provided such merger was approved by the Company&#8217;s board of directors, or (ii) the Company&#8217;s board of directors approving a sale of securities by the Company to such Person.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt">A &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.46pt">Acquisition of Stock by Third Party.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any Person (as defined below) becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company&#8217;s then outstanding securities&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:23.76pt">Change in Board Composition.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During any period of two consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constituted the Company&#8217;s board of directors and any Approved Directors cease for any reason to constitute a majority of the members of the Company&#8217;s board of directors.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Approved Directors</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means new directors whose election or nomination by the board of directors was approved by a vote of at least two thirds of the directors then still in office who either were directors at the beginning of such two-year period or whose election or nomination for election was previously so approved&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:21.06pt">Corporate Transactions.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation that would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect a majority of the board of directors or other governing body of such surviving entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.56pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Corporate Status</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; describes the status of a person who is or was a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">DGCL</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the General Corporation Law of the State of Delaware.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.63pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Disinterested Director</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.68pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Enterprise</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Company and any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.95pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; include all actually and reasonably incurred attorneys&#8217; fees, retainers, court costs, transcript costs, fees and costs of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding.  Expenses also include (i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersede as bond or other appeal bond or their equivalent, and (ii) for purposes of Section 11(d), Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company.  Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt"> &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Independent Counsel</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a law firm, or a partner or member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent (i) the Company, any Enterprise or Indemnitee in any matter material to any such party (other than as Independent Counsel with respect to matters concerning Indemnitee under this Agreement, or other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder.  Notwithstanding the foregoing, the term Independent Counsel shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.46pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning used for such term in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended&#59; provided, however, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.36pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Proceeding</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative or investigative nature, whether formal or informal, including any appeal therefrom and including without limitation any such Proceeding pending as of the date of this Agreement, in which Indemnitee was, is or will be involved as a party, a potential party, a non-party witness or otherwise by reason of (i) the fact that Indemnitee is or was a director or officer of the Company, (ii) any action taken by Indemnitee or any action or inaction on Indemnitee&#8217;s part while acting as a director or officer of the Company, or (iii) the fact that he or she is or was serving at the request of the Company as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification or advancement of Expenses can be provided under this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.89pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">to the fullest extent permitted by applicable law</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means to the fullest extent permitted by all applicable laws, including without limitation&#58; (i) the fullest extent permitted by DGCL as of the date of this Agreement&#59; and (ii) the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(l)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.46pt">In connection with any Proceeding relating to an employee benefit plan&#58; references to &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">fines</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall include any excise taxes assessed on a person with respect to any employee benefit plan&#59; references to &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">serving at the request of the Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries&#59; and a person who acted in good faith and in a manner he or she reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">not opposed to the best interests of the Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as referred to in this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt">Indemnity in Third-Party Proceedings</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company shall indemnify Indemnitee in accordance with the provisions of this Section 2 if Indemnitee is, or is threatened to be made, a party to or other participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor.  Pursuant to this Section 2, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was unlawful.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt">Indemnity in Proceedings by or in the Right of the Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or other participant in any Proceeding by or in the right of the Company to procure a judgment in its favor.  Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company.  No indemnification for Expenses shall be made under this Section 3 in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged by a court of competent jurisdiction to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the Delaware Court of Chancery or such other court shall deem proper.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt">Indemnification for Expenses of a Party Who is wholly or partly Successful</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of this Agreement and except as provided in Section 6, to the extent that Indemnitee is a party to or a participant in, and is successful (on the merits or otherwise) in defense of, any Proceeding or any claim, issue or matter therein, the Company shall indemnify Indemnitee against all Expenses incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection therewith.  If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with each successfully resolved claim, issue or matter.  For purposes of this Section 4, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt">Indemnification for Expenses of a Witness</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a witness in any Proceeding to which Indemnitee is not a party and is not threatened to be made a party, Indemnitee shall be indemnified against all Expenses incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt">Exclusions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any provision in this Agreement to the contrary, the Company shall not be obligated under this Agreement to make any indemnity in connection with any Proceeding (or any part of any Proceeding)&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.73pt">for which payment has actually been made to or on behalf of Indemnitee under any statute, insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt">for an accounting or disgorgement of profits pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of federal, state or local statutory law or common law, if Indemnitee is held liable therefor (including pursuant to any settlement arrangements)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.56pt">for any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company, as required in each case under the Securities Exchange Act of 1934, as amended (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Sarbanes-Oxley Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act), if Indemnitee is held liable therefor (including pursuant to any settlement arrangements)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt">initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees, agents or other indemnitees, unless (i) the Company&#8217;s board of directors authorized the Proceeding (or the relevant part of the Proceeding) prior to its initiation, (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (iii) otherwise authorized in Section 11(d) or (iv) otherwise required by applicable law&#59; provided, for the avoidance of doubt, Indemnitee shall not be deemed for purposes of this Section 6(d), to have initiated any Proceeding (or any part of a Proceeding) by reason of (i) having asserted any affirmative defenses in connection with a claim not initiated by Indemnitee or (ii) having made any counterclaim (whether permissive or mandatory) in connection with any claim not initiated by Indemnitee&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.63pt">if prohibited by the DGCL or other applicable law.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt">Advances of Expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company shall advance the Expenses incurred by Indemnitee in connection with any Proceeding prior to its final disposition, and such advancement shall be made as soon as reasonably practicable, but in any event no later than 30 days, after the receipt by the Company of a written statement or statements requesting such advances from time to time (which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall include invoices received by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditure made that would cause Indemnitee to waive any privilege accorded by applicable law shall not be included with the invoice).  Advances shall be unsecured and interest free and made without regard to Indemnitee&#8217;s ability to repay such advances.  Indemnitee shall qualify for advances under this Section 7 upon the execution and delivery to the Company of this Agreement which shall constitute an undertaking providing that Indemnitee undertakes to the fullest extent required by law to repay the advance if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">except</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, with respect to advances of expenses made pursuant to Section 11(c), in which case Indemnitee makes the undertaking provided in Section 11(c).  This Section 7 shall not apply to the extent advancement is prohibited by law and shall not apply to any Proceeding (or any part of any Proceeding) for which indemnity is not permitted under this Agreement, but shall apply to any Proceeding (or any part of any Proceeding) referenced in Section 6(b) or 6(c) prior to a determination that Indemnitee is not entitled to be indemnified by the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt">Procedures for Notification and Defense of Claim</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.73pt">Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses as soon as reasonably practicable following the receipt by Indemnitee of notice thereof.  The written notification to the Company shall include, in reasonable detail, a description of the nature of the Proceeding and the facts underlying the Proceeding.  The failure by Indemnitee to notify the Company will not relieve the Company from any liability that it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights, except to the extent that such failure or delay materially prejudices the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt">If, at the time of the receipt of a notice of a Proceeding pursuant to the terms hereof, the Company has directors&#8217; and officers&#8217; liability insurance in effect that may be applicable to the Proceeding, the Company shall give prompt notice of the commencement of the Proceeding to the insurers in accordance with the procedures set forth in the applicable policies.  The Company shall thereafter take all commercially reasonable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.56pt">In the event the Company may be obligated to make any indemnity in connection with a Proceeding, the Company shall be entitled to assume the defense of such Proceeding with counsel approved by Indemnitee, which approval shall not be unreasonably withheld, conditioned or delayed, upon the delivery to Indemnitee of written notice of its election to do so.  After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee for any fees or expenses of counsel subsequently incurred by Indemnitee with respect to the same Proceeding.  Notwithstanding the Company&#8217;s assumption of the defense of any such Proceeding, the Company shall be obligated to pay the Expenses of Indemnitee&#8217;s separate counsel to the extent (i) the employment of separate counsel by Indemnitee is authorized by the Company, (ii) counsel for the Company shall have reasonably concluded that there is a conflict of interest between the Company and Indemnitee in the conduct of any such defense such that Indemnitee needs to be separately represented, (iii) the Company is not financially or legally able to perform its indemnification obligations, or (iv) the Company shall not have retained, or shall not continue to retain, counsel to defend such Proceeding. Regardless of any provision in this Agreement, Indemnitee shall have the right to employ counsel in any Proceeding at Indemnitee&#8217;s personal expense.  The Company shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim brought by or in the right of the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt">Indemnitee shall give the Company such information and cooperation in connection with the Proceeding as may be reasonably appropriate.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.63pt">The Company shall not be liable to indemnify Indemnitee for any settlement of any Proceeding (or any part thereof) effected without the Company&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed.  The Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a party to avoid expense, delay, distraction, disruption and uncertainty.  In the event that any action, claim or proceeding to which Indemnitee is a party is resolved in a settlement to which the Company has given its prior written consent, such settlement shall be treated as a success on the merits in the settled action, suit or proceeding.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.68pt">The Company shall not settle any Proceeding (or any part thereof) in a manner that imposes any penalty or liability on Indemnitee not paid by the Company without Indemnitee&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt">Procedures upon Application for Indemnification</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.73pt">To obtain indemnification, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and as is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of the Proceeding.  Any delay in providing the request will not relieve the Company from its obligations under this Agreement, except to the extent such failure materially prejudices the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt">Upon written request by Indemnitee for indemnification pursuant to Section 9(a), a determination with respect to Indemnitee&#8217;s entitlement thereto shall be made as follows, provided that a Change in Control shall not have occurred&#58; (i) by a majority vote of the Disinterested Directors, even though less than a quorum of the Company&#8217;s board of directors&#59; (ii) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Company&#8217;s board of directors&#59; (iii) if there are no such Disinterested Directors or, if a majority of Disinterested Directors so direct, by Independent Counsel in a written opinion to the Company&#8217;s board of directors, a copy of which shall be delivered to Indemnitee&#59; or (iv) if so directed by the Company&#8217;s board of directors, by the stockholders of the Company.  If a Change in Control shall have occurred, a determination with respect to Indemnitee&#8217;s entitlement to indemnification shall be made by Independent Counsel in a written opinion to the Company&#8217;s board of directors, a copy of which shall be delivered to Indemnitee.  If it is determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten days after such determination.  Indemnitee shall cooperate with the person, persons or entity making the determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information that is not privileged or otherwise protected from disclosure and that is reasonably available to Indemnitee and reasonably necessary to such determination.  Any Expenses incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company, to the extent permitted by applicable law.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.56pt">In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 9(b), the Independent Counsel shall be selected as provided in this Section 9(c).  If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Company&#8217;s board of directors, and the Company shall give written notice to Indemnitee advising him or her of the identity of the Independent Counsel so selected.  If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Company&#8217;s board of directors, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected.  In either event, Indemnitee or the Company, as the case may be, may, within ten days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection&#59; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;Independent Counsel&#8221; as defined in Section 1, and the objection shall set forth with particularity the factual basis of such assertion.  Absent a proper and timely objection, the person so selected shall act as Independent Counsel.  If such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit.  If, within 20 days after the later of (i) submission by Indemnitee of a written request for indemnification pursuant to Section 8(a) and (ii) the final disposition of the Proceeding, the parties have not agreed upon an Independent Counsel, either the Company or Indemnitee may petition a court of competent jurisdiction for resolution of any objection that shall have been made by the Company or Indemnitee to the other&#8217;s selection of Independent Counsel and for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 9(b).  Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 11(a), the Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt">The Company shall pay the reasonable fees of any Independent Counsel and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Presumptions and Effect of Certain Proceedings</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.73pt">In making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption by clear and convincing evidence.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt">The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">nolo</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">contendere</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner that he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.56pt">For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith to the extent Indemnitee relied in good faith on (i) the records or books of account of the Enterprise, including financial statements, (ii) information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, (iii) the advice of legal counsel for the Enterprise or its board of directors or counsel selected by any committee of the board of directors or (iv) information or records given or reports made to the Enterprise by an independent certified public accountant, an appraiser, investment banker or other expert selected with reasonable care by the Enterprise or its board of directors or any committee of the board of directors.  The provisions of this Section 10(c) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt">Neither the knowledge, actions nor failure to act of any other director, officer, agent or employee of the Enterprise shall be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Remedies of Indemnitee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.73pt">Subject to Section 11(e), in the event that (i) a determination is made pursuant to Section 9 that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 7 or 11(d), (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 9 within 30 days after the later of the receipt by the Company of the request for indemnification or the final disposition of the Proceeding, (iv) payment of indemnification pursuant to this Agreement is not made (A) within ten days after a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">determination has been made that Indemnitee is entitled to indemnification or (B) with respect to indemnification pursuant to Sections 2, 3, and 11(d), within 30 days after receipt by the Company of a written request therefor, or (v) the Company or any other person or entity takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or proceeding designed to deny, or to recover from, Indemnitee the benefits provided or intended to be provided to Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court of competent jurisdiction of his or her entitlement to such indemnification or advancement of Expenses.  Alternatively, Indemnitee, at his or her option, may seek an award in arbitration with respect to his or her entitlement to such indemnification or advancement of Expenses, to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association.  Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 11(a)&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under Section 4.  The Company shall not oppose Indemnitee&#8217;s right to seek any such adjudication or award in arbitration in accordance with this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt">Neither (i) the failure of the Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders to have made a determination that indemnification of Indemnitee is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor (ii) an actual determination by the Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders that Indemnitee has not met the applicable standard of conduct, shall create a presumption that Indemnitee has or has not met the applicable standard of conduct.  In the event that a determination shall have been made pursuant to Section 9 that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 11 shall be conducted in all respects as a </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">de novo</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> trial, or arbitration, on the merits, and Indemnitee shall not be prejudiced by reason of that adverse determination.  In any judicial proceeding or arbitration commenced pursuant to this Section 11, the Company shall, to the fullest extent not prohibited by law, have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be, and the burden of proof shall be by clear and convincing evidence.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.56pt">To the fullest extent not prohibited by law, the Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 11 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.  If a determination shall have been made pursuant to Section 11 that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 11, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statements not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt">To the extent not prohibited by law, the Company shall indemnify Indemnitee against all Expenses incurred by Indemnitee in connection with any action for indemnification or advancement of Expenses from the Company under this Agreement, the Company&#8217;s bylaws or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company to the extent Indemnitee is successful in such action, and, if requested by Indemnitee, shall (as soon as reasonably practicable, but in any event no later than 30 days, after receipt by the Company of a written request therefor) advance such Expenses to Indemnitee, subject to the provisions of Section 6.  Indemnitee hereby undertakes to repay such advances to the extent the Indemnitee is ultimately unsuccessful in such action or arbitration.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.63pt">Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification shall be required to be made prior to the final disposition of the Proceeding.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Contribution</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amounts incurred by Indemnitee, whether for Expenses, judgments, fines or amounts paid or to be paid in settlement, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the events and transactions giving rise to such Proceeding&#59; and (ii) the relative fault of Indemnitee and the Company (and its other directors, officers, employees and agents) in connection with such events and transactions.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Non-exclusivity</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Company&#8217;s bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise.  To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Company&#8217;s bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change, subject to the restrictions expressly set forth herein or therein.  Except as expressly set forth herein, no right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.  Except as expressly set forth herein, the assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Primary Responsibility</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company acknowledges that to the extent Indemnitee is serving as a director on the Company&#8217;s board of directors at the request or direction of a private equity or venture capital fund or other entity and&#47;or certain of its affiliates (collectively, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Secondary Indemnitors</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Indemnitee may have certain rights to indemnification and advancement of expenses provided by such Secondary Indemnitors. The Company agrees that, as between the Company and the Secondary Indemnitors, the Company is primarily responsible for amounts required to be indemnified or advanced under the Company&#8217;s bylaws or this Agreement and any obligation of the Secondary Indemnitors to provide indemnification or advancement for the same amounts is secondary to those Company obligations. To the extent not in contravention of any insurance policy or policies providing liability or other insurance for the Company or any director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise, the Company waives any right of contribution or subrogation against the Secondary Indemnitors with respect to the liabilities for which the Company is primarily responsible under this Section&#160;14. In the event of any payment by the Secondary Indemnitors of amounts otherwise required to be indemnified or advanced by the Company under the Company&#8217;s bylaws or this Agreement, the Secondary Indemnitors shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee for indemnification or advancement of expenses under the Company&#8217;s bylaws or this Agreement or, to the extent such subrogation is unavailable and contribution is found to be the applicable remedy, shall have a right of contribution with respect to the amounts paid. The Secondary Indemnitors are express&#160;third-party&#160;beneficiaries of the terms of this Section&#160;14.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">No Duplication of Payments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 14, the Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received payment for such amounts under any insurance policy, contract, agreement or otherwise.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Insurance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, trustees, general partners, managing members, officers, employees, agents or fiduciaries of the Company or any other Enterprise, Indemnitee shall be covered by such policy or policies to the same extent as the most favorably-insured persons under such policy or policies in a comparable position.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Subrogation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 14, in the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Services to the Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Indemnitee agrees to serve as a director or officer of the Company or, at the request of the Company, as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of another Enterprise, for so long as Indemnitee is duly elected or appointed or until Indemnitee tenders his or her resignation or is removed from such position.  Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position.  This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee.  Indemnitee specifically acknowledges that any employment with the Company (or any of its subsidiaries or any Enterprise) is at will, and Indemnitee may be discharged at any time for any reason, with or without cause, with or without notice, except as may be otherwise expressly provided in any executed, written employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), any existing formal severance policies adopted by the Company&#8217;s board of directors or, with respect to service as a director or officer of the Company, the Company&#8217;s certificate of incorporation or bylaws or the DGCL.  No such document shall be subject to any oral modification thereof.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">19.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Duration</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall continue until and terminate upon the later of (a) ten years after the date that Indemnitee shall have ceased to serve as a director or officer of the Company or as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of any other Enterprise, as applicable&#59; or (b) one year after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any Proceeding commenced by Indemnitee pursuant to Section 11 relating thereto.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">20.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Successors</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be binding upon the Company and its successors and assigns, including any direct or indirect successor, by purchase, merger, consolidation or otherwise, to all or substantially all of the business or assets of the Company, and shall inure to the benefit of Indemnitee and Indemnitee&#8217;s heirs, executors and administrators.  Further, the Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company, by written agreement, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">21.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Severability</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of applicable law.  The Company&#8217;s inability, pursuant to court order or other applicable law, to perform its obligations under this Agreement shall not constitute a breach of this Agreement.  If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever&#58; (i) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law&#59; (ii) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto&#59; and (iii) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">22.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Enforcement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">23.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Entire Agreement&#59; Amendment and Restatement of Prior Indemnification Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that this Agreement is a supplement to and in furtherance of the Company&#8217;s bylaws and applicable law. In addition, if Indemnitee entered into a prior indemnification agreement with the Company, including, for example, an agreement with those same or similar terms as the &#8220;Form of Indemnity Agreement&#8221; filed with the Securities and Exchange Commission as Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-96335) on March 17, 2000, then this Agreement shall amend, restate, and supersede any such prior indemnification agreement and shall govern Indemnitee&#8217;s rights and obligations with respect to indemnification from the Company, even if the Proceeding giving rise to a claim for indemnification arises from circumstances that occurred prior to the execution of this Agreement.    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">24.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Modification and Waiver</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No supplement, modification or amendment to this Agreement shall be binding unless executed in writing by the parties hereto.  No amendment, alteration or repeal of this Agreement shall adversely affect any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal.  No waiver of any of the provisions of this Agreement shall constitute or be deemed a waiver of any other provision of this Agreement nor shall any waiver constitute a continuing waiver.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">25.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Notices</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail or otherwise delivered by hand, messenger or courier service addressed&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.73pt">if to Indemnitee, to Indemnitee&#8217;s address, facsimile number or electronic mail address as shown on the signature page of this Agreement or in the Company&#8217;s records, as may be updated in accordance with the provisions hereof&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.26pt">if to the Company, to 1851 Harbor Bay Parkway, Alameda, CA 94502, Attention&#58; Executive Vice President and General Counsel, or at such other current address as the Company shall have furnished to Indemnitee, with a copy to the Company&#8217;s Corporate Legal Affairs department via electronic mail at CorporateLegalAffairs&#64;exelixis.com.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given (i) if delivered by hand, messenger or courier service, when delivered (or if sent </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">via</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day delivery, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or (iii) if sent via facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation of delivery when directed to the relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient&#8217;s next business day.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">26.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Applicable Law and Consent to Jurisdiction</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules.  Except with respect to any arbitration commenced by Indemnitee pursuant to Section 11(a), the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court of Chancery, and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court of Chancery for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not otherwise subject to service of process in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">State of Delaware, The Corporation Trust Company, Wilmington, Delaware as its agent in the State of Delaware as such party&#8217;s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court of Chancery, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court of Chancery has been brought in an improper or inconvenient forum.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">27.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Counterparts</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement.  This Agreement may also be executed and delivered by facsimile signature, or by electronic mail in PDF format (including use of a verified electronic signature) and in counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement.  Only one such counterpart executed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">28.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.93pt">Captions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">signature page follows</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div></div></div><div id="i6c108de0226d49efa6e41ded88c8e5b4_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties are signing this Indemnification Agreement as of the date stated in the introductory sentence.</font></div><div style="margin-bottom:24pt;padding-left:252pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis, Inc.</font></div><div style="margin-bottom:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;____________________________________</font></div><div style="margin-bottom:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;_________________________________</font></div><div style="margin-bottom:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; __________________________________</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________________________________</font></div><div style="margin-bottom:24pt;padding-left:252pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;indemnitee name&#93;</font></div><div style="margin-bottom:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address&#58;________________________________</font></div><div><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:252pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> _______________________________________</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>4
<FILENAME>exel20211231exhibit1018.htm
<DESCRIPTION>EX-10.18
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id433f0f01a344b5eb6f23daa69c82181_1"></div><div style="min-height:72pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:787px"></div></div><div style="margin-top:24pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.18</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2, 2021</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicki L. Goodman, M.D.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dear Vicki&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are proud to invite you to join our team.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our offer of employment is to join Exelixis, Inc. (the &#8220;Company&#8221;). Your title will be that of Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer, in our Development Administration department reporting to Michael Morrissey, President and Chief Executive Officer. Your primary work location will be in reasonable proximity to your home in Pennsylvania at a final location to be determined by Exelixis, with your input. You will be required to travel to corporate headquarters in Alameda, California or elsewhere in person to be agreed to by you and Dr. Morrissey as part of your responsibilities leading the joint development and medical affairs activities on both the east and west coasts. Other terms of employment include&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base Salary&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Your base salary will be twenty-five thousand dollars ($25,000.00) per pay period. We are on a bi-weekly pay schedule. This equates to a base compensation of six hundred and fifty thousand dollars ($650,000.00) on an annual basis (&#8220;Base Salary&#8221;).  This is an exempt position. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sign-on Bonus&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  You will receive a sign-on bonus as follows&#58; (i) in the event you leave your current employer and are ineligible to receive a 2021 bonus from them, you will receive a sign-on bonus of five hundred thousand dollars ($500,000.00), minus all applicable taxes and withholding, payable on the first pay date following your hire date. Should you elect to voluntarily terminate employment with the Company, other than a &#8220;Constructive Termination&#8221; (defined in the Company&#8217;s Change in Control and Severance Benefit Plan), within twelve (12) months of your Start Date (defined below), twenty-five percent of the net sign-on bonus actually received by you must be re-paid by you to the Company within 14 days after your last day of employment.  By way of example, if you actually receive a net amount of $300,000 from the payment of the $500,000 sign-on bonus after applicable taxes and withholdings are deducted, the repayment amount would be $75,000 which is twenty-five percent of the net amount actually received&#59; or, (ii) in the event you leave your current company and are eligible to receive a 2021 bonus from them, you will receive a sign-on bonus of two hundred and fifty thousand dollars ($250,000.00), minus all applicable taxes and withholding, payable on the first pay date following your hire date. Should you elect to voluntarily terminate employment with the Company, other than a &#8220;Constructive Termination&#8221;, within twelve (12) months of your Start Date (defined below), twenty-five percent of the net sign-on bonus actually received by you must be re-paid by you to the Company within 14 days after your last day of employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Annual Incentive Award&#58;&#160; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Your initial target bonus shall be 50% of your annual Base Salary. Bonus payouts are awarded at the discretion of the Board and paid in accordance with the company&#8217;s standard payout cycle for bonuses in the calendar year immediately following the end of the applicable bonus period&#59; provided that you are employed by the company on the date that the bonus is paid. If your start date is on or before September 30</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> your bonus for 2021, if any, will be prorated for your partial year of employment in 2021. If your start date is on or after October 1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, you will not be eligible for a bonus for 2021.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:787px"></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicki L. Goodman, M.D.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2, 2021</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page Two</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-Term Equity Incentive Award&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As an inducement that we understand is material to your entering into employment with Exelixis, you will be eligible to elect to receive an equity award (referred to as the &#8220;Equity Award&#8221;), subject to approval by the Board of Directors in the form of either (i) a stock option to purchase two hundred and fifty thousand (250,000) shares of Exelixis common stock  and a restricted stock unit (&#8220;RSU&#8221;) award for eighty-two thousand eight hundred and ninety-five (82,895) shares of Exelixis common stock (referred to as &#8220;Alternative 1&#8221;)&#59; or (ii) a RSU award for two hundred and seven thousand eight hundred and ninety-five (207,895) shares of Exelixis common stock (referred to as &#8220;Alternative 2&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard vesting schedule for our stock options is &#188; following the one year anniversary of your hire date and 1&#47;48th of the original number of shares subject to the stock option every month thereafter over a total of four years, provided that vesting ceases upon termination of your employment.&#160; The standard vesting schedule for our RSU awards is &#188; on the first established RSU vesting date following the one year anniversary of your hire date and 1&#47;4th of the original number of shares subject to the RSU award every year thereafter over a total of four years until fully-vested, provided that vesting ceases upon termination of your employment.&#160; The grant date for your Equity Award will be your hire date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Please select the form in which you prefer to receive the Equity Award by selecting one of the alternatives below at the time you accept this offer of employment by returning the signed copies of this letter as provided below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I hereby prefer to receive the Equity Award as follows (select one)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font><font style="color:#000000;font-family:'Palatino',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Alternative 1&#59; or</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Palatino',serif;font-size:10pt;font-weight:700;line-height:100%">X    </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alternative 2</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All compensation shall be subject to the customary withholding tax and other employment taxes and deductions as required by law.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">By signing and returning this letter as provided below, you acknowledge that you understand that, after 5&#58;00p.m., Pacific Time on the last business day prior to your Start Date, you may not withdraw or change your designated Equity Award preference.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Long-Term Equity Incentive Award&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You will be eligible to receive an additional equity award (referred to as the &#8220;Additional Equity Award&#8221;), subject to approval by the Board in the form of a RSU award for forty-two thousand one hundred and five (42,105) shares of Company common stock , with 26,315 shares subject to the RSU award vesting on your hire date, 7,895 shares subject to the RSU award vesting on February 15, 2023, and the remaining 7,895 shares subject to the RSU award on February 15, 2024, provided that in all cases vesting ceases upon termination of your employment with the Company. The grant date for your Additional Equity Award will be your hire date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Control and Severance Benefits&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You will be eligible to participate in the Company&#8217;s Change in Control and Severance Benefit Plan (CIC Plan) as Executive Participant &#8211; EVP&#47;SVP. A copy of the CIC Plan along with a Participation Notice notifying you of the terms and conditions of your participation will be provided. A signed copy of the Participation Notice must be returned to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:787px"></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicki L. Goodman, M.D.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2, 2021</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page Three</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Severance&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  In addition to and independent of the benefits outlined under the Company&#8217;s CIC Plan, if, outside of a Change in Control event, you are required at any time to relocate full time to a new location that is not </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in reasonable proximity, within 35 miles, of your home in Pennsylvania</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, and you decline such relocation and resign your position, you will be eligible to receive a severance payment equal to twelve (12) months of your then current salary and twelve (12) months of your then current bonus target within thirty (30) days of your termination date. In order to receive this severance, you must first sign and not revoke a full and complete release of claims. Severance under this provision is not affected by Paragraph 7(d) of the CIC Plan or any other provision of the CIC Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clawback Policy&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any other provisions in this offer, all forms of compensation you are eligible to receive, except Base Salary, shall be subject to recoupment pursuant to the Company&#8217;s Policy for Recoupment of Variable Compensation (&#8220;Clawback Policy&#8221;) or any other clawback policy the Company is required to adopt pursuant to applicable law or regulation. As a condition of your employment, you will need to acknowledge your receipt and understanding of the Clawback Policy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Benefits&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  All full-time employees of the Company enjoy a generous benefits package, which is outlined on the Summary of Benefits.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Review&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Focal reviews will take place annually. If eligible for a performance review increase, the merit increase will typically be effective in March.&#160; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Start Date&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To be determined.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Confidentiality and Company Policies&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As you are aware, it is very important for us to protect our confidential information and proprietary material.  Therefore, as a condition of employment, you will need to sign the Company&#8217;s Employee Proprietary Information and Inventions Agreement.  This confirms that you have previously disclosed to the Company that you are bound by a two-year non-solicitation agreement with your former employer which the company believes will not prevent you from performing your duties to the Company.  You will also be required to abide by the Company&#8217;s policies and procedures, including the Corporate Code of Conduct.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reference Verification&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This offer is contingent upon verification of your references.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Background Check&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  This offer is contingent upon successfully passing your background check.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  This offer expires on Friday, December 3, 2021 unless accepted by you prior to this date.  In addition to performing the duties and responsibilities of your position, you will be expected to perform other duties and responsibilities that may be assigned to you from time to time.  No provision of this letter shall be construed to create or express an implied employment contract for a specific period of time.  Either you or the Company may terminate this employment relationship at any time, with or without cause.  This letter shall be governed by the laws of the State of California.  Also, by signing this letter, you are indicating that you are legally authorized to work in the U.S.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employment Authorization&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our offer of employment is at will and contingent upon your ability to document your employment authorization in the United States.  If you are unable to document your right to work within the United States within three days of your date of hire, your employment will be terminated.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:787px"></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicki L. Goodman, M.D.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2, 2021</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page Four</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You may accept this offer of employment by signing this letter via DocuSign.  If you are unable to sign this letter via DocuSign, you may request a hard-copy letter from Human Resources to be mailed to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicki, we are delighted to extend to you this offer of employment and we look forward to your coming on board.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sincerely,</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laura Dillard</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laura Dillard</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Human Resources</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACCEPTED BY&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Vicki Goodman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">12&#47;2&#47;2021&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicki L. Goodman, M.D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date</font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>5
<FILENAME>exel20211231exhibit1042.htm
<DESCRIPTION>EX-10.42
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i727b43620faa46df9823bb34fbbdba88_1"></div><div style="min-height:90.72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.42</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential                                                                                                               </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Execution Version</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THIRD AMENDMENT TO SUPPLY AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment to the Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of 10 December, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware company having an address at 1851 Harbor Bay Parkway, Alameda CA 94502, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ipsen Pharma SAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Exelixis and Licensee may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font><font style="color:#2e2e2e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Recitals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Exelixis and Licensee are parties to that certain Collaboration and License Agreement dated February 29, 2016, as amended by Amendment No. 1 dated effective December 20, 2016, Amendment No. 2 dated effective September 14, 2017, and Amendment No. 3 dated effective October 26, 2017 (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant to which the Parties have been collaborating on the development and commercialization of cabozantinib&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Exelixis and Licensee are parties to that certain Supply Agreement dated February 29, 2016, as amended by that certain Side Letter between the Parties dated August 26, 2016, Amendment No. 1 dated effective October 26, 2017, a second Side Letter dated effective December 7, 2017, subsequently extended on April 6, 2018, and Amendment No. 2 dated effective May 17, 2019 (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant to which Exelixis has been manufacturing and supplying cabozantinib to Licensee for development and commercial use under the License Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Parties desire to enter into this Amendment to amend the Supply Agreement to reflect updates to the supply process, in particular to outline the ongoing process for the delivery of the Finished Product, all on the terms and conditions set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Now, Therefore,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Product Supply</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Section 2.3(c) is deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Delivery and Shipping Terms. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Purchase Orders submitted for quantities of Product that are in accordance with Section 2.3(a) and&#47;or Section 2.3(b) as applicable will be binding on both Parties after acceptance in writing by Exelixis&#59; provided, however, that should Exelixis neither reject a Purchase Order nor provide written confirmation of acceptance within twenty (20) business days of receipt, Exelixis shall be deemed to have accepted the Purchase Order effectively. The Purchase Order will specify a single delivery date for such order to be delivered.  Except as provided below, Exelixis shall deliver all Finished Product Delivery at Place (Paris Airport) (&#8220;DAP&#8221; Incoterms 2020).  For Finished Product supplied by Rottendorf Pharma Inc., such Finished Product shall be delivered Ex Works (Rottendorf Pharma Inc.&#8217;s facility in Ennigerloh, Germany) (&#8220;EXW&#8221; Incoterms 2020) and Licensee shall be responsible for removing such Product from such facility within twenty (20) days after the Rottendorf Pharma Qualified Person releases such Product.  For Purchase Orders placed for commercialization </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90.72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.42</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential                                                                                                               </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Execution Version</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in Canada&#59; Exelixis shall deliver Delivery at Place (&#8220;DAP&#8221; Incoterms 2020) to the warehouse in Canada, as notified by Licensee.  Licensee shall deliver all Reworked Product to Third Party Subcontractor&#59; Delivery Duty Paid (&#8220;DDP&#8221; Incoterms 2020). Exelixis shall deliver all Reworked Product from their Third Party subcontractor Ex-Works (&#8220;EXW&#8221; Incoterms 2020).  Exept as provided in the next sentence, Exelixis shall be responsible for obtaining all licenses or other authorizations for the exportation of such shipments and shall supply Licensee with the documentation required for filing or claiming credit or deduction for any applicable taxes and&#47;or duties.  For Finished Product supplied by Rottendorf Pharma Inc., Exelixis shall be responsible for providing Licensee with the packing slip and commercial invoice.  For all shipments, Licensee shall be responsible for obtaining all freight, handling, insurance, and shipping expenses, and shall be the importer of record and responsible for all duties and taxes for such shipments, and shall be responsible for obtaining all distribution licenses for the Products.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">General Provisions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Effect of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly modified herein, all terms and conditions set forth in the Supply Agreement, as in effect on the Amendment Effective Date, shall remain in full force and effect.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Supply Agreement as modified by this Amendment, and together with the License Agreement, is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to its subject matter.  They supersede all prior and contemporaneous agreements and communications, whether written or oral, of the Parties regarding this subject matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, for any reason, any part of this Amendment is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Amendment.  All remaining portions shall remain in full force and effect as if the original Amendment had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Counterparts&#59; Electronic or Facsimile Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> &#123;Signature Page Follows&#125;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i727b43620faa46df9823bb34fbbdba88_4"></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties hereto have caused this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to be executed and entered into by their duly authorized representatives as of the Amendment Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.911%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Exelixis, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;  &#47;s&#47; Michael M. Morrissey</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Michael M. Morrissey, Ph.D.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  President and CEO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Ipsen Pharma S.A.S</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58;  &#47;s&#47; Roman Stephens</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58;  Ronan Stephens</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58;  SVP of Supply Chain</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:66.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>exel20211231exhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i46bb291892834b51a9210aa042ccc297_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF EXELIXIS, INC.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:298.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:201.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State or Other Jurisdiction of Incorporation or Organization</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis Patent Company, LLC</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis Plant Sciences, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis U.S., LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>exel20211231exhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib76bc1f874b04a25911ae9dc42cd7d33_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333- 241667, 333-226493, 333-223225, 333-218236, 333-214766, 333-212866, 333-209824, 333- 203758, 333-196761, 333-176674, 333-165389, 333-159280, 333-157825, 333-149834, 333- 147063, 333-133237, 333-124536, 333-113472, 333-102770, 333-82724, 333-82722, 333-57026 and 333-35862) of Exelixis, Inc. and the Registration Statement (Form S-3 No. 333-205397) and related Prospectus of Exelixis, Inc. of our reports dated February 18, 2022, with respect to the consolidated financial statements of Exelixis, Inc. and the effectiveness of internal control over financial reporting of Exelixis, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2021.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst&#160;&#38; Young&#160;LLP</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redwood City, California</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;18, 2022</font></div><div style="margin-top:9pt"><font><br></font></div><div style="margin-top:9pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>exel20211231exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ica553a147adb421399f761ce722852f0_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael M. Morrissey, Ph.D., certify that&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Form 10-K of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORRISSEY</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 18, 2022 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>exel20211231exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie043127387f44f988ddab6ce9dfa358a_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher J. Senner, certify that&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Form 10-K of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;C</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HRISTOPHER</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. S</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ENNER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 18, 2022 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>exel20211231exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if0e30cbccbce4292a5ba70c50c4cca10_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   1. &#160;&#160;&#160;&#160;The Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In Witness Whereof, the undersigned have set their hands hereto as of the 18th day of February 2022.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;C</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HRISTOPHER</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. S</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ENNER&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>exel-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:15eb203a-3ec7-40cd-9655-d78f522bbe80,g:fdc51e9e-f0fc-4164-a9b2-d81298576ebe-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20211231">
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.exelixis.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofIncome">
        <link:definition>1003005 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004006 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>1005007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1006008 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1007009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2104102 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2305301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails">
        <link:definition>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedbyProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
        <link:definition>2407403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
        <link:definition>2408404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
        <link:definition>2409405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
        <link:definition>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesContractAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails">
        <link:definition>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivities" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities">
        <link:definition>2112103 - Disclosure - Collaboration Agreements And Business Development Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables">
        <link:definition>2313302 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
        <link:definition>2414408 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
        <link:definition>2415409 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
        <link:definition>2416410 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
        <link:definition>2417411 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails">
        <link:definition>2418412 - Disclosure - Collaboration Agreements And Business Development Activities - GSK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails">
        <link:definition>2419413 - Disclosure - Collaboration Agreements And Business Development Activities - Other Collaborations Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails">
        <link:definition>2420414 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestments" roleURI="http://www.exelixis.com/role/CashandInvestments">
        <link:definition>2121104 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsTables" roleURI="http://www.exelixis.com/role/CashandInvestmentsTables">
        <link:definition>2322303 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails">
        <link:definition>2424416 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails">
        <link:definition>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
        <link:definition>2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails">
        <link:definition>2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2128105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2329304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>2430420 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2131106 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2332305 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>2433421 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.exelixis.com/role/PropertyandEquipment">
        <link:definition>2134107 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.exelixis.com/role/PropertyandEquipmentTables">
        <link:definition>2335306 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>2436422 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>2437423 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlans">
        <link:definition>2138108 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansTables" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansTables">
        <link:definition>2339307 - Disclosure - Employee Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2440424 - Disclosure - Employee Benefit Plans - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
        <link:definition>2441425 - Disclosure - Employee Benefit Plans - Schedule of Employee Service Share - Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansNarrativeDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails">
        <link:definition>2442426 - Disclosure - Employee Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails">
        <link:definition>2443427 - Disclosure - Employee Benefit Plans - Weighted Average Grant Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails">
        <link:definition>2444428 - Disclosure - Employee Benefit Plans - Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails">
        <link:definition>2445429 - Disclosure - Employee Benefit Plans - Summary of All Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails">
        <link:definition>2446430 - Disclosure - Employee Benefit Plans - Summary of All RSU &amp; PSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansEstimateGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails">
        <link:definition>2447431 - Disclosure - Employee Benefit Plans - Estimate Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxes" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxes">
        <link:definition>2148109 - Disclosure - Provision For Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesTables" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesTables">
        <link:definition>2349308 - Disclosure - Provision For Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>2450432 - Disclosure - Provision For Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails">
        <link:definition>2451433 - Disclosure - Provision For Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails">
        <link:definition>2452434 - Disclosure - Provision For Income Taxes - Schedule of Deferred Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesNarrativeDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails">
        <link:definition>2453435 - Disclosure - Provision For Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>2454436 - Disclosure - Provision For Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.exelixis.com/role/NetIncomePerShare">
        <link:definition>2155110 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.exelixis.com/role/NetIncomePerShareTables">
        <link:definition>2356309 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>2457437 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails">
        <link:definition>2458438 - Disclosure - Net Income Per Share - Potentially Dilutive Shares of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.exelixis.com/role/CommitmentsandContingencies">
        <link:definition>2159111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesTables">
        <link:definition>2360310 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2461439 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails">
        <link:definition>2462440 - Disclosure - Commitments and Contingencies - Balance Sheet Classification of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" roleURI="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails">
        <link:definition>2463441 - Disclosure - Commitments And Contingencies - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>2464442 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>2464442 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exel_FinalTierMember" abstract="true" name="FinalTierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" abstract="false" name="EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold" abstract="false" name="RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CotellicMember" abstract="true" name="CotellicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_TaxCreditCarryforwardAmountWithExpirationPeriod" abstract="false" name="TaxCreditCarryforwardAmountWithExpirationPeriod" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_SalesRevenuePercentDiscountForPromptPayment" abstract="false" name="SalesRevenuePercentDiscountForPromptPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" abstract="false" name="LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" abstract="false" name="LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" abstract="true" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AreaOfRealEstatePropertyAvailableToLease" abstract="false" name="AreaOfRealEstatePropertyAvailableToLease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="srt-types:perUnitItemType"/>
  <xs:element id="exel_OperatingLeaseLiabilitiesAbstract" abstract="true" name="OperatingLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_NotProbableMember" abstract="true" name="NotProbableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" abstract="false" name="LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductGrossMember" abstract="true" name="ProductGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_MilestonePaymentsEarned" abstract="false" name="MilestonePaymentsEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AccountsReceivableForUnsettledInvestmentSales" abstract="false" name="AccountsReceivableForUnsettledInvestmentSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" abstract="false" name="EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_RoyaltyTier" abstract="false" name="RoyaltyTier" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_InitialMember" abstract="true" name="InitialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LeaseArrangementsDomain" abstract="true" name="LeaseArrangementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" abstract="false" name="LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" abstract="false" name="LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" abstract="false" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" abstract="false" name="ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" abstract="false" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_AccruedClinicalLiabilitiesCurrent" abstract="false" name="AccruedClinicalLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" abstract="false" name="CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_SalesRevenueDiscountExpectedtobeEarnedPercent" abstract="false" name="SalesRevenueDiscountExpectedtobeEarnedPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_PerformanceSharesAchievedBeforeDecember312020Member" abstract="true" name="PerformanceSharesAchievedBeforeDecember312020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_StatusAxis" abstract="true" name="StatusAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_PerformanceSharesAchievedBeforeDecember312021Member" abstract="true" name="PerformanceSharesAchievedBeforeDecember312021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithGenentechMember" abstract="true" name="CollaborativeArrangementwithGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" abstract="false" name="CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesOfAmerisourceBergenCorporationMember" abstract="true" name="AffiliatesOfAmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" abstract="false" name="MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_MilestonePaymentsEarnedToDate" abstract="false" name="MilestonePaymentsEarnedToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_HeadquartersLease2021AmendmentMember" abstract="true" name="HeadquartersLease2021AmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" abstract="true" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_CollaborativeArrangementAchievedMilestoneAmount" abstract="false" name="CollaborativeArrangementAchievedMilestoneAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NumberofProductsinCommercialMarket" abstract="false" name="NumberofProductsinCommercialMarket" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" abstract="true" name="ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_RoyaltytierDomain" abstract="true" name="RoyaltytierDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" abstract="true" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_MedicarePartDFundingMandate" abstract="false" name="MedicarePartDFundingMandate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_OperatingLeaseAssetsAbstract" abstract="true" name="OperatingLeaseAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_ProbableMember" abstract="true" name="ProbableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductSalesDiscountsAndAllowancesMember" abstract="true" name="ProductSalesDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LeaseArrangementsAxis" abstract="true" name="LeaseArrangementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_PercentOfRoyaltyOnNetSale" abstract="false" name="PercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" abstract="true" name="LesseeOperatingLeaseReductionOfPaymentsDueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductsDerivedFromOtherCompoundsMember" abstract="true" name="ProductsDerivedFromOtherCompoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" abstract="true" name="CollaborativeAgreementWithGamaMabsPharmaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_RevenueFromContractWithCustomerRegulatoryMilestone" abstract="false" name="RevenueFromContractWithCustomerRegulatoryMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_UpfrontPayments" abstract="false" name="UpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ChargebacksAndDiscountsForPromptPaymentMember" abstract="true" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithTakedaMember" abstract="true" name="CollaborativeArrangementwithTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsFinalPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsFinalPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_PeriodOfSpecificSalesVolumeThreshold" abstract="false" name="PeriodOfSpecificSalesVolumeThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_CometriqMember" abstract="true" name="CometriqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" abstract="false" name="NumberOfCountriesWithDrugApprovalExcludingTheUS" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_HeadquartersLeaseApril2019AmendmentMember" abstract="true" name="HeadquartersLeaseApril2019AmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" abstract="false" name="LesseeOperatingLeaseOptionToTerminateAfterPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_AllowanceForProductRebatesMember" abstract="true" name="AllowanceForProductRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CabometyxMember" abstract="true" name="CabometyxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_RevenueFromContractWithCustomerCommercialSalesMilestone" abstract="false" name="RevenueFromContractWithCustomerCommercialSalesMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ResultingFromDiscoveryEffortsMember" abstract="true" name="ResultingFromDiscoveryEffortsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_RoyaltyTierAxis" abstract="true" name="RoyaltyTierAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_CollaborationAgreementwithDaiichiSankyoMember" abstract="true" name="CollaborationAgreementwithDaiichiSankyoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_BuiltToSuitLeaseMember" abstract="true" name="BuiltToSuitLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_HeadquartersLeaseMember" abstract="true" name="HeadquartersLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AffiliatesofCVSHealthCorporationMember" abstract="true" name="AffiliatesofCVSHealthCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AffiliatesofOptumSpecialtyPharmacyMember" abstract="true" name="AffiliatesofOptumSpecialtyPharmacyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" abstract="false" name="ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithIpsenMember" abstract="true" name="CollaborativeArrangementwithIpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AccruedCollaborationLiabilityCurrent" abstract="false" name="AccruedCollaborationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesofMcKessonCorporationMember" abstract="true" name="AffiliatesofMcKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AssetAcquisitionPaymentUponClosingOfTransaction" abstract="false" name="AssetAcquisitionPaymentUponClosingOfTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AchievedMember" abstract="true" name="AchievedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_A2018PerformanceStockUnitsMember" abstract="true" name="A2018PerformanceStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_HeadquartersLeaseDecember2020AmendmentMember" abstract="true" name="HeadquartersLeaseDecember2020AmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_IpsenMember" abstract="true" name="IpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_OtherLongtermAssetsMember" abstract="true" name="OtherLongtermAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_TakedaMember" abstract="true" name="TakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_StatusDomain" abstract="true" name="StatusDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" abstract="false" name="AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_InvestmentsPurchasesIncurredButNotYetPaid" abstract="false" name="InvestmentsPurchasesIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationAgreementWithIconicTherapeuticsIncMember" abstract="true" name="CollaborationAgreementWithIconicTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_PerformanceSharesClinicalTrialResultsMember" abstract="true" name="PerformanceSharesClinicalTrialResultsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_TenantLeaseImprovementsAllowance" abstract="false" name="TenantLeaseImprovementsAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>exel-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:15eb203a-3ec7-40cd-9655-d78f522bbe80,g:fdc51e9e-f0fc-4164-a9b2-d81298576ebe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c9439227-a453-48ba-bffd-1b8a86f30e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a9a49fae-9a04-4ec0-8970-3ac910bd1fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c9439227-a453-48ba-bffd-1b8a86f30e0f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a9a49fae-9a04-4ec0-8970-3ac910bd1fc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_e99ec1d6-c6ef-4e1b-939b-3ebe6f439608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c9439227-a453-48ba-bffd-1b8a86f30e0f" xlink:to="loc_us-gaap_ShortTermInvestments_e99ec1d6-c6ef-4e1b-939b-3ebe6f439608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_c9c43047-799f-4ca4-bedc-f17ea4896757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c9439227-a453-48ba-bffd-1b8a86f30e0f" xlink:to="loc_us-gaap_ReceivablesNetCurrent_c9c43047-799f-4ca4-bedc-f17ea4896757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ec09accd-73ee-40c4-b372-6f355b069d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c9439227-a453-48ba-bffd-1b8a86f30e0f" xlink:to="loc_us-gaap_InventoryNet_ec09accd-73ee-40c4-b372-6f355b069d80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b09a289b-26e4-400a-a5b8-891535d50636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c9439227-a453-48ba-bffd-1b8a86f30e0f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b09a289b-26e4-400a-a5b8-891535d50636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_573432a3-dfb9-48c1-9d9a-ec8d3473c68e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_13f77879-4a17-4d00-9dbd-7a465df38ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_573432a3-dfb9-48c1-9d9a-ec8d3473c68e" xlink:to="loc_us-gaap_PreferredStockValue_13f77879-4a17-4d00-9dbd-7a465df38ef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9bcfc6ba-6f62-4a0e-9054-5b3e8c8b9c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_573432a3-dfb9-48c1-9d9a-ec8d3473c68e" xlink:to="loc_us-gaap_CommonStockValue_9bcfc6ba-6f62-4a0e-9054-5b3e8c8b9c13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f8b0d7b9-55c2-4e41-a3da-0a55875d1e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_573432a3-dfb9-48c1-9d9a-ec8d3473c68e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f8b0d7b9-55c2-4e41-a3da-0a55875d1e2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5815a7e7-a033-4586-bf5c-1cc314e80e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_573432a3-dfb9-48c1-9d9a-ec8d3473c68e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5815a7e7-a033-4586-bf5c-1cc314e80e84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_867ad678-396a-4361-82fc-0bda8f1a8db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_573432a3-dfb9-48c1-9d9a-ec8d3473c68e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_867ad678-396a-4361-82fc-0bda8f1a8db7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4ef1b60a-084c-43aa-9c9a-bb9d90fb9fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8b48b272-9ed8-43e6-8797-095a6f9b5d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4ef1b60a-084c-43aa-9c9a-bb9d90fb9fc3" xlink:to="loc_us-gaap_AssetsCurrent_8b48b272-9ed8-43e6-8797-095a6f9b5d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_f3fd86cb-6102-4f50-8c64-34c349f9412f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4ef1b60a-084c-43aa-9c9a-bb9d90fb9fc3" xlink:to="loc_us-gaap_LongTermInvestments_f3fd86cb-6102-4f50-8c64-34c349f9412f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2568cae2-560c-44e1-acb5-d48c28f821fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4ef1b60a-084c-43aa-9c9a-bb9d90fb9fc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2568cae2-560c-44e1-acb5-d48c28f821fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_1d094416-37d1-4d32-a5cf-f9be466a1eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4ef1b60a-084c-43aa-9c9a-bb9d90fb9fc3" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_1d094416-37d1-4d32-a5cf-f9be466a1eca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_266425cb-1e85-48d3-9808-13ababd5e921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4ef1b60a-084c-43aa-9c9a-bb9d90fb9fc3" xlink:to="loc_us-gaap_Goodwill_266425cb-1e85-48d3-9808-13ababd5e921" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e97c2a3a-a4c2-4269-b0b9-69feb74ff674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4ef1b60a-084c-43aa-9c9a-bb9d90fb9fc3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e97c2a3a-a4c2-4269-b0b9-69feb74ff674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fbd3ee02-8d40-4303-963d-875702cf3bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2db5e0a5-979c-47ed-8e36-65a56ebe6615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fbd3ee02-8d40-4303-963d-875702cf3bc1" xlink:to="loc_us-gaap_Liabilities_2db5e0a5-979c-47ed-8e36-65a56ebe6615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9f80841d-d0e1-4f41-bb5a-028e444daa7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fbd3ee02-8d40-4303-963d-875702cf3bc1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9f80841d-d0e1-4f41-bb5a-028e444daa7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_badfa56f-cebe-4959-9e2e-1cf994dbc1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fbd3ee02-8d40-4303-963d-875702cf3bc1" xlink:to="loc_us-gaap_StockholdersEquity_badfa56f-cebe-4959-9e2e-1cf994dbc1fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_73bf728d-c9ca-4b40-b314-1e4f0aa387f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e9ee75bd-7f1c-451d-94fe-0d59035389c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_73bf728d-c9ca-4b40-b314-1e4f0aa387f0" xlink:to="loc_us-gaap_LiabilitiesCurrent_e9ee75bd-7f1c-451d-94fe-0d59035389c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8763da82-0746-4df3-a02f-e0bf3991bd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_73bf728d-c9ca-4b40-b314-1e4f0aa387f0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8763da82-0746-4df3-a02f-e0bf3991bd41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e3ce7339-0a0e-4237-a201-78f9830e6202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_73bf728d-c9ca-4b40-b314-1e4f0aa387f0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e3ce7339-0a0e-4237-a201-78f9830e6202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ce65dbe7-93f7-430c-89c0-63671f7dfcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_73bf728d-c9ca-4b40-b314-1e4f0aa387f0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ce65dbe7-93f7-430c-89c0-63671f7dfcf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b0189d4c-82d4-4743-9646-6ecbc7685dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_18e1b1d8-11df-4034-9c11-03ba4214fd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0189d4c-82d4-4743-9646-6ecbc7685dd3" xlink:to="loc_us-gaap_AccountsPayableCurrent_18e1b1d8-11df-4034-9c11-03ba4214fd5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6a697d20-5bac-4655-a0ac-09cc6302776c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0189d4c-82d4-4743-9646-6ecbc7685dd3" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6a697d20-5bac-4655-a0ac-09cc6302776c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_47ef886c-e8fc-4613-89ae-42d965b925f6" xlink:href="exel-20211231.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0189d4c-82d4-4743-9646-6ecbc7685dd3" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_47ef886c-e8fc-4613-89ae-42d965b925f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_08f96409-bf78-433b-be3f-a5f7a31a1003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0189d4c-82d4-4743-9646-6ecbc7685dd3" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_08f96409-bf78-433b-be3f-a5f7a31a1003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_e73394c6-d652-4bdb-84dd-b1e50717c8fa" xlink:href="exel-20211231.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0189d4c-82d4-4743-9646-6ecbc7685dd3" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_e73394c6-d652-4bdb-84dd-b1e50717c8fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5d1aadf6-ea3e-41b6-ac08-3a56fe020a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0189d4c-82d4-4743-9646-6ecbc7685dd3" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5d1aadf6-ea3e-41b6-ac08-3a56fe020a05" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20211231.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_24590e20-5af1-4c6d-be51-edbe174d0d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e9c61570-340c-43dc-bb0a-b576a9b0a2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_24590e20-5af1-4c6d-be51-edbe174d0d4e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e9c61570-340c-43dc-bb0a-b576a9b0a2a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0f83de5c-263a-4f19-a362-16949d0da4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_24590e20-5af1-4c6d-be51-edbe174d0d4e" xlink:to="loc_us-gaap_CostsAndExpenses_0f83de5c-263a-4f19-a362-16949d0da4fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_311825a0-ad14-4d75-99c4-4a2fdf126c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6b27d4ea-7f0b-47dd-9f06-f6c178998a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_311825a0-ad14-4d75-99c4-4a2fdf126c68" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6b27d4ea-7f0b-47dd-9f06-f6c178998a5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3b1a4964-e390-4049-b02c-be34a546924b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_311825a0-ad14-4d75-99c4-4a2fdf126c68" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3b1a4964-e390-4049-b02c-be34a546924b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5221c847-8acf-464f-a162-805bdae9c5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_311825a0-ad14-4d75-99c4-4a2fdf126c68" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5221c847-8acf-464f-a162-805bdae9c5b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_00cb1d20-6993-47bd-8794-f38b10c5ad41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9cdb1dd9-970c-4259-b2d7-2fc46d8b159f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_00cb1d20-6993-47bd-8794-f38b10c5ad41" xlink:to="loc_us-gaap_OperatingIncomeLoss_9cdb1dd9-970c-4259-b2d7-2fc46d8b159f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_97a28f8e-f883-45a4-a3a9-9d4d58837e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_00cb1d20-6993-47bd-8794-f38b10c5ad41" xlink:to="loc_us-gaap_InterestIncomeOther_97a28f8e-f883-45a4-a3a9-9d4d58837e02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bf683927-b03b-4f77-8297-6ed891f451a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_00cb1d20-6993-47bd-8794-f38b10c5ad41" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bf683927-b03b-4f77-8297-6ed891f451a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_007e3baf-f722-4fe7-9122-c0bb28a1ea72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_b1fb2042-a858-45c7-ac89-d4a7b1cefd25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_007e3baf-f722-4fe7-9122-c0bb28a1ea72" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_b1fb2042-a858-45c7-ac89-d4a7b1cefd25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_35641486-4bac-4ec0-93fc-6084905a79d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_007e3baf-f722-4fe7-9122-c0bb28a1ea72" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_35641486-4bac-4ec0-93fc-6084905a79d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20211231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ab7cf56f-b9c2-4f7d-b8e0-4dbd641a3ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a30ddb4f-f455-421e-8f35-fbf992370d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ab7cf56f-b9c2-4f7d-b8e0-4dbd641a3ff9" xlink:to="loc_us-gaap_NetIncomeLoss_a30ddb4f-f455-421e-8f35-fbf992370d53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c26d8ac8-e9e0-4c93-8e7a-89ef2c9dc632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ab7cf56f-b9c2-4f7d-b8e0-4dbd641a3ff9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c26d8ac8-e9e0-4c93-8e7a-89ef2c9dc632" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6144b452-beea-4ac6-9847-d06ac2423200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c95e40e5-cc59-4c70-b732-f4bd1569e6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6144b452-beea-4ac6-9847-d06ac2423200" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c95e40e5-cc59-4c70-b732-f4bd1569e6bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a00cc06c-00ca-4974-a0d9-774093ce6b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6144b452-beea-4ac6-9847-d06ac2423200" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a00cc06c-00ca-4974-a0d9-774093ce6b5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_956b1c81-aadb-4c52-9081-7ffd0d819557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6144b452-beea-4ac6-9847-d06ac2423200" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_956b1c81-aadb-4c52-9081-7ffd0d819557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55533746-e22d-41d6-aa97-ec91e38529d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_29f31f1d-75ce-4397-9a37-9e872512631b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55533746-e22d-41d6-aa97-ec91e38529d6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_29f31f1d-75ce-4397-9a37-9e872512631b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_223b4df8-c34a-40f0-9da5-f6a883a8ec06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55533746-e22d-41d6-aa97-ec91e38529d6" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_223b4df8-c34a-40f0-9da5-f6a883a8ec06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_6f60f1a3-fa82-46b9-ab1b-8524aee03421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55533746-e22d-41d6-aa97-ec91e38529d6" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_6f60f1a3-fa82-46b9-ab1b-8524aee03421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53aec9eb-f548-4a21-9cd1-72acaec3e055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f19c4d4e-326c-4cfc-8919-e837ff123806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53aec9eb-f548-4a21-9cd1-72acaec3e055" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f19c4d4e-326c-4cfc-8919-e837ff123806" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c9aa0b5e-36be-4bc2-a6f7-b60e1832b168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53aec9eb-f548-4a21-9cd1-72acaec3e055" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c9aa0b5e-36be-4bc2-a6f7-b60e1832b168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4719e916-9ba3-4c61-af25-0f06b1160eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53aec9eb-f548-4a21-9cd1-72acaec3e055" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4719e916-9ba3-4c61-af25-0f06b1160eef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_233fe371-a22f-4764-a741-54483d1634e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_307b30ce-14c0-42ac-a4ee-b79b97d52637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_233fe371-a22f-4764-a741-54483d1634e7" xlink:to="loc_us-gaap_NetIncomeLoss_307b30ce-14c0-42ac-a4ee-b79b97d52637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_42ce4ff3-7540-4f07-a909-ae34c2858920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_233fe371-a22f-4764-a741-54483d1634e7" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_42ce4ff3-7540-4f07-a909-ae34c2858920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_701cc238-2a90-478b-b50a-b70b597e2baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_233fe371-a22f-4764-a741-54483d1634e7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_701cc238-2a90-478b-b50a-b70b597e2baa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_641ebc00-a4c9-4c7e-9da2-51b01b23a7a8" xlink:href="exel-20211231.xsd#exel_NoncashLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_233fe371-a22f-4764-a741-54483d1634e7" xlink:to="loc_exel_NoncashLeaseExpense_641ebc00-a4c9-4c7e-9da2-51b01b23a7a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_367ec09a-8624-4feb-895b-4a10c6cc3c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_233fe371-a22f-4764-a741-54483d1634e7" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_367ec09a-8624-4feb-895b-4a10c6cc3c69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_57df7211-c226-49cb-9ff1-b5a621f25870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_233fe371-a22f-4764-a741-54483d1634e7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_57df7211-c226-49cb-9ff1-b5a621f25870" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6fb265ce-221a-43b5-bc59-03d8d034f7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_233fe371-a22f-4764-a741-54483d1634e7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6fb265ce-221a-43b5-bc59-03d8d034f7dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_31fedfcd-ab93-4bd7-8be2-c506c9ac71bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_233fe371-a22f-4764-a741-54483d1634e7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_31fedfcd-ab93-4bd7-8be2-c506c9ac71bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d18ae142-bbaa-40b3-a1c7-06acd0d9bb57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_233fe371-a22f-4764-a741-54483d1634e7" xlink:to="loc_us-gaap_ShareBasedCompensation_d18ae142-bbaa-40b3-a1c7-06acd0d9bb57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_afc341fe-79af-4d27-9905-799e3d04e23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_233fe371-a22f-4764-a741-54483d1634e7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_afc341fe-79af-4d27-9905-799e3d04e23a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f6477f2f-f192-4b21-9d90-98f32d19161d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_233fe371-a22f-4764-a741-54483d1634e7" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f6477f2f-f192-4b21-9d90-98f32d19161d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_21a5724d-58b9-42a5-8137-35ee18955740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_233fe371-a22f-4764-a741-54483d1634e7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_21a5724d-58b9-42a5-8137-35ee18955740" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_54fbd58a-0eea-4328-8890-9470eaf99dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a5a4929e-7b98-4ddd-a82a-5ccd307505a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_54fbd58a-0eea-4328-8890-9470eaf99dcb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a5a4929e-7b98-4ddd-a82a-5ccd307505a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bcc0e897-f58c-480d-ad89-7e2ab5094b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_54fbd58a-0eea-4328-8890-9470eaf99dcb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bcc0e897-f58c-480d-ad89-7e2ab5094b10" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a58cd86-4791-455d-b008-e82ba946ffd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_496bd9e8-93ab-4033-b23d-3e09bc4b38ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a58cd86-4791-455d-b008-e82ba946ffd7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_496bd9e8-93ab-4033-b23d-3e09bc4b38ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_ca1a3d2c-4d59-430e-82b3-f09515f8aa52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a58cd86-4791-455d-b008-e82ba946ffd7" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_ca1a3d2c-4d59-430e-82b3-f09515f8aa52" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5ad98cf6-a00e-4115-81ba-fed2dd315526" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5ba74f1d-a262-4855-a76e-ee8283e6cca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5ad98cf6-a00e-4115-81ba-fed2dd315526" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5ba74f1d-a262-4855-a76e-ee8283e6cca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_5e052e47-0d15-4d5e-a915-6afaadb26bc3" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5ad98cf6-a00e-4115-81ba-fed2dd315526" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_5e052e47-0d15-4d5e-a915-6afaadb26bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_52a3bc7d-1c43-4911-a87d-30ddaff7a0e5" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5cb448f9-f6ee-4c36-8fdf-1b7e67390ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_52a3bc7d-1c43-4911-a87d-30ddaff7a0e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5cb448f9-f6ee-4c36-8fdf-1b7e67390ea5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_bfaa7102-5e25-4a1d-9e66-9d2ba11677c1" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_52a3bc7d-1c43-4911-a87d-30ddaff7a0e5" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_bfaa7102-5e25-4a1d-9e66-9d2ba11677c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_766a9623-9e67-4e7e-8d12-c0cabf0c6e2f" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dd647cc1-4ace-4544-9ef4-8dbf87bda95f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_766a9623-9e67-4e7e-8d12-c0cabf0c6e2f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dd647cc1-4ace-4544-9ef4-8dbf87bda95f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_a8b6d3d9-fe92-41ea-a6be-f36ce40a7a5a" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_766a9623-9e67-4e7e-8d12-c0cabf0c6e2f" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_a8b6d3d9-fe92-41ea-a6be-f36ce40a7a5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_41137b92-a9c1-4801-bccd-5519764aa577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e84da4ed-63fa-4ff0-8370-640d65d0858f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_41137b92-a9c1-4801-bccd-5519764aa577" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e84da4ed-63fa-4ff0-8370-640d65d0858f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b16b00af-3651-415f-a937-8aea2628595d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_41137b92-a9c1-4801-bccd-5519764aa577" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b16b00af-3651-415f-a937-8aea2628595d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e19acb36-764b-4594-b1e3-d641ab44c5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_41137b92-a9c1-4801-bccd-5519764aa577" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e19acb36-764b-4594-b1e3-d641ab44c5f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_def3fa32-1188-4132-b939-4736f26af1bc" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7271e562-1ea3-476c-bd36-5199a469c1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_def3fa32-1188-4132-b939-4736f26af1bc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7271e562-1ea3-476c-bd36-5199a469c1d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_424d532f-bd75-4ed9-addc-6239732007f4" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_def3fa32-1188-4132-b939-4736f26af1bc" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_424d532f-bd75-4ed9-addc-6239732007f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a7fcbafb-f324-4005-8021-f381a936c40c" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_7d059f26-8fce-4403-85a5-d9607c60e2a2" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a7fcbafb-f324-4005-8021-f381a936c40c" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_7d059f26-8fce-4403-85a5-d9607c60e2a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_e5c8cdac-aa31-4336-87fd-9834fe5a381b" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a7fcbafb-f324-4005-8021-f381a936c40c" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_e5c8cdac-aa31-4336-87fd-9834fe5a381b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_c5f247c2-f6dd-48f9-a7e1-282a791473b4" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a7fcbafb-f324-4005-8021-f381a936c40c" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_c5f247c2-f6dd-48f9-a7e1-282a791473b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_86621633-0b38-4b66-9962-43eba0ad5cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_20f73680-67e4-4711-a746-8e272ad8acbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_86621633-0b38-4b66-9962-43eba0ad5cc5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_20f73680-67e4-4711-a746-8e272ad8acbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2d1d4abf-c90b-42ed-8f0b-d7c471760078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_86621633-0b38-4b66-9962-43eba0ad5cc5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2d1d4abf-c90b-42ed-8f0b-d7c471760078" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7caad17f-76e8-4fde-9075-7a812ddcc8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c1f622a9-04f0-4ae4-a8a0-a96ba9e9bd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7caad17f-76e8-4fde-9075-7a812ddcc8dd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c1f622a9-04f0-4ae4-a8a0-a96ba9e9bd56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_120df693-65b2-4ccf-baad-9ca883bff034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7caad17f-76e8-4fde-9075-7a812ddcc8dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_120df693-65b2-4ccf-baad-9ca883bff034" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_2d7638a1-811d-4217-9cf3-12f78f722783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_13948dea-52de-4c4b-8d13-cb2892fa4c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2d7638a1-811d-4217-9cf3-12f78f722783" xlink:to="loc_us-gaap_InventoryRawMaterials_13948dea-52de-4c4b-8d13-cb2892fa4c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_e694f44b-2f23-4cc3-b3a0-39c3f7893e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2d7638a1-811d-4217-9cf3-12f78f722783" xlink:to="loc_us-gaap_InventoryWorkInProcess_e694f44b-2f23-4cc3-b3a0-39c3f7893e07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_86f84551-22d4-44c0-9867-a7f476410334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2d7638a1-811d-4217-9cf3-12f78f722783" xlink:to="loc_us-gaap_InventoryFinishedGoods_86f84551-22d4-44c0-9867-a7f476410334" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_774c4190-1893-444f-9a60-2646523e64e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_87102121-f206-4dd3-94fc-9a3e1f0e273b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_774c4190-1893-444f-9a60-2646523e64e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_87102121-f206-4dd3-94fc-9a3e1f0e273b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6bdac4fe-fe8b-47e4-b65e-56232d397aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_774c4190-1893-444f-9a60-2646523e64e9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6bdac4fe-fe8b-47e4-b65e-56232d397aef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0df60005-067b-46c9-8936-f858fca83e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e7688ffa-3029-41ea-9861-5159aee53ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0df60005-067b-46c9-8936-f858fca83e91" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e7688ffa-3029-41ea-9861-5159aee53ae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d7cf4e09-9561-45c5-9a0a-8d55178c7e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0df60005-067b-46c9-8936-f858fca83e91" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d7cf4e09-9561-45c5-9a0a-8d55178c7e50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_da159345-d54f-4189-8b4d-3ad5b50387d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e7efe837-a93d-41c7-9885-f6878998fdac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_da159345-d54f-4189-8b4d-3ad5b50387d3" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e7efe837-a93d-41c7-9885-f6878998fdac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5ceb3e61-c0a8-4593-810f-59b77dd808c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_da159345-d54f-4189-8b4d-3ad5b50387d3" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5ceb3e61-c0a8-4593-810f-59b77dd808c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6590069d-a581-4ce3-b586-e84229eaa638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0390862d-2298-4b9f-9df5-dd3e65ece463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6590069d-a581-4ce3-b586-e84229eaa638" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0390862d-2298-4b9f-9df5-dd3e65ece463" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5c8a7bc3-8683-49d0-a58c-451733feb404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6590069d-a581-4ce3-b586-e84229eaa638" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5c8a7bc3-8683-49d0-a58c-451733feb404" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_10afbb05-1dc7-4b51-91d4-dee37f473d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d459c82f-d45a-4a6a-9550-e9461c74da72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_10afbb05-1dc7-4b51-91d4-dee37f473d60" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d459c82f-d45a-4a6a-9550-e9461c74da72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_08a25275-4c69-4036-b7bd-c7248a2c71f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_10afbb05-1dc7-4b51-91d4-dee37f473d60" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_08a25275-4c69-4036-b7bd-c7248a2c71f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0a84b71f-5ee3-4b1d-82a9-d443beec23ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_10afbb05-1dc7-4b51-91d4-dee37f473d60" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0a84b71f-5ee3-4b1d-82a9-d443beec23ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_e517054e-581b-4744-bafb-ecec2066e145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_10afbb05-1dc7-4b51-91d4-dee37f473d60" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_e517054e-581b-4744-bafb-ecec2066e145" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_06b519c3-c479-41da-943c-486e4c1ad138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_10afbb05-1dc7-4b51-91d4-dee37f473d60" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_06b519c3-c479-41da-943c-486e4c1ad138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_48632b39-0856-463f-8bff-b1863c318a0a" xlink:href="exel-20211231.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_10afbb05-1dc7-4b51-91d4-dee37f473d60" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_48632b39-0856-463f-8bff-b1863c318a0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_801a5885-d737-438a-8db6-4980543c9708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_10afbb05-1dc7-4b51-91d4-dee37f473d60" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_801a5885-d737-438a-8db6-4980543c9708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_85ac48cb-ee19-419a-9f7b-c43471e86929" xlink:href="exel-20211231.xsd#exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_10afbb05-1dc7-4b51-91d4-dee37f473d60" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_85ac48cb-ee19-419a-9f7b-c43471e86929" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a8b8995b-6b6e-4f8b-b6d4-a82f668fb204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_cb2e711a-5731-40d1-bc7e-ec5b83769249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_a8b8995b-6b6e-4f8b-b6d4-a82f668fb204" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_cb2e711a-5731-40d1-bc7e-ec5b83769249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_12956541-33df-4c51-9844-eaf4c4455988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_a8b8995b-6b6e-4f8b-b6d4-a82f668fb204" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_12956541-33df-4c51-9844-eaf4c4455988" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a57b736f-89c3-4079-95cc-de28222dd650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc919cac-d686-456f-994d-85a4b06eb650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a57b736f-89c3-4079-95cc-de28222dd650" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc919cac-d686-456f-994d-85a4b06eb650" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_cf7145f6-3280-44e4-9f9e-8aa2f6a684b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a57b736f-89c3-4079-95cc-de28222dd650" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_cf7145f6-3280-44e4-9f9e-8aa2f6a684b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_0e26123a-629c-47a0-91f4-2276fcb9ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a57b736f-89c3-4079-95cc-de28222dd650" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_0e26123a-629c-47a0-91f4-2276fcb9ceca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxAssetsLeaseLiabilities_f8f1d9cf-eb9d-4ad8-856f-47120d3e03da" xlink:href="exel-20211231.xsd#exel_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a57b736f-89c3-4079-95cc-de28222dd650" xlink:to="loc_exel_DeferredTaxAssetsLeaseLiabilities_f8f1d9cf-eb9d-4ad8-856f-47120d3e03da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_b458ece0-6cb5-4389-9a5f-cfa9f9f92a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a57b736f-89c3-4079-95cc-de28222dd650" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_b458ece0-6cb5-4389-9a5f-cfa9f9f92a3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3602a1d0-700d-43db-b76c-15bc6eaa4611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a57b736f-89c3-4079-95cc-de28222dd650" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3602a1d0-700d-43db-b76c-15bc6eaa4611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_bfbf2f28-899d-4cd4-ae4a-65bf4c70c36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a57b736f-89c3-4079-95cc-de28222dd650" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_bfbf2f28-899d-4cd4-ae4a-65bf4c70c36e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d93afdff-6f21-412c-aca0-fd3975a5d4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a57b736f-89c3-4079-95cc-de28222dd650" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d93afdff-6f21-412c-aca0-fd3975a5d4ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_827e86b9-a811-408b-93a7-ea5e83064b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_bd71b20f-e267-4a6d-92d0-4ffd54d89753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_827e86b9-a811-408b-93a7-ea5e83064b93" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_bd71b20f-e267-4a6d-92d0-4ffd54d89753" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_87d7863b-aa88-426a-a77e-306e62efe12f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_827e86b9-a811-408b-93a7-ea5e83064b93" xlink:to="loc_us-gaap_DeferredTaxLiabilities_87d7863b-aa88-426a-a77e-306e62efe12f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_e6a5980b-78e4-4210-bff8-c5e665e54d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_a4027421-4766-411e-9217-2a31cb13ac13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_e6a5980b-78e4-4210-bff8-c5e665e54d09" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_a4027421-4766-411e-9217-2a31cb13ac13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_436c6bf0-1126-4a6e-bcca-8ee3fa504078" xlink:href="exel-20211231.xsd#exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_e6a5980b-78e4-4210-bff8-c5e665e54d09" xlink:to="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_436c6bf0-1126-4a6e-bcca-8ee3fa504078" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d6ba196f-090d-4c66-a8d3-e6df9e11c8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c2ba8f06-bb71-46f8-af02-d4ba57409753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d6ba196f-090d-4c66-a8d3-e6df9e11c8f6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c2ba8f06-bb71-46f8-af02-d4ba57409753" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_56cae8a7-66f4-4d4c-a076-291801ae95ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d6ba196f-090d-4c66-a8d3-e6df9e11c8f6" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_56cae8a7-66f4-4d4c-a076-291801ae95ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2a7f17bd-af6a-424f-9f97-3c1b779de916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_531ba980-1da5-4e8c-a3a9-64547551e2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_2a7f17bd-af6a-424f-9f97-3c1b779de916" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_531ba980-1da5-4e8c-a3a9-64547551e2ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0539cf49-71a8-43a7-986c-fb7a18ca0af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_2a7f17bd-af6a-424f-9f97-3c1b779de916" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0539cf49-71a8-43a7-986c-fb7a18ca0af1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f8a520c5-9d7b-4434-9b7f-880eb2377c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_cb211f0e-1cd1-432b-8f24-cef549e12eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f8a520c5-9d7b-4434-9b7f-880eb2377c80" xlink:to="loc_us-gaap_OperatingLeaseCost_cb211f0e-1cd1-432b-8f24-cef549e12eb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_f5cd0a1c-1cd9-4547-a4a3-44c61d607793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f8a520c5-9d7b-4434-9b7f-880eb2377c80" xlink:to="loc_us-gaap_VariableLeaseCost_f5cd0a1c-1cd9-4547-a4a3-44c61d607793" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_483aa2a0-0477-4f0d-b9dc-7c725c2ddd52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_49b41924-2ed1-4c1d-871b-fd625a19a1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_483aa2a0-0477-4f0d-b9dc-7c725c2ddd52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_49b41924-2ed1-4c1d-871b-fd625a19a1e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0c9effa-53fc-4756-98f2-a7d9c53c9264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_483aa2a0-0477-4f0d-b9dc-7c725c2ddd52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0c9effa-53fc-4756-98f2-a7d9c53c9264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dcbce174-90ba-4149-a12e-672997df7ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_483aa2a0-0477-4f0d-b9dc-7c725c2ddd52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dcbce174-90ba-4149-a12e-672997df7ba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6437cf55-201a-4320-9cba-5a84b7c79030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_483aa2a0-0477-4f0d-b9dc-7c725c2ddd52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6437cf55-201a-4320-9cba-5a84b7c79030" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_51606f34-7e23-4326-900a-7d9bf0f8ea8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_483aa2a0-0477-4f0d-b9dc-7c725c2ddd52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_51606f34-7e23-4326-900a-7d9bf0f8ea8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ce8cbdec-ff96-4ce9-ae7b-4b2038eb4a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_483aa2a0-0477-4f0d-b9dc-7c725c2ddd52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ce8cbdec-ff96-4ce9-ae7b-4b2038eb4a45" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="exel-20211231.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e87cbc3-331e-4c2d-bc67-5e160a9ced2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f5d84750-d1e5-44e1-b995-f184824c04de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e87cbc3-331e-4c2d-bc67-5e160a9ced2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f5d84750-d1e5-44e1-b995-f184824c04de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_e4cc59ba-450c-41d7-8e72-5fc74b31fa71" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e87cbc3-331e-4c2d-bc67-5e160a9ced2b" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_e4cc59ba-450c-41d7-8e72-5fc74b31fa71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5fa6b822-4431-4a39-863c-68aba29f4031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e87cbc3-331e-4c2d-bc67-5e160a9ced2b" xlink:to="loc_us-gaap_OperatingLeaseLiability_5fa6b822-4431-4a39-863c-68aba29f4031" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>exel-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:15eb203a-3ec7-40cd-9655-d78f522bbe80,g:fdc51e9e-f0fc-4164-a9b2-d81298576ebe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20211231.xsd#ConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="extended" id="i9a09f8e32de240b1957a749534708b27_ConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6184de34-3dc0-4ea5-9c59-35e510d1e574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_RevenuesAbstract_6184de34-3dc0-4ea5-9c59-35e510d1e574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_416a8b4f-b8d3-4e14-ad77-aed8635f8d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_6184de34-3dc0-4ea5-9c59-35e510d1e574" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_416a8b4f-b8d3-4e14-ad77-aed8635f8d0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c6c07aff-9b10-46ad-af8f-b4c93d896d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c6c07aff-9b10-46ad-af8f-b4c93d896d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5991c192-e59d-4950-b80a-002898bf5edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6c07aff-9b10-46ad-af8f-b4c93d896d5a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5991c192-e59d-4950-b80a-002898bf5edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b1217515-2a5a-4df0-9c3e-1828d3ed059d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6c07aff-9b10-46ad-af8f-b4c93d896d5a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b1217515-2a5a-4df0-9c3e-1828d3ed059d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_163ed90b-e4c4-4147-be53-276514b6c0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6c07aff-9b10-46ad-af8f-b4c93d896d5a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_163ed90b-e4c4-4147-be53-276514b6c0b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_52185dde-a329-4475-8c89-a672b3ba59dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6c07aff-9b10-46ad-af8f-b4c93d896d5a" xlink:to="loc_us-gaap_CostsAndExpenses_52185dde-a329-4475-8c89-a672b3ba59dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c661d5f3-94dd-4e8c-a317-e3d2160d8e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_OperatingIncomeLoss_c661d5f3-94dd-4e8c-a317-e3d2160d8e8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_de9cb7c4-4690-431e-ad71-8fbdb89a300b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_InterestIncomeOther_de9cb7c4-4690-431e-ad71-8fbdb89a300b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_14614db3-4988-4ace-a33e-d96bb27999ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_14614db3-4988-4ace-a33e-d96bb27999ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_840bde54-d883-4402-bf22-4b5b652853be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_840bde54-d883-4402-bf22-4b5b652853be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b88b3dd7-caa9-42c2-bcd1-db041a4e5e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b88b3dd7-caa9-42c2-bcd1-db041a4e5e70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b64561aa-0672-4d6c-af17-4ac3ba3f39ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_NetIncomeLoss_b64561aa-0672-4d6c-af17-4ac3ba3f39ad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b12169f0-4a0b-40d1-a729-c1d27ea360a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_EarningsPerShareAbstract_b12169f0-4a0b-40d1-a729-c1d27ea360a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1875eeac-920c-4a17-adf1-06b18633231a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b12169f0-4a0b-40d1-a729-c1d27ea360a6" xlink:to="loc_us-gaap_EarningsPerShareBasic_1875eeac-920c-4a17-adf1-06b18633231a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8b05225a-06a5-4f12-a699-b460fde8ac76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b12169f0-4a0b-40d1-a729-c1d27ea360a6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8b05225a-06a5-4f12-a699-b460fde8ac76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af507361-33fb-48a3-a468-e262c3ac87a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af507361-33fb-48a3-a468-e262c3ac87a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fced1729-c746-4b7d-9efa-1b3161fa4d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af507361-33fb-48a3-a468-e262c3ac87a4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fced1729-c746-4b7d-9efa-1b3161fa4d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46accf5a-da5d-4d0b-a3a2-f3fe061585bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af507361-33fb-48a3-a468-e262c3ac87a4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46accf5a-da5d-4d0b-a3a2-f3fe061585bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_46b89001-28d8-4ce4-93e6-5b85651bb55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_StatementTable_46b89001-28d8-4ce4-93e6-5b85651bb55e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_49c0d60b-ac9c-4c5f-b149-b1e87a65284e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_46b89001-28d8-4ce4-93e6-5b85651bb55e" xlink:to="loc_srt_ProductOrServiceAxis_49c0d60b-ac9c-4c5f-b149-b1e87a65284e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_49c0d60b-ac9c-4c5f-b149-b1e87a65284e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_49c0d60b-ac9c-4c5f-b149-b1e87a65284e" xlink:to="loc_srt_ProductsAndServicesDomain_49c0d60b-ac9c-4c5f-b149-b1e87a65284e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a131704a-95dd-4b05-bef4-2d60375aa435" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_49c0d60b-ac9c-4c5f-b149-b1e87a65284e" xlink:to="loc_srt_ProductsAndServicesDomain_a131704a-95dd-4b05-bef4-2d60375aa435" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_097b3f6b-f0ca-44c4-a999-a9d7526f52ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a131704a-95dd-4b05-bef4-2d60375aa435" xlink:to="loc_us-gaap_ProductMember_097b3f6b-f0ca-44c4-a999-a9d7526f52ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b5ea5fa9-1dc6-45e5-8294-c6b8dc53c64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a131704a-95dd-4b05-bef4-2d60375aa435" xlink:to="loc_us-gaap_LicenseMember_b5ea5fa9-1dc6-45e5-8294-c6b8dc53c64a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_cba76970-3e5f-4231-be12-f5249bdfde4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a131704a-95dd-4b05-bef4-2d60375aa435" xlink:to="loc_us-gaap_ServiceMember_cba76970-3e5f-4231-be12-f5249bdfde4d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ic3d17e75b7274157b4efc75e053b779e_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4e9372ef-f740-42ec-a25f-c8106805ea18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e9372ef-f740-42ec-a25f-c8106805ea18" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_63360254-e566-4b81-b4eb-f1a38b2fd724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_63360254-e566-4b81-b4eb-f1a38b2fd724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e4f85521-467e-4b47-b3ff-18a02993618b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_StockholdersEquity_e4f85521-467e-4b47-b3ff-18a02993618b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc1bae8a-33db-45d5-8e2f-829340fac1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_NetIncomeLoss_fc1bae8a-33db-45d5-8e2f-829340fac1a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_475b5ca2-106e-4788-a960-8494e024dc24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_475b5ca2-106e-4788-a960-8494e024dc24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4133c5e0-b6fc-4edb-bd26-f813b8672db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4133c5e0-b6fc-4edb-bd26-f813b8672db9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e9e00755-c95e-4b82-a995-de8055486992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e9e00755-c95e-4b82-a995-de8055486992" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_81bc1978-a8a4-4407-b757-8911e8c160d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_81bc1978-a8a4-4407-b757-8911e8c160d4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6fa88d73-efb8-4efa-adb9-7ea89c97c2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6fa88d73-efb8-4efa-adb9-7ea89c97c2f1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4e61b574-6195-458a-92dc-777f1a02dded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5f2bb433-b360-4098-b15e-77189761fe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f703e211-f76e-4071-9c00-c73dcf9cb7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4e9372ef-f740-42ec-a25f-c8106805ea18" xlink:to="loc_us-gaap_StatementTable_f703e211-f76e-4071-9c00-c73dcf9cb7a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_60e1dd48-ce46-464a-876d-d1470b8584b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f703e211-f76e-4071-9c00-c73dcf9cb7a5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_60e1dd48-ce46-464a-876d-d1470b8584b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_60e1dd48-ce46-464a-876d-d1470b8584b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60e1dd48-ce46-464a-876d-d1470b8584b1" xlink:to="loc_us-gaap_EquityComponentDomain_60e1dd48-ce46-464a-876d-d1470b8584b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_97895a05-e8d3-43b7-a826-dca88f7be7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60e1dd48-ce46-464a-876d-d1470b8584b1" xlink:to="loc_us-gaap_EquityComponentDomain_97895a05-e8d3-43b7-a826-dca88f7be7b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bdf4155b-b622-462c-95cf-361dc0033672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_97895a05-e8d3-43b7-a826-dca88f7be7b2" xlink:to="loc_us-gaap_CommonStockMember_bdf4155b-b622-462c-95cf-361dc0033672" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ce74e7b4-9060-4d62-9bc2-5bcd17aa9f61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_97895a05-e8d3-43b7-a826-dca88f7be7b2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ce74e7b4-9060-4d62-9bc2-5bcd17aa9f61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5267b3ec-6728-44b7-bfe7-e942fdb80709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_97895a05-e8d3-43b7-a826-dca88f7be7b2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5267b3ec-6728-44b7-bfe7-e942fdb80709" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d922bf42-2559-49a7-9814-e95e43d88e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_97895a05-e8d3-43b7-a826-dca88f7be7b2" xlink:to="loc_us-gaap_RetainedEarningsMember_d922bf42-2559-49a7-9814-e95e43d88e3d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="id63fd038c1e147e2929441c1df3e50d5_OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:href="exel-20211231.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_569440f5-014b-4a1d-8af6-8191e48470f6" xlink:href="exel-20211231.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_exel_NumberofProductsinCommercialMarket_569440f5-014b-4a1d-8af6-8191e48470f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_9463e810-a3b1-4b2b-8bdb-987bb76cf5fa" xlink:href="exel-20211231.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_9463e810-a3b1-4b2b-8bdb-987bb76cf5fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2bf3f4cb-1081-4912-ab60-09df0bdc76a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2bf3f4cb-1081-4912-ab60-09df0bdc76a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_7ce56ec6-0ae3-4178-8dec-3189c4d41f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_7ce56ec6-0ae3-4178-8dec-3189c4d41f55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2e367485-0554-4484-8cf8-ac30116f49c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2e367485-0554-4484-8cf8-ac30116f49c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_9b3e8451-fef1-4dc8-912a-ec3fcc2c4719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_DerivativeTermOfContract_9b3e8451-fef1-4dc8-912a-ec3fcc2c4719" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_9a3ae70b-ba06-4050-aee2-e103e78d19e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_9a3ae70b-ba06-4050-aee2-e103e78d19e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4bf80499-215c-4d00-b567-3c381b338736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4bf80499-215c-4d00-b567-3c381b338736" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_016e48ac-f39c-4983-b246-6bbcd1e5e6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_016e48ac-f39c-4983-b246-6bbcd1e5e6fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_7ca788bc-9492-4fd1-ac47-a8e3a24554dd" xlink:href="exel-20211231.xsd#exel_SalesRevenuePercentDiscountForPromptPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_7ca788bc-9492-4fd1-ac47-a8e3a24554dd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_582d1879-6f48-47ac-b523-c860f11e88bf" xlink:href="exel-20211231.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_582d1879-6f48-47ac-b523-c860f11e88bf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MedicarePartDFundingMandate_ec95c4c7-ca60-40b2-8e13-b4137ee0809a" xlink:href="exel-20211231.xsd#exel_MedicarePartDFundingMandate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_exel_MedicarePartDFundingMandate_ec95c4c7-ca60-40b2-8e13-b4137ee0809a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_39c10c41-c8b5-47a7-9598-8789703dced0" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_39c10c41-c8b5-47a7-9598-8789703dced0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_983a3da2-ba6f-466e-991c-39d97cc93a15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_AdvertisingExpense_983a3da2-ba6f-466e-991c-39d97cc93a15" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_71f4e964-bd3e-4634-99bf-0c28bbdf6f1e" xlink:href="exel-20211231.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_71f4e964-bd3e-4634-99bf-0c28bbdf6f1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6c477758-448a-48ef-9988-cf6e9d3c5071" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_71f4e964-bd3e-4634-99bf-0c28bbdf6f1e" xlink:to="loc_srt_ProductOrServiceAxis_6c477758-448a-48ef-9988-cf6e9d3c5071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6c477758-448a-48ef-9988-cf6e9d3c5071_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6c477758-448a-48ef-9988-cf6e9d3c5071" xlink:to="loc_srt_ProductsAndServicesDomain_6c477758-448a-48ef-9988-cf6e9d3c5071_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1b09b838-c5c9-479c-9b3c-d016b7d6c0dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6c477758-448a-48ef-9988-cf6e9d3c5071" xlink:to="loc_srt_ProductsAndServicesDomain_1b09b838-c5c9-479c-9b3c-d016b7d6c0dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_14e8d34f-bce7-4976-93d6-37d36c65e4ce" xlink:href="exel-20211231.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1b09b838-c5c9-479c-9b3c-d016b7d6c0dd" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_14e8d34f-bce7-4976-93d6-37d36c65e4ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_867aabad-a847-4ef2-a6aa-2d71676cb867" xlink:href="exel-20211231.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1b09b838-c5c9-479c-9b3c-d016b7d6c0dd" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_867aabad-a847-4ef2-a6aa-2d71676cb867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_518c07f7-718c-4c35-972f-020340776bbd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_71f4e964-bd3e-4634-99bf-0c28bbdf6f1e" xlink:to="loc_srt_RangeAxis_518c07f7-718c-4c35-972f-020340776bbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_518c07f7-718c-4c35-972f-020340776bbd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_518c07f7-718c-4c35-972f-020340776bbd" xlink:to="loc_srt_RangeMember_518c07f7-718c-4c35-972f-020340776bbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc108f2f-63a2-4dd0-86aa-e68cc4b941e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_518c07f7-718c-4c35-972f-020340776bbd" xlink:to="loc_srt_RangeMember_fc108f2f-63a2-4dd0-86aa-e68cc4b941e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1b9b9760-b2b5-4ab7-bcaf-d0a2372dbf28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fc108f2f-63a2-4dd0-86aa-e68cc4b941e4" xlink:to="loc_srt_MaximumMember_1b9b9760-b2b5-4ab7-bcaf-d0a2372dbf28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_369b25ce-4458-428e-acaa-1e9d3d40e845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_71f4e964-bd3e-4634-99bf-0c28bbdf6f1e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_369b25ce-4458-428e-acaa-1e9d3d40e845" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_369b25ce-4458-428e-acaa-1e9d3d40e845_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_369b25ce-4458-428e-acaa-1e9d3d40e845" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_369b25ce-4458-428e-acaa-1e9d3d40e845_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f2a069dc-5623-4f06-a8ce-e5a477835327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_369b25ce-4458-428e-acaa-1e9d3d40e845" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f2a069dc-5623-4f06-a8ce-e5a477835327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_f0b0b7e8-5c42-4127-b550-0061e21696f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f2a069dc-5623-4f06-a8ce-e5a477835327" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_f0b0b7e8-5c42-4127-b550-0061e21696f9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended" id="idfbacb382ae44ecdbbd030e9df69f9c6_RevenuesRevenuesbyDisaggregatedCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4d1101c4-c3be-4a02-bbb3-d3a5f000ed20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aabe25c9-3216-485e-83c4-20446e90bfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4d1101c4-c3be-4a02-bbb3-d3a5f000ed20" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aabe25c9-3216-485e-83c4-20446e90bfe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7b735f7d-7934-431d-9620-e3c1b666992f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4d1101c4-c3be-4a02-bbb3-d3a5f000ed20" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7b735f7d-7934-431d-9620-e3c1b666992f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a2b453be-096b-4251-8a2a-d17f168052c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7b735f7d-7934-431d-9620-e3c1b666992f" xlink:to="loc_srt_ProductOrServiceAxis_a2b453be-096b-4251-8a2a-d17f168052c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a2b453be-096b-4251-8a2a-d17f168052c6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a2b453be-096b-4251-8a2a-d17f168052c6" xlink:to="loc_srt_ProductsAndServicesDomain_a2b453be-096b-4251-8a2a-d17f168052c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a2b453be-096b-4251-8a2a-d17f168052c6" xlink:to="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_7188cb64-bee8-4d4b-9c3e-ec2e466db2e5" xlink:href="exel-20211231.xsd#exel_ProductGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:to="loc_exel_ProductGrossMember_7188cb64-bee8-4d4b-9c3e-ec2e466db2e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_138151a7-8468-422c-a272-4f3423b92ca1" xlink:href="exel-20211231.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_138151a7-8468-422c-a272-4f3423b92ca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7109df5d-6508-446e-960c-b54004f3ba40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:to="loc_us-gaap_ProductMember_7109df5d-6508-446e-960c-b54004f3ba40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_043e02ad-6aa1-4a67-9d17-032825b81a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:to="loc_us-gaap_LicenseMember_043e02ad-6aa1-4a67-9d17-032825b81a5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_118e651d-b79f-49f1-9596-fa5263d5f05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:to="loc_us-gaap_ServiceMember_118e651d-b79f-49f1-9596-fa5263d5f05f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_7b74b15e-7179-436c-acca-69164e775e60" xlink:href="exel-20211231.xsd#exel_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:to="loc_exel_CollaborationMember_7b74b15e-7179-436c-acca-69164e775e60" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended" id="ibf7abfb804544efbb322119638d7eaa0_RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_672d7709-7378-4448-bfc7-dcff8d8f1edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fedae6e3-fdb7-47ff-a82c-acba628fd921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_672d7709-7378-4448-bfc7-dcff8d8f1edc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fedae6e3-fdb7-47ff-a82c-acba628fd921" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a44c71a5-5ddc-4eea-99e4-6815218447e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_672d7709-7378-4448-bfc7-dcff8d8f1edc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a44c71a5-5ddc-4eea-99e4-6815218447e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_249b3aa5-f1cd-4751-97b6-56edb0379e51" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a44c71a5-5ddc-4eea-99e4-6815218447e6" xlink:to="loc_srt_ProductOrServiceAxis_249b3aa5-f1cd-4751-97b6-56edb0379e51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_249b3aa5-f1cd-4751-97b6-56edb0379e51_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_249b3aa5-f1cd-4751-97b6-56edb0379e51" xlink:to="loc_srt_ProductsAndServicesDomain_249b3aa5-f1cd-4751-97b6-56edb0379e51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_450fc00a-ca74-42d3-94b6-1d5719173268" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_249b3aa5-f1cd-4751-97b6-56edb0379e51" xlink:to="loc_srt_ProductsAndServicesDomain_450fc00a-ca74-42d3-94b6-1d5719173268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_24858166-5680-4b7b-9adf-f343ddcb2ffa" xlink:href="exel-20211231.xsd#exel_CabometyxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_450fc00a-ca74-42d3-94b6-1d5719173268" xlink:to="loc_exel_CabometyxMember_24858166-5680-4b7b-9adf-f343ddcb2ffa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_3b53b372-ab52-4ed8-9df6-b4e3f111a6fc" xlink:href="exel-20211231.xsd#exel_CometriqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_450fc00a-ca74-42d3-94b6-1d5719173268" xlink:to="loc_exel_CometriqMember_3b53b372-ab52-4ed8-9df6-b4e3f111a6fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5b07d030-5e3c-48c0-b6c0-e56ff44d4273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_450fc00a-ca74-42d3-94b6-1d5719173268" xlink:to="loc_us-gaap_ProductMember_5b07d030-5e3c-48c0-b6c0-e56ff44d4273" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended" id="icaa09ed766fb4b4eb3be67eaec999fcb_RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_47333a37-a912-417e-8ff3-213a97acd989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7b1ee562-bd64-4d14-a8da-5ab71cc99f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_47333a37-a912-417e-8ff3-213a97acd989" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7b1ee562-bd64-4d14-a8da-5ab71cc99f43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_eb17912c-7753-4fe0-9aea-dd1f08a60da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_47333a37-a912-417e-8ff3-213a97acd989" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_eb17912c-7753-4fe0-9aea-dd1f08a60da9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9605eec3-264c-49b5-bbb6-aeb469a34165" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_eb17912c-7753-4fe0-9aea-dd1f08a60da9" xlink:to="loc_srt_MajorCustomersAxis_9605eec3-264c-49b5-bbb6-aeb469a34165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9605eec3-264c-49b5-bbb6-aeb469a34165_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9605eec3-264c-49b5-bbb6-aeb469a34165" xlink:to="loc_srt_NameOfMajorCustomerDomain_9605eec3-264c-49b5-bbb6-aeb469a34165_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9605eec3-264c-49b5-bbb6-aeb469a34165" xlink:to="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_a06519a6-a935-4d10-b4fa-7503dc50babb" xlink:href="exel-20211231.xsd#exel_IpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:to="loc_exel_IpsenMember_a06519a6-a935-4d10-b4fa-7503dc50babb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_0a7700e1-8b1a-4737-bc70-b6764b7b7b54" xlink:href="exel-20211231.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_0a7700e1-8b1a-4737-bc70-b6764b7b7b54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_8b193e76-f70b-4316-a556-afc8f3595033" xlink:href="exel-20211231.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_8b193e76-f70b-4316-a556-afc8f3595033" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_31f5412e-b7f2-4064-8b48-1e391e8d4d12" xlink:href="exel-20211231.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_31f5412e-b7f2-4064-8b48-1e391e8d4d12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_f8fb5e71-893b-4ffb-ae22-638c6803db32" xlink:href="exel-20211231.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_f8fb5e71-893b-4ffb-ae22-638c6803db32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_aba1f5d6-85da-4a11-99c6-750227854cd0" xlink:href="exel-20211231.xsd#exel_TakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:to="loc_exel_TakedaMember_aba1f5d6-85da-4a11-99c6-750227854cd0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2ebbbfd-a4cf-436f-aa6e-fb0072b05bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_eb17912c-7753-4fe0-9aea-dd1f08a60da9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2ebbbfd-a4cf-436f-aa6e-fb0072b05bc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2ebbbfd-a4cf-436f-aa6e-fb0072b05bc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2ebbbfd-a4cf-436f-aa6e-fb0072b05bc4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2ebbbfd-a4cf-436f-aa6e-fb0072b05bc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3bf08257-5e99-4178-82cc-ed17f90971af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2ebbbfd-a4cf-436f-aa6e-fb0072b05bc4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3bf08257-5e99-4178-82cc-ed17f90971af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f59802b4-4226-48ee-a812-3e8fdc7aea52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3bf08257-5e99-4178-82cc-ed17f90971af" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f59802b4-4226-48ee-a812-3e8fdc7aea52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_045c19ad-1f79-4c0d-bd9b-25ac49fcee5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3bf08257-5e99-4178-82cc-ed17f90971af" xlink:to="loc_us-gaap_AccountsReceivableMember_045c19ad-1f79-4c0d-bd9b-25ac49fcee5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_dc455194-355e-4bcf-a4c4-8408ddec1fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_eb17912c-7753-4fe0-9aea-dd1f08a60da9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_dc455194-355e-4bcf-a4c4-8408ddec1fb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_dc455194-355e-4bcf-a4c4-8408ddec1fb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_dc455194-355e-4bcf-a4c4-8408ddec1fb0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_dc455194-355e-4bcf-a4c4-8408ddec1fb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f0a67365-bbfd-4b89-a90a-4a1ef338a3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_dc455194-355e-4bcf-a4c4-8408ddec1fb0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f0a67365-bbfd-4b89-a90a-4a1ef338a3eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d2880e51-5616-4954-aa9b-153457669d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f0a67365-bbfd-4b89-a90a-4a1ef338a3eb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d2880e51-5616-4954-aa9b-153457669d80" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended" id="i7bfc3ea46a85435192a00ec401dd687f_RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_50d6f130-965d-4a1d-a4f4-2c18e4b46135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_64dd1c10-8f92-4a3a-a0a4-dcc765900596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_50d6f130-965d-4a1d-a4f4-2c18e4b46135" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_64dd1c10-8f92-4a3a-a0a4-dcc765900596" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d458ac8e-6608-4d2b-b8b3-4eb3952bfc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_50d6f130-965d-4a1d-a4f4-2c18e4b46135" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d458ac8e-6608-4d2b-b8b3-4eb3952bfc6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_040b4ec3-3720-4721-bd4a-eab33cd39ba0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d458ac8e-6608-4d2b-b8b3-4eb3952bfc6d" xlink:to="loc_srt_StatementGeographicalAxis_040b4ec3-3720-4721-bd4a-eab33cd39ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_040b4ec3-3720-4721-bd4a-eab33cd39ba0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_040b4ec3-3720-4721-bd4a-eab33cd39ba0" xlink:to="loc_srt_SegmentGeographicalDomain_040b4ec3-3720-4721-bd4a-eab33cd39ba0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_39a5a9e8-670b-4e11-9860-b89eff87d2ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_040b4ec3-3720-4721-bd4a-eab33cd39ba0" xlink:to="loc_srt_SegmentGeographicalDomain_39a5a9e8-670b-4e11-9860-b89eff87d2ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6ab10fcd-3dcd-4ea6-b971-0855c9c21848" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_39a5a9e8-670b-4e11-9860-b89eff87d2ec" xlink:to="loc_country_US_6ab10fcd-3dcd-4ea6-b971-0855c9c21848" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_04803668-0e40-4be8-8239-9c4d4301ff5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_39a5a9e8-670b-4e11-9860-b89eff87d2ec" xlink:to="loc_srt_EuropeMember_04803668-0e40-4be8-8239-9c4d4301ff5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_18b2caab-c740-47b2-90b0-dd597486a7d6" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_39a5a9e8-670b-4e11-9860-b89eff87d2ec" xlink:to="loc_country_JP_18b2caab-c740-47b2-90b0-dd597486a7d6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended" id="iff70078ce7b24b7e9e0674b8f6485b59_RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6b1e1bce-f405-4d82-9ac5-1f5448530672" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_894e1741-4d54-432f-a46c-ffb3180e8cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6b1e1bce-f405-4d82-9ac5-1f5448530672" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_894e1741-4d54-432f-a46c-ffb3180e8cc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_627c02b4-e44e-4f15-a723-de61552c8206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_894e1741-4d54-432f-a46c-ffb3180e8cc0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_627c02b4-e44e-4f15-a723-de61552c8206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_c928a055-e6a4-42d1-95ef-987db26ac874" xlink:href="exel-20211231.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_894e1741-4d54-432f-a46c-ffb3180e8cc0" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_c928a055-e6a4-42d1-95ef-987db26ac874" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_70aef5fa-8e05-4cfb-8b64-57a34c145260" xlink:href="exel-20211231.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_c928a055-e6a4-42d1-95ef-987db26ac874" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_70aef5fa-8e05-4cfb-8b64-57a34c145260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2d810135-b075-42b2-bc7b-67bca4372f09" xlink:href="exel-20211231.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_c928a055-e6a4-42d1-95ef-987db26ac874" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2d810135-b075-42b2-bc7b-67bca4372f09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_6cccd3d4-da77-408d-a498-2446b291e5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_894e1741-4d54-432f-a46c-ffb3180e8cc0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_6cccd3d4-da77-408d-a498-2446b291e5f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a614dda2-0518-4419-8144-e3ebb0091fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c35139dd-7490-42e0-8f30-59270c4d6649" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6b1e1bce-f405-4d82-9ac5-1f5448530672" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c35139dd-7490-42e0-8f30-59270c4d6649" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cf2a3128-40ba-4faf-8a9e-246a4449441e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c35139dd-7490-42e0-8f30-59270c4d6649" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cf2a3128-40ba-4faf-8a9e-246a4449441e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_cf2a3128-40ba-4faf-8a9e-246a4449441e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cf2a3128-40ba-4faf-8a9e-246a4449441e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_cf2a3128-40ba-4faf-8a9e-246a4449441e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_99756883-e79d-44f8-8f23-e9d6cb7a2080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cf2a3128-40ba-4faf-8a9e-246a4449441e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_99756883-e79d-44f8-8f23-e9d6cb7a2080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5f0ab49c-7f42-4285-9a27-d80a788f23c3" xlink:href="exel-20211231.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_99756883-e79d-44f8-8f23-e9d6cb7a2080" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5f0ab49c-7f42-4285-9a27-d80a788f23c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_d2679092-5160-4820-918d-ade11a21930a" xlink:href="exel-20211231.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_99756883-e79d-44f8-8f23-e9d6cb7a2080" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_d2679092-5160-4820-918d-ade11a21930a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_2575ac3c-b5f4-4d8f-b603-998b6e3eb0fb" xlink:href="exel-20211231.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_99756883-e79d-44f8-8f23-e9d6cb7a2080" xlink:to="loc_exel_AllowanceForProductRebatesMember_2575ac3c-b5f4-4d8f-b603-998b6e3eb0fb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended" id="i79ef8d32e98b470b801cd84b14556441_CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a217d946-c699-43ae-9733-2089576457d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a217d946-c699-43ae-9733-2089576457d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_2238081d-5841-4eec-b703-7d1fa5cf23ce" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_2238081d-5841-4eec-b703-7d1fa5cf23ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_8fc8dd2a-288a-4f9d-9e62-8ef0b31921ca" xlink:href="exel-20211231.xsd#exel_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_UpfrontPayments_8fc8dd2a-288a-4f9d-9e62-8ef0b31921ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_fc7e3bc5-ab2d-415f-a638-867f44a0f84c" xlink:href="exel-20211231.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_fc7e3bc5-ab2d-415f-a638-867f44a0f84c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_b017613a-f03d-45b2-9b03-9803ab9d4d87" xlink:href="exel-20211231.xsd#exel_MilestonePaymentsEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_MilestonePaymentsEarned_b017613a-f03d-45b2-9b03-9803ab9d4d87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_1fd7327b-776d-454e-9d6f-63853d216ce1" xlink:href="exel-20211231.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_1fd7327b-776d-454e-9d6f-63853d216ce1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_b2467928-63fd-4646-b5ec-2790723f5714" xlink:href="exel-20211231.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_b2467928-63fd-4646-b5ec-2790723f5714" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a68b14fc-6cd8-43d4-b135-ed12d737be9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a68b14fc-6cd8-43d4-b135-ed12d737be9f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_4a3748b4-1cad-4d72-bbac-af1341f6b409" xlink:href="exel-20211231.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_4a3748b4-1cad-4d72-bbac-af1341f6b409" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_b814efe1-ee16-4d33-9478-03e6448adfde" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_b814efe1-ee16-4d33-9478-03e6448adfde" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_ec9a8e75-0f4f-4fdb-b433-c4639b27ea06" xlink:href="exel-20211231.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_ec9a8e75-0f4f-4fdb-b433-c4639b27ea06" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_8ac84ad3-3a21-4183-8f11-869ab06aa8ef" xlink:href="exel-20211231.xsd#exel_RevenueFromContractWithCustomerCommercialSalesMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_8ac84ad3-3a21-4183-8f11-869ab06aa8ef" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold_18e847cb-8bf3-44e8-8740-e62d85428746" xlink:href="exel-20211231.xsd#exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold_18e847cb-8bf3-44e8-8740-e62d85428746" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestone_75063dba-a0b9-410f-b20c-7905df4960cf" xlink:href="exel-20211231.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestone_75063dba-a0b9-410f-b20c-7905df4960cf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85335336-1c5b-4e97-8e2b-61f6298a333f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85335336-1c5b-4e97-8e2b-61f6298a333f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4abe2726-6375-44cd-8f5c-1ef1c1889eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85335336-1c5b-4e97-8e2b-61f6298a333f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4abe2726-6375-44cd-8f5c-1ef1c1889eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4abe2726-6375-44cd-8f5c-1ef1c1889eb2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4abe2726-6375-44cd-8f5c-1ef1c1889eb2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4abe2726-6375-44cd-8f5c-1ef1c1889eb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca039346-a03a-41d0-bd04-6c3bc86d6cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4abe2726-6375-44cd-8f5c-1ef1c1889eb2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca039346-a03a-41d0-bd04-6c3bc86d6cac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_1f8541a0-b7ce-4c94-a06d-5c34a3cab3d8" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca039346-a03a-41d0-bd04-6c3bc86d6cac" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_1f8541a0-b7ce-4c94-a06d-5c34a3cab3d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f3606a8-f622-4c04-9ea3-997b270ccfda" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85335336-1c5b-4e97-8e2b-61f6298a333f" xlink:to="loc_srt_RangeAxis_6f3606a8-f622-4c04-9ea3-997b270ccfda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f3606a8-f622-4c04-9ea3-997b270ccfda_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6f3606a8-f622-4c04-9ea3-997b270ccfda" xlink:to="loc_srt_RangeMember_6f3606a8-f622-4c04-9ea3-997b270ccfda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_170ccc7f-c7c7-443f-8b51-226b15633a04" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6f3606a8-f622-4c04-9ea3-997b270ccfda" xlink:to="loc_srt_RangeMember_170ccc7f-c7c7-443f-8b51-226b15633a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a3eed883-78b5-4e07-8dce-59754dff0d7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_170ccc7f-c7c7-443f-8b51-226b15633a04" xlink:to="loc_srt_MinimumMember_a3eed883-78b5-4e07-8dce-59754dff0d7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0d5ad35b-45e0-44a0-928f-57de59730198" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_170ccc7f-c7c7-443f-8b51-226b15633a04" xlink:to="loc_srt_MaximumMember_0d5ad35b-45e0-44a0-928f-57de59730198" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis_5b96d1f6-bd6f-48a2-85e0-2943116668e8" xlink:href="exel-20211231.xsd#exel_RoyaltyTierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85335336-1c5b-4e97-8e2b-61f6298a333f" xlink:to="loc_exel_RoyaltyTierAxis_5b96d1f6-bd6f-48a2-85e0-2943116668e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain_5b96d1f6-bd6f-48a2-85e0-2943116668e8_default" xlink:href="exel-20211231.xsd#exel_RoyaltytierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltyTierAxis_5b96d1f6-bd6f-48a2-85e0-2943116668e8" xlink:to="loc_exel_RoyaltytierDomain_5b96d1f6-bd6f-48a2-85e0-2943116668e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain_ad836579-1bb9-4339-a465-b9d3977aa0bc" xlink:href="exel-20211231.xsd#exel_RoyaltytierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltyTierAxis_5b96d1f6-bd6f-48a2-85e0-2943116668e8" xlink:to="loc_exel_RoyaltytierDomain_ad836579-1bb9-4339-a465-b9d3977aa0bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember_91bb5a7f-df06-4dce-815b-0e7b6415d729" xlink:href="exel-20211231.xsd#exel_FinalTierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_ad836579-1bb9-4339-a465-b9d3977aa0bc" xlink:to="loc_exel_FinalTierMember_91bb5a7f-df06-4dce-815b-0e7b6415d729" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b0553531-b6a5-4b4a-8b95-13648b30ed16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85335336-1c5b-4e97-8e2b-61f6298a333f" xlink:to="loc_srt_ProductOrServiceAxis_b0553531-b6a5-4b4a-8b95-13648b30ed16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b0553531-b6a5-4b4a-8b95-13648b30ed16_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b0553531-b6a5-4b4a-8b95-13648b30ed16" xlink:to="loc_srt_ProductsAndServicesDomain_b0553531-b6a5-4b4a-8b95-13648b30ed16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_63011eb9-be13-4c08-80e8-3bfc50e37328" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b0553531-b6a5-4b4a-8b95-13648b30ed16" xlink:to="loc_srt_ProductsAndServicesDomain_63011eb9-be13-4c08-80e8-3bfc50e37328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_574ebf36-cb3c-41c0-a29b-a4c80c56e0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_63011eb9-be13-4c08-80e8-3bfc50e37328" xlink:to="loc_us-gaap_ServiceMember_574ebf36-cb3c-41c0-a29b-a4c80c56e0e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended" id="i51a2dcf19c2443f9a1bb61462ce74afa_CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cd9bd1f1-112f-4220-bc2d-5664cf0c4bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4945ef50-2ca5-4ac9-b56f-f74b344a8112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cd9bd1f1-112f-4220-bc2d-5664cf0c4bf9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4945ef50-2ca5-4ac9-b56f-f74b344a8112" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743762e0-d6ba-48b6-b398-551c32bafad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cd9bd1f1-112f-4220-bc2d-5664cf0c4bf9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743762e0-d6ba-48b6-b398-551c32bafad6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9e1c30f3-2228-4076-a994-13aaedcffb63" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743762e0-d6ba-48b6-b398-551c32bafad6" xlink:to="loc_srt_ProductOrServiceAxis_9e1c30f3-2228-4076-a994-13aaedcffb63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9e1c30f3-2228-4076-a994-13aaedcffb63_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9e1c30f3-2228-4076-a994-13aaedcffb63" xlink:to="loc_srt_ProductsAndServicesDomain_9e1c30f3-2228-4076-a994-13aaedcffb63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_048f9959-882d-416f-9e92-61b59450434d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9e1c30f3-2228-4076-a994-13aaedcffb63" xlink:to="loc_srt_ProductsAndServicesDomain_048f9959-882d-416f-9e92-61b59450434d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_4c523360-447f-40bb-95e0-39ac301bfcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_048f9959-882d-416f-9e92-61b59450434d" xlink:to="loc_us-gaap_LicenseMember_4c523360-447f-40bb-95e0-39ac301bfcbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_a332192b-add6-4d42-84f8-d6cad16c11c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_048f9959-882d-416f-9e92-61b59450434d" xlink:to="loc_us-gaap_ServiceMember_a332192b-add6-4d42-84f8-d6cad16c11c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d7724c01-45a7-4f68-bfd1-7661d128dafc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743762e0-d6ba-48b6-b398-551c32bafad6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d7724c01-45a7-4f68-bfd1-7661d128dafc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7724c01-45a7-4f68-bfd1-7661d128dafc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d7724c01-45a7-4f68-bfd1-7661d128dafc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7724c01-45a7-4f68-bfd1-7661d128dafc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a0e8ccb-3818-48f2-a326-d021f3e62861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d7724c01-45a7-4f68-bfd1-7661d128dafc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a0e8ccb-3818-48f2-a326-d021f3e62861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_97b4d5dc-79a3-4164-8a3e-d0641d3420b0" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a0e8ccb-3818-48f2-a326-d021f3e62861" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_97b4d5dc-79a3-4164-8a3e-d0641d3420b0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended" id="i7841b3433cac4db0801ced720e08ddb9_CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_b9841f33-885b-4e25-b54d-aae5b3a0e517" xlink:href="exel-20211231.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_b9841f33-885b-4e25-b54d-aae5b3a0e517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_29bb118f-2f32-46c0-8def-7a2c8a68db50" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_29bb118f-2f32-46c0-8def-7a2c8a68db50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_6a96f58d-92bd-41bf-9ac4-b42a94a4bc04" xlink:href="exel-20211231.xsd#exel_PeriodOfSpecificSalesVolumeThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_PeriodOfSpecificSalesVolumeThreshold_6a96f58d-92bd-41bf-9ac4-b42a94a4bc04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_f5944674-bdc8-4ff7-8b14-53490a25c7cc" xlink:href="exel-20211231.xsd#exel_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_UpfrontPayments_f5944674-bdc8-4ff7-8b14-53490a25c7cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_88acead2-0187-4aee-9068-926ab1f9bdd2" xlink:href="exel-20211231.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_88acead2-0187-4aee-9068-926ab1f9bdd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_fa64d1f8-b9b2-4e14-9fc2-0a4c82b5309c" xlink:href="exel-20211231.xsd#exel_MilestonePaymentsEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_MilestonePaymentsEarned_fa64d1f8-b9b2-4e14-9fc2-0a4c82b5309c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_4bb60cb9-ae72-4244-9ec2-3bb47bbc9408" xlink:href="exel-20211231.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_4bb60cb9-ae72-4244-9ec2-3bb47bbc9408" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_442e636d-1843-4232-8db1-a1a087e402a4" xlink:href="exel-20211231.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_442e636d-1843-4232-8db1-a1a087e402a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTier_21021150-f5d8-41bc-b9a6-49be9ad30840" xlink:href="exel-20211231.xsd#exel_RoyaltyTier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_RoyaltyTier_21021150-f5d8-41bc-b9a6-49be9ad30840" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_b695739f-cba9-48e5-899b-d8bed01d691e" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_b695739f-cba9-48e5-899b-d8bed01d691e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_46e28330-4558-43ea-b89c-3445b812696c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_46e28330-4558-43ea-b89c-3445b812696c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_8114f4cc-d73b-45da-82ab-b13e73c92358" xlink:href="exel-20211231.xsd#exel_RevenueFromContractWithCustomerCommercialSalesMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_8114f4cc-d73b-45da-82ab-b13e73c92358" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_036f8292-1f79-47de-b016-fb09dffc33b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_036f8292-1f79-47de-b016-fb09dffc33b0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec4f5fa5-6d2b-4381-bfa7-fb18f3fff98b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec4f5fa5-6d2b-4381-bfa7-fb18f3fff98b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cf797e3a-3a7d-45a3-b0a4-900f7cc2ac3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec4f5fa5-6d2b-4381-bfa7-fb18f3fff98b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cf797e3a-3a7d-45a3-b0a4-900f7cc2ac3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf797e3a-3a7d-45a3-b0a4-900f7cc2ac3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cf797e3a-3a7d-45a3-b0a4-900f7cc2ac3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf797e3a-3a7d-45a3-b0a4-900f7cc2ac3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d3d091a-a23b-4d03-9153-701e5175a4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cf797e3a-3a7d-45a3-b0a4-900f7cc2ac3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d3d091a-a23b-4d03-9153-701e5175a4f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_c61421e0-f763-4d92-aa50-d1cb4aa94097" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d3d091a-a23b-4d03-9153-701e5175a4f6" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_c61421e0-f763-4d92-aa50-d1cb4aa94097" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6ddaa265-c43d-444c-b4f9-8ec5afef75b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec4f5fa5-6d2b-4381-bfa7-fb18f3fff98b" xlink:to="loc_srt_StatementGeographicalAxis_6ddaa265-c43d-444c-b4f9-8ec5afef75b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6ddaa265-c43d-444c-b4f9-8ec5afef75b0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6ddaa265-c43d-444c-b4f9-8ec5afef75b0" xlink:to="loc_srt_SegmentGeographicalDomain_6ddaa265-c43d-444c-b4f9-8ec5afef75b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b8037b10-97b8-4b18-856d-5a5cc99d5420" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6ddaa265-c43d-444c-b4f9-8ec5afef75b0" xlink:to="loc_srt_SegmentGeographicalDomain_b8037b10-97b8-4b18-856d-5a5cc99d5420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_214c0667-902e-401d-9887-58a84e00a4f9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b8037b10-97b8-4b18-856d-5a5cc99d5420" xlink:to="loc_country_JP_214c0667-902e-401d-9887-58a84e00a4f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis_f636f7f2-9b7d-4cae-842f-0a8f3de8f06d" xlink:href="exel-20211231.xsd#exel_RoyaltyTierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec4f5fa5-6d2b-4381-bfa7-fb18f3fff98b" xlink:to="loc_exel_RoyaltyTierAxis_f636f7f2-9b7d-4cae-842f-0a8f3de8f06d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain_f636f7f2-9b7d-4cae-842f-0a8f3de8f06d_default" xlink:href="exel-20211231.xsd#exel_RoyaltytierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltyTierAxis_f636f7f2-9b7d-4cae-842f-0a8f3de8f06d" xlink:to="loc_exel_RoyaltytierDomain_f636f7f2-9b7d-4cae-842f-0a8f3de8f06d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain_4784dfea-f374-4417-a32b-1e88c6a2d400" xlink:href="exel-20211231.xsd#exel_RoyaltytierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltyTierAxis_f636f7f2-9b7d-4cae-842f-0a8f3de8f06d" xlink:to="loc_exel_RoyaltytierDomain_4784dfea-f374-4417-a32b-1e88c6a2d400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InitialMember_9daba4f8-a7cc-4ac8-b25d-d961b6bd9696" xlink:href="exel-20211231.xsd#exel_InitialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_4784dfea-f374-4417-a32b-1e88c6a2d400" xlink:to="loc_exel_InitialMember_9daba4f8-a7cc-4ac8-b25d-d961b6bd9696" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember_7491764e-db49-45fd-a904-8cee5f118e49" xlink:href="exel-20211231.xsd#exel_FinalTierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_4784dfea-f374-4417-a32b-1e88c6a2d400" xlink:to="loc_exel_FinalTierMember_7491764e-db49-45fd-a904-8cee5f118e49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e40a4be8-80a7-4dec-9690-f66e8d0805bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec4f5fa5-6d2b-4381-bfa7-fb18f3fff98b" xlink:to="loc_srt_RangeAxis_e40a4be8-80a7-4dec-9690-f66e8d0805bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e40a4be8-80a7-4dec-9690-f66e8d0805bc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e40a4be8-80a7-4dec-9690-f66e8d0805bc" xlink:to="loc_srt_RangeMember_e40a4be8-80a7-4dec-9690-f66e8d0805bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aae96015-6d4f-4f79-a4a8-6f911b3cf339" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e40a4be8-80a7-4dec-9690-f66e8d0805bc" xlink:to="loc_srt_RangeMember_aae96015-6d4f-4f79-a4a8-6f911b3cf339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6c8f9d5c-6f4a-46de-a57e-420b3d6e5317" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aae96015-6d4f-4f79-a4a8-6f911b3cf339" xlink:to="loc_srt_MinimumMember_6c8f9d5c-6f4a-46de-a57e-420b3d6e5317" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_26c4b122-b4e9-42ce-ae8f-75a36cfdf1a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aae96015-6d4f-4f79-a4a8-6f911b3cf339" xlink:to="loc_srt_MaximumMember_26c4b122-b4e9-42ce-ae8f-75a36cfdf1a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended" id="i08cbb349042e42f0a45a010b5f16cff9_CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3d13ea00-aa41-4200-96c3-4a7c73bff551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_260a8cff-35b1-45bb-908c-974a6c1e6da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3d13ea00-aa41-4200-96c3-4a7c73bff551" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_260a8cff-35b1-45bb-908c-974a6c1e6da7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84435ab7-c58d-4c1a-beab-ec990ed1bd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3d13ea00-aa41-4200-96c3-4a7c73bff551" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84435ab7-c58d-4c1a-beab-ec990ed1bd8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_895c49ce-fbf6-4a62-8efa-859c8257e0d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84435ab7-c58d-4c1a-beab-ec990ed1bd8d" xlink:to="loc_srt_ProductOrServiceAxis_895c49ce-fbf6-4a62-8efa-859c8257e0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_895c49ce-fbf6-4a62-8efa-859c8257e0d3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_895c49ce-fbf6-4a62-8efa-859c8257e0d3" xlink:to="loc_srt_ProductsAndServicesDomain_895c49ce-fbf6-4a62-8efa-859c8257e0d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_68079519-2737-4ef6-a02e-111d0eda4c0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_895c49ce-fbf6-4a62-8efa-859c8257e0d3" xlink:to="loc_srt_ProductsAndServicesDomain_68079519-2737-4ef6-a02e-111d0eda4c0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_4c97f977-f532-4abf-a30b-af66f2f854bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_68079519-2737-4ef6-a02e-111d0eda4c0a" xlink:to="loc_us-gaap_LicenseMember_4c97f977-f532-4abf-a30b-af66f2f854bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ce2d7ac1-bc19-4618-b605-2d55681f6014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_68079519-2737-4ef6-a02e-111d0eda4c0a" xlink:to="loc_us-gaap_ServiceMember_ce2d7ac1-bc19-4618-b605-2d55681f6014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b2a8bc9f-eac8-4e18-bdda-24e0efe444da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84435ab7-c58d-4c1a-beab-ec990ed1bd8d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b2a8bc9f-eac8-4e18-bdda-24e0efe444da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2a8bc9f-eac8-4e18-bdda-24e0efe444da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b2a8bc9f-eac8-4e18-bdda-24e0efe444da" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2a8bc9f-eac8-4e18-bdda-24e0efe444da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e437dda-9d2f-4752-8620-6eaf333f2261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b2a8bc9f-eac8-4e18-bdda-24e0efe444da" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e437dda-9d2f-4752-8620-6eaf333f2261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_0be3568b-1db8-408e-886a-489a27cbf2ca" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e437dda-9d2f-4752-8620-6eaf333f2261" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_0be3568b-1db8-408e-886a-489a27cbf2ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="extended" id="i60362247eb214e529d13898b1ba440ca_CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5909caa5-b020-4b21-863a-b96b910945ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_ef052923-7d35-40d9-9936-e76779b4ec60" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5909caa5-b020-4b21-863a-b96b910945ae" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_ef052923-7d35-40d9-9936-e76779b4ec60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_9c8b77b5-7c3f-48e5-a315-e71d78668141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5909caa5-b020-4b21-863a-b96b910945ae" xlink:to="loc_us-gaap_RoyaltyExpense_9c8b77b5-7c3f-48e5-a315-e71d78668141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1690e4a6-c424-4be9-bb85-8dda9c67b07e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5909caa5-b020-4b21-863a-b96b910945ae" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1690e4a6-c424-4be9-bb85-8dda9c67b07e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8041e8f5-32e3-4f33-a5be-3562af72359a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1690e4a6-c424-4be9-bb85-8dda9c67b07e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8041e8f5-32e3-4f33-a5be-3562af72359a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8041e8f5-32e3-4f33-a5be-3562af72359a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8041e8f5-32e3-4f33-a5be-3562af72359a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8041e8f5-32e3-4f33-a5be-3562af72359a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e93af35a-1438-4e52-bee1-850029c614c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8041e8f5-32e3-4f33-a5be-3562af72359a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e93af35a-1438-4e52-bee1-850029c614c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_98378ea8-1c6c-453f-8148-7fa799e38770" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e93af35a-1438-4e52-bee1-850029c614c6" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_98378ea8-1c6c-453f-8148-7fa799e38770" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails" xlink:type="extended" id="i720115bd91bd4362936cfe3a63aa93d0_CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c1a6057a-ec33-4cd0-b62a-a07791c00f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38215af6-f29b-40ea-96f3-0c9bc7518a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c1a6057a-ec33-4cd0-b62a-a07791c00f1b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38215af6-f29b-40ea-96f3-0c9bc7518a47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_579a1c72-7069-4c55-b969-f544803cceb8" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementAchievedMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c1a6057a-ec33-4cd0-b62a-a07791c00f1b" xlink:to="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_579a1c72-7069-4c55-b969-f544803cceb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_3285d35c-951e-461f-94c9-8d49fa96d687" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c1a6057a-ec33-4cd0-b62a-a07791c00f1b" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_3285d35c-951e-461f-94c9-8d49fa96d687" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61179fd8-b1e2-4409-aba3-21c62d5e296c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c1a6057a-ec33-4cd0-b62a-a07791c00f1b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61179fd8-b1e2-4409-aba3-21c62d5e296c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6cb3e683-b913-43ae-a1dd-824d9c640aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61179fd8-b1e2-4409-aba3-21c62d5e296c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6cb3e683-b913-43ae-a1dd-824d9c640aee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6cb3e683-b913-43ae-a1dd-824d9c640aee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6cb3e683-b913-43ae-a1dd-824d9c640aee" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6cb3e683-b913-43ae-a1dd-824d9c640aee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4054d52e-5d7e-4cb0-b43d-bbe89f2206d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6cb3e683-b913-43ae-a1dd-824d9c640aee" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4054d52e-5d7e-4cb0-b43d-bbe89f2206d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_b28bbaf0-e79f-4041-8c9a-8e6debbe3337" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4054d52e-5d7e-4cb0-b43d-bbe89f2206d9" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_b28bbaf0-e79f-4041-8c9a-8e6debbe3337" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_a41f3923-d5c4-46e1-ba53-5fe132b75050" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4054d52e-5d7e-4cb0-b43d-bbe89f2206d9" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_a41f3923-d5c4-46e1-ba53-5fe132b75050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2a665028-5c92-4335-a243-cc296647f04e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61179fd8-b1e2-4409-aba3-21c62d5e296c" xlink:to="loc_srt_ProductOrServiceAxis_2a665028-5c92-4335-a243-cc296647f04e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2a665028-5c92-4335-a243-cc296647f04e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2a665028-5c92-4335-a243-cc296647f04e" xlink:to="loc_srt_ProductsAndServicesDomain_2a665028-5c92-4335-a243-cc296647f04e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4feaae6b-1f0e-4740-9bb3-4b02b56c3176" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2a665028-5c92-4335-a243-cc296647f04e" xlink:to="loc_srt_ProductsAndServicesDomain_4feaae6b-1f0e-4740-9bb3-4b02b56c3176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_e30fa1b5-af49-412c-9bb5-0572bd64b4e2" xlink:href="exel-20211231.xsd#exel_CotellicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4feaae6b-1f0e-4740-9bb3-4b02b56c3176" xlink:to="loc_exel_CotellicMember_e30fa1b5-af49-412c-9bb5-0572bd64b4e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails" xlink:type="extended" id="ifb57f73e5eed49f0af14febaaad999d0_CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_e53b5ca8-cff9-430b-bed0-468434693cc0" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_e53b5ca8-cff9-430b-bed0-468434693cc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_519591b4-6949-41e4-9458-b583a752c4ba" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_519591b4-6949-41e4-9458-b583a752c4ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_d56ba9b1-cb35-4230-bc0a-eb668a0fd494" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_d56ba9b1-cb35-4230-bc0a-eb668a0fd494" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_308b32e8-0204-4b13-8a8c-002d8d7591ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_308b32e8-0204-4b13-8a8c-002d8d7591ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_89b2e573-130f-47a7-9c2b-9e64044a9550" xlink:href="exel-20211231.xsd#exel_AssetAcquisitionPaymentUponClosingOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_89b2e573-130f-47a7-9c2b-9e64044a9550" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_c1f93d14-82ab-48cc-a0a4-e8d98e115941" xlink:href="exel-20211231.xsd#exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_c1f93d14-82ab-48cc-a0a4-e8d98e115941" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_a4104bbf-2f81-46a7-9e0a-390c37735919" xlink:href="exel-20211231.xsd#exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_a4104bbf-2f81-46a7-9e0a-390c37735919" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsFinalPayment_ea0612d9-7732-4a4a-a0d8-040c8b39a73b" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementRightsAndObligationsFinalPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsFinalPayment_ea0612d9-7732-4a4a-a0d8-040c8b39a73b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_664d537e-dc4c-4d81-9777-23f7a98f549a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_664d537e-dc4c-4d81-9777-23f7a98f549a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_db560bd7-fdd5-4c4c-bbaf-ddee4e1a9c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_db560bd7-fdd5-4c4c-bbaf-ddee4e1a9c3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3535e118-d257-474e-98d0-8bf158436220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_db560bd7-fdd5-4c4c-bbaf-ddee4e1a9c3f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3535e118-d257-474e-98d0-8bf158436220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3535e118-d257-474e-98d0-8bf158436220_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3535e118-d257-474e-98d0-8bf158436220" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3535e118-d257-474e-98d0-8bf158436220_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d674979-f989-41d8-9b6e-7061e799ba33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3535e118-d257-474e-98d0-8bf158436220" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d674979-f989-41d8-9b6e-7061e799ba33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_26bee9b6-c853-4a2b-b135-f602e7c5d5a7" xlink:href="exel-20211231.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d674979-f989-41d8-9b6e-7061e799ba33" xlink:to="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_26bee9b6-c853-4a2b-b135-f602e7c5d5a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsIncMember_bf277a87-020c-4eec-8757-7f86ed021659" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementWithIconicTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d674979-f989-41d8-9b6e-7061e799ba33" xlink:to="loc_exel_CollaborationAgreementWithIconicTherapeuticsIncMember_bf277a87-020c-4eec-8757-7f86ed021659" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_0512f4c8-2d54-4eda-a81b-f61f90148059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_db560bd7-fdd5-4c4c-bbaf-ddee4e1a9c3f" xlink:to="loc_us-gaap_AssetAcquisitionAxis_0512f4c8-2d54-4eda-a81b-f61f90148059" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_0512f4c8-2d54-4eda-a81b-f61f90148059_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_0512f4c8-2d54-4eda-a81b-f61f90148059" xlink:to="loc_us-gaap_AssetAcquisitionDomain_0512f4c8-2d54-4eda-a81b-f61f90148059_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_e0702aab-46d5-402c-87ef-f8a27b98e78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_0512f4c8-2d54-4eda-a81b-f61f90148059" xlink:to="loc_us-gaap_AssetAcquisitionDomain_e0702aab-46d5-402c-87ef-f8a27b98e78e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_47719f77-f632-4879-ab68-d7877f40d69e" xlink:href="exel-20211231.xsd#exel_CollaborativeAgreementWithGamaMabsPharmaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e0702aab-46d5-402c-87ef-f8a27b98e78e" xlink:to="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_47719f77-f632-4879-ab68-d7877f40d69e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended" id="i14fdb26c02fb4f23ae468dc60568f197_CashandInvestmentsInvestmentsbySecurityTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e0fe95a1-9a99-40a5-ae60-049a24399e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e0fe95a1-9a99-40a5-ae60-049a24399e30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b57bb098-6127-4ebc-aed0-ee3b7278bbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e0fe95a1-9a99-40a5-ae60-049a24399e30" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b57bb098-6127-4ebc-aed0-ee3b7278bbc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e85551d7-7915-433a-960f-74166a50388c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e0fe95a1-9a99-40a5-ae60-049a24399e30" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e85551d7-7915-433a-960f-74166a50388c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4ac0aae1-afb9-49f1-a8d0-9cbc3b298d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e0fe95a1-9a99-40a5-ae60-049a24399e30" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4ac0aae1-afb9-49f1-a8d0-9cbc3b298d2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3acd844b-be21-4a1f-a5c8-47695d6d1292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e0fe95a1-9a99-40a5-ae60-049a24399e30" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3acd844b-be21-4a1f-a5c8-47695d6d1292" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1b2836a1-41d7-480a-90c4-9c25bac65831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1b2836a1-41d7-480a-90c4-9c25bac65831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_ccfc7bd1-ef8b-4cbf-9601-9c98d8576bac" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1b2836a1-41d7-480a-90c4-9c25bac65831" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_ccfc7bd1-ef8b-4cbf-9601-9c98d8576bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_426b7648-8ab3-4940-a97a-1a0c7ae95f72" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1b2836a1-41d7-480a-90c4-9c25bac65831" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_426b7648-8ab3-4940-a97a-1a0c7ae95f72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_aabc7fdf-30be-4a17-9648-baf94f378545" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1b2836a1-41d7-480a-90c4-9c25bac65831" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_aabc7fdf-30be-4a17-9648-baf94f378545" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_ae1e5fb0-cca3-4a85-87ed-1ab932b384c5" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1b2836a1-41d7-480a-90c4-9c25bac65831" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_ae1e5fb0-cca3-4a85-87ed-1ab932b384c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_7b0f43b8-ef7e-410e-987e-3964badd9976" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_7b0f43b8-ef7e-410e-987e-3964badd9976" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f16d46e-3c3e-47fc-a75c-4e0781a9f26a" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f16d46e-3c3e-47fc-a75c-4e0781a9f26a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cbc270fd-7b75-41ad-a118-517e173611a1" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cbc270fd-7b75-41ad-a118-517e173611a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04360efe-3f3d-42d8-bc83-4022c91b4222" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04360efe-3f3d-42d8-bc83-4022c91b4222" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f8a0fcd5-641e-4eda-87dd-4864727a8c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f8a0fcd5-641e-4eda-87dd-4864727a8c24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6f0b612e-caf5-4b27-8114-d024069b5c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f8a0fcd5-641e-4eda-87dd-4864727a8c24" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6f0b612e-caf5-4b27-8114-d024069b5c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f0b612e-caf5-4b27-8114-d024069b5c34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6f0b612e-caf5-4b27-8114-d024069b5c34" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f0b612e-caf5-4b27-8114-d024069b5c34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6f0b612e-caf5-4b27-8114-d024069b5c34" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9ef03fe7-41d7-46aa-8c30-12bf39816a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_CommercialPaperMember_9ef03fe7-41d7-46aa-8c30-12bf39816a2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_1c0ce415-8de9-4302-8b4c-dfb7525ac9df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_1c0ce415-8de9-4302-8b4c-dfb7525ac9df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_7730aa09-ac87-47cb-87d0-27ebefadf401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_7730aa09-ac87-47cb-87d0-27ebefadf401" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_f9372147-9b09-47d6-acbc-f6066c132b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_MunicipalBondsMember_f9372147-9b09-47d6-acbc-f6066c132b19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_780bcb8a-8e3b-43e5-b17e-9cfc6ce52d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_CashMember_780bcb8a-8e3b-43e5-b17e-9cfc6ce52d42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_04d7d492-1aad-4d38-b31d-be0001f78911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_MoneyMarketFundsMember_04d7d492-1aad-4d38-b31d-be0001f78911" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_cafc9479-8834-49eb-ba3e-94ee7587a93b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_CertificatesOfDepositMember_cafc9479-8834-49eb-ba3e-94ee7587a93b" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended" id="ic505afcb4e594daabea92a9240a10f71_CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4f44fd65-3f25-46ec-8aa7-74165d29972c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c331f23b-0fe9-4ff5-b3d1-bc51b07387a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4f44fd65-3f25-46ec-8aa7-74165d29972c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c331f23b-0fe9-4ff5-b3d1-bc51b07387a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_4ee4e039-0e1b-4c51-9d40-065a0f90430c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4f44fd65-3f25-46ec-8aa7-74165d29972c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_4ee4e039-0e1b-4c51-9d40-065a0f90430c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d8af3df-a830-4bbb-97bb-aa17b688c260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4f44fd65-3f25-46ec-8aa7-74165d29972c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d8af3df-a830-4bbb-97bb-aa17b688c260" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_01267435-33f4-486b-844a-9e361bb16ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d8af3df-a830-4bbb-97bb-aa17b688c260" xlink:to="loc_us-gaap_FinancialInstrumentAxis_01267435-33f4-486b-844a-9e361bb16ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01267435-33f4-486b-844a-9e361bb16ee7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_01267435-33f4-486b-844a-9e361bb16ee7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01267435-33f4-486b-844a-9e361bb16ee7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3aba385-2559-4111-ab90-3d3567501ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_01267435-33f4-486b-844a-9e361bb16ee7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3aba385-2559-4111-ab90-3d3567501ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_93662802-28d4-4783-bc61-6e4c313f909d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3aba385-2559-4111-ab90-3d3567501ba6" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_93662802-28d4-4783-bc61-6e4c313f909d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9c1ae88d-8349-42a1-b230-b0ef5f4927de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3aba385-2559-4111-ab90-3d3567501ba6" xlink:to="loc_us-gaap_CommercialPaperMember_9c1ae88d-8349-42a1-b230-b0ef5f4927de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_50276502-814c-41b2-98c4-4c6a566ea939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3aba385-2559-4111-ab90-3d3567501ba6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_50276502-814c-41b2-98c4-4c6a566ea939" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_cd57e0ae-94d4-456c-a11b-6a45fc22df43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3aba385-2559-4111-ab90-3d3567501ba6" xlink:to="loc_us-gaap_MunicipalBondsMember_cd57e0ae-94d4-456c-a11b-6a45fc22df43" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="iee8e10b21dc24fd2ad70ffe9fd41d293_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b679941c-79b9-4e01-8c55-5175222dfba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74e91be0-876a-4ca2-8273-d20e41e6cd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b679941c-79b9-4e01-8c55-5175222dfba5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74e91be0-876a-4ca2-8273-d20e41e6cd6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7387d4cc-a9c7-4b95-b80d-1dac103af486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b679941c-79b9-4e01-8c55-5175222dfba5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7387d4cc-a9c7-4b95-b80d-1dac103af486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d17f1a67-0806-486a-a7ed-e91c3ad0a706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b679941c-79b9-4e01-8c55-5175222dfba5" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d17f1a67-0806-486a-a7ed-e91c3ad0a706" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639f3fd7-d1e0-4d79-9cc7-4dd5acba71e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b679941c-79b9-4e01-8c55-5175222dfba5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639f3fd7-d1e0-4d79-9cc7-4dd5acba71e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_48a2e546-27e7-4e2f-8d93-35c55630be70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639f3fd7-d1e0-4d79-9cc7-4dd5acba71e3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_48a2e546-27e7-4e2f-8d93-35c55630be70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_48a2e546-27e7-4e2f-8d93-35c55630be70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_48a2e546-27e7-4e2f-8d93-35c55630be70" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_48a2e546-27e7-4e2f-8d93-35c55630be70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_48a2e546-27e7-4e2f-8d93-35c55630be70" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7df293e9-5c1c-4365-bad6-e9dc8312249f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:to="loc_us-gaap_CommercialPaperMember_7df293e9-5c1c-4365-bad6-e9dc8312249f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_d151e65b-864d-4830-9c22-7c6b9b55092f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_d151e65b-864d-4830-9c22-7c6b9b55092f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_2b2fc4b1-d244-4cd6-b417-2bafd8ef0886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_2b2fc4b1-d244-4cd6-b417-2bafd8ef0886" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_be044d1a-670f-483d-99b1-4957890af2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:to="loc_us-gaap_MunicipalBondsMember_be044d1a-670f-483d-99b1-4957890af2df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a3984024-8b3b-4ece-a7a2-ccf87d5aae94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a3984024-8b3b-4ece-a7a2-ccf87d5aae94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_12361b24-9589-4926-9b65-1c0416eb4bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:to="loc_us-gaap_CertificatesOfDepositMember_12361b24-9589-4926-9b65-1c0416eb4bb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_987fb338-726b-4b13-a789-04fc10b8dbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639f3fd7-d1e0-4d79-9cc7-4dd5acba71e3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_987fb338-726b-4b13-a789-04fc10b8dbfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_987fb338-726b-4b13-a789-04fc10b8dbfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_987fb338-726b-4b13-a789-04fc10b8dbfd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_987fb338-726b-4b13-a789-04fc10b8dbfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8711abd-5c8b-486c-bd7f-420f9172542e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_987fb338-726b-4b13-a789-04fc10b8dbfd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8711abd-5c8b-486c-bd7f-420f9172542e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_18af50b3-74aa-49b9-b006-0d115cdbf314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8711abd-5c8b-486c-bd7f-420f9172542e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_18af50b3-74aa-49b9-b006-0d115cdbf314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f2a7d4d0-39f7-4c01-bd75-dfb03154d7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8711abd-5c8b-486c-bd7f-420f9172542e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f2a7d4d0-39f7-4c01-bd75-dfb03154d7e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bf03d77-d757-47b0-9028-ad3c76f60775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639f3fd7-d1e0-4d79-9cc7-4dd5acba71e3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bf03d77-d757-47b0-9028-ad3c76f60775" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7bf03d77-d757-47b0-9028-ad3c76f60775_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bf03d77-d757-47b0-9028-ad3c76f60775" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7bf03d77-d757-47b0-9028-ad3c76f60775_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f477d48f-1e1b-46d4-b435-92dc0f9151c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bf03d77-d757-47b0-9028-ad3c76f60775" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f477d48f-1e1b-46d4-b435-92dc0f9151c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7a84a66b-5bcb-4b7f-811f-c10d6f82a5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f477d48f-1e1b-46d4-b435-92dc0f9151c6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7a84a66b-5bcb-4b7f-811f-c10d6f82a5c5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended" id="idf306fbf35384300813cfde0d5494ddd_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_e2720058-9a92-42e6-8e2c-b857b6c2c0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_d60a4c2e-c345-4fe1-a44c-8c4ea61be07d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_e2720058-9a92-42e6-8e2c-b857b6c2c0c7" xlink:to="loc_us-gaap_InventoryRawMaterials_d60a4c2e-c345-4fe1-a44c-8c4ea61be07d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_d7317998-4d91-47b4-b105-7d85da5a3328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_e2720058-9a92-42e6-8e2c-b857b6c2c0c7" xlink:to="loc_us-gaap_InventoryWorkInProcess_d7317998-4d91-47b4-b105-7d85da5a3328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_2312de91-58fd-4a03-993c-a40326f347aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_e2720058-9a92-42e6-8e2c-b857b6c2c0c7" xlink:to="loc_us-gaap_InventoryFinishedGoods_2312de91-58fd-4a03-993c-a40326f347aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_9dbac1b9-c338-410d-84b6-eafcb3e81e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_e2720058-9a92-42e6-8e2c-b857b6c2c0c7" xlink:to="loc_us-gaap_InventoryGross_9dbac1b9-c338-410d-84b6-eafcb3e81e9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_e4a9f54d-9312-48c3-a28e-9df96785de42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_e2720058-9a92-42e6-8e2c-b857b6c2c0c7" xlink:to="loc_us-gaap_InventoryCurrentTable_e4a9f54d-9312-48c3-a28e-9df96785de42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c42a6b01-1355-4fc4-970e-55074486a781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_e4a9f54d-9312-48c3-a28e-9df96785de42" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c42a6b01-1355-4fc4-970e-55074486a781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c42a6b01-1355-4fc4-970e-55074486a781_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c42a6b01-1355-4fc4-970e-55074486a781" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c42a6b01-1355-4fc4-970e-55074486a781_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f66108ce-0b78-44eb-8dfb-22407752ce11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c42a6b01-1355-4fc4-970e-55074486a781" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f66108ce-0b78-44eb-8dfb-22407752ce11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_89044f73-1e64-40d3-ac9a-99e8da216ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f66108ce-0b78-44eb-8dfb-22407752ce11" xlink:to="loc_us-gaap_InventoriesMember_89044f73-1e64-40d3-ac9a-99e8da216ed4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_60778be7-2f0d-4bd5-b845-4fca774e2c45" xlink:href="exel-20211231.xsd#exel_OtherLongtermAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f66108ce-0b78-44eb-8dfb-22407752ce11" xlink:to="loc_exel_OtherLongtermAssetsMember_60778be7-2f0d-4bd5-b845-4fca774e2c45" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="iaf53d55121fd4e4a8d76158632bad2ee_PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_940c1540-637d-4737-95d9-e8e102666806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d9fb163e-c4f3-4217-a597-820ffd177705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_940c1540-637d-4737-95d9-e8e102666806" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d9fb163e-c4f3-4217-a597-820ffd177705" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2e88d3d9-6637-46f0-9ae0-90a62cc7eb74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_940c1540-637d-4737-95d9-e8e102666806" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2e88d3d9-6637-46f0-9ae0-90a62cc7eb74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b0ee0fa8-8013-4622-819c-b0088aba79c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_940c1540-637d-4737-95d9-e8e102666806" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b0ee0fa8-8013-4622-819c-b0088aba79c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2b7ccb91-50fa-40c5-be6e-4f1eaa6b6134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_940c1540-637d-4737-95d9-e8e102666806" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2b7ccb91-50fa-40c5-be6e-4f1eaa6b6134" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9afda594-f041-441a-9364-9583694857ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_940c1540-637d-4737-95d9-e8e102666806" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9afda594-f041-441a-9364-9583694857ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0458e57-d4c5-4370-a3bf-b58e35967640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9afda594-f041-441a-9364-9583694857ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0458e57-d4c5-4370-a3bf-b58e35967640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b0458e57-d4c5-4370-a3bf-b58e35967640_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0458e57-d4c5-4370-a3bf-b58e35967640" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b0458e57-d4c5-4370-a3bf-b58e35967640_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0458e57-d4c5-4370-a3bf-b58e35967640" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_73bdb45c-11b7-4b2b-b2e7-d45c3919b3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_73bdb45c-11b7-4b2b-b2e7-d45c3919b3f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_b9d08fa7-85dd-427a-8057-f40ca90b8d95" xlink:href="exel-20211231.xsd#exel_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_b9d08fa7-85dd-427a-8057-f40ca90b8d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_74d5dd50-47d7-433e-b3e4-1827c3a4770e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_74d5dd50-47d7-433e-b3e4-1827c3a4770e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LaboratoryEquipmentMember_b826aaa6-142e-43ee-96f0-b577e85cf9a8" xlink:href="exel-20211231.xsd#exel_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:to="loc_exel_LaboratoryEquipmentMember_b826aaa6-142e-43ee-96f0-b577e85cf9a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b7e221f1-a3f8-40d2-b4e0-48b3614591b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:to="loc_us-gaap_ConstructionInProgressMember_b7e221f1-a3f8-40d2-b4e0-48b3614591b5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" id="id0d1e380f17d4ccc8eab145190aa8b18_EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db6e2077-8487-446b-bb8d-2e99cfb55095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_68199ea4-9e17-4270-b466-c37def635ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db6e2077-8487-446b-bb8d-2e99cfb55095" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_68199ea4-9e17-4270-b466-c37def635ef3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94ffe4b3-86a2-4688-a99c-ded2002fd0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db6e2077-8487-446b-bb8d-2e99cfb55095" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94ffe4b3-86a2-4688-a99c-ded2002fd0fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_839a0e99-2efe-434d-b4e7-c8dd76185842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94ffe4b3-86a2-4688-a99c-ded2002fd0fb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_839a0e99-2efe-434d-b4e7-c8dd76185842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_839a0e99-2efe-434d-b4e7-c8dd76185842_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_839a0e99-2efe-434d-b4e7-c8dd76185842" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_839a0e99-2efe-434d-b4e7-c8dd76185842_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_88b467a5-a649-4e73-8086-2c7d36367832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_839a0e99-2efe-434d-b4e7-c8dd76185842" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_88b467a5-a649-4e73-8086-2c7d36367832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_67341d32-c257-4d79-9b98-c8b3c43b933d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88b467a5-a649-4e73-8086-2c7d36367832" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_67341d32-c257-4d79-9b98-c8b3c43b933d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3ec28c67-c32e-416c-8f61-9726f5de5fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88b467a5-a649-4e73-8086-2c7d36367832" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3ec28c67-c32e-416c-8f61-9726f5de5fc9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended" id="i4fad39fd33fe44df99839b7ac50b181d_EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67ade02d-c5fe-47e8-be3a-0fa911bf5252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_57c983a6-2a6c-4c67-b17b-443150cc5aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67ade02d-c5fe-47e8-be3a-0fa911bf5252" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_57c983a6-2a6c-4c67-b17b-443150cc5aec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0c693a-ac11-4bda-8da3-d2459cb2b3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67ade02d-c5fe-47e8-be3a-0fa911bf5252" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0c693a-ac11-4bda-8da3-d2459cb2b3bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1770c061-9e4c-4bfd-a217-9a029c0c5a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0c693a-ac11-4bda-8da3-d2459cb2b3bf" xlink:to="loc_us-gaap_AwardTypeAxis_1770c061-9e4c-4bfd-a217-9a029c0c5a17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1770c061-9e4c-4bfd-a217-9a029c0c5a17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1770c061-9e4c-4bfd-a217-9a029c0c5a17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1770c061-9e4c-4bfd-a217-9a029c0c5a17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183a6f4b-208a-462b-ac4e-0f463258e75f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1770c061-9e4c-4bfd-a217-9a029c0c5a17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183a6f4b-208a-462b-ac4e-0f463258e75f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bf12f4f3-50ed-4f86-bcb6-ea7d162d66cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183a6f4b-208a-462b-ac4e-0f463258e75f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bf12f4f3-50ed-4f86-bcb6-ea7d162d66cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_676d22e1-7586-4777-ac61-0073d7954959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183a6f4b-208a-462b-ac4e-0f463258e75f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_676d22e1-7586-4777-ac61-0073d7954959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_dffc53f1-c845-44df-aed3-3f1105448f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183a6f4b-208a-462b-ac4e-0f463258e75f" xlink:to="loc_us-gaap_PerformanceSharesMember_dffc53f1-c845-44df-aed3-3f1105448f5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_17586be2-ffc5-4e76-a481-9e6158883ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183a6f4b-208a-462b-ac4e-0f463258e75f" xlink:to="loc_us-gaap_EmployeeStockMember_17586be2-ffc5-4e76-a481-9e6158883ff8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended" id="i6645d0000d9d45ecbad97985707ef28d_EmployeeBenefitPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_59ba5acd-6e17-4d7e-85b0-f02e60b8097c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_59ba5acd-6e17-4d7e-85b0-f02e60b8097c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_f6b46e61-684b-481b-8c1f-0446c920d597" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_f6b46e61-684b-481b-8c1f-0446c920d597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_405479c8-68fa-4f6f-9ef4-b69fd91a2d3d" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_405479c8-68fa-4f6f-9ef4-b69fd91a2d3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ec45282c-87a0-4776-b804-5f8ec3a97735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ec45282c-87a0-4776-b804-5f8ec3a97735" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_709cb8c3-29be-4f60-9d79-5b601b97128f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_709cb8c3-29be-4f60-9d79-5b601b97128f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23ae9b63-ba14-4bfc-90ac-3074f901f5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23ae9b63-ba14-4bfc-90ac-3074f901f5f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_cb1995f8-ada2-423b-ab02-421776d5bf34" xlink:href="exel-20211231.xsd#exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_cb1995f8-ada2-423b-ab02-421776d5bf34" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_0e53ba4c-55b5-40e1-95d9-468c86a01905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_0e53ba4c-55b5-40e1-95d9-468c86a01905" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1fa5cb39-04e6-411c-8fa5-c3195f8111cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1fa5cb39-04e6-411c-8fa5-c3195f8111cb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d727d937-1072-4cf9-a043-e161c8017e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d727d937-1072-4cf9-a043-e161c8017e38" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_505e7631-0538-4afc-abb1-ba158c0fe585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_505e7631-0538-4afc-abb1-ba158c0fe585" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_7474f676-5dd5-47c8-9990-ecd032bf4a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ProceedsFromStockPlans_7474f676-5dd5-47c8-9990-ecd032bf4a5d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fc3cd3a7-a89f-477d-86de-405e7b799174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fc3cd3a7-a89f-477d-86de-405e7b799174" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3d0c6f43-058e-490f-9032-37445bc7db99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3d0c6f43-058e-490f-9032-37445bc7db99" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f2b0a072-6eef-421d-976b-338c8c5723b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f2b0a072-6eef-421d-976b-338c8c5723b1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9df6b70d-61ee-42c4-b91b-2353dcd6d088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9df6b70d-61ee-42c4-b91b-2353dcd6d088" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f2a22efd-dba4-4286-a37b-ea9ebde9ab16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f2a22efd-dba4-4286-a37b-ea9ebde9ab16" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0c0d582d-63ed-42dd-8ca1-d7e0590b4e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0c0d582d-63ed-42dd-8ca1-d7e0590b4e65" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_51ae539a-a1f9-4a5f-935c-bc4dea8f4e5a" xlink:href="exel-20211231.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_51ae539a-a1f9-4a5f-935c-bc4dea8f4e5a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_2045cbec-ebba-4545-87ef-168c21d39dde" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_2045cbec-ebba-4545-87ef-168c21d39dde" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_37ff193b-d3db-456d-9024-1e9f38b8060f" xlink:href="exel-20211231.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_37ff193b-d3db-456d-9024-1e9f38b8060f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2dca547c-7de9-408a-b27e-b0d76d2726eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2dca547c-7de9-408a-b27e-b0d76d2726eb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1df8ea93-36ff-4b10-a2c0-7f4adc1f4629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1df8ea93-36ff-4b10-a2c0-7f4adc1f4629" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3f75837a-29ec-441e-969b-4ba20aef5624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3f75837a-29ec-441e-969b-4ba20aef5624" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f5e872f7-65c8-45e7-9975-e3119717c08a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f5e872f7-65c8-45e7-9975-e3119717c08a" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_37609c52-af85-4716-9718-78592d08235a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_37609c52-af85-4716-9718-78592d08235a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a7c266b-fd38-4d21-bd7b-6ee8b1bf80a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:to="loc_us-gaap_AwardTypeAxis_8a7c266b-fd38-4d21-bd7b-6ee8b1bf80a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a7c266b-fd38-4d21-bd7b-6ee8b1bf80a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8a7c266b-fd38-4d21-bd7b-6ee8b1bf80a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a7c266b-fd38-4d21-bd7b-6ee8b1bf80a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d086e28-3dc6-4d9f-a3f5-f9f5c9ee77dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8a7c266b-fd38-4d21-bd7b-6ee8b1bf80a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d086e28-3dc6-4d9f-a3f5-f9f5c9ee77dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b95f1107-7783-4ac9-ab89-0a88e20707c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d086e28-3dc6-4d9f-a3f5-f9f5c9ee77dc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b95f1107-7783-4ac9-ab89-0a88e20707c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_40002090-f3a2-4bf2-afeb-587f4c2f729f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d086e28-3dc6-4d9f-a3f5-f9f5c9ee77dc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_40002090-f3a2-4bf2-afeb-587f4c2f729f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_88a7335c-a958-4eed-b32a-c74df1f8de1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d086e28-3dc6-4d9f-a3f5-f9f5c9ee77dc" xlink:to="loc_us-gaap_EmployeeStockMember_88a7335c-a958-4eed-b32a-c74df1f8de1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_50d90662-b6bf-4dfa-988e-da118d59ab1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d086e28-3dc6-4d9f-a3f5-f9f5c9ee77dc" xlink:to="loc_us-gaap_PerformanceSharesMember_50d90662-b6bf-4dfa-988e-da118d59ab1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesClinicalTrialResultsMember_d424c57f-8807-451f-94a0-c5c91764ccd7" xlink:href="exel-20211231.xsd#exel_PerformanceSharesClinicalTrialResultsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PerformanceSharesMember_50d90662-b6bf-4dfa-988e-da118d59ab1b" xlink:to="loc_exel_PerformanceSharesClinicalTrialResultsMember_d424c57f-8807-451f-94a0-c5c91764ccd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_43f467d7-1506-40cd-a199-539c7fddd3f0" xlink:href="exel-20211231.xsd#exel_PerformanceSharesAchievedBeforeDecember312020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PerformanceSharesMember_50d90662-b6bf-4dfa-988e-da118d59ab1b" xlink:to="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_43f467d7-1506-40cd-a199-539c7fddd3f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312021Member_20fed20f-0f76-42f1-8e94-365f6b51f75e" xlink:href="exel-20211231.xsd#exel_PerformanceSharesAchievedBeforeDecember312021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PerformanceSharesMember_50d90662-b6bf-4dfa-988e-da118d59ab1b" xlink:to="loc_exel_PerformanceSharesAchievedBeforeDecember312021Member_20fed20f-0f76-42f1-8e94-365f6b51f75e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_A2018PerformanceStockUnitsMember_705fd2cc-c11f-4cf3-8b48-4c42079047ab" xlink:href="exel-20211231.xsd#exel_A2018PerformanceStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PerformanceSharesMember_50d90662-b6bf-4dfa-988e-da118d59ab1b" xlink:to="loc_exel_A2018PerformanceStockUnitsMember_705fd2cc-c11f-4cf3-8b48-4c42079047ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_cb635874-996c-4b5d-8710-4125cd3f9e45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:to="loc_us-gaap_GranteeStatusAxis_cb635874-996c-4b5d-8710-4125cd3f9e45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_cb635874-996c-4b5d-8710-4125cd3f9e45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_cb635874-996c-4b5d-8710-4125cd3f9e45" xlink:to="loc_us-gaap_GranteeStatusDomain_cb635874-996c-4b5d-8710-4125cd3f9e45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_a7e4594c-8e32-49fc-8c86-25d2660a3fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_cb635874-996c-4b5d-8710-4125cd3f9e45" xlink:to="loc_us-gaap_GranteeStatusDomain_a7e4594c-8e32-49fc-8c86-25d2660a3fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_72074df8-de90-42b5-8059-eddaa188a6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_a7e4594c-8e32-49fc-8c86-25d2660a3fee" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_72074df8-de90-42b5-8059-eddaa188a6e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d22c8073-0848-406a-a215-fc552fd7c686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_a7e4594c-8e32-49fc-8c86-25d2660a3fee" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d22c8073-0848-406a-a215-fc552fd7c686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis_b0bff0c1-0a81-45a5-962e-3f82f94f8f29" xlink:href="exel-20211231.xsd#exel_StatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:to="loc_exel_StatusAxis_b0bff0c1-0a81-45a5-962e-3f82f94f8f29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_b0bff0c1-0a81-45a5-962e-3f82f94f8f29_default" xlink:href="exel-20211231.xsd#exel_StatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_StatusAxis_b0bff0c1-0a81-45a5-962e-3f82f94f8f29" xlink:to="loc_exel_StatusDomain_b0bff0c1-0a81-45a5-962e-3f82f94f8f29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_fab30a24-5512-447d-b56c-da39062ff676" xlink:href="exel-20211231.xsd#exel_StatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_StatusAxis_b0bff0c1-0a81-45a5-962e-3f82f94f8f29" xlink:to="loc_exel_StatusDomain_fab30a24-5512-447d-b56c-da39062ff676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember_aa28a8cf-48ba-4a65-98d6-c6012dccb557" xlink:href="exel-20211231.xsd#exel_AchievedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_fab30a24-5512-447d-b56c-da39062ff676" xlink:to="loc_exel_AchievedMember_aa28a8cf-48ba-4a65-98d6-c6012dccb557" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember_8a887bd1-062b-4337-86c3-dc8f11c561a9" xlink:href="exel-20211231.xsd#exel_ProbableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_fab30a24-5512-447d-b56c-da39062ff676" xlink:to="loc_exel_ProbableMember_8a887bd1-062b-4337-86c3-dc8f11c561a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NotProbableMember_8f18cb25-265b-4ae4-8891-a4d7129c3ebd" xlink:href="exel-20211231.xsd#exel_NotProbableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_fab30a24-5512-447d-b56c-da39062ff676" xlink:to="loc_exel_NotProbableMember_8f18cb25-265b-4ae4-8891-a4d7129c3ebd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_1aa12afc-62f5-48cd-8b70-8bf53a0004e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:to="loc_us-gaap_VestingAxis_1aa12afc-62f5-48cd-8b70-8bf53a0004e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_1aa12afc-62f5-48cd-8b70-8bf53a0004e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_1aa12afc-62f5-48cd-8b70-8bf53a0004e1" xlink:to="loc_us-gaap_VestingDomain_1aa12afc-62f5-48cd-8b70-8bf53a0004e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d9427d9d-1905-4c22-a02a-fa36c59d9a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_1aa12afc-62f5-48cd-8b70-8bf53a0004e1" xlink:to="loc_us-gaap_VestingDomain_d9427d9d-1905-4c22-a02a-fa36c59d9a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_922bef24-7f82-48f6-bcd1-a5957f94760c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d9427d9d-1905-4c22-a02a-fa36c59d9a64" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_922bef24-7f82-48f6-bcd1-a5957f94760c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4a63c6e1-b502-46c0-a40a-91a68894774f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d9427d9d-1905-4c22-a02a-fa36c59d9a64" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4a63c6e1-b502-46c0-a40a-91a68894774f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5810af38-386e-4598-9b52-9b2feeb282fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:to="loc_srt_RangeAxis_5810af38-386e-4598-9b52-9b2feeb282fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5810af38-386e-4598-9b52-9b2feeb282fa_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5810af38-386e-4598-9b52-9b2feeb282fa" xlink:to="loc_srt_RangeMember_5810af38-386e-4598-9b52-9b2feeb282fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75342ee1-1508-4adc-ba57-dd2d2a534de3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5810af38-386e-4598-9b52-9b2feeb282fa" xlink:to="loc_srt_RangeMember_75342ee1-1508-4adc-ba57-dd2d2a534de3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_063cbd81-3663-45fe-a91c-6bc5f7320eb0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75342ee1-1508-4adc-ba57-dd2d2a534de3" xlink:to="loc_srt_MinimumMember_063cbd81-3663-45fe-a91c-6bc5f7320eb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a7369c68-2346-4539-bb49-5e85bb46fd66" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75342ee1-1508-4adc-ba57-dd2d2a534de3" xlink:to="loc_srt_MaximumMember_a7369c68-2346-4539-bb49-5e85bb46fd66" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="extended" id="i52dfa18649964f6a8fa9459142c98cd8_EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55044ff2-4d44-4922-a240-f25e2269e809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a92fc287-1353-4c6c-b9f5-e243ad30e748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55044ff2-4d44-4922-a240-f25e2269e809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a92fc287-1353-4c6c-b9f5-e243ad30e748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3bf28d5-7c44-49bd-a57c-1e5f5981bf07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55044ff2-4d44-4922-a240-f25e2269e809" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3bf28d5-7c44-49bd-a57c-1e5f5981bf07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1fa21158-076e-40b9-b8e4-7e41785ae44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3bf28d5-7c44-49bd-a57c-1e5f5981bf07" xlink:to="loc_us-gaap_AwardTypeAxis_1fa21158-076e-40b9-b8e4-7e41785ae44c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1fa21158-076e-40b9-b8e4-7e41785ae44c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1fa21158-076e-40b9-b8e4-7e41785ae44c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1fa21158-076e-40b9-b8e4-7e41785ae44c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55735c3a-a496-46d2-9c84-b9ecdb3d65ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1fa21158-076e-40b9-b8e4-7e41785ae44c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55735c3a-a496-46d2-9c84-b9ecdb3d65ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5f9a7ae4-328d-4e28-87a3-67c054d3fcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55735c3a-a496-46d2-9c84-b9ecdb3d65ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5f9a7ae4-328d-4e28-87a3-67c054d3fcb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_67938551-6520-4b4f-a7cb-5cd8e4113559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55735c3a-a496-46d2-9c84-b9ecdb3d65ba" xlink:to="loc_us-gaap_EmployeeStockMember_67938551-6520-4b4f-a7cb-5cd8e4113559" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="extended" id="ibf758560a5db431981dd79cfa283de0d_EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70ba2711-2074-4fbb-a61c-8cc264b91996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_140ec350-f19a-4a8e-abef-a5b9e796cded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70ba2711-2074-4fbb-a61c-8cc264b91996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_140ec350-f19a-4a8e-abef-a5b9e796cded" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4d7cbde5-4f0b-4bc7-9c4c-b94fde2d7197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70ba2711-2074-4fbb-a61c-8cc264b91996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4d7cbde5-4f0b-4bc7-9c4c-b94fde2d7197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_7576e4b1-a671-42d4-b18c-01d94567510c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70ba2711-2074-4fbb-a61c-8cc264b91996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_7576e4b1-a671-42d4-b18c-01d94567510c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_71a920fd-12a1-4c8f-888b-7e1e1ef939fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70ba2711-2074-4fbb-a61c-8cc264b91996" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_71a920fd-12a1-4c8f-888b-7e1e1ef939fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e51ddad-381b-4922-9671-8345b5f54f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70ba2711-2074-4fbb-a61c-8cc264b91996" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e51ddad-381b-4922-9671-8345b5f54f5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4ec76a21-6324-43ce-960a-462fd03ef4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e51ddad-381b-4922-9671-8345b5f54f5c" xlink:to="loc_us-gaap_AwardTypeAxis_4ec76a21-6324-43ce-960a-462fd03ef4c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ec76a21-6324-43ce-960a-462fd03ef4c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4ec76a21-6324-43ce-960a-462fd03ef4c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ec76a21-6324-43ce-960a-462fd03ef4c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffa8501c-7ab8-483e-8dd5-b52b0c6a168a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4ec76a21-6324-43ce-960a-462fd03ef4c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffa8501c-7ab8-483e-8dd5-b52b0c6a168a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_71a49cad-ef6e-430f-8aa9-b6a5abd835ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffa8501c-7ab8-483e-8dd5-b52b0c6a168a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_71a49cad-ef6e-430f-8aa9-b6a5abd835ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_775749f9-ec5a-4975-9484-dcab7d5cdc09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffa8501c-7ab8-483e-8dd5-b52b0c6a168a" xlink:to="loc_us-gaap_EmployeeStockMember_775749f9-ec5a-4975-9484-dcab7d5cdc09" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="extended" id="ib7962747f9cb4a92adf8261f665eb0f6_EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10de6383-1d5b-4985-9775-071e3fb4dcca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3443bad-81bc-4117-a462-8479efc25946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10de6383-1d5b-4985-9775-071e3fb4dcca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3443bad-81bc-4117-a462-8479efc25946" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a9eef49e-78ef-48b1-b6bd-0d56accc55d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3443bad-81bc-4117-a462-8479efc25946" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a9eef49e-78ef-48b1-b6bd-0d56accc55d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c58bdb23-085d-4519-90de-5013a2c7d5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3443bad-81bc-4117-a462-8479efc25946" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c58bdb23-085d-4519-90de-5013a2c7d5e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_d3367e7c-4f38-4fd8-9dc7-eeff7b088343" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3443bad-81bc-4117-a462-8479efc25946" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_d3367e7c-4f38-4fd8-9dc7-eeff7b088343" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b1925f1a-fc7e-4747-af23-338aaa22669c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3443bad-81bc-4117-a462-8479efc25946" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b1925f1a-fc7e-4747-af23-338aaa22669c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b277bea-6fba-4e03-83f2-6b8385374660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6516570-d2e1-4c0a-b861-3a04c4743721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10de6383-1d5b-4985-9775-071e3fb4dcca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6516570-d2e1-4c0a-b861-3a04c4743721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_babde05a-0e0d-4212-bcb9-0d64b70c4e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6516570-d2e1-4c0a-b861-3a04c4743721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_babde05a-0e0d-4212-bcb9-0d64b70c4e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbc420c4-ee4d-4335-9ac2-4b15553a609a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6516570-d2e1-4c0a-b861-3a04c4743721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbc420c4-ee4d-4335-9ac2-4b15553a609a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_d5da722f-b9f9-4cb2-aa5a-0744c6dd46c2" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6516570-d2e1-4c0a-b861-3a04c4743721" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_d5da722f-b9f9-4cb2-aa5a-0744c6dd46c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1327718a-3485-4537-8cd5-8a6316188665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6516570-d2e1-4c0a-b861-3a04c4743721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1327718a-3485-4537-8cd5-8a6316188665" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1dabb56f-fe31-40a5-887d-70a6f1aed17c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7dd20e8f-313e-4e88-8d0c-e14b6e074e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10de6383-1d5b-4985-9775-071e3fb4dcca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7dd20e8f-313e-4e88-8d0c-e14b6e074e7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_64be5344-14dd-4ca9-a1d2-9c9afc5e5069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10de6383-1d5b-4985-9775-071e3fb4dcca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_64be5344-14dd-4ca9-a1d2-9c9afc5e5069" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6dac5b91-9bb2-4222-9fd8-329aeb8c2287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10de6383-1d5b-4985-9775-071e3fb4dcca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6dac5b91-9bb2-4222-9fd8-329aeb8c2287" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75a42797-6b05-4f5d-b3eb-2842d0ea8a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6dac5b91-9bb2-4222-9fd8-329aeb8c2287" xlink:to="loc_us-gaap_AwardTypeAxis_75a42797-6b05-4f5d-b3eb-2842d0ea8a81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75a42797-6b05-4f5d-b3eb-2842d0ea8a81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_75a42797-6b05-4f5d-b3eb-2842d0ea8a81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75a42797-6b05-4f5d-b3eb-2842d0ea8a81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bba80251-4ebd-448b-998a-6c53b310265e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_75a42797-6b05-4f5d-b3eb-2842d0ea8a81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bba80251-4ebd-448b-998a-6c53b310265e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_28afa338-fae6-4c5c-a9f4-2f2377bd50e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bba80251-4ebd-448b-998a-6c53b310265e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_28afa338-fae6-4c5c-a9f4-2f2377bd50e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_93ac03e7-6aae-460d-8c4c-48be356efec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bba80251-4ebd-448b-998a-6c53b310265e" xlink:to="loc_us-gaap_PerformanceSharesMember_93ac03e7-6aae-460d-8c4c-48be356efec1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansEstimateGrantDateFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails" xlink:type="extended" id="i54084863569647bc8bceb06971f3ac21_EmployeeBenefitPlansEstimateGrantDateFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9bfe5a4e-e3df-4f01-bfc0-5f5e3cb08f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9bfe5a4e-e3df-4f01-bfc0-5f5e3cb08f5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ec73361b-2dc8-48ed-85dd-02e1e024d215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:to="loc_us-gaap_SharePrice_ec73361b-2dc8-48ed-85dd-02e1e024d215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_63313fc5-affd-411e-b7ef-85f9c4c29175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_63313fc5-affd-411e-b7ef-85f9c4c29175" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a18d70f8-384f-4261-ab06-6fec7f6eae38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a18d70f8-384f-4261-ab06-6fec7f6eae38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f41f14fa-894f-4684-a1a7-db3a87fcd3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f41f14fa-894f-4684-a1a7-db3a87fcd3a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7766c1ae-e196-4406-ac4f-720fa67d4b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7766c1ae-e196-4406-ac4f-720fa67d4b32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1aee4be3-87f7-442c-acdb-7056201af89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7766c1ae-e196-4406-ac4f-720fa67d4b32" xlink:to="loc_us-gaap_AwardTypeAxis_1aee4be3-87f7-442c-acdb-7056201af89c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aee4be3-87f7-442c-acdb-7056201af89c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1aee4be3-87f7-442c-acdb-7056201af89c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aee4be3-87f7-442c-acdb-7056201af89c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a18c11d2-4364-4193-b14c-7489c499ad03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1aee4be3-87f7-442c-acdb-7056201af89c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a18c11d2-4364-4193-b14c-7489c499ad03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_507b0318-3b4f-4393-9f47-37b8419f18aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a18c11d2-4364-4193-b14c-7489c499ad03" xlink:to="loc_us-gaap_PerformanceSharesMember_507b0318-3b4f-4393-9f47-37b8419f18aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#ProvisionForIncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails" xlink:type="extended" id="i468f97bc6ed74c65baed0f52c679fcc0_ProvisionForIncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6d5f0e65-c52c-4b0d-a787-05fa016266ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6d5f0e65-c52c-4b0d-a787-05fa016266ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_eee4ae1e-29a5-4f00-aa84-d6e29cf09df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_eee4ae1e-29a5-4f00-aa84-d6e29cf09df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_90ecbb76-1cfd-432d-a467-b5bd55e1419e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_90ecbb76-1cfd-432d-a467-b5bd55e1419e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_a01aca19-d9ca-403e-9558-7b69b75d985a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_us-gaap_OperatingLossCarryforwards_a01aca19-d9ca-403e-9558-7b69b75d985a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_0f460239-df04-4a08-9d60-58ec26e89608" xlink:href="exel-20211231.xsd#exel_TaxCreditCarryforwardAmountWithExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_0f460239-df04-4a08-9d60-58ec26e89608" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4edd778b-0a51-46b3-acc2-607e9ef78a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4edd778b-0a51-46b3-acc2-607e9ef78a52" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e3cff8e5-8e64-47cf-921c-79d4ca3d9451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e3cff8e5-8e64-47cf-921c-79d4ca3d9451" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_27818512-95a3-4fbc-a27c-5838b9aba616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_27818512-95a3-4fbc-a27c-5838b9aba616" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8135d782-d505-4e66-9264-f866e5dab99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_27818512-95a3-4fbc-a27c-5838b9aba616" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8135d782-d505-4e66-9264-f866e5dab99b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8135d782-d505-4e66-9264-f866e5dab99b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8135d782-d505-4e66-9264-f866e5dab99b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8135d782-d505-4e66-9264-f866e5dab99b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a7fdc3a7-b74f-466f-9804-185138eedb95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8135d782-d505-4e66-9264-f866e5dab99b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a7fdc3a7-b74f-466f-9804-185138eedb95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_058f215d-f19d-478f-bc57-ad5969ef4f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7fdc3a7-b74f-466f-9804-185138eedb95" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_058f215d-f19d-478f-bc57-ad5969ef4f6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_687fae53-5d6d-49ca-aec7-28edbbe4d234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7fdc3a7-b74f-466f-9804-185138eedb95" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_687fae53-5d6d-49ca-aec7-28edbbe4d234" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_72bff5fb-2386-40cc-a503-04e4d9aaa69d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_27818512-95a3-4fbc-a27c-5838b9aba616" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_72bff5fb-2386-40cc-a503-04e4d9aaa69d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_72bff5fb-2386-40cc-a503-04e4d9aaa69d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_72bff5fb-2386-40cc-a503-04e4d9aaa69d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_72bff5fb-2386-40cc-a503-04e4d9aaa69d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_01a1fc1c-eaab-45ee-8a94-a56d99f30b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_72bff5fb-2386-40cc-a503-04e4d9aaa69d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_01a1fc1c-eaab-45ee-8a94-a56d99f30b0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_edb1c877-3dde-4610-af88-67282e2cce9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_01a1fc1c-eaab-45ee-8a94-a56d99f30b0f" xlink:to="loc_us-gaap_ResearchMember_edb1c877-3dde-4610-af88-67282e2cce9f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="extended" id="icdbbcf6924384485a4cc2a637f8a3d2f_NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8de37e1b-434d-411b-a33c-bbbe6d33a095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ae68683d-cf8b-4141-9438-68be31faaa9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8de37e1b-434d-411b-a33c-bbbe6d33a095" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ae68683d-cf8b-4141-9438-68be31faaa9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aee3e483-3d25-41f2-9205-2c0413c90f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8de37e1b-434d-411b-a33c-bbbe6d33a095" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aee3e483-3d25-41f2-9205-2c0413c90f4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2844b685-c5d9-42df-bc30-fc62366e2d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aee3e483-3d25-41f2-9205-2c0413c90f4c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2844b685-c5d9-42df-bc30-fc62366e2d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2844b685-c5d9-42df-bc30-fc62366e2d37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2844b685-c5d9-42df-bc30-fc62366e2d37" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2844b685-c5d9-42df-bc30-fc62366e2d37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c93372e1-7751-472f-9898-06d5f77d7dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2844b685-c5d9-42df-bc30-fc62366e2d37" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c93372e1-7751-472f-9898-06d5f77d7dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_42b6995a-d9c6-4923-929e-09810722e1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c93372e1-7751-472f-9898-06d5f77d7dff" xlink:to="loc_us-gaap_StockCompensationPlanMember_42b6995a-d9c6-4923-929e-09810722e1d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i4a1727d8881d49a1b639d66d5462afdf_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_c0f52915-396c-46d0-9d00-88b620f19fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_c0f52915-396c-46d0-9d00-88b620f19fd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_f6b97732-7612-4d94-880d-2f6d44b3a544" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_f6b97732-7612-4d94-880d-2f6d44b3a544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3aede9bd-4b3d-4d40-b71b-748c500c51d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3aede9bd-4b3d-4d40-b71b-748c500c51d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_a16e0b67-5d6d-460d-bc0f-9dcb23008987" xlink:href="exel-20211231.xsd#exel_TenantLeaseImprovementsAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_a16e0b67-5d6d-460d-bc0f-9dcb23008987" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1087f2e2-7f33-423f-9153-093fbbff17d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_OperatingLeasePayments_1087f2e2-7f33-423f-9153-093fbbff17d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_84b0dc56-c661-4614-a7c7-8514bc8f76d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_84b0dc56-c661-4614-a7c7-8514bc8f76d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7f686b13-cd64-4f94-a853-028b3a74de31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7f686b13-cd64-4f94-a853-028b3a74de31" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e1f3acc0-7c6a-4a5a-83c9-d8d947001eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e1f3acc0-7c6a-4a5a-83c9-d8d947001eb4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_b5ced680-effe-492d-a384-c5eb7ba45651" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_b5ced680-effe-492d-a384-c5eb7ba45651" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_ae43c259-d2f5-42ed-a5a9-17576cf07a73" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_ae43c259-d2f5-42ed-a5a9-17576cf07a73" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_80445106-6644-4be2-8b85-fc8f52797b83" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_80445106-6644-4be2-8b85-fc8f52797b83" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_eb422226-6af8-44c0-9571-133f5c852619" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_eb422226-6af8-44c0-9571-133f5c852619" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AreaOfRealEstatePropertyAvailableToLease_99497f90-9f6c-4d92-9553-4c6f8958b371" xlink:href="exel-20211231.xsd#exel_AreaOfRealEstatePropertyAvailableToLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_AreaOfRealEstatePropertyAvailableToLease_99497f90-9f6c-4d92-9553-4c6f8958b371" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_253b31bd-6efe-4f3f-b405-6180687573f7" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_253b31bd-6efe-4f3f-b405-6180687573f7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_2a16ae89-a1f0-4ac3-a08f-8ae79e6829e6" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_2a16ae89-a1f0-4ac3-a08f-8ae79e6829e6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_0a9c1cfc-6785-4ce5-a744-0c2c5490a684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_TenantImprovements_0a9c1cfc-6785-4ce5-a744-0c2c5490a684" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_da41cad3-08b1-4774-b587-935edcd30af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_da41cad3-08b1-4774-b587-935edcd30af0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_e14c11aa-fb94-4a1a-a46a-f2f60213eada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_e14c11aa-fb94-4a1a-a46a-f2f60213eada" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_78db1b2c-1b05-4e49-822b-f5bd22576458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_78db1b2c-1b05-4e49-822b-f5bd22576458" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis_84bcc4a5-70df-4909-a2c5-983383a7848f" xlink:href="exel-20211231.xsd#exel_LeaseArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_78db1b2c-1b05-4e49-822b-f5bd22576458" xlink:to="loc_exel_LeaseArrangementsAxis_84bcc4a5-70df-4909-a2c5-983383a7848f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_84bcc4a5-70df-4909-a2c5-983383a7848f_default" xlink:href="exel-20211231.xsd#exel_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_LeaseArrangementsAxis_84bcc4a5-70df-4909-a2c5-983383a7848f" xlink:to="loc_exel_LeaseArrangementsDomain_84bcc4a5-70df-4909-a2c5-983383a7848f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_0d408e24-2dae-4464-a70e-a8dd14568d70" xlink:href="exel-20211231.xsd#exel_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_LeaseArrangementsAxis_84bcc4a5-70df-4909-a2c5-983383a7848f" xlink:to="loc_exel_LeaseArrangementsDomain_0d408e24-2dae-4464-a70e-a8dd14568d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseMember_b931eb70-8a82-42f8-88e4-3c9606850d04" xlink:href="exel-20211231.xsd#exel_HeadquartersLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_0d408e24-2dae-4464-a70e-a8dd14568d70" xlink:to="loc_exel_HeadquartersLeaseMember_b931eb70-8a82-42f8-88e4-3c9606850d04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseApril2019AmendmentMember_05812237-052a-4978-af96-8e88f2098f02" xlink:href="exel-20211231.xsd#exel_HeadquartersLeaseApril2019AmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_HeadquartersLeaseMember_b931eb70-8a82-42f8-88e4-3c9606850d04" xlink:to="loc_exel_HeadquartersLeaseApril2019AmendmentMember_05812237-052a-4978-af96-8e88f2098f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseDecember2020AmendmentMember_d92ead2f-165c-4940-b1a7-c7a5046a5e4b" xlink:href="exel-20211231.xsd#exel_HeadquartersLeaseDecember2020AmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_HeadquartersLeaseMember_b931eb70-8a82-42f8-88e4-3c9606850d04" xlink:to="loc_exel_HeadquartersLeaseDecember2020AmendmentMember_d92ead2f-165c-4940-b1a7-c7a5046a5e4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLease2021AmendmentMember_02c031f4-a8c1-4702-82e4-114354c559d6" xlink:href="exel-20211231.xsd#exel_HeadquartersLease2021AmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_HeadquartersLeaseMember_b931eb70-8a82-42f8-88e4-3c9606850d04" xlink:to="loc_exel_HeadquartersLease2021AmendmentMember_02c031f4-a8c1-4702-82e4-114354c559d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseMember_5928c2e7-0e85-4e3b-a5e8-7760d369e405" xlink:href="exel-20211231.xsd#exel_BuiltToSuitLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_0d408e24-2dae-4464-a70e-a8dd14568d70" xlink:to="loc_exel_BuiltToSuitLeaseMember_5928c2e7-0e85-4e3b-a5e8-7760d369e405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_21720468-3b41-4406-b7e6-1c5ba5e78764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_78db1b2c-1b05-4e49-822b-f5bd22576458" xlink:to="loc_us-gaap_CreditFacilityAxis_21720468-3b41-4406-b7e6-1c5ba5e78764" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_21720468-3b41-4406-b7e6-1c5ba5e78764_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_21720468-3b41-4406-b7e6-1c5ba5e78764" xlink:to="loc_us-gaap_CreditFacilityDomain_21720468-3b41-4406-b7e6-1c5ba5e78764_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_79614b96-2767-4d97-a301-5b664fab2476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_21720468-3b41-4406-b7e6-1c5ba5e78764" xlink:to="loc_us-gaap_CreditFacilityDomain_79614b96-2767-4d97-a301-5b664fab2476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_80d09166-f43a-4b4a-8e71-27db5fb8c14f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_79614b96-2767-4d97-a301-5b664fab2476" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_80d09166-f43a-4b4a-8e71-27db5fb8c14f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>exel-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:15eb203a-3ec7-40cd-9655-d78f522bbe80,g:fdc51e9e-f0fc-4164-a9b2-d81298576ebe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_4549944a-bf2a-4fcb-b5c8-4e55e965e8b1_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_599baadf-65e9-4007-b1cb-85ca4ec6f544_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_f54b0744-5261-432d-9959-e6b6f45bf1c6_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProbableMember_92cf4984-9465-4dcd-8042-8f9a3554784b_terseLabel_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable</link:label>
    <link:label id="lab_exel_ProbableMember_label_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable [Member]</link:label>
    <link:label id="lab_exel_ProbableMember_documentation_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember" xlink:href="exel-20211231.xsd#exel_ProbableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProbableMember" xlink:to="lab_exel_ProbableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_b4dbc377-47ca-490a-b77a-71a91a4a7943_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1f088281-6fce-4ed6-a4c4-f31a7187365a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1b45022e-938e-44c0-909a-d83f902bf124_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards vested in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_6fa6ece3-ac5f-4ce6-a760-13157c3a44bf_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_827b836c-4fab-49d8-8d07-f569a8c1e440_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_6e96471e-fc05-4f00-b3c9-1feb2c4cf9cc_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6ba28b33-ba8d-4808-9708-234a4ae35b2c_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d1c2ce25-246f-4a75-a0de-286337af227d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_15be85f1-a517-4012-bcef-550ccc057c26_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b8be205c-d40d-41eb-80ef-6c94722b4fb2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_89f1f1ca-0674-4e1d-a1c0-5e5152e61365_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f83c2eb8-d041-4c5d-bee1-1b38b0f03952_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_HeadquartersLeaseDecember2020AmendmentMember_e3debf3e-ad20-49d2-b87f-b5f25b5e134b_terseLabel_en-US" xlink:label="lab_exel_HeadquartersLeaseDecember2020AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease, December 2020 Amendment</link:label>
    <link:label id="lab_exel_HeadquartersLeaseDecember2020AmendmentMember_label_en-US" xlink:label="lab_exel_HeadquartersLeaseDecember2020AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease, December 2020 Amendment [Member]</link:label>
    <link:label id="lab_exel_HeadquartersLeaseDecember2020AmendmentMember_documentation_en-US" xlink:label="lab_exel_HeadquartersLeaseDecember2020AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease, December 2020 Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseDecember2020AmendmentMember" xlink:href="exel-20211231.xsd#exel_HeadquartersLeaseDecember2020AmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_HeadquartersLeaseDecember2020AmendmentMember" xlink:to="lab_exel_HeadquartersLeaseDecember2020AmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_5b3e5f58-933f-4a38-96d3-eb3c5cfac46a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d29fad35-2f3e-47f7-aa6d-44986cced86f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonemployee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1a373525-2bfc-4060-82be-f02f20ca8ca5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_62d1ad03-6160-47bf-9757-51bfca870cd4_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:href="exel-20211231.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:to="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f772533c-adcb-4d96-81d5-16c1a026d579_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_222f6251-96f5-4066-9036-15afc8ffaf36_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IpsenMember_be9de791-3838-4889-a1e1-534a81bb2435_terseLabel_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Pharma SAS</link:label>
    <link:label id="lab_exel_IpsenMember_label_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_documentation_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember" xlink:href="exel-20211231.xsd#exel_IpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember" xlink:to="lab_exel_IpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_e6daad33-48d5-4667-9e09-6703d88b7da7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate from market value on purchase date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_ffe9250b-46b8-4c6d-8e43-05aee5eaa055_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b24f6657-b9fd-4a74-963d-4bb5db2758b1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_5752cbbb-e587-4258-8709-fa07ab88ca72_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_46161986-6e02-4f34-84ec-52bcaead7df2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term for operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_06848439-d670-4fa7-9375-14f0aac880a7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ae0c6e67-fd3a-4b8b-84f2-762247f32084_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5391198b-4076-43b4-aade-2de8190962e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_c201fff6-1198-48bd-8f87-de4c15582a7f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Foreign Currency Contracts</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3a7756c5-df9d-400a-97e9-9636778f2ccd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a92979c7-e3a8-4388-81b3-1b852d2e64c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cf3b84c3-00c3-4646-8494-5ddcfbf2afae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_a8330b83-5e08-413f-9ace-1d5104aeb18d_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future development milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0d22abc7-df55-4056-9ba6-667cc36c7857_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_9f6eae48-ad10-4cef-ac4d-fc993345d0a7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9ced64e2-5b74-4ab6-ab73-ebdd706bf728_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_6dbd4b21-8b29-471d-9cf9-a14a6b2ff4c8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_21380152-a20f-42f5-af8a-96342d906e2b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a355b3f4-0b83-489c-bcb3-78c66f0966b4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9bd782e5-de92-4e10-8c89-d2784a56820b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_3b1146ba-ed5f-464b-9387-bdb245ae9885_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_d2e4786c-28f2-439c-a993-cb729e950418_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_2c92a062-c29c-4ae3-a54e-538a830e285e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_43bb6ad9-75c1-4154-908f-977975dd131c_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_e920b27e-7354-4fbf-ac7c-04cdf069bc8c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_9f24a4f5-0da8-4810-b176-0b853b923d3d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1dc48908-b3eb-463f-83f9-f272c412bafb_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_839f6afb-e724-4b75-9d5b-d6630398541c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change relating to prior year provision</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_ba2b32ef-85ea-4682-bf1b-3e4ccbde1ada_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OtherLongtermAssetsMember_359438aa-0c49-4d74-8e5c-ca2284bfe7e1_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion included in other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember" xlink:href="exel-20211231.xsd#exel_OtherLongtermAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember" xlink:to="lab_exel_OtherLongtermAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_cf3b0659-4be4-4d6d-bd30-d586fec3373e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f9bc48c7-94b7-444a-91c3-8ff1d55b5bde_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average operating discount rate used to determine the operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7ad0af43-469e-482d-b530-04f30256c786_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities and contingently issuable shares excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_aa28c58e-459c-4bc2-8968-c31bd192f765_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_945661c0-a384-453c-a648-20771d9eca4b_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:href="exel-20211231.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_33c26975-c61c-497a-ba42-ed44e4593dc8_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative catch-up revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dbe6844c-2bee-4486-96b4-a0ab8ea41c57_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenues recognized included in the beginning contract liability balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8b032b3b-81a0-4f0d-96fe-d11ac13ebf81_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MedicarePartDFundingMandate_4b71bc39-b3aa-4ac5-8652-12b1b11a6361_terseLabel_en-US" xlink:label="lab_exel_MedicarePartDFundingMandate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Part D funding mandate</link:label>
    <link:label id="lab_exel_MedicarePartDFundingMandate_label_en-US" xlink:label="lab_exel_MedicarePartDFundingMandate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Part D Funding Mandate</link:label>
    <link:label id="lab_exel_MedicarePartDFundingMandate_documentation_en-US" xlink:label="lab_exel_MedicarePartDFundingMandate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Part D Funding Mandate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MedicarePartDFundingMandate" xlink:href="exel-20211231.xsd#exel_MedicarePartDFundingMandate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MedicarePartDFundingMandate" xlink:to="lab_exel_MedicarePartDFundingMandate" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AreaOfRealEstatePropertyAvailableToLease_931b2b47-799f-40b5-bcb6-ecdd5bc8c145_terseLabel_en-US" xlink:label="lab_exel_AreaOfRealEstatePropertyAvailableToLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of property available for lease (in squire feet)</link:label>
    <link:label id="lab_exel_AreaOfRealEstatePropertyAvailableToLease_label_en-US" xlink:label="lab_exel_AreaOfRealEstatePropertyAvailableToLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Real Estate Property, Available To Lease</link:label>
    <link:label id="lab_exel_AreaOfRealEstatePropertyAvailableToLease_documentation_en-US" xlink:label="lab_exel_AreaOfRealEstatePropertyAvailableToLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Real Estate Property, Available To Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AreaOfRealEstatePropertyAvailableToLease" xlink:href="exel-20211231.xsd#exel_AreaOfRealEstatePropertyAvailableToLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AreaOfRealEstatePropertyAvailableToLease" xlink:to="lab_exel_AreaOfRealEstatePropertyAvailableToLease" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_HeadquartersLeaseMember_9fda258f-12a0-466f-b3c7-833fb9f14e9b_terseLabel_en-US" xlink:label="lab_exel_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease</link:label>
    <link:label id="lab_exel_HeadquartersLeaseMember_label_en-US" xlink:label="lab_exel_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease [Member]</link:label>
    <link:label id="lab_exel_HeadquartersLeaseMember_documentation_en-US" xlink:label="lab_exel_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseMember" xlink:href="exel-20211231.xsd#exel_HeadquartersLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_HeadquartersLeaseMember" xlink:to="lab_exel_HeadquartersLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_86ec068e-413d-4126-8d88-90239fef0024_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember" xlink:href="exel-20211231.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember" xlink:to="lab_exel_AllowanceForProductRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_f81689c1-9b93-4198-8470-a7fd3046836a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_86e77e8a-fa31-4784-b8d6-10e10ef227f9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b8054cab-d0a4-4b0f-8876-dbc6eb190224_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_6bd706c9-f057-44ce-9f26-e318bf7c9216_terseLabel_en-US" xlink:label="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet Classification of Lease Liabilities</link:label>
    <link:label id="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="exel-20211231.xsd#exel_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_db2380f1-0c50-4354-a96d-4edd4d6bea92_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_1906fd61-17cc-4602-8fa5-53ace87902ca_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b402911c-5283-4bca-ab63-1663dba72ba6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $1,481, $(394), and $(1,049), respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_7be26d80-cfff-403f-8a0c-32398dbe2e36_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_793c389c-9fa7-4c40-9e49-3576ca184315_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf6d7537-2e01-4495-8df5-18ce718fcf3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1d2e9cee-12fc-472b-9cae-c90e08b6df2b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_3d6d41f5-5e20-43f9-8ec1-90be07299194_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2f0c9645-56a5-4b42-9b6e-1a9dff23f192_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_da9920cb-d8df-46dc-b1ca-d1b28cc2264f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_be1eb093-55bd-46da-bbae-0d7b89c9d5bc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsIncMember_dc44c07c-43c6-4268-afc5-ecf8c1365a7f_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Iconic Therapeutics Inc</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsIncMember_label_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Iconic Therapeutics Inc [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsIncMember_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Iconic Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsIncMember" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementWithIconicTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementWithIconicTherapeuticsIncMember" xlink:to="lab_exel_CollaborationAgreementWithIconicTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_46810d85-1de8-494c-8949-63135f52c7eb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_6f1b31af-4d0e-4f0d-a4c5-7f92782a0559_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential regulatory milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_3698f444-6bce-4b07-ab32-c71ffe7f42de_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_581d1729-64ba-4650-b3e7-41e81314b6d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c2f1ee9f-7099-41dd-9961-fdbbb60527ed_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_76893266-15bd-4535-9e2c-6201c6f50deb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9becb6ea-3db2-4e15-ac86-74a753f69485_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ad8cd104-690a-4543-8090-ade7c2dabc83_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f5a69759-9907-4e04-a5ed-b697c215772b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a35ecdc5-8095-4530-8362-0b0e5e40843c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at beginning of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6bc94828-36ae-4dca-b338-8c2e39b4a293_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at ending of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_90c1775f-b140-4110-880f-73a2d4278258_terseLabel_en-US" xlink:label="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of months following change in control in which an employee was terminated</link:label>
    <link:label id="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_label_en-US" xlink:label="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement By Share-Based Payment Award, Termination Of Employment Following Change In Control, Period</link:label>
    <link:label id="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_documentation_en-US" xlink:label="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement By Share-Based Payment Award, Termination Of Employment Following Change In Control, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" xlink:href="exel-20211231.xsd#exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" xlink:to="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_db0430a6-74de-4293-a970-f3882be16143_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9c7e84af-4b37-4f25-ab97-aa118376c8bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_b47baccd-9000-44d2-aa8d-8bce2b36c1b6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_299ff4f7-b8f3-43ee-994c-f64af15955e3_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of leased property (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_664c1a5e-85ab-48e8-b80a-a424d13c7893_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6a2342d9-fa7d-4533-84d3-8d983de0866e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationMember_808f71fa-2bc5-4d85-90da-e7dcc9f81f30_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_label_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_documentation_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember" xlink:href="exel-20211231.xsd#exel_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember" xlink:to="lab_exel_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_74645646-4f6e-43e0-896e-e73f2ba0912a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_abbe1f74-a946-483a-88c7-428836792031_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_0f078bad-7d1c-463c-bd08-e46ef2df5850_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6f47185d-b59a-4ff9-bd18-7c30ad51e3c9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_46e93348-dcc5-4214-a8cf-b6fcda500715_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5bb213d7-3943-464c-abc2-5898aa129ac4_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2da73b18-e671-4da4-9c2f-5a49968e7bb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_703474df-5d5f-49c0-ae44-4b38330093d9_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future tenant improvement reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_fb27b0ec-aa82-46bf-8c9d-e5257834159b_negatedTerseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future tenant improvement reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:to="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_52c75032-5790-4ad0-9ce8-8a6e33419bc9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_89849970-fa52-46b2-bf8e-901ce65c8dff_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0078ec72-b0c0-41b1-bbb8-62d26fc8da59_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting award percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85cb1cb1-ae0a-4107-84e0-768691cd1058_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction_537f5045-1b76-4b71-bda2-0a39bb93f596_terseLabel_en-US" xlink:label="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment upon closing of transaction</link:label>
    <link:label id="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction_label_en-US" xlink:label="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Payment Upon Closing Of Transaction</link:label>
    <link:label id="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction_documentation_en-US" xlink:label="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Payment Upon Closing Of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:href="exel-20211231.xsd#exel_AssetAcquisitionPaymentUponClosingOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:to="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_6d85a58d-4f75-4526-98ac-cffeca65a992_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_005f397c-e838-4a78-bf5f-d7313a26b1f0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ecb3ef18-0674-4cf3-802b-ec9002f48fd9_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_793939fd-1a99-4a75-bfc8-d7f720402eb9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_af210ce1-f10f-4497-996b-ffcf06930f69_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_7ba59298-ab4c-45da-b45e-56fc4f91c5af_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_82754e4b-b251-4c81-b893-bf985a3fa851_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_a4809242-b132-4a86-923c-1c9c41b64205_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_b842fcbb-287e-4e97-a5ea-0c82549ac361_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_76eceeea-656b-482b-929f-edf1d2a1a302_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64327983-3da1-498f-b995-ed600530143c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a2ecd1f1-7169-4baa-b1b1-e97ff97462f1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_6c060c24-7e72-4d57-8bd0-91c651bd3728_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_8c5a1b50-ebe9-4ac1-84f9-4615a9fa61a1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_5de12c27-d402-445a-a98e-27e40bf06b92_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_ae402712-e3c7-4603-afb5-4b3e5763c7bb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses relating to stock match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b82f7d9-878a-4ecd-8878-6e1778ae25ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_7d0d2cff-1e19-48ed-be5c-1c928dcc4bac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_79ad25b1-7beb-4c65-87a6-ec52c555db0e_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_9c97729b-adba-4e92-8907-8a44ca7236d5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8b4ee833-ab07-4d9c-91a3-694836505a87_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock transactions associated with taxes withheld on equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_c3926a5a-8126-4d64-a8e7-da176c30ed8b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_98fc60a4-d904-4a41-bf86-bd59ff1483af_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_717a1a02-b262-4985-89bd-1a214b96c9af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_344e3ef6-b2a4-4434-9312-7b4e9cb6d25b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_3d0d0b17-234e-4fe6-8a7c-8d9403b3f4ff_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after stock option or stock appreciation award (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_172fbc27-097e-4af8-89e8-f7dbe41d2463_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_aecb4679-d76e-4bb6-b7f9-d9778a8880d6_terseLabel_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:href="exel-20211231.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:to="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_271c09e6-6a16-44cc-ab16-367714cd1cce_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:href="exel-20211231.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_cfea7d0c-248e-4741-97c4-2570b6940731_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration period to achieve specified levels of commercial performance</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:to="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_08706502-2cd5-4cb1-a2a8-cf86b0b0ab75_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseArrangementsDomain_8132e21d-b039-4fb5-8f7b-fc6e505f3b71_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_label_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Lease Arrangements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain" xlink:href="exel-20211231.xsd#exel_LeaseArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsDomain" xlink:to="lab_exel_LeaseArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TakedaMember_f2e75807-50a7-4122-9beb-08c63d9898a3_terseLabel_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:label id="lab_exel_TakedaMember_label_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:label id="lab_exel_TakedaMember_documentation_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember" xlink:href="exel-20211231.xsd#exel_TakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TakedaMember" xlink:to="lab_exel_TakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_5b47b7ef-c3f6-4d1b-9983-6f648f583695_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_47c75718-9c31-41ba-95ce-5b72aa73291f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1ba36cca-fcc8-456c-aff8-3acdb2d17296_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_679cfb16-68b0-4afe-ac3c-8068beef9de5_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase percentage</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_BuiltToSuitLeaseMember_c1982547-d2a6-4db6-b641-bf5499af1a57_terseLabel_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Built-To-Suit Lease</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseMember_label_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Built-To-Suit Lease [Member]</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseMember_documentation_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Built-To-Suit Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseMember" xlink:href="exel-20211231.xsd#exel_BuiltToSuitLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BuiltToSuitLeaseMember" xlink:to="lab_exel_BuiltToSuitLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ce66632c-e30e-4ffb-b8e8-00c4de5ee84b_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_d91992a4-75d4-4eb0-8fd7-235630c88177_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charge on goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3ee72f85-510b-4a8f-a48c-4b7c0a8b0ec3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2e120912-7205-4a45-8b7e-12091aaf1299_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_611a66ee-6870-4e54-b537-316747201834_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c4fb0449-a486-4b48-8d97-facd6b560d1f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_a9ad8bbc-c2d8-415d-92da-920ec6445373_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change relating to current year provision</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_75ddb025-da44-41b7-8d4b-6cb6e13d8d2d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4eb3fd9f-5fad-463e-a9bd-fc2cc09cba2b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_f0433d02-9feb-4f66-8ca0-6517b0f2a3e7_terseLabel_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible executive compensation</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_label_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_documentation_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:href="exel-20211231.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:to="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5a53129d-5db9-4ad2-8175-edd0b49275b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a114caa8-09b3-4ffd-b3e7-16cf2763593f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a4396b66-a5ca-4258-a23f-0e4332243629_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_8a485bbe-2746-4dd9-928f-682463e062b3_terseLabel_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</link:label>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_label_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member]</link:label>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:href="exel-20211231.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:to="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_7e4ad8ce-3618-4f2d-ae4c-09cbb22d824a_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_205c6fd8-db65-4f95-9c81-bd74e11ba1bf_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_859ce3d4-3caa-4add-82b3-4186403c0a10_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2e49e418-f529-4461-87a1-2f98f2e3cf05_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_8e09cf2b-c256-413b-bc2e-5255a371644f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_4837b273-bed9-4c29-a999-46820196ca50_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:href="exel-20211231.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f68271a5-1d2b-4a04-8d0b-556f37ccf584_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5ac773bd-29d9-4132-af7f-6c987f0c6dba_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would reduce income tax provision and effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0bd115b4-70b5-4d01-9a37-ea75ca7ff3cd_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_57072fdd-1672-403c-920f-241ea1e6aed2_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_37628897-fd46-4320-b425-7065b7ba738b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_9baf326d-94ec-4d74-9d0e-bcc39372b754_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5f4322c9-59c5-4c8c-993e-432a79d50336_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_17f5f7a3-60d4-402b-989e-0dd5246dbef2_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_51048bf6-6861-43eb-b120-9dd105e906d3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_394db9df-68fe-412d-b03f-7cc83d8bbeb2_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_label_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliatesof Optum Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliatesof Optum Specialty Pharmacy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:href="exel-20211231.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:to="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f2039eac-21dd-4edd-813a-0dbfbb3bb043_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_4630466e-259c-40f9-a18f-84244058fd37_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_d46b6e50-ba2c-4328-ac76-3aa458172a4b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_f5b3fae7-27d4-45d3-92f6-719bfd4434d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_f475e575-84b7-43c9-b08a-7f9968b42f89_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c646bfc7-d551-4676-a211-b723c0089aa8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_617f2405-3393-4583-91a5-1ef64f25145b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a844da47-d25a-4fb4-93ca-8f010fe6281d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_daac3c3e-95d4-45a1-81e4-3b2285d7a164_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_788c55de-9769-47b1-bb7c-b46e47837df4_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_b1895d88-1c6e-4858-81b6-d7df1487d128_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_efac7393-59b6-4668-b324-2c6f97b20076_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_7074e389-45c1-4370-af0a-b28c9e31c08f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_0f2c2def-5eea-482e-aaad-0844e11ccfbe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ace04fcc-f614-45f1-9bf8-29baabe8e7e1_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_858e80ab-1281-4ba2-96c9-a831c72e7f0e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_cd84957e-5a93-47b8-b29c-49d6c7405b5d_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones under collaborations agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NoncashLeaseExpense_dd6ddb24-a4a1-4b17-8f42-9507655eed7d_terseLabel_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_label_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense" xlink:href="exel-20211231.xsd#exel_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NoncashLeaseExpense" xlink:to="lab_exel_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bf75ddc5-f020-4c63-a035-b94963fc9b1b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_230e420f-c7fe-432b-bb29-c469532763e9_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_d1d6d287-d2ff-414e-8921-99341b440fc6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_62e17f00-b625-4be7-91a8-8d8d38acf59d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_dacea201-0b14-407e-a19a-19f6cc9cd943_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_c7f6f8f2-bfe9-4350-b7fa-5050acf16118_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract" xlink:href="exel-20211231.xsd#exel_OperatingLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract" xlink:to="lab_exel_OperatingLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2cfd90c5-8a11-4b09-bf0f-1b8d8ba8663e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9f7ffe9b-30e8-43b8-a612-324ad63a3a17_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_70191846-5cbc-4fcc-986c-81931761f508_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate from market value on offering date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f3463442-48c2-40b4-a63a-1f614b40bad4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_40b5b3f6-cb7e-4c7e-a68a-c7f1bc5d9876_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_38d4de1c-a0ea-42d9-ba53-eeb46c9dd895_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15daa209-c286-4bb5-b475-a00c559aac3b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_2019fb78-c170-488f-a121-1fbab8d67cec_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_ef456185-e2fa-431a-af51-a82f817bbd24_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_UpfrontPayments_eae2b884-5d6f-4348-9cbf-f5b0aa000cdf_terseLabel_en-US" xlink:label="lab_exel_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments</link:label>
    <link:label id="lab_exel_UpfrontPayments_label_en-US" xlink:label="lab_exel_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment(s)</link:label>
    <link:label id="lab_exel_UpfrontPayments_documentation_en-US" xlink:label="lab_exel_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment(s)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments" xlink:href="exel-20211231.xsd#exel_UpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontPayments" xlink:to="lab_exel_UpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5fd515f4-ef7e-4977-bc42-a3b6d660cb95_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_00001816-cda2-4542-8b3b-4afaf79700ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_d61b2f1c-90ac-4cb1-bc86-9f036926005a_terseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_bb409203-d030-4a76-88e8-2a529c8b0927_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_41ac9eda-c3af-421e-8b51-96ef78d55421_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_60bd7eac-43e5-46d7-9507-7b5026827d40_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 318,842 and 311,627 at December&#160;31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9b2ecf76-b7ce-47fe-b8d8-66d00f3781f0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_07b284cd-f263-49f5-b24c-e86b78f6bf7f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and reserves not currently deductible</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_83621008-2efc-4fef-9314-918fb3e26c54_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense weighted-average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8bd77187-e02e-4a1f-91db-ac2ca2784f36_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6736221-27d7-4285-aa7c-892cb046dc91_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_a718d534-de93-458a-a667-3523706c003a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_be465eab-09a8-4814-9bf0-8e6ae5ef79ff_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_2981db04-4e3a-4802-b627-ca0b85356916_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_fbcc96bc-8fb4-4261-a143-0a7f18b98e1d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_47843a09-9d5e-4ce7-b34e-83d11207cf83_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OperatingLeaseAssetsAbstract_bf7546d0-e534-48e1-910d-0525464856bf_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_exel_OperatingLeaseAssetsAbstract_label_en-US" xlink:label="lab_exel_OperatingLeaseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Assets [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseAssetsAbstract_documentation_en-US" xlink:label="lab_exel_OperatingLeaseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseAssetsAbstract" xlink:href="exel-20211231.xsd#exel_OperatingLeaseAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseAssetsAbstract" xlink:to="lab_exel_OperatingLeaseAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0d3bea65-f66a-4cbe-a8eb-f67b36ecadde_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_b94c22a4-f9e3-46e2-b3e3-eafdbeb3f42a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_82cf5647-0d61-4927-b42d-ffd08b33af3e_terseLabel_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_label_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory, Milestone Achievement Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_documentation_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory, Milestone Achievement Under Collaborations Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:href="exel-20211231.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:to="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_dc7d7172-6e7f-40b8-869b-1f71e6460cd8_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_766189a2-126a-4715-bcc6-f3f871dbcf07_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_cef49a93-249b-423f-a438-62d87a3dd6c0_terseLabel_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement performed for others, reimbursement for costs incurred, percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_label_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_documentation_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:href="exel-20211231.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:to="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1c9d0aa7-eba7-43db-89e2-79a7358d67eb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_e5ce485e-9573-4d35-ab09-fb4c451626c2_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a297de47-6d78-400f-980f-334fdabcaf31_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RoyaltytierDomain_5e44abba-15d6-435e-bbd1-ed0719b3fef1_terseLabel_en-US" xlink:label="lab_exel_RoyaltytierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_label_en-US" xlink:label="lab_exel_RoyaltytierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_documentation_en-US" xlink:label="lab_exel_RoyaltytierDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for royalty tier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain" xlink:href="exel-20211231.xsd#exel_RoyaltytierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltytierDomain" xlink:to="lab_exel_RoyaltytierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_0d5b4680-d733-408b-a581-6c321e74616f_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_cc1650d2-39aa-4824-aa8b-773e0b6f0d18_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues Disaggregated by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_87fbd9ca-dfa4-4d8f-b13d-a85fb836e170_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2f64e30f-e704-4441-ba4b-7583d7599f82_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_77efe4e3-09f6-4c2d-b208-bf116d06c4eb_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9c1581a4-6241-42e9-b071-bbd8a838efd3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_d1ebc11a-bf97-44a6-9db5-fa602c528982_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_2e5dd1b3-bedd-40a4-bbc0-8a97eb1cc42b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_404fe8d6-a411-49c2-bb14-f6a3e42c6401_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact of available-for-sale, unrealized holding gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_13d051d5-2161-44d4-8305-11c230ca707d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_40fe5250-7b22-48f2-bac9-942e22435307_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3befd0f9-36ba-45ed-bbfa-1518bc2ab5ae_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1b96d84f-e3f5-413c-9fc9-101b0854ad83_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_92a1b8fe-3a6e-4432-8988-3a93ea64f136_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4638c7aa-1b50-4c76-a7f8-2b95ee7ce4d4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_21d9fa70-80ee-4aef-83a3-8e3e4a66e63e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_9630c737-f0ec-4f43-be95-15b0143c393c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d5be3a9c-6b3c-4f64-b0c5-2c7525d9d9cc_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ed634fb1-f899-4f1a-b3fe-b7b700145ce0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_17418203-57c4-4934-a425-bbf0933c1973_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_79765ac8-d9cc-4739-9027-1b9960c1adb0_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_a88a5d08-6200-4ecd-a9db-1dac1cf3088d_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:href="exel-20211231.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_6fb4656f-afb0-4007-83c9-9377e820807e_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in dollars per share)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PerformanceSharesClinicalTrialResultsMember_373b90cc-ac66-4cd8-bdc4-3631aace3f83_terseLabel_en-US" xlink:label="lab_exel_PerformanceSharesClinicalTrialResultsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Clinical Trial Results</link:label>
    <link:label id="lab_exel_PerformanceSharesClinicalTrialResultsMember_label_en-US" xlink:label="lab_exel_PerformanceSharesClinicalTrialResultsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Clinical Trial Results [Member]</link:label>
    <link:label id="lab_exel_PerformanceSharesClinicalTrialResultsMember_documentation_en-US" xlink:label="lab_exel_PerformanceSharesClinicalTrialResultsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Clinical Trial Results [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesClinicalTrialResultsMember" xlink:href="exel-20211231.xsd#exel_PerformanceSharesClinicalTrialResultsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceSharesClinicalTrialResultsMember" xlink:to="lab_exel_PerformanceSharesClinicalTrialResultsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0b0d0559-7d67-4dee-b00c-c6527e2f41b1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold_81e7cc5e-c269-4cb0-aaba-4229a0cb023c_terseLabel_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial sales milestone, net sales threshold</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold_label_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Commercial Sales Milestone, Net Sales Threshold</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold_documentation_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Commercial Sales Milestone, Net Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold" xlink:href="exel-20211231.xsd#exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold" xlink:to="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_568b2625-5056-4854-9ce6-0b52de85b79c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_f115ce1c-eda3-47c8-a556-55226ebceeeb_negatedTerseLabel_en-US" xlink:label="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease right-of-use assets</link:label>
    <link:label id="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_label_en-US" xlink:label="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Lease Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:href="exel-20211231.xsd#exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:to="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_df126cd6-4b9c-47fe-a6f7-1cede7de606c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_2f224bed-f131-459f-884a-885272d790a3_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend the lease</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_fbe1e9aa-37ff-4293-9b78-d7b5825abdce_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_59f022ec-00c6-4f56-86f0-d3b0954ec63e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_12f081ca-0c97-42ca-815c-0c92916b8157_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3c31e727-aba5-4241-b70c-2a6508bc735d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_7af64fe6-d947-4b0c-b3b8-7fa22d29342b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_ceabc911-f5f0-4678-8f91-904686f5d814_terseLabel_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, maximum aggregate regulatory milestone payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:href="exel-20211231.xsd#exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_fb1e5281-403e-4772-b9c6-cf8747626533_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements And Business Development Activities</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8cd63d03-450b-4087-9b3c-a89ce447f9f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_43417dad-83bb-4b62-a4e5-7bfa102dcc74_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_90e2f297-7424-42ff-aa55-f9bd07b49353_terseLabel_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant lease improvements allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_label_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_documentation_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TenantLeaseImprovementsAllowance" xlink:href="exel-20211231.xsd#exel_TenantLeaseImprovementsAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TenantLeaseImprovementsAllowance" xlink:to="lab_exel_TenantLeaseImprovementsAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_584e36ce-0d0f-404c-8016-5cd12c89597b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone_7cf13a02-d72a-4217-a0ad-616628f24233_terseLabel_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone_label_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Regulatory Milestone</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone_documentation_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Regulatory Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestone" xlink:href="exel-20211231.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestone" xlink:to="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d561adfa-b7ef-41fa-ac36-4df71b68b931_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_44141cce-497e-4863-ae3e-4a5b5b800edc_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_b9302896-7e8c-44db-a2f8-c27c0cd3a3b6_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_cade17a5-9d57-492b-8b41-6e29b5912b8c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7c0690c-0b6c-4dbd-882f-11f5b902659f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0de37019-67ae-4646-ab38-363d52d58877_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e9176c54-2a77-4b70-a1eb-f365d24f99d9_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_fdf12f9a-889b-469f-86e3-726a01741238_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AuditInformationAbstract_label_en-US" xlink:label="lab_exel_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_exel_AuditInformationAbstract_documentation_en-US" xlink:label="lab_exel_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AuditInformationAbstract" xlink:href="exel-20211231.xsd#exel_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AuditInformationAbstract" xlink:to="lab_exel_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CometriqMember_ad81d246-2192-43b3-b2fa-e1e2f793b7e2_terseLabel_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_label_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_documentation_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember" xlink:href="exel-20211231.xsd#exel_CometriqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember" xlink:to="lab_exel_CometriqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_453aa112-99a0-41b1-91d0-5017fb678191_terseLabel_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount expected to be earned</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_label_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_documentation_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:href="exel-20211231.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:to="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_8794d28f-b677-4cf6-a424-3a91d784959d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_a8ec451d-1e81-4c17-87fd-27899ab6a8c7_negatedLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_99b7dab4-8610-4a62-bafc-26338fc2cffe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c97e434c-ad33-4b8d-9ae3-1a1d2e64bdee_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6f45a34e-79dd-44d4-89cc-bc5ac53f6260_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_402d87ca-a752-4baf-9034-b0fd5478b3a3_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:href="exel-20211231.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_671b7585-b5c6-470c-af9f-5af445768e96_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contract outstanding, amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_10bf5672-0135-4cb5-81b5-abe14dabd3c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b8d8c41b-735e-48af-a52e-7e2ce0a230c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RoyaltyTier_828b8ac0-5fca-48f9-a682-c46e22c2dc01_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTier" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_label_en-US" xlink:label="lab_exel_RoyaltyTier" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_documentation_en-US" xlink:label="lab_exel_RoyaltyTier" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTier" xlink:href="exel-20211231.xsd#exel_RoyaltyTier"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTier" xlink:to="lab_exel_RoyaltyTier" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsFinalPayment_641fec4c-e27c-4914-9717-53d967e0ac55_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsFinalPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, final payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsFinalPayment_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsFinalPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Final Payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsFinalPayment_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsFinalPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Final Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsFinalPayment" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementRightsAndObligationsFinalPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsFinalPayment" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsFinalPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c8a91f01-7135-498d-9bf6-a805559fe573_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_c0b1d2a2-babf-4721-afda-bfa53488d0db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_dea15e63-1053-43d9-8832-ec7a9179e171_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_89b323aa-46ab-4dc8-9a47-c81aa25c2ddf_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_395ac73b-652a-4c01-90ea-3ef996344ecb_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_2d8f55d5-a023-4084-924a-e2a362b53550_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_fb327dd8-efd8-417b-a2ee-f6e5d522aaf4_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_ba4e3d45-b99c-4e20-a87c-5340be7641ed_terseLabel_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries with FDA approval, excluding the U.S.</link:label>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_label_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Countries With Drug Approval, Excluding The U.S.</link:label>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_documentation_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Countries With Drug Approval, Excluding The U.S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:href="exel-20211231.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:to="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_ee91f073-4617-49da-af4b-94fc6d284d96_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_fca7e052-9c8b-47a2-a2aa-a105deef9b19_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0420a7e3-c1d1-40ca-bbca-460fb53c6794_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b8b0ab23-81d5-4979-9041-16905a622f76_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductGrossMember_d7362862-6656-4746-b303-f42280ed53f4_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_label_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_documentation_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember" xlink:href="exel-20211231.xsd#exel_ProductGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember" xlink:to="lab_exel_ProductGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c626294e-68b8-470c-b033-225fa695d8d8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_67185df3-4d89-4340-b3af-c6e6419722da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_A2018PerformanceStockUnitsMember_673f7376-513e-4f47-8800-79306d14a99d_terseLabel_en-US" xlink:label="lab_exel_A2018PerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Performance Stock Units</link:label>
    <link:label id="lab_exel_A2018PerformanceStockUnitsMember_label_en-US" xlink:label="lab_exel_A2018PerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Performance Stock Units [Member]</link:label>
    <link:label id="lab_exel_A2018PerformanceStockUnitsMember_documentation_en-US" xlink:label="lab_exel_A2018PerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Performance Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_A2018PerformanceStockUnitsMember" xlink:href="exel-20211231.xsd#exel_A2018PerformanceStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_A2018PerformanceStockUnitsMember" xlink:to="lab_exel_A2018PerformanceStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_87893211-d11c-4650-8778-3b760b0e1828_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6d50d7f5-9772-4858-8c16-47da87f3a61f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b77e4569-1da7-4d9c-86e9-c94071c1beff_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2373db9e-575b-40a5-b585-55db3b36618e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_d5f5674f-01e5-49dd-88c4-a252e08cc13b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_dce620ae-4f80-4036-b5db-7670066893bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_30a7f666-7696-4841-a9f9-566c09e74bc9_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_f6eda9ed-a3b6-4a92-b974-b3c9b0e25e7a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bb91d163-c681-4eb4-8a5a-6ac563d699fd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_50a1901c-1eab-4b5c-beda-a9c9bb38ea8c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_84481902-b207-41b7-a73e-c59c25c94aa3_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable at end of the year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_db0af654-334c-491d-ae23-df5dddfda6d7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_25492dde-6250-4b16-9a66-5c4540166012_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment commencement period</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_10eee60f-13da-4499-8b07-cf1effcab96b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2f7c22a3-2440-4c97-a3d6-c73b53c9636a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_536bae2e-a9c0-49ba-97df-f407108d4e3c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5a2ca8be-0585-432e-965d-6e59e4906fd4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_689735ae-19ec-439e-8955-105d6ac6a2a2_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_7b2c8fff-f37f-4caa-9658-8babb4ab6ddf_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_InitialMember_67074b18-6628-4f5f-9b6c-4cb97820e6e8_terseLabel_en-US" xlink:label="lab_exel_InitialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial</link:label>
    <link:label id="lab_exel_InitialMember_label_en-US" xlink:label="lab_exel_InitialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial [Member]</link:label>
    <link:label id="lab_exel_InitialMember_documentation_en-US" xlink:label="lab_exel_InitialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InitialMember" xlink:href="exel-20211231.xsd#exel_InitialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InitialMember" xlink:to="lab_exel_InitialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9c22c49f-ef7c-4fa7-bc2e-08ccf5fa830e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_de85b22b-1a67-4fde-b331-c53aef522bf4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_6f5fbd95-ce7b-4bb1-841c-a5691e8be924_terseLabel_en-US" xlink:label="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward amount with expiration dates</link:label>
    <link:label id="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_label_en-US" xlink:label="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount With Expiration Period</link:label>
    <link:label id="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_documentation_en-US" xlink:label="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount With Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:href="exel-20211231.xsd#exel_TaxCreditCarryforwardAmountWithExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:to="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_7a55f4d9-1d2b-407d-81e9-f991dcab3da9_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CotellicMember_5d57b55f-464b-4b48-bd48-c89dbda85262_terseLabel_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic</link:label>
    <link:label id="lab_exel_CotellicMember_label_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_documentation_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember" xlink:href="exel-20211231.xsd#exel_CotellicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember" xlink:to="lab_exel_CotellicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_da29eb78-9524-47ac-a24e-748c2a17beee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_5cc9b5aa-19ad-4830-b15a-3f61efeb9200_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Company's common stock on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_eb5db661-7128-4334-b3fc-a665904ea9bc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_4ea9a71f-c0cd-4ed9-acb6-98f394fe23b4_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_4d0e3a51-8b0a-4cc6-bdd2-529f09bc443e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build-to-suit lease period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_683091d6-99ea-4718-af8b-7c1bf4237f26_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_da4b827e-e40d-42c0-9a42-458ad6d73caf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_12d74148-1e7a-4e47-a1ee-f94f2a94834b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_15774c8b-b23d-4143-9154-b6a243fa6d62_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_ab24b904-4771-476c-ae7b-8632f50d7bd8_terseLabel_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded prescription drug fee</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_label_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_documentation_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:href="exel-20211231.xsd#exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:to="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fd1387d4-1c8d-4e70-839e-631943951ffe_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_e12c89e1-913d-49ad-9a0c-98c1988bfe56_terseLabel_en-US" xlink:label="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With Gama Mabs Pharma S A</link:label>
    <link:label id="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_label_en-US" xlink:label="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With Gama Mabs Pharma S A [Member]</link:label>
    <link:label id="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_documentation_en-US" xlink:label="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With Gama Mabs Pharma S A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:href="exel-20211231.xsd#exel_CollaborativeAgreementWithGamaMabsPharmaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:to="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_ac77afa1-68fc-417d-a2ec-9b1de5a68b7a_verboseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold is related to product</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_7f90481e-4834-43f5-8794-9efc1fa67a24_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1f5603b1-24a6-4b3c-964d-8d874164de78_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fb19381c-ec61-44cc-af5f-d17067a45cac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2d134485-7bf9-4230-a502-453acf76e900_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_48bb22ea-5c93-4626-8290-6695195c103f_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue recognized, including revenue from deferred revenue beginning balance</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="exel-20211231.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_6c947336-d7c8-455e-9639-c428e7580013_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f57fe071-7143-4c8d-9ac2-a62b01e60cf0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_17e18cb0-599b-422b-8172-83470df6e45d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f962815a-3ac4-4ad2-965d-3dc3eb24aa66_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_c7e83f6c-7513-4389-be32-4410c24982f5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_3c6387b8-c5a3-4698-bb57-399ffcd4f6e6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of forward contract outstanding</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_a78ae09f-a835-4ddc-a36b-742e12c396a9_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_3faf24cb-54c5-4814-9e54-214961b4d75c_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:href="exel-20211231.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AchievedMember_fc72a8a1-609c-4305-9f39-e44aecc59c04_terseLabel_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved</link:label>
    <link:label id="lab_exel_AchievedMember_label_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved [Member]</link:label>
    <link:label id="lab_exel_AchievedMember_documentation_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember" xlink:href="exel-20211231.xsd#exel_AchievedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AchievedMember" xlink:to="lab_exel_AchievedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_6d738419-5e12-4a05-a418-02dc5b2b014e_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:href="exel-20211231.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_FinalTierMember_0891e592-0d62-4f1e-9c3d-2dbca787d69c_terseLabel_en-US" xlink:label="lab_exel_FinalTierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final tier</link:label>
    <link:label id="lab_exel_FinalTierMember_label_en-US" xlink:label="lab_exel_FinalTierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Tier [Member]</link:label>
    <link:label id="lab_exel_FinalTierMember_documentation_en-US" xlink:label="lab_exel_FinalTierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Tier[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember" xlink:href="exel-20211231.xsd#exel_FinalTierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinalTierMember" xlink:to="lab_exel_FinalTierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_cce02e5f-f36a-41ce-8089-f60352c54509_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_1e830ed9-8823-436b-9a58-dbb4cad0e5c8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from option exercises and purchases under the ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_28976f53-df85-4f46-9bb3-3337c804cc33_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_f119f88f-e38d-440f-96b2-ad8da0be6826_negatedLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_0ce32d3f-cf9a-4bc0-9797-5afbdb0e9831_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:href="exel-20211231.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_47081b2d-b477-452e-82b3-0edbda669366_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_e039c37a-6cbf-4303-b8eb-97a5b1b5fea1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contract maturity (in months)</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_bbacecf4-26ac-4fd2-9549-96d7d99b773a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_426554c1-d3c3-4ea2-bc83-b1f32c2ddeb9_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9daf3951-714f-465f-8808-712d68fcd87d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_fc9763ee-52d0-475e-9956-5ce52f081fb9_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currently estimated amount</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d6af1202-8231-47c7-81cf-5459932f6d36_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ca3e4d04-7304-4dc1-80d0-f14b4af762db_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fcb313fa-d5a5-41b5-9e1d-b2fa1bb95df6_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_f229993e-6e1a-4d76-9435-26169ef1ee8c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7980dad6-83fa-45be-98c5-55975ad762c3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_48e551f2-c66c-46c6-a723-95b429c828bd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c32106d9-d70e-4491-b350-25707cd6d9f5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1042592f-f424-412a-9f6c-c3a7564ef872_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_4d6a1a82-6caf-486d-9a44-626d030ef015_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract other long-term assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_190cb2df-9ce1-4c16-b80d-2054967676eb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_dfa906ce-2a10-4d6b-9a09-3824baf4c150_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_93e83240-7645-45e0-bb98-016fc6485ba3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d68b1c3b-5071-4234-b552-c3ecc41fd9ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e8edca8d-c1c9-4faf-9c91-fa8435626571_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_2998884c-29ef-4b93-9ffe-777980097dda_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4f56bcc9-0c5a-4c19-95ee-919f39bc560c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c06109d6-d821-4671-8f41-a0681a4bb8ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_9f848dbe-e34a-44d9-b8d0-88e740723ca1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_297e54fe-6587-4636-8d76-8b50cec71fce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_dc014f0f-40e8-417e-b02b-e6ca2972be71_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f4889e76-d080-4eea-a897-d199000fe0ee_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c4574868-3d1d-41a9-bfee-923edf6043b4_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance increase (decrease)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_22009140-a021-40ec-8208-02d20df8ee27_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_4726c895-c0fb-4844-9bfe-71d899e695fe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_8747078d-4e94-4705-8e2a-5f068caf3ac3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_ebefbee8-467b-40b8-a914-c859476f8680_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_bfef4e30-eac0-43aa-b41d-fb34471c2bbd_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be earned (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8949ab37-6556-4395-902b-765ee4f98d56_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_f4d24851-39e3-4f2d-bb99-6f41d19ed2d4_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_d9e2648f-02e2-40f7-b054-44cbcfaca8a6_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c3e5ff40-71de-42b9-b114-12418590999e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b4f8dca5-d1ad-4f4c-86f7-d9de27afe3ab_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_178ccf61-5133-488d-a7b6-bdc5cba81455_terseLabel_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales volume period</link:label>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_label_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Specific Sales Volume, Threshold</link:label>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_documentation_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Specific Sales Volume, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold" xlink:href="exel-20211231.xsd#exel_PeriodOfSpecificSalesVolumeThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PeriodOfSpecificSalesVolumeThreshold" xlink:to="lab_exel_PeriodOfSpecificSalesVolumeThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_db815f93-29fc-463f-a4b5-1c7efb6f9cc1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c0cc09ab-c9a0-47ec-925b-67aa97cbff7f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d1f2ad0b-1f49-448d-ae1b-f4812c68b9b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_6ada3091-c25c-4599-a092-b62a5fbba8ce_terseLabel_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_label_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_documentation_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:href="exel-20211231.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:to="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_48d0bddf-66c7-4c0e-b1f5-b88b7d84ec4f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_6c594d64-f5cf-4f3e-8654-4d5af01ac438_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LaboratoryEquipmentMember_71bd0f26-e982-4464-8be9-f1e61be349de_terseLabel_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LaboratoryEquipmentMember" xlink:href="exel-20211231.xsd#exel_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LaboratoryEquipmentMember" xlink:to="lab_exel_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_245d1cd8-4111-4d7c-8319-63021d0f7f9d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_be78e28b-d5f6-490b-9039-45b4820f143f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_696ee59f-4321-4791-8fbf-67e1d191e6d6_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb2bfe4b-2893-4cc9-830c-e9b5571321b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160; Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_0e74e046-b6d2-436f-b693-42d87a9733e0_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price allocated to our performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_472a0feb-45be-4d3b-823e-b1b3ebfeb44d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_3cf48485-2596-4983-9c53-755dc5e04ffe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1950a7f8-096c-48f2-a47d-2319f209ef13_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_be79a357-5dd0-4759-b64a-6129c0d65f49_terseLabel_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, maximum aggregate development milestone payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_label_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Development Milestone Payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:href="exel-20211231.xsd#exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:to="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_59f08cef-38c8-43b4-a441-6a504ddda46d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7e71873b-561e-48a0-8f6d-4f75194594b2_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d1c1e353-ddbf-42b2-94a2-5c3369897773_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_91f3698b-4506-4e43-8784-d0b44f0f6079_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3ee81edb-2c2a-489c-b68c-856045039f75_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6b8d90a5-5404-41dd-bf7d-4c0d4b3f2314_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3fd82c8e-c12f-4878-bc23-048b852d6e86_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_144a427b-169a-4fda-abfe-d3364d962a7d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6b089e46-b79d-42b7-8c75-c34b3134dd47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_540810cb-524f-407b-abfb-060dd8e718da_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_43578127-7af2-4ded-8d1b-debdf67af2e7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_fa3e1b6e-e5e3-49a9-98d9-760021ed82cf_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_2fa0b886-d5d3-4e0f-8165-169e290bb727_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_fefbd847-9e72-444e-b723-aa5e04ba15d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_0f35ab56-b957-402a-bc70-c820e110b2cb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on maturity of forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1c4ac0e8-8b41-49f3-a95c-745d4dd28f45_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_849d5ae3-7e6a-425d-857f-479aa31071eb_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket" xlink:href="exel-20211231.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket" xlink:to="lab_exel_NumberofProductsinCommercialMarket" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_c5ea64eb-121b-442a-bc85-a6b3dd49806f_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_25adaee2-ea3b-4607-b6c4-d099b946aec3_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3071b371-d568-403f-a55c-f5fe32b06aa6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2490556f-b279-4f76-bbcf-e50453b74203_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_05546e8e-b6a0-4032-a0a1-12c324810ef6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementAchievedMilestoneAmount_716ce790-e6b5-488c-abf2-ecc8c67ec342_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved milestone amount</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievedMilestoneAmount_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Achieved Milestone Amount</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievedMilestoneAmount_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Achieved Milestone Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementAchievedMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:to="lab_exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_ac9676e5-49ec-4369-8d5b-68496671de23_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d3487a5a-a9cf-43db-b822-06741c8937e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d9c4e519-6c20-44b2-9676-5f9d763c5685_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_956cbfc5-6928-43b0-b086-c3364d9d3bca_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NotProbableMember_4df97ba7-4762-4a9f-86c7-89df3d0d78eb_terseLabel_en-US" xlink:label="lab_exel_NotProbableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Probable</link:label>
    <link:label id="lab_exel_NotProbableMember_label_en-US" xlink:label="lab_exel_NotProbableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Probable [Member]</link:label>
    <link:label id="lab_exel_NotProbableMember_documentation_en-US" xlink:label="lab_exel_NotProbableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Probable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NotProbableMember" xlink:href="exel-20211231.xsd#exel_NotProbableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NotProbableMember" xlink:to="lab_exel_NotProbableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f15f2e1c-cb93-4568-a17a-f72ccf483e7f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_f5d67461-8175-4aea-a36c-e76edf6dc0c5_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:href="exel-20211231.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_8d228674-11ce-4352-9d77-7e70f0c69355_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b3638133-97a0-4f4b-831d-24c5144e6f4b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_d1765c84-42c3-4891-927a-e15576577586_terseLabel_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent discount for prompt payment</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_label_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_documentation_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:href="exel-20211231.xsd#exel_SalesRevenuePercentDiscountForPromptPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:to="lab_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_606296f1-8527-4ff0-990c-a93498deb50c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_9f411151-de13-473c-97ec-a4083e75f54d_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a60a20d4-2a97-40a5-903b-4ac324734156_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CabometyxMember_5a6c1ad1-6322-4dc8-81bb-7b11b3656b19_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_label_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_documentation_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember" xlink:href="exel-20211231.xsd#exel_CabometyxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember" xlink:to="lab_exel_CabometyxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_60e3bc0c-0697-431a-ba18-87b7ebcd59ca_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of All RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_e99ae913-6313-48ad-adb1-7f58afea0d90_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_8b4540bd-ebf3-43da-8d19-8707abd12e4f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_78b940e7-d078-4a3f-9db2-37d234b62813_terseLabel_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial sales milestone</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_label_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Commercial Sales Milestone</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_documentation_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Commercial Sales Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone" xlink:href="exel-20211231.xsd#exel_RevenueFromContractWithCustomerCommercialSalesMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone" xlink:to="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_8581e693-ea8d-4e1b-891c-2fd484b52a73_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after all other awards (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_e638a01b-ff4f-4981-b949-b70097a05f3c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_0cb235d5-0570-4ecd-aa26-acebdd8bd94f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_fcd20fbb-02c2-4812-8fe3-8ccdee98afe9_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:to="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MilestonePaymentsEarned_d9e11ac6-b4cf-4b66-8ee9-b5c61ab58954_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_label_en-US" xlink:label="lab_exel_MilestonePaymentsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned" xlink:href="exel-20211231.xsd#exel_MilestonePaymentsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsEarned" xlink:to="lab_exel_MilestonePaymentsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34cc9cef-d889-439b-8011-5eb0e6f4df1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_HeadquartersLeaseApril2019AmendmentMember_8030db57-74c5-40ab-a1db-23d0ce79ed39_terseLabel_en-US" xlink:label="lab_exel_HeadquartersLeaseApril2019AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease, April 2019 Amendment</link:label>
    <link:label id="lab_exel_HeadquartersLeaseApril2019AmendmentMember_label_en-US" xlink:label="lab_exel_HeadquartersLeaseApril2019AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease, April 2019 Amendment [Member]</link:label>
    <link:label id="lab_exel_HeadquartersLeaseApril2019AmendmentMember_documentation_en-US" xlink:label="lab_exel_HeadquartersLeaseApril2019AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease, April 2019 Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseApril2019AmendmentMember" xlink:href="exel-20211231.xsd#exel_HeadquartersLeaseApril2019AmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_HeadquartersLeaseApril2019AmendmentMember" xlink:to="lab_exel_HeadquartersLeaseApril2019AmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_c7f1bf25-f905-416a-94a6-14302179f79e_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MilestonePaymentsEarnedToDate_8a158bce-9c69-4f92-a520-14ba77369d30_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsEarnedToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments earned to date</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarnedToDate_label_en-US" xlink:label="lab_exel_MilestonePaymentsEarnedToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned To Date</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarnedToDate_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsEarnedToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned To Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate" xlink:href="exel-20211231.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsEarnedToDate" xlink:to="lab_exel_MilestonePaymentsEarnedToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9eda35d2-617f-43fa-867d-7337bf2e7551_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3ac33282-064b-4940-a2f7-f94705f3f892_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_00f2a7b9-e1ab-4929-a5be-517112d7bd31_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_a98fc50b-e7b1-448c-a0c5-4afff5564006_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d21dae08-9518-4b13-8e4f-c531b4b47273_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_062cf9a8-6d86-4e9f-8104-68d26b9564f9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_StatusDomain_84899327-95f4-4c48-b0db-e7be4bdf2310_terseLabel_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_label_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_documentation_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain" xlink:href="exel-20211231.xsd#exel_StatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusDomain" xlink:to="lab_exel_StatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_06122435-e7a9-47a3-9eed-882e930640b1_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_398b3236-4e16-45bc-a272-7e9ae5180c5c_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_9a0e5704-1ca8-4738-b810-714bb35b110d_terseLabel_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember" xlink:href="exel-20211231.xsd#exel_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ComputerEquipmentAndSoftwareMember" xlink:to="lab_exel_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_c3732ad6-6b70-4b33-ba79-3585abb94fe6_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:href="exel-20211231.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_2ccfe6d3-b012-4e2a-a0cc-92f1bb7a08b8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_d947f818-7404-4834-8b67-1f49f81a0e95_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_00ba2867-20ac-4fa3-ba15-ac9d90840739_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:href="exel-20211231.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e4c9c60f-a574-432a-a562-4f26015f64f4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7c0df91c-1f9d-4b4f-ba81-92f56b3c3236_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_28928c0d-2a21-4e33-bf9e-b780fec8288e_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4264f3b0-5c93-4b9b-92d0-33df2151422d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_338756d2-329d-4601-9130-aa5f198ca29e_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4d85ebe9-3120-40b4-90e0-3ac97ddfba8e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_cc004058-5279-4a9c-b7cd-ce434eec5139_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_353c25ca-d97a-4782-9606-44ad11979035_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_bff1b7d0-c61d-4374-b778-206f7b6de020_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_3d741a8e-5a5d-49c7-931f-ccad47eb6669_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f9d1c4d4-c2d6-41c5-8890-1b7dc2180ffb_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_19379ab8-0f40-4ddf-9287-b1b62a26d2eb_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_e185d24e-f13a-40b1-96a0-404d4bf1af18_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Investment Impairment</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_5c1291e4-3b89-484f-b09a-a69fba902714_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to terminate lease (after period)</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:to="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_4baeb927-d480-47b2-a826-9636d526334f_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts for Prompt Payment and Other</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:href="exel-20211231.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_52bed6dc-8a9d-4276-bd6a-9af15519a2fd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_65e62b8a-3e1a-48bb-8f2a-f53547737d4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160; Average Remaining Contractual&#160; Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f0f7fb51-4bda-4056-a374-5fdb841cccae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_60e5ff8b-9bda-48d1-9b9d-432c0194ec35_terseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:href="exel-20211231.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:to="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_9991ac19-0e0d-4507-b08f-aa8761729a58_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:href="exel-20211231.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6b7a70d5-8eff-47b8-97da-95b8018df4a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0734bad2-c83f-4f86-8f01-50bcc779a7ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_e1f6a1dc-8bf7-4a0a-80d2-2197c60a3a7c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b24fae9e-6712-4fd0-a959-61727bfb3e0f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_416a4423-c210-4a0f-84f4-7a4a23a41640_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_5a361a71-fd3b-41ff-8a9b-9911c7f12aa8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9f73ecfd-bfdc-459d-9f9c-6d9d00d24a4f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_9d5060be-2a1e-411b-b584-e1fdb475d072_terseLabel_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="exel-20211231.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_264ce832-b1c0-4f1b-ba13-c7fcccfa76ed_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_6e109ed2-59a8-417e-9bc2-856d5d3943c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f2634bfd-5094-4a73-8e58-59a48ba500ec_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_43f007b5-e7f5-4ea2-ba78-2aa0959c223c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d96d2343-c3cb-43a4-822d-8d9b1cf4752a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_a500fa5d-a403-4a3d-95ea-f4ea558565e6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_b9e18292-db41-413b-81ae-f0a8cc9e696b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6549bbf6-61ad-4a12-bc55-1fc070bbdc81_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_dae86dde-2017-41e6-b266-cc3a5d01b5e7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred in asset acquisition</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_e598cb9e-81b3-4786-9b57-3d466451a0b7_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_25109588-8d95-4390-a0cd-d923ffcf5646_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_91618b16-32a7-4a59-8b25-cf439947f448_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_c4174aa0-5c60-4999-8fe8-3c96a2fa1598_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_40fd7ad7-613e-463c-a1eb-478b83fab462_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b3a07958-259d-4c7b-bf9e-ab5923eeb15b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_cdf31d1e-c0d2-4f08-a267-803691015f1b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_e62c19e5-f3c8-4adf-8b62-0e9659608d84_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e18bfe2-cd4b-4775-b18d-aa021be35070_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ba48a981-3679-418e-af27-e0a7a8635563_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9a0a6956-3a53-4ada-9612-0f505b04ccc4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_7121c05d-cb7d-479a-9f92-be2ca26dd7ec_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7fe60b88-7970-47eb-b37a-08a287c583f9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c2c16635-9ad2-4730-b6fd-59797ac586fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_899dc4f4-ed89-4f8b-b3a2-5307de401fc2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_598266b3-0368-47d9-ab7f-b2c407de642a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in share reserve under 2017 plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_cf91c2b8-faae-4036-b48c-f6703ecd5fc6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_05b72836-0f6c-446b-8d51-358929445744_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f8632c09-fbff-4671-83fc-8be68a1abd81_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2ef9f3de-2681-4066-92e3-3f3ca001f8a3_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a8698744-9d0b-4e38-97bb-4912767271e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_db341484-6e0d-4047-bc8a-2096fc685c6f_terseLabel_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2020</link:label>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_label_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2020 [Member]</link:label>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_documentation_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:href="exel-20211231.xsd#exel_PerformanceSharesAchievedBeforeDecember312020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:to="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_83d8992d-8acf-4220-a40c-7fc5a024f0b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_f2b7c626-b4b4-45dd-857a-eed744c7619e_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_97638ad1-5240-4e15-8d6b-d841d9625217_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9f545a4d-2445-4e01-9df2-bce3986ac5a0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_fe978ff0-2e04-4fa5-9e06-3646ecb27450_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_35d5b93c-7f11-471f-8721-6988bcad509f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_fe7a6d41-6055-4eee-8cc4-c21f8117cc0b_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_95303a4f-102a-4f61-a65a-d6618da00599_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_6d3b338c-6812-4565-b075-894f4bd9ffef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_ac1384b7-c2fd-47cb-808a-d357615eda11_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential to vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:href="exel-20211231.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:to="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_c4c796b0-c083-447a-80af-86c3f5c3b592_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_StatusAxis_e5c253d6-5ce8-4d3d-866a-06269bb3680f_terseLabel_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_label_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_documentation_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis" xlink:href="exel-20211231.xsd#exel_StatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusAxis" xlink:to="lab_exel_StatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_3ee1ce19-097f-4891-ada5-dd36c20e6995_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_7364aff2-8bdb-4e8b-8d06-8aef39faf6f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_52bb03a8-16c7-4c01-a92a-93c0ec76e03a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at beginning of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_182022a9-c4cb-4bce-bd5b-2b1e100e55e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at ending of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_ed7e568c-0aec-4de1-acf3-a6713187d3bf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c1c08638-0d9f-4128-b312-ae6a236f42b3_negatedTotalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_3d23f122-c1d4-4b02-bf01-9e4a6feacdee_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_431fa2e3-4119-43c5-9c82-b77351987658_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a65d28a4-63e0-4445-adf2-990e17d1f6c5_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b4c20804-7aeb-4f23-b6d8-0594a1595e9f_netLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member_7b663db0-f8ce-49a4-b9f8-2fff0e577f57_terseLabel_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2021</link:label>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member_label_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2021 [Member]</link:label>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member_documentation_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312021Member" xlink:href="exel-20211231.xsd#exel_PerformanceSharesAchievedBeforeDecember312021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceSharesAchievedBeforeDecember312021Member" xlink:to="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cc9bc43d-7d7c-4e55-ac03-25e8818b8b61_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, exercisable at end of the year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_1131cf63-3966-4435-9836-fbf4d1353c13_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_39d02ad5-f673-4808-ba96-9963461cfa90_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_e5c284ef-02b2-432b-b469-afdbf8062c69_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99b6237f-8802-4f15-8399-e959b6d4ae03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160; Average Grant&#160;Date Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_3f6b7847-1948-459f-bd2b-40f961f63796_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid_e4b41c9b-8a7a-4b4f-b23e-157891fb5a68_terseLabel_en-US" xlink:label="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred for unsettled investment purchases</link:label>
    <link:label id="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid_label_en-US" xlink:label="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Purchases Incurred But Not Yet Paid</link:label>
    <link:label id="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Purchases Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:href="exel-20211231.xsd#exel_InvestmentsPurchasesIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:to="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_888dfed4-455b-4f60-9c7c-4b93ac578170_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_304cb7c9-bd9e-4c32-ae1d-7ffb6ff751f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_94d91155-fe9d-49b1-9bba-9f316c5389ac_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_9b7971dd-8018-4218-81f4-41c3ed7a066f_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of excess costs</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:to="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_38b268df-4c5b-4a2e-999b-957778820437_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_01904f40-95d0-4d9a-a6bc-c75a64aa8f5c_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_a9efdeff-84a6-4f51-ba7a-a1f9ee39cc7a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_99d51091-34a5-4db5-aa15-8855cb89fb58_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_b598ab4d-7473-4347-8b73-3383205378b2_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration Risks</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_47c1f4b8-70a4-45e6-8f10-3cbcf2761731_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_433514c9-4046-4b6e-8ea9-ceca56c05287_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b3007bb3-bbe5-4a53-a5db-dceb3f256f7d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_DeferredTaxAssetsLeaseLiabilities_a6fce47c-7a4e-4f34-823b-df4cfded1a29_terseLabel_en-US" xlink:label="lab_exel_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_exel_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_exel_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxAssetsLeaseLiabilities" xlink:href="exel-20211231.xsd#exel_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_exel_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_03d6ec8e-59ba-43e6-a0d8-794d975d9d54_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3eeaf957-da1f-4758-babf-7b61c5ee10fc_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_014c9029-6e15-4e77-bcd0-dd6df9bc1c05_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_471a429b-4180-4b73-b033-42a3954f5359_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_73c07773-3b59-4141-81db-c508762d4adf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_1d4242ab-3755-4b12-88d2-ba244cfa7dc9_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_89b5f5ca-9dee-460e-a045-b463f106fe3b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_36d60cb4-60f9-4471-9a6a-7eb84333f417_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_001f0fce-2f65-4970-9e3a-941b8e8b3eba_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_393b9afd-79d9-40d5-9477-b6ebeb4abc76_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_edb8df10-02c0-4546-b735-714bf33b2e9c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_b83a62dc-8cf4-4352-9867-543a11114a45_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_111691b7-ae0e-4827-89a7-1477c00d3515_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of All Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseArrangementsAxis_02413abd-84fc-4a13-8389-f56e05e64853_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_label_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis" xlink:href="exel-20211231.xsd#exel_LeaseArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsAxis" xlink:to="lab_exel_LeaseArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_71e814dc-c07e-496a-be1c-266feb997bfe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions based on the lapse of the applicable statutes of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_224640ba-7f4d-4d58-a1a8-dbea6c15cad3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5b350eb0-03a6-4118-83bc-f880eec57049_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_23a8cc45-06a9-4239-aaa4-014333252de9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_711fc6a0-b3ec-4602-a287-4ee5d75ff53d_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccountsReceivableForUnsettledInvestmentSales_038c8a95-150d-446b-b3f1-7e170947074a_terseLabel_en-US" xlink:label="lab_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable for unsettled investment sales</link:label>
    <link:label id="lab_exel_AccountsReceivableForUnsettledInvestmentSales_label_en-US" xlink:label="lab_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable For Unsettled Investment Sales</link:label>
    <link:label id="lab_exel_AccountsReceivableForUnsettledInvestmentSales_documentation_en-US" xlink:label="lab_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable For Unsettled Investment Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:href="exel-20211231.xsd#exel_AccountsReceivableForUnsettledInvestmentSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:to="lab_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_86a90bb2-5ba6-4230-9f9f-2a3ef279e7fd_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_81797d16-159e-4f62-8d95-a45e2097be82_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_cc18fbc7-bd30-442b-95ea-f69abf857f7c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53cb95c4-6497-4e7f-801c-4e7063f4bddb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45f8ffb1-130d-4d02-be70-362d66f8bc99_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RoyaltyTierAxis_289af71f-0d53-4032-b435-defe3e83961a_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltyTierAxis_label_en-US" xlink:label="lab_exel_RoyaltyTierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltyTierAxis_documentation_en-US" xlink:label="lab_exel_RoyaltyTierAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">royalty tier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis" xlink:href="exel-20211231.xsd#exel_RoyaltyTierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTierAxis" xlink:to="lab_exel_RoyaltyTierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9aa14d1f-c2ef-4748-acce-beac26ba81b5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9cf9e8f0-0ade-4e00-a422-a3d1fdbb9a0d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7ae94d44-8335-4946-a047-cf10566a9297_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b3795222-5dd7-47a8-a5c1-239bedc9dfe6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_a9762a7b-2c76-4e10-bd77-f280cea487a4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_1f44e182-16fe-4547-9bc7-13c64400f82b_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c1fc1ff6-83b0-459d-9b0c-07cee06f94eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_23c32593-2b87-4764-b4ad-ea87741f54a9_terseLabel_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale" xlink:href="exel-20211231.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PercentOfRoyaltyOnNetSale" xlink:to="lab_exel_PercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_339fa4f3-211d-456e-9d32-817dd1f1af25_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5d4cf70b-8088-4c70-9d04-801a98bb817f_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_f0c3a219-9175-4455-9b31-e6f81f2482ac_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_93a94f5f-4b0e-43ec-8461-6250a802f092_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_e58f1474-2098-4217-a581-fc5133676c77_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:href="exel-20211231.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:to="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_40a895c4-2845-44e6-93ca-431bbbf007f3_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_0729f3c0-38e0-46c9-90cc-0bfa0dff3a1d_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo</link:label>
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_label_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:to="lab_exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_HeadquartersLease2021AmendmentMember_a88954a9-dae7-4929-9219-f468e5953acf_terseLabel_en-US" xlink:label="lab_exel_HeadquartersLease2021AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease, 2021 Amendment</link:label>
    <link:label id="lab_exel_HeadquartersLease2021AmendmentMember_label_en-US" xlink:label="lab_exel_HeadquartersLease2021AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease, 2021 Amendment [Member]</link:label>
    <link:label id="lab_exel_HeadquartersLease2021AmendmentMember_documentation_en-US" xlink:label="lab_exel_HeadquartersLease2021AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease, 2021 Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLease2021AmendmentMember" xlink:href="exel-20211231.xsd#exel_HeadquartersLease2021AmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_HeadquartersLease2021AmendmentMember" xlink:to="lab_exel_HeadquartersLease2021AmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_d6eb82c2-5ffd-4c3d-9e38-8c4bce2575cc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2eef85f1-361c-4310-98e7-586334ec8c66_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_0a26a31e-4db2-4c92-8531-c2e9c26e4024_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8448662d-7f4f-4ef8-9f34-8a2b1c6e63d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_c804b699-c782-4ea7-b2d0-96f0e55a0ed8_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_44e460f2-591d-46d1-ba84-8b02d450a0a4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_9e0188ef-f88c-4b4e-94b9-889ccd171775_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b0399c87-50c6-4a37-925d-6bcdbbcd7c23_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_e7333032-cdcd-463c-9908-e496a2b2f877_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities:</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_23844970-9046-414a-9b74-bfd7d9f5cf68_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_d9115b41-1f00-4dc3-9ef8-c3e1dcd7ceb8_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2c077dfc-5dc8-497c-98f1-8d79a8965262_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. federal income tax provision at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_6c38293a-1972-4238-9b66-02aaf0ea1915_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f58984c7-1863-4a58-b211-5528e25339bd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_c19a9b4e-4580-4d19-8012-4c21e02987d0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_1575c757-5c0c-47a2-af22-48032f436e5c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_ebccebf3-95a5-4ae1-b5ba-0fe946febe72_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_262fd0e2-f730-46e4-b26d-f28b2ed2a1dc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ce3b33b7-9f77-416c-a57c-5df35a276faa_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_924654e9-e046-45e2-ab91-c5208c175b84_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_c32af9a3-39e4-4f75-a667-8aee983bf625_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_90402099-aca5-46d7-baf9-627b4d3bace9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_05e28346-d209-4aeb-93ad-bcb182b38575_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_d0997801-13bc-4fe4-b982-a11827cc998f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_5b9590a2-cc34-4fb2-8107-07dc55683762_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f47ea2bf-e2d7-4976-8a6e-dd69d6f3f857_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>exel-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:15eb203a-3ec7-40cd-9655-d78f522bbe80,g:fdc51e9e-f0fc-4164-a9b2-d81298576ebe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7840d143-763d-4d87-87f5-8ade4c71536a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_DocumentType_7840d143-763d-4d87-87f5-8ade4c71536a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_e57b7a7a-57f3-46db-9325-25dbfbc0507b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_DocumentAnnualReport_e57b7a7a-57f3-46db-9325-25dbfbc0507b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e05ee16d-7904-4548-a9ea-1e221d309867" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_DocumentPeriodEndDate_e05ee16d-7904-4548-a9ea-1e221d309867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7c5a2e14-62e5-47f2-9090-6d62a996c0b1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_CurrentFiscalYearEndDate_7c5a2e14-62e5-47f2-9090-6d62a996c0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_06ca6e9e-26e9-4332-bfd5-58dff8cfa459" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_DocumentTransitionReport_06ca6e9e-26e9-4332-bfd5-58dff8cfa459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_cca5d20f-87dc-4321-a254-201c0255b65d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityFileNumber_cca5d20f-87dc-4321-a254-201c0255b65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_aebdc89c-86ba-4d37-99ec-1fc6b60db577" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityRegistrantName_aebdc89c-86ba-4d37-99ec-1fc6b60db577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6951cb5c-033c-4781-a1c2-63c77b169238" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6951cb5c-033c-4781-a1c2-63c77b169238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f0b4fd82-1feb-4df3-850c-2124f9e7072c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityTaxIdentificationNumber_f0b4fd82-1feb-4df3-850c-2124f9e7072c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_87a37155-8d22-46fd-88ad-8a5652cbb426" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityAddressAddressLine1_87a37155-8d22-46fd-88ad-8a5652cbb426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3dc68cb8-7d17-4d8c-bb52-785dcb01d0aa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityAddressCityOrTown_3dc68cb8-7d17-4d8c-bb52-785dcb01d0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d46f65ff-eaf5-4196-9d43-f1961c44f380" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityAddressStateOrProvince_d46f65ff-eaf5-4196-9d43-f1961c44f380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8342c3cd-06a1-4490-99b7-66d319e15430" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityAddressPostalZipCode_8342c3cd-06a1-4490-99b7-66d319e15430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a48c27fe-a151-43a6-972e-7bba30e905ed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_CityAreaCode_a48c27fe-a151-43a6-972e-7bba30e905ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e091b313-29e2-4647-bc02-d6c9f21c2743" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_LocalPhoneNumber_e091b313-29e2-4647-bc02-d6c9f21c2743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_74be4a3b-dc56-4a13-8e0f-c1d5b82a8b2d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_Security12bTitle_74be4a3b-dc56-4a13-8e0f-c1d5b82a8b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7d74adc4-0577-4a2d-b5e1-c28cc867c880" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_TradingSymbol_7d74adc4-0577-4a2d-b5e1-c28cc867c880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_41924b46-9c45-4bd0-b37b-0e0d34deb83f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_SecurityExchangeName_41924b46-9c45-4bd0-b37b-0e0d34deb83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_5cbbb63a-9764-4eb5-a486-fa38b01d044d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_5cbbb63a-9764-4eb5-a486-fa38b01d044d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_f0dfeb58-7b59-4988-8361-c382c789ddd9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityVoluntaryFilers_f0dfeb58-7b59-4988-8361-c382c789ddd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9b76aa25-ecf0-4e32-85fd-2ff346501b51" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityCurrentReportingStatus_9b76aa25-ecf0-4e32-85fd-2ff346501b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b908ac44-2172-4020-85e4-4f8ee6e78a1d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityInteractiveDataCurrent_b908ac44-2172-4020-85e4-4f8ee6e78a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a1a0a2a1-31b3-4dc0-8e0b-04e8666d7626" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityFilerCategory_a1a0a2a1-31b3-4dc0-8e0b-04e8666d7626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c98e19a2-9dae-4dd6-ae12-6b3f899b7d3a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntitySmallBusiness_c98e19a2-9dae-4dd6-ae12-6b3f899b7d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7a840980-23b3-4f86-9f8f-2d6901dee0ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityEmergingGrowthCompany_7a840980-23b3-4f86-9f8f-2d6901dee0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_bbcfd822-80d0-4653-9df0-112ead1fecab" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_IcfrAuditorAttestationFlag_bbcfd822-80d0-4653-9df0-112ead1fecab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3a31f5ef-5aeb-47ff-ae32-5152d0d015f4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityShellCompany_3a31f5ef-5aeb-47ff-ae32-5152d0d015f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_a4e12ada-a50b-4c39-b381-bd6709295d4f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityPublicFloat_a4e12ada-a50b-4c39-b381-bd6709295d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c06fbdc9-fee7-41b9-82f5-296088e2bc86" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c06fbdc9-fee7-41b9-82f5-296088e2bc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2d4364b9-d17e-45c5-b91d-f7df4e7a15aa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2d4364b9-d17e-45c5-b91d-f7df4e7a15aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f368dff6-28ca-4989-a3e8-445c67162942" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_AmendmentFlag_f368dff6-28ca-4989-a3e8-445c67162942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ec70cb22-6ee7-435b-bc07-ecba122d2518" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_DocumentFiscalYearFocus_ec70cb22-6ee7-435b-bc07-ecba122d2518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_da6ca02f-c976-4913-a609-0ad0687053b5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_DocumentFiscalPeriodFocus_da6ca02f-c976-4913-a609-0ad0687053b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_878b85fa-b948-4590-b363-427ff93040dd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7432e082-d68b-4065-a863-b668a6501716" xlink:to="loc_dei_EntityCentralIndexKey_878b85fa-b948-4590-b363-427ff93040dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/AuditInformation" xlink:type="simple" xlink:href="exel-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_AuditInformationAbstract_36ecfecd-ffbc-4822-a9d1-6eba0c634f63" xlink:href="exel-20211231.xsd#exel_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_6b754688-4cbb-47c1-8f82-9841624b7ec9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_AuditInformationAbstract_36ecfecd-ffbc-4822-a9d1-6eba0c634f63" xlink:to="loc_dei_AuditorName_6b754688-4cbb-47c1-8f82-9841624b7ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_6190ef8a-75ed-40a8-83d5-75442503bee2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_AuditInformationAbstract_36ecfecd-ffbc-4822-a9d1-6eba0c634f63" xlink:to="loc_dei_AuditorLocation_6190ef8a-75ed-40a8-83d5-75442503bee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_879a030b-57a5-4dfd-926a-10cd6c8669d1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_AuditInformationAbstract_36ecfecd-ffbc-4822-a9d1-6eba0c634f63" xlink:to="loc_dei_AuditorFirmId_879a030b-57a5-4dfd-926a-10cd6c8669d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_41ed5434-84e5-4431-a919-4d9225c96a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c71ac8e0-d671-4af7-8dd9-255ef9f5eb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_41ed5434-84e5-4431-a919-4d9225c96a51" xlink:to="loc_us-gaap_AssetsAbstract_c71ac8e0-d671-4af7-8dd9-255ef9f5eb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3072687b-8baa-4895-9e22-5d9b12b0f7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c71ac8e0-d671-4af7-8dd9-255ef9f5eb5b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3072687b-8baa-4895-9e22-5d9b12b0f7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019d7f33-58d9-48f5-8338-c05f6f9f495d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3072687b-8baa-4895-9e22-5d9b12b0f7fc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019d7f33-58d9-48f5-8338-c05f6f9f495d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_4a6b5911-b2e5-4bc1-9747-b9019113f997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3072687b-8baa-4895-9e22-5d9b12b0f7fc" xlink:to="loc_us-gaap_ShortTermInvestments_4a6b5911-b2e5-4bc1-9747-b9019113f997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_6d67573d-06c5-4cc6-a531-d086bce7c4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3072687b-8baa-4895-9e22-5d9b12b0f7fc" xlink:to="loc_us-gaap_ReceivablesNetCurrent_6d67573d-06c5-4cc6-a531-d086bce7c4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c0b4a53c-b1b3-4518-bf16-34b8dc6f88e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3072687b-8baa-4895-9e22-5d9b12b0f7fc" xlink:to="loc_us-gaap_InventoryNet_c0b4a53c-b1b3-4518-bf16-34b8dc6f88e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_247d8e6c-66a8-49df-887f-ef0dd787f09c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3072687b-8baa-4895-9e22-5d9b12b0f7fc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_247d8e6c-66a8-49df-887f-ef0dd787f09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c92bc80f-5ade-470f-aed0-94546de22e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3072687b-8baa-4895-9e22-5d9b12b0f7fc" xlink:to="loc_us-gaap_AssetsCurrent_c92bc80f-5ade-470f-aed0-94546de22e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_6c164e75-2f03-47b1-88d0-ca51940ce295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c71ac8e0-d671-4af7-8dd9-255ef9f5eb5b" xlink:to="loc_us-gaap_LongTermInvestments_6c164e75-2f03-47b1-88d0-ca51940ce295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3e8108a1-1a2e-4314-8031-6932bb20aaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c71ac8e0-d671-4af7-8dd9-255ef9f5eb5b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3e8108a1-1a2e-4314-8031-6932bb20aaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_8d686093-8a07-4c1a-8874-19b970da2e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c71ac8e0-d671-4af7-8dd9-255ef9f5eb5b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_8d686093-8a07-4c1a-8874-19b970da2e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fdb56748-bf02-47e5-b4b9-2df31559a00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c71ac8e0-d671-4af7-8dd9-255ef9f5eb5b" xlink:to="loc_us-gaap_Goodwill_fdb56748-bf02-47e5-b4b9-2df31559a00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_13d80be7-d5a6-4d20-8aa2-7e1d203d67d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c71ac8e0-d671-4af7-8dd9-255ef9f5eb5b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_13d80be7-d5a6-4d20-8aa2-7e1d203d67d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_85af38c1-716c-4e7b-b7ac-b518f4e5d595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c71ac8e0-d671-4af7-8dd9-255ef9f5eb5b" xlink:to="loc_us-gaap_Assets_85af38c1-716c-4e7b-b7ac-b518f4e5d595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46afa2ee-7c0a-43b4-9267-bff7b8f93d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_41ed5434-84e5-4431-a919-4d9225c96a51" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46afa2ee-7c0a-43b4-9267-bff7b8f93d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0de5b239-42ab-4774-8575-2758273b2612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46afa2ee-7c0a-43b4-9267-bff7b8f93d84" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0de5b239-42ab-4774-8575-2758273b2612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_747349e3-57f7-46a3-8de5-a1933060af27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0de5b239-42ab-4774-8575-2758273b2612" xlink:to="loc_us-gaap_AccountsPayableCurrent_747349e3-57f7-46a3-8de5-a1933060af27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_8c166cbb-c56b-48bb-83e5-c3c63ddf8602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0de5b239-42ab-4774-8575-2758273b2612" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_8c166cbb-c56b-48bb-83e5-c3c63ddf8602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_361627b5-b633-47d5-89cc-570b10675cc6" xlink:href="exel-20211231.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0de5b239-42ab-4774-8575-2758273b2612" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_361627b5-b633-47d5-89cc-570b10675cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_6216eb72-99e9-4716-a648-800f1f5ab844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0de5b239-42ab-4774-8575-2758273b2612" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_6216eb72-99e9-4716-a648-800f1f5ab844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_2997b627-dd4a-4047-a74b-96faf8b882cf" xlink:href="exel-20211231.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0de5b239-42ab-4774-8575-2758273b2612" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_2997b627-dd4a-4047-a74b-96faf8b882cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_dd9f8c0d-f418-4a73-bf5b-1fc510ae6cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0de5b239-42ab-4774-8575-2758273b2612" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_dd9f8c0d-f418-4a73-bf5b-1fc510ae6cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0db9250a-7ded-4901-b8e9-147f66737ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0de5b239-42ab-4774-8575-2758273b2612" xlink:to="loc_us-gaap_LiabilitiesCurrent_0db9250a-7ded-4901-b8e9-147f66737ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6df92631-bf37-4753-9db9-9864b6f792ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46afa2ee-7c0a-43b4-9267-bff7b8f93d84" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6df92631-bf37-4753-9db9-9864b6f792ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fa73bb80-288d-4fd7-881c-c3dfdf3a7033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46afa2ee-7c0a-43b4-9267-bff7b8f93d84" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fa73bb80-288d-4fd7-881c-c3dfdf3a7033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e3f1347a-919b-40c0-8c68-35ea397d80bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46afa2ee-7c0a-43b4-9267-bff7b8f93d84" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e3f1347a-919b-40c0-8c68-35ea397d80bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7fcf6083-b798-4edf-8eb3-159505d4916d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46afa2ee-7c0a-43b4-9267-bff7b8f93d84" xlink:to="loc_us-gaap_Liabilities_7fcf6083-b798-4edf-8eb3-159505d4916d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c6f534bc-89fe-4079-8c93-0363c53c492f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46afa2ee-7c0a-43b4-9267-bff7b8f93d84" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c6f534bc-89fe-4079-8c93-0363c53c492f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_eba4ee79-456b-4996-af5d-bd3014054022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_41ed5434-84e5-4431-a919-4d9225c96a51" xlink:to="loc_us-gaap_StockholdersEquityAbstract_eba4ee79-456b-4996-af5d-bd3014054022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b8532ad7-2246-4272-8a96-fcc42a2ffe0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eba4ee79-456b-4996-af5d-bd3014054022" xlink:to="loc_us-gaap_PreferredStockValue_b8532ad7-2246-4272-8a96-fcc42a2ffe0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_13f15ca8-96ee-413c-b56e-6cf4dcb6952d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eba4ee79-456b-4996-af5d-bd3014054022" xlink:to="loc_us-gaap_CommonStockValue_13f15ca8-96ee-413c-b56e-6cf4dcb6952d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_680da02d-376d-4eff-8657-da6c92fc87fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eba4ee79-456b-4996-af5d-bd3014054022" xlink:to="loc_us-gaap_AdditionalPaidInCapital_680da02d-376d-4eff-8657-da6c92fc87fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ffd5dcd6-ffe4-45e7-9abe-c118b1502409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eba4ee79-456b-4996-af5d-bd3014054022" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ffd5dcd6-ffe4-45e7-9abe-c118b1502409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44e75416-9ada-4f93-b385-f142a1238077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eba4ee79-456b-4996-af5d-bd3014054022" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44e75416-9ada-4f93-b385-f142a1238077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_caf9b544-701e-4735-b055-b79ded8f35d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eba4ee79-456b-4996-af5d-bd3014054022" xlink:to="loc_us-gaap_StockholdersEquity_caf9b544-701e-4735-b055-b79ded8f35d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f5dee937-b132-4eeb-93bd-6a82505297b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_41ed5434-84e5-4431-a919-4d9225c96a51" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f5dee937-b132-4eeb-93bd-6a82505297b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_78d22976-e480-4968-ab50-b0bceae09e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8f03afde-22f3-4be8-b089-b3bf1bf24ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_78d22976-e480-4968-ab50-b0bceae09e43" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8f03afde-22f3-4be8-b089-b3bf1bf24ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a138b4e4-1aad-4264-a13b-51f6302715f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8f03afde-22f3-4be8-b089-b3bf1bf24ee6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a138b4e4-1aad-4264-a13b-51f6302715f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_eec10893-5c6e-4d70-a52d-859fe488b617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8f03afde-22f3-4be8-b089-b3bf1bf24ee6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_eec10893-5c6e-4d70-a52d-859fe488b617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_98c128df-b127-4aae-a1d6-bf19849893db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8f03afde-22f3-4be8-b089-b3bf1bf24ee6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_98c128df-b127-4aae-a1d6-bf19849893db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_58436cc3-addb-44b9-9d6a-cca38549a3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_78d22976-e480-4968-ab50-b0bceae09e43" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_58436cc3-addb-44b9-9d6a-cca38549a3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f084ceea-3774-493d-8d55-9d72578434ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_58436cc3-addb-44b9-9d6a-cca38549a3bd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f084ceea-3774-493d-8d55-9d72578434ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_da2aed97-348a-4413-80b4-d1479febb946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_58436cc3-addb-44b9-9d6a-cca38549a3bd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_da2aed97-348a-4413-80b4-d1479febb946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f3aa3822-02d3-4632-afc8-fe3261f6f2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_58436cc3-addb-44b9-9d6a-cca38549a3bd" xlink:to="loc_us-gaap_CommonStockSharesIssued_f3aa3822-02d3-4632-afc8-fe3261f6f2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e34fa637-2ee7-4320-b9f8-9a243691e7da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_58436cc3-addb-44b9-9d6a-cca38549a3bd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e34fa637-2ee7-4320-b9f8-9a243691e7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20211231.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8a28560f-e04b-4c6c-b31a-d8fdffdbc2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_46b89001-28d8-4ce4-93e6-5b85651bb55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a28560f-e04b-4c6c-b31a-d8fdffdbc2c9" xlink:to="loc_us-gaap_StatementTable_46b89001-28d8-4ce4-93e6-5b85651bb55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_49c0d60b-ac9c-4c5f-b149-b1e87a65284e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_46b89001-28d8-4ce4-93e6-5b85651bb55e" xlink:to="loc_srt_ProductOrServiceAxis_49c0d60b-ac9c-4c5f-b149-b1e87a65284e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a131704a-95dd-4b05-bef4-2d60375aa435" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_49c0d60b-ac9c-4c5f-b149-b1e87a65284e" xlink:to="loc_srt_ProductsAndServicesDomain_a131704a-95dd-4b05-bef4-2d60375aa435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_097b3f6b-f0ca-44c4-a999-a9d7526f52ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a131704a-95dd-4b05-bef4-2d60375aa435" xlink:to="loc_us-gaap_ProductMember_097b3f6b-f0ca-44c4-a999-a9d7526f52ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b5ea5fa9-1dc6-45e5-8294-c6b8dc53c64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a131704a-95dd-4b05-bef4-2d60375aa435" xlink:to="loc_us-gaap_LicenseMember_b5ea5fa9-1dc6-45e5-8294-c6b8dc53c64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_cba76970-3e5f-4231-be12-f5249bdfde4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a131704a-95dd-4b05-bef4-2d60375aa435" xlink:to="loc_us-gaap_ServiceMember_cba76970-3e5f-4231-be12-f5249bdfde4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_46b89001-28d8-4ce4-93e6-5b85651bb55e" xlink:to="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6184de34-3dc0-4ea5-9c59-35e510d1e574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_RevenuesAbstract_6184de34-3dc0-4ea5-9c59-35e510d1e574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_416a8b4f-b8d3-4e14-ad77-aed8635f8d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_6184de34-3dc0-4ea5-9c59-35e510d1e574" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_416a8b4f-b8d3-4e14-ad77-aed8635f8d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c6c07aff-9b10-46ad-af8f-b4c93d896d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c6c07aff-9b10-46ad-af8f-b4c93d896d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5991c192-e59d-4950-b80a-002898bf5edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6c07aff-9b10-46ad-af8f-b4c93d896d5a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5991c192-e59d-4950-b80a-002898bf5edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b1217515-2a5a-4df0-9c3e-1828d3ed059d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6c07aff-9b10-46ad-af8f-b4c93d896d5a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b1217515-2a5a-4df0-9c3e-1828d3ed059d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_163ed90b-e4c4-4147-be53-276514b6c0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6c07aff-9b10-46ad-af8f-b4c93d896d5a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_163ed90b-e4c4-4147-be53-276514b6c0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_52185dde-a329-4475-8c89-a672b3ba59dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6c07aff-9b10-46ad-af8f-b4c93d896d5a" xlink:to="loc_us-gaap_CostsAndExpenses_52185dde-a329-4475-8c89-a672b3ba59dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c661d5f3-94dd-4e8c-a317-e3d2160d8e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_OperatingIncomeLoss_c661d5f3-94dd-4e8c-a317-e3d2160d8e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_de9cb7c4-4690-431e-ad71-8fbdb89a300b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_InterestIncomeOther_de9cb7c4-4690-431e-ad71-8fbdb89a300b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_14614db3-4988-4ace-a33e-d96bb27999ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_14614db3-4988-4ace-a33e-d96bb27999ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_840bde54-d883-4402-bf22-4b5b652853be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_840bde54-d883-4402-bf22-4b5b652853be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b88b3dd7-caa9-42c2-bcd1-db041a4e5e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b88b3dd7-caa9-42c2-bcd1-db041a4e5e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b64561aa-0672-4d6c-af17-4ac3ba3f39ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_NetIncomeLoss_b64561aa-0672-4d6c-af17-4ac3ba3f39ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b12169f0-4a0b-40d1-a729-c1d27ea360a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_EarningsPerShareAbstract_b12169f0-4a0b-40d1-a729-c1d27ea360a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1875eeac-920c-4a17-adf1-06b18633231a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b12169f0-4a0b-40d1-a729-c1d27ea360a6" xlink:to="loc_us-gaap_EarningsPerShareBasic_1875eeac-920c-4a17-adf1-06b18633231a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8b05225a-06a5-4f12-a699-b460fde8ac76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b12169f0-4a0b-40d1-a729-c1d27ea360a6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8b05225a-06a5-4f12-a699-b460fde8ac76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af507361-33fb-48a3-a468-e262c3ac87a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3fa8a28-cefa-430b-80b0-cdd860927487" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af507361-33fb-48a3-a468-e262c3ac87a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fced1729-c746-4b7d-9efa-1b3161fa4d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af507361-33fb-48a3-a468-e262c3ac87a4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fced1729-c746-4b7d-9efa-1b3161fa4d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46accf5a-da5d-4d0b-a3a2-f3fe061585bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af507361-33fb-48a3-a468-e262c3ac87a4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46accf5a-da5d-4d0b-a3a2-f3fe061585bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20211231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_007c1a21-a640-4fa6-91b6-25a6593b0ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_42fd97ae-b5ae-4f37-8452-f372b86e7441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_007c1a21-a640-4fa6-91b6-25a6593b0ed3" xlink:to="loc_us-gaap_NetIncomeLoss_42fd97ae-b5ae-4f37-8452-f372b86e7441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fec60c67-885b-44ac-8c67-5803fe001f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_007c1a21-a640-4fa6-91b6-25a6593b0ed3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fec60c67-885b-44ac-8c67-5803fe001f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_90371077-ba06-4559-a234-383f2ddacb62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fec60c67-885b-44ac-8c67-5803fe001f9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_90371077-ba06-4559-a234-383f2ddacb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_74645998-4d6b-491d-b576-c4e9d160665a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fec60c67-885b-44ac-8c67-5803fe001f9f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_74645998-4d6b-491d-b576-c4e9d160665a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="exel-20211231.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_69082a9b-2786-4daf-9003-baa9db2a65d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_05a9c746-97c1-45cc-aea2-815136911113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_69082a9b-2786-4daf-9003-baa9db2a65d9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_05a9c746-97c1-45cc-aea2-815136911113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_efd58bed-dabc-4560-9e98-5a239bf5a420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f703e211-f76e-4071-9c00-c73dcf9cb7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_efd58bed-dabc-4560-9e98-5a239bf5a420" xlink:to="loc_us-gaap_StatementTable_f703e211-f76e-4071-9c00-c73dcf9cb7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_60e1dd48-ce46-464a-876d-d1470b8584b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f703e211-f76e-4071-9c00-c73dcf9cb7a5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_60e1dd48-ce46-464a-876d-d1470b8584b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_97895a05-e8d3-43b7-a826-dca88f7be7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60e1dd48-ce46-464a-876d-d1470b8584b1" xlink:to="loc_us-gaap_EquityComponentDomain_97895a05-e8d3-43b7-a826-dca88f7be7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bdf4155b-b622-462c-95cf-361dc0033672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_97895a05-e8d3-43b7-a826-dca88f7be7b2" xlink:to="loc_us-gaap_CommonStockMember_bdf4155b-b622-462c-95cf-361dc0033672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ce74e7b4-9060-4d62-9bc2-5bcd17aa9f61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_97895a05-e8d3-43b7-a826-dca88f7be7b2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ce74e7b4-9060-4d62-9bc2-5bcd17aa9f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5267b3ec-6728-44b7-bfe7-e942fdb80709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_97895a05-e8d3-43b7-a826-dca88f7be7b2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5267b3ec-6728-44b7-bfe7-e942fdb80709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d922bf42-2559-49a7-9814-e95e43d88e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_97895a05-e8d3-43b7-a826-dca88f7be7b2" xlink:to="loc_us-gaap_RetainedEarningsMember_d922bf42-2559-49a7-9814-e95e43d88e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4e9372ef-f740-42ec-a25f-c8106805ea18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f703e211-f76e-4071-9c00-c73dcf9cb7a5" xlink:to="loc_us-gaap_StatementLineItems_4e9372ef-f740-42ec-a25f-c8106805ea18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e9372ef-f740-42ec-a25f-c8106805ea18" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_63360254-e566-4b81-b4eb-f1a38b2fd724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_63360254-e566-4b81-b4eb-f1a38b2fd724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e4f85521-467e-4b47-b3ff-18a02993618b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_StockholdersEquity_e4f85521-467e-4b47-b3ff-18a02993618b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc1bae8a-33db-45d5-8e2f-829340fac1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_NetIncomeLoss_fc1bae8a-33db-45d5-8e2f-829340fac1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_475b5ca2-106e-4788-a960-8494e024dc24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_475b5ca2-106e-4788-a960-8494e024dc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4133c5e0-b6fc-4edb-bd26-f813b8672db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4133c5e0-b6fc-4edb-bd26-f813b8672db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e9e00755-c95e-4b82-a995-de8055486992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e9e00755-c95e-4b82-a995-de8055486992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_81bc1978-a8a4-4407-b757-8911e8c160d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_81bc1978-a8a4-4407-b757-8911e8c160d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6fa88d73-efb8-4efa-adb9-7ea89c97c2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6fa88d73-efb8-4efa-adb9-7ea89c97c2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4e61b574-6195-458a-92dc-777f1a02dded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4e61b574-6195-458a-92dc-777f1a02dded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5f2bb433-b360-4098-b15e-77189761fe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a2abd6ff-ed07-4f4d-88c0-68aa2cb954ac" xlink:to="loc_us-gaap_StockholdersEquity_5f2bb433-b360-4098-b15e-77189761fe7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6189fbbc-b05d-4c23-b691-7b73801ee607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3f231e84-8c6d-4de5-b9e4-682623a4b9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6189fbbc-b05d-4c23-b691-7b73801ee607" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3f231e84-8c6d-4de5-b9e4-682623a4b9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_827e4af0-a275-4bb5-8712-4e8627b379e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3f231e84-8c6d-4de5-b9e4-682623a4b9ee" xlink:to="loc_us-gaap_NetIncomeLoss_827e4af0-a275-4bb5-8712-4e8627b379e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8fb4b736-5c42-45e2-9c9e-5858f673ff3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3f231e84-8c6d-4de5-b9e4-682623a4b9ee" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8fb4b736-5c42-45e2-9c9e-5858f673ff3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_eb2eac6d-59da-43f1-be76-82f3731954f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8fb4b736-5c42-45e2-9c9e-5858f673ff3e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_eb2eac6d-59da-43f1-be76-82f3731954f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6d46152d-0617-48a2-be3d-2dbe76dd920d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8fb4b736-5c42-45e2-9c9e-5858f673ff3e" xlink:to="loc_us-gaap_ShareBasedCompensation_6d46152d-0617-48a2-be3d-2dbe76dd920d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_565dcae6-a2a6-42f1-b0f3-6da6cd84d8f5" xlink:href="exel-20211231.xsd#exel_NoncashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8fb4b736-5c42-45e2-9c9e-5858f673ff3e" xlink:to="loc_exel_NoncashLeaseExpense_565dcae6-a2a6-42f1-b0f3-6da6cd84d8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_f51f9113-0e71-4c88-87fb-cfc6253b12e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8fb4b736-5c42-45e2-9c9e-5858f673ff3e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_f51f9113-0e71-4c88-87fb-cfc6253b12e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_93d6f255-c107-4645-b117-534edc65a054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8fb4b736-5c42-45e2-9c9e-5858f673ff3e" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_93d6f255-c107-4645-b117-534edc65a054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ccaa66b-86ae-4cd3-ad15-0d7aec9de9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8fb4b736-5c42-45e2-9c9e-5858f673ff3e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ccaa66b-86ae-4cd3-ad15-0d7aec9de9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_747e26dd-8e68-4829-ad2b-dd277311eac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ccaa66b-86ae-4cd3-ad15-0d7aec9de9f3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_747e26dd-8e68-4829-ad2b-dd277311eac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_80c3155d-b80c-45c8-aa50-3c1a364f4fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ccaa66b-86ae-4cd3-ad15-0d7aec9de9f3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_80c3155d-b80c-45c8-aa50-3c1a364f4fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0cfca42d-2726-431e-8dba-89100abdea23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ccaa66b-86ae-4cd3-ad15-0d7aec9de9f3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0cfca42d-2726-431e-8dba-89100abdea23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3a8b71f1-0f6d-481a-aed1-32bc590fa5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ccaa66b-86ae-4cd3-ad15-0d7aec9de9f3" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3a8b71f1-0f6d-481a-aed1-32bc590fa5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_01e79fa9-74c8-474e-a3c8-a018f8e8d768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ccaa66b-86ae-4cd3-ad15-0d7aec9de9f3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_01e79fa9-74c8-474e-a3c8-a018f8e8d768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9fef6550-c9ed-4d57-88ea-0422a1028c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ccaa66b-86ae-4cd3-ad15-0d7aec9de9f3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9fef6550-c9ed-4d57-88ea-0422a1028c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8713bfc8-7620-4da1-9a27-49f8fad2adc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3f231e84-8c6d-4de5-b9e4-682623a4b9ee" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8713bfc8-7620-4da1-9a27-49f8fad2adc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d4e6627-9bbc-429b-a1fb-074202c44aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6189fbbc-b05d-4c23-b691-7b73801ee607" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d4e6627-9bbc-429b-a1fb-074202c44aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_07c291ff-a4f9-4c4b-b0d5-135171f42494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d4e6627-9bbc-429b-a1fb-074202c44aae" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_07c291ff-a4f9-4c4b-b0d5-135171f42494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_d8269df6-b085-4d86-8f11-3b44b4356519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d4e6627-9bbc-429b-a1fb-074202c44aae" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_d8269df6-b085-4d86-8f11-3b44b4356519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f730ed2e-d3ff-4192-81d7-566ff232e02a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d4e6627-9bbc-429b-a1fb-074202c44aae" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f730ed2e-d3ff-4192-81d7-566ff232e02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0d2e04e9-31d2-4d50-a0b4-afe55c7688bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d4e6627-9bbc-429b-a1fb-074202c44aae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0d2e04e9-31d2-4d50-a0b4-afe55c7688bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d694604-9df2-436a-88ca-110fe81d6bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6189fbbc-b05d-4c23-b691-7b73801ee607" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d694604-9df2-436a-88ca-110fe81d6bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_9e1a9369-0c39-4036-9b7b-0fe4c59d6da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d694604-9df2-436a-88ca-110fe81d6bb7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_9e1a9369-0c39-4036-9b7b-0fe4c59d6da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_20a6781f-e2b8-4848-bef8-b48dbb679cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d694604-9df2-436a-88ca-110fe81d6bb7" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_20a6781f-e2b8-4848-bef8-b48dbb679cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7b01ee3d-8105-4e59-a906-30d54e1db967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d694604-9df2-436a-88ca-110fe81d6bb7" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7b01ee3d-8105-4e59-a906-30d54e1db967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_12719693-9f92-4390-8fbd-60dadd5e105f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d694604-9df2-436a-88ca-110fe81d6bb7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_12719693-9f92-4390-8fbd-60dadd5e105f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c1010c54-5996-48a5-9066-5b34524fc15a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6189fbbc-b05d-4c23-b691-7b73801ee607" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c1010c54-5996-48a5-9066-5b34524fc15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5d4c14c-6632-4f86-9621-2c8222c0302f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6189fbbc-b05d-4c23-b691-7b73801ee607" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5d4c14c-6632-4f86-9621-2c8222c0302f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7c34d8fb-8d00-4e51-b744-9a4e24297c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6189fbbc-b05d-4c23-b691-7b73801ee607" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7c34d8fb-8d00-4e51-b744-9a4e24297c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_4a3badd4-c815-4b8b-b851-a79c78e6ea54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6189fbbc-b05d-4c23-b691-7b73801ee607" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_4a3badd4-c815-4b8b-b851-a79c78e6ea54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_1cb93a2c-7908-4964-af59-407eb75ef9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4a3badd4-c815-4b8b-b851-a79c78e6ea54" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_1cb93a2c-7908-4964-af59-407eb75ef9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_3f5cc470-9f9a-4e1d-a607-8a5c877c7d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4a3badd4-c815-4b8b-b851-a79c78e6ea54" xlink:to="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_3f5cc470-9f9a-4e1d-a607-8a5c877c7d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_defd50f2-7332-471a-bbe9-59adf6ed482d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_3f5cc470-9f9a-4e1d-a607-8a5c877c7d04" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_defd50f2-7332-471a-bbe9-59adf6ed482d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3c355e2e-923e-43b5-8d74-327545f60582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4a3badd4-c815-4b8b-b851-a79c78e6ea54" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3c355e2e-923e-43b5-8d74-327545f60582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_5eace89a-74dd-4af5-a8b3-1d0d85958153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3c355e2e-923e-43b5-8d74-327545f60582" xlink:to="loc_us-gaap_LiabilitiesAssumed1_5eace89a-74dd-4af5-a8b3-1d0d85958153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_79549453-5edd-422c-92ef-acf8e29d2dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3c355e2e-923e-43b5-8d74-327545f60582" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_79549453-5edd-422c-92ef-acf8e29d2dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InvestmentsPurchasesIncurredButNotYetPaid_bb298ff6-4f21-4c93-b64a-c173e7f4a890" xlink:href="exel-20211231.xsd#exel_InvestmentsPurchasesIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3c355e2e-923e-43b5-8d74-327545f60582" xlink:to="loc_exel_InvestmentsPurchasesIncurredButNotYetPaid_bb298ff6-4f21-4c93-b64a-c173e7f4a890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccountsReceivableForUnsettledInvestmentSales_5f056825-c6d0-4f9e-b9df-d167052109c0" xlink:href="exel-20211231.xsd#exel_AccountsReceivableForUnsettledInvestmentSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3c355e2e-923e-43b5-8d74-327545f60582" xlink:to="loc_exel_AccountsReceivableForUnsettledInvestmentSales_5f056825-c6d0-4f9e-b9df-d167052109c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20211231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54616b8a-fe60-46fd-b6aa-a1a356de7736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_0aac3f15-a471-4d1d-bdb1-64587056a98d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54616b8a-fe60-46fd-b6aa-a1a356de7736" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_0aac3f15-a471-4d1d-bdb1-64587056a98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2c9becea-ca45-46a7-b930-cda3439fd6be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2c9becea-ca45-46a7-b930-cda3439fd6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_93950b7a-67c3-4cf1-9fbe-7a62d8385964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_FiscalPeriod_93950b7a-67c3-4cf1-9fbe-7a62d8385964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_f9da6cb9-33b5-4d4e-91fb-99fc48b657a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_f9da6cb9-33b5-4d4e-91fb-99fc48b657a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c081ac68-b8f6-4929-ae2b-94fa8ea9bcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_UseOfEstimates_c081ac68-b8f6-4929-ae2b-94fa8ea9bcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6d6151ae-0416-40d2-a489-c3360bf354db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6d6151ae-0416-40d2-a489-c3360bf354db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b433c1ff-3db0-4c16-b5e5-7fe0f52dafd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b433c1ff-3db0-4c16-b5e5-7fe0f52dafd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_adf01b1b-51ad-4ac9-80ae-8efed3a4ded3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_adf01b1b-51ad-4ac9-80ae-8efed3a4ded3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_372b035d-c9db-48d7-b042-ea7f3f931b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_372b035d-c9db-48d7-b042-ea7f3f931b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_febc86b6-2225-4290-8b05-549eed5c30a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_febc86b6-2225-4290-8b05-549eed5c30a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3f8202ea-c4d0-4f93-929e-0f5fd03ab543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3f8202ea-c4d0-4f93-929e-0f5fd03ab543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_92e6bfb8-f1ba-4b9d-a910-0898d6e79c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_92e6bfb8-f1ba-4b9d-a910-0898d6e79c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_fc9437a3-f223-46c7-8e69-038e726a1613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_fc9437a3-f223-46c7-8e69-038e726a1613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_02a91cee-e933-4ea9-bd1f-d1a3cd2a1a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_02a91cee-e933-4ea9-bd1f-d1a3cd2a1a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4314d9d9-0147-4b6b-a61f-612dd1c93fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4314d9d9-0147-4b6b-a61f-612dd1c93fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_2017f8c9-e635-4a50-9d7d-f0886a43ac89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_2017f8c9-e635-4a50-9d7d-f0886a43ac89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9aee6346-b4e1-4972-8424-a1ed4a7a8660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9aee6346-b4e1-4972-8424-a1ed4a7a8660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_027de879-eba2-41f4-845b-4fcb76dc6c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_027de879-eba2-41f4-845b-4fcb76dc6c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_05d4f68f-f28a-4a97-9d5f-e8b696427727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_05d4f68f-f28a-4a97-9d5f-e8b696427727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_d68f83d1-6983-4ccc-86d5-3537537f4613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_d68f83d1-6983-4ccc-86d5-3537537f4613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_41476e75-9061-4e0a-b6e8-30266e0ead30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_41476e75-9061-4e0a-b6e8-30266e0ead30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_8b8ec531-5820-4707-9e71-fc3f69487ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68574ce3-b5dd-44ae-bf9c-0bdd49d9c5a9" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_8b8ec531-5820-4707-9e71-fc3f69487ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e1bb261b-ba35-4929-97cd-ca1a37ca604a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_71f4e964-bd3e-4634-99bf-0c28bbdf6f1e" xlink:href="exel-20211231.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e1bb261b-ba35-4929-97cd-ca1a37ca604a" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_71f4e964-bd3e-4634-99bf-0c28bbdf6f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6c477758-448a-48ef-9988-cf6e9d3c5071" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_71f4e964-bd3e-4634-99bf-0c28bbdf6f1e" xlink:to="loc_srt_ProductOrServiceAxis_6c477758-448a-48ef-9988-cf6e9d3c5071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1b09b838-c5c9-479c-9b3c-d016b7d6c0dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6c477758-448a-48ef-9988-cf6e9d3c5071" xlink:to="loc_srt_ProductsAndServicesDomain_1b09b838-c5c9-479c-9b3c-d016b7d6c0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_14e8d34f-bce7-4976-93d6-37d36c65e4ce" xlink:href="exel-20211231.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1b09b838-c5c9-479c-9b3c-d016b7d6c0dd" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_14e8d34f-bce7-4976-93d6-37d36c65e4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_867aabad-a847-4ef2-a6aa-2d71676cb867" xlink:href="exel-20211231.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1b09b838-c5c9-479c-9b3c-d016b7d6c0dd" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_867aabad-a847-4ef2-a6aa-2d71676cb867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_518c07f7-718c-4c35-972f-020340776bbd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_71f4e964-bd3e-4634-99bf-0c28bbdf6f1e" xlink:to="loc_srt_RangeAxis_518c07f7-718c-4c35-972f-020340776bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc108f2f-63a2-4dd0-86aa-e68cc4b941e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_518c07f7-718c-4c35-972f-020340776bbd" xlink:to="loc_srt_RangeMember_fc108f2f-63a2-4dd0-86aa-e68cc4b941e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1b9b9760-b2b5-4ab7-bcaf-d0a2372dbf28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fc108f2f-63a2-4dd0-86aa-e68cc4b941e4" xlink:to="loc_srt_MaximumMember_1b9b9760-b2b5-4ab7-bcaf-d0a2372dbf28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_369b25ce-4458-428e-acaa-1e9d3d40e845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_71f4e964-bd3e-4634-99bf-0c28bbdf6f1e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_369b25ce-4458-428e-acaa-1e9d3d40e845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f2a069dc-5623-4f06-a8ce-e5a477835327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_369b25ce-4458-428e-acaa-1e9d3d40e845" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f2a069dc-5623-4f06-a8ce-e5a477835327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_f0b0b7e8-5c42-4127-b550-0061e21696f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f2a069dc-5623-4f06-a8ce-e5a477835327" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_f0b0b7e8-5c42-4127-b550-0061e21696f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:href="exel-20211231.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_71f4e964-bd3e-4634-99bf-0c28bbdf6f1e" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_569440f5-014b-4a1d-8af6-8191e48470f6" xlink:href="exel-20211231.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_exel_NumberofProductsinCommercialMarket_569440f5-014b-4a1d-8af6-8191e48470f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_9463e810-a3b1-4b2b-8bdb-987bb76cf5fa" xlink:href="exel-20211231.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_9463e810-a3b1-4b2b-8bdb-987bb76cf5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2bf3f4cb-1081-4912-ab60-09df0bdc76a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2bf3f4cb-1081-4912-ab60-09df0bdc76a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_7ce56ec6-0ae3-4178-8dec-3189c4d41f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_7ce56ec6-0ae3-4178-8dec-3189c4d41f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2e367485-0554-4484-8cf8-ac30116f49c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2e367485-0554-4484-8cf8-ac30116f49c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_9b3e8451-fef1-4dc8-912a-ec3fcc2c4719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_DerivativeTermOfContract_9b3e8451-fef1-4dc8-912a-ec3fcc2c4719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_9a3ae70b-ba06-4050-aee2-e103e78d19e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_9a3ae70b-ba06-4050-aee2-e103e78d19e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4bf80499-215c-4d00-b567-3c381b338736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4bf80499-215c-4d00-b567-3c381b338736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_016e48ac-f39c-4983-b246-6bbcd1e5e6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_016e48ac-f39c-4983-b246-6bbcd1e5e6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_7ca788bc-9492-4fd1-ac47-a8e3a24554dd" xlink:href="exel-20211231.xsd#exel_SalesRevenuePercentDiscountForPromptPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_7ca788bc-9492-4fd1-ac47-a8e3a24554dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_582d1879-6f48-47ac-b523-c860f11e88bf" xlink:href="exel-20211231.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_582d1879-6f48-47ac-b523-c860f11e88bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MedicarePartDFundingMandate_ec95c4c7-ca60-40b2-8e13-b4137ee0809a" xlink:href="exel-20211231.xsd#exel_MedicarePartDFundingMandate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_exel_MedicarePartDFundingMandate_ec95c4c7-ca60-40b2-8e13-b4137ee0809a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_39c10c41-c8b5-47a7-9598-8789703dced0" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_39c10c41-c8b5-47a7-9598-8789703dced0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_983a3da2-ba6f-466e-991c-39d97cc93a15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_2a2862e6-a620-4bae-ac24-557427e34f22" xlink:to="loc_us-gaap_AdvertisingExpense_983a3da2-ba6f-466e-991c-39d97cc93a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20211231.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3fdcfee9-f187-4118-b4bb-8ddbbf387161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a0c3f0a4-352e-4167-a1a6-11fd23673929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3fdcfee9-f187-4118-b4bb-8ddbbf387161" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a0c3f0a4-352e-4167-a1a6-11fd23673929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20211231.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_82b96484-85e0-49c4-9d0a-1d991941195f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6583f47c-3ff4-4c08-a2a4-2e26bf46d0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_82b96484-85e0-49c4-9d0a-1d991941195f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6583f47c-3ff4-4c08-a2a4-2e26bf46d0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_10a834fb-b986-4fba-a5c2-918452d383e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_82b96484-85e0-49c4-9d0a-1d991941195f" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_10a834fb-b986-4fba-a5c2-918452d383e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_dd606b6f-6539-4db0-a2cd-010f00e99566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_82b96484-85e0-49c4-9d0a-1d991941195f" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_dd606b6f-6539-4db0-a2cd-010f00e99566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_adf701d5-9802-4330-8d83-58eea3f9217c" xlink:href="exel-20211231.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_82b96484-85e0-49c4-9d0a-1d991941195f" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_adf701d5-9802-4330-8d83-58eea3f9217c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_79ba8e83-6e22-413b-b3e5-20b04d40c243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_82b96484-85e0-49c4-9d0a-1d991941195f" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_79ba8e83-6e22-413b-b3e5-20b04d40c243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0ee33d77-4b61-4ab7-afc7-34abfaa74e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7b735f7d-7934-431d-9620-e3c1b666992f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0ee33d77-4b61-4ab7-afc7-34abfaa74e8a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7b735f7d-7934-431d-9620-e3c1b666992f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a2b453be-096b-4251-8a2a-d17f168052c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7b735f7d-7934-431d-9620-e3c1b666992f" xlink:to="loc_srt_ProductOrServiceAxis_a2b453be-096b-4251-8a2a-d17f168052c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a2b453be-096b-4251-8a2a-d17f168052c6" xlink:to="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_7188cb64-bee8-4d4b-9c3e-ec2e466db2e5" xlink:href="exel-20211231.xsd#exel_ProductGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:to="loc_exel_ProductGrossMember_7188cb64-bee8-4d4b-9c3e-ec2e466db2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_138151a7-8468-422c-a272-4f3423b92ca1" xlink:href="exel-20211231.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_138151a7-8468-422c-a272-4f3423b92ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7109df5d-6508-446e-960c-b54004f3ba40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:to="loc_us-gaap_ProductMember_7109df5d-6508-446e-960c-b54004f3ba40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_043e02ad-6aa1-4a67-9d17-032825b81a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:to="loc_us-gaap_LicenseMember_043e02ad-6aa1-4a67-9d17-032825b81a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_118e651d-b79f-49f1-9596-fa5263d5f05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:to="loc_us-gaap_ServiceMember_118e651d-b79f-49f1-9596-fa5263d5f05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_7b74b15e-7179-436c-acca-69164e775e60" xlink:href="exel-20211231.xsd#exel_CollaborationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0771e451-e3a2-4348-b53e-d9b312e96ddf" xlink:to="loc_exel_CollaborationMember_7b74b15e-7179-436c-acca-69164e775e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4d1101c4-c3be-4a02-bbb3-d3a5f000ed20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7b735f7d-7934-431d-9620-e3c1b666992f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4d1101c4-c3be-4a02-bbb3-d3a5f000ed20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aabe25c9-3216-485e-83c4-20446e90bfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4d1101c4-c3be-4a02-bbb3-d3a5f000ed20" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aabe25c9-3216-485e-83c4-20446e90bfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a25f7f47-f1e8-407a-8aa6-494e1fbbbb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a44c71a5-5ddc-4eea-99e4-6815218447e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a25f7f47-f1e8-407a-8aa6-494e1fbbbb79" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a44c71a5-5ddc-4eea-99e4-6815218447e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_249b3aa5-f1cd-4751-97b6-56edb0379e51" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a44c71a5-5ddc-4eea-99e4-6815218447e6" xlink:to="loc_srt_ProductOrServiceAxis_249b3aa5-f1cd-4751-97b6-56edb0379e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_450fc00a-ca74-42d3-94b6-1d5719173268" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_249b3aa5-f1cd-4751-97b6-56edb0379e51" xlink:to="loc_srt_ProductsAndServicesDomain_450fc00a-ca74-42d3-94b6-1d5719173268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_24858166-5680-4b7b-9adf-f343ddcb2ffa" xlink:href="exel-20211231.xsd#exel_CabometyxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_450fc00a-ca74-42d3-94b6-1d5719173268" xlink:to="loc_exel_CabometyxMember_24858166-5680-4b7b-9adf-f343ddcb2ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_3b53b372-ab52-4ed8-9df6-b4e3f111a6fc" xlink:href="exel-20211231.xsd#exel_CometriqMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_450fc00a-ca74-42d3-94b6-1d5719173268" xlink:to="loc_exel_CometriqMember_3b53b372-ab52-4ed8-9df6-b4e3f111a6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5b07d030-5e3c-48c0-b6c0-e56ff44d4273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_450fc00a-ca74-42d3-94b6-1d5719173268" xlink:to="loc_us-gaap_ProductMember_5b07d030-5e3c-48c0-b6c0-e56ff44d4273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_672d7709-7378-4448-bfc7-dcff8d8f1edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a44c71a5-5ddc-4eea-99e4-6815218447e6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_672d7709-7378-4448-bfc7-dcff8d8f1edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fedae6e3-fdb7-47ff-a82c-acba628fd921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_672d7709-7378-4448-bfc7-dcff8d8f1edc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fedae6e3-fdb7-47ff-a82c-acba628fd921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7a0208ee-a37a-420f-9a19-a0ad65f47e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_eb17912c-7753-4fe0-9aea-dd1f08a60da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7a0208ee-a37a-420f-9a19-a0ad65f47e52" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_eb17912c-7753-4fe0-9aea-dd1f08a60da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9605eec3-264c-49b5-bbb6-aeb469a34165" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_eb17912c-7753-4fe0-9aea-dd1f08a60da9" xlink:to="loc_srt_MajorCustomersAxis_9605eec3-264c-49b5-bbb6-aeb469a34165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9605eec3-264c-49b5-bbb6-aeb469a34165" xlink:to="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_a06519a6-a935-4d10-b4fa-7503dc50babb" xlink:href="exel-20211231.xsd#exel_IpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:to="loc_exel_IpsenMember_a06519a6-a935-4d10-b4fa-7503dc50babb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_0a7700e1-8b1a-4737-bc70-b6764b7b7b54" xlink:href="exel-20211231.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_0a7700e1-8b1a-4737-bc70-b6764b7b7b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_8b193e76-f70b-4316-a556-afc8f3595033" xlink:href="exel-20211231.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_8b193e76-f70b-4316-a556-afc8f3595033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_31f5412e-b7f2-4064-8b48-1e391e8d4d12" xlink:href="exel-20211231.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_31f5412e-b7f2-4064-8b48-1e391e8d4d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_f8fb5e71-893b-4ffb-ae22-638c6803db32" xlink:href="exel-20211231.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_f8fb5e71-893b-4ffb-ae22-638c6803db32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_aba1f5d6-85da-4a11-99c6-750227854cd0" xlink:href="exel-20211231.xsd#exel_TakedaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0d48acc4-ff08-4797-a296-bac8bcd604f7" xlink:to="loc_exel_TakedaMember_aba1f5d6-85da-4a11-99c6-750227854cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2ebbbfd-a4cf-436f-aa6e-fb0072b05bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_eb17912c-7753-4fe0-9aea-dd1f08a60da9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2ebbbfd-a4cf-436f-aa6e-fb0072b05bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3bf08257-5e99-4178-82cc-ed17f90971af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2ebbbfd-a4cf-436f-aa6e-fb0072b05bc4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3bf08257-5e99-4178-82cc-ed17f90971af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f59802b4-4226-48ee-a812-3e8fdc7aea52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3bf08257-5e99-4178-82cc-ed17f90971af" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f59802b4-4226-48ee-a812-3e8fdc7aea52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_045c19ad-1f79-4c0d-bd9b-25ac49fcee5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3bf08257-5e99-4178-82cc-ed17f90971af" xlink:to="loc_us-gaap_AccountsReceivableMember_045c19ad-1f79-4c0d-bd9b-25ac49fcee5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_dc455194-355e-4bcf-a4c4-8408ddec1fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_eb17912c-7753-4fe0-9aea-dd1f08a60da9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_dc455194-355e-4bcf-a4c4-8408ddec1fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f0a67365-bbfd-4b89-a90a-4a1ef338a3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_dc455194-355e-4bcf-a4c4-8408ddec1fb0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f0a67365-bbfd-4b89-a90a-4a1ef338a3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d2880e51-5616-4954-aa9b-153457669d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f0a67365-bbfd-4b89-a90a-4a1ef338a3eb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d2880e51-5616-4954-aa9b-153457669d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_47333a37-a912-417e-8ff3-213a97acd989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_eb17912c-7753-4fe0-9aea-dd1f08a60da9" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_47333a37-a912-417e-8ff3-213a97acd989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7b1ee562-bd64-4d14-a8da-5ab71cc99f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_47333a37-a912-417e-8ff3-213a97acd989" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7b1ee562-bd64-4d14-a8da-5ab71cc99f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a9c1bd55-5eba-4c0b-ac68-c52d3219473e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d458ac8e-6608-4d2b-b8b3-4eb3952bfc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a9c1bd55-5eba-4c0b-ac68-c52d3219473e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d458ac8e-6608-4d2b-b8b3-4eb3952bfc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_040b4ec3-3720-4721-bd4a-eab33cd39ba0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d458ac8e-6608-4d2b-b8b3-4eb3952bfc6d" xlink:to="loc_srt_StatementGeographicalAxis_040b4ec3-3720-4721-bd4a-eab33cd39ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_39a5a9e8-670b-4e11-9860-b89eff87d2ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_040b4ec3-3720-4721-bd4a-eab33cd39ba0" xlink:to="loc_srt_SegmentGeographicalDomain_39a5a9e8-670b-4e11-9860-b89eff87d2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6ab10fcd-3dcd-4ea6-b971-0855c9c21848" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_39a5a9e8-670b-4e11-9860-b89eff87d2ec" xlink:to="loc_country_US_6ab10fcd-3dcd-4ea6-b971-0855c9c21848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_04803668-0e40-4be8-8239-9c4d4301ff5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_39a5a9e8-670b-4e11-9860-b89eff87d2ec" xlink:to="loc_srt_EuropeMember_04803668-0e40-4be8-8239-9c4d4301ff5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_18b2caab-c740-47b2-90b0-dd597486a7d6" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_39a5a9e8-670b-4e11-9860-b89eff87d2ec" xlink:to="loc_country_JP_18b2caab-c740-47b2-90b0-dd597486a7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_50d6f130-965d-4a1d-a4f4-2c18e4b46135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d458ac8e-6608-4d2b-b8b3-4eb3952bfc6d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_50d6f130-965d-4a1d-a4f4-2c18e4b46135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_64dd1c10-8f92-4a3a-a0a4-dcc765900596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_50d6f130-965d-4a1d-a4f4-2c18e4b46135" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_64dd1c10-8f92-4a3a-a0a4-dcc765900596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e539961b-9401-4e7d-8bc7-c9e3ea194317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c35139dd-7490-42e0-8f30-59270c4d6649" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e539961b-9401-4e7d-8bc7-c9e3ea194317" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c35139dd-7490-42e0-8f30-59270c4d6649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cf2a3128-40ba-4faf-8a9e-246a4449441e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c35139dd-7490-42e0-8f30-59270c4d6649" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cf2a3128-40ba-4faf-8a9e-246a4449441e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_99756883-e79d-44f8-8f23-e9d6cb7a2080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cf2a3128-40ba-4faf-8a9e-246a4449441e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_99756883-e79d-44f8-8f23-e9d6cb7a2080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5f0ab49c-7f42-4285-9a27-d80a788f23c3" xlink:href="exel-20211231.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_99756883-e79d-44f8-8f23-e9d6cb7a2080" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5f0ab49c-7f42-4285-9a27-d80a788f23c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_d2679092-5160-4820-918d-ade11a21930a" xlink:href="exel-20211231.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_99756883-e79d-44f8-8f23-e9d6cb7a2080" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_d2679092-5160-4820-918d-ade11a21930a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_2575ac3c-b5f4-4d8f-b603-998b6e3eb0fb" xlink:href="exel-20211231.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_99756883-e79d-44f8-8f23-e9d6cb7a2080" xlink:to="loc_exel_AllowanceForProductRebatesMember_2575ac3c-b5f4-4d8f-b603-998b6e3eb0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6b1e1bce-f405-4d82-9ac5-1f5448530672" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c35139dd-7490-42e0-8f30-59270c4d6649" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6b1e1bce-f405-4d82-9ac5-1f5448530672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_894e1741-4d54-432f-a46c-ffb3180e8cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6b1e1bce-f405-4d82-9ac5-1f5448530672" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_894e1741-4d54-432f-a46c-ffb3180e8cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_627c02b4-e44e-4f15-a723-de61552c8206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_894e1741-4d54-432f-a46c-ffb3180e8cc0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_627c02b4-e44e-4f15-a723-de61552c8206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_c928a055-e6a4-42d1-95ef-987db26ac874" xlink:href="exel-20211231.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_894e1741-4d54-432f-a46c-ffb3180e8cc0" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_c928a055-e6a4-42d1-95ef-987db26ac874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_70aef5fa-8e05-4cfb-8b64-57a34c145260" xlink:href="exel-20211231.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_c928a055-e6a4-42d1-95ef-987db26ac874" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_70aef5fa-8e05-4cfb-8b64-57a34c145260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2d810135-b075-42b2-bc7b-67bca4372f09" xlink:href="exel-20211231.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_c928a055-e6a4-42d1-95ef-987db26ac874" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_2d810135-b075-42b2-bc7b-67bca4372f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_6cccd3d4-da77-408d-a498-2446b291e5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_894e1741-4d54-432f-a46c-ffb3180e8cc0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_6cccd3d4-da77-408d-a498-2446b291e5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a614dda2-0518-4419-8144-e3ebb0091fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_894e1741-4d54-432f-a46c-ffb3180e8cc0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_a614dda2-0518-4419-8144-e3ebb0091fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9a0d2299-3f68-4f1f-a737-609e974a5e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_bae10225-251a-43b3-8332-5331cfcc42eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9a0d2299-3f68-4f1f-a737-609e974a5e8f" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_bae10225-251a-43b3-8332-5331cfcc42eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_aaa72740-d6af-44ac-b1f1-5df7ad2a4140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9a0d2299-3f68-4f1f-a737-609e974a5e8f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_aaa72740-d6af-44ac-b1f1-5df7ad2a4140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_30b6f82d-c468-4acb-847f-06b5f52e7dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_aaa72740-d6af-44ac-b1f1-5df7ad2a4140" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_30b6f82d-c468-4acb-847f-06b5f52e7dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5c19dfc8-2639-4b80-8750-0e36f3062265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_aaa72740-d6af-44ac-b1f1-5df7ad2a4140" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5c19dfc8-2639-4b80-8750-0e36f3062265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5919bfcd-1dcb-4851-9d47-1b1b6fd2058f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_aaa72740-d6af-44ac-b1f1-5df7ad2a4140" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5919bfcd-1dcb-4851-9d47-1b1b6fd2058f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_0d7623bf-621e-4cf6-a955-86b52f924039" xlink:href="exel-20211231.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9a0d2299-3f68-4f1f-a737-609e974a5e8f" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_0d7623bf-621e-4cf6-a955-86b52f924039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_44250e55-ecfb-46e2-afbc-7f974760e5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9a0d2299-3f68-4f1f-a737-609e974a5e8f" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_44250e55-ecfb-46e2-afbc-7f974760e5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1615ba78-4695-4a0a-acc6-7a6fccb6aaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9a0d2299-3f68-4f1f-a737-609e974a5e8f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1615ba78-4695-4a0a-acc6-7a6fccb6aaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivities"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_baf6c408-9fdd-45ce-a228-8684488c51f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_63700e31-c4a8-4f2c-ade6-084701e433c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_baf6c408-9fdd-45ce-a228-8684488c51f2" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_63700e31-c4a8-4f2c-ade6-084701e433c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9bf80f15-1fed-493b-b8d5-4a285b1059ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_aaecd3a6-47b7-446f-875f-e387d1732894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9bf80f15-1fed-493b-b8d5-4a285b1059ad" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_aaecd3a6-47b7-446f-875f-e387d1732894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17a09a36-5c1f-4e3e-bc81-719b9ec0aad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85335336-1c5b-4e97-8e2b-61f6298a333f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17a09a36-5c1f-4e3e-bc81-719b9ec0aad8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85335336-1c5b-4e97-8e2b-61f6298a333f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4abe2726-6375-44cd-8f5c-1ef1c1889eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85335336-1c5b-4e97-8e2b-61f6298a333f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4abe2726-6375-44cd-8f5c-1ef1c1889eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca039346-a03a-41d0-bd04-6c3bc86d6cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4abe2726-6375-44cd-8f5c-1ef1c1889eb2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca039346-a03a-41d0-bd04-6c3bc86d6cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_1f8541a0-b7ce-4c94-a06d-5c34a3cab3d8" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca039346-a03a-41d0-bd04-6c3bc86d6cac" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_1f8541a0-b7ce-4c94-a06d-5c34a3cab3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f3606a8-f622-4c04-9ea3-997b270ccfda" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85335336-1c5b-4e97-8e2b-61f6298a333f" xlink:to="loc_srt_RangeAxis_6f3606a8-f622-4c04-9ea3-997b270ccfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_170ccc7f-c7c7-443f-8b51-226b15633a04" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6f3606a8-f622-4c04-9ea3-997b270ccfda" xlink:to="loc_srt_RangeMember_170ccc7f-c7c7-443f-8b51-226b15633a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a3eed883-78b5-4e07-8dce-59754dff0d7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_170ccc7f-c7c7-443f-8b51-226b15633a04" xlink:to="loc_srt_MinimumMember_a3eed883-78b5-4e07-8dce-59754dff0d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0d5ad35b-45e0-44a0-928f-57de59730198" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_170ccc7f-c7c7-443f-8b51-226b15633a04" xlink:to="loc_srt_MaximumMember_0d5ad35b-45e0-44a0-928f-57de59730198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis_5b96d1f6-bd6f-48a2-85e0-2943116668e8" xlink:href="exel-20211231.xsd#exel_RoyaltyTierAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85335336-1c5b-4e97-8e2b-61f6298a333f" xlink:to="loc_exel_RoyaltyTierAxis_5b96d1f6-bd6f-48a2-85e0-2943116668e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain_ad836579-1bb9-4339-a465-b9d3977aa0bc" xlink:href="exel-20211231.xsd#exel_RoyaltytierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltyTierAxis_5b96d1f6-bd6f-48a2-85e0-2943116668e8" xlink:to="loc_exel_RoyaltytierDomain_ad836579-1bb9-4339-a465-b9d3977aa0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember_91bb5a7f-df06-4dce-815b-0e7b6415d729" xlink:href="exel-20211231.xsd#exel_FinalTierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_ad836579-1bb9-4339-a465-b9d3977aa0bc" xlink:to="loc_exel_FinalTierMember_91bb5a7f-df06-4dce-815b-0e7b6415d729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b0553531-b6a5-4b4a-8b95-13648b30ed16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85335336-1c5b-4e97-8e2b-61f6298a333f" xlink:to="loc_srt_ProductOrServiceAxis_b0553531-b6a5-4b4a-8b95-13648b30ed16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_63011eb9-be13-4c08-80e8-3bfc50e37328" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b0553531-b6a5-4b4a-8b95-13648b30ed16" xlink:to="loc_srt_ProductsAndServicesDomain_63011eb9-be13-4c08-80e8-3bfc50e37328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_574ebf36-cb3c-41c0-a29b-a4c80c56e0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_63011eb9-be13-4c08-80e8-3bfc50e37328" xlink:to="loc_us-gaap_ServiceMember_574ebf36-cb3c-41c0-a29b-a4c80c56e0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85335336-1c5b-4e97-8e2b-61f6298a333f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a217d946-c699-43ae-9733-2089576457d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a217d946-c699-43ae-9733-2089576457d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_2238081d-5841-4eec-b703-7d1fa5cf23ce" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_2238081d-5841-4eec-b703-7d1fa5cf23ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_8fc8dd2a-288a-4f9d-9e62-8ef0b31921ca" xlink:href="exel-20211231.xsd#exel_UpfrontPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_UpfrontPayments_8fc8dd2a-288a-4f9d-9e62-8ef0b31921ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_fc7e3bc5-ab2d-415f-a638-867f44a0f84c" xlink:href="exel-20211231.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_fc7e3bc5-ab2d-415f-a638-867f44a0f84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_b017613a-f03d-45b2-9b03-9803ab9d4d87" xlink:href="exel-20211231.xsd#exel_MilestonePaymentsEarned"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_MilestonePaymentsEarned_b017613a-f03d-45b2-9b03-9803ab9d4d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_1fd7327b-776d-454e-9d6f-63853d216ce1" xlink:href="exel-20211231.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_1fd7327b-776d-454e-9d6f-63853d216ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_b2467928-63fd-4646-b5ec-2790723f5714" xlink:href="exel-20211231.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_b2467928-63fd-4646-b5ec-2790723f5714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a68b14fc-6cd8-43d4-b135-ed12d737be9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a68b14fc-6cd8-43d4-b135-ed12d737be9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_4a3748b4-1cad-4d72-bbac-af1341f6b409" xlink:href="exel-20211231.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_4a3748b4-1cad-4d72-bbac-af1341f6b409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_b814efe1-ee16-4d33-9478-03e6448adfde" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_b814efe1-ee16-4d33-9478-03e6448adfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_ec9a8e75-0f4f-4fdb-b433-c4639b27ea06" xlink:href="exel-20211231.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_ec9a8e75-0f4f-4fdb-b433-c4639b27ea06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_8ac84ad3-3a21-4183-8f11-869ab06aa8ef" xlink:href="exel-20211231.xsd#exel_RevenueFromContractWithCustomerCommercialSalesMilestone"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_8ac84ad3-3a21-4183-8f11-869ab06aa8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold_18e847cb-8bf3-44e8-8740-e62d85428746" xlink:href="exel-20211231.xsd#exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold_18e847cb-8bf3-44e8-8740-e62d85428746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestone_75063dba-a0b9-410f-b20c-7905df4960cf" xlink:href="exel-20211231.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestone"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8dd79e-1969-440e-8e9d-95d1e7726d92" xlink:to="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestone_75063dba-a0b9-410f-b20c-7905df4960cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_11a4d7b6-d16a-471c-aed4-281c97e274db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743762e0-d6ba-48b6-b398-551c32bafad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_11a4d7b6-d16a-471c-aed4-281c97e274db" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743762e0-d6ba-48b6-b398-551c32bafad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9e1c30f3-2228-4076-a994-13aaedcffb63" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743762e0-d6ba-48b6-b398-551c32bafad6" xlink:to="loc_srt_ProductOrServiceAxis_9e1c30f3-2228-4076-a994-13aaedcffb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_048f9959-882d-416f-9e92-61b59450434d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9e1c30f3-2228-4076-a994-13aaedcffb63" xlink:to="loc_srt_ProductsAndServicesDomain_048f9959-882d-416f-9e92-61b59450434d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_4c523360-447f-40bb-95e0-39ac301bfcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_048f9959-882d-416f-9e92-61b59450434d" xlink:to="loc_us-gaap_LicenseMember_4c523360-447f-40bb-95e0-39ac301bfcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_a332192b-add6-4d42-84f8-d6cad16c11c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_048f9959-882d-416f-9e92-61b59450434d" xlink:to="loc_us-gaap_ServiceMember_a332192b-add6-4d42-84f8-d6cad16c11c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d7724c01-45a7-4f68-bfd1-7661d128dafc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743762e0-d6ba-48b6-b398-551c32bafad6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d7724c01-45a7-4f68-bfd1-7661d128dafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a0e8ccb-3818-48f2-a326-d021f3e62861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d7724c01-45a7-4f68-bfd1-7661d128dafc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a0e8ccb-3818-48f2-a326-d021f3e62861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_97b4d5dc-79a3-4164-8a3e-d0641d3420b0" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a0e8ccb-3818-48f2-a326-d021f3e62861" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_97b4d5dc-79a3-4164-8a3e-d0641d3420b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cd9bd1f1-112f-4220-bc2d-5664cf0c4bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743762e0-d6ba-48b6-b398-551c32bafad6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cd9bd1f1-112f-4220-bc2d-5664cf0c4bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4945ef50-2ca5-4ac9-b56f-f74b344a8112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cd9bd1f1-112f-4220-bc2d-5664cf0c4bf9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4945ef50-2ca5-4ac9-b56f-f74b344a8112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb80eed6-a480-4f11-a238-1e4dee3a248a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec4f5fa5-6d2b-4381-bfa7-fb18f3fff98b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb80eed6-a480-4f11-a238-1e4dee3a248a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec4f5fa5-6d2b-4381-bfa7-fb18f3fff98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cf797e3a-3a7d-45a3-b0a4-900f7cc2ac3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec4f5fa5-6d2b-4381-bfa7-fb18f3fff98b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cf797e3a-3a7d-45a3-b0a4-900f7cc2ac3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d3d091a-a23b-4d03-9153-701e5175a4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cf797e3a-3a7d-45a3-b0a4-900f7cc2ac3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d3d091a-a23b-4d03-9153-701e5175a4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_c61421e0-f763-4d92-aa50-d1cb4aa94097" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d3d091a-a23b-4d03-9153-701e5175a4f6" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_c61421e0-f763-4d92-aa50-d1cb4aa94097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6ddaa265-c43d-444c-b4f9-8ec5afef75b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec4f5fa5-6d2b-4381-bfa7-fb18f3fff98b" xlink:to="loc_srt_StatementGeographicalAxis_6ddaa265-c43d-444c-b4f9-8ec5afef75b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b8037b10-97b8-4b18-856d-5a5cc99d5420" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6ddaa265-c43d-444c-b4f9-8ec5afef75b0" xlink:to="loc_srt_SegmentGeographicalDomain_b8037b10-97b8-4b18-856d-5a5cc99d5420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_214c0667-902e-401d-9887-58a84e00a4f9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b8037b10-97b8-4b18-856d-5a5cc99d5420" xlink:to="loc_country_JP_214c0667-902e-401d-9887-58a84e00a4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis_f636f7f2-9b7d-4cae-842f-0a8f3de8f06d" xlink:href="exel-20211231.xsd#exel_RoyaltyTierAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec4f5fa5-6d2b-4381-bfa7-fb18f3fff98b" xlink:to="loc_exel_RoyaltyTierAxis_f636f7f2-9b7d-4cae-842f-0a8f3de8f06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain_4784dfea-f374-4417-a32b-1e88c6a2d400" xlink:href="exel-20211231.xsd#exel_RoyaltytierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltyTierAxis_f636f7f2-9b7d-4cae-842f-0a8f3de8f06d" xlink:to="loc_exel_RoyaltytierDomain_4784dfea-f374-4417-a32b-1e88c6a2d400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InitialMember_9daba4f8-a7cc-4ac8-b25d-d961b6bd9696" xlink:href="exel-20211231.xsd#exel_InitialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_4784dfea-f374-4417-a32b-1e88c6a2d400" xlink:to="loc_exel_InitialMember_9daba4f8-a7cc-4ac8-b25d-d961b6bd9696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember_7491764e-db49-45fd-a904-8cee5f118e49" xlink:href="exel-20211231.xsd#exel_FinalTierMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_4784dfea-f374-4417-a32b-1e88c6a2d400" xlink:to="loc_exel_FinalTierMember_7491764e-db49-45fd-a904-8cee5f118e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e40a4be8-80a7-4dec-9690-f66e8d0805bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec4f5fa5-6d2b-4381-bfa7-fb18f3fff98b" xlink:to="loc_srt_RangeAxis_e40a4be8-80a7-4dec-9690-f66e8d0805bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aae96015-6d4f-4f79-a4a8-6f911b3cf339" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e40a4be8-80a7-4dec-9690-f66e8d0805bc" xlink:to="loc_srt_RangeMember_aae96015-6d4f-4f79-a4a8-6f911b3cf339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6c8f9d5c-6f4a-46de-a57e-420b3d6e5317" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aae96015-6d4f-4f79-a4a8-6f911b3cf339" xlink:to="loc_srt_MinimumMember_6c8f9d5c-6f4a-46de-a57e-420b3d6e5317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_26c4b122-b4e9-42ce-ae8f-75a36cfdf1a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aae96015-6d4f-4f79-a4a8-6f911b3cf339" xlink:to="loc_srt_MaximumMember_26c4b122-b4e9-42ce-ae8f-75a36cfdf1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ec4f5fa5-6d2b-4381-bfa7-fb18f3fff98b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_b9841f33-885b-4e25-b54d-aae5b3a0e517" xlink:href="exel-20211231.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_b9841f33-885b-4e25-b54d-aae5b3a0e517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_29bb118f-2f32-46c0-8def-7a2c8a68db50" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_29bb118f-2f32-46c0-8def-7a2c8a68db50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_6a96f58d-92bd-41bf-9ac4-b42a94a4bc04" xlink:href="exel-20211231.xsd#exel_PeriodOfSpecificSalesVolumeThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_PeriodOfSpecificSalesVolumeThreshold_6a96f58d-92bd-41bf-9ac4-b42a94a4bc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_f5944674-bdc8-4ff7-8b14-53490a25c7cc" xlink:href="exel-20211231.xsd#exel_UpfrontPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_UpfrontPayments_f5944674-bdc8-4ff7-8b14-53490a25c7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_88acead2-0187-4aee-9068-926ab1f9bdd2" xlink:href="exel-20211231.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_88acead2-0187-4aee-9068-926ab1f9bdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_fa64d1f8-b9b2-4e14-9fc2-0a4c82b5309c" xlink:href="exel-20211231.xsd#exel_MilestonePaymentsEarned"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_MilestonePaymentsEarned_fa64d1f8-b9b2-4e14-9fc2-0a4c82b5309c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_4bb60cb9-ae72-4244-9ec2-3bb47bbc9408" xlink:href="exel-20211231.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_4bb60cb9-ae72-4244-9ec2-3bb47bbc9408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_442e636d-1843-4232-8db1-a1a087e402a4" xlink:href="exel-20211231.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_442e636d-1843-4232-8db1-a1a087e402a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTier_21021150-f5d8-41bc-b9a6-49be9ad30840" xlink:href="exel-20211231.xsd#exel_RoyaltyTier"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_RoyaltyTier_21021150-f5d8-41bc-b9a6-49be9ad30840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_b695739f-cba9-48e5-899b-d8bed01d691e" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_b695739f-cba9-48e5-899b-d8bed01d691e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_46e28330-4558-43ea-b89c-3445b812696c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_46e28330-4558-43ea-b89c-3445b812696c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_8114f4cc-d73b-45da-82ab-b13e73c92358" xlink:href="exel-20211231.xsd#exel_RevenueFromContractWithCustomerCommercialSalesMilestone"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_8114f4cc-d73b-45da-82ab-b13e73c92358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_036f8292-1f79-47de-b016-fb09dffc33b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_03cbff15-2d76-4ecf-87ba-92f1deb6dc09" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_036f8292-1f79-47de-b016-fb09dffc33b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0ef505df-9003-4c4a-b3af-0f7877fd92d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84435ab7-c58d-4c1a-beab-ec990ed1bd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0ef505df-9003-4c4a-b3af-0f7877fd92d6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84435ab7-c58d-4c1a-beab-ec990ed1bd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_895c49ce-fbf6-4a62-8efa-859c8257e0d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84435ab7-c58d-4c1a-beab-ec990ed1bd8d" xlink:to="loc_srt_ProductOrServiceAxis_895c49ce-fbf6-4a62-8efa-859c8257e0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_68079519-2737-4ef6-a02e-111d0eda4c0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_895c49ce-fbf6-4a62-8efa-859c8257e0d3" xlink:to="loc_srt_ProductsAndServicesDomain_68079519-2737-4ef6-a02e-111d0eda4c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_4c97f977-f532-4abf-a30b-af66f2f854bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_68079519-2737-4ef6-a02e-111d0eda4c0a" xlink:to="loc_us-gaap_LicenseMember_4c97f977-f532-4abf-a30b-af66f2f854bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ce2d7ac1-bc19-4618-b605-2d55681f6014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_68079519-2737-4ef6-a02e-111d0eda4c0a" xlink:to="loc_us-gaap_ServiceMember_ce2d7ac1-bc19-4618-b605-2d55681f6014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b2a8bc9f-eac8-4e18-bdda-24e0efe444da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84435ab7-c58d-4c1a-beab-ec990ed1bd8d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b2a8bc9f-eac8-4e18-bdda-24e0efe444da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e437dda-9d2f-4752-8620-6eaf333f2261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b2a8bc9f-eac8-4e18-bdda-24e0efe444da" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e437dda-9d2f-4752-8620-6eaf333f2261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_0be3568b-1db8-408e-886a-489a27cbf2ca" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e437dda-9d2f-4752-8620-6eaf333f2261" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_0be3568b-1db8-408e-886a-489a27cbf2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3d13ea00-aa41-4200-96c3-4a7c73bff551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84435ab7-c58d-4c1a-beab-ec990ed1bd8d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3d13ea00-aa41-4200-96c3-4a7c73bff551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_260a8cff-35b1-45bb-908c-974a6c1e6da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3d13ea00-aa41-4200-96c3-4a7c73bff551" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_260a8cff-35b1-45bb-908c-974a6c1e6da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34c85be2-a835-403f-9fc0-c8b205207478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1690e4a6-c424-4be9-bb85-8dda9c67b07e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34c85be2-a835-403f-9fc0-c8b205207478" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1690e4a6-c424-4be9-bb85-8dda9c67b07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8041e8f5-32e3-4f33-a5be-3562af72359a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1690e4a6-c424-4be9-bb85-8dda9c67b07e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8041e8f5-32e3-4f33-a5be-3562af72359a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e93af35a-1438-4e52-bee1-850029c614c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8041e8f5-32e3-4f33-a5be-3562af72359a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e93af35a-1438-4e52-bee1-850029c614c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_98378ea8-1c6c-453f-8148-7fa799e38770" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e93af35a-1438-4e52-bee1-850029c614c6" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_98378ea8-1c6c-453f-8148-7fa799e38770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5909caa5-b020-4b21-863a-b96b910945ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1690e4a6-c424-4be9-bb85-8dda9c67b07e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5909caa5-b020-4b21-863a-b96b910945ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_ef052923-7d35-40d9-9936-e76779b4ec60" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5909caa5-b020-4b21-863a-b96b910945ae" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_ef052923-7d35-40d9-9936-e76779b4ec60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_9c8b77b5-7c3f-48e5-a315-e71d78668141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5909caa5-b020-4b21-863a-b96b910945ae" xlink:to="loc_us-gaap_RoyaltyExpense_9c8b77b5-7c3f-48e5-a315-e71d78668141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3c57075c-2f26-43a4-992b-0371eebfbf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61179fd8-b1e2-4409-aba3-21c62d5e296c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3c57075c-2f26-43a4-992b-0371eebfbf1c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61179fd8-b1e2-4409-aba3-21c62d5e296c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6cb3e683-b913-43ae-a1dd-824d9c640aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61179fd8-b1e2-4409-aba3-21c62d5e296c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6cb3e683-b913-43ae-a1dd-824d9c640aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4054d52e-5d7e-4cb0-b43d-bbe89f2206d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6cb3e683-b913-43ae-a1dd-824d9c640aee" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4054d52e-5d7e-4cb0-b43d-bbe89f2206d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_b28bbaf0-e79f-4041-8c9a-8e6debbe3337" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4054d52e-5d7e-4cb0-b43d-bbe89f2206d9" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_b28bbaf0-e79f-4041-8c9a-8e6debbe3337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_a41f3923-d5c4-46e1-ba53-5fe132b75050" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4054d52e-5d7e-4cb0-b43d-bbe89f2206d9" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_a41f3923-d5c4-46e1-ba53-5fe132b75050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2a665028-5c92-4335-a243-cc296647f04e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61179fd8-b1e2-4409-aba3-21c62d5e296c" xlink:to="loc_srt_ProductOrServiceAxis_2a665028-5c92-4335-a243-cc296647f04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4feaae6b-1f0e-4740-9bb3-4b02b56c3176" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2a665028-5c92-4335-a243-cc296647f04e" xlink:to="loc_srt_ProductsAndServicesDomain_4feaae6b-1f0e-4740-9bb3-4b02b56c3176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_e30fa1b5-af49-412c-9bb5-0572bd64b4e2" xlink:href="exel-20211231.xsd#exel_CotellicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4feaae6b-1f0e-4740-9bb3-4b02b56c3176" xlink:to="loc_exel_CotellicMember_e30fa1b5-af49-412c-9bb5-0572bd64b4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c1a6057a-ec33-4cd0-b62a-a07791c00f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61179fd8-b1e2-4409-aba3-21c62d5e296c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c1a6057a-ec33-4cd0-b62a-a07791c00f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38215af6-f29b-40ea-96f3-0c9bc7518a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c1a6057a-ec33-4cd0-b62a-a07791c00f1b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38215af6-f29b-40ea-96f3-0c9bc7518a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_579a1c72-7069-4c55-b969-f544803cceb8" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementAchievedMilestoneAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c1a6057a-ec33-4cd0-b62a-a07791c00f1b" xlink:to="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_579a1c72-7069-4c55-b969-f544803cceb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_3285d35c-951e-461f-94c9-8d49fa96d687" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c1a6057a-ec33-4cd0-b62a-a07791c00f1b" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_3285d35c-951e-461f-94c9-8d49fa96d687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2af090d-74c9-4566-bda5-1323d95d4a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_db560bd7-fdd5-4c4c-bbaf-ddee4e1a9c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2af090d-74c9-4566-bda5-1323d95d4a32" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_db560bd7-fdd5-4c4c-bbaf-ddee4e1a9c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3535e118-d257-474e-98d0-8bf158436220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_db560bd7-fdd5-4c4c-bbaf-ddee4e1a9c3f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3535e118-d257-474e-98d0-8bf158436220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d674979-f989-41d8-9b6e-7061e799ba33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3535e118-d257-474e-98d0-8bf158436220" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d674979-f989-41d8-9b6e-7061e799ba33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_26bee9b6-c853-4a2b-b135-f602e7c5d5a7" xlink:href="exel-20211231.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d674979-f989-41d8-9b6e-7061e799ba33" xlink:to="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_26bee9b6-c853-4a2b-b135-f602e7c5d5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsIncMember_bf277a87-020c-4eec-8757-7f86ed021659" xlink:href="exel-20211231.xsd#exel_CollaborationAgreementWithIconicTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d674979-f989-41d8-9b6e-7061e799ba33" xlink:to="loc_exel_CollaborationAgreementWithIconicTherapeuticsIncMember_bf277a87-020c-4eec-8757-7f86ed021659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_0512f4c8-2d54-4eda-a81b-f61f90148059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_db560bd7-fdd5-4c4c-bbaf-ddee4e1a9c3f" xlink:to="loc_us-gaap_AssetAcquisitionAxis_0512f4c8-2d54-4eda-a81b-f61f90148059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_e0702aab-46d5-402c-87ef-f8a27b98e78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_0512f4c8-2d54-4eda-a81b-f61f90148059" xlink:to="loc_us-gaap_AssetAcquisitionDomain_e0702aab-46d5-402c-87ef-f8a27b98e78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_47719f77-f632-4879-ab68-d7877f40d69e" xlink:href="exel-20211231.xsd#exel_CollaborativeAgreementWithGamaMabsPharmaSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e0702aab-46d5-402c-87ef-f8a27b98e78e" xlink:to="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_47719f77-f632-4879-ab68-d7877f40d69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_db560bd7-fdd5-4c4c-bbaf-ddee4e1a9c3f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_e53b5ca8-cff9-430b-bed0-468434693cc0" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_e53b5ca8-cff9-430b-bed0-468434693cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_519591b4-6949-41e4-9458-b583a752c4ba" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_519591b4-6949-41e4-9458-b583a752c4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_d56ba9b1-cb35-4230-bc0a-eb668a0fd494" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_d56ba9b1-cb35-4230-bc0a-eb668a0fd494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_308b32e8-0204-4b13-8a8c-002d8d7591ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_308b32e8-0204-4b13-8a8c-002d8d7591ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_89b2e573-130f-47a7-9c2b-9e64044a9550" xlink:href="exel-20211231.xsd#exel_AssetAcquisitionPaymentUponClosingOfTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_89b2e573-130f-47a7-9c2b-9e64044a9550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_c1f93d14-82ab-48cc-a0a4-e8d98e115941" xlink:href="exel-20211231.xsd#exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_c1f93d14-82ab-48cc-a0a4-e8d98e115941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_a4104bbf-2f81-46a7-9e0a-390c37735919" xlink:href="exel-20211231.xsd#exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_a4104bbf-2f81-46a7-9e0a-390c37735919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsFinalPayment_ea0612d9-7732-4a4a-a0d8-040c8b39a73b" xlink:href="exel-20211231.xsd#exel_CollaborativeArrangementRightsAndObligationsFinalPayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsFinalPayment_ea0612d9-7732-4a4a-a0d8-040c8b39a73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_664d537e-dc4c-4d81-9777-23f7a98f549a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f9fb7-55dc-4342-82a0-6b3e871e396f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_664d537e-dc4c-4d81-9777-23f7a98f549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20211231.xsd#CashandInvestments"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff91f31c-85e2-4e11-b605-34f31832f280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_9a505d68-35e3-41d5-853c-bb422d279e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff91f31c-85e2-4e11-b605-34f31832f280" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_9a505d68-35e3-41d5-853c-bb422d279e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20211231.xsd#CashandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c38332b5-4441-403f-9af5-70e71b46aae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_94b2f7af-65d1-4b40-a9d0-0bc410b31144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c38332b5-4441-403f-9af5-70e71b46aae4" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_94b2f7af-65d1-4b40-a9d0-0bc410b31144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_3898ce25-74c7-4b75-9df3-5d790b874f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c38332b5-4441-403f-9af5-70e71b46aae4" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_3898ce25-74c7-4b75-9df3-5d790b874f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_4c3f40fa-fb2d-428f-92cb-6a0c6c912dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c38332b5-4441-403f-9af5-70e71b46aae4" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_4c3f40fa-fb2d-428f-92cb-6a0c6c912dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_67a04fc9-df83-4aa9-b07f-10a0bf4d2bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c38332b5-4441-403f-9af5-70e71b46aae4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_67a04fc9-df83-4aa9-b07f-10a0bf4d2bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e9124933-e054-44ed-9a96-b71d8cd4f106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c38332b5-4441-403f-9af5-70e71b46aae4" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e9124933-e054-44ed-9a96-b71d8cd4f106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a3bb7fd6-054e-4210-bacc-bd6fb7991abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3bcb51a-baeb-4b9d-a9e2-c501db22e4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a3bb7fd6-054e-4210-bacc-bd6fb7991abd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3bcb51a-baeb-4b9d-a9e2-c501db22e4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_78dde35d-444a-40d8-962e-3da9e7623a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a3bb7fd6-054e-4210-bacc-bd6fb7991abd" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_78dde35d-444a-40d8-962e-3da9e7623a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e919aa5-b52d-4ae8-bed1-e400cbf52cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a3bb7fd6-054e-4210-bacc-bd6fb7991abd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e919aa5-b52d-4ae8-bed1-e400cbf52cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e59b6073-9a5b-496a-97f2-1ac974598b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_77d87529-e70f-476d-a87a-4ae9845b203c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e59b6073-9a5b-496a-97f2-1ac974598b43" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_77d87529-e70f-476d-a87a-4ae9845b203c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_06abf681-4a6c-4e39-a5f0-de0b11f90c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e59b6073-9a5b-496a-97f2-1ac974598b43" xlink:to="loc_us-gaap_InterestReceivable_06abf681-4a6c-4e39-a5f0-de0b11f90c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_870910fd-8333-48d1-a01d-a500a6fe8e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e59b6073-9a5b-496a-97f2-1ac974598b43" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_870910fd-8333-48d1-a01d-a500a6fe8e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_a4189aa9-63ea-42a9-8df1-019ac47259d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e59b6073-9a5b-496a-97f2-1ac974598b43" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_a4189aa9-63ea-42a9-8df1-019ac47259d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a79b50ca-e2ea-4650-88ce-6322c8529599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f8a0fcd5-641e-4eda-87dd-4864727a8c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a79b50ca-e2ea-4650-88ce-6322c8529599" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f8a0fcd5-641e-4eda-87dd-4864727a8c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6f0b612e-caf5-4b27-8114-d024069b5c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f8a0fcd5-641e-4eda-87dd-4864727a8c24" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6f0b612e-caf5-4b27-8114-d024069b5c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6f0b612e-caf5-4b27-8114-d024069b5c34" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9ef03fe7-41d7-46aa-8c30-12bf39816a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_CommercialPaperMember_9ef03fe7-41d7-46aa-8c30-12bf39816a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_1c0ce415-8de9-4302-8b4c-dfb7525ac9df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_1c0ce415-8de9-4302-8b4c-dfb7525ac9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_7730aa09-ac87-47cb-87d0-27ebefadf401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_7730aa09-ac87-47cb-87d0-27ebefadf401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_f9372147-9b09-47d6-acbc-f6066c132b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_MunicipalBondsMember_f9372147-9b09-47d6-acbc-f6066c132b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_780bcb8a-8e3b-43e5-b17e-9cfc6ce52d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_CashMember_780bcb8a-8e3b-43e5-b17e-9cfc6ce52d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_04d7d492-1aad-4d38-b31d-be0001f78911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_MoneyMarketFundsMember_04d7d492-1aad-4d38-b31d-be0001f78911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_cafc9479-8834-49eb-ba3e-94ee7587a93b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3403c458-3337-4301-8dc8-0d1a282e7358" xlink:to="loc_us-gaap_CertificatesOfDepositMember_cafc9479-8834-49eb-ba3e-94ee7587a93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f8a0fcd5-641e-4eda-87dd-4864727a8c24" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e0fe95a1-9a99-40a5-ae60-049a24399e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e0fe95a1-9a99-40a5-ae60-049a24399e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b57bb098-6127-4ebc-aed0-ee3b7278bbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e0fe95a1-9a99-40a5-ae60-049a24399e30" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b57bb098-6127-4ebc-aed0-ee3b7278bbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e85551d7-7915-433a-960f-74166a50388c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e0fe95a1-9a99-40a5-ae60-049a24399e30" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e85551d7-7915-433a-960f-74166a50388c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4ac0aae1-afb9-49f1-a8d0-9cbc3b298d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e0fe95a1-9a99-40a5-ae60-049a24399e30" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4ac0aae1-afb9-49f1-a8d0-9cbc3b298d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3acd844b-be21-4a1f-a5c8-47695d6d1292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e0fe95a1-9a99-40a5-ae60-049a24399e30" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3acd844b-be21-4a1f-a5c8-47695d6d1292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1b2836a1-41d7-480a-90c4-9c25bac65831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1b2836a1-41d7-480a-90c4-9c25bac65831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_ccfc7bd1-ef8b-4cbf-9601-9c98d8576bac" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1b2836a1-41d7-480a-90c4-9c25bac65831" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_ccfc7bd1-ef8b-4cbf-9601-9c98d8576bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_426b7648-8ab3-4940-a97a-1a0c7ae95f72" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1b2836a1-41d7-480a-90c4-9c25bac65831" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_426b7648-8ab3-4940-a97a-1a0c7ae95f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_aabc7fdf-30be-4a17-9648-baf94f378545" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1b2836a1-41d7-480a-90c4-9c25bac65831" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_aabc7fdf-30be-4a17-9648-baf94f378545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_ae1e5fb0-cca3-4a85-87ed-1ab932b384c5" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1b2836a1-41d7-480a-90c4-9c25bac65831" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_ae1e5fb0-cca3-4a85-87ed-1ab932b384c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_7b0f43b8-ef7e-410e-987e-3964badd9976" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_7b0f43b8-ef7e-410e-987e-3964badd9976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f16d46e-3c3e-47fc-a75c-4e0781a9f26a" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3f16d46e-3c3e-47fc-a75c-4e0781a9f26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cbc270fd-7b75-41ad-a118-517e173611a1" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cbc270fd-7b75-41ad-a118-517e173611a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04360efe-3f3d-42d8-bc83-4022c91b4222" xlink:href="exel-20211231.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_68a661a2-3810-46a8-8b58-e661be5b6bbe" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04360efe-3f3d-42d8-bc83-4022c91b4222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f18f6241-c811-41a2-8cd1-2829dc477e92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d8af3df-a830-4bbb-97bb-aa17b688c260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f18f6241-c811-41a2-8cd1-2829dc477e92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d8af3df-a830-4bbb-97bb-aa17b688c260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_01267435-33f4-486b-844a-9e361bb16ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d8af3df-a830-4bbb-97bb-aa17b688c260" xlink:to="loc_us-gaap_FinancialInstrumentAxis_01267435-33f4-486b-844a-9e361bb16ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3aba385-2559-4111-ab90-3d3567501ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_01267435-33f4-486b-844a-9e361bb16ee7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3aba385-2559-4111-ab90-3d3567501ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_93662802-28d4-4783-bc61-6e4c313f909d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3aba385-2559-4111-ab90-3d3567501ba6" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_93662802-28d4-4783-bc61-6e4c313f909d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9c1ae88d-8349-42a1-b230-b0ef5f4927de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3aba385-2559-4111-ab90-3d3567501ba6" xlink:to="loc_us-gaap_CommercialPaperMember_9c1ae88d-8349-42a1-b230-b0ef5f4927de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_50276502-814c-41b2-98c4-4c6a566ea939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3aba385-2559-4111-ab90-3d3567501ba6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_50276502-814c-41b2-98c4-4c6a566ea939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_cd57e0ae-94d4-456c-a11b-6a45fc22df43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3aba385-2559-4111-ab90-3d3567501ba6" xlink:to="loc_us-gaap_MunicipalBondsMember_cd57e0ae-94d4-456c-a11b-6a45fc22df43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4f44fd65-3f25-46ec-8aa7-74165d29972c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1d8af3df-a830-4bbb-97bb-aa17b688c260" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4f44fd65-3f25-46ec-8aa7-74165d29972c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c331f23b-0fe9-4ff5-b3d1-bc51b07387a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4f44fd65-3f25-46ec-8aa7-74165d29972c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c331f23b-0fe9-4ff5-b3d1-bc51b07387a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_4ee4e039-0e1b-4c51-9d40-065a0f90430c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4f44fd65-3f25-46ec-8aa7-74165d29972c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_4ee4e039-0e1b-4c51-9d40-065a0f90430c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6f2a9820-88a0-4634-873e-d706c62efbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d9d6e366-7f74-45bd-a3ba-02c2482253a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6f2a9820-88a0-4634-873e-d706c62efbf7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d9d6e366-7f74-45bd-a3ba-02c2482253a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_147d935b-cbfd-44e0-b391-fd26c17adac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6f2a9820-88a0-4634-873e-d706c62efbf7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_147d935b-cbfd-44e0-b391-fd26c17adac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c3691a5e-f72a-4dfc-8978-ed74847ae600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6f2a9820-88a0-4634-873e-d706c62efbf7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c3691a5e-f72a-4dfc-8978-ed74847ae600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20211231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f953b394-8d98-4266-9abc-01ab64bbcf83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c5f4041c-6d58-4a78-ab17-ca90aab255c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f953b394-8d98-4266-9abc-01ab64bbcf83" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c5f4041c-6d58-4a78-ab17-ca90aab255c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20211231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d4875453-8919-43e3-a593-b38d6f8d43ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2f4e8636-75e8-48b2-9b5b-62c5b680fd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d4875453-8919-43e3-a593-b38d6f8d43ff" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2f4e8636-75e8-48b2-9b5b-62c5b680fd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f20bb072-cf6a-45a7-9182-d7784f51dfa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639f3fd7-d1e0-4d79-9cc7-4dd5acba71e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f20bb072-cf6a-45a7-9182-d7784f51dfa7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639f3fd7-d1e0-4d79-9cc7-4dd5acba71e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_48a2e546-27e7-4e2f-8d93-35c55630be70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639f3fd7-d1e0-4d79-9cc7-4dd5acba71e3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_48a2e546-27e7-4e2f-8d93-35c55630be70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_48a2e546-27e7-4e2f-8d93-35c55630be70" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7df293e9-5c1c-4365-bad6-e9dc8312249f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:to="loc_us-gaap_CommercialPaperMember_7df293e9-5c1c-4365-bad6-e9dc8312249f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_d151e65b-864d-4830-9c22-7c6b9b55092f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_d151e65b-864d-4830-9c22-7c6b9b55092f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_2b2fc4b1-d244-4cd6-b417-2bafd8ef0886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_2b2fc4b1-d244-4cd6-b417-2bafd8ef0886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_be044d1a-670f-483d-99b1-4957890af2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:to="loc_us-gaap_MunicipalBondsMember_be044d1a-670f-483d-99b1-4957890af2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a3984024-8b3b-4ece-a7a2-ccf87d5aae94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a3984024-8b3b-4ece-a7a2-ccf87d5aae94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_12361b24-9589-4926-9b65-1c0416eb4bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_119d249a-ecdc-4d03-a3ad-a3ca657b8276" xlink:to="loc_us-gaap_CertificatesOfDepositMember_12361b24-9589-4926-9b65-1c0416eb4bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_987fb338-726b-4b13-a789-04fc10b8dbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639f3fd7-d1e0-4d79-9cc7-4dd5acba71e3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_987fb338-726b-4b13-a789-04fc10b8dbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8711abd-5c8b-486c-bd7f-420f9172542e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_987fb338-726b-4b13-a789-04fc10b8dbfd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8711abd-5c8b-486c-bd7f-420f9172542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_18af50b3-74aa-49b9-b006-0d115cdbf314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8711abd-5c8b-486c-bd7f-420f9172542e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_18af50b3-74aa-49b9-b006-0d115cdbf314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f2a7d4d0-39f7-4c01-bd75-dfb03154d7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8711abd-5c8b-486c-bd7f-420f9172542e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f2a7d4d0-39f7-4c01-bd75-dfb03154d7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bf03d77-d757-47b0-9028-ad3c76f60775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639f3fd7-d1e0-4d79-9cc7-4dd5acba71e3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bf03d77-d757-47b0-9028-ad3c76f60775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f477d48f-1e1b-46d4-b435-92dc0f9151c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bf03d77-d757-47b0-9028-ad3c76f60775" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f477d48f-1e1b-46d4-b435-92dc0f9151c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7a84a66b-5bcb-4b7f-811f-c10d6f82a5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f477d48f-1e1b-46d4-b435-92dc0f9151c6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7a84a66b-5bcb-4b7f-811f-c10d6f82a5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b679941c-79b9-4e01-8c55-5175222dfba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639f3fd7-d1e0-4d79-9cc7-4dd5acba71e3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b679941c-79b9-4e01-8c55-5175222dfba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74e91be0-876a-4ca2-8273-d20e41e6cd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b679941c-79b9-4e01-8c55-5175222dfba5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74e91be0-876a-4ca2-8273-d20e41e6cd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7387d4cc-a9c7-4b95-b80d-1dac103af486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b679941c-79b9-4e01-8c55-5175222dfba5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7387d4cc-a9c7-4b95-b80d-1dac103af486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d17f1a67-0806-486a-a7ed-e91c3ad0a706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b679941c-79b9-4e01-8c55-5175222dfba5" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d17f1a67-0806-486a-a7ed-e91c3ad0a706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20211231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2fad5631-1baf-4447-a300-a08614385ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_ea7126f5-8964-471b-8d3d-e73c951323da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2fad5631-1baf-4447-a300-a08614385ab0" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_ea7126f5-8964-471b-8d3d-e73c951323da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20211231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_654711a5-372a-4e6c-887e-36b64134add5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c97cf660-126f-48d9-9050-1d365021774d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_654711a5-372a-4e6c-887e-36b64134add5" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c97cf660-126f-48d9-9050-1d365021774d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_907a9186-5bde-42fa-ae83-aa77374b85a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_e4a9f54d-9312-48c3-a28e-9df96785de42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_907a9186-5bde-42fa-ae83-aa77374b85a9" xlink:to="loc_us-gaap_InventoryCurrentTable_e4a9f54d-9312-48c3-a28e-9df96785de42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c42a6b01-1355-4fc4-970e-55074486a781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_e4a9f54d-9312-48c3-a28e-9df96785de42" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c42a6b01-1355-4fc4-970e-55074486a781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f66108ce-0b78-44eb-8dfb-22407752ce11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c42a6b01-1355-4fc4-970e-55074486a781" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f66108ce-0b78-44eb-8dfb-22407752ce11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_89044f73-1e64-40d3-ac9a-99e8da216ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f66108ce-0b78-44eb-8dfb-22407752ce11" xlink:to="loc_us-gaap_InventoriesMember_89044f73-1e64-40d3-ac9a-99e8da216ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_60778be7-2f0d-4bd5-b845-4fca774e2c45" xlink:href="exel-20211231.xsd#exel_OtherLongtermAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f66108ce-0b78-44eb-8dfb-22407752ce11" xlink:to="loc_exel_OtherLongtermAssetsMember_60778be7-2f0d-4bd5-b845-4fca774e2c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_e2720058-9a92-42e6-8e2c-b857b6c2c0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_e4a9f54d-9312-48c3-a28e-9df96785de42" xlink:to="loc_us-gaap_InventoryLineItems_e2720058-9a92-42e6-8e2c-b857b6c2c0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_d60a4c2e-c345-4fe1-a44c-8c4ea61be07d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_e2720058-9a92-42e6-8e2c-b857b6c2c0c7" xlink:to="loc_us-gaap_InventoryRawMaterials_d60a4c2e-c345-4fe1-a44c-8c4ea61be07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_d7317998-4d91-47b4-b105-7d85da5a3328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_e2720058-9a92-42e6-8e2c-b857b6c2c0c7" xlink:to="loc_us-gaap_InventoryWorkInProcess_d7317998-4d91-47b4-b105-7d85da5a3328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_2312de91-58fd-4a03-993c-a40326f347aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_e2720058-9a92-42e6-8e2c-b857b6c2c0c7" xlink:to="loc_us-gaap_InventoryFinishedGoods_2312de91-58fd-4a03-993c-a40326f347aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_9dbac1b9-c338-410d-84b6-eafcb3e81e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_e2720058-9a92-42e6-8e2c-b857b6c2c0c7" xlink:to="loc_us-gaap_InventoryGross_9dbac1b9-c338-410d-84b6-eafcb3e81e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="exel-20211231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_10f97922-3a86-4ae8-b9ff-cf3068caf2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_aa0da512-c909-490f-885d-3fc0db312c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_10f97922-3a86-4ae8-b9ff-cf3068caf2ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_aa0da512-c909-490f-885d-3fc0db312c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="exel-20211231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4dc14b86-9c3d-4908-aec5-baeb8d487c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0b896789-b7a2-4745-811e-89a3df5284f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4dc14b86-9c3d-4908-aec5-baeb8d487c09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0b896789-b7a2-4745-811e-89a3df5284f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_322af8ef-0a01-48a2-8e2c-7529edc76b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9afda594-f041-441a-9364-9583694857ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_322af8ef-0a01-48a2-8e2c-7529edc76b6c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9afda594-f041-441a-9364-9583694857ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0458e57-d4c5-4370-a3bf-b58e35967640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9afda594-f041-441a-9364-9583694857ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0458e57-d4c5-4370-a3bf-b58e35967640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0458e57-d4c5-4370-a3bf-b58e35967640" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_73bdb45c-11b7-4b2b-b2e7-d45c3919b3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_73bdb45c-11b7-4b2b-b2e7-d45c3919b3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_b9d08fa7-85dd-427a-8057-f40ca90b8d95" xlink:href="exel-20211231.xsd#exel_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_b9d08fa7-85dd-427a-8057-f40ca90b8d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_74d5dd50-47d7-433e-b3e4-1827c3a4770e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_74d5dd50-47d7-433e-b3e4-1827c3a4770e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LaboratoryEquipmentMember_b826aaa6-142e-43ee-96f0-b577e85cf9a8" xlink:href="exel-20211231.xsd#exel_LaboratoryEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:to="loc_exel_LaboratoryEquipmentMember_b826aaa6-142e-43ee-96f0-b577e85cf9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b7e221f1-a3f8-40d2-b4e0-48b3614591b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a031269b-8a82-49b1-8ab7-c2f1747eb43a" xlink:to="loc_us-gaap_ConstructionInProgressMember_b7e221f1-a3f8-40d2-b4e0-48b3614591b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_940c1540-637d-4737-95d9-e8e102666806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9afda594-f041-441a-9364-9583694857ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_940c1540-637d-4737-95d9-e8e102666806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d9fb163e-c4f3-4217-a597-820ffd177705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_940c1540-637d-4737-95d9-e8e102666806" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d9fb163e-c4f3-4217-a597-820ffd177705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2e88d3d9-6637-46f0-9ae0-90a62cc7eb74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_940c1540-637d-4737-95d9-e8e102666806" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2e88d3d9-6637-46f0-9ae0-90a62cc7eb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b0ee0fa8-8013-4622-819c-b0088aba79c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_940c1540-637d-4737-95d9-e8e102666806" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b0ee0fa8-8013-4622-819c-b0088aba79c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2b7ccb91-50fa-40c5-be6e-4f1eaa6b6134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_940c1540-637d-4737-95d9-e8e102666806" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2b7ccb91-50fa-40c5-be6e-4f1eaa6b6134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_656538fb-bdfb-40bb-adb0-bb2f127a35b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0ca55dba-1c04-4f0c-a3a3-17eebcd2085e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_656538fb-bdfb-40bb-adb0-bb2f127a35b8" xlink:to="loc_us-gaap_Depreciation_0ca55dba-1c04-4f0c-a3a3-17eebcd2085e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_55d9e014-afa2-4e6b-838d-e594040b3d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ca6572ab-871b-4dd5-86cb-cd3af2e924a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_55d9e014-afa2-4e6b-838d-e594040b3d19" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ca6572ab-871b-4dd5-86cb-cd3af2e924a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc89fb3-9969-4425-889f-3424a425d2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2b9387ae-fc73-42db-90f4-c94f38791931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc89fb3-9969-4425-889f-3424a425d2b5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2b9387ae-fc73-42db-90f4-c94f38791931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_9026a2f3-0c2f-4e83-9737-8c8b86a62109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc89fb3-9969-4425-889f-3424a425d2b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_9026a2f3-0c2f-4e83-9737-8c8b86a62109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_415c6544-0190-49a1-8d62-d8d7b3eaf126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc89fb3-9969-4425-889f-3424a425d2b5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_415c6544-0190-49a1-8d62-d8d7b3eaf126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_54a1ae38-9a7f-4b93-a361-a56936af0edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc89fb3-9969-4425-889f-3424a425d2b5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_54a1ae38-9a7f-4b93-a361-a56936af0edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_278cd40c-5f9a-4afd-ad6b-d996a17f4f31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc89fb3-9969-4425-889f-3424a425d2b5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_278cd40c-5f9a-4afd-ad6b-d996a17f4f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_4fbeb4b7-f39b-45af-ba3b-97944bae0c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc89fb3-9969-4425-889f-3424a425d2b5" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_4fbeb4b7-f39b-45af-ba3b-97944bae0c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_2397db82-e4c7-4e85-946b-e16d6720f7b3" xlink:href="exel-20211231.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fc89fb3-9969-4425-889f-3424a425d2b5" xlink:to="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_2397db82-e4c7-4e85-946b-e16d6720f7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac1b8ec8-05e6-4c1c-89ad-cc4b5844ad95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94ffe4b3-86a2-4688-a99c-ded2002fd0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac1b8ec8-05e6-4c1c-89ad-cc4b5844ad95" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94ffe4b3-86a2-4688-a99c-ded2002fd0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_839a0e99-2efe-434d-b4e7-c8dd76185842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94ffe4b3-86a2-4688-a99c-ded2002fd0fb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_839a0e99-2efe-434d-b4e7-c8dd76185842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_88b467a5-a649-4e73-8086-2c7d36367832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_839a0e99-2efe-434d-b4e7-c8dd76185842" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_88b467a5-a649-4e73-8086-2c7d36367832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_67341d32-c257-4d79-9b98-c8b3c43b933d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88b467a5-a649-4e73-8086-2c7d36367832" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_67341d32-c257-4d79-9b98-c8b3c43b933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3ec28c67-c32e-416c-8f61-9726f5de5fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88b467a5-a649-4e73-8086-2c7d36367832" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3ec28c67-c32e-416c-8f61-9726f5de5fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db6e2077-8487-446b-bb8d-2e99cfb55095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94ffe4b3-86a2-4688-a99c-ded2002fd0fb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db6e2077-8487-446b-bb8d-2e99cfb55095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_68199ea4-9e17-4270-b466-c37def635ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db6e2077-8487-446b-bb8d-2e99cfb55095" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_68199ea4-9e17-4270-b466-c37def635ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d930c6b3-ca3d-454c-868f-aca53abcb578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0c693a-ac11-4bda-8da3-d2459cb2b3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d930c6b3-ca3d-454c-868f-aca53abcb578" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0c693a-ac11-4bda-8da3-d2459cb2b3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1770c061-9e4c-4bfd-a217-9a029c0c5a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0c693a-ac11-4bda-8da3-d2459cb2b3bf" xlink:to="loc_us-gaap_AwardTypeAxis_1770c061-9e4c-4bfd-a217-9a029c0c5a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183a6f4b-208a-462b-ac4e-0f463258e75f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1770c061-9e4c-4bfd-a217-9a029c0c5a17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183a6f4b-208a-462b-ac4e-0f463258e75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bf12f4f3-50ed-4f86-bcb6-ea7d162d66cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183a6f4b-208a-462b-ac4e-0f463258e75f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bf12f4f3-50ed-4f86-bcb6-ea7d162d66cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_676d22e1-7586-4777-ac61-0073d7954959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183a6f4b-208a-462b-ac4e-0f463258e75f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_676d22e1-7586-4777-ac61-0073d7954959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_dffc53f1-c845-44df-aed3-3f1105448f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183a6f4b-208a-462b-ac4e-0f463258e75f" xlink:to="loc_us-gaap_PerformanceSharesMember_dffc53f1-c845-44df-aed3-3f1105448f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_17586be2-ffc5-4e76-a481-9e6158883ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183a6f4b-208a-462b-ac4e-0f463258e75f" xlink:to="loc_us-gaap_EmployeeStockMember_17586be2-ffc5-4e76-a481-9e6158883ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67ade02d-c5fe-47e8-be3a-0fa911bf5252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e0c693a-ac11-4bda-8da3-d2459cb2b3bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67ade02d-c5fe-47e8-be3a-0fa911bf5252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_57c983a6-2a6c-4c67-b17b-443150cc5aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67ade02d-c5fe-47e8-be3a-0fa911bf5252" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_57c983a6-2a6c-4c67-b17b-443150cc5aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_55205694-d7a8-4b16-926f-65c02a8e4ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_55205694-d7a8-4b16-926f-65c02a8e4ef8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a7c266b-fd38-4d21-bd7b-6ee8b1bf80a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:to="loc_us-gaap_AwardTypeAxis_8a7c266b-fd38-4d21-bd7b-6ee8b1bf80a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d086e28-3dc6-4d9f-a3f5-f9f5c9ee77dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8a7c266b-fd38-4d21-bd7b-6ee8b1bf80a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d086e28-3dc6-4d9f-a3f5-f9f5c9ee77dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b95f1107-7783-4ac9-ab89-0a88e20707c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d086e28-3dc6-4d9f-a3f5-f9f5c9ee77dc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b95f1107-7783-4ac9-ab89-0a88e20707c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_40002090-f3a2-4bf2-afeb-587f4c2f729f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d086e28-3dc6-4d9f-a3f5-f9f5c9ee77dc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_40002090-f3a2-4bf2-afeb-587f4c2f729f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_88a7335c-a958-4eed-b32a-c74df1f8de1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d086e28-3dc6-4d9f-a3f5-f9f5c9ee77dc" xlink:to="loc_us-gaap_EmployeeStockMember_88a7335c-a958-4eed-b32a-c74df1f8de1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_50d90662-b6bf-4dfa-988e-da118d59ab1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d086e28-3dc6-4d9f-a3f5-f9f5c9ee77dc" xlink:to="loc_us-gaap_PerformanceSharesMember_50d90662-b6bf-4dfa-988e-da118d59ab1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesClinicalTrialResultsMember_d424c57f-8807-451f-94a0-c5c91764ccd7" xlink:href="exel-20211231.xsd#exel_PerformanceSharesClinicalTrialResultsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PerformanceSharesMember_50d90662-b6bf-4dfa-988e-da118d59ab1b" xlink:to="loc_exel_PerformanceSharesClinicalTrialResultsMember_d424c57f-8807-451f-94a0-c5c91764ccd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_43f467d7-1506-40cd-a199-539c7fddd3f0" xlink:href="exel-20211231.xsd#exel_PerformanceSharesAchievedBeforeDecember312020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PerformanceSharesMember_50d90662-b6bf-4dfa-988e-da118d59ab1b" xlink:to="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_43f467d7-1506-40cd-a199-539c7fddd3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312021Member_20fed20f-0f76-42f1-8e94-365f6b51f75e" xlink:href="exel-20211231.xsd#exel_PerformanceSharesAchievedBeforeDecember312021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PerformanceSharesMember_50d90662-b6bf-4dfa-988e-da118d59ab1b" xlink:to="loc_exel_PerformanceSharesAchievedBeforeDecember312021Member_20fed20f-0f76-42f1-8e94-365f6b51f75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_A2018PerformanceStockUnitsMember_705fd2cc-c11f-4cf3-8b48-4c42079047ab" xlink:href="exel-20211231.xsd#exel_A2018PerformanceStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PerformanceSharesMember_50d90662-b6bf-4dfa-988e-da118d59ab1b" xlink:to="loc_exel_A2018PerformanceStockUnitsMember_705fd2cc-c11f-4cf3-8b48-4c42079047ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_cb635874-996c-4b5d-8710-4125cd3f9e45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:to="loc_us-gaap_GranteeStatusAxis_cb635874-996c-4b5d-8710-4125cd3f9e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_a7e4594c-8e32-49fc-8c86-25d2660a3fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_cb635874-996c-4b5d-8710-4125cd3f9e45" xlink:to="loc_us-gaap_GranteeStatusDomain_a7e4594c-8e32-49fc-8c86-25d2660a3fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_72074df8-de90-42b5-8059-eddaa188a6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_a7e4594c-8e32-49fc-8c86-25d2660a3fee" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_72074df8-de90-42b5-8059-eddaa188a6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d22c8073-0848-406a-a215-fc552fd7c686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_a7e4594c-8e32-49fc-8c86-25d2660a3fee" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d22c8073-0848-406a-a215-fc552fd7c686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis_b0bff0c1-0a81-45a5-962e-3f82f94f8f29" xlink:href="exel-20211231.xsd#exel_StatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:to="loc_exel_StatusAxis_b0bff0c1-0a81-45a5-962e-3f82f94f8f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_fab30a24-5512-447d-b56c-da39062ff676" xlink:href="exel-20211231.xsd#exel_StatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusAxis_b0bff0c1-0a81-45a5-962e-3f82f94f8f29" xlink:to="loc_exel_StatusDomain_fab30a24-5512-447d-b56c-da39062ff676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember_aa28a8cf-48ba-4a65-98d6-c6012dccb557" xlink:href="exel-20211231.xsd#exel_AchievedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_fab30a24-5512-447d-b56c-da39062ff676" xlink:to="loc_exel_AchievedMember_aa28a8cf-48ba-4a65-98d6-c6012dccb557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember_8a887bd1-062b-4337-86c3-dc8f11c561a9" xlink:href="exel-20211231.xsd#exel_ProbableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_fab30a24-5512-447d-b56c-da39062ff676" xlink:to="loc_exel_ProbableMember_8a887bd1-062b-4337-86c3-dc8f11c561a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NotProbableMember_8f18cb25-265b-4ae4-8891-a4d7129c3ebd" xlink:href="exel-20211231.xsd#exel_NotProbableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_fab30a24-5512-447d-b56c-da39062ff676" xlink:to="loc_exel_NotProbableMember_8f18cb25-265b-4ae4-8891-a4d7129c3ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_1aa12afc-62f5-48cd-8b70-8bf53a0004e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:to="loc_us-gaap_VestingAxis_1aa12afc-62f5-48cd-8b70-8bf53a0004e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d9427d9d-1905-4c22-a02a-fa36c59d9a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_1aa12afc-62f5-48cd-8b70-8bf53a0004e1" xlink:to="loc_us-gaap_VestingDomain_d9427d9d-1905-4c22-a02a-fa36c59d9a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_922bef24-7f82-48f6-bcd1-a5957f94760c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d9427d9d-1905-4c22-a02a-fa36c59d9a64" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_922bef24-7f82-48f6-bcd1-a5957f94760c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4a63c6e1-b502-46c0-a40a-91a68894774f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d9427d9d-1905-4c22-a02a-fa36c59d9a64" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4a63c6e1-b502-46c0-a40a-91a68894774f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5810af38-386e-4598-9b52-9b2feeb282fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:to="loc_srt_RangeAxis_5810af38-386e-4598-9b52-9b2feeb282fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75342ee1-1508-4adc-ba57-dd2d2a534de3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5810af38-386e-4598-9b52-9b2feeb282fa" xlink:to="loc_srt_RangeMember_75342ee1-1508-4adc-ba57-dd2d2a534de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_063cbd81-3663-45fe-a91c-6bc5f7320eb0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75342ee1-1508-4adc-ba57-dd2d2a534de3" xlink:to="loc_srt_MinimumMember_063cbd81-3663-45fe-a91c-6bc5f7320eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a7369c68-2346-4539-bb49-5e85bb46fd66" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75342ee1-1508-4adc-ba57-dd2d2a534de3" xlink:to="loc_srt_MaximumMember_a7369c68-2346-4539-bb49-5e85bb46fd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5edf98f6-247c-4db1-9b6f-2da7e2f52149" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_59ba5acd-6e17-4d7e-85b0-f02e60b8097c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_59ba5acd-6e17-4d7e-85b0-f02e60b8097c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_f6b46e61-684b-481b-8c1f-0446c920d597" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_f6b46e61-684b-481b-8c1f-0446c920d597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_405479c8-68fa-4f6f-9ef4-b69fd91a2d3d" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_405479c8-68fa-4f6f-9ef4-b69fd91a2d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ec45282c-87a0-4776-b804-5f8ec3a97735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ec45282c-87a0-4776-b804-5f8ec3a97735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_709cb8c3-29be-4f60-9d79-5b601b97128f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_709cb8c3-29be-4f60-9d79-5b601b97128f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23ae9b63-ba14-4bfc-90ac-3074f901f5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23ae9b63-ba14-4bfc-90ac-3074f901f5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_cb1995f8-ada2-423b-ab02-421776d5bf34" xlink:href="exel-20211231.xsd#exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_cb1995f8-ada2-423b-ab02-421776d5bf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_0e53ba4c-55b5-40e1-95d9-468c86a01905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_0e53ba4c-55b5-40e1-95d9-468c86a01905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1fa5cb39-04e6-411c-8fa5-c3195f8111cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_1fa5cb39-04e6-411c-8fa5-c3195f8111cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d727d937-1072-4cf9-a043-e161c8017e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d727d937-1072-4cf9-a043-e161c8017e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_505e7631-0538-4afc-abb1-ba158c0fe585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_505e7631-0538-4afc-abb1-ba158c0fe585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_7474f676-5dd5-47c8-9990-ecd032bf4a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ProceedsFromStockPlans_7474f676-5dd5-47c8-9990-ecd032bf4a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fc3cd3a7-a89f-477d-86de-405e7b799174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fc3cd3a7-a89f-477d-86de-405e7b799174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3d0c6f43-058e-490f-9032-37445bc7db99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3d0c6f43-058e-490f-9032-37445bc7db99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f2b0a072-6eef-421d-976b-338c8c5723b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f2b0a072-6eef-421d-976b-338c8c5723b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9df6b70d-61ee-42c4-b91b-2353dcd6d088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9df6b70d-61ee-42c4-b91b-2353dcd6d088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f2a22efd-dba4-4286-a37b-ea9ebde9ab16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f2a22efd-dba4-4286-a37b-ea9ebde9ab16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0c0d582d-63ed-42dd-8ca1-d7e0590b4e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0c0d582d-63ed-42dd-8ca1-d7e0590b4e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_51ae539a-a1f9-4a5f-935c-bc4dea8f4e5a" xlink:href="exel-20211231.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_51ae539a-a1f9-4a5f-935c-bc4dea8f4e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_2045cbec-ebba-4545-87ef-168c21d39dde" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_2045cbec-ebba-4545-87ef-168c21d39dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_37ff193b-d3db-456d-9024-1e9f38b8060f" xlink:href="exel-20211231.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_37ff193b-d3db-456d-9024-1e9f38b8060f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2dca547c-7de9-408a-b27e-b0d76d2726eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2dca547c-7de9-408a-b27e-b0d76d2726eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1df8ea93-36ff-4b10-a2c0-7f4adc1f4629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1df8ea93-36ff-4b10-a2c0-7f4adc1f4629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3f75837a-29ec-441e-969b-4ba20aef5624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3f75837a-29ec-441e-969b-4ba20aef5624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f5e872f7-65c8-45e7-9975-e3119717c08a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f5e872f7-65c8-45e7-9975-e3119717c08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_37609c52-af85-4716-9718-78592d08235a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e449ba6-6667-419e-8f15-660262d6f8c9" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_37609c52-af85-4716-9718-78592d08235a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18f9174e-f8d1-4d6b-8ab0-0c9eb90ed811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3bf28d5-7c44-49bd-a57c-1e5f5981bf07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18f9174e-f8d1-4d6b-8ab0-0c9eb90ed811" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3bf28d5-7c44-49bd-a57c-1e5f5981bf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1fa21158-076e-40b9-b8e4-7e41785ae44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3bf28d5-7c44-49bd-a57c-1e5f5981bf07" xlink:to="loc_us-gaap_AwardTypeAxis_1fa21158-076e-40b9-b8e4-7e41785ae44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55735c3a-a496-46d2-9c84-b9ecdb3d65ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1fa21158-076e-40b9-b8e4-7e41785ae44c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55735c3a-a496-46d2-9c84-b9ecdb3d65ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5f9a7ae4-328d-4e28-87a3-67c054d3fcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55735c3a-a496-46d2-9c84-b9ecdb3d65ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5f9a7ae4-328d-4e28-87a3-67c054d3fcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_67938551-6520-4b4f-a7cb-5cd8e4113559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55735c3a-a496-46d2-9c84-b9ecdb3d65ba" xlink:to="loc_us-gaap_EmployeeStockMember_67938551-6520-4b4f-a7cb-5cd8e4113559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55044ff2-4d44-4922-a240-f25e2269e809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3bf28d5-7c44-49bd-a57c-1e5f5981bf07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55044ff2-4d44-4922-a240-f25e2269e809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a92fc287-1353-4c6c-b9f5-e243ad30e748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55044ff2-4d44-4922-a240-f25e2269e809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a92fc287-1353-4c6c-b9f5-e243ad30e748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd319de7-402b-4c9f-9f75-0b21fabe417b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e51ddad-381b-4922-9671-8345b5f54f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd319de7-402b-4c9f-9f75-0b21fabe417b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e51ddad-381b-4922-9671-8345b5f54f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4ec76a21-6324-43ce-960a-462fd03ef4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e51ddad-381b-4922-9671-8345b5f54f5c" xlink:to="loc_us-gaap_AwardTypeAxis_4ec76a21-6324-43ce-960a-462fd03ef4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffa8501c-7ab8-483e-8dd5-b52b0c6a168a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4ec76a21-6324-43ce-960a-462fd03ef4c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffa8501c-7ab8-483e-8dd5-b52b0c6a168a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_71a49cad-ef6e-430f-8aa9-b6a5abd835ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffa8501c-7ab8-483e-8dd5-b52b0c6a168a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_71a49cad-ef6e-430f-8aa9-b6a5abd835ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_775749f9-ec5a-4975-9484-dcab7d5cdc09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffa8501c-7ab8-483e-8dd5-b52b0c6a168a" xlink:to="loc_us-gaap_EmployeeStockMember_775749f9-ec5a-4975-9484-dcab7d5cdc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70ba2711-2074-4fbb-a61c-8cc264b91996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e51ddad-381b-4922-9671-8345b5f54f5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70ba2711-2074-4fbb-a61c-8cc264b91996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_140ec350-f19a-4a8e-abef-a5b9e796cded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70ba2711-2074-4fbb-a61c-8cc264b91996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_140ec350-f19a-4a8e-abef-a5b9e796cded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4d7cbde5-4f0b-4bc7-9c4c-b94fde2d7197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70ba2711-2074-4fbb-a61c-8cc264b91996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4d7cbde5-4f0b-4bc7-9c4c-b94fde2d7197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_7576e4b1-a671-42d4-b18c-01d94567510c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70ba2711-2074-4fbb-a61c-8cc264b91996" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_7576e4b1-a671-42d4-b18c-01d94567510c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_71a920fd-12a1-4c8f-888b-7e1e1ef939fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70ba2711-2074-4fbb-a61c-8cc264b91996" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_71a920fd-12a1-4c8f-888b-7e1e1ef939fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_272b83ed-fccb-41fc-8500-ac7d05f4f8be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e87ce9-f323-46e7-82ba-0c5b514cadf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_272b83ed-fccb-41fc-8500-ac7d05f4f8be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e87ce9-f323-46e7-82ba-0c5b514cadf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9b19e068-3b25-4a66-93b2-23a607658bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e87ce9-f323-46e7-82ba-0c5b514cadf9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9b19e068-3b25-4a66-93b2-23a607658bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9d9d9b4e-ed3e-495f-a37f-4e0c469d8cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e87ce9-f323-46e7-82ba-0c5b514cadf9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9d9d9b4e-ed3e-495f-a37f-4e0c469d8cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1ca56d2e-f214-45fa-9aab-facc91b7a45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e87ce9-f323-46e7-82ba-0c5b514cadf9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1ca56d2e-f214-45fa-9aab-facc91b7a45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_605a8ebb-e27f-423f-b0c9-3340b4abe393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e87ce9-f323-46e7-82ba-0c5b514cadf9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_605a8ebb-e27f-423f-b0c9-3340b4abe393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d1887a60-fb7a-4184-918f-e38aa61326a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e87ce9-f323-46e7-82ba-0c5b514cadf9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d1887a60-fb7a-4184-918f-e38aa61326a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2611bf78-864f-4c84-afbd-e5f36919a793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_272b83ed-fccb-41fc-8500-ac7d05f4f8be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2611bf78-864f-4c84-afbd-e5f36919a793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1eca636a-2286-4a83-9c5e-e3f35390fa01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_272b83ed-fccb-41fc-8500-ac7d05f4f8be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1eca636a-2286-4a83-9c5e-e3f35390fa01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_33d3c4b2-dfdc-4cbb-842d-6fe5a40a4cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1eca636a-2286-4a83-9c5e-e3f35390fa01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_33d3c4b2-dfdc-4cbb-842d-6fe5a40a4cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_581a13de-4369-48aa-bf13-4f9fefac0eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1eca636a-2286-4a83-9c5e-e3f35390fa01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_581a13de-4369-48aa-bf13-4f9fefac0eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_579f4a83-499b-4fd4-a1a4-2407360c3e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1eca636a-2286-4a83-9c5e-e3f35390fa01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_579f4a83-499b-4fd4-a1a4-2407360c3e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_b2e8991b-a36e-448d-addf-3c9b489c8f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1eca636a-2286-4a83-9c5e-e3f35390fa01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_b2e8991b-a36e-448d-addf-3c9b489c8f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ecc3c722-5253-4b8b-9540-adca7c1f28c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1eca636a-2286-4a83-9c5e-e3f35390fa01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ecc3c722-5253-4b8b-9540-adca7c1f28c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_58d19afb-5ccc-4e6f-858c-ffb220228bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_272b83ed-fccb-41fc-8500-ac7d05f4f8be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_58d19afb-5ccc-4e6f-858c-ffb220228bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cd2606b0-27ba-4eba-82fa-946fd9c3fa84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_272b83ed-fccb-41fc-8500-ac7d05f4f8be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cd2606b0-27ba-4eba-82fa-946fd9c3fa84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e8e809ea-52e2-438b-bb41-432abd3a645a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_272b83ed-fccb-41fc-8500-ac7d05f4f8be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e8e809ea-52e2-438b-bb41-432abd3a645a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56c2c767-fe6b-44b4-9d61-07c4de84a1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_272b83ed-fccb-41fc-8500-ac7d05f4f8be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56c2c767-fe6b-44b4-9d61-07c4de84a1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3f68d917-7654-495c-b54b-f5e33362e784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_272b83ed-fccb-41fc-8500-ac7d05f4f8be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3f68d917-7654-495c-b54b-f5e33362e784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b70b21a9-8b98-4d65-a5f3-c95360c820aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6dac5b91-9bb2-4222-9fd8-329aeb8c2287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b70b21a9-8b98-4d65-a5f3-c95360c820aa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6dac5b91-9bb2-4222-9fd8-329aeb8c2287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75a42797-6b05-4f5d-b3eb-2842d0ea8a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6dac5b91-9bb2-4222-9fd8-329aeb8c2287" xlink:to="loc_us-gaap_AwardTypeAxis_75a42797-6b05-4f5d-b3eb-2842d0ea8a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bba80251-4ebd-448b-998a-6c53b310265e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_75a42797-6b05-4f5d-b3eb-2842d0ea8a81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bba80251-4ebd-448b-998a-6c53b310265e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_28afa338-fae6-4c5c-a9f4-2f2377bd50e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bba80251-4ebd-448b-998a-6c53b310265e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_28afa338-fae6-4c5c-a9f4-2f2377bd50e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_93ac03e7-6aae-460d-8c4c-48be356efec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bba80251-4ebd-448b-998a-6c53b310265e" xlink:to="loc_us-gaap_PerformanceSharesMember_93ac03e7-6aae-460d-8c4c-48be356efec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10de6383-1d5b-4985-9775-071e3fb4dcca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6dac5b91-9bb2-4222-9fd8-329aeb8c2287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10de6383-1d5b-4985-9775-071e3fb4dcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3443bad-81bc-4117-a462-8479efc25946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10de6383-1d5b-4985-9775-071e3fb4dcca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3443bad-81bc-4117-a462-8479efc25946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a9eef49e-78ef-48b1-b6bd-0d56accc55d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3443bad-81bc-4117-a462-8479efc25946" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a9eef49e-78ef-48b1-b6bd-0d56accc55d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c58bdb23-085d-4519-90de-5013a2c7d5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3443bad-81bc-4117-a462-8479efc25946" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c58bdb23-085d-4519-90de-5013a2c7d5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_d3367e7c-4f38-4fd8-9dc7-eeff7b088343" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3443bad-81bc-4117-a462-8479efc25946" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_d3367e7c-4f38-4fd8-9dc7-eeff7b088343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b1925f1a-fc7e-4747-af23-338aaa22669c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3443bad-81bc-4117-a462-8479efc25946" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b1925f1a-fc7e-4747-af23-338aaa22669c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b277bea-6fba-4e03-83f2-6b8385374660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3443bad-81bc-4117-a462-8479efc25946" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b277bea-6fba-4e03-83f2-6b8385374660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6516570-d2e1-4c0a-b861-3a04c4743721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10de6383-1d5b-4985-9775-071e3fb4dcca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6516570-d2e1-4c0a-b861-3a04c4743721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_babde05a-0e0d-4212-bcb9-0d64b70c4e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6516570-d2e1-4c0a-b861-3a04c4743721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_babde05a-0e0d-4212-bcb9-0d64b70c4e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbc420c4-ee4d-4335-9ac2-4b15553a609a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6516570-d2e1-4c0a-b861-3a04c4743721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbc420c4-ee4d-4335-9ac2-4b15553a609a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_d5da722f-b9f9-4cb2-aa5a-0744c6dd46c2" xlink:href="exel-20211231.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6516570-d2e1-4c0a-b861-3a04c4743721" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_d5da722f-b9f9-4cb2-aa5a-0744c6dd46c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1327718a-3485-4537-8cd5-8a6316188665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6516570-d2e1-4c0a-b861-3a04c4743721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1327718a-3485-4537-8cd5-8a6316188665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1dabb56f-fe31-40a5-887d-70a6f1aed17c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6516570-d2e1-4c0a-b861-3a04c4743721" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1dabb56f-fe31-40a5-887d-70a6f1aed17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7dd20e8f-313e-4e88-8d0c-e14b6e074e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10de6383-1d5b-4985-9775-071e3fb4dcca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7dd20e8f-313e-4e88-8d0c-e14b6e074e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_64be5344-14dd-4ca9-a1d2-9c9afc5e5069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10de6383-1d5b-4985-9775-071e3fb4dcca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_64be5344-14dd-4ca9-a1d2-9c9afc5e5069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#EmployeeBenefitPlansEstimateGrantDateFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0ad5922-192d-4b9c-88bf-0b645c6e9e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7766c1ae-e196-4406-ac4f-720fa67d4b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0ad5922-192d-4b9c-88bf-0b645c6e9e38" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7766c1ae-e196-4406-ac4f-720fa67d4b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1aee4be3-87f7-442c-acdb-7056201af89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7766c1ae-e196-4406-ac4f-720fa67d4b32" xlink:to="loc_us-gaap_AwardTypeAxis_1aee4be3-87f7-442c-acdb-7056201af89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a18c11d2-4364-4193-b14c-7489c499ad03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1aee4be3-87f7-442c-acdb-7056201af89c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a18c11d2-4364-4193-b14c-7489c499ad03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_507b0318-3b4f-4393-9f47-37b8419f18aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a18c11d2-4364-4193-b14c-7489c499ad03" xlink:to="loc_us-gaap_PerformanceSharesMember_507b0318-3b4f-4393-9f47-37b8419f18aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7766c1ae-e196-4406-ac4f-720fa67d4b32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9bfe5a4e-e3df-4f01-bfc0-5f5e3cb08f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9bfe5a4e-e3df-4f01-bfc0-5f5e3cb08f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ec73361b-2dc8-48ed-85dd-02e1e024d215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:to="loc_us-gaap_SharePrice_ec73361b-2dc8-48ed-85dd-02e1e024d215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_63313fc5-affd-411e-b7ef-85f9c4c29175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_63313fc5-affd-411e-b7ef-85f9c4c29175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a18d70f8-384f-4261-ab06-6fec7f6eae38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a18d70f8-384f-4261-ab06-6fec7f6eae38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f41f14fa-894f-4684-a1a7-db3a87fcd3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8c3629a8-0ba6-486b-bc18-e46bfebd3982" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f41f14fa-894f-4684-a1a7-db3a87fcd3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxes" xlink:type="simple" xlink:href="exel-20211231.xsd#ProvisionForIncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_46969cd7-ee60-4e75-810d-6ce7d61febe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_b1751dd0-9a19-428c-8d47-4fb5d46c0edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46969cd7-ee60-4e75-810d-6ce7d61febe6" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_b1751dd0-9a19-428c-8d47-4fb5d46c0edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesTables" xlink:type="simple" xlink:href="exel-20211231.xsd#ProvisionForIncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6e7913fb-7bd6-410c-8e09-dd74f82e8372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_69ab7530-3e7b-435d-b406-21d28e7f139b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6e7913fb-7bd6-410c-8e09-dd74f82e8372" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_69ab7530-3e7b-435d-b406-21d28e7f139b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e7d21e19-08fc-49ed-8dc1-0ec4c0fb4022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6e7913fb-7bd6-410c-8e09-dd74f82e8372" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e7d21e19-08fc-49ed-8dc1-0ec4c0fb4022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_96d5bc4d-2402-4a1f-8a24-1af883d25762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6e7913fb-7bd6-410c-8e09-dd74f82e8372" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_96d5bc4d-2402-4a1f-8a24-1af883d25762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_34d6e42a-0cdf-42cb-ba42-a69998c9d3af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6e7913fb-7bd6-410c-8e09-dd74f82e8372" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_34d6e42a-0cdf-42cb-ba42-a69998c9d3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a266e901-99b2-42a2-a7be-f1b38493fea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7a2b0993-4d61-4c19-ab0d-e4fa6f858e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a266e901-99b2-42a2-a7be-f1b38493fea7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7a2b0993-4d61-4c19-ab0d-e4fa6f858e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b7f086ee-8c57-47ba-b25a-4d77c6a40b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7a2b0993-4d61-4c19-ab0d-e4fa6f858e62" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b7f086ee-8c57-47ba-b25a-4d77c6a40b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d7959ca6-722e-448c-9b3b-67b979313a84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7a2b0993-4d61-4c19-ab0d-e4fa6f858e62" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d7959ca6-722e-448c-9b3b-67b979313a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_164d54d3-2a58-47ad-8f61-273196262aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7a2b0993-4d61-4c19-ab0d-e4fa6f858e62" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_164d54d3-2a58-47ad-8f61-273196262aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_365f166b-f8b5-4a1f-8e7d-d88e04497dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a266e901-99b2-42a2-a7be-f1b38493fea7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_365f166b-f8b5-4a1f-8e7d-d88e04497dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_bf479fa2-ad47-45bc-ba57-f48604473bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_365f166b-f8b5-4a1f-8e7d-d88e04497dcb" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_bf479fa2-ad47-45bc-ba57-f48604473bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3ceac47c-d8be-4741-aecb-e05d81791b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_365f166b-f8b5-4a1f-8e7d-d88e04497dcb" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3ceac47c-d8be-4741-aecb-e05d81791b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1766ef49-6fd1-4fdd-8352-a1cf252f986d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_365f166b-f8b5-4a1f-8e7d-d88e04497dcb" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1766ef49-6fd1-4fdd-8352-a1cf252f986d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_24fc9d36-fe7f-47d4-86dd-9b2240185b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a266e901-99b2-42a2-a7be-f1b38493fea7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_24fc9d36-fe7f-47d4-86dd-9b2240185b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b721a433-5b47-4e1e-b7b1-1127ac17c4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_84fd4343-d95f-45a4-b4d5-911534fc36e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b721a433-5b47-4e1e-b7b1-1127ac17c4bd" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_84fd4343-d95f-45a4-b4d5-911534fc36e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_803d8130-0c7a-4fc2-852d-f9034055b7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b721a433-5b47-4e1e-b7b1-1127ac17c4bd" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_803d8130-0c7a-4fc2-852d-f9034055b7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_eee4d89b-9307-4fd9-90e4-6c990e614c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b721a433-5b47-4e1e-b7b1-1127ac17c4bd" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_eee4d89b-9307-4fd9-90e4-6c990e614c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_05e76ac7-0b70-4820-b69d-2ca77aa36e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b721a433-5b47-4e1e-b7b1-1127ac17c4bd" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_05e76ac7-0b70-4820-b69d-2ca77aa36e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_cf024e0e-2113-464f-b667-fc1a84021e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b721a433-5b47-4e1e-b7b1-1127ac17c4bd" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_cf024e0e-2113-464f-b667-fc1a84021e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_efcb0e12-0862-4db7-802d-9cdcc45fa094" xlink:href="exel-20211231.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b721a433-5b47-4e1e-b7b1-1127ac17c4bd" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_efcb0e12-0862-4db7-802d-9cdcc45fa094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_4da67969-72ef-4500-9a62-b911ef6d0a01" xlink:href="exel-20211231.xsd#exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b721a433-5b47-4e1e-b7b1-1127ac17c4bd" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_4da67969-72ef-4500-9a62-b911ef6d0a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8569daef-3b93-49b6-8c56-a53853c29759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b721a433-5b47-4e1e-b7b1-1127ac17c4bd" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8569daef-3b93-49b6-8c56-a53853c29759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_34570664-3a7f-44be-91e1-b8b190d05787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b721a433-5b47-4e1e-b7b1-1127ac17c4bd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_34570664-3a7f-44be-91e1-b8b190d05787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_314d79cd-d1ab-4e5a-ba11-08bdffc266a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_282da632-3440-4d9b-9377-372fff57fe91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_314d79cd-d1ab-4e5a-ba11-08bdffc266a1" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_282da632-3440-4d9b-9377-372fff57fe91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1ab7c371-825c-4ac0-a3e3-9afdc91cf50d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_282da632-3440-4d9b-9377-372fff57fe91" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1ab7c371-825c-4ac0-a3e3-9afdc91cf50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_d2ab3560-0c15-4c6b-b279-b02708a1aff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_282da632-3440-4d9b-9377-372fff57fe91" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_d2ab3560-0c15-4c6b-b279-b02708a1aff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_212ced31-78ff-4bd0-955a-97bedeee2e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_282da632-3440-4d9b-9377-372fff57fe91" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_212ced31-78ff-4bd0-955a-97bedeee2e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_de65aa38-1366-4b8a-861e-847cd108c7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_282da632-3440-4d9b-9377-372fff57fe91" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_de65aa38-1366-4b8a-861e-847cd108c7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxAssetsLeaseLiabilities_fe85b8c1-9d2d-4901-a689-76fbbdf7cbfc" xlink:href="exel-20211231.xsd#exel_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_282da632-3440-4d9b-9377-372fff57fe91" xlink:to="loc_exel_DeferredTaxAssetsLeaseLiabilities_fe85b8c1-9d2d-4901-a689-76fbbdf7cbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_b31ddc13-b144-4787-aa08-f06f4ae49464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_282da632-3440-4d9b-9377-372fff57fe91" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_b31ddc13-b144-4787-aa08-f06f4ae49464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_37272940-a578-4dbf-a673-b12c42cf2e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_282da632-3440-4d9b-9377-372fff57fe91" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_37272940-a578-4dbf-a673-b12c42cf2e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_e723e09c-ff79-4331-8fb3-11ae5ca38041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_282da632-3440-4d9b-9377-372fff57fe91" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_e723e09c-ff79-4331-8fb3-11ae5ca38041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_57a27f79-2b61-4031-8144-6bc666fea8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_282da632-3440-4d9b-9377-372fff57fe91" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_57a27f79-2b61-4031-8144-6bc666fea8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_38bef756-1058-4631-9913-d32b2f40afd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_282da632-3440-4d9b-9377-372fff57fe91" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_38bef756-1058-4631-9913-d32b2f40afd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_baf8ef8a-7667-4bb6-9ea1-6bd01eb78910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_282da632-3440-4d9b-9377-372fff57fe91" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_baf8ef8a-7667-4bb6-9ea1-6bd01eb78910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e70cd128-bf2c-47e1-8093-524062568cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_314d79cd-d1ab-4e5a-ba11-08bdffc266a1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e70cd128-bf2c-47e1-8093-524062568cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_616d5401-62cc-4036-a35e-8b46139f4b95" xlink:href="exel-20211231.xsd#exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e70cd128-bf2c-47e1-8093-524062568cdb" xlink:to="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_616d5401-62cc-4036-a35e-8b46139f4b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_7766a2da-ce68-4c77-a9a6-2bc5c4aee764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e70cd128-bf2c-47e1-8093-524062568cdb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_7766a2da-ce68-4c77-a9a6-2bc5c4aee764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1580455d-5977-4b71-9dae-a1dea1e3ff39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_e70cd128-bf2c-47e1-8093-524062568cdb" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1580455d-5977-4b71-9dae-a1dea1e3ff39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ceae9aa9-c1d4-4535-ac6f-da0b2060756d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_314d79cd-d1ab-4e5a-ba11-08bdffc266a1" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ceae9aa9-c1d4-4535-ac6f-da0b2060756d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#ProvisionForIncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_82cb0492-b670-4c8d-b4dd-54e3c79b8955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_27818512-95a3-4fbc-a27c-5838b9aba616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_82cb0492-b670-4c8d-b4dd-54e3c79b8955" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_27818512-95a3-4fbc-a27c-5838b9aba616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8135d782-d505-4e66-9264-f866e5dab99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_27818512-95a3-4fbc-a27c-5838b9aba616" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8135d782-d505-4e66-9264-f866e5dab99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a7fdc3a7-b74f-466f-9804-185138eedb95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8135d782-d505-4e66-9264-f866e5dab99b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a7fdc3a7-b74f-466f-9804-185138eedb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_058f215d-f19d-478f-bc57-ad5969ef4f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7fdc3a7-b74f-466f-9804-185138eedb95" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_058f215d-f19d-478f-bc57-ad5969ef4f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_687fae53-5d6d-49ca-aec7-28edbbe4d234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7fdc3a7-b74f-466f-9804-185138eedb95" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_687fae53-5d6d-49ca-aec7-28edbbe4d234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_72bff5fb-2386-40cc-a503-04e4d9aaa69d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_27818512-95a3-4fbc-a27c-5838b9aba616" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_72bff5fb-2386-40cc-a503-04e4d9aaa69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_01a1fc1c-eaab-45ee-8a94-a56d99f30b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_72bff5fb-2386-40cc-a503-04e4d9aaa69d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_01a1fc1c-eaab-45ee-8a94-a56d99f30b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_edb1c877-3dde-4610-af88-67282e2cce9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_01a1fc1c-eaab-45ee-8a94-a56d99f30b0f" xlink:to="loc_us-gaap_ResearchMember_edb1c877-3dde-4610-af88-67282e2cce9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_27818512-95a3-4fbc-a27c-5838b9aba616" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6d5f0e65-c52c-4b0d-a787-05fa016266ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6d5f0e65-c52c-4b0d-a787-05fa016266ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_eee4ae1e-29a5-4f00-aa84-d6e29cf09df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_eee4ae1e-29a5-4f00-aa84-d6e29cf09df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_90ecbb76-1cfd-432d-a467-b5bd55e1419e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_90ecbb76-1cfd-432d-a467-b5bd55e1419e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_a01aca19-d9ca-403e-9558-7b69b75d985a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_us-gaap_OperatingLossCarryforwards_a01aca19-d9ca-403e-9558-7b69b75d985a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_0f460239-df04-4a08-9d60-58ec26e89608" xlink:href="exel-20211231.xsd#exel_TaxCreditCarryforwardAmountWithExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_0f460239-df04-4a08-9d60-58ec26e89608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4edd778b-0a51-46b3-acc2-607e9ef78a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4edd778b-0a51-46b3-acc2-607e9ef78a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e3cff8e5-8e64-47cf-921c-79d4ca3d9451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5e4195ab-cc0c-4136-9b9c-992a601c7dbd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e3cff8e5-8e64-47cf-921c-79d4ca3d9451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_12df5977-05c5-4ba2-a3c7-0714b9bfeae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_dda038fd-e921-42fd-98f5-8a3cc2ff733d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_12df5977-05c5-4ba2-a3c7-0714b9bfeae6" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_dda038fd-e921-42fd-98f5-8a3cc2ff733d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_61fccc22-26e5-4a6e-81ad-ef795bc909ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_dda038fd-e921-42fd-98f5-8a3cc2ff733d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_61fccc22-26e5-4a6e-81ad-ef795bc909ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3f91c3be-9dfc-4c90-b6a8-115c87be5480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_dda038fd-e921-42fd-98f5-8a3cc2ff733d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3f91c3be-9dfc-4c90-b6a8-115c87be5480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3fa14b44-6bd9-4e41-91a4-31ed69666595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_dda038fd-e921-42fd-98f5-8a3cc2ff733d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3fa14b44-6bd9-4e41-91a4-31ed69666595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e5157054-d4a1-4b97-b350-73c95ac8ff36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_dda038fd-e921-42fd-98f5-8a3cc2ff733d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e5157054-d4a1-4b97-b350-73c95ac8ff36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7b3cf358-225c-48ac-bfe3-7275decf1294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_dda038fd-e921-42fd-98f5-8a3cc2ff733d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7b3cf358-225c-48ac-bfe3-7275decf1294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="exel-20211231.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dd0eb657-98e3-48b7-bbec-1e65395c5d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_09e6d806-fa17-4f7d-9f4d-702e5b38fe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dd0eb657-98e3-48b7-bbec-1e65395c5d9c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_09e6d806-fa17-4f7d-9f4d-702e5b38fe7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="exel-20211231.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8b968ee4-b3a3-4a0f-9070-1590f51a64bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7e8b848f-92c2-445f-85e2-6e49b4944977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8b968ee4-b3a3-4a0f-9070-1590f51a64bb" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7e8b848f-92c2-445f-85e2-6e49b4944977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1f190d04-3c6f-41a8-a1b2-c5bf74b03f31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8b968ee4-b3a3-4a0f-9070-1590f51a64bb" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1f190d04-3c6f-41a8-a1b2-c5bf74b03f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4515ad45-487b-406e-bd49-7f216a9af054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_37d21781-1dd1-42cb-acaf-5700293ffd81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4515ad45-487b-406e-bd49-7f216a9af054" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_37d21781-1dd1-42cb-acaf-5700293ffd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7c85e250-eaf5-4ceb-8f20-6e335af15dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_37d21781-1dd1-42cb-acaf-5700293ffd81" xlink:to="loc_us-gaap_NetIncomeLoss_7c85e250-eaf5-4ceb-8f20-6e335af15dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_941c5945-73cf-421c-b2e5-b251c76bfa1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4515ad45-487b-406e-bd49-7f216a9af054" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_941c5945-73cf-421c-b2e5-b251c76bfa1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9d0607c-1964-4414-9b5d-a1670f4a5190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_941c5945-73cf-421c-b2e5-b251c76bfa1d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9d0607c-1964-4414-9b5d-a1670f4a5190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9cf4b8e7-e602-4bcb-879a-c84c933f9e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_941c5945-73cf-421c-b2e5-b251c76bfa1d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9cf4b8e7-e602-4bcb-879a-c84c933f9e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_36cdae0b-5801-427d-9cf1-04cdb0d0c497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_941c5945-73cf-421c-b2e5-b251c76bfa1d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_36cdae0b-5801-427d-9cf1-04cdb0d0c497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_96b241c6-36c0-4e47-b51b-5141ad12cca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_941c5945-73cf-421c-b2e5-b251c76bfa1d" xlink:to="loc_us-gaap_EarningsPerShareBasic_96b241c6-36c0-4e47-b51b-5141ad12cca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ec362534-b6f8-4759-b383-a9f6f0bb6b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_941c5945-73cf-421c-b2e5-b251c76bfa1d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ec362534-b6f8-4759-b383-a9f6f0bb6b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_36f4cdfa-3a61-427f-9284-8043157de98b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aee3e483-3d25-41f2-9205-2c0413c90f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_36f4cdfa-3a61-427f-9284-8043157de98b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aee3e483-3d25-41f2-9205-2c0413c90f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2844b685-c5d9-42df-bc30-fc62366e2d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aee3e483-3d25-41f2-9205-2c0413c90f4c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2844b685-c5d9-42df-bc30-fc62366e2d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c93372e1-7751-472f-9898-06d5f77d7dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2844b685-c5d9-42df-bc30-fc62366e2d37" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c93372e1-7751-472f-9898-06d5f77d7dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_42b6995a-d9c6-4923-929e-09810722e1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c93372e1-7751-472f-9898-06d5f77d7dff" xlink:to="loc_us-gaap_StockCompensationPlanMember_42b6995a-d9c6-4923-929e-09810722e1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8de37e1b-434d-411b-a33c-bbbe6d33a095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aee3e483-3d25-41f2-9205-2c0413c90f4c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8de37e1b-434d-411b-a33c-bbbe6d33a095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ae68683d-cf8b-4141-9438-68be31faaa9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8de37e1b-434d-411b-a33c-bbbe6d33a095" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ae68683d-cf8b-4141-9438-68be31faaa9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3b13961-42cf-43e6-9f30-9187602592bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5c9b85cd-37b5-4111-9600-10830339a8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3b13961-42cf-43e6-9f30-9187602592bc" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5c9b85cd-37b5-4111-9600-10830339a8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="exel-20211231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63349038-45b6-4c78-92e1-d387a765d229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock_b9b79432-bced-442f-b7eb-491c36bbb880" xlink:href="exel-20211231.xsd#exel_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63349038-45b6-4c78-92e1-d387a765d229" xlink:to="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock_b9b79432-bced-442f-b7eb-491c36bbb880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_e26e6f02-a1bf-4d29-a436-20cd0a928a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63349038-45b6-4c78-92e1-d387a765d229" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_e26e6f02-a1bf-4d29-a436-20cd0a928a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_17a13eec-cb80-4f1e-980a-3a1ad1d6ef3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63349038-45b6-4c78-92e1-d387a765d229" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_17a13eec-cb80-4f1e-980a-3a1ad1d6ef3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0e0f05f4-c8eb-4cfa-b6d3-2078b9ab6bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_78db1b2c-1b05-4e49-822b-f5bd22576458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0e0f05f4-c8eb-4cfa-b6d3-2078b9ab6bd7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_78db1b2c-1b05-4e49-822b-f5bd22576458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis_84bcc4a5-70df-4909-a2c5-983383a7848f" xlink:href="exel-20211231.xsd#exel_LeaseArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_78db1b2c-1b05-4e49-822b-f5bd22576458" xlink:to="loc_exel_LeaseArrangementsAxis_84bcc4a5-70df-4909-a2c5-983383a7848f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_0d408e24-2dae-4464-a70e-a8dd14568d70" xlink:href="exel-20211231.xsd#exel_LeaseArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsAxis_84bcc4a5-70df-4909-a2c5-983383a7848f" xlink:to="loc_exel_LeaseArrangementsDomain_0d408e24-2dae-4464-a70e-a8dd14568d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseMember_b931eb70-8a82-42f8-88e4-3c9606850d04" xlink:href="exel-20211231.xsd#exel_HeadquartersLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_0d408e24-2dae-4464-a70e-a8dd14568d70" xlink:to="loc_exel_HeadquartersLeaseMember_b931eb70-8a82-42f8-88e4-3c9606850d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseApril2019AmendmentMember_05812237-052a-4978-af96-8e88f2098f02" xlink:href="exel-20211231.xsd#exel_HeadquartersLeaseApril2019AmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_HeadquartersLeaseMember_b931eb70-8a82-42f8-88e4-3c9606850d04" xlink:to="loc_exel_HeadquartersLeaseApril2019AmendmentMember_05812237-052a-4978-af96-8e88f2098f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseDecember2020AmendmentMember_d92ead2f-165c-4940-b1a7-c7a5046a5e4b" xlink:href="exel-20211231.xsd#exel_HeadquartersLeaseDecember2020AmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_HeadquartersLeaseMember_b931eb70-8a82-42f8-88e4-3c9606850d04" xlink:to="loc_exel_HeadquartersLeaseDecember2020AmendmentMember_d92ead2f-165c-4940-b1a7-c7a5046a5e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLease2021AmendmentMember_02c031f4-a8c1-4702-82e4-114354c559d6" xlink:href="exel-20211231.xsd#exel_HeadquartersLease2021AmendmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_HeadquartersLeaseMember_b931eb70-8a82-42f8-88e4-3c9606850d04" xlink:to="loc_exel_HeadquartersLease2021AmendmentMember_02c031f4-a8c1-4702-82e4-114354c559d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseMember_5928c2e7-0e85-4e3b-a5e8-7760d369e405" xlink:href="exel-20211231.xsd#exel_BuiltToSuitLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_0d408e24-2dae-4464-a70e-a8dd14568d70" xlink:to="loc_exel_BuiltToSuitLeaseMember_5928c2e7-0e85-4e3b-a5e8-7760d369e405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_21720468-3b41-4406-b7e6-1c5ba5e78764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_78db1b2c-1b05-4e49-822b-f5bd22576458" xlink:to="loc_us-gaap_CreditFacilityAxis_21720468-3b41-4406-b7e6-1c5ba5e78764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_79614b96-2767-4d97-a301-5b664fab2476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_21720468-3b41-4406-b7e6-1c5ba5e78764" xlink:to="loc_us-gaap_CreditFacilityDomain_79614b96-2767-4d97-a301-5b664fab2476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_80d09166-f43a-4b4a-8e71-27db5fb8c14f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_79614b96-2767-4d97-a301-5b664fab2476" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_80d09166-f43a-4b4a-8e71-27db5fb8c14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_78db1b2c-1b05-4e49-822b-f5bd22576458" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_c0f52915-396c-46d0-9d00-88b620f19fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_c0f52915-396c-46d0-9d00-88b620f19fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_f6b97732-7612-4d94-880d-2f6d44b3a544" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_f6b97732-7612-4d94-880d-2f6d44b3a544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3aede9bd-4b3d-4d40-b71b-748c500c51d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3aede9bd-4b3d-4d40-b71b-748c500c51d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_a16e0b67-5d6d-460d-bc0f-9dcb23008987" xlink:href="exel-20211231.xsd#exel_TenantLeaseImprovementsAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_a16e0b67-5d6d-460d-bc0f-9dcb23008987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1087f2e2-7f33-423f-9153-093fbbff17d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_OperatingLeasePayments_1087f2e2-7f33-423f-9153-093fbbff17d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_84b0dc56-c661-4614-a7c7-8514bc8f76d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_84b0dc56-c661-4614-a7c7-8514bc8f76d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7f686b13-cd64-4f94-a853-028b3a74de31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7f686b13-cd64-4f94-a853-028b3a74de31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e1f3acc0-7c6a-4a5a-83c9-d8d947001eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e1f3acc0-7c6a-4a5a-83c9-d8d947001eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_b5ced680-effe-492d-a384-c5eb7ba45651" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_b5ced680-effe-492d-a384-c5eb7ba45651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_ae43c259-d2f5-42ed-a5a9-17576cf07a73" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_ae43c259-d2f5-42ed-a5a9-17576cf07a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_80445106-6644-4be2-8b85-fc8f52797b83" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_80445106-6644-4be2-8b85-fc8f52797b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_eb422226-6af8-44c0-9571-133f5c852619" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_eb422226-6af8-44c0-9571-133f5c852619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AreaOfRealEstatePropertyAvailableToLease_99497f90-9f6c-4d92-9553-4c6f8958b371" xlink:href="exel-20211231.xsd#exel_AreaOfRealEstatePropertyAvailableToLease"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_AreaOfRealEstatePropertyAvailableToLease_99497f90-9f6c-4d92-9553-4c6f8958b371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_253b31bd-6efe-4f3f-b405-6180687573f7" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_253b31bd-6efe-4f3f-b405-6180687573f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_2a16ae89-a1f0-4ac3-a08f-8ae79e6829e6" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_2a16ae89-a1f0-4ac3-a08f-8ae79e6829e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_0a9c1cfc-6785-4ce5-a744-0c2c5490a684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_TenantImprovements_0a9c1cfc-6785-4ce5-a744-0c2c5490a684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_da41cad3-08b1-4774-b587-935edcd30af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_da41cad3-08b1-4774-b587-935edcd30af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_e14c11aa-fb94-4a1a-a46a-f2f60213eada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ea092ed-73cc-4e3c-91a5-7715f770ec86" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_e14c11aa-fb94-4a1a-a46a-f2f60213eada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_935663ed-3289-43e7-b06f-911c5847ab51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseAssetsAbstract_95ea651b-5a49-45df-9780-eda59d21c3f9" xlink:href="exel-20211231.xsd#exel_OperatingLeaseAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_935663ed-3289-43e7-b06f-911c5847ab51" xlink:to="loc_exel_OperatingLeaseAssetsAbstract_95ea651b-5a49-45df-9780-eda59d21c3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_17cd9292-adaa-466c-96b1-043f470e3e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseAssetsAbstract_95ea651b-5a49-45df-9780-eda59d21c3f9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_17cd9292-adaa-466c-96b1-043f470e3e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_70f09ea5-48ce-44b1-8b3a-d69a287e59b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseAssetsAbstract_95ea651b-5a49-45df-9780-eda59d21c3f9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_70f09ea5-48ce-44b1-8b3a-d69a287e59b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract_1e08bf90-5b01-4637-9363-ffe4de9147b8" xlink:href="exel-20211231.xsd#exel_OperatingLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_935663ed-3289-43e7-b06f-911c5847ab51" xlink:to="loc_exel_OperatingLeaseLiabilitiesAbstract_1e08bf90-5b01-4637-9363-ffe4de9147b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0dcc505c-9753-4d8d-9fc4-c48c0691d28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_1e08bf90-5b01-4637-9363-ffe4de9147b8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0dcc505c-9753-4d8d-9fc4-c48c0691d28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35f5c2b0-6770-4c33-a946-a7af5a903c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_1e08bf90-5b01-4637-9363-ffe4de9147b8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35f5c2b0-6770-4c33-a946-a7af5a903c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_803f7b15-2915-4493-8dc5-96f8ccd81a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_1e08bf90-5b01-4637-9363-ffe4de9147b8" xlink:to="loc_us-gaap_OperatingLeaseLiability_803f7b15-2915-4493-8dc5-96f8ccd81a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6a808880-4d8e-4bb1-b19e-64dd008a5ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_1e08bf90-5b01-4637-9363-ffe4de9147b8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6a808880-4d8e-4bb1-b19e-64dd008a5ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d354dbd0-b3ac-4b91-a14a-c32f40d6cf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_51d28e9a-c6ff-4c77-acb3-5ac611cfa030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d354dbd0-b3ac-4b91-a14a-c32f40d6cf6f" xlink:to="loc_us-gaap_OperatingLeaseCost_51d28e9a-c6ff-4c77-acb3-5ac611cfa030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_c7329c30-9a21-490f-a694-7c59427754c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d354dbd0-b3ac-4b91-a14a-c32f40d6cf6f" xlink:to="loc_us-gaap_VariableLeaseCost_c7329c30-9a21-490f-a694-7c59427754c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_47d1c69a-2fc2-4b2d-80e2-16819c11a2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d354dbd0-b3ac-4b91-a14a-c32f40d6cf6f" xlink:to="loc_us-gaap_LeaseCost_47d1c69a-2fc2-4b2d-80e2-16819c11a2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20211231.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b525841e-0926-49f9-b324-e84abc66cdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_47e6e8bc-1a0a-443d-bbce-cb6b1aeefdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b525841e-0926-49f9-b324-e84abc66cdb7" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_47e6e8bc-1a0a-443d-bbce-cb6b1aeefdc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_425f3d1e-f75f-446c-ab1b-b2a1a55c330d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_47e6e8bc-1a0a-443d-bbce-cb6b1aeefdc4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_425f3d1e-f75f-446c-ab1b-b2a1a55c330d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_51c9ce4e-a98b-4dc8-97a2-0155e6a3a843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_47e6e8bc-1a0a-443d-bbce-cb6b1aeefdc4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_51c9ce4e-a98b-4dc8-97a2-0155e6a3a843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c0ee21de-c0a0-43af-ae69-fe9656e7cd72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_47e6e8bc-1a0a-443d-bbce-cb6b1aeefdc4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c0ee21de-c0a0-43af-ae69-fe9656e7cd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cb7589d6-fe5a-492b-9cc7-84e0273d5b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_47e6e8bc-1a0a-443d-bbce-cb6b1aeefdc4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cb7589d6-fe5a-492b-9cc7-84e0273d5b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_19e86a28-235d-4acc-afe1-091e736c0e08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_47e6e8bc-1a0a-443d-bbce-cb6b1aeefdc4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_19e86a28-235d-4acc-afe1-091e736c0e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6bdfeff4-331d-4026-8ad5-af8be53e2a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_47e6e8bc-1a0a-443d-bbce-cb6b1aeefdc4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6bdfeff4-331d-4026-8ad5-af8be53e2a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_388507ed-67f3-41fc-9427-724a14342729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_47e6e8bc-1a0a-443d-bbce-cb6b1aeefdc4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_388507ed-67f3-41fc-9427-724a14342729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_0595267c-69b0-4ce4-9b36-4d444e49ce91" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_47e6e8bc-1a0a-443d-bbce-cb6b1aeefdc4" xlink:to="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_0595267c-69b0-4ce4-9b36-4d444e49ce91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a57d381e-e303-41c4-916c-5091e98ebdde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_0595267c-69b0-4ce4-9b36-4d444e49ce91" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a57d381e-e303-41c4-916c-5091e98ebdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_775bdb85-760d-44dc-ab39-dc59f217fe7d" xlink:href="exel-20211231.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_0595267c-69b0-4ce4-9b36-4d444e49ce91" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_775bdb85-760d-44dc-ab39-dc59f217fe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_37b7358e-a086-4f1f-9f4f-f650e8b582df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_0595267c-69b0-4ce4-9b36-4d444e49ce91" xlink:to="loc_us-gaap_OperatingLeaseLiability_37b7358e-a086-4f1f-9f4f-f650e8b582df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="exel-20211231.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exel-20211231_g1.jpg
<TEXT>
begin 644 exel-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^%(8VAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N-BUC,3,W(#<Y
M+C$U.3<V."P@,C Q-B\P."\Q,2TQ,SHR-#HT,B @(" @(" @(CX-"@D\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@T*"0D\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@
M>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O
M:6UG+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X;6QN
M<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O
M<B\Q+C O(B!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N
M,R\B/@T*"0D)/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF;W)M870^#0H)
M"0D\9&,Z=&ET;&4^#0H)"0D)/')D9CI!;'0^#0H)"0D)"3QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^=%\P-C(Q,3<\+W)D9CIL:3X-"@D)"0D\+W)D
M9CI!;'0^#0H)"0D\+V1C.G1I=&QE/@T*"0D)/'AM<#I-971A9&%T841A=&4^
M,C Q-RTP-RTQ-%0R,3HT,SHT-"TP-SHP,#PO>&UP.DUE=&%D871A1&%T93X-
M"@D)"3QX;7 Z36]D:69Y1&%T93XR,#$W+3 W+3$U5# T.C0S.C0W6CPO>&UP
M.DUO9&EF>41A=&4^#0H)"0D\>&UP.D-R96%T941A=&4^,C Q-RTP-RTQ-%0R
M,3HT,SHT-"TP-SHP,#PO>&UP.D-R96%T941A=&4^#0H)"0D\>&UP.D-R96%T
M;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-#(#(P,3<@*$UA8VEN=&]S:"D\
M+WAM<#I#<F5A=&]R5&]O;#X-"@D)"3QX;7 Z5&AU;6)N86EL<SX-"@D)"0D\
M<F1F.D%L=#X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^#0H)"0D)"0D\>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^
M#0H)"0D)"0D\>&UP1TEM9SIH96EG:'0^,3$V/"]X;7!'26UG.FAE:6=H=#X-
M"@D)"0D)"3QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X-
M"@D)"0D)"3QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5"3$%%
M<T%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%"
M3$%!04%!14$-"D%117-!04%!05%!0B\K24U716Q$43$Y455K.4=357A&04%%
M0D%!04U317AP8FTX0T5!04%B5S4P8VQ*2%%I0EE75F]G0C@T04%G04H-"D%!
M64%-44%!65=.>F-%,512;%%!04%!05-55D1)2$Y34C!)04%!04%!04%!04%!
M04%!04%!4&)704%%04%!04$P>3%)54-!9T%!04$-"D%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M4EDS0GED04%!059!04%!07H-"EI'5GI9=T%!05E104%!0G-D,U)W9$%!04%F
M04%!04%566UT=V1!04%!9U%!04%!56-L:%I79T%!06AG04%!055:,6A:5V=!
M04%I=T$-"D%!0559;&A:5V=!04%K04%!04%56D<Q=5I!04%!;%%!04%"=UI'
M,6M:04%!07-104%!0TED;E9L6D%!04$P=T%!04-'9&UL;&1W04$-"D$Y44%!
M04%K8DA6=&%104%!+V=!04%!56)75FAC=T%!0D%W04%!06MD1U9J84%!04)$
M04%!04%-8VQ24U%W04%"1'=!04%G35HQ4E,-"E%W04%"1'=!04%G35EL4E-1
M=T%!0D1W04%!9TUD1U8T9$%!04%!0D1B,T(U8VUL;F%(46=+1TUP241%-4]4
M9V=31U8S8D=6,&1#,5$-"EE73G)96$IK245.=F)80FAB;FM!04=2;&,R34%!
M04%!04%!045N3E-2,$EG4U561$YJ135.:EET36DT>$%!04%!04%!04%!04%!
M05,-"F,Q2DA1:4)*4E5-,DU4:S).:3!Y3&I%04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04$-"D%!04%!04%!
M04%!04%&:%I7:4%!04%!04%!1'I544%"04%!04%28DU71FQA24%!04%!04%!
M04%!04%!04%!04%!04)95U9O9T%!04$-"D%!04%B-DE!041J,4%!041K1FA:
M5VE!04%!04%!04)I;5%!070T54%!0FIA5T9L84E!04%!04%!04-39T%!05!H
M04%!=',Y:UI83FH-"D%!04%!04%!04):2E)536=A2%(P8T1O=DPS9#-D>35P
M6E=-=5DR9T%!04%!04%!04%!04%!0EI*4E5-9V%(4C!C1&]V3#-D,V1Y-7 -
M"EI73759,F=!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!6D=6>EEW04$-"D%!04%!04%U4U56
M1$E$67A/5%DR3%1)=4U30D5:5UIH9%=X,$E&2DA1:4)J8C)X=F1826=C,T)H
M63)59TQ30GI5:V1#04%!04%!04$-"D%!04%!04%U4U561$E$67A/5%DR3%1)
M=4U30D5:5UIH9%=X,$E&2DA1:4)J8C)X=F1826=C,T)H63)59TQ30GI5:V1#
M04%!04%!04$-"D%!04%!04%!04%!04%!04%!04%!04=2;&,R34%!04%!04%!
M04Q&2FQ:;59Y6E<U:EI30E=A5U8S85<U;DE%3G9B;5)P9$=L=F)I0G -"F)I
M0DI254TR351K,DYI,'E,:D5!04%!04%!04%!04%!04-X4UI76FQC;59U63)5
M9U9M;&QD,FQU6GE"1&(R-6MA6%)P8C(T9V%7-&<-"E-55D1.:D4U3FI9=$UI
M-'A!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!0C)A5U8S04%!
M04%!051P4#1!1D8X=4%"1% -"D9!040W8W=!0D)-3$%!3F-N9T%!04%&65=6
M;V=!04%!04%"34-664%504%!049C9C4R,6Q96$U!04%!04%!04%!44%!04%!
M04%!04$-"D%!04%!04%!04%!04%!2U!!04%!06Y.<%IY04%!04%!43%*54E'
M3C%C;EE!04%!04%!045!04%!04%504-G05!!0E%!1U%!94%#34$-"DM!071!
M1$E!3G=!-T%%04%244)+044X059!0EI!1C1!67=";T%',$%C9T(S04AW06=1
M0T=!27-!:T%#5D%*;T%N=T-K04MK07)G0WD-"D%,8T%V041"04U907EW1%%!
M3E5!,G=$9T%/54$V=T1W05!902MW14)!46-"1%%%5$%2:T)(=T5L05-S0DUG
M131!5#1"4E%&34%624(-"E=11F=!5V-"8F=&,4%8=T)G=T=,05I)0FUG1VA!
M86M"<U%'-4%C14)Y44A2061K0C112'!!9DE"*V=)1$%G=T-&04ED06E90TQW
M230-"D%K14-3=TI506PP0UIW2GA!;F]#:$%+3T%P9T-O9TMS07)90W=13$Q!
M=%5#-$%,<D%V541!04U,07A91$E1371!>F=$47=.4$$Q;T0-"EIG3GE!,S1$
M:6=/5T$V241R9T\V03AC1#!W4&=!*W=$*U%11T)"345)05%T0D1S15-!4E9"
M1TU%8U%2*T))=T5M9U-O0DQ917A!5%0-"D)/144X050K0E$P1DA!57)"5&]&
M4U%664)78T9D=U='0EI91G!G5S%"8U5&,5%8;$)F64="9UE70FEC1TYW6DE"
M;&M'86=:-T)O=T<-"FY1879"<T%',%%B:D)V54A"=V-:0GES2%!19%!",D5(
M9$%E1T(U:TAR064O0CE)2#519C1#07-)2'=G>4-%64E79VAU0TE)26QG:7$-
M"D-,-$DP9VIN0U!S2D5!:VQ#5&]*5'=L:T-8:TIJ=VUK0V)O2GIW;FQ#9G-+
M15%O;D-J,$M607!Q0V]%2VU!<75#<U5+,T%R>D-W<TP-"DEG<S5#,45,85%U
M04,U9TQS079)0RM%3"M1=U-$0V]-47=X8T1(54UJ9WEN1$U!33)1>GI$43!.
M2F<Q0416;TYD03)/1&%K3G=W,V4-"D1F9T]%=S1U1&MK3UI!-2]$<'-/=&<W
M4T1U-%!#43AL1#!%4%AG.39$-5E0<W<O4$0K=U%#4D%M145-45E20BM%2G-1
M=5)$6$5055(-"D5X17A%53A28E)'345A;U)Y4DAO16=C4TIH2D9%;5%3:$)+
M:D5S35,T>$U$17E-5%%X3FI%-$U4<$)01D4K555":%%N1D5K56%H4TP-"D9+
M,%5Z:%1W1E))5DY"5E=&6&=6;7A7.49E05=!>%EM1FMK5V)"85!&<DE7,6AB
M-D9X,%A14F1L1C1K6')H9E-&+V-91WAH04='55D-"FEH:79'3E59*VAK9T=5
M55IA>&U21V)C6C-2;T5':6]A55)P,T=P-&%X4G)S1WA18D]X=&I'-&]B<VAV
M84A!26-+:'A32$AS8V]X>DT-"DA0561(:#%(2%A!9&U2,T1(97=E1F@U04AM
M;V5L0C8K2'5K9D5X."M(,FMF;$(K+T@K;V=&4T)"24=W9VU#1$5)4$%H2$-&
M24E856@-"F]32$])9G-I2GE*5DEO26ER>4QD27=O:D]#3FU)-5%J=VE0=TI"
M.&M44U(X2DMS:S)I54I*5&=L84-76$IC8VPY>5EN2FQC;6AY83,-"DIU9VY'
M0V1*2C-O;G%Y9F-+03!O4'EH>$M+26\Q0VM'2U1G<&%Y;61+9$%Q06EO,4MM
M9W%M>7)02W=)<DYI='!+-3!R,%-W1DQ$:W,-"F)I>6E,3F-T1$,Q0DQ8671Q
M>3-H3&A9=51#-D-,<F-U-VDX:TPQ;W9K4R](3"\T=TY40G--2U%W,GI%4TU5
M;WAG:D<V369)>4MJ2FH-"DUP<WDQ1$U.33!9>F9Z3S1-+T4P2WI2;$Y*-# R
M1%543E4P,6AZ6$-.9C R3GI:>4YQ-#(V5&-K3C)!,VY$9EA/0E$T541I34]-
M9S4-"D)4;$-/6#@U=D1N-4]J639D1'%Y3W4X-TQ4=')/-F\W-D1W;E!'53AP
M1'IJ4%-).5E4,FA094$K240U9U!Q02LT1#AH4#)%+V]J+VD-"E%#3D%:14-M
M44]D0DM51G%187A"-VM)=U%N2D-T54PS47IP1&954$%204Y%4C!32U)--49%
M:U964EIP1C-K66E2;61'<3!B=U)Z5D@-"F4P9D%3059)4S!I4E-.9$I(56QJ
M4V%L2CA%;S-3;C%+>$5S35,Q3DQM:W9I5$-P36-K>39444I.4VLR5%1D>$]*
M535U5')D4$%%.4H-"E0U3E S5D%N54A&474Q14=55D)2;3%(;55J1E-F1DQ(
M57A.5%@Q3W%5+UI546Q34%9.=%9+1E8Q5F-*5T0Q6F-6<6Q7.3%D158U2E@-
M"C1&9W972#%9>3%K85=7;%IU1F](5VQ:87!L<C%7,%9B;%9V;%A$5F-H;'I7
M6%-D9&5&,TI8:'!E8D8V.5AW.6995BMZ64%69U8R0W$-"EE0>&A4,D=I6696
M:5-72V-9=D)J43)/6%DK=&M11U-56D]L;%!75U-:961M4%=A4UIU:&Y05V54
M6BML;U R:5=A3WAP43)M86%F1G$-"E-'<69A=F1R5#)U;F$O.7-6,GEV8E%H
M=%E',C5B:$IU83(W16)X-79E1R]28T-T=VAN1&=C5'!X;%A(=V-K='EP;DU"
M8S$Q>G5(454-"F1(0C!Z2%5O9%E6,31862MD<'0R*TAD5V0W3C1%6&AU94UX
M-4MN;4IE960V4FYQ;&5W4C=9,W9#9D-&.&=8>FAF548Y;U@T0F9M2BL-"G=N
M.&IF-%(O-5E"2&=+:4)#;T9R9V,R0TU)2U-G=E-$5C1/-FA",D5G251J:%5E
M1G$T64]H;DM',31C-V@U*TE"26AP:4TV2DTT;5H-"FEF-DM:27)+:7I#3&QO
M=CAJ1T]->6\P>&I::4XO-#5M:G,V4$YO*V5K06%18G!$5VM4*U)Q2DE2:VYQ
M4S0U3DYK-V%524I32VQ04U8-"E@U6$IL:E-7;C5C2VPS5U@T2FA-;4QI6DI*
M;5%M9GEA84IR5FTP2V)R-7=C;DEM8SDU,6MN9$ME44HV=6YX,F9I-2\V;T=M
M9S)+1D@-"F]B86E*<4M7;W=A:F1Q4&UP1F%K>#95-'!A;6U'<6%,<'8R;F)Q
M9F=Q1DMO>$MK,W%A;7%(2W%0<7=+<F1A=G!R1GES,$LQ17)B:74-"DQA-FAR
M>&%V:3=!07-(5W<V<D9G<V1A>5,W3$-S>FEZ<G)1;'1*>3%%-U=+=&=',F5B
M8G=T,FDS-$QH6G5.1S53<FY#=6IU-G1B<W4-"G4V93A)8GEB=E)7.6HW-$MV
M;U,K+S<Y-G8O6$%C341S=U=F0C0X2F9W='9$5TU057A&2$5Z<U9,>&-J1U)S
M8D1X,$A(=CAG.7E,>DH-"D]S;35Y:FI+=#AS,GDW8DU.8WDQ>E183G1C-#)Z
M<F)03C@K-#!$;E%U=$4X,&(W4U Y3$(P,%14>'122C%-=E94=%A2,6Q85S).
M9&,-"C$K1%E:3FIO,E=Z6CAD<#(R=G9B9TYW1C-)<F1%3C)7,VAZ96]T.' S
M-B]G3G5#.3155&AZ3TI4-'1V:EDK4'(U2%!K+T]7135G,VT-"FQU8V8U-FYO
M375I.#958G P3W!B-G58<F-/=C<W26)T164R8S=I:G5T3SE!-SAZ=U=01&PX
M6$QX+R]+33AX;GIP+U$P.4U,,5506&4-"CEM,S(K+V5+*T)N-'%0:S0K8V8V
M5B]R;BLS9CA"+WE9+U-N.75V-4PO='HO8F8O+R\K-$%$:T9K8C)*;$%'5$%!
M04%!068O8D%)44$-"D)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&8-
M"DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8-"DAX.&9(>#AF2'@X
M9DAX.&9(>#AF+SA!04519T%D045!07=%4D%!25)!44U2068O14%A24%!04%(
M05%%0D%114%!04%!04%!04%!448-"D%W24=!44%(0T%K2T-W14%!9TE$05%%
M0D%114%!04%!04%!04%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$
M0D%)1T%N34(-"D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E0
M0E5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%4-"EI(
M5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]013%/5#!:6%=&;&%7
M,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95@-"G W9D@Q*V8S3T5H66%(
M:4EM2VDT>4YJ;RM#:S535FQP95EM6G%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R
M839V;U)!04E#05%)1$)1544-"D)1645#04U$8E%%04%H141"0T53355%1E52
M3FA)9UIX9UI%>6]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,
M0T(S4%,-"DYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<# K
M4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<-"C%U8C)2
M,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM$;$I75VPU:5IM<'5C
M;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V$-"D%!=T1!44%#15%-4D%$.$$Y
M531Q-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3<-"D9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M;#D-"GHU:#!#,75H85A/<%<P1C!D=E)K;5)8<65L5DIQ2S563%!J:6%-9T0W
M,TIX-DQ.3U!&1T5J2'9!2UE!9VEO,T(V2$Q81V1I<5A7=74-"C)L,W)&>G!L
M<T=L97E65&1Z0VYP;S<O6FER,V5L4V9$-3542$U*5$U2,#4O<6-R2G!*47A2
M>5,R12M1-FYZ.7E9-6,T<G-69&ER<U8-"F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7%895I,=39S
M+TPR<%AD<B]V5$(-"F)3>5%K8C!:54I"<#=D8W Q16I(2$EJ;4%82S!/3TTX
M.$EY*VMY05!Z9DU5:VIY3S!K:D8U2$I:,UDQ2DHS2DI/8U548C8T04%+2$H-
M"C=R*U1T+V989FQ)<F1->G)A,T1W5S=T=6940TEW6&9S<%EG9F0R>G%/>5IY
M;&DS-D=N>G(R;7=W:'%B:B]&1WHW-TM*+TU,>G%D1'0-"D5S3E O938U9F9"
M8E)Q3U)J1$AJ-FA(:EA:0C-0>7EE=C%N:$1H:CEC=516,DPR6"M9;'AZ,G=W
M-2MF;"MT3F9*,VPT849O8TYO-34-"C-K:$TY.4U457902G4U2E!7;E0V378P
M;41W;T%D95HY-V@Y<#8S.'AM36@Y23)I3S9)-4HS;5,V.3)+=7A6,DMU>%8R
M2W5X5C)+<TH-"B].=GIB<69L<GDQ2%!P:D-/.74U,6=367%'.4YE3$]Z04U#
M2R]$5&-946=V1G8X06QA+S5H9CA!5C5K+S5&=R\X,%EA4F)V*U9R+VT-"D8O
M,65:4#A!:UA$+T%-,%DP='-O+TQ0>G@U.3%Z>FI:5V1Z9GDS5FE/8C-I8TEW
M;VI61V]72W%+9D94=FE1:TUS+TYU9GHQ;SA3-C,-"F]7<%-P<&]!4SET5E-.
M=E-B;W-G2E5N:3-1*T(K97=#;$EF>7DO3B]56CE56%-F33%Y2F\W;VAB4SE:
M55%P251S:FQ1;S1T,E!9*S,-"E))548W5&=3.$TO368X-$Y53W1'>#AS,VYO
M5V1M4VMT,&=2+U=K-DYX3$)H=UAO0T]V6'!42D%)=&U(-510-3(Q3WIB5R]-
M1V]Y>3(-"FMW-#)&;WEX<GE(95IU2W%A9&PK+W=!34)5354O3E@X>2].5VTK
M8EHY2C!Q-TYL8E=34FAU0TEZ4U!*1W-P66PQ8F](<%%9449,1'8-"BM6<B]!
M2FAF.5AM5"]K6$0O=T$P63!I,V8X<E@O34PO04MV36XO275(+VUJ1VQT-T(K
M5&UT95IT6C!/-W8Y8FYE-%9P*T9N3$EQ<%8-"E98-"M014Q58W1Q*T]!<$1'
M9GIE+TU8>E!P2&U.3DHP:34K<'=1=W!*239O:D\W>59/-6-.44%D:&E!<%HW
M*U=7<F%H<3-K:E1D43$-"D=9,T8U4#8O<7I-04,S0S1K4F1L04=Y<4)I56AL
M1T)71R]M>#5R,4QY,3571C-P<%9,>35U171O-6U!8C K4T\U64LQ45133VTK
M14D-"DQ%=GE:.#9E6CEE,3(K='17=C-U-%ER6#%),%I55VIE;V]R.$MR,D]*
M54DO.#!.5C@V84)Q160U<"MO>4IP5C,X2V]%:DEI;%5B<%4-"G%44F@X42MN
M3D@R;&QZ67!C55IE:W999&=A9E-A;4)H3T$X4U!V,TAF>BM#<BM74#5H,V5R
M,T5M:F$S2W-T,#9L<E-C<7%M44%F2$<-"G=5045G8FIB<%A*9&TV.#5$=U0U
M.4=(8C-9<V-%4FQW:6\Y4C-D>%(Y-RM44&Q7-79M=55K=4QA2C(U3F)236Y!
M5C-)6&MR1E(W6EH-"E!S:D5:6'502GAS6'12<5EW-%-)>5!E8G8W,#,Q<E9D
M1#AJ*U=L5T-.55-)1T]X=$%F:6MK3RLU-CED,F(K3UI'8DQ$5%ET=F=(0S -
M"G5N>F1O86IC,V4X:C-$.&-G=V8X<V1*=F9-4&U+-3@R87543#9,;C!#=S)A
M8VHY:V9Y>$PP2&)B=WI79&TT<%IC:'EZ-F9F*W@V1'0-"C=543 R0T]M>&)7
M3B]W0W(O=T%E4#95-B]/5'IL<EAL>E,W1DY*:T5%.3E)-G9C1E%Z2W-953!5
M34-T5S5D8S9%4$5&1"]K<#5P,2\-"E@W6%9N,64X83=A,V5%46QL4F5)65!Y
M*WE&-C!X2VAK;FXO>C%:955D2U<T:U0Q-S(T2E-Y=&$P-4UO*TIM4%I6<4LT
M9TIE139N*V$-"G9N,U4W:FM.4VMT9W@O9'=79T53:7998V9J8B]!1U)/1VU.
M<4YL*UHS;C)Y;35P<D4W:TAD2C942V99:5%.:E,R.64O3$@X,')J>E0-"D\K
M;3,Y;#9D+T1'6E1C=T%M0FQ"02M)16MO,B]I469B05%K1DMR>E@O37AV:'%0
M-E%K=#1V5&UK:TIQ3&5+84Y*;5<P-$(K2EE.0T4-"DEA3W)F1E)G,T59<3E9
M:5IM:5)M6&EZ2T-Y*T))-EE%<G-695=F.$%/468O04-J3VYF.$%-8B]Z2V9#
M149I+S5$439F3'$K<4,Y4T8-"C%&=6Y!5$)32S@K,TQ#5D0R:C9L-5HO-5HW
M3"]!24-,*VU24VER2TQ466=Y,E-1;T1U-G=H4CE*-#1Q<E1W43-%16M%-DQ,
M1$MP4U<-"DYH5E=6:%%G9SEI359F32\U;651<"]+=7-K=V=V<$8R4S%L2V0K
M4&-X368U;#=E22MN2D%S4VU&>"MC3W1Z95-6,$4X=C!I9C-%=7 -"F-V:6$R
M06]"-"MO9G-L=D0S3TY*=$0O;%HK6#AN;6I69G).-&A':3)403-,9%!69G%)
M5E!V*S!2,$AZ1TI+02MK;S0T-#0Q:FI52D<-"F=#;VEI9T%'=T%!-UI&:RM:
M+WII+W=$2FHV=B]!3D<O+U5,1FMG>$PR4#A!3'$P,$(O2D=J=%!$871-8F-C
M,FM737-453EA:75!<%H-"D@Y4SAS+SA!3%!:9CA"1B]406Q-62]4.4YF4W V
M9%!G-# T,#EQ67$K9&9Z>"\U5#)8+VU(:"]58VM%1C9Z*U1V+VMU3DDO-D]0
M.$$-"G%+;'=&47I006PU;B]W035!9CA!2T<R9B]B4FDO=T-413)%24Q%=BMC
M9E K56TQ2"]M0R\U;7!H2V@W4C5G,$\P,7I33&I48F]F=34-"C%O<C!Q56-B
M<38K-$]9*V9#37-$13E83#!7<FQP.&]Y4C5J-V9*.#185G1Q96=A,CA,:W=A
M:' X=V\V.6U1,59L<C%",DDY<S0K55H-"EEP,7EL179Q94]E4%4T8D<X2F@W
M-6]V;FI3<C-Y;4YF=5I&9VIH5VPV;E5P2W5X441V>4I(2#5J3W%W-C)%<UAI
M2&%U9G9F3CE6,E0-"FMX-FYW26EY9G X>#,O<F5-835R3W(K9&9-,%-O<#54
M=4E,0S%R.$UA13DO*TI/,SA--7I.;6YQ8W9V,D%E.#!M;'AA1%1M*V=U4C<-
M"B]W061!.3@P2%)R6%)D271T3G1H*S=T,$-L=6AD:G5Z;C-:=#@V<D)H1T]!
M:4]J-79R3E9,4&QL:VQZ:V9W2&PS+T]22"LX96@O.$$-"D=3-"\T:DAL=V-5
M=2]W0V-D+SA!95!84"M-;'8O=T%2:WA+:$IV.$%N24U82"M*=$],5BMR1WE(
M<"M(4#%8-2]H>'=H4W4O2C-Z=C4-"E P0S!U3%165BMQ6#@X=DID44M&=S!:
M54)9>7EH;5AI450P<'9I46]E<E-W*U)F3CEU56(V;'%Y.6%O>5!)=BMY52MO
M;C1:1DM-.'8-"BM6=$$X=E<X:T=J,F%7:V-P-5-K1FY::4]N2C-,36%D=#A6
M5D@X=6%&2F9F6#-S65=U*U%K37!58G5V4GE/:%ED;7!81E5X>%8R2W8-"DQ0
M.$%N25 O04I2;E1V.$%M3B\U;%!H0T,X5S!B>3ER5W13>5)A5EIY6&MK2VAP
M1FI!2E9384%M=5-1;3,O2W,O4&XO049:3&XW:"\-"EA"83 Y62]*5'E8<FUG
M439J96%T06)6-WHP:V=G66=V>&HU17-W0DY+;'1H9TM1.4]W2EE&*V,R=&%&
M6F55<')(54EX8UA6.3A.:$(-"E=J3$EV*S=Q.6A(6#9E;F,T46=V;D1*2694
M2#53-C%O5V]E54Q7,S!U3F)A4WA54EAL<E=R3$MD>DE4,T5H<3%F;S=:17!$
M3DU#6'H-"DXK8U@O:W@Y6"\V3B]W1'%&:7E166Q+-TAY1C5X=C=32SAS.4IN
M;G1:,3524W%">%IF16(T,G%*:B],1'HY239O3D9N0EDP0F)I;RL-"FML9T)J
M83 K:V9+*VQZ-E8U8S S5%HR5G W4S)J:&Q:3C$U2V]"<%AT6$ES;F<S-30O
M.$%+97DO.'<X4#9J:V=G=E=F>60O.&QX<$@-"B]2>"\Q1E,T0V]:;F=3.'HO
M=T-C9U X06Q$8E O=&]X9CAM2G-)45=*9CA!3U!N+T%#:S)O+SA!348O>DY4
M0U9$,VY)<&5(+T%*>E@-"C)M6$AM84M',E%F5S=714IE>D0Y<&HX4TEF9$90
M6#-P,GIM93$U>$]7:'I!,V91=EIF1FMJ<'E:2#!Y4'!(,VXT+VIM>'!F3"]M
M0F8-"DMS;7)H6%A2,VY25U-P05IL0E9:4W94:4,S2&PT;DU0=TUN:&-F.$%"
M9C1,=%1R34(Q27AF-5AH+T$O5%-C9FQ0<65M,DAM,DPV-F<-"C582TY"8E1N
M<$A+-490.$%G=G,O5&U2,EAK:DA,-G5U=V-(,FDP*U1*<&IW9G=M>4\X9G,U
M=F9C-G X,F50.$$O3U)(*SAE:"]W1$<-"E,T+S1J2&A#0S<O;DAF.$$S:C%Z
M+VI*8B]W1$5:35-O6B\U,3AK-E@U<S!X8D\X2FEM:$IE,75K04QX<U)1-TAQ
M<"]A6'9G=$QX3%<-"G9Y5#@W864W1S%H:C%+059):W0S06%N=DA*=V%V<W1C
M;&%+661E861R3VHS4W)E5S%X65A+;7%E;VIX4%5D,4I!4#!J0V@V,RM4+S4-
M"FUA<&9A:VYL,U=P:F1'6E=.:F1U87EC:U5S63-B.7%Q9VM%-R]/=5))4T,Y
M:W=*9&ER<U9E5V8X-4(O.&]Z<#,O36(O04UY;G=H0ED-"DXK5"]!2G4P3'DQ
M<5=O5#9V33!-9'A#:5)&56%3<D(V;C=)3T5Q2'%F+TLV=GDY+S5B<% K4D4S
M+TY/0VQT1V%0*V%F:WI73E-G,#(-"G=U,VMU-VML66M-36EG:TM73S=+0C!'
M3DIT4%!-1W9A9F]/:S-'<5@W.$QE0F$P2#)N62]:4D(S6FHP=TLK661D,6Y7
M=D]0;54S3&\-"C Q-61U27)3,51C271A2D=N>7(Q*UIY5$8V>&-F:V9:1'E3
M=&Y%5E!M4E Y24XS5VEV2U)V0E4O-W(R;T0T-SEY349P<#56-58X>38-"G0U
M3SAX0S921U8T5TU.+UI05F5A03!E3F@R645B2'-C2T@P+V\R<U='<S9:8C9L
M65-E<F$S2SAK8G5/>%9H,EI4<U)K5U0U>B]/3"\-"D%-;5!Q+SA!,&(O.5%S
M5U-$17924$I(-7)E4W1+.' V6G Q-V502&17,$E36D)$2W=$5DHV:%-$9TE4
M865F.$%+-G9Y.2\U8G!0.$$-"FM23B]Z5&I3,GE$>7HU=3!,>DQ"3E!P17I4
M4C(W0DI3>4Y(4FE+:C=11T),=WHX.&8K53EL+S5H-&8Q2$I"0EID*UA(-6XK
M5'1%.&T-"F%D<&5O,V)X6&QV-C-Q;W--:F=C-35(6#1L56HW3$1!471S;"]W
M0U8Q9FPW+W=!=#!N+TEI8B]M;D=L=$M0>C5N:FXX:F%D4$5A>'D-"C,X3&]E
M;%9A,VU)>$-L:3,O3U!N+TM486HO>D)F.'I5=VQ1.6DX,F5965!,*VA83W!3
M56%20G=T-'HK,TLR>4PO12LQ8WAD5FY'3$<-"EI(.$9Z*WIT1614;6IJ2$QR
M-41R*T\Y-'0U23AP6'9M+UA*8G$Y6FI9<$E:9%%U5'-89&IY.4Y4+TTS9G=(
M,%IZ96HP<W123S5F5#$-"DPS=F$S855.1FA%66985E)(9#4O1#=8=3AU;5=%
M=6UT<')W3#E284PP1$%"4E)(5&IX04A48D]P3T]*:G<Q-F54-3%(4$U:4$5"
M.60-"C-F;2MC9DYF;#(V.'4V-U!P.'!*5D1Z='!U;D]*:CA$9E!S9F9/4#%7
M;D]'6FEF9RMP9&YA,D]Q=VE9*TDW:C$O2&,Y<B],9GIC4$T-"D]H2THS<G%6
M;E-+-TAD='9G:R\R44<O=EA/:S=0,5AI=S,K;V,O,79!.75D;2]L<S-P+W4U
M8FHY22M(,TU,+S5Y22\S:C!0+T%)>5@-"D@O15DX,D%D25AF.#0W+S=X-C4O
M>&MT+RM)>5EL46YV-6AF;35B958Y4EA3-U,P1CEF2W%V8SAN-$I'1S-69&=3
M5TLW*S(S6$5"8E<-"C9$*V58;$,O:%5A:UI.2W5F,FMK5G!9-B]W0U1*1W!0
M+T)+36%7,'0O37(X>E!),F]E5C=R5&)346%P9#-+.%E&5TYW<U16,FQ,=7$-
M"C!+.75/+S!99TM3.#DO2T14<FDY."]A8UEG949R>G5*,U@Y;$519U8Y:7I+
M=C T4V=0<&Y)<VY9<3=&5TDO;58U2G5V3C)L5W1L8E@-"DM7<E<X+W)&-4%7
M0DA";'!T+W)9459E9&8Y0S@V>B\Q9')B+T%*1G9H=$9/+W=#:&5D6B\V=3%T
M+W=!:3-X=&%:2C5$+TIK*UAT8VD-"C%I+W8Q=7!B64XY6&AI47%V2FQ+.&U:
M:G9113=5=T5R4TXO36(X=F9-;FTV.6E#86Y$8F%88D%'0S%+=5-:0U!I:V5M
M>&)S4$%F330-"F=Q,RM84#555R]L83=M,4,Y;E,Y,45J:&)/<6Q6:5%J-&E+
M+W1.,'(T9E!%;&%E9S1%=E!0>D$O2TMZ.'I8=S%/>75266%G=T,S1E4-"C52
M>3!&07I524EA;3%D.7-)2TM6=GDT.&@K62]+33 X12MP43-E;#-!-4YB2W)H
M:VQ(4C!R='5.;3AF;WA*5DIV3R\U3C9N-6DX,%@-"G5S=S9J1$)&9&5L>&ED
M2$Q$,#15:DY33G1Y;&-15G!)=BMH961:+S9U,70O>4QF1&$P-R]!2T8U,6XO
M<3<R+R]!0TQF1S%P-EHK6"\-"D%*2'0O2T=K4U=A6$)U<FDT:SE7-&Y+.$%4
M44M&5F%T44%$>"]P9TI3>&8X=U!Y:C%(>E U:69664PK1S-J84M/4# U15ET
M5D)3=%(-"FE#:6U.+SA!479/<R]W1%8R='8K4F(T8E=K4EDO=T1/4$XS.6%J
M3CEQ.&8Q545'4EE9,C5S3S1"66=#=FIV.$%,0F$P>C<X>%!*33,-"FUJ>3EA
M-E1:>G@R;C%A-%-:5V-&;#12>'9(>$90.69%1DM$+T%#,R]!0WEJ.&]08S-5
M,3,Y8W9R;%)(>5)3:4I'1'E)04I*2DQ$<FD-"E-I;4TK9%HW-WIR-7EI.'4V
M5S%B3%1Y4E!.,5)8-E-Y3E0K5#=#*R]Z>FYT6DM7<'I$2$AL2#A%=F,Y;%%H
M;TY+8RM4-C4X:#$X:#@-"F5:+UDY43!04F)$4F1-:# V>%1H0D-/<"LP-T@W
M5'-E-5DU=3A/1T]/26I(:TAK3EAQ<#4X:'E43S4O1DDO3%A'67HU-#AJ,F9M
M;3 -"FE2<&9Q,35B:VU#-4,X.6HY<$=&5G%P*V4R65=T,%%Z9V1#3W)T=7EE
M,7!A3U).8U5:8W@K;&IV;$0X<W1F.$%,;71X86A&<6-,>&8-"EEU;T%R:C%)
M;39J-6IQ4&9-4%-D;EI-37A)4TAM-U1T3'0W1'%S2F=94W9O9'1I;5@U;2M1
M3'IZ:$)P.&1T9'@R<',R:UIJ27).>3D-"E%+0E1J+W$U=6=8;$-I=GDW.&=W
M*U0Y3W5)4')2=3=Q-V18;FPT.$9!445+<7)6=6Q4=EA%;$M*.#,K45!,=FUQ
M141526I(9'AI:TX-"C=#47-Q:G=*24E:9EIH.'%9,G)Y+U50*V-E=&%342]O
M-U9B86%/=G<O5T9K:$Y09F=*<TYO<%I9+W=$3U!F;4(U44PO049/,&AI<G4-
M"C!!:VUA;GED65(K3TYR5#%8>6(U1S!4>7!:3D)P-FPU-7%'-74U2T=346IO
M3G5I:G-O>4YP6D1I<G-69&ER<U9D:7)S5F1I<G-69&D-"G)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U931'IP<F1Z<'5K*VQP-FU85CE18C9R<#!3+V%-
M:FID+VMI+T95-V5/66US>D=%2VH-"CEC=&<W3'-V4WAY-6)N=&EH-G!(>3=V
M:GE7*U-V2T9T-6(P<U$Q170O4%(W,C4V;#,X051V>%AT.2]F2%(V55E9,2]%
M95I4,G(R;$P-"E9:3#512#!J.&17435L=7-D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U8-"F1I
M<G-69&ER<U9D:7%K,7!B4&-P8W9%:EA%4VQ9-5-!5U97*S!&2C96-S!Y2FE,
M=G%Z1U-1:5EG*VLY1EA*34A9<3=&6%EQ-T9867$-"C=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3<-"D9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T8-"EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@-"EEQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%D-"G$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$-"C=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T98+R\R43T]/"]X;7!'26UG.FEM86=E/@T*"0D)"0D\+W)D9CIL
M:3X-"@D)"0D\+W)D9CI!;'0^#0H)"0D\+WAM<#I4:'5M8FYA:6QS/@T*"0D)
M/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#IB-3!A,C8X,BTU.60V+30R,&0M
M8C=F."TX93$X,&5F-60T8V,\+WAM<$U-.DEN<W1A;F-E240^#0H)"0D\>&UP
M34TZ1&]C=6UE;G1)1#YX;7 N9&ED.F(U,&$R-C@R+34Y9#8M-#(P9"UB-V8X
M+3AE,3@P968U9#1C8SPO>&UP34TZ1&]C=6UE;G1)1#X-"@D)"3QX;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U
M.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@T*"0D)/'AM
M<$U-.E)E;F1I=&EO;D-L87-S/G!R;V]F.G!D9CPO>&UP34TZ4F5N9&ET:6]N
M0VQA<W,^#0H)"0D\>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@T*"0D)"3QS=%)E9CII;G-T86YC94E$/G5U:60Z8F1C,S)B
M,S<M-&$X82TQ-30Q+6$P-V8M.#)F9C$W9F,W-#$W/"]S=%)E9CII;G-T86YC
M94E$/@T*"0D)"3QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z.3%F-S8Y9F(M
M838P."TT.#4Y+6%B-S<M.3(U960Q-CEC9CED/"]S=%)E9CID;V-U;65N=$E$
M/@T*"0D)"3QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR
M-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/@T*"0D)"3QS=%)E9CIR96YD:71I;VY#;&%S<SYP<F]O9CIP9&8\
M+W-T4F5F.G)E;F1I=&EO;D-L87-S/@T*"0D)/"]X;7!-33I$97)I=F5D1G)O
M;3X-"@D)"3QX;7!-33I(:7-T;W)Y/@T*"0D)"3QR9&8Z4V5Q/@T*"0D)"0D\
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"3QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX-"@D)"0D)"3QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z9C1B.3AA,3<M,F8W,"TT-38W+6(U8S M968U
M,C0Q-F8R969D/"]S=$5V=#II;G-T86YC94E$/@T*"0D)"0D)/'-T179T.G=H
M96X^,C Q-RTP-2TR.%0R,CHS-3HP,BTP-SHP,#PO<W1%=G0Z=VAE;CX-"@D)
M"0D)"3QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-#
M(#(P,3<@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^#0H)"0D)
M"0D\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@T*"0D)"0D\+W)D
M9CIL:3X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M#0H)"0D)"0D\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^#0H)
M"0D)"0D\<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F(U,&$R-C@R+34Y9#8M
M-#(P9"UB-V8X+3AE,3@P968U9#1C8SPO<W1%=G0Z:6YS=&%N8V5)1#X-"@D)
M"0D)"3QS=$5V=#IW:&5N/C(P,3<M,#<M,314,C$Z-#,Z-#0M,#<Z,# \+W-T
M179T.G=H96X^#0H)"0D)"0D\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!)
M;&QU<W1R871O<B!#0R R,#$W("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@T*"0D)"0D)/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X-"@D)"0D)/"]R9&8Z;&D^#0H)"0D)/"]R9&8Z4V5Q/@T*"0D)/"]X;7!-
M33I(:7-T;W)Y/@T*"0D)/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R
M:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X-"@D)"3QP9&8Z4')O
M9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,34N,# \+W!D9CI0<F]D=6-E<CX-
M"@D)/"]R9&8Z1&5S8W)I<'1I;VX^#0H)/"]R9&8Z4D1&/@T*/"]X.GAM<&UE
M=&$^#0H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_>'!A
M8VME="!E;F0])W<G/S[_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M
M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
M!0__ (6'HEK\(O&5]NU[2X2OAV\G?YM0MT4DVS$]9(E!*^L:XZIEORF^;VJW
MX>\07WA+7K+5-,NI['4M-G2ZM;F!RDEO*C!D=2.0P8 @^HJ91NK%1E9G]+5%
M?-__  37_;QL?VU_@^K7LD%KXX\/HD.MVBX42DC"W4:_\\Y,'('W&RO3:3[M
M\1/B%H_PG\#:KXD\07T.FZ-HMNUU=W$A^6-%_F3P !R20!DD5SVL[&QY_P#M
MH_M;Z'^QI\$[[Q5JQCN;YLV^DZ=OVR:C=$':@[A1]YF[*#U) /X+_%_XM:]\
M=?B5K'BSQ-?/J&M:W<&XN)3]U>RH@_A15 55' 50.U>D?MX_MG:Q^VO\;KG7
M[SSK30=/W6NA::6^6RMMWWF'3S9,!G;G)PN=JJ!XI\WM6\(VU,92N'S>U'S>
MU'S>U'S>U62'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[5]J
M_P#!(7_@GB?VE?'B^//%UCN\!^&[C]S!,F5UN\7!$>#UA3@N>C'"<Y?:G*VH
M+4^A_P#@C)_P3O/PWT2V^+GC2PV^(-4A)\/64Z?-IULZX^TL#TDE4D+W6,GN
MY"_H30JA%P. .@]**YI2;=V;I6"BBBD,**** "BBB@ HHHH **** "OS?_X.
M(?\ D3/A;_U^:C_Z!;U^D%?F_P#\'$/_ ")GPM_Z_-1_] MZJ.Y,MC\NOF]J
M/F]J/F]J/F]JZ3$/F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VK],_P#@
MW3Z?&+_N"_\ N0K\S/F]J_3/_@W3Z?&+_N"_^Y"HJ?"5'<_3*BBBN<V"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .
M%_:@_P"3:?B)_P!BSJ7_ *2RU_.I\WM7]%?[4'_)M/Q$_P"Q9U+_ -)9:_G4
M^;VK:D9U ^;VH^;VH^;VH^;VK4S#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;V
MH ]-_8I_Y/(^$O\ V.6C_P#I=#7]#%?SS_L4_P#)Y'PE_P"QRT?_ -+H:_H8
MK"IN:T]@HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYE
M_P""Q7_*./XC?]PW_P!.=I7TU7S+_P %BO\ E''\1O\ N&_^G.TJH[H#\-/F
M]J/F]J/F]J/F]JZ3G#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]JZ?X*
M_P#)8_"7_89L_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444
M %%%% !1110 4444 %?-_P#P4Q_9$'[4'P*DN=+MA)XN\*A[W2]H^>Z3 \VV
M_P"!A05_VT49 +5](45YN<95A\RP=3 XI7A-6?EV:\T]5YH]GA[/L7DN94<T
MP3M4I2379]T_*2NFNJ;/YY71HW*LI5E."".0:;7V!_P5P_9!_P"%*?%@>.-%
MM?+\,^,IV:=47"6-^06=/99 #(ON)!@ "OC^OX=S[)<1E./J8#$_%![]&NC7
MDUJ?Z>\*<383/\JHYM@W[M17MUC+:47YQ=UY[K1A1117CGT04444 %%%% !7
MZH?\$A?VO_\ A;GPQ;X?ZY=>9XB\(P#[$\C9>\L 0J_5HB50_P"R8^O-?E?7
M5_!+XOZQ\!/BGHOBS0Y?+U'1[@3*I.$G0\/$W^RZ%E/L:^OX(XHJ9%FD,6OX
M;]V:[Q>_S6Z]+;-GY[XF\#4N*LCJ8!V56/O4Y=IK9>DOA?D[[I'[XT5RGP3^
M+VD?'KX6Z+XMT.7S-/UJW$RJ2"T#]'B;'\2,&4^X-=77]KT*].M3C6I.\9)-
M-;-/5/YG^:.*PM7#5IX>O%QG!N,D]TT[-/S3"BBBMCG"BBB@ HHHH 9)(L,;
M.[*JJ,LQ. !ZFOR@_P""H'[>C?M%^,7\'>%[MO\ A!]"G/F31M\NLW"\>83W
MB0Y"#H>7Y^7;[#_P5G_;[_L>UO/A3X-O?]+G4Q^([Z%O]0A_Y<T/]YA_K".@
M.SDEPOYR5_.'BQQ][64LCR^7NK2I)=7_ ")]E]KN].CO_9'@#X4>PC#BC-X>
M_)7HQ:V3_P"7C7=_8[+WMVK%%%%?@1_6 4444 %%%% '9?L_?!;4_P!H?XQ:
M#X/TD;;K6;D1O+C*VT0^:65O9$#-[XQU-?N=\-_A]I?PI\!:1X;T6W6VTO1+
M5+2W0==JC&3ZLQR2>Y)/>OD/_@C=^RK_ ,*W^&=S\1M8MMFL>+H_)TT./FM[
M ,#N]O-<!O\ =1"/O&OMBOZQ\(^%?[-RWZ_77[VO9^:A]E?/XG\NQ_ _T@>/
M/[9SK^RL+*]#"MK3:53[3_[=^%>:DUHPHHHK];/Y_"BBB@ HHHH **** "BB
MB@ KYE_X+%?\HX_B-_W#?_3G:5]-5\R_\%BO^4<?Q&_[AO\ Z<[2JCN@/PT^
M;VH^;VH^;VH^;VKI.</F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VKI_@
MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
MZ/2D!_1]1117*= 4444 %%%% !1110 4444 %%%% !6+X^^'6@_%3PO<:+XD
MT?3==TFZ&);2^MUGB;T.U@<,.Q'(/(Q6U10!^>?[3?\ P0/\->*WN-2^%NO2
M^&+QR772-4+7-@3_ '4E&9HAU^]YN?:O@7]H/]@WXK_LQ2S/XJ\(:E'ID)/_
M !-;-?M>GL.<$S1Y5,X)P^UL#I7] U#*'7!Y!ZCUK15&B7!,_F:^;VH^;VK]
MY_CK_P $QO@K^T!YTVJ>"['2M2FR3J.B_P#$ON-QZNPCQ'(WO(C5\@?&?_@W
MNO(7FN/A[X]M[A.?+L?$%L8V4>]Q""&)_P"N*_KQHJB(Y&?FO\WM1\WM7O?Q
M?_X)B_'+X+-(^I> -8U*SCR1=Z,%U*)E[L1"6=!_OJO3\:\)U#3KC2;V2VNH
M)K6XA;;)%*A1T/H0>0:I.^Q!%\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #
MYO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:C
MYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J]4_8W_ &KM=_8Z^.&F^+=':2:U5A;Z
MK8;]L>I6C$;XSV#<;E;^%U4\C(/E?S>U'S>U+<#^DCX:?$?1_B]\/]'\3^'[
MQ;[1M<M4N[2=>-R,,X(_A8<@J>000>0:W:_,3_@@I^UFUOJ.L?!_6+K,=P'U
M?P]YC?=<<W-NOU7$H X&V8]Z_3NN:2LS=.Z"BBBD,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /Y^?\ @H'_ ,GN?%7_ +&:^_\ 1K5Y!\WM7K__  4#_P"3W/BK_P!C
M-??^C6KR#YO:NJ.QSA\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #YO:CYO:
MCYO:CYO:@#] OV?O^"%7_"]?@?X5\9?\+2_LO_A)M,@U'['_ ,(UY_V;S$#;
M-_VI=V,XSM&?05V/_$.G_P!5B_\ +4_^[*^TO^"?O_)D/PJ_[%BQ_P#1*U[!
M7/SLV458_,W_ (AT_P#JL7_EJ?\ W91_Q#I_]5B_\M3_ .[*_3*BESR#E1^9
MO_$.G_U6+_RU/_NRC_B'3_ZK%_Y:G_W97Z944<\@Y4?F;_Q#I_\ 58O_ "U/
M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OF7_@L5_P HX_B-_P!PW_TYVE?35?,O_!8K_E''\1O^X;_Z<[2JCN@/PT^;
MVH^;VH^;VH^;VKI.</F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VKI_@K
M_P EC\)?]AFS_P#1Z5S'S>U=/\%?^2Q^$O\ L,V?_H]*0']'U%%%<IT!1110
M 4444 %%%% !1110 4444 %%%% 'GW[4'Q]T_P#9G^"&N>+]0\N1M/AVV=LS
M;?MERW$40[\MC)'10Q[5^&WC'Q=J'C[Q7J6N:M<O>:GJUS)=W4[]9978LQ]!
MR3P.!TKZR_X+ _M5'XN?&6/P+I5PSZ!X)D9+G8WR7.H$;9"1W\H9C'<,9>QK
MX[K^2?%CBK^T\T^IT'^ZH72[.7VG\OA7HVMS_0#P"X#_ +#R-9CB8VKXJTG?
M>-/[$?*]^9^J3^$****_*3]X"BBB@ HHHH *]P_83_8WU']L'XM)8'S[/POI
M)2?6K]!S'&3\L*$\>;)@@9Z ,V#MP>#^ 7P+U[]H[XIZ9X3\.P>9?:@^9)6!
M\JTA'WYI".B*/S. ,D@']K/V;_V>]!_9C^$^G>$] C_<6@\RYN60"6_N"!OF
M?'\38''90JC@"OU#PUX%EG>*^M8I?[/3>O\ ?>_*O+K)]%IN[K\/\:/%*'#&
M ^HX&5\967N_].X[.;\^D$]WKJDT^H\'^$--\ >%M/T71[.#3]+TN!+:UMX5
MPD4:C  _Q/)/)YK4HHK^NJ=.,(J$%9+1)=#_ #ZJ5)U)NI4;;;NV]6V]VWW9
MQ_QV^#&C_M!?"C6O".N1[K'6(#&) ,O;2#F.5/\ :1@&'KC!X)K\.?C#\*=7
M^!_Q-UGPIKD'DZIHMP;>4#[L@ZI(OJKJ58'N&%?OM7Q/_P %A?V0C\3OAY'\
M2-#M?,USPI 4U..-?FN[ $L7]VA)+?[C/D_*HK\C\6N$/[2P']I8:/[VBM;;
MRANUZQW7ES+=H_H+Z/\ XA?V-FO]C8R5L/B6K7VA4VB_)2TB_/E>B3/R[HHH
MK^43^\PHHHH **** "BBB@#[6_X(]_M>_P#"L?B))\-]<NMFA>*IP^F22-\M
MI?D !/99@ O^^J8^\QK]1J_GGMKF2SN(YH9'BFB8/'(C%61AR"".A%?LY_P3
MO_:TC_:N^ ]O=7DR?\)5X?VV.LQ\ R.%^2X _NR*">PW!P. *_I+P;XO]K2>
M1XJ7O1NZ;?6.[C\MUY7Z(_C/Z1WA[]7KKBC Q]R;4:J726T9^DOA?]Y)ZN3/
M?****_>C^4PHHHH **** "BBB@ HHHH **** "OF7_@L5_RCC^(W_<-_].=I
M7TU7S+_P6*_Y1Q_$;_N&_P#ISM*J.Z _#3YO:CYO:CYO:CYO:NDYP^;VH^;V
MH^;VH^;VH /F]J/F]J/F]J/F]J #YO:NG^"O_)8_"7_89L__ $>E<Q\WM73_
M  5_Y+'X2_[#-G_Z/2D!_1]1117*= 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7+_ !(^"7@[XPV7V?Q7X5\/^(XMNU1J.GQ7)3_=+J2I]P01
M7444 ?(_Q3_X(G? GXB"233])UKPA<O\QDT?4GVEO^N<XE0#V4+QZ=:^<?BA
M_P &]&L6HDE\%_$33;[J4MM:L7MBOH#+$9,_7RQ7ZC457,R>5'X2?%?_ ()1
M_'CX2>9)<>!;[7+./.+C0Y$U /\ 2.,F4?B@KP'7_#FH>%-4DL=4L;S3;V'B
M2WNH&AE3ZJP!'Y5_2S6'XY^&GAWXG:9]A\2:!HOB"SY_<:E91W4?/^S(I%4J
MCZD^S['\VWS>U'S>U?MG\8?^"+OP,^*4<LEAHNI>#;Z3)\_1+UE3=VS%+YD8
M'LJKD=QP1\E_&_\ X(!>./"ZSW7@/Q3H_BJW7++9WZ'3[P^BJ<O$Q]V9!]*T
M51$\C/@#YO:CYO:NU^,O[./CO]GK5OL?C3PKK7AV5G*1R75N1!.1U\N49CDZ
M'E&(KBOF]JI$A\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #YO:CYO:CYO:C
MYO:@ ^;VH^;VH^;VH^;VH ZOX%_%O4/@-\8_#?C'2V87OAW4(KQ5#;?.56^>
M,G^ZZ;D/LQK^BKPIXGL_&WA;3=:TV87&G:O:Q7MK*.DL4B!T;\58'\:_FJ^;
MVK]P_P#@CM\6&^*G[!OA5)I/.O/"\L^A3MGH(7W1#VQ!)"/PSWK*HNII3['U
M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
M2Z&OZ&*_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6%3<UI[!1116984444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7S+_P6*_Y1Q_$;_N&_^G.TKZ:KYE_X
M+%?\HX_B-_W#?_3G:54=T!^&GS>U'S>U'S>U'S>U=)SA\WM1\WM1\WM1\WM0
M ?-[4?-[4?-[4?-[4 'S>U=/\%?^2Q^$O^PS9_\ H]*YCYO:NG^"O_)8_"7_
M &&;/_T>E(#^CZBBBN4Z HHHH **** "BBB@ HHHH ***K:IJ=MHFF7%[>3P
MVMG9Q-//-*P6.%%&YF8G@  $DGTI2DDKO8J,7)\L=SYI_P""J'[57_#/'[/\
MND:7<F+Q/XT$EA:%&Q):V^,3S@]00K!%/!#2 C[IK\@J]<_;9_:7N/VJOV@=
M7\2;I5TB(_8M'@?@PVB$[,CLSDEV'9G(Z 5Y'7\7>(?%+SO-I5:;_=0]V'HM
MY?\ ;SU]++H?Z2>$/ JX8X?IT*RM7J^_4[\S6D?^W%IVOS-;A1117PI^I!11
M10 445]#?\$]?V(;S]KKXF>=J"3V_@G0Y%?5;I<J;ENJVL;?WV_B(^ZN3G)4
M'T<IRO$YEBX8+"1YIS=DOU?9+=OHCR,^SW!9-@*F99A/EI4U=O\ ))=6WHEU
M;L>N?\$H?V!_^%E:Q;?$WQ?9AO#NG2DZ+93)E=2G0X,S C!BC8$ ?Q.#V4AO
MTZJGH>BV?AG1;33M/M8+*QL(4M[:WA0)'!&@"JBJ. H   ]!5RO[3X1X7PV0
MX".#H:RWG+K*7?T6R71>=V_\UO$#CK&\59K+,,5I!:4X7TA'HO-O>3ZOR22*
M***^H/APHHHH **** "OS<_X++?L@?V#K,7Q8T&UQ9Z@R6NOQQI@0S\+%<$#
ML_",>/F"=2YK](ZQ_'?@?2_B7X-U3P_K5JEYI6L6SVEU"W\<;C!P>Q'4$<@@
M$<BOF>+N&Z6>99/ U-);Q?\ +);/TZ/R;/MO#WC3$<+YW2S.E=Q^&<?YH/XE
MZ]8_WDNA_/W17HG[4G[/.J?LO?&O5_".I;Y5LW\VQNBNT7MJQ/E2CZ@8(&<,
MK#/%>=U_$.,PE7"UYX:O'EG%M-/HUHS_ $VR_'X?'8:GC,+)2IU$I1:V::NF
M%%%%<YV!1110 4444 :_@3QQJGPT\9Z7X@T6Z:SU71[E+NUF7^!T.1D=P>A!
MX()!R":_<']EK]H72_VH/@GH_B[3=D;7B>5?6H;<;*Z4#S8C]"<@GJK*>]?A
M/7U!_P $M_VOO^&;_C8NAZQ=>7X1\82):W9=ODLKC.V*X]AD[7/ VMDYV"OU
M+PLXP_LC,OJN(E:C6LGVC+[,OT?D[O8_#?'3P]_UAR;Z]A(WQ.'3E&V\H;RA
MYO[4?--+XF?KY1117]='^?(4444 %%%% !1110 4444 %?,O_!8K_E''\1O^
MX;_Z<[2OIJOF7_@L5_RCC^(W_<-_].=I51W0'X:?-[4?-[4?-[4?-[5TG.'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5T_P5_Y+'X2_[#-G_P"CTKF/
MF]JZ?X*_\EC\)?\ 89L__1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\B?^"_'PLMO"O[
M2_AOQ1;1I&WBS1O+NL=99[9]F\_]LGA7Z1U^NU?EE_P<.^*8;OXB?#'1%9?M
M&GZ=?7SK@9"SRPHI]>3;M^1]ZNGN3+8_.?YO:CYO:CYO:CYO:N@Q#YO:CYO:
MCYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J_0#_@WOT]I/V@O'5UN79#X>2(CN2]
MS&1_Z ?S%?G_ /-[5^D/_!N[X?\ /\5?%/5MO_'K::=: G//F/<.0!T/^J'N
M,CU-1/X2H[GZB4445SFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S\_P#!0/\ Y/<^
M*O\ V,U]_P"C6KR#YO:O7_\ @H'_ ,GN?%7_ +&:^_\ 1K5Y!\WM75'8YP^;
MVH^;VH^;VH^;VI@'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!_0+_P3]_Y,
MA^%7_8L6/_HE:]@KQ_\ X)^_\F0_"K_L6+'_ -$K7L%<AO'8****!A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M7/\ Q4^*&A_!;X>ZMXI\27T>G:+HMNUQ=3OV4=%4=69B0JJ.22 .M 'G?[<7
M[8NB?L6?!*[\2:AY5WJ]SFVT732V&U"Y(X!QR(T^\[=AP/F90?P;^)_Q,UOX
MR?$#5O%'B.^EU+6]<N&N;NXDZNQX  Z*J@!54<*H &  *]$_;@_;$US]M+XW
M7GB;4O-M=)M\VVBZ:6RNGVH.0#V,C?>=N[<?=50/'OF]JZ(1LC&4KA\WM1\W
MM1\WM1\WM5DA\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U?<
MG_!'G_@GA_PT#XSC^(WC"Q\SP3X>N/\ 0+6=/W>M7B'N#]Z&,\MV9@%Y <4G
M*RN"U/HC_@C7_P $\/\ A3OAB#XJ>,;#9XJURW_XDMI.GSZ3:..96!^[-*I^
MJH<<%V4??-%%<S=W<Z$K!1112 *\P_:[_98T#]L#X*:EX/UU5A:;]_I]\$#2
M:;=*#LF3\R&&1N5F&1G->GT4 ?SB_&_X+^(/V>OBEK'@_P 469L]8T68Q2J.
M4E4\I(A_B1U(93W!'TKE/F]J_;?_ (*H?\$_8?VP_A;_ &UH%O"OQ"\,PLVG
MM@*=4@&6:T=O?)9"> Y(X#L1^)E[93:;>36]Q#+;W%N[1RQ2(5>-@<%2#R""
M""#R"*Z(RN8RC8C^;VH^;VH^;VH^;VJR0^;VH^;VH^;VH^;VH /F]J/F]J/F
M]J/F]J #YO:OU)_X(O?\%$3XGT^S^#OC2^SJ%E&5\,WT\G-S$HS]C8G^)!GR
M_51MXVJ#^6WS>U3Z1J]UX?U:UO[&YGL[VQF2XM[B"0QRP2(0RNK#E6! ((Y!
MI2C=6&G8_I>HKYC_ ."8W[?-K^VC\(_LVK2P0^/?#<:1:Q;J @O%Z+=QK_=?
M^(#A7R, %<_3E<NQN%%%% !1110 4444 %%%% !7YO\ _!Q#_P B9\+?^OS4
M?_0+>OT@K\W_ /@XA_Y$SX6_]?FH_P#H%O51W)EL?EU\WM1\WM1\WM1\WM72
M8A\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U?IG_ ,&Z?3XQ?]P7_P!R
M%?F9\WM7Z9_\&Z?3XQ?]P7_W(5%3X2H[GZ94445SFP4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_ ";3\1/^
MQ9U+_P!)9:_G4^;VK^BO]J#_ )-I^(G_ &+.I?\ I++7\ZGS>U;4C.H'S>U'
MS>U'S>U'S>U:F8?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U 'IO[%/\ R>1\
M)?\ L<M'_P#2Z&OZ&*_GG_8I_P"3R/A+_P!CEH__ *70U_0Q6%3<UI[!1116
M984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S+_P %BO\ E''\
M1O\ N&_^G.TKZ:KYE_X+%?\ *./XC?\ <-_].=I51W0'X:?-[4?-[4?-[4?-
M[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5T_P5_P"2Q^$O^PS9
M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
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MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
MEW!]?*<OL]4O>T]V^U9V<.F6<-O;PQ6]O;HL<44:!4B0# 50.  !@ <8J:BB
MOZN225D?P8VV[L****!!1110 4444 %%%% !1110 4444 %%%% %;5-,MM;T
MRXLKR"&ZL[R)H)X95#1S(PVLK \$$$@@^M?BM^WC^RK<?LF?'B^T>)97\/:G
MF^T6=OFWV[,?W9;N\9RI[XVMQN%?ME7AW[?O[*$'[67P&O=+MXX_^$FT?=?Z
M),<*1.!S"6/1)5^4Y. =C'.T5^=^)/"*SO+&Z*_?TKRAW?>/SZ>:7F?L'@OX
M@OAG.U'$R_V:O:-3M'^6?_;K>O\ =;ZV/Q4HJ:_L9M+OIK6YADM[BW=HI8I%
M*O&ZG!4@\@@@C%0U_'#33LS_ $8335T%%%%( HHHH **** /</V OVKY_P!D
MWX]6>J7$DA\,ZQML=<A7)'D$\3!1U>)OF&!DKO48W&OVEL;Z'5+*&ZMIH[BW
MN$66*2-@R2HPR&!'!!!!!K^>JOTW_P"".7[7W_"<^"I/A?KEUNU;P]$9M&>1
MN;FS!^:$>K1$\#KL8 <(:_=_!OC#V%9Y'BG[LW>FWTEUC_V]NO[U^LC^6?I&
M>'OUK#+B? Q]^FE&JEUATGZPV?\ =:>T3[EHHHK^E3^+0HHHH **** "OF7_
M (+%?\HX_B-_W#?_ $YVE?35?,O_  6*_P"4<?Q&_P"X;_Z<[2JCN@/PT^;V
MH^;VH^;VH^;VKI.</F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VKI_@K_
M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
M!I+_ /&:.9!RL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\.'/C=_S]
M^!?_  :2_P#QFCF0<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#AS
MXW?\_?@7_P &DO\ \9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS
M1_PX<^-W_/WX%_\ !I+_ /&:.9!RL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@
MTE_^,UU'A'_@WR^)%]>JNO>-O!.FVQ(W/8BYO9 /]UXXAG_@5+G0<K/@3YO:
MOLK_ ()J?\$K=8_:CURS\6>-K.\T?X<6["5 X,,_B CD1Q=&$/\ >E'4?*A+
M99/M_P#9G_X(O_"7X#7]KJFM1W?C[7+9@Z2ZLJK91.#PRVR_*?I(9!GGCC'U
MU%$L$:QQJJ(@"JJC 4#H *F53HBHP[D&D:1:^'M)M;"QMH+.QL84M[>W@01Q
M01H JHJCA5    X %6:**Q- HHHH **** "BBB@#A?VH/^3:?B)_V+.I?^DL
MM?SJ?-[5_1_\:?"5UX_^#GBS0;$Q+?:UHUY86YE8K&))8'C7<<' RPR<'BOR
M3_X<.?&[_G[\"_\ @TE_^,UK3DEN9S39\6?-[4?-[5]I_P##ASXW?\_?@7_P
M:2__ !FC_APY\;O^?OP+_P"#27_XS6G,B>5GQ9\WM1\WM7VG_P .'/C=_P _
M?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\ XS1S(.5GQ9\WM1\WM7VG_P .'/C=
M_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\ XS1S(.5GQ9\WM1\WM7VG_P .
M'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\ XS1S(.5GQ9\WM1\WM7VG
M_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\ XS1S(.5GQ9\WM1\W
MM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\ XS1S(.5GQ9\W
MM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\ XS1S(.5G
MQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\ XS1S
M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
MXS1_PX<^-W_/WX%_\&DO_P 9KHYD8\K/BSYO:CYO:OM/_APY\;O^?OP+_P"#
M27_XS1_PX<^-W_/WX%_\&DO_ ,9HYD'*SXL^;VH^;VK[Z\(?\&^?Q(O;]1KW
MC;P3IEJ<9>Q^U7L@]?D>*(?^/5]5_LT?\$6?A-\"KRWU+7H[KXA:U#AE?5HU
M6QC8=UM5RI^DK2#Z4O:(.5GPU_P3>_X)9Z]^U7XAL?%'BRTN]%^&]NXF,C@Q
MS:Y@Y\J#N(ST:7IC(7)R5_9G0="LO"^B6>FZ;:P6.GZ?"EM;6\"!(X(T 545
M1P%    Z 59@@2V@6.-5CCC4*B*,*H'  'I3ZQE)LTC&P4445)04444 %%%%
M $-W=PV%I+<7$L<$$"&2261@J1J!DL2>  .237XI?MZ?M/R_M5_M"ZGK4$DA
MT#3_ /B7Z+$W&VV0G]X1_>D8LY[@,!_"*^[/^"P7[5?_  J7X.1^!=)N-FO>
M-8F6Y*-\]MIX.V0_]M3F,>JB3N!7Y55_-OC1Q5[6M'),._=A:4_.7V8_):OS
M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
M]G?60Q/P]2WD9=H>WUB_CV_11/MS]0:P-2_X(D_ &^*>5H6O6>W.?)UF<[^G
M7>6Z>V.O>OK:BJYF*R/C_P#X<<_ ;_H'^)__  </_A4UC_P1#^ =I<;Y-'\0
M72XQY<NLRA?_ !W:?UKZZHHYF'*CYCT;_@CM^SOHY1CX!:[D0DA[C6K]\^Q7
MS@I_$5VWAG_@GE\#O"6W[)\+?!<GE@ &\TY+P\#'_+;?S[]<\]>:]FHI<S'9
M&/X5\ :#X$M_*T/1-(T:(C!2QLX[=2/H@'M6Q112 **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exel-20211231_g2.jpg
<TEXT>
begin 644 exel-20211231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\O\ B?\ ML?L
MD?!CQ,?!GQ1_:*\):+JZ,!-IEWK,?GP$]/,123'_ ,# H ]0HK-\(>,O"/Q
M\.6OC#P)XHT[6M)OH]]GJ>E7J7%O.N<922,E6&01P>U:5 !1110 4444 %%9
M7C?QUX+^&GA:[\<?$/Q7IVAZ-8*K7VJZK>)!;VX9PBEY'(5<LRJ,GJ0.]:5M
M<V]Y;1WEI.DL4J!XI$;*NI&001U!% #Z**JW&N:+:I>27.KVT8T^+S+\O.H^
MS)M+;I.?D&T$Y..!F@"U167X,\;>#_B-X8L_&O@'Q18:UH^H1E['5-+NTGM[
MA0Q4LDB$JPR",@]0:U* "BBB@ HKC_BI^T'\"O@8]C%\9_C#X:\*-J8D.G+X
MAUJ&T-R(]N\Q^:PW[=Z9QTW#UKDO^&__ -AO_H[WX;?^%G9__'* /7:*S?"/
MC#PIX_\ #5GXR\#>)+'6-(U&$2V&IZ;=+-!<1YQN1T)5AP>0:TJ "BHH;^QN
M+J:QM[V%Y[?;]HA20%XMPRNX#E<CD9ZU+0 45C>+_B'X#^'[Z7%XY\9:9H[:
MYJT.EZ,NI7J0F^OI<^5;1;R/,E?!VHN2<' K9H **\P\3_MK_L?>"O$5[X1\
M8?M0> M+U73;E[?4-.O_ !7:13VTJG#1NC2 JP/!!&16W\,?VD/V?/C7>SZ9
M\'_CAX2\475M'YEQ::!XAMKN6),@;F2-RP7) R1B@#M**** "BHK._L=1C:;
M3[V*=$E>)WAD#!71BKJ2.A5@01U!!!J6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWQ;^TE!\3OVD]1^(OP^\'RZ0GC/5KCQBD.L3S/'J,=G\MK K1@2VQ4;2[%6
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M]S>:3:SZD;=(+N-8W_>.>! D9ED<_>(CP,9R,?QU^W/^UU\*_'7PQ^!?BO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,?P<T.99]83XE-XEN+6(Y>"QL(2\DK@<JI^8 G 8HP&2#7UM0 5P?Q!_:>^
M'PJ\1MX2^(GQ4TO2-22%)6L[N1@X1N5;@'@UWE9>K>"/!>O7AU#7/"&EWMP5
M"F>[T^.1R!T&YE)Q0!Q/AS]L/]F/Q?KEMX:\-?&?1KR_O)-EM:PRL6D;&<#Y
M?0&NX_X3'PQ_T&H/^^J\/_:5\,>&O#/QJ^"Z^&_#UCIXNO&\B70L;1(O.46[
M$*^T#<,\X->^?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T
M&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%
M%/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_
M 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#S
MXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_
M ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#
M_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\
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M^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I
M_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\
MWZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I_
M_/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G
M:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO\ :P_Y+9\#
M_P#L>Y?_ $F:O=*\+_:P_P"2V? __L>Y?_29J]TH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /"_P!K#_DMGP/_ .Q[E_\ 29J]TKPO]K#_
M )+9\#_^Q[E_])FKW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \+_ &L/^2V? _\ ['N7_P!)FKW2O"_VL/\ DMGP/_['N7_TF:O=* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 4444 >%_M8?\ );/@?_V/<O\ Z3-7NE>%_M8?\EL^!_\ V/<O_I,U>Z4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,QN,S'$2Q&*J2J3EO*3;;^;/7ITZ=&"C!))=$%%%%<I84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!X7^UA_R6SX'_ /8]R_\ I,U>Z5X7^UA_R6SX'_\
M8]R_^DS5[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\
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ML45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\
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MQH^Q>-_^@W9?^ Q_QK$HV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
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M#_DMGP/_ .Q[E_\ 29J]TH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110!X7^UA_R6SX'_ /8]R_\ I,U>Z5X7^UA_R6SX'_\ 8]R_^DS5[I0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7(_&KX[_"G]GGP7-X^^+GC"VTG3X\K$)3NEN9,9$<,8^:1SZ*
M#@<G !->!_MI_P#!4OX5_LW-=> /AHMOXM\;*3$UG!+NL].DZ?Z1(A^9P?\
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M]3N]E_A70****^"/5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_:P_Y+9\#_ /L>Y?\ TF:O
M=*\+_:P_Y+9\#_\ L>Y?_29J]TH **** "BBB@ HHHH **** "BBB@ HHHH
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M+2N>[,2>@Z "OT3DX7\/M:G+C<P73>A1?G_S\FNVR?\ *U=^1?'9MM>G2_\
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M%%?G1ZX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR&&&X(5B/<*^3/\ @HT3H7[1?[+OC?2QLU.'XPII<<Z<.+6\A\NX3/\ =95
M(KZSH ***\O^*WQY^)7P^\7/X<\+_LR^*/%-HL"2#5M)GA6%F8<IASG([T <
MW^UA_P EL^!__8]R_P#I,U>Z5\A?%WXW?$/Q_P#'+X/1>)_V<_$OA=;/QH7@
M?59H6%T6A*E4V'J =QSV%?4O_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2U:TK5;W4)'2ZT2>U"KD-*1AO;B@"]1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%P3LOH1Q\K,)%S@L-OEU^D7P<^-OPJ_: \#VWQ'^#OC>QU[1[H86YLI,F-\
MF.1#AHI!D91P&&>17IY=G&$S*\(WC46\):27RZKS1\1QCX>9]P=R5ZO+6PM3
M6GB*3YJ4T]K27PO^Z[/1VNE<ZJBBBO5/A HHHH **** "BBB@ HHHH ****
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M1@JG\/$4GS4I)[7:OR2_NRZW2<K7.WHHHKUC\_"BBB@ HHHH **** "BBB@
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MT\+^![G4K3PAH%J4NM:U&&%Y ;Z=O^7='"$0H"'QD[2 :]-^&WQ#_P"%1_\
M!+_PY\4A)L;P[\";+48SW+PZ,DB@>Y90![F@#K+C]M_]BVUG>UNOVO?A?'+&
MY22.3Q_IP96!P009N"#VKN+[XA^ -+\$?\+-U+QQH]OX;-BEZ/$$VI1+9&V=
M0R3^>6\ORV#*0^<$$$'FOS$_9:\3_L>_!_\ 9*\$>)/CU_P3+\1:]HL6E1R^
M)OBQJ?PWL[J RSRM(T[-(3/+;H9 @F(P0H"!AMS] ?M6+\./CY^T;^RW^R]X
M;33[SX6:['?^)9]*L$ L-0L]/T]9-.B$:@*UOU'ED;2K 8XH ^I?A3\??@A\
M=+6YO?@S\7/#GBF.R8+>G0=8ANC;DYQY@C8E,X.,XSCBNNKXV_:R\#>"OV9O
MVT/V?/CA\'O">G>';KQ/XND\%^*(-&LTMHM4LKN("$3)& KF)UWJ<9R%SD*H
M'V30 445P?Q!_:>^ 'PJ\1MX2^(GQ4TO2-22%)6L[N1@X1N5;@'@T </^UA_
MR6SX'_\ 8]R_^DS5[I7RI\<OVD/@9\4_CC\&X/A[\3--U9[#QLTEXMI(Q\I&
M@**3D#@L0*^F?^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\
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M5+"WN@FZ+2;7-Q>2\<8AC!8 _P!YL+ZD5\>?$C_@KE\?_CKKDOP]_8H^"UU
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M4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\
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MNJ6Q7SV6/):*V=V5F7/1<9S7Z"+I6F+J#:LNFP"Z9-C7(A7S"OH6QG''2IR
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M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
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M9\#_ /L>Y?\ TF:O=*\+_:P_Y+9\#_\ L>Y?_29J]TH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KXS_X*7_\%3="_9;MI?@E\#7@UOXFWZ"+
M9&GG1:&''RO(HSYEP<@I#[AG&-JOSW_!2S_@JC/\+-4E_9<_9)9M;^(VH3"Q
MOM2TZ'[0-(E<[1!"J@^==DG&T B,GD%OE6[_ ,$T/^"5L'P*NHOVD/VG577/
MB5?N;NVM;R;[0FBNYW-(SDGSKLDDM)DA"2%).7/S6-S'$X_$/ Y<]5\=3I#R
M7>7Y?>U^U<-<'Y+PIE%/BCC"%X2UPV%VGB'TE-?9HK1MM>\NZ<8SY[_@F_\
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M+PM8ZUH^H1&.]TW4K99895]U88R#R#U! (P17YQ_M*?\$D/C;^S%XW;]I/\
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MX5GNO[4^,_[3^LZK-,VZYCT31H[=B>_[Z=YBQ]R@^E>W^ ?^")__  3^\%1
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MPO\ :M[XNT3=U_M3P[OV_7[-)+^E3?L ?\$E/@Y^SG\-CJ7Q\\$:!XS\::U
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M^U# MO&>FY/19+M4)_!B#7T6%\2,UG_ S>;\E7E^7,/ZME53[$'\HGSA?_\
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M&VQF8WFL.3V)BM(XL'VW'ZU$?&?_  <!?M"_\@?PK+X*T^?[X^P:?I?E@_\
M7T6NA_P'GUK].K*QLM-M4L=.LXK>")=L<,$81$'H .!4M']B8^O_ +SC9O\
MPVA^5P_XB=PKEG_(EX;PM.VSKN>)?K[[CK^1^8 _X(Z?\%!OCF?-_:;_ &UE
M,$_,EL^LZAK!C![>5*88Q]%;%>A_#S_@WP_9HT/RY_B3\7?%_B"5/O1V(M["
M!_JNR5\?1Q]:^_**TI\,9-"7-.GSOO)M_K;\#DQGCAXD8BE['#XI8>G_ "T:
M=.FEZ-1YO_)CYY^'G_!*;]@'X;>7)I7[.6D:C,GWIO$,\VH[SZE+AWC_  "@
M>U>V^#_AW\/_ (>67]F^ / NC:';8Q]GT?3(K5,>FV-0*V:*]>A@\)A5^YIQ
MCZ)+\C\]S3B/B#.W?,,75K?XZDI_^E-A11172>,%%%% &7XT\%^$_B-X3U#P
M+XZ\/VNJZ/JMJUOJ&GWL0>*>)A@J0?S!Z@@$8(KPK]C?_@F=^SY^Q=XLUWQU
MX%ANM5UC5;J0:?J&KA7ETJQ8Y%K"1^32?><  X Y^B:*YJF#PM:O"M."<H[/
MJCV<%Q#GF797B,NPV(G"A7M[2"=HRMM=?GW6CN@HHHKI/&"BBB@ HHHH ***
M* "N:\4?!GX/^-PP\:?"GPUJX?[XU30K>XW?7S$.:Z6BIE"$U:2N;4,1B,-/
MGHS<7W3:?X'BOB?_ ()R_L*^+PW]K?LK>#(M_P!XZ9I"61_\E]F*\[\3_P#!
M%/\ X)Z>(0QL/A/J6CNW5]+\3WO!]0)I)%'Y8KZNHKAJ93E=;XZ$'_VZO\CZ
M?!<>\<9=;ZMF>(@NRK5+?=S6_ ^"_$__  ;Y?LGZB&D\*_%/Q[ICMT6>\L[F
M-?H/LZ-^;5P6K?\ !O'?Z1='4_AK^U]<VDZY\I;OPL48?]M8KH$?]\U^F-%<
M%3AC(JFKHI>C:_)GU6$\<?%/!KECF4I+M.%.=_\ P.#9^88_X)2_\%4OAU\_
MPG_;J#11_=@'C;5[/>/3RQ&Z'Z$XH'PL_P"#A'X9'/ASXBMX@2/K_P 3C2+O
M</\ M^56/\_QK]/**S_U9P</X56I#_#-_K<[O^(V\0XC_?\  8+$_P#7W#0=
M_P#P%Q/S#'[7G_!=WX9G_BJOV8F\0^7][_BB&N]W_@NE7/X4#_@MK^VE\/S_
M ,7F_8;6#R_]=_H>HZ9CU_UZ2X_'-?IY11_8N8T_X6.FO\24OSL'_$2^#L7_
M +_PQA9?]>I5*/\ Z2Y6/SA\,?\ !Q3\-KLJ/&?[,FN6']\Z7XAAN\?3S(H<
MUZ+X8_X+W_L0:YM76=(\<:*3]YK_ $*&11^,$\A(_#\*^N_$_P +?ACXVW?\
M)E\.=!U??]_^T](AN-WUWJ<UYUXG_P"">W[#WB_<=8_95\#H7^\VGZ!%:,??
M, 0Y]Z/JG$U+X<3"?^*%O_20_P!8/!/&_P ;)<1A_P#KUB?:6_\ !J1YAXF_
MX+5_L!:3X$U'Q7X=^*5WK&HVELSVGAZ'0+V"XNY?X8U>6%8UR>K%L 9//0_D
M9^UG^UG\6/VQOBQ<_%+XI:GZQ:1I$#G[-I=MG*PQ*?S9S\SMR>P'VW_P4[_X
M(Y:-X*\-R_'?]CGPI-'8:=;%O$?@R":6=TC49-U;&1F=L#EXLG@;EZ%:_-6O
MA.*,?GDJJPN-2BEJN6_++SU>MNW3L?U/X&<+>&%' SSOAN4ZM2?NR=9P=6CW
MA:,4HWWNK\RVDUH>G_LF?M9_%C]CGXL6WQ2^%NI^D6KZ1.Y^S:I;9RT,JC\U
M<?,C<CN#^Z_[)G[6?PG_ &Q?A/;?%+X6ZGZ1:OI$[C[3I=SC+0RJ/S5Q\KKR
M.X'\[-?K%_P1/_8"^+'P<\S]J3XI:UJF@_V]I9@TCP@DAC^U6SX9;F\0_G'&
M?F&=QQD"NG@S'YC#&?5J<>:F]7_=\_\ @=3Q_I)<)\'XCAW^V\545#&PM&FT
MKNM_T[:6KLM5/['71V/T2HHHK]5/X+"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /"_P!K#_DMGP/_ .Q[E_\ 29J]
MTKPO]K#_ )+9\#_^Q[E_])FKW2@ HHHH **** "BBB@ HHHH **** "BBJ'B
MGQ3X;\$>'+WQ?XPURUTS2]-MGN+_ %"]F$<5O$HRSLS<  4FU%794(3JS4(*
M[>B2U;;V218U+4M.T;3KC6-8OX;2TM86FNKJYE"1PQJ"S.S,0%4 $DG@ 5^7
M_P"V;^WC\9/^"A?Q0/[$?[!5E=SZ#>R-#KOB& M%_:<(($C-)C_1[%<_,Q^:
M7(&,,$?+_:7_ &L?V@/^"M/QB/[)/['.GW=CX AF#:SJTX>%;Z)6YN[Q@,Q6
MP(RD'WG."06*HGWQ^Q=^Q+\(OV)OAFG@GX>V8N]4NU1_$/B2YA N=3F ZGKL
MB7)V1 X4$\LQ9F^4JXC$<0U70PK<<.M)36\O[L/+N_TW_>LORC*/!_ T\USR
MG&MFTTI4,,]8T$]JM=?S=80W3_O:PP_V"/\ @GW\+/V&_ 'V+14CU;Q=J4"C
MQ%XIEAQ).>#Y$(/,4"GHO5B S$G 7W^BCIUKZ7#8:A@Z$:-&/+%;(_%\ZSK-
M.(LSJ9AF-5U*U1WE)_DNB26B2LDM$K!17E_Q4_;2_96^"WF1?$/XY:!:W,6?
M,L+6[^UW2GT,, >0?BHKYM^*/_!<CX+:([Z?\'_A5KOB2XSMCN-1E2PMV)Z%
M<>9(P]BBD]/>OK\IX*XKSNSP>#G*+^TURQ_\"E:/XGSU?,L#AOXE1+RW?W+4
M^XJKZIJVE:'82:KK>IV]G:PKNFN;J98XT'J68@ ?6OS<U?\ ;+_X*J_M"YB^
M''P]MO VF3C]W=?V='9[XSW$^HL=_P!8@#Z#-8!_8,^+'Q;OX]>_:I_:ZNM0
ME#;S:6'VK5ID_P!@/<M%%&?]S>HKTL5PMPYD&O$6=X;#-;PC+VM7T<([/YL\
MZ>=J6E"DY>;M%?B?:'Q4_P""F7[%WPF\RWU'XS6>LW<><67AF-K]F(ZCS(LQ
M _[SBOGCQM_P6ZU3Q/J?_",_LU_LWZAJM[,2+676IFDD;_MUM0Q;\):F^'7[
M$O[&'@"6(P?"+6/&5\O*7'BG66*;O^O>V5$8>S;OQZU[_P"";#XE^'M,&B_"
M#X.:1X3L6  AT;0(;.,CU.\ $^]>++Q \&LIERY=A,3F51=[PA?R44FUY2.=
MXK,\3ISJ*[0BY/[WI]Q\P>5_P6I_:I^_)<?#_2+CU,>BB+/TW7O3ZU<\-_\
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M3_,]?+^(,^RFWU'%U:5OY*DX_P#I+1\8^,O^"$'["GB;>=!A\7^'2<[!I/B
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MPQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#C?VL/CY_PS!\
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M $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J
M-*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3
M'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^J -*JM[HFC:GG^T=(M;C/7S[=7_F*K_P#"8^&/
M^@U!_P!]4?\ "8^&/^@U!_WU4SA"HK25UYB:3W/'?VBO^$/TC4;7PUX;\/6-
MM<JOG7LMM;JA /"I\H^K'_@->9UZUX@^#NB^)-;NM>U'XM0&:ZF,C_\ $L.!
MGH!^]Z 8 ]A5/_A07AC_ **O!_X+/_MM?B><\+<2YEF=3$0PJC%O1*5-62T6
MTM^K\SY_$8/%U:SDH67JO\R;]F?5M DU*Z\.:EI5HUVP\^RNI(%,A X9-Q&?
M1@/]ZO;*\9\/_!W1?#>MVNO:=\6H!-:S"1/^)8<''4'][T(R#[&O5/\ A,?#
M'_0:@_[ZK]#X/PN9X#*_JV-I<CB]'>+NGKKRMZIZ:]+'J8&%:E1Y*D;6]/T-
M*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJOJSM-*BLW_A,?#'_0:@_P"^J/\
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M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
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M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
M\)_X*"? +P)\<?V?9M UW1+#[=:ZQ82Z5J#P@36G^E1"Y,3=0S6WGKCH<C/0
M8\OL+"STJP@TS3K9(;>VA6*"&,86-% "J!V   KZQ\5>"?#/C:WBM/$VG-<Q
MP.7C3[1(@#$8S\C#/'K[^M<AXT_9J\!^(O">H:'X8ENO#^HW5JT=EK5E*9Y;
M.4CY9!'.7C?!ZJRD$9''4?#\7Y-Q%Q!"GAJ-2"P])RG&+;3<YJ"E)VC:[4(Q
M6NB72[//Q>!KYABH<U1**2BG)R:BN9O9)M).3;44]V[-L^?=0L+/5;"?3-1M
MDFM[F%HIX9!E9$8$,I'<$$BO4/\ @GW\ O GP._9]AT#0M$L/MUUK%_+JNH)
M"#-=_P"E2BV,K=2RVWD+CH,''4Y[+P7^S5X#\.^$]/T/Q/+=>(-1M;58[W6K
MV4P2WDH'S2&. I&F3T55  P.>IZ_PKX)\,^";>6T\,Z<UM'.X>1/M$C@L!C/
MSL<<>GMZ4<(9-Q%P_"IAJU2#P]5QG**;;4X*:C)7C:Z4YQ=GJGUL@PF!KY?B
MI\M1.+3BW%R2DN9/9I-IN*:4DMD[)HO_ -G:?_SXP_\ ?H4?V=I__/C#_P!^
MA4U%?<'H$/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A
M1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9V
MG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/
M_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ
M%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\
M9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_
M -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A
M1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9V
MG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/
M_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ
M%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\
M9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_
M -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A
M1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9V
MG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/
M_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ
M%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\
M9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_
M -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A
M1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9V
MG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/
M_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ
M%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\
M9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_
M -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A
M1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9V
MG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/
M_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ
M%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\
M9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_
M -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A
M1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9V
MG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/
M_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ
M%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\
M9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_
M -^A4U% $/\ 9VG_ //C#_WZ%/BMK: DP6Z(3U*(!FGT4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X7^UA_R6SX'_P#8]R_^DS5[I7A?[6'_
M "6SX'_]CW+_ .DS5[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 >%_M8?\EL^!_\ V/<O_I,U>Z5X7^UA_P EL^!__8]R_P#I,U>Z4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?[6'_);/@?_ -CW
M+_Z3-7NE>%_M8?\ );/@?_V/<O\ Z3-7NE !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M116+\1_&=C\./AYKWQ#U3'V;0=%NM1N-QP/+@A:5L_@IH VJ*_+[]E;PK\-?
MC'\+_!VH_'#_ (+'_%;0?B'XKLA>7?A?3/C0MNEN\TKF"%8Y-QC<Q&+]VS;B
M6X ! KZ2_;"\2?%#1?$/P._8#^$_Q=\0Z7J'CZ6>V\0^.A>[]972=+LTDN)!
M<$?+=3@9\X#.Y6X^:@#ZOHKXVO\ 1/&?_!/W]K#X6^'/#WQK\:>*?AU\5=1N
M/#VK:+XWU^34Y-,U01A[6YMII?G02-E73.W[QY)79]DT %%%% 'A?[6'_);/
M@?\ ]CW+_P"DS5[I7A?[6'_);/@?_P!CW+_Z3-7NE !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^!G@*]\(:KK4%_)=>(;[45FMXV556>4N$P>X!P:]!H \%_X=U? __H;O'?\
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M (5\]'_#NKX'_P#0W>.__"OGKWJB@#P7_AW5\#_^AN\=_P#A7ST?\.ZO@?\
M]#=X[_\ "OGKWJB@#P7_ (=U? __ *&[QW_X5\]'_#NKX'_]#=X[_P#"OGKW
MJB@#P7_AW5\#_P#H;O'?_A7ST?\ #NKX'_\ 0W>._P#PKYZ]ZHH \%_X=U?
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MJ^!__0W>._\ PKYZ]ZHH \%_X=U? _\ Z&[QW_X5\]'_  [J^!__ $-WCO\
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M_P#"OGKWJB@#P7_AW5\#_P#H;O'?_A7ST?\ #NKX'_\ 0W>._P#PKYZ]ZHH
M\%_X=U? _P#Z&[QW_P"%?/1_P[J^!_\ T-WCO_PKYZ]ZHH \%_X=U? __H;O
M'?\ X5\]'_#NKX'_ /0W>.__  KYZ]ZHH \%_P"'=7P/_P"AN\=_^%?/1_P[
MJ^!__0W>._\ PKYZ]ZHH \%_X=U? _\ Z&[QW_X5\]'_  [J^!__ $-WCO\
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M_P#A7SU[U10!X+_P[J^!_P#T-WCO_P *^>C_ (=U? __ *&[QW_X5\]>]44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBFM)&C*CR*"YP@)Y8XS@>O - #J*^:_\ @H/XY\=R^(/A/^S9X/\
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M +:GP6F;QO;0V/CSPL\5KXLL(DV)/O4M!>Q+VCF4$X' 96Q\NTGZ6H ****
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M_$?_ ()F:Q\<OA1H&I7\GQ!\)II7A[2X;<R7$=]J;"P2%]F5#QS3%6YV[H\
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M^^&OP\^$_AJ+P;\+_ VD>'=)@8M%INBZ=':P*QZMLC &XXY/4]ZVZ "BBB@
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M#&*5& *NI)!]<9'!%;]%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8D\6?#'QWI2:+XO;3;SPQX]T"X3;)HVLHA3S-AR0GF!9DZXQMR2C5M?\$O\
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M#7?V8OB;XL;1/&7CRR\&^)/ .M^();ZUNK.=6'VR*.0_NF@"EB5X&4 VJ6#
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M&_A'IO[:?Q/^%_PX7X97#V-SJ_@K2[B[?7=,TR[DC2*8W#$0RS@RQ[D";?F
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M-]\1_BEXOL="T/38M][J6HS!(XP3@#U9B2 % +,2  20* -ZO'_VK_VK+/X
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M;_M:_L,>(O!O[-/B&SO+WQAIMA)HUVE^(H+ZR>Y@ED'F]DDMPX]PVWO7"_\
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M:9IKB]N9#F2YGE<EI97(&6)[ #   [*B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O&OVB/V1;/XS_%[X>_'WP=XVE\*>,O 6L!UUJULQ,=0TI]WVC3I5W+N
M20$@$D[-[D#+&O9:* $\N/S/-V#=C&['./3-+110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 >-:'^R)9^"?VR=1_:M^'?C:71K
M7Q1X?^Q>./"D5D&M]9NXR/L][NW#RI47<"0I+>V]RWLBQQHS,B %SER!]XX
MR?7@ ?A2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #9(XYHVAFC5T=2&5AD$'J"*\>_9-_9)M_P!DK4/&^A>#/'4UQX+\0^(O
M[5\,>$9+0*GATR)FXBBEW$M&\G*IM4(%'5F9C['10 D<<<,:Q1(%50 JJ,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **YCXE?&CX4?!W^R/\ A:7Q TO0?[>U1-.TC^TKH1_:KE_NQKG]2>!D9(R*
MZ>I4X2DXIZK?R-IX;$4J,*LX-0G?E;32E;1V>SL]';8****HQ"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHJ'3]0LM5LTU#3KI)H)1F.6,Y#<XI<T5+EOK_7^:"ZN34444P"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+=WMS;>'K66T^PQ2RBXD63RDD(W;I1*01]XY- 'K5%%% !1110!^,G_!5_\
MY/\ ?'W_ '"O_359U\[5ZM^W!\-_$7PF_:L\9^!O%7B;^V+V#48[A[_<YWI<
M01W$:?.2?D254_X!QQBO*:_T#X6ITJ/#.!ITY\\51I)2M;F2A&SL]5=:V/RG
M&RE+&U6U9N4M.VK/HG_@E!_R?[X!_P"XK_Z:KROV;K\(/V3_ (/^+?CW\?\
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M&B*,GECR?0#))( !)H \:_X)R?M->//VD_@?J,7QDM+>#QWX%\47OA;QF+5
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MCV\NMZ;X=L'OKZPN/D2:!K>(%PT;,2PQ]Q2XRN"0#RG]GKQ[\:OV4?VS+?\
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MIH>KZE_9^F^/[[PS<0^'KBZR1Y:7S@(W((WC]W\I.[:-U7_!?_!37]F/QO\
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M /:=;_X*N?LJ:7?:C=:7:^-M<\-:+>-;:UX]\/>";R\T*QD4X</=QJ00O]Y
MP(Y!((SZ3\5/VO?@%\(?A'I/QM\1^-UO-"\12V\/AEM#MWO9]9FG4M#%:Q1
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M<@D$9]1_:]M/%=_^RA\3;'P*LS:U-X UA-*6VSYIN#92A F.=^[&/?%>=_\
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MM5TVT6.1;]W/!&V1E+]Q'DDMN)V-$_X*K_LK:O?Z?=7UMXUTCPQJ]ZMII'Q
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MR/)_P3>^&#2.6(TZ]&2>PU&Z 'Y"@#Z5HHHH ***Y7XJ>!-;\=:?:6FB:_\
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M;3O$I^)G_!0K2_ $$JWDG@WPW(L-HIW.&T6X:?:!R69#)TY)/K7TQ^SCXB^
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M5@)C@=%D1 Q B<-'CJIKN*** .*\%?L[?!WX=?%CQ3\;_!7@_P#L_P 3>-1
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M &0?@GX\L?B9X.^&ES<:UI"%-#N]>\07NI#2TZ8MTNIG6(@<!@-P[$5[G10
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MO$_@*_MM<UA$37;G0?$M_IJZJJ@ "X2UFC67@8)(R>Y-='\,OV.OV9?@U?\
MB&^^&/P?TO1U\6:5;:;XBL;8R&SOK6WB:**-[9G,/".ZLP0,^]BQ8L2?2Z*
M/G;1/^"4W[#&@:Y;ZK:_""XGM+.]^UV?A^^\2ZA<:7!/NW;Q9R3M"1DD[64K
MSTKT3]H/]E'X#?M1:5IVF_&?P,NHR:/.9]&U*UO)K2\T^0XR8;B!TD0':N5#
M;3M7(.!CT6B@#R/X*_L*_LL_L]^,X/B-\)_A@-.\00Z7/I\FM2:O=W%Q<PS2
MK+*9C+*PF=G13YC@N H4$* M<U-_P2\_8FF\4WWB7_A4LT<&IWYOM1\/0>(K
MZ/2+FY)R9'L5F$#<_P !39_LU] T4 >?^ ?V6?V?OACX"\1?"SP7\,;&V\->
M*]3N[_7M!GDDN+2YFN559L13,ZQ1L%4>5&%C7'RJ*^1OV^O^"7'P5\'_ +*/
MB"?]E[X%:QJGBL7NG1Z'8QZG?:F]A;F_@>=;2&:600+L5MQ0 [01G&17WS10
M 5X)\;/^"8?[#?[1?Q,U'XP_&3X(?VQXCU80C4-1_P"$EU.W\T10I#'^[@N4
MC7$<:+PHSC)R237O=% 'CW[/_P"P#^QY^RWK[>*_@9\#-,T756B:)=4EN;B\
MN8T;AE26ZDD>,$<':1D<'BNT\(_ SX5^!?B1XO\ BWX6\*BV\0^/#9'Q9?M>
M32"_^R1-#;_NW<QQ[8W9?W:KNSELGFNMHH ^=K__ ()3?L)ZAXCEUV7X*F.V
MN+[[;<>'K?7KZ+29;C.?,-BDP@Z@?($"<?=KT[XW?LR_ S]HOX7Q_!GXN_#V
MTU/PW!+#+9Z;%));"T>%2L30M R-$54E1M(^4E>A(KNZ* /(_'7["O[+GQ*^
M%/AOX->-/AF+W1_!\*1^%YFU2Z6^TP*  8KQ9!.I^5<_.0VU<@[1BU^SY^QE
M^SI^S!J&I:_\(O ;6VL:P@35=>U/4KB_O[E 00C3W+NX3A?D4A25!() ->I4
M4 >&?%K_ ()O?L??&KQU?_$?QG\,9XM5UD :_+HFOWNG1ZL!VN8[:9$F)YRQ
M&XY.2:[/4/V5_P!G_4=/\$:0_P -+2"S^&^HQW_@JTL)YK:+3+A%*JZI"ZK)
MP3D2!@222"3FO0** .3^)'P/^%WQ<UOPQXC^(?AC^T+WP;KB:QX;F^VSQ?8[
MU00LN(G428!/RN&7VH\(? _X7> _B=XM^,?A3PQ]D\2>.38_\)3J/VV>3[;]
MCB,-O^[=S''LC8K^[5=V<MD\UUE% ')>$_@9\+/ WQ+\7?&#POX5%MXB\=_8
MO^$KU WD\@OOLD+0V_[MW,<>R-BO[M5W9RV3S7DFI?\ !*?]A35/$D^O3_!8
MQVUU??;;KP_:Z_?0Z3-<9SYC623"#J!\H0)Q]VOHBB@#C?&O[/OP=^(=[X0O
MO%?@F&9_ 6J1:CX12VN);:/3;B--B,L<+HC*J\!&#( /NUR_Q\_8>_9J_:3\
M2V?CGXG> Y3X@L+?[/:^(=%U:YTZ^$//[IIK:1&D3DX5]P&3C&37K5% 'FG@
M7]GCP3^S#\%=;\$?LD_#G1='U!K*YN=+@U!YI8KW4C$?*>\F9S-*"X0,Q?<%
MX!&!7PAXE^&OPP\4^#-6M-)_X(]^/=-^-VM:=<6C"+0)T\)V>K31-$;^*9[D
MV2QH6,B.$W @ ,/]97Z=44 ?,EWK'C3]@O\ 8H\"?!?2/V?O%GQ0UZ'PNFBM
M9>#M&^V6J7XMQN-V2P,5HTC./,VGY1R!FNM_X)W?LOR?LA_LE^%_A!JUM#'K
M8A?4/$S0,&5M0N&WR+N'#",;(0PZK$IKVZB@ KD/&_P&^%'Q'^)/A'XO>,_"
MGVSQ%X$DNY/"NH_;IX_L+74:QSGRXW6.7<J*/WBMC'&#FNOHH H>*?"WAOQO
MX<OO!_C'0K35-*U*V>WU#3KZ!98;B)AAD=&!# CL:\-\#?\ !+S]B3X>^+]/
M\9Z'\(I;B71KG[1H>GZOX@OKZQTV7.=\-M<3/$I!Y!VG:0"N,"OH&B@#S#]I
M+]C?]G/]K>VTFW^/GP\&LMH4LDFD7,6I7-I/;&0*) LEO(C;6V+E22/E!QD
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M[;/!YJPRQS1CS(721<21(W##.W!R"0>IM[>&TMX[6W3;'$@1%SG  P!S3Z*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M4:7L,EU) LL;31@,\88;D!Z$CJ,T 24444 %%%% !114=W>PV$/F3RQPQY"[
MI&"KDG &3ZF@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HJ-[V&.ZC@:6-9I 62,L-S@=2!U.*DH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+<Q2N?(7]LWG_/U<_P#?UO\ &C^V;S_GZN?^_K?XU]__ /$/3XY_Z*!X3_\
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MJ !7V]_P;W7TUW\8_B&)9I9 NC6Y =RV/WYK\[:_0[_@WF_Y++\1/^P+;_\
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MS!81',<;,#P6PQP>C- ><BOL[3=.M]'TZWL[6&.WM;6-888HUVK&B@!5 [
M 4G)VU!+4\G_ &K/V'_ ?[9BZ"/'%MJ5P/#GV@V0M+QK?;Y_E;]V/O?ZI,>G
M/K7PW_P49_X)T_!O]F;X3:3:>#]'UZ\^(GC;58='\.6DFJ/+OD+KYCE#@, I
M5.O#3)VS7ZA5\2?!0C]N7_@I9XD^($C-=^ _@FAT+PZ<?N;G4FR)IAV;:?,.
M1V^SMV%$9,))&C^U5XQ\1?L+?L6?#'X6^ [P-XZ\3S67@_3;W^**1E GN$!!
MP3(RJO\ =\T'JHJC<?\ !%?PW;>##J%CX\\>1_%*.'SH_%+:JP9[K&1N4#=Y
M6[' ;?C^(GK8_P""G8.F_M8_LIZI<-LTNU\8R6\[L?D266:Q\HGMQL<Y/3!]
MZ^T*+M+0+:GSC_P3%_:6U[]H?X!7EKXQ;=XV\#:K-X>UIR &N)(L;96 XW$$
MJ2.K1L>,UX;X(^&M]_P5K^./C[6O%_B#7K+X0^!]8E\/Z'H>EW7V>+4Y8\%Y
MIC@[B5,;_P!X>:J@@*=W8?\ !)Y3J7Q:_:8UBV;=I&I?$.Z%H1G:<37#G'\/
MW9(^A]/:C_@A>#I_[)WB32[AO^)II/C&^M[]"?G$HAM\D]SGID]=I]*>UV@W
ML<GJ_@34?^"4/[3/P\_X1OQ%KFH_!OXC:D-"U#2-4NOM"Z+=.0(Y8C@;5&[=
MD#)6-PV?E(^D?^"A/[35Q^R5^RIXB\7:<L+ZVOEV.E+*NY!<S,%5R.AV+ODP
M>#LQWKQK_@M<IU;X2_"O1[5L:OJ7Q#T\68&=W$-PAQCYOO21]!Z>U._X+FV\
M@_9*\-WNUFLM+\:6%U? #.81#=(<CO\ ,Z<'VHW:N&US-\!_\$=='^(G@*U\
M0?$SQAX\U/XH:M MY=:M'JFQM*N'&XQQ*5/"$X.>N#C:, =A_P $T?C7XNN-
M;^(GP>^(6J2:WXJ^%6H);P:G*Q:74[&3=Y3L3RQ 53N;YBLJ Y()KZN@GCNH
M$DC=9(Y%#(ZG<K \@@]P:^,?V75.L_\ !8;]H?4;-MVGVND:;9S;<[?/\BT7
MG'&0T,W7GK[XF]T[A:VQ]H445\R_\%B6*_\ !./XC8X_Y!H_\J=I26KL4?35
M%?'_ .P]^V'_ ,(1^Q9XHA^($^WQ-\"XI-,UF)W/F74,2G[&ZDY+"5 L:N1\
M[(3W%>?_ /!%C4_$VN_&7X_ZIXOW+XBUR;0M7O$8G]V;J.]N%7!^[A)$&W^'
M&.U/E)YC] **^8?^"KOQ!OM._9WL? .AR[?$OQ<UBV\*V2KG<L4KCSWQ_=V8
MC;VF_$9/_!)GQ=>>'/A]XV^#^LS22:U\'?$-QI2&3&Z6QED=[>3L2"PFQZ+L
M[8 .72X[ZV/K2BOEG_@JMJ]WH_@SX.-:75Q:M-\5=$BD,,A0R(4NB5.#RIP.
M#QP*^DO&[%?!>L$<$64Q!';]VU*PS4HK\U?^",GQ\USX.:/X3\!^+V9?"GQ0
MAO-3\%WK$F.*[@N98+JR)/ +&+S N< N.IEKWW_@BO(TG_!/KPMN9F_T[4>I
M_P"GN6G*-B5*Y]6T445)04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5^8W_!Q7_Q^_"'_ '-8_G8U^G-?
MF-_P<5_\?OPA_P!S6/YV-:4_B)EL?FA7[G?\$=/^4<7PY_[B?_ITNZ_#&OK#
M]FC_ (+"_$?]EGX):+X#T'0/!-[I.A>?Y$U_:W3W#^=/).VXI.B\-*P&%' '
M4\G6I%M61G%V9^W%%?D'_P 1 WQ?_P"A6^&__@%>_P#R51_Q$#?%_P#Z%;X;
M_P#@%>__ "567LY&G.C]?**_(/\ XB!OB_\ ]"M\-_\ P"O?_DJOUVT^X:[L
M()6P&DC5R!TR1FIE%K<:E<FHHHJ1GY _\%BO^"=W_"A/&$OQ*\'V.WP7X@N/
M^)E:PI\FBWCGJ /NPRG[O97)7@%!7PK7]*?CCP1I/Q)\'ZEH&N6,&I:/K%N]
MK=VLPRDT;#!!]/8CD'!&"*_"/_@H'^Q+JW[$OQLFT>3S[SPQJQ>YT'47'_'Q
M!GF-R./-CR%8<9RK8 8"NBG.^C,I1ZGT;^P'_P %BX_@#^SEK7A/QQ%>:Q?>
M%[+=X3=<LUX,A5LI7YV*A(97/ C#+U5%;XA^,7Q=U[X\?$O6/%OB:]:_UK6I
MS/<2'A5[*B#^%%4!57LJ@5S-6M$T6\\2:S::=I]K/>W]],EO;6\*%Y)Y'(54
M51R6)(  ZDU2BD[DW;.N_9R_9]\1?M0?%_2?!OAFW\[4-4D^>5@?)LH1S)/(
M>R(.3W)P!DD _OA^S%^SAX=_92^#>E>#/#<.VTT]-]Q<NH$VH7#8\R>0]V8C
MZ* JCA0*\F_X)E?L$6?[%?P@$VIQP7'CSQ'&DVLW*X;[*O5;2-O[B9^8C[[Y
M/("@?3-8U)7V-8QL%%%%9E'\U_Q#_P"1_P!<_P"PA<?^C&KV7_@ES_R?[\,?
M^PFW_HB6O&OB'_R/^N?]A"X_]&-6Q\ OC3JG[.WQAT'QKHUO8W>J>'YS<6\-
MZCO;NQ1DPX1E8C#'HPKKZ'.MS^CBBOR#_P"(@;XO_P#0K?#?_P  KW_Y*H_X
MB!OB_P#]"M\-_P#P"O?_ )*K#V<C;G1^OE%?D'_Q$#?%_P#Z%;X;_P#@%>__
M "57U-_P2S_X*2>-OVXO'WBK2O%6D>%]-M]#T^*[@;2H)XW=FDV$-YDT@QCT
M I.FTKL.9'VM7@__  4\_P"3!_B=_P!@G_VK'7O%>#_\%//^3!_B=_V"?_:L
M=3'<H_ ^OT._X-YO^2R_$3_L"V__ */-?GC7Z'?\&\W_ "67XB?]@6W_ /1Y
MKHJ?"8QW/U:HHHKF-@HHHH _GM_;K_Y/3^+'_8VZG_Z525Q_P4_Y++X1_P"P
MU9_^CTKL/VZ_^3T_BQ_V-NI_^E4E<?\ !3_DLOA'_L-6?_H]*ZNAAU/Z0J**
M*Y3<^1/^"MG['_\ PO7X0_\ "9:+:^9XI\&PM(ZQKE[ZQY:2/U+1\R*/3S
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M;F4^6DDYP;Z-:RC_ -O;I?S76KD>UX\^%.)SFK1SK):?-7;C3J17VDW:,_\
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M#5U[P3X@L==T_(67RB5FM7(SLEC8!XV]F R.1D<UVM9E!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK/@7_A2-UI%O9QW['7_M9@'R9C\LOYHR80/-WB+]YRN,]OH:BGS:W"W0X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'O%&EVPM6>9!S%+&JJO]T$!!M,BG<P/R_9%)JPPHHHI %%%% !1110 4444
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M?AO_ ,)&R_\ C%?5'@+3]6TCP-HMKK^H1:MKMK801:C?10B%+VY6-1+*J#A
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M\/L?V??^ADUC_P $MS_\31_P^Q_9]_Z&36/_  2W/_Q-?B314>R1?.S]MO\
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MXXXU"K&H&  !P !Q@5-271%0CU)****Q- HHHH **** "BBB@ HHHH ****
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M  4=B_8I^%>G_"WXW^&/%NB>*/!,(TNQN+2P^TVNM6\?RP>2^X!B(PB CY2
M#D$D W5D'FSK/&ZMHW_!<[P=]A7_ )"WP]D.H%1G@27F"V.G^JA'/M[5]H5\
M<?L,>"_%/[0W[5/C']H;QAX>OO"]CJ%@F@^$-+OX_+N8[(%2T[J>5+;>#T)E
MEQ\H4GSC_@J7_P %$XM,^*,GP1TO7+WP;IK"-/%WB2"U:XN8(98A+]FMHU()
M+1NNYLC._;D ,2<MW8+V5SJ]0\0Q_P#!0'_@I=X5G\.;KKX?? 'S[FZU=$S#
M?:G*4_<Q/_$ T47/0B&0CAE8_<=?"O[,W_!3#]F/]G_P#H?@/P7+XDM;&*18
MD+Z1(TUW/(0&FE8?>=VQDXXX    'W52D$0HHHJ2@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KY5_P""ROQ=U#X5_L0:M:Z7))'?>,K^
MW\.HT0)D*3!Y)47']^*&1/HY[XKZJKYY_P""GO[-6L?M0?LHZAI/AM%F\3:'
M>PZYI4.0IGGAW*8U). [1R2!<\%L X!R*CN*6QXC\)/$/[4G[/OP-T.R\(_!
M'P+I_A'P]8J!HUUJ)DUV[4#,DS,DRQ^=(<N5V%LL1MS@5ZY=?$9?^"F/_!/'
MQ))X.MX]-U;Q18S:6]E?RE5L+Q&7?&[A>@X(8+R&' .0./\ #?\ P6'\-KX(
MCL=:\#_$&W^*$,/DS>%(=$E>XFNQ\I"-@#RR^.2 P!^Z3P=C]B[X>^,/V+?V
M&/$FO:SX5O\ 7O&VM:C>>+;GPUII'VCSI_+1;=<;L,$C1F #%<L &(P:]1'$
M^'_@#^V-\"_@_I*:%\1? .LKX3TN"RM?"RZ4ABF@MX@B1K<-"LCR%44?,R D
MGYAP:^AOV&/VJHOVQ?V=],\8?85TO4O.DL-3LU)9+:ZB(WA2>=I!5P#R X!R
M1FO']1_X+(>"-0\,S6_A_P (_$+5O'C1^7#X7.AR+=+<-PJR,,J%W=2N6P#A
M<X%=I_P2W_9NU[]F;]E>#3_%,2VWB7Q'J=QK^I6RD'[+),(T6-B.-PCB3<!P
M&)'.,E/;4%OH>=_\$+R=0_9.\2:I<+_Q--6\8WUQ?N1\YE,-OD'N,=<'IN)[
MT?\ !;!6L/A'\+-4M%W:Q8?$+3Q9[1E\F&X8@ <G+1Q]/;VKD/!7Q)O/^"2G
MQT\?:+XN\/Z]>_!_QQJ\GB#0];TRU^T1Z7-( )(9@"-N (T_O'RE8 ACMGOO
M'M]_P5;_ &G/AZWA_P .:YI_P:^&^H?V]?ZMJEK]G76[M,&**(9.Y> , YVR
M2%L?*"^O-T%TL??%?*?_  5]\/\ A/4_V8K;4-<U;4M'\3:-JL-UX0DTV+SK
MVXU7#"*&.,$%@W4D$%=H;DJ%/3?'3]NB\^#?[9'P_P#A3#X$U?6+?QJL;2:Q
M%(52VWR-&2B;")%BV[Y267:C9^O'?\%0?"?B;2O%7P=^)VB^'M0\7:3\+M>E
MU#6-'LHS+/)%)Y)%PJ#JT7E-@X.TN"< $U,5J-['SE^U'\6?VE8/V=M#\._&
MWPU)IOP]U>6T;Q/XE\/6T=QJ0LRZ,T$T:R".&0D ,VU4)(49^96_1_X-:QX;
MU[X3>&[KP?-;S^%9--@&DO!GR_LRH%C !Y&% &#R",'D&OD?XJ_\%;? /QE^
M&&O^$_ OA3QMXR\8>(-/FTZWT0Z&WR231F/]_P GY%W?,%W9QCH=P].^ ^A>
M(OV"?^"=GARQNO#.N>-/$7A>P,UUH^D%9[II+BY>:2-2/O"+SB#M#<1\9'-5
M+8%N>3?M=_L_?'R']KRW^-&CZ'X%^(&A^"(63P_X;EO+C[3:Q;,R3B,A$-R3
MN(*N_(3"L53'TS^Q]^U'I'[87P)TOQMI%O)8_:V>WO+&1][V-S&</&6P PY5
M@P RKJ2 <@>*7W_!8WP!JV@3P>&/#/Q"U[QGLV0>'$T&5;I9V'R)*1E5!/4J
M6. < UUW_!+O]FO7OV9?V7ET_P 40I:^)/$NJW'B#4K1&#"SDF6-%BR"1N$<
M29 R Q(R<9*>VH+?0X__ (*P_$75/%/AKPC\#?"LH7Q1\8-12SF<-_QY:?&Z
MM-(P!SM)QG^\B3#FOI[X6_#C3/A!\.-#\+:+#Y&E^'[**QMEQSLC4+D^K'&2
M>Y)-?)_[#OA74_VD_P!LOXF?'CQ'I][8V>F7#^$?"=E?0M%-:00X$LFQ@&1B
M#T(^]/..U>D?MT?MT7G[&^L^!;2T\":OXQ_X3&_:T=[20Q^1M,8V)A&WS/YF
M40[<[&Y]$_Y4'F;'_!1;PMX%\7?L?^+[7XB:I+HOAV.!)_MT"![BWN$<&'RD
M.-[F3:H3(W!B,@'(^)=9^,_[7?A7]AGR=9\,M?\ A36=,,+>(([82>(-*TTJ
M59Y;=9 =QAY#E<J,EW!PP^K/^"LGP>\3_%_]EVU_X173)=>OO"_B"SUZ?2(T
M+MJUO")5>$(.7_UBOM ).S@$XKEE_P""U7PSO=)^RV_AGX@W7C!XL#PTNC$W
M9GZ>43G&,_Q#)QSMS\M5'8'N>S_L&ZGX#U#]DSP9'\-[J:\\)V-D+:!YUV7(
ME4GSO.7HLID+LP'&6RN5(-=-^T7^T%X=_9@^$>K>,O%%U]GT_38_W<2G]]>S
M$'RX(AW=R,#L.22%!(\+_P""?/@;4/V,_P!B+Q'XD^(%C)H,EY>ZEXTU#2XD
MW-I%N8U(@6,?=81P!MG4%\'!R!\>:;^W_P##?]J/]HM/'GQPU35K?PWX5N2?
M"G@FSL'NK6,C!%S=."%D?/5<?,0 <(-K+ENPYK(^P_\ @D_\'M>\+_"OQ5\0
M_%EJUAXD^,&NS>)9[,H8_LL,C.\0*GH6,DCCI\KIQG-<W_P3+)U;]KS]JW4K
MM=VHCQD+(,P^9;>*>]6(#/(!4#V.T>@KV+]EO_@H-\-_VPO%&I:/X*N]6N+W
M2;47EP+JP>W41EPG#'C.2..OY&O!OBEJ.N?\$W_VW?%GQ,;P[K7B#X3?%:"%
M]:ETF#SYM%OXL_O'7(^7F5LG /G, <KAGJ[I@>A_\%FM.M[W_@G;XXDF53)9
MS:=-;Y[.;^W0X_X [_K47[5/[._BS]LC_@G7X5\+Z*^GP>(M2LM'OIFU&5X8
MD*Q(TFXA68')/&":\?\ V@/VAIO^"LMWX=^%OPNT/Q(O@>?5(+[Q9XFO;(V]
MM#;1'=Y49).6SR <$NB #;N:OL']HKXOS?LP_!I=<TCP7KGB^WTN6WM6TS14
MW3V]MD*\H7!)6-!G ')P"5&65:JR#<^9_BL/VPOV:O!-]X^NO'/@7X@Z;H<+
M7^JZ FCI;"*W0;I3#(L<<CA5#$EG#87(#'Y:^K/V=OC78?M&?!#PSXWTV%[>
MT\162W7D.VYK=^5DC)[['5ESWVYKY5^.?_!43P]\>_@WKW@OX5>%O''BSQOX
MJL)]&BL1HTD*Z8T\;1L\[-\HV*Q;C(Z9(&2/HK]B/X$77[,W[*G@OP3?/#)J
M&BV1-X8FW1BXFE>>4*>X$DK 'N!G Z4I;:@M]#U2O-OVQ/'^K?"O]E?X@>)-
M!N_L&M:)H=U>65QY22^3*D9*MM<,K8/9@1[5Z37CO_!0;_DR#XJ_]BS>_P#H
MHTEN4>:?LO\ PV^/GQ$\&_#OQWK'[0WVS2-=LM-UZ^T+_A ].C\^"9(IY+3[
M0K!ERK&/S%4$9W  \5]$_&/XG6/P6^%'B+Q;J9_T'P[ITVH2C.#((T+!!_M,
M0%'N17S;^PC^QC_8_P )?A/XW_X6Q\:KK?X?TS4O[ N/$^_0U\RTC;[.+;RO
M]0N["INX"J,G%5?^"N6KZY\2?!O@GX)>$V@_X23XLZP(F\Z1DBCL[7$TKR%5
M+! WELQ )VQO@&GN[$]"G_P2N_;%^('QQU_Q7X5^*EU'/XFCL;'Q1HY%I%;>
M9IEW$C@*L:J"B;X3N;<V9B"QQ7U;\4M#USQ+\.M9L?#.MMX<\07-JZZ=J7V>
M.X%I/C*,R2*ZLN0 P*GY2<8."/@+XG:!\7_V4?VK?A/\7_B%9_#&S\/PRV_@
M2^_X0TWWEQ6,PD$;7"W(SB/.Y64]8D4]L_>WQE^+FB? ?X7:WXO\17/V71]!
MMFN9V'+/CA40=W=BJJ.[,!1+>Z"/F?%</_!2KQM>?LW1>!5A2/\ :9DU[_A"
MS9-#$I6Y!YU(QE?*\KR^2=OE[\G'EXK[@^'6BZOX=\":18Z_K#>(=;M;6.._
MU)K>.W^VS@?/((XU5$!;.% X&.IYK\Y9OA;\4/"]I:_MG36K2>*I]1;5M2\*
MB%=L/AIHA"JJ<9\U;<!RQ .QMQPRL#^BOPM^)FC_ !E^'6C>*O#]T+S1]>M4
MN[67H2K#HP[,IRK#LP([4Y>01OU-^BBBH*"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR[]H_\
M8S^''[6KZ.WC_P /MKC:")A8XO[FU\GSO+\S_4R)NSY2?>SC'&,FO4:*-@/F
M#_AS;^SG_P!"#+_X/M1_^/T?\.;?V<_^A!E_\'VH_P#Q^OI^BJYF+E1\P?\
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M,5GN84N%<N=EI.M+I&/1/_TJW5N/F?T=X2T<#PME%;CO-U=ZT\/#K.6TFO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 1W=G#?P^7/#'-'D-MD4,N0<@X/H:DHHH CM+.
M&PA\N"&.&/);;&H5<DY)P/4T-9PM=K<&&,SJI19"HWA3R0#UQ[5)10 4444
M%%%% !1110!P'[4WPSUKXT?L\^+?"/A^^L=-U/Q-8-I8N;P,8889B(YR0H))
M\EI-H[M@$@9(V?@S\*M,^!WPI\/^$-'5ETWP[8Q6,);[T@1<%V_VF;+'W8UT
MU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !4&J:G;Z)IEQ>7DT=M:6<333S2-M2)%!+,Q[  $D^U3UR_P 9OA/8_''X
M<:AX6U2\U2RTO5E6.[-A,L,T\08%HBQ5L(X&UL8)4D9&:QQ$JD:4I45S2L[)
MNR;Z)OHK]3HP<*,Z\(XB3C!M<S2NTKZM+JTMEU/ACX._"&[_ ."GO[6^K?%+
MQ1;S+\+_  W<BQT:TF4J-32(DI%@_P !),DOO)L&>2OZ&Q1+!$L<:JD: *JJ
M,!0.@ K+\"^!=)^&?@_3] T&Q@TS1]*A$%K;0C"Q(/U))R23DDDDDDDUK5X/
M#7#\<LHRE5?/7JOFJ3_FD^W:*VBNB\VSZOC3BZ6=XF$*,?9X:A%0HT_Y8+2[
M[SE:\WU>E[)!1117TA\8%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?$_A7XX_'[]OO4=6U[X1:[X?^&'PSTV\DL--U34=/2^U#7'C.'E$<B.BQY]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVK0^!?#-CX=CURY%U?"W9V\]QG;R[,51=S;47"KN. ,FE>^HS\X?^"?GP"\
M?$/X>7'A/Q=\8_BM\-?B!X4OKFRU+PW!XLATNVCQ*[;[>)XCD<D. S$.&8X#
M+GZ-_9N_94^"7A;]L/2]3T3XR>,OB#\1O"%C<3PV.J^([?5%@@DC>W<,4A!^
M43D[ X(+!B,'GW/XZ?L*?"3]I/6/[2\:>!]+U;4F55:]1Y;.ZD"_=#2P.CL
M.!N)XXK<^!W[+?P]_9LLYX? _A/2?#WVH!9YH(R]Q.HQA7F<M(RC&<%B,\]:
MIRN)1/FW_@HYJ1_;!^)'A_\ 9M\+):7&J7D\6N^*-4DA$R^&+*+!5E])GWX
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M?&WAG2_$5K;L6@%U%^\MR1@F.1<.A(Z[2,X'I7'?!G_@GQ\&?V?O$,.K>%/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273738448888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 07, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,680,065,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,448,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Certain portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than April 30, 2022, in connection with the registrant&#8217;s 2022 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273743318904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Redwood City, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273739864440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 647,169<span></span>
</td>
<td class="nump">$ 319,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">819,905<span></span>
</td>
<td class="nump">887,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">282,650<span></span>
</td>
<td class="nump">160,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">27,493<span></span>
</td>
<td class="nump">20,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">57,530<span></span>
</td>
<td class="nump">57,011<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,834,747<span></span>
</td>
<td class="nump">1,445,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">371,112<span></span>
</td>
<td class="nump">330,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">104,031<span></span>
</td>
<td class="nump">67,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">111,663<span></span>
</td>
<td class="nump">156,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">131,002<span></span>
</td>
<td class="nump">73,408<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,616,239<span></span>
</td>
<td class="nump">2,137,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">24,258<span></span>
</td>
<td class="nump">23,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">61,969<span></span>
</td>
<td class="nump">51,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">77,544<span></span>
</td>
<td class="nump">52,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">33,700<span></span>
</td>
<td class="nump">20,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">86,753<span></span>
</td>
<td class="nump">12,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">53,366<span></span>
</td>
<td class="nump">44,447<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">337,590<span></span>
</td>
<td class="nump">204,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">8,739<span></span>
</td>
<td class="nump">3,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">51,272<span></span>
</td>
<td class="nump">49,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">8,023<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">405,624<span></span>
</td>
<td class="nump">258,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 318,842 and 311,627 at December&#160;31, 2021 and 2020, respectively</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,427,561<span></span>
</td>
<td class="nump">2,321,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(758)<span></span>
</td>
<td class="nump">4,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(216,507)<span></span>
</td>
<td class="num">(447,570)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,210,615<span></span>
</td>
<td class="nump">1,879,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,616,239<span></span>
</td>
<td class="nump">$ 2,137,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273739829912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">318,842,000<span></span>
</td>
<td class="nump">311,627,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">318,842,000<span></span>
</td>
<td class="nump">311,627,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273739288728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,434,970<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">52,873<span></span>
</td>
<td class="nump">36,272<span></span>
</td>
<td class="nump">33,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">693,716<span></span>
</td>
<td class="nump">547,851<span></span>
</td>
<td class="nump">336,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">401,715<span></span>
</td>
<td class="nump">293,355<span></span>
</td>
<td class="nump">228,244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,148,304<span></span>
</td>
<td class="nump">877,478<span></span>
</td>
<td class="nump">598,305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">286,666<span></span>
</td>
<td class="nump">110,060<span></span>
</td>
<td class="nump">369,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">7,672<span></span>
</td>
<td class="nump">19,865<span></span>
</td>
<td class="nump">27,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(184)<span></span>
</td>
<td class="nump">912<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Income before income taxes</a></td>
<td class="nump">294,154<span></span>
</td>
<td class="nump">130,837<span></span>
</td>
<td class="nump">398,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">63,091<span></span>
</td>
<td class="nump">19,056<span></span>
</td>
<td class="nump">77,097<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 231,063<span></span>
</td>
<td class="nump">$ 111,781<span></span>
</td>
<td class="nump">$ 321,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">314,884<span></span>
</td>
<td class="nump">308,271<span></span>
</td>
<td class="nump">302,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">322,359<span></span>
</td>
<td class="nump">318,001<span></span>
</td>
<td class="nump">315,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,077,256<span></span>
</td>
<td class="nump">$ 741,550<span></span>
</td>
<td class="nump">$ 759,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">249,956<span></span>
</td>
<td class="nump">167,295<span></span>
</td>
<td class="nump">165,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 107,758<span></span>
</td>
<td class="nump">$ 78,693<span></span>
</td>
<td class="nump">$ 41,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273741035656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 231,063<span></span>
</td>
<td class="nump">$ 111,781<span></span>
</td>
<td class="nump">$ 321,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $1,481, $(394), and $(1,049), respectively</a></td>
<td class="num">(5,234)<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
<td class="nump">3,770<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 225,829<span></span>
</td>
<td class="nump">$ 113,188<span></span>
</td>
<td class="nump">$ 324,782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273745040888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Tax impact of available-for-sale, unrealized holding gain (loss)</a></td>
<td class="num">$ (394)<span></span>
</td>
<td class="nump">$ 1,481<span></span>
</td>
<td class="num">$ (1,049)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273743096664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 28, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 28, 2018</a></td>
<td class="nump">$ 1,287,453<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 2,168,217<span></span>
</td>
<td class="num">$ (701)<span></span>
</td>
<td class="num">$ (880,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">321,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">3,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">27,037<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">27,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(9,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">56,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jan. 03, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jan. 03, 2020</a></td>
<td class="nump">1,685,970<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">2,241,947<span></span>
</td>
<td class="nump">3,069<span></span>
</td>
<td class="num">(559,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">111,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">1,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">24,903<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">24,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(50,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 105,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jan. 01, 2021</a></td>
<td class="nump">311,627<span></span>
</td>
<td class="nump">311,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jan. 01, 2021</a></td>
<td class="nump">$ 1,879,113<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">2,321,895<span></span>
</td>
<td class="nump">4,476<span></span>
</td>
<td class="num">(447,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">231,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="num">(5,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">24,367<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">24,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(39,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 120,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">318,842<span></span>
</td>
<td class="nump">318,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 2,210,615<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="nump">$ 2,427,561<span></span>
</td>
<td class="num">$ (758)<span></span>
</td>
<td class="num">$ (216,507)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273739796472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 231,063<span></span>
</td>
<td class="nump">$ 111,781<span></span>
</td>
<td class="nump">$ 321,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">13,630<span></span>
</td>
<td class="nump">9,141<span></span>
</td>
<td class="nump">8,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">119,820<span></span>
</td>
<td class="nump">105,070<span></span>
</td>
<td class="nump">56,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">5,332<span></span>
</td>
<td class="nump">4,830<span></span>
</td>
<td class="nump">2,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">46,529<span></span>
</td>
<td class="nump">15,265<span></span>
</td>
<td class="nump">71,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">23,443<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="num">(122,324)<span></span>
</td>
<td class="num">(42,470)<span></span>
</td>
<td class="nump">43,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(13,209)<span></span>
</td>
<td class="num">(21,897)<span></span>
</td>
<td class="num">(5,731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(39,875)<span></span>
</td>
<td class="num">(25,831)<span></span>
</td>
<td class="num">(5,723)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">11,008<span></span>
</td>
<td class="num">(1,051)<span></span>
</td>
<td class="num">(9,301)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued collaboration liabilities</a></td>
<td class="nump">70,297<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">4,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other liabilities</a></td>
<td class="nump">55,090<span></span>
</td>
<td class="nump">50,509<span></span>
</td>
<td class="nump">39,687<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">400,804<span></span>
</td>
<td class="nump">208,982<span></span>
</td>
<td class="nump">526,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and other</a></td>
<td class="num">(64,225)<span></span>
</td>
<td class="num">(30,345)<span></span>
</td>
<td class="num">(12,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(1,357,168)<span></span>
</td>
<td class="num">(1,070,269)<span></span>
</td>
<td class="num">(1,182,682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities and sales of investments</a></td>
<td class="nump">1,378,509<span></span>
</td>
<td class="nump">969,399<span></span>
</td>
<td class="nump">608,269<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(42,884)<span></span>
</td>
<td class="num">(131,215)<span></span>
</td>
<td class="num">(587,247)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">24,307<span></span>
</td>
<td class="nump">24,886<span></span>
</td>
<td class="nump">22,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(39,108)<span></span>
</td>
<td class="num">(50,018)<span></span>
</td>
<td class="num">(9,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(14,801)<span></span>
</td>
<td class="num">(25,132)<span></span>
</td>
<td class="nump">12,553<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash equivalents</a></td>
<td class="nump">343,119<span></span>
</td>
<td class="nump">52,635<span></span>
</td>
<td class="num">(47,738)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at beginning of period</a></td>
<td class="nump">320,772<span></span>
</td>
<td class="nump">268,137<span></span>
</td>
<td class="nump">315,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at end of period</a></td>
<td class="nump">663,891<span></span>
</td>
<td class="nump">320,772<span></span>
</td>
<td class="nump">268,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">12,960<span></span>
</td>
<td class="nump">4,115<span></span>
</td>
<td class="nump">7,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract', window );"><strong>Non-cash operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">4,893<span></span>
</td>
<td class="nump">4,017<span></span>
</td>
<td class="nump">29,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Unpaid liabilities incurred in asset acquisition</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid liabilities incurred for purchases of property and equipment</a></td>
<td class="nump">2,739<span></span>
</td>
<td class="nump">842<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_InvestmentsPurchasesIncurredButNotYetPaid', window );">Unpaid liabilities incurred for unsettled investment purchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccountsReceivableForUnsettledInvestmentSales', window );">Accounts receivable for unsettled investment sales</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,180<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccountsReceivableForUnsettledInvestmentSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable For Unsettled Investment Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccountsReceivableForUnsettledInvestmentSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_InvestmentsPurchasesIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments Purchases Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_InvestmentsPurchasesIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273740791976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.</span></div><div><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 61 other countries as: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA, for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important drug in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo). </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan is to utilize our operating cash flows and cash and investments to expand the cabozantinib franchise by potentially adding new indications in areas of unmet medical need. We will also leverage our operating cash flows to continue advancing our diverse small molecule and biotherapeutics programs, exploring multiple modalities and mechanisms of action to discover new oncology drugs. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021, fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January&#160;3, 2020. For convenience, references in this report as of and for the fiscal years ended January&#160;1, 2021 and January&#160;3, 2020 are indicated as being as of and for the years ended December&#160;31, 2020 and 2019, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reclassifications to our prior years&#8217; Consolidated Financial Statements to conform to the current year&#8217;s presentation. These reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders&#8217; equity.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted the Accounting Standards Board&#8217;s (FASB) Accounting Standards Update (ASU) 2019-12</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740)-Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, Income Taxes and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly, we assess each of our investments in available-for-sale debt securities whose fair value is below its cost basis to determine if the investment&#8217;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded as a reduction of other comprehensive income (loss), net of applicable taxes. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchange rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had one forward contract outstanding to sell &#8364;9.8&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Consolidated Balance Sheets. The unrealized loss on the forward contract is not material as of December&#160;31, 2021. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the year ended December&#160;31, 2021, we recognized $0.8&#160;million of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the accompanying Consolidated Statements of Income. Net foreign currency gains or losses were immaterial for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current economic conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. We write off trade receivables and related allowances for credit losses when it becomes probable we will not collect the amount receivable. Write-offs for the years ended December 31, 2021 and 2020 have been insignificant.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to 15 years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did not recognize any impairment charges in any of the periods presented.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenues under the guidance of ASU Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts for Prompt Payment:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Customers in the U.S. receive a discount of 2% for prompt payment. We expect our Customers will earn 100% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our Customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to Customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Customer Credits: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Up-front License Fees: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory and Development Milestone Payments: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Cost Reimbursements:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation, which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Arrangements: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Sales-based Milestone Payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty we are required to pay on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-02</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842) for short-term leases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expenses were $31.8 million, $25.1 million and $17.9 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock&#160;Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatility when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for income taxes in the period of such reversal. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273845740728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">REVENUES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,825&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on total net sales of any product containing cabozantinib for non-U.S. markets </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,950&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,775&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216,738)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,404&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,536&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,868)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Contract assets as of December&#160;31, 2021 are primarily related to contract assets from Ipsen Pharma SAS (Ipsen) and c</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ontract liabilities as of </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Presented in other long-term assets in the accompanying Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020 and 2019, we recognized $8.5 million, $9.2 million and $6.5 million, respectively, in revenues that were included in the beginning deferred revenues balance for those years. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2021, 2020 and 2019, we recognized $148.7 million, $169.7 million and $161.2 million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to milestone and royalty payments allocated to our license performance obligations for our collaborations with Ipsen Pharma SAS (Ipsen), Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $87.5 million of the combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements&#8212; Cabozantinib Collaborations &#8212;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; for additional information about the expected timing to satisfy these performance obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273740882552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements And Business Development Activities</a></td>
<td class="text">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading biopharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have made considerable progress under our existing research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading biopharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, to receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. See &#8220;Note 2. Revenues&#8221; for additional information on revenues recognized under our collaboration agreements during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, Ipsen opted into and is now co-funding the development costs for COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with RAI-refractory DTC who have progressed after up to two VEGF receptor-targeted therapies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ipsen </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s now obligated to reimburse us for their share of COSMIC-311 global development costs, as well as an additional payment calculated as a percentage of such costs, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">triggered by the timing of the exercise of its option. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the decision to opt in and co-fund the development costs for COSMIC-311 represented a contract modification for additional distinct services at their standalone selling price and therefore was treated as a separate contract under Topic 606. Accordingly, collaboration services revenues for the year ended December&#160;31, 2021, includes a cumulative catch-up of $43.2&#160;million for Ipsen&#8217;s share of global development costs incurred since the beginning of the study and through the opt-in date.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (1) the expiration of patent claims related to cabozantinib, (2) the expiration of regulatory exclusivity covering cabozantinib or (3) ten years after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the FDA or European Medicines Agency (EMA) orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration under the Collaboration</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, we received aggregate upfront payments of $210.0 million from Ipsen in 2016. As of December&#160;31, 2021, we have achieved aggregate milestones of $462.5 million related to regulatory, development and sales-based threshold by Ipsen since the inception of the collaboration agreement, including $112.5 million, $20.0 million and $55.0 million in milestones achieved during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of $46.5 million, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $350.0 million and CAD$26.5 million. We excluded these milestones from the transaction price as of December&#160;31, 2021 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will adjust the constraint applied to the variable consideration at each reporting period as uncertain events are resolved or other changes in circumstances occur. As of December&#160;31, 2021, $44.2 million of the transaction price allocated to our research and development services performance obligation had not been satisfied. See &#8220;&#8212;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221;, below, for additional information related to the revenue recognition for this collaboration.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receive royalty revenues on the net sales of cabozantinib by Ipsen outside of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he U.S. and Japan. During the year ended December&#160;31, 2021 and going forward, we are entitled to receive a tiered royalty of 22% to 26% on annual net sales, with separate tiers for Canada; these royalty tiers reset each calendar year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay a 3% royalty on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for 35% of such costs, provided Ipsen chooses to opt into such trials. Ipsen has opted into and is co-funding certain clinical trials, including: CheckMate -9ER, COSMIC-021, COSMIC-311, COSMIC-312, CONTACT-01 and CONTACT-02.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Relatedly, we entered into a supply agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product is supplied at our cost, as defined in the agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from the Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,073&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues for the year ended December&#160;31, 2021 included $100.0 million related to a commercial sales milestone from Ipsen upon their achievement of $400.0 million of net sales of cabozantinib in the related Ipsen license territory over four consecutive quarters and a $12.5 million regulatory milestone achieved upon submission of a variation application to the EMA for CABOMETYX as a treatment for patients with previously treated RAI-refractory DTC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018, May 2019 and September 2020, to, among other things, modify the amount of reimbursements we receive, for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive, as well as modify certain cost-sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02. We determined the amendment in September 2020 represented a contract modification that was treated as a termination of an existing contract and the creation of a new contract under Topic 606. As a result, we allocated the remaining transaction price to the performance obligations identified in the contract. The two remaining performance obligations are the research and development services associated with committed studies and the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. In allocating the transaction price for the modified contract we estimated the standalone selling price for the performance obligations. We utilized development costs incurred for these obligations in process and the projections of costs through the term of the arrangement. Revenue is recognized when, or as, we satisfy our performance obligations by transferring the promised services to Takeda. Revenue is being recognized using the cost proportional performance method, based on costs incurred to perform the research and development services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda is responsible for a portion of the costs associated with the cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and 100% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Takeda has opted into and is co-funding CheckMate -9ER, certain cohorts of COSMIC-021, CONTACT-01 and CONTACT-02. Under the collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (1) two years after first generic entry with respect to such product in Japan or (2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first six years of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration under the Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of $50.0 million from Takeda in 2017. As of December&#160;31, 2021, we have also achieved regulatory and development milestones in the aggregate of $127.0 million since the inception of the collaboration agreement, including $35.0 million, $66.0 million and $16.0 million in milestones achieved during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, as amended in 2020, we are eligible to receive additional regulatory and development milestone payments, without contractual limit, for additional potential future indications. We are further eligible to receive commercial milestones, including milestone payments earned for the first commercial sale of a product, of up to $119.0 million. We excluded these milestones from the transaction price as of December&#160;31, 2021 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will adjust the constraint applied to the variable consideration at each reporting period as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also receive royalty revenues on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of 15% to 24% on the initial $300.0&#160;million of net sales, and following this initial $300.0&#160;million of net sales, we are then entitled to receive a tiered royalty of 20% to 30% on annual net sales thereafter; these 20% to 30% royalty tiers reset each calendar year. Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay a 3% royalty on all net sales of any product incorporating cabozantinib, including net sales by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Additionally, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#8217;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues for the year ended December&#160;31, 2021 included $18.9&#160;million recognized in connection with a $20.0&#160;million milestone we achieved upon Takeda&#8217;s first commercial sale in Japan of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable, advanced or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $43.3&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified two performance obligations for the Ipsen collaboration agreement: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib; and (2) research and development services, </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified two remaining performance obligations for the Takeda collaboration agreement due to the amendment in September 2020: (1) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements) and (2) the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. As part of the original contract, we had a performance obligation associated with the exclusive license for the commercialization and further development of cabozantinib, which was transferred in 2017.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have allocated the transaction price for each of these collaborations to the identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and costs. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of the transaction price allocated to our license performance obligation is recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union for the Ipsen Collaboration and Japan for the Takeda Collaboration, both of which are early 2030. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust the constraint applied to the variable consideration for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the years ended December&#160;31, 2021, 2020 and 2019, the transaction price of the Ipsen and Takeda collaboration agreements increased as a result of the achievement of various milestones, and the reimbursements of research and development services related to committed and opt-in studies. We further updated the transaction price based upon the actual research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of December&#160;31, 2021, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Development Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BMS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab as a treatment option for RCC in the COSMIC-313 trial. Under the collaboration agreement with BMS, we may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement with BMS, as subsequently amended effective March 2019, May 2019 and November 2019, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial is conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party is responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each such trial will be determined on a trial-by-trial basis. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">F. Hoffmann-La Roche Ltd. (Roche) Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Under this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, and in December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, including in the phase 3 pivotal clinical trials in advanced non-small cell lung cancer (CONTACT-01), metastatic castration-resistant prostate cancer (CONTACT-02) and RCC (CONTACT-03). If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond these phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, a supplement to the joint clinical research agreement was signed amongst us, Roche and Takeda due to Takeda opting into fund the combined therapy trial of CONTACT-01 sponsored by Roche. Chugai was added as an affiliate of Roche.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All parties including Chugai conduct combined therapy trials in Japan upon the terms of the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#8217;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#8217; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply of their drug for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the contract is within the scope of Topic 808 as it involves joint operating activities where both parties have active participation in the arrangement and are exposed to significant risks and rewards. Payments between us and Roche under this arrangement are not subject to other accounting literature. Payments due to Roche for our share of clinical trial costs incurred by Roche will be recorded as research and development expense and payments due from Roche for their share of clinical trial costs incurred by us will be recorded as a reduction of research and development expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK and Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GSK, that required us to pay a 3% royalty to GSK on the total worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. As disclosed in Note 2, we received notification that, effective January 1, 2021, Royalty Pharma acquired from GSK all rights, title and interest in royalties on total net sales of any product containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalty revenues earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalty revenues were $46.6 million, $32.7 million and $31.3 million during the years ended December&#160;31, 2021, 2020 and 2019, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have out-licensed to Genentech under a worldwide collaboration agreement, the development and commercialization of cobimetinib, under the brand name COTELLIC. The terms of the collaboration agreement require that we share in the profits and losses received or incurred in connection with the commercialization of COTELLIC in the U.S. In addition to our profit share in the U.S., we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020, and 2019, we recognized $12.1 million, $11.3 million, and $10.3 million, in revenues from profits and losses on U.S commercialization and royalties on ex-U.S. sales under the collaboration agreement with Genentech and are included within license revenues on our Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. In January 2019, the Japanese Ministry of Health, Labour and Welfare approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have achieved milestones of $20.0&#160;million for the year ended December&#160;31, 2019 for the first commercial sale of MINNEBRO and are eligible to receive additional sales-based milestone payments of up to $90.0 million under this collaboration agreement. In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue under the collaboration agreement with Daiichi Sankyo w</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as $3.8&#160;million, $1.3&#160;million </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $20.1&#160;million</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into collaborative arrangements with other pharmaceutical or biotechnology companies to develop and commercialize drug candidates or intellectual property. Our research collaborations and in-licensing arrangements are intended to enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, development, regulatory, commercial milestone payments and royalty payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then assume the responsibilities for all subsequent clinical development, manufacturing and commercialization. In conjunction with each of these collaborative in-licensing arrangements, we were subject to upfront payments and will make payments for potential future development milestones of up to $254.3&#160;million, regulatory milestones of up to $426.5&#160;million and commercial milestones of up to $1,911.5&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales. In conjunction with an asset purchase agreement, we made payments of $10.0&#160;million for the initial technology transfer, and subject to certain conditions, will make a $4.0&#160;million payment upon the completion of the technology transfer of certain materials and documents specified in the asset purchase agreement. We will also make payments for potential future development milestones of up to $42.0&#160;million and regulatory milestones of up to $22.5&#160;million, per product.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we amended our collaboration agreement with Iconic to acquire broad rights to use the anti-TF antibody used in XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics. Under the amended agreement, we agreed to pay a final one-time payment to Iconic of $55.0&#160;million and will not owe any further payments, but we will continue to be responsible for milestone payments and royalties owed to other companies pursuant to prior agreements between Iconic and those companies. Upon signing the amendment, we recognized $55.0&#160;million in research and development expense, which amount was payable as of December 31, 2021 and presented in accrued collaboration liabilities in our Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020, and 2019, we recognized </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$176.1&#160;million,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$96.4&#160;million and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$47.7&#160;million</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, relating to upfront license payments, research and development funding, development milestones, option fees and other fees within research and development expenses on the Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273740705176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">Cash and Investments</a></td>
<td class="text">CASH AND INVESTMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of December&#160;31, 2021, restricted cash equivalents included $15.2 million of short-term investments, which is collateral under our January 2021 standby letter of credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,982&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,842&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $2.9 million and $4.5 million as of December&#160;31, 2021 and 2020, respectively, and is included in prepaid and other current assets in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities presented have been in an unrealized loss position for less than 12 months. There were 133 and 14 debt securities in an unrealized loss position as of December&#160;31, 2021 and 2020, respectively. During the years ended December&#160;31, 2021 and 2020, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273740701096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS <div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652,724&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415,905&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div>The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273740712264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">INVENTORY<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273740871656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up to 15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,862&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,068&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,031&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $13.6 million, $9.1 million and $8.3 million during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273741195928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans and ESPP</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several equity incentive plans under which we granted stock options and RSUs, including PSUs, to employees and directors. At December&#160;31, 2021, 11,004,584 shares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option award and 1.5 shares for full value awards granted in the form of RSUs or PSUs. On May 20, 2020, at our 2020 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of the 2017 Plan. The amendment and restatement increased the share reserve under the 2017 Plan by 21,000,000 shares, subject to adjustment for certain changes in our capitalization, which became effective immediately upon stockholder approval. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors delegated responsibility for administration of our equity incentive plans to the Compensation Committee of our Board of Directors, including the authority to determine the term, exercise price and vesting requirements of each grant. Stock options granted to our employees and directors generally have a four-year vesting term and a one-year vesting term, respectively, an exercise price equal to the fair market value on the date of grant, and a seven-year life from the date of grant. RSUs granted to our employees and directors generally have a four-year vesting term and a one-year vesting term, respectively. PSUs granted pursuant to our equity incentive plans vest upon specified service conditions and the achievement of a performance target or market condition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Change in Control and Severance Benefit Plan for certain executive officers. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#8217;s employment is terminated without cause during a period commencing one month before and ending thirteen months following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all their outstanding equity awards accelerated and the exercise period for their stock options extended to no more than one year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of 85% of the closing price at the beginning of the offering period or 85% of the closing price at the end of each six-month purchase period. As of December&#160;31, 2021, we had </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,168,354</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares available for issuance under our ESPP. Pursuant to the ESPP, we issued 536,226, 534,419 and 483,009 shares of common stock at an average price per share of $17.76, $14.55 and $12.60 during the years ended December&#160;31, 2021, 2020 and 2019, respectively. Cash received </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from purchases under the ESPP for the years ended December 31, 2021, 2020 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $9.5 million, $7.8 million and $6.1 million, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used a Black-Scholes Merton option pricing model to value stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered both implied and historical volatility in developing our estimate of expected volatility. The assumption for the expected life of stock options is based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs, including PSUs, was based on the closing price of the underlying common stock on the date of grant. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for stock options during the year ended December&#160;31, 2021 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercisable at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,962&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $27.8 million of unrecognized compensation expense related to our unvested stock options. The compensation expense for the unvested stock options will be recognized over a weighted-average period of 2.7 years.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal 2021 and the exercise prices, multiplied by the number of in-the-money stock options) that would have been received by the stock option holders had all stock option holders exercised their stock options on December&#160;31, 2021. The total intrinsic value of stock options exercised during the years ended December&#160;31, 2021, 2020 and 2019 was $76.0 million, $106.5 million and $54.1 million, respectively. Cash received from stock option exercises during the years ended December&#160;31, 2021, 2020 and 2019 was $14.8 million, $26.9 million and $16.4 million, respectively.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Activity for RSUs during the year ended December&#160;31, 2021 was as follows (in thousands, except per share amounts):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,020)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,828&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $123.6 million of unrecognized compensation expense related to our unvested RSUs which will be recognized over a weighted-average period of 2.9 years.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for PSUs, during the year ended December&#160;31, 2021 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(736)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, in connection with our long-term incentive compensation program, we awarded certain employees 1,027,650 (the 2021 target amount) PSUs, subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to 200% of the 2021 target amount, or up to 2,055,300 total shares, depending on the level of achievement of the performance condition related to certain net product revenues and a total shareholder return (TSR) market condition. The TSR market condition is based on our relative TSR percentile rank compared to companies in the Nasdaq Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. Fifty percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately one year later subject to an employee&#8217;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023. The performance condition for a threshold of net product revenues relative to the 2021 PSUs was deemed probable of achievement in the fourth quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, in connection with our long-term incentive compensation program, we awarded 2,327,840 PSUs (the 2020 target amount) that will vest upon the achievement of performance targets related to clinical trial positive top-line results and product approvals by the FDA (the 2020 PSUs). Pursuant to the terms of the 2020 PSUs, employees may earn up to 200% of the 2020 target amount, or 4,655,680 total shares, depending on the volume and timing of achievement of the performance targets. The 2020 PSUs will be forfeited if the performance targets are not met by December 31, 2024. The performance condition for threshold achievement of a product approval by the FDA relative to the 2020 PSUs occurred in the third quarter of 2021 representing 25% of the 2020 target amount.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December&#160;31, 2019, in connection with our long-term incentive compensation program, we awarded 1,926,605 PSUs (the 2019 target amount) that vest upon the achievement of performance targets related to product approvals by the FDA (the 2019 PSUs). Pursuant to the terms of the 2019 PSUs, employees may earn up to 200% of the 2019 target amount, or 3,853,210 total shares, depending on the volume and timing of achievement of the performance targets. The performance condition for early achievement of the 2019 PSUs occurred during 2020 representing 150% of the 2019 target amount. The performance condition for earning the remaining 50% of the 2019 target amount occurred in early 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2018, we awarded 693,131 PSUs that vest upon the achievement of certain product revenue, late-stage clinical development programs and discovery pipeline expansion performance targets (the 2018 PSUs). The performance targets for 167,726 remaining 2018 PSUs were achieved in 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognition for PSUs commences when it is determined that attainment of the performance target is probable. Of the aggregate outstanding PSUs, 4,853,112 relate to awards for which we achieved the performance target. As of December&#160;31, 2021, the remaining unrecognized compensation expense for the PSUs achieved or deemed probable of achievement related to the PSUs was $12.1 million, which will be recognized over a weighted-average period of 3.0 years. The total unrecognized compensation expense for the PSUs for which we have not yet determined that attainment of the performance target is probable was $121.6 million as of December&#160;31, 2021.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exelixis, Inc. 401(k) Plan (the 401(k) Plan)</span></div>We sponsor the 401(k) Plan under which we have historically made matching contributions to our employees&#8217; 401(k) accounts in the form of our common stock. Beginning in 2020, our matching contributions are in the form of cash. We recorded compensation expense of $9.5 million, $6.7 million and $4.6 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively, for matching contributions to our employees 401(k) accounts.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273740913624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Provision For Income Taxes</a></td>
<td class="text">PROVISION FOR INCOME TAXES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income before income taxes is derived solely from within the U.S. Our provision for income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,529&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,002&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the years ended December&#160;31, 2021, 2020, and 2019 primarily relates to the utilization of federal tax attributes and state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our historical net operating losses were sufficient to fully offset any federal taxable income for the years ended December 31, 2020 and 2019 but were not sufficient to fully offset federal taxable income for the year ended December&#160;31, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2021, 2020 and 2019, respectively, to our provision for income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal income tax provision at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax (benefit) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,356)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves not currently deductible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,638&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,063&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,907)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,907)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,167)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,711&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 740: Income Taxes (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December&#160;31, 2021, based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position as of December&#160;31, 2021 and forecasts of future operating results, as well as considering the utilization of net operating losses and tax credits prior to their expiration, management determined that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets are realizable. As of December&#160;31, 2021 and 2020, we continue to carry a valuation allowance of $70.1 million and $67.2 million, respectively, against our California state deferred tax assets. The valuation allowance increased by $2.9 million and $5.5 million during the years ended December 31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, we had federal business tax credits of approximately $101.0 million which expire in the years 2025 through 2041. We also had state net operating loss carryforwards of approximately $426.0 million, which expire in the years 2022 through 2036, California research and development tax credits of approximately $45.0 million, which do not expire, and California Competes Tax Credits of approximately $2.0 million, which expire in 2026.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 analysis through December&#160;31, 2021, and concluded that an ownership change, as defined under Section 382, had not occurred. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to prior year provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to current year provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on the lapse of the applicable statutes of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,583&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,941&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate that the amount of unrecognized tax benefits existing as of December&#160;31, 2021 will significantly change over the next 12 months. As of December&#160;31, 2021, we had $83.6 million in unrecognized tax benefits, of which $52.6 million would reduce our provision for income taxes and the effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Income as a component of income taxes. </span></div>We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 2001 through 2021 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273741183880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">NET INCOME PER SHARE<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,009&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, unvested RSUs and PSUs and ESPP contributions. Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. See &#8220;Note 8. Employee Benefit Plans&#8221; for a further description of our equity awards. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273740716872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Headquarters Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located in Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018, April 2019, August 2019, January 2020 and December 2020, resulting in, among other things, an increase to the amount of space leased and changes to the lease term. Our right-of-use asset, lease liability and the related lease costs reflect the 254,690 square feet of space we have taken possession of as of December 31, 2021 (the Current Premises) under the amended Lease, including 25,749 square feet of space we took possession of in 2021. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Lease continues through October 31, 2031 (the Lease Term). We have two five-year options to extend the Lease; these optional periods have not been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made certain tenant improvements on the Initial Premises, for which we received $8.2 million in reimbursements in January 2019. During 2020, we also made certain tenant improvements for which we have received $1.7&#160;million in reimbursements in 2021 related to the additional space we obtained under the April 2019 amendment. We were also provided an allowance of up to $1.4 million in 2021 for certain planned tenant improvements to the additional space obtained under the December 2020 amendment. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_7a0e4465-a6b5-4b02-b58f-7014879a369f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_dc2f3847-52aa-4192-8d7c-2b18b469e239">Right-of-use assets included in other long-term assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_5d4462a3-e4ad-42c2-8f32-f51e009f8ca0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_ae5d588d-a5da-417a-8318-ddd0d907793d">Current portion included in other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,111&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities for the years ended December&#160;31, 2021, 2020 and 2019 was $5.0 million, $4.6 million and $2.9&#160;million, respectively, and was included in net cash provided by operating activities in our Consolidated Statements of Cash Flows.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.186%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future tenant improvement reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the weighted average discount rate used to determine the operating lease liability was 3.1% and the weighted average remaining lease term was 9.8 years. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Build-to-Suit Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we entered into a build-to-suit Lease Agreement (the Build-to-Suit Lease) for approximately 220,000 square feet of office space located in Alameda, California (the New Premises), adjacent to the Current Premises.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Build-to-Suit Lease is for a period of 242 months (the Term), which will begin upon the substantial completion of the building and tenant improvements by the lessor. We currently anticipate that the Term will begin in the first quarter of 2022 (which date will be the Lease Commencement Date). The monthly base rent under the Build-to-Suit Lease will equal a percentage of the total development costs incurred in connection with the development of the New Premises (excluding the cost of the tenant improvements in excess of the allowance provided by the lessor and any development costs we pay) and is currently estimated to be about $0.7 million, subject to an annual increase of 3% during the Term. We will also be responsible for paying operating expenses related to the New Premises. The rent payments will begin sixty days following commencement of the Term. We have been provided a tenant improvement allowance for the New Premises of approximately $16.5 million. To the extent that the total development costs of the New Premises exceeds $525 per square foot, we will also pay 50% of such excess costs prior to the commencement of the Term, and we are required to secure such amount by providing a letter of credit or depositing such amounts in an account with the lessor&#8217;s lender.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Build-to-Suit Lease includes two five-year options to extend the term of the Build-to-Suit Lease, exercisable under certain conditions and at a market rate determined in accordance with the Build-to-Suit Lease. We have a one-time option to terminate the Build-to-Suit Lease without cause after the 180</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month of the Term, exercisable under certain conditions as described in the Build-to-Suit Lease and subject to a termination payment calculated in accordance with the Build-to-Suit Lease. In addition, we have a right of first offer to purchase the New Premises, subject to certain procedures and exclusions set forth in the Build-to-Suit Lease. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that, under the guidance provided in Topic 842, we do not have control of the New Premises during the construction period. Therefore, we will not record a right-of-use asset or lease liability for the Build-to-Suit Lease until the Lease Commencement Date. We will evaluate the classification of the Build-to-Suit Lease as an operating lease or financing lease at the Lease Commencement Date. We determined the cost of tenant improvements during the construction period are lessor assets and considered a prepayment of lease under Topic 842. The costs incurred as of December&#160;31, 2021 of $36.8 million are recorded as other long-term assets in the Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of $16.7 million and $1.6 million as of December&#160;31, 2021 and 2020, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a standby letter of credit as guarantee of our obligation to fund our portion of the tenant improvements related to our build-to-suit lease at our corporate campus. The letter of credit is secured by our short-term investments, which are recorded as restricted cash equivalents and presented in Other long-term assets in our Consolidated Balance Sheets and is reduced as we fund our portion of the tenant improvements. As of December&#160;31, 2021, restricted cash equivalents included $15.2 million of short-term investments as collateral under our standby letter of credit for our portion of the tenant improvements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473 (composition of matter) or U.S. Patent No. 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patent Nos. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent Nos. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent Nos. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patent Nos. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patent Nos. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patent Nos. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. A bench trial has been scheduled for May 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of four previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patent Nos. 11,091,439 (salt and polymorphic forms) 11,091,440 (formulations) and 11,098,015 (methods of treatment). We have 45 days from receipt of the January 11, 2022 notice to file a patent infringement claim against MSN relating to the newly challenged patents.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with Teva Pharmaceutical Industries Limited (Teva Parent), asserting infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On February 8, 2022, the parties filed a stipulation to stay all proceedings, which was granted by the Delaware District Court on February 9, 2022. The stipulation and order were filed under seal.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273743005448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021, fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January&#160;3, 2020. For convenience, references in this report as of and for the fiscal years ended January&#160;1, 2021 and January&#160;3, 2020 are indicated as being as of and for the years ended December&#160;31, 2020 and 2019, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reclassifications to our prior years&#8217; Consolidated Financial Statements to conform to the current year&#8217;s presentation. These reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders&#8217; equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted the Accounting Standards Board&#8217;s (FASB) Accounting Standards Update (ASU) 2019-12</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740)-Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, Income Taxes and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments and Investment Impairment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly, we assess each of our investments in available-for-sale debt securities whose fair value is below its cost basis to determine if the investment&#8217;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded as a reduction of other comprehensive income (loss), net of applicable taxes. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Forward Foreign Currency Contracts</a></td>
<td class="text">In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchange rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Remeasurement</a></td>
<td class="text">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the accompanying Consolidated Statements of Income.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text">Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current economic conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. We write off trade receivables and related allowances for credit losses when it becomes probable we will not collect the amount receivable. Write-offs for the years ended December 31, 2021 and 2020 have been insignificant.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to 15 years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">We recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text">The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenues under the guidance of ASU Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts for Prompt Payment:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Customers in the U.S. receive a discount of 2% for prompt payment. We expect our Customers will earn 100% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our Customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to Customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Customer Credits: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Up-front License Fees: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory and Development Milestone Payments: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Cost Reimbursements:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation, which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Arrangements: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Sales-based Milestone Payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty we are required to pay on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. </span></div>We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-02</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842) for short-term leases.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text">We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock&#160;Compensation</span>,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatility when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for income taxes in the period of such reversal. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273739242200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,825&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,950&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration Risks</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues Disaggregated by Geographic Region</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,775&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216,738)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,404&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,536&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,868)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Other Assets and Other Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Presented in other long-term assets in the accompanying Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets.</span></div>(3)&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273741193976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,073&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273745036728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Investments by Security Type</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,982&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,842&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):<div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273740773688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652,724&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415,905&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273740775928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273740773688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up to 15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,862&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,068&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,031&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273744930952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of All Stock Option Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for stock options during the year ended December&#160;31, 2021 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercisable at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,962&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of All RSU Activity</a></td>
<td class="text">Activity for RSUs during the year ended December&#160;31, 2021 was as follows (in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,020)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,828&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for PSUs, during the year ended December&#160;31, 2021 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(736)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</a></td>
<td class="text">A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273738420344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income before income taxes is derived solely from within the U.S. Our provision for income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,529&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,002&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2021, 2020 and 2019, respectively, to our provision for income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal income tax provision at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax (benefit) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,356)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves not currently deductible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,638&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,063&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,907)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,907)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,167)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,711&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to prior year provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to current year provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on the lapse of the applicable statutes of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,583&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,941&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273740769896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,009&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share</a></td>
<td class="text">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273831850088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Balance Sheet Classification of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_7a0e4465-a6b5-4b02-b58f-7014879a369f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_dc2f3847-52aa-4192-8d7c-2b18b469e239">Right-of-use assets included in other long-term assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_5d4462a3-e4ad-42c2-8f32-f51e009f8ca0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_ae5d588d-a5da-417a-8318-ddd0d907793d">Current portion included in other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,111&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.186%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future tenant improvement reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742715752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Narrative (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>product </div>
<div>country</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>derivative_instrument</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS', window );">Number of countries with FDA approval, excluding the U.S. | country</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charge on goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SalesRevenuePercentDiscountForPromptPayment', window );">Percent discount for prompt payment</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent', window );">Discount expected to be earned</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MedicarePartDFundingMandate', window );">Medicare Part D funding mandate</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Cost of goods sold is related to product</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 31,800,000<span></span>
</td>
<td class="nump">$ 25,100,000<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of forward contract outstanding | derivative_instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Forward contract outstanding, amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Forward contract maturity (in months)</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Net gain on maturity of forward contracts</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting From Discovery Efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember', window );">Products Derived From Other Compounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MedicarePartDFundingMandate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medicare Part D Funding Mandate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MedicarePartDFundingMandate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Countries With Drug Approval, Excluding The U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberOfCountriesWithDrugApprovalExcludingTheUS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Discount Expected to be Earned, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenueDiscountExpectedtobeEarnedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenuePercentDiscountForPromptPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Percent Discount for Prompt Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenuePercentDiscountForPromptPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273739671800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,434,970<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,452,913<span></span>
</td>
<td class="nump">962,591<span></span>
</td>
<td class="nump">957,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">(375,657)<span></span>
</td>
<td class="num">(221,041)<span></span>
</td>
<td class="num">(197,671)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,077,256<span></span>
</td>
<td class="nump">741,550<span></span>
</td>
<td class="nump">759,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">249,956<span></span>
</td>
<td class="nump">167,295<span></span>
</td>
<td class="nump">165,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">107,758<span></span>
</td>
<td class="nump">78,693<span></span>
</td>
<td class="nump">41,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 357,714<span></span>
</td>
<td class="nump">$ 245,988<span></span>
</td>
<td class="nump">$ 207,825<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273739701896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 1,434,970<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">1,054,050<span></span>
</td>
<td class="nump">718,687<span></span>
</td>
<td class="nump">733,421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">23,206<span></span>
</td>
<td class="nump">22,863<span></span>
</td>
<td class="nump">26,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 1,077,256<span></span>
</td>
<td class="nump">$ 741,550<span></span>
</td>
<td class="nump">$ 759,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742824296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Significant Customer (Details) - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Sales revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Sales revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Sales revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Sales revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember', window );">Affiliates of Optum Specialty Pharmacy | Sales revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_TakedaMember', window );">Takeda Pharmaceutical Company Limited | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273743012056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,434,970<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,089,396<span></span>
</td>
<td class="nump">752,890<span></span>
</td>
<td class="nump">770,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">302,073<span></span>
</td>
<td class="nump">151,631<span></span>
</td>
<td class="nump">152,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 43,501<span></span>
</td>
<td class="nump">$ 83,017<span></span>
</td>
<td class="nump">$ 44,760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742653400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 30,536<span></span>
</td>
<td class="nump">$ 26,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">374,208<span></span>
</td>
<td class="nump">220,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">1,449<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(357,868)<span></span>
</td>
<td class="num">(216,738)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">48,325<span></span>
</td>
<td class="nump">30,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks, Discounts for Prompt Payment and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">9,853<span></span>
</td>
<td class="nump">7,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">243,119<span></span>
</td>
<td class="nump">146,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(64)<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(238,283)<span></span>
</td>
<td class="num">(144,231)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">14,625<span></span>
</td>
<td class="nump">9,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">3,279<span></span>
</td>
<td class="nump">3,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">30,728<span></span>
</td>
<td class="nump">16,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(111)<span></span>
</td>
<td class="num">(352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(25,021)<span></span>
</td>
<td class="num">(16,028)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">8,875<span></span>
</td>
<td class="nump">3,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">17,404<span></span>
</td>
<td class="nump">15,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">100,361<span></span>
</td>
<td class="nump">58,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">1,624<span></span>
</td>
<td class="nump">612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(94,564)<span></span>
</td>
<td class="num">(56,479)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 24,825<span></span>
</td>
<td class="nump">$ 17,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742901752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Contract other long-term assets</a></td>
<td class="nump">$ 1,665<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">7,814<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">8,739<span></span>
</td>
<td class="nump">3,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total contract liabilities</a></td>
<td class="nump">16,553<span></span>
</td>
<td class="nump">5,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Contract revenue recognized, including revenue from deferred revenue beginning balance</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">148,700<span></span>
</td>
<td class="nump">$ 169,700<span></span>
</td>
<td class="nump">$ 161,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to our performance obligations</a></td>
<td class="nump">$ 87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract Revenue, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742452968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarnedToDate', window );">Milestone payments earned to date</a></td>
<td class="nump">$ 462.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 87.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Collaboration agreement percent of royalty on net sale</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">$ 112.5<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="nump">$ 55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">46.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 44.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RevenueFromContractWithCustomerCommercialSalesMilestone', window );">Commercial sales milestone</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold', window );">Commercial sales milestone, net sales threshold</a></td>
<td class="nump">400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RevenueFromContractWithCustomerRegulatoryMilestone', window );">Regulatory milestone</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen | Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Cumulative catch-up revenue recognized</a></td>
<td class="nump">$ 43.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen | Minimum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen | Maximum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory, Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarnedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned To Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarnedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RevenueFromContractWithCustomerCommercialSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Commercial Sales Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RevenueFromContractWithCustomerCommercialSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Commercial Sales Milestone, Net Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RevenueFromContractWithCustomerRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Regulatory Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RevenueFromContractWithCustomerRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273738612328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,434,970<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">302,073<span></span>
</td>
<td class="nump">151,631<span></span>
</td>
<td class="nump">152,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">249,956<span></span>
</td>
<td class="nump">167,295<span></span>
</td>
<td class="nump">165,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">207,982<span></span>
</td>
<td class="nump">93,495<span></span>
</td>
<td class="nump">117,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">107,758<span></span>
</td>
<td class="nump">78,693<span></span>
</td>
<td class="nump">41,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 94,091<span></span>
</td>
<td class="nump">$ 58,136<span></span>
</td>
<td class="nump">$ 35,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742452184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarnedToDate', window );">Milestone payments earned to date</a></td>
<td class="nump">$ 462.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Collaboration agreement percent of royalty on net sale</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 87.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PeriodOfSpecificSalesVolumeThreshold', window );">Sales volume period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarnedToDate', window );">Milestone payments earned to date</a></td>
<td class="nump">$ 127.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">35.0<span></span>
</td>
<td class="nump">$ 66.0<span></span>
</td>
<td class="nump">$ 16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">119.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amount of revenues recognized included in the beginning contract liability balance</a></td>
<td class="nump">18.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RevenueFromContractWithCustomerCommercialSalesMilestone', window );">Commercial sales milestone</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">43.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Initial | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Initial | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Final tier | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Final tier | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarnedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned To Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarnedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PeriodOfSpecificSalesVolumeThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Of Specific Sales Volume, Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PeriodOfSpecificSalesVolumeThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RevenueFromContractWithCustomerCommercialSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Commercial Sales Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RevenueFromContractWithCustomerCommercialSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_InitialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_InitialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742806344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,434,970<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">39,725<span></span>
</td>
<td class="nump">81,672<span></span>
</td>
<td class="nump">24,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">249,956<span></span>
</td>
<td class="nump">167,295<span></span>
</td>
<td class="nump">165,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">26,058<span></span>
</td>
<td class="nump">61,115<span></span>
</td>
<td class="nump">18,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">107,758<span></span>
</td>
<td class="nump">78,693<span></span>
</td>
<td class="nump">41,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 13,667<span></span>
</td>
<td class="nump">$ 20,557<span></span>
</td>
<td class="nump">$ 6,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273740940312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - GSK (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Collaboration agreement percent of royalty on net sale</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaborative Arrangements with Glaxo Smith Kline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 46.6<span></span>
</td>
<td class="nump">$ 32.7<span></span>
</td>
<td class="nump">$ 31.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273743317048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Other Collaborations Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,434,970,000<span></span>
</td>
<td class="nump">$ 987,538,000<span></span>
</td>
<td class="nump">$ 967,775,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech | Cotellic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12,100,000<span></span>
</td>
<td class="nump">11,300,000<span></span>
</td>
<td class="nump">10,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember', window );">Collaboration Agreement with Daiichi Sankyo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievedMilestoneAmount', window );">Achieved milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievedMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achieved Milestone Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievedMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273739671432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,716<span></span>
</td>
<td class="nump">$ 547,851<span></span>
</td>
<td class="nump">$ 336,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=exel_CollaborativeAgreementWithGamaMabsPharmaSAMember', window );">Collaborative Agreement With Gama Mabs Pharma S A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetAcquisitionPaymentUponClosingOfTransaction', window );">Payment upon closing of transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments', window );">Asset acquisition, maximum aggregate development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments', window );">Asset acquisition, maximum aggregate regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember', window );">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments', window );">Potential future development milestone payments</a></td>
<td class="nump">$ 254,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="nump">426,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">426,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments', window );">Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments</a></td>
<td class="nump">1,911,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,911,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,100<span></span>
</td>
<td class="nump">$ 96,400<span></span>
</td>
<td class="nump">$ 47,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsIncMember', window );">Collaboration Agreement With Iconic Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsFinalPayment', window );">Collaboration agreement, final payment</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Maximum Aggregate Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetAcquisitionPaymentUponClosingOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Payment Upon Closing Of Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetAcquisitionPaymentUponClosingOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Final Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=exel_CollaborativeAgreementWithGamaMabsPharmaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=exel_CollaborativeAgreementWithGamaMabsPharmaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273744863240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 647,169<span></span>
</td>
<td class="nump">$ 319,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash equivalents included in other long-term assets</a></td>
<td class="nump">16,722<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 663,891<span></span>
</td>
<td class="nump">$ 320,772<span></span>
</td>
<td class="nump">$ 268,137<span></span>
</td>
<td class="nump">$ 315,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742582152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted cash equivalents</a></td>
<td class="nump">$ 15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742201832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,534,464<span></span>
</td>
<td class="nump">$ 1,349,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">934<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,730)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,533,668<span></span>
</td>
<td class="nump">1,355,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,855,704<span></span>
</td>
<td class="nump">1,532,923<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">934<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,730)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,854,908<span></span>
</td>
<td class="nump">1,538,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">945,801<span></span>
</td>
<td class="nump">569,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">945,841<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">541,774<span></span>
</td>
<td class="nump">543,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">5,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,672)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">540,978<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">33,965<span></span>
</td>
<td class="nump">208,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">33,945<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">12,924<span></span>
</td>
<td class="nump">28,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">12,904<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">135,653<span></span>
</td>
<td class="nump">82,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">135,653<span></span>
</td>
<td class="nump">82,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">66,531<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">66,531<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">119,056<span></span>
</td>
<td class="nump">60,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 119,056<span></span>
</td>
<td class="nump">$ 60,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742375544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">$ 454,780<span></span>
</td>
<td class="nump">$ 56,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,730)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">385,053<span></span>
</td>
<td class="nump">28,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,672)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">43,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">18,962<span></span>
</td>
<td class="nump">21,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">7,475<span></span>
</td>
<td class="nump">5,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (35)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273739222104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 1,168,256<span></span>
</td>
<td class="nump">$ 1,034,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">365,412<span></span>
</td>
<td class="nump">321,751<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,533,668<span></span>
</td>
<td class="nump">$ 1,355,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273735780264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,533,668<span></span>
</td>
<td class="nump">$ 1,355,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,533,668<span></span>
</td>
<td class="nump">1,355,901<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,719,255<span></span>
</td>
<td class="nump">1,456,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">66,531<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,533,668<span></span>
</td>
<td class="nump">1,355,901<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,652,724<span></span>
</td>
<td class="nump">1,415,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">945,841<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">945,841<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">945,841<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">540,978<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">540,978<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">540,978<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">33,945<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">33,945<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">33,945<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">12,904<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">12,904<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">12,904<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">66,531<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">66,531<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">119,056<span></span>
</td>
<td class="nump">60,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 119,056<span></span>
</td>
<td class="nump">$ 60,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742386216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 8,867<span></span>
</td>
<td class="nump">$ 7,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">27,717<span></span>
</td>
<td class="nump">20,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">12,927<span></span>
</td>
<td class="nump">7,291<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">49,511<span></span>
</td>
<td class="nump">35,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">27,493<span></span>
</td>
<td class="nump">20,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 22,018<span></span>
</td>
<td class="nump">$ 14,701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742806328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 144,862<span></span>
</td>
<td class="nump">$ 102,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(40,831)<span></span>
</td>
<td class="num">(34,684)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 104,031<span></span>
</td>
<td class="nump">67,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 73,589<span></span>
</td>
<td class="nump">40,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 14,877<span></span>
</td>
<td class="nump">18,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 15,780<span></span>
</td>
<td class="nump">14,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 23,744<span></span>
</td>
<td class="nump">11,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 16,872<span></span>
</td>
<td class="nump">$ 16,360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742669320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 13.6<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742798744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Schedule of Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 119,820<span></span>
</td>
<td class="nump">$ 105,070<span></span>
</td>
<td class="nump">$ 56,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">46,654<span></span>
</td>
<td class="nump">37,198<span></span>
</td>
<td class="nump">19,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 73,166<span></span>
</td>
<td class="nump">$ 67,872<span></span>
</td>
<td class="nump">$ 37,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273739759992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Schedule of Employee Service Share - Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 119,820<span></span>
</td>
<td class="nump">$ 105,070<span></span>
</td>
<td class="nump">$ 56,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">19,048<span></span>
</td>
<td class="nump">19,863<span></span>
</td>
<td class="nump">23,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">53,629<span></span>
</td>
<td class="nump">35,675<span></span>
</td>
<td class="nump">26,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">43,428<span></span>
</td>
<td class="nump">47,106<span></span>
</td>
<td class="nump">4,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,715<span></span>
</td>
<td class="nump">$ 2,426<span></span>
</td>
<td class="nump">$ 2,246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273733552792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 20, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,004,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward', window );">Reduction in share reserve after stock option or stock appreciation award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards', window );">Reduction in share reserve after all other awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve under 2017 plan (in shares)</a></td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,820<span></span>
</td>
<td class="nump">$ 105,070<span></span>
</td>
<td class="nump">$ 56,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses relating to stock match</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod', window );">Number of months following change in control in which an employee was terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod', window );">Number of months following change in control in which an employee was terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="nump">106,500<span></span>
</td>
<td class="nump">54,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercises and purchases under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,800<span></span>
</td>
<td class="nump">26,900<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,048<span></span>
</td>
<td class="nump">$ 19,863<span></span>
</td>
<td class="nump">23,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Share-based Payment Arrangement, Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,828,000<span></span>
</td>
<td class="nump">5,378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,629<span></span>
</td>
<td class="nump">$ 35,675<span></span>
</td>
<td class="nump">$ 26,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Share-based Payment Arrangement, Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,168,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount rate from market value on purchase date (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Discount rate from market value on offering date (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536,226<span></span>
</td>
<td class="nump">534,419<span></span>
</td>
<td class="nump">483,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Average price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.76<span></span>
</td>
<td class="nump">$ 14.55<span></span>
</td>
<td class="nump">$ 12.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,715<span></span>
</td>
<td class="nump">$ 2,426<span></span>
</td>
<td class="nump">$ 2,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,027,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,056,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,853,210<span></span>
</td>
<td class="nump">693,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest', window );">Additional shares to be earned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,055,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,655,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,310,000<span></span>
</td>
<td class="nump">7,378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,428<span></span>
</td>
<td class="nump">$ 47,106<span></span>
</td>
<td class="nump">$ 4,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting award percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Share-based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,853,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Not Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesClinicalTrialResultsMember', window );">Performance Shares, Clinical Trial Results</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,327,840<span></span>
</td>
<td class="nump">1,926,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312020Member', window );">Performance Shares, Achieved Before December 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312021Member', window );">Performance Shares, Achieved Before December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_A2018PerformanceStockUnitsMember', window );">2018 Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of awards vested in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement By Share-Based Payment Award, Termination Of Employment Following Change In Control, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_AchievedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_AchievedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_ProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_ProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_NotProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_NotProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesClinicalTrialResultsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceSharesClinicalTrialResultsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_A2018PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_A2018PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273744754360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Weighted Average Grant Date Fair Value (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 9.04<span></span>
</td>
<td class="nump">$ 9.44<span></span>
</td>
<td class="nump">$ 8.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273743065256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.74%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.77%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.08%<span></span>
</td>
<td class="nump">0.79%<span></span>
</td>
<td class="nump">2.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273837840120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Summary of All Stock Option Activity (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of the year (in shares) | shares</a></td>
<td class="nump">16,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(4,486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at ending of the year (in shares) | shares</a></td>
<td class="nump">13,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of the year (in shares) | shares</a></td>
<td class="nump">9,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted&#160; Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">21.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">4.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">21.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at ending of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">16.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, options outstanding</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable at end of the year</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding | $</a></td>
<td class="nump">$ 48,860,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable at end of the year | $</a></td>
<td class="nump">$ 48,171,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742853944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Summary of All RSU &amp; PSU Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased', window );">Vested and released (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,020,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(750,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160; Average Grant&#160;Date Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted&#160; Average Remaining Contractual&#160; Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares)</a></td>
<td class="nump">1,027,650<span></span>
</td>
<td class="nump">2,056,000<span></span>
</td>
<td class="nump">3,853,210<span></span>
</td>
<td class="nump">693,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased', window );">Vested and released (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,388,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(736,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160; Average Grant&#160;Date Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted&#160; Average Remaining Contractual&#160; Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742010504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Estimate Grant-Date Fair Value (Details) - Performance stock units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="nump">$ 24.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of the Company's common stock on grant date (in dollars per share)</a></td>
<td class="nump">$ 21.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.29%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273739895912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 11,338<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">5,224<span></span>
</td>
<td class="nump">3,791<span></span>
</td>
<td class="nump">6,095<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">16,562<span></span>
</td>
<td class="nump">3,791<span></span>
</td>
<td class="nump">6,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">46,416<span></span>
</td>
<td class="nump">14,886<span></span>
</td>
<td class="nump">71,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="num">(578)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="nump">46,529<span></span>
</td>
<td class="nump">15,265<span></span>
</td>
<td class="nump">71,002<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 63,091<span></span>
</td>
<td class="nump">$ 19,056<span></span>
</td>
<td class="nump">$ 77,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273735722856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax provision at statutory rate</a></td>
<td class="nump">$ 61,772<span></span>
</td>
<td class="nump">$ 27,476<span></span>
</td>
<td class="nump">$ 83,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax (benefit) expense</a></td>
<td class="nump">1,336<span></span>
</td>
<td class="num">(2,232)<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">2,883<span></span>
</td>
<td class="nump">5,525<span></span>
</td>
<td class="nump">3,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(6,263)<span></span>
</td>
<td class="num">(11,356)<span></span>
</td>
<td class="num">(8,299)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(11,831)<span></span>
</td>
<td class="num">(20,399)<span></span>
</td>
<td class="num">(9,177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation', window );">Non-deductible executive compensation</a></td>
<td class="nump">11,182<span></span>
</td>
<td class="nump">18,067<span></span>
</td>
<td class="nump">4,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee', window );">Branded prescription drug fee</a></td>
<td class="nump">2,897<span></span>
</td>
<td class="nump">2,537<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="num">(562)<span></span>
</td>
<td class="nump">1,287<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 63,091<span></span>
</td>
<td class="nump">$ 19,056<span></span>
</td>
<td class="nump">$ 77,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273743180024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provision For Income Taxes - Schedule of Deferred Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 17,993<span></span>
</td>
<td class="nump">$ 37,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">101,460<span></span>
</td>
<td class="nump">126,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">7,764<span></span>
</td>
<td class="nump">18,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">23,162<span></span>
</td>
<td class="nump">19,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">12,385<span></span>
</td>
<td class="nump">11,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Accruals and reserves not currently deductible</a></td>
<td class="nump">19,531<span></span>
</td>
<td class="nump">12,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">8,040<span></span>
</td>
<td class="nump">7,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other assets</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">191,638<span></span>
</td>
<td class="nump">234,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(70,068)<span></span>
</td>
<td class="num">(67,185)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">121,570<span></span>
</td>
<td class="nump">166,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets', window );">Lease right-of-use assets</a></td>
<td class="num">(9,907)<span></span>
</td>
<td class="num">(9,510)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(657)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(9,907)<span></span>
</td>
<td class="num">(10,167)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 111,663<span></span>
</td>
<td class="nump">$ 156,711<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273739674888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 70,068<span></span>
</td>
<td class="nump">$ 67,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">83,583<span></span>
</td>
<td class="nump">$ 80,941<span></span>
</td>
<td class="nump">$ 79,078<span></span>
</td>
<td class="nump">$ 76,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would reduce income tax provision and effective tax rate</a></td>
<td class="nump">52,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">426,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TaxCreditCarryforwardAmountWithExpirationPeriod', window );">Tax credit carryforward amount with expiration dates</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TaxCreditCarryforwardAmountWithExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Amount With Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TaxCreditCarryforwardAmountWithExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742146104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 80,941<span></span>
</td>
<td class="nump">$ 79,078<span></span>
</td>
<td class="nump">$ 76,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Change relating to prior year provision</a></td>
<td class="nump">728<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Change relating to current year provision</a></td>
<td class="nump">2,215<span></span>
</td>
<td class="nump">3,305<span></span>
</td>
<td class="nump">2,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions based on the lapse of the applicable statutes of limitations</a></td>
<td class="num">(301)<span></span>
</td>
<td class="num">(2,033)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 83,583<span></span>
</td>
<td class="nump">$ 80,941<span></span>
</td>
<td class="nump">$ 79,078<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273745161912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 231,063<span></span>
</td>
<td class="nump">$ 111,781<span></span>
</td>
<td class="nump">$ 321,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">314,884<span></span>
</td>
<td class="nump">308,271<span></span>
</td>
<td class="nump">302,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="nump">7,475<span></span>
</td>
<td class="nump">9,730<span></span>
</td>
<td class="nump">12,425<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">322,359<span></span>
</td>
<td class="nump">318,001<span></span>
</td>
<td class="nump">315,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273745812056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Potentially Dilutive Shares of Common Stock (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share-based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities and contingently issuable shares excluded (in shares)</a></td>
<td class="nump">14,305<span></span>
</td>
<td class="nump">10,959<span></span>
</td>
<td class="nump">9,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273736249896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_options </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_options</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average operating discount rate used to determine the operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Future tenant improvement reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_HeadquartersLeaseMember', window );">Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend the lease | renewal_options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant lease improvements allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_HeadquartersLeaseApril2019AmendmentMember', window );">Headquarters Lease, April 2019 Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant lease improvements allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_HeadquartersLeaseDecember2020AmendmentMember', window );">Headquarters Lease, December 2020 Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant lease improvements allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_HeadquartersLease2021AmendmentMember', window );">Headquarters Lease, 2021 Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseMember', window );">Built-To-Suit Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend the lease | renewal_options</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Build-to-suit lease period</a></td>
<td class="text">242 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment', window );">Currently estimated amount</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage', window );">Annual increase percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod', window );">Payment commencement period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Future tenant improvement reimbursements</a></td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AreaOfRealEstatePropertyAvailableToLease', window );">Area of property available for lease (in squire feet) | $ / ft&#178;</a></td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts', window );">Percentage of excess costs</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod', window );">Option to terminate lease (after period)</a></td>
<td class="text">180 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AreaOfRealEstatePropertyAvailableToLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area Of Real Estate Property, Available To Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AreaOfRealEstatePropertyAvailableToLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Terminate After Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TenantLeaseImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Lease Improvements, Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TenantLeaseImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_HeadquartersLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_HeadquartersLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_HeadquartersLeaseApril2019AmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_HeadquartersLeaseApril2019AmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_HeadquartersLeaseDecember2020AmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_HeadquartersLeaseDecember2020AmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_HeadquartersLease2021AmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_HeadquartersLease2021AmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273742143848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Balance Sheet Classification of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets included in other long-term assets</a></td>
<td class="nump">$ 45,122<span></span>
</td>
<td class="nump">$ 43,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other long-term assets<span></span>
</td>
<td class="text">Other long-term assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion included in other current liabilities</a></td>
<td class="nump">$ 5,137<span></span>
</td>
<td class="nump">$ 3,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">51,272<span></span>
</td>
<td class="nump">49,086<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 56,409<span></span>
</td>
<td class="nump">$ 52,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273744814568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 5,332<span></span>
</td>
<td class="nump">$ 4,825<span></span>
</td>
<td class="nump">$ 2,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">2,685<span></span>
</td>
<td class="nump">2,830<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease costs</a></td>
<td class="nump">$ 8,017<span></span>
</td>
<td class="nump">$ 7,655<span></span>
</td>
<td class="nump">$ 3,868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140273739887208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 5,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">5,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">6,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">6,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">6,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">35,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">66,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(9,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Future tenant improvement reimbursements</a></td>
<td class="num">(426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 56,409<span></span>
</td>
<td class="nump">$ 52,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>exel-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:exel="http://www.exelixis.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20211231.xsd" xlink:type="simple"/>
    <context id="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79749347e30142e593fb3dd2087883ee_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i42b7e9e44a8149b69bfbe9366605fc00_I20220207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-02-07</instant>
        </period>
    </context>
    <context id="ia71123bf4ed74085ad4ac0a89679baa1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i048f2416fccc4e10b7965efb1a171533_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i890a097ba13b4d2aa44ba45c617df112_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81474236dfb14ff1ac531c41f5c16947_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ief6bfa79af1c49bbac2074ef89ab2c4b_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i31f5b5f30b734b15b1054bfb509ae021_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i23f991a8511f4c6bb78932ffbb88e05a_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i69ce00236de4479e9a6c6986301e7731_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="if5185d285db34c6d9e4c918f1420364c_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8016a7106ab5473891bf09f72524f38e_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i35edcd5425bb4e4f8597665dcf1e7e5b_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="if4d4436bfbe6489187e15748fba98eba_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6aefcca4ad074b29b6a51fd6d458319c_D20201003-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-10-03</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i9805c5e25eb64ed985d666f4c24de9ba_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i4d64ce6b48d24a04a0c93e22acd3904f_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i867ed8b4453c4a1a9044dab4bd539d50_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="ia8210e6b19c34f939af1ed9a98c8914a_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i396cffc473714e59a1c966a366a443e2_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="ie5a94021373d4840b95f6959bc4accd9_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="iff7c60d6d3b24087a7d0758be8cb1f5c_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i9883712cd8e1413e8d0219e4ed8aad8d_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ic73ea98630ee4a65b62bf4da8d1c3f41_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i3e8c40dbf5a94938b3a235b6331b0204_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i99338e5e4fa243d89959abbe305c1ddc_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i6020ec58ca0b4ac4b002e4acc9448876_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i012b294c4e2c4931a14f4be10ec2fe36_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i2d03c75ce0024c01a62fcd27957b4f04_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i0d4126cc2fa94615bd40a5daa4ef585e_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="id2944e77d8c04388810195fe26496810_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i7ccde781cd17461fb3e9f797e81654e9_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i0f7ff0b5436e42b3a597987061001835_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i4ce529a2e2894a0e92ed4a60ed0b95f9_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i8a546fb4a49e431a956a77f1680095df_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i4109c1b12d9d4433bb8db86bc3cae091_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="id655252138f44944870c02853be75c73_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i7ce7ca557f444499972aa47b8a85d655_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibd55184171ad45c8be33cab3d4171b5f_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i84b17fef833a40479881088e5855fc81_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac855e1b2d284da3adfcc70d50d6b045_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5ff5eb1df65416581656de05ef86494_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0dcdcda3fc10404397110c8f9aaa5353_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebee7996e33a4d07b3a22638e4c253b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib427a6bae515457884e12ccece2b4122_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i02820d73f6c54d589b048d50797c40a6_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ca33a540eff4370b1fd9baefd112b43_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1b9becbae9d413a818538229404c8e0_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6362d549434c4a3ebfb9ed76266ced8a_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ce7596693de4c309e4046ee44e221d0_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4442ea86bfb449ca9e6184c51952a1e9_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="iad06c636df9d4082a61cd0476a607cb2_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i0431c045c7b749419b8cb122e47b2fd8_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4d4c8762b46415b8ba90c8fc8e8bd01_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i2e8b773d3cd2476b9a6f98f0ec19f343_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i5511677067b74ebb913d887f52a2848c_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i10a667976104461cb71d5603b4d4af97_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ia9af17feaeb349989438dbf0d666ce00_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i2da812635cea4a9b9116e4146e6cdea4_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i17406e0670124dc6aa021883b5f49f2e_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ia06ec631ab45435d9aa467e475199d25_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i1f3560ad4cbe4f5fa9e33117ca1cc45b_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a39ad000947444189cd4862efda588c_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ie886e01e3e2442248812abddb9a3357c_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i802f06ff953349dcbd6e18868ae5c8ff_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a10a7f26ddf4e71ae1239be47deed9d_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i1e023361e8434930804854afbfdfd16d_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i82d9fb00ead242beaea5c7ba0738621a_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i23f80ed12dd445599bf289f8b30b88c0_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i0937e3d1b0e1474a8b6f5365e91705d4_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i55441d6740314dfba8168bd2502b1101_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i259af2d579ef48a689f2076724ddc735_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i594dc7db46f143248c87766268ac1585_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i0a26379cbf1740a7a0004b7311e38cc3_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b64a741d8eb4bc7bbac3a5db68a20bf_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ib21e644bf9d94035b284ae2d64be8538_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ica4c1bf73b7a497ea0f0cf3ee3121416_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8fa15b9421324d2a8abcc78e7bf8af23_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i829c8635dc1a41a8867b90164ddc5c42_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i1a81f07947fc466f9ec4626bef20395b_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iadbe770de5cb48ad8f72003a3c009cde_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i8b058fe448f6453eb17990c3983c40ce_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4e8a704120c54d7d9733625903a75c0a_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ieb7ad7b5987c4c759bd3da195cccdda9_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6bc15983150c43b49a8bcd610f1d7622_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i5510c7d658a0420fa7c4fd22f06b733d_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1d553018b3f4e6ea41bdee893c4681c_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ieb41f135273846d2a5abf0e5b9d0f811_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56b939a4e3604e77961f68608050b413_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ibdceca8137604720b9dfc7e6e415d661_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i985f069de23b4373be549c007d2be40a_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ie4c022e03b6b47659fb5320a00e0aff4_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i64d8b101cb28463dbafce9a36192a9ec_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82c4a22039764f45bfeb541853e2006b_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i49d04f48075d4d9e9f242c365cff4b71_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i2625931db6f641d1b8631cee45c5421e_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3cfec9cb4d04224a58db1a0560d4779_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i0f60afd811e645cc996074e0cd13ebbc_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ie2cf41534cf94f309749ad6b44872d98_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ic57cbc70ed644ce9845fcfed669b497f_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i0df0a5ea74244280ad89970ab96c16ea_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ib3769502a95e4f3684d2ef761cae6724_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ief35aa55eff1427188342697996d37a8_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i8d6813dbf9b54533b3a13aa017eea398_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ib163363f39ee47a1982ba34ffc40df1c_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i4afda954bcde4a2d8442e84ea5f75854_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i08840e0ec9404f91bb1ed1e90793003e_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i397c48f49ccd409781be83e43c34403b_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0fd2c26c82744565a4a050d7c6936320_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4bf39a5ebec49a9b8c7c07b6ba5968f_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3093413adbae48879b92be020f6b4f95_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i759ddcce81f44cffa575713b1c443bd0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4de04499606844f9a42cd833027456e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7706be95a9254624abab7ee85d40a352_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i17d251f0fc574727b702a0a5caffb000_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf154a58f6564ff1becceb69660b10e2_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i6b9226f40009479393c872a6348134a4_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i63e4041671b44fd599695a551a6412e2_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ief888e56632141638b8427491992f9d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id33282d755fe4cb187a33fa5ce4b49b5_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4bf5c222f64a420686d2836dfecb6b8a_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b9b091c2fe54910a111a558a4e92d80_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i648d323ea30a42229de3c89c4cb186d1_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ic25f4e281d6f4588b0be1be89c974405_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ib32003bccc214ae19d1adc2aa36ec6bc_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="if22970cfc6004d70bfd9ff40c42079f6_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i34b71d32c3af4d2c99a249ce89216823_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idf4b8b36a8a1401ba536bf1da7af7544_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i38b1163356184b27816cbad77cdf95c1_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i1538f2b66fd943739c868b40f8b82675_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i942a6148cba44afbb7ce565e8f31caa4_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i3d7a173be1fe468581278e8058aaa8ce_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ic3c4c0bb7d7c4d5ca6fcc41491abf1d5_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c892d9cb5bb4832a7807f3de3873c13_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7de05268deff4e19bf1b0d6402584ef5_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia18f9c05acb24284aaefe29c49159029_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d5c9f1076cb460cb26ed364b3298866_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i80cf15e8b90b415da4f4ddf22cf5de86_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7549b7123a984430b1eeb8ed0453f49d_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i5bbf116ba95d4f99b046b08cf6886f20_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i88285abefe55431da86d133798712f97_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idfa84e1a7dfa4fe394d99b30db90a03d_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i323181841f1447e19487c305609f6987_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i8c3ac03ee7454b6cac8c397afd4482c4_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i40846f2291b646d0925baa2444ab430c_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="id1f0fc047c9c4e42b491251f2246216c_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i52b8f7772fdd4b28b6761a4c19816e52_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ae90a8873dd4429b24fbecb4ac765cc_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ib5410770ddf84f099461a42667531965_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i7c1a218589024464b368812dcad02030_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i719737a56e4940dbaa44028a2131e87c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17469019aafd4e60b3681951461b5e32_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i248a08fc00de455a8ba90662b6913cf3_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i845d978e80a94a059981545b4eaedc37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b021f45a0fa49c89d6035c19eaadbb3_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:CollaborativeAgreementWithGamaMabsPharmaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i80195f3436714ec884ca333c40f2ee26_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:CollaborativeAgreementWithGamaMabsPharmaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="ia542815387ba453f9fd900fe25937400_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i839b859fbed548e38efc5fce9e64593a_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib5a2784ff7d840bb982a4bc7823f075a_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="iad9dc6f5753a41ed9d96d235cc5108ba_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i05641e68bc9f435c9afd7cdec45e36aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ff13830445e478385149192df956f88_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23bea1dd75274b42a74758ecc6636623_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2a61bcc4c3649f59f6a080941f4f893_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic64b739b318847c59da0eae266f9d1f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a311ca42562471db4f27e25d6d36db3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i602bcc576371462380cb7add7c08ac3a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iba29b67627794a5d9e0a76791c683b2e_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i59895032150e486295f216709b152e49_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i8be401936c61402c92d2967c8b58ca3b_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iee1391eefb1148f5911a99610fca2132_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i2243e5b1033e41bfa89446b83583a6e5_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i9d6624d1a18a4542beeee361e4b2e980_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0e000d5830443279e6e124a4a3d90d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ed69927364241c79f4eb66d77b1b1b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0119576597c942bdb66a97f6e76ccf98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41e5087e044b46b29140a50002f1b602_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icda5e1974a7947e9b26e6b6e44e0d15d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2a433ba7c0841bc8a3e6d4e20f17f7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00dab545a5c24f8dbd1d9cc27963df2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5653f5a5eb54376bc10cfab4779dffe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f237af0ca95413b867a2e778f5fca0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa6e56eab91648cb8e0e757751bd275b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f12d2d69a4a4b56b51d7aaed03de152_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7258799b1a84728ace446b81f5e78f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2f80e9affa24a878bb82bc127dda141_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ccf77987385492998beaa7a87e03520_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d31a47bdaf94ea5ae092cf7132fada9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1abd401dbcc74a548779de9fef26b749_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia52a40c4b843407a840ac64aba523a6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93fadded2a81419dbf152f6fb044f9b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf16f215bd6842bd888163d7cadeea0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc382618cb454f7599202e9cac5b81e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea02ce752e444b2a83abe7a10a418b16_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="icf02d3488e39407e8c46e5743eff50d5_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i795179da2aab43418fa6db779e91263a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i57679c13f2684cdd9f8cd6fd98ab8756_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="id320ab8c9604499fbad568b50ccc1165_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i4b54dd876a1f4562af4c3afa7aa2048a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="icfbde743d8914198ab03af7fe8139476_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i427be21f708a40d28d6462416ac218ee_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i2b0e966652f44398a8c2e0a70b2baef5_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ia54c8642ecfb409e951b6239615168c9_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i1463aefcf3c149bbb077c0d3005c9401_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i45ebd9c173484d88a6e494342999d3be_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i0b7e323ee87c4f05bfdbb7c4c7e201cd_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i9b3c6f3004bc4c89bcf1c9c12bd459ea_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i0c51f12115f14ed1b61d2747c01ae661_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ib769eff617c64124810ebe511d945893_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i3268bbdfa0414552b47fa9a338981cb9_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ia1eb5b5c04cc43349b70b9321ebc782f_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ic984d9c89f24479a89d0d07b78b1cdaa_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="idfd60ccd881041a5ac4297dc0b25b292_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i2d7389a754974512a4e774e51ae8a974_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ibd92c80358ee496096d3c673a7de6191_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i746a14780d0147c7824e0bef77b916db_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i4dd7d2bd3e3e490fa8ce9475ab03c7f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0471012a562a4c27b88456f2732a0744_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i3886df95730147449641343484c7d238_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ide48db818a80458abbca38f5ab70bdd1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f085c7986f04f109f77b9011f31264d_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i8b4047a98c284e9286babc06d5858821_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic5c9cdc8841b46d8adc324d34793217d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a99337c2ce04dcfa30ad4ccee42117a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6230988b2ca747a8b89fd3cae1298175_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i178f5c4c23ca48a38655383d6e5977f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id73f4cd7fcee499eaf78ce808bb71d03_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i248ba0f7c8cb4181ad74bb080d0aeca1_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i935b27fac1984932861fb968e47b9877_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ec14dcaa36142b2a22ec45b2e3e2493_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i73ca698aa2a74a4e937a5a3b1de87b32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1089920ccded4380b0fbc39e750f1eb7_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6b96bd3389d2490a8a78bc00fddfe7ce_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife6c6471ca35413da83fd2469f9c00a1_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i38d5186b034a4d0999fca6ecb2ec9ece_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ibbb974755c29460293662406b5c181e4_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f33a19a84a140d380dc777b506fc9ba_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ifecb0e7726f341c6ba6992570d045296_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i810b03546f7b400baf8f30d8a400ff09_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ibf28ef3d9ddd45609325a52b344679e7_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76a39cce3d904d388c3adad8a7bfed10_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i7abafca0ed6e40f88895c38bb6b81247_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="iff13c02dcfbe458cb3a8363106ef81dd_D20200520-20200520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-05-20</startDate>
            <endDate>2020-05-20</endDate>
        </period>
    </context>
    <context id="i940612d122c84082acb652dba5991c69_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34532b015c584cba952c0caa678ee2fd_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib08f62d50d8d4c1793cae2caa25a90ec_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id6d6926fdea445e7a6ebdc4a3ba1f78b_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b29032b66954a8db9da85d19b1be6a2_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie93bf1a0871644278ca4b892fe456191_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85c17b70c74043af9b0e2017ab4409e8_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i1d0c6bc2e80b4232ae06f54a57a62638_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ib29b3c5e0f37409da408786f8267b076_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74355fce090d4783894ca8f36c2a26dd_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i4c4744c0eeaa4ef89dc73f7f709e54b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fa59b8b15c4457ea85611acce275f22_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="if0c146506a74415eb481d9e61dae42b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i838b498a0efd4d9d9f799adee2661362_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1ad4423cf59549fa83e3e98aa40b0aba_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i74e6a3ef845a4a2c9ac7e354707c8e1f_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ieac0ed4a145142fcaad1faa3308fe4da_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesClinicalTrialResultsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i18d80baf7ec441d59bd2914f26cc7048_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ia1182bc4873c402f9d17b55ecb40b430_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesClinicalTrialResultsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="if6856ab9da0245a0b58e4a5a9d78c7c1_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesAchievedBeforeDecember312020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i7e812dfe05ab46da90f8b209737fba1e_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesAchievedBeforeDecember312021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i96ebe2ef748948f0a75ba0527c466487_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i58f94a8c90d4404fbf57c14383810126_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:A2018PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="iad0a49c0e2794ae58f9a3ccbe473b7fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1cca4ef6d104b9db13688910f87a10c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf4e68b211e4463fb19f878a36d3a54a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:NotProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i420a84572c824730897fc79711ca81fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if84d627e667d48f29f5af7ff692d0370_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b39280de5b64a109031af851502c539_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13ee6cf1e5c848d2b6f0a4bd3a76af26_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i345c9b326f5c4c488b5009d48f08f45f_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i045cc234fe6d42e29ebae3f4719abd7e_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ia8b2c55942a54b85b0a416b604b6a2b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70af130f4dae44efb4c5edbc61ae24bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLease2021AmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09d02a3201ea4cd9abf78408a6c51ddc_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia7f4ccf1863646c7ad5275dd80a4cbd4_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="ib15b9dd84185469e883fb78ad72ac110_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseApril2019AmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3b3d07f431b4ca096bce3b9f83ca347_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseDecember2020AmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1ee46f49349499882d7dd859933eb48_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i2e77e8a209894b9ea42d468fd28563b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7054208b42f440b38822d84184f73e38_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="country">
        <measure>exel:country</measure>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="derivative_instrument">
        <measure>exel:derivative_instrument</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="renewal_options">
        <measure>exel:renewal_options</measure>
    </unit>
    <unit id="usdPerSqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF80L2ZyYWc6OTc0Mzc2NmQzZjdiNDJhN2FlOWYwMWZhMjU0NTNhMTIvdGFibGU6NDVjNjRkMjU0OGMzNDNlM2E3Y2JhNDA3OWI1YmFlNDMvdGFibGVyYW5nZTo0NWM2NGQyNTQ4YzM0M2UzYTdjYmE0MDc5YjViYWU0M18yLTEtMS0xLTI1NzM5_878e1b87-4310-4548-b062-0d2011688c54">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF80L2ZyYWc6OTc0Mzc2NmQzZjdiNDJhN2FlOWYwMWZhMjU0NTNhMTIvdGFibGU6NDVjNjRkMjU0OGMzNDNlM2E3Y2JhNDA3OWI1YmFlNDMvdGFibGVyYW5nZTo0NWM2NGQyNTQ4YzM0M2UzYTdjYmE0MDc5YjViYWU0M180LTEtMS0xLTI1NzM5_840bc647-7fc5-4951-883e-2c50eb9786a4">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF80L2ZyYWc6OTc0Mzc2NmQzZjdiNDJhN2FlOWYwMWZhMjU0NTNhMTIvdGFibGU6NDVjNjRkMjU0OGMzNDNlM2E3Y2JhNDA3OWI1YmFlNDMvdGFibGVyYW5nZTo0NWM2NGQyNTQ4YzM0M2UzYTdjYmE0MDc5YjViYWU0M181LTEtMS0xLTI1NzM5_8d33ec1a-02d8-4aba-a968-464758c9f24a">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF80L2ZyYWc6OTc0Mzc2NmQzZjdiNDJhN2FlOWYwMWZhMjU0NTNhMTIvdGFibGU6NDVjNjRkMjU0OGMzNDNlM2E3Y2JhNDA3OWI1YmFlNDMvdGFibGVyYW5nZTo0NWM2NGQyNTQ4YzM0M2UzYTdjYmE0MDc5YjViYWU0M182LTEtMS0xLTI1NzM5_71562e9a-0eb9-47b8-ad01-126a08b6fd83">0000939767</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_7a0e4465-a6b5-4b02-b58f-7014879a369f">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_dc2f3847-52aa-4192-8d7c-2b18b469e239">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_5d4462a3-e4ad-42c2-8f32-f51e009f8ca0">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_ae5d588d-a5da-417a-8318-ddd0d907793d">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6YmFkYzVjYWRiMDU3NDI2ZDk3M2IwMzVlNzg0NTAzYmEvdGFibGVyYW5nZTpiYWRjNWNhZGIwNTc0MjZkOTczYjAzNWU3ODQ1MDNiYV8wLTEtMS0xLTI1NzM5_8ccc0a83-a238-48f8-9ac2-6ab60da473bf">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTY5_6365c179-7f8e-45fa-aa8d-cda21d54ddfa">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18xOTQ_e9899c78-0497-4b45-abfc-1c743211bfc1">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18xOTQ_7527d47e-9ae2-420b-92b2-8aec6d3c5590">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTcz_2c56a141-8348-4d2b-9e19-f28d5e92f236">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zODU_916897d9-5290-4eb4-9099-f5dc941bf21f">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6OTljZjdlMjI4MzBhNGQwODlhMGQ2Y2IzNzg2ZWUwMWUvdGFibGVyYW5nZTo5OWNmN2UyMjgzMGE0ZDA4OWEwZDZjYjM3ODZlZTAxZV8xLTAtMS0xLTI1NzM5_c8aea761-f3ca-48e4-abc9-f9758105014c">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6MWJhYWQyZWNjYzNlNDdiYmEwNDY3MjQyYThhNjQ3MjIvdGFibGVyYW5nZToxYmFhZDJlY2NjM2U0N2JiYTA0NjcyNDJhOGE2NDcyMl8wLTAtMS0xLTI1NzM5_c8e2014a-4ed2-4c16-9b61-71d8b08d86d4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6MWJhYWQyZWNjYzNlNDdiYmEwNDY3MjQyYThhNjQ3MjIvdGFibGVyYW5nZToxYmFhZDJlY2NjM2U0N2JiYTA0NjcyNDJhOGE2NDcyMl8wLTEtMS0xLTI1NzM5_26b23738-db9d-44a3-8c44-afd8d05b844b">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTU_9b2d0a0c-bcff-430e-909c-cbe344295904">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTk_76aae436-447f-4868-a10d-be68b6dce7b2">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM180MDI_cc1b2cb2-25b3-47c8-8a22-4a5d89fc8d45">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM180MDU_0a91ce8e-ca0b-43b3-9c79-5b2f9a3446f2">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM180MTA_69110b24-b0e8-4a3e-8ea2-7bdc17d51600">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM180MTQ_3e17aba7-7721-49e2-bb45-93001e0666ee">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6MjNkMTc1NTA1NmZhNDBiMTllYWNjODY4ODdjMjMzZWEvdGFibGVyYW5nZToyM2QxNzU1MDU2ZmE0MGIxOWVhY2M4Njg4N2MyMzNlYV8xLTAtMS0xLTI1NzM5_6d7aafdc-f08f-446b-b5fb-ed45e7853fd2">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6MjNkMTc1NTA1NmZhNDBiMTllYWNjODY4ODdjMjMzZWEvdGFibGVyYW5nZToyM2QxNzU1MDU2ZmE0MGIxOWVhY2M4Njg4N2MyMzNlYV8xLTEtMS0xLTI1NzM5_342e7bd3-9f00-4d8a-9d20-94eaedffb2ef">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6MjNkMTc1NTA1NmZhNDBiMTllYWNjODY4ODdjMjMzZWEvdGFibGVyYW5nZToyM2QxNzU1MDU2ZmE0MGIxOWVhY2M4Njg4N2MyMzNlYV8xLTItMS0xLTI1NzM5_bca6e70d-66f0-4db2-aeb6-1eee3c712086">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTY0_3042264f-7615-4744-b478-d11750063828">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTcw_b6625946-5f41-45e9-a72b-be8be3d464fe">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTY1_da9d2bdc-b0af-4b72-bbae-c7987bc29cdd">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTcx_cb6a9cab-083e-460e-8bfc-09903b031c69">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6YWI5NWU5ZGNlNzdmNDkwMTk0YTAwZjYzNjhiYmUxOGMvdGFibGVyYW5nZTphYjk1ZTlkY2U3N2Y0OTAxOTRhMDBmNjM2OGJiZTE4Y18wLTAtMS0xLTI1NzM5_784265cc-bd73-47b5-98f2-37d7f35fea44">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6YWI5NWU5ZGNlNzdmNDkwMTk0YTAwZjYzNjhiYmUxOGMvdGFibGVyYW5nZTphYjk1ZTlkY2U3N2Y0OTAxOTRhMDBmNjM2OGJiZTE4Y18xLTQtMS0xLTI1NzM5_dca6f3e6-ac10-41ec-b3bc-4e5c770e4792">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGFibGU6YWI5NWU5ZGNlNzdmNDkwMTk0YTAwZjYzNjhiYmUxOGMvdGFibGVyYW5nZTphYjk1ZTlkY2U3N2Y0OTAxOTRhMDBmNjM2OGJiZTE4Y18yLTQtMS0xLTI1NzM5_83f2edd8-9731-49ed-9fd8-2de03205e698">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTY2_d43a6770-45c4-43e1-81fb-5a78f2516c26">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTY3_da1271e4-a851-45aa-a09a-139514c3c4b8">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i79749347e30142e593fb3dd2087883ee_I20210702"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18yOTk5_a17fce87-e2cd-4229-8093-46ef98dd22bf"
      unitRef="usd">5680065864</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i42b7e9e44a8149b69bfbe9366605fc00_I20220207"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zNTkz_0130330a-90bf-415b-a2c0-b855508c9ce8"
      unitRef="shares">319448174</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xL2ZyYWc6OTUxZTVlMTQ3NGRhNGExZDk3NzlmY2MwZmQ1MjAyYzMvdGV4dHJlZ2lvbjo5NTFlNWUxNDc0ZGE0YTFkOTc3OWZjYzBmZDUyMDJjM18zOTcy_4b78e0cf-fff1-4ef7-ad2d-07b66d0c5c21">Certain portions of the registrant&#x2019;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than April 30, 2022, in connection with the registrant&#x2019;s 2022 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF81OC9mcmFnOmZmMWIyYmFlZWU5ZDRiNjg5NDFmYjI1NzZhZTc3ZmIyL3RhYmxlOjZhOWQyNDdhNWZlMDQ4NmJhYjU3MTAzNmZkODg0N2RmL3RhYmxlcmFuZ2U6NmE5ZDI0N2E1ZmUwNDg2YmFiNTcxMDM2ZmQ4ODQ3ZGZfMS0wLTEtMS00MjcwNy90ZXh0cmVnaW9uOjljZWFhODQ1Yzg0YjRiODY4YzcyNTQwYjMyNmFmOTJmXzYwNDczMTM5NTI5ODM_9e593fa1-5c1a-4d4b-9c71-32a259653196">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82MS9mcmFnOjliZmE1YTQwMGFlYzQ1ZTlhOGNkMDI1NzMxYzNjYTQ5L3RleHRyZWdpb246OWJmYTVhNDAwYWVjNDVlOWE4Y2QwMjU3MzFjM2NhNDlfNjA0NzMxMzk3MDUzOA_2aad73da-c51c-4b78-9fa8-ec47121dc3cf">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82MS9mcmFnOjliZmE1YTQwMGFlYzQ1ZTlhOGNkMDI1NzMxYzNjYTQ5L3RleHRyZWdpb246OWJmYTVhNDAwYWVjNDVlOWE4Y2QwMjU3MzFjM2NhNDlfNjA0NzMxMzk3MDUzOQ_88e64418-1427-4647-b1a8-0480caa75909">Redwood City, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNi0xLTEtMS0yNTczOQ_1dfb53d8-3993-4513-a9e3-4fcf0bd6b409"
      unitRef="usd">647169000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNi0zLTEtMS0yNTczOQ_56cb6928-3e6f-4dbc-8a16-e74ff4be9f4e"
      unitRef="usd">319217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNy0xLTEtMS0yNTczOQ_2cb0a842-e8c1-4249-9422-4a885e546ee3"
      unitRef="usd">819905000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNy0zLTEtMS0yNTczOQ_b5b9816d-f6ea-4902-a729-3beef9aa1b1b"
      unitRef="usd">887319000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfOC0xLTEtMS0yNTczOQ_8881ac8d-3f07-46eb-87bb-030c294b6b99"
      unitRef="usd">282650000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfOC0zLTEtMS0yNTczOQ_6cbd578b-1a00-4e1d-b284-940c5aab3765"
      unitRef="usd">160875000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfOS0xLTEtMS0yNTczOQ_4ab3dfc0-c71a-47b2-83ed-eb4108f1857b"
      unitRef="usd">27493000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfOS0zLTEtMS0yNTczOQ_c0ce2a77-4bf6-4658-b06e-d74f595121cf"
      unitRef="usd">20973000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTEtMS0xLTEtMjU3Mzk_049806b5-bc96-4a1a-8e61-2f829cf7d6ba"
      unitRef="usd">57530000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTEtMy0xLTEtMjU3Mzk_fe4030af-2a68-44ff-815f-ce1a3f8e0195"
      unitRef="usd">57011000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTItMS0xLTEtMjU3Mzk_258c906a-7938-46be-b944-bfa2371b8911"
      unitRef="usd">1834747000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTItMy0xLTEtMjU3Mzk_45dd5956-94fc-4ac7-acbf-faa644f12134"
      unitRef="usd">1445395000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTMtMS0xLTEtMjU3Mzk_125d4740-b928-4e3a-b87e-f190bb297ab0"
      unitRef="usd">371112000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTMtMy0xLTEtMjU3Mzk_7bb537cd-72b8-4640-a1ea-610cfc4d182a"
      unitRef="usd">330751000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTQtMS0xLTEtMjU3Mzk_69c1c3ae-ffe3-41a8-9407-fc6af030431e"
      unitRef="usd">104031000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTQtMy0xLTEtMjU3Mzk_e247d190-0cd3-4416-9fde-8e34158fd8ab"
      unitRef="usd">67384000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTUtMS0xLTEtMjU3Mzk_93bf3888-6355-4e62-a1c2-74f950efdb6a"
      unitRef="usd">111663000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTUtMy0xLTEtMjU3Mzk_8792d4cd-3ab8-4dc6-86f4-d9a5d726e7c8"
      unitRef="usd">156711000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTYtMS0xLTEtMjU3Mzk_3e55b267-62c1-40e6-b4d2-637e0df88dd4"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTYtMy0xLTEtMjU3Mzk_3c876e0d-d326-449a-a784-2c07856e9e07"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTctMS0xLTEtMjU3Mzk_de6fd91d-0a2a-4475-b1c6-e0cea6c6967b"
      unitRef="usd">131002000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTctMy0xLTEtMjU3Mzk_f5905f39-44de-4358-be57-1d12663051a2"
      unitRef="usd">73408000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTgtMS0xLTEtMjU3Mzk_a3cb295c-fa24-483d-a57c-4fd01d660289"
      unitRef="usd">2616239000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMTgtMy0xLTEtMjU3Mzk_8dcde3ec-e84c-4664-bf2c-cb4773ce3de6"
      unitRef="usd">2137333000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjEtMS0xLTEtMjU3Mzk_d16c3150-a4f2-4c8b-b952-cd0d0055b578"
      unitRef="usd">24258000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjEtMy0xLTEtMjU3Mzk_d05ceee6-954d-4c81-ae89-efc46a6c704c"
      unitRef="usd">23632000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjItMS0xLTEtMjU3Mzk_d4c426fa-0880-4c70-b92f-fd1caa3cd71c"
      unitRef="usd">61969000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjItMy0xLTEtMjU3Mzk_810eb5a9-7211-4f72-89da-556ec6312146"
      unitRef="usd">51189000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjMtMS0xLTEtMjU3Mzk_aa558a47-f9b5-463b-b0fd-a00444ae2e5a"
      unitRef="usd">77544000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjMtMy0xLTEtMjU3Mzk_216c558a-7894-41d7-a331-1c77ba062ca6"
      unitRef="usd">52251000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjQtMS0xLTEtMjU3Mzk_ef61b14a-6a43-4b74-9e05-ceaa9a819ce5"
      unitRef="usd">33700000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjQtMy0xLTEtMjU3Mzk_0de1a269-2349-4e1d-9a66-dacd39d22c7a"
      unitRef="usd">20683000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjUtMS0xLTEtMjU3Mzk_e7f15412-5e2e-429c-823e-6ad4105292c6"
      unitRef="usd">86753000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjUtMy0xLTEtMjU3Mzk_65f1f7cf-1b9f-4e7d-bbd2-74a72ebfef54"
      unitRef="usd">12456000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjctMS0xLTEtMjU3Mzk_4416b5f7-8cbb-451d-b46a-2c9ca0a52819"
      unitRef="usd">53366000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjctMy0xLTEtMjU3Mzk_7160b599-261a-4f06-8325-b0ea4659bef6"
      unitRef="usd">44447000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjgtMS0xLTEtMjU3Mzk_09f89234-c30c-4af6-be69-abe172101a9f"
      unitRef="usd">337590000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjgtMy0xLTEtMjU3Mzk_4f319852-379a-427b-a07b-098b45113cc3"
      unitRef="usd">204658000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjktMS0xLTEtMjU3Mzk_fad9e3a3-cf35-4e25-901a-e49628584313"
      unitRef="usd">8739000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMjktMy0xLTEtMjU3Mzk_f6f13c8b-36b3-4091-8097-9021916f9fcf"
      unitRef="usd">3755000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzAtMS0xLTEtMjU3Mzk_56941edc-7112-4fb8-9d63-ab635d5aa88b"
      unitRef="usd">51272000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzAtMy0xLTEtMjU3Mzk_bb3f2269-4f8d-4d79-b2b2-20163d13fc23"
      unitRef="usd">49086000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzEtMS0xLTEtMjU3Mzk_cb64106d-fe2e-4dc3-b22c-242941141a45"
      unitRef="usd">8023000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzEtMy0xLTEtMjU3Mzk_17df630a-ae4f-43b0-a542-0ef15524124d"
      unitRef="usd">721000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzItMS0xLTEtMjU3Mzk_14c361ee-a0a8-4ce6-839d-ec7df26911e7"
      unitRef="usd">405624000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzItMy0xLTEtMjU3Mzk_5eb3a4f1-dffc-46a2-b0f4-8e4931e7974c"
      unitRef="usd">258220000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzMtMS0xLTEtMjU3Mzk_efa2ca68-7bb5-4cab-afbd-efeb6b5650d2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzMtMy0xLTEtMjU3Mzk_48c4b64f-9b97-4282-92d8-18af70e59e19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpmYzBmZmIwMmMyZDE0MmYyODkzOWVmMWY5MDExYzFhNF8yMQ_08b579ad-9015-4037-a464-055b01ebf271"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpmYzBmZmIwMmMyZDE0MmYyODkzOWVmMWY5MDExYzFhNF8yMQ_e93a6e82-b8b1-409a-a1df-53b45dad86de"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpmYzBmZmIwMmMyZDE0MmYyODkzOWVmMWY5MDExYzFhNF8zNQ_29218d86-a733-494c-bf3c-8a023a802947"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpmYzBmZmIwMmMyZDE0MmYyODkzOWVmMWY5MDExYzFhNF8zNQ_9c92b8ac-df28-487f-821a-ea3ce64d19ba"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpmYzBmZmIwMmMyZDE0MmYyODkzOWVmMWY5MDExYzFhNF82MA_c6d7a1a6-2ef1-4578-9616-4ad0ec8f11bd"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpmYzBmZmIwMmMyZDE0MmYyODkzOWVmMWY5MDExYzFhNF82MA_f5f2d8d3-4ffc-447e-a3cf-f98dc6b404ab"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMS0xLTEtMjU3Mzk_e153c552-76af-4781-85ee-3d73ed867621"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzUtMy0xLTEtMjU3Mzk_f7794b8b-0938-483f-a0ce-5e2b6f66ecd2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF8xOA_64542db4-fd54-4713-b9d7-a15f655fb9c8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF8xOA_cbf7d80f-3ecb-46f7-bc8c-18daed58641c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF8zMg_019c8a59-0089-4be0-95c3-b37126c7a49b"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF8zMg_e8e3fa62-dc34-42d8-a30a-45061a41776c"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF83OA_27dce633-5aef-4982-8db9-db9fb1a0786f"
      unitRef="shares">318842000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF83OA_9eeee5a2-d8f4-4806-a912-e61ef8a81756"
      unitRef="shares">318842000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF84NQ_4090fa26-1a66-4754-bcec-e34039cf9c17"
      unitRef="shares">311627000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMC0xLTEtMjU3MzkvdGV4dHJlZ2lvbjozNDE2MDVlNDYwZTY0Y2RjYWNkN2M3YzhiZjFmZmU3ZF84NQ_a9cc6cb3-0680-4c55-b9cd-e24b2367432d"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMS0xLTEtMjU3Mzk_57649489-6c87-4324-b1ec-efa04a7cda22"
      unitRef="usd">319000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzYtMy0xLTEtMjU3Mzk_73554caa-a047-4d5a-af6c-178eb2c4816f"
      unitRef="usd">312000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzctMS0xLTEtMjU3Mzk_92f129cf-cb58-460f-9459-41176070f37c"
      unitRef="usd">2427561000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzctMy0xLTEtMjU3Mzk_943a1845-9bd6-46d7-aaea-5a0062ce84b2"
      unitRef="usd">2321895000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzgtMS0xLTEtMjU3Mzk_ab88a867-11b1-4c3b-b7b8-b421e6df28e0"
      unitRef="usd">-758000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzgtMy0xLTEtMjU3Mzk_04f4e833-c932-4e2e-8c5d-8504719f532d"
      unitRef="usd">4476000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzktMS0xLTEtMjU3Mzk_780f986b-f883-45e3-84b6-e0b76ab50691"
      unitRef="usd">-216507000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfMzktMy0xLTEtMjU3Mzk_afdf665d-e7a3-4437-a82a-7881e52aae2a"
      unitRef="usd">-447570000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNDAtMS0xLTEtMjU3Mzk_c06bcb8f-1e76-4e66-9b4c-ed741a106403"
      unitRef="usd">2210615000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNDAtMy0xLTEtMjU3Mzk_ff646de9-8e7e-45f1-bcef-c710f84a0133"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNDEtMS0xLTEtMjU3Mzk_8f614ffc-5731-4304-9ee4-1d8eaa769455"
      unitRef="usd">2616239000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82NC9mcmFnOjEyOGFkODY2MDVkYjRhYTFiZjg1MDYxM2IzNTU4YzcxL3RhYmxlOjA4ZWYyYTdlMjVhYTRjZWVhYjhiNGQ3YjEzZmFmOGE2L3RhYmxlcmFuZ2U6MDhlZjJhN2UyNWFhNGNlZWFiOGI0ZDdiMTNmYWY4YTZfNDEtMy0xLTEtMjU3Mzk_c88782b0-7f89-4b8f-93c1-341109d1081c"
      unitRef="usd">2137333000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i890a097ba13b4d2aa44ba45c617df112_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMy01LTEtMS0yNTczOQ_089ee80f-a944-41cd-ae48-f04fd5b135eb"
      unitRef="usd">1077256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81474236dfb14ff1ac531c41f5c16947_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMy03LTEtMS0yNTczOQ_45797d43-e52d-454c-9dbe-40b3eed8e716"
      unitRef="usd">741550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief6bfa79af1c49bbac2074ef89ab2c4b_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMy05LTEtMS0yNTczOQ_ca0e978a-609c-446c-b3f1-9f7b9b6f9fc6"
      unitRef="usd">759950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31f5b5f30b734b15b1054bfb509ae021_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNC01LTEtMS0yNTczOQ_a76a7ad9-62ed-4342-a3e6-ed13690fa5f8"
      unitRef="usd">249956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23f991a8511f4c6bb78932ffbb88e05a_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNC03LTEtMS0yNTczOQ_e0093d0a-6d8d-4890-8d9b-863d8b7cd29d"
      unitRef="usd">167295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69ce00236de4479e9a6c6986301e7731_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNC05LTEtMS0yNTczOQ_d06f031e-7998-479e-863b-885cab836319"
      unitRef="usd">165914000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5185d285db34c6d9e4c918f1420364c_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNS01LTEtMS0yNTczOQ_381474ae-b46d-4839-b26e-91c442c7be4b"
      unitRef="usd">107758000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8016a7106ab5473891bf09f72524f38e_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNS03LTEtMS0yNTczOQ_9d0e04ca-f94a-4585-95bf-803e3da9ff1c"
      unitRef="usd">78693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35edcd5425bb4e4f8597665dcf1e7e5b_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNS05LTEtMS0yNTczOQ_28a56a09-3347-4845-9365-585fdf44720b"
      unitRef="usd">41911000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNi01LTEtMS0yNTczOQ_3214d4bd-db52-4442-a55f-819bb52b0d9a"
      unitRef="usd">1434970000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNi03LTEtMS0yNTczOQ_d2f6e443-5e77-4278-951d-c452e8ec367f"
      unitRef="usd">987538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfNi05LTEtMS0yNTczOQ_c0d6a82c-37b3-4abd-abef-c1ba5eb1a105"
      unitRef="usd">967775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfOC01LTEtMS0yNTczOQ_46888da1-3667-4ad8-9bc9-ee7b23f9ea12"
      unitRef="usd">52873000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfOC03LTEtMS0yNTczOQ_bc8cd585-50c0-4663-a826-abde17847895"
      unitRef="usd">36272000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfOC05LTEtMS0yNTczOQ_af6e88a7-6933-4523-ae86-65e8ff21e6c7"
      unitRef="usd">33097000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfOS01LTEtMS0yNTczOQ_29e98532-387a-4ef0-af83-933be973275d"
      unitRef="usd">693716000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfOS03LTEtMS0yNTczOQ_a7efbbb0-1869-4b0c-a9bc-c2c6de9d7aa7"
      unitRef="usd">547851000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfOS05LTEtMS0yNTczOQ_b062dc90-a7ab-4403-9f7e-b4b322637a75"
      unitRef="usd">336964000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTAtNS0xLTEtMjU3Mzk_b55e7558-8115-4911-ada4-80ab7d69025f"
      unitRef="usd">401715000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTAtNy0xLTEtMjU3Mzk_5f1dbd9c-cd6d-47e3-ac36-08f4dc3b7bc3"
      unitRef="usd">293355000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTAtOS0xLTEtMjU3Mzk_67535ccf-1353-4129-a187-acd3cc2c689e"
      unitRef="usd">228244000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTEtNS0xLTEtMjU3Mzk_03fabc03-6408-4512-987e-1dc953e10c4a"
      unitRef="usd">1148304000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTEtNy0xLTEtMjU3Mzk_9beaae9a-c642-4b6f-8cf0-52554ee6cea1"
      unitRef="usd">877478000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTEtOS0xLTEtMjU3Mzk_93a9a18e-e9ef-4b76-9e7d-8f4009121259"
      unitRef="usd">598305000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTItNS0xLTEtMjU3Mzk_e511c699-086b-43f4-ba6b-0cc9bcdad3ac"
      unitRef="usd">286666000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTItNy0xLTEtMjU3Mzk_ffb2aa1d-5947-4104-9679-4f8e27a73b2c"
      unitRef="usd">110060000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTItOS0xLTEtMjU3Mzk_3246c2ea-dd29-42fa-877b-b502de534fb0"
      unitRef="usd">369470000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTMtNS0xLTEtMjU3Mzk_fbc84dc2-8d9e-4b1c-a3e7-687313108c9d"
      unitRef="usd">7672000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTMtNy0xLTEtMjU3Mzk_0cda92d0-5035-43d0-bae3-30bac54e0be7"
      unitRef="usd">19865000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTMtOS0xLTEtMjU3Mzk_94b65be8-1678-4092-8c7e-5af3b8cd320d"
      unitRef="usd">27959000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTQtNS0xLTEtMjU3Mzk_c9188f1a-a226-4213-a211-35eefebe21a0"
      unitRef="usd">-184000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTQtNy0xLTEtMjU3Mzk_435b1e72-4d9b-4e09-9b17-7729721189ed"
      unitRef="usd">912000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTQtOS0xLTEtMjU3Mzk_b840c816-ba2b-49a2-b1fd-a26035e66a9a"
      unitRef="usd">680000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTUtNS0xLTEtMjU3Mzk_540d90ad-80dd-4eb8-9745-f72ff5c2d11a"
      unitRef="usd">294154000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTUtNy0xLTEtMjU3Mzk_50425cda-d572-47e5-8b75-c90ddc54c6a8"
      unitRef="usd">130837000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTUtOS0xLTEtMjU3Mzk_99b78927-1930-4602-b403-8cea995d5b47"
      unitRef="usd">398109000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTYtNS0xLTEtMjU3Mzk_8c10b8ab-8e4f-4627-b24d-81ecaac0db34"
      unitRef="usd">63091000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTYtNy0xLTEtMjU3Mzk_bd55152b-cfa4-4f4f-89b0-de43f09085c9"
      unitRef="usd">19056000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTYtOS0xLTEtMjU3Mzk_00aab2be-6f54-4810-b99f-c08b0cd47dba"
      unitRef="usd">77097000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="if4d4436bfbe6489187e15748fba98eba_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTctNS0xLTEtMjU3Mzk_a4a0e49b-538b-4769-b3b0-0a000826d2d8"
      unitRef="usd">231063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTctNy0xLTEtMjU3Mzk_8de384b5-b560-4513-8421-2ea9f5137b05"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTctOS0xLTEtMjU3Mzk_bc76ab92-7f7e-4c2e-90b3-592155118fc0"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTktNS0xLTEtMjU3Mzk_d0412897-a7a9-418b-ba1d-386e5c427995"
      unitRef="usdPerShare">0.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTktNy0xLTEtMjU3Mzk_17cb74be-19a8-408b-9aa9-1777d90d4f3d"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMTktOS0xLTEtMjU3Mzk_3ef80348-21aa-44cd-ae45-1f3f7622a84a"
      unitRef="usdPerShare">1.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjAtNS0xLTEtMjU3Mzk_c137cefc-10d3-4f81-b90e-008ea0bcc9e2"
      unitRef="usdPerShare">0.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjAtNy0xLTEtMjU3Mzk_2bcdf78e-5712-4513-a37f-463e77663f96"
      unitRef="usdPerShare">0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjAtOS0xLTEtMjU3Mzk_96fe491a-ecd6-4aa7-8be4-4584925d4d52"
      unitRef="usdPerShare">1.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjItNS0xLTEtMjU3Mzk_990c6d4e-41a0-40a9-9d5e-c73d6ccb9a7e"
      unitRef="shares">314884000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjItNy0xLTEtMjU3Mzk_02b76316-39b2-4876-99df-4550bd25a008"
      unitRef="shares">308271000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjItOS0xLTEtMjU3Mzk_ff47dd4e-b9d8-41fd-87c0-f315a2fb6270"
      unitRef="shares">302584000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjMtNS0xLTEtMjU3Mzk_aef297bc-1597-4d3f-94bd-a22bd69182d0"
      unitRef="shares">322359000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjMtNy0xLTEtMjU3Mzk_349d63f5-0ad2-431c-849c-c7d646aaf297"
      unitRef="shares">318001000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF82Ny9mcmFnOjExNTBkMGUzMzg4YjQ2Mjc4ZWU0NWU0YmE2MGYzYTZjL3RhYmxlOjE3MjlkNmJjZjc3NTQ4NDFiYTM2MTEyZTU4ZjMzMTRjL3RhYmxlcmFuZ2U6MTcyOWQ2YmNmNzc1NDg0MWJhMzYxMTJlNThmMzMxNGNfMjMtOS0xLTEtMjU3Mzk_239622e7-c18b-4fb3-82ea-4f174f5375bc"
      unitRef="shares">315009000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="if4d4436bfbe6489187e15748fba98eba_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfMi01LTEtMS0yNTczOQ_a4a0e49b-538b-4769-b3b0-0a000826d2d8"
      unitRef="usd">231063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfMi03LTEtMS0yNTczOQ_8de384b5-b560-4513-8421-2ea9f5137b05"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfMi05LTEtMS0yNTczOQ_bc76ab92-7f7e-4c2e-90b3-592155118fc0"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNC0wLTEtMS0yNTczOS90ZXh0cmVnaW9uOjNmODE5ZmJiMDk5MDQ4MWM4N2M5MDEwMDU1NzNmZDc4Xzk1_ace109e8-cfdb-41d4-9b65-bb4e97e1bb31"
      unitRef="usd">1481000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i6aefcca4ad074b29b6a51fd6d458319c_D20201003-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNC0wLTEtMS0yNTczOS90ZXh0cmVnaW9uOjNmODE5ZmJiMDk5MDQ4MWM4N2M5MDEwMDU1NzNmZDc4Xzk5_0e36ccfa-fb39-4b79-acff-95d6ed603b66"
      unitRef="usd">-394000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNC0wLTEtMS0yNTczOS90ZXh0cmVnaW9uOjNmODE5ZmJiMDk5MDQ4MWM4N2M5MDEwMDU1NzNmZDc4XzEwNw_e6ff9858-e8a3-4fde-9ae0-efcbc685bcfd"
      unitRef="usd">-1049000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNC01LTEtMS0yNTczOQ_c9f6adea-0999-4076-99b7-bd5b99c50f02"
      unitRef="usd">-5234000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNC03LTEtMS0yNTczOQ_312b3d6d-3f88-4086-b5ed-e39b967d7030"
      unitRef="usd">1407000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNC05LTEtMS0yNTczOQ_ac39bacc-ae49-4798-b694-ecaf6a6f1bad"
      unitRef="usd">3770000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNi01LTEtMS0yNTczOQ_3db2bda0-ae2a-42d2-9964-cf09b42ab380"
      unitRef="usd">225829000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNi03LTEtMS0yNTczOQ_ad935a7a-3cc6-45f9-b584-e3e5ab538124"
      unitRef="usd">113188000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83MC9mcmFnOmU4ZTIwY2U4M2RhZTQzMDNhNDhkOGU3NmY4MzYyZjBiL3RhYmxlOmFlZWY3YTlhZTJhNTQ1YmVhOGY1YjY5ZWIzYTgyZWU3L3RhYmxlcmFuZ2U6YWVlZjdhOWFlMmE1NDViZWE4ZjViNjllYjNhODJlZTdfNi05LTEtMS0yNTczOQ_ed6cb400-ef4e-425b-8a07-96b4f65dda1d"
      unitRef="usd">324782000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9805c5e25eb64ed985d666f4c24de9ba_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzAtMS0xLTEtMjU3Mzk_27f667f0-03e4-401d-a7f5-5f5dab26ab65"
      unitRef="shares">299876000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9805c5e25eb64ed985d666f4c24de9ba_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzAtMy0xLTEtMjU3Mzk_464158c5-6fe7-484f-9682-8795796618cc"
      unitRef="usd">300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d64ce6b48d24a04a0c93e22acd3904f_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzAtNS0xLTEtMjU3Mzk_fd5e5996-af9a-4144-bc61-8a316b71a298"
      unitRef="usd">2168217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i867ed8b4453c4a1a9044dab4bd539d50_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzAtNy0xLTEtMjU3Mzk_8b2ade16-c9d0-449f-869a-732b6ae24046"
      unitRef="usd">-701000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8210e6b19c34f939af1ed9a98c8914a_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzAtOS0xLTEtMjU3Mzk_eabe5a67-19bf-4c0f-8031-26150b9f581a"
      unitRef="usd">-880363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i396cffc473714e59a1c966a366a443e2_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzAtMTEtMS0xLTI1NzM5_cf68ef65-18b0-42bd-b144-81586e70fbb8"
      unitRef="usd">1287453000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie5a94021373d4840b95f6959bc4accd9_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzEtOS0xLTEtMjU3Mzk_f13f2b9c-f09e-4669-b108-d2e48ba62af3"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzEtMTEtMS0xLTI1NzM5_0f223680-3b87-4b21-abe9-ed2503862980"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iff7c60d6d3b24087a7d0758be8cb1f5c_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzItNy0xLTEtMjU3Mzk_4d592821-d9a7-43fc-b696-fa12e1608a69"
      unitRef="usd">3770000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzItMTEtMS0xLTI1NzM5_af8a8967-5ebd-44b9-91d4-09f0d2d47b53"
      unitRef="usd">3770000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9883712cd8e1413e8d0219e4ed8aad8d_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzMtMS0xLTEtMjU3Mzk_5461889a-a5fc-4d06-bea8-5f70f30fdc8e"
      unitRef="shares">4955000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9883712cd8e1413e8d0219e4ed8aad8d_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzMtMy0xLTEtMjU3Mzk_e6d7b96a-4e63-41da-b00e-6dcc7d886c1e"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic73ea98630ee4a65b62bf4da8d1c3f41_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzMtNS0xLTEtMjU3Mzk_db005461-6f7d-4c16-9860-a2222927f161"
      unitRef="usd">27032000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzMtMTEtMS0xLTI1NzM5_2ccad43e-b201-43cf-a095-310a55bbf755"
      unitRef="usd">27037000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic73ea98630ee4a65b62bf4da8d1c3f41_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzQtNS0xLTEtMjU3Mzk_2449ab2e-a385-4daa-aa41-cb1d061b9204"
      unitRef="usd">9904000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzQtMTEtMS0xLTI1NzM5_d2b0f386-7a8a-4a34-9e07-6f1062067f61"
      unitRef="usd">9904000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic73ea98630ee4a65b62bf4da8d1c3f41_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzUtNS0xLTEtMjU3Mzk_e33e4a94-4a25-4351-90fd-17d9b079bfc0"
      unitRef="usd">56602000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzUtMTEtMS0xLTI1NzM5_73369e16-08cc-407a-97b0-7c67f06cfd58"
      unitRef="usd">56602000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3e8c40dbf5a94938b3a235b6331b0204_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtMS0xLTEtMjU3Mzk_b73bd6d9-4356-4038-8c35-d078f7148f5e"
      unitRef="shares">304831000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3e8c40dbf5a94938b3a235b6331b0204_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtMy0xLTEtMjU3Mzk_71ac8517-afa5-4682-a457-e955319fccbe"
      unitRef="usd">305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99338e5e4fa243d89959abbe305c1ddc_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtNS0xLTEtMjU3Mzk_30da5d05-8319-4243-bc46-5ee11806b72b"
      unitRef="usd">2241947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6020ec58ca0b4ac4b002e4acc9448876_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtNy0xLTEtMjU3Mzk_376c4c19-ce7a-4924-bfeb-f84f3d948a57"
      unitRef="usd">3069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i012b294c4e2c4931a14f4be10ec2fe36_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtOS0xLTEtMjU3Mzk_c3bde12a-8aff-4635-825e-2502378c8693"
      unitRef="usd">-559351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d03c75ce0024c01a62fcd27957b4f04_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtMTEtMS0xLTI1NzM5_1552c64a-4810-4830-a773-bf9c22450a00"
      unitRef="usd">1685970000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i0d4126cc2fa94615bd40a5daa4ef585e_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzctOS0xLTEtMjU3Mzk_2e9f2daa-7e6e-4daa-9ae4-8e4b350b11d0"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzctMTEtMS0xLTI1NzM5_a156dc7c-0236-4670-8718-f19d64fcc43d"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id2944e77d8c04388810195fe26496810_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzgtNy0xLTEtMjU3Mzk_9c1a9856-e7ad-40f0-ad8e-e4cb7b93f875"
      unitRef="usd">1407000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzgtMTEtMS0xLTI1NzM5_dcd596b9-f668-48f8-8bf0-2acffd152722"
      unitRef="usd">1407000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7ccde781cd17461fb3e9f797e81654e9_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzktMS0xLTEtMjU3Mzk_53703487-6004-484c-8d54-c43b1a1a8e25"
      unitRef="shares">6796000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7ccde781cd17461fb3e9f797e81654e9_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzktMy0xLTEtMjU3Mzk_ddfcc248-a843-44b4-829a-2eb7314b4dd8"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0f7ff0b5436e42b3a597987061001835_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzktNS0xLTEtMjU3Mzk_5a528ed7-b5ff-4b57-9de5-4fa6dc52a941"
      unitRef="usd">24896000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzktMTEtMS0xLTI1NzM5_992402b5-32d2-4f5c-b2ff-2c6e2c75c146"
      unitRef="usd">24903000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0f7ff0b5436e42b3a597987061001835_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtNS0xLTEtMjU3Mzk_8aa871d9-dc56-4e07-9d9a-1bf8a4d0ff77"
      unitRef="usd">50018000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtMTEtMS0xLTI1NzM5_5b4b4453-8cae-4cdb-8f73-70e5026eb7fd"
      unitRef="usd">50018000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0f7ff0b5436e42b3a597987061001835_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDEtNS0xLTEtMjU3Mzk_b787f5ed-c864-42bd-a373-69144ca3ced3"
      unitRef="usd">105070000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDEtMTEtMS0xLTI1NzM5_79e53d11-e210-432e-8039-b2e819e77373"
      unitRef="usd">105070000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4ce529a2e2894a0e92ed4a60ed0b95f9_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDItMS0xLTEtMjU3Mzk_6a74b238-f8a1-4acb-b5cd-830213ce205b"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4ce529a2e2894a0e92ed4a60ed0b95f9_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDItMy0xLTEtMjU3Mzk_fac44488-c7a7-49d3-9277-304c97f2d2a8"
      unitRef="usd">312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a546fb4a49e431a956a77f1680095df_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDItNS0xLTEtMjU3Mzk_b76b0a24-82f5-4fee-a475-8ca76df86d33"
      unitRef="usd">2321895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4109c1b12d9d4433bb8db86bc3cae091_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDItNy0xLTEtMjU3Mzk_bcbafec4-899b-4eff-93f6-98568deee11c"
      unitRef="usd">4476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id655252138f44944870c02853be75c73_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDItOS0xLTEtMjU3Mzk_527ebb72-7b47-47a0-a21e-7a5bb4301270"
      unitRef="usd">-447570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDItMTEtMS0xLTI1NzM5_98f1aec9-5cd8-459e-9e45-db8bbbfb5d52"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzUtMTEtMS0xLTMxODIy_96d472c4-4e24-489c-971b-83255af6f8c5"
      unitRef="usd">231063000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7ce7ca557f444499972aa47b8a85d655_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtNy0xLTEtMzE4MDg_e72a7c0c-d309-46ea-a4a6-4fc86682134a"
      unitRef="usd">-5234000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzYtMTEtMS0xLTMxODIy_7c853193-b300-45ca-942e-ecaa336b95dd"
      unitRef="usd">-5234000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ibd55184171ad45c8be33cab3d4171b5f_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzctMS0xLTEtMzE3Nzc_b81d0a5a-8e6b-40ee-bd07-f78754e6eae0"
      unitRef="shares">7215000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibd55184171ad45c8be33cab3d4171b5f_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzctMy0xLTEtMzE3ODU_01f700ba-bc2b-4640-a2fe-ec28d4dd04f8"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i84b17fef833a40479881088e5855fc81_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzctNS0xLTEtMzE3OTI_c32a5cfb-472d-4039-ab06-e560ac48017a"
      unitRef="usd">24360000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzctMTEtMS0xLTMxODIy_67921937-865f-4c1b-acdd-9fd8c6178fe1"
      unitRef="usd">24367000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i84b17fef833a40479881088e5855fc81_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzgtNS0xLTEtMzE3OTI_a7605029-dba1-4976-be39-58a988835ca4"
      unitRef="usd">39142000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzgtMTEtMS0xLTMxODIy_298fe3e8-3049-45b2-9191-895665c5f72a"
      unitRef="usd">39142000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i84b17fef833a40479881088e5855fc81_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzktNS0xLTEtMzE3OTI_1d046f2f-c1bb-477a-bfc8-047760d49846"
      unitRef="usd">120448000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfMzktMTEtMS0xLTMxODIy_77766f7b-0154-472c-be4f-e0280b8432e0"
      unitRef="usd">120448000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iac855e1b2d284da3adfcc70d50d6b045_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtMS0xLTEtMzIzMjQ_f85ce704-9157-402b-90c8-7006dd82f05a"
      unitRef="shares">318842000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iac855e1b2d284da3adfcc70d50d6b045_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtMy0xLTEtMzIzMjQ_01cbc102-9496-4659-9a55-36d9668bbfbb"
      unitRef="usd">319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5ff5eb1df65416581656de05ef86494_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtNS0xLTEtMzE3OTI_acef0950-a57e-4e8a-9663-43fb290d39ee"
      unitRef="usd">2427561000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0dcdcda3fc10404397110c8f9aaa5353_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtNy0xLTEtMzIzMjQ_df5872a6-f362-4792-8ddb-6493b09914b2"
      unitRef="usd">-758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iebee7996e33a4d07b3a22638e4c253b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtOS0xLTEtMzIzMjQ_8a150c22-16d1-4b94-971b-c777519ceea1"
      unitRef="usd">-216507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83My9mcmFnOjUzMzE0MWI3YzcxNTQwZTViN2IwYzA5YmJhYTAyYWI4L3RhYmxlOmFmOWUyMDUyYTliNzQ4ZDI5NWNkZGUwMWQyYjA4YTFhL3RhYmxlcmFuZ2U6YWY5ZTIwNTJhOWI3NDhkMjk1Y2RkZTAxZDJiMDhhMWFfNDAtMTEtMS0xLTMyMzI0_2b008141-10e4-4066-976a-9f0229e4380c"
      unitRef="usd">2210615000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if4d4436bfbe6489187e15748fba98eba_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMi0xLTEtMS0yNTczOQ_a4a0e49b-538b-4769-b3b0-0a000826d2d8"
      unitRef="usd">231063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMi0zLTEtMS0yNTczOQ_8de384b5-b560-4513-8421-2ea9f5137b05"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMi01LTEtMS0yNTczOQ_bc76ab92-7f7e-4c2e-90b3-592155118fc0"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNC0xLTEtMS0yNTczOQ_91012b16-0d60-4bdd-9463-4c5850d75a4e"
      unitRef="usd">13630000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNC0zLTEtMS0yNTczOQ_a99bf2de-b133-4cb5-8418-671f5a519942"
      unitRef="usd">9141000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNC01LTEtMS0yNTczOQ_8329191e-c9b1-4568-be37-c309f98e2f02"
      unitRef="usd">8348000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNS0xLTEtMS0yNTczOQ_27e28292-5bf3-49f0-a775-a09e83e51be7"
      unitRef="usd">119820000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNS0zLTEtMS0yNTczOQ_b3e4ff72-ee1d-42fe-b845-4ab5b9437e28"
      unitRef="usd">105070000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNS01LTEtMS0yNTczOQ_590e7b92-b03d-48da-87c0-b34898164b03"
      unitRef="usd">56602000</us-gaap:ShareBasedCompensation>
    <exel:NoncashLeaseExpense
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNi0xLTEtMS0yNTczOQ_8f176fc3-f7d2-4d0e-a5f9-6e902d030454"
      unitRef="usd">5332000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNi0zLTEtMS0yNTczOQ_71b9cf29-2b4f-431d-bb98-8848b081e06a"
      unitRef="usd">4830000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNi01LTEtMS0yNTczOQ_260e84a1-5ff3-467a-848f-9e449edad55e"
      unitRef="usd">2819000</exel:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNy0xLTEtMS0yNTczOQ_9d3db304-469d-4106-8448-767ea798d215"
      unitRef="usd">-46529000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNy0zLTEtMS0yNTczOQ_14e655ae-64f2-4518-a55f-bed399839923"
      unitRef="usd">-15265000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNy01LTEtMS0yNTczOQ_06188e56-0f18-4b7b-82ff-01b3608a3845"
      unitRef="usd">-71002000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfOC0xLTEtMS0yNTczOQ_03aa28fa-a078-45dc-aa01-795ba24e2e86"
      unitRef="usd">-23443000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfOC0zLTEtMS0yNTczOQ_afdde090-fa23-4817-9e93-4ae7386ca341"
      unitRef="usd">-3035000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfOC01LTEtMS0yNTczOQ_09319e31-44ae-4a28-8dfd-cbcd7755e4a0"
      unitRef="usd">-88000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTAtMS0xLTEtMjU3Mzk_eb739c39-c210-4b16-815f-788717d1f3c6"
      unitRef="usd">122324000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTAtMy0xLTEtMjU3Mzk_bf946926-3e44-4431-84be-b85dd732131f"
      unitRef="usd">42470000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTAtNS0xLTEtMjU3Mzk_0194ae3c-bf74-46b1-a1d6-68d001c690fc"
      unitRef="usd">-43716000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTEtMS0xLTEtMjU3Mzk_89aef772-d6b8-4cf0-bf09-0fb07f1d795c"
      unitRef="usd">13209000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTEtMy0xLTEtMjU3Mzk_b5ace612-3172-4dac-b455-3062199f8fc2"
      unitRef="usd">21897000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTEtNS0xLTEtMjU3Mzk_6a8d28c0-6bef-44e9-9e48-6e2fea3d226d"
      unitRef="usd">5731000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTMtMS0xLTEtMjU3Mzk_ea5fc9dc-f4da-4d78-98f4-e646905e90cf"
      unitRef="usd">39875000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTMtMy0xLTEtMjU3Mzk_f3c619bd-f52c-4f33-a715-a7adad495466"
      unitRef="usd">25831000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTMtNS0xLTEtMjU3Mzk_b7674318-3e38-45dd-b721-89e3b6220ad3"
      unitRef="usd">5723000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTUtMS0xLTEtMjU3Mzk_f12662d0-37e9-46f6-95b5-969cc16bbdae"
      unitRef="usd">11008000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTUtMy0xLTEtMjU3Mzk_3adb487b-ff3d-4f37-abc9-696d5a56dc98"
      unitRef="usd">-1051000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTUtNS0xLTEtMjU3Mzk_5b32a0ec-e46d-4d9c-90eb-ad88b910a819"
      unitRef="usd">-9301000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTYtMS0xLTEtNDUzMjM_ed651d24-fece-4b8b-a33c-572ec0ba5c1f"
      unitRef="usd">70297000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTYtMy0xLTEtNDUzMzA_aa187cd3-f112-4b2b-8642-48eba1e8835d"
      unitRef="usd">600000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTYtNS0xLTEtNDUzMzc_1c345b1b-f3ce-4a7f-aa59-b7db9accd05e"
      unitRef="usd">4437000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTYtMS0xLTEtMjU3Mzk_2c9a1db6-d5d6-4bfa-91bc-9c8107043a7e"
      unitRef="usd">55090000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTYtMy0xLTEtMjU3Mzk_d77d51e9-3581-44be-b1e2-f5469d6906e9"
      unitRef="usd">50509000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTYtNS0xLTEtMjU3Mzk_a98ed54e-072a-411b-87b1-8b22cd1b65b1"
      unitRef="usd">39687000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTctMS0xLTEtMjU3Mzk_e06e405b-39c2-4da7-8397-2f5d063e76f1"
      unitRef="usd">400804000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTctMy0xLTEtMjU3Mzk_36df1c26-89c4-4f39-8458-9e74bc21c2ac"
      unitRef="usd">208982000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTctNS0xLTEtMjU3Mzk_85387ceb-341f-4a0c-8794-abefacca8799"
      unitRef="usd">526956000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTktMS0xLTEtMjU3Mzk_0755a419-1c83-48a0-ae1d-3583c39c2431"
      unitRef="usd">64225000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTktMy0xLTEtMjU3Mzk_984fb9d6-0506-400e-9f51-1adebead0d54"
      unitRef="usd">30345000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMTktNS0xLTEtMjU3Mzk_cb4f755a-350f-40f4-88a4-70f92135d06d"
      unitRef="usd">12834000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjEtMS0xLTEtMjU3Mzk_67276339-9fca-4dc8-bfe9-a1c8df463535"
      unitRef="usd">1357168000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjEtMy0xLTEtMjU3Mzk_d0ba90ba-9087-45d2-b0f3-c9d54a78962d"
      unitRef="usd">1070269000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjEtNS0xLTEtMjU3Mzk_fa23c800-8a8c-4b6d-9628-45efb517c2a4"
      unitRef="usd">1182682000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjItMS0xLTEtMjU3Mzk_9ee06343-d935-438f-b94f-26bc8619308a"
      unitRef="usd">1378509000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjItMy0xLTEtMjU3Mzk_fab8da98-6f33-4ac8-89f9-e68ff0f78b39"
      unitRef="usd">969399000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjItNS0xLTEtMjU3Mzk_a4aa3b36-85ea-4644-a869-fbd7a96b9750"
      unitRef="usd">608269000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjMtMS0xLTEtMjU3Mzk_5facec09-c04e-4a1d-bfa8-9e1c6fc4bd13"
      unitRef="usd">-42884000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjMtMy0xLTEtMjU3Mzk_6a770d88-71e6-4cc9-940c-99ec10a9bc25"
      unitRef="usd">-131215000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjMtNS0xLTEtMjU3Mzk_e854a0f0-7670-40e7-b7a8-6622942ac03a"
      unitRef="usd">-587247000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjUtMS0xLTEtMjU3Mzk_ede224be-be5b-4fc5-a62c-30bdefd3f6e1"
      unitRef="usd">24307000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjUtMy0xLTEtMjU3Mzk_312b44e4-a366-4e52-aab0-80c028564bd3"
      unitRef="usd">24886000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjUtNS0xLTEtMjU3Mzk_760361e5-f46a-4106-81ee-1f20db8b3f2f"
      unitRef="usd">22499000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjYtMS0xLTEtMjU3Mzk_4de96e3d-c467-489f-9a9f-ad1007838f6a"
      unitRef="usd">39108000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjYtMy0xLTEtMjU3Mzk_63679ff1-77cc-4276-868a-c0963efd6d2d"
      unitRef="usd">50018000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjYtNS0xLTEtMjU3Mzk_000c516c-20e3-416d-894a-3a677c666749"
      unitRef="usd">9904000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjctMS0xLTEtMjU3Mzk_6238bde9-8167-43cb-825c-9828a4ec8b71"
      unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjctMy0xLTEtMjU3Mzk_4cd67300-f75d-418e-9fb4-b3cfc475455d"
      unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjctNS0xLTEtMjU3Mzk_85dab201-e0c0-4310-bf3a-40e5c9fb6361"
      unitRef="usd">-42000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjgtMS0xLTEtMjU3Mzk_16c18c99-6920-4424-ace7-669846ad6212"
      unitRef="usd">-14801000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjgtMy0xLTEtMjU3Mzk_375e51ca-248f-43c6-ba6f-9f79d3bd76ca"
      unitRef="usd">-25132000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjgtNS0xLTEtMjU3Mzk_11722aee-e9d5-4fb5-a758-6814beac2d38"
      unitRef="usd">12553000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjktMS0xLTEtMjU3Mzk_d089a5c3-0f1b-4fc8-bdcd-87e5835f23b5"
      unitRef="usd">343119000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjktMy0xLTEtMjU3Mzk_a41c5a75-907b-44c2-a1f4-de0b8dd01d27"
      unitRef="usd">52635000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMjktNS0xLTEtMjU3Mzk_110cc771-3a22-4016-9ed0-50fb0ec7ba27"
      unitRef="usd">-47738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzAtMS0xLTEtMjU3Mzk_a9ce197f-43ee-4036-8de0-110d3af5a137"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2d03c75ce0024c01a62fcd27957b4f04_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzAtMy0xLTEtMjU3Mzk_bccfb82c-797d-494c-af9a-335f3a86313c"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i396cffc473714e59a1c966a366a443e2_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzAtNS0xLTEtMjU3Mzk_c3c1a330-92a2-4468-a167-848ba9becc56"
      unitRef="usd">315875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzEtMS0xLTEtMjU3Mzk_abb0e486-5e3f-4fd6-bdb4-78ac0489b934"
      unitRef="usd">663891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzEtMy0xLTEtMjU3Mzk_278adff1-c8fc-4a8c-b48d-5f9cd85ee790"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2d03c75ce0024c01a62fcd27957b4f04_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzEtNS0xLTEtMjU3Mzk_348814f5-a507-46f2-9154-2cd6275024c2"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzQtMS0xLTEtMjU3Mzk_c5835151-520b-42dc-ad91-af8305d7d8d0"
      unitRef="usd">12960000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzQtMy0xLTEtMjU3Mzk_91eff752-fdff-4da5-8a1d-52ab1777f4a8"
      unitRef="usd">4115000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzQtNS0xLTEtMjU3Mzk_221648f7-6bf1-4b10-805f-f5e691de9a30"
      unitRef="usd">7873000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzYtMS0xLTEtMjU3Mzk_08aa28ec-b87d-46dc-a68f-e5358cd72ed2"
      unitRef="usd">4893000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzYtMy0xLTEtMjU3Mzk_5a385480-ecee-4d2d-84cc-6ac6665a0d29"
      unitRef="usd">4017000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzYtNS0xLTEtMjU3Mzk_d71af29b-4e5c-47fa-b3d6-dd48f5ce5cee"
      unitRef="usd">29562000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzgtMS0xLTEtMzc0NjU_7c1366f3-2cb6-4add-a84c-f7dc02ab6c5e"
      unitRef="usd">4000000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzgtMy0xLTEtMzc0Njc_1e3e049d-ab46-447a-860b-87876b11de08"
      unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzgtNS0xLTEtMzc0Njk_d90810b9-38f6-4282-81a9-356c8d9058f6"
      unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzgtMS0xLTEtMjU3Mzk_9d826623-8190-498b-97f2-0ee8de9b4fc0"
      unitRef="usd">2739000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzgtMy0xLTEtMjU3Mzk_d1a015ef-e4b7-471c-9f2f-e8296a49f25b"
      unitRef="usd">842000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzgtNS0xLTEtMjU3Mzk_6344471e-c2bd-440b-b621-2cf9739f3762"
      unitRef="usd">26000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <exel:InvestmentsPurchasesIncurredButNotYetPaid
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzktMS0xLTEtMjU3Mzk_fc5570d6-78d3-4ed2-98a6-b3793090c493"
      unitRef="usd">0</exel:InvestmentsPurchasesIncurredButNotYetPaid>
    <exel:InvestmentsPurchasesIncurredButNotYetPaid
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzktMy0xLTEtMjU3Mzk_4cf1f3e1-9a5e-483c-88e8-09d6edfb1e1e"
      unitRef="usd">1615000</exel:InvestmentsPurchasesIncurredButNotYetPaid>
    <exel:InvestmentsPurchasesIncurredButNotYetPaid
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfMzktNS0xLTEtMjU3Mzk_560cfe42-0aad-49cf-9b58-d72340417a9e"
      unitRef="usd">0</exel:InvestmentsPurchasesIncurredButNotYetPaid>
    <exel:AccountsReceivableForUnsettledInvestmentSales
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNDAtMS0xLTEtMjU3Mzk_e481fc58-4147-4fb8-8280-5deb77f46120"
      unitRef="usd">0</exel:AccountsReceivableForUnsettledInvestmentSales>
    <exel:AccountsReceivableForUnsettledInvestmentSales
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNDAtMy0xLTEtMjU3Mzk_4396cdeb-31a4-490b-85d2-19734a5b2af5"
      unitRef="usd">6180000</exel:AccountsReceivableForUnsettledInvestmentSales>
    <exel:AccountsReceivableForUnsettledInvestmentSales
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF83Ni9mcmFnOmMxMzEwYWIyZDY1YjRkNWQ5OTIxMTVlODY4YWI3YWY2L3RhYmxlOmM1ZDViMDc5MWE2MDQ5YjI5MzQ3MTQyYTZjMjZiZGYyL3RhYmxlcmFuZ2U6YzVkNWIwNzkxYTYwNDliMjkzNDcxNDJhNmMyNmJkZjJfNDAtNS0xLTEtMjU3Mzk_db550d98-5dab-42e7-a5d9-ca39a4511e58"
      unitRef="usd">0</exel:AccountsReceivableForUnsettledInvestmentSales>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwOTQ_b0a3a511-6fe9-4c33-8e6f-63d11326d167">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 61 other countries as: CABOMETYX&#xae; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#x2019;s (BMS) OPDIVO&#xae; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA, for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#xae; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important drug in their selection of effective therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other two products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our plan is to utilize our operating cash flows and cash and investments to expand the cabozantinib franchise by potentially adding new indications in areas of unmet medical need. We will also leverage our operating cash flows to continue advancing our diverse small molecule and biotherapeutics programs, exploring multiple modalities and mechanisms of action to discover new oncology drugs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021, fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January&#160;3, 2020. For convenience, references in this report as of and for the fiscal years ended January&#160;1, 2021 and January&#160;3, 2020 are indicated as being as of and for the years ended December&#160;31, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made reclassifications to our prior years&#x2019; Consolidated Financial Statements to conform to the current year&#x2019;s presentation. These reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, we adopted the Accounting Standards Board&#x2019;s (FASB) Accounting Standards Update (ASU) 2019-12&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Income Taxes&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 740)-Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, Income Taxes and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investment Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quarterly, we assess each of our investments in available-for-sale debt securities whose fair value is below its cost basis to determine if the investment&#x2019;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded as a reduction of other comprehensive income (loss), net of applicable taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to exclude accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Forward Foreign Currency Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchange rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, we had one forward contract outstanding to sell &#x20ac;9.8&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Consolidated Balance Sheets. The unrealized loss on the forward contract is not material as of December&#160;31, 2021. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the year ended December&#160;31, 2021, we recognized $0.8&#160;million of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the accompanying Consolidated Statements of Income. Net foreign currency gains or losses were immaterial for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current economic conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. We write off trade receivables and related allowances for credit losses when it becomes probable we will not collect the amount receivable. Write-offs for the years ended December 31, 2021 and 2020 have been insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to 15 years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did not recognize any impairment charges in any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenues under the guidance of ASU Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 606). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discounts for Prompt Payment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our Customers in the U.S. receive a discount of 2% for prompt payment. We expect our Customers will earn 100% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to our Customers, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to Customer, plus an accrual balance for known prior quarters&#x2019; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment Assistance: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Customer Credits: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Up-front License Fees: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regulatory and Development Milestone Payments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development Cost Reimbursements:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation, which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit-sharing Arrangements: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Sales-based Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty we are required to pay on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2016-02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842) for short-term leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising expenses were $31.8 million, $25.1 million and $17.9 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock&#160;Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatility when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Provision for Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our provision for income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for income taxes in the period of such reversal. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="ib427a6bae515457884e12ccece2b4122_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfOTM0NTg0ODkwNzk2Ng_2354357b-4353-42bf-8a76-e48d1613f24d"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberOfCountriesWithDrugApprovalExcludingTheUS
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDM5ODA0NjU4Nzg2Nw_3acdec0d-dc4a-4344-9337-323b5ac5fc45"
      unitRef="country">61</exel:NumberOfCountriesWithDrugApprovalExcludingTheUS>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i02820d73f6c54d589b048d50797c40a6_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfOTM0NTg0ODkwNzk3NA_91e118d9-2a1b-4521-aa2f-88abac5fa3c4"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwODY_28a44bf3-e057-440f-b8ec-7d92a6ea275a">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxMDI_bb5629bb-023a-4ef0-be8a-6f7897d8bbc3">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021, fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January&#160;3, 2020. For convenience, references in this report as of and for the fiscal years ended January&#160;1, 2021 and January&#160;3, 2020 are indicated as being as of and for the years ended December&#160;31, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made reclassifications to our prior years&#x2019; Consolidated Financial Statements to conform to the current year&#x2019;s presentation. These reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:FiscalPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwOTg_a0b60fdb-bb59-4519-8681-540b7b553b3d">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMzY0NA_f802fc8f-5085-4215-b721-e3a89be935f1"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxNjc_c9b7dc7d-4986-467d-b1f8-a31487f406a6">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwOTU_a9279812-7950-41d2-a12a-73fbbe92df7e">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, we adopted the Accounting Standards Board&#x2019;s (FASB) Accounting Standards Update (ASU) 2019-12&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Income Taxes&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 740)-Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, Income Taxes and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwMzU_b7eafb5c-08cd-42d5-85f6-b46b1232dbab">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNjA0NzMxNDAyOTQ1Nw_5d30ca3e-4ed3-45b2-adcd-4b66b2b853bf">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investment Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quarterly, we assess each of our investments in available-for-sale debt securities whose fair value is below its cost basis to determine if the investment&#x2019;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded as a reduction of other comprehensive income (loss), net of applicable taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to exclude accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwNjM_df78b44e-799f-4bd5-96ef-4cf333616f6f">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfOTM0NTg0ODg5NDY3MQ_5b375de1-e03a-4538-9b2e-26ed0ce066c7">In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchange rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i2ca33a540eff4370b1fd9baefd112b43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjE5OTAyMzMwMzUyNQ_9255cee1-fd71-4982-ba75-508d90dbcc92"
      unitRef="derivative_instrument">1</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2ca33a540eff4370b1fd9baefd112b43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjE5OTAyMzMwMzU2OA_a3959ac4-d05b-458b-815d-eec26bf397f4"
      unitRef="eur">9800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract
      contextRef="ib1b9becbae9d413a818538229404c8e0_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfOTM0NTg0ODg5NDcwNw_ac328d56-26c5-4cf0-bfee-c893a022464a">P3M</us-gaap:DerivativeTermOfContract>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ib1b9becbae9d413a818538229404c8e0_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjE5OTAyMzMwMzk4Mg_3fd84b7f-e769-4f3c-aa7f-a5edd10a3274"
      unitRef="usd">800000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfOTM0NTg0ODg5NDY3Mw_157a6abb-4ad0-4838-854b-912283263dad">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the accompanying Consolidated Statements of Income.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwODI_4ddf94c3-7e5d-4dda-b9fa-57745f1d6e04">Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current economic conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. We write off trade receivables and related allowances for credit losses when it becomes probable we will not collect the amount receivable. Write-offs for the years ended December 31, 2021 and 2020 have been insignificant.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxNTI_5dae78cc-f890-4e74-a531-0aa650d0a0fc">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxMjc_2227e592-92b9-48fe-8336-a136403a1ecb">We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to 15 years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6362d549434c4a3ebfb9ed76266ced8a_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMTQ1MTI_6528f80f-fe31-4deb-9f2d-c2a3e9564da2">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxMjg_f764c444-20c2-45e7-8a17-b5bf8cb1ffb3">We recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMTYxMDA_f802fc8f-5085-4215-b721-e3a89be935f1"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMTYyNTc_3d8dfc74-019f-43b1-bf3b-df35f655cae9"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMTYyNTc_6a315e70-063a-4770-bf41-3ca1af4c4f47"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMTYyNTc_c8fc913d-4616-4d6b-b6db-b97d0546b953"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwMzc_fba7f1dc-a88b-4906-bd2c-21e6126afb90">The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxNzg_4df8dee2-f8a7-4b96-ab62-c065a96fa127">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenues under the guidance of ASU Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 606). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discounts for Prompt Payment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our Customers in the U.S. receive a discount of 2% for prompt payment. We expect our Customers will earn 100% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to our Customers, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to Customer, plus an accrual balance for known prior quarters&#x2019; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment Assistance: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Customer Credits: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Up-front License Fees: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regulatory and Development Milestone Payments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development Cost Reimbursements:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation, which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit-sharing Arrangements: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Sales-based Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty we are required to pay on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. &lt;/span&gt;&lt;/div&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <exel:SalesRevenuePercentDiscountForPromptPayment
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjEzMTI_aede4932-0be7-41da-8ed7-6f1779657b03"
      unitRef="number">0.02</exel:SalesRevenuePercentDiscountForPromptPayment>
    <exel:SalesRevenueDiscountExpectedtobeEarnedPercent
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjEzNjk_2bffda3a-5d57-4c89-91e6-0abf500ef567"
      unitRef="number">1</exel:SalesRevenueDiscountExpectedtobeEarnedPercent>
    <exel:MedicarePartDFundingMandate
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjI4MTY_8fa20206-a272-46d9-a130-7a43ee5d3feb"
      unitRef="number">0.70</exel:MedicarePartDFundingMandate>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMzA3NDY_be10e243-5402-4393-8922-bf4c0436cdb1"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxNjE_5cb7dcb4-5c5d-4211-b321-0cff653c4c46">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwNTg_8c8d1521-9d86-4240-b5a0-bfa81bf067e8">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2016-02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842) for short-term leases.&lt;/span&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMzQzODg_0ab083a6-8187-404e-98b5-17d5d8ff36d3"
      unitRef="usd">31800000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjE5OTAyMzI5NTg1Ng_cf2168b2-fc89-48a5-96cd-83b26b5f8c05"
      unitRef="usd">25100000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfMjE5OTAyMzI5NTgzMw_45ebd3b4-0551-405b-85e4-69dd183f07ff"
      unitRef="usd">17900000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAxODA_2bdd96a7-5788-4474-a99a-a29d2547abc3">We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwNDg_1bc43e81-1918-4dca-8b40-822b3e3322c8">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock&#160;Compensation&lt;/span&gt;,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatility when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84Mi9mcmFnOmVmNzEzOGFiYTcyZDQxMTQ5MmQ5OWQwMmRkMWU0NGE5L3RleHRyZWdpb246ZWY3MTM4YWJhNzJkNDExNDkyZDk5ZDAyZGQxZTQ0YTlfNDAwNjc_83ac73e1-e953-47fb-94a5-b2b000567024">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our provision for income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for income taxes in the period of such reversal. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfNDE5NA_682ea583-75bf-462e-9e9e-1ec05e9316b9">REVENUES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(375,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197,671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on total net sales of any product containing cabozantinib for non-U.S. markets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Contract assets as of December&#160;31, 2021 are primarily related to contract assets from Ipsen Pharma SAS (Ipsen) and c&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ontract liabilities as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Presented in other long-term assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020 and 2019, we recognized $8.5 million, $9.2 million and $6.5 million, respectively, in revenues that were included in the beginning deferred revenues balance for those years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; December&#160;31, 2021, 2020 and 2019, we recognized $148.7 million, $169.7 million and $161.2 million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to milestone and royalty payments allocated to our license performance obligations for our collaborations with Ipsen Pharma SAS (Ipsen), Takeda, Daiichi Sankyo and Genentech.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, $87.5 million of the combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#x201c;Note 3. Collaboration Agreements&#x2014; Cabozantinib Collaborations &#x2014;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#x201d; for additional information about the expected timing to satisfy these performance obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfNDIwMA_458fa646-f550-4696-bada-9a8950de91ec">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(375,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197,671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ce7596693de4c309e4046ee44e221d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMy01LTEtMS0yNTczOQ_dd3905c4-b182-427b-84ec-e7998060ce6f"
      unitRef="usd">1452913000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4442ea86bfb449ca9e6184c51952a1e9_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMy03LTEtMS0yNTczOQ_f01af313-5657-40c0-8cb0-7a1c5d6a0fac"
      unitRef="usd">962591000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad06c636df9d4082a61cd0476a607cb2_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMy05LTEtMS0yNTczOQ_87f9538d-6721-4c29-80a2-d021224a01a1"
      unitRef="usd">957621000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0431c045c7b749419b8cb122e47b2fd8_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNC01LTEtMS0yNTczOQ_dd7b5f62-bce9-49f8-9ef0-97b780522fec"
      unitRef="usd">-375657000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4d4c8762b46415b8ba90c8fc8e8bd01_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNC03LTEtMS0yNTczOQ_a58f9fa2-d60f-4899-a663-14afb0d93151"
      unitRef="usd">-221041000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e8b773d3cd2476b9a6f98f0ec19f343_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNC05LTEtMS0yNTczOQ_f528421b-8184-4f8a-9f95-6bedc57128d8"
      unitRef="usd">-197671000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i890a097ba13b4d2aa44ba45c617df112_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNS01LTEtMS0yNTczOQ_089ee80f-a944-41cd-ae48-f04fd5b135eb"
      unitRef="usd">1077256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81474236dfb14ff1ac531c41f5c16947_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNS03LTEtMS0yNTczOQ_45797d43-e52d-454c-9dbe-40b3eed8e716"
      unitRef="usd">741550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief6bfa79af1c49bbac2074ef89ab2c4b_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNS05LTEtMS0yNTczOQ_ca0e978a-609c-446c-b3f1-9f7b9b6f9fc6"
      unitRef="usd">759950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31f5b5f30b734b15b1054bfb509ae021_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNy01LTEtMS0yNTczOQ_a76a7ad9-62ed-4342-a3e6-ed13690fa5f8"
      unitRef="usd">249956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23f991a8511f4c6bb78932ffbb88e05a_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNy03LTEtMS0yNTczOQ_e0093d0a-6d8d-4890-8d9b-863d8b7cd29d"
      unitRef="usd">167295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69ce00236de4479e9a6c6986301e7731_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfNy05LTEtMS0yNTczOQ_d06f031e-7998-479e-863b-885cab836319"
      unitRef="usd">165914000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5185d285db34c6d9e4c918f1420364c_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfOC01LTEtMS0yNTczOQ_381474ae-b46d-4839-b26e-91c442c7be4b"
      unitRef="usd">107758000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8016a7106ab5473891bf09f72524f38e_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfOC03LTEtMS0yNTczOQ_9d0e04ca-f94a-4585-95bf-803e3da9ff1c"
      unitRef="usd">78693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35edcd5425bb4e4f8597665dcf1e7e5b_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfOC05LTEtMS0yNTczOQ_28a56a09-3347-4845-9365-585fdf44720b"
      unitRef="usd">41911000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5511677067b74ebb913d887f52a2848c_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMTAtNS0xLTEtMjU3Mzk_0b61a127-94c0-421f-9499-508aee48ede2"
      unitRef="usd">357714000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10a667976104461cb71d5603b4d4af97_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMTAtNy0xLTEtMjU3Mzk_e35d1bea-c905-482e-8523-e2529f3c1bf7"
      unitRef="usd">245988000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9af17feaeb349989438dbf0d666ce00_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMTAtOS0xLTEtMjU3Mzk_7405fd64-7c73-4205-a1a2-a3c631c532d5"
      unitRef="usd">207825000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMTEtNS0xLTEtMjU3Mzk_3214d4bd-db52-4442-a55f-819bb52b0d9a"
      unitRef="usd">1434970000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMTEtNy0xLTEtMjU3Mzk_d2f6e443-5e77-4278-951d-c452e8ec367f"
      unitRef="usd">987538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjY2OTQ1Y2EzMTNlMjRmNTFhOTFkNzkwZjQ1ODY1OTMyL3RhYmxlcmFuZ2U6NjY5NDVjYTMxM2UyNGY1MWE5MWQ3OTBmNDU4NjU5MzJfMTEtOS0xLTEtMjU3Mzk_ef9a96b7-d84c-48c6-8597-e376ff2323cc"
      unitRef="usd">967775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2da812635cea4a9b9116e4146e6cdea4_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfMi01LTEtMS0yNTczOQ_f93f5746-dd5e-4b86-8682-1f6d42da6a72"
      unitRef="usd">1054050000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17406e0670124dc6aa021883b5f49f2e_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfMi03LTEtMS0yNTczOQ_d5ee8937-7e86-4b21-aaec-769f3577a709"
      unitRef="usd">718687000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia06ec631ab45435d9aa467e475199d25_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfMi05LTEtMS0yNTczOQ_802a0c65-d95b-4509-b5b2-e582e16ff6d3"
      unitRef="usd">733421000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f3560ad4cbe4f5fa9e33117ca1cc45b_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfMy01LTEtMS0yNTczOQ_129bb0d4-ab84-40b3-b4f5-d95c642c2b24"
      unitRef="usd">23206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a39ad000947444189cd4862efda588c_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfMy03LTEtMS0yNTczOQ_bd3c82ea-81a9-46ad-aea2-2e8d3dc3ebfd"
      unitRef="usd">22863000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie886e01e3e2442248812abddb9a3357c_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfMy05LTEtMS0yNTczOQ_b08832dd-f67a-444c-8290-5d32f1bc8406"
      unitRef="usd">26529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i890a097ba13b4d2aa44ba45c617df112_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfNC01LTEtMS0yNTczOQ_563a0f44-1917-414f-bc71-b259d2f30690"
      unitRef="usd">1077256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81474236dfb14ff1ac531c41f5c16947_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfNC03LTEtMS0yNTczOQ_dac231fc-d174-4684-9cae-d09d4420027b"
      unitRef="usd">741550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief6bfa79af1c49bbac2074ef89ab2c4b_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjUwZDk4OTg3ZmQ5NDQ0MGZiZGY2YzRmMzg5OTg2OGM5L3RhYmxlcmFuZ2U6NTBkOTg5ODdmZDk0NDQwZmJkZjZjNGYzODk5ODY4YzlfNC05LTEtMS0yNTczOQ_6812d777-a44a-4b6a-9973-886d7b58f184"
      unitRef="usd">759950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfNDIwMQ_f7aa61e8-2cf0-4778-b7ec-331f14ab60a0">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i802f06ff953349dcbd6e18868ae5c8ff_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfMi0xLTEtMS0yNTczOQ_31c75f12-5ffb-43dc-844f-f5b834622327"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0a10a7f26ddf4e71ae1239be47deed9d_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfMi0zLTEtMS0yNTczOQ_bf1c123a-05f2-4ac1-93d0-c0211e81c97a"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1e023361e8434930804854afbfdfd16d_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfMi01LTEtMS0yNTczOQ_8544c863-1c10-4e34-9d06-93e7cdb0a3c7"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i82d9fb00ead242beaea5c7ba0738621a_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfMy0xLTEtMS0yNTczOQ_e496b01f-f7a6-4610-8681-3bbeef8a08c8"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i23f80ed12dd445599bf289f8b30b88c0_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfMy0zLTEtMS0yNTczOQ_0f989277-5600-4488-9e4a-31070f3d5b2e"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0937e3d1b0e1474a8b6f5365e91705d4_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfMy01LTEtMS0yNTczOQ_ae98de8f-9413-419f-a34b-8b6a1d2b45a1"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i55441d6740314dfba8168bd2502b1101_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNC0xLTEtMS0yNTczOQ_0476584f-4a95-4e8c-a218-46f82f246730"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i259af2d579ef48a689f2076724ddc735_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNC0zLTEtMS0yNTczOQ_07e4a93b-627a-4e9f-b634-eec3c6fa1fce"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i594dc7db46f143248c87766268ac1585_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNC01LTEtMS0yNTczOQ_12a500c3-03f9-4e2c-8fe1-6a411fd92831"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0a26379cbf1740a7a0004b7311e38cc3_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNS0xLTEtMS00MTc1MA_ae3e5369-f058-4330-8302-2dd1dad6832b"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9b64a741d8eb4bc7bbac3a5db68a20bf_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNS0zLTEtMS00MTc1MA_0deb5798-0c7e-47f9-88df-5d509822a386"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib21e644bf9d94035b284ae2d64be8538_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNS01LTEtMS00MTc1MA_29821df6-bf70-4591-b9e6-56bf8368e269"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ica4c1bf73b7a497ea0f0cf3ee3121416_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNS0xLTEtMS0yNTczOQ_fc1b1e31-592a-486e-a84d-993f37d1741d"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8fa15b9421324d2a8abcc78e7bf8af23_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNS0zLTEtMS0yNTczOQ_c126edf4-2dda-45b8-9fc3-7d9e4a8a1ce9"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i829c8635dc1a41a8867b90164ddc5c42_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjBiZDM4YmMwMWEyODRmYmQ4ZGY1ZmRiOWRiMDgzNDgwL3RhYmxlcmFuZ2U6MGJkMzhiYzAxYTI4NGZiZDhkZjVmZGI5ZGIwODM0ODBfNS01LTEtMS0yNTczOQ_29eb2ed3-8805-446b-be1f-31ecf2209f05"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1a81f07947fc466f9ec4626bef20395b_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfMy0xLTEtMS0zMjQ1NQ_c5340b95-e11d-4a8b-95aa-eca730c9bf4d"
      unitRef="number">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iadbe770de5cb48ad8f72003a3c009cde_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfMy0zLTEtMS0zMjQ1NQ_876f3390-5f6e-4a13-8252-436ffe23d6db"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8b058fe448f6453eb17990c3983c40ce_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfNC0xLTEtMS0zMjQ1NQ_a43a2e62-6c28-4d4a-830a-76999643e655"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4e8a704120c54d7d9733625903a75c0a_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfNC0zLTEtMS0zMjQ1NQ_24a43235-8541-4ec0-a4eb-78f4dd5eb8ea"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ieb7ad7b5987c4c759bd3da195cccdda9_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfNi0xLTEtMS0zMjQ1NQ_5a652560-2c68-416c-9af8-c628830dd235"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6bc15983150c43b49a8bcd610f1d7622_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfNi0zLTEtMS0zMjQ1NQ_356d6530-a4d3-425a-9323-85eaa05561de"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5510c7d658a0420fa7c4fd22f06b733d_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfOS0xLTEtMS00MTc2OQ_5915003f-aa14-4d20-bf16-3cf504f22def"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id1d553018b3f4e6ea41bdee893c4681c_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfOS0zLTEtMS00MTc2OQ_97af8ebf-f6df-478d-a163-d27089cbe67f"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ieb41f135273846d2a5abf0e5b9d0f811_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfMTAtMS0xLTEtNDE3NzU_b34dde6c-d988-4974-bddc-dc7c324ce227"
      unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i56b939a4e3604e77961f68608050b413_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjA0MGMwM2IxNjE4MDQwNmJiZDAzZWMzMGQ5ZDExZmNjL3RhYmxlcmFuZ2U6MDQwYzAzYjE2MTgwNDA2YmJkMDNlYzMwZDlkMTFmY2NfMTAtMy0xLTEtNDE3NzU_9883cebc-c659-4457-b602-0ea559e91394"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfNDE4OQ_9c6eb15b-6004-48f3-842c-e221cf3d6efc">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdceca8137604720b9dfc7e6e415d661_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfMi01LTEtMS0yNTczOQ_b28e0de5-efee-4e70-96c5-78f922118256"
      unitRef="usd">1089396000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i985f069de23b4373be549c007d2be40a_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfMi03LTEtMS0yNTczOQ_cd1d3c59-c1a7-43e6-8a0d-4f5189fb036f"
      unitRef="usd">752890000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4c022e03b6b47659fb5320a00e0aff4_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfMi05LTEtMS0yNTczOQ_8b10bd5f-dc5a-40e5-8368-3ef08bdc4a99"
      unitRef="usd">770244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64d8b101cb28463dbafce9a36192a9ec_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfMy01LTEtMS0yNTczOQ_d5409cc4-7d04-4110-bfcb-4521549e9cd5"
      unitRef="usd">302073000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82c4a22039764f45bfeb541853e2006b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfMy03LTEtMS0yNTczOQ_a9ea0cc1-a6e0-4952-ba90-1ba05ccaee53"
      unitRef="usd">151631000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49d04f48075d4d9e9f242c365cff4b71_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfMy05LTEtMS0yNTczOQ_064d2c92-dfc9-4a96-9940-6078519e67ba"
      unitRef="usd">152771000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2625931db6f641d1b8631cee45c5421e_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfNC01LTEtMS0yNTczOQ_25a64611-7d02-4ebd-a134-8d807fe84377"
      unitRef="usd">43501000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3cfec9cb4d04224a58db1a0560d4779_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfNC03LTEtMS0yNTczOQ_ea71a971-2c1f-42e2-9f8b-92f8c558281a"
      unitRef="usd">83017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f60afd811e645cc996074e0cd13ebbc_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfNC05LTEtMS0yNTczOQ_96a77890-a4f4-4121-99a1-32ee3aa2ad0f"
      unitRef="usd">44760000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfNS01LTEtMS0yNTczOQ_ba27ca9c-cbb3-46d9-a1d7-dd40a10addca"
      unitRef="usd">1434970000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfNS03LTEtMS0yNTczOQ_fdcb3b06-c9cb-4e0c-84be-bad62c53f0d5"
      unitRef="usd">987538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjc0ZGY1MDNiM2RiZDQwZGY5NWE0MTM0MTE1N2EzOWRjL3RhYmxlcmFuZ2U6NzRkZjUwM2IzZGJkNDBkZjk1YTQxMzQxMTU3YTM5ZGNfNS05LTEtMS0yNTczOQ_cb4c7dec-8fa0-4c60-bbed-a7af5f5d0014"
      unitRef="usd">967775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfNDE5MA_a06f3eeb-f8e4-41f6-b460-f0953e5901c8">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie2cf41534cf94f309749ad6b44872d98_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMS0xLTEtMS0yNTczOQ_8cda6f4a-04c3-4c35-82a4-327a236e6dcc"
      unitRef="usd">7514000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic57cbc70ed644ce9845fcfed669b497f_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMS0zLTEtMS0yNTczOQ_0bf81d6a-73af-41c8-bcff-97dc31c1819d"
      unitRef="usd">3497000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0df0a5ea74244280ad89970ab96c16ea_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMS01LTEtMS0yNTczOQ_11b338b1-3d34-4163-8267-846bb0847d6f"
      unitRef="usd">15222000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2d03c75ce0024c01a62fcd27957b4f04_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMS03LTEtMS0yNTczOQ_007350c7-a43f-4da3-a1a8-a65388eefb9b"
      unitRef="usd">26233000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="ib3769502a95e4f3684d2ef761cae6724_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMy0xLTEtMS0yNTczOQ_eb375826-ad11-4810-b91d-887b1342b7aa"
      unitRef="usd">146537000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="ief35aa55eff1427188342697996d37a8_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMy0zLTEtMS0yNTczOQ_757ed7fb-44b4-4d81-b745-18e1e31edd8c"
      unitRef="usd">16162000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i8d6813dbf9b54533b3a13aa017eea398_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMy01LTEtMS0yNTczOQ_88b71eb6-a231-43a8-87fa-3725711ce673"
      unitRef="usd">58049000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMy03LTEtMS0yNTczOQ_b16763d3-f0b4-4cf5-a904-64f52f899569"
      unitRef="usd">220748000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="ib3769502a95e4f3684d2ef761cae6724_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNC0xLTEtMS0yNTczOQ_a104c8ff-abfb-42c9-8ae6-6567cdcac9ba"
      unitRef="usd">33000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="ief35aa55eff1427188342697996d37a8_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNC0zLTEtMS0yNTczOQ_1816f2f2-4897-4152-ba4f-f639b5ed78a9"
      unitRef="usd">-352000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i8d6813dbf9b54533b3a13aa017eea398_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNC01LTEtMS0yNTczOQ_17a1b369-48e6-4f25-a4a1-6e283b42e73b"
      unitRef="usd">612000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNC03LTEtMS0yNTczOQ_9f436ddf-b5d6-4cf1-9dd2-01c96d35d569"
      unitRef="usd">293000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib3769502a95e4f3684d2ef761cae6724_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNS0xLTEtMS0yNTczOQ_ba98845e-6eef-4578-b016-80ec078dfb2d"
      unitRef="usd">144231000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ief35aa55eff1427188342697996d37a8_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNS0zLTEtMS0yNTczOQ_d524a1a7-b468-4010-a5e4-53b1ad90f7f2"
      unitRef="usd">16028000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i8d6813dbf9b54533b3a13aa017eea398_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNS01LTEtMS0yNTczOQ_a3fad96b-18d1-4d59-956e-c25d479d92a6"
      unitRef="usd">56479000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNS03LTEtMS0yNTczOQ_adbdad9e-1c7f-4a2f-a955-55b2fc19a013"
      unitRef="usd">216738000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib163363f39ee47a1982ba34ffc40df1c_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNi0xLTEtMS0yNTczOQ_d8952650-df2d-4f49-a937-74a72b9c70d0"
      unitRef="usd">9853000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4afda954bcde4a2d8442e84ea5f75854_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNi0zLTEtMS0yNTczOQ_ce3d8e55-3667-4b99-91ce-0870413cc0ab"
      unitRef="usd">3279000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i08840e0ec9404f91bb1ed1e90793003e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNi01LTEtMS0yNTczOQ_882d3af2-f7fe-4367-bf36-726dc6678a69"
      unitRef="usd">17404000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfNi03LTEtMS0yNTczOQ_96209a2b-16b9-4b18-af78-02ba704a154b"
      unitRef="usd">30536000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i397c48f49ccd409781be83e43c34403b_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOC0xLTEtMS0yNTczOQ_2a249ee7-ae25-4f2f-aa08-3060df1908be"
      unitRef="usd">243119000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i0fd2c26c82744565a4a050d7c6936320_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOC0zLTEtMS0yNTczOQ_080ef138-ae83-4424-b62c-76649543b55a"
      unitRef="usd">30728000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="ib4bf39a5ebec49a9b8c7c07b6ba5968f_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOC01LTEtMS0yNTczOQ_445da589-e5a5-492a-940b-dddc7b642712"
      unitRef="usd">100361000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOC03LTEtMS0yNTczOQ_6633008a-8f91-4478-bda4-c8554350c186"
      unitRef="usd">374208000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i397c48f49ccd409781be83e43c34403b_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOS0xLTEtMS0yNTczOQ_2063d1ba-a27a-42ae-81fc-d6783e47637f"
      unitRef="usd">-64000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i0fd2c26c82744565a4a050d7c6936320_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOS0zLTEtMS0yNTczOQ_57705240-d062-4592-a9b5-a7ca353f7412"
      unitRef="usd">-111000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="ib4bf39a5ebec49a9b8c7c07b6ba5968f_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOS01LTEtMS0yNTczOQ_5f07217a-cbde-40af-8a1c-acab85cb8f50"
      unitRef="usd">1624000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfOS03LTEtMS0yNTczOQ_31e8f387-f66e-472b-9935-abdd61cc0a94"
      unitRef="usd">1449000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i397c48f49ccd409781be83e43c34403b_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTAtMS0xLTEtMjU3Mzk_3cf58799-39d5-4311-b4b9-bca50631379e"
      unitRef="usd">238283000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i0fd2c26c82744565a4a050d7c6936320_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTAtMy0xLTEtMjU3Mzk_c8ebca88-ed14-48a3-946c-8beed679c45b"
      unitRef="usd">25021000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib4bf39a5ebec49a9b8c7c07b6ba5968f_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTAtNS0xLTEtMjU3Mzk_0c209b4f-ee2e-4e6d-9f94-0d4c53d6d792"
      unitRef="usd">94564000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTAtNy0xLTEtMjU3Mzk_fd463a2d-8462-4bcf-af36-f1cb75c9f64e"
      unitRef="usd">357868000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3093413adbae48879b92be020f6b4f95_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTEtMS0xLTEtMjU3Mzk_e795381b-061b-4b02-b370-8e1eaaaa8bc9"
      unitRef="usd">14625000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i759ddcce81f44cffa575713b1c443bd0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTEtMy0xLTEtMjU3Mzk_f45f3a24-ad03-4a2b-bfa7-93e7890a7da6"
      unitRef="usd">8875000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4de04499606844f9a42cd833027456e2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTEtNS0xLTEtMjU3Mzk_ab5a902f-e532-4319-a95b-97f78cb7439d"
      unitRef="usd">24825000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjU4MWI5MTZkYzU2NjQ0YTc5ZDNkOGIwZjk1ZmQxODMwL3RhYmxlcmFuZ2U6NTgxYjkxNmRjNTY2NDRhNzlkM2Q4YjBmOTVmZDE4MzBfMTEtNy0xLTEtMjU3Mzk_b582cd15-5aa8-49f9-9d69-eabc67db0397"
      unitRef="usd">48325000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfNDE5MQ_40beb6d0-f808-40da-aa99-f27622828759">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Presented in other long-term assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;(3)&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfMi0xLTEtMS0yNTczOQ_6f0f0aab-6b98-4585-9b5a-c0121bf68510"
      unitRef="usd">1665000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfMi0zLTEtMS0yNTczOQ_e081fd4e-eae9-4262-9ce3-a4b97adbec13"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfNS0xLTEtMS0yNTczOQ_3021528c-8e79-40b2-811c-86c36d0c1ed8"
      unitRef="usd">7814000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfNS0zLTEtMS0yNTczOQ_8c11ea6b-ed51-4593-a087-3064abf83b69"
      unitRef="usd">1790000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfNi0xLTEtMS0yNTczOQ_ca131d4e-05ca-4266-aeb0-9352a2227368"
      unitRef="usd">8739000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfNi0zLTEtMS0yNTczOQ_d3a12f0b-22d9-497c-b79d-2281e944bb51"
      unitRef="usd">3755000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfNy0xLTEtMS0yNTczOQ_d066e0b3-9496-42ea-97ec-9442c18b0a60"
      unitRef="usd">16553000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RhYmxlOjFlYmRiYmQzMDQyMDQ1ZjJhOWY4MDcyODdhMWVkMGM0L3RhYmxlcmFuZ2U6MWViZGJiZDMwNDIwNDVmMmE5ZjgwNzI4N2ExZWQwYzRfNy0zLTEtMS0yNTczOQ_21686083-358b-4956-8aee-4ea6da590ab8"
      unitRef="usd">5545000</us-gaap:ContractWithCustomerLiability>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzMwOA_daae3495-e660-43d4-aae3-c80f64771952"
      unitRef="usd">8500000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzMxMg_7e08d216-04b4-4e33-b047-a6202eee833a"
      unitRef="usd">9200000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzMxOQ_5fa24314-b2d6-4d76-a84f-da489a50b632"
      unitRef="usd">6500000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzQ3OQ_7033d39d-cef5-4ada-a50d-eeb41b84f675"
      unitRef="usd">148700000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzQ4Mw_60197d4e-3fe7-45a4-a9b6-9538eee16c12"
      unitRef="usd">169700000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzQ5MA_02383aac-3c6d-40c6-b44e-03cf8b21c9c0"
      unitRef="usd">161200000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84NS9mcmFnOmI5MDJhNjBmYTRkZjRlMTViYTE5MWZlOTA5YzQzYTczL3RleHRyZWdpb246YjkwMmE2MGZhNGRmNGUxNWJhMTkxZmU5MDljNDNhNzNfMzc4Mg_8cb3f766-db17-4d50-9db6-45bd2f9e9170"
      unitRef="usd">87500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMzg1NTI_ab8b01dc-ee38-4de5-a938-69409ab487cf">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established multiple collaborations with leading biopharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have made considerable progress under our existing research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading biopharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, to receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. See &#x201c;Note 2. Revenues&#x201d; for additional information on revenues recognized under our collaboration agreements during the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Commercial Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ipsen Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Description of the Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#x2019; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#x2019;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#x2019;s ongoing development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021, Ipsen opted into and is now co-funding the development costs for COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with RAI-refractory DTC who have progressed after up to two VEGF receptor-targeted therapies. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ipsen &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s now obligated to reimburse us for their share of COSMIC-311 global development costs, as well as an additional payment calculated as a percentage of such costs, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;triggered by the timing of the exercise of its option. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the decision to opt in and co-fund the development costs for COSMIC-311 represented a contract modification for additional distinct services at their standalone selling price and therefore was treated as a separate contract under Topic 606. Accordingly, collaboration services revenues for the year ended December&#160;31, 2021, includes a cumulative catch-up of $43.2&#160;million for Ipsen&#x2019;s share of global development costs incurred since the beginning of the study and through the opt-in date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (1) the expiration of patent claims related to cabozantinib, (2) the expiration of regulatory exclusivity covering cabozantinib or (3) ten years after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the FDA or European Medicines Agency (EMA) orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#x2019;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consideration under the Collaboration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, we received aggregate upfront payments of $210.0 million from Ipsen in 2016. As of December&#160;31, 2021, we have achieved aggregate milestones of $462.5 million related to regulatory, development and sales-based threshold by Ipsen since the inception of the collaboration agreement, including $112.5 million, $20.0 million and $55.0 million in milestones achieved during the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of $46.5 million, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $350.0 million and CAD$26.5 million. We excluded these milestones from the transaction price as of December&#160;31, 2021 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will adjust the constraint applied to the variable consideration at each reporting period as uncertain events are resolved or other changes in circumstances occur. As of December&#160;31, 2021, $44.2 million of the transaction price allocated to our research and development services performance obligation had not been satisfied. See &#x201c;&#x2014;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#x201d;, below, for additional information related to the revenue recognition for this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;receive royalty revenues on the net sales of cabozantinib by Ipsen outside of t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he U.S. and Japan. During the year ended December&#160;31, 2021 and going forward, we are entitled to receive a tiered royalty of 22% to 26% on annual net sales, with separate tiers for Canada; these royalty tiers reset each calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to pay a 3% royalty on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for 35% of such costs, provided Ipsen chooses to opt into such trials. Ipsen has opted into and is co-funding certain clinical trials, including: CheckMate -9ER, COSMIC-021, COSMIC-311, COSMIC-312, CONTACT-01 and CONTACT-02.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Relatedly, we entered into a supply agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product is supplied at our cost, as defined in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from the Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone revenues for the year ended December&#160;31, 2021 included $100.0 million related to a commercial sales milestone from Ipsen upon their achievement of $400.0 million of net sales of cabozantinib in the related Ipsen license territory over four consecutive quarters and a $12.5 million regulatory milestone achieved upon submission of a variation application to the EMA for CABOMETYX as a treatment for patients with previously treated RAI-refractory DTC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Description of the Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018, May 2019 and September 2020, to, among other things, modify the amount of reimbursements we receive, for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive, as well as modify certain cost-sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02. We determined the amendment in September 2020 represented a contract modification that was treated as a termination of an existing contract and the creation of a new contract under Topic 606. As a result, we allocated the remaining transaction price to the performance obligations identified in the contract. The two remaining performance obligations are the research and development services associated with committed studies and the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. In allocating the transaction price for the modified contract we estimated the standalone selling price for the performance obligations. We utilized development costs incurred for these obligations in process and the projections of costs through the term of the arrangement. Revenue is recognized when, or as, we satisfy our performance obligations by transferring the promised services to Takeda. Revenue is being recognized using the cost proportional performance method, based on costs incurred to perform the research and development services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Takeda is responsible for a portion of the costs associated with the cabozantinib development plan&#x2019;s current and future trials, provided Takeda opts into such trials, and 100% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Takeda has opted into and is co-funding CheckMate -9ER, certain cohorts of COSMIC-021, CONTACT-01 and CONTACT-02. Under the collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#x2019; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (1) two years after first generic entry with respect to such product in Japan or (2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#x2019;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first six years of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#x2019; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consideration under the Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of $50.0 million from Takeda in 2017. As of December&#160;31, 2021, we have also achieved regulatory and development milestones in the aggregate of $127.0 million since the inception of the collaboration agreement, including $35.0 million, $66.0 million and $16.0 million in milestones achieved during the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, as amended in 2020, we are eligible to receive additional regulatory and development milestone payments, without contractual limit, for additional potential future indications. We are further eligible to receive commercial milestones, including milestone payments earned for the first commercial sale of a product, of up to $119.0 million. We excluded these milestones from the transaction price as of December&#160;31, 2021 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will adjust the constraint applied to the variable consideration at each reporting period as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also receive royalty revenues on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of 15% to 24% on the initial $300.0&#160;million of net sales, and following this initial $300.0&#160;million of net sales, we are then entitled to receive a tiered royalty of 20% to 30% on annual net sales thereafter; these 20% to 30% royalty tiers reset each calendar year. Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to pay a 3% royalty on all net sales of any product incorporating cabozantinib, including net sales by Takeda.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Additionally, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#x2019;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from the Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone revenues for the year ended December&#160;31, 2021 included $18.9&#160;million recognized in connection with a $20.0&#160;million milestone we achieved upon Takeda&#x2019;s first commercial sale in Japan of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable, advanced or metastatic RCC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, $43.3&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We identified two performance obligations for the Ipsen collaboration agreement: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib; and (2) research and development services, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We identified two remaining performance obligations for the Takeda collaboration agreement due to the amendment in September 2020: (1) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements) and (2) the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. As part of the original contract, we had a performance obligation associated with the exclusive license for the commercialization and further development of cabozantinib, which was transferred in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have allocated the transaction price for each of these collaborations to the identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and costs. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The portion of the transaction price allocated to our license performance obligation is recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union for the Ipsen Collaboration and Japan for the Takeda Collaboration, both of which are early 2030. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adjust the constraint applied to the variable consideration for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the years ended December&#160;31, 2021, 2020 and 2019, the transaction price of the Ipsen and Takeda collaboration agreements increased as a result of the achievement of various milestones, and the reimbursements of research and development services related to committed and opt-in studies. We further updated the transaction price based upon the actual research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of December&#160;31, 2021, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Development Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BMS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#x2019;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab as a treatment option for RCC in the COSMIC-313 trial. Under the collaboration agreement with BMS, we may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement with BMS, as subsequently amended effective March 2019, May 2019 and November 2019, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#x2019;s compounds in the conduct of each clinical trial. The parties&#x2019; efforts are governed through a joint development committee established to guide and oversee the collaboration&#x2019;s operation. Each trial is conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party is responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each such trial will be determined on a trial-by-trial basis. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;F. Hoffmann-La Roche Ltd. (Roche) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#x2019;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Under this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#x2019;s atezolizumab in patients with locally advanced or metastatic solid tumors, and in December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, including in the phase 3 pivotal clinical trials in advanced non-small cell lung cancer (CONTACT-01), metastatic castration-resistant prostate cancer (CONTACT-02) and RCC (CONTACT-03). If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond these phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2020, a supplement to the joint clinical research agreement was signed amongst us, Roche and Takeda due to Takeda opting into fund the combined therapy trial of CONTACT-01 sponsored by Roche. Chugai was added as an affiliate of Roche.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All parties including Chugai conduct combined therapy trials in Japan upon the terms of the joint clinical research agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#x2019;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#x2019; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply of their drug for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the contract is within the scope of Topic 808 as it involves joint operating activities where both parties have active participation in the arrangement and are exposed to significant risks and rewards. Payments between us and Roche under this arrangement are not subject to other accounting literature. Payments due to Roche for our share of clinical trial costs incurred by Roche will be recorded as research and development expense and payments due from Roche for their share of clinical trial costs incurred by us will be recorded as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GSK and Royalty Pharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GSK, that required us to pay a 3% royalty to GSK on the total worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. As disclosed in Note 2, we received notification that, effective January 1, 2021, Royalty Pharma acquired from GSK all rights, title and interest in royalties on total net sales of any product containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalty revenues earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalty revenues were $46.6 million, $32.7 million and $31.3 million during the years ended December&#160;31, 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genentech Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have out-licensed to Genentech under a worldwide collaboration agreement, the development and commercialization of cobimetinib, under the brand name COTELLIC. The terms of the collaboration agreement require that we share in the profits and losses received or incurred in connection with the commercialization of COTELLIC in the U.S. In addition to our profit share in the U.S., we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021, 2020, and 2019, we recognized $12.1 million, $11.3 million, and $10.3 million, in revenues from profits and losses on U.S commercialization and royalties on ex-U.S. sales under the collaboration agreement with Genentech and are included within license revenues on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Daiichi Sankyo&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. In January 2019, the Japanese Ministry of Health, Labour and Welfare approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have achieved milestones of $20.0&#160;million for the year ended December&#160;31, 2019 for the first commercial sale of MINNEBRO and are eligible to receive additional sales-based milestone payments of up to $90.0 million under this collaboration agreement. In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License revenue under the collaboration agreement with Daiichi Sankyo w&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as $3.8&#160;million, $1.3&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;an&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d $20.1&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Research Collaborations, In-Licensing Arrangements and Other Business Development Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into collaborative arrangements with other pharmaceutical or biotechnology companies to develop and commercialize drug candidates or intellectual property. Our research collaborations and in-licensing arrangements are intended to enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, development, regulatory, commercial milestone payments and royalty payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then assume the responsibilities for all subsequent clinical development, manufacturing and commercialization. In conjunction with each of these collaborative in-licensing arrangements, we were subject to upfront payments and will make payments for potential future development milestones of up to $254.3&#160;million, regulatory milestones of up to $426.5&#160;million and commercial milestones of up to $1,911.5&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales. In conjunction with an asset purchase agreement, we made payments of $10.0&#160;million for the initial technology transfer, and subject to certain conditions, will make a $4.0&#160;million payment upon the completion of the technology transfer of certain materials and documents specified in the asset purchase agreement. We will also make payments for potential future development milestones of up to $42.0&#160;million and regulatory milestones of up to $22.5&#160;million, per product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, we amended our collaboration agreement with Iconic to acquire broad rights to use the anti-TF antibody used in XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics. Under the amended agreement, we agreed to pay a final one-time payment to Iconic of $55.0&#160;million and will not owe any further payments, but we will continue to be responsible for milestone payments and royalties owed to other companies pursuant to prior agreements between Iconic and those companies. Upon signing the amendment, we recognized $55.0&#160;million in research and development expense, which amount was payable as of December 31, 2021 and presented in accrued collaboration liabilities in our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021, 2020, and 2019, we recognized &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$176.1&#160;million,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$96.4&#160;million and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$47.7&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, relating to upfront license payments, research and development funding, development milestones, option fees and other fees within research and development expenses on the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i7706be95a9254624abab7ee85d40a352_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNDM5ODA0NjYwMzAyNw_81d33703-1625-424e-a804-cdd4c9e96bc9"
      unitRef="usd">43200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
      contextRef="i17d251f0fc574727b702a0a5caffb000_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjI1Ng_1dc8ba26-9853-465e-86fd-3656cc5cb616">P10Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
    <exel:UpfrontPayments
      contextRef="icf154a58f6564ff1becceb69660b10e2_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNDA1MA_2a77414c-7386-4481-b54b-4a241807840a"
      unitRef="usd">210000000</exel:UpfrontPayments>
    <exel:MilestonePaymentsEarnedToDate
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNDEyNA_110d251b-b945-4267-9deb-60f00269c015"
      unitRef="usd">462500000</exel:MilestonePaymentsEarnedToDate>
    <exel:MilestonePaymentsEarned
      contextRef="i17d251f0fc574727b702a0a5caffb000_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNDI1OQ_84212d65-2513-41bf-88a0-814a5accf04f"
      unitRef="usd">112500000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="i6b9226f40009479393c872a6348134a4_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNDI2Mw_c69ee499-e791-4524-a55e-fc4936d34d36"
      unitRef="usd">20000000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="i63e4041671b44fd599695a551a6412e2_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NDQwMw_2d1ae6a5-b2f4-44e9-ac5e-26240c4dc6ac"
      unitRef="usd">55000000</exel:MilestonePaymentsEarned>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="ief888e56632141638b8427491992f9d0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNDQ4MA_036b1387-6264-43b7-998a-030bef089eb3"
      unitRef="usd">46500000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="ief888e56632141638b8427491992f9d0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NDQxMQ_05779994-adf0-4b56-90d4-9b548fd514e5"
      unitRef="usd">350000000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="ief888e56632141638b8427491992f9d0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NDQyMQ_d921d854-6eca-4158-b615-949117f55320"
      unitRef="cad">26500000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ief888e56632141638b8427491992f9d0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNTA5MQ_35146024-96ca-4258-9954-e558cdde784a"
      unitRef="usd">44200000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="id33282d755fe4cb187a33fa5ce4b49b5_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNTYxMA_f489aa67-f4e0-4d13-a62a-f12c774a173d"
      unitRef="number">0.22</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i4bf5c222f64a420686d2836dfecb6b8a_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNTYxNg_956ba169-aceb-4944-bf82-49614a52433d"
      unitRef="number">0.26</exel:PercentOfRoyaltyOnNetSale>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNjAwNw_be10e243-5402-4393-8922-bf4c0436cdb1"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
      contextRef="i17d251f0fc574727b702a0a5caffb000_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfNjM5Mg_eff1a6c6-b3e1-46c7-b655-e0a7de617ff3"
      unitRef="number">0.35</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMzg1NzY_2c4ef8c6-241b-4439-a98b-6904b24e36fa">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b9b091c2fe54910a111a558a4e92d80_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfMi01LTEtMS0yNTczOQ_1bfd73bb-de74-45d3-8aa2-ad12179cebb9"
      unitRef="usd">207982000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i648d323ea30a42229de3c89c4cb186d1_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfMi03LTEtMS0yNTczOQ_706dad96-e620-4798-9e7b-9c85e8783fe6"
      unitRef="usd">93495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic25f4e281d6f4588b0be1be89c974405_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfMi05LTEtMS0yNTczOQ_cd8ace9b-51f7-49e4-a7c5-a44de2a48d6e"
      unitRef="usd">117360000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7706be95a9254624abab7ee85d40a352_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfMy01LTEtMS0yNTczOQ_34b652d2-4755-48a4-847d-6385f52c7729"
      unitRef="usd">94091000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib32003bccc214ae19d1adc2aa36ec6bc_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfMy03LTEtMS0yNTczOQ_9471515c-0795-4520-9bc3-65ded36f8992"
      unitRef="usd">58136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if22970cfc6004d70bfd9ff40c42079f6_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfMy05LTEtMS0yNTczOQ_a93c9613-b6f9-4e77-9a7b-a213e0e7b5a2"
      unitRef="usd">35411000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17d251f0fc574727b702a0a5caffb000_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfNC01LTEtMS0yNTczOQ_46a7d01d-00a6-4bd2-b74c-99c3278067e5"
      unitRef="usd">302073000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b9226f40009479393c872a6348134a4_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfNC03LTEtMS0yNTczOQ_ad488190-c279-4606-b7de-e1f355381515"
      unitRef="usd">151631000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63e4041671b44fd599695a551a6412e2_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmI4MDg0NjkwNDkzMzRkYjQ4MTY3MmNlZmE2YWRiYTU1L3RhYmxlcmFuZ2U6YjgwODQ2OTA0OTMzNGRiNDgxNjcyY2VmYTZhZGJhNTVfNC05LTEtMS0yNTczOQ_2842d041-8e0f-4cdc-af61-901a9e35fb36"
      unitRef="usd">152771000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:RevenueFromContractWithCustomerCommercialSalesMilestone
      contextRef="ief888e56632141638b8427491992f9d0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUwOTg0OQ_8b9a9d94-3a31-465a-810e-67e9c7e9b82b"
      unitRef="usd">100000000</exel:RevenueFromContractWithCustomerCommercialSalesMilestone>
    <exel:RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold
      contextRef="ief888e56632141638b8427491992f9d0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUwOTg1Ng_708c507e-6d29-449b-a4f1-918d2354e4ac"
      unitRef="usd">400000000</exel:RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold>
    <exel:RevenueFromContractWithCustomerRegulatoryMilestone
      contextRef="ief888e56632141638b8427491992f9d0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NjQwMw_e161a1ff-e361-410e-bf7d-a493e7904b98"
      unitRef="usd">12500000</exel:RevenueFromContractWithCustomerRegulatoryMilestone>
    <exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
      contextRef="i34b71d32c3af4d2c99a249ce89216823_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTE1Mw_32104c94-2254-4d97-966d-464d376bf42d"
      unitRef="number">1</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
    <exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
      contextRef="i34b71d32c3af4d2c99a249ce89216823_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTAwMTE_e0185446-7d9d-45ff-95cf-5dd00095c145">P2Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
    <exel:PeriodOfSpecificSalesVolumeThreshold
      contextRef="idf4b8b36a8a1401ba536bf1da7af7544_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTA1NzA_2f8c737d-e1d5-4a27-b269-1842cbb7fefb">P6Y</exel:PeriodOfSpecificSalesVolumeThreshold>
    <exel:UpfrontPayments
      contextRef="i38b1163356184b27816cbad77cdf95c1_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTEzOTU_ba87c100-80fb-4272-819f-7e03653757af"
      unitRef="usd">50000000</exel:UpfrontPayments>
    <exel:MilestonePaymentsEarnedToDate
      contextRef="i1538f2b66fd943739c868b40f8b82675_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTE1MDk_a8cf5406-1c4a-49f0-a99f-8163474c111f"
      unitRef="usd">127000000</exel:MilestonePaymentsEarnedToDate>
    <exel:MilestonePaymentsEarned
      contextRef="idf4b8b36a8a1401ba536bf1da7af7544_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTE1NzQ_83c2f2c2-601b-43ac-bd1b-5047f569656c"
      unitRef="usd">35000000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="i942a6148cba44afbb7ce565e8f31caa4_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTE1Nzg_a5d20a02-89c4-4591-8184-6a1812ac9c2a"
      unitRef="usd">66000000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="i3d7a173be1fe468581278e8058aaa8ce_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NDQ0OQ_f1e84ccd-0168-4daa-b273-92b557e0b43d"
      unitRef="usd">16000000</exel:MilestonePaymentsEarned>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="i1538f2b66fd943739c868b40f8b82675_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTIyNDY_f6318d70-da7a-4a6e-8656-81714c59bc48"
      unitRef="usd">119000000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="ic3c4c0bb7d7c4d5ca6fcc41491abf1d5_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTI4NDA_130eaf6e-66fa-4ad0-afd0-acffe1aceb85"
      unitRef="number">0.15</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i6c892d9cb5bb4832a7807f3de3873c13_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTI4NDY_d46cc5de-0477-4606-a2aa-316c2bdb89c7"
      unitRef="number">0.24</exel:PercentOfRoyaltyOnNetSale>
    <exel:RoyaltyTier
      contextRef="i7de05268deff4e19bf1b0d6402584ef5_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTI4NjQ_b9c15334-c153-45f0-b7ad-77c3cda897a1"
      unitRef="usd">300000000</exel:RoyaltyTier>
    <exel:RoyaltyTier
      contextRef="i7de05268deff4e19bf1b0d6402584ef5_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTI5MDg_77094316-e2f2-4667-94f5-c432dfdb9484"
      unitRef="usd">300000000</exel:RoyaltyTier>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="ia18f9c05acb24284aaefe29c49159029_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTI5Nzc_11759e8a-8459-4811-bb44-e06dad689684"
      unitRef="number">0.20</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i9d5c9f1076cb460cb26ed364b3298866_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTI5ODM_ca04499a-1392-42be-a726-c4ba2bdbc791"
      unitRef="number">0.30</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="ia18f9c05acb24284aaefe29c49159029_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTMwMjQ_1455ea66-a5cb-4780-83b1-e9bf106ad58e"
      unitRef="number">0.20</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i9d5c9f1076cb460cb26ed364b3298866_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTMwMzA_31673828-4d04-40b5-a317-afb6e5b57952"
      unitRef="number">0.30</exel:PercentOfRoyaltyOnNetSale>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTMzNjI_be10e243-5402-4393-8922-bf4c0436cdb1"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80cf15e8b90b415da4f4ddf22cf5de86_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfMi01LTEtMS0yNTczOQ_f6c07c3a-e819-46cc-9796-831ed9d331d7"
      unitRef="usd">26058000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7549b7123a984430b1eeb8ed0453f49d_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfMi03LTEtMS0yNTczOQ_a6b20100-802c-4899-89b7-cadd39fc928a"
      unitRef="usd">61115000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bbf116ba95d4f99b046b08cf6886f20_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfMi05LTEtMS0yNTczOQ_d642c015-e4fa-4ba4-9a5a-12ac83adae54"
      unitRef="usd">18112000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88285abefe55431da86d133798712f97_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfMy01LTEtMS0yNTczOQ_cd223be8-b81a-4e25-85e6-0d2be5b71971"
      unitRef="usd">13667000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfa84e1a7dfa4fe394d99b30db90a03d_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfMy03LTEtMS0yNTczOQ_65f5cf5f-5f93-4fc6-a362-c18bf882e77a"
      unitRef="usd">20557000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i323181841f1447e19487c305609f6987_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfMy05LTEtMS0yNTczOQ_bb5f79cc-1d0b-4193-9c9a-2cad2abf8f15"
      unitRef="usd">6510000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf4b8b36a8a1401ba536bf1da7af7544_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfNC01LTEtMS0yNTczOQ_0554db00-c98f-486a-bdec-8371ab4a8045"
      unitRef="usd">39725000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i942a6148cba44afbb7ce565e8f31caa4_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfNC03LTEtMS0yNTczOQ_6c2fc843-013b-4614-80e8-5a277ef42bf9"
      unitRef="usd">81672000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d7a173be1fe468581278e8058aaa8ce_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RhYmxlOmNmZmNmNjc3YmJlNDQwZjI4Y2FkYWRkYjRiZDllYjQ1L3RhYmxlcmFuZ2U6Y2ZmY2Y2NzdiYmU0NDBmMjhjYWRhZGRiNGJkOWViNDVfNC05LTEtMS0yNTczOQ_da127449-4380-40d1-b9dd-77241b29ba82"
      unitRef="usd">24622000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="idf4b8b36a8a1401ba536bf1da7af7544_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NjY5Nw_ad5af46f-7612-43d8-a077-8467d8bdfc3e"
      unitRef="usd">18900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <exel:RevenueFromContractWithCustomerCommercialSalesMilestone
      contextRef="i1538f2b66fd943739c868b40f8b82675_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5NjcwNg_4fa19c6a-3884-408a-befe-e543e8ef661b"
      unitRef="usd">20000000</exel:RevenueFromContractWithCustomerCommercialSalesMilestone>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i1538f2b66fd943739c868b40f8b82675_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTQ2NDU_14900b7c-d960-4062-b8a8-ac89fef3f26e"
      unitRef="usd">43300000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzI5ODMzNg_be10e243-5402-4393-8922-bf4c0436cdb1"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="i8c3ac03ee7454b6cac8c397afd4482c4_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjYyOTE_887ea585-d8f2-48b4-9cac-3f9e1fc69218"
      unitRef="usd">46600000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i40846f2291b646d0925baa2444ab430c_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjYyOTU_fc8f3dac-f31f-40b1-b5cc-e20c188825a5"
      unitRef="usd">32700000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="id1f0fc047c9c4e42b491251f2246216c_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjYzMDI_39d7eee5-283b-445f-88a4-5881ce0c1fb5"
      unitRef="usd">31300000</us-gaap:RoyaltyExpense>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52b8f7772fdd4b28b6761a4c19816e52_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUxNDIwNQ_0157a15e-e8b5-407c-a329-b8c6200369a8"
      unitRef="usd">12100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ae90a8873dd4429b24fbecb4ac765cc_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUxNDE2OQ_edb8e951-b223-4f1e-b8df-1df11c9aa825"
      unitRef="usd">11300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5410770ddf84f099461a42667531965_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUxNDE4OA_eb248088-e1cb-4857-8af0-5ea4995bcd89"
      unitRef="usd">10300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborativeArrangementAchievedMilestoneAmount
      contextRef="i7c1a218589024464b368812dcad02030_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzMyMTU0OA_e30a3398-aa65-4c30-abfd-365a2727b20e"
      unitRef="usd">20000000</exel:CollaborativeArrangementAchievedMilestoneAmount>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="i719737a56e4940dbaa44028a2131e87c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMzAzOTg_3ed4007f-473f-42f0-a7f5-7cf1ae955d61"
      unitRef="usd">90000000</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17469019aafd4e60b3681951461b5e32_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzMyMTY5OA_0f45fe3e-e122-48bc-8079-b315c5a6a5a4"
      unitRef="usd">3800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i248a08fc00de455a8ba90662b6913cf3_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzMyMTY4Mg_44406912-8ea7-4433-a096-aa4dee20c405"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c1a218589024464b368812dcad02030_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMjE5OTAyMzMyMTcwOA_af45bced-0553-4ff6-bb27-bfb59cd95025"
      unitRef="usd">20100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
      contextRef="i845d978e80a94a059981545b4eaedc37_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUyODk2OA_dce34e8e-90ad-4b26-9ace-81e0aee596a0"
      unitRef="usd">254300000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
      contextRef="i845d978e80a94a059981545b4eaedc37_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUyODk5MA_5d367b47-8a74-4f87-ab3e-3f4cd2c3eade"
      unitRef="usd">426500000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments
      contextRef="i845d978e80a94a059981545b4eaedc37_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUyOTAxMQ_fda5f99c-8c6f-48ef-a82c-c3d5903f751e"
      unitRef="usd">1911500000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i2b021f45a0fa49c89d6035c19eaadbb3_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTM0NTg0ODk2NTEwMw_ce3bd48e-9a9b-4a7c-bd76-9e953cdb0766"
      unitRef="usd">10000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <exel:AssetAcquisitionPaymentUponClosingOfTransaction
      contextRef="i80195f3436714ec884ca333c40f2ee26_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTM0NTg0ODk2NTExOA_7fd8dbdb-46c2-43b8-a382-871c72541ba5"
      unitRef="usd">4000000</exel:AssetAcquisitionPaymentUponClosingOfTransaction>
    <exel:AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments
      contextRef="i80195f3436714ec884ca333c40f2ee26_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTM0NTg0ODk2NTEzMg_f8c467c6-28bc-4afd-a8a8-7bc42f14911f"
      unitRef="usd">42000000</exel:AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments>
    <exel:AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments
      contextRef="i80195f3436714ec884ca333c40f2ee26_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTM0NTg0ODk2NTE0Nw_3a89be01-efb3-4a9d-b842-acde54f567a7"
      unitRef="usd">22500000</exel:AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsFinalPayment
      contextRef="ia542815387ba453f9fd900fe25937400_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTM0NTg0ODkyNjU0OQ_b846acd1-2430-46ef-b7fb-e3a65a5c17d7"
      unitRef="usd">55000000</exel:CollaborativeArrangementRightsAndObligationsFinalPayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia542815387ba453f9fd900fe25937400_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfOTM0NTg0ODkyNjU2NA_56c166ca-b02f-4b3b-9902-73b399a2f5b4"
      unitRef="usd">55000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i839b859fbed548e38efc5fce9e64593a_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUyOTA1OA_4a9064c1-e54c-4054-9b20-cc9a519d9555"
      unitRef="usd">176100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib5a2784ff7d840bb982a4bc7823f075a_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUyOTA2MQ_5ed9a110-c976-4b58-b27e-b5f739d1246a"
      unitRef="usd">96400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iad9dc6f5753a41ed9d96d235cc5108ba_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF84OC9mcmFnOjRmYzExN2M1NDgwZDRmYjlhMzBjMTVhMzRhZmM5ZDMwL3RleHRyZWdpb246NGZjMTE3YzU0ODBkNGZiOWEzMGMxNWEzNGFmYzlkMzBfMTY0OTI2NzUyOTA2NA_23c89de0-cfa6-42f9-8c3c-0609844a8a1d"
      unitRef="usd">47700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjI2NA_b55c9f48-cd0b-483f-84cb-eb2e6b021ac1">CASH AND INVESTMENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of December&#160;31, 2021, restricted cash equivalents included $15.2 million of short-term investments, which is collateral under our January 2021 standby letter of credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable was $2.9 million and $4.5 million as of December&#160;31, 2021 and 2020, respectively, and is included in prepaid and other current assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were insignificant during the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All securities presented have been in an unrealized loss position for less than 12 months. There were 133 and 14 debt securities in an unrealized loss position as of December&#160;31, 2021 and 2020, respectively. During the years ended December&#160;31, 2021 and 2020, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjI1NA_c55eb145-dc84-4c3a-b4c9-a1acdcc0935b">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjI2NQ_0e558e71-bd49-40e8-ad72-96d0342961bf">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjYwNDEzMDZmZGE5ZjQyNjQ5ZjUwM2Q1MGVlOTQwM2UwL3RhYmxlcmFuZ2U6NjA0MTMwNmZkYTlmNDI2NDlmNTAzZDUwZWU5NDAzZTBfMi0xLTEtMS0yNTczOQ_1dfb53d8-3993-4513-a9e3-4fcf0bd6b409"
      unitRef="usd">647169000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjYwNDEzMDZmZGE5ZjQyNjQ5ZjUwM2Q1MGVlOTQwM2UwL3RhYmxlcmFuZ2U6NjA0MTMwNmZkYTlmNDI2NDlmNTAzZDUwZWU5NDAzZTBfMi0zLTEtMS0yNTczOQ_56cb6928-3e6f-4dbc-8a16-e74ff4be9f4e"
      unitRef="usd">319217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjYwNDEzMDZmZGE5ZjQyNjQ5ZjUwM2Q1MGVlOTQwM2UwL3RhYmxlcmFuZ2U6NjA0MTMwNmZkYTlmNDI2NDlmNTAzZDUwZWU5NDAzZTBfNC0xLTEtMS0yNTczOQ_35eb06ba-6baa-4051-906d-c54444bf92b4"
      unitRef="usd">16722000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjYwNDEzMDZmZGE5ZjQyNjQ5ZjUwM2Q1MGVlOTQwM2UwL3RhYmxlcmFuZ2U6NjA0MTMwNmZkYTlmNDI2NDlmNTAzZDUwZWU5NDAzZTBfNC0zLTEtMS0yNTczOQ_2f007c27-94a1-4b54-9222-392ae79e999d"
      unitRef="usd">1555000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjYwNDEzMDZmZGE5ZjQyNjQ5ZjUwM2Q1MGVlOTQwM2UwL3RhYmxlcmFuZ2U6NjA0MTMwNmZkYTlmNDI2NDlmNTAzZDUwZWU5NDAzZTBfNS0xLTEtMS0yNTczOQ_fd388c80-a10f-49ba-a4b3-c60734104b9d"
      unitRef="usd">663891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjYwNDEzMDZmZGE5ZjQyNjQ5ZjUwM2Q1MGVlOTQwM2UwL3RhYmxlcmFuZ2U6NjA0MTMwNmZkYTlmNDI2NDlmNTAzZDUwZWU5NDAzZTBfNS0zLTEtMS0yNTczOQ_03306313-354a-4f47-9835-5262fa016aba"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMTY0OTI2NzQ0NDA3NA_fb7af98d-924a-4b74-997a-6822f3e39066"
      unitRef="usd">15200000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjI3Mw_3b872c3a-d7dc-4e40-8fbe-f1437b3c0034">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i05641e68bc9f435c9afd7cdec45e36aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMy0xLTEtMS0yNTczOQ_801142b0-935b-44ea-adc3-0966e28c1283"
      unitRef="usd">945801000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i05641e68bc9f435c9afd7cdec45e36aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMy0zLTEtMS0yNTczOQ_abb812ed-b5dd-4dbf-8be2-ed0884749da0"
      unitRef="usd">42000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i05641e68bc9f435c9afd7cdec45e36aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMy01LTEtMS0yNTczOQ_c5c88b1b-ab20-43bf-8e8c-d5a21829dbf9"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i05641e68bc9f435c9afd7cdec45e36aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMy03LTEtMS0yNTczOQ_2ac6f97b-4ec2-45bf-b3b3-7276948dbe12"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6ff13830445e478385149192df956f88_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNC0xLTEtMS0yNTczOQ_e5d21e5f-33cc-4ad8-aab9-c987cd9d97a9"
      unitRef="usd">541774000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6ff13830445e478385149192df956f88_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNC0zLTEtMS0yNTczOQ_5d344eed-dc5e-4d4d-a82e-5cc2516eb296"
      unitRef="usd">876000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6ff13830445e478385149192df956f88_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNC01LTEtMS0yNTczOQ_c392538b-d9b8-4075-8129-e89abf29234b"
      unitRef="usd">1672000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ff13830445e478385149192df956f88_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNC03LTEtMS0yNTczOQ_e86e36f6-e0d4-46c7-8518-268319693fcc"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNS0xLTEtMS0yNTczOQ_2fd98055-8a58-4e9c-b258-20b60be415e8"
      unitRef="usd">33965000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNS0zLTEtMS0yNTczOQ_5ccb3dc2-04df-4680-95e6-ceb47089e43a"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNS01LTEtMS0yNTczOQ_5cd5418c-6adb-428c-9161-884452b643c0"
      unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNS03LTEtMS0yNTczOQ_aaeea0bc-be76-40ff-a395-1ccb7b542b60"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i23bea1dd75274b42a74758ecc6636623_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNi0xLTEtMS0yNTczOQ_50b4c5f3-9626-47d4-b3e1-4d7d46933f90"
      unitRef="usd">12924000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i23bea1dd75274b42a74758ecc6636623_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNi0zLTEtMS0yNTczOQ_310fe16c-5432-4800-a7b0-a83a49d82c4b"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i23bea1dd75274b42a74758ecc6636623_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNi01LTEtMS0yNTczOQ_7cb95608-c818-4f8e-9271-684c6b5a7b26"
      unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i23bea1dd75274b42a74758ecc6636623_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNi03LTEtMS0yNTczOQ_eb566ba9-92f9-4749-9e21-6f511752de38"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNy0xLTEtMS0yNTczOQ_9c8a523b-6f4e-4482-9efd-b92880360ff3"
      unitRef="usd">1534464000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNy0zLTEtMS0yNTczOQ_0493851b-51c5-4b8f-a66d-9e10ba828ed2"
      unitRef="usd">934000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNy01LTEtMS0yNTczOQ_f270e733-2986-491d-8f10-1bc0015a1ac7"
      unitRef="usd">1730000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfNy03LTEtMS0yNTczOQ_da77f391-9687-44b2-9d29-6828cad70771"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ia2a61bcc4c3649f59f6a080941f4f893_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOC0xLTEtMS0yNTczOQ_19df3ce2-7283-457e-afe4-dc6b4f3bef4e"
      unitRef="usd">135653000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ia2a61bcc4c3649f59f6a080941f4f893_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOC0zLTEtMS0yNTczOQ_433f0e02-97de-4a60-944f-53440f1fed8c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ia2a61bcc4c3649f59f6a080941f4f893_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOC01LTEtMS0yNTczOQ_bd162880-ce1d-43bd-a866-c06323ccf485"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ia2a61bcc4c3649f59f6a080941f4f893_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOC03LTEtMS0yNTczOQ_d421a32c-52c9-495e-967e-8eb91084df74"
      unitRef="usd">135653000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ic64b739b318847c59da0eae266f9d1f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOS0xLTEtMS0yNTczOQ_0bf224e2-d668-4ca9-af82-9a344ae01570"
      unitRef="usd">66531000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ic64b739b318847c59da0eae266f9d1f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOS0zLTEtMS0yNTczOQ_62eacf0e-d08e-4cd7-8591-f4a40ec68adc"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ic64b739b318847c59da0eae266f9d1f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOS01LTEtMS0yNTczOQ_5db4a0f6-d918-4af3-a227-14dd4c3ba4c2"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ic64b739b318847c59da0eae266f9d1f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfOS03LTEtMS0yNTczOQ_41750981-cb63-47f8-af86-3445ae164ea6"
      unitRef="usd">66531000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i6a311ca42562471db4f27e25d6d36db3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTAtMS0xLTEtMjU3Mzk_cb0351cd-3077-490a-b9b7-4e06e42484a6"
      unitRef="usd">119056000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i6a311ca42562471db4f27e25d6d36db3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTAtMy0xLTEtMjU3Mzk_f9de7242-ad2f-4470-95c2-1ce90b71bba3"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i6a311ca42562471db4f27e25d6d36db3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTAtNS0xLTEtMjU3Mzk_21b80362-3447-4d26-a57c-0cd921307a3c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i6a311ca42562471db4f27e25d6d36db3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTAtNy0xLTEtMjU3Mzk_5a35f522-bc33-4a9a-bf3f-491a300c9b2d"
      unitRef="usd">119056000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTEtMS0xLTEtMjU3Mzk_934abce3-29a8-4eac-8380-005c13ef7960"
      unitRef="usd">1855704000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTEtMy0xLTEtMjU3Mzk_3e5ce290-13ec-4665-950b-d1fa4a66f757"
      unitRef="usd">934000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTEtNS0xLTEtMjU3Mzk_037f9b22-03dc-4180-a4fc-b7dac70bf1c5"
      unitRef="usd">1730000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjFiZDY2ZDYwNzY4NDQyYmI5MjM4MjBjZmYxOTU0ZDU4L3RhYmxlcmFuZ2U6MWJkNjZkNjA3Njg0NDJiYjkyMzgyMGNmZjE5NTRkNThfMTEtNy0xLTEtMjU3Mzk_154cf489-2816-4e4c-8113-aad7de4d7bb0"
      unitRef="usd">1854908000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i602bcc576371462380cb7add7c08ac3a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMy0xLTEtMS0yNTczOQ_f5e83414-7070-4996-9b1d-64d49d66b7d6"
      unitRef="usd">569456000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i602bcc576371462380cb7add7c08ac3a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMy0zLTEtMS0yNTczOQ_2a39a544-459b-48e3-bc10-17e77534b18d"
      unitRef="usd">372000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i602bcc576371462380cb7add7c08ac3a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMy01LTEtMS0yNTczOQ_88a032cc-5449-4c20-9046-b00cf0fb6d23"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i602bcc576371462380cb7add7c08ac3a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMy03LTEtMS0yNTczOQ_18b59206-1090-4ee1-8948-3359b694eeea"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNC0xLTEtMS0yNTczOQ_89aaa9e6-7a77-4f57-9453-d9a4cdcc3ef0"
      unitRef="usd">543520000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNC0zLTEtMS0yNTczOQ_c4dbae42-52bd-4ff7-a202-a46d75dc22fc"
      unitRef="usd">5244000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNC01LTEtMS0yNTczOQ_a728d4c8-ddf5-49c6-9745-cc93d98aada5"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNC03LTEtMS0yNTczOQ_c46a9a15-1d11-4574-9d9e-4e34cab34a9d"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iba29b67627794a5d9e0a76791c683b2e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS0xLTEtMS0yODgyMw_80b62a8b-ad75-4f06-aed5-2c3a2d95b2c8"
      unitRef="usd">208326000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iba29b67627794a5d9e0a76791c683b2e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS0zLTEtMS0yODgyOA_f9de3a2f-b6b2-4ae1-9128-b71ad9da083b"
      unitRef="usd">232000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iba29b67627794a5d9e0a76791c683b2e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS01LTEtMS0yODgzMA_0305aa8e-f4c7-498f-98d5-f64210af976e"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iba29b67627794a5d9e0a76791c683b2e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS03LTEtMS0zNzQ0NA_d29004d3-da3b-4a3c-9c2d-6a5c272d0ae5"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i59895032150e486295f216709b152e49_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS0xLTEtMS0yNTczOQ_1cc839f1-eb98-49b8-97c3-634041eb5e0b"
      unitRef="usd">28680000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i59895032150e486295f216709b152e49_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS0zLTEtMS0yNTczOQ_0055c7ae-bfcb-412a-9001-f01a3ea4e2b2"
      unitRef="usd">83000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i59895032150e486295f216709b152e49_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS01LTEtMS0yNTczOQ_69362d3e-72ec-494c-957f-7bd22e88daa6"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i59895032150e486295f216709b152e49_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNS03LTEtMS0yNTczOQ_548f33a3-4cda-4e17-867f-708a3cd33696"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNi0xLTEtMS0yNTczOQ_99f6bb5b-e8f1-4595-bc70-36e083474555"
      unitRef="usd">1349982000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNi0zLTEtMS0yNTczOQ_d015db6c-5adf-4998-96bb-68bcf3720f11"
      unitRef="usd">5931000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNi01LTEtMS0yNTczOQ_1cfc59c5-140c-4417-bc68-41e288ab2a95"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNi03LTEtMS0yNTczOQ_c7ece3ad-00f8-46e4-ac62-75b03963f7b5"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i8be401936c61402c92d2967c8b58ca3b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNy0xLTEtMS0yNTczOQ_e7bc631f-bb22-4483-8584-d59fdf8f7dad"
      unitRef="usd">82176000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i8be401936c61402c92d2967c8b58ca3b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNy0zLTEtMS0yNTczOQ_8b85de3d-5892-40e0-9f59-a90f64546250"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i8be401936c61402c92d2967c8b58ca3b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNy01LTEtMS0yNTczOQ_92439379-1afc-4dcc-a263-61387c15c999"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i8be401936c61402c92d2967c8b58ca3b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfNy03LTEtMS0yNTczOQ_f27a8792-0f51-4d0d-991f-5015f46ca045"
      unitRef="usd">82176000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="iee1391eefb1148f5911a99610fca2132_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOC0xLTEtMS0yNTczOQ_f2bcdfc1-7c21-4779-a776-331553a04f84"
      unitRef="usd">40761000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="iee1391eefb1148f5911a99610fca2132_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOC0zLTEtMS0yNTczOQ_f61523cc-a891-4ce3-bef5-818ac8d4ccfc"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="iee1391eefb1148f5911a99610fca2132_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOC01LTEtMS0yNTczOQ_3a346472-560d-445e-8d34-70aca3b504d9"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="iee1391eefb1148f5911a99610fca2132_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOC03LTEtMS0yNTczOQ_fb2ebd49-6a98-4f55-80b8-ccbd01a26e1e"
      unitRef="usd">40761000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i2243e5b1033e41bfa89446b83583a6e5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOS0xLTEtMS0yNTczOQ_09fcaa36-58bd-4ca5-810f-c9528d9662da"
      unitRef="usd">60004000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i2243e5b1033e41bfa89446b83583a6e5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOS0zLTEtMS0yNTczOQ_55f4cb0a-d71a-4ed7-8124-b9ae59b1f78d"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i2243e5b1033e41bfa89446b83583a6e5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOS01LTEtMS0yNTczOQ_9d172530-1cbc-454b-adc8-c383419a4374"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i2243e5b1033e41bfa89446b83583a6e5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfOS03LTEtMS0yNTczOQ_0a6c1274-f98c-4edf-bf96-1b4762619356"
      unitRef="usd">60004000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMTAtMS0xLTEtMjU3Mzk_511c9a9b-f013-4020-9f5e-190a83bd52e3"
      unitRef="usd">1532923000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMTAtMy0xLTEtMjU3Mzk_1a5554fe-e4fa-45e4-8509-4d6a4cd4151a"
      unitRef="usd">5931000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMTAtNS0xLTEtMjU3Mzk_b537a872-e6d6-4047-8374-78a8d43624d3"
      unitRef="usd">12000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjAzNjJjZjg2MWM5MjRhM2VhNTVlMGMxZDAyMjYyMzZhL3RhYmxlcmFuZ2U6MDM2MmNmODYxYzkyNGEzZWE1NWUwYzFkMDIyNjIzNmFfMTAtNy0xLTEtMjU3Mzk_3d559598-0083-43e0-bcaf-a7d9e87557d8"
      unitRef="usd">1538842000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfNzcy_5cc3720c-6fe7-42f4-84da-c2af49db6bca"
      unitRef="usd">2900000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfNzc5_f38c699e-f763-485e-81ed-cdaf7e55e2a8"
      unitRef="usd">4500000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjI2OA_812f488c-58a4-4123-be2a-1686903bbdfd">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i6ff13830445e478385149192df956f88_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfMy0xLTEtMS0yNTczOQ_f4ab5e43-4566-49a0-81d2-4bbc7da34b7f"
      unitRef="usd">385053000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i6ff13830445e478385149192df956f88_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfMy0zLTEtMS0yNTczOQ_243724af-9943-428c-bc93-af78e09f80dd"
      unitRef="usd">1672000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i05641e68bc9f435c9afd7cdec45e36aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNC0xLTEtMS0zOTQ3Mg_22d4b1c5-d339-4e51-8126-075522e9887e"
      unitRef="usd">43290000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i05641e68bc9f435c9afd7cdec45e36aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNC0zLTEtMS0zOTQ3Mg_e8901ba2-7f89-46d7-8fa1-98e02c2c5c08"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNC0xLTEtMS0yNTczOQ_c3363991-4f61-4e80-af63-40da475ff5a0"
      unitRef="usd">18962000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i88fe82fc80f7414a8c96da62ea63ce9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNC0zLTEtMS0yNTczOQ_97a7c9e7-5454-4e73-8731-4f349e5ed0d9"
      unitRef="usd">21000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i23bea1dd75274b42a74758ecc6636623_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNS0xLTEtMS0yNTczOQ_04b4997e-2702-4687-8f0d-cf9e9a950b38"
      unitRef="usd">7475000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i23bea1dd75274b42a74758ecc6636623_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNS0zLTEtMS0yNTczOQ_47dcf772-d3d6-4534-a658-a4bd88a7cc94"
      unitRef="usd">35000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNi0xLTEtMS0yNTczOQ_1e686174-fab5-4155-8362-e525ff17ab80"
      unitRef="usd">454780000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjUzOWEwYjBjN2QyMzQ1ZGJhZTcwZTkyMGViZDY0ZjM1L3RhYmxlcmFuZ2U6NTM5YTBiMGM3ZDIzNDVkYmFlNzBlOTIwZWJkNjRmMzVfNi0zLTEtMS0yNTczOQ_a2771157-dc74-4b3e-bf86-6e85fa4f386f"
      unitRef="usd">1730000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfMy0xLTEtMS0yNTczOQ_455f7881-6719-4f7e-a0cd-cd4faf025a4f"
      unitRef="usd">28445000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ie02d925b7fb94ce39a2dfd7a3a1896ae_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfMy0zLTEtMS0yNTczOQ_b7ea8ad9-826e-4f3f-82fe-9cacb42c70a0"
      unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iba29b67627794a5d9e0a76791c683b2e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfNC0xLTEtMS0yNTczOQ_f57bb86b-acf7-44f3-88b3-399ef2e9a458"
      unitRef="usd">21989000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iba29b67627794a5d9e0a76791c683b2e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfNC0zLTEtMS0yNTczOQ_d1447609-113c-4af3-9800-1fe6d600d2f8"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i59895032150e486295f216709b152e49_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfNS0xLTEtMS0yODg2Ng_fef4fb51-21e7-4d31-ad15-4c4cc141069d"
      unitRef="usd">5865000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i59895032150e486295f216709b152e49_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfNS0zLTEtMS0yODg3NA_7a0cbcd0-d29d-4656-a149-5f8f48686604"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfNi0xLTEtMS0yNTczOQ_986e3a6b-016f-421f-ad8a-dc23f7583fe9"
      unitRef="usd">56299000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOjJjZTY5N2ViYjNiNTRjZWVhM2YyYTAyMTZmZjcwYWExL3RhYmxlcmFuZ2U6MmNlNjk3ZWJiM2I1NGNlZWEzZjJhMDIxNmZmNzBhYTFfNi0zLTEtMS0yNTczOQ_5a6a4211-17da-4996-93c9-22a618d17545"
      unitRef="usd">12000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMTUxMw_89e3861a-2c13-4552-b92c-7184e52775e6"
      unitRef="investment">133</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMTUyMA_cf23f732-b273-4b36-addf-08b189940f94"
      unitRef="investment">14</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjE5OTAyMzI1Nzg4Ng_020b9f73-a6b3-487b-b17a-416b2f24345e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjE5OTAyMzI1Nzg4Ng_cacfafd7-0f99-4e0c-847f-dd511fe95eeb"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RleHRyZWdpb246NWM4YzVlYzFjY2QwNGNiZDk3M2IwN2U3Mjg3MjY3YjBfMjI1MA_79e451ff-8368-42bb-b7e7-fce96471a742">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOmE2YjA0Zjk3YWE1YzRjZDE4ZDU2OGYxOThmZjYwYmFiL3RhYmxlcmFuZ2U6YTZiMDRmOTdhYTVjNGNkMThkNTY4ZjE5OGZmNjBiYWJfMi0xLTEtMS0yNTczOQ_39fc381b-8980-4cd6-9da5-f853a8a7fdf5"
      unitRef="usd">1168256000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOmE2YjA0Zjk3YWE1YzRjZDE4ZDU2OGYxOThmZjYwYmFiL3RhYmxlcmFuZ2U6YTZiMDRmOTdhYTVjNGNkMThkNTY4ZjE5OGZmNjBiYWJfMi0zLTEtMS0yNTczOQ_9d6a7319-0db2-4f53-9328-ce0be1573c59"
      unitRef="usd">1034150000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOmE2YjA0Zjk3YWE1YzRjZDE4ZDU2OGYxOThmZjYwYmFiL3RhYmxlcmFuZ2U6YTZiMDRmOTdhYTVjNGNkMThkNTY4ZjE5OGZmNjBiYWJfMy0xLTEtMS0yNTczOQ_49a8511f-cc2a-488d-85ae-519ee1a6681b"
      unitRef="usd">365412000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOmE2YjA0Zjk3YWE1YzRjZDE4ZDU2OGYxOThmZjYwYmFiL3RhYmxlcmFuZ2U6YTZiMDRmOTdhYTVjNGNkMThkNTY4ZjE5OGZmNjBiYWJfMy0zLTEtMS0yNTczOQ_021dbf4e-2d3d-4dbe-a098-c2ba9c7310a2"
      unitRef="usd">321751000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOmE2YjA0Zjk3YWE1YzRjZDE4ZDU2OGYxOThmZjYwYmFiL3RhYmxlcmFuZ2U6YTZiMDRmOTdhYTVjNGNkMThkNTY4ZjE5OGZmNjBiYWJfNC0xLTEtMS0yNTczOQ_395a3cfe-4546-4ede-981a-04a91f3f95c7"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85MS9mcmFnOjVjOGM1ZWMxY2NkMDRjYmQ5NzNiMDdlNzI4NzI2N2IwL3RhYmxlOmE2YjA0Zjk3YWE1YzRjZDE4ZDU2OGYxOThmZjYwYmFiL3RhYmxlcmFuZ2U6YTZiMDRmOTdhYTVjNGNkMThkNTY4ZjE5OGZmNjBiYWJfNC0zLTEtMS0yNTczOQ_ce9af42c-ec12-42f0-9216-6f97dafd5ee0"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RleHRyZWdpb246NTQwMWIzYTY3MTNkNDU0MzlhMmNhM2IwYWIxNjg5NDJfMTU0NQ_c84d7673-fcd4-4065-8b2c-9ae087af32d7">FAIR VALUE MEASUREMENTS &lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt"&gt;Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt"&gt;Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt"&gt;Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,456,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RleHRyZWdpb246NTQwMWIzYTY3MTNkNDU0MzlhMmNhM2IwYWIxNjg5NDJfMTU0MA_32a7bf84-a62f-414b-be07-4854c8e5f8f6">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,456,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9d6624d1a18a4542beeee361e4b2e980_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfMi0xLTEtMS0yNTczOQ_e1e805af-afaf-423d-8662-7f612aa40ca5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0e000d5830443279e6e124a4a3d90d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfMi0zLTEtMS0yNTczOQ_18ef9b8c-1d91-4ed2-a9c0-a3286996d8a2"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4ed69927364241c79f4eb66d77b1b1b4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfMi01LTEtMS0yNTczOQ_a8dd5fcb-0b4d-465a-a0f0-e1be33004b4a"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0119576597c942bdb66a97f6e76ccf98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfMy0xLTEtMS0yNTczOQ_4cba3750-19d4-41ef-aefc-37dd0edd9381"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i41e5087e044b46b29140a50002f1b602_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfMy0zLTEtMS0yNTczOQ_be7b1704-6593-448e-ac49-0d1130cad733"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icda5e1974a7947e9b26e6b6e44e0d15d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfMy01LTEtMS0yNTczOQ_5d4b1029-dd2d-4f5c-b0d1-d41196d6f6ca"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2a433ba7c0841bc8a3e6d4e20f17f7e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNC0xLTEtMS0yNTczOQ_69870659-fd9d-46c2-bd48-d349986c6a16"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00dab545a5c24f8dbd1d9cc27963df2a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNC0zLTEtMS0yNTczOQ_d2ac6283-a7a6-4943-b32d-01cfeb9505bd"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if5653f5a5eb54376bc10cfab4779dffe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNC01LTEtMS0yNTczOQ_977e487d-1283-49ed-9753-819c8ab13939"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f237af0ca95413b867a2e778f5fca0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNS0xLTEtMS0yNTczOQ_23b44f80-a53a-4fcc-a13b-c856a03c884b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa6e56eab91648cb8e0e757751bd275b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNS0zLTEtMS0yNTczOQ_650702ce-4d25-47e5-953d-c1a502e3bb67"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f12d2d69a4a4b56b51d7aaed03de152_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNS01LTEtMS0yNTczOQ_7e8d8dd5-fd75-49f2-856a-f499a266605d"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie7258799b1a84728ace446b81f5e78f4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNi0xLTEtMS0yNTczOQ_c85bd46a-a58a-4e08-81da-9ee2828c3b4c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if2f80e9affa24a878bb82bc127dda141_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNi0zLTEtMS0yNTczOQ_effcf39f-a13c-4860-9313-4298f82a3423"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ccf77987385492998beaa7a87e03520_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNi01LTEtMS0yNTczOQ_348658cb-a9e4-4f86-8362-ee6a7a83a4ef"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8d31a47bdaf94ea5ae092cf7132fada9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNy0xLTEtMS0yNTczOQ_822627d2-131c-48e4-8606-40855372a951"
      unitRef="usd">66531000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1abd401dbcc74a548779de9fef26b749_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNy0zLTEtMS0yNTczOQ_9b724d6b-b756-411b-8297-9016437631b0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia52a40c4b843407a840ac64aba523a6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfNy01LTEtMS0yNTczOQ_6178cf0d-cb97-471e-88b2-639dda945760"
      unitRef="usd">66531000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i93fadded2a81419dbf152f6fb044f9b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfOC0xLTEtMS0yNTczOQ_10a4d650-13ad-46c4-9f9b-50f957b7e3ac"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibf16f215bd6842bd888163d7cadeea0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfOC0zLTEtMS0yNTczOQ_17a3a390-16a4-45a2-8d48-a75f2d43efc7"
      unitRef="usd">119056000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idc382618cb454f7599202e9cac5b81e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfOC01LTEtMS0yNTczOQ_4f0b14f0-c087-483e-be29-2d0d3c5082e7"
      unitRef="usd">119056000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie7258799b1a84728ace446b81f5e78f4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfOS0xLTEtMS0yNTczOQ_4beadd9e-56bf-4b0b-893d-ee2db7f90531"
      unitRef="usd">66531000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if2f80e9affa24a878bb82bc127dda141_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfOS0zLTEtMS0yNTczOQ_e4f897de-9553-45f9-a8f4-3d4012d9b98a"
      unitRef="usd">1652724000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3ccf77987385492998beaa7a87e03520_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOjI1MTg1ZGNkYjllNjRiZWM5NzY1YmNhYTNiNThkZDEzL3RhYmxlcmFuZ2U6MjUxODVkY2RiOWU2NGJlYzk3NjViY2FhM2I1OGRkMTNfOS01LTEtMS0yNTczOQ_e2dd0b26-7e87-427f-8eb6-1c6f37840d60"
      unitRef="usd">1719255000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea02ce752e444b2a83abe7a10a418b16_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfMi0xLTEtMS0yNTczOQ_33d9140a-8109-4ee9-9a8d-d70a57ec623e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf02d3488e39407e8c46e5743eff50d5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfMi0zLTEtMS0yNTczOQ_b3002fd9-19a9-46f4-8d7e-fd5e0fbdd147"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i795179da2aab43418fa6db779e91263a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfMi01LTEtMS0yNTczOQ_150f991c-a56b-4625-b674-8329d2bdff4a"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57679c13f2684cdd9f8cd6fd98ab8756_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfMy0xLTEtMS0yNTczOQ_6a560182-8509-4c4b-939b-9f339717da2d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id320ab8c9604499fbad568b50ccc1165_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfMy0zLTEtMS0yNTczOQ_6a2b702e-788a-4c8f-87da-0247358ab658"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4b54dd876a1f4562af4c3afa7aa2048a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfMy01LTEtMS0yNTczOQ_2a3f5847-fa74-43eb-9780-7a01e73a9418"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfbde743d8914198ab03af7fe8139476_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNC0xLTEtMS0yNTczOQ_040831f2-0da7-4d37-9b14-394d5c73a6d3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i427be21f708a40d28d6462416ac218ee_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNC0zLTEtMS0yNTczOQ_c4d92fb1-a4d6-4be7-9d60-89960a575697"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b0e966652f44398a8c2e0a70b2baef5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNC01LTEtMS0yNTczOQ_d28a0456-786a-4f5a-834f-471b9e1ed69f"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia54c8642ecfb409e951b6239615168c9_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNS0xLTEtMS0zMTMyMQ_48ad5779-8f0e-42a2-994a-de3b081e2e62"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1463aefcf3c149bbb077c0d3005c9401_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNS0zLTEtMS0zMTMyNA_a5bc9cdf-e8d9-4d95-ae18-78b4b444b31b"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i45ebd9c173484d88a6e494342999d3be_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNS01LTEtMS0zNzQ0Mg_8eb1f288-7b01-41fd-addf-0846f1240c78"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b7e323ee87c4f05bfdbb7c4c7e201cd_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNS0xLTEtMS0yNTczOQ_48ff4e9d-b801-47a2-b027-0cd7831981dc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b3c6f3004bc4c89bcf1c9c12bd459ea_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNS0zLTEtMS0yNTczOQ_f4664582-9205-42d0-9ac3-0828a2d807d5"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0c51f12115f14ed1b61d2747c01ae661_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNS01LTEtMS0yNTczOQ_c6994359-c346-421b-8626-3945a22f9b3b"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib769eff617c64124810ebe511d945893_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNi0xLTEtMS0yNTczOQ_028634e0-c7ca-4b65-8b88-a14ab64730c0"
      unitRef="usd">40761000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3268bbdfa0414552b47fa9a338981cb9_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNi0zLTEtMS0yNTczOQ_b6f20bc8-4a3e-4256-ae1e-4834358e9e89"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia1eb5b5c04cc43349b70b9321ebc782f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNi01LTEtMS0yNTczOQ_c50d108a-82f8-416a-8e96-2274ba3c0374"
      unitRef="usd">40761000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic984d9c89f24479a89d0d07b78b1cdaa_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNy0xLTEtMS0yNTczOQ_01217f36-b80e-485d-bb66-19e24f03c429"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idfd60ccd881041a5ac4297dc0b25b292_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNy0zLTEtMS0yNTczOQ_94ed5638-6c91-4f59-a520-5e033fc7a0c0"
      unitRef="usd">60004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2d7389a754974512a4e774e51ae8a974_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfNy01LTEtMS0yNTczOQ_6cde899d-df35-4e55-aeca-33b8a4676821"
      unitRef="usd">60004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0b7e323ee87c4f05bfdbb7c4c7e201cd_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfOC0xLTEtMS0yNTczOQ_7c6349bf-4465-4426-a19a-e2265e121f6f"
      unitRef="usd">40761000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9b3c6f3004bc4c89bcf1c9c12bd459ea_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfOC0zLTEtMS0yNTczOQ_8bb354c2-da67-4fb6-a570-0c36679e3863"
      unitRef="usd">1415905000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0c51f12115f14ed1b61d2747c01ae661_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85NC9mcmFnOjU0MDFiM2E2NzEzZDQ1NDM5YTJjYTNiMGFiMTY4OTQyL3RhYmxlOmY5ZTIxMzMwYWFhMTQ0ZjM5ZGIxY2Y3MjBkMmI3N2MyL3RhYmxlcmFuZ2U6ZjllMjEzMzBhYWExNDRmMzlkYjFjZjcyMGQyYjc3YzJfOC01LTEtMS0yNTczOQ_03c5b0bd-3a34-48f6-94fb-382d0cd3ad25"
      unitRef="usd">1456666000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RleHRyZWdpb246NTU2N2FhNmRkNjJmNDc4N2I0NWEwYmVkZTljYWFlYzJfMjAy_02e1aa11-9619-4d39-b721-65b2533e7168">INVENTORY&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RleHRyZWdpb246NTU2N2FhNmRkNjJmNDc4N2I0NWEwYmVkZTljYWFlYzJfMjA4_b650412d-dc14-4dd8-be86-3e1ceca42c36">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfMi0xLTEtMS0yNTczOQ_eb24006f-5ea4-441c-86c6-5bfbe9d48dab"
      unitRef="usd">8867000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfMi0zLTEtMS0yNTczOQ_8c6e5b00-af80-4766-91fe-16ce0c1c54b0"
      unitRef="usd">7773000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfMy0xLTEtMS0yNTczOQ_3bc15b33-b627-466e-9803-092dd4cc48bc"
      unitRef="usd">27717000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfMy0zLTEtMS0yNTczOQ_b7d13b49-bbb5-4f95-b496-87de8553ded8"
      unitRef="usd">20610000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfNC0xLTEtMS0yNTczOQ_14840674-44b4-49fb-a9fc-b39a06c09351"
      unitRef="usd">12927000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfNC0zLTEtMS0yNTczOQ_12ba293a-ef37-4177-9b25-18bc57970ebd"
      unitRef="usd">7291000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfNS0xLTEtMS0yNTczOQ_aa9fd968-f4c2-47a8-860e-aab08ee3f920"
      unitRef="usd">49511000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfNS0zLTEtMS0yNTczOQ_fdddc330-0601-4a53-bcf1-72fd353e4d11"
      unitRef="usd">35674000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ibd92c80358ee496096d3c673a7de6191_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfOC0xLTEtMS0yNTczOQ_6134d3fa-2272-4920-94ad-d2c01528246c"
      unitRef="usd">27493000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i746a14780d0147c7824e0bef77b916db_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfOC0zLTEtMS0yNTczOQ_9372b7b4-2a7a-456c-a9e2-b13b266f64b2"
      unitRef="usd">20973000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i4dd7d2bd3e3e490fa8ce9475ab03c7f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfOS0xLTEtMS0yNTczOQ_b26c2214-85ba-4616-9aea-ff67ea97f2fb"
      unitRef="usd">22018000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i0471012a562a4c27b88456f2732a0744_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfOS0zLTEtMS0yNTczOQ_dbfe681d-82e6-4a44-9c41-8fab83e196c6"
      unitRef="usd">14701000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfMTAtMS0xLTEtMjU3Mzk_169bff4d-4fb4-4545-b89a-9df082612672"
      unitRef="usd">49511000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF85Ny9mcmFnOjU1NjdhYTZkZDYyZjQ3ODdiNDVhMGJlZGU5Y2FhZWMyL3RhYmxlOjVkZTAxZGQxNDllYzQxYTk5MTE1MjZhNDA1NDdlMWI3L3RhYmxlcmFuZ2U6NWRlMDFkZDE0OWVjNDFhOTkxMTUyNmE0MDU0N2UxYjdfMTAtMy0xLTEtMjU3Mzk_8beb0c5d-cba4-472c-9c19-8d1da426526b"
      unitRef="usd">35674000</us-gaap:InventoryGross>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90ZXh0cmVnaW9uOmYyOTY0MzI2ZTIzZDQ4NmVhODYwMDMwODE1ODdhOTc3XzE5OQ_a909225c-3c24-471e-b13f-d0213aeb8939">PROPERTY AND EQUIPMENT&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;up to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $13.6 million, $9.1 million and $8.3 million during the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90ZXh0cmVnaW9uOmYyOTY0MzI2ZTIzZDQ4NmVhODYwMDMwODE1ODdhOTc3XzIwMw_d3bc5a85-07c7-4bf5-9f63-d9a5758fca33">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;up to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3886df95730147449641343484c7d238_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzItMS0xLTEtMjU3MzkvdGV4dHJlZ2lvbjpkZTJhMjMyNGMyZDE0NDQ5YTMxZWY3ZjU2OTAzMDZlMl8xMA_b7c87905-ae9d-4c5d-b44c-73c35f3bd8ea">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ide48db818a80458abbca38f5ab70bdd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzItMy0xLTEtMjU3Mzk_3188889c-80b4-4b5c-aa68-add61757e17b"
      unitRef="usd">73589000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3f085c7986f04f109f77b9011f31264d_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzItNS0xLTEtMjU3Mzk_613e7d61-548a-4cf3-bae6-3f9c6ae7f4e3"
      unitRef="usd">40694000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8b4047a98c284e9286babc06d5858821_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzMtMS0xLTEtMjU3Mzk_0df44cc7-ea71-442b-988a-ea8c7620b1e3">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic5c9cdc8841b46d8adc324d34793217d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzMtMy0xLTEtMjU3Mzk_981446c0-727a-451d-8817-6caf3b7a3e04"
      unitRef="usd">14877000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1a99337c2ce04dcfa30ad4ccee42117a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzMtNS0xLTEtMjU3Mzk_069d106b-0ac8-4521-ab00-009c272238aa"
      unitRef="usd">18376000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6230988b2ca747a8b89fd3cae1298175_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzUtMS0xLTEtMjU3Mzk_58c021ee-94db-404f-b53f-0b27d2e8ccda">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i178f5c4c23ca48a38655383d6e5977f8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzUtMy0xLTEtMjU3Mzk_d7198d29-16d8-4157-ab7f-1de73e329540"
      unitRef="usd">15780000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id73f4cd7fcee499eaf78ce808bb71d03_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzUtNS0xLTEtMjU3Mzk_e3b3a903-8cd3-4fb9-add3-5521d5c9d67e"
      unitRef="usd">14931000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i248ba0f7c8cb4181ad74bb080d0aeca1_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzYtMS0xLTEtMjU3Mzk_e3bc4468-4b7a-4ae2-810c-31b1fea568e9">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i935b27fac1984932861fb968e47b9877_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzYtMy0xLTEtMjU3Mzk_4c5693e6-458e-436b-87ae-4b0705296bf7"
      unitRef="usd">23744000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1ec14dcaa36142b2a22ec45b2e3e2493_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzYtNS0xLTEtMjU3Mzk_6a9752a0-fd14-485e-861a-18e60bb0ae4c"
      unitRef="usd">11707000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i73ca698aa2a74a4e937a5a3b1de87b32_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzctMy0xLTEtMjU3Mzk_ce23bb1f-03af-44cb-b213-356982a2a9d9"
      unitRef="usd">16872000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1089920ccded4380b0fbc39e750f1eb7_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzctNS0xLTEtMjU3Mzk_19963210-dcfa-4208-87c0-03210e6a04cc"
      unitRef="usd">16360000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzgtMy0xLTEtMjU3Mzk_e53f4a33-d7e5-49f2-8776-e01594d7629c"
      unitRef="usd">144862000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzgtNS0xLTEtMjU3Mzk_86ecb5ca-deaf-4264-893f-1c3535030172"
      unitRef="usd">102068000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzktMy0xLTEtMjU3Mzk_7c0fce51-06c2-4d26-a10b-832818c21b8b"
      unitRef="usd">40831000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzktNS0xLTEtMjU3Mzk_c4a6d502-4153-40fa-9a4d-8cd29d428478"
      unitRef="usd">34684000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzEwLTMtMS0xLTI1NzM5_4c05067f-b1bc-44bf-98d4-7a70fde10650"
      unitRef="usd">104031000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90YWJsZToyZWU3Y2NhYjM1YTQ0NDEwYWRjYWFlYWNhMjc4ODJlOS90YWJsZXJhbmdlOjJlZTdjY2FiMzVhNDQ0MTBhZGNhYWVhY2EyNzg4MmU5XzEwLTUtMS0xLTI1NzM5_12c16409-2f8b-4ee8-94a2-5efcd5073507"
      unitRef="usd">67384000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90ZXh0cmVnaW9uOmYyOTY0MzI2ZTIzZDQ4NmVhODYwMDMwODE1ODdhOTc3XzEyOQ_4ce54c97-b335-448c-8d15-a460deec8e76"
      unitRef="usd">13600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90ZXh0cmVnaW9uOmYyOTY0MzI2ZTIzZDQ4NmVhODYwMDMwODE1ODdhOTc3XzEzMw_887ea35d-0a49-4b96-8423-1cf27d5032c7"
      unitRef="usd">9100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDAvZnJhZzpmMjk2NDMyNmUyM2Q0ODZlYTg2MDAzMDgxNTg3YTk3Ny90ZXh0cmVnaW9uOmYyOTY0MzI2ZTIzZDQ4NmVhODYwMDMwODE1ODdhOTc3XzE0MA_711c6f68-bfdb-4234-8320-47c397574005"
      unitRef="usd">8300000</us-gaap:Depreciation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNjY_bf15f99d-87fa-4366-8fbd-581e462d1ac0">EMPLOYEE BENEFIT PLANS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Incentive Plans and ESPP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have several equity incentive plans under which we granted stock options and RSUs, including PSUs, to employees and directors. At December&#160;31, 2021, 11,004,584 shares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option award and 1.5 shares for full value awards granted in the form of RSUs or PSUs. On May 20, 2020, at our 2020 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of the 2017 Plan. The amendment and restatement increased the share reserve under the 2017 Plan by 21,000,000 shares, subject to adjustment for certain changes in our capitalization, which became effective immediately upon stockholder approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board of Directors delegated responsibility for administration of our equity incentive plans to the Compensation Committee of our Board of Directors, including the authority to determine the term, exercise price and vesting requirements of each grant. Stock options granted to our employees and directors generally have a four-year vesting term and a one-year vesting term, respectively, an exercise price equal to the fair market value on the date of grant, and a seven-year life from the date of grant. RSUs granted to our employees and directors generally have a four-year vesting term and a one-year vesting term, respectively. PSUs granted pursuant to our equity incentive plans vest upon specified service conditions and the achievement of a performance target or market condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a Change in Control and Severance Benefit Plan for certain executive officers. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#x2019;s employment is terminated without cause during a period commencing one month before and ending thirteen months following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all their outstanding equity awards accelerated and the exercise period for their stock options extended to no more than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of 85% of the closing price at the beginning of the offering period or 85% of the closing price at the end of each six-month purchase period. As of December&#160;31, 2021, we had &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,168,354&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares available for issuance under our ESPP. Pursuant to the ESPP, we issued 536,226, 534,419 and 483,009 shares of common stock at an average price per share of $17.76, $14.55 and $12.60 during the years ended December&#160;31, 2021, 2020 and 2019, respectively. Cash received &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from purchases under the ESPP for the years ended December 31, 2021, 2020 and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was $9.5 million, $7.8 million and $6.1 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used a Black-Scholes Merton option pricing model to value stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We considered both implied and historical volatility in developing our estimate of expected volatility. The assumption for the expected life of stock options is based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#x2019; current expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs, including PSUs, was based on the closing price of the underlying common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for stock options during the year ended December&#160;31, 2021 was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options exercisable at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, there was $27.8 million of unrecognized compensation expense related to our unvested stock options. The compensation expense for the unvested stock options will be recognized over a weighted-average period of 2.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal 2021 and the exercise prices, multiplied by the number of in-the-money stock options) that would have been received by the stock option holders had all stock option holders exercised their stock options on December&#160;31, 2021. The total intrinsic value of stock options exercised during the years ended December&#160;31, 2021, 2020 and 2019 was $76.0 million, $106.5 million and $54.1 million, respectively. Cash received from stock option exercises during the years ended December&#160;31, 2021, 2020 and 2019 was $14.8 million, $26.9 million and $16.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Activity for RSUs during the year ended December&#160;31, 2021 was as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, there was $123.6 million of unrecognized compensation expense related to our unvested RSUs which will be recognized over a weighted-average period of 2.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for PSUs, during the year ended December&#160;31, 2021 was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, in connection with our long-term incentive compensation program, we awarded certain employees 1,027,650 (the 2021 target amount) PSUs, subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to 200% of the 2021 target amount, or up to 2,055,300 total shares, depending on the level of achievement of the performance condition related to certain net product revenues and a total shareholder return (TSR) market condition. The TSR market condition is based on our relative TSR percentile rank compared to companies in the Nasdaq Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. Fifty percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately one year later subject to an employee&#x2019;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023. The performance condition for a threshold of net product revenues relative to the 2021 PSUs was deemed probable of achievement in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, in connection with our long-term incentive compensation program, we awarded 2,327,840 PSUs (the 2020 target amount) that will vest upon the achievement of performance targets related to clinical trial positive top-line results and product approvals by the FDA (the 2020 PSUs). Pursuant to the terms of the 2020 PSUs, employees may earn up to 200% of the 2020 target amount, or 4,655,680 total shares, depending on the volume and timing of achievement of the performance targets. The 2020 PSUs will be forfeited if the performance targets are not met by December 31, 2024. The performance condition for threshold achievement of a product approval by the FDA relative to the 2020 PSUs occurred in the third quarter of 2021 representing 25% of the 2020 target amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the year ended December&#160;31, 2019, in connection with our long-term incentive compensation program, we awarded 1,926,605 PSUs (the 2019 target amount) that vest upon the achievement of performance targets related to product approvals by the FDA (the 2019 PSUs). Pursuant to the terms of the 2019 PSUs, employees may earn up to 200% of the 2019 target amount, or 3,853,210 total shares, depending on the volume and timing of achievement of the performance targets. The performance condition for early achievement of the 2019 PSUs occurred during 2020 representing 150% of the 2019 target amount. The performance condition for earning the remaining 50% of the 2019 target amount occurred in early 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2018, we awarded 693,131 PSUs that vest upon the achievement of certain product revenue, late-stage clinical development programs and discovery pipeline expansion performance targets (the 2018 PSUs). The performance targets for 167,726 remaining 2018 PSUs were achieved in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recognition for PSUs commences when it is determined that attainment of the performance target is probable. Of the aggregate outstanding PSUs, 4,853,112 relate to awards for which we achieved the performance target. As of December&#160;31, 2021, the remaining unrecognized compensation expense for the PSUs achieved or deemed probable of achievement related to the PSUs was $12.1 million, which will be recognized over a weighted-average period of 3.0 years. The total unrecognized compensation expense for the PSUs for which we have not yet determined that attainment of the performance target is probable was $121.6 million as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exelixis, Inc. 401(k) Plan (the 401(k) Plan)&lt;/span&gt;&lt;/div&gt;We sponsor the 401(k) Plan under which we have historically made matching contributions to our employees&#x2019; 401(k) accounts in the form of our common stock. Beginning in 2020, our matching contributions are in the form of cash. We recorded compensation expense of $9.5 million, $6.7 million and $4.6 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively, for matching contributions to our employees 401(k) accounts.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNjQ_5e5b4fa9-5e8f-45fc-8b47-a071a083408e">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6b96bd3389d2490a8a78bc00fddfe7ce_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzItMS0xLTEtMjU3Mzk_4681a601-ec2c-49ad-94c8-fc54c2fe73ff"
      unitRef="usd">46654000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ife6c6471ca35413da83fd2469f9c00a1_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzItMy0xLTEtMjU3Mzk_69628424-388d-45d5-9ffb-cf9652a48cc9"
      unitRef="usd">37198000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i38d5186b034a4d0999fca6ecb2ec9ece_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzItNS0xLTEtMjU3Mzk_e86141a9-6e28-4883-b115-e1f01d540aad"
      unitRef="usd">19374000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibbb974755c29460293662406b5c181e4_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzMtMS0xLTEtMjU3Mzk_b3c0e547-a616-4072-8ed5-d1fb49b00b5d"
      unitRef="usd">73166000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8f33a19a84a140d380dc777b506fc9ba_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzMtMy0xLTEtMjU3Mzk_7d3a3a0f-987d-4d54-9b6e-b120a9a0a137"
      unitRef="usd">67872000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifecb0e7726f341c6ba6992570d045296_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzMtNS0xLTEtMjU3Mzk_4a923a24-7900-4d2d-9ee8-45075e6e221e"
      unitRef="usd">37228000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzQtMS0xLTEtMjU3Mzk_f1d30119-b803-43e2-9306-071c9038a1fd"
      unitRef="usd">119820000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzQtMy0xLTEtMjU3Mzk_e637f339-8706-428f-93f1-00ee0152fb73"
      unitRef="usd">105070000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZToxYjhkNDEzOTBjYmQ0MzI5YjA4MTA2MTUxYWJhYzJlZi90YWJsZXJhbmdlOjFiOGQ0MTM5MGNiZDQzMjliMDgxMDYxNTFhYmFjMmVmXzQtNS0xLTEtMjU3Mzk_560af215-8279-4cb1-97b7-50475cb44d52"
      unitRef="usd">56602000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzItMS0xLTEtMjU3Mzk_5184b696-2a63-4242-90a5-fdc261c9773f"
      unitRef="usd">19048000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzItMy0xLTEtMjU3Mzk_00c4e59a-a49a-448a-8897-6efc6477c3a0"
      unitRef="usd">19863000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzItNS0xLTEtMjU3Mzk_73d1932f-32b3-4602-8910-ca7757269222"
      unitRef="usd">23422000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzMtMS0xLTEtMjU3Mzk_7524f015-73de-464e-9f9c-50806e14f4b1"
      unitRef="usd">53629000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i810b03546f7b400baf8f30d8a400ff09_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzMtMy0xLTEtMjU3Mzk_1885e278-f3ce-4ce5-9526-e5ba3e8e8e3f"
      unitRef="usd">35675000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibf28ef3d9ddd45609325a52b344679e7_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzMtNS0xLTEtMjU3Mzk_5c6a8d4f-1b04-49f6-9dc7-7f33d3392330"
      unitRef="usd">26056000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzQtMS0xLTEtMjU3Mzk_3c58e678-e1fa-42b4-b83d-a528dae06b93"
      unitRef="usd">43428000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i76a39cce3d904d388c3adad8a7bfed10_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzQtMy0xLTEtMjU3Mzk_03eed95e-bde7-4a63-a5d0-a88903596f66"
      unitRef="usd">47106000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7abafca0ed6e40f88895c38bb6b81247_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzQtNS0xLTEtMjU3Mzk_d7496e1b-74b6-4648-a0db-94660055a8b5"
      unitRef="usd">4878000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzUtMS0xLTEtMjU3Mzk_d0fcbdf5-b1fc-4ac3-b3d9-8dad2d4acf6d"
      unitRef="usd">3715000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzUtMy0xLTEtMjU3Mzk_95a8a2ad-3ce4-4b8b-8171-857cf814638d"
      unitRef="usd">2426000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzUtNS0xLTEtMjU3Mzk_fc5a1668-00a2-40f8-a610-ed1159df6073"
      unitRef="usd">2246000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzYtMS0xLTEtMjU3Mzk_91ec8503-2d7f-4628-a75d-5ee7176929a5"
      unitRef="usd">119820000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzYtMy0xLTEtMjU3Mzk_c53b3bc3-10b7-4246-9ceb-e08457525e56"
      unitRef="usd">105070000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo3ODJkNWYxMTA5NTE0Yzc4OTFkNzUxOTQyZmNiNTU5MC90YWJsZXJhbmdlOjc4MmQ1ZjExMDk1MTRjNzg5MWQ3NTE5NDJmY2I1NTkwXzYtNS0xLTEtMjU3Mzk_f5bb0736-1bc7-479f-87b6-46267503ab79"
      unitRef="usd">56602000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzM0MA_d2a81c37-05d3-4efb-9a32-39bdd004cc2f"
      unitRef="shares">11004584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzUwMQ_23fcf4b9-91d1-45e8-b8ea-891653f56ffb"
      unitRef="shares">1</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzU2OQ_b4249c02-cd04-4100-be2b-f92acf4c31a7"
      unitRef="shares">1.5</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="iff13c02dcfbe458cb3a8363106ef81dd_D20200520-20200520"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzg1NA_8e5dc5fd-1552-4957-8720-faf9a7758229"
      unitRef="shares">21000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i940612d122c84082acb652dba5991c69_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNjU_537a763e-ec17-4765-a277-4419522ee8b9">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i34532b015c584cba952c0caa678ee2fd_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNDM_66c47682-db95-49e8-983f-525bbd603d52">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNDg_8610ffa9-8917-410c-8f24-1fa95a0bfe1e">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib08f62d50d8d4c1793cae2caa25a90ec_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxMzI_ba597d37-d7e2-4a41-8601-af5f38e07127">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id6d6926fdea445e7a6ebdc4a3ba1f78b_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxMzA_73a41860-74c5-46ed-803e-7a006fa558d4">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exel:ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod
      contextRef="i1b29032b66954a8db9da85d19b1be6a2_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzYwNDczMTM5NzA2MDM_9ad16dd3-01f1-4359-97a8-5b87526cd4be">P1M</exel:ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod>
    <exel:ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod
      contextRef="i6362d549434c4a3ebfb9ed76266ced8a_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzYwNDczMTM5NzA2MTg_23f45ebd-4301-4206-85af-e5477b593775">P13M</exel:ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI1ODI_42170df1-87ff-4bfa-8d84-71878dfd16c4"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI2NDk_92edfd19-be99-4851-81b8-4bcbb25421e2"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod
      contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNzY_f03b04f2-0cd4-45f1-b9d9-367552c577ae">P6M</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ie93bf1a0871644278ca4b892fe456191_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI3MzU_15cce0d6-af59-4b82-a2fe-9f6a0e9e84df"
      unitRef="shares">3168354</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI4MTY_d5ac8bfe-717f-4ce1-ac05-d0cc2cd020fb"
      unitRef="shares">536226</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI4MjA_522bc071-73e7-4a7b-8cc7-8c6eb23d6e8b"
      unitRef="shares">534419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI4Mjc_46014ca1-d0f0-46fc-bf2c-022c8c95c070"
      unitRef="shares">483009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="ie93bf1a0871644278ca4b892fe456191_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI4ODY_3b83dba8-f0e3-4873-b8c8-a09974d8a226"
      unitRef="usdPerShare">17.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i85c17b70c74043af9b0e2017ab4409e8_I20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI4OTA_f867450d-f5cf-4c56-befa-a146f1dc3814"
      unitRef="usdPerShare">14.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i1d0c6bc2e80b4232ae06f54a57a62638_I20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzI4OTc_e76cf039-0393-4c8d-ba05-6c701cc8a2b1"
      unitRef="usdPerShare">12.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzMwNDc_086b3b07-f613-4b02-8d40-799d1761287e"
      unitRef="usd">9500000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzMwNTE_6f907b92-1122-4ac3-96be-38bcc8096585"
      unitRef="usd">7800000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzMwNTg_58c74c9e-9459-4593-a321-eb8f0e0eeb35"
      unitRef="usd">6100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEyNjQ0MzgzNzM0ODY1_f4a02110-390f-4ddf-a0f7-02c1c48fe78a">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTphYjNhNTk3MDljNzg0MjdmOWI5YTg3NWIwNjdkMGNlMC90YWJsZXJhbmdlOmFiM2E1OTcwOWM3ODQyN2Y5YjlhODc1YjA2N2QwY2UwXzItMS0xLTEtMzkwOTA_8de5165e-1801-4c2f-8d7e-db440523a506"
      unitRef="usdPerShare">9.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTphYjNhNTk3MDljNzg0MjdmOWI5YTg3NWIwNjdkMGNlMC90YWJsZXJhbmdlOmFiM2E1OTcwOWM3ODQyN2Y5YjlhODc1YjA2N2QwY2UwXzItMy0xLTEtMzkwOTA_fbbaa0bd-95c3-438e-9429-735cb15293b2"
      unitRef="usdPerShare">9.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTphYjNhNTk3MDljNzg0MjdmOWI5YTg3NWIwNjdkMGNlMC90YWJsZXJhbmdlOmFiM2E1OTcwOWM3ODQyN2Y5YjlhODc1YjA2N2QwY2UwXzItNS0xLTEtMzkwOTA_8d368206-1d01-4d6c-9362-83ba5737c5ff"
      unitRef="usdPerShare">8.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTphYjNhNTk3MDljNzg0MjdmOWI5YTg3NWIwNjdkMGNlMC90YWJsZXJhbmdlOmFiM2E1OTcwOWM3ODQyN2Y5YjlhODc1YjA2N2QwY2UwXzMtMS0xLTEtMzkwOTA_a98d0805-1ca5-45ec-8933-801731b9d09f"
      unitRef="usdPerShare">6.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTphYjNhNTk3MDljNzg0MjdmOWI5YTg3NWIwNjdkMGNlMC90YWJsZXJhbmdlOmFiM2E1OTcwOWM3ODQyN2Y5YjlhODc1YjA2N2QwY2UwXzMtMy0xLTEtMzkwOTA_0d9b5d68-cf5b-47ce-92af-299c187d2d45"
      unitRef="usdPerShare">6.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTphYjNhNTk3MDljNzg0MjdmOWI5YTg3NWIwNjdkMGNlMC90YWJsZXJhbmdlOmFiM2E1OTcwOWM3ODQyN2Y5YjlhODc1YjA2N2QwY2UwXzMtNS0xLTEtMzkwOTA_50f3bda2-4152-4e44-8f2f-f7fdb298ae37"
      unitRef="usdPerShare">4.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxMTk_6c26d1d3-6077-4b03-a387-5d64de756dc4">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxNTA_53ead616-6578-4805-bda8-6f4dcad0cab4">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzMtMS0xLTEtMjU3Mzk_267ce474-52c0-42fa-85ab-41d87b128817"
      unitRef="number">0.0074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzMtMy0xLTEtMjU3Mzk_53ad4b9e-fd70-42b6-93b9-7ce2c8502f7b"
      unitRef="number">0.0030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzMtNS0xLTEtMjU3Mzk_17e8fb79-8f43-4fd3-ba59-99748e193ec6"
      unitRef="number">0.0177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzQtMS0xLTEtMjU3Mzk_3db70f18-3e08-4319-bc6c-cc2675258cc5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzQtMy0xLTEtMjU3Mzk_2306ad0b-cfd4-4d1c-80ac-a1dd95874daf"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzQtNS0xLTEtMjU3Mzk_61a284a7-20dd-4522-9d2b-4e93ec7f6be4"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzUtMS0xLTEtMjU3Mzk_0e8dd21a-e02c-450c-b635-f699901ea078"
      unitRef="number">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzUtMy0xLTEtMjU3Mzk_d0a73ba7-6c3d-47e4-8caf-c0c6a93b6ecc"
      unitRef="number">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzUtNS0xLTEtMjU3Mzk_46b86dea-2edb-443b-a21a-1fb24d9424b9"
      unitRef="number">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzYtMS0xLTEtMjU3Mzk_c0d0d93e-d717-4113-afdc-a8c87393654e">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzYtMy0xLTEtMjU3Mzk_935dab74-6a01-4145-b691-d8f5e5262061">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzYtNS0xLTEtMjU3Mzk_2eaecd8d-c359-4ca4-b905-27e862d83ff1">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzgtMS0xLTEtMjU3Mzk_2c5ef23f-135c-4c6f-80c5-0f0a631bdc55"
      unitRef="number">0.0008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzgtMy0xLTEtMjU3Mzk_d5c292ed-05e3-43c4-9ab7-a05e83456c18"
      unitRef="number">0.0079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzgtNS0xLTEtMjU3Mzk_ad8da521-5bd7-424c-ab26-c56eacc08896"
      unitRef="number">0.0216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzktMS0xLTEtMjU3Mzk_7246493d-2e41-4554-aade-8c7a4f597895"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzktMy0xLTEtMjU3Mzk_6251e86e-4d8d-4fbc-b153-317c569855d0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzktNS0xLTEtMjU3Mzk_eef16548-4cdb-4f1c-96a0-7e864965acc1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzEwLTEtMS0xLTI1NzM5_6533d633-ec69-4298-990f-b9a946400160"
      unitRef="number">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzEwLTMtMS0xLTI1NzM5_42cca744-8749-458d-8e57-bd92a4e11b1d"
      unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzEwLTUtMS0xLTI1NzM5_36d9655a-1973-4c6e-bb5a-d7e453f27c14"
      unitRef="number">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic16fd02834d74e738ba8af1446ad3d65_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzExLTEtMS0xLTI1NzM5_2808fe17-6d84-464a-83b5-3523500615f8">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie38192ffb2ee457d896f3689043e97f5_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzExLTMtMS0xLTI1NzM5_68b5970d-c959-42f7-b324-543c7d504df7">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0c2336d183a64561aeb1516e08437ebc_D20181229-20200103"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTo2YjYyMzZiMTcyOTM0MDA2OGZjMDJjZWI1ZDM5ZjBjNC90YWJsZXJhbmdlOjZiNjIzNmIxNzI5MzQwMDY4ZmMwMmNlYjVkMzlmMGM0XzExLTUtMS0xLTI1NzM5_6e5675dd-1fb1-4479-aedc-bef57ef709a2">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxMjE_b85d2b85-26a4-456f-820f-2b2d7d18ecbb">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for stock options during the year ended December&#160;31, 2021 was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options exercisable at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzEtMS0xLTEtMjU3Mzk_24f322f0-d777-4eaf-bfdd-78ce900931f1"
      unitRef="shares">16129000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzEtMy0xLTEtMjU3Mzk_ced73734-4d4b-4cd7-989c-373702aa01ba"
      unitRef="usdPerShare">12.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzItMS0xLTEtMjU3Mzk_1106d7d1-02eb-4d72-8e83-a47cc4ee2f55"
      unitRef="shares">2573000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzItMy0xLTEtMjU3Mzk_536baf00-8650-41f7-8a07-a8e257ef2cdc"
      unitRef="usdPerShare">21.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzMtMS0xLTEtMjU3Mzk_c3547dba-bfe0-4b86-b562-f81b322176cd"
      unitRef="shares">4486000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzMtMy0xLTEtMjU3Mzk_bff857bc-c1ef-41b6-b119-2a152df92739"
      unitRef="usdPerShare">4.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzQtMS0xLTEtMjU3Mzk_c6a4cd3b-9bed-4fb3-8433-51559909d480"
      unitRef="shares">545000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzQtMy0xLTEtMjU3Mzk_57c1c286-9027-41a2-a896-5d3a88f99dcd"
      unitRef="usdPerShare">21.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzUtMS0xLTEtMjU3Mzk_e4f1c69f-c3df-4172-916e-0f4f18da0740"
      unitRef="shares">13671000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzUtMy0xLTEtMjU3Mzk_a1e38f60-70ab-4852-8233-674ada7edcdd"
      unitRef="usdPerShare">16.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzUtNS0xLTEtMjU3Mzk_d51307c4-d965-4592-878b-41cfada89b2d">P3Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzUtNy0xLTEtMjU3Mzk_74ed5260-034f-4875-90b9-9d5dada8f25a"
      unitRef="usd">48860000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzYtMS0xLTEtMjU3Mzk_5c068ce9-aae3-4c8a-9930-f98e499f0a64"
      unitRef="shares">9962000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzYtMy0xLTEtMjU3Mzk_39a201d8-e0cc-4bc0-ab07-29d94880752d"
      unitRef="usdPerShare">15.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzYtNS0xLTEtMjU3Mzk_8dfe60df-1432-453a-bc61-819b54fa60bc">P2Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTplMDEyOWJiZDczMWY0NzVjODE1NjJkMThlN2UxNmU3My90YWJsZXJhbmdlOmUwMTI5YmJkNzMxZjQ3NWM4MTU2MmQxOGU3ZTE2ZTczXzYtNy0xLTEtMjU3Mzk_c4eb1a99-a2f9-4172-9a0d-52e2e46a6f67"
      unitRef="usd">48171000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib29b3c5e0f37409da408786f8267b076_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQyMzM_d6506f25-d4e7-4e31-bea9-057500d940f3"
      unitRef="usd">27800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ0Mzc_06a17866-3194-401c-9a10-91d83f7a63c3">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ5NDc4MDIzMzcyNzE_757730f2-6600-4593-866d-356459bd7c48"
      unitRef="usd">76000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ5NDc4MDIzMzcyNzc_ba3daa24-2c50-47c8-a879-c0fe3921110a"
      unitRef="usd">106500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ5NDc4MDIzMzcyODU_9424ed8d-482a-416a-a198-cd8bd9fa5824"
      unitRef="usd">54100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie06171677cb042a49e3187edc6c068fc_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ5NDc4MDIzMzczOTE_41849f92-6a12-4e9f-8706-3d8f4139ef11"
      unitRef="usd">14800000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i88e16b6008b442baa2d261b7a4facd2f_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ5NDc4MDIzMzczOTc_8bf4c320-2e74-4d01-bc07-df5fa1474fc6"
      unitRef="usd">26900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i1a1b1023a1da4a3e83b65f61fce0b224_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQ5NDc4MDIzMzc0MDU_0852b81d-ca3e-41b3-8c6d-e2d4cd234d76"
      unitRef="usd">16400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkxMjI_d8434ac3-dfb0-4df2-a7d2-479012c6fb0b">Activity for RSUs during the year ended December&#160;31, 2021 was as follows (in thousands, except per share amounts):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for PSUs, during the year ended December&#160;31, 2021 was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i74355fce090d4783894ca8f36c2a26dd_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzEtMS0xLTEtMjU3Mzk_d1f61ffd-3317-4cf7-a2d8-bf6c508de8a1"
      unitRef="shares">5378000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i74355fce090d4783894ca8f36c2a26dd_I20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzEtMy0xLTEtMjU3Mzk_da164b5d-9ebd-49e7-9349-6c6e3081c276"
      unitRef="usdPerShare">21.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzItMS0xLTEtMjU3Mzk_c08d0350-b047-45b2-ad1c-201482c810a6"
      unitRef="shares">4220000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzItMy0xLTEtMjU3Mzk_d776183c-0839-4754-b895-c64fa9720585"
      unitRef="usdPerShare">21.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased
      contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzMtMS0xLTEtMjU3Mzk_3fd4c021-8640-4de7-942c-23cd741af6af"
      unitRef="shares">2020000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzMtMy0xLTEtMjU3Mzk_01d1ad91-fb96-405e-96bc-cec9b31261c4"
      unitRef="usdPerShare">22.03</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzQtMS0xLTEtMjU3Mzk_ffdc17ce-dbfb-46a4-b458-9f8d38cc8c74"
      unitRef="shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzQtMy0xLTEtMjU3Mzk_9361343d-d771-4877-809d-c5c6a2c71428"
      unitRef="usdPerShare">21.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4c4744c0eeaa4ef89dc73f7f709e54b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzUtMS0xLTEtMjU3Mzk_017d7ce0-47da-42cf-9b2f-ae7a398011d3"
      unitRef="shares">6828000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4c4744c0eeaa4ef89dc73f7f709e54b9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzUtMy0xLTEtMjU3Mzk_8449757d-61e6-45ca-8c95-dafc989a1b9b"
      unitRef="usdPerShare">21.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzUtNS0xLTEtMjU3Mzk_4145e987-6b69-4031-b6aa-acf10d6d9910">P1Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i4c4744c0eeaa4ef89dc73f7f709e54b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTowNzA5ZDA2YTE3MmM0OGUyYTVhYWE1MGVmM2IyZGIwNi90YWJsZXJhbmdlOjA3MDlkMDZhMTcyYzQ4ZTJhNWFhYTUwZWYzYjJkYjA2XzUtNy0xLTEtMjU3Mzk_d1e2aa7f-ce23-44ea-886c-802148132633"
      unitRef="usd">124824000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i4c4744c0eeaa4ef89dc73f7f709e54b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzYxMjQ_47b6ca1d-d859-4491-afb6-1ce23a72b990"
      unitRef="usd">123600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzYyNTI_43185869-728f-4534-be8a-d158130e6621">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6fa59b8b15c4457ea85611acce275f22_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzEtMS0xLTEtMjU3Mzk_6141777f-7050-4334-94a9-52c55939e15d"
      unitRef="shares">7378000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6fa59b8b15c4457ea85611acce275f22_I20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzEtMy0xLTEtMjU3Mzk_015bf64a-3ca2-49b9-9d7d-bdad9b786880"
      unitRef="usdPerShare">21.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzItMS0xLTEtMjU3Mzk_a3bd8bf1-2a5c-4f98-a8c4-b61c868aa10c"
      unitRef="shares">2056000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzItMy0xLTEtMjU3Mzk_fb09a280-4016-45f2-904b-8618a98c41f1"
      unitRef="usdPerShare">24.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased
      contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzMtMS0xLTEtMjU3Mzk_70813ead-d19e-4974-87c5-a1e1f2fefb62"
      unitRef="shares">2388000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzMtMy0xLTEtMjU3Mzk_05d238ed-7e5a-4601-8047-1a78d95d64d7"
      unitRef="usdPerShare">19.76</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzQtMS0xLTEtMjU3Mzk_9c8851c5-dd7f-4802-a6cf-b7044baf4d20"
      unitRef="shares">736000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzQtMy0xLTEtMjU3Mzk_e5e03752-5082-47f1-b828-0dc31ab88cc1"
      unitRef="usdPerShare">22.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if0c146506a74415eb481d9e61dae42b4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzUtMS0xLTEtMjU3Mzk_701e2bf5-4b9a-44c7-8ee5-df1c4bb3b49b"
      unitRef="shares">6310000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if0c146506a74415eb481d9e61dae42b4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzUtMy0xLTEtMjU3Mzk_ddc34466-218c-4fd5-b244-41f533936769"
      unitRef="usdPerShare">23.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzUtNS0xLTEtMjU3Mzk_763869ca-e6e5-4695-ac95-4b853ee0ac95">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="if0c146506a74415eb481d9e61dae42b4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpiZDZhZDlmZTFhMzM0NzFjODI0N2ViZmViMzE3NWUzNC90YWJsZXJhbmdlOmJkNmFkOWZlMWEzMzQ3MWM4MjQ3ZWJmZWIzMTc1ZTM0XzUtNy0xLTEtMjU3Mzk_7908a649-b21d-4aac-836b-16ef9b8aea53"
      unitRef="usd">98121000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i838b498a0efd4d9d9f799adee2661362_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzk4OTU2MDQ2NjI1MzM_0d005f36-7a81-4759-90cf-b4b6c665b979"
      unitRef="shares">1027650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i838b498a0efd4d9d9f799adee2661362_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzk4OTU2MDQ2NjI1NDQ_058f7d47-8a71-45df-92f2-2308b327e4db"
      unitRef="number">2</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest
      contextRef="i838b498a0efd4d9d9f799adee2661362_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzMxMzM2MDgxNDA5MjQx_c9341423-30bc-4e64-89a6-3a6fc7bba822"
      unitRef="shares">2055300</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i1ad4423cf59549fa83e3e98aa40b0aba_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzk4OTU2MDQ2NjI1NDk_3d8a02e3-34f3-4372-901b-748f5b55f4e9"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i74e6a3ef845a4a2c9ac7e354707c8e1f_D20210301-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkzNDU4NDg4NDg2OTQ_22729623-adef-448b-963f-2a8d3ce576f5">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEwOTk1MTE2MjkwMjg0_463ffc31-ece0-44db-8ea6-b13560c877ab">A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEwOTk1MTE2MjkwMjc3_57b233b6-17e9-4bba-a3d1-b9c1223f3ffd"
      unitRef="usdPerShare">24.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharePrice
      contextRef="if0c146506a74415eb481d9e61dae42b4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpjZmU3MzMwNTY5Zjk0NGE1YjlhNmVhMzgzNzI3OWUxZC90YWJsZXJhbmdlOmNmZTczMzA1NjlmOTQ0YTViOWE2ZWEzODM3Mjc5ZTFkXzAtMS0xLTEtMzc1MTk_a81469b8-ccc6-4b5e-b30d-8f02f0f5fffb"
      unitRef="usdPerShare">21.31</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpjZmU3MzMwNTY5Zjk0NGE1YjlhNmVhMzgzNzI3OWUxZC90YWJsZXJhbmdlOmNmZTczMzA1NjlmOTQ0YTViOWE2ZWEzODM3Mjc5ZTFkXzEtMS0xLTEtMzc1MjE_d78e04e3-050b-42ae-8b4e-4821952b9082"
      unitRef="number">0.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpjZmU3MzMwNTY5Zjk0NGE1YjlhNmVhMzgzNzI3OWUxZC90YWJsZXJhbmdlOmNmZTczMzA1NjlmOTQ0YTViOWE2ZWEzODM3Mjc5ZTFkXzItMS0xLTEtMzc1MjM_a6eca7d8-d349-4dc9-a83a-f360954140f4"
      unitRef="number">0.0029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90YWJsZTpjZmU3MzMwNTY5Zjk0NGE1YjlhNmVhMzgzNzI3OWUxZC90YWJsZXJhbmdlOmNmZTczMzA1NjlmOTQ0YTViOWE2ZWEzODM3Mjc5ZTFkXzMtMS0xLTEtMzc1MjU_30fb5dd5-d74f-422f-89be-76548558d837"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ieac0ed4a145142fcaad1faa3308fe4da_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEwOTk1MTE2MzgyMzY_42e476ea-3e4f-4e33-8c00-19fe5ba3ad9f"
      unitRef="shares">2327840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i76a39cce3d904d388c3adad8a7bfed10_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzY3MDk_7d16be56-e7f9-48e6-9cc4-a474bb74ab3d"
      unitRef="number">2</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest
      contextRef="i76a39cce3d904d388c3adad8a7bfed10_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEwOTk1MTE2MzgyNDM_5fcb6f03-ddd8-4387-9dba-443817024e30"
      unitRef="shares">4655680</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i18d80baf7ec441d59bd2914f26cc7048_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzMxMzM2MDgxNDA5MjUy_00796f34-efcb-490c-92c4-52b612ccdab3"
      unitRef="number">0.25</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia1182bc4873c402f9d17b55ecb40b430_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzQzOTgwNDY1Mjg1OTk_d8f8fc9e-7038-4e0c-8a5a-8eefc2621150"
      unitRef="shares">1926605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i7abafca0ed6e40f88895c38bb6b81247_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzcyNjk_26705ac2-8f1d-49d0-bd83-06c4eee8c75f"
      unitRef="number">2</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7abafca0ed6e40f88895c38bb6b81247_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEwOTk1MTE2MzgyNTg_f8771d9f-9846-4afc-8f05-99d9b9f547f5"
      unitRef="shares">3853210</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="if6856ab9da0245a0b58e4a5a9d78c7c1_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzc1MzU_58361aef-98e5-4329-a358-30d91e7be41a"
      unitRef="number">1.50</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i7e812dfe05ab46da90f8b209737fba1e_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzc2MDk_28e97fdc-bf8c-4b48-bdc8-84d153f81f64"
      unitRef="number">0.50</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i96ebe2ef748948f0a75ba0527c466487_D20180101-20181228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzEwOTk1MTE2Mzg0MTM_fff9e8aa-ddbc-48d7-b59f-dceb37905f78"
      unitRef="shares">693131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i58f94a8c90d4404fbf57c14383810126_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzIxOTkwMjMyNzEwMzI_fc85db1f-f1b3-475f-b437-f4d4913301ec"
      unitRef="shares">167726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iad0a49c0e2794ae58f9a3ccbe473b7fe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzIxOTkwMjMyNjQ3ODQ_3d7ecfac-3802-46e2-9eaf-78d9044fdc1d"
      unitRef="shares">4853112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id1cca4ef6d104b9db13688910f87a10c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzg0NTY_f35bf111-dcb2-4e33-b6ed-3c8b915fe436"
      unitRef="usd">12100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzg1MTk_736eae15-6157-4e9f-a32c-98b7b8b62754">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="icf4e68b211e4463fb19f878a36d3a54a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzg2NzU_e083f4c7-7775-4391-8c3d-8fb5b2149b36"
      unitRef="usd">121600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzg5OTU_5b02cccb-0316-4fd2-a3e1-33bd1e305d91"
      unitRef="usd">9500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzg5OTk_bc73e6c6-ae29-4754-8909-9eb833b1c9ed"
      unitRef="usd">6700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDYvZnJhZzpkZTI5YzljNDZmODU0NDQyOGY0Y2ZmYjE3ZDkyZjZlMS90ZXh0cmVnaW9uOmRlMjljOWM0NmY4NTQ0NDI4ZjRjZmZiMTdkOTJmNmUxXzkwMDY_c4219260-d888-493a-b4a5-181773578d84"
      unitRef="usd">4600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzQ3MDg_904b6d2e-5b86-4f3b-90fc-10c5f312ee4e">PROVISION FOR INCOME TAXES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income before income taxes is derived solely from within the U.S. Our provision for income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes for &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the years ended December&#160;31, 2021, 2020, and 2019 primarily relates to the utilization of federal tax attributes and state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our historical net operating losses were sufficient to fully offset any federal taxable income for the years ended December 31, 2020 and 2019 but were not sufficient to fully offset federal taxable income for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2021, 2020 and 2019, respectively, to our provision for income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal income tax provision at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 740: Income Taxes (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December&#160;31, 2021, based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position as of December&#160;31, 2021 and forecasts of future operating results, as well as considering the utilization of net operating losses and tax credits prior to their expiration, management determined that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets are realizable. As of December&#160;31, 2021 and 2020, we continue to carry a valuation allowance of $70.1 million and $67.2 million, respectively, against our California state deferred tax assets. The valuation allowance increased by $2.9 million and $5.5 million during the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, we had federal business tax credits of approximately $101.0 million which expire in the years 2025 through 2041. We also had state net operating loss carryforwards of approximately $426.0 million, which expire in the years 2022 through 2036, California research and development tax credits of approximately $45.0 million, which do not expire, and California Competes Tax Credits of approximately $2.0 million, which expire in 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 analysis through December&#160;31, 2021, and concluded that an ownership change, as defined under Section 382, had not occurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change relating to prior year provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change relating to current year provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions based on the lapse of the applicable statutes of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not anticipate that the amount of unrecognized tax benefits existing as of December&#160;31, 2021 will significantly change over the next 12 months. As of December&#160;31, 2021, we had $83.6 million in unrecognized tax benefits, of which $52.6 million would reduce our provision for income taxes and the effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Income as a component of income taxes. &lt;/span&gt;&lt;/div&gt;We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 2001 through 2021 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzQ3MDM_21402c46-3993-452b-86bc-99773e519514">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income before income taxes is derived solely from within the U.S. Our provision for income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzMtMS0xLTEtMjU3Mzk_173e3bda-88dc-4924-b0b8-2cee0d8c2cbf"
      unitRef="usd">11338000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzMtMy0xLTEtMjU3Mzk_e31b9c67-060b-4b94-aebf-af42327fee6c"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzMtNS0xLTEtMjU3Mzk_a7d53d10-7651-40a2-97ae-9c081ceba855"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzQtMS0xLTEtMjU3Mzk_13a97c56-bc23-4e3e-9396-5462a594220a"
      unitRef="usd">5224000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzQtMy0xLTEtMjU3Mzk_f33615bf-30c4-407a-bfcb-811cca7863ab"
      unitRef="usd">3791000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzQtNS0xLTEtMjU3Mzk_e3c4af76-f7a9-4f15-99d5-0cdb10e6c6ff"
      unitRef="usd">6095000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzUtMS0xLTEtMjU3Mzk_69809c97-94b3-4dd1-bc39-0cfb42cd6032"
      unitRef="usd">16562000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzUtMy0xLTEtMjU3Mzk_55c01b20-863f-43b6-97b0-adc519d6fd7a"
      unitRef="usd">3791000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzUtNS0xLTEtMjU3Mzk_5dcf5275-13f2-4809-9c2d-663e20fab323"
      unitRef="usd">6095000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzctMS0xLTEtMjU3Mzk_2beb7f9f-877e-412c-8cb9-d2889d094fb4"
      unitRef="usd">46416000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzctMy0xLTEtMjU3Mzk_b1b33849-ffd9-4d11-9a3e-f7895d7e83f9"
      unitRef="usd">14886000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzctNS0xLTEtMjU3Mzk_415d1999-dbd6-4adb-b8dd-9d7493a7578f"
      unitRef="usd">71580000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzgtMS0xLTEtMjU3Mzk_7173114e-6d70-4d4a-9069-32793a1b60b8"
      unitRef="usd">113000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzgtMy0xLTEtMjU3Mzk_1ac6479e-1bdf-487f-aed1-59e43cbb39b1"
      unitRef="usd">379000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzgtNS0xLTEtMjU3Mzk_3e76f0d3-5c2c-4e52-96fe-5d24c537397f"
      unitRef="usd">-578000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzktMS0xLTEtMjU3Mzk_2c9328e3-82ac-4ade-8f94-0188bd5d41a2"
      unitRef="usd">46529000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzktMy0xLTEtMjU3Mzk_99b574d2-212a-4cfc-95d7-017978fdbd67"
      unitRef="usd">15265000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzktNS0xLTEtMjU3Mzk_ffbdb562-4875-4178-aa3e-ce6f4c34e0ff"
      unitRef="usd">71002000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzEwLTEtMS0xLTI1NzM5_e77c8404-d728-4c84-969c-47836b3a1947"
      unitRef="usd">63091000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzEwLTMtMS0xLTI1NzM5_ad197e0a-8bc6-425e-ad1b-b0a4885bc963"
      unitRef="usd">19056000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTpmZWE5MWFiNGM2NmM0NjYzOWI0NjFkOTdkMTljZTkwOC90YWJsZXJhbmdlOmZlYTkxYWI0YzY2YzQ2NjM5YjQ2MWQ5N2QxOWNlOTA4XzEwLTUtMS0xLTI1NzM5_d257f71b-a6a2-42f1-810a-f42ee6b57b80"
      unitRef="usd">77097000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzQ2ODc_b9e3ce94-2ad3-476f-8d6f-a3ec87cfe494">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2021, 2020 and 2019, respectively, to our provision for income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal income tax provision at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzItMS0xLTEtMjU3Mzk_e26e27cb-d84a-4565-b467-86e0bbb678d1"
      unitRef="usd">61772000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzItMy0xLTEtMjU3Mzk_633179db-0300-4d17-a8eb-f891906388a3"
      unitRef="usd">27476000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzItNS0xLTEtMjU3Mzk_b076d806-3091-487c-9a7b-dbe0cbeb821e"
      unitRef="usd">83603000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzMtMS0xLTEtMjU3Mzk_5e6b6334-3406-4a27-a71b-33ce54fbe4dd"
      unitRef="usd">1336000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzMtMy0xLTEtMjU3Mzk_5d3e15ac-a0fc-4ca9-bc9a-1c56da9b2a35"
      unitRef="usd">-2232000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzMtNS0xLTEtMjU3Mzk_035a2f65-8229-4ce9-a2c2-19e465c9d7f8"
      unitRef="usd">1148000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzQtMS0xLTEtMjU3Mzk_bc70cc98-abfd-4948-9395-2cd24c8d7aba"
      unitRef="usd">2883000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzQtMy0xLTEtMjU3Mzk_fdb05746-5c3c-40a9-9d87-4bbdfbcae5ac"
      unitRef="usd">5525000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzQtNS0xLTEtMjU3Mzk_131ac572-4f69-477b-8622-4a41b6e3aabe"
      unitRef="usd">3208000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzUtMS0xLTEtMjU3Mzk_dce2b892-8430-498e-b89a-8aa8d4b098ef"
      unitRef="usd">6263000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzUtMy0xLTEtMjU3Mzk_85435b8a-c19d-4b14-8cea-9259931da9a1"
      unitRef="usd">11356000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzUtNS0xLTEtMjU3Mzk_646b5792-a646-438f-b274-4c70f809234d"
      unitRef="usd">8299000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzYtMS0xLTEtMjU3Mzk_21c47cef-4ee2-4aeb-8fd3-a96dc5c01c18"
      unitRef="usd">-11831000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzYtMy0xLTEtMjU3Mzk_c31d9e13-aac9-4738-941a-807a389367d5"
      unitRef="usd">-20399000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzYtNS0xLTEtMjU3Mzk_d328041c-bda5-4ed8-83cc-746e78752958"
      unitRef="usd">-9177000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzctMS0xLTEtMjU3Mzk_413f5490-64c5-4f09-97bf-8d223fe39d5f"
      unitRef="usd">11182000</exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzctMy0xLTEtMjU3Mzk_ff2f3d8e-613c-4bd4-8ebb-f5b04af8d066"
      unitRef="usd">18067000</exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzctNS0xLTEtMjU3Mzk_2e8a3807-360e-4961-9bd0-4397f5fcc93f"
      unitRef="usd">4228000</exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation>
    <exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzgtMS0xLTEtMjU3Mzk_a08a1dcc-b2f3-4997-818e-89617136ec7c"
      unitRef="usd">2897000</exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee>
    <exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzgtMy0xLTEtMjU3Mzk_ecc706b1-b4dc-409b-ab82-8cd0dc4d9b6d"
      unitRef="usd">2537000</exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee>
    <exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzgtNS0xLTEtMjU3Mzk_6beb0647-e979-4b8a-9694-565faa55ce9b"
      unitRef="usd">1099000</exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzktMS0xLTEtMjU3Mzk_61e983b7-c891-45eb-8dcb-18f34213b640"
      unitRef="usd">1115000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzktMy0xLTEtMjU3Mzk_d76a6f0b-80a7-4d36-ab3c-459451ec2a25"
      unitRef="usd">-562000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzktNS0xLTEtMjU3Mzk_7f96afcd-f895-48dd-a8fb-2b967ad45cce"
      unitRef="usd">1287000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzEwLTEtMS0xLTI1NzM5_b6b21ea5-12e1-403e-aada-b0f69015468e"
      unitRef="usd">63091000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzEwLTMtMS0xLTI1NzM5_16145e79-4c28-415a-affa-5f5e79ab41b3"
      unitRef="usd">19056000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo1ZjNlYTQ5YzQ0MDM0ZDkyODlkOGI4MTE2ZmY1MGM4Yi90YWJsZXJhbmdlOjVmM2VhNDljNDQwMzRkOTI4OWQ4YjgxMTZmZjUwYzhiXzEwLTUtMS0xLTI1NzM5_9c6a85c7-0f7e-4ae2-97c3-dee875474fd4"
      unitRef="usd">77097000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzQ2OTk_e92c3276-ae83-476b-a855-64046a47b4e7">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzMtMS0xLTEtMjU3Mzk_75036b15-ec57-43cf-b493-de578c5fe206"
      unitRef="usd">17993000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzMtMy0xLTEtMjU3Mzk_0eddf34b-45c4-4356-b139-11494f25ec1f"
      unitRef="usd">37454000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzQtMS0xLTEtMjU3Mzk_034aed2e-c143-4769-8ed2-2e3e4c0ff701"
      unitRef="usd">101460000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzQtMy0xLTEtMjU3Mzk_089d2136-fc97-48b0-afc6-2ebb947bf09d"
      unitRef="usd">126625000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzUtMS0xLTEtMjU3Mzk_febcc0c0-a2d0-4edc-86b3-9d802f576a57"
      unitRef="usd">7764000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzUtMy0xLTEtMjU3Mzk_04072062-6338-4852-b69d-b807af94dc75"
      unitRef="usd">18414000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzYtMS0xLTEtMjU3Mzk_8c7265db-51ae-44b9-8fad-a91a82b53c77"
      unitRef="usd">23162000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzYtMy0xLTEtMjU3Mzk_e5c682bd-c6c1-4c55-a78a-a462b3d082b9"
      unitRef="usd">19818000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <exel:DeferredTaxAssetsLeaseLiabilities
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzctMS0xLTEtMjU3Mzk_cca9c06b-4628-4a26-b5b8-54cd1799a655"
      unitRef="usd">12385000</exel:DeferredTaxAssetsLeaseLiabilities>
    <exel:DeferredTaxAssetsLeaseLiabilities
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzctMy0xLTEtMjU3Mzk_0bdd156a-3701-4549-a595-fc81e939ada8"
      unitRef="usd">11908000</exel:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzgtMS0xLTEtMjU3Mzk_1f1f6f98-ce07-48dc-bca2-0f4d045f218b"
      unitRef="usd">19531000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzgtMy0xLTEtMjU3Mzk_67fcf444-3e23-47f3-8ff3-dd975297b1cf"
      unitRef="usd">12207000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzktMS0xLTEtMjU3Mzk_0b0d2698-0644-4fa6-b909-f72459c5c1c5"
      unitRef="usd">8040000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzktMy0xLTEtMjU3Mzk_2950c7c6-338c-4831-86b2-4ff152ea0c2c"
      unitRef="usd">7637000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzEwLTEtMS0xLTI1NzM5_7fed7fed-b11a-4682-b2f6-6a0e3db807be"
      unitRef="usd">1303000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzEwLTMtMS0xLTI1NzM5_dc0f13a5-8bd3-458e-9e91-20f775dd2da6"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzExLTEtMS0xLTI1NzM5_6ee3bf51-9faa-4473-9843-80761b559ce8"
      unitRef="usd">191638000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzExLTMtMS0xLTI1NzM5_2c1d370a-8b2f-41d2-b788-2c9637bf345f"
      unitRef="usd">234063000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzEyLTEtMS0xLTI1NzM5_5422e5b9-d47b-4f5f-8c89-f515a844ff94"
      unitRef="usd">70068000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzEyLTMtMS0xLTI1NzM5_def5c630-308f-4e9e-87de-affab0c5b4a1"
      unitRef="usd">67185000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzEzLTEtMS0xLTI1NzM5_61f0e040-9a50-4117-8831-db284fc6da7b"
      unitRef="usd">121570000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzEzLTMtMS0xLTI1NzM5_94f64b7b-8167-4f91-90fd-a3750f741935"
      unitRef="usd">166878000</us-gaap:DeferredTaxAssetsNet>
    <exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE1LTEtMS0xLTI1NzM5_926d6136-4287-4ee1-9033-9458ce9bd184"
      unitRef="usd">9907000</exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets>
    <exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE1LTMtMS0xLTI1NzM5_28c7017c-1717-4a89-a5cc-89074266bfdc"
      unitRef="usd">9510000</exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE2LTEtMS0xLTI1NzM5_fd7a1c1a-d6bb-4968-935a-781b52754538"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE2LTMtMS0xLTI1NzM5_6d1ba847-2fa3-4b36-8363-a8e49a0e5d51"
      unitRef="usd">657000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE3LTEtMS0xLTI1NzM5_cf811a8b-dc1d-4327-bc2e-e265d22051e2"
      unitRef="usd">9907000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE3LTMtMS0xLTI1NzM5_849df4de-e6af-4640-af15-eef8d25092b5"
      unitRef="usd">10167000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE4LTEtMS0xLTI1NzM5_98bbd16b-0545-40c5-a5e7-0fa2cb35ca1e"
      unitRef="usd">111663000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTphY2I3ZjhhMGFhYmQ0NTQ0YWQwMDA5NDQ0Y2QyYmNhZi90YWJsZXJhbmdlOmFjYjdmOGEwYWFiZDQ1NDRhZDAwMDk0NDRjZDJiY2FmXzE4LTMtMS0xLTI1NzM5_8982027f-e461-44e0-b204-2855ce62713d"
      unitRef="usd">156711000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzI0ODE_395164de-60e8-45fe-9c1e-bd81524479d1"
      unitRef="usd">70100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzI0ODg_1c7462fb-bda0-40d6-a2cf-2e58085856f5"
      unitRef="usd">67200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzI1ODY_62ead1ee-2993-49da-9236-db3d74501b9f"
      unitRef="usd">2900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzI1OTM_75113d47-43c5-43b3-8a88-f37c17176b1f"
      unitRef="usd">5500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i420a84572c824730897fc79711ca81fe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzE2NDkyNjc0NTEyMjM_ecadc0c8-b7e7-49ba-9fcf-c48a81c5bc11"
      unitRef="usd">101000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="if84d627e667d48f29f5af7ff692d0370_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzE2NDkyNjc0NTEzNTc_e4a29ece-da63-4317-8111-3868c85595ce"
      unitRef="usd">426000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i8b39280de5b64a109031af851502c539_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzMwMjQ_3f5c73ee-d135-40a1-9fcf-8f1aa10bcb53"
      unitRef="usd">45000000</us-gaap:TaxCreditCarryforwardAmount>
    <exel:TaxCreditCarryforwardAmountWithExpirationPeriod
      contextRef="i8b39280de5b64a109031af851502c539_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzMwOTE_c7254881-7cc7-478c-b0f8-9ba1494de37c"
      unitRef="usd">2000000</exel:TaxCreditCarryforwardAmountWithExpirationPeriod>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzQ2OTQ_03af2b89-1ae4-49af-bdac-0b71a6ff37a3">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change relating to prior year provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change relating to current year provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions based on the lapse of the applicable statutes of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzItMS0xLTEtMjU3Mzk_e8cfe093-115a-4f3c-b930-56954a53c395"
      unitRef="usd">80941000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2d03c75ce0024c01a62fcd27957b4f04_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzItMy0xLTEtMjU3Mzk_03160533-1bc5-4ae0-b02a-aed877c28a3b"
      unitRef="usd">79078000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i396cffc473714e59a1c966a366a443e2_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzItNS0xLTEtMjU3Mzk_ec25aa6a-dcb1-4727-855d-036edcd4b700"
      unitRef="usd">76060000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzMtMS0xLTEtMjU3Mzk_9a2dc768-71db-4f29-a8cb-4d8b580297d8"
      unitRef="usd">728000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzMtMy0xLTEtMjU3Mzk_b7ed7b32-7068-4a14-96e5-438d73f12201"
      unitRef="usd">591000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzMtNS0xLTEtMjU3Mzk_3257ae65-9d27-4141-bf79-4ef1a1855ce7"
      unitRef="usd">589000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzQtMS0xLTEtMjU3Mzk_bae2f2fe-6916-472c-876a-2f5c95eef12f"
      unitRef="usd">2215000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzQtMy0xLTEtMjU3Mzk_5eec1d32-c078-4251-b4f2-7c38c858557f"
      unitRef="usd">3305000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzQtNS0xLTEtMjU3Mzk_30c897c2-9a5a-4f82-b7fd-d1812fcf067c"
      unitRef="usd">2429000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzUtMS0xLTEtMjU3Mzk_c010d732-15e8-4be3-bcd2-95d3c0e228c2"
      unitRef="usd">301000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzUtMy0xLTEtMjU3Mzk_02d2c597-f1ea-4ddc-a31c-1bc1fc88833e"
      unitRef="usd">2033000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzUtNS0xLTEtMjU3Mzk_1a750d71-76a9-47bf-aaa0-05525060e5d5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzYtMS0xLTEtMjU3Mzk_dad5a72f-f460-44f1-9a21-dafcd20985a7"
      unitRef="usd">83583000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzYtMy0xLTEtMjU3Mzk_f8842de1-ca51-4d7b-a2a9-eeba21064b7d"
      unitRef="usd">80941000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2d03c75ce0024c01a62fcd27957b4f04_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90YWJsZTo2ZDRiOWVhMjBlYjE0ZTA1ODUwNDVhZWU2ZjFlNWIyMy90YWJsZXJhbmdlOjZkNGI5ZWEyMGViMTRlMDU4NTA0NWFlZTZmMWU1YjIzXzYtNS0xLTEtMjU3Mzk_7b57dc3d-3a7c-4b50-811b-84ce721c41c9"
      unitRef="usd">79078000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzM5MDI_9b08bb47-0077-4781-babc-540a2e13303b"
      unitRef="usd">83600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMDkvZnJhZzozNTY4YjdmMzZkZDE0OTk3YWQ3NThhY2MwMzkyODQ4Mi90ZXh0cmVnaW9uOjM1NjhiN2YzNmRkMTQ5OTdhZDc1OGFjYzAzOTI4NDgyXzE2NDkyNjc0NTE4OTE_576043d6-0275-475f-b0bb-a273ac29a719"
      unitRef="usd">52600000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90ZXh0cmVnaW9uOjg0OWNjMjY1OWUzOTQ5NjRiYmRhYTcwYjI1NGIwZjIyXzgzNA_82dc7508-93fd-4e6c-8b23-472752eba188">NET INCOME PER SHARE&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities included outstanding stock options, unvested RSUs and PSUs and ESPP contributions. Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. See &#x201c;Note 8. Employee Benefit Plans&#x201d; for a further description of our equity awards. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90ZXh0cmVnaW9uOjg0OWNjMjY1OWUzOTQ5NjRiYmRhYTcwYjI1NGIwZjIyXzgzMA_c2936f21-74b7-48e9-8400-99f6a0163045">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="if4d4436bfbe6489187e15748fba98eba_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzMtNS0xLTEtMjU3Mzk_a4a0e49b-538b-4769-b3b0-0a000826d2d8"
      unitRef="usd">231063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzMtNy0xLTEtMjU3Mzk_8de384b5-b560-4513-8421-2ea9f5137b05"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzMtOS0xLTEtMjU3Mzk_bc76ab92-7f7e-4c2e-90b3-592155118fc0"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzYtNS0xLTEtMjU3Mzk_990c6d4e-41a0-40a9-9d5e-c73d6ccb9a7e"
      unitRef="shares">314884000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzYtNy0xLTEtMjU3Mzk_02b76316-39b2-4876-99df-4550bd25a008"
      unitRef="shares">308271000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzYtOS0xLTEtMjU3Mzk_ff47dd4e-b9d8-41fd-87c0-f315a2fb6270"
      unitRef="shares">302584000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzctNS0xLTEtMjU3Mzk_2e047825-8911-4491-ba3b-456d79f5f541"
      unitRef="shares">7475000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzctNy0xLTEtMjU3Mzk_923d8b8b-1462-4c91-83be-9cc94f2a98c8"
      unitRef="shares">9730000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzctOS0xLTEtMjU3Mzk_5271fe29-afc6-4cc9-ba8e-71313f89c5f7"
      unitRef="shares">12425000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzgtNS0xLTEtMjU3Mzk_7b0f2823-8a19-4caa-8ce4-ede2d5e74a78"
      unitRef="shares">322359000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzgtNy0xLTEtMjU3Mzk_cbba7e85-8ef4-45d2-8ee4-fe645921e55d"
      unitRef="shares">318001000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzgtOS0xLTEtMjU3Mzk_ce175e41-5be8-4387-8b13-db0cec65ba3a"
      unitRef="shares">315009000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzEwLTUtMS0xLTI1NzM5_d0412897-a7a9-418b-ba1d-386e5c427995"
      unitRef="usdPerShare">0.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzEwLTctMS0xLTI1NzM5_17cb74be-19a8-408b-9aa9-1777d90d4f3d"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzEwLTktMS0xLTI1NzM5_3ef80348-21aa-44cd-ae45-1f3f7622a84a"
      unitRef="usdPerShare">1.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzExLTUtMS0xLTI1NzM5_c137cefc-10d3-4f81-b90e-008ea0bcc9e2"
      unitRef="usdPerShare">0.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzExLTctMS0xLTI1NzM5_2bcdf78e-5712-4513-a37f-463e77663f96"
      unitRef="usdPerShare">0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo5ZTU3YjI5MjUwYzI0NGU2OGU2YzU3MzllNGRmY2Q0Mi90YWJsZXJhbmdlOjllNTdiMjkyNTBjMjQ0ZTY4ZTZjNTczOWU0ZGZjZDQyXzExLTktMS0xLTI1NzM5_96fe491a-ecd6-4aa7-8be4-4584925d4d52"
      unitRef="usdPerShare">1.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90ZXh0cmVnaW9uOjg0OWNjMjY1OWUzOTQ5NjRiYmRhYTcwYjI1NGIwZjIyXzgxOA_0a1495bc-89a9-428f-946a-62964258b542">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i13ee6cf1e5c848d2b6f0a4bd3a76af26_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo2NmQ2YWNhMzMxZmE0NzM1OGVhMGM2ZjkxYjA2NWU0OS90YWJsZXJhbmdlOjY2ZDZhY2EzMzFmYTQ3MzU4ZWEwYzZmOTFiMDY1ZTQ5XzItNS0xLTEtMjU3Mzk_dc97d33f-e0da-42d9-a8b9-d23feb5a8bbe"
      unitRef="shares">14305000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i345c9b326f5c4c488b5009d48f08f45f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo2NmQ2YWNhMzMxZmE0NzM1OGVhMGM2ZjkxYjA2NWU0OS90YWJsZXJhbmdlOjY2ZDZhY2EzMzFmYTQ3MzU4ZWEwYzZmOTFiMDY1ZTQ5XzItNy0xLTEtMjU3Mzk_952f0bde-dc9b-4a1c-a7d5-efd82338b809"
      unitRef="shares">10959000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i045cc234fe6d42e29ebae3f4719abd7e_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTIvZnJhZzo4NDljYzI2NTllMzk0OTY0YmJkYWE3MGIyNTRiMGYyMi90YWJsZTo2NmQ2YWNhMzMxZmE0NzM1OGVhMGM2ZjkxYjA2NWU0OS90YWJsZXJhbmdlOjY2ZDZhY2EzMzFmYTQ3MzU4ZWEwYzZmOTFiMDY1ZTQ5XzItOS0xLTEtMjU3Mzk_e0dcb058-62a0-4cf2-8a88-1c4f142273ba"
      unitRef="shares">9111000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkwNDE_3e2507bf-0cf7-48f3-9b3d-09e2ae77116f">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Headquarters Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located in Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018, April 2019, August 2019, January 2020 and December 2020, resulting in, among other things, an increase to the amount of space leased and changes to the lease term. Our right-of-use asset, lease liability and the related lease costs reflect the 254,690 square feet of space we have taken possession of as of December 31, 2021 (the Current Premises) under the amended Lease, including 25,749 square feet of space we took possession of in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The term of the Lease continues through October 31, 2031 (the Lease Term). We have two five-year options to extend the Lease; these optional periods have not been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made certain tenant improvements on the Initial Premises, for which we received $8.2 million in reimbursements in January 2019. During 2020, we also made certain tenant improvements for which we have received $1.7&#160;million in reimbursements in 2021 related to the additional space we obtained under the April 2019 amendment. We were also provided an allowance of up to $1.4 million in 2021 for certain planned tenant improvements to the additional space obtained under the December 2020 amendment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_7a0e4465-a6b5-4b02-b58f-7014879a369f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_dc2f3847-52aa-4192-8d7c-2b18b469e239"&gt;Right-of-use assets included in other long-term assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_5d4462a3-e4ad-42c2-8f32-f51e009f8ca0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_ae5d588d-a5da-417a-8318-ddd0d907793d"&gt;Current portion included in other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities for the years ended December&#160;31, 2021, 2020 and 2019 was $5.0 million, $4.6 million and $2.9&#160;million, respectively, and was included in net cash provided by operating activities in our Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future tenant improvement reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the weighted average discount rate used to determine the operating lease liability was 3.1% and the weighted average remaining lease term was 9.8 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Build-to-Suit Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, we entered into a build-to-suit Lease Agreement (the Build-to-Suit Lease) for approximately 220,000 square feet of office space located in Alameda, California (the New Premises), adjacent to the Current Premises.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The term of the Build-to-Suit Lease is for a period of 242 months (the Term), which will begin upon the substantial completion of the building and tenant improvements by the lessor. We currently anticipate that the Term will begin in the first quarter of 2022 (which date will be the Lease Commencement Date). The monthly base rent under the Build-to-Suit Lease will equal a percentage of the total development costs incurred in connection with the development of the New Premises (excluding the cost of the tenant improvements in excess of the allowance provided by the lessor and any development costs we pay) and is currently estimated to be about $0.7 million, subject to an annual increase of 3% during the Term. We will also be responsible for paying operating expenses related to the New Premises. The rent payments will begin sixty days following commencement of the Term. We have been provided a tenant improvement allowance for the New Premises of approximately $16.5 million. To the extent that the total development costs of the New Premises exceeds $525 per square foot, we will also pay 50% of such excess costs prior to the commencement of the Term, and we are required to secure such amount by providing a letter of credit or depositing such amounts in an account with the lessor&#x2019;s lender.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Build-to-Suit Lease includes two five-year options to extend the term of the Build-to-Suit Lease, exercisable under certain conditions and at a market rate determined in accordance with the Build-to-Suit Lease. We have a one-time option to terminate the Build-to-Suit Lease without cause after the 180&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; month of the Term, exercisable under certain conditions as described in the Build-to-Suit Lease and subject to a termination payment calculated in accordance with the Build-to-Suit Lease. In addition, we have a right of first offer to purchase the New Premises, subject to certain procedures and exclusions set forth in the Build-to-Suit Lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have determined that, under the guidance provided in Topic 842, we do not have control of the New Premises during the construction period. Therefore, we will not record a right-of-use asset or lease liability for the Build-to-Suit Lease until the Lease Commencement Date. We will evaluate the classification of the Build-to-Suit Lease as an operating lease or financing lease at the Lease Commencement Date. We determined the cost of tenant improvements during the construction period are lessor assets and considered a prepayment of lease under Topic 842. The costs incurred as of December&#160;31, 2021 of $36.8 million are recorded as other long-term assets in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of $16.7 million and $1.6 million as of December&#160;31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we entered into a standby letter of credit as guarantee of our obligation to fund our portion of the tenant improvements related to our build-to-suit lease at our corporate campus. The letter of credit is secured by our short-term investments, which are recorded as restricted cash equivalents and presented in Other long-term assets in our Consolidated Balance Sheets and is reduced as we fund our portion of the tenant improvements. As of December&#160;31, 2021, restricted cash equivalents included $15.2 million of short-term investments as collateral under our standby letter of credit for our portion of the tenant improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#x2019;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Orange Book&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for CABOMETYX. MSN&#x2019;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473 (composition of matter) or U.S. Patent No. 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#x2019;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patent Nos. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent Nos. 7,579,473 and 8,497,284 arising from MSN&#x2019;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent Nos. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#x2019;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#x2019;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patent Nos. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#x2019;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#x2019;s ANDA product prior to the expiration of U.S. Patent Nos. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#x2019;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patent Nos. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. A bench trial has been scheduled for May 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of four previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patent Nos. 11,091,439 (salt and polymorphic forms) 11,091,440 (formulations) and 11,098,015 (methods of treatment). We have 45 days from receipt of the January 11, 2022 notice to file a patent infringement claim against MSN relating to the newly challenged patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approval to market a generic version of CABOMETYX tablets. Teva&#x2019;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#x2019;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with Teva Pharmaceutical Industries Limited (Teva Parent), asserting infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#x2019;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#x2019;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from infringing these patents. On February 8, 2022, the parties filed a stipulation to stay all proceedings, which was granted by the Delaware District Court on February 9, 2022. The stipulation and order were filed under seal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ia8b2c55942a54b85b0a416b604b6a2b5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzQ5NDc4MDIzNTg5ODk_c88af4b2-ac08-41bf-88ad-96396b6ce6f6"
      unitRef="sqft">254690</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i70af130f4dae44efb4c5edbc61ae24bc_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzMxMzM2MDgxNDM5NTM1_c6ce4674-330f-4df6-a76e-c0dd38cae610"
      unitRef="sqft">25749</us-gaap:AreaOfRealEstateProperty>
    <exel:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i09d02a3201ea4cd9abf78408a6c51ddc_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkxNQ_f957ccb9-4ac5-4b90-8268-b7eb91fdecbe"
      unitRef="renewal_options">2</exel:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ia8b2c55942a54b85b0a416b604b6a2b5_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkwMzg_d62ec43e-abc7-4784-bf4c-d455df9c373d">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="ia7f4ccf1863646c7ad5275dd80a4cbd4_I20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzEyNjI_217cfd58-83d6-499b-b82f-9aa031a2cdad"
      unitRef="usd">8200000</exel:TenantLeaseImprovementsAllowance>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="ib15b9dd84185469e883fb78ad72ac110_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2Xzk4OTU2MDQ2ODQ5ODE_7f20659e-ccd7-428b-9c0c-075db83b2bd5"
      unitRef="usd">1700000</exel:TenantLeaseImprovementsAllowance>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="ia3b3d07f431b4ca096bce3b9f83ca347_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzIxOTkwMjMyNjQ2MTE_c8ec33d8-9bfa-4228-bc46-c014c976b6bb"
      unitRef="usd">1400000</exel:TenantLeaseImprovementsAllowance>
    <exel:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkwNTE_69bf3b4e-871e-4b25-ac22-227dc1315073">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_7a0e4465-a6b5-4b02-b58f-7014879a369f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMC0xLTEtMjU3Mzk_dc2f3847-52aa-4192-8d7c-2b18b469e239"&gt;Right-of-use assets included in other long-term assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_5d4462a3-e4ad-42c2-8f32-f51e009f8ca0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMC0xLTEtMjU3Mzk_ae5d588d-a5da-417a-8318-ddd0d907793d"&gt;Current portion included in other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMS0xLTEtMjU3Mzk_ccd9d4b0-2b05-4583-b6fe-7c52cde9d843"
      unitRef="usd">45122000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzMtMy0xLTEtMjU3Mzk_c5cca64d-1062-4967-b0f6-b2cec75ab456"
      unitRef="usd">43010000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMS0xLTEtMjU3Mzk_9eb860e7-cfd0-4237-b86a-7b29552ab7ed"
      unitRef="usd">5137000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzUtMy0xLTEtMjU3Mzk_36271583-8c85-4c00-a096-2876a256b08e"
      unitRef="usd">3025000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzYtMS0xLTEtMjU3Mzk_ed5cac00-d484-4771-a568-18ecba1a31d7"
      unitRef="usd">51272000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzYtMy0xLTEtMjU3Mzk_7837c2e2-65a4-48da-9db2-d432aad095fa"
      unitRef="usd">49086000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzctMS0xLTEtMjU3Mzk_9a5c588e-f803-4519-aaf2-4d23b417e74a"
      unitRef="usd">56409000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i048f2416fccc4e10b7965efb1a171533_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTozYTllNWI1OTMxYzk0ZTAyYWM3YWI2ODNlOGFkZjYwNS90YWJsZXJhbmdlOjNhOWU1YjU5MzFjOTRlMDJhYzdhYjY4M2U4YWRmNjA1XzctMy0xLTEtMjU3Mzk_1a03f2a9-100e-44ab-8134-49c2ec9912ba"
      unitRef="usd">52111000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkwNDk_a9409f2a-45cf-43de-b749-e38ec1f01e43">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzItNS0xLTEtMjU3Mzk_271ed6f4-dc65-42f8-985e-e5958fbb11b1"
      unitRef="usd">5332000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzItNy0xLTEtMjU3Mzk_93573153-583a-416f-af0f-35c650aa106a"
      unitRef="usd">4825000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzItOS0xLTEtMjU3Mzk_2930490d-d382-4f21-b8bb-93e4aee779ee"
      unitRef="usd">2844000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzMtNS0xLTEtMjU3Mzk_5a0da772-878a-4913-a0c8-04a024571ad3"
      unitRef="usd">2685000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzMtNy0xLTEtMjU3Mzk_f1943849-f7fc-47a8-84a7-939e074d266d"
      unitRef="usd">2830000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzMtOS0xLTEtMjU3Mzk_12b1a84a-0dfe-4251-a1c4-0c5cc7add315"
      unitRef="usd">1024000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzUtNS0xLTEtMjU3Mzk_949e76a0-3433-4dde-ba43-496bdaee4665"
      unitRef="usd">8017000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzUtNy0xLTEtMjU3Mzk_4b249734-cf5e-4aba-b977-9d4262e0c564"
      unitRef="usd">7655000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTpkNTNkMmE2MDc2Mzk0NGE4YmQ0NDMwNzMzMTY3NzcwNS90YWJsZXJhbmdlOmQ1M2QyYTYwNzYzOTQ0YThiZDQ0MzA3MzMxNjc3NzA1XzUtOS0xLTEtMjU3Mzk_57612d3b-df11-41ff-9efd-f16d66c53902"
      unitRef="usd">3868000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzE5NzA_b83ccdc0-7f33-4932-9c20-4ea1f1e3ca1f"
      unitRef="usd">5000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9f64fd82fa174225acd596e1590d5f5f_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzgyNDYzMzcyNTYxMjk_885b7a23-6551-4adb-8a6e-2a9bb3b7f613"
      unitRef="usd">4600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="if3c269a9722c4b68928c1422c431ad44_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzgyNDYzMzcyNTYxMzk_e74c05e9-5cc1-4084-a452-a07295954d1f"
      unitRef="usd">2900000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkwNTA_ffc3261c-d1a0-4986-89c2-125f3ca5d538">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future tenant improvement reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzEtMi0xLTEtMjU3Mzk_14cf74ed-9406-4c26-99d0-04e01404a114"
      unitRef="usd">5638000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzItMi0xLTEtMjU3Mzk_2de9a818-bbcb-40b0-bb2c-ce6ae71821e8"
      unitRef="usd">5995000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzMtMi0xLTEtMjU3Mzk_b3f85c94-f6b2-49c3-beaa-8f5b76efa099"
      unitRef="usd">6283000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzQtMi0xLTEtMjU3Mzk_7de7937b-4f85-4a97-8fba-e675d223bf56"
      unitRef="usd">6478000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzUtMi0xLTEtMjU3Mzk_9662aa75-864e-491c-aed1-70d4bfdb5eec"
      unitRef="usd">6675000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzYtMi0xLTEtMjU3Mzk_d9cec6a5-7799-4061-a4b8-66c25a290c4b"
      unitRef="usd">35170000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzctMi0xLTEtMjU3Mzk_dcedd2cd-c5bd-4a0a-8f26-dec6b3bd057b"
      unitRef="usd">66239000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzktMi0xLTEtMjU3Mzk_b8c5c61a-829b-4fc0-ab14-3566f59abc2a"
      unitRef="usd">9404000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzEwLTItMS0xLTI1NzM5_e163305e-a08d-4b08-8430-eccb14e356ca"
      unitRef="usd">426000</exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90YWJsZTphZDUzMzY3NjUzNzE0MTZjYWVkNDJlYzdjNTQ2MTAyZS90YWJsZXJhbmdlOmFkNTMzNjc2NTM3MTQxNmNhZWQ0MmVjN2M1NDYxMDJlXzExLTItMS0xLTI1NzM5_96145ddd-d2ef-4a6c-a5bb-1bab4e14f751"
      unitRef="usd">56409000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzIyNzM_846d51cf-ac51-4c4f-89ff-47b3bdd18336"
      unitRef="number">0.031</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzIzMjU_133d7649-3d1a-4a62-b834-c5416519bbec">P9Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="id1ee46f49349499882d7dd859933eb48_I20191031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzI0NTk_08b31d5f-253d-4942-af2e-7058539a8887"
      unitRef="sqft">220000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="id1ee46f49349499882d7dd859933eb48_I20191031"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzI2MzA_19868f12-398c-487e-90b1-ca7146ef6355">P242M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment
      contextRef="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzMxOTE_5f09c697-1938-4bb9-a7a7-6b06bede1dad"
      unitRef="usd">700000</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage
      contextRef="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzMyMjg_7fddd606-8380-4e5c-ae43-a9a825be0784"
      unitRef="number">0.03</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage>
    <exel:LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod
      contextRef="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzMzNjQ_238f328b-9476-4800-85df-ef5137cab52f">P60D</exel:LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod>
    <exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
      contextRef="id1ee46f49349499882d7dd859933eb48_I20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzM0OTQ_d41cb13d-bddd-4d90-8e8b-69b1f0122a42"
      unitRef="usd">16500000</exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements>
    <exel:AreaOfRealEstatePropertyAvailableToLease
      contextRef="id1ee46f49349499882d7dd859933eb48_I20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzM1NzM_3a0803ad-4323-4f2f-b261-599c688c0868"
      unitRef="usdPerSqft">525</exel:AreaOfRealEstatePropertyAvailableToLease>
    <exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts
      contextRef="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzM2MTA_eddbdb9d-5cb6-43b0-8ff0-101c964798a3"
      unitRef="number">0.50</exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts>
    <exel:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzM4NDc_4d07c997-4001-4b96-894a-ba49608ef7ea"
      unitRef="renewal_options">2</exel:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="id1ee46f49349499882d7dd859933eb48_I20191031"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzkwNTM_512b72e6-0557-4ca6-a38c-61634a92e437">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod
      contextRef="i113d63ba8fb3489b8c2be7e51533bb7e_D20191001-20191031"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzQxMTM_c0e989b7-3dd2-4089-9e6a-b5f32be63050">P180M</exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod>
    <us-gaap:TenantImprovements
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzE2NDkyNjc0NTA3MzQ_2958b243-1de0-4579-a9af-48c0f71d68b4"
      unitRef="usd">36800000</us-gaap:TenantImprovements>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2e77e8a209894b9ea42d468fd28563b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzQzOTgwNDY1NDYxODE_e29bf672-f4d5-4d99-9c0c-7a668c7203c7"
      unitRef="usd">16700000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7054208b42f440b38822d84184f73e38_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzQ5NDc4MDIzNTc4OTI_aa26e2bc-e833-448b-bb21-d7375c129ffc"
      unitRef="usd">1600000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="ia71123bf4ed74085ad4ac0a89679baa1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xMTUvZnJhZzowYjg1Njg2ZTAyYzQ0MzM1YjczNjQ1OWRjZDY3YjliNi90ZXh0cmVnaW9uOjBiODU2ODZlMDJjNDQzMzViNzM2NDU5ZGNkNjdiOWI2XzE2NDkyNjc0NzU5MjQ_fb7af98d-924a-4b74-997a-6822f3e39066"
      unitRef="usd">15200000</us-gaap:RestrictedCashEquivalentsCurrent>
    <dei:AuditorFirmId
      contextRef="i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxZGM3NzlhZjZhMzQ5MWM5YWVmNTkyNDZmMDhmZTA0L3NlYzpiMWRjNzc5YWY2YTM0OTFjOWFlZjU5MjQ2ZjA4ZmUwNF8xNTQvZnJhZzoyNDgxMDA5NTdhNjk0YWYyYWZiNTE1YWNiODkzNjI4YS90YWJsZTowNjI1NjBlMmUzYTM0NjMwODUyNjZjNWIwYzUxZmJhNy90YWJsZXJhbmdlOjA2MjU2MGUyZTNhMzQ2MzA4NTI2NmM1YjBjNTFmYmE3XzEtMC0xLTEtNDc2MzkvdGV4dHJlZ2lvbjo1NzM1YWUxNjUwMjg0OTY0YjljMGE5OGJiNjUyMTA1ZV80Mzk4MDQ2NTExMTc1_9e593fa1-5c1a-4d4b-9c71-32a259653196">42</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>93
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M-YS!##(/P/V5$/IP8EY0?!*Z^@]02P,$%     @ IHA25'W28[@B @  <P4
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MM[7238LW$U2E;ZN#0MND?EC85Q&T"[#[1Z7P-'$'=.]L\A=02P,$%     @
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MB;<X:.> [^=*V1?#!6C_%XS_ %!+ P04    " "FB%)4[:V\XHT"   \!@
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M^O^:<_G]1K_0.+Y36_P'4$L#!!0    ( *:(4E2:*D[B! @  #,B   8
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M<T="KXCRBE8#'8>V8_-=FI="XS3L3E_:7-8<M.?Q2S:U@>WT%$[?V%%^==/
M95(G&&<)M!_82A8.Z\4C,V[4_7]Q?:F)J1\>_3"+]R @+^(P^XE_[#308%0E
M(08*"O-^XTASJ 'D\9YA:)Z]P\V'3+5.I\+I'-"4DBWV$6#QP49N/Q)1D81-
MN M+2@[1U#%!#"9KHT579&1U=R3N&#^W5GV]V',=)4K..16-.H<0X@P9UR'-
ME7*ZR+)TGO*.I,QFYG+6$U5!(?>G<5]Z :-XI8E75"?ZP^_99*I#>/K)&#4Q
MWLING(R,T)1DG^EECPC1#7$#;1Y 71#6A 4GTF@"15Z/@4"LZP"0WA(GXPN*
M7K@C3VLN?YST#8VK+A23$3V-=^@V&):QB 6V$0QIMJ'?8 :R%B"%.2XD_,$V
MT)4<W%AI\07#&P>J;;49UP!9Y?TLL]X\:W&PV6.:'.7 ?#142B8IVFA9\=U#
MGFTD19*.#Z%L'Z'5AA&O$KGNQ4MXA(,XV:@:2TIE6*Z6[=*D@+B%/J(KDC5-
ML/NLE=G37O!*Q =TC^(E;B)MO97D,^Q/,7B@=;!#9$33;DYRGQ,* C_TTK-_
MH*?FV;'&EF?W]<@\NZO#1M+E2;M.B#-/]>MP"Z2-Y%6[,AY"=(A<C:\PC(<]
MLC;^PV91I;6*O6\FX-G4J@$U/N9ET1'!8O6I(81NKKXEJSZ[?0(1S"HC@"A3
M$<8I8GX"&^HQSI'XE+D*PAH\[""Y PTGL-]"YDA3UZZR!R="#B&Y4VHZ@WM\
MK3,IHAMRR%$H=)9],GK[1>GMM4.P2:N0C COY)JIJJ1#(T:LHZ/%& <HCR@A
M;:8<Y7./L ^;<U8@XKU:.X_/7]L'*/W38HCVX/$P@\!_@)I#3>EQ'1WZOM2'
M]2?6A\U#"(&3D 7GKIE</"*,)_2CK%*B>\T]R(48:#Z5)UI)FY45O5*V)*QC
M$Y5C#E'+C--"*M5M,\S&!K].\\312N#[7B1,2;D,[E8*^DN9,WY8!2 !5M(Q
M_CD)(,1J1GL1".PPK<%FIA\,EC2BD:&07TDVHG1LQ!_VM\$CYK9@J[01E<5)
M*#,-/:E\G-J!V7(,&0WYI&35"'=Q[]A$D1>B<8GX?QE)E#=>_&L,'7'C_I"\
M&-S87I$$H)4VQ$)JJDLS'H$8TX)_5CN30D&NSRK2YC*#MP4,&G[P,80H@.#C
M!O<D0D//"@]ID-IL6\1ZOZY67YG=%&1KEE-\>I^S5%H,4P(":GR5Y+WPGD5W
M%$R%>"*BFH#ZHRNQU/%!$BVRB>8\1"3!P]PY,F$KWGD/.>;/\BP0$L!5AF&(
M;##U^X.!")X5L7SXR0I,6R4W2X/HAS<D\[GK5!K?H7]GTLLG7L3-'7I<6\A"
MD<V4FN 2AC9(_&,:*)J-:<,#V#4UV75FC!1S?"A".V!^55KS1)!$U1=BF@/W
M>(<O<CR .+K5F+,XR;;W,N)(*8&O#.BU,&!*#,5);],$C11.3)'N1;U7DO.A
MJU%S/=]<5 A ]UULYL/.9@_[XBU-YJHM^C1U[6-IE.6FU4(#H,3NU)Y%=QMB
MR&;FLG6GC9!35A<'LGP031>QGM8QI\'(:IUZ&W'R(YXJT=F/Y9Q%P8_2_ 7[
M(1VK]<O#+ OV22:-#7J[:V82QN"?Q2E\23J7H1(G\%3?H_1\ENB%2XC&#XEU
M+]G5XPY58M.:71&U2T_BEL/4N(PN7[E^'Q5-\R\121-3&DX!J:J+)G$:7$[9
M]Z*(P;5,<=[?CNK0)"8;>==JINV/Q-&\"16_?WR8@94.^<-/7D1^WU7,@G#R
MK"9*BZ<^U2,42O>ACY>K6?^;*\SWX5^7\J5&WIN*KNYLLOC1^U@!E=V=$C$1
M?Y'IYN,'$V;16?;GYA;ZD^T>F:ED(^_R_CBR+?X119%"*7R1! %1R85!+=I#
M&A&?#^M)0;MTU@CY>%5[.*OKZ'H6$F6I%?O!L:QZJMT'=A]1Z==DP'/T^S :
M5_<_:S.;JN?.$;L1/'."3=SR\;!1B2!+96>MO\SCU?;D+/MHW[-QUP8/A4\B
M6IQ\(9)B.N&%H^"937J+'4&M7V>N 0:P2M"R 2-).]9A(03K%6UC3IGC+CH_
MIA:G;)H)?,;6P)%[/%:R_[4E<X?E<DF335HO1U8_AUK$Y+^.(CY3)O_KR3X0
M/^;5!VV^9B)+^"&SPV^M)#?\2H=TE ;M:J/E0B'XR.M> IT6-9#+<$L>)@2:
MZ]TVE%VFC"SFCP3P)Z,#IM*A; &#MP#30F$IGKO?0DP[>5J]C?"[;=ZX]1]%
MIN.ESEWXF</'U\@W7QX.:2@/?M!NLIS0)V"3RKL\>_)'#Y:R73SZ#CFNAN%,
M W4P):,I$ TYS_Z'C.*?SA->$)A#/EY_U4-+OYE1+#XE Q-E3D5T+!Z<866[
MVJ[FQR_,./^[LZ^M2KILEW.IFZZ:-=1Z,<J(B\%K>88(<V?)K.T)-RG*J^%G
M.Y:<\;+9V=X9,C7,CT75"-%TYJFUHS9&ON"AYG;EJ4<QKX);*-C3D.IK07J"
M[.B4$U![J^%.J'@>%?N%^:[L=09;'MU"1ABU?)8$<=G%/*(F&2)$):+O8]OS
ME646/]RG:'U)*=T)FLV4JM@>-A+S-E- 1/J3GM)Y-NS2*'ID1MDT0N[/<(Y_
M*T(>TDGR$CH$^<G?[@NDF8;B9UPRP*&9Z#03HM'?A5S5(OI-RZ080N*J<X%A
M'&77V-[=\[8\)+YLCZ<3IU;Y712AK6_<=C<V1,?ZDF$QT[]G+T;Q.FY!%CQ:
M+:K5% <J2*IULY/+#^].3?3R2.6F_6P3[!9NDU<KG<0UO7G\,U[\.S4&L(Y]
M,B\@B!+:D$'V/6L\&8/-)[8.;28LDOS\NP,576(UVK^+ZR4\';-1E\(9Y9Q]
MZ[\OPR5(XH)'CC+X-MQ@,3!*T+=<.9T;RT$(WD!_7RO=-/S$">=#(K/$FCSX
MUWM+7\4C 2&I;/'WJ)Q'4)IHY_#Q8+]GZ']%UM4M.OB6XP<TC>Z!ZTH15IR=
MUZ>7PT'+E-04^E^HE>2E[1$";*5F-^Q'<S'SB7M@"C27J'3ZE<?S\"]%VG.R
MDO0ORX"A9&I7N*^T5<+WUI@G!KR@^(8K_$4_V[1GZ9+Q(DOZZ/U/^6!TB?0X
M^#)2]B#N^.T8P+&0N<)^0EKTD[EJ\L!+BQPQ:V\<_0B3=)!PST'RH[N##<_%
M UP2RY7K^D,],@*#?]" ?5[OTF(6:MS.T6E1()J=;RR)HUTKL5VB]GL<49+6
M^GMTQ<%^P8!39/*M>OKCMG^=LL9'4-7.VG;I?V1XA4$J*&=8-/@!5M/_7JSS
M3[UI:M?:1H[(9CVLG_#P=_B>9]DOCG]..)FB5JX.R@TL<I_KK*-\(NB?>%TB
M+^*)_?KB. %K]S,Q. (Q3SF<3<CS 2U)BHD;54F7%K]AGD*8R"3Q3/T@U)L=
M+)U:XDR+\HY=#:D'7^$CWQP==1&-+AV/=.\C\-B1T1\'DEG52:>75/E)D,$/
M6$AABB=8A1%45X<3KI-DKDAEE#OD5<&_&O*U^TG>K[,)=X64A*!>DF22=/2W
M!^>X4Y8<P83HXDJ(,XX4-N%W@EA@2K^FCL=QT9)A0/<X9Q+11N1D^YJ2O6?*
MI$/>6VFY!:E]4)9YR$_S,J.K2:FE&PVYD.'KR1@T'3D_=:7C2?<\Q:B)BH[B
MBIVD(K/QOUOTW?P1?@M*.=[*V[XA:Q8@1S\1(O"2X%K>X'=WV&J,_^UE)%OZ
M?WAR'F8/S[(_//[V[-R/(@8[_.'\^[,_^4^^?CKM\X?]3\\?EAW]7T'_(_JB
M_^\PN.YEWN<_/=^Z=NTN':K8F+9_?'#^(/H4G9@_/K@X?WKQ^,%#>C,\_M/S
M7;YV;_)VC8[RRJWHU4=GWW_[0#C:_NB;'99$W5[?;/F?&T?BN<4#]/VJ:7K[
M QO ?&+P?OIO4$L#!!0    ( *:(4E1NC=^%% P  $@A   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;*U:"6_;1A;^*P.OL[ !1N9-*A?@*&F:;=)X
MHZ3=8K%84.1(&H3DL$/2COKK]WLS)$5==M)M@$@\YKUYQ_>ND9_=2?6E7G/>
ML*]%7M;/S]9-4SVYNJK3-2^2>B(K7N+-4JHB:7"K5E=UI7B2::(BOW)M.[PJ
M$E&>O7BFG]VH%\]DV^2BY#>*U6U1)&KSDN?R[OF9<]8_^"A6ZX8>7+UX5B4K
M/N?-Y^I&X>YJX)*)@I>UD"53?/G\[-IY\M*G]7K!+X+?U:-K1IHLI/Q"-V^S
MYV<V"<1SGC;$(<'7+9_Q/"=&$./WCN?9L"41CJ][[C]HW:'+(JGY3.:_BJQ9
M/S^+SUC&ETF;-Q_EW8^\TR<@?JG,:_W)[LQ:/SIC:5LWLNB((4$A2O.=?.WL
M,"*([1,$;D?@:KG-1EK*5TF3O'BFY!U3M!K<Z$*KJJDAG"C)*?-&X:T 7?/B
M([_E9<OK9U<-N-&SJ[2C?&DHW1.4CLO>R[)9U^QUF?%LE\$5Q!AD<7M97KKW
M<GS%TPGS'(NYMNO<P\\;=/,T/^]^W=A2R8+-(*L"!F#?9LUFVK)<L7]?+VK]
M_#_W;.@/&_IZ0_]/&/,!RM>_O/[Y\^LYZUFP5 +X=<,S)I>L64,+F2."1+EB
M%Z+$$]G629G5ET_8;SQ1Q@D,)N3% GKU9J0/&Q_.E-THF;4P@.JV>,+>*%G7
MK-I[SLZ98_F!:TT=#]?3T+6"J4-7062%8/E*U*ELRZ9F$( E)%92IB"\\*+
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MS#'S)2)0E168Q;5%@JGL0S0>8$[K<04&<K& I8TJ[V&+)FXP][@P%3RNYR/
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M2N1Q=&V:O.#@<);1V@,T=)OM'&PBJU.$']3='"E("CRIQK-#X%$@PJ/C86^
M/D9F\4#,YJ39,=(F[L$U4)."TM'H8R)0(U ]>1Z0W51UNA(4L8[$;X&BAT!1
MB'<4BD&&WB^ZIQKE@7@!\1=ODPV0/]P<CF:N0?1JQ%",=B"Q7L[A:'5H'1[F
MH!K(L,*OY2-&VQJ>@C\T.;,18$L4U./^$^'>A2Y=, ;Z@;"0)7J.E,FL3(9Z
M)8X>#[H>+M44R8&JQ%I6U+#D:Z_I)J#*XR', DJ '1O6,CCK1)>F"DQR9)),
MM>U=+$XK8 C\E_<W5Q]OK_\3&,X!+3Y@Z'EDF<,EBAT8/$5,B]@)M^))%;A
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M?W/IZI5K^Q#98Q 3D);\T$5SL6_CB!XC/)WM%?ZXR'I(O&ES1-9*SBG15^C
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MC'4XJ.%Y2R"$P=6$XM!@&<Y;M*!-5LXV[0F"!LV\P'  (X,8XX3?[:D0=_H
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MX@#X?5( N\@?N !$5)\(O)?_ U!+ P04    " "FB%)4AXG1KL8(   ;&
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M_#67AGWD12W8C>"V-@(9=_9T[&"<1,9I:^BR,10^8V@:LANM7&[9M<I$]M#
M&*AZ:&$'[3+\KL57(CUDLVG PDDX_8Z]61_JS-N;_3C45]*FA:9H+?O[(K'.
M@!W_?,?'O/<Q]S[FOY[.'QBZ>'O+/EZ\N[]F-]<7=_>WUS?7?WZX8][!QCL
M?8G;EKE<,%[J6ODY=S@(=9&QA$12 =)GK*YP BPO!-,KQG$8K,6!UX957&;,
M:88,*+L2AG%62)[(0KH=DXIDM<F$*7:-"&\.4R+<5@@%)IK/,%1QXV0J*TX0
M ( 0E?OX6<:=.&0?L+O:X\^E,-RD^8[EO EBI0LT":G66!DA6"$VHK#'[/??
MEF$8G[!WM&93=L"^U-HAK,K(%"7\HU8\^Q>'160O/6A_U%MP%F8-DQEPR)07
M3>A J;(^4BGLR3=.0CB1JJHAJ0'-4&)5 P@ ?):Y0383*\R&)TBLD%XNDTBZ
M0[K(J>I6 ;I>FL/W-\B?!FME*0M.^F!F[1E$YI!W6$289L=*G2$UK+:4+:27
MMVCWCJ1R OQVS"#Y3;RM4X\^Y53% 5P?"9#!4:J-T8DFQ>PQQ!-OZV&Z9DA7
MK0;9:'/7)\K65:4-V4MVR+MS1$7#E.XHY'T0Z?8J<JWD"C4#@8BA#]DSH%?#
MK+1 9;T\,=2BC[H<V-USI,-!T+5A*ZFX2N6>&,T)0NHZ%YF/%VFB@Y 1O0?V
MZ&*A;[4Q5 E<$-(VVMRV? 8_/0Y=6QBR+X\9.ILH$Y"EZVX]LSOR?= .B*YT
M60KCP56\@OP+G_9I>(+9T3P*EO/I8':E3>6+QA(-1[UL-)\$1XME/]X?WB%E
MQD>W\\&M]4881;D\L.@45E/4@@@$REBQ-S6;!?#6#3>U\J>^^,;A- R.)O-N
M:&+)1.*8I43Y\\;XAH/CH,H!&'_@6U.O'D1P$,?+P0QWB]AU7%G5Y"V.\77:
M:[7+*X%6Y%D )ZAQ)BIMI=L;GQX%DRCNQP;=(Q:D' 5]5.T7G9<7@!9'8; (
MYWZ^@+4PBAY5=O(SE8WBHV 9+@>SYRN[#!;1HA]_H;+A9!E$T;P?GZMM"$]Q
MV T_4=M9%($6T\'LB=J"J8MX7]MV^:/:QI-@ L*UP_^L;.N#JCF?$K"HF4<Q
M"!BS3SFNNSZP &>\U91J@R[;-&EZ'V;4$QYV>>KI./]6#- ,>CN,Y1)-&YV#
M]WSQ#?20_846A2Z'US6UEZ$O:I$>0=;> FAW)CN@JWCG'=.>18L#@LY#;1]<
M6=WM[5$&3]T8.RGPDD!A-Y3QO29=(*"P5K@YVEB]-@ ]O,*ZV_:!=GLYD%P+
M](D4A&T*GGJ5C0</7IRCM7_6H[3T!FK>OOUN_\_AHGDP[\6;OQTWW*Q1"USM
M*ZA.#A?1B)GF*=\LG*[\\SG1#H]Q/\WQ[T<8$L#WE4;X[8(<]/^GSO\#4$L#
M!!0    ( *:(4E3^\ABMOP(  +\%   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;)U4VV[;, S]%<+HPP9X]25IG 1)@*87K,#:%6G781CVH-BT+526
M/$ENVK\?92=N!K09L!>+HG@.#V61LXW2CZ9$M/!<"6GF7FEM/0T"DY98,7.L
M:I1TDBM=,4M;702FULBR%E2)( [#45 Q+KW%K/7=ZL5,-59PB;<:3%-53+\L
M4:C-W(N\G6/%B](Z1["8U:S .[3?ZEM-NZ!GR7B%TG E06,^]TZCZ7+HXMN
M!XX;LV>#JV2MU*/;7&5S+W2"4&!J'0.CY0G/4 A'1#)^;SF]/J4#[ML[]LNV
M=JIES0R>*?&=9[:<>V,/,LQ9(^Q*;3[CMIX3QY<J8=HO;+K80>Q!VABKJBV8
M%%1<=BM[WM[#'F <O@.(MX"XU=TE:E6>,\L6,ZTVH%TTL3FC+;5%DS@NW4^Y
MLYI..>'LXDH^H;1*O\P"2W3.&:1;Z+*#QN] HQBNE;2E@0N98?8W04 Z>C'Q
M3LPR/LAXCNDQ#"(?XC".#O -^N(&+=_@7\7!.3>I4*;1"#]/U\9J>@V_#F08
M]AF&;8;A_US?0:CKMJFI68ISC]K)H'Y";W%U\W!Q<_]U]0->M:>*6L!8S$#E
M8$N$7 GJ)2X+^, E>51CF,S,QRG0!6*U1MU?HON$L&(;>C,6-6?"P!&,_?$H
MH37QDV0 WZEM@(AJK5(T!F)R1PDA_5$4PB67G)Y7!H52F8$H]B=Q0LAX$L&]
MLDP0SW#BGT01&8,3?Y0,8<D$DRG"73M64L&,X3E/F>O#*9PU6E-I4"O=-B:7
MJ6CH 3D-O*_ZR.D83@;."/T)Z?RB9/&)BJC>1"JZ&0VBCZ&<:*F8V ^C,41#
M/PG?%_S62PCVFJI"7;2CP]#?:*3M^JOW]M/IM&O*U_!NM%TS77!I0&!.T/ X
M.?% =^.BVUA5MRVZ5I8:OC5+FK"H70"=YTK9W<8EZ&?VX@]02P,$%     @
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MW55HKT@F#W'I39C+\11?@>O'W\!E1%L<!?3A[7$9M\%Q_^(W3G(HFI=4L16
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M1EIVW?R."C&8TE+ A'/!,TFXP3I;V,9-R'&S,6K\CS1GL)Q4Q9S=67"SU?\
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M_22A=@)T7B@*^G[A#!Q^N^9_ 5!+ P04    " "FB%)4*"G(3I(3  !@/
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M:+*Y-D':?<99P+UR+B;38!2&]&$<#$=#\;'AZ7F=I%" 2JOG?8J1>Z,MRKD
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MG*K%3<I7]S*IO,\>]OY'78DL<8 OP=(*_I1&K4%!^2@?':NT2FU/F3VM6LZ
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M13X[A2*MJ#8J=\>K60_8A":'BU$P&2].MM/U>Y/A7CMM 15]2[=CID?ZNV:
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M965T,C$N>&ULS3UI<]M&EG\%Y:V9LJI(69+C).,<5;(29[R;C+56,JFMK?T
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M0K5X#_RI=!%L[A]#U1_FN,/G@3M\/DO>=VZ#<,[>-*PSG>#1\Y/ ]?/9$,D
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MS@JOQAD,Y,ZSN??.Q8[=5_.=M=]9&6$5J^]%1DS5SGW*G%-R)V18 L2Q]DJ
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M[\5HZ\%2(56,%96389=05]7(.=DNR+%LL:+6AK>5.7E/?A%<=]XBL+5H9C#
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MI6GJS9I^7ZB= YWOE;*GA2.8?HCK?P%02P,$%     @ IHA25 5%<V$T!@
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MM\1_*2#- IPOA-##P!",_WLV_P)02P,$%     @ IHA25'FD R'$ @  R@4
M !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULA51-;]LP#/TKA+%#"WCU
M5Q(G01*@:5>LP H43;<>AAT4F[:%RI(GR4W[[T?9B9<!37>Q*(I\?)3UN-@I
M_6PJ1 NOM9!FZ576-O,@,%F%-3,7JD%))X72-;.TU65@&HTL[Y)J$<1A. EJ
MQJ6W6G2^>[U:J-8*+O%>@VGKFNFW-0JU6WJ1=W \\+*RSA&L%@TK<8/V>W.O
M:1<,*#FO41JN)&@LEMYE-%^/7'P7\(/CSAS9X#K9*O7L-K?YT@L=(12868?
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MYN9\#G2%6&]1#]?H/B$\L!T]'XN:,V'@$TS]Z22E-?73-($G4A 04*-5AL9
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MP=G?M  J0DT)0L21&SIN3*,0X;ALUWU9]X*<D6!=0W>#Q1Z2R,<!\YV ,3*
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M3!0 _7[-N3H-B@7JYGCQ'U!+ P04    " "FB%)4@I@@?1(#  !N"@  &0
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M>4.\C'.(SU&$SQ )"3X0T,P/_Y7R<Q0VP^=O@4<E//1D$]62125?OX'OME#
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M 5X-\(PSE13C0X0EGHXYVP*NHQ6;'A@S#5K)SZC>][GDZFVF<')Z3S:$ED2
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MJ&KB5:]2321;F]M[P:3J!<PP5?T=X3I O5\Q)G<3G:#I&*?_ 5!+ P04
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M%"L#-M8]"MO%VV?E309*%]6M -E;P7D40S7<D1WN+U,,=3&-W1"U]PP]9C"
M 1I(1(USA,]C6.G?+'0(V_)ZK+ _I*YN LC>!-Z*,=1%_ACY^8^?INP>.QBX
M:& GANK6@.RMX3400]T&$$5AFV$]5HUR:0JM&P6R-XJ%WH<I*FV+O28W"M\/
MF6I*(SNEWT"F[@8=AI[;;MQ]9CY"0XN^!CRR _X\-N$:V?B%;?B+;,)=^$+7
MQ4&[C'KL_,CU!A8GKBF-X7EP*OV;5$3MB>JQ"N# -.$:[=B.]K>R"7=)/IYX
M?F=?V&>GK89*'I\<WMB1_QHVE:$:QQ]>U-E@]9@U*Z:0ZIP<".ID;?)S4@GR
MWW_%85CUM#J+O<E/(%O/;^'5O#A1K<,4![Q?]4]+EDF0T+4.Z5Z&6I,HSDR+
M&\5W^;'C U=ZQO+++=5E)8R!?K_F7#W?F ]4)]>S_P!02P,$%     @ IHA2
M5.H+\(F' P  G H  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&ULC5;?
M;]LV$/Y7"*$/+=!&ORS+#FP#2;QA*UH@2-KM8=@#+9TMHA3ID93=[:_?D5)H
MQ[*$O-@B]=W=]]U1QUL<I?JA*P!#?M9<Z&50&;._#4-=5%!3?2/W(/#-5JJ:
M&ERJ7:CW"FCIC&H>)E$T#6O*1+!:N+U'M5K(QG FX%$1W=0U5?_> Y?'91 '
M+QM/;%<9NQ&N%GNZ@V<PW_>/"E>A]U*R&H1F4A %VV5P%]^N8V?@$'\P..JS
M9V*E;*3\81>_E\L@LHR 0V&L"XI_!W@ SJTGY/%/YS3P,:WA^?.+]U^=>!2S
MH1H>)/^3E:9:!K. E+"E#3=/\O@;=((RZZ^07+M?<NRP44"*1AM9=\;(H&:B
M_:<_NT2<&<33 8.D,T@N#28#!FEGD+[58-(93%QF6BDN#VMJZ&JAY)$HBT9O
M]L$ETUFC?"9LW9^-PK<,[<SJ"0X@&M#D$WF0PBBL [G3&HPF5)3D"Z,;QIEA
MB'B_!D,9UQ\0^_UY3=Z_^T#>$2;(MTHV&M%Z$1JD9!V'11?^O@V?#(2/$_(5
MPU::_")**%\["%&+%Y2\"+I/1CVNH;@A:?R1)%$27R'T,&[^F8H;$@V;K]]B
MGCKS:$1-ZLN3.G_I>'G(5LGZ5* C,Q5Y<(<#%/GK;J/=_M\C 2<^X,0%G P$
M]#&DJ= WEV+WR8"J"76'XEJ%6X>9<VC;S&$53Z?9(CR<9[T/BCSB%=',$\U&
M,^.)\M,1O1U)P-3[G8XGH%$*A"%[J6QCNB:X=3 ]TY+/XLF%X#XHSN<#FG//
M+1_E]L578X1=W@L\R]/Y!;L^*,VS[#J[F6<W&V7W31K*27&E+M=HSOKYF699
M>L&SC\JRR0#/N><Y?]L15]W'I:"0.\'^@_(CMK."-R43.__6?7IXDP">B]+O
M;F#'A+"X#>54%'!-X[Q?BBR*+B3V0?/D$K2>]SZ?Z;FG5WF(HU/OCT8SX9O_
M*0,$1PFR!^4F"I1%Y(:S';6'31.-_WK+$(5='\>, \/&;]%,#C3_J%_ER2SO
MY:##O>XA\QYN?147)X.9.+L%X_&SJZC0M!U%]HJA;LJY+*A!K482V0PFY:KL
MN$=SEO?K%9Y=V]C(=V[\T?@%-<*T%Y[?]2/6G1LL+O;O[>CEQH&3FW9N^TH5
MGE--.&S19723(R?5CD+MPLB]&PXVTN!MXAXK'!]!60"^WTII7A8V@!](5_\#
M4$L#!!0    ( *:(4E3<'OOE) 4   <5   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;,U8VV[C-A#]%<+8 KM UA(IWS9P##AQ@F;1M$&"M ]%'VB9
MMHB51)6D[+C8C^^0DG5))-G)4UXL4>*,SLP<SJ$YW0GY0P6,:?0<A;&ZZ 5:
M)^>.H_R 153U1<)B>+,6,J(:AG+CJ$0RNK)&4>@0UQTY$>5Q;S:US^[E;"I2
M'?*8W4NDTBBB<G_)0K&[Z.'>X<$#WP3:/'!FTX1NV"/33\F]A)%3>%GQB,6*
MBQA)MK[HS?'Y#1D; SOC3\YVJG*/3"A+(7Z8P>WJHN<:1"QDOC8N*%RV[(J%
MH?$$./[-G?:*;QK#ZOW!^XT-'H)94L6N1/@77^G@HC?IH15;TS34#V+W*\L#
M&AI_O@B5_46[?*[;0WZJM(AR8T 0\3B[TN<\$14#@EL,2&Y 3C7P<@/O5(-!
M;C XU6"8&PQ/-1CE!B.;^RQ9-M,+JNEL*L4.23,;O)D;6RYK#0GFL6'6HY;P
MEH.=GD%%0KH4DMHZSS>2,>"-5F@>K]!EJF"Z4FC!ML#!Q+Q!<\,%KCE3Z"NZ
M312+4=W)[U2:NRU#GQ=,4QZJ+^@3XC&ZXV$($]19?3AU- 1BX#A^#OHR TU:
M0&."[D2L X6NXQ5;U1TXD($B#>20ADO2Z7'!_#[R\!DB+L%/CPOT^=.7!EQ7
MW5Z^T[B/W*->%J=X\:P7M]W+]<D1X5&[EYLWY.5JWN"EEFZO8)UGW7K'60<T
MF0-?XHWE':) N^KX#QTPB71 :RP#H[]_ Y_H5K-(_=.!:% @&EA$@Q9$0$8&
MBPU<)G2?K0!&9<Q62 NTHIHUL31SB5WKT_3P[6PP(OWAU-DV0!D64(:=4!Z8
M400>;U#"I-6.V&=(+$.^L0NL"<GP-9+)N W(J  RZ@127];TT!L,+-]<Q1I)
ML:>AWB-X'X,,*AHV)JK[.U[?=7_IJ.&XP#L^%2\0A%98M.,ZR'I5QV<FQ6<F
M'X2\WPI$W]Y0*"@/%Y:WU \X=&ZD$N;S-0<RAZ:1*U,Y7T01U)'3L$JSIN)U
M?QN[: \K176$@=U2C-Q.9T_)6@K#L'P--K6]W,6P0G6"W6:FXXH,XO>M_T9U
MPJ^7&\;5A9^I13ZO!M6MSUDTS!FVK%M,RFA(9S37T"OX,BR"09#6"$I>I0F4
M'+9@I:X;\DJV24.JA=S#7N.0D)Q%=E(*>BOKCE39&1ISE2'%N-8DVUH3+A4$
M>]T%H\\\2B-$(Y$",':(V(15X781AGH/]@S"J +=&[XHX$T^J48&TAY@*4BX
M6Y'>(P.X29$&?=*"I50D?$R2%*P&/[ DJ9&FTNURF-!E3 V$Z7VPU9.,1\M4
MJFQ.5AT%JXO'?BHE6YT=Y*0QGFY8WO"(<N!2ZO QK2LH8T1,E<1IQ#5ZM6BQ
MV]:#2OG"Q_2K#<-9H:X*Y$0R%8BPN3.-7S%VT JL%#P\.5+^UVVA\>N3UVL=
MM^Z'<"EO^&1]:Q5V]//%WQ#%Y);[D# )?(U3UJ50I%0HXGX0\2>E=I%N[;I*
M(U,>X]NGV@^^ILDA:+CZ8A/S_YJ%C#0(V<!KZQ>DU!_2K3\G%NP.^IOIX3_1
M#8^!]?"G4G9EI!0'\E'^7Y"RGY/N?G[_YEWS$8>$'.E^I.SOI+N1GEJO7'-/
MK5?9?<GHH]2K[,:DNQN_HU[=#F%3T%(OIW)^ PJPL2=M"H02=C;9&4;QM#C-
MF]LSK!?/+_'Y=78F5[K)C@COJ-QPV.^$; TNW?X8""&S4[=LH$5B3XF60FL1
MV=N 4=@QF0GP?BV$/@S,!XJSS]G_4$L#!!0    ( *:(4E3&M'W"K@,  #(/
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;,V7WX^;.!#'_Q4+]:&5
M[A;,;ZHD4K*YTVW5ZE:[[=W#J0_>X 14L'.VD[12__@;&Q82"'1/Z4->$FS/
M=YB9#]C,Y,#%%YE1JM#7LF!R:F5*;=_:MEQEM"3RAF\I@Y4U%R51,!0;6VX%
M):D1E87M.DYHER1GUFQBYN[%;,)WJL@9O1=([LJ2B&\+6O##U,+6\\1#OLF4
MGK!GDRW9T$>J/FWO!8SLQDN:EY3)G#,DZ'IJS?';)4ZTP%C\E=.#/+I&.I4G
MSK_HP5TZM1P=$2WH2FD7!/[V])86A?8$<?Q;.[6:>VKA\?6S]]]-\I#,$Y'T
MEA=_YZG*IE9LH92NR:Y0#_SP!ZT3"K2_%2^D^46'VM:QT&HG%2]K,410YJSZ
M)U_K0AP)<#@@<&N!VQ7X P*O%G@O%?BUP#>5J5(Q=5@21683P0](:&OPIB],
M,8T:TL^9YOZH!*SFH%,SJ%=!GK@@AL)\(R@%JDJB.4O18B?!7$JTI'MX0K9Z
M!<TUJ5SE5*)?T:G\ <S8#A9V+*4"J8RB ?^0I<K0W592AEXOJ2)Y(=^ OT^/
M2_3ZU1OT"N4,?<SX3A*6RHFM(%4=L+VJTUI4:;D#:6$7?>!,91+]!J&DIPYL
MJ%%3*/>Y4 MWU..2KFZ0AW]!KN/B,P'=CLO?$7:#G&'Y\B5RS\B=D6R\!KMG
M_'D_QKZG:"X$89L*#-3[9/PG4-0H"4.GHG_>@T]TIV@I/X]$Y#<1^28B?R"B
MCUR1 G:2Z@DZ1[S2!T:OM[/]#/N>GT10C_TQB+Y=$D>!%Y^:+<^8A5$4!8W9
M21I!DT8PFL9P8=LG?J1:87.;\$KX14U$T87\*GUX5' /'N;(Z^#KF^$ AQ[N
MX#MGYD81/H\O;K*(1[-XGZ_@3*,#>9RX3!J7R96@PDZ[Z3L7PJH='-?7]9,D
M"#NTSMCA,'*3H(/KK%V08/\\+WQT?N'_10Q]1Q>^@]AM[^U>"]IV8\?>I6B]
M/EHG2F*WB[9OE\!^VR/;-\,X\D)G@&Q[(.#Q$^'TTT%2L0?4\B6O)FYW:QQ<
M"\%V:\?AI03#?LD=.+KB+L&^712'B=<EV#?S<8('ME+<G@AX_$CX <"?\*:V
MVSJ.KX5S>R[@Y%+.2?\;Q7<2W,7<-PMB[(5=S'TS+_![F.VC9J*D8F.:,HE6
M?,=4];G<S#:-W]RT.YWYA6X(39/2NJFZR0]$;'(F44'7X-*YB2 F435HU4#Q
MK6E9GKB"!LA<9M#44J$-8'W-N7H>Z!LT;?+L/U!+ P04    " "FB%)41>H4
M#U<%  !4&   &0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6S-65MOVS84
M_BN$T0$MT-DBY4M2. :<.L52-%N0K-O#L =:HFVB%.F15-P,^_$[E!11:23:
M"?+@EYB2> Z_<^''PY/I3NEO9L.81=\S(<U9;V/M]L-@8)(-RZCIJRV3\&6E
M=$8M/.KUP&PUHVDAE(D!B:+Q(*-<]F;3XMVUGDU5;@67[%HCDV<9U??G3*C=
M60_W'E[<\/7&NA>#V71+U^R6V:_;:PU/@UI+RC,F#5<2:;8ZZ\WQAXMXY 2*
M&7]PMC.-,7*F+)7ZYAXNT[->Y! QP1+K5%#XN6,?F1!.$^#XIU+:J]=T@LWQ
M@_9/A?%@S)(:]E&)/WEJ-V>]DQY*V8KFPMZHW2^L,J@ F"AABK]H5\V->BC)
MC559)0P(,B[+7_J]<D1# (\[!$@E0'X4&'8(Q)5 ?*C L!(8'BHPJ@0*TP>E
M[87C%M32V52K'=)N-FAS@\+[A33XBTN7*+=6PU<.<G8&#A9TJ30MPC9?:\8@
M#:Q!<YFB\]S =&/0@MU!2FW=%S1WH>66,X-^1K_3;RREZ+&67ZEVHSN&WBZ8
MI5R8=S#UZ^T"O7WS#KU!7*(K+@1,-=.!!2,<E$%2 3XO 9,.P)B@*R7MQJ +
MF;+TL8(!6%^[@#RXX)P$-2Y8TD<Q?H](1' +H(]A\<]4]E'4+;XX1#PNQ*,6
M\8N#P>-)P!EQG0]QH2_>GP\0OSD$4JZ+C$ 4$J+Y_)O=,(WLADKT6.BO+Z 3
M75J6F;\#B(8UHF&!:-B!"%*%P38 E5MZ7^8FHUJR%%F%4FI96PZ5*G%4Z'1D
M>3<;CDE_-!W<M4 9U5!&02B/TYP^;!:T93IQOVJ%M+JGPMXC^"Z!Y@T5K?C"
MZ\3]*/HIX+IQC7<<U'/#W%'!Y=HA+ X5F3"DEH*O"Q/:D(V?>NYDTN6X20UD
M<JCC($%H(XMVW&XJ%@D8?%*O<W(DV7M:(SH-6GX+"6#0G1)YQEP4N$K;O!Y6
M,D;WD/(F  ='GN^CH*ZOVY56+F>KS=1&.96*42,'1E%[!N#&08-??Q]7.IM(
M,)ET0"$>"GD9E%8(I:YQ T+LMT-Y0E1SFC#'X\=S%BUS\+C#$L_6. Y;0K_S
M+,\0S50.066PL_E2, 2;'24JRX"8.!50.%0&&Y3#J>F^-9C,>"IK=4#\Q $8
MGW8@]ZR.P[0^+Q$[RH3B0N8 3;-$K27_%U*"RT3D:3& 3<K0DJVY+)@L@>35
M4%XBP>F2"PY<NZ3"$5LK]NH@P$WP)_TN]/X@P/M.@MJWIMCAM8=;48R>>)!T
M[2?/[?CUR;U2^<@=P[@?=V#Q](Y?@=_1?^A20N%(18C(/-7C8^%Z[,D>AXGZ
MICK]H3K6K?X_?<(!<=21"<13.@E3^C.]#Z,K2!R@C5#Q['F=X".) _$$3\($
M?_WL@FR/0CS:4Y(13]DD3-DOB%9)\J'5/>V2X;%$RY,I"9/I"Z(55DB&^Z+E
M69:$6?;0:'WB$F+E]OUAV\M3*YD<2\ \]9*3UPY86"&)]@7,4S )4_#+ K9W
MA\6>C>/H2 (6>XZ.P[7W\P.V1V&\+V"QY^HX3*V'!NPSW5(96K'1XCB6'D?L
M>3D.E\,WS, 5)-D4$-)&NZWID*K0@[+8U??*@3/OH6SFV3+7IIQ35OX&KC10
M0^=:L_3]0W^B-<YA6#C:&VA/\_%SNB?E7=C=_6BRX6 P,EN6\!4'ZX2SW[AL
M;=QA&E5NJR%[CH3N*_2@T3V%Q=9%V]K TG _*;N(]=NZ-3XO&L(_O#_''R[*
M!K=74_;;KZB&^XL!PU:@,NI/ *PN6]CE@U7;HD>[5-:JK!AN&(6;FIL WU=*
MV8<'MT#]CX39_U!+ P04    " "FB%)4S5X$WZP#   P#P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T,BYX;6S-ETV/VS80AO\*(>20 .U*U+<"VX"]:M$$
M";K8W22'H@>N15O"2J1+4G8*],>7I+3ZM)0MW(,OMDC..YJ91R(UBQ-ESSS%
M6(#O14[XTDB%.+PW3;Y-<8'X#3U@(E=VE!5(R"';F_S ,$JTJ,A-V[)\LT 9
M,58+/7?'5@M:BCPC^(X!7A8%8G]O<$Y/2P,:+Q/WV3X5:L)<+0YHCQ^P^'*X
M8W)D-EZ2K,"$9Y0 AG=+8PW?QS!2 FWQ-<,GWKD&*I4G2I_5X$.R-"P5$<[Q
M5B@72/X=\2W.<^5)QO%7[=1H[JF$W>L7[[_JY&4R3XCC6YI_RQ*1+HW0  G>
MH3(7]_3T&ZX3\I2_+<VY_@6GVM8RP+;D@A:U6$909*3Z1]_K0G0$T)\0V+7
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M4P9R?4>I>!FH&S1-\NI?4$L#!!0    ( *:(4E03ZNC\QP(  +('   9
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M16D=S/I""+TS[ 9MFQ[_ 5!+ P04    " "FB%)4&Z#K_%L#  #Q"@  &0
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MTNWLYM??N@SM4_>#J@43FG"8(S%H=C""*I^/LF/DTMV/,VGPMG7-'%]<4!:
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M3(T[&V"@<1Y<*A^ZGIY+"*O,D1%P;]F!9^1$U[@7:9($_:2P"2F.8^(RJ!<
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M.A#;=^K; \FK]K7TC$O)B_;CBJ4+)AJ!^G[)N7PZ:-YT[W[9,/D/4$L#!!0
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M(G.>22XT*[T"D0MV1>TR;*-MV'NV#C=BA<?5ZI$.^U?EQ=$LZ&ZA'C."9]&
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M6^(HX^;/GGY8I1\ZT_\@US)&/OH/'3OU)E4+DR%./=\#'O=.-OFV5==A\?:
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M/G7&#LC($J^9OA';;Z0)*+1\J6"J>H)M;1OZ#DC72HNB 1L%!>7U&S\WB>@
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M,8/? U=ZC#3+M9[TB2@-]/TEYVJW*1,T_SN8_0)02P,$%     @ IHA25)P
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M%5I4SL&>+Z0TFXT+,$AW_@]02P,$%     @ IHA25,1DEYXS P  ]PD  !D
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M&61<0GJ!0OP1D8#@GH0NA\-_4'Z!@O/ARY>$ARX\&% 3-L4,'5]XKICKU6J
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MDM746&VTV+DYZDYH,Y6Y96XF;9 68-YOA-#/&_L%S>P^_PM02P,$%     @
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MKMI.\/+X438D*\R&_)%)M;TWEQMU9 .N'U#W4\;DH:%?4!\"I_\ 4$L#!!0
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MQ<OZ<0DL V$FZ-_GG*O'%Y.@O3:>_ ]02P,$%     @ IHA25+.9V6'& @
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M.^J985C2)87&&]#W0FMWF/@ S;4W^0U02P,$%     @ IHA25/S6U#]  P
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M1?H38J(P@T]0P#I59T]9T"$P]ORQ=T(SZ,1V[$Q&]%AJV94*)TYXDJ?5&:G
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M21Z?D;R" Q/NDSO*J4AAZ%34(28NA*U8C\LXN!GC@C^>;E4?-;L)9O%+5#*
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M? I( 25MN+U3VR_0Y>,)YHH;_R7;SC8*2-X8JT0'1@:"R7:DC]T][ 'B\P.
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M5A:[CI_6^",![0SPO%38%+J%"]#_FK)_4$L#!!0    ( *:(4E2 '!X60P8
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M$Q5Z +R?<JY6-]I _0WK_!]02P,$%     @ IHA25-NB$_$6 P  B D  !D
M  !X;"]W;W)K<VAE971S+W-H965T-S$N>&ULK5;=;MHP&'T5*^I%*P'Y@P 5
M(+5AU39U&BKM=C'MPB0.L>K8S'9*^_:SG>#1$M)6ZPW8R?<=GW-R'&>R9?Q>
MY A)\%@0*J9.+N7FW'5%DJ,"BA[;(*KN9(P74*HI7[MBPQ%,35-!W,#S(K>
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M+[OGO0^*DF#\%I3M@X(DBGK0&Q?CWL7XI(LG+ A>4OB/B58DW@T=)X/\%@=
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M%     @ IHA25)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *:(4E1V:KT"[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *:(
M4E297)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ IHA25*NDO**5!@  'AH  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *:(
M4E1]TF.X(@(  ',%   8              " @=@.  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " "FB%)4-?G<H*X&  !M&@  &
M        @($P$0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ IHA25"FSJV*C @  U @  !@              ("!%!@  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( *:(4E1\K^G!@@4  &@6   8
M              " @>T:  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " "FB%)4^*'<3A0#   C"   &               @(&E(   >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ IHA25.VMO.*- @
M/ 8  !@              ("![R,  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( *:(4E1D /&QS04  %\;   8              " @;(F
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "FB%)4FBI.
MX@0(   S(@  &               @(&U+   >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ IHA25+2BIQK=*@  184  !D
M ("![S0  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "F
MB%)4;HW?A10,  !((0  &0              @($#8   >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( *:(4E1A; U4A2,  %B%   9
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M970Q-BYX;6Q02P$"% ,4    " "FB%)47G1B;PD0  #T,0  &0
M    @($PI0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M *:(4E0JDW2([@H  %<<   9              " @7"U  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ IHA25**= -(G!   @@D  !D
M             ("!E<   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " "FB%)4*"G(3I(3  !@/   &0              @('SQ   >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( *:(4E3-2"O03RD
M #>)   9              " @;S8  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ IHA25.-UU00\!P  @!,  !D              ("!
M0@(! 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " "FB%)4
M7[R%'1T#   <!P  &0              @(&U"0$ >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( *:(4E0%17-A- 8  " 5   9
M      " @0D- 0!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ IHA25&_FI'.Z P   PD  !D              ("!=!,! 'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "FB%)4>:0#(<0"  #*!0
M&0              @(%E%P$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( *:(4E3]EP'[$@,  ' &   9              " @6 : 0!X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ IHA25&#XW._?
M!@  4Q<  !D              ("!J1T! 'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " "FB%)4[\Y!P&$&   O$   &0
M@(&_) $ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( *:(
M4E1X\H9^A ,  &8(   9              " @5<K 0!X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ IHA25/>1V@XK!   @@H  !D
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M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " "FB%)4N,+
M/V($  !5&   &0              @($;0 $ >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( *:(4E0)O%"'#P,  #T*   9
M  " @;1$ 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
MIHA25'$S'(,W!0  Q18  !D              ("!^D<! 'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " "FB%)4Z@OPB8<#  "<"@  &0
M            @(%H30$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( *:(4E3<'OOE) 4   <5   9              " @291 0!X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ IHA25,:T?<*N P
M,@\  !D              ("!@58! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " "FB%)41>H4#U<%  !4&   &0              @(%F
M6@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( *:(4E3-
M7@3?K ,  # /   9              " @?1? 0!X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ IHA25!/JZ/S' @  L@<  !D
M     ("!UV,! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *:(4E3YC,;V$08  .4@   9              "
M@0AU 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ IHA2
M5.M+&CN' P  =PT  !D              ("!4'L! 'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " "FB%)4'%9!)YX"  !'!@  &0
M        @($.?P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( *:(4E3Q-1JCL@8  - S   9              " @>.! 0!X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ IHA25.*A-(74 @  W @
M !D              ("!S(@! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    " "FB%)4BX-#._8#  !'$   &0              @('7BP$
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( *:(4E2< .E/
M8 (  ,8%   9              " @020 0!X;"]W;W)K<VAE971S+W-H965T
M-30N>&UL4$L! A0#%     @ IHA25,1DEYXS P  ]PD  !D
M ("!FY(! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " "F
MB%)4K8&DN4P#  #'"P  &0              @($%E@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( *:(4E0Y%:FZS D  )HU   9
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M970V,2YX;6Q02P$"% ,4    " "FB%)4LYG98<8"   "!P  &0
M    @(& LP$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    (
M *:(4E3\UM0_0 ,  )0*   9              " @7VV 0!X;"]W;W)K<VAE
M971S+W-H965T-C,N>&UL4$L! A0#%     @ IHA25#V%9]$#!   I P  !D
M             ("!]+D! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"
M% ,4    " "FB%)4P^X'R <$   R#@  &0              @($NO@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( *:(4E1B/1^?XP,
M !X-   9              " @6S" 0!X;"]W;W)K<VAE971S+W-H965T-C8N
M>&UL4$L! A0#%     @ IHA25([#I<1> P  BPD  !D              ("!
MAL8! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " "FB%)4
MHAVD6V@#  #)"@  &0              @($;R@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8X+GAM;%!+ 0(4 Q0    ( *:(4E1AZ:"HO@(  *8&   9
M      " @;K- 0!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%
M  @ IHA25( <'A9#!@  SQH  !D              ("!K] ! 'AL+W=O<FMS
M:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    " "FB%)4VZ(3\18#  "("0
M&0              @($IUP$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+
M 0(4 Q0    ( *:(4E3\0K/)N@(  &X'   9              " @7;: 0!X
M;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ IHA25 #S^M(-
M P  *PD  !D              ("!9]T! 'AL+W=O<FMS:&5E=',O<VAE970W
M,RYX;6Q02P$"% ,4    " "FB%)4D^09D4 #   .%   #0
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:+GAM;%!+!08     40!1 "X6   I[P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>298</ContextCount>
  <ElementCount>479</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1007009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - Collaboration Agreements And Business Development Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities</Role>
      <ShortName>Collaboration Agreements And Business Development Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121104 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2128105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131106 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2134107 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2138108 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2148109 - Disclosure - Provision For Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxes</Role>
      <ShortName>Provision For Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2155110 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2159111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables</Role>
      <ShortName>Collaboration Agreements And Business Development Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2322303 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2329304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2332305 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2335306 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyandEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2339307 - Disclosure - Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansTables</Role>
      <ShortName>Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2349308 - Disclosure - Provision For Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesTables</Role>
      <ShortName>Provision For Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ProvisionForIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2356309 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2360310 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsandContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Significant Customer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenues - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2418412 - Disclosure - Collaboration Agreements And Business Development Activities - GSK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - GSK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2419413 - Disclosure - Collaboration Agreements And Business Development Activities - Other Collaborations Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Other Collaborations Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2420414 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2424416 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2430420 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2433421 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2436422 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2437423 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2440424 - Disclosure - Employee Benefit Plans - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Employee Benefit Plans - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2441425 - Disclosure - Employee Benefit Plans - Schedule of Employee Service Share - Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails</Role>
      <ShortName>Employee Benefit Plans - Schedule of Employee Service Share - Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2442426 - Disclosure - Employee Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails</Role>
      <ShortName>Employee Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2443427 - Disclosure - Employee Benefit Plans - Weighted Average Grant Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails</Role>
      <ShortName>Employee Benefit Plans - Weighted Average Grant Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2444428 - Disclosure - Employee Benefit Plans - Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails</Role>
      <ShortName>Employee Benefit Plans - Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2445429 - Disclosure - Employee Benefit Plans - Summary of All Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails</Role>
      <ShortName>Employee Benefit Plans - Summary of All Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2446430 - Disclosure - Employee Benefit Plans - Summary of All RSU &amp; PSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails</Role>
      <ShortName>Employee Benefit Plans - Summary of All RSU &amp; PSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2447431 - Disclosure - Employee Benefit Plans - Estimate Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails</Role>
      <ShortName>Employee Benefit Plans - Estimate Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2450432 - Disclosure - Provision For Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Provision For Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2451433 - Disclosure - Provision For Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails</Role>
      <ShortName>Provision For Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2452434 - Disclosure - Provision For Income Taxes - Schedule of Deferred Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails</Role>
      <ShortName>Provision For Income Taxes - Schedule of Deferred Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2453435 - Disclosure - Provision For Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails</Role>
      <ShortName>Provision For Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2454436 - Disclosure - Provision For Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Provision For Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2457437 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2458438 - Disclosure - Net Income Per Share - Potentially Dilutive Shares of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails</Role>
      <ShortName>Net Income Per Share - Potentially Dilutive Shares of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2461439 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2462440 - Disclosure - Commitments and Contingencies - Balance Sheet Classification of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Balance Sheet Classification of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2463441 - Disclosure - Commitments And Contingencies - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Commitments And Contingencies - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="exel-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2464442 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="exel-20211231.htm">exel-20211231.htm</File>
    <File>exel-20211231.xsd</File>
    <File>exel-20211231_cal.xml</File>
    <File>exel-20211231_def.xml</File>
    <File>exel-20211231_lab.xml</File>
    <File>exel-20211231_pre.xml</File>
    <File>exel20211231exhibit101.htm</File>
    <File>exel20211231exhibit1018.htm</File>
    <File>exel20211231exhibit1042.htm</File>
    <File>exel20211231exhibit211.htm</File>
    <File>exel20211231exhibit231.htm</File>
    <File>exel20211231exhibit311.htm</File>
    <File>exel20211231exhibit312.htm</File>
    <File>exel20211231exhibit321.htm</File>
    <File>exel20211231exhibit42.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20211231_g1.jpg</File>
    <File>exel-20211231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="944">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel-20211231.htm": {
   "axisCustom": 3,
   "axisStandard": 24,
   "contextCount": 298,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "exel-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 621,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 4,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 8
   },
   "keyCustom": 69,
   "keyStandard": 410,
   "memberCustom": 42,
   "memberStandard": 45,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Revenues",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - Collaboration Agreements And Business Development Activities",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities",
     "shortName": "Collaboration Agreements And Business Development Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121104 - Disclosure - Cash and Investments",
     "role": "http://www.exelixis.com/role/CashandInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128105 - Disclosure - Fair Value Measurements",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131106 - Disclosure - Inventory",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134107 - Disclosure - Property and Equipment",
     "role": "http://www.exelixis.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138108 - Disclosure - Employee Benefit Plans",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148109 - Disclosure - Provision For Income Taxes",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxes",
     "shortName": "Provision For Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155110 - Disclosure - Net Income Per Share",
     "role": "http://www.exelixis.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.exelixis.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.exelixis.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Revenues (Tables)",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables",
     "shortName": "Collaboration Agreements And Business Development Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322303 - Disclosure - Cash and Investments (Tables)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332305 - Disclosure - Inventory (Tables)",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335306 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.exelixis.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339307 - Disclosure - Employee Benefit Plans (Tables)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansTables",
     "shortName": "Employee Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349308 - Disclosure - Provision For Income Taxes (Tables)",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesTables",
     "shortName": "Provision For Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356309 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2360310 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:NumberOfCountriesWithDrugApprovalExcludingTheUS",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:NumberOfCountriesWithDrugApprovalExcludingTheUS",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails",
     "shortName": "Revenues - Revenues by Disaggregated Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i0ce7596693de4c309e4046ee44e221d0_D20210102-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
     "shortName": "Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i2da812635cea4a9b9116e4146e6cdea4_D20210102-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i802f06ff953349dcbd6e18868ae5c8ff_D20210102-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails",
     "shortName": "Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i802f06ff953349dcbd6e18868ae5c8ff_D20210102-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
     "shortName": "Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ibdceca8137604720b9dfc7e6e415d661_D20210102-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i048f2416fccc4e10b7965efb1a171533_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails",
     "shortName": "Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i2d03c75ce0024c01a62fcd27957b4f04_I20200103",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)",
     "role": "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
     "shortName": "Revenues - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:MilestonePaymentsEarnedToDate",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i17d251f0fc574727b702a0a5caffb000_D20210102-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i17d251f0fc574727b702a0a5caffb000_D20210102-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:MilestonePaymentsEarnedToDate",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "idf4b8b36a8a1401ba536bf1da7af7544_D20210102-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "exel:PeriodOfSpecificSalesVolumeThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "idf4b8b36a8a1401ba536bf1da7af7544_D20210102-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborationAgreementPercentOfRoyaltyOnNetSale",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418412 - Disclosure - Collaboration Agreements And Business Development Activities - GSK (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - GSK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i8c3ac03ee7454b6cac8c397afd4482c4_D20210102-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419413 - Disclosure - Collaboration Agreements And Business Development Activities - Other Collaborations Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Other Collaborations Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i52b8f7772fdd4b28b6761a4c19816e52_D20210102-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420414 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i2b021f45a0fa49c89d6035c19eaadbb3_D20210501-20210531",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424416 - Disclosure - Cash and Investments - Narrative (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
     "shortName": "Cash and Investments - Investments by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
     "shortName": "Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Income",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
     "shortName": "Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430420 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i3ccf77987385492998beaa7a87e03520_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433421 - Disclosure - Inventory (Details)",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436422 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "role": "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437423 - Disclosure - Property and Equipment - Narrative (Details)",
     "role": "http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440424 - Disclosure - Employee Benefit Plans - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Employee Benefit Plans - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i6b96bd3389d2490a8a78bc00fddfe7ce_D20210102-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441425 - Disclosure - Employee Benefit Plans - Schedule of Employee Service Share - Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
     "shortName": "Employee Benefit Plans - Schedule of Employee Service Share - Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442426 - Disclosure - Employee Benefit Plans - Narrative (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
     "shortName": "Employee Benefit Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ie06171677cb042a49e3187edc6c068fc_D20210102-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443427 - Disclosure - Employee Benefit Plans - Weighted Average Grant Date Fair Value (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails",
     "shortName": "Employee Benefit Plans - Weighted Average Grant Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ie06171677cb042a49e3187edc6c068fc_D20210102-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ie06171677cb042a49e3187edc6c068fc_D20210102-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444428 - Disclosure - Employee Benefit Plans - Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
     "shortName": "Employee Benefit Plans - Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ie06171677cb042a49e3187edc6c068fc_D20210102-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i048f2416fccc4e10b7965efb1a171533_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445429 - Disclosure - Employee Benefit Plans - Summary of All Stock Option Activity (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails",
     "shortName": "Employee Benefit Plans - Summary of All Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i048f2416fccc4e10b7965efb1a171533_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i74355fce090d4783894ca8f36c2a26dd_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446430 - Disclosure - Employee Benefit Plans - Summary of All RSU & PSU Activity (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
     "shortName": "Employee Benefit Plans - Summary of All RSU & PSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ic7419d2b25ac468e82f7b65050bffbc6_D20210102-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i87217ca562074f3489c9e0b1ef6e428a_D20210102-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447431 - Disclosure - Employee Benefit Plans - Estimate Grant-Date Fair Value (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
     "shortName": "Employee Benefit Plans - Estimate Grant-Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "if0c146506a74415eb481d9e61dae42b4_I20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450432 - Disclosure - Provision For Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
     "shortName": "Provision For Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451433 - Disclosure - Provision For Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails",
     "shortName": "Provision For Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452434 - Disclosure - Provision For Income Taxes - Schedule of Deferred Assets and Liabilities (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails",
     "shortName": "Provision For Income Taxes - Schedule of Deferred Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453435 - Disclosure - Provision For Income Taxes - Narrative (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails",
     "shortName": "Provision For Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i048f2416fccc4e10b7965efb1a171533_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454436 - Disclosure - Provision For Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "Provision For Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457437 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i13ee6cf1e5c848d2b6f0a4bd3a76af26_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458438 - Disclosure - Net Income Per Share - Potentially Dilutive Shares of Common Stock (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails",
     "shortName": "Net Income Per Share - Potentially Dilutive Shares of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i13ee6cf1e5c848d2b6f0a4bd3a76af26_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i6aefcca4ad074b29b6a51fd6d458319c_D20201003-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i6aefcca4ad074b29b6a51fd6d458319c_D20201003-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461439 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462440 - Disclosure - Commitments and Contingencies - Balance Sheet Classification of Lease Liabilities (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Balance Sheet Classification of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463441 - Disclosure - Commitments And Contingencies - Components of Lease Expense (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails",
     "shortName": "Commitments And Contingencies - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464442 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "ia71123bf4ed74085ad4ac0a89679baa1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i9805c5e25eb64ed985d666f4c24de9ba_I20181228",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i9805c5e25eb64ed985d666f4c24de9ba_I20181228",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007009 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211231.htm",
      "contextRef": "i5659e21e0b1b4cba83d356c734f291a6_D20210102-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 87,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_A2018PerformanceStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Performance Stock Units",
        "label": "2018 Performance Stock Units [Member]",
        "terseLabel": "2018 Performance Stock Units"
       }
      }
     },
     "localname": "A2018PerformanceStockUnitsMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AccountsReceivableForUnsettledInvestmentSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable For Unsettled Investment Sales",
        "label": "Accounts Receivable For Unsettled Investment Sales",
        "terseLabel": "Accounts receivable for unsettled investment sales"
       }
      }
     },
     "localname": "AccountsReceivableForUnsettledInvestmentSales",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AchievedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achieved [Member]",
        "label": "Achieved [Member]",
        "terseLabel": "Achieved"
       }
      }
     },
     "localname": "AchievedMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesOfAmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "label": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AffiliatesOfAmerisourceBergenCorporationMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofCVSHealthCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of CVS Health Corporation [Member]",
        "label": "Affiliates of CVS Health Corporation [Member]",
        "terseLabel": "Affiliates of CVS Health Corporation"
       }
      }
     },
     "localname": "AffiliatesofCVSHealthCorporationMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofOptumSpecialtyPharmacyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliatesof Optum Specialty Pharmacy",
        "label": "Affiliatesof Optum Specialty Pharmacy [Member]",
        "terseLabel": "Affiliates of Optum Specialty Pharmacy"
       }
      }
     },
     "localname": "AffiliatesofOptumSpecialtyPharmacyMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AreaOfRealEstatePropertyAvailableToLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area Of Real Estate Property, Available To Lease",
        "label": "Area Of Real Estate Property, Available To Lease",
        "terseLabel": "Area of property available for lease (in squire feet)"
       }
      }
     },
     "localname": "AreaOfRealEstatePropertyAvailableToLease",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Maximum Aggregate Development Milestone Payments",
        "label": "Asset Acquisition, Maximum Aggregate Development Milestone Payments",
        "terseLabel": "Asset acquisition, maximum aggregate development milestone payments"
       }
      }
     },
     "localname": "AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Asset acquisition, maximum aggregate regulatory milestone payments"
       }
      }
     },
     "localname": "AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AssetAcquisitionPaymentUponClosingOfTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Payment Upon Closing Of Transaction",
        "label": "Asset Acquisition, Payment Upon Closing Of Transaction",
        "terseLabel": "Payment upon closing of transaction"
       }
      }
     },
     "localname": "AssetAcquisitionPaymentUponClosingOfTransaction",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Balance Sheet Classification of Lease Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.exelixis.com/20211231",
     "xbrltype": "stringItemType"
    },
    "exel_BuiltToSuitLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Built-To-Suit Lease [Member]",
        "label": "Built-To-Suit Lease [Member]",
        "terseLabel": "Built-To-Suit Lease"
       }
      }
     },
     "localname": "BuiltToSuitLeaseMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "totalLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks, Discounts for Prompt Payment and Other"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Collaboration agreement percent of royalty on net sale",
        "verboseLabel": "Cost of goods sold is related to product"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationAgreementWithIconicTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement With Iconic Therapeutics Inc",
        "label": "Collaboration Agreement With Iconic Therapeutics Inc [Member]",
        "terseLabel": "Collaboration Agreement With Iconic Therapeutics Inc"
       }
      }
     },
     "localname": "CollaborationAgreementWithIconicTherapeuticsIncMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementwithDaiichiSankyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement with Daiichi Sankyo [Member]",
        "label": "Collaboration Agreement with Daiichi Sankyo [Member]",
        "terseLabel": "Collaboration Agreement with Daiichi Sankyo"
       }
      }
     },
     "localname": "CollaborationAgreementwithDaiichiSankyoMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeAgreementWithGamaMabsPharmaSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement With Gama Mabs Pharma S A",
        "label": "Collaborative Agreement With Gama Mabs Pharma S A [Member]",
        "terseLabel": "Collaborative Agreement With Gama Mabs Pharma S A"
       }
      }
     },
     "localname": "CollaborativeAgreementWithGamaMabsPharmaSAMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementAchievedMilestoneAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Achieved Milestone Amount",
        "label": "Collaborative Arrangement, Achieved Milestone Amount",
        "terseLabel": "Achieved milestone amount"
       }
      }
     },
     "localname": "CollaborativeArrangementAchievedMilestoneAmount",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Achievement Levels of Commercial Performance, Period",
        "label": "Collaborative Arrangement, Achievement Levels of Commercial Performance, Period",
        "terseLabel": "Collaboration period to achieve specified levels of commercial performance"
       }
      }
     },
     "localname": "CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount eligible for development and regulatory milestones under collaborations agreement.",
        "label": "Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones",
        "terseLabel": "Maximum amount eligible for development and regulatory milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsFinalPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Final Payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Final Payment",
        "terseLabel": "Collaboration agreement, final payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsFinalPayment",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments",
        "terseLabel": "Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "terseLabel": "Potential future development milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Potential regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaborative Arrangements with Glaxo Smith Kline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen",
        "verboseLabel": "Collaborative arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment And Software [Member].",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "label": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "terseLabel": "Contract revenue recognized, including revenue from deferred revenue beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CotellicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cotellic [Member]",
        "label": "Cotellic [Member]",
        "terseLabel": "Cotellic"
       }
      }
     },
     "localname": "CotellicMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liabilities",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Lease Right-Of-Use Assets",
        "label": "Deferred Tax Liabilities, Lease Right-Of-Use Assets",
        "negatedTerseLabel": "Lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeaseRightOfUseAssets",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee",
        "label": "Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee",
        "terseLabel": "Branded prescription drug fee"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation",
        "terseLabel": "Non-deductible executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligible Payment From Collaboration For Development And Regulatory, Milestone Achievement Under Collaborations Agreement",
        "label": "Eligible Payment From Collaboration For Development And Regulatory, Milestone Achievement Under Collaborations Agreement",
        "terseLabel": "Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement"
       }
      }
     },
     "localname": "EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_FinalTierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Tier[Member]",
        "label": "Final Tier [Member]",
        "terseLabel": "Final tier"
       }
      }
     },
     "localname": "FinalTierMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_HeadquartersLease2021AmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headquarters Lease, 2021 Amendment",
        "label": "Headquarters Lease, 2021 Amendment [Member]",
        "terseLabel": "Headquarters Lease, 2021 Amendment"
       }
      }
     },
     "localname": "HeadquartersLease2021AmendmentMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_HeadquartersLeaseApril2019AmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headquarters Lease, April 2019 Amendment",
        "label": "Headquarters Lease, April 2019 Amendment [Member]",
        "terseLabel": "Headquarters Lease, April 2019 Amendment"
       }
      }
     },
     "localname": "HeadquartersLeaseApril2019AmendmentMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_HeadquartersLeaseDecember2020AmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headquarters Lease, December 2020 Amendment",
        "label": "Headquarters Lease, December 2020 Amendment [Member]",
        "terseLabel": "Headquarters Lease, December 2020 Amendment"
       }
      }
     },
     "localname": "HeadquartersLeaseDecember2020AmendmentMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_HeadquartersLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headquarters Lease [Member]",
        "label": "Headquarters Lease [Member]",
        "terseLabel": "Headquarters Lease"
       }
      }
     },
     "localname": "HeadquartersLeaseMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_InitialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial [Member]",
        "label": "Initial [Member]",
        "terseLabel": "Initial"
       }
      }
     },
     "localname": "InitialMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_InvestmentsPurchasesIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments Purchases Incurred But Not Yet Paid",
        "label": "Investments Purchases Incurred But Not Yet Paid",
        "terseLabel": "Unpaid liabilities incurred for unsettled investment purchases"
       }
      }
     },
     "localname": "InvestmentsPurchasesIncurredButNotYetPaid",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen Pharma SAS"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LeaseArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Axis]",
        "terseLabel": "Lease Arrangements [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementsAxis",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_LeaseArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Domain]",
        "terseLabel": "Lease Arrangements [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementsDomain",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements",
        "label": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements",
        "negatedTerseLabel": "Future tenant improvement reimbursements",
        "terseLabel": "Future tenant improvement reimbursements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReimbursements",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs",
        "label": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs",
        "terseLabel": "Percentage of excess costs"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "terseLabel": "Currently estimated amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage",
        "terseLabel": "Annual increase percentage"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period",
        "terseLabel": "Payment commencement period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of options to extend the lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Option To Terminate After Period",
        "label": "Lessee, Operating Lease, Option To Terminate After Period",
        "terseLabel": "Option to terminate lease (after period)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminateAfterPeriod",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Reduction Of Payments Due [Abstract]",
        "label": "Lessee, Operating Lease, Reduction Of Payments Due [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseReductionOfPaymentsDueAbstract",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount eligible for commercial milestones under collaborations agreement.",
        "label": "Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "terseLabel": "Maximum amount eligible for commercial milestones under collaborations agreement"
       }
      }
     },
     "localname": "MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_MedicarePartDFundingMandate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Part D Funding Mandate",
        "label": "Medicare Part D Funding Mandate",
        "terseLabel": "Medicare Part D funding mandate"
       }
      }
     },
     "localname": "MedicarePartDFundingMandate",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_MilestonePaymentsEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Earned",
        "label": "Milestone Payments Earned",
        "terseLabel": "Milestone payments earned"
       }
      }
     },
     "localname": "MilestonePaymentsEarned",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_MilestonePaymentsEarnedToDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Earned To Date",
        "label": "Milestone Payments Earned To Date",
        "terseLabel": "Milestone payments earned to date"
       }
      }
     },
     "localname": "MilestonePaymentsEarnedToDate",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NotProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not Probable [Member]",
        "label": "Not Probable [Member]",
        "terseLabel": "Not Probable"
       }
      }
     },
     "localname": "NotProbableMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_NumberOfCountriesWithDrugApprovalExcludingTheUS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Countries With Drug Approval, Excluding The U.S.",
        "label": "Number Of Countries With Drug Approval, Excluding The U.S.",
        "terseLabel": "Number of countries with FDA approval, excluding the U.S."
       }
      }
     },
     "localname": "NumberOfCountriesWithDrugApprovalExcludingTheUS",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OperatingLeaseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Assets [Abstract]",
        "label": "Operating Lease Assets [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "OperatingLeaseAssetsAbstract",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OperatingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liabilities [Abstract]",
        "label": "Operating Lease Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesAbstract",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of royalty on net sale.",
        "label": "Percent of royalty on net sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "PercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_PerformanceSharesAchievedBeforeDecember312020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Shares, Achieved Before December 31, 2020 [Member]",
        "label": "Performance Shares, Achieved Before December 31, 2020 [Member]",
        "terseLabel": "Performance Shares, Achieved Before December 31, 2020"
       }
      }
     },
     "localname": "PerformanceSharesAchievedBeforeDecember312020Member",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PerformanceSharesAchievedBeforeDecember312021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Shares, Achieved Before December 31, 2021",
        "label": "Performance Shares, Achieved Before December 31, 2021 [Member]",
        "terseLabel": "Performance Shares, Achieved Before December 31, 2021"
       }
      }
     },
     "localname": "PerformanceSharesAchievedBeforeDecember312021Member",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PerformanceSharesClinicalTrialResultsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Shares, Clinical Trial Results [Member]",
        "label": "Performance Shares, Clinical Trial Results [Member]",
        "terseLabel": "Performance Shares, Clinical Trial Results"
       }
      }
     },
     "localname": "PerformanceSharesClinicalTrialResultsMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PeriodOfSpecificSalesVolumeThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period Of Specific Sales Volume, Threshold",
        "label": "Period Of Specific Sales Volume, Threshold",
        "terseLabel": "Sales volume period"
       }
      }
     },
     "localname": "PeriodOfSpecificSalesVolumeThreshold",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_ProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probable [Member]",
        "label": "Probable [Member]",
        "terseLabel": "Probable"
       }
      }
     },
     "localname": "ProbableMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductSalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Sales Discounts And Allowances [Member]",
        "label": "Product, Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "ProductSalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromOtherCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Derived From Other Compounds [Member]",
        "label": "Products Derived From Other Compounds [Member]",
        "terseLabel": "Products Derived From Other Compounds"
       }
      }
     },
     "localname": "ProductsDerivedFromOtherCompoundsMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities",
        "label": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member]",
        "terseLabel": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities"
       }
      }
     },
     "localname": "ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent",
        "label": "Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent",
        "terseLabel": "Research and development arrangement performed for others, reimbursement for costs incurred, percent"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting From Discovery Efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RevenueFromContractWithCustomerCommercialSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Commercial Sales Milestone",
        "label": "Revenue From Contract With Customer, Commercial Sales Milestone",
        "terseLabel": "Commercial sales milestone"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerCommercialSalesMilestone",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Commercial Sales Milestone, Net Sales Threshold",
        "label": "Revenue From Contract With Customer, Commercial Sales Milestone, Net Sales Threshold",
        "terseLabel": "Commercial sales milestone, net sales threshold"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerCommercialSalesMilestoneNetSalesThreshold",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RevenueFromContractWithCustomerRegulatoryMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Regulatory Milestone",
        "label": "Revenue From Contract With Customer, Regulatory Milestone",
        "terseLabel": "Regulatory milestone"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerRegulatoryMilestone",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RoyaltyTier": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Tier",
        "label": "Royalty Tier",
        "terseLabel": "Royalty tier"
       }
      }
     },
     "localname": "RoyaltyTier",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RoyaltyTierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "royalty tier [Axis]",
        "label": "Royalty Tier [Axis]",
        "terseLabel": "Royalty Tier [Axis]"
       }
      }
     },
     "localname": "RoyaltyTierAxis",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_RoyaltytierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for royalty tier [Axis]",
        "label": "royalty tier [Domain]",
        "terseLabel": "royalty tier [Domain]"
       }
      }
     },
     "localname": "RoyaltytierDomain",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_SalesRevenueDiscountExpectedtobeEarnedPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Revenue, Discount Expected to be Earned, Percent",
        "label": "Sales Revenue, Discount Expected to be Earned, Percent",
        "terseLabel": "Discount expected to be earned"
       }
      }
     },
     "localname": "SalesRevenueDiscountExpectedtobeEarnedPercent",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_SalesRevenuePercentDiscountForPromptPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Revenue, Percent Discount for Prompt Payment",
        "label": "Sales Revenue, Percent Discount for Prompt Payment",
        "terseLabel": "Percent discount for prompt payment"
       }
      }
     },
     "localname": "SalesRevenuePercentDiscountForPromptPayment",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions",
        "label": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released In Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest",
        "terseLabel": "Additional shares to be earned (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "terseLabel": "Reduction in share reserve after all other awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "terseLabel": "Reduction in share reserve after stock option or stock appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement By Share-Based Payment Award, Termination Of Employment Following Change In Control, Period",
        "label": "Share-Based Payment Arrangement By Share-Based Payment Award, Termination Of Employment Following Change In Control, Period",
        "terseLabel": "Number of months following change in control in which an employee was terminated"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "terseLabel": "Maximum potential to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_StatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status [Axis]",
        "label": "Status [Axis]",
        "terseLabel": "Status [Axis]"
       }
      }
     },
     "localname": "StatusAxis",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_StatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Status [Axis]",
        "label": "Status [Domain]",
        "terseLabel": "Status [Domain]"
       }
      }
     },
     "localname": "StatusDomain",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda [Member]",
        "label": "Takeda [Member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited"
       }
      }
     },
     "localname": "TakedaMember",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TaxCreditCarryforwardAmountWithExpirationPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Amount With Expiration Period",
        "label": "Tax Credit Carryforward, Amount With Expiration Period",
        "terseLabel": "Tax credit carryforward amount with expiration dates"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmountWithExpirationPeriod",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_TenantLeaseImprovementsAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Lease Improvements, Allowance",
        "label": "Tenant Lease Improvements, Allowance",
        "terseLabel": "Tenant lease improvements allowance"
       }
      }
     },
     "localname": "TenantLeaseImprovementsAllowance",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment(s)",
        "label": "Upfront Payment(s)",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20211231",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r179",
      "r293",
      "r299",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r261",
      "r267",
      "r316",
      "r317",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r520",
      "r557",
      "r561",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r261",
      "r267",
      "r316",
      "r317",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r520",
      "r557",
      "r561",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r179",
      "r293",
      "r299",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r175",
      "r293",
      "r297",
      "r524",
      "r556",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r175",
      "r293",
      "r297",
      "r524",
      "r556",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r261",
      "r267",
      "r306",
      "r316",
      "r317",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r520",
      "r557",
      "r561",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r261",
      "r267",
      "r306",
      "r316",
      "r317",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r520",
      "r557",
      "r561",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r176",
      "r177",
      "r293",
      "r298",
      "r559",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r176",
      "r177",
      "r293",
      "r298",
      "r559",
      "r572",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r38",
      "r489"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r41"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36",
      "r236"
     ],
     "calculation": {
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r57",
      "r59",
      "r60",
      "r544",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r56",
      "r60",
      "r68",
      "r69",
      "r70",
      "r112",
      "r113",
      "r114",
      "r427",
      "r562",
      "r563",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Operating Activities [Abstract]",
        "terseLabel": "Non-cash operating activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20",
      "r360",
      "r489"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r357",
      "r358",
      "r359",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Stock transactions associated with taxes withheld on equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r319",
      "r322",
      "r363",
      "r364"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r322",
      "r353",
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "netLabel": "Stock-based compensation expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities and contingently issuable shares excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of leased property (in sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r101",
      "r158",
      "r167",
      "r173",
      "r207",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r424",
      "r428",
      "r462",
      "r487",
      "r489",
      "r527",
      "r542"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r52",
      "r101",
      "r207",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r424",
      "r428",
      "r462",
      "r487",
      "r489"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r191"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r188",
      "r214"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt securities available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r193",
      "r195",
      "r538"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r193",
      "r194",
      "r537"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r187",
      "r189",
      "r214",
      "r531"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total debt securities available-for-sale",
        "verboseLabel": "Total debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r324",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r437",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid liabilities incurred for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r32",
      "r92"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r87",
      "r92",
      "r98"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash equivalents at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r87",
      "r463"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r416",
      "r417",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements And Business Development Activities"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r245",
      "r532",
      "r549"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r246",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r489"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 318,842 and 311,627 at December\u00a031, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r63",
      "r65",
      "r66",
      "r72",
      "r534",
      "r552"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r179",
      "r459",
      "r460",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r179",
      "r459",
      "r460",
      "r569",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r179",
      "r459",
      "r460",
      "r569",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r146",
      "r147",
      "r179",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r179",
      "r459",
      "r460",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Other Assets and Other Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r271",
      "r273",
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Contract other long-term assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r271",
      "r272",
      "r294"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability [Abstract]",
        "terseLabel": "Contract liabilities:"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r271",
      "r272",
      "r294"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r271",
      "r272",
      "r294"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenue",
        "verboseLabel": "Long-term portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amount of revenues recognized included in the beginning contract liability balance",
        "verboseLabel": "Cumulative catch-up revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "verboseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r75",
      "r524"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r102",
      "r396",
      "r404"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r102",
      "r396",
      "r404",
      "r406"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r102",
      "r396",
      "r404"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r145",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r190",
      "r214",
      "r220",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r199",
      "r215",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r200",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r198",
      "r218",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r201",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r102",
      "r397",
      "r404"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r102",
      "r397",
      "r404",
      "r405",
      "r406"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r102",
      "r397",
      "r404"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r392",
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves",
        "terseLabel": "Accruals and reserves not currently deductible"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails",
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r373",
      "r389"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expenses relating to stock match"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r90",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r90",
      "r156"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Net gain on maturity of forward contracts"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r53",
      "r438",
      "r440",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r432",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Forward contract outstanding, amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r432",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of forward contract outstanding"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Forward contract maturity (in months)"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r431",
      "r433",
      "r435",
      "r436",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Forward Foreign Currency Contracts"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r293",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r73",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r125",
      "r127",
      "r129",
      "r130",
      "r131",
      "r135",
      "r136",
      "r447",
      "r448",
      "r535",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "netLabel": "Basic (in dollars per share)",
        "terseLabel": "Net income per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r73",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r127",
      "r129",
      "r130",
      "r131",
      "r135",
      "r136",
      "r447",
      "r448",
      "r535",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "netLabel": "Diluted (in dollars per share)",
        "terseLabel": "Net income per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "verboseLabel": "Total unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Unrecognized compensation expense weighted-average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r68",
      "r69",
      "r70",
      "r112",
      "r113",
      "r114",
      "r116",
      "r122",
      "r124",
      "r139",
      "r208",
      "r269",
      "r270",
      "r357",
      "r358",
      "r359",
      "r400",
      "r401",
      "r446",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r562",
      "r563",
      "r564",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets Measured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r262",
      "r264",
      "r265",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r450",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r449",
      "r450",
      "r452",
      "r453",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r262",
      "r307",
      "r308",
      "r313",
      "r314",
      "r450",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r262",
      "r264",
      "r265",
      "r307",
      "r308",
      "r313",
      "r314",
      "r450",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r262",
      "r264",
      "r265",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r454",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r196",
      "r197",
      "r203",
      "r204",
      "r205",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r218",
      "r219",
      "r222",
      "r223",
      "r263",
      "r268",
      "r445",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Remeasurement"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r227",
      "r229",
      "r489",
      "r526"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r90",
      "r228",
      "r230",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment charge on goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r318",
      "r320",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r233",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r70",
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r238",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r376",
      "r385",
      "r391",
      "r402",
      "r407",
      "r409",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Provision For Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r123",
      "r124",
      "r157",
      "r374",
      "r403",
      "r408",
      "r555"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r370",
      "r371",
      "r385",
      "r386",
      "r390",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Provision for Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U.S. federal income tax provision at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedTerseLabel": "Research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r89",
      "r521"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r49",
      "r489"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r50",
      "r99",
      "r138",
      "r224",
      "r225",
      "r226",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r206",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments and Investment Impairment"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "Cash and Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r484",
      "r486"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Build-to-suit lease period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r101",
      "r168",
      "r207",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r425",
      "r428",
      "r429",
      "r462",
      "r487",
      "r488"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r101",
      "r207",
      "r462",
      "r489",
      "r528",
      "r546"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Unpaid liabilities incurred in asset acquisition"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r101",
      "r207",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r425",
      "r428",
      "r429",
      "r462",
      "r487",
      "r488",
      "r489"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "verboseLabel": "Line of credit borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds",
        "verboseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r87",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r61",
      "r64",
      "r70",
      "r71",
      "r91",
      "r101",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r123",
      "r124",
      "r128",
      "r158",
      "r166",
      "r169",
      "r172",
      "r174",
      "r207",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r448",
      "r462",
      "r533",
      "r551"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r158",
      "r166",
      "r169",
      "r172",
      "r174"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r478",
      "r486"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion included in other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r474",
      "r480"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets included in other long-term assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r483",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average operating discount rate used to determine the operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r482",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term for operating lease"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r2",
      "r111",
      "r152",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r62",
      "r65",
      "r422",
      "r423",
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r54",
      "r57"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $1,481, $(394), and $(1,049), respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r55",
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Tax impact of available-for-sale, unrealized holding gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r41",
      "r489"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r81",
      "r413",
      "r414",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to acquire assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property, equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r489"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r83",
      "r356"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r84",
      "r86"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r83",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Cash received from option exercises and purchases under the ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r36",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r240",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r35",
      "r235"
     ],
     "calculation": {
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r237",
      "r489",
      "r539",
      "r548"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r237",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r13",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r13",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r19",
      "r26",
      "r489",
      "r547",
      "r571"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r368",
      "r523",
      "r592"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r3",
      "r12",
      "r98",
      "r573",
      "r575"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Current",
        "terseLabel": "Restricted cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r7",
      "r15",
      "r98",
      "r574"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash equivalents included in other long-term assets"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r270",
      "r360",
      "r489",
      "r545",
      "r565",
      "r567"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r112",
      "r113",
      "r114",
      "r116",
      "r122",
      "r124",
      "r208",
      "r357",
      "r358",
      "r359",
      "r400",
      "r401",
      "r446",
      "r562",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r154",
      "r155",
      "r165",
      "r170",
      "r171",
      "r175",
      "r176",
      "r179",
      "r292",
      "r293",
      "r524"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r146",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Sales revenue, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r296",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenues Disaggregated by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation",
        "verboseLabel": "Transaction price allocated to our performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r481",
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r322",
      "r352",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r322",
      "r352",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "verboseLabel": "Schedule of All RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r36",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r12",
      "r98",
      "r525",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r324",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r329",
      "r341",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule of All Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r384",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r144",
      "r146",
      "r147",
      "r148",
      "r459",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration Risks"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Collaboration services revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Discount rate from market value on offering date (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Discount rate from market value on purchase date (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of awards granted (in shares)",
        "verboseLabel": "Awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, awarded (in dollars per share)",
        "verboseLabel": "Awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Awards outstanding at end of period (in shares)",
        "periodStartLabel": "Awards outstanding at beginning of period (in shares)",
        "terseLabel": "Number of awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Awards outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Awards outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted\u00a0 Average Grant\u00a0Date Fair\u00a0Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted\u00a0 Average Remaining Contractual\u00a0 Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Number of awards vested in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in share reserve under 2017 plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable at end of the year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of the year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock options granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r331",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding at ending of the year (in shares)",
        "periodStartLabel": "Options outstanding at beginning of the year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding at ending of the year (in dollars per share)",
        "periodStartLabel": "Options outstanding at beginning of the year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted\u00a0 Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r321",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Average price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r321",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r324",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r320",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Share-based Payment Arrangement, Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r318",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Share-based Payment Arrangement, Nonemployee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of the Company's common stock on grant date (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting award percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r347",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value, exercisable at end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining contractual term, exercisable at end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r16",
      "r529",
      "r530",
      "r541"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r247",
      "r248",
      "r420",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r45",
      "r68",
      "r69",
      "r70",
      "r112",
      "r113",
      "r114",
      "r116",
      "r122",
      "r124",
      "r139",
      "r208",
      "r269",
      "r270",
      "r357",
      "r358",
      "r359",
      "r400",
      "r401",
      "r446",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r562",
      "r563",
      "r564",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r139",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Share-based Payment Arrangement"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r269",
      "r270",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r270",
      "r323",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r23",
      "r24",
      "r101",
      "r185",
      "r207",
      "r462",
      "r489"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r196",
      "r197",
      "r203",
      "r204",
      "r205",
      "r263",
      "r268",
      "r445",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r307",
      "r536",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government-sponsored enterprises",
        "verboseLabel": "U.S. Treasury and government-sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r369",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails",
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Change relating to current year provision"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Change relating to prior year provision"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Reductions based on the lapse of the applicable statutes of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would reduce income tax provision and effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "verboseLabel": "Valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r106",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r479",
      "r486"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r126",
      "r131"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r125",
      "r131"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e12803-110250"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=d3e5291-111683"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r593": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r594": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r595": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r596": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r597": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r598": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r599": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r600": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r601": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r602": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r603": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r604": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r605": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r606": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r607": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r608": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r609": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0000939767-22-000026-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-22-000026-xbrl.zip
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MMA,2/'M1VH9RY\'?VZ;_V!SMTV",V7"CWTO'@P&C]C42A*Z._%B L@/A#6;
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MV<#:4XE%A7P.*'?VX$>(;!^AH4@) H;HDTO"11O1!.N;M%'7W!+U[%'6W-W
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MK+(  +W8VAZ,*WJ?,C\^Z;^A0:^>U!" E(Z$,F=GE(,("ATXXRDE:[6U2B\
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M[;<+$;4?/Z1V6 N%#>,B^P<@%+AX"@OT!\NYD6JZY9FJ21I@RB%YP4QNI+C
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M4]Z7X32= 2*ZP.M\^B\@E/RB_+C*<:M1,G?5(@H*0 KR'?MD.XUE &]-J75
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ML'55$>SPXQ3+<& ##>#*J8/IQ&#L!MCGRD?]IOR^"W@?:UCSV2+!AMW(7?!
ME!5'CN=T,9>*G>"7BG2AL(\2GK&D4OW"TW^117'E$+-X]H-XZ(K3R758(4F^
MDP(??IS9\H(\"U"":2:]BW*NQ;8_^0-T!FN>?0#'!9@0QP+BNAJ>G9_W>^:6
MHY$'%T>7W%AB&1=GO^47#G GG[O-2FP"BN44E@HY79?$,"J?Z,E$7 E8D]5T
M&@ S).3GE!P4D*8TU"F%'H@R/X 4#%&]T-J) VOH( Q2RB!RX=\/(';GNV+'
M/*ZP^Z)_>7GV;F#H52;.%R0+8 9\[HC2X>%W,+TDHBQEQS/:8,Z['[F?\Y<!
MOF'^?.1&V(,%$5RS2D#QP6Z12J@^-Q>I$S%;H#,0O<,1 AR, 40ARI6F( 0+
MB5/' Q/& ^D1?EY$F@LUQ#GFB< C.\4'%%D5*GIR1S<7<C-]Y<G-B92Z)HVX
M6^=MKQAGPSUI)1O,C5Q+ZIJ,!/5%GG!9_'I+U;1M$7$9LY9,1_:'30#]Z.^8
MB6OGAW!%=AJEY'Y3V1+ $.^0>Q,*?-&YD0>'?Q-DBZJT,RJ;!*P?8T8)5VS
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MKN%1IU.:8VY&[)II;/O[#;BD_$3EJ6DTX>>X30^9V0I\U%C^*_, S,DB266
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M,YR3#>BJHJB7,@6-_+/8N>SU+G<;&S4(D>#"(#%@ U!*11]ADZ='HT.*A0E
MPU>&JRXOH#RJI/)<WWW[R#! !_6SL<*&E9AJU7AKQ=<(Q6O,*?7@=!\RL)KP
M-8Q0RA)4]T@HT@/"F&+Z:1L8A#'5C2;U(/*X/H[EQJI?"WT +]1 9U"/DJ+X
ML&@-W^_F[P=, \,8*43-L<=S)487R7>15'1M*>Y#&=+X@GS5W%Y4$DR_!E=#
MW"BOD63S.4Z7MU5M@U4Z94\KD:0?&CCY\/[$=>9;([/ 2-&C#*.2!UG9T&W2
M_/3T;1H#26S ]:,$+7HSF+S2R:Q\D'2C!%5$)41::\@BL^DI9TDO^Z)!08;O
M\>67L*CH 2@J/^2MH*<8#^MQX.6[/ZJ3.%]O$N=S(AI+ *3N*B71:);Y/%:/
M2I'1(#:B"02"GA"+#KOYW%<3X)@Q:!VI%".K>A\/<&5AX,F$94;BP7F=^&%^
MIN)3])2* &E_U5+0J8O<AW5\K;NMV"=LX><\&/>PY,<C\[",L0$#G/6H#5]'
M[7E%L*VAE Q/^8$OV-R\2<GOI1X\^]30 3G^WF_P/= =' P@O8N=OSRP)(:.
M=X=/W,!;9N(W4+4<@F,W0VX.2I9M7*)V4Q @Z.AF*(TQ0%D6/,2Z4610_$P%
M0LV\W]P[CA PZL (3,N)EQH'.PH98VB!#(&+:JV6 9L>BUG99<6.QUQAA"$A
M$RU 68LNJ:X/3#LD4581C;G.C:ZA<BA\W)JX3-<%3LJX'(DY6&U>,D-]+P4$
M1[KVO=N\>IAB5;G*GR72BF^PP6;B#>BE(CK2#N0 \!NMR%"\V=NC* )]@\.E
M)^I/H;R#]1+ 6.FX,RHZ:R'X9U$VY68+RLEB15W( "1CQ-HKV.;.9WQU-E>^
M=?(6-B? E?"EBD[S31UPO(1?7EI,2!66(<(;22O*8[M!QQDYSCAFLL)?1'3L
M4R0(0U DO>#J;N6X!8B$[F!X [JNB'' YM"S0QXE=!CG7J6R/EX9-_N(5@6'
M,]A\!Y5=.2WF(/T0V(:%@]R(Y6KW[D>C#C[L1=,N,_.'!UMBM,0' #>_TD.G
M)KHO%?/&7>**QAN!;AJZ-V9('D5'C"#*F3.Z6&Q!8#U4"*Q(D4CTF#;I-7!-
MF'.$IAN+('U\"U0S[6V+4BI&]0T_MAS9[$R"#>!>J'J2Q#-'(PGT^57-5>)
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MXI3++%:CC*RQ+L8'PD-.,%<$6*$O9E$<4"&MZN@@=BX_#I\L&6E+D?'O H3
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M!E+=F*P>85&'P[X1*%$4@^$U]B83&<LP]=C^*O(I$QC[UE$5/VID[/MXC=>
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M49!_E/)%20QM8-OGZ<,[Z/?ZB9@YMV"TSZ*[$+E8X"4T1=U-O5LO7< /<92
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M%U<U!7F9)P$5BS2QXD#%=?,TLI8X"UW0M)TIWKN<8%#996Q6B$WJ%NQ1@-2
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M&1U=1ZTWVJI:R\M1);(.6AU[#7-$OCS:O1=P/@1#$TTU%3=3<$^< *X9-"<
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M^AP;T34PX:0ANG^<XT\#RX9E"R/!QKO46I![:5@SZ9 G3./HCNI>QFI*'C5
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M>7M\-:UXZH76Y53C4:F!2-[$$]^*[8RM/PUZO88@H,)U8-- ]K/L] :]W8:
M-8,(0*35O[Q](2:3)*E^G.?&XO)9C-J@3_T'N:\(&H"?>B_4=&ZC<*O0Z 3[
M]3INU>2HD@2F\DQK &K5+"FD[*HI4S^R KEB:OLSM/0\!6H(E'QIK]0".RNT
MP >4P)4JG\$8K=M5L@[5T=7*\ER5X$G=$3:*/AY(-"4)Z)7ZVO=.VYU.$]0>
MW<?)%_WS9H>T^O9;U0D"1'2$?5V*LO-2?@;+4!6>J^KI'?[C"W$K"WF^4E<?
M5LAGQCM;"A?[1*]H-E?H=&+:EYL^2JJM>E%.%AK$(C^C>0;JU8RT50&8#>/3
MIQ0U5=WVJS0>U<&T4;@P9--/*Y9SJ?JI5VJ3598>&L9EV:&T!AZ<+;^@%,_[
M?O$,>_AFQ1!XGKF@&JW<^V;]BG&66PK8= 6=&W/X/DHFV#TV$TB1#5*^) X:
M&>N>W(CF&3<L!O0<99:]8;>1R0=HHJ*KIZTMP]J6EXQSRU//O.4N,*A;5R+G
MB\RLVQS!_9 TM.%H1%LVYU87N5G#"C\[!<V@0W1;%S+%\P%[/#)PQ23H'(65
M#U4A0]'UC7_!1AH-RTM96(=QA9VJNM]7E*7FBVIV#Z^J7>S*CK'2U1MJLH-N
MV+6F#:#Z3 .>13$(_8?Z:P<>^@FQ;R&H!)C12^X)T-/SCOW6.%Q*\T8)SPWY
M69L(4S/B5'7B(#ITXC%W\HAE2UP#3S?>2O3MD* )T'5@S42DWLVV:\GRD_&@
M05]'=5?Y&-!7ZX7P/5>JD2:^)R?Z)NN6Q^5$_Z,ZT?^5)OH_,Z9%-'@,V]TO
M;+)F78!]G4XYIF)"+5%%FSFGD-EA>45Q@@V%8:09_6!<K*3)2M=+E&@Q(L)B
MO-2$&=V>:E@:Z_7Y4%6'V&.NY_2N;B[ZO299;<ARC%^>78BKQB"LYP;D,:[=
MBS[LKF%&MK2IU^-C5@8]"I]6$SC*?R*U*09^K*RX%G9#S5DR\5[CJE5"KKJY
M/G;+%Q_*[0DK^^7; XI;Q4FV>N:(D7E+;1?S-"L*B7'?2B>.';)DU4!E>VZ=
M:6(**(<[+T!L1KU<]>0([(E=\H0LN=FWUP="A0Y;'.OF_>\ #P'U 6B]W[NZ
M;'9VD6J1^K")LQB^MVH4NJ<]'175_(:<*WG;,D+R/A@*GJLGQ_)ONRW!K_.H
M.2.NQ'/@).DV,Z"54 3=$7OK09T;OC<CDTPQ!&&T(]Q%&J71%]V LH7/PF,S
M.!J< A19I6.9MIQHLB5:V2&KA?Y,&IL,;[TX"@/*VJ49YN\%1?MY&1K-S!%I
M'&D;A6Z$O41=')HB<<+;Q''1!T3:M!-./?Q8)AZH3[JQNV=GD@/X<)@YQ^&!
M[6F=CS94:+%&440UF2@*6Z)+&N/(8\L7OH,;+9RPD8-8S[S$MI?YC+82X/#!
M&&?I)O@0JXX\E<A*>#?+P^Z<=&9?HXB5EP>@SBD"U*.[F+2 -TT7Z5/;O:FD
M*69S[$^'+ NP\K.,FW-GX2/?2:4["VE<2"L?"P[/!UY"KI"2\KM1;HG&B_@[
M*5:#HPP)6)1_H0<'YI,%]0A!=7=%%^E>Z>YQ$2=)LD 9%-CUUU..3IJ,Z?LT
MBY1G?:V< $OO:HGW^ TS]U"011$H1X2:E9AA)Y4D6=5AD"T2Q5,2*04EUV)!
M]9M.N_.V9P_)8U)[IU>T>7/7K*B^"()94D2PN +R+<70B.?%U,,Y,&W9N9OF
M>J_@7;=HP^VWF^5%^ZI,BW?D-T>5 _N$5/C7*UWJH,W-)0#5&:'J47"OOZCS
M9B/NP7!.NZ>XER8U9*I"+8VE+)RU\FV6'#>5;G2V:HP+_D'_/ELNS6=S\ULC
M:K6_-Z()K<3M)\;YKXDZ<+Z@%:( F.H@ ';=+@<&4#K[B1KD"ZK[K0PQV0W8
M=::'<+/PJ!CWTM7"PD2?<Q./7<@\2F\9 @W+T5T&(]V 11O68'",AJO1@VJ,
M+)]KD@LXRVVM5!CV/FN]U79"HT2B] C5#AP,K%OB4!P]!^Z%N7].:'[_! \E
M_\J< $%$NM$,=66*$TCW<S[&>Y[/^M#?E4D$QYM*:WGET >(S%'-E%.G(H2/
MBZ\9[F]8TVPU0UD1F*;9I>79'E9[>8*G$0RKT]U*R5!V(I;.)(GT]-H*+[3&
M%%V-6DP=,O>J>C ;,U?U;=>VKG%!6/K&>MD]-NLM9F;9.%7I)KV_2M2,@Z!)
M[U73(.Q45MNV5DMB+AD/OU N8="UX7C*PADMK$G6^(DI,#1VF[V=EKCQ:$*/
MRDI6;((/.+<3V0L)9)5:)1Y;JY4.6"FD(=FZ6EG-I*0KQ_U7YL523\= 9D_0
MQQ'AN!7BW6#8Z&IX07,=8"7>HQ[C;HU'M^%7-!25P<6617%J@GHQ[A857CVA
MD*S+,*,=H^:3ES?E6\);+82IM6::;P-WF7&P%:P?-=8+M2(S"J'4%+QBP,WS
MEH?42KI1TC?'=_/HRHOV=GNC:/^Y-ZK[:0!_(&\4<@;R1IEX(@])YR(+A2!N
M85@ZX6,7Y 6Z(L2IJ;D8:@<#(NTYJ(S(+';T@[LMT4_51.]R(3<S^JI:;E /
M?%GHE8B^[-/?CK6RP3ZOW.$3RVD&\H@?) U(CT;!:DR<;C)7E$A:)LWWQJ'<
MH+6XP+#@')9W1 +WRF)G:A7(;H3VON2L4<&*]E['<A[B <TU+?G ]SM/:@4=
MM0[7"2PMARV11)K[K8H62SC1G,->X7BSP']VV2U&"8I% IOOJR)^\$R^*GS7
M.KZJ>YC,MHD]O>\G%GS;Y<]B;E0,H=4NK=JEM?DN+9W'LY0ZMRJGYX$1<'K,
M\,F;DB?*"P'3J=:J(?S(93OSX88LM2\-&8R>IHJJG!I>F6=ALH1;NL&"I5IU
MDU;CCHK$U75K0O*FSJN[?BRO3KZJ%HBE?&QC ;VF//8:<[K1.3,RE;=RO%F.
MPASV=2I;.97MN$YEJU/97E9./B#1[)REU:[^W"57]N"SK[U9[6M?OZZ./'OL
MO5_3Y5Y@[L2$-L&[3LS0]JYOCL_H\5ZP]L%V>\%@_R4OV %YP39*D754(J&M
M3QKO'"=NL3<L88W5+E(7O7<7NH<39F)2@P_\;JC,<9XGC<@XCNXPDU Z-&_L
M79,SM)KD$K-ZGJC<5T#T"#&^^)SI<Y1D\2WLQ->Y55BMSPP7%1IXCY=F[.DK
M[!A6 PY0>JFU1W(7JC'0$^E0OB1]S10/E3:2F(PLX.VHH=SE[0H0-.PN=-(T
M=E@=5<F\NJJBY+P(Y5VU6F]IN';G4ZK349L!==@>>/TR)9N7$=9*+!IEW"#%
MKH@ P]\:N9N58K9\]5A%X<Q5JG(.@ GEKL78<D;?A[D$[*%@+V2_V$( 5&7S
MF]),EMU5Y;JQ69YO&V,.(/L< .2P;VO;&T7(H)6GA8J.Y[SY+C YS#1'RR!R
M\T9):N:P]H)M%,!$-PQ1U[B04GLANV!!^LIU]")@5*Z\S8)3[LU?B@3L=$<)
M<3?1[AP=[5H9XVQN.]BO 06A_$)$(W7S269T%N_6W%HE^3C"1UZ)B1?2S\<?
M<PP%]YA0$)ZBM*@6S63@I!0.RO,]*"!=J*[ERNTON @59:F0$#7RN<5J;G03
M^YR$J[2RA[S<>=*T.FG10=]NO(BO[*E]ZPU@GV&&#>]9MU0=7E7"@O>7[0II
M'[P6![Q8X8%_JJ+2%VV@\?ZTJQSN"OO1UV[E:VB_>P7*Z]XS2U6GSC?T9OC*
MA,&\60ZKM.0I B:E\C8J,@K#!UML5E?!<C;32Y![[J U->)?Z:7-K5_'"ZS^
M-Z22??$"K(I=B/;!P2K/+(!G;4]O19^#C1)\W\=3#/12QL'OY5!]$='#OA-&
M&Y J?^;]SSA%CPOMO,D$,ZM8R)-0+ZGU#>'.8DH_X[^X"_288(,2&7@.7D(2
M..9Y]:GY+OESL/!1+5[\I.C>V2B<0U_32&>$Z%TW3;Z9DMYPJMC#)IK.6@X>
M'E+X7$.;Z1QG!A,5LIIVJ]?>G!(MML2/HUJVW47Q9]VO#8_&(M$D',YYXKR8
MJ\/I)@?E3K%R,K&3ES'E)YB#;D:K 0Q :94*L0/@.F[F<RBGE&>HB_<2%1O!
MG5%L&_..@V@,!R?]A,A #WHGX]AQV4U"_1:(JSOL<$%Y@6P)B^^ *6,B*)6-
M@A6M=46B7,1 Y:A4W@RE12O!XF#P/A%9PJY,#S:7 KA5[JON=4N6@>4MH:X*
MB"93]&E@DTC<-,?Y%Y[T.:L60.6FD\RW>T4FR#Q-_SL$(Q>L3A=<>GQ?JU[.
M&J]./".OLZ4A.F4-D>-DZF5 FI3QQ>!5YP.,NY6J0R%ZFZ6Z9;V7$2Q#890<
M< INJ'=591N;HCI4K5)*=\_SIS&/@;(<T(^D#A+A:["MKVJR@QOH^DX@QPX8
M2<$\T_-O0&GC7I6 @R"^R*VNVQ_G&7+PKP#B<QDIBP7F,L0;TQJ<Z\!CVN^-
MOR@<TG=41/$E J%+59P#G=_\,Z"LLMD'$E/P.+DY+J94WZI=!!PR!$[1WK->
M8"A')9#G3G>JT%31\PF*8(2C[:*#@XX]=L637E6PAJWG"MGM5N,6VB[)'M4
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M2VZ4^6,@$W1<5<9:T.F8FC#55A0T5$<,WI5"N%L6,E!Q<+*Z27/1?K35 59
M/>,[5#[ /#RGIW"6(]N$,B8<7,AW'V'6C5Q5^9K@=#\'%S39$GFGGT;>P"=2
MSFM0J3CMU(R[4#6J%((N=H[23)1#!^@K'TD9"HE!<W+[CA;L]=3!!M,89*&R
MV1T_L8<I*'^L2!SVU]#N%(^?8UU20DU6?9J.D-!4C[P_K0J4DX9G-I>S]#L=
M4+&"<];&OD8E(D>SDG<4^GPX^*T3[#.=(<8A;73/Y_V7.+6!YI0T+*<UN<F!
M&Z6<$>6I\ECR,7.VF>%V52%QP\!D0&$&>.?_8^]-F]NXDG3AOX*XXYD@(T!:
MI"QWNW6C(RB*MC4V)5U2'O>\WPK  5$64(6N113\Z]_<3YZJ A=9"VES8F8L
MDD#567-]\DGAL0U#K+8U%3\GM$YQB/LCS)5I%X</6[TYYRN& 1R"0OC'C5*A
M#W[H]7[HK^V_\M&SG+'@]>@%FO.P/4(1A&5*EXL2,R'E)<(E$/B<SW+)47:^
MO'.<;599L2N.7"Q07 JP 1YDF EJC54)MW5MC]KB\@F+,AX6_:2A30WTOCJ:
MU-NJA>#DCE-A-[,2&;Z>[#22CG;<W]V3Z""]]:>+8GTQ0-T5I_,+C6E+W&N6
M$742GS3Y:<O98>4KG[%3<W[T_0E2[;TY]5+1M0[@\[#*ZK?P&!5\/778/1\D
M<=,.M]9+PGV0TL'O_Y1AT#MU3HZSADC*.+ADFS\LTU#'GH7995G.4,!0UGD:
M^*OCT=G^Z_W1^133HU7"IS8>_?PS]T/3MXU>4XX=FT2V%IJXM4C4IWUH%,RL
M&#J\? OTF5%X.E+Z\].CLS?9Q7_]Q\'?OGD*+DP3]CQUH]),4BF/79D_Y1G^
M$D?UY1VZ3.!_G>PEV:*C'T8[+Y^=?)RS"/:_4^CP6#N.;9'_NPT.UR(URW9&
MH]G*-*.#:</DD7"JC_?LOF[@]]_\_?#I:"?KG/#AX[TK;1!1%RBGZL.1_TA'
M7HE3MQTI@2;I(<IZ_LBV-BV47G:EC ^IJX^Y:\6[4%29-;KA'_]8KD;<V@'.
M8.?_JFD?.VY:I6L_T,7K],__.ZF^_N?6G?]R42+B'U8P9[:$&<TV8&S.0A(Z
MC#AK(G[EV$4OUJ"1QR&\] QK>C4<R W!.*PLH1(,AX?WV8KBHI/K6\_X?AAW
M16'16GZ$AC"X&A_8'*1;#M]A4MR2L/ -13YW')T6[9ILB.SSG<IZR-.W-B&S
MJN*C95V.N7APEE>!49$@6F(0T%^D,0-MB=X$]PR>?_"($<"<14+M8I!?[3-%
M:2IZPV P'O87DZ.\OP_ R1YP\KL'X.2?'CCY>06:7%MI$&X9.FU]A\8$F(^C
M)V^^(7>AK-:X%!1;-S.CADL_M:9^;-UPMBZCIGQ<NQ%FVUQJ<:.O=J#5C]F>
MH=MBF]QMBR9)R(+X.\T<M_"=LA? 6)@2K!_!LUC<A6C^*>GI3E^/'[)5=@JR
MU:(Z1Z,=_1U8O6R:&;,[6F#PR[78OM-ER;D_+F?HOJF8:=4W]:B5@#0<%%Y#
M!&!(ZQ#$=G#_CO&HR9NE=K'&-%--G>-U3*I)K9F(.D6L!AFI06G!T__ZC\,G
MAT^7RT L@4+_%\F^#D<[1Z<_GAWN8AZ@ ZJ2 B&I<@5W/I,*)'/UK;^0F.BC
M(S3NL=(!7X!E,%T*:NJ^_D7LH*PHX Q.Y3@@5P'MOX":^!0??/<A[6"^:/>7
MF\%=?+W\1Z_M[>##MF7V_JP L<],)'#[);L_@(KM:?I.?IFN'P)[)($G%6]T
MXK*E*T;H0PQ\1966^'8"%ERO[7H_S^$831?@=X*$LYN&PDVA!>36H^&0SYA1
MO.O7L[N:UXU03GU UMP30!="!H!/S:KE9H\J$2/;0JQ'Y8)U*39W571CRX)U
MJ:N"YDG[;(M:9LU8!APA%L6Y8(TC#Q1 BM'B")8VQT8#FSJ'=Q5UA^B5^Q 0
MGB(*M#$5PE94]!B7ZUU@L8.O6^1K+$$4-J-8Q.T;XA "@DD0K3ZF"]395J-M
M)?A(I0E;:/(_:1^E+ O,\:!5HH.<8-'EE%K#\>CXU>G)F[,7_X\K^!%3-  O
MN>H2;+T!48W\$)"&-$R97N%YEH,]DX_.L^+MIN3R7ZOD$2RU=FIF7 9WKH>E
MF)?+O-P?_4(G6TLL>QQFM;$18*:T6;*&0,, =P\$!USTLA#02U5NLB6#I*JQ
M G^FPNWC2CS'[I-DO2-@"-E"&KQZ]*U?]L_W&5LUJA<94Y82L3"<BQV8)9AK
M=:AW^>O]_9%WXU/NCN"\);3NV NOXXBN2G7'/9C>L*9XL:[!PTLF<W?F<O7(
MB]'W85*)-7SP+5V1Y*9GG8+QJ\Q/6H8/TG!>N^E%YH<D[];WC>5=<GEGSDKN
MOU:L7](! A,C01(1$QS_2S1LTB!2+K-H8KR)8PP/9C-VTO\[@QUC:.*6\9(?
M'QD<,1.O'1_Q=A.5SQ2DBYJ^L4VE#Q<??"M<-<2*LW6B\"4>7*1NX%),' W)
MO#C*X'=.<R?;M^;Z173KQBN"! -J)H.'Z"OT+U#/42L)*?K,1K\1EA!4&B-2
M<8YY S^Q_%QS6I9 Q^W$_E@G)AJ""5O<+C(VB+ I],^2A4ZHY8H=S^A1L.<*
MOW^J2,D9LM5?!K)5%,!8!?*>Y\2!, .?!K=P;Y41%576-@MD5^H3,_DUC2,1
MTOB$U^">R!&$Q9NY:>231)A@-].DAOEO<F Q>02KR [HE;?>NZ#7G7Z5$>LL
MQ[@9/ :>@T[KJ%V#JL545[9A2Q9.^5>'!X_V'QG]"1>*?*LL1WH)_^L_#KY]
M]/3QP3A&F+!/8$ 1%)]OID3ZAF^^/=Q_8F]P3JK'(B>V;S3:L?LIS:8F\A!F
M'%3R$&/0O';5LO[8'!G2 0WSP(^2@DKTYM@\H9VL\EJ9X[@^05[IN$?%W#PY
M/:*3<'ST# W*__T7YRZBA=[O>[.NPCL$GA/)%7*-P;T[.WJQ5X4Y$DW@*CU_
M<]SG;4+*QXHI->VHP:-"T1)MVE<'C_P&QW7@F"LM+L?!"B%+,R]#ME@%XE??
M)$\B)HY&[;YY5XW0$W2S^34Z.M"R54X3(AJ1.5NL\)<ID^/_&]1R8]PLE]XS
M4:N5,.V]+4UJD>0I5HYTWZEOOTC5J"^N (_V(D>7VNV#:+^D92]Z$?%F#PB%
M>/*02+?A'@=$K*"2A,5&]SZZX%JL71@X>7V5C(/Z&F[<;W#G:_BM!GQCHQ1.
MY%,S&"^\F'3MJ\=/_,DG_.'1\Z\._0@SX9</,VVA18/@ZQ&=++)-"#J@%J$N
MI?.\BBMNEDG$ >O,6V7XFE 902OQX/6]/Q!).=F\_':"FA_^)W[B /XCAI%R
MO'YU\&2; 'C*)'C8KUZL/JJ<BJH-+G<)@TLNY<'?]T?/60KC1Q F,6+K<%CO
MT/385@#QB1Q)5WJV@W/CR1U^2Y/+F+//9B$=V^H QAN5L^0(E"$Y3JKUJ41Q
MW5/TV?Q1#"@U[(E/,5,U@QGAM+KZ=)2H4HZV9602NE. ROEOA_L'<<%O="YN
MKRD?\N4]N7?XZ"%?_J?/E]\S ^#7$/W^HG2L@^B4.9942_.9C#D3(259U?5R
M.MI)?[>KF3/)Q?^PS-Z7Y^!F+GZB./;.#^<_[=X@,9HH,=+MJ<C"Y)I2$HO[
M0UY-U]=&JGO2:+ W;T,3\P?S=HFU==5*99H*8 JRR(?<-\W'/L=^ 8H_^Q9T
M/UY812_D*_E2'#_I:+2CJV:$6XX"'Q8!)/D4[6WL'B>%\U_"+IL.1,!! 8/%
MQ32GG;3Z^4^F*:L@^XP\L=A$<_38:;&R>U:NW\:([>CNI/? XM=54=VAJ.Y-
M3&!K3\+I=CB(3"#H)[RG_DZ"42MK.[_$-(UX1/+7*0]%;*+2C)[.83<0>87B
M=D&LIZ.+93GI)$SBJWUA*K^?.%0Q+(^@UN82JX:;&+8:^_A8%?+5I*TH$];R
M\QX_^4]JH]92\HQ()35:)%^:+LJR)C)+S$;Q5.CC_'[V8^DJ40;-G,YK(I]8
MXEQ2YP^.TJ+\0>M]S_9#@1T)_M-'%_\Q.EZ$Z=M3M/#VOCLYPZ3/^>F+XSV2
ME?+OQP?^WX?X[Y=OCH[?[#UB,]1^/ 13.XURW17LC02HDB"&ANJN,LO!T/:;
MQJ$96E^W./USICL$VX'<GMW[(B>&LI?;3BJJ[?@&V=MR F9@#!GQ40QZ$*4
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ML#9YW(OH9?FRY;RC!#N5K0E&A!S:4FSF@I.A(HHG8J[G25"HD*W(=^6RI:9
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M&NF^-Z>>?A%,E?+K=5:5_NA[KLXK4!(+K3DEHLMH#DAG0:^&30)/.PT0<M\
M(>LV0! <&*\?@CDBTZ@=)[ 1)#3A:0!Y2#<2RGK+#,XQ)MP .N8KLO%AZE70
M>X( *[:)UZ'$&!R]6[1J1LXG+1?%_V#'*0J*OW '8NL)[)XO\R2B+O!VA(8W
M06NW"DS3J*N46''/3 E18@Y^U;7ZY.NUM^7]1I"BGI646L0E8H=%@YYHHF$
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MT<) C[&XV%N&.<S@26>]]CX_7H%,LV^??OZRALY2[#\ZQ+D796%RP456R;4
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M3I6&<BTK/IPO<@LAP #U\1MK6N127U*P2]5G<!&H+&^)!"[2DI(R&5@F1U7
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MF^<5P4RYMO&*28*IC$Y]"VKK92!1+TFE-6U'[^JY5]2K?^&-SV=B_N*.I9[
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M/>%NP;QI1BB,FE_(5JO.8K/M:+7B2EJ=O)P;NWXR]?+V+]_$!?@4LG(Z>K,
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M[^GH#6<2Z4K<\+A,MMWL9$9&F#Y-S(TN(UQKO>"2 R">2 9,/B=/>BH7(,5
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M;@(3X\0.J)E"Q^>/BB;K%&H;/S#"CEE,"8#<MIC0,93AKYR@.O;1?:B=PWQ
MTN6[[K D'1.PBRZ3\=.S%Q5)8\6/JCR>0.9Y+*JK3CRLPT-G=@:%MUM.J6="
MS9P!ZQH8</>.8O"!Q( 7F8QW I)HE<+R-)IZ+EQ:BYU&'OC "7 <;@I>N9ON
MN"4?R*J!=HQ.T_J$3P-Z2H2/&JM?<WUN:P RQI&0:[A45$1>*5-5>MR:#[4U
MKFRJB64I=L9Q9MU45^#>5$%.W$:]C:3:,RD%F.BG'$5]ZXLAM$G*GAC37*[B
MA-1I-M:I6O<GO'AD^!K%0G2P*#8CVH+>R5#N1JU!7=>IRH62HA#K,2AIN5/4
M+-Y8 T8 A9H$%'+T^'21.&G(94^SRK$D1/UZ8?6/0O]AA%ZFS !F029 /#,R
M\_6VT.E#*A6\+]CB,@/$QHZI?-"(G!\E!)33<M13'XP#1D^N)KX\;A<L9@5F
M96I1,<=I9_T>E9SOACYKYCO%'MH5>/9 -EHTZ:,9QG\@U\"82.Z-$U>!2]L5
MK<BQ^?Y#;C<KSD6UU,;@[N!!WH&H.G6#:7NW;6P<Q2"7254P;DN.YLH&SUAT
MUC5LZ,+DZ7AC(')-!)JV842D29),8##)<IG#*'R <RGW,V=7.H*TIHBR@WH8
ML@(P C;T(08Q&7;0IFP=?'\@25(S;T*H-@YZ%=Y'9N.LE*BP'DXY?C9984D_
MZDP%B\+3Z,-\&PWVLC=%JIO-O<[#F;7!NGSUDIHH&^H[YUDBXPQUFT@-)"]G
M-8*^"<%Q@$6$O*1F6ATE%-NBIYVV:(<FOJZ%&1,%I5WBL,LT9[!ED3>[<_NV
MK'#FQ6<.FB*C$T>E#!\JELM4Y>B]YRSP!;'FUN*@M+MP^L*L>\3Q,A'Z2+N*
M%Y,TL@R5X;.K"Z)0GB0]61$5 I/!.[@Q8U$VX5HQ*9BZP-4?/,M&N[:BC/"9
M"29[VM:,-W# ;WJ_YCB(;J@:U*EO;=JZ:</OM)M<>D?;ENX1"Y (8:[*;4S<
MN>ND\GSX.C.N#\<LG-@\HS1:#!E*)0"<&!]5X+*F<W,*X-7 (7 K=%$B;A+B
MZ_CKL5]#\VE1AV1>O5F['/RR2ZC,Y2U=6)^177=6,$U6LJNEKOV(%_&SQ:0;
M<-8Z[J2MS=CU1EE?^1*HBBR%URD 2C$M[PK(C0)?*>.>=6SVS5_DRXN"O4B2
M7>Z,B9N^CX01X&=6:Y1"3LI#I<ZO1>5A7,F.1Q!\_HQRH;@TZ5)*H7O2;KKW
MBA= VLMJ.K'::*&,K;(@TO!V)#G9J&3)W(Q(("^@3V-[U6>B0,[7-I[:3PR]
MS@*/:6L9:]QJ7^Z4OY_R*FK<I6R)+VX3MW\VR9W=5#YG&#<'P)Y8N$QT]72;
M%119VC>3Q44=5/ET*N3&O@^7;@\;)N?(TN$&/*K:[8E.];6>K178>:[W=JZ"
M-,.@A"BW0W$Q=G=5+O\^[H6834.YP3&E!Z<C4UE_:EWM%*RNXSE;V,.!9; R
MOOA6OU4D__U_3^H___MG<)$O%LGU_1')]84BN>X>//QMSUA#-\@F9!ZBM@/Q
M'%$-2D!"-^ U@GO-0.()$"X]L[$'0D:KCR,$)'>R>AY-D]"N/) CFS)(T_P:
M-_D8J_1*A&\OMRZMK+M84DKC/6A?+_3L0!1S+=:PT]N&Z@M0#ZD%QWH$34(M
M%YXDAX=TE2&;O)ZQ)4YV7JRO"X)(.&HNTY?:PIB?%1D6Y/BA<]GM[P^UD]2)
MKQIUT:Q+M2)#L,;01_:=R,'9T38TPHEF![=LW(AK#8740=Z!GDUBCD0YMK0Q
M8^U&9X)S$_@X5=VD(K0FEVFYW0W&#HW2$X5N.ZN.F=5QY5S0^$7'F4LSE+;:
MI1G$VF?@V&JS)*N?)ZT_>O8"%^85\9\"+3:Q_CHMA-QPD[.=& ^$2ZNVT='O
M%UXT][,[HF,*V3NW=:HME!//T<!AWTFC\(35ST5Q<(S2P2+Y]H.-#BXVY2B5
M#H2W.S^!^K9IB'S$G%]$QMW4P1H^M=JY/Z=-.F3FB'\JZP&!,'F!119^*AV.
M.N(8;4GH>^DD&.)M_/8ZB[6I@RW4..L"L=9B;;/HH[PE5<;]D2EOC/7ZIS4Q
MNJ,LEA7+MJGH4.QR8R<17TH^9^OC+YJ:8^+)0IF[DX*^SM3V=+GSIBT+<@VX
M;>25P,Y&+S<4O;>-=KJ?C:2+2/D<^7C)",9*.UEF# ^O^#=108#CC*<E!.-&
MX%,_*R]6$*$U'X2+G7"_.@,6^\L9V<RCE[UEB:,7M:-2JQ=;83-%ABW>!"WO
M^0.(C)E7,Y.!ANP(:>9*YA]7]'42_)J[XNAH!YW>YT%?TN=E)?_ESN5VN'M9
ME:VM%E=4RLMJFWHWZ;#4Z-S)H]%HVB=EU2%L,;0^F9%IP2#>PAFNAA4:U\-
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MF#@V(Z04G[&RW]2E *%Q*D3LXZ7'T<.@/\]&+^60EU/,L&WHZY=EP_[*$PJ
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M.H+__?KY?WJ$[F,)B$E:Z<?F$V:GPY<<\ED9J2,HU8VO;XF2#KCTMJF1" F
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MZX?\Y)!.O$.6XO:MV:03WHG,7/%(TW7+W7!MW==4FI.-I_V2>5E^'G"B&,O
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M!AR7<['.KTZX=("PUYEPYH=2PO]K%6\VQS3'0/2R2^2*.DY'WFFH*\% /@S
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M!?#3T:-[C[Z:?/W5_:]'_*=N4<NO\K@7R*.LS^S\:*'(,!T*_SVXB_W4\9/
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MX*)2VN#PM?P'"[2\G[G45A(*.J^0L7YJICS/)5:/FL3J"TVL;F5]X5S<EPM
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MX/7YL?DS<$YHW8GQE=GFW!W![W/Z0"B_;;9A%UYW,H\FM;=($*^I_:X0J4!
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M-V(IC;A;OK>X-'E!,0G6K>C!21KY:]+PX@-J@B"V 1!50Q(J.3+1CV# ,(+
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M;W14J^7]I)AR^+WYS[V0RRYP?"$J:%(,TVF"@,\B_A=BLDD"(=>SVO0)ZB&
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M7V2BA(QI D8@H<761HA(T)%@J*#Y8H#.C639F6N(@,P\)8TFH,I%9$/!C!]
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MY>$TC,()_173@D4V9]1C<=BBGX3Q8GO;1KO-N5$4:$*!7;5'VB!)TCVLO>+
M_MLXA>,P1H\] >(L3C9)PL]UKR2<Q47%7+](9@%("Z9I:JN::=(\UI/M#;%N
M"VUZK(I6F37:^&AU_2DQ_W40C?#7-%A\1X34E<E-HV;BRVY9PA(X<Y7[K;"E
ME216([,F=%CN3GGV*0&3WMQ-> /0*E=_)6!>(?NT-(7QSF!IE9@5S.N=/HF:
M697),YYKS:%<K'BDBL%9E=%K%^2^?9YY _C/D/T]Q0^\(Z7 &%,DBT%6_J0K
MW56,$]"#,:Y881%E,.#URM))_9M4A ))/<8\1(G_?$]JU&$3UV0 VPP-DQ5=
M64=YT[>\0_>TRKN;G'WZN&JN1\5_P5-R8,<AQ7)_P*!)/\3JTI0*QP8JU\,V
M*>@;*CJ>-!B&"<TM@=,9@AD2< D+%W!QA"!+1G U0YQURRYDK$O:: <+U__^
M\NS=JNN'6P;<QI(VCI."%F>M+G-8)$AF5FACJ2'7FI+>'>(\QXA<>U=OZ5_+
MQ,2WEQ<?^!%G8**FXON7C9Y=$1JG47Z-AJ[OI,5TD1BWDF0V5D+5?KIDEL95
MHE>$5HOC5U&0AXEO+-9Y4X."?\2@W"\"-PLC$)+%-2=N6A\<6EH18ODBC+,\
M+5"1L"0?%^'05"QK \TUJG%P<Z[&LWGO;9DCI"^?^*%:0HGP%%%KM%AW)3V^
MG@P3G6WBD"34ENK@7W78#UP:I>K7D_&+YZKM2)[[L*/W5Z=G5WOMCO/GKJ0(
MY:]@M%3D]A*C9!7A[(A=D@2^\ N)D%),LVQLV<56%D@VF+B+[*31]B00L#<J
M:* %S=-\[6X3%%7I5T4V_Q-Z$L6$_P6&NY@IMZXPJO>INFQQ,U-@#1@*6[%:
MP*N>H+4)SNL4O&FZ!6J2Q,2ZQ(6VM4;7E$_8S?5^.O]TAFU6''3[^/.EEEW:
M'=</#Z1'#$\1O&%-.S+18!UU(AU;!8#'KG'?O:._Z_%B\Q'R*[H:V. T,>\Q
M,B%3Z'_/;9(:T2Y-6Q,R<BY6P(0:C91V&*H[H"?#3N&40$>C=$II !CQ4,91
M0GMB ^6>?&B2CQ3DR\PQZ71M&).W9_OI<(W(S(-P2M?-F>')%N2?X"GD'-WA
M4=IBM-KAP3K6#K+^_9M3_2HLGE@J-T=:^MA  R_OPZ5983.2<2Y=>M"D2U]H
MNO2I3:PEA=^Z2]95C7.QP<5UX*:EQBWZ_B@UO+I6W'UVS?>>2?GWFB69'\.I
MHDB!+9'?GKW<6<I>J>2V%=2Z?IM-'5=-@(F>]#$^)1X<_(=SZ:,T0-,9$US*
M-7$##Q>+"A;X8+]UB$67$?*LJ;(F;XN+P+Y0-\2-<GQ#'4_!29@YZ5R34<5F
MN(E3V$1EX -<T9#[P,<!VO-.)()J\N!FD$7#(T>EH@B7/(J"R<0^'@W'/MB5
MQB$MA35M@7/"Q6NL:>G257R@5.V5+?MJO;JM3Z>$;.>(PE9WUIYS*( WE54Z
MQ'RG=^SB[2>G6=UTF4TX7<YA,<X<F9#+.$UN<VY;R, M"(9DDPX5&3ZP+5D;
MMC&:MDKN=Z0*6@D<:1)R?K@43$S10XZ903*@8A2DFCS ?#@B&SQV_%\V2/&+
MG]7,&UP'F'Z'!Z,E5O*ER);C9"YV)BLT^#'\MA>%(S32$FI"=KM#=:0*&YVX
MF\\$D*I9)@HHF8V_\BZQQ^GTTUY;O /[=[#$W0\I.K7@L:ZC(P=J$VMN2?&B
MO)H*B:(E_P=X^D*E@\_>OW\)3DOQ[H\C$ ^6Q' &$0?3)*SL6*[$TQA2M;X4
M%6922BG)U)[*8!>\$AUFTI6%SB)U?Y<3G*J$7*F]$UDD591#)3]H2,/0<4EN
M)2#>5LXV[G&V48Z,_G.WP\O-$PN_*H?A.X%<BDY0U89S'B3R,G??\[4C@PCG
M&@ZHVS\>4B.9\T_D:IY]@O^!WP.5U9Z^M#;=@:9CEION1.NP_G;FLE=W/?9:
MQD,F4K\XSD]P#^4/WZO/<&D-2_759*K&001R(E(%7$+#6WQZ\[$YXX"[$5%<
MYP(N8P;B3*SDT>IXTH1[W+/"_-AFJ5BFRQ4V'>>H"<A$I49L">O0)&<T?DQ]
MKU.+:UI$?2>'%&"'HZB^^=7B5C0R!9/62<;+]0C+-1/XH/.S\P7INDJ!A6$D
M!G[@X^$7\<UEI<$.Z:TR95]:ICK^JU0FUX>O' >5E6EM\@3_!>OW?4>+5<).
M>""L='7&73HAZ8?2^<%/-2XY"R3-(3V,/-&5-S4/*TH6":7!89:":8N"4),0
M*Q806B#">0D9E^: 0'!+!RMU3FCY$SP()RYB4P=6[?HW3?^[!%^!>:.@&'/N
M=)E9ZAA*NJX"X^Z4T1O,][+"+KF3@,R,%,YM['83Z.P!PF*$VKBC[A0CE8R-
M2AJ \BUN^47IF4@@:OCS6(F K!B:F@O;&(BM?-*8/%^.0NLZ+=(0K3W?;?C3
M_VAD;7S/EKL%Z2:W&@%CY$YGQA>L;**?D%4'4H=,= -%8?LU*$X&',C'8%;/
M1Z9W(*31QI=17TNU%SZODCA_72MX%CZ.)1BN9G&"=E<NS4]<&5N^)P[P";?Z
MZO)H./:$2CIT19S;7.M$P2E_B=^K=O,NJ4,3F 27#1UUQG!*^$#3NH_?["=#
M^OCTS9F+HN7BL6@]"+>2OA6R,8FP,D&JLVU ["(._RR0%]%#A;_DG(C!EF&]
M'/,HWQM3XI[Q&ES(&+<DQ=W*-)A%5*Z&3<<D<L77HGNJ:_"XV3@D!<T^RP0X
M;R*-+B!=!A3MN%9!E%_/)(,IEHS-/$GML W&&J^UM@#>T9Q2>>AE 0>X]($1
ML=",S*CI.^(>.+)31L$ MZXUM7A[IE+'MF\;(> 8XL["[B-[*7#@=GLQ]261
M!BP"?XBS8.#4/VF G$);C0,JE,;*;L-.5$E'3^J'9'[Y2 SD/ZY40A7)F3;.
M#U!QK"YW<\)J#F(2@IHQU 2M MT6$*$)-5^).Z[FG',Z?<SVXRG5L+V-=@01
M.M;8RP1;<W,P6OV+FJC3-51/'B%"6RWTT##QJ!:#Q!HW*C .F+  AA+5EP 5
M@F^!]K!XC LPJ]J I2<WNI_#B\*!T4.DYJJM[YJ#?/;UEBD05W_0&RJ-K-WV
MJ@HC=))F;DR):Q[HY;6,HTV)>0OA]^*_(8X=P*0V0VK!>@5" 7>J/[>=PD$,
M2AD134[[-OX$B@$H"1(7N^2&.LRA;[";3>;;ZY<%YM!4=#!_L^8G5\DY]8K0
M-JE:VAI[$=@()WX'XHR ?4F9]P$=I^FU%'R48!)<!'T"/:1&6;I+PFN^[9/&
M/0EF'Y6J5AZ*6JKH_R'E5;8R1: C<9F#/XN0BMHBZ:D$\RG,(VTGH*#(R)O1
M2]+E^$)"$ZT$I9:R:P*7]?3BUT]="Y9GE<X<#I]&ERIAV]289>>()I8&6JQ@
MA,[P5KG'0 JTR3L+8E>X=-NVA5%TB6^D6UE N2(^YLBJT(XDC%M77!&_7/3R
MTUMI9LH)3\(7L!*)E"%@$7@?>X;-X"5_%!KP3XM #=$A>C"K-"LMLE^' 9NO
MSJ4IB$GD$UO?>_KS6Z*@(W2=AEIF]$F0?8:':+DZ9RO,,;Z<9^98*@1+QT\5
M"572%V5SAY7[1/K.G8^H!AP,Z-.,,"*1V2328%6G*T1(^G',E"07B+=.FX^-
MC4^4E.4:1^G5)V_>%0PFJHVLAKAE(N7DD<R2VCJAH +5^2+CPXE[!U?[%"I-
MTBF2BLAJY!\#Z4D=F7 YQ^FXEY:9#^&4,MVZHKG*4O+B]--5,*XP%9RLRU=:
MGS99Y;FL\F&356ZRREN856:A!D9C-!-P) FX"=SAG5A0&H?,R<M];2::P<?J
MON#M@8K1D%7Z4=I<^)DMX#-V[:XDM7)FEO55">QEJ&R2#S-2<8';Y-_A,RUU
MDRI@EFM!=#T /MPGO<6SRA;/W2V>5K?(E%WA%<^@T&!Y-:U)IY6 DTL;,WV%
M%DS3XK5-N#\'5MQIU^;UI?Z:[7+K<$ZISP?-*@RAU%H@D@HLN8C.]Z2 C>-I
M)7.QSE%5\1B%"M#20+.[#]-I<X0J-M7#XR2(&"H./0=MDI0NC_5DC;EMG7EN
M/\Z4!1Z/36N3S2__I235Q+9HCJ FUH0F3]:)B2QLYBKOQBV2V,)HXP+8L0__
M.7^SUSGQ?J-DT-:M^OY7J"0;.&IO-DN>W80](V)7"AMPX 8A#,DI-<&]TG !
M@]3#3:].X/*VTLI?*BOG*$:YG;@$GV,"1_05>XDL<'L)5-L)]TY"ZE95!I:
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M">=G!6UQ5$34S8[FF'188$@"-;1,[-!'*-) =[S3"Q>TO _YVM=2QTJ)(;8
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M(":O V[MZSR $^JS[B?-W]0HAS6! K=@85$Y!XUH$% GAJJG\;:V>C88\E1
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M YGA^^!LHG#,L$BKU_F5N)F<"AQ.-6B*_IZ$3;\R"++<<J<*4.<K^@L55J+
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M8[6$@]JO/]F8MYW2)8W 3U*Y0I/=!;ZOVM+L=#M3)6FL] QDMX&1@K43')4
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MM(MRR2;VU8S +D_3('8X@6+1FFY#TYN:26%EUO)^36[5#=;=87L?YET1Z<#
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M@XCZYS=_"_N=X>#HZ"08'0:]_9/.X"10HX.3[O[AJ'T\4NW]_SL"$X0Z#U!
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MPR3UR^+&.D\2@*ZJY)]9TTW &O4KW!T7E-;!G5;XV5Q+#(;W*=Y<=T9X)BH
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MT J>*'9CE%#C&,&03%&>0;7EDDHG-HNXW5^1$N5JM9\);]'NP8;(<M3 O7P
MJAX]GBEA7CN]2%LY=8$[B4>/:@RHL0 5UQ00CN%BT)>K!%U=*0.IZ M#HJSX
M7:E+6(RDG6E_"U@4[Z! /9=KP:5U<G!;T@1D+\J_/B+TYR61(8CZ6 <#*KST
M.HTVN4)+>_7]</ #S94L#7<[1S@/($Y5)..;D,TZF3JHVH+@L IY-L@B!8=?
MB)N;]$8.'8&U@+M_>:6XI:DDP)^$LVWHB.*M<!6E"&_2O'&';BC%24<BT8O+
M-%+X^SRJ:37I^2EIU%BZ6EU=G"A>G"=2D%:&(] YNYVW:<:S2/O0N:@9!O"%
M<0^U)UA"*AR4@FC54/J]AJ5=T."PL+2UWKTMJ%;;8G!:4O*$.&0!W'#4>K5S
M0PK(RV.74<4\'^/H [QG?-+H%E8\'N)!]0=#8730[I,-.Y=2-X1P<_ K923#
M/_-Q @27%NI36T$URU4&(L;(-#5]):T^HR3DJ\$@%TM:?D>--@'*5:,SI*&2
MJBL>U"]?3DR)"Q-UC<26?-+B36;OQ&B$2A*]2!GD69^=_$P 2PH:A*@T!28Z
M@%;"6[!_R@VIJ-6D62L-)/@>\&I-,39'U=3_*ME9S0C!$1'JF3W0P4H\_H.Z
MNQXJ0.6W9=+U<ZM?W.$LJGB6C-L#9]ZH"%CO=F-&#!TUAYE(CI11+X%N+@Z"
MF;B5VJ7 N5S"-T$OB-)=K4Z]U#?X:U236I?(T2O@/N)4CCZF4:;UK=*<:2^&
M4R+Y&.]*7C@OALP4,V\BWK\9:Y-J:GE@#>?@<.).8/43KFG#A5=V+_I90PSH
M8(";XX) 5*01KFG2YY:W?H,Z*!O)@](T5WFU/,^%4O#XXGT@0BSSD1O\G?>D
MP#J]$D(_J@B4#C$8J]X.]W"/T]OMW!W1N&LO2K\*)'IGURJI'IXV^[R4E]K#
MV\+8LK)\Y?'.(Y1"(RRPCQ6%V^\I41_*O6_^%0Y_>[,^(N">VS^M61B?<% /
M:A8DFZ=(AORD;;AM =ZZ3RY\I&T+\+-J 6['MJS9)S>L!;CM^VW[?I\5?[9]
MOQO1]]L.:MGNUM_/@^$7E:.3(=RV?Z1MGES&IM>SB)T:+/ ,ZCP,)[)M^7WJ
M>WQN5&LQT_#L#:+:MNOW:3H#VZ;?[6_ZQ6"W,:/2\F<IH5J6I+7R?JV!;5NT
MXJRMK:=(HX;O,",P[PMSOW[S:%HZ6V\Z<VS?\%D[7.<9]33?VUYJ>YHWO7I@
M3KCK,9N47CU%H4)GLD?\6_,@[JPCF^H%G]TW-*<[G&>-%]^SHZ=18MOYAZQQ
M*,N JK)P6>RM*_15_=, ?)L8"Z4BD7XMBM>Q(%,5H_?[@Z(IM2H2*KM8=+$F
MO!HH%]M&52,0GF)>G:.&D9_5+ZV&"D0]GN>RY+DL5M9E@/62);FR6CD3%IG-
MKMB:Z+.=6].4#?!3<)A?A?84QKFNR9]9+BX+6U55'1:>9JI-0E4FJE)IV1"
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M@Y!:24:R&]$5F;-M/E'BDO$>6J>Y )M5,9Z*@=_YH )[ISG]MBP'&HH0#\3
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MG]JK9Z/J><O"/E!\D\G?9GDB%"YLL8M!R9"[LJQ;!NVQ,4T7WFFA$$_)R J
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MITI!2= 1K"64A"J?HK-924$+TD0LJ:$R&&>@J.YV/NH6S,:?ZVVLM3+5;Z)
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M^ZMLD'7!JQ_""M$>AD/YB)M/'=<)A$6%&=*012'W[=AVW,BS66(%E+M_'R"
MH$E-B^ /U++I3B<#P_'?.[%(7TDH_,$0=WH4[R@3(;;_N@T/!E_?61^_GMO'
MX_CZ\.O%'\'U2?_H^\4?QW;W1^_JXOKBZOC'!^?X\[%S_OFO?O?LRVWWX*)_
M?'#5OSC;,]_9W=[YCYOT^//'Z^Z/"#YS;IV?'9LG9V^O3SZ_[5U<?W*.KS]8
M%]=[[*+_Z5OWK4]/]H-^U'^;G?3A.9^/;L_[\+G/GYR+@X]I]_K2Z1Z\[9]?
M']'NCXNKB[/(ON@?W;ZS/UZ=][_W3F ])Y\_P!KBJ^[GB][QP0?6[?]Y=7[]
MR3X^V_O1[5]\.3FX-+O6QW[Q'7C7^,+ZY';[A_".(_C;(95K.;BTX-UI]RSZ
M?GQP;%WT/["3@P_VQ1\7R?&I^>W=V>$(_FD>7T??NK>!>?'?*S/J_Y7QS\'X
MY+IW??'Y[15\GI[_N#3/KS^F)P?G[/Q'=-L]^_#M_/KXMMM_VS\Y^[/_WQ_G
M\*[HQ_'9L=,].W).#H[_#H03V FGQ(DH)RQF(0DBCQ+;XI83N(Y- W?G#;/^
M]5N#)MZ\G,AHSI>F6JU*2^X&:Z)Z:=PIB/=7U<:O62JMR+I;9/EL1JZZU2UK
M=E%,#IF<!P<SYP:7:[6U[+>*6_7=EOW6_Z*\"?:K10:DK8>EE2T3;NS=^E[+
MA&M_49YY)Q,B<L!08/@;4RHM2V[X3;<LN0D79=_)DA(90W72Y[IKN7,H9S>V
MC+FQ]^W[+6.N_T6Y=^M*S."]Q0Q>RX@;>[]^T#+B^E]4L/-F\:ZIEALW]I(#
M\RYN_$WFC]M.MZK3S9[?Z;9X&0G&K]OVN.ULCWOJ8I1?3.5.5::H5;_Y5SC\
M[<VO_/&Q.%+CT=1]MK*0;WIH.?[+X7?12[\C//]1%DU7%3W)WF;?Y<E-FND)
MA;B=V:IW'98_MTE$U?%A'EW#-6(G>!_6<*M Q6N&1:A30[E,#4U?5.>%&BX@
MO_U28O<E<Z8!_LFS,=:ZZ=\9#1S?QDOSAG^AL 8,"2Q3Q>2*W^8SP@)"A@54
M"T=97EBAN.MJYM$5XC8F:8YUD24.2!V^:/9HPPKSLEA\)FVR%UCNI1!+9 MC
M@;<P4/,DR[[WQE9G(;7HS[V4XVFPHG*@*,XH.RON_'JG0'G#;@59ZBHQ(6H%
MI0I918,(5H\H]']Q0/I6$4IEP1NM#J:L]L0"WUK%9]$SM))[44-]L21;0D5B
MF;OJ61*9G!QUBX0N;N1,@CKV@>Q]ZLU"O5TOOM5XE17SJKN5\(>\A&4>U<;"
ME*T+6K\45UK3,R=8PXOOT8+YQ:<L+9W\_*6N)GIIU$FB1 TL$:G+8<J(-S<3
MKV>V9# J/)@(!\@ @38@=&!_1\4[]M4["/[B<JC\GB'O"SE5HMFJ!NL$&A@)
M:2><WB#+R!:PDT89OCZ;,S#O8K#JU+=RB67RPC*IW4F*QRLX7%7W+36Y=KM$
M.%0<X,OM6%C]C9!O$N:L,\YDCZ4<D:5Y6.&F#K(U(;79&NYW"=*$?*EUW7HL
M=HZI(7O(9@I"/BRF$R-R>1WI=A8M5SB5JF=\XEMIKJ<824@_B0[:L ,F'S=S
M126Q2TQN9&+5O*T[;A23UD=.8CW?L#(32P97)7Y%STR].UVVY58VIOR&EOA%
M<UXA!>8(#RDS$X%S WKU5D2)=C8!\HFF^'#<$P7:>XF#5ISR::WI$CY1MHG5
M>*UXI-S3FC#&'?!VF9Z17%WAXE)8[K!S)KNFJK\6"-9%-\A-CZM3T0U&ZL#Q
M57)@KAI?CVT;@TSAX8/L&RK$)PDT49]'.9<Q)&JU;#O59@%>1_$1HWQ&K'HZ
MP9892,!Z$(GC6#%(N7D-/J=7J_&$(A%+[ MI_U1S&V0SR[S7EO-Q9RSZ)TLR
MZ@<VN00%$R['%R@>P//70!2G"%)5^W"Y'?&=*SA!0XU*&XEB#IG1$=A;A0?>
M1/\LX3(UB&>!_W$'+%_C**6"KQ:@,;V*A\\R612"A>P,G(F26#3J5<+-J -M
M3[RBF+"I+4A>MP9G+_[S1"]3C2D*C&E>)]6P5"TUPW95/+^'!#:'XX.?:4)J
M24B)5/5-R:KCSK'$?E]G"86 T5&Q:"4R^G+1LNU^C&V,TJT3".&BT=OEGQO]
M9;-P5>6S[J %+;UXWGR3[%1O:*?&G[5&4D^/2JNM:%][U7E!7VH_2XD2Q02R
M=:S.8:K7;5@A/1=/GBW_X/$OK)<%H'6LAU_<(.0^N@F@HWJ(G"Z9OS8_0$X5
M5Y,%2G1A!=)=;:K&,K,O(A[ >K&=CO?4<'4)YX?V9XTE"JOBI]Z>(?':,P6Z
M\PT<X1(\6_<4&LC^M>5I5I^]-DD7AF9=:;:# 7##95?]Y,IF/D#..Z^+J^F;
M&E38E_IB[\W_C]MU%02[OD-_I>F*^KN>-;^QZJZFJ[O_%@36TENY/&_7][UE
MMG*9F$JJ/6\Y'[U7JO&QP!%FJX^/>F*OAM24LH&4K>NJ-5[:\ 6OJ"9^)-25
M=V8]&6R$/)F#::#*">6Z-31SI[X^& \+B8RAKOFQK5DNYN5PD.?3(/82W^0?
MU&".M1M@3WQ/HM/NY5(.CW,]0T(!>]YM<M>]11Q)FW>T98=OS!NP02#7M0(=
M(10SCA8*QZ-BUFCUIYLK/NSSZ+:P#X<*H+X>/#4Z^^,<Y*\8EB! Y2]J0^ME
ME%4.RJT!0F@D''C552>J 2'H=113-Q'^H1CPC1;/!$\.:S"XL1HZ4T2X, Z@
M)Y(,*P.F6-_N--^VZ=K)="UK@4FW/O/:&FFMD;:."E<Z\H7*G52H32T@?=F&
M)XA*+"E!\7MU#U8D">8%ZKZN<HP*S5"H%@4">EN+BQ5Q+="E. +NJQPJ@PDT
MI:<EYZC9!=\C/4XF%GUI-V9Q^6VIHL=RFC8<#X]4%+8OQ*ATUV1V)1F4B%-U
MNQ05;9I7'G'AWZJTF5RH# ],@?5KC#6UHDISJV7+8)4>F%?[&Z*F97+"K9KN
M:DQ/!]6#7,H3&<BA#/$,_;IZN]ABEF_%CV(7_V?P#6-J>W&LTTB598P4@+%"
M2<'/S$R&(U%A[R*QABR!\7/)ESJ*J4\K%A@*52$DA4Y:&\P$]*A0V8"H,LU,
MVK++]3<5\Q83B6M#;">IMIQ =,6S3/0J?#8]UZ9&[IJ,RS%/);?I(>VX4#6<
M A[-U>1FM:9R@%=]IFU^"_OJUZ)>*<Y 0=C)0ARER-6\P%[2\_'D"A%'3(_A
M*L1 0V+4HL/3BU#1KY$Z.NVYCH=HS1=327 2(,:D?XE1UT 7_5(XUZ*68P4K
MH/LR-U#/4)2W<;?Z*O((!J8E\,)136#N0N8URD!E1=4%':L4MXK2C[-Q+F7R
M4"!^JP*?GDDLM=0+SWCO5@4'FXD@G!L4:>!8"9R97F)DD6>#/IR61CO57(64
MM(NS.*82,RI]4SU.;5?.FJU2\\599.A5%ZYU?;T%RRU$UK7)=&I=136&.DPM
M8^:- 4?5G.$4;+C,OO+P"WVGT1@K][8HD*DPU6;=M![BU-&PY=5ZL/XEE9"$
M=RVH>GLL:_!ZNEH&H[W2"U>D4:ZJ#G%>2RX.59!9 A;6\"65Y,4W8Y1;2BTT
M(B:'5)4@B27$H=[S0AL^RLJ!WQ)1KU0/WX:80LBJ:9<Z'RW=_+X,JY3YV!H4
M<3+.HE$]&ZWM&JP8RF6H97Q3R_85"'Q8B#\EYJLL>8.PBOJF69>B>*XR)WOP
MIEX]-BA)#T/Q"@EY(F1^1[1AC9)3O^6_/0(R4!=^\;2X0-;QJ<8%NNZE%_U#
M>G[VX=OQ'V_A.1_HQ5GOZN2/[I?C \0%.OY^_J-[#7]WWMD?>^(_'V\O/L<W
M(?C=)Y__[)^?_775/=C[!NNZ[A[\U3OY?,C.+7@68@3]>'M];'7A[[VD>[UG
MXK..?WRQCP\^_3C9^]OB//;LF)/(H1%AH>>3(.$^$1'SJ 7.OATE.V\.APAT
M^?]X_^9UYQS([++S[MW[2:2>=<YW%M6L4BK$1:7EI/3@BC(0H3X2'<LTK;4N
M,UD]C[P;J$SE<^>3#W_[OG 9HSZAS/((<YE'0@I\8C+?C#CWG, ,,)$3?QL,
MXLZ^Q%''2P:UEJ5\059Y+,(IZA$54&%1E'@_4G_VT6EG*<U$K&TFVK:0]KHT
M$VT( &\#=_?WO7=[W?W#SNE_#@_O0-Q]ZC6_D+[)8 S/B*6KC.T"Z-J";RG!
MZ<'Y>SEW]=N$%^S9NX&Y KQ@<]<WV4J2+2M:K+N,9$MQH6 JB+N#5H_UR6U;
M\$_C@D&%)\JC+^C/9S'1\B21_[D+2_0Q8)M_6I*J*D9JM2$KBK'^*N#J^AP2
MNCX+I$@6VNAS.3#S/M0TS4-1),3=/#0KZ-Y/X[@G'D_+2Y6V=WI:-T+NN-=Y
MNUP:X?SL&!_RC/LO\MZ7_G/!^027/AN3?%_7LZO9YZ]^Z?8GMOM+E[/J9RR)
M<3ORG]:NY:SK?6('<=GBC6477WFOT7S?M-D6VKC9>9+Q$PMN^1\/VEI]2T-\
MZEKL2<<ZWPY52E&.A)*1SG$>[S1#G]S#<&:8,!%[S/0='C,>F=P/7"\(.:=_
M'U41SUA$:9_W\G_O$+N(?XYS<LGYS2NDG+TLQG\<5F2S-]KGPR&F^/[" 7\[
M*G$U@O=^'[W*QGT2#V3  1\+W 3')B1?/6D M5L,(+@^O#WYX^V7DX-SZ_C@
MKR_GUQ^OSL_>IA?7E_3XX/S[L77THWOV"4']OU<#". YG\]OS\_BWO'U7_#Y
MC]<7G^&?UU=I]X\/]OGUX8\+!/[_X]":'$  :X;U_'G5M3[==C^_O>K^T>U=
M?'Z;GOQQ9%X<Q.GQ6;</ZV?G9Q=)-S6_ZP$$M]VS"(.N-$Y"QXY]8@>!39A#
M;<(# 3\E46*&L1LR#+JZS#.H&Q0QUH)$YHQA^17Y=@^>6*82;R72ED@DD_F)
MQ:B;1%'$!#5#+W =D8244X\ZMJTDD@G_UTJD]9)(/R8DDN-&H1M8()&$FQ 6
MAQ'Q.76)\%B2L% $H'5VWM@T,"SJK9%$6I+%OO;6WFDU/K@V#WJN$6_=[P1F
M"MF-E$C+LI'D>9_!<1]5I]T*H*4)H-LID\B*0K@F9A'A1Y0PBP4D8)9%&/=]
M1SC,%0+QDD$ !:;S4 %TAQ!8E4FTJ-O[;#EW6;9$R[DKYMQ)TR%TPL"G;DP2
M5W#" M,BW+,"8H>@Y0.0N2$-$>G<,\!\6"/.?2Z!HK,A8J!4G=6Y@8/,?\ET
M6-0_VT@!M"S3X6-UTETQTF'75@(M2P*=[$_9#K[O4Q[Y,;$3$VO81$A\+PR)
M:9N1%;#0#8-@YXWE6X;KF&ODO"P[)_)L67=9MD/+NJMFW4GCP8W"V/'\D%!N
MF@3N+B:AY3.P_<W(X3RT/=?9>0,,:OC>@\W^-NYP;R8\*KJCVE##JNR%\HA!
MY+2R9FFRYG3*3& @3N(D,DGDX:1F+[2(;XN8B)!1TT^H[WC@J%B>P0)[C?R4
M-L*P9E9"R[ K8MA)XR R(V%Q#TSZ,''!KG=\$IJN("!O$R=PJ$6QA\LRC<!;
M)X;=MM+2K8F$O!^*&YXBLNV-R'+=IBK;PDNT3U4=U09'5F7LZ"LX5#>PE\4G
M>/Q[\M1;?VO)(O58B5-E!\E6P"]_FRSP33=T2!@%(%,Y6$*^<"FQ$M\*HL2+
MW9#OO'$\P[';4,D6,O*RC*"6D1^;D6^;C)P(9MHF3XC%79\PEB3$ITY"(D&Y
MG?C"I($C&=FD=(T8>9F!$\O9]=;5UC@;C' LS,/-"KW_A5LLMD=4+<OF:(72
MBH32T91U83E^%)@N)UY@@U!R0T'"@#$2)MRR/1KZ :4[;ZCAV\SPV(,+R>[+
M&QL4@GF&_+XLTZ3E]]7Q^X01PIPX=@+')0%+(O F(H_P*$R A+@+)@FUJ,V0
MWQES##M85MW6ROE].YK_9C/DNT%VN9Q"TJWVDY9E?.!QM]5H*Q-)QU,F"+6<
MF,&5@>%A@0DB;$Y"WQ,DH8$9AE;@\=#<>0/&B &WMT:.41OA6#,SHN7<57/N
MA#'AA:%C>U%,/"M$YP%XF%/!B4O-*(E83'V+ ^?:IN$Y6QC26$MKX?T0@:/U
M,&EL,KY1,_1^M8)TJQ/,RTN2J$-_W^/9:"^+#XMS;Q/.2Q5!'Z:,!S>(:&1S
ML!82;,=%(,2 F1Y)(I<GIFTRFP('4I,9IOU@$=36B*P?"R\O/=*R\".Q\(05
M(2SFQ6#K$S.*@87A+DF0Q(+XPF;4\9/8Y^'.&]<S;)S#M#8<O,TAAP-1# OC
MWW4JI.U!6:D%49SX418-^N*,?U<QT5;X+%7X?)JR'P*X.]OW?>+:CD.8<"UP
M82*+>"P)'%,D<>B""T,I-5SWP25K;?!A_1AX6?9#R\"/Q, 3UH/O!5;,HIC8
M'&,0<>02WTT8B0/NQ)[E"B_R@8$=U_"VL:QB+<V'/P:#^%O:Z[4!AU69"\4)
MM[)E>;+E?,HXL(7CA);K$=="B M3N"1DL06V@B?,./'].&;@F=B&NU:>21M;
M6#/;H.76E7#KA"5@1[[G E^2V+9<PEC "?=\1JS(]'S'%8$PO37DUFV.(\@2
MXTZO+&!HFS56:Q;42KJ[@RQJ"ZJ6+76B*1LA%FX2!S0F)K<X2!W/(2$%)T28
MD>!NY,(5AN!_V-0PS;9Z80MY=UE&0LN[J^?=R8X,)S"=Q Z ;6-!F(WMJL+Q
M"(VIY;JVZ5!N[;SQ; -D\AJQ[O/JR)AM,ZRV&GL#X8KOO>^-%[S+[39I)>WR
M).WEE)7$[2BT B<"8K$88;X=$^YX$6%);-+8=4W+1\ OPZ6N8=G+ AW<E#:3
M5I@]>V&VW%::5I@M59A-IISB*!:VB(CP&8@PU\5V.2LB4<@\SXZ$#3XA"C-J
M>X9M+POHI.VA><  K7='>[\?O3LZ.SH\[>QU#SJG9R?[__N?DW<'AQ]/]=#M
MSN&'3T=GYTL:LF7#)<2#,<[.7.,I6XNN<IN3E<68K5[*P[27CE+1SMK:>."@
MO2B"78SRS@V_1730=L36E@ZT69H3J GFO:*7MA=YV7;4]32R44S=R*:.23A+
M+,(B/R1AX%@DBLW8-!TG=#P?["AF6,XZA=_:F5JM"%J)Z]:*H-6+H E7+C8=
M($GADL!A,8H@2KCP R*2B+G<C3R312"";,.UUREY]US K($EAF.!>^PC:AF7
MK(B-C:'(1)*V\[16:A#AT1_V;WJ#6R%^UP?>2J6E2Z5I4*:81<QR$TY,WS=!
M*GD2&R$A24PCSNTH]BA()9<:P<.'C;9UA^O'PTNT*%H>?BP>G@P24U.$#@^(
M!]*6L,2SB!_$G#B.*R+7IA9E[LX;AQK47R<>?D8!(F59P)]P+9W1,(7_K04!
MVRK%99L6XKOH%3)I7Y_[N^K 6[&T=+$T#;;$N>/XG'DD"4*',-<.26@F,>&F
MR1CCPA(.WWGC>8;#'EPDO7XQEY:''VI:M#S\!#P\85I8U(V0BXGG!XPP&GN$
MVS8E-/*\D)NN%7$T+2S#VD;4I;4W+3Z*D(_TK(I$P _Q6'1&@TXTSN$TQ+ -
M6JPL:+&OCQB>"D=7R*7;5BHM72I-(S&)Q*4A99RXG-F$A1XC@3 =$@G. ^[3
M(!(.@L$9GOG@.15MT&+]>'A908N6AQ^1AR<L"S,6E%MN0"R;!6JX9\!=E\0\
MBNT@MJS(XW)^E^MOT/RN[0M:#'H]'@Z&*A_2QBP>*V91/_96,*U.,$W#- DO
MH0ZC%G&$)0BS@HCXEBW UH@9-1TKL")P>7S7\)P6I6D+V7BI88N6C1^-C2?L
M"]=):.)%":%AD(!]X<4D#&-$6^.>)<)$) Y.G[ ,YKAKQ,;;/Q_TX:&6)Y$@
M)XU1H \UA+;:/5LJQ$0;\5VEW)P&F4!0W-!)/.)'84B8 WY9R%Q.K"B(N,D=
MRZ?!SAO'-FSWP7*SC:VL'_,N%6.B9=X5,^_DE Q@O] ) F*YE!.6F"[Q;<LA
MH2DX<YT@% GX+HP9;&GS]=8MJ++^*!/+LB&F>^R>RS# I<W?:L73"L73-#2#
M&21^8-F,1+:)$P$3EX3"#0@/!?50J? @P;R-9SC!L@:,KPTPPQ(#+\^0Y9<V
MN*ME^=6R_.00T,2F@>]8Q/8"L$@L+R3<A/\Q S\$YX+:461CFH<9[M(Z[]8/
MON#7>M2?A">K$: W@Z'DRD$"'*6'= S%5Y&-IWJ<6[=I:64E\%!\W>=T=%6D
MI\O <0O6MPJA]67*3DEX' B;VR1*;)S4 1Y4 ,8)$2QP+=_QF4U!:/F&MS3X
MJ#8$LD:\O+3RDI:7GX"7)X$WW02,##\DMAO:A)D!);X9>,#0%@W@CH,D0I_#
M\)QE32!?HXC(6D9!9EH8.!&/CV#IG9[@N6@K31XEP5(<^CL\\U8TK5(T_=B;
M,C,<-V!4Q!'!ZR0L"7T2Q*Y->.C:3NQP[ONA[-NSO'5"!&@K3=;,SFC9^''9
M>,+""$,[L;"2E25^3%CL!22T0HM8)G7MF-I)9(&WP +#]#>HTF2C@?8FAX&T
MY1I/4*[1RI]5R)]I;+,H=!DUW9@DLF UCFR0/U9$+&:!?4$9Y<S!:(5IK5,A
M?1NM6#<KX@[V;3GT?APZ82%0+TY<V^2$"Y809H<FX0ZSB"D2ZCAP>1:+=]YX
MUH-;:-<O K$A-1EM+<936P\UR=.:"\L31M.(7Y1%MDN%(!QNB;!(8(U8$!,1
M@90"-X92X8&[8CJ&:RT+EZ,MPM@*7E]!$4;+ZTOE]0G#PQ&AS5E"29PD.#Z"
M6PC!PX@O6& #GP>>Q!QU?,.R-J;@:IL#%_N#?C\=]07BR2.H![(?K%ED$?!*
MYT5W,!(=2E\^9&C 0O=3",;5V '?\_15EO;^O3,:CL5TUK0\@KTLWJ\?0"L/
M[B4/IB&Y1,(1L<<G7HB07!$/"4]"T/V)"-W0<1TSMI#-)@3!DPV66!&MWD>/
MM;3Z6+0Z63GH1RQTP5\.PL CS/(M$EBQ3ZC/$\\43B"P$6D.K3Y2_OQ)#+;3
MT2#Z<C7H 6?DQ4 A\7_C='3[:\-DECCO9V7/>&R='Z=?BV?K1Q#\_"M*98?J
M(]_X^V%1?YGCW1N=?]PE[-Z+X>D5'XJE..I'W;>30J]<C23$]WQX,CP=\9&(
M_^*]L:C>KN6?V<J_!>3?I]'Q?D/^?8W_^(O%__FS=V'UOH;7-_WS'[_W+_I'
MWX[[Q[<7!X?F<?_\]N3@RX\3.*?CS^?.\<'A]_,?\)ZW_NWQA[]-/W2\@,=8
MN0BJWK0]PIG+" X[,:D($\NC=RO-.73T:TY@2T<;2D<BL+DK0/F&?DBQ?HX3
M3N.$.';(G)C'OAN#P#1W37,Z>CWUB\X-'W:^XO4:G;FDE^.UYX]#=9+$\KWQ
MZ&HP!($<M^&(-27%']T/?UN!17T@.,(]VR8L8!$)$SLB/C<MF_NF%3#O#I$V
MDZY6I!5;NMH@N@JBP I]'I$XL7S"?"\A8%5S(K@="9?%%"AAYPTU#7,&G.2T
MC%-TUN'EY<M(SAJ)NZ,\'T^0)%BF$9+E-W"X<Y&U2O?I*-(ZWOL[<F./4^X2
M2R2@=!W/)X%+7<)X;(K(3R@-X[62="U)K3M))4YBQ7X,>E.F I@G"(BWA"2!
M'T=NR$S&PYTWV6!Q 9?*.R]##N RMV4YR\^+-[E-ND9-8R))OXN8_!##06M'
MW)?%)L/CH%HCQ[&(Y_*$,,^GQ'>$(';LV0(,3\^UP&>6,3?K]1K5ZK2U=&N6
MX&Z9=H5,.]G@YWD!"WV$%+#1>K<3PLU(('QKZ":N*R+,::T?TSYVB]_<D+9?
M/"3-8I&-7I'@T0/<ZA8PFS;('A+C7IK;I);2!B:7Q[CG/S%H!S^Z!X>X[E[W
MX/S;Q=FY>6Y]O#[_W/W2M8[M\Q]7L(^W8/!^LB_>^M]/]OYVF<.L.&0DB1T&
MRIK:) QP/@UU$M=QDC"(_%\*<"_-46J):.V)* H3+_;-A-@B"@ES$X^$D1\1
MZL=<Q([O,AQ_>N_H]NNG"O?42*X-06X('?XXOOS;I""MN!,0T_0#PD)ADL#!
M1A[;HY8;>9P%X9,%?%JBVDRB$KZP$^Y:)(YLT)!8/,.Q"X4YIDLYHY[G1ECI
M_<N![=<Z!B0#W(/Q*!_!#VB;WE/\+0\\:8)03ZHUM92ZII1J@QJVO#@2KFT3
MAXN$L,"WB!^' 8'_HA(T/=]-'D?\+4!4,V+=+3VM%ST% O[C<)!\?@*2SS==
MP@-J$>%2D?C<IY[C[KRQJ6_X;!I:8UKR/58"KZ6^3:<^UOWP-S,#,^&62R@.
M-&,>N*=A)"(B;&;:090$$;UWG<+*Z*E5D9M!5#R((C<*;6*ZODE8Y#@D#**8
M"(N%ENUZS+9B%&G4<*UI;/<9(FW4.1"1Z(=BJ*)O-C4Z2$-2V,$/IM$!\K@1
M\/FOHG?[@#S?5H/XK,#,T/F"EM_NQV^3Z%J>RP(&WK0;^1X!]@ I3%$*)]QD
MW(MB;EG(, ^&\&RAM=:/*U>@+ENN_"6NG)Q08CL.BS@GP(3 E;$#/R5N1*CG
MB]"*F$_1T[/I.@'>/9=I\GNP7#QJWNO<\#0F:=:)^$TZXKT6-&M5:K\Z\_=P
MY$?9OCKPUA1?GA":GG$66 FUP!$C4>CXA+EF0@+F!(11ZKFF9R:VAVWQ!K,\
MPW'7"96GK?19,P.AY=_'X-\)(R)@-J<^<T@0QB[P+V;]N>#$X:;I6I'PP25&
M_K4M:OC!%N)ZK[\I$47C_KB']0Z=@9J<.NC?#,65R/+TJ^BD&?S[KXT1V3R_
MY<6CV!4Y[ ]^FA)0U4U(A+_]^CT<R6MX-\CSKAB=)&?\>RN;[B6;IF><\=#W
MN>]ZA%+LEXSLD(1>Z).0652XV&$DS)TWWHQA1U.H+FW$X:DY]RD,BOOR:VMH
M+)&9)PP-DX$@]FV;1(%MX2 @0?S(B8GOF,RC0>+(H#LSF+>%R-X;963$(DFC
M=/1, A5/:E%\%",.*XH/^3"#\\IKUW"@;J$52LL32M/3R3S?3 +?#4GB^S9A
MCK ).#PN$:!S7!XZIAM0\'ZH:SCF="9P<2NC#5NL(3?_NIG1<O-Z</.$B<&3
M.'%=L"F$QX&;&>+T^!8GGN]3X5B<"XOCR';/<+SI(LTGX>9E!C%L<R'[XDGX
M4D&#YW/AUEJD\"=)F=3Q[P[E1;02:ED2JGLP/:8L,MTP"OV$4.&YX 2Y+@E"
M%A&\1E [ILM,'.%L@-HQ7/K@:&L+&;Y-3+^LL$C+]"MF^LFNZL1E;BP"X@M/
M@).14*QA34CD43/Q&3>I#4Q/#=\+#$H?/%AHP[##-\1TJ4TUD56=BYLR"P(S
MJ[V]LN%$XL$X[(GRLAXFZM;F'/_QA >S\;)_!:-A]K*XU02KU 33X^7\Q*42
M,\KQ;$J8;3(2",$(C7W!N><&S''0_'.I:UCV@ZMIE\Y'3QRS:B5I*TG7QHIN
M)>FC2M()FSKR?<^W0I-XB6SR!Y<ZL"-*;$:I&<34]*DL.Z2V9]CVLH9U/KTD
ME4;W;R,.+RWZAVI@1'T^O$PS^?J@*;LB 2PP?#RNM*3E?"4Z/,)J)9[=PLX[
MV6"$YO,0?IUU4EC1Y5 62 ]'G4'2&5V)7'3V!YD\-IF*?)MF/(M2^) $?)'3
M07:;[5.U[>N7.PQ6=S/(93'AJZ'H<6R[>OTMC4=7A;RH?4O?IEE]A8>P@O%H
M_E?6[)QQ%G:CHZSVO[AJ*6%"&D>>%_#$Y38+:!1PD3B!Q=S$]!-ALK]=;*14
M7[H:5O!6EX*$0\&_$)[ SE[QWC=^F^_\UCP/.(SZX2]V;O-/*4GN<TK^ H>D
M[@BD[P#'N\,= W.+(7X*5L&?>@F=JR'JIO_Y^27!'9TA\R._X(P<9(A__<;?
MS"* VL$_'H5Z,RGT\+^'[X[^>W1J=(ZZ^_,9^*F7N7_2/3UY=W2P=W9XT#D]
M@W\<'W;/3CLG;W'=)\>':[OR%VD&\G,PAF?$N=$1WR,!&N9&#!722 ?$*7\Y
M=_4+R#.I<BJ1*=4<;*K';W+QJOCA=9SF-SU^^RK-Y!+EEU[KIVLYBV&>"14G
MWZ?^7(F.75.)#QUATF_6?]Z5?YI0V^IOKKGKFVSNG\U=^L^[W9)B#V NB+7Y
MY,+;I_?:_CW^%@3S7WK7-[=KL?Y"C_U):/17)V-)MEV*5 E^)E1J4)(_Z59?
M!3M09Y&S4K)IM?[G3P]*2M]SP8>=0U#G<0D$T+&IT7 O6II8&V$Z*Q9U#\=M
M/6D0HQ:+S*R[SQC(;3\PLSVP>QT8 CPL+M*6#KO\F!'%C^*KR,8B7V0.Y,8(
MN0?EBI]ZF.66+O*Y=!AT!?BCPT$\CD:=H6:N3>6M!Q=,;VXJ:;N207Y@<C/P
M0D[MD,46YXR%G#F12[TXH=3Z^T G@RRR6'Y=JXVWPT$?PW.XA,_IZ&I_G,,Y
MB.'A]Z@WQO/;RW,!_Q]O3MO9;9DH^MX]^_W+\1^??AS_N&3G\+GCZXA=?/YD
M=N&_Y_U#Z_B/\Q_G9Q?75:+HT#Z^[GWI]O^\OKB.[.[9!]8]>)O".ZWCL\/;
MB[-/[.+Z^,?QV<?KJ431671[\OF#==[O]F&MM'MP:1Y__A/V=_[]^.S/7O?L
MJ@_?_-[]HYL<WYI4)HE.S=ON6?3C!$>W!D(@*#D/&".,1C'A@ODD,5D2.R&U
M'1%B[97I>8;E/+CS;/WZ/%I1M2VBBC*/6;8;)R'6D% >.3:-&$V<B+H!\Z2H
M,D%4,;)8 KL554\KJNP)4<4<+_!B9A/A6#%A#HM($(>",#.TA8A]X5%WYXW'
MJ.$XT]TKK:!J!=5Z""J1N&'",8D)XBD(8=>6Z3&1^ %'5+H0!17UJ64%1$LL
MNQ54ZRRHG E!%7%3!)[/B6L&./[2C4AH)Y0$B1<&H9L$282"R@F,8*T$U7,!
M#'J71B++Q<9[V2T0B@W67>@DMAEZ-@LI^"NFP\(D=,R "S#R6O=TDT1I=W_*
M/>6>RST>!\2U!-A\-K,(MX5+1$QM%Y'OG<3?>6,Q%*7K!(O20ATMB<,M.PD"
MRGV'TH1%;AAZ?F!;21*&OB],A[=>W89Q^*17)TPSL&,3C*78!P[W Y/X<1 2
MW[5C/_2BV KBG3?4]0SKX>B*+8>O'X>[000T@($;P9@7B("[D1O ]9M4>)Y-
M6W=HPSA\TAV*33<Q;2J(%P0^P2M&Y@8.]YV(A[[MVC1 #G>,@+(UXO#GDGC<
MQ^+44!===^ A7\$_RI^'=[1Y $[WD*R)0WTGMN"_H0VV4QP(%@743RBS3-ME
M4>L=;91D/9WRCFR9\^""A,Q%V\D.2&BY@@0T8LR*O% P3-Z9GC$+ W;C(^(M
MA_LF!?^8F@C%QSS;#VB8F$'B68[%$ML7K7>T81P^Z1T%L2E,%G&2! R'Z?H.
M"9PP(;YI"SOF09)@&Z?G&VZPK![.EL'7B,%M1\11[##+"4,F6.([@8<(?E$"
MSI%PVES1IC'XI'-D^=QQN1D0V\8957+0A.TZ!#@]B1-PB"T35#BCX!NMTVR8
M9::*+&?76U??2&$;/0M7Z&<%NELJ81W7"81%A1G2D$4A]^W8=MS(LUEB!92[
MK9.T41(VG7:2+,IB%L8D#AV+,(8I),<!$XH&(?PF-.. 8X4CLYD1S("]73*Z
MW*8&GY^;7 @2ER6Q;R6<>LRR' YF6. *Z@1F["1.TKI6&R87)EVKV$I<P9A-
M'.&!Y65Y/KA6%,B>.9;P162[7K+S)O ]P[$?'#QII<)V2(7$CBPWX(%G8:6>
MZP>6'U&&_V)3'C/6^F,;)A6F:O?,V.6^%1';"VW".-@-/$0L6AIR1R (FNF
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M>S$\15&^W-(%:]*R.N3##$XI+UXGJ;TTHLS6B%K B/HR%?J*348M/_!P3FA
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M@T.Y@%OTPHB O>L1%ML)"5B(4P.L,'8#ZENQ;!NS#'NMQI8] 83MUG+X8WE
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MOX+ NL8S*@@\ A!8#(U8#]QNO<]3)D )4$8C)PU'T>=J)IF(LV ?L*Y2>(U
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M!V'K* ^T_/*(&C4^!C&Z]W+)]6& 6M01B7#(!H++TPMX+HKR0@L<E+ \@H'
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MAC8'0Z!7G@YX..SG_?MY.+H<[2JFK0[3ECOL\Q!!M65PJ+E4B&N3$$B[A&R
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MPBQ$/95BD\4G%"5BYKDK #O3=7) .D-U*9:=V \Q1\YG+;2F53.QW>WI[LP
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M!K(B%!&=F3^+[5DVZEQYST45F0Y2C&%+'.G6B&<6=3X7^>\K3X;/)VZ]Q\*
M+1IJK6%50<J=7L'J^+3/TZ?1I01NE./7Z1[-T3!_8&9<'/^7E_OOWT%MH"2:
M XFD !12#Y0T#"#AF),A$.[(SBY!3^32X7 *K US$NAM5EP%3H.3.&@D*,9,
M6\<4]X@IZ%A@(:\XC"M.0;7TW8JOBX>=O3S:NSSX\AN+!CPZ?/_.!HRX-!B$
MQ,9.I69 <>N ) 9SPX*TD.WL8O8$7;GXV3J\S?H'8C%76@F,+35<*BPMHND7
M@K2C-*T_D@AC!2I!(-WZ?X?U_W)P\8XR;QPQ%$#&4%1^9H!DG@*NG$.2!"A"
MV-E%XHFZ>OUK]^0RTWWZ''[?]]'N-8F+,]'T$-1/U,3EWS +3%QBU:^;S>86
MOD]ZW]F#;XE)RH7JO/C/+_?WWF'CG.): ":D!)0*"K12&FBL'&94:&/)HA?_
MU\PQJ%-XDDU>%EO/IKF=!YGJ#$95!'$64M;M'-Z5!L5<\N\M.0*?+-M\FYA2
M^'H:Q0_\DMW+9Z.3-/;L6&YL+.QU2D+/XVT/]V5V'?=.W6^G*0\D+L3OPS@K
M#_6(^.(P&E?(Q%W-2P200E&[G-5 &@J!Q-@03TC<]>1BH@)D%#$M8;3"%(5(
M&!EQV0>JXUK N$7>=4RM71PPR:);(B-M]BQ_<C8<7>8#V1D$O!_KRGFOBG2J
M"^,N,(UB.O6N($B^:?DQF1&3WJ-7K_^</.ZW<XQO?.GOY=*Y)RY]MP[ Y".@
MJJ]:G?J?PA[1"H&]Y]4[];*^UIW<?"])>>_1\]>___YX16U$U3/U];.>0)O&
M9#G37?!Z-ADK(6@!1^\^:?%:+=FM)KON^)W#1U52_TJQ?;38<;<JM;/U?(S&
MEX_+R5,3\+HI">U<\' P[@4=_Y7CD9.E@IOX3_"#="HUVU3; ]:9.+.J;ZMH
M3TK=>SM:U[["ME9TK@U,IG],6EDBM;-1-:'O]*QR\RN_EY0S:\[O^8?QW+GS
MI"K!:=VS%=_.U4RM0JF3D]R;)H[\*\]<?$8I-]2]@[3+]9[I\3!QCI:2FJIN
M/!=BC)P?EE/U*A2:QYO/]ZN.UY_237-^Z&DY[:PJW7N_#'6<S-?V>)0RG _B
M]>ETX.R*^Y<4X_P:LWCJ+XE2==4EDX8.K\25S\K1<T6&FYDG9VQU-8E=7=/4
M'+#WFWS3%$4=#DX&)3>Z7XETQ:#_:91FI:[]3Y->AEG(#&H^GAGA?KL&L^)K
M;><"9Y[8P4G%6#G?1J#UJ(M"D9I/)DM*Q%S%_XK1%;*8-B5''DI9ZM9#$KUU
M4_Q52EGFA+W6B";^G.<ZY0[4.T)#HG]:]03PPQ3B]JZ*7.="V*)Q%7MI)2RC
M>=JE1F9*;M)5@? PXTJME'-.3HJ\53/];-6;M-+>L_S.!^#S3,_1Q5[9.'RQ
M:.?]2 ]G*1(U)4>KOK>JD\^O5O5&2$2[F52ARUS^6YG+O,M<?H"9RUN4B?Q[
MXA*8U%&>RI8YTI]_; IR>6Y\[(,/V5P<?K#O)-%Q^CP"7C$"J @&**H9,-A$
M*6!<0$RW)^_X9:FL:HG9H(C9-(E9VK?2CIYS,5LUXSDQHIV7<-D0;;UNI2C.
M$M_F:M<&\\D$HZ\.(=XQ_=R02,_?L[&E<X;>V=A/JY39;-@,BD$9[],;ZHO,
M E5E^#;T,S/+Q?F:)S%^_8K4BZ5&BU7^6KHDF669"<H6FSJGS%4>SRRS=3%S
M(+6X/"UUQRW'99SO&-_F?)S&65,;Q-4HT]R_T6@S4\F,"*!./BPI :%*XEC9
M7SS=M/G>57<OYNI@W(HCMUYGQH95=]!Z%%\OE2*.+UN/G3Q.:1O^M#3[SF]=
MU8'U?&G!-!_@'IRV4DM;MVF*O>I65:7@/U%6]0K_UJ#42E:M.5-.8YQQ,QQ,
MCJMD\U53.DME+49<3CNL&.;BRIZ6K(GLU"8I;0C[Q[DLLY[DY1NW S.94V&6
MV5&(#_+L)JDJC6_Z,QZ"[ *7DK<LP<6"KKC4QQZTV3!]S26S<@[T^^B'51Q@
MJUZ^4:[D[XQ2NF25<CP;>[JTY1"DVOJ<1)M68CPH<G69[IF^_.%\/)C$D1;F
MFO2&-05OF_QG-A51KLZ'E>0M=#2]R9S-TOJ+F.8ZU:JM0QNE&BK1P60.HT[T
MQY+K-)A4UG==,-#O+08K,M]$PS%1%^'.VC>D>?H[2S!C&VC1A:9^!EE#*W+6
MVFMH)X6U[OLU>%_L9):SD.KWV"12K.O"HC,<;\U,E> [JX%-G]7^2O*E4O>!
M<*UJUXA87]E,^.1\4NI=2]*__ZQSSECZ2E47D)>R:F210',N]C,C?4Z&V[0!
MY?HYB6ZOEP]TLN>9O:M:GI8:(TS\E>^9BW\OZU6VF=.RM)69<:L-3LY2 <JH
MIILHFI>>=%91MM2[GYY6=[HFLWFE\:U0-)T4E9Q&"]P@IBCR7IMDB#,,4P/R
MC3&^7_GDE?;V9LT6HCE^.CJO<@HGO<,H'V\B#NVYT5G<=+9$5XYRKY2J@#KB
MZ,5<KY/Y-QQ,)N<I1C+(M"(12L)@V&I$N7=ZFI+T7^6=/HG.KZ/Q20]!\+]S
MF_;"H72O.H^&=7!C3B#;%2Z5 3!:$>7]M;$S9O'>%?)XB_X1-UNEW?\QXY]6
M'&1FX;[6=Y5L9]-./P]?'CWOX>]^^E^U3_LUPG%=[/;78'I<MZ;;%)_R\'7M
M4_[&#O:C3_CAEY,W1Z\^OOWP:GAP])_H7SZ/SWL[?'FTQ]Y\^>-+]#>_+/J4
M;SY\C#[G<WSPXNWQX8M7)X<O_OQ\&/W+@Z./G^-SXGV''P[W#Z._>1A]RN?L
M<.\=E]AK)@D0S 1 .?9 >>4!\A8RKPCB1BT55&.=@C326^JH@=) A(12D"!B
M',5XT05]]?P_SP__?/[ZZX?RJR,FUSYJ?FB6*NL9)8%Q1+GQ!@>)$&(B,,."
MY=_]A'Q_,-'OWT=7KYR,ATKZ<MSHX8K:;Q<'>^\HDT%SRD%@#$914QP8[310
M6BH&G5=1YA;74U(5:$0V*E&@PA.-E(=Q.8@GRA.S)&J;N_G571R;IE]NJ:U4
M[U$VBJ.[$PW]R>.GM]K6%Z+9TQRH; +FX^C%@UQI=C;Q3^L??G:#R=E07SX=
MG.8!YXM^KNY>1=E9?$#.SHG&8O60_+SR\2S:_ 26B/-T'/]Q]9.KCY_DCWZ:
MNN7/.'PB(;WR8_@$M3^+(T]S\O_MD)WZ>_4[1*7V&_/-&[\^NM7KW^*S"))_
MZ\K[-5AYH]O^E(5V?-4:GZ4:V-/W3_'9YQY:I6]+V+*H,459UH4XZD;FU7S&
MR0]1"\1N,6<;,$5ODHOP?,E%F)NS3C8V#EQ7?+/:X=*.&%>AE[VU7IJ^G[="
M$),U>8/5N/XM87K'^SY5L)NJ&TX54K?!,J/MQ_?CT?FI ]7(K/4^A*^][="'
M)40[&3@W_('YJ;#=(Z,F,'UZG]#MJH6Y4D!O*^C7K?RWW..>#O+6RA3R_Q:5
MJ9?_JS94JUZ,1Y/)$CGPMJK6;98&]FZ(=NM%]ANNRW\O+L&M7JW]2IGV82/>
MZ1:5A-!ZP13GBCA/+8'*4TBY]Y1ZC)&#U]4.DUL&B9]_KDZ=]_)AK'='^O/-
M2@W)=L;ZCM^<?!Z^_/ &OSSZ [W!S[\<'!T.#SZ\BF/Z]3@^[^/AEX\7;S_\
M@5[NOT$OCPXNZVOBL\[?XC_YX8<W['#_/Q_B^#X?X#\O#U^\00=_I6?]05X>
M_7)RN/\G/4SC_?*O<' )T;^/GD\/7L/+P_C\EW^\<XXHR"P%!DD,*!8&2.HM
M\$(I"7E<?Y[*$_N4X;Y"R^S5JQV<OP/-MU"66^T["X]<W+LZJ+HG4$4IQ5Y+
M;H*A5%FM/$>26H84PQIY=5W1>P=5&P959 &J D0Z$$0 XRS1*%@(I#40"(TL
M<US#H&W*^,9]II:+Z3N@ZH!J,X!*.\@M)]P%Y2B46'-D':2":PZ%-?@Z=H8.
MJ#8,J-@"4$D1%"/2 2XP M3&A9108^#BMH,QU1''4"+5%WV.-PFHUA2UVFQ'
M>[^BM*L*P>HLS:UUM9MOXMLMU,HM8G/P]-%MG%1*D(6466$$510I$^V"J&F>
M"H.#DS=P4E-*6ORI0]8-0M;#9RN\56%8X!@8ZQ6@*DB@?(! Q967D&$<?#0!
MB6#]:"(N(>OC&X/J5X#M>UE_-PVQ/EPU-]11*P7'AG**F)%&*VAEL-)+XR"Z
M@8/7J?E&JOFBIZ>9#"HDBXG# *A4"FC."4!4!P.=(HA% PICU(=TV8#JU'RK
MU1Q';1:".&(=CDZ149H')0/T%JE *+F!>]2I^4:J^:*?%!B6%".3>#$IH$%J
MH*+G!+CQSC*!L'1R9Q>IZ">)#5'S=9Y%$K&A+M)A9O2^'R>1-P+4:I%N=#2]
M!6A["["5"FH8K6>-2#2OL-:4&AT]*8Z$"]%3ZL[WM@IC7R]Y3% J[V6THK2B
M$6.1=4![*D& -#AF$&'>I/,]*$0?,[ZF:-2-->F.8^H=.GP='1 5%*=(M4$T
M!*0M(\A2%)A%7%'1':EM&3HL.EJ4"24<)< S[ !EU +EC <4&N*]DUX@OK,K
M*.HS!CMLZ+!AA@T^<!-TJH2-B*!,G!H,!?5!*FT2ZWAWBK5EV+#HG5D-O1+1
M)^-064 IM\"0@**+)HPRT2?/59Z"J;[:'FRXSXG9S^;ZVW7IV=N?^;P5@WP0
MZ=G_KCHD/Z1PR/VT6PC*# 4$&D$2.XU!D%$3#(-*^^C$=!&/K;);EC.:M>!:
M:*< QS[Z-(1BH(GGP#M$N()!LR!W=C%-=LNZXAU;ZK;<3PW')"B%M&0(!6JY
M,4(J@D,P1DH/F>ZB%ENFX8M1"P^A(@Y&S\1)EXZ'(9!.&2 Y<=((Z[!R.[N(
MBSY6K-/P^Z?A7-DH RDPZ2D5RBO-+5=Q^2'R0A#4Q1ZV3,,78P\.\@ )\B!5
M(8&TQ$FYHX9+9K61A!.DDH:SOD)T@S3\!X47FH>VJ(JJ6X#T_:=(_DC:I171
MAZH!PV3982J\?9OE##W4)-O;M)1D2#*'XS^&1*/**4^M0C(@BB'AU'9NTS9!
M[LOEU%J2#_NT!X;R9%01!0SF'BAD*<56&$_303$4?<&6^]3>$G*[Q+O-TW )
M472<$>3:,"J(5,@$J(+ #-- I._<IBW3\$6W23GH(;4:!$4UH$PRH!(7J83$
M$Z=5",CN[ K9Y^J;Z[P[!=\\!2?,.^L8Q<P8ZFF03 G.F;,A>DV>=2>VVZ;@
MBUX3EIIQ#14@A(JXA=.HX(0S$#4]N! ]90SC%DY1=)J^N>SPQ^74;K9#\-"^
M^:,3H.\$5(]&4SU,K[?B//TAG/P]P'0FQA#B0D">:DB],0H1)Z4(#&LLJ>S\
MVZW:' ^.]J:'K^'GO$%^^),<?/GX#AJ.-,("*&HAH!B%^)-2@$&IO:?2.X]W
M=@F+#N[:8HI=KN.]  <$-><B6LO1^:4<62.08QRFD@FJ@^KRH+</'"[GP<$3
MYI#Q&E@%632=L0>280(\9E@%8I$)(B4-L+Z2WQS]ZL#A/H&#3BG0(GCM#8G[
MB5242&<"=)SS=$S9N=7;!@XO%RP'06%TH#D%P@H2+8>($!KIE%9D.4&6$>Q8
M(H$6?8G7E6^P+9G0^=F,;6C:9G'DMMUUNV'.;M5'AL1%<:/SU)6FGMAO0^6-
M<<MOSANW_HG9^FWJ;[7<ZK:IC=VFGB\YN 2CU+O- 6<8!HD.%6C& I!(F?B7
M1)RB,Y4OH7TEOKED9^TZ=L<'1!W*=BC[S2BK J?!21PT$A1CIJUCBGO$%'0L
ML-!%"K8.91<B!0X'[BDE@'DA$F&Z!(JAJ!.482^])5R$G5TE19^1=>7)=!C;
M86R'L4TJ(K&8*ZT$3G7F7"HL+:+I%X*TH[0+N&P;QBX&7'R(R\N- $Y2"ZBT
M'*1D%>")X"%@@HG-3.^B+\0W!UPV!F-S1.:GW!IVM]7?O-W'>6.;[JZB#,L$
MR\.%PMF>'J=?;)I,UQN<YL[T8Y<HF'L74>EZ>Z^?]8Y&9P/;XY#W>_4RKOEE
M\IV>#J;QZ_8&KU<A1"]$B.C5&#$I ZYA8O*=AOK5@?4>-7/U^$EOL4HYSF^"
M+I^['Z=)?Q]1-:%KU1#Y;#2N?XUC\O$]3N,?]>6)S_S8P^'(ZM0_>3K*7X]O
M?3H)?IR^/XB /!QZ.SW7P[3R9U&R+^O5GB1T[%T<#^QQ;S#M'6O7,_'I)SY]
MT^2&R;D!L^_9\_$X/JP7+Q^,XH..]33_?3:<B]'Y,%T>!>5X$-_+%=[NS/$X
M"%&93HO$C2=Q('%@S;N7"T]'T][(QL?T>SK^+8XY_7<\NM3#.-XY41V=CWN3
MXR2?\39QH&$0)R$"17KA^-%\.HA^/_8^S5,1@A?^-'4CM,=/>M<40L0Q7*L!
M?_;2#@:0W!3Y;[W3)]_;&T=!>.^+E%0"**%\_+3W;*CC$R]3B^VTBK^E!HW5
MAF[\],+[TU[S]3SGC?3>B?*D$9C+^!\]'+V_3&+>C.?Z=?R*;CD?M60<5[?Y
M<M*'!8T[/XMH$N4G#>(Z[4OR-_83K\=1H](%+MYX.#K+ M@,+2I1MDJ2)(U,
MW&'RT"?]N6_;T20IS.#$G(\GU1K&^Y[&!UTKZ_%6-<A/SL_.AC,%ZO=.XPY0
M]*;]>7I:_# -.<]3UKM!UH+XJG$#35,;;:5)Z]K<N7VJ!Z=)C&P<QA>=.M4/
M3%JKY=&=Z?'T-*K_D]Y?>2'\((%$U/N,#ODK"5;ZO;C+1[Q* OPO?7JNQY<]
MU.\E+[S?>U7AP>]1_4]T[VQH>X_F__8XJNG_/1^D1<V;P(NA_CQZ?1+U]7^3
M8/4>O7C]OX_3HO7R3A_?>3J81IQ+;YZP,J[>-"G[; ;2N/+Q1)JY9@[TZ64S
MAU=-0Q*F:!6 /Y^\?M*+=L!''^=LH< J&@[I\D%\T6P4M4V'2@D8C5IR-IID
ML7TZ]L.LW;-&\_^8+S"K+",XNT2;: 2=3Z^^9)6-HEN]6W^PD:+$PB2U_GT\
MGA72O?? C+W^"'2(@WRJAQ?Z<K+ST_RKQ?=JS^/-IN#J%P[A-B\L;_"^9;I=
MVFBR"#S-ZIV^%4>A[WH(O>-Q<N;^:V"0LR+1B'%-J$)6:1^8PI0'*(.'])W8
MV3W*)D/4CF1Z)1SZGY_T[JJU7)#ZXGU9JJQGE 3&$>7&&QPD0HB)3 1B>7$O
MXS7>[26'#L)49DJ",%K'2[$D2E&+O8+!69>JH/[. G\7B:ZWE7 >@2?*ZDEM
MV=4&3H*?^DLMN(B_1Q_H_7'OM3^;EG;L$0BCN9TEOK+<IH.3ZJ(6; ^&Y3QU
M/.TE5RIM3A'YGBS S\IUD%0%&M>:2A2H\$0CY2&A@7BB/#'X>NS8,/_&S* Z
M&W4Z[?.IH4RTBK)].SJ/SW23QT_G9^=V")D=PAD(9R<T[X!G$_^T_N'G^NAX
M<)H'GR_ZN;I[A=SID'[! <W/*Q_/$.P)+"A6)0=43ZX^?I(_6G"JRV<</I&0
M7ODQ?(+^\9T/RK_CX?OUKX]N]?JW^$RIJQ_ZM2OOUV#EC6Y[35;++1C2UB=B
MB"T]?Z.[V;^)[D#O^6GR3O>C.9UW!X+ZMVEP?R?S_)VY!V\1_MO,=4VNS@U2
MH-9&4W@?)@QV$W:K"4/J-C#Q/?E0[LHN+V0H>[^\/'A^].;_WV[:DQN>F3S4
MT]B'<-B*G98(<\*LUU0KHQ#BGD8_VG/KXI^ZM,'U'+;^>?%V_R-]>?2>O#WY
M@QWN_P$/7KP=O'T1G_OEU<G!E_<L?H9?OCA@2X>M1[]\C)^QE_ON)-X#QFLO
MWI[\*S[W[8?#%V^^O-S_&#][0]]\&8:#P1+O2U D,$$Y<(YY0(WD0'*) 0K<
MT;CZ7 N<&X0P&O]9<];@?4E8Z1#P_B(@$A1R#[F "%-GN=81YZ0DA@6J NYX
M<;8- 1=Y<2+N>:F( ,)'\*,&(Z"UMT!P%0@30@NH=G8%DGTNEYO*=OC7X=^]
MQC\=T2_5N6E#&27,*:TI%YX*AI1RF'7I=EN&?XNT01)B#2UGP"EF &50 <,,
M!IY)[!$/T1 D$?\(Z5.\+MZ@S2MO7,U3LWV1AQ1W>/7;']L=>+A-R?G]K"I'
MT?3@4#MJC:>!!:T\(0@)JY&UM)"U=7[WUJ#N<IL*A)4QT%&@36I^# T!)BYT
M F'+*;;88+JSBTD?PZY+Q3U4<*Z)TBX.0U%!*45264<EQSXXS61%.-6YE=NC
MX(MNI7'$1@-* XFT I3KU'E71[CVTA%GB3?!107'?<F_F6ZU4_#-4W O)?<0
M>>(QI1A3&7TD;9PS2A/"A.W\IBU3\$6_R4 I"78.!"YTJK>W0&(% 7,$!V2L
MI)!'!>=]AM4&*?C&G,G6=ZQ:5J GF/UP=VE57M]VNTY=B6U78OOMO0 4U% )
MHU'B.,1:4VHTC8X)$BY$9[/S/K=I[SI<[O;!.-$P4 J00@)01 ,P5B!@,%,.
M!P*Y@OG45X@^_O8VB1M38]OQ&'0@NS$@FQKNI"9VP43]"TA;1I"E*#"+N*(=
MJ^RV@>S2P;*V<6,,%C@D**!<4J"L]L!!Y:)+""$69F=74-1GZTZLZ2"V@]@.
M8@<^<!-TJBZ,P*I,G#,,!?5!*FT2>4P7@]DRB%V,P?"X>$X( :*'H@$U7 .E
M! %2<B<,DP%)&B&6I6;?]P=BKV"*F2_XGJ..60,7Z+PBO+;'WIT/_>1EB(J0
M2A!*B>_+\&HP^?C+9?KWKW&:1^.C^-A?AB/[<3LE?.C_^>KR[5_NS&#*WWSX
M>'%P\AQ'Z3X^?/'JY/#%GY\/__K7\<'1Q\_Q.?&^PP^'^X?'AU\.P^'^;Q<'
M?[P+0FN.O 38!@BH$!(8X2T@T3) 5!L>/>V=GH\P<!:G=SH^]YM<!WN4."S\
M.*VW?I]+LJ=S%,NI)M968-B[.![UXE 'GP;N7 ^'EYGIY/PT<5I$2"S*A^ _
MR@^C<>]D5+A7$L?#PFT7ZFN[@MH'5?NY58-=:Z'JWPBV_ZB*KRS3"SOHZHCY
M RZ O1?K=[]*%+LBV*X(]CX6P=Y)@XW?HJET6M-FO=Y[?:6DW*#K[KWO'11]
M_[B5++7=Q@'R$!0CA"IGC>,>1?=5:L^L#.&:HS:\Z)C->6/)"_N],==1$VT
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MP 0! 64* :,\!XR;( F7'G/5X<,#.E9Z>38]/^F]/HOZF!MXE](J>]D=+:V
M.JNI15%SB!&:*N$U#- &XCU!&%&TFL>B@[H?ZRHUC>;B4D47%@&FL 94<@^T
MI XH10(1B2(+N9U=^< C0UWD>(T)ND$C9A3%B.#$8BJUL59(+^+>J@,FG:>T
M 9Y2#0\68>Y=H"ET$N&!&0E4L 0(E_+PI$;6K\42NBD^;([0=P#Q_3+X5:J,
M8<XB39&6D@NC(.+IY)E9BCM7:0-<I1H@L/(&>Y>XW2 #E'(#C$<!$.1MP!BJ
M %D$B&_NI;'M +&"'&YCZ<3VLL]3D^R4A2*HWTO;<4^?NO0#[/>FRZQC8^U\
M;QPO''Q*;WH;XK$>@O_H+=*-+=UOD7&L]R HQP1YHF#'XB4A[UB\%@P%M5TD
M7AUSU[WC5>J8N[Z-N>L:R=^\=C9K"OL6EP5N:/QWG11:]]93B\X9"E H*H*E
MG ?EXW\P-SY@2-2U[5 ?I*>V!P]>1"\-__;Y\,-S>K#_Q\7AR;^BQ[7WY>U?
M!U\.7OS!WNX___SVY/##DJ<6OQN]M"]O/CS'!T?O+P[W]_";D^B][:=W.+AX
MNS_\>'#TZ\D;?-BNM?X2QX\._WAG&:'0* 8\0@ZDPC:@F-; 6RT(M,H$ZG9V
MU\;'O;6>6L=7\X/00SOCA8#.,VNHU$X&@2$DFE@(E76^"P3?(7I\64 /*7@@
M)/51#-Q']$ $2,PPH(2'X#%QW)G4&'DC^&HV1R.^2X+Q9EM.7:;Q-X:_#60R
M>$IEX)01;Y!0"EJB)+$46M\957<%BZW*S!H6-24:>XX!MU@"ZJA.F<8:"*Z4
MXI1XSMB/S!3:'*'O4@F_%T!0+[6 %&%H&77"*4$(QTQ%TTDP"W5G-]TA0"S:
M39A&B,"$ <DH M1;"#3U!@@9W2W'O)%>=P#11<&VP9;KR#5NB-#>")T:G2DI
M++6"*>.(TT@Q:ZUS6G4FW)TA]&#)A&.:,\PX!-CR:,(A;H'200++L8RVG',1
MO2-"=W&Q+L5I;0#!C441'0ABT%)BJ-+26,<1#,@)CG%GPMTA0"R:<(1QQQE)
MAILC@&*F@8HF7;3HO-:0,8[<#V77V!RA?_#1K8Z7^1:$8PA:$15):D@Q##J:
M1L'AU&;'1 ?6=3;174'>R_D">OPRVD0J[DR0!* UHH Z#($)B -B X,T8.Q\
MV-E5#]UI[:):Z\,'AQR+FRR2A@3JN=<4&>>]5,12+I'M3*([Q(<O"_B@1/20
MO D@<!< %=(!C3@!#@LHE36>B]!%M1Y(D.A(?_1.US6Q_CP/*-I#)W$,E[U_
M#TX&4^^Z.-'*.!%% 1&&!9&4.ZR9-@%Z9I2#0:*.A/7N,B".]A+>9;OH</]Y
MG(L_WQE"G?/< J>D!%0)"HQS\5<K+,'4>IS;##YT-["+$ZW1:>)&$:6I)QQ2
M+X3B*'#)H80,1NSH:F7O%B NYP$BP@*QWEA@.5. 4B: X1&[H=>,*:\04;2+
M)&_K6=]\\5ZUA(?G*;_)UFI=_;JHQ''Q,?+0($.MT9(XPK@5)#K2"NG5?!CS
M>OO*?_*GY_[7\>CD^>>I'Y_JX;.JK&[RR^4+/WH_UF?' [LW]GIRE,9Y%!__
MRW!D/VZG+@_]/U]=OOW+G1E,^9L/'R\.3J).OGA[?/CBU<GABS\_'_[UK^.#
MHX]1C^,S]X<?#O</CP^_'(:HBS0Y*)9[@Y@!'$9LI#(0("FV(.[1R ;BN ]V
MI^<CXIW%:9Z.S_W.!A=D'HVFT:(>%R'(197OFR6/?WZ?-I*%RLC>H\%I;WH\
M.H_/=9/'3Q]$G22_54'C5D#/_:[GW*K!RG46G]Z@UFU](H;8=E6)OO%ZW'L>
MX=;UOK5@](?.\_?]YKVH?>R*1;^I6+2;L.LF#*F[X"AL%YROMJQ^L,?UYY/7
M3VY<AKZ1"/A]B^8VAFCNO[];:=2&Q@*NC("=3]PB::ZSWFJ)B."0"@R-<L$*
MSSU%S'%^77P<D*_XT<]&*0YFIW\-IL>U+_W\LQV>I_G;FTQ\_+\[TI]W$CG-
MB9[&X7R>/CT]/P%N- 750YJ8&=E.-[L*F5F8F*(.]@\'!_C5X.W^'Q?Q=W;X
MUW-X$)][</0<'>+G7U[&\2R&S Z_I&?\F<)M7]Z^^-?'P_U?XN\?T9NC/S['
M=_Q\</0GB6-G;U\<AH/!$GN4P=*G E#@@_> >@&!XI:E['@5/74D,4M$W'TH
M59\HO@7%A>L,@7<(^. 14$D6(%?.8V(H$<1X1I6%4#AL/+VVUJ=#P$U#0+)(
ML.F0(Y8I8)$6(!4, JFA S0P)%4PD/"PLRL8[DNUKH.##O\Z_-L2_//40HP]
M)(:;U 0U:@0C&&H(/=0A7->-N\._3<,_MH!_TB!H' O 6:8!A=$63!T6 /$!
MRFC_4ZU4Q#\!^YBNJ[_M=\>_']1(;N."#L_/QZ,SO]UAAX>6C+N,N9RZI)7(
MIAXUG#BC@_5*$XX4ULK;SNO>*LR]7/*Z':-064N!<.EP'*&4W6\-H RCZ%YX
M91W;V240]Z'X9D*?]:3P=NGVZ]1PB>.^BA-'G^ T4&:"-XPBR8B/-A0WG5>Y
M91J^Z%5&F-;06@0T]Q!0Q3 P6D& C(;,6NT](SN[B*$^)QN2I-]I^#HUG*H(
M[8%**)BC+D)ZP!1;PIF-3I,1J/.;MDS#%_TF&*TT;!4&+E@%HI?$@5(4 @Z%
M9$AY+DSBE6&X+\0F:?A#/8_]EXX/>P">T3W*R%]&59QHM@ARA@=.D4-&QNTS
MOC!EEE&,KJ/FZU!UHU#U\-ER-QNF.>4()<\( ^I-JFLD%$@7=]+@)25"[.Q2
MTF=P0UI>=24W:TTX(#9XJZRAT7S"F&HFG4'19N;042%4YQAMF8(O.D9>"Z25
M0 !;% #%'@,5$A,Z#M(R)K%$T6R2I ^1Z!3\_BDX#!SJX"1*W;BC)ZQ4-)BI
MA]8AXHVQG5^T90J^Z!<IKH60*I$UA13;Q"CZ11H!@KTG6F/M8(@[..T+OB%U
M>)MU8E3?$:3+GR+T!+,?[BO-ESMMM]-TW0)69Y%5@12)XN-&YZG<JI[>!Y?D
ML/Z)V?I=ZV]5D':[UJ;N6LM=5(W&PFIE@36& ,J=BGZG$\ Y"C6"49AMBN;U
M*:%]);YYXUJ[BMUQO+\#V0YDOSW5-G :/0,<-!+1]V?:.J:X1TQ!QP(+G>^_
M92"[Z/L'9PTQD(,4X ')Z0.2&@^,=AQ;1@),:0]*BCXCLH/8#F([B%TSQ 9B
M,5=:"8PM-5PJ+"VBZ1>"M*-=-N^V0>QB],5&]T3$N00R: BHY1 8XQW00L<=
ME+FXI#1"+!=](=B]@=@;T -M"[7,X#1IC.^=^FGO;#QRYW8Z^U!/I^.!.9]Z
MUYN.EBEH)CVCHX[U(@9,C@=G\0U[PY'-5&,]?>IZPX'UIQ.??\ZL,:;BR^[%
ML7^*'T[^SJ.FQW[VF%'HC<['"W<_T^/IJ1]/_L]_28S$S[UCK]W_/8]_C'];
MK)&.RY80:W!ZGJ^=6[AJWAA-4;+19)"^\'3LA_&;G_R,O.8?\^&U2B[A[!)M
MH@C&5[ORDAM0\OQ($5%R89):_SX>SP@WWD=3:NSU1Z!#'.13/;S0EY.=G^9?
M+;Y7>QYO-@57OW (MWEA>8/W+=,=,:P2GZ<1<?PX?2N.0M_U$'K'X[23_M?
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MZ22ZX5($#8C 3"!DHP%'=G:9[$.J.D6_?XJ^MJKT3M$W2]$7@VX&<<&)(R#
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M$$PRVD' ID+ 8ES!>N*DCT8*X5P :E3T0I#U $H!*2+60FT2\PM>X81T$/"
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MT;_"\GU/55+%5H!&8^CDO:Y2)"5'^T94;,O)L;^H>I1@4R0/05J6?_U=JQL
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MN'(X=2BQ'?,1A2KN3G[C_)!A^=IW)6[NFBU;D>19FUQ8(VE6!63Q6XYSML:
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MD+^![X;K:R+NKIWK-3<]J5QIC=8'BR (-(D(=,,&VO\""+^#8",X"PUG?*R
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M-)KK* HU5JLEW2#.'G? QQ;>>1KSD5JI]SU*O31F7&(#O. 98U$@0V-D9G3
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M[3'.2B^XZ%2C3E#DX(1QC%Y,=1,Y;(.XZ79&UP+DHAI^R*_ROI./M=I$P>/
MV%0^\EL+_T=XT>&TZ+P;YH-)_5"X^B?0S1YXK9Y!BZ!R.&1FG6 M?GXJ]NJR
M1AE7AN)6W5+-LU^#G-68W.-F>+E?P@:^,J.)QV[!L*370??0"=\3==2ZT./?
M;3/S1%$,0>7B2SJGZ>B\=W%X=$$"<"GJGZF?@S#;E^OA>.*\D:/S5V>G1P1#
M3.4>N5&X^(Z513H<PSX,7*V0]^#+<;@:)XJM)(.E1:V>Y_Q@NZ$Z>+20FU"Z
MU5#?I\-GY7#AVLA?Z0C@?CET1W\PQ0(P75%Q5(-IU[&I1SX>>I!$"9Y_!_Z
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MR.BZBVM#T2W5#50!*5A-1ZOMTJ&W NL!.*6MO/#PP9T?UNI67_HR JCBSFW
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MW8AL&6(GFU)SK1(;IW$D6 C'H'FB:10K%8=!)L5GE(.W#/% A@";DD:8.C;
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MR(L)_O9F.#!W!%[UO?&- [[J%A&Q$.S  X!;X'J'V%*BC</6.P@#X-;IV#?
MPC4\Z&AQY_#"^Z8H_)#JC8X'+%OU15%X;"ULQUT9$.WXN5DUKM?8W(C<-XKC
M126VEX<%<=Y*]5 '<7PXU^6["*._:7UUJ':G]J#/LU=7=06MEI-'NX0]OG%C
MT->O9JT;@UX$( ZCWN&EE:FP/-.$4Q1],F6$\U20)*/41B;"B3?/GH?QP;+<
MJP=N 0$5U^ A>ZK,9]T857=Y-8G+,5X),(X-X;/!CS0$20&L)>]*IFSP)+#M
M%5R&LR\]!/ZPAMC SY M.Z*#+GH3RVXX<4B* X1=R&_<>,B;LF*U7\.HP,WD
M-.]K$&.DF,*S^L8AUDU*X)?Q"-O9@0_%S6A:.&ZY-?Z)'O][Q0.Z%5[['.=(
M@^T^P-4?1-X7%:($C@KP6"%[.I5B7=1DH^!RLPTJ(OB:;0BS;AYLX<$.GO-!
MHSGH1^]"B,YN+R.9I11[#W2J%6&&!22STA ;LBB5D0J"B"VVRL2I"#+%=!:#
MT XS*Z3,M#(L5&FJ$\:>3N7[P\FYJ,P#!(?RHL97FZ-F_1'KS;%G-.!MO7F[
MV"^VV/M1UT,KV&GX=$OY.TLEZ]^^GG]C\&MQF-27P*S<NHU.X!W>H.$()L/F
M:5??;H%'PV+!B-KCGH0G<NA_CL$VW-<#GUFQ^[I"UR#?TF1+DWNT0H_7T!+E
MX^[J'R(?=US1]8J=_9Z[O!!&I%,8545PZ[@-L<,QP6DPO]ZG1?!!%<_W(;]=
M,Z+M(I_&(A^I -QGI>D!C?>4SV8#M#HC,3+CAQ3$?2\Y^%6O]O2SZ''"0I-D
M$@&%HEAQ876JM%$L-E$BQ'TKE0XK0?S'</P*Q# *ZE>UG*Z].?2:?A=%_D,D
MSO_(WQZ_H?#GMO?I#>L=O[A[<W,*SSAC9^]^?_?VYLW'\XO7P=OCUVPQ<7[V
M[W_>]]Z]A3^'4>_=5= [_D_^YMW[N[-/5W=G?_9NWKX[B7L7+]_W+J[MV=U2
M<5(6A"&C,B (7D,8,X((K2(2\"0Q-%,AS:)GSSF+NW#E'I7 /E+Y>BN<6N&T
MBW!2:GHS==E'Y^S-IZM^-R"HS(7XV JEW8328C4/IJ=":C21L=;8P6A))@TE
M1@=9QE+&-0["9=]A.TTKC_99'OWTA 021E-:@?29 BE<$$@J5EDF0TD$0K*S
M" 62R131L:!A1CE(*/[L^;(\^KD517O MM^C*-H#23230O,RJ?77'E$218L-
MBT(EEJ?@JAD<)AN#))*1C$A*TX2S3$L3TM)?8_ODKSUJR^)>1\.JBD,Y'.C/
MPSI8\>K?3[MT8FT895' 0/JP-(NR&,?!<JHMCQ.;96T4:=^ET@H,!!-K&IK8
MDBA2..]79T0(R8GB&6@:KGDJP#Z*6=A-TW4#.W9MO]BC)K66J[\25[?AER_!
MS4L 4CIBS!A-M(H-89KA]&YJ2*P4C</$2,J39\^S-&DY^8EP\BZ!BV_-R@N!
MBU9K/QJ?+T4U(D[C*)-$<YD1%J0QR4+*B<FXD)9R&C&)X"?)BI;)^T<V6B;_
M<=1U&Q+X"FR\&!(P66*BQ";$!)H1EJB4P'EFA"99%/*$1U8I-+Z#+D^S/5+9
M/TJ!S.N#5P>="U!OQ71\YYJ1KH:PK@$V(Q$WGQITG>ZXVL#1.&_60+8@:]70
MVLR:C%J5!39E(1.9XHD6"34BB93AMHT:[+W@6@;&H5;S+(C!ZA QV!^&*R(I
M_$0#F032L# VV;/G4=3ER3ZAK[7(B4^+J=N@P9=@YJ6@@5(RTHJ2@&D+5D@6
M$!Z;A"@C61IDW+!(@#/1\O$3X>-=0@;?FI';6H<',/)B5"!6.F9AID@BM"2,
MPD\\3$*29> M4IFP2 7/GM-E3G[*Q0[?*1/O 0^W(8&OP,.+(0$AC!&!!'O:
MI EA@;5$1#PF(2CI5,8,V#CPEC7;)\OZ48L$@CT-!YP!$ZI\)/IMA<!J240C
M:42H=1K3E$E&1<K2.#-*)4F4)#1J??V]ETC+T[?B0#(5VXCPA()$2C4C,C(A
M83B\.^%19#E(I)!V.6T+!%JF;GW]?6+F15\_"@-KPD21F$64L"P(B$@E_)5%
M@G&=4>42AP\V+5I&WD-G_UMS<NOL/X"3%YW]5$D>)T%&5!9FA-G,$$[3D"09
M4XF,@:MI H[",B>W^?^]8^(]X.'6V?\*/+R4_Y=QDDC!@7,M)]@>21"&E20V
M#D,X86VBS)O6P3Z9UH^9_J?Q0;JOZ?\+AV.LMZ+1/"3IOQ:=Y#N57X\U-*<-
M$7PS.;8,1<%5)F(X51!<S!#&,@IRS&HB.<VR($H":R,WBRUB798\6)3MQ#I/
M*#W1RH(O(@O:R,*7D %+<UP8QV)42>)0Q83)S!*1)!H$01A(D=',:&QOC%KN
M_YZY?Y=PQ+=F_[9=X4O)AL58A:5I8-(H(I1G"6$\U"2S84!"J8(@C$4H5(KV
M01H%#Z]-: 7#/@J&/9 +;8CC*[#^8HA#BS2U$0\)3[(47 ,)KH&F'&<<94KH
M-$C3T+L&43=)'MSD\%5DP/>,O8M36MK"AB611$4"RDHQ%26,VYC;1 19P%EH
MF<WXUJBK^6CZ#YM!.1?1:"768TFL\V5$A)!K&RE#24JSB+ X-418PXA6B60V
MD@84$TBL*.XF<;1'4=DVQ?+=,/N*.,4\R]O\H]'DDQD/6V[?C=L7PQ8LBFQ@
M K!*4FT($TE .&.6Q!%C@0VMT9EZ!ER=T9#^UG)[R^U?G-LQ+-%R^^-P^V(@
M0NHPP90$42;4B :)^"A)0E201#12RK(L;KF]Y?8OR.TXU<4-=3G."]4?%M.Q
M:<WY1V3YI0 $HZ&(J"(Q59PP'AO"$[#I,R-Y&&1,VY3MHSG_2$46>QED.,/1
M[IWF:/<6-V%14JF$R33B,@H1.%W%B)QNA*%)8KD.;1MR>+(R:AE.(9"64F8H
MT4F2$:8$)\)B$84 +T28((S3X-GS).G&4=N&W?)Z&W%X2LR^&'' QEQE T-T
MD!E@=HV@3SPDE@D6&)5D0C]>Q*'E]I;;VXC#5^3V)4P&+9D(;$(TQS8-82,B
M*$U)R+0&)U0*IFC+[2VWMQ&')\ORBQ$'%J9QP+.0*)E$A*4V0VL^(6#+Q\*$
M"3,BV4-K_KNN:L U6%C%Q!2=H05&&PV+?-(6.BS!RXHH#)5@-$XH2T-07I:F
MAL8ZT5&B91MU>*IRZNSB$&64CSR\>QV=?7I_J600Q:'2) K2E# >""*YA)],
MD!A&6<904(4A[P9QBQC?<GL;=WA:['XWS^Y@;YJ4,DJ$II8PEB+.HZ(D5(8'
M,@VE%%&;_&S9O0T\/$EV[RUH=QI*[+VDZ'> 3M<T(2).%0F4YC0$E2^BMK*I
M9?<V\O"4>7Y!Q<<BBFU,*9$JB@@3'"QZ&UELN1)1$"@NJ=Y'B_XQ$258LB((
MX?Z=#S10Y:^$C_:#ESV^A *>Z;J_.V;&.MW.N.:JI0_=*(I\\ &NP%$42]43
M]VR/\2_]:P0;IX=3V3>=ZEW7]L_<J^ML;\(^.X\/?L2->?+JXZ%M>(\0"AKH
M%N;CVZF7DZ6 $8^8D,I@'Z_ L1]"D2S* A($L0HC8U..X,1A-XOC;OIPR*)'
M9\H]G\O>BN56+'\78KE%7/DRXGC!VH],K SE 0'9JPA+DICP.)!$AU8PD20V
MC=,O +G2"N)6$'^O@OAKXM=\4TG<@M]\,3&]&(@-HM1R22D)(@UB.@2#63"K
MB$RU4&D@;:CBQT:_:65T*Z._5QG]?8GH5O8^JNQ=,)'#F&%3+R<T"Q/"#%,D
M"\.("*%3;9A.I2PC%JS+@T>&'_J&0M@%U'^9(-7!?W7^X7GU:KWI#;"=\O]&
M9LD'4^'>]?_"9=6KE0P7,^!(5RH'%_PZ-F!)Y!_,;[>YGEQ7W-CX5OG"P>PK
M0L*[32?KOW(CQE?YP.T$GY? RHU5_GJRA>+2PB"M#]OO6N/OZW&UC)&X,D2"
M+?6>" NK_%7T;\5=\>R7^7>#%VMNY/WV8/T;6[O+&V?W>&&_WR!LAF-' [\"
M+9LQ7@6K$-]Z"9WK,4KQ_R>7H59IRH5-1,1XJ+@P-N:4)3;(K G8);BY%TCK
M6-MYA K )47$\U5GN4#V7JY&"4UBK4V*0XU4A*AE"=AHL4TE#8(D]GH%OF/T
M(8KJ_Y^]-V]J*TG6A[_*">[OOC$3H:)K7SP31. &^]K1$FTWM@?^<=1J!!)B
M)&0,G_[-.@(;)-R $7 DJCN:%N@LM3U/96;E8H)EE%*3ZIP!!CO83:SEW@NB
MI';TSHO\VE8)9;'V/&@!VQ?1R3JG@X^<P&@$R3G<5T/\!_YJ6H'YZMFC47QQ
M\>%?H3LZZMG3%]W#>OCKF_YUWJIST(K90[&ZG9.O?ZS=53Q9O^>G=>=O/O]Z
MM?YJBB8GWW&UJK#YZ==XE?STN[][+,&K&O-?>NS??V?,SU]:&MO(QMYN==UP
MUGRS/PF9N?8:_6$"[(>5E\T4O:IKM[2-Z&/?Q6'%2*L"<1=?D6;N.QJ7-+P[
MR#2WUK0ND>B#B08W#F-->-_/&J_N*<UI8#X#G=KO[CE99=)KHUE3)_R',:^I
M+<S'/:.R)LN:;% +L^$[ED4YYU'-GIY5[>IYS<@N<V3AQHW5H5[\-,KP%D,P
MM^7WR^[3I9&-;N0\/6<)7:5-K<7V^Z#?CT/?M;WJR![%X7TBI)?LP&>YCFPD
MILY[H213A$O*-/9.00^5Q]IZ9B='-AC^+07B[GH.LW[6V7^[O[O_A>8VM???
M[[7IQ[W.]L=>^W7[V^[&^FE[?^>T?;:[-W,.L]&F[7ZGO[6Q\VWG#/KQ>O-L
M]],FZ7SZ<+)S]@K>_^:TL__FK--_E=JS!>*2B)IQPI'""B-NC$3&D8 D#]P$
M*9T*<F5-2-/B]X]+:%X6E$).A9Q*Q;JG)J7I1&S4,F,%YX@+XQ#7D2'G<U4J
M%942C#NBP\H:4[004B&D0DAW=2-<NE#N1R.JZ1QR6EO,J/<(R,H@[BE&!G.)
M',8^X>1DH/-+W%#(JI#5@I'5<R[L]VBD-)WECF@G#,42$6Q I8N1(&VX1HR!
M-"4-_"':B4JGZ;S\ZAJ4YFX!#&;#H^Q2%2LW^-4$^TN='B-B&@P53B5GN(^@
M"]"0@K+,$FVDC<70U'16ZLP6[]/&6FNB1,KFE'9)*&2X8"@8RWWPGL6$@94X
M:PDZ&VU1DMX45,_70E.@/C>H3YMO/ _.1DZ1H"X U)-"%N8662Z#$L%3FCQ
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M2X#E")!F2CI/L$_6<:5,2.F!=^4"YGN!>5IU,$I%KE5 )".:&Y!XC!(,:6)
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M#2?9]V9YBH85!BT,VA0&G9LS8V'01V#0:?,"9EXX[ )BEG'$=9+( (\BIFG
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M]=;1@'@<[I,:R3*WX88SGDU8=,F9&)2DX!#$<$O9E"(UBR4U.]_S1@]P$1=
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M;';#I9O^DC[WXW(+HF$N$8NU(I)SJK2WW&E#4\Q'L4U)9%Q4L=YDK8LO>T0
M^\5!Y@"HR:43*+*P=L@D:7$T4?.0:S,WB=1-)B83&:<)Z*MQU1&GO)E0F3/1
M*D>BSJ7);#.ST=7&;]="<B..6FG>,'?M<8JP0&2@UH3-:A:;TS:9BAI<J0%O
M[>SN!6&]=B#WBN3CJ#X29#T6*&#OJ8=EQ3GW43#9I%-JB#PV^?N916B*J+R:
MJ!Q\W!.4.H\508I5)2F50]I[!?_(Z"AH>M25J/ F)Y,]*IZ0[_K,\B9%6EY/
M6OP>EYAP;PD@2<*(R^212]0CG/.=O!$@27AEC6O6Q'B*M%P%228"),=@YF+/
M?A\E2@"O'.:.PK?_YZY3;;!NU4+.A,G1F0G7:%A?*Y,>P\=Z>D-7I1:]D9OR
MGI/U-_GV^NX>R\6M@6*@A",#7U8QY+3/E32-43QH"X9J98VH537-7CU%/K3P
M1#F%O>)@J&PR#L><E&P=YQB88BT?X\:JR,<KR,?.Q[VDI>("!Y2$SXQ&2.1B
MLL@2 "$2/% 0#O+!5\64Q/MLI)XB(@3XDG2>1HT=IXSFLNM)<"N4E52R6D0F
M+%01D=<0$;\7E?0),X/@/X 0KP-R%DBO] H3[P%"<K,M0E?EE#SRX<YS]IOR
M/D?>BLG[(+?%,ZH#%UFL #',>*+$+[:_#W_RL9T/5[Q&S*/*%!N%:/K73]_E
M/8_A[L_4B3:FS'&AG.+\PE_CE3;.;/]N$)EQN5TQ#B._];H^QM#/,?$JD3WO
M(/8?QE?EN\.$5MXGWL-:.N:P0DD2P 276X4&CI$R)A E"=4JKJR9::>U0'8Z
MU<F0QRSZ<^NQED5_[J+O;.S)9+!RAB)0*EK71#;2100J"&8 &RFT6%E3JY/E
MV$>+?C]CF''-SK+NSU[W[WM" Y?W)B+#<_!7  NPC!(4G0:O L?H&*R[7)UR
MYO=2V6]:\IO9#OFJO.KMXU-;1XNOY3\,C87@8$U.NOTJ+_%#+W9LOM?/9^TP
MV!]5:+EVU;!F!KZZQ+I^MW,ZN/V2:8D6=66,G'H9>R^<TD@(&7M+U_[=[XV&
M<0*\%;E>M(?()ACE!]LYL^?]E7_>G!M,[/J+?-@[N'W&*3UFQOH!$Z[?-VA<
MMS[R\*'B5OE;, K[VD-H[/<R'/VM[< E4LK8)"WCAGAC8Q*&@J^$=8J8[ZF5
MM9UJ2Z&;JCRE?%KN7_^T:]/6<DSL:W"A4>#(DU$1$,_GHVX^^9BPU)H9SG -
MD' -N"T9KRPGV& 6;3Z5;\$L&\<%@*16U%*5JR,N=-KN:;]*U_UW!W@O^L/O
M=SO JUNQ-\A'(NL" #ENE7V(HVZ(58Y/?:1GLDY+1<(OV?GJG9OL3ZH.,"/W
MLZXOT:^V'?NC^.B8+UI]F'?</]EV[\\\X4JL=F "_^[ Q-^=*=HXWSKXC%L7
MWR^V+F!LZ[MD#^0]+PU&S."$> @)69P4PM03ST$?E;83ZF(UI91PKQ+EU.(<
M6B6@RD8$*XS5*XT(UOX$EGG0.XWUR=ZSX=)<1E*K9'U4G1:JCIK5 GDCLGJ?
M= Y+NO2'^9']#Q/EE1Z3$#AFIZ8"R[TS7_M75>[IRH16]:4  SKVI!\_C'[X
M.;3[)QU[_J%]7&ET=='/PU$-[:XXF2@O58VS_OC*_*SBV@0-2V$/GSS\>+7Z
M:*Q85OV9Q*L:\UL_QJODUL_NNBUY^FWO_LR8VQ_Z?@:K'W3;>VJC/[5/4J5&
M,S%N9LRVJ:GU L=*OM5F?[PZ)1$/F5>MU_.M@GCOI"J#O1MMK[$Q$=BZ4=CN
M/:W?M>JBMU7CFU*0;S'7-M.<6YM[/7*BMS8?>6,O#)<7]J@7=A5B?O-=MF^4
M1'EBY<]W63SX[94'OBV1XBFU)>:Q'?HT?W3I]T7KBL(G^[L'6_LP#M9:[^2*
MP+AU$(ZVO\)]=KZSK:^;9UL'X;#UZU9GHJ+PT:=VBVZ0[1U_!CXLVX9G;=%=
ML7O0V=]>]V3WX"/=HI_/=NF7L_]>;%[UMK@X/,M;[SI$0:2(B.A\OL[3A'10
M$86<*"$HLP++O(>")]-IGU5/^$U47;_?#+X7='R[ *EU)-))C#5H!'76TD E
M<<KR9'V@]S6C* "Y; !Y?A,@DX,UQRZ@W,P;<:;S#A0U2#'A'1'4,$<S0/*Y
M V3!R(*1BXF1Q!('#)%9$FPNMJ"9DR))DGS$CM+[>DT4C%PRC-R:()%,ZER:
M@81,(H/TR#!)$<B!%8HI+U):6=.K4\X8+"A&/CHH,+TOYT(B6MX#>DZ_T;>"
MU].F]F8@^9D)B@62EPJ26Q-^O34Z8(T%(MZ*W"#!(VT80^#E*T:<"=BD*EWJ
MV7V"%J_+> &S-P9FSTR\+6"V;& VYH/C8)P(4B.?A$-<>?#!J4V(&N.)5H$&
M+@J8%3!;"C![9C9Y ;,E [-Q9UG@Q%RP%'&2VZ)$SG.Y\(222L%1HVUD:F6-
MKTXI[?1Z8':S$^-$JOP3"P:N_<OU_CF69#CG=%F_'\-I9W3 <D(G-H9U >M3
M&:,Z4QU[G&6_5JQ^__2HUIQWG@Q[^*.U<[@G/04P"PQ)G/ML.)S/96B%P%[S
M$)60P?/Q?-977N1K_?7Z95VGU1#+,,6B#9)()(72B&=7$E!+(YEX\#9@;]WD
MNBYLDG_.H)Z>,#V6)EU_:WJRM.TW<K76HZKZZFE_=*3X6G'9*QGZ\)S4Z9("
MO6Q9Q4LUV)("75*@W];ZO:T$U9("75*@2PKT/%*@/SQ$3IZUZ?P0 7ILIDT9
MY*SVX^OX*%VE8D&E]?=V_Q"E7LPM)@ M<H.EW.SA5K&ECWL%4P/$2Q!-G5K1
M_IFIZWQF@=3+V.BU&$)>R$^PCIO#9?S]312UKV.G7;I[L'O>NLB! W^^#<]J
MK7^DV[]^.VBM_^?@V]=-\FV]);X=_/M@:SQV>O"MO76P>;$%\]NZV!0PKS,8
M"XRK==8Z@GD<_'G8NN@<M7YMX1N[V@=?6.OB<(]*Y2-7'.4^JXC3W&U!6(<X
M"5HY0K4F:F4-KZIG)V,^-':Z,,CQ]R>9MGLVGPK./#\#O.#,$N#,^4V<$<P&
M[DQ$*:B,,TXBPYQ!@#[4:X%I4B[C#)LL-EAPIN#,TW#FF5G4!6<6'V>VQO@,
M45$GIPS2B3/$4V H-_U%N2PR6!W#HL^%D5>5>N<X,Z,(Q<+[?^OMOW+?U= X
M;\=.>)+;-V7F;PHFG^GVS;+%P#2@W/B12PS&,%K)&BBO5W9,[1\QH(O8ZQ8
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MH-IIB9R0%"5-'*.4*.G#RAIO<CU9\_:G%SZ/^I)AV+?(-Z=-;3%1ZBWPS1&
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MA,<RGX9&UL;<#4);9 S#*!D=N3$)6\E7UDS3R&<?")REZI5]T[)O^@8#2=?
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MQX5&)NG M/<:I&-E38GG4-;%BTV4&&RAK*\4@[W6";OPU)FCVQA/-4P2QEE
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M:,V9T)9ZH&\&ZL:COB)0IF- *@J+N,0$Z=S:@UBE@Q%!\J!6UHA95;-J!+5
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MN>G&%!?[[R.9FI3R9J/;NT^TY@RM\\CY&TR(5AT8WTYU1;R1?!60G29[K1\
MK"![WW]LK7_,X_FQYPWCA%.&&'8>\2@YTL9*Q*Q,7CEG-:7U^3O19%-$$ 1L
M8#MU8=1<7C;"&E>;5]WC2C([\:_8R6)J_7X;?LY+.9+:ZZ![A;/7"D&/:,(Q
MB#70B' *<-V#FQR? F.H8?K:XVN<A2\,3@%6_['SQ^\_3:#X:F,''@P?3>)[
MN]^H\"V//!.;:AR9S>1OPU K<M.)#9#<PXKAP"/K4>:?C]LPI'8]YRW;#_;_
M&O]N ^KY_6.@:=_/&YO XWY<+[][??9UN>KFL,XUC.0_%OAA[[Q!AY5X!_O
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MR 8OB DR!65GY$46@"L MQ0 -R_7N@#<"P#<N$^=3^D)J@0B+%'$=2XQX&E
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MN)$:@9=KD=+$":H$%TPO8MIAV41;%!KQ(/4M:OI(-1TC!S(09S57B";+$'=
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M(E\1+W*DEWB)I@@'*(+9ZR%/31$;HXA.ZRCP")B2++"9*SSX$;MVR,/03MQ
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MM[)&Q\VCX^$".LI(*.%SSPZ"*+*9XQ.;LSBT?5]0C]/($2Q^]=[U&B38_DI
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M7^A@=^](T2A._(#:"9,>GLN![2L<80?<]T,14,<5@3Z76QV^<N/NOH'C,>J
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ML#;K-Y#*02?*5?D4G !N9(+EGHI\UF*G323TZQ1&KO.@2]G5F)F(CJ/.!&J
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M//AV -A3,:006"9D,D-*)]I6FJF!=T-RN;*B I[#3 T#4^?.F M&;]7N??B
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MU.H7E!J\5K6YAWEUC4*HT8+27I-1#ZD%4@O9-12J?/[G:D$%'8520VX1![?
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M#M#W9]W4JO.0HM$60/]*K:#BJ @I4HN'(OH/_I4S<GC?2>NJ&YRS]T+Y;@J
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M@8#!OXF^6RR(-_'E%_ 5%YM/L>S<XTFLZG,[7<$"%?_YA*A-?;=B-1\OJ+_
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MZ_HOHGU+X=@=(4HY OM9'!Z4R=&*+.'N2,*,B++X!(\90%M6FR34<<\HH4_
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M,5]C86PN>&ULY7U9<ULYLN9[_PI/W==!&_O2T=TW;%>YIR+<98?MZK[SQ$@
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M"[H@X]D$KHSR(<G>PQI@9F]?R=]A^_:9\88F<+J<0UK^<[P\>7&V6%* .;_
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MX>GY#// 1VZD-'5G L-T$9*!#8%%;7G)Z"&Y_>P "T"/E /;B+M!(."_L&8
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M<C0+O)K'V4H68I+,U(X-#B 4V\IUO0?68R!"?W)OL N\2.G\['P>QEEWB;(
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M(8/E=V[$T./7Q4][N(38]%$]WD;LM,J5:XE8',02/==&:RPQ*DF+#5;Y[!"
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M8(7.&23C1M3>\"(P+S19APICY#R( FTJ+;8PVMO$#"YN/I,R0H6<F=.!TP:
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M="X<= 5/AO_?#D]Z]*[:+7K>%'?^6].!)NO>A>1I<;4#5K&%K+>B6;2AY"!
MYM4,N7V^!->0/I/]8'IOX/#M?)*]R'FN?CA=G&GGLX_C24VF'V#21GJ9F'=0
MZ\[)*Z$33#-3/"8%P3G5IIRNX:*>#/N/C2 MNOYMN[3Y'__$Z6PX.KDH&1$#
MQT.*=2B*#+'V+;2<A9I::Z+E(@8GI#_0O=,&JWAF][XHL+;"?D<ZQX?7$E?7
M\M.73\/)1?_6^4H&4@&&:!6+('2]\TNUE7!BBCM= A?%E#;Y)KTMX6D2>>_*
MO\UBTY.5O83XL/P^X.1L.%J4\ET$U>K/?AZ?GH[_HK?SY<?Z":]'+\>C&2ET
ML<H410ATSC#(M;!/JL@@<CGOL.YL-K&L]OQ]T-QN#/G)4/J(F7";[_9@1LBK
MX32-S^N,[_'9;S#Y$V=O)\.$;\\GZ2/][BN8X8"C41%T8L9$PS1'<=&"5UN?
MO 4N0J-Q#BU7]61>A*.CR&WZNV.C_YM2L,ZCGZ]-%# IJL"X1DM"%[4X"0Q+
M2M0W7M W&O6!:+BJ9_H?BB*WZ>\/1O\+7_KU='J.^?72=,M.NAR48X([.L!2
M"0RX5@R%%<ESX5"UN:GO=1G/!-\;"6XS.AR,T01__H/_PN')QQGF%Y]Q B>X
M>&4OEKH\N?+ <(/.*B*CJ9.F@;P4B%%4I\7XQ L:?V26S4;K>WX'#D^;.ZZ0
M^IBGE1#SM!Y)_W][7];;5I*D^SZ_8C#O,9W[ MQ[ 9?+A?&@VC9<KF[,$Q&Y
ME8F1R!J2<MGSZV\D1<F61(D\Y$GRD%(WX"[;U3JQ?)D9>RRS7,NRCY%5Y%L;
M:Z".: 5EHP/O/8,<$Y,B%(6M"O36TO/LT->#6M:@I;]:\Z=ZH-]-)U_RO")_
MF5#Z-%W@Q8]_7Z<9O9LN_BLOOL\Y&I4H8Y)H 9TO-?*>P)F4R?ZG\Q&L][S1
MXK9F+#T[S X#'&M@WU\1:M^<75M(OTQGJS^J_QX?R<2B*60A,>V(2<\*>#K>
M(*U2.D2;@F]3XG98/E\.R'!@M.;4'"^;>5UU,W_S-<_B>$[^Q,J36,KB[61!
MOO)\'/^!%U=Y5$1@6/T*DW.I(=($WIH 4KKHHK9"AC8K[P_!W;,[(8.#S)IS
ML7=:](%M=X_X-/*IF&!9 L,SG5P1%03/ PBI98K)).;:A$TVDO;L$-FOLM;
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MYXN</DXO+GZ9SNK_:812*1GH]2!/,H+BW *2201.69]+%-JK@:7R=^)S@*]
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M48*@H@03C **2&)GA>HC.B0QN]8]C ?DO0;E!16$ST4H@"KPMI,=_QR2(5R
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M7SP7UL)ANF @-B&.(;Y(,!LAG0X>4"H60?X3$E74AM=M]HB&:W32W:YI]1*
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M$[@\&)O!>)0>C[K >+;)-'R4M,LXM\NX)C1K':)<9:VE=_ZJ2=\,[I ^Q.'
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M3[<[:^E-GDRY+F?L_*7GYS"S\!U;F+ E*A8[!HU$QMR)_<XW2-\<H2;5<QO
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M=U[5%VB>!7ZFLA0IIE1/Y$BE"+T0*:'GXZE8'_%R?<O,U?((='DI>7*?#4O
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MBDL3L W24A\\,Q]\[-J3PM @K?2M<W\(\B;3%_]9_#>LE[HH62HOG+S'Q"C
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M)  "R'"*;,C#PLM_.?!4%=_&;GI=++BXI>&4LN.X@T@%,<,/=XM$E+3NN__
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M^DN"<S M72'B3OJRYE*"K_$21&(@>DL8R><K5*U"DC/AQ%DM?>[*C=5QY&6
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M->)&I3]5\2I*KJ^W:V1X1+.[0S:$ZX0&[[T[WB"0CF@)XB*R3AOI!%A%^^5
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M_&8VXA.$3RY\[_RCM!MBRNU*D>4W1FRFSVOUNER8;6LH\5E$'KI#*'$IR0A
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MO?.YX*F2?JI2COU1D;R[(V^K"A.3XR&P..US*GMGM9CEWF3E^V<5;5U-P?R
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M4Y(AXC#<!"#-^E1OLLZTCBONQN*#S\H3D^H1<B &2'M21)_\%KUC@'H^T]O
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MP^JR#F>DL[2T+-KFO8_Y]8(O1P;MD$_L(F^'Z [2(M-HKQ!*7\V'+@(:&[1
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MI$T\!R9JF?L!_>V)D-2##XGB>)6)@D*<YR1OT80_M&=PD>O8\."H:@_]O8C
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M:@ /A1"*\(AE=_PA+=\FKL01!U'1O',"HAL#:)PJK[.\193AI\M:]\U=+42
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M;4DU<IW[-LN;6?OSW3[[O]$0M?=GDB(Q,,_O KXI?A+,-*Z5L6@D73=J9-(
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M2A$-#V:[-9&>R!NCGL7^L>'&&H_^G+M;CZ=EYYZ5#O@S\?0_DW#Z7W%1@,(
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M#OYV/+_!\]%WW.T-U[SVWL_N4&B_4" S/5H>/"$E)$(?6R'J<!3[X^$'WH)
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M2FK:J]?IN7GY!85%;XM+*JNJ:VKK/M0WM+5W='9U?^KY/#@T/#(Z-CXQ.;^
M_;&XM/QSY1=^:WMGE[ '[A_\(1<=P$#W/],_*Q<W32[Z/\: Y0^YZ.A]_\C
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MW0:#C^YJ(QTF;?94P%G^[ N'!K90PBUR&-0!$X)DN.C.Z0QCJQ9QL<0,+GS
M6W\L6WEJ;?4KK?*-_XSN(Y-'1FOCUYZP-.O^I )N"1,+RX12<C+<!2>AGWT)
MO5LFK90LWE?#](.GH//#(PJ_0D=T=V7%ZF"3WIPIB3^9X(<S;1?BBJ3I\^&/
M;TF7P)CY("4I.3Y'T1/?RO=Z527%7**.2V;9QU]K'&9 97QH/\^20Q(GIUQT
M'_?86^CNV S+EO3&Q=<_.AC-PBVO(:Q2$P*9&B^B&2*OF!@UY>:&T_'9G1K3
MP+$3TL<0YRD=D^[KAL5^-H/]=YIQ63/E!_=X+UQ#'WD9QH%X#)'V'$O?ADX0
ML5SK)XE.EO#[8+A[CK4CBE71@+,G'RX[6--W6@:M:!'Q+%7_^E-Z#79E-L&4
M4QJQ?,YXY$0,X2=X&K=-8>WA6JLO-2B%Q*A (Q2A7,KM*=_*X_,/GBFSQ=3U
M3E;,CTQ>:S6\[M8J^(;+%)]&XFNGJ3\YH9D3,?0$?CS4=%A=PB]W2+<>-Y/E
MTSK\I>ZTT?>,8XGIC(:8A,SE E,\:AU+="(!8/%\0B2L6F"M8+YWI5FLH!,3
M[*K*M9"6?F,XN7?**5"F[=PYRJ[REU#G\B6ZMA>JYM^8R:'(AR_:Q2@"F' 0
MNHOWA6D@OK^!3%D0[GVB J^GS*C H.!/!M@\U[H3\:83I,8MBWB.,HHY1)+)
MFP&+VL=4,&$U:&:7"U86-V6^VM>^O!T]U69?%\P" +YV/K,5=>L7RA%#Z<H=
MG 96N,["U)G#8$$I:#+A>L9!X,C$_I5'KM]%FMI?7!)$7P3)5."L(TA'!6Q@
MT="=3-/7E$^H&G0+;:E"=<&$FUD00];B#;CNJ')U11?KDP./92_&O(:9#FW"
M454]SJ?BF@8IAFWQMW?W6N@18YCJKXW$VU2@58X*./99_*7M(V#HTWD7N^K7
MF9;7'8J=B']M' Z6X8G8R&>8>1C\*#F3PHQL,UR \3J>6M)WL<QVT>?2K(O@
MZYV>UA9*]5&5UMT6;0XF&3B5. =LDG@8"&_'%-%<5BL":1BAW2LQ9><H:LD3
M.GN3=R\JR.$:>(PC;3@#!=;#\9XF@S0PF @HB[HRY9NZ%'@7YVX$NJ45=<SP
M-0<RCW@7V!1^=AG6<C1\R$;T8_&56&*ZJN8Y;[#N0-1S@E1/PRH-UO5P&6T!
MR"A%#+OEJC4/GB54L?3YSNKFB?FY1%DQ,ULQQ@WU5ZV?%!=0.(/9HY3!._#;
MY/Q=2!2&JPDB^R+[PDBYJLV+5=XO^%_R$Z3:]U):C+6=6H-KQL&4XS\0 &JB
M6Y\*A+R#GQ^!.C#CU?/F/QJT!2SF@LL=!W'D0;^8._$L2<:UZ;O/4VQBN]BU
MZ(]ZQF(E/I(S*-)^7"U0"-09/3'59=Z1[ANKJKOPW=;BFU=@QMD4]+O;V?W+
M8FL3<:&^TJPL8A?I1N!\Y-I%G$0+>J*],\"]%<+EY]("Y:WQKQ:YR2DR<PE^
MQ5\ZF?UT^-/J;NDH8HRM&^NF=3^^G_!ZC )!#&#8D8\V 3_K(9.1)E]_7\]W
M/=X7) >K8W3:^YZ&4Y0D;!Q"6A)N[F/G("VL5, )"9[<C%0_NL+6;HYD,PB:
M+\Z[8BUS>Y+@M!Y=9WSFQB$=BH#S$$UL&%C4":T5Z#000+9>53_E6&E^ZX Y
M8P[-:7$[0[]AJE7X($.2\B.M_&9B+).]:H@D0T4U&8UQWIR$=,U(U9"CU3G\
ME*A &X)CM'!@4]48VQ>P,*%8"LHOM]N+5+M=*S[!:KGV.+3[U$<HX3KY;1G2
M&4+OG)Y=-->;P.&7US9)[@K'0MF_3[_K+W0^;QL@'0VD*C$J? (8[7P4:3V%
MC,14U*U-O07'YAS6L=C^XR!OI[ER].;&3NEXD]6[<:<#2HK49L3&N/FEN/&0
MZY)"!P[2@G*C,)Q>_V'X>2H0CER@ M&00Y1#8$:;BD2TZIW-PE^BTGB1D=WE
MYS(Y3#;#T99Q..EG\7RI$HP_@EF!/4P4E%F="VX>J*M^CB2!&WN>WG*IPOW(
M3Y.]PFGU[Q189ER5S\A7^:P\-2:X$_$PHH]F0S T%^QQ_V1H>_9ID'WNXW6#
M 56K?,W<<9B?^:#C8[' P) >>E5[&Z.KXI+ BPN#S3CT"RKP@&M?'3;93^G6
M%Z "NN6.#+4@D:CS"T6GZCM'4_Y-@AYX,M_%6G&LNL?=:_W(UP:WQ#=.AO(F
MC9D=D8_MV\]U'P_I4+X\B=:;KUOWQV^VS4)V-B=@A ;08/X[>\?,V<%R-,W%
M,V#]M6WY\V X=:79!3:;V\OQ]H/[*^'0*:G&&'(!W,"%*(YLU56]3+2!&U4T
M)<R//4<(],SUF7:\,.M15>'?FHWY,(/MY1CH/L'VK"(V32+81:X#<[1)A!A(
MF84R;U"!1QGU31KS!F%5SNG=L7 '5Z=3]SL5.QNTW>WYRDO$4U[3V5N2RK)]
MS@."5 "G#Q6D#/K (+3U@!.VH!P"5TJ_ 3LBYP:WETTLMOQN->7,/77VOO3"
M5I6JA2F0";UZM#&/>(^VG&DW6>!J]PAQ.,A:WER65)O):)U [0P_'AFU>8(V
MEIFGGWO$'(I@L;_6IOPX]MGV$X-L$B.XAF G>9'?J1\&@X1))B-P_5(P89XV
M)3:J5YZ/$)SZ+TJ'R78QYF85/'N@I3*6[&?0.5N)Z4)-O/5+P,+69?"F"]U=
M,NXW/IBI'RV*\CXMOZHI')2JIO1-J^*Z\*M>Y0U"L6WKQ%71*:(%R6, Z@0+
MI0*5<MWNAU?NWI\$,PA1N*S)\>E+OK5!>^SBFL%TM0V5&RV?CK5\E=H((&%P
MV3D.Q<A6*.;A_N-R'@V!==XWU\^,?AW3(^[:JX<=\4,/LP&D83(*H4!I17)
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M.BPO*2W0:E0W:B*/PLI9#/<>5F69[]/6P'T1$!#E]1UQ4#:/'5R]J^TEF_R
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MFE.[L&+PEV!,:G;%W+KD;7IAAKO'J2#\\WG3\9D\L=!-D_\1K E=E+>\\<V
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MHK-<. JGFQ!'!415;Z%H\9,;%8@UCZV[.X_2K,((*&=XHF26+T<SB2C=$'Z
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M"Q;0H,/FN$![6D-M:=#).G6)B$]-E9 %HO@M=6.&=UL T,,&<%E[>@NL8Z@
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MO:.:^KY]T:VH-#4H(B)@5$"DB4@5@=@ $1'I4J,B("!&1'I(* (" DI56E1
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MM:M#J]37K*Y^T)WAQ=AE>:S[!_KYGG,V,E+ZQ?;7$\Z/#IOO6WZ]ITSTX9N
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M"N73]A0VV[^&6>?60Z+AE9/1+[#LS_6*G'8&J!D-.&+YC?6E"'J8XNC\SE;
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M."Z$(XQ[U*MM,KUC>E[9\6EW?4'T-J7B_MOO; C[N(/LNW:-8[7^W-8^3)A
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M27I/I.5ZU6Y$B') !</18P$IAPB^!SN0NG5[CGX5*_DB(>3Z_BXI\K+)G?,
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M9W5O/G.M^MACLV9M,I[ZV/M=L^0GWEVJ<3..CBZ5N;_I44$0G,0$3-.90.(
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MFP:(2X3&ZW1-B14Z>88F0I5MHLB=X^&C7QG%B(=Z-Z9&J"GD8^HOQB5+HIG
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MTI_4T86R*ZK0W-FUQP%NBM<?H>C)AD=>9 (A>MAY[48F8 ?R14('[T>R*/W
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M!'PIZ:1+H+[NMUE+@<W,,M-75)I2&E=9]U58=H<GEAL[$0K?HW TBC:UVG3
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M*$0 1B+F?'*81[![9U!KFE.VVM;C]B1MHXV:VS<9 E]TV5.FGLW9[5%AS/M
M/O4=.;]=!-'V)+ WSR#KZ0D7^<.T^S6*4V"Z:"]5G8Q_XT5$\0*-3>N\VX]'
MYQ-&1BOZ<Q(>@+>6^ME.PI#U"$.!#5KR%!]X2?--_@?&EK9K1QV6RJ,$=[%
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MC ]2GSP-).DT[<2PHZ55L&ZH6C#J7F<,6&25-(AWPXPL+)J^/+_N:D\MM'[
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M>C/(9H4%*N2,A\]ID^AK=^(=E(_K(51)/6=A:1-0RVFSJ\*_,!+_N^CE^K7
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MI[79;C^Y,ZYPJI1R_NW@V;H9$K34(/BL6&=;HW8 ;6?P" DZG%^'/$I.S\@
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M!=7_8D]79U<6:)TDP-@10OU_/X75A';]?7FTBW]:_6GUI]6?5G]:_6GU#ZR
MPL+W<O6>D=";D7M=-_[A:QZNL'^S2PZ'+=NS>5@)$<5 /V:!YE4LJ_[S;Y/^
M+RM_NO5/M_Y/+L(Q%'#+4PB_KHP[X<#FC: TO6[/,LFX5LZ.$)%7)<")]WR?
M%-=H5 LRMA$6B^*A2^?2'['A>"O=H@MY!"AJL[L+P&X 7>7SGNO79_=9:*J+
MC37=9XR>G[()WL6!2V1\KC&D7+Y*$:A;'1*8A#03#LP'1*"STT>;="^(5F^^
MZGE2K9HXI?=(O\-70WP]^.>,IZX;: <7#8RP0%<H&+K@%O4S8#/9*8!PI^1$
M(Z41YGV>VCKY+CCUP>F^Z5XU/;% FS37[.TN@V'+&\NTUD1+YS_>"@KMFD25
M1="3.Y^Q0%2=#A8HZX?=O)WHWYZ9^?+WI7^6_Z!8<M',W"&\3P2&!UM2L2VU
M_"S033("*54EH_"Y=_='_P*)<R6?MDWBN9)MY.\8V+Z-M?0WLQN^LV#Q>'XD
M+LM29.N@JD^]JGW/%?MPBUOUNP_MTS[@PCG=&0/;A2*F;^')QG>=FY""@,.D
ME@!'1>-\F1*GI8U8V/=#DO<'UF+"OW]<_'$\QZ>D)#&N6@XL"3CG W,-$]J,
M,*0Z_7%-NAJ.C"N>I#&@9O>YH;[V%2:'5%!2;:8/U@SN^V.S"E#$E_C/R9@I
MC<TA)(^*=2.*^@NA=1X?="Q!NL5GED?D=?T@Y(CQ6Y*GXB#N+)T7,*)=I.M4
M N:4B+J!@-G0)Z:U874/UL9U22V_S*=\Y_C#K!X$^ZON6L?2A0Y9:7O1K)C?
M45RJFLE!]KKRZE&>2O<UX:<>'E&6*^(ZF3,+>KOW>-V#4)B-91*RDP4J%E@:
MIZD T;06#(^VP(7%D;C/Y56#9>_LYLQJSA-#CMSQ?/ T7COL6]&N$96WO $_
M0,(S+) P_@$V'"]68\M4I5S#3\4$5CP[<G9>5S9U1#KW#'^31F?>JEW&51#\
M,@M4KXW<TWZT0SV2[BY[V%[2:&J88.]XTF#\K91,:2?@9UG' NU(UOBQ0&&(
MS=7;IEPA+%!C%8X=/KO&27BZXMP'IG0_&<(,7Y5F@29A.H']0KN(>/(*ECU_
M-M3AJRP0]_8O%BC"]_>.1T9U*PJP[+3;9#]:F:Z5SXZX?!-:+% #+@ R.0[C
M9(%^>5((3.'UP5JSBS(\+!#_PN\Y=]DOG@4B8]/1_VO5H:0L1=&D$"I ";G3
ME*(076,^M5D9VFS]ZN7]CJ;>*^FW55[>>-9?W+>%O?4W%;W;N31(=KX%B!,5
M"?O<JOI$U^["PVEF=PI)CN9W9DX+<GWEVEN[-UA;]*\?"O[KYB].Y+X7V/,W
MM];_Z^9O?3K.68_Z*Q]T_VWS:Q>B06387_M@ _57K<<&9/Z?69MIKY$DJCQ@
M3NZ@(B@P=(WZ%%Y<C9F2K4K-7&T6-!*_]TW7$0+WZ:G"<J+J(3A>=^3^[LTT
M@@A -/;+MND\CFXN^;0"[X_GLD_JJ0VDA@#.0904(CX2)SJ?^M;"4F+B[4#W
M79.PQ',&FH<?ZPMW 4;74AK3A7JU=;0[9(=<R:,UD6>DLMRRT [1(,K_I7WP
MWU@;NSN4+:H&X$R$1F%XM=4S@/SFV=&FB9.)'3?5=8^]&;MR^+3V%R3I@:\P
MU<-_JP42>@'31) !.)NI%_I$B@&M)N7<L4;5A]:3-ZZ>/R'-;^+_GE_R?W>?
M_!]1&Z"C 57<VJAC2?U*\6J(P0K#\33EZ^3"L.5\A:B/@N*.3_DJ=[Y0ZI;M
M<O[6O!K#CQ#OVX".&#5AI!P'W@<:^S0.!#RQ4)3<?]3%*G%ZX_#LG['YOZ$V
M@\G(-@R[3R$Q$-Y-@4/P_&8[99O7VN9Y=ZZ=JC%6-9RYK'FE3=I&&AI .U]#
MH[H#*GET7K+PZG.UNVX\VZ=K+@?E%@Q0OGPJ6$O9'SK&&7I12OV_#"K\#T,N
M_YW5*>*D9C&BD,*(<PR,MB5IE0_ MABCLN>-=7*K*5=Z6JS.H=] )Z0VL$7N
M\8SW.'$"PA%0GE(.VW'*$7[54I&C5FIY*^-!;"*_@51",\A?X!F>B"'L5</O
M_K7S8S4&\>A8=4_AW$O]J>%^/VVW5L[/[?/6?]/:Q9$:^0]&DYW<KNDRZ8X)
M2ZJ Q\05,?Z;:C?UBYM=_N<[<)"(76HFLT!$W<+  KB6-86OKX*ZR-M1L/CX
M[M%<C[I<5)7/1*W(/SXYY=^6U)YKL;EKQT\_"DZW(FG(U'!>Y,_$N;/I=2@P
MU_H8")V$+ T362!I-UW!4B"/I-^K?7G*XZC7R;6)%C'>3B\O97IQJD^9B%Y;
M?9TF]@A9N14"**#H@KTD3+0J;!_= 7@7Y!(C\FZJ6D^)6O;>Q2_S1LV7;^;1
M8^G"Y27+VRF@:9! 36X!VZ- ?B-2D]P?$5LC762]$&"1YY)RX6F&XYE$Q<B[
MEQ4_\.\[')K:]<_)E":,RUZ6BQ>^[?@F'B13&F+P/?S@T13S/2G:P3ZAZ#KF
M-1R4LE4G,$*C3E!6L).H$4D[KW 4UY-E$W<K[2.3=V\;?8)7B8WEIJ[,0_IL
M#/9.'@INMN&MY)$'!6D2,3* [)1%,.XD$#BUK&[;*S-E)6C:XW5S2B3QA(2F
MT(5#6?GY)^H7%*UQOU\9JEC/7X NN3#%>AX.C+DPM0<+/I;?A+[L")@Q3334
MN*;7WGE]!Q?\;XY6^7?+QZR$;_NCK]X3"[D]MUOJX.]^VD5NB9OT&LUI9H'$
M:UQI)LQ^W1/D6W0M2LN'3!>D:!?]+@/-%;ZD=-&J3/P6^OP=R4!QF.+K;_$@
MGGD(^7KGJ%<#3%IW%]Q]LK,)C=XYC:<<&]%J^UB:NFUIABL+GS(/\8NK].?E
MCA\:&]K&)/;MVBS\F[?^_WXQ->"4Z]IUU9L 9AX;IQ\&N$B0V OG7U?%,B7(
MZ1GY(]8/7GV%*Z4[WM37,C1+U!*$':=+,M!(660/I(0K N\ZPRA!RM938,U(
MF9B[O9N+ D+M,J]RQGZ(O3IU-41 SN;(T1.RHXF7TVDNG,L[BK,8X)C"<A\+
M5)Y3[YK60NT: M8;.H6Q,:>.&D?I;BKM63(:T7PI^*S.\2&BVG#'^I]S]XD2
M8[Y28V_ODZT2)YS]'N[AK%3(AH/I0FFDUC@<)[)= HM&BKE37 /"J-DYKB^
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ME)YS%X7QZ\H EH:U7=HGW'V]/7+<4RRC[8Q&WQPYZ73V@*Q!AT/(1=HV2?<
M\[LN9R_$%1I/(!O7RLR9)DV*5!)Y^.X/7OY:FTB$/]Z9I$X-9Y^ZO<+ARPL]
M>\PG!-K%IH]0Y:@+6TW*PY:-.UYQ&.9)%)>A]R14N.5'BO%EXY<CE0[C[QSB
M8317V G$048E?3]YG=3:ZA6YHQ^V"9%!F%.VFN:?"'#1=<E+CBLSO4\BP\IJ
MUG6Y1RX::3I[(B_56RD>V+6 ^J*_' ->ZA?"%#LO;Y*"( T3I\BV' +\<#RL
MRN:N5K/U!43YUMFQ;Y?\/P7+*IZ?NOC3UD#4B+D_.-4D@Z0<SU0#S*0PY'RZ
M'D4-BSCXJ/B<S?C/>SRYT(?[Q(._"YN_]-#:!W[R;)' @Y2&SY' ]3\T(9Z$
MYSA0O_8UKV-5%]3*4U.H 0%:24+^7_EYVY[+LBE6D9Z.>Y_JN+I)=RF@^@X,
M#>D9&)&/'AD9.2+E?31VC[DI1[ &Z-%QCH!_B/2QKYF:[ %\E:Y.YJ%2R.BE
M8C:6U*C1G(+R7Y6?B_Q27_KCYM24U;+LFY+BH[[/(@X?>& A=UQUUQ+^(%,+
M#IM$-75R(,Y19-("Y^ LT,WJSSV;Q[MU.[R\]Y38[LN^7Q>18/;\'F=B8:)&
MYS=8R=92)7F.R7T,!P&&:0_A*&L*?YX7:1G6N",0X54F6:T%X1L::3MJL.P0
MU6U]N7]VN^),Z^[S0=5,;DVB1V 3_LM*#JESMXU_NCS@DSL"[VVT$H>X]CX0
MK K6U"(*ML8SG33G[^*C=77@3UNIMGUX5P)O@F^V'O$$'>J V7;G&%;KX42;
M<ZKNFL*0K[^[W'2!4(<11RA2!JHA4:6KX031330?W-)\P%N[=\BJG6?4X$[$
M][:EIQ7D)=.O0V=13&YQ,E?K8,Q[YC"^Q#<9>1RAI.SCX2J! 7)5XXT'WARV
M@ST6?2#U-H4G_%'C7.=0&K6$HOX<Y8CA8GXG%#L'LT.?(\*J?PEL2XFO>/1#
M)FIRM/"29:6K+T]"\%IF6]YTQM@-1Y_:I^"NU?W8:,&&$3?XA(W"0'+#P7S<
M:RD;M9_ULZ]#Z0WG:.4K<V*=JKLN3SK'#TZA&CUXIDX"7K>Z\>4;N<HF204C
MJJ(63E=X[[\2XRC*>A'DG5 OC/]/$8X'\*U6)C=P=Y*'C>SH5RG&\3&9\X_$
ML9LZUXA7>4^\?5"\8@CBSWH!DGMV46)SFE#FM7PK@_D3PB4'1+S_-3\59[<%
MJR!OA6]H*4[#*MP%O]V/'YZ>OEH6*MIY\F"XRC,K#">>F 7Y E[FH\A GK-
M_$BY3D:U+R<T:WAA1[X_@OKV)(^X4ER3B[RDWD.!U\$&8KO16H 7^=;DJ]5E
M0XH^U0 HF7S5IVI)N8:A>-598'WD[&Q[DX1',^)>/A/>>%CO4\&03?BY;_?
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MQH.@PI;BNJRP&MVYXI-OXXL&Y%#:Y1O9LSW8I@KQA-\1R9'-^R#@1%$\VH+
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MNAEIMFGE9]Y,O-0?:UJU]*>L/[T!%);"D("3L%VX"'#59ZI0)U0,1O@=@I5
MX"&5Q($P#XU?LD\Z/V?O6MTQ^L0U(6,Y)H=0# EB\Z-="JV64K5)[%U'T.^C
M+TTP@I"WIIW!\<-=E<5.J]-^!6,:!3_5DRV7=K@PUK<.Y0P#J+V.'"S- +"G
MUI-X.P'#"G[TQ0DMQFE2R>L(,4??^DNR&G%-29-1%C\O'&\'W<6')2ZC_]4-
M<V-UM<I0C,KH9QE"U*D"2MC5JK'EB0#3?UXI:2OX(NQ&DW7_F)YT?.^ R*6H
M\/N^G#B&>&@/M,8P:]V84@J0NK*+(M$!90QS"NL5B0^M4%Y;$Z]:>26+7WS$
MR$A?D'"_'^*Z$A!R9I,AN@D?-RBN!4?C*%?!*7_A3]\EMF:$EJ'-_>DGCX&/
MY7[O:KWKN>O62?V%!I-6V.,1OZB(6\H$5R]V8Q-]L03E28S6+VQ@@^]Y[]\>
MC5]B-2+?@@0J+=/D07SH< Z)OT=(^Z"G"YR /<$?)X>VH6+RWOTVTC68=OB;
M,=8MJYR8Z[CU!-2G&LYQ--S4G\771[^,VJ:E ^"/W=2TL04A!4"J6ZI5DOJR
MUOSY8)C?#9E)<XYS)0+AG)L.;5P@="6UD_8&8!-J017BXEQ]>Z[9-)1P RT/
MI.<#^M<IY P&[M9$Z<6!PV4/*<>W?F2>WK@ETBHD$ =5*M.9+2'%%M#-,.UP
M\#X(^7H>XG::I8J^,%6[R.DT;Q671;9[JOGZ]O+/T#M6#Y[6W0MVQA[8!]U!
M L=PL>S?"L#+(HBB96I"-#N\['^\PM'?SJ\U@/;;ZU%!\C69AJ3\MGL-UT5#
MYK[R3F%KV4*1L ^:S:+!J5"R$K6SV.77W[/?$:FEN.8ON=[69>GW6+QICEN=
M[].L+E+@,5 *#*[(P%*T\ZA1M%%F8:OJ(M#;)1FTV)I$R!.W*4"T@K=OG'&9
M:S_8ANKD\3G-$W=N[W7/W24@AWZ='1#RK".L_K\QI?5048S *M>YR9J&K:WO
M1U^%RE<&N%<TX=7C39K;@B8<9A8/00.@T8I09IKF/LA/1\C-W>^O6WD*4KN^
M$'C8OEE1J@TYGWV@_JF4H-Q)S9-[X@W]2ZE"QYFY+6'4$MHU9K76/NBV3A)8
MPA"FB()W+RCF.0!P(D[X5/J-F+(]PYZ\$!W%1XZCWZT?M;E'T(JF("K4 QD$
MJ! <*')K%)[YG6DWOW#)$MWPX>S&8F2D/]',A+@7C@M<!$Y8=>#D,<.R*[2]
M:)88H&,W:6I!Y/=_I!*C;2BM>#" +\1.3<;RF*6EJG2_+M@3[4IQQ8E"Q($\
MPG<I9:EIAEE8D>K@F+ZID+!'RN79MT+)6!^A:*@8=*D(PI]%*V7F0PR!10M*
M+NZCFTXX2QXP=G^B-S4,>^83X]V$BJ7'SSX?LI&6CZKM4"]$<P$\=#O, +RF
M%,-+F>[2"NO-XPX9E'7*Q<JLC7Y?A4A-7%=3>6:E[+24SG$VYDBHYU(Q0A^[
ME (7K]%"TLZ.87C\TJUNDV"Q]<;9X 2TL4E,4U6F2?'#9JN].KTJ!M!#67M3
M7'&!"B;G$%[#YU0Z<97U$0S=!97)S9VP+[;=V1FQ;]]#!=I%HZ3PXAI>!1[U
M@3^\=$3:13E!^ICCV'9+# AM",1_8FB,U2!E@'%GRE84T1\+ BQ7["]+J4!_
MZYTWLK0\;*Y:?E!)Y-DO-68]UN<XUEMC$;]WCEKMUWIP?$G4W?WW5/EVQX+?
M^5%338FQ"SY7KX4KR>\HY2FPL<A@N+"3#D4-G)W,-:3F9'6;W4-MR>AJ7Z##
M.B\*#?;S@'+Y;G*E^O_<!X%AA7[8JGT0>;H<#4TSIKA-IP1@*PMJVFO3_GC'
MD8=%P,<'7L9KM// +EWEG3['.E1-5U%/J"&+[ME3%0KC2E;ALW^1*9LM^D%"
M<>7:55:964.<QDI)I#WL<9.ZI$EL.Y9R'3Z;TK,/DC" Q63&=3L_HMKWU5/B
MGM;B^+[/_G;>^9(V1K3GO/P]0)7G3C^'6CC$ZA]WHO1$>+'A.W\$;>A?<#;3
M*(G@J%66 7+\(#K76VO^>TNTY>'1)K;7=>?D9,5".,IR2H/XX7C;CN*[RN;O
MU3B7>5P?2'-%_#([QH4#V-F41X"9RQ)A.$RV<J]2@=<WJ;F9F4E2,0QC0N/F
M9HA0S?EQG=D/3\64'">J*SL*;XAE@G:AU47DVY106M[8KG]%G&P2L^X=8:W2
MGP@[O/;W;N:9S.<GN:,;ZE\<N!1S5[<_IU0_XY:ISE+&8L2[_ZHA>;=VTK,6
M+CRX),A%%[]HGE$6?2PPTB=]^\G+5#/> K9R[_VXNP\29<UC:X( L2;_!.2L
M\\_>+JW"K<6Y#;?2D8Q]4.8^R%O:=0O4ZP>BY2!9AQKI)Q"A^*2I+']20'"G
MLQ;)Q=_=C+(7B=0QT) 1)W3.]^0+XQ;,VY(ME!+_PKIA^+TEJ0YP]&-8SZ((
M,(\TT!&Q10K%NIRK#YO=?55D-]+M+VY>4[XD"I*_M9SHP%;JW, T2Z"((88D
MT(I\GN3W$E[KQ%%UXA6]8=47],YB:]#K%.B3E:SY59LUN"IK$'H8+40%TWB
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MX8\=5FIQZX_HIS'3>92;4+R8-?,]1 ';<0[YWG=!^K5M"MU]:[SOD<%7B:&
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M9@%#X2-JG(!]-G#A@^N7^J>:ABX^U<UCZE=MK8(%WCDK@P)A_0_K^-I[,X4
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MO^W$MPLSXI8_0FZX\]Y_<N;9%F46XA;5 Q.[*/D&=YA&QA1]]\&H!,4)4S;
MJKU$5\J.D9L7,BYG$W(A'UG_>D(C'9BG0 FA9#G*]%7 @IK5"9Z#*$S*2N+&
M6^?,<-EW,HZF[*6>L6YX<*Y3@,2K]-S-2V(5?!C-9NB'[?^5!L6.UF)__"C=
M!VUYA3KK,,2*:,:4O4XW]:6-+$H8,F8')BXDXN@;C(J[EKE(M^;A1-RTC:*%
M<T;\&&B%X'2^!9-?7.65H(;10@$3ZL)V9U->-_@@UM<=9>MXV:$SE/8WIKN@
M)^]A0V>O5LOSUL-2QVPL\?E1-1XO@$WZ0<PW:(U/ @%(H(+;]-6?$NKHNM3#
M,:5NB/HTBWV0Z7+:U'F]\E,<>[?NZ6K,''LK9$B!K6/IQHS3 +@$,^3.![@A
MBE!0]YJ&NJF=N;!775F_3;U/9[LDL<*:C\S]E%H @40B$B[3M= 'O0!4V9([
M1+SM,\#+.AH*IVI<J+>]!YUB[8/VK!->U>?J3Z2[1UP !6$/_H/2J'T0YV:+
MU2>&+B5N1@?M5@HI(=K2D\X2-XBLW]59CP)50]OZ.CA%_H_VKCP:ZO??CZ7L
M)OLR,94I2D*B0H8*R4\CLI3D6W9"LFO,V->84!0Q*K+%9!<R=HG(EK5FL21F
MF%'&1[.XX]Y[SOWSGG//_?/WQ_/?\YSGG/?K>5[+.9_/^PG3FX1D1!QF\G$&
MRFG,6X MN"M;+G%K%R2EFJRK(:L4R=88?ETKQ#]Z9'A?\WP%LKG1+#3Z1O2^
M1V+2/$OP>@$*@GD.-7Z+@5T I_[8GV,5=C6ZLQ2(NS)9'<Q<N0O+EBOP.Z+S
M]N;[JB=GM4&2/H0NPHP!T;P#GIBWT8V+AXII4/UT 0_]SXBRX6W%=QC(8:;I
M_./?VH>?^\,H\U=CQCZ>2@7]AD[/$2_T4[XP=<-=B 6$&5D_94A2GI*1]]&F
MIHCUD@]>]R)0$9(ZVNG.M*$#VJ L=31YNR,@ :K\SU>-=G7 EFEGJ$VV]$-?
M<FE"",PT0!YT*> ?_L+[,W:@#P]NEJ:NK12)(SC2Z"X2'<]1-.!(8 #N<2+)
M[X+BPYB>5.Y)^W26"O7:-"S@./PEY*.^L)M<4^$D<]8I*(0[[PU^;VKJR-XZ
M<W0C:@[.BD.-,C J X0E=-5.$X4P%WJNNC851 M((="LH-/C9$)&B&;RG9.
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M$'E4C3I439E9S"$6*(1>1(2(!"%>9!6#:-CNU$:1!G8M%2WPNCCSMN#/^?*
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MF'8+IH-,JD5P+'GL0S]A#*+8"R"6)()1J!#@1"V1F54ZY4MY',6M=G 6S5:
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MP21F?AA')#&:RO:',#4QWBT9MK$":#- ;0?H&J($@5E$'_;KIM-B.P[YKK?
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MBR,2?2N69%G>/*@UYE-=+EED#W2MU*@Z]IPG7H@2Q)5X\DA"E#(/$H&03F"
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M!![R D&MSCG[4SKFK%VM<;,E6SV(+9LS0!U3;3A^74J@:S^*O6R.,U!A''!
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MHL(-M\"!LI>MJR,[U@%M$6(P:"^>%LI7[9O)')WN&+>M3=W:MU,]\K7ZT2+
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MY.*AITW<KR)ZYOJ> 1JE6GO2YP^BU-_;)_DV%SPK&T<6/Y&13$@(8X\CB+R
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MEAN@H$(Z PV36[##Z9X9*8/*V9DF1U4I,_-?BH_A78,F+9P3C! G2$W]@HA
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M&GGA$_+GU4(]3<>M5)G?$R]!(L1J 1(QG8D@\2"1'H$TP"P5H<\\/'3]],'
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M(DZR-,,T]J*X/C/.U$Q/2\PJ21(\+^>^Q5+G,'6S-@&0&MB\M$&J1!S C[D
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M:-4O=0=OCA/UVEN9-R^@?=WVX-#"= ,JH%IEBD5=^6RQJ@\4BQM0OY5V*6L
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MVAK6$MU2U)EIJIUQ2XOXYKF8+U5A/'/;6F=5Y3;?"J-ECXP<GPERVV\-!/O
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M8D;\HJQR\\6\]*G>&/]+&H?+O)AB/2_[O+U;/S]\4&K&>((XC6Q*91Z;/["
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M5(E8^CWK6DCPRWP)"JMQ\1>/F,V8;X!#:&QJLSHB'R9XTTV!_*:F0*ZO.Z!
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MVBI]5FGO]0>>C D_[,7B)ZO^>44AM!X=Z;BQ$+=[AM@<6"6U_3=-(L_-Z;V
M[=JI%<-H*C,]ASQ-O@+/P'(__G8,K/[3&ZAC,:#^CXJK#?2;^KF^_[>:O:A?
M%_/UC]5$I$*DE'$@*$L!*I4 -,,<%"5CM!1<ZU+'D <Z-&1L%&O>XBR.-M!1
M%[CQXA# 1B9'7X6@2AOH;OX&TD#G0'P3=: C8T8I$'0.LKX:06>?-_!Y6TW:
M-9EO:_1"G3&9<@ UH@ ANWV@( <:$9B)@G#*_6+2D-:-C4K?[T:HT\K4-ZC
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ML,!V"T)E-.6\S)PF@1//'AO1-^8EK7UN#',*M&X6N1**R$SAC((S&73X>V+
MKY3XZ\/BY7^:;U5C_5_(_@CJ'ZL!?NIY@PSB#D?:@=KUD;YK\]ULN\.LO-_G
M2\5FT_]6\LMBM?JZJ'/L)UII+@DJ 56E5<-'RBS;LQPP9J_4<P:Q3/V6C?Y&
MC&UX]TUN[]4!KNO)N+!&7V!>3/&]2;9>)-:-I/4CY*JS/XJ!EZ$]#!EX7=H?
MJN.%ZA7/ZLN%R^D+LV=N?V/3N7WPW7S[N]_4>I+J'#.."\ I+@%*,P:X*%,@
M2)8J"%.>">Y'?!=:'!O+&9.2!V9UG^=M&O"K7; V^E^):")(SP/?R\B[,EY
M/*/36VO736*M37ZQ]O[%(KO[)V-T2"YSQ"<P<5UJ=6"6<@3AF))<OQCF0N$!
M!3[:G8G_MK?U5^MW;&5/; 5B(E4$$(X@0%2;$(QB 4J$)9(R(QKA:^Z[73+
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M<X!LVBV#)0.ZS(30B.2J=+H:<^KA8V.IRBB[2H39+_PO[?W@5_=#@"/T+A\
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M;)21/;9F^G:(PV;6 #!'CT\J#Q+K0M+ZD%@GDM:+F]TJE'7^U:\#=H/'3MH
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M-@?E$4< #JG$]6L]]DQ./[J)@.YT$QBM3/1SRU<5BTVTD%FJ.0=I)C* ",P
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MG^>;(^-&8&2J5I.<B3S/2 ;2 G& *$H!RW1I%EZHM#G(FM#,IQ"4>]->%#1
ML2AC>2+LJN2IL=UNA2\V*1)L8[@?'WGTA1LMQ4$X,CM9<*LEW]<=<'^QEB?3
M^5]V,E%N+\/L35K^B 7E+H_F!Z4P?U@.F:S'$_H1VCW[^7ZIY-0TMUR^ZL72
M'B[</MH"#),TU1DK.04*,LM@&36K4JX AJ6)4&7)9>X5/76T-;:HZ9QP4;)F
M/Q-1.>')5EU N]%3(/@B\Y&Q,JG-3';MO$EJ2\-QCP,<0<FFJ[U!V<7!\4,Z
M<?E*SU78\W(^79M(ZW8N/TU_VI]6S1XJHT0+G'*@2@X!0D0 EMK30Z:UQKA
M:>JD/WVYJ;&QQ\;2BCYT8ZOG:NL\L(Z+K"!P16:+?:1:,R-L7U]&(^RJZGQS
MPRZF+KI]M(:Z_(TK]VOJ,J#F\5^FC$]G5133+-?DW?R;$L]+6Z#7?."WQ7S9
M_O,=6TU7E6[C1&90,I420#$D '&8 Z*0!@+GD"..RLQ-2"*X9:/C(>-84GEF
M,] ;<ZN1MFM_(Y7:=S?HZN[TW#,:LI-BLU^8_NF_UQ0*RS@[4E=;]S;[5J%
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M8$4SANM*WT(:03&_4%@C3%M#%MH(BLY!X8VPSPZ9E6DO6&1"F%E5FIDVA1E
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M4%J"08'WU!7L@UVWQ*#7$P=4&^SCZ;[P8*\G!*VE^\G,1W.Q7[\59US)0@I
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MPP9P)]H9-H [[^A1 -?QT;XG-JOUG?[;8B&W9*16WQ<S.5&8$F'6;&:1QG.
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M=(GW2U_JNU/"U]N=_ML7-IW9^>738OF=S50UUTP(I5+8XLY*$@J0)C:P81G
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M9ME %4 BM[(=4()2:UYH76*H2U\9PX'[-[XX8?_>;3+DAN]7BB2%$&.@%94
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M39)Q++2GF4E(18(@B7,A8A4SA9Q.IAP3=FE4V>D*>F5!IZUC:<1C\-HY@+Y
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M P#9RF%+?(K!&F\92"1;JD3M7H%< ,%:^9A+1C7,S<D-,L;)S0P'D,-EW )
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M2\]FJ3<5-'&B;2>U;S?$=OS;)#H79<X64@AU+D8B-E+FD"-3/"C4:(>IF7^
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M%Q\_SC:B#+.=*%_.RV)Y?JG,G5!5D)&<,%5'-M5>0RY"=,1?H*C6.C08!JI
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MO'%+SL?':/\Z;,*H?KT,N<U*R(7QR"/01JOE!,F#8R0Q1Z1F&52F7P<J"7Z
MI'&KS,>'8#^Z:L >O@C3Y;^%V05>D]7+.4GHXIK-GT@K(I,Z0_(Y@G*98GNF
M!&"P118O>13#W(]T(J\3&-V/"\;^==@ ,)_ADBQ[;:!RQ[(7C,F9:$ (H6LG
M+08N,@U:><2LDV0#)54?IJD3!/V/"\&>M-4 [EXLEC@]FS^MQ2]SXF,9YJMP
MV?V/I+GYZVPCS#N,RN((-S4!JBZ+%R10)$>.<=$E,QFB5L.<T@>3W"VSS7Y<
MV)Y&V0V@FEC)7T?GW*G)V1X17J"))3HH/ 90T6<(GC-@SKMLT/K$ANFLT(F\
M;FC]@2]B^E=B \C<#2&[FVA-7DD;)!0A)"B3;)V!YX%)AU:8P T?+NBYCZ)N
M^/N!+VAZ454#D'NP]?EMOIB@G9,0 ;TDOC!XB)G7<L0@4Q:!!Y4&@6!7"KM!
M\@>^LQE$E0U ]&^+1?YS.IL12R])B/.S*1GXRY%WNV]MS;V27&62$J%(63+W
M)D(PQ)CA(F>>O"PXC)GL3&(WD/[ MSW#*+,!E+X\_QBFRTV[A^6SZ>KC8A5F
MK\NKQ?SL%46"^9+%.W4BC-OBD@<TDN+!.F349YNA,.=,4#(D-U!_@P.H[8;=
M'_@^:' 5-P#CMTA^S076EI'W37*\S9T/2'PI U$A!^6M *>$@L QJV"#,V:8
M*H[]Z.P&W1_XFFA M38!VA42 ?4B[!DQ.EMLW)[MD-SM<<*$S>@L[<,8!"A>
M%+&D(ZB2HC4YF330V)L.Q'6#YP]\A=2W AO Y"NDXP WG1WNG E,9U6,*Q0C
MND!G@K=T)N@"Z*+Q1@EKQ3#=DA\AJAL&?^";H[X4U@#VGN1/% A.5W7BZ6)U
MUR?)Q(J3F8/QKA:4I@3.9 U22TO_%354.ND;A'7#X ]\==2GXAK X?TM\2\'
M.VP"P.U8B,WTAUW81]&>0;MI34NN![( T: #R80QR#!D.5!=\/[$=JM2_X'O
MC(96< ,8ONJ*=WLONN@P:<E!NSI&US(Z$]!R*$D6XY6SI0PV]OU>BKJA\0>^
M$^I%53_42\C?PG*YJ41XANLPG9WN1>2=A<=[&?FX#)IZ(8D\1F%XA!AJKJC6
MOGN;,J3ZOMBF8)@:YLYYU!>2F]X8UREX<J7:U]=5>_7"N5[P3NKT7:P-26.N
M73B,5.!]+,"2<#'F8@K_)K0/6OE'> *Y#]!NM# 95$TCGO:KY;K>G^6+M'Z]
M?(?+3].$3\CV3$Q2UEKMZ"BJD9_#0O0[!ZD8]%DFS2SOLB5I@6O;D?YV>RL^
M1,$X<#N!LA<]2KX-Y-0ZJ2T'JV>+\S"=3WAD/CI)5.ODR?,@3\9'F2 S;J+-
M)K'<J;O'/O"Y2\8X&.I'LW=A<J28QV[%]197%[/JH-1D?.WKL:"8_\OS4A;+
M]>I7/(^XG'"%+DM5(":T-?]NP,ML0-HL33(:R47N=+AU6&QT<!RKS\6 PAT;
M+#L1;6J*,5>N-A5O-=PF/S?O>'+&AA!#AN#J93D6 :$VIA'9<F--BN[V_+T'
M --QP7'>YP\$FB&$//*)]+:VF-X86\U=8K98L/0'4(G\/6\%G<F"2<6L-70P
M]W8"72T[#CY.Z[4<)N,6@+'%<TF<N4)T&EEOU')FX"J>T;B45/2*8Z>7G=VA
M,?:)<Z#*;BO] /F-K/9?P^?I^<7Y[@2,/M*QQR"*VK<A1$MG82AD*8.05N18
M1*?492?%WUAZ9-4?HKA%'U)L()']]5G2U_=P;Z>K/S;;01H?A4YD_E3URX5#
M"(DDPJM#GA5#IW071!SQC.PN5>,T83G=(=*[9II"V:[.Z#W]RZV'5D1@QN<$
MVM3:^,(,N5+$&NI $:&36@Y4]_ 85>/F\_K3_8.@.E(1#8!J^S3MVNB4/\,R
M[XPYBRQ:=*"3JG5!@LRPU@P8,QP%-]Z480J['J.J%5 =J_O[WP@>KXBQX^H]
M[/NKZ1PW#< G(@AG!)*\3+U&C*%N1Z% :ZN$1:F*N#6^YO@KAZO5QVD3=;K#
M\#1J&1MWOUW4K;(HNY3#=/YT<7Z.RWI/\VM8_H'KB39>*59T??<0R:WD&5PH
M!ASWY)8Z95DQG5#V[;6^C[N% S6]&$[L;:#H=7E:K[J7)*):R_UL>7'VY./'
MY>)3G8>RG0+^_@/^_F[B:0NBXPR"C)SD)B*XF"-X9V.T)A5=PAZ0ZKSP]Y$%
MZ@U?PRBD ?]KQ][5P+IM>TB26"RRJ!2! NKZ4( +")%"8N8SN0,Y61.&B1L?
M).G["!J/PUR_>FD 8%\=UAU+UWKV_#/.\L0FU :3 1:0O%9N';B,B6#A?%)9
M\:*'3E \0-KWX9CU [A^]=06\!:;JK+9D_-JPR<"I;'*D3N@M:H7U0I<*HY$
M)1GGIBB?ADY5W*1HG&:<H\/L<*TTA:[WN#RO[L%E-#[Q4=;<#8>"I8[F2 [(
M1 ? )$M*(BD[T&.TAR@:IXWFV.@Z0BM-H>MO83I_M5BM7L^O[1R*:7R0 2VK
M97ZL]J/5Y' B"D#.)%J7N<>AC=@#I(W3,W-LO/6AIP: ]V"CD=]76"YFKZ8%
M)RH6QY3W(+A.M)<8@ZB-!9FDXU%*-]04L0[$C=,C<QSP]:VK!N"WZQ/RM1U#
MW5,3Q@TJ%Q(4Z8F+^D N"F7 Q)@R1XVF#--6_7YZQNF".0[(>M#(V"FUS<S-
M;9>$-[BL[]8VY8/D=;Y8+&D7G7]<OPE?*F\4XP3K7$S@E1>@2N8D*F4A.)1!
M*')-;Q?U/I!.VV/1D=I3CI!+&TH3+2%LQU#M<)#6F->+B,_#<HYYR_%$.Y%Y
M[79 08T#96D712TD)&=8X1R)Z[(WQKZY[$AM)4=&6;_:&!MGOV(F82WQ35BN
MG[VXF->L\Z]AGL,:)YB\3BI9J$]\R-&, AQR,LN*2XO('//=+@(>662DUI C
M8*@O28^-F*>+&7UIL;P4V]D2-Z_%MMA_7=XNOH39^LOK.84J==M,Z#3G+"E.
M\*^%;S98\-H[<-9YRV1.F+N-!]]SX9$Z/(Z K"$UTL1\CVN-+K9=?B;D'@:9
M@Z @V!10QB!XSQ-(G[U-R<O A\GPWZ5EI"Z-XSCO1ZJBU??RV[/]H"?O5_^V
MEU?K]U/2T\/S;S1VNWKQ*TM.!=%#(3\&%.>.CJ(8P>4<8Z$0GYM.[UC[;M37
MUWC=;RQS;28-2[*PH$!J@20(8^OT;@.<ERRDL=*+H?K =:-PW-+!(?"T9S/"
MPW35NAW:5,8=98VVG]"K3;J/JA-;)B>B-YN;/(UT=OFDP&<6@&<Z<SPAR^OR
M/5LFBB[#&;EP9]N^#-ME-Y*_-CI0.UF4I3.V% 4J,0=!$/(%"A.+,IG=?O';
MUU5-%_*^#YNT#Y+N7-+TKJ4&,N7OT@?,%[3!-Y><-798[MB;KO[XY4O]]05)
M;G'-YG(6'/F+$:)W!N@/ 8). CQW2HLLG<1ASL<#B!UW2O@I8#FT!AL Z34Q
M/J>39SD/LYT(5[]\^1LNSI;AXX=I>K+$L+JU'W,VS$2*48R6'E0=;AE$RH0N
M5AA#[[49YI;Q"*+''2U^"M">2J-CY\W>8J(].9U-MUMRDU/>)9,I=G\RFRW^
M#+1K5[6_\?(3_A)FF[_>XCGD8AG/&KQC I24C-QH)T$[Q""+%]RF;SF)?1(T
M[D3R(1$ZFMH:L+/W"K..+""67TU#)(&LO]QBT?H8'!)/!D5]TB7I4)&H"7J1
MJ:Q8$@.-\3N V'&GE9_"K@ZMP=9#Z-WO\<LU;QWS4_KE;+'\<D2/RSU7Z#4$
M/X2K$X?H#%'*;#=3>/AEIX-0D@5)?RPA6(5NF+Z4#83H$QNMU,5FL%Y2S"=Y
M!E^S["@3C\88[\4P^8G'J/H^ O)]<+-/0+Z73MKH#7BS UX046D9$9@W$930
M'%P0 3*WA1O'M$B=XI;OK*MD_[K]5A/)?03=!E#N:6S&K.58Z])QTZY&*@=1
M2X3LH^0"O<FYDP7ZH9I([J793DTD]Q'SV*'GEHN_+1>K77<ZRYU+L3ZZ1W04
M.:L(/A'YF 0J8W(4J+_E!SWPV:.K_EAMW=/M[U#1-:+Y&T'KZD;4NFM/)1W7
M/%APRM3F,2)!$+9624HE9/0B!;X/'KZY8HL](8]%2;]B;B +L.7K"OCU0;#.
M8#2K[7AKH8=AM;A1,48<Q*"&&;9R@XQQ,J+] ^=X&3< D%<DA/EJURF/*8E,
M!"(^A.K!FSKXBEM@4CBAH^-!#W,M>8.,<1*2PP'D<!DW )"M'';FCSLTFGST
M:'T!Y0NOE8<&2M#"R*P+&^CV_@89X^3^A@/(X3(>VSVY4;FZLX#1JL@U@N76
MDR0,'9$I!3">&X76:KP])+9+O? >FN_]X?) 3L>QPFNBM/>!X/[55;&JRIPS
MGA2D&KZIP 3$&"5D&0C*C&$6PS@=WZ)LW'*"WI,B@RBD@0/H&]G'JU9+]6J$
M_LOOP^=)H(\1M2V\%-R <K2?G"2.!:L.F6>QH!@$<P<0VV1N[D"T[%?Y>;3J
M>C2  ]UA_8;K[<&Q^\J-6Y_X9?O='BZS]EVJUUNMH_@\\?56$&1:B[)0>$W_
M,!O A4!8\PIY(7"3W_7#7F\%I9*E$ -TS@D48@#O48%Q7 ONE+(X3 G5]W^]
MM0]N]KK>VD<G;=Q:W,S-"T6>;B#Z"T\9E"57V-MH0!O:^4Q:C_I'')K6OVZ_
M=;VUCZ#; ,H]X9+2K"3& J1@R;<568)7Q 3/VG+/K12FOVD4W\OUUEZ:[72]
MM8^81\\B4!1\CNLOG[=!L""WSW%3V7?U?:.-X$,N4*22M(VB*!T;V-[ZX-&5
M?JR>%CT);72%5\J7T__8DBZCEE':VK14"S*2V8'/Q4!4* OG/)C2K2+VYN>V
M>$-UN+H/%UD#0?S-.Q(=F<U,,M HZ5!TB4$T] MJ4XI260D[3)UI\_=0A\#C
M>!E_'XE$8T6VEGFPTM:;M9IGK>5E.97BLB.O/*=!4/,=)Q(/<3\'44@#-NB0
M;%3!'-"@A)*C);^L% BNWOFG&(QP)7LQRCOZ[S"1N!=:>D@D[J.Z_='I+]$Y
MQ_7I"N%OI=2NM0C9":+'FOCNBPU2'G\@KR=.)=K !'.($*0-=%RS0CXW]Q!8
MR$87LJYZE'N&GMMLO)Q/U],P>_+QXXQ44)7[!I?317YZ<7XQV[2U?5X*IO7[
M99BOIO7[EZ</1FX]ISUGK:ZSIY"1>.@(RID7YH)A.0R::3V0[N\C';D/]AZP
MIZ?0Z^B34/_/8GGU''63:_&&:<0D01A5^Y1&76^T# 2,RO@@%3>=.D]U'(=Z
M>_TFT'42S2]Z4\/((/HMG./K<H.'7>U'KAUODX)2:K6?]1:"\!2&A^1BRH:I
MTJGE>B<L/4C&>'FM8_6ZZ%O(8V>V7GXDV6]#\,",YCX0ZUYJ4)E3"*Y* *MK
MCS[-8HCQ6V[9[0\=3]4]Z6?1@[#&5O*34C;OR7&U*$__[=T_8YC1 ;U8?KQ9
MR\4"Q3L,.;C(Z82FN =BLC4/8TW-S]JH52?]=UMOO'3G - 80,0MH>;7]*\4
MJ"[F=SDB1KQ$:Z#4"1%*<MH16IOZDM(5J3UM![DW:!Y<;KP<Z,"8Z4? [4#F
M=7E"$IJN%A?+A+_@\@SO84WRHA47"-$6 8H91?M".> H/4>7R:IVFUB[W[KC
MU>L/"J+>1=X.FA;E]<?UQ?F[CUA'HJZ_O/D0EN<A?=F-=G8E:K1D5;VD+5)*
M).]-"##2)>/H/(YR7QP]ON)X!?T#FZ'>Q#PV=MZ'/S"'G:\6 \$^&W ZASH\
MEX/WR51?30CKM$H=.X)?_]3Q2OL'P,#!XFK@GN1&Y[G+OG._X#Q]. _+/S81
M7A9($5W)$%0J]8U"@1 ,0HF,61&9CNF67]M?FZ!'*6NB0> I4RN#J*Q)".ZX
MV6Y,&4DF0EO0Z/UV[JA(";#V _#,6QZ&>8?V+<K&S>[UBX-O@NP(I30 LF\D
MVG>'M*[]WF(MQA#U/4)-N#LN0*(K.5G:H>-<\8R9#AH&$?O=^1Z@G@8P]R1=
MMA9XBPFGGZK=OWH5K!/W(0,O]=U?8AEB]A&$#DGYDA '>EC[$$7CGJ6#(JL7
M)30 IGNL_7OZIY>&/BFMN:^]]#6"BF3MR>13<*J8RQD3)XM_*A]M1U03K7 ;
M<<\.4E2+F*N,;/=D8<%8:>I]#WD8*CH/P;--Q(-%2A<D#C.2\Q&B6CL@#U3\
MMP!UH!9: -3V/+_#TM8F9^$<0\U!F_H>U&M%'BO99*ZETM88G]U ANQQPAH#
MUJ$ N VL'K71 +@.MOFOOKY_ME+*("W)D->.NA;!E2)!<!F\#2E[UU@-TZN]
MZI*';NP]QGE[8K4W /0[^W4[/#"<(9_8R,ES-8*<6:/JU3IM6I<#Z! M3\G[
M,EQ;[P>I^D[+H Y$R+?.[T/5];WT\+Y5SOMU*,1;/*.EAJM;?FBE4Q0M=^+R
MU,T/?.(Q:TUQ<PPUQ(T0DG&0ZJ@80>ZHE<-T>&NA^4%6VH7D$(RIUSE91(@N
MTNF"47HM8DDF#\+\#]#\8 _<[-7\8!^=C%P&^H[4LIG,^W5CT]E18SFF6%2U
MYE':.I#5$@AB5@$P1"E3ECZ&3D%*IS+0!\EH\@'0 5I>]"WRL7&#9[=9V&4Q
M?=#!HP.SJ47">C/L#"/9>"S%V2RPTY/&;KAYB(SQ:DI[4N^B;UF/")A-:GKY
M9?+[NXD)D;.2,LA<FT)@,!"]);4ZK9-/]?WF8YTR5IC^>K;X]//V$R\!LOW+
M!A\;9'Q=;T08]*.TQ5$2'-E(/+]8+CY^O8AP3!HZ7AFJVLL!Z^V&]."3RDHR
M7DJWVZ!.=N'ZRN/5$/>+@:,DVL#N_Y<W$^ZB2"%$2+92;*, SR*#G+6WRIE@
M\V.=NO;;_?_R9KQ*X&%V_YX2;""'\\T7U)IE4[ADX(W.-9U;RSB* I&X0Q65
MX;+3P[7_2@T0#G$\!U%( P [Y!6]43GSQ!FXX@6Q*$-]8*H@IV2-]HQI/_C(
MU1^D <)>:.FA <(^JFN_D^J3M)Y^FJZGN KS_'Q>F;TUK[,LEM?;!%P.U)O6
M*NRKB1[A^D2/'I*.PQ'5:W[R1+([<2H3M?3>\ A>D?E0:#.XF"PDCQ(#]TKR
M3F]O6TME5I_HW\+LXM)RS?/_=Q%FT_*E[NYMX5+5R6RQNEAN#[DD-9<^9[#*
MDZ,CL.[YVOK)"\O(P35&=;JC[!0N[$7:]Y'<W =)UR.,X;34@+?PE;FK74]L
M;NW&ZJJ,)141)!>U(6Y-#)=0P)'/#D*9H)3R2O%A+A2ZT3=>4F- <"P&UU3S
M^-M&B-Y;;9R3@-:33Z4*A?5%T%]]-BG:(-A U4%=J!O7^ V!BKV =X"*QG[E
M]O1#6)YA#.F/RLB5Z_-BL7Q#\OVX?A.^U%3%KL5B82$JG\ 610ZV<!I\$!:R
M8\&ZRF3J]E1[KV5;1M4A*E^<1/YC(^M*7"^^/C)\2C1,B3O<^.5/%\0=Q6_3
MU;K^W%7!G;&>4?RFN:%SP0D*'[FCR#$CYT%P+UFW5L@'$C!N:F=8M)U")RWA
M[FI"1ZR/DW=MH[75(<DZH+#4:B-7(!HFP7L7#;F_D95N36J^M=*XU?^G0]+1
M4A[Y(JJKW_HUL64B1QX30E&LMNYQ@NQPTE!;(RBG)3.VTQ.Y7L//D9/3IXD
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M)"8>2XK#N"TWR!@=(\>J==&7C!L R,TW8$%*P;V($'*NUR1*@%/%06VB1:Y
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MP,+(-_#D*C!%7D?T""Z;E(DX*>7^JZ4??.EQA6T'27[;>LA]Q- 1O![T@_^
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M$71U@XNR=--< ;YI@C5)0:@3VKQ(L=YAS6.;(/06A^ODL1T+$%O8=?M(IU/
MK6_N[74^$9U"0V:P#K':PO1<.,X+D"%<JS %ZD9]:]N<KA/(C06);5R)?>33
M$^;V>#U^N9E)$(SUOG8;V&K6JDPH<E'K.O]?BSHJ*&!C<(Y!QK2YE,[>\X/C
MHH-+L74KGU79\T#,=;96B<8ZE5I8"4FPK'@V,9DVH<A1.R^[KG3<$42[-F<.
MD6@70?.KO15;K.>KTX:2BA'05R40O(;@6 *>D!XGB44U*IC8^HB=^.Z3H[6-
M3+N ZR5OGR(E<5LX&@O,,5.#(0A8MT?2?8P2$T/+VL#SV2,=OU\_DO(<16:]
MMK+7\0 + NV775JR;O_C4?JOGCG+B%.1-I]^*\&;?A=1,&DC.?" !912%E R
M!LB<X4HZC:%-B\8+A]I7USSQT;<-AIG,7V&*!N=-G1U.WJ!+DJ!K9?2:2R$3
M'HK@3KH_Q\+'0_TQFAQZ;?2\(7#WIO2''S&N.FG8?/X2:(Q6-<&A06XFG9#U
M#&ZSY-8$H[A42([HL2F5VR&--U_R/;VX]*<-D^],7O V%F,85'C3VYC(^V::
M_C7).KN;6ZO:^(;;GK!?93,$-\]/$QY1/MTKGCVZRA]]QKBJI_68Q^<PY)E%
MSYT!'5(&1>\78'82$*V55@5ZL=KDI@]AT-Q%]"PK]$6K!%YR04".1*1P&7PJ
MWEBG4U;MUNP].DZ_6F4((IXU87;F? =AS>_P#!<Q__$AY_-?ZF]7H=0\7%0"
M32 !<TDNH2I1@;<L@];,JNK56=>FP/>Y$W4"HMV%O6S ^4X1=)U8,X8S%S.P
M8%T=KUCM^!) "%73N")F?C@,]9  'T?F6P!I!P%T *7K2W;;G^@\4ZI8"3Q7
M3Y ENF#1(WB?74+!34YM"A8?':4_X.PBXV>>L-T8/B%B-KN[?SO_D%>_+!?O
MZ?,^7@^1VE!1JT1<R!9$80E42#4$KC87BQYVE454^C4;^.6OF#8M,3(<1N1F
M1UKDRVVD.PM+WZ0=>/3T3HMLP-&QB0QM@XDBLMANH/O]LTP_H7E<,V9/;O>$
MEW?X[W\@?>X<S]:S9!BJ*#)$N8%ZYH!*17!1930U'6S;A&J>/$XGQN^.,GX.
M,CLSO"?4_-=R]:^WB]]7RYC71(65W/HZL#5Y7LL7%03.--A$UP@U2BE<6]C<
M.T\GVF9DW.S.\IZ \]-\,5]_R.GGY3*M9V1VB)2) .WJ*'IDDFPN&>D.,"E,
MD<IBX]S3O?-,/YZ]!7!V9WE/P/EY57<M^10P\N!)7TK"/B?3S*E@(&.)06;'
MLV_32WC_'-,61K8"RG 6]UK*0%KR4UZ=?\'+%0>?:H'R+BF!)S]GE+3 ZR<<
M*35P_46_D_-TO?)A\VTWX6#.BK=>")#H#&F$["#X4B 6R8R+6$1N,[[EU:/M
MJSR>_8*G\N^(C!Y.<@6B9W5* "O@Z"T%62)+@;1F;!2W&W+*:4WB<;'T4 \U
MD]:(]7X'T%.[ETZ\\&G-=%;#@HK7T:92Y"H0T'R4J8+  >98YPKFX.J4]LC:
MI#:GTURW-X %5^,4'D*=IZ,L^8^.\PS.HTQ%"Z=*FZG7KY^M=RTU!#=;:ZG=
M)--K0<53=_VZHF19GOK;/2HO=O^R9GIM!UH/IO:D$%A<+L"0;F<=*'QI[%LM
M?$[1&K+XCU/MW=8L/7_--L%;CX6>?Z^@,$4L4!S!2[.9\"2-5^3U-%KFLNT)
M>U>!0S#T?&79B%+J(-;P+#7??:G#RS8YZ\"4=EE;2(H>#"4MJXM""P3ZJ=2D
M]HUJ4QZ^Q>%Z64 _)BJV?7UW%%'/J*L$7>4WD9%'8WP AT[443F<_A0L1%&X
M538')=O$2;<X7*>:;E= ;&WN[2:=#@#W2\9U_K \2V\_?EHM/U]V[U\W[<N0
M@M(1. ^UC4X$"")7SNDH/?=!-G(J7CA4IP#;%0#+-M*8NB[E^^7'3Q?T6;>F
MQB+]L2SG_R8N7X\?]HFY@A:<3N1V"8O@&%W+HEC=PDBNE]^N0.7U[YHV!=@*
M,RT8W8%"^NEBM9B?UPKE1?II_G?]T\T-4(E(T(R\Z$0W0,H,068%W D;)2IK
M6:/9D<^>:=HD86MU-)(LIM9&] EU_\-R]>6&0==WPPF#B :X$KDN;\S@36%D
M#%B;G8[%H]M*"3W[%=,F!YOJGG'8VH'*^7ZYF3X=JU0V117O24PW8_)M%H(7
M3E9B<;4<5$!0=7","])PI3T/;;KU7CK5M&/F6ZN=T>31 ;:>Y=4O-^EZ3P\Q
MUXJ!D98>:"LM>;_)0W:9,V&,<8U&/+Q^MFDMIVF#"+L)J&?(_;7.Y>+LEWG)
ML^1+X(8>[:B*)*.0V[JUF&Q$P4I)W-+SW4:K;7&X3EV\'?&P+=QV%$[/>+LL
M(1+9U=$%'@RQ"U2U SSF.M,2C8B1G@+;IH'EY7-UZA0V1MEPD70 L#<Q7GR\
M.,/SG'[(=(@XOVSWR)_.\D9@B_3FXW)U/O_/YN?/$C\++&=6T)$#S.EB&2'
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MOS,7^S5.APSY$%DI']" ,<:"XCZ#*US3OS)1IQ$6UVJWRV&& S5;HMQ'C.?
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MZCS+Z4;Y!.Z%+ARA1)M!6442+*2+9)V_A4(8XSL;C#N<R"-M;CRE)V\_X)W
MM,3!9KH-PMJ0$4S9%. S"4X6 28XZ;2TRAAV9!=S%]^POX[&4[J6^X#NV/L9
MMV?.@\+]C?G^ ^F5F^5$]P1M-#?:,D@BUWU$#"$X0[<,F8JDYJ05G8VD:\.(
M(_4SCR; V@R47T<$]E7VS0*&E)E&8)F16RZX@!"#!Y:,"I9%E6UGNX='I/[D
MX[;MKD^'JF 0EK^ZF.\6[ M1">(2Y*R(?5+24X!1@ I<:UUWZ?C.:@;&9L&1
MON9?E3YHB>JO*NZ\/0N33FB%*!!\\74XJ0#$JF:M4M&DI$Q\D,"=/D ][IT_
MYDAV\SO?K6@' ?>D'8([L]A>YQJ7PEKN$*0B;U!I:<'%I,&AD=QPYXSI;/?B
MJ/2??!S]!(R 9G@^[D$38SI3/&$(VA0H69+@&1+#G$U@&9K",2=NCRUE-G)@
MX)B#]B>@ QIA^>0#_L/G9*UG-B7!LBMT5^N>T.P<N,0B9*Z"R61.Y:-3!CNP
MX4A=A=Z#_:T!V8ME'UYG7AC,O#?OWZ\VZ?_[TT_N\'1F5,A:*@5<I43J&ST@
M3P)\]%BBSIJ9AIL*)Z+Z2*WX$>_J,<!MM*MY@*$[/Z[/YQ^)\L?VQ<A#=U[_
MHF9#=P;2V,?0';)'D_9" />" !=\).LN%&#!*!U-]EFZ)OKM5(;N6&M,)#.8
M7D]O0"EF *,J8 4K:&Q2039JT/DV=&<@?ML-W1D"@@XLJOOS-^C<F9X="<X6
M2X<7D0Z? CEXV@C&L;A&];TG.71G$!1>'+HS1"X=@&IWQKTPT "YB[P:0$H:
M!8I["8&K"+:N,5'>8V(3K>PX\J$[@\!UB*$[0R3= =J?FY:AF0U,<@<RU)7,
MDLCP15F0-C@BJG#7:(CA/D-.CFO0SB"D;#GD9(C8.D#?""ZRB]((CXXL):1W
MRID (1(#LC*AY)"D=YTUEO]R:D-.]C$5#HR 8\;\Z%51/FP6"]<]4XF412&,
MAQ(9Z#H<.0;FBCZV@'Z+6K_^:G]WQ'ZWY7E#@-C+#;[>BF:E-#R 2-$1_W,"
MIU,")C+/3*@D>,,RF6->&#TBAH>+HA<0[<*XFVOS9KV^^'AYX1Y<L7\NS^C3
MSNB2OJ-[-C-2<EFB!BPEU8:\#,'FNF.LD*$9A>>VLUJNP30>?59V$D7>%DJG
M=LG>S=?_^FF5:]8K$\#.-PPA)RY95LCA<M7A$H8#!C* 32%]5$S&5GF'YJ0=
M??*TFRNU-W!.[2;]^/>G7(<$_S#_/$]YD38,*8H7K@J"\Y4AQFV6MUM(0:*S
M)2:)G4T!V):T(RTD[/ F[0V<7FL-?E\M/\_7]"$_+5=O%_3C_"?^G7>J)GCN
MHT:I%]CJG"-5!-Q\_FUJ]29=JHPW/J8ZV<@P4-EJ<)PE,#';9#B!,K<9W?K"
MH?95L4]\])_$RN_H=_XU"V18\908>.2>G@L7P25ER5D.NK:PL)S:Q&I>.M6T
MX9.Q\/%08XTFAR-3-IM@[I@JY^H#6RJ>I\Y\ /5CLO7D!P6P(=&#R!FA(#,/
M*5E5G,A.VC9)AX;JYS8?4!_JY6(3V"LW7UB?WL7ZNE!LP_?;6V$\!JLE YEM
M "7KZI.:!A \"9=MX=*'QL5#@P_=K_(:@J[G:X':2K$'E^2&U!\+.4WG\\_Y
MALYJ&+[+<;F(\[/Y1J@/:*5G0/!,*IRY$D'Y&BU,D2"6HXJL$-VB=;G;\%-/
M&^IM#]G&<NP*LS]<'8"() <GGZ_?+,CCPE!C;?.KA^V63&^2#E$E$$00*.0%
M' H%M<#%R22T-:WA.NC T\9CVR.UG?2Z NE?BQ5=OO>+^7\VI%X]&^L[?8$/
M*)4JF:P$ HLUDR=B@(!* !KOO8N>?/'2&*=#SSQMG+,]5)O*\,A<G%N;:/F<
M3;1''\?^7]K25=J5]@.X4RB,R9XNM?>;+4E(8+,A0^%!.N5ER=AFX6]#=^K[
MBU6]_\]PNO8RSA<7\\7[WS[E%5ZV55VSPZ((S'M9=^_65FNR;C"P!%D5-,5I
MEQL]]KN?N5]G:@BV'BK1 \FP@R?_BM*?,@D*SQZ1.@NV,&=R!A>U!64#0A :
MB3IKHT'%B-B6D'SN8-/B[E#X>!J6HPBK'^S]07*K5=*_T'_P!%')>NTC&K!"
MY+H2,H(/,H"QP5LON4379EO-5L>;UC.?%H<C"JX?-#[#RQDW*FF5) C4CNY6
M'7->B'/"2NZ-, )SF[Z(E\\UK;\]+?[&$-7NP%N>X]DHP+L.*>S"16ETX<8$
M*"[HJP!#M@F2(X=1*6]3;!-_W^/0_08S]S$9#R7%#C3E-:E7=LASUS 497VI
M/-SD276($)#LDJ*<(:JL#*F-Z;C=^2;N&C\47)Z!Z8BRZPB1]RR2YVB3,6-4
M-A*_PF8K#P?,,4!F.CEN/0^L357TD%-.JR2G1N?H<NP(H\]:+98>GZ(\F))X
M7>%&5HO4= -Y+$*+XIUILXOAE8--:V%.C<0QI-6!C?D<&4*5&M<W4+(M=(>2
M CIX(D=-",6XT\&TJ6+O$FRM;,,QN#\:B Z3<+E.0RW+_2S^G11$7N/Y^8=<
M=?T%H??+0Y.DE@"<+W_-YW?^B_&3-(T/VC*Q<T@>'R 9%*S@J*0$':K-F3<M
M1H$#B=!BY#:JT.8!/$1I[WT)/:,0WER'=F_D=4]0,T?OC))*0O*:](5&!4$E
M#9YS+4F72)/;=$J,2D:_*:,A"'Q6QQ]<TAW8ML\0_[09G]<SQR29Z)(!BQ;)
M>HH"G!8)BF=2,:V#C6VJ108>M-]050.HCB*M?L'X_8?:>/1V\:B"J_8:7<KT
M[&SY[SI99Y;KNB#G WC):HE_JNOJLP(3/?V_X2KR-E.[]C][OQ9T \BVDFF_
M**8??$^'J75<)%DZX8<9T]D:C!98L R4$PR"\0E$1&L1Z:EH-/YPZR/V6VG7
M )-[2JB?/>#/T/?KLOH!%_%\'L[RE57S=*]G'7TZBX4)E5D&<L4D**,*T6XL
ME,C1*0)6UHT;]O8Y_K0=O =&;D/)3JA0-PO*MFDP>(K\ZX?E+O&S7&)@F0M@
MS@A0*5APC.PA'U.,2A=D_D%%RC,;\<8\U59(-<>"U&F%=@QH_6Z%E?+?2=!Q
M-=]TR?^PNGC_4\XSE=!8;SQ8D:OSR&K3*A$=R'O,Q22&C(^&S^?/L14B[<DA
M<B3!]&N";H:^O4G_YV)]OAD"-W.:C!DDBF2H]3P^F%J : "U=%I&X:UND^C?
M\H!; =$="Q!;2J<GT#W,]BIMF3$*)-9<B0H9/,\<@@O<L\2T=8U;!7;(5/FC
M!=4>W#_:3-6UW7 90L![C7TM$T_;?.]A\DB#.7" M)#D*EFRTB!Q# 1GC1"0
MTTUU(942A3'(VU[\\=-"C^)5O^;S&X*%$V0G2 %2*4:6ZB9D9>LH;U%*T;9D
MWX;@ET[5;])F"#Z>J_+86PX=/)R/:+FJB%F\_V6Y7G^/J]67<MGV69<G!!NE
MY>"$CJ P,D"9)5FC)47/8]&L;:W1%H?LHSYS?V2\!KF1Q-0C F]"H??)2@*#
MU*;FD[@&%>M4.6$]!"8L<\BQE ,IN*</V$?M97ODC2">'E%'5@Y=J?,O=>O&
M^9O%9FKYI^H+S007,2?)P;I"5FRHT[PTO1?>AIQRSB++-C[$]F?LH]JR/?;&
M$5*/\*M6RM7/KIRHNW%((O5Z$,,+H?64C4:4#K@TAGC@$)PA/\XI&Q-G+MK2
MICZB!3739O\.JDX/*OBIH]2/&/!+)IKN>(RSDIT.+G+PJ>XVK-6S:)P':TH@
MX]S&4!YDII\)1+_Z5=/FZ4;'6 /^'H>JK"GSU>=<IRJ]B7%U@6?KZQ_-@N0I
M1;Y9EJ5 66<!D3DHS!2%67EEVC2"[W?N:1-S4ZJ_L839(W3O]X?,B&-6>&(B
M:NMJ=K'03;25.A&5B$7D1G-!7SG8M#FXPX%O#W'TB*Y-$F=&AY29^0BED/NE
M)-G$K@0)G&/6D:P$I@[D)V_.,VT:[8 !F<',[Q%"/Z^6Z_5,6Q2V$B!"G;+
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M/,? #:#8*X)SY_V,P*72U#(2YDI9K&22N* 2NKO:T"R]0D=X4-1V9 YK0(?
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MQ9E4.;8SZUL93RKVW.S]*042AR)B$&#PD,S[U]]^G2<.*,JQ33#CK=J))9'
MP4&??GS]=?=W__'BG\_?_M^?7R;+;E4F/__KAY]>/4^^.KEW[]>+Y_?NO7C[
M(OGOM__X*;D\/3M/WC99U19=45=9>>_>R]=?)5\MNV[][;U[-S<WIS<7IW5S
M=>_M+_?P4I?WRKINU6G>Y5]]_QW^!OY79?GW_^N[_S@Y25[4\WZEJBZ9-RKK
M5)[T;5%=);_FJGV7G)S(IY[7ZTU37"V[Y/[9_?O)KW7SKKC.^.]=T97J>WV=
M[^[QS]_=HYM\-ZOSS???Y<5U4N1_^ZIX.#\_>YPKN,C#_/*)6F0/U>5YKO+'
MC^>/U8/9Y6_GL,A[\''^3MMM2O6WKU9%=;)4>/]O'U^>WK]<=T]OBKQ;?GM^
M=O:?7_D?S9HK^'17K[^ESW7J?7>2E<55]2T] 'QZ4</CRL?G=5DWWWY]1O_W
M%/]RLLA61;GY]K^>P[=F3?%?:0N;?=*JIECP!]KB_RFX,UR<?KSAA3V"[Y=%
MI?1">6DOWR^+6=$EYV>GY]_=P\]''F]DC;!YS??^EX8[PX\[J[NN7@V>> XO
M1#7CEQN]T-GIUDO]^=T[WVWW_N?E3Z_^Y]6;-'GU^ODIK1_^_]7K%R__\?K5
MCZ^>/WO[ZI^ODV=__^7ERW^\?/UVEPV^PY9\SF]-<ON3'9=[?M]?[.]]VQ6+
MS2=;[65TM=]\??[P[.GP?]\NBU8_R&?=O5=5KE95L2CF&:KJY-E5HQ3KR$^Y
MFOCN)$<=[$/RS=>/[]\_>_J)5D!7^K;HX./S'79HKQM".W'^]#B!7<G)\F5M
M4B^2W\+_2\'F_?9;DE4Y?G2FNANEJN3E>U46[XL65%,U/TV3+'FARNPF:U0R
MKYMUW? [AUU7T]KTY_5JG56;?6YY2IOI[W)R-*E=DK/;*;7/C3I-/E0%[\5>
M_*+FN,'MGS,;_*L"7D#5?7OQ</WQ7+;=GN+9Z7Y>>=QZ64%$H3A_]+1-X [7
MQ5PE79V@=I$#G;3]K.VRJBNRLMR GJK4HNA:]R-\[JZ*:]!?^.LJZWK05Z#T
MVGZ^U-<%E89_O((+-%F9K)NZ4W-49BW^^[H ;QUO;1>6S#9)ME[#P<IFI4I
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M;X5TC>PSF8"-9-2YOC41W8_3,".^]1UXP;%^"47W)S:_2E1!D2NMV(O,?4I
MJOM 4^T"P]PXW'*3;C.]0\J*W=^P[3<AR:EV)08U/HTOA/'U.-X-E<&(?^._
MV>VCS[F3M?FVINCI^G9J(RXH]54#FVK)$+?M-QAAQ49VI90=D 7B8X;O28^6
MR(6<83VY6I ;Y9:%V,-LER[0BF'PD4GD%K=]F37,PF4N<)_!\<G:PI+?^('%
M L\H5Y]))V^^5;%"QH6Y6^H86^^A1=KGU"$T\F"L NB>7Y*[4TKN/CS@Y.YG
M+E8=*IV"PF'I5I$3CZW+*NXPL<6..><&%8\>XJM&SHX[WP#[1Y6A]L*.WW#J
M\R:[X6('*2PD$G,0D,6_BND6RL;1.37*_OZ9J^OQ>;CJ7;J"$)[;$C%IR*<?
M@%:[PE2/C[+C8/;I[2"I*"94>Z!]R=Q0D1L"F[E,9ZABFYMJTQB8(:]N#]-9
M'=_Y]J+-!8U;-2/5)57N6"IZ#8%9C/@@P2K$4E*LYA *M9T5BE4H.KB/IM7,
M>ET75<?=H>*21B].J_? UY3GIMH)9Q"$?%K;:6\LA*!BUFR-C,*\66+E"'S%
M[%)+P%5;VURU[MUE;(\\S@[&1Z!NU]$'.?^7X>+V0TH][C]!VS1GW6_OWLR*
MKAF7W_-SPEEO]6(QN%Z"FI,J[4:/>I&[+V C<7]QFV _"E-E$$SY/G)J@0/J
M/M%@P7]M=6LS18<U*PT5$[Z "06%43P66!Y^*#LA-MTPPZYIP@Z,P[QH?N5C
M!QC>+'>5M_0<CZ!M>E +]=8?*:<;ZNLT?"%3Y?)LE2$71O>Z0QL "R'M96<$
M!R7WTGI,55>9=!TU1X 3 P>?2C\_VW\N_?STR04GTY7FJO,[>\EE15@7RQRA
M"8R4/'"%,:%<^JM*HY6W90YNP<!,7:4;KWT .&I T* O!D/(07\!S/PI877?
M!?G?4NDY@*WNN"!#A9_U3:XJ,8/H/-9)?:T:L/JRVK4]:?CM>:FR1KC-U751
MS7&7%"()X",<OLQ/*+_]=AD=<^)/U-D^^Z330W5F&Z=-"O;5 ?GW*9[T-@7)
M@!\Y+DC6\+;Q'M-H@%+!'?>ARB?R^%@U@SY0H_:R"=K!^:,OKK.2N:T&KC^R
MPZALSDR]1^71EIMA.L"HLV.IXU/E B%=T,,(JV6Z2-@I;?$COD@G@SD1:@FF
MLRHKU+AYD7/\.^]N&3O)<VP_W0A>Y!9LG<#KQ_#^8^ <WFD-X?TWS\Z%0ZNX
M%4.@OZVTQ<?GV"%39)]CPU']W*MS$8J2PT_#;77I9*.PWIL$8E;7[WB1W'==
M2^9+%-5U0\,M;"K>E LZG1BE?-)-HK<]AM<A T)#)+HYP/!6M@826\3+WXLF
MR7N,Q]PR1LSX<!*%>\^%Q9O.-45717HUDZD3O,&!<;BEKD-HHO,;_3IS:9PG
MI[B0-Y>K >@7Z[KI6C.3)%@?W9%TF(YJL;*!>RNM^QG8 _UN,O;XJ PL@Z\B
M(:G"MLUDN&=9]<[I$4+5%(@RZ2<3_>+HB<:\DEVW:\>MD:*2+?.9S\^P"U6L
M;S/K4<5#B+AW,788+) 3*S69-P(0R(Q5;P"L23L&T.3P1*TD[Q2!@ABW9"T9
M='UP[=7A*\T)X4"O'839U""E4N>"J<+&<&O1.-H*:5V0Q+)GNKQ+9W<*XZ3;
M>T3AV&EEJW7?#316V$1<:W'#*];%P[M$:X</^IQ/!_3Y!<]R$?80^ +N'#BX
M\\;"]$ZF0!V;AK5.B1]Z,R$$5&SI//DD!KF$S0UW@UW(XQGKEJ9')C(K8'0Y
MCU UT8@$[=A4]9UY7-$,6?SA)5MY,9ZM%-=PI"6W6T<1RU**Y[53&I+\)DUE
MI3X9XQG/ %N7W:4'/7IV/,*XR;X0*"9%H'CTA4"QZU;Y*@#9"<Y$P[MAQABA
M_' \0!9VX!>TR?TTN6!\67145'_LTL'?$@MY-!-WBPF:Q4APX67++0+/[:=)
MP_ <6NY%K5MBV:9IN9J7&-<$2H/*RQ'*K!0&:W/%$PM(BTG7PU::,G92^N5,
MX)CKGYT4-Z?M>=O!<&]2"50P^D/*'C+#O<">0:!*\>1!C8'1"CJ>E\:1CRT,
MBC>!C*,%7E,OB))R2LMG&JF_G8]1+UR(*+ ZTL]DUWZA2),K03HJ4JFE-Q^8
MNA(Z=ZK7C#-CC$9M27'U-QB#8;#GD A"(?YHJTUEXR7@T]5)F.W% @)9 @<"
M7E_$YZ:%7_+,6>@O?6EGZSU#OM <GLG]Q+.VK>?%EA(,9EE(K8.5.=P?[ESJ
MOV"9>3FV:_"K\\=R:OVZRISF448BYD71M,R,\J*<T94-[+5'\_#GJNT7.!]2
M7?<"H!N>+&@C=57C'H+BZEMWEA6W_Z96MRSUS#MR)M?;]D\^("Y*SCTCW+4U
MX/A<CC:K8O0Z5K=CA$%.JQEV$ AD3!JCK2;_6HC*A)*&&E'1J*_IR!N,_8S#
M?6D(]B&-?88T[_4X\)?&^7*-7RYH$#B>(1]I0#_0WN'(1V%?:[S8@P!G:C!8
M!#79;GA?2D@3QW>5#)4.5AB60'W^_1LD@#25?K<G%#.S2XH,+XT:Y$YWB#?D
MB=:5[12YWCUL3W>E)FJ+EF\S8=;-LCX"JC(JFB'5W'+GGFF8N!Q9O=?[R8YW
MV/,@#78Y]5L9C=3Y2!K =$O(_0&++$2<%8Z4L7[4%QYI9OI1.#4TMO%N^-,V
MOS5:]2.$H)#+8\LX__*\G0EE@M_>16:&Y8=\'*3/+ \.X%(D:=O],76<\4B=
MCN<H(FN77:G3>#:RYLX)$&'#'H)3/2LJ,US!";6=J3H@(^L>(4?]!)JD*[1Y
M1 B4XU?:^,NLT.EA.Z.J,PS8N,]Z+.?H>I=48?F!ADAOTAVJ]:.OU*PY0BC\
MR&\5] '7JS%6CG4H9IQBI!A%-ZVA.KA4XLI:5Z\,/^)7K%.'\DC$X QM9.36
M=,:!*X,J8DAXI"7J%L0Y-0-Q,W.<9)U1"" VROCPM=V$4KAO/3[*SEHNVD[3
ML/4=EOX=!Z!FMM)H=ZMJA]G[$[###%"T#'H#3]@RSDBBAKR?#QV/H2<NP'DI
M*NZ<':*LH_P?K+ASNFY*,8QN&0DKH$XV<K2&K?SYM1Q]])&O'P(6FS1;,,0R
M*( .RGM\*V FH/EH&]YAM@GF&T;F-PY&W*A@KYW9A1"PC6U\H, /7_-,J&EO
M.-$ Q IQSZLA9T>_3"30-F"XTF'6-6MW*!XPUMQ,OW3Z:9CI>CLF1+\T\YY8
MNO+Q :<K]\X2NC\=EA!U4"EF5&.\K]GNT1"0&B6!6XUN:,PO3:4WW3!7J].#
M"SWQ(61']-5(NRG/:2&'NRQ4[](O-CX^89!"O8N&OJI'3,4=LM3T ,5%6KQ"
MEYW /[%K!S-*S;"J0H^,QJ@7?T+S:>I2H@&"G83A%F-F3I=5V@5V3>)^G+;1
M""C7C=;_U*.-V**+K&C\/EV*=TXJ$:@>>Q%!H>.3MJC>AOV,!?)R'4HV:W2;
M(W;'>[ON4@">!=.]#.K*T3O8N*K5',JK@@ H(C[J/*E='F?IO)8"9E&+3"X?
M-"]SUW5$11-=&Q R6\/(Q":.PL3DQ1%!LSV.O5E:V\AS'#Z/\F(Z&O)U79UH
MLC4$(/M2DCK+W,;88%+=+0=BVY12HQWIS'B:,<8U=UCF+I=85A(;$8 PJTP7
MH+&*+O4BKL?' T5.4F1.,:?IA.IWUVSXA#N],MS#Y70FM.;&'<>9)7/34NP%
MG.@;Q.QH;5I-(Q;5933[$RYGP*=<S2F(2LW(ABO*&=TIGJ9 \*;NRYQZ1RT6
MJ +SA.P&C3+3>GDTGF9%$ZAM,G5L(#MERU9,;Q/NOQOB=2P$JOJ]WD1$I*,^
M5OR$1@UC#PV]:(W9\7X.HDXL[6H*4;:VX,U6$ 1MN@L, E^:8KGQ;U"0(L5O
M&$:#[&[TQ7#<F"(;7+0AEVB;?-LK<=) \7@\YP-L]>A>-@'6KWJQ";I&+N=1
M 10S;;L&U\-XPVRK^D;X"3(>4[TOVDYF;>$P=O9Q,,+B(0FNI.^V<>2MZ/Y=
MMAC [6 2VUBA6KFW=$L<L1F(EAB<!,?"?-N-HKM_^-;L,FK-9MG\'3>%.Y$5
M+.C_GNZI1T2Q0ICZ%Z]/S)[6/68&72K.<!#/5K1/-=<R-2PSQD%G76_OUJ@G
M!6OPK=;NFX']L14NYFSL443Y1S;)/%MC9AH"G,JVR=6\33C^WWQ]^>@I5MI)
M*PXN\46="J\@0][E$>PL-6ABKB N1'K_?>[W,YIHCTO^&X5\ !0K_39@+R<E
M4](I\3@-?1A*=^E78OV=F.<5&'8SFM3UM<@J1K<CD&JTM2S/E+X>&XN)/T<O
MY^</B B$![N@@9=RM$L9QB6190#0F4=D]JT\77Z[&U*'P:,9LV[G16@W)+IV
M7(!LVFT.E"YCI=FM)MC&<ZZO2]H *7H&1;=#*TZ382:&/04(H_#<.BTD@H0#
M'6V3>K"=MYWI1/J(VV^&$U-K/_4![ZP!4X6X  1\JL&T)KAI%1K8559E5WB#
ME5K-E%N]IT-%IXYO4>0].*:-*4>)DL?=RF7W0S33OG4M_L(B&_(.P*%K:GF5
M.@,U_CYCTW;=_E&X+\-)8:-"ZP 4;W1W5@1 P<#Z?"IY=;I^1O"!^!KQLR(_
MMAG#CD<B ![N?D+2+0NS?8IESVVO!!%;C: X+>\=M,6&BT*YWP3XQ&YY/Z/.
M/N#\DV@/1\"X0A3@<<*YL3)7H)3TE7X3 ;=.^^<.12$;$=Z8++K8&NOA^*O
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M+-X7[2DH]0,RW'&+]3*;2\-"-EHV:>^9+'D?E.]&<,H9*QWH!6P$0&W(B(S
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M_6Q5.+T(=7_1<);P]L<@T^$Z0!]S;U.Q(U*@&6W11*V--"'*QNE.M90.Q7F
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MI8JZS(ML.'C.AA*6%U=Q06^8<"*B/!9==CD!&0:T#S1.LHP[&$(062(UCJV
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M030,['Y=&'_%0^7E0"5*'SYKTS]'>*41\9%,)H<_#N1(&/9!C-FE&O'T1\_
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MX+\/0;@?4T)X*0)I>6(>6]:W?#6?$$FX\=::72R'/:0\F7,4EQ-!M F$MAR
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MJQ4-OD4<)P)/P'K.MN:%GP$<T4-P;)U::QC9/BFWA@K :R(8(H :E5)D'VH
M/5BL$194LWF( #2"1D(*.T-^?VQ;!*R+I@N4Q]J]J2O%WI'<76%0ENL,@&)<
M/8ICI9E3P)7](4^AS$C "XSP#(&(4Z"E\9@ P(H,>.95H2+>)>&$RMSE%;J,
M)PG473$!8\TC]7-13;;@"7_Y>$EU(("%D./&%^Y(Y7:S!MLP&5W,YMB5)/_>
MG9%HWN\X7'/O"=#'Q1 W>"UQ9)#=WD7KKL;&NRB&;N31>#XCIY'.51SG&AVZ
MPIV/2!TK8^$^'I!!EHE!T-\Y4"^(WMFP) %D0+8]F%TH#JT==V<&/$ZD^4*O
M7:_5B)I%H<$\=4CBS!&8\T=!+C,X&=QR61P@'LPO_V<7/0L]/T'/N/<?>D9W
MS&5SZ)67&84)OAK^97)A )]1?-9Z@X5V%/H#J[19\+V[ 2+'<'ZTG#]!7Y&"
MBH+C3(!^3L@.@ 38PB ;P5_L4N;(YG_G M1W*,[3V!TU=E];:]B!\Q7680$1
MQ!87F^58</!WP=6+%FW*Z2V2KZ^#CGY=!7='\_E9ZUE1++HI?\!X) DI@X6&
M+W)P8\2+N@]+(&Q0GLN^ AB@?Y./P>G@%&=,P7V/GDI?';M#[]8!$D\T +P,
MON0N+2$:[O%$$;:RYT"13I2<<"3"E Z+IRRZR&0^SJ2:<1B=CI3/77H/%!#$
M;U(EJD\_-_T.OCS<RI5OWP3OZL_+VONO7*SK38OI$2"0ZPKH+&EF>'O^Y0@(
M,9-TUA:I4\$M.BJ$1\I:-7;R)TBL4.:*/=QV?KAX3]1J5M_5 WQ59#7\9_.-
MB[=(5?<6J6;9^MCA0?6POGFX7@T68S4GV\L'"TQ&T_>E9FF^(*,,>^]V([LC
MP7VG2)ZL&>'U+_V@9^5K4:_[J+< O>Z3G,^#_TT4.-AJ_U[W4R<\^Z8;;VFY
M>[#^ RR^[/=[U]?AUP?O-+> 6Y%3F(* -N)._62NYQ-8],#:B,;O8OO:FQEG
M^Q/O-!;N^(YY]Y+PNH*#ET J=S6W.Q+<O=B(<SR_D4O?+.*[[9TK?SZ&&K$V
MOKONE9ICS*<)NO7B=?@4*JWK^LA''ND<WT $!V7_NX*-)67UY7^F_$\?VO[!
MUX2O_1Q@F06N2-272V@$J9#;S4LVD>S&WQ84G_YG#NX'%R?_ %!+ P04
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MCG!<!-816J4!][S%1!+,3: )!&!ZB#(@&8.+26.R\E)H(< &P%*":\RX<X^
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M,C,Q7V-A;"YX;6Q02P$"% ,4    " "FB%)4?<DUAT=M   O @4 %0
M        @ '!T 0 97AE;"TR,#(Q,3(S,5]D968N>&UL4$L! A0#%     @
MIHA25&'1*I%9$0$ PL8! !0              ( !.SX% &5X96PM,C R,3$R
M,S%?9S$N:G!G4$L! A0#%     @ IHA25'C-7H,L&P$ ^HD! !0
M     ( !QD\& &5X96PM,C R,3$R,S%?9S(N:G!G4$L! A0#%     @ IHA2
M5,[2M8>K*P$ $L$, !4              ( !)&L' &5X96PM,C R,3$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( *:(4E331U8=*K,  /F3"  5
M  "  0*7" !E>&5L+3(P,C$Q,C,Q7W!R92YX;6Q02P$"% ,4    " "FB%)4
MO?N"7\P\   ;@P$ &@              @ %?2@D 97AE;#(P,C$Q,C,Q97AH
M:6)I=#$P,2YH=&U02P$"% ,4    " "FB%)4HL^"9,L2   Z<0  &P
M        @ %CAPD 97AE;#(P,C$Q,C,Q97AH:6)I=#$P,3@N:'1M4$L! A0#
M%     @ IHA25,7Z;\A6#@  )U8  !L              ( !9YH) &5X96PR
M,#(Q,3(S,65X:&EB:70Q,#0R+FAT;5!+ 0(4 Q0    ( *:(4E2$;_N%&@,
M "D-   :              "  ?:H"0!E>&5L,C R,3$R,S%E>&AI8FET,C$Q
M+FAT;5!+ 0(4 Q0    ( *:(4E3;*K]?G0,  %,*   :              "
M 4BL"0!E>&5L,C R,3$R,S%E>&AI8FET,C,Q+FAT;5!+ 0(4 Q0    ( *:(
M4E0%$:Y'+ @  ,LA   :              "  1VP"0!E>&5L,C R,3$R,S%E
M>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    ( *:(4E2:TU4?- @  /TA   :
M          "  8&X"0!E>&5L,C R,3$R,S%E>&AI8FET,S$R+FAT;5!+ 0(4
M Q0    ( *:(4E2H9VS>R@4  (T=   :              "  >W "0!E>&5L
M,C R,3$R,S%E>&AI8FET,S(Q+FAT;5!+ 0(4 Q0    ( *:(4E0K YCI< \
M ,]*   9              "  >_&"0!E>&5L,C R,3$R,S%E>&AI8FET-#(N
9:'1M4$L%!@     1 !$ EP0  );6"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
